

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date: _____
 Art Unit: _____ Phone Number 30 _____ Serial Number: _____
 Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____


Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Noble</u>	NA Sequence (#) <u>15</u>	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orhit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: <u>11/02/04</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>20</u>	Fulltext _____	Sequence Systems <u>CompuGen, 6CG</u>
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>130</u>	Other _____	Other (specify) _____

This Page Blank (uspto)



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 136621

TO: Terra Gibbs
Location: 2d10/2c18
Art Unit: 1635
Tuesday, November 02, 2004

Case Serial Number: 10/003354

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

This Page Blank (uspto)

Schreiber, David

erfe 136621

From: Gibbs, Terra
Sent: Monday, November 01, 2004 9:16 AM
To: Schreiber, David
Subject: Sequence search request...

Hi David,

I have another request for a score over length search:

I need a length limited nucleotide sequence search of SEQ ID NO:3 in USSN 10/003,354, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched.

*Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
Mailbox 2C18
571-272-0758*

This Page Blank (uspto,

SEARCH REQUEST FORM**Scientific and Technical Information Center**

Requester's Full Name: _____ Examiner #: _____ Date: _____
 Art Unit: _____ Phone Number 30 _____ Serial Number: _____
 Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

STAFF USE ONLY**Type of Search****Vendors and cost where applicable**

Searcher: <u>Noble</u>	NA Sequence (#) <u>15</u>	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: <u>11/02/04</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>20</u>	Fulltext _____	Sequence Systems <u>CompuGen, 60G</u>
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>130</u>	Other _____	Other (specify) _____

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 25.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



107	14.8	0.4	19	1	AJ666205	ACCESSION:AJ666205
108	14.8	0.4	19	1	BQ587387	ACCESSION:BQ587387
109	14.8	0.4	19	1	CF309636	ACCESSION:CF309636
C 110	14.8	0.4	19	1	AZ810717	ACCESSION:AZ810717
C 111	14.6	0.4	21	1	AJ661013	ACCESSION:AJ661013
C 112	14.6	0.4	21	1	CN763587	ACCESSION:CN763587
C 113	14.4	0.4	19	1	AZ597219	ACCESSION:AZ597219
C 114	14.4	0.4	19	1	AZ604234	ACCESSION:AZ604234
C 115	14	0.4	15	1	AW250976	ACCESSION:AW250976
C 116	13.8	0.4	17	1	BG673623	ACCESSION:BG673623
C 117	13.8	0.4	17	1	CF297251	ACCESSION:CF297251
C 118	13.8	0.4	17	1	CF299997	ACCESSION:CF299997
C 119	13.8	0.4	17	1	CF302447	ACCESSION:CF302447
C 120	13.8	0.4	17	1	CF313013	ACCESSION:CF313013
C 121	13.8	0.4	18	1	AL048754	ACCESSION:AL048754
C 122	13.8	0.4	18	1	AW246505	ACCESSION:AW246505
C 123	13.8	0.4	18	1	CF301057	ACCESSION:CF301057
C 124	13.8	0.4	18	1	CF320418	ACCESSION:CF320418
C 125	13.8	0.4	18	1	CF329285	ACCESSION:CF329285
C 126	13.4	0.4	21	1	AZ345540	ACCESSION:AZ345540
C 127	13	0.4	21	1	CF293087	ACCESSION:CF293087
C 128	12.8	0.3	16	1	AI564678	ACCESSION:AI564678
C 129	12.8	0.3	16	1	BQ590166	ACCESSION:BQ590166
C 130	12.8	0.3	16	1	BQ590207	ACCESSION:BQ590207
C 131	12.8	0.3	16	1	BQ592600	ACCESSION:BQ592600
C 132	12.8	0.3	16	1	BQ592965	ACCESSION:BQ592965
C 133	12.8	0.3	16	1	BQ595177	ACCESSION:BQ595177
C 134	12.8	0.3	16	1	CF279325	ACCESSION:CF279325
C 135	12.8	0.3	16	1	CF311057	ACCESSION:CF311057
C 136	12.8	0.3	16	1	CF312586	ACCESSION:CF312586
C 137	12.8	0.3	16	1	CF314377	ACCESSION:CF314377
C 138	12.8	0.3	16	1	CF315789	ACCESSION:CF315789
C 139	12.8	0.3	16	1	CF316056	ACCESSION:CF316056
C 140	12.8	0.3	16	1	CF317718	ACCESSION:CF317718
C 141	12.8	0.3	16	1	CF318894	ACCESSION:CF318894
C 142	12.8	0.3	16	1	CF320356	ACCESSION:CF320356
C 143	12.8	0.3	16	1	CF327722	ACCESSION:CF327722
C 144	12.8	0.3	16	1	CF327923	ACCESSION:CF327923
C 145	12.8	0.3	16	1	CF328223	ACCESSION:CF328223
C 146	12.8	0.3	16	1	CF333386	ACCESSION:CF333386
C 147	12.8	0.3	17	1	AJ666382	ACCESSION:AJ666382
C 148	12.8	0.3	17	1	AW246518	ACCESSION:AW246518
C 149	12.8	0.3	17	1	BQ590128	ACCESSION:BQ590128
C 150	12.8	0.3	17	1	BQ590687	ACCESSION:BQ590687
C 151	12.8	0.3	17	1	BQ591177	ACCESSION:BQ591177
C 152	12.8	0.3	17	1	BQ591588	ACCESSION:BQ591588
C 153	12.8	0.3	17	1	CF290854	ACCESSION:CF290854
C 154	12.8	0.3	17	1	CF294668	ACCESSION:CF294668
C 155	12.8	0.3	17	1	CF295807	ACCESSION:CF295807
C 156	12.8	0.3	17	1	CF295988	ACCESSION:CF295988
C 157	12.8	0.3	17	1	CF298341	ACCESSION:CF298341
C 158	12.8	0.3	17	1	CF298589	ACCESSION:CF298589
C 159	12.8	0.3	17	1	CF299639	ACCESSION:CF299639
C 160	12.8	0.3	17	1	CF310219	ACCESSION:CF310219
C 161	12.8	0.3	17	1	CF334566	ACCESSION:CF334566
C 162	12.8	0.3	17	1	CF336950	ACCESSION:CF336950

RESULT 1	AJ661491	26 bp	mRNA	linear	EST 28-JUN-2004
LOCUS	AJ661491				
DEFINITION	AJ661491 CSEQRAN09 Sus scrofa CDNA clone C0000936_M06, mRNA				
ACCESSION	AJ661491				
VERSION	AJ661491.1	GI:49345614			
KEYWORDS	EST.				
SOURCE	Sus scrofa (pig)				
ORGANISM	Sus scrofa				
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.					

REFERENCE	1 (bases 1 to 26)					
AUTHORS	Anderson,S.I., Finlayson,H.A. and Archibald,A.L.					
TITLE	Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle					
JOURNAL	Unpublished (2004)					
COMMENT	Contact: Anderson SI Genomics and Bioinformatics Roslin Institute Roslin, Midlothian, EH25 9PS, UNITED KINGDOM Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross match with the -minscore 20 and -mismatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1: EcoRI R. Site 2: NotI Description: Normalised library constructed from pooled tissue from day 30 placentas. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.					
FEATURES	Location/Qualifiers					
source	1..26					
	/organism="Sus scrofa"					
	/mol_type="mRNA"					
	/db_xref="taxon:9823"					
	/clones="C0000936 M06"					
	/tissue_type="placenta"					
	/clone_lib="CSEQRAN09"					
	/note=Vector: pBlueScriptII(KS+); Site 1: EcoRI; Site_2: NotI; Single pass sequencing. Normalised library constructed from pooled tissue from day 30 placentas."					
Query Match	0.5%;	Score 19.6;	DB 1;	Length 26;		
Best Local Similarity	84.6%;	Pred. No. 26;				
Matches	22;	Conservative	0;	Mismatches	4;	
			Indels	0;	Gaps	0;

QY	2577	TTTTTTTTTCTGAAAAAGGAAAAA	2602
Db	1	TTTTTTTTTTTAAAAA	26

RESULT 2	AZ310034	26 bp	DNA	linear	GSS 29-SEP-2000
LOCUS	AZ310034				
DEFINITION	IM0018H12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0018H12 R, genomic survey sequence.				
ACCESSION	AZ310034				
VERSION	AZ310034.1	GI:10351618			
KEYWORDS	GSS.				
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.					
REFERENCE	1 (bases 1 to 26)				
AUTHORS	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.				
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts				
JOURNAL	Unpublished (2000)				
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: dunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0018 row: H column: 12 Seq primer: CACACAGAAACAGCTATGACC Class: plasmid ends High quality sequence stop: 26.				
FEATURES	Location/Qualifiers				
source	1..26				
	/organism="Mus musculus"				

```

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UGC1M0018H12"
/sex="Male"
/lab_host="B. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UGC1M library"
/note="Vector: pWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydronically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match      0.5%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 26;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2577 TTTTTCGAAAGGAAAAA 2602
DB 1 TTTTTCGAAAGGAAAAA 26

RESULT 3
TA136F12P
LOCUS T. brucei sheared genomic DNA clone 136f12, forward sequence,
DEFINITION genomic survey sequence.
ACCESSION AL466119
VERSION AL466119.1 GI:11835507
KEYWORDS GSS.
SOURCE Trypanosoma brucei
ORGANISM Trypanosoma brucei
Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
Trypanosoma.
1 (bases 1 to 26)
Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
Melville,S.E., Rajandream,M.A. and Barrell,B.G.
Direct Submission
Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
nh@sanger.ac.uk
COMMENT Constructed at the Institute for Genomic Research (TIGR),
Rockville, MD. Genomic DNA isolated from a cloned population of
Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
to give a tight size distribution (
4 kb). The v + i method used for the library construction is
described in detail in Smith, H. and Venter, J.C. (Making small
insert libraries for whole genome shotgun sequencing projects. In
Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
Barrell, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available
at http://www.sanger.ac.uk/Projects/T_brucei/.

FEATURES
source
1..26
/organism="Trypanosoma brucei"
/mol_type="genomic DNA"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="136f12"

Query Match      0.5%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 26;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2577 TTTTTCGAAAGGAAAAA 2602
DB 26 TTTTTCGAAAGGAAAAA 1

RESULT 5
CF328535
LOCUS NACL--03-H21-g1 Rice callus plasmid cDNA library (NACL) Oryza
DEFINITION sativa (japonica cultivar-group) cDNA clone NACL--03-H21, mRNA
sequence.
ACCESSION CF328535
VERSION CF328535.1 GI:33805314
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)

/mol_type="genomic DNA"
/organism="Trypanosoma brucei"

```

```

/strain="TREU927"
/db_xref="taxon:5691"
/clone="136f12"

Query Match      0.5%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 26;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2577 TTTTTCGAAAGGAAAAA 2602
DB 1 TTTTTCGAAAGGAAAAA 26

RESULT 4
TA136F12P/c
LOCUS T. brucei sheared genomic DNA clone 136f12, forward sequence,
DEFINITION genomic survey sequence.
ACCESSION AL466119
VERSION AL466119.1 GI:11835507
KEYWORDS GSS.
SOURCE Trypanosoma brucei
ORGANISM Trypanosoma brucei
Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
Trypanosoma.
1 (bases 1 to 26)
Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
Melville,S.E., Rajandream,M.A. and Barrell,B.G.
Direct Submission
Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
nh@sanger.ac.uk
COMMENT Constructed at the Institute for Genomic Research (TIGR),
Rockville, MD. Genomic DNA isolated from a cloned population of
Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
to give a tight size distribution (
4 kb). The v + i method used for the library construction is
described in detail in Smith, H. and Venter, J.C. (Making small
insert libraries for whole genome shotgun sequencing projects. In
Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
Barrell, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available
at http://www.sanger.ac.uk/Projects/T_brucei/.

FEATURES
source
1..26
/organism="Trypanosoma brucei"
/mol_type="genomic DNA"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="136f12"

Query Match      0.5%; Score 19.6; DB 1; Length 26;
Best Local Similarity 84.6%; Pred. No. 26;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2577 TTTTTCGAAAGGAAAAA 2602
DB 26 TTTTTCGAAAGGAAAAA 1

RESULT 5
CF328535
LOCUS NACL--03-H21-g1 Rice callus plasmid cDNA library (NACL) Oryza
DEFINITION sativa (japonica cultivar-group) cDNA clone NACL--03-H21, mRNA
sequence.
ACCESSION CF328535
VERSION CF328535.1 GI:33805314
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)

```


with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 18.6; DB 1; Length 26;
Best Local Similarity 84.0%; Pred. No. 49;
Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2577 TTTCTTTTCTGAAAAAGGAAAA 2601
|||||||
Db 25 TTTCTTTTCTGAAAAAGGAAAA 1

RESULT 8
AZ330773/c 23 bp DNA linear GSS 29-SP-2000
LOCUS 1M0056008F Mouse 10kb plasmid UUGCIM library Mus musculus genomic
DEFINITION clone UUGCIM0056008 F, genomic survey sequence.

ACCESSION AZ330773
VERSION AZ330773.1 GI:10392809
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS 1 (bases 1 to 23)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0056 row: 0 column: 08
Seq primer: CGTTGTAACGACGCGCCACT
Class: plasmid ends
High quality sequence stop: 23.

FEATURES
source
1..23
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGCIM0056008"
/sex="Male"
/lab_hosts="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGCIM library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and

purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 17.8; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2574 TTTCTTTTCTGAAAAA 2594
|||||||
Db 23 TTTCTTTTCTGAAAAA 3

RESULT 9
TA303G05P/c 22 bp DNA linear GSS 13-DFC-2000
LOCUS T. brucei sheared genomic DNA clone 303G05, forward sequence,
DEFINITION genomic survey sequence.

ACCESSION AL497383
VERSION AL497383.1 GI:11865504
KEYWORDS GSS.
SOURCE Trypanosoma brucei
ORGANISM Trypanosoma brucei

REFERENCE Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
AUTHORS 1 (bases 1 to 22)
Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
Melville,S.E., Rajandream,M.A. and Barrall,B.G.
TITLE Direct Submission
JOURNAL Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, E-mail: barrall@sanger.ac.uk and
nh@sanger.ac.uk

COMMENT Constructed at the Institute for Genomic Research (TIGR),
Rockville, MD. Genomic DNA isolated from a cloned population of
Trypanosoma brucei (TREU927/4 Gurat 10.1) was mechanically sheared
to give a tight size distribution (4 kb). The v + i method used for the library construction is
described in detail in Smith, H. and Venter, J.C. (Making small
insert libraries for whole genome shotgun sequencing projects. In
Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
Barrall, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available
at http://www.sanger.ac.uk/Projects/T_brucei/.

FEATURES
source
1..22
/organism="Trypanosoma brucei"
/mol_type="genomic DNA"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="303G05"

Query Match 0.5%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 31;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTTCTTCTTCT 2588
|||||||
Db 22 TTTCTTCTCTTTTCTTCTTCT 1

RESULT 10
BX548564
LOCUS BX548564
DEFINITION Glossina morsitans morsitans adult infected gut Glossina
morsitans morsitans cDNA clone Tse101g03_plc, mRNA sequence.

ACCESSION BX548564
VERSION BX548564.1 GI:33298798
KEYWORDS EST.
SOURCE Glossina morsitans morsitans

JOURNAL
COMMENT

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0201 row: F column: 07
Seq primer: CGTTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 19.

FEATURES
source

1. .19
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUC2M0201F07"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3335 TTCTATCCCTTCTCTA 3350

|||||
4 TTCTATCCCTTCTCTA 19

RESULT 16

AA953971/c
LOCUS 19 bp mRNA linear EST 07-JUL-1998
DEFINITION o088h01.s1 NCI CGAP Kid5 Homo sapiens cDNA clone IMAGE:1573297 3', similar to TR:Q00484 Q00484 MINI-COLLAGEN PRECURSOR ; contains element MSRI repetitive element ;, mRNA sequence.

ACCESSION AA953971

VERSION AA953971.1

KEYWORDS GI:3116889

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 19)

AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.

TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index

JOURNAL Unpublished (1997)

COMMENT Contact: Robert Strausberg, Ph.D.

Email: cgapbs-remail.nih.gov

Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: M. Bento Soares, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Insert Length: 485 Std Error: 0.00
Seq primer: -40m13 fwd. ET from Amersham
High quality sequence stop: 1.

FEATURES
source

1. .19
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:1573297"
/tissue_type="2 pooled tumors (clear cell type)"
/lab_hosts="DH10B"
/clone_lib="NCI CGAP Kid5"
/notes="Organ: kidney; Vector: pT7T3D-Pac (Pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5', AACTGGAGGAAATTCGGCGCAATATTTTATTTTATTTT 3'], double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M. Fatima Bonaldo. "

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 23;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 GGGAGGCCCGAGGGGGCG 282

|||||
19 GGGGGGGCCCGGGGGGGCG 1

RESULT 17

CF319596 19 bp mRNA linear EST 15-AUG-2003
LOCUS HD-10-C14.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
DEFINITION HD-10-C14, mRNA sequence.
ACCESSION CF319596
VERSION CF319596.1

KEYWORDS GI:33691357

SOURCE EST.

ORGANISM Oryza sativa (japonica cultivar-group)

Oryza sativa (japonica cultivar-group)

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE 1 (bases 1 to 19)

AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, F.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

UNPUBLISHED (2003)

COMMENT Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division

of Bioscience and Bioinformatics, Myongji University

Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.

Location/Qualifiers

1. .19

/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/db_xref="taxon:39947"

[illegible]

```

ACCESSION  AJ661013
VERSION      AJ661013.1  GI:49345046
KEYWORDS     EST.
SOURCE       Sus scrofa (pig)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.

REFERENCE    1 (bases 1 to 21)
AUTHORS      Anderson, S.I., Finlayson, H.A. and Archibald, A.L.
TITLE        Development of cDNA and EST resources for studying reproduction and
              embryo development in pigs and cattle
JOURNAL      Unpublished (2004)
COMMENT      Contact: Anderson SI
              Genomics and Bioinformatics
              Roslin Institute
              Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
              Single pass sequencing. Bases called and trimmed with phred
              v0.020425.c. Vector identified by cross match with the -minscore 20
              and -minmatch 12 options. Vector:pBluescriptII(KS+) R. Site 1:
              EcoRI R. Site 2: NotI Description: Normalised library constructed
              from pooled tissue from day 30 placentas. Clones available from UK
              Centre for Functional Genomics in Farm Animals, Roslin Institute,
              Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.

FEATURES     source
              1..21
              /organism="Sus scrofa"
              /mol_type="mRNA"
              /db_xref="taxon:9823"
              /clone="C0000935.H04"
              /tissue_type="placenta"
              /clone_lib="CSEORAN09"
              /note="Vector: pBluescriptII(KS+); Site 1: EcoRI; Site 2:
              NotI; Single pass sequencing. Normalised library
              constructed from pooled tissue from day 30 placentas."

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2577 TTTTTCCTGAAAAA 2595
Db 1 TTTTTCCTGAAAAA 19

RESULT 21
CN763587/c
LOCUS
DEFINITION  ID0AAA7BH12RM1 ApMs Acyrthosiphon pisum cDNA clone ID0AAA7BH12 5',
              mRNA sequence.
ACCESSION  CN763587
KEYWORDS
SOURCE     CN763587.1  GI:47537510
ORGANISM   Acyrthosiphon pisum (pea aphid)
              Eukaryota; Metazoa; Arthropoda; Insecta; Pterygota;
              Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;
              Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Hunter, W., Martinez-Torres, D., Rahbe, Y., Sabater-Munoz, B.,
              Stern, D., Tagu, D. and Wincker, P.
TITLE      An expressed sequence tags database for the pea aphid Acyrthosiphon
              pisum
JOURNAL    Unpublished (2004)
COMMENT    Contact: D. Tagu
              INRA Rennes
              UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France
              Tel: +33-2-23-48-51-65
              Fax: +33-2-23-48-51-50
              Risk of contamination by bacterial sequences from obligatory
              (Buchnera) or facultative endosymbionts. These sequences were
              obtained in the frame of the International Consortium of Aphid
              Genomics in collaboration with Genoscope
              PCR Primers

ACCESSION  AJ661013
VERSION      AJ661013.1  GI:49345046
KEYWORDS     EST.
SOURCE       Sus scrofa (pig)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.

REFERENCE    1 (bases 1 to 21)
AUTHORS      Anderson, S.I., Finlayson, H.A. and Archibald, A.L.
TITLE        Development of cDNA and EST resources for studying reproduction and
              embryo development in pigs and cattle
JOURNAL      Unpublished (2004)
COMMENT      Contact: Anderson SI
              Genomics and Bioinformatics
              Roslin Institute
              Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
              Single pass sequencing. Bases called and trimmed with phred
              v0.020425.c. Vector identified by cross match with the -minscore 20
              and -minmatch 12 options. Vector:pBluescriptII(KS+) R. Site 1:
              EcoRI R. Site 2: NotI Description: Normalised library constructed
              from pooled tissue from day 30 placentas. Clones available from UK
              Centre for Functional Genomics in Farm Animals, Roslin Institute,
              Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.

FEATURES     source
              1..21
              /organism="Sus scrofa"
              /mol_type="mRNA"
              /db_xref="taxon:9823"
              /clone="C0000935.H04"
              /tissue_type="placenta"
              /clone_lib="CSEORAN09"
              /note="Vector: pBluescriptII(KS+); Site 1: EcoRI; Site 2:
              NotI; Single pass sequencing. Normalised library
              constructed from pooled tissue from day 30 placentas."

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2577 TTTTTCCTGAAAAA 2595
Db 1 TTTTTCCTGAAAAA 19

RESULT 21
CN763587/c
LOCUS
DEFINITION  ID0AAA7BH12RM1 ApMs Acyrthosiphon pisum cDNA clone ID0AAA7BH12 5',
              mRNA sequence.
ACCESSION  CN763587
KEYWORDS
SOURCE     CN763587.1  GI:47537510
ORGANISM   Acyrthosiphon pisum (pea aphid)
              Eukaryota; Metazoa; Arthropoda; Insecta; Pterygota;
              Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;
              Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Hunter, W., Martinez-Torres, D., Rahbe, Y., Sabater-Munoz, B.,
              Stern, D., Tagu, D. and Wincker, P.
TITLE      An expressed sequence tags database for the pea aphid Acyrthosiphon
              pisum
JOURNAL    Unpublished (2004)
COMMENT    Contact: D. Tagu
              INRA Rennes
              UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France
              Tel: +33-2-23-48-51-65
              Fax: +33-2-23-48-51-50
              Risk of contamination by bacterial sequences from obligatory
              (Buchnera) or facultative endosymbionts. These sequences were
              obtained in the frame of the International Consortium of Aphid
              Genomics in collaboration with Genoscope
              PCR Primers

FORWARD: CAGGAACAGCTATGACC
Plate: 7 row: H column: 12.
Location/Qualifiers
1..21
/organism="Acyrthosiphon pisum"
/mol_type="mRNA"
/cultivar="developmentstage"
/db_xref="taxon:7029"
/clone="ID0AAA7BH12"
/tissue_type="whole insect"
/dev_stage="nymphs and adults (parthenogenetic females)"
/lab_host="XLI-Blue"
/clone_lib="ApMS"
/note="Vector: PBS-SK minus; Site 1: EcoRI; Site 2: XhoI;
Sample name: ID0AAA; Plant growth place: Department of
Ecology & Evolutionary Biology, Princeton University;
Soil conditions: Soil; Sowing date: 01/06/1999;
Harvesting date: 01/06/1999; Stress date: no stress;
Description: Aphids inoculated on one-week old Vicia faba
under non-sterile conditions. All parthenogenetic stages
and both winged and wingless adults were collected for
library construction.; experimental condition: long
photoperiod (16-hr light/8-hr dark at 18 c)"

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2577 TTTTTCCTGAAAAA 2595
Db 21 TTTTTCCTGAAAAA 3

RESULT 22
AZ345540
LOCUS
DEFINITION  1M080P05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
              clone UUGC1M0080P05 F, genomic survey sequence.
ACCESSION  AZ345540
VERSION     AZ345540.1  GI:10424777
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
              1 (bases 1 to 21)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Rielly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0080 row: P column: 05
Seq primer: CGTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
Location/Qualifiers
1..21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0080P05"

```

/sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGCLM library"
 /note="Vector: FWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (GI:4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 52;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTCTCTCTTTTCTCTCT 2588

DB 1 CTTTCTCTTTTCTCTCT 19

RESULT 23

AW251033

LOCUS

DEFINITION 17 bp mRNA linear EST 07-JAN-2000
 2821399.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2821399 3',
 mRNA sequence.

ACCESSION AW251033

VERSION AW251033.1 GI:6593979

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 17)

NIH-MGC http://mgc.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished (1999)

Other ESTs: 2821399.5prime

Contact: Robert Strausberg, Ph.D.

Email: cgabbs@mail.nih.gov

Tissue Procurement: DCTD/DTF cDNA Library Preparation: Ling Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing project

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html Base Calling / Quality

Trimming: PHRED from University of Washington Genome Center. Vector Scores: cross match from University of Washington Genome Center PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley Drosophila Genome Project. University of Washington Genome Center: http://www.genome.washington.edu Low Quality Sequence: 17

contiguous PHRED high quality bases following vector sequence. Very Low Quality Sequence: Trace file contained 17 contiguous distinct peaks following vector sequence. Polyadenylation: Based upon the presence of a XhoI site followed by a run of 14 or more T residues at the beginning of the sequence, this cDNA insert was

polyadenylated.

Plate: LLCM6 row: L column: 8

High quality sequence stop: 17.

Location/Qualifiers

1. 17

/organism="Homo sapiens"

FEATURES

source

/mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:2821399"
 /tissue_type="small cell carcinoma"
 /cell_line="MGC3"
 /lab_host="DH10B (phage-resistant)"
 /clone_lib="NIH_MGC_7"

/note="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Query Match 0.4%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 11;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2579 TTTTCTCTGAAAAA 2595

DB 1 TTTTCTCTGAAAAA 17

RESULT 24

AW249970

LOCUS

DEFINITION 18 bp mRNA linear EST 07-JAN-2000
 2821763.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2821763 3',
 mRNA sequence.

ACCESSION AW249970

VERSION AW249970.1 GI:6592963

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 18)

NIH-MGC http://mgc.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished (1999)

Other ESTs: 2821763.5prime

Contact: Robert Strausberg, Ph.D.

Email: cgabbs@mail.nih.gov

Tissue Procurement: DCTD/DTF cDNA Library Preparation: Ling Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing project

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html Base Calling / Quality

Trimming: PHRED from University of Washington Genome Center. Vector Scores: cross match from University of Washington Genome Center PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley Drosophila Genome Project. University of Washington Genome Center: http://www.genome.washington.edu Low Quality Sequence: 9 contiguous

PHRED high quality bases following vector sequence. Very Low Quality Sequence: Trace file contained 18 contiguous distinct peaks following vector sequence. Polyadenylation: Based upon the presence of a XhoI site followed by a run of 14 or more T residues at the beginning of the sequence, this cDNA insert was polyadenylated.

Plate: LLCM7 row: K column: 12

High quality sequence stop: 9.

Location/Qualifiers

1. 18

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:2821763"

/tissue_type="small cell carcinoma"

/cell_line="MGC3"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH_MGC_7"

/note="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2:

EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 19;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2579 TTTTCTCTGAAAAAG 2596
||||| |
Db 1 TTTTCTCTGAAAAAG 18

RESULT 25
AZ408157/c
LOCUS 19 bp DNA linear GSS 03-OCT-2000
DEFINITION IM0179A16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0179A16 F, genomic survey sequence.
ACCESSION AZ408157
VERSION AZ408157.1 GI:10532170
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 19)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0179 row: A column: 16
Seq primer: CGTTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers
1..19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0179A16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number

FEATURES

source
1..19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0179A16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 29;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3479 TTTTCTCTGAAAAAG 3495
||||| |
Db 18 TTTTCTCTGAAAAAG 2

RESULT 26
AJ666402
LOCUS 20 bp mRNA linear EST 28-JUN-2004
DEFINITION AJ666402 CSEQRAN09 Sus scrofa cDNA clone C0000033_C23, mRNA sequence.
ACCESSION AJ666402
VERSION AJ666402.1 GI:49350853
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Anderson, S.I., Finlayson, H.A. and Archibald, A.L.
TITLE Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle
JOURNAL Unpublished (2004)
COMMENT Contact: Anderson SI
Genomics and Bioinformatics
Roslin Institute
Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross match with the -minscore 20 and -mismatch 12 options. Vector: pBluescriptII (KS+) R. Site 1: EcoRI R. Site 2: NotI Description: Normalised library constructed from pooled tissue from day 30 placentas. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.

FEATURES

source
1..20
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="C0000033_C23"
/tissue_type="placenta"
/clone_lib="CSEQRAN09"
/note="Vector: pBluescriptII (KS+); Site 1: EcoRI; Site 2: NotI; Single pass sequencing. Normalised library constructed from pooled tissue from day 30 placentas."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTTTTTTTT 2586
||||| |
Db 1 TTTCTCTCTCTTTTTTTT 20

RESULT 27
AL038460/c
LOCUS 20 bp mRNA linear EST 06-JUL-2004
DEFINITION AL038460 DKFP566B2246 r1 566 (synonym: hfk2) Homo sapiens cDNA clone DKFP566B2246, mRNA sequence.
ACCESSION AL038460
VERSION AL038460.1 GI:49682131
KEYWORDS EST.

/clone lib=Rice leaf plasmid cDNA library II (7LEAF) "
/note=Vector: PCR-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR. "

ORGANIS

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Db 1 TTTTTTTTTTTTTTTTTT 20

RT-PCR."

Db 1 TTTTTTTTTTTTTTTTTT 20

CFP313569	20 bp	linear	EST 15-AUG-2003
LOCUS	HD-01-L22.b1	OshDAC1-overexpressing transgenic rice plasmid cDNA	
DEFINITION	library (HD)	Oryza sativa (japonica cultivar-group) cDNA clone	
	HD-01-L22,	mRNA sequence.	
ACCESSION	CFP313569		
VERSION	CFP313569.1	GI:33695330	
KEYWORDS	EST.		
SOURCE	Oryza sativa (japonica cultivar-group)		
ORGANISM	Oryza sativa (japonica cultivar-group)		
	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;		
	Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;		
	Ehrhartoideae; Oryzoideae; Oryza.		
REFERENCE	1 (bases 1 to 20)		
AUTHORS	Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,		
	Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.		
	Large-scale Sequencing Analysis of Rice ESTs		
	Unpublished (2003)		
TITLE	Contact: Nahm B.H.		
JOURNAL	Genomics and Genetics Institute, GreenGene Biotech Inc.; Division		
COMMENT	of Bioscience and Bioinformatics, Myongji University		
	Yongin, Kyeonggi, Korea		
	Tel: 82 31 330 6193		
	Fax: 82 31 321 6355		
	Email: bhnahm@bio.mvongji.ac.kr.		

```

FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="Oryza sativa (japonica cultivar-group)"
        /mol_type="mRNA"
        /cultivar="Nackdong"
        /db_xref="taxon:39947"
        /clones="HD-01-L22"
        /tissue_type="callus"
        /dev_stage="proliferated callus on 2N6 media for 2 weeks"
        /lab_host="E.coli DH10B"
        /clone_lib="oeHDAc1-overexpressing transgenic rice plasmid
        cDNA library (HD)"
        /note="vector: PCR4-TOPO; Site 1: EcoRI; Callus was
        treated with ABA(20um) for 1hr. Oligo-capped mRNA was
        reverse transcribed and then used for PCR. mRNA was
        derived from rice Histone Deacetylase overexpression
        line."
      Query Match 0.4%; Score 15.2; DB 1; Length 20;
      Best Local Similarity 85.0%; Pred. No. 51;
      Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
      Qy 2567 TTTCTTCTTTCTTTTTTTTT 2586
      Db 1 TTTTTTTTTTTTTTTTTTTT 20

```

RESULT 40	CF319133	20 bp	mRNA	linear	EST 15-AUG-2003				
LOCUS	HD-09-I13.1	OshDACL-overexpressing transgenic rice plasmid cDNA library (HD) (japonica cultivar-group) cDNA clone							
DEFINITION	HD-09-I13.1	mRNA sequence.							
ACCESSION	CF319133	GI:33690894							
VERSION	CF319133.1	EST.							
KEYWORDS	Oryza sativa (japonica cultivar-group)								
SOURCE	Oryza sativa (japonica cultivar-group)								
ORGANISM	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.								
REFERENCE	1 (bases 1 to 20)								
AUTHORS	Kim, J.-S., Jun, K.-M., Cheong, P. J., Kim, M. J., Lee, T. H., Shin, Y. C., Song, S. I., Kim, J. K., Kim, Y.-K. and Nahm, B. H.								
TITLE	Large-scale Sequencing Analysis of Rice ESTs								
JOURNAL	Unpublished (2003)								
COMMENT	Contact: Nahm B.H. Genomics and Genetics Institute. GreenGene Biotech Inc.; Division								

```

of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhahm@bio.com, bhahm@bio.myongji.ac.kr.

Location/Qualifiers
1. .20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD-09-113"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OshDAC1-overexpressing transgenic rice plasmid
cDNA library (HD)"
/note="Vector: pCRA-TOPO; Site 1: EcoRI; Callus was
treated with ABA(20um) for 1hr. Oligo-capped mRNA was
reverse transcribed and then used for PCR. mRNA was
derived from rice Histone Deacetylase overexpression
line."

```

Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. NO. 51;		
Matches	17;	Conservative	0;	Mismatches 3; Indels 0; Gaps 0;

QY	2567	TTCTCTTCCTTTTTTTTTT	2586
Ddb	1	TTTTTTTTTTTTTTTTTTTT	20


```

RESULT 41
CF321721
LOCUS
DEFINITION HD--13-B05_g1 OshDAC1-overexpressing transgenic rice plasmid cDNA
library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
HD--13-B05, mRNA sequence.
ACCESSION CF321721
VERSION CF321721.1 GI:33693482
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
```

```

FEATURES
source
Location/Qualifiers
1.20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39347"
/clone="HD-13-B05"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E. coli DH10B"
/clone_lib="OSHDAC1-overexpressing transgenic rice plasmid
cDNA library (HD)"
/note="Vector: pCRA-TOPO; Site 1: EcoRI; Callus was
treated with ABA(20um) for 1hr. Oligo-capped mRNA was
reverse transcribed and then used for PCR. mRNA was

```

of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 5355
Email: bhahn@qbio.com, bhahn@bio.myongji.ac.kr.

derived from rice Histone Deacetylase overexpression line."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2567 TTTCTTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 20

RESULT 42
CF328565/c
LOCUS
DEFINITION NACL--03-I14.b1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--03-I14, mRNA sequence.
CF328565.1 GI:33805376

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
1 (bases 1 to 20)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
source
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL-03-I14"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2567 TTTCTTCTCTTTT 2586
Db 20 TTTTCTTTTCTTTT 1

RESULT 43
CF333173
LOCUS
DEFINITION JMT--01-P11.g1 AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone JMT--01-P11, mRNA sequence.
CF333173.1 GI:33814617

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
1 (bases 1 to 20)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
source
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="JMT--01-P11"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was prepared from Arabidopsis Jasmonate Carboxyl methyltransferase overexpression line."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2567 TTTCTTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 20

RESULT 44
CF334170
LOCUS
DEFINITION JMT--03-F17.g1 AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone JMT--03-F17, mRNA sequence.
CF334170.1 GI:33816671

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
1 (bases 1 to 20)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
source
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"

```

/clone="JMT--03-F17"
/tissue type="leaf"
/dev stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid
cDNA library (JMT)"
/notes="Vector: pCR4-TOPO; Site 1: EcoRI; Oligo-capped mRNA
was reverse transcribed and then used for PCR. mRNA was
prepared from Arabidopsis Jasmonate Carboxyl
methyltransferase overexpression line."

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 45
CF336525      20 bp mRNA linear EST 18-AUG-2003
LOCUS
DEFINITION
JMT--06-J21.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
JMT--06-J21, mRNA sequence.
CF336525      1 GI:33821425
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 20)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.
Location/Qualifiers
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="JMT--06-J21"
/tissue type="leaf"
/dev stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid
cDNA library (JMT)"
/notes="Vector: pCR4-TOPO; Site 1: EcoRI; Oligo-capped mRNA
was reverse transcribed and then used for PCR. mRNA was
prepared from Arabidopsis Jasmonate Carboxyl
methyltransferase overexpression line."

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 46
CF336525      20 bp mRNA linear EST 18-AUG-2003
LOCUS
DEFINITION
JMT--06-J21.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
JMT--06-J21, mRNA sequence.
CF336525      1 GI:33821425
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 20)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.
Location/Qualifiers
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="JMT--06-J21"
/tissue type="leaf"
/dev stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid
cDNA library (JMT)"
/notes="Vector: pCR4-TOPO; Site 1: EcoRI; Oligo-capped mRNA
was reverse transcribed and then used for PCR. mRNA was
prepared from Arabidopsis Jasmonate Carboxyl
methyltransferase overexpression line."

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 47
CN545446      20 bp mRNA linear EST 30-APR-2004
LOCUS
DEFINITION
EST 17390 Green Grape Skin Triplex2 Library Vitis vinifera cDNA
clone B3CS00GL005C02 3', mRNA sequence.
CN545446      1 GI:46910071
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Vitis vinifera
Vitis vinifera
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; Vitaceae; Vitis.
1 (bases 1 to 20)
Abbal,P., Agase,A., Ageorges,A., Atanassova,R., Barrieu,F.,
Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
Hamdi,S., Romieu,C. and Terrier,N.
Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
or seeds) at Various Developmental Stages
Unpublished (2002)
Contact: Hamdi S.
UMR 619 - Equipe Biologie de la Vigne

```

```

CF337494      20 bp mRNA linear EST 18-AUG-2003
LOCUS
DEFINITION
JMT--07-P04.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
JMT--07-P04, mRNA sequence.
CF337494      1 GI:33823378
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 20)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.
Location/Qualifiers
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="JMT--07-P04"
/tissue type="leaf"
/dev stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid
cDNA library (JMT)"
/notes="Vector: pCR4-TOPO; Site 1: EcoRI; Oligo-capped mRNA
was reverse transcribed and then used for PCR. mRNA was
prepared from Arabidopsis Jasmonate Carboxyl
methyltransferase overexpression line."

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 47
CN545446      20 bp mRNA linear EST 30-APR-2004
LOCUS
DEFINITION
EST 17390 Green Grape Skin Triplex2 Library Vitis vinifera cDNA
clone B3CS00GL005C02 3', mRNA sequence.
CN545446      1 GI:46910071
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Vitis vinifera
Vitis vinifera
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; Vitaceae; Vitis.
1 (bases 1 to 20)
Abbal,P., Agase,A., Ageorges,A., Atanassova,R., Barrieu,F.,
Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
Hamdi,S., Romieu,C. and Terrier,N.
Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
or seeds) at Various Developmental Stages
Unpublished (2002)
Contact: Hamdi S.
UMR 619 - Equipe Biologie de la Vigne

```


Class: plasmid ends
High quality sequence stop: 20.
Location/Qualifiers

1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0099A20"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
||| ||| ||| ||| ||| ||| |||
Db 20 TTTTCTCTCTTTTTTTT 1

RESULT 57
AZ369734/c
LOCUS
DEFINITION
1M0120024F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0120024 F, genomic survey sequence.

ACCESSION
AZ369734
VERSION
AZ369734.1 GI:10483434
GSS.
SOURCE
Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunne@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0120 row: O column: 24
Seq primer: CTTGTAAACAGCGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES
source

High quality sequence stop: 20.
Location/Qualifiers

1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0120024"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
||| ||| ||| ||| ||| ||| |||
Db 20 TTTTCTCTCTTTTTTTT 1

RESULT 57
AZ369734/c
LOCUS
DEFINITION
1M0120024F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0120024 F, genomic survey sequence.

ACCESSION
AZ369734
VERSION
AZ369734.1 GI:10483434
GSS.
SOURCE
Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunne@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0120 row: O column: 24
Seq primer: CTTGTAAACAGCGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

[illegible]

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG1M0272006"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUCG1M library"
/note="Vector: pWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|47321114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No. 51;
Matches 17; Conservative 0; Indels 3; Gaps 0;

 2567 TTCTGTCCTCTTTTTTTT 2586

Qy	2567	TTTCTTCTTCTTTT	2586
p _b	1	TTTTTTTTTTTTTTTT	20

[illegible]

KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS
GSS	Mus musculus (house mouse)	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.	1 (bases 1 to 20)	Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,

plasmid inserts

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu
Insert Length: 10000 std Err

Insert Length: 10000
Plate: 0297 row: E column: 23

Seq primer: CGTTGTAAACGACGGCCAGT

Class: plasmid ends

High quality sequence scop: 20

Location/Qualifiers

1. .20

```
/organism="Mus musculus"
/total_time="genomic DNA"
```

/usr_cybe= genome3000000000

```

/db_xref="taxon:10090"
/clone="UUGC1M0300P01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTCTTTTTTTTTT 2586
      ||||| ||||| ||||| ||||| |||||
Db 1 TTTTCTTCTCTCTTTTTTTTTT 20

RESULT 64
AZ486787
LOCUS
DEFINITION
  IM0315D23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
  clone UUGC1M0315D23 F, genomic survey sequence.
ACCESSION
  AZ486787
VERSION
  AZ486787.1 GI:10653904
KEYWORDS
  GSS.
SOURCE
  Mus musculus (house mouse)
ORGANISM
  Mus musculus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0315 row: D column: 23
Seq primer: CGTTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 20.
Location/Qualifiers
  1..20
  /organism="Mus musculus"
  /mol_type="genomic DNA"
  /strain="C57BL/6J"
  /db_xref="taxon:10090"

FEATURES
  source

```

```

/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UGClM library"
/note="Vector: pWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match          0.4%;   Score 15.2;   DB 1;   Length 20;
Best Local Similarity 85.0%;   Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2567  TTCTCTCTCTTTTTTTTTT 2586
           |||||
Db       1    TTTTCTTTTTTTTTTTTTT 20

```

RESULT 66
AZ514729/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source

AZ514729 20 bp DNA linear GSS 05-OCT-2000
1M0361E11R Mouse 10kb plasmid UGCGIM library Mus musculus genomic
clone UGCGIM0361E11 R, genomic survey sequence.
AZ514729
AZ514729.1 GI:10696045
GSS.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,R., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0361 row: E column: 11
Seq primer: CACACGGAACACGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.
Location/Qualifiers
1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UGCGIM0361E11"
/sex="Male"


```

source
1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUC1M0498E13"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The

```


was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2569 TTTCTTCTCTTTTCTTCT 2588

Db 1 TTTTCTTCTTCTTCTTCTTCT 20

RESULT 75

AZ645829

LOCUS

DEFINITION 20 bp DNA linear GSS 14-DEC-2000
clone UUGC1M0511D03 R, genomic survey sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE
AUTHORS

1 (bases 1 to 20)

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, R., Stokes, R., Tingey, A., von

Niederhauser, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0511 row: D column: 03

Seq primer: CACACGGAACACCTATGACC

Class: plasmid ends

High quality sequence stop: 20.

Location/Qualifiers

1..20

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0511D03"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/notes="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adaptor DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and

polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 51;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTTCTTCTTCT 2586

Db 1 TTTTCTTCTTCTTCTTCTTCTTCT 20

RESULT 76

AZ650271

LOCUS

DEFINITION

20 bp DNA linear GSS 14-DEC-2000

clone UUGC1M0520C21 F, genomic survey sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

1 (bases 1 to 20)

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, R., Stokes, R., Tingey, A., von

Niederhauser, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0520 row: C column: 21

Seq primer: CGTTGTAAACGACGCGCAGT

Class: plasmid ends

High quality sequence stop: 20.

Location/Qualifiers

1..20

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0520C21"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/notes="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adaptor DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and

purified. The sheared, adaptor mouse DNA was annealed to

ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWP42 [gil7432114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy	2567	TTCTCTCTCTTTT	2586
pB	20	TTTTTTTTTTTTTTT	1

RESULT 77					
AZ760838/c					
LOCUS	AZ760838	20 bp	DNA	linear	GSS 16-FEB-2001
DEFINITION	1M055A24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M055A24 R, genomic survey sequence.				

Accession	AZ760838
Version	AZ760838.1
Keywords	GSS.
Source	Mus musculus (house mouse)
Organism	Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 20)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausen, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

**JOURNAL
COMMENT**

Received: 12/1/98
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT
84112, USA

Tel: 801 585 5606
 Fax: 801 585 7177
 Email: cdunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Seq: 0554 row: A column: 24
 Seq primer: CACACGAGAAACAGTATGACC
 Class: plasmid ends
 High quality sequence stop: 20.

```

FEATURES
    source
        Location/Qualifiers
            1..20
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"
                /db_xref="taxon:10090"
                /clone="UUGC1M0554A24"
                /sex="Male"
            /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
            /clone_lib="Mouse 10kb plasmid UUGC1M library"
            /notes="vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The

```

adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy 2567 TTCTCTTCTTTTTTTT 2586
||| || | ||| ||| |||
pB 20 TTTTCTTTTCTTTTCTTTT 1

RESULT 78					
AZ764504/c					
LOCUS	AZ764504	20 bp	DNA	linear	GSS 16-FEB-2001
DEFINITION	1M0560M02R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0560M02 R, genomic survey sequence.				

ACCESSION	AZ764504	
VERSION	AZ764504.1	GI:12879535
KEYWORDS	GSS.	
SOURCE	Mus musculus (house mouse)	
ORGANISM	Mus musculus	

REFERENCE 1 (bases 1 to 20)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

AUTHORS
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausen, A. and Wright, D., Weiss, R.

TITLE	JOURNAL
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts	Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT
84112. USA

Tel.: 801 585 5606
Email: adunn@genetics.utah.edu
Fax: 801 585 7177
Insert length: 10000 Std Error: 0.00
Plate: 0560 row: M column: 02
Seq primer: CACACGGAAACACTATGACC
Class: plasmid ends
High quality sequence ston: 20.

FEATURES
source

```

1. 20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M056W02"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Ti-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to

```


of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2567 TTCTCTCTCTCTCTCTCTCT 2586
|||||
Db 20 TTTTCTCTCTCTCTCTCTCTCT 1

RESULT 81
AZ779425
LOCUS 20 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0015M18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0015M18 R, genomic survey sequence.

ACCESSION AZ779425
VERSION AZ779425.1 GI:12910066

KEYWORDS GSS.
SOURCE Mus musculus (house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 20)

REFERENCE
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL

COMMENT Contact: Robert B. Weiss

University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0015 row: M column: 18

Seq primer: CACACAGGAACAGCTATGACC

Class: plasmid ends

High quality sequence stop: 20.

Location/Qualifiers

FEATURES

source

1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0015M18"
/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 Kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2567 TTCTCTCTCTCTCTCTCTCT 2586
|||||
Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 82

AZ784041/c

LOCUS

DEFINITION 2M0026B21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0026B21 F, genomic survey sequence.

ACCESSION AZ784041

VERSION AZ784041.1 GI:12919375

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 20)

REFERENCE
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL

COMMENT Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0026 row: B column: 21

Seq primer: CGTGTAAACACGACGCCACT

Class: plasmid ends

High quality sequence stop: 20.

Location/Qualifiers

FEATURES

source

1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0026B21"
/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 Kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated

and selected for ampicillin resistance."

Query Match	0.4%	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred.No. 51;		
Matches 1;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
QY	2567	TTTCTCTCTCTTTTTTTT	2586	
Db	20	TTTTTTTTTTTTTTTTTTTT	1	

RESULT 87
 AZ806585/c
 LOCUS
 DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 COMMENT

AZ806585 20 bp DNA linear GSS 20-FEB-2001
 2M0068C15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC2M0068C15 R, genomic survey sequence.
 AZ806585
 AZ806585.1 GI:12970081
 GSS.
 Mus musculus (house mouse)
 Mus musculus
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 20)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
 Reilly,M., Rose,M., Stokes,R., Stokes,R., Tingey,A., von
 Niederhausern,A. and Wright,D., Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: dunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0068 row: C column: 15
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 20.

FEATURES

source

1. 20

Location/Qualifiers

1. 20

organism="Mus musculus"

mol_type="genomic DNA"

strain="C57BL/6J"

db_xref="taxon:10090"

clone="UUGC2M068C15"

sex="Male"

lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

clone_lib="Mouse 10kb plasmid UUGC1M library"

notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g1473114[gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 51;		
Matches 17;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
Qy	2567	TTTCTTCTTCTTTTTTTTTT	2586	
Db	20	TTTTTTTTTTTTTTTTTTTTTTT	1	

RESULT	88
AZ809306/c	
LOCUS	2M007D15F Mouse 10kb plasmid UGCM library Mus musculus genomic clone UGC2M007D15 F, genomic survey sequence.
DEFINITION	
ACCESSION	AZ809306
VERSION	AZ809306
KEYWORDS	GSS.
SOURCE	Mus musculus (house mouse)
ORGANISM	Mus musculus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1 (bases 1 to 20) Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islan,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.: Weiss,R.
AUTHORS	

TITLE Mouse whole genome scaffolding with paired end reads from 10kb
JOURNAL plasmid inserts
COMMENT Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0073 row: D column: 15
 Seq primer: CGTTGTAACACGACGGCCAGT
 Class: plasmid ends
 High quality sequence stop: 20.

```

FEATURES
source
1. .20
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0073D15"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gii4732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```


Query Match	0.4%	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 51;		
Matches 17;	Conservative	0;	Mismatches 3;	Indels 0;


```

RESULT 97
AZ837491/c
LOCUS
DEFINITION
    AZ837491      20 bp      DNA      linear      GSS 20-FEB-2001
    2M0132K13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
    clone UUGC2M0132K13 R, genomic survey sequence.
ACCESSION
    AZ837491
VERSION
    AZ837491.1   GI:13007399
KEYWORDS
    GSS.
SOURCE
    Mus musculus (house mouse)
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
    1 (bases 1 to 20)
AUTHORS
    Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
    Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
    Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
    Niederhausern,A. and Wright,D., Weiss,R.
TITLE
    Mouse whole genome scaffolding with paired end reads from 10kb
    plasmid inserts
JOURNAL
    Unpublished (2000)
COMMENT
    Contact: Robert B. Weiss
    University of Utah Genome Center
    University of Utah
    Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
    84112, USA
    Tel: 801 585 5606
    Fax: 801 585 7177
    Email: ddunn@genetics.utah.edu
    Insert Length: 10000 Std Error: 0.00
    Plate: 0132 row: K column: 13
    Seq primer: CACACAGGAACAGCTATGACC
    Class: plasmid ends
    High quality sequence stop: 20.
FEATURES
            source
                1..20
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"
                /db_xref="taxon:10090"
                /clone="UUGC2M0132K13"
                /sex="Male"
                /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
                /clone_lib="Mouse 10kb plasmid UUGC1M library"
                /note="Vector: PWD42nv; Purified genomic DNA from M.
                musculus C57BL/6J (male) was obtained from the Jackson
                Laboratory Mouse DNA Resource
                (http://www.jax.org/resources/documents/dnares/). The DNA
                was hydrodynamically sheared by repeated passage through a
                0.005 inch orifice at constant velocity. The sheared DNA
                was blunt end-repaired with T4 DNA polymerase and T4
                polynucleotide kinase. Adaptor oligonucleotides were
                ligated to the blunt ends in high molar excess. The
                adaptedore DNA was purified and size-selected for a 9.5 to
                10.5 kb range using preparative agarose gel
                electrophoresis. Vector DNA was prepared from a derivative
                of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                inducible derivative of plasmid RI. The vector was ligated
                with adaptors complementary to the insert adaptors and
                purified. The sheared, adaptor mouse DNA was annealed to
                adaptor vector DNA, and transformed into
                chemically-competent E. coli XL10-Gold (Stratagene) cells
                and selected for ampicillin resistance."
Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy' 2567 TTTCCTCTCTCTTTTTTTT 2586
      |||||
Db 20 TTTTCTTTCTCTTTTTTTT 1

RESULT 98
AZ841342/c
LOCUS
DEFINITION
    AZ841342      20 bp      DNA      linear      GSS 20-FEB-2001
    2M0139H16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
    clone UUGC2M0139H16 F, genomic survey sequence.
ACCESSION
    AZ841342
VERSION
    AZ841342.1   GI:13011250
KEYWORDS
    GSS.
SOURCE
    Mus musculus (house mouse)
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
    1 (bases 1 to 20)
AUTHORS
    Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
    Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
    Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
    Niederhausern,A. and Wright,D., Weiss,R.
TITLE
    Mouse whole genome scaffolding with paired end reads from 10kb
    plasmid inserts
JOURNAL
    Unpublished (2000)
COMMENT
    Contact: Robert B. Weiss
    University of Utah Genome Center
    University of Utah
    Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
    84112, USA
    Tel: 801 585 5606
    Fax: 801 585 7177
    Email: ddunn@genetics.utah.edu
    Insert Length: 10000 Std Error: 0.00
    Plate: 0139 row: H column: 16
    Seq primer: CGTTGTAAACGACGCCAGT
    Class: plasmid ends
    High quality sequence stop: 20.
FEATURES
            source
                1..20
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"
                /db_xref="taxon:10090"
                /clone="UUGC2M0139H16"
                /sex="Male"
                /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
                /clone_lib="Mouse 10kb plasmid UUGC1M library"
                /note="Vector: PWD42nv; Purified genomic DNA from M.
                musculus C57BL/6J (male) was obtained from the Jackson
                Laboratory Mouse DNA Resource
                (http://www.jax.org/resources/documents/dnares/). The DNA
                was hydrodynamically sheared by repeated passage through a
                0.005 inch orifice at constant velocity. The sheared DNA
                was blunt end-repaired with T4 DNA polymerase and T4
                polynucleotide kinase. Adaptor oligonucleotides were
                ligated to the blunt ends in high molar excess. The
                adaptedore DNA was purified and size-selected for a 9.5 to
                10.5 kb range using preparative agarose gel
                electrophoresis. Vector DNA was prepared from a derivative
                of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                inducible derivative of plasmid RI. The vector was ligated
                with adaptors complementary to the insert adaptors and
                purified. The sheared, adaptor mouse DNA was annealed to
                adaptor vector DNA, and transformed into
                chemically-competent E. coli XL10-Gold (Stratagene) cells
                and selected for ampicillin resistance."
Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCCTCTCTCTTTTTTTT 2586
      |||||
Db 20 TTTTCTCTCTCTTTTTTTT 1

RESULT 99

```

LOCUS	ZM58052	20 bp	DNA	linear	GSS 21-FEB-2000
DEFINITION	W0163003F Mouse 10kb plasmid UUGCIM library Mus musculus genomic clone UUGC2M0163003 F, genomic survey sequence.				
ACCESSION	ZM58052				
VERSION	A2858052				
KEYWORDS	GSS.				
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 20)				
AUTHORS	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duvai,B., Hamill,C., Islam,H., Longacre,S., Mahmoud M., Meenen,E., Pedersen,T., Kelly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.				
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts				
JOURNAL	Unpublished (2000)				
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLCT, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: dunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0163 row: 0 column: 03 Seq primer: CGTTGTAACGACGGCCAGT Class: plasmid ends High quality sequence stop: 20. Location/Qualifiers				
FEATURES					

1. .20

source

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0163003"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: pWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (G114732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Best Local Similarity 85.08; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTTCTCTTTTTTTTTT 2586
||| ||| ||| ||| ||| ||| |||
Db 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 101
AZ936914/c
LOCUS AZ936914 20 bp DNA linear GSS 26-APR-2001

```


ACCESSION	AZ963973	VERSION	AZ963973.1	GI:13835200	KEYWORDS	GSS.	SOURCE	Mus musculus (house mouse)	ORGANISM	Mus musculus	REFERENCE	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.	AUTHORS	1 (bases 1 to 20)	TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts	JOURNAL	Unpublished (2000)	COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0233 row: J column: 01 Seq primer: CGTTGTAACGACGCCAGT Class: plasmid ends High quality sequence stop: 20.	FEATURES	source	1..20 /organism="Mus musculus" /mol_type="genomic DNA" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUCG2M0233J01" /sex="Female" /lab_host="E. coli strain XL10-Gold, T1-resistant, F-" /clone_lib="Mouse 10kb plasmid UUCG2M library" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi 4732114 gb AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
ACCESSION	AZ963973	VERSION	AZ963973.1	GI:13835200	KEYWORDS	GSS.	SOURCE	Mus musculus (house mouse)	ORGANISM	Mus musculus	REFERENCE	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.	AUTHORS	1 (bases 1 to 20)	TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts	JOURNAL	Unpublished (2000)	COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0233 row: J column: 01 Seq primer: CGTTGTAACGACGCCAGT Class: plasmid ends High quality sequence stop: 20.	FEATURES	source	1..20 /organism="Mus musculus" /mol_type="genomic DNA" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUCG2M0233J01" /sex="Female" /lab_host="E. coli strain XL10-Gold, T1-resistant, F-" /clone_lib="Mouse 10kb plasmid UUCG2M library" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi 4732114 gb AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
ACCESSION	AZ963973	VERSION	AZ963973.1	GI:13835200	KEYWORDS	GSS.	SOURCE	Mus musculus (house mouse)	ORGANISM	Mus musculus	REFERENCE	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.	AUTHORS	1 (bases 1 to 20)	TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts	JOURNAL	Unpublished (2000)	COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0233 row: J column: 01 Seq primer: CGTTGTAACGACGCCAGT Class: plasmid ends High quality sequence stop: 20.	FEATURES	source	1..20 /organism="Mus musculus" /mol_type="genomic DNA" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUCG2M0233J01" /sex="Female" /lab_host="E. coli strain XL10-Gold, T1-resistant, F-" /clone_lib="Mouse 10kb plasmid UUCG2M library" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi 4732114 gb AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
ACCESSION	AZ963973	VERSION	AZ963973.1	GI:13835200	KEYWORDS	GSS.	SOURCE	Mus musculus (house mouse)	ORGANISM	Mus musculus	REFERENCE	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.	AUTHORS	1 (bases 1 to 20)	TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts	JOURNAL	Unpublished (2000)	COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0233 row: J column: 01 Seq primer: CGTTGTAACGACGCCAGT Class: plasmid ends High quality sequence stop: 20.	FEATURES	source	1..20 /organism="Mus musculus" /mol_type="genomic DNA" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUCG2M0233J01" /sex="Female" /lab_host="E. coli strain XL10-Gold, T1-resistant, F-" /clone_lib="Mouse 10kb plasmid UUCG2M library" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi 4732114 gb AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
ACCESSION	AZ963973	VERSION	AZ963973.1	GI:13835200	KEYWORDS	GSS.	SOURCE	Mus musculus (house mouse)	ORGANISM	Mus musculus	REFERENCE	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.	AUTHORS	1 (bases 1 to 20)	TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts	JOURNAL	Unpublished (2000)	COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0233 row: J column: 01 Seq primer: CGTTGTAACGACGCCAGT Class: plasmid ends High quality sequence stop: 20.	FEATURES	source	1..20 /organism="Mus musculus" /mol_type="genomic DNA" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUCG2M0233J01" /sex="Female" /lab_host="E. coli strain XL10-Gold, T1-resistant, F-" /clone_lib="Mouse 10kb plasmid UUCG2M library" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA


```

SOURCE      Beta vulgaris
ORGANISM    Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Anaranthaceae; Beta.
REFERENCE   1 (bases 1 to 19)
AUTHORS    Hwang, R., Schulz, B., Weisshaar, B., Hennig, S., Steinfath, M.,
            Drungowski, M., Stahl, D., Wruick, W., Menze, A., O'Brien, J., Lehrach, H.
            and Radelof, U.
TITLE      Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL    Plant J. 32 (5), 845-857 (2002)
MEDLINE    22362189
PUBMED     12472698
COMMENT    Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaar@piz-koeln.mpg.de
            Insert Length: 19 Std Error: 0.00
            Plate: 10 row: H column: 05
            Seq primer: SP6; CATACGATTAGGTGACACTATAG.
            Location/Qualifiers
FEATURES   1..19
            /organism="Beta vulgaris"
            /mol_type="mRNA"
            /cultivar="KWS2320 (double haploid, monogerm breeding
            line)"
            /db_xref="GABI:185481"
            /db_xref="taxon:161934"
            /clone="024-010-H05"
            /tissue_type="leaf"
            /lab_host="EMDH108"
            /notes="Vector: pCMVSPORT6; Site 1: Sali; Site 2: NotI;
            cDNA library from sugar beet, library provided by KWS
            Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
            b.schulz@kws.de; Cloning sites Sali-NotI, primer sites and
            orientation:
            SP6-Sali-CCAGCGCTCCG-5prime-cDNA-polyA-CC-NotI-TT; Note:
            Sequencing granted in the context of the GABI-Beet
            project, local PI: Dr. Katharina Schneider, coordinator:
            Prof. Christian Jung; Sequence submission managed by
            RZPD/GABI-Primary database:http://gabi.rzpd.de"
            Query Match      0.4%; Score 14.8; DB 1; Length 19;
            Best Local Similarity 88.9%; Pred. No. 44;
            Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      86 CTTGGTCTGGCGCAAGG 103
            |||||
Db      2 CTTGCTCTGGCGCAAGG 19

RESULT 109
CF309636
LOCUS     CF309636
DEFINITION Oryza sativa (japonica cultivar-group) cDNA clone
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--03-008, mRNA sequence.
ACCESSION CF309636
VERSION    CF309636.1 GI:33681397
KEYWORDS   EST.
SOURCE     Oryza sativa (japonica cultivar-group)
            Oryza sativa (japonica cultivar-group)
ORGANISM   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE   1 (bases 1 to 19)
AUTHORS    Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
            Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
            Large-scale Sequencing Analysis of Rice ESTs
TITLE      Large-scale Sequencing Analysis of Rice ESTs

JOURNAL    Unpublished (2003)
COMMENT    Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, Myongji University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.
            Location/Qualifiers
FEATURES   1..19
            /organism="Oryza sativa (japonica cultivar-group)"
            /mol_type="mRNA"
            /cultivar="Nackdong"
            /db_xref="taxon:39947"
            /clone="ABF--03-008"
            /tissue_type="leaf"
            /dev_stage="14 days after germination"
            /lab_host="E.coli DH10B"
            /clone_lib="ABF3-overexpressing transgenic rice plasmid
            cDNA library (ABF)"
            /note="Vector: pCR4-TOPO; Site 1: EcoRI; Leaf was dried
            for 2hrs. Oligo-capped mRNA was reverse transcribed and
            then used for PCR. mRNA was prepared from ABA-responsive
            element binding transcription factor 3 overexpression
            line."
            Query Match      0.4%; Score 14.8; DB 1; Length 19;
            Best Local Similarity 88.9%; Pred. No. 44;
            Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      2574 TTCTTTTTTTTTTCTGAA 2591
            |||||
Db      1 TTTTTTTTTTTTTGAA 18

RESULT 110
AZ810717/c
LOCUS     AZ810717
DEFINITION 2M0076N24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0076N24 F, genomic survey sequence.
ACCESSION AZ810717
VERSION    AZ810717.1 GI:12978242
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
            1 (bases 1 to 19)
REFERENCE   1 (bases 1 to 19)
AUTHORS    Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
            Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
            Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
            Niederhausern, A. and Wright, D. Weiss, R.
            Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
            Unpublished (2000)
            Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0076 row: N column: 24
            Seq primer: CGTTGTAACACGACGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
            Location/Qualifiers
FEATURES   1..19
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /strain="C57BL/6J"

```

```

/db_xref="taxon:10090"
/clone="UUGC2M0076N24"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

```

Query Match      0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2577 TTTTTCGAAAAA 2594
      |||||
Db 18 TTTTTCGAAAAA 1

```

```

RESULT 111
AJ661013/c
LOCUS
DEFINITION
AJ661013
VERSION
AJ661013.1 GI:49345046
KEYWORDS
SOURCE
Sus scrofa (pig)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
1 (bases 1 to 21)
REFERENCE
Anderson,S.I., Finlayson,H.A. and Archibald,A.I.
Development of cDNA and EST resources for studying reproduction and
embryo development in pigs and cattle
Unpublished (2004)
JOURNAL
COMMENT
Contact: Anderson SI
Genomics and Bioinformatics
Roslin Institute
Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
Single pass sequencing. Bases called and trimmed with phred
v0.020425.c. Vector identified by cross_match with the -minscore 20
and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1:
EcoRI R. Site 2: NotI Description: Normalised library constructed
from pooled tissue from day 30 placentas. Clones available from UK
Centre for Functional Genomics in Farm Animals, Roslin Institute,
Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.

```

```

FEATURES
source
1..21
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="C0000935_H04"
/tissue_type="placenta"
/clone_lib="CSQRAN09"
/notes="Vector: pBlueScriptII(KS+); Site 1: EcoRI; Site 2:
NotI; Single pass sequencing. Normalised library
constructed from pooled tissue from day 30 placentas."

```

```

Query Match      0.4%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 2580 TTTTTCGAAAAAAGGAAA 2600
      |||||
Db 21 TTTTTCGAAAAAAGGAAA 1

```

```

RESULT 112
CN763587
LOCUS
DEFINITION
CN763587
ACCESSION
CN763587.1 GI:47537510
VERSION
CN763587
KEYWORDS
SOURCE
Acyrtosiphon pisum (pea aphid)
ORGANISM
Acyrtosiphon pisum
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;
Aphidoidea; Aphididae; Macrosiphini; Acyrtosiphon.
1 (bases 1 to 21)
REFERENCE
Hunter,W., Martinez-Torres,D., Rahbe,Y., Sabater-Munoz,B.,
Stern,D., Tagu,D. and Wincker,P.
An expressed sequence tags database for the pea aphid Acyrtosiphon
pisum
Unpublished (2004)
JOURNAL
COMMENT
Contact: D. Tagu
INRA Rennes
UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France
Tel: +33.2.23.48.51.65
Fax: +33.2.23.48.51.50
Risk of contamination by bacterial sequences from obligatory
(Buchner) or facultative endosymbionts. These sequences were
obtained in the frame of the International Consortium of Aphid
Genomics in collaboration with Genoscope
PCR Primers
FORWARD: CAGGAACAGCTATGACC
Plate: 7 row: H column: 12.
Location/Qualifiers
1..21
/organism="Acyrtosiphon pisum"
/mol_type="mRNA"
/cultivar="developmentstage"
/db_xref="taxon:7029"
/clone="ID0AAA7BH12"
/tissue_type="whole insect"
/dev_stage="nymphs and adults (parthenogenetic females)"
/lab_host="XL1-Blue"
/clone_lib="ApMS"
/notes="Vector: pBS-SK minus; Site 1: EcoRI; Site 2: XhoI;
Sample name: ID0AAA ; Plant growth place: Department of
Ecology & Evolutionary Biology, Princeton University ;
Soil conditions: Soil ; Sowing date: 01/06/1999 ;
Harvesting date: 01/06/1999 ; Stress date: no stress ;
Description: Aphids inoculated on one-week old Vicia faba
under non-sterile conditions. All parthenogenetic stages
and both winged and wingless adults were collected for
library construction. ; experimental condition: long
photoperiod (16-hr light/8-hr dark at 18 c)"

```

```

Query Match      0.4%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 2580 TTTTTCGAAAAAAGGAAA 2600
      |||||
Db 1 TTTTTCGAAAAAAGGAAA 21

```

```

RESULT 113

```

```

AZ597219/c
LOCUS          AZ597219      19 bp      DNA      linear      GSS 13-DEC-2000
DEFINITION    1M0411K23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0411K23 F, genomic survey sequence.
ACCESSION     AZ597219
VERSION       AZ597219.1  GI:11719505
KEYWORDS      GSS.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus

REFERENCE
AUTHORS       Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
              Islem,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
              Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
              Niederhausern,A. and Wright,D.,Weiss,R.
TITLE         Mouse whole genome scaffolding with paired end reads from 10kb
              plasmid inserts
JOURNAL
COMMENT       Unpublished (2000)
              Contact: Robert B. Weiss
              University of Utah Genome Center
              University of Utah
              Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
              84112, USA
              Tel: 801 585 5606
              Fax: 801 585 7177
              Email: ddunn@genetics.utah.edu
              Insert Length: 10000 Std Error: 0.00
              Plate: 0411 row: K column: 23
              Seq primer: CGTTGTAACGACGCGCCAGT
              Class: plasmid ends
              High quality sequence stop: 19.
FEATURES      source
              1..19
                  Location/Qualifiers
                  /organism="Mus musculus"
                  /mol_type="genomic DNA"
                  /strain="C57BL/6J"
                  /db_xref="taxon:10090"
                  /clone="UUGC1M0411K23"
                  /sex="Male"
                  /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                  /clone_lib="Mouse 10kb plasmid UUGC1M library"
                  /notes="Vector: PWD42nv; Purified genomic DNA from M.
                  musculus C57BL/6J (male) was obtained from the Jackson
                  Laboratory Mouse DNA Resource
                  (http://www.jax.org/resources/documents/dnares/). The DNA
                  was hydrodynamically sheared by repeated passage through a
                  0.005 inch orifice at constant velocity. The sheared DNA
                  was blunt end-repaired with T4 DNA polymerase and T4
                  polynucleotide kinase. Adaptor oligonucleotides were
                  ligated to the blunt ends in high molar excess. The
                  adapted DNA was purified and size-selected for a 9.5 to
                  10.5 kb range using preparative agarose gel
                  electrophoresis. Vector DNA was prepared from a derivative
                  of pWD42 (GI|4732114|gb|AF129072.1), a copy-number
                  inducible derivative of plasmid R1. The vector was ligated
                  with adaptors complementary to the insert adaptors and
                  purified. The sheared, adapted mouse DNA was annealed to
                  adapted vector DNA, and transformed into
                  chemically-competent E. coli XL10-Gold (Stratagene) cells
                  and selected for ampicillin resistance."
              Query Match          0.4%; Score 14.4; DB 1; Length 19;
              Best Local Similarity 93.8%; Pred. No. 56;
              Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

              QY 273 GGAGGGGGCGGGGAGG 288
                  |||||||
              DB 16 GGAGGGGGGGGGGAGG 1

RESULT 114
AZ604234

```

```

LOCUS          AZ604234      19 bp      DNA      linear      GSS 13-DEC-2000
DEFINITION    1M0425C04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0425C04 F, genomic survey sequence.
ACCESSION     AZ604234
VERSION       AZ604234.1  GI:11726424
KEYWORDS      GSS.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus

REFERENCE
AUTHORS       Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
              Islem,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
              Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
              Niederhausern,A. and Wright,D.,Weiss,R.
TITLE         Mouse whole genome scaffolding with paired end reads from 10kb
              plasmid inserts
JOURNAL
COMMENT       Unpublished (2000)
              Contact: Robert B. Weiss
              University of Utah Genome Center
              University of Utah
              Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
              84112, USA
              Tel: 801 585 5606
              Fax: 801 585 7177
              Email: ddunn@genetics.utah.edu
              Insert Length: 10000 Std Error: 0.00
              Plate: 0425 row: C column: 04
              Seq primer: CGTTGTAACGACGCGCCAGT
              Class: plasmid ends
              High quality sequence stop: 19.
FEATURES      source
              1..19
                  Location/Qualifiers
                  /organism="Mus musculus"
                  /mol_type="genomic DNA"
                  /strain="C57BL/6J"
                  /db_xref="taxon:10090"
                  /clone="UUGC1M0425C04"
                  /sex="Male"
                  /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                  /clone_lib="Mouse 10kb plasmid UUGC1M library"
                  /notes="Vector: PWD42nv; Purified genomic DNA from M.
                  musculus C57BL/6J (male) was obtained from the Jackson
                  Laboratory Mouse DNA Resource
                  (http://www.jax.org/resources/documents/dnares/). The DNA
                  was hydrodynamically sheared by repeated passage through a
                  0.005 inch orifice at constant velocity. The sheared DNA
                  was blunt end-repaired with T4 DNA polymerase and T4
                  polynucleotide kinase. Adaptor oligonucleotides were
                  ligated to the blunt ends in high molar excess. The
                  adapted DNA was purified and size-selected for a 9.5 to
                  10.5 kb range using preparative agarose gel
                  electrophoresis. Vector DNA was prepared from a derivative
                  of pWD42 (GI|4732114|gb|AF129072.1), a copy-number
                  inducible derivative of plasmid R1. The vector was ligated
                  with adaptors complementary to the insert adaptors and
                  purified. The sheared, adapted mouse DNA was annealed to
                  adapted vector DNA, and transformed into
                  chemically-competent E. coli XL10-Gold (Stratagene) cells
                  and selected for ampicillin resistance."
              Query Match          0.4%; Score 14.4; DB 1; Length 19;
              Best Local Similarity 93.8%; Pred. No. 56;
              Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

              QY 2579 TTTTTCCTGAAAAA 2594
                  |||||||
              DB 1 TTTTTCCTGAAAAA 16

RESULT 115
AW250976
LOCUS          AW250976      15 bp      mRNA      linear      EST 07-JAN-2000

```

```

DEFINITION      2822229.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2822229 3',
                  mRNA sequence.
ACCESSION        AW250976
VERSION          AW250976.1 GI:6594065
KEYWORDS         EST.
SOURCE           Homo sapiens (human)
ORGANISM         Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE        1 (bases 1 to 15)
AUTHORS          NIH-MGC http://mgc.nci.nih.gov/.
TITLE            National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL          Unpublished (1999)
COMMENT          Other_ESTs: 2822229.5prime
                  Contact: Robert Strausberg, Ph.D.
                  Email: cgapbs-remail.nih.gov
                  Tissue Procurement: DCTD/DPF cDNA Library Preparation: Ling
                  Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E.
                  Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing
                  project Clone distribution: MGC clone distribution information can
                  be found through the I.M.A.G.E. Consortium/LLNL at:
                  www.bio.lnl.gov/bbrp/image/image.html Base Calling / Quality
                  Scores: PHRED from University of Washington Genome Center. Vector
                  Trimming: cross match from University of Washington Genome Center
                  PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley
                  Drosophila Genome Project. University of Washington Genome Center:
                  http://www.genome.washington.edu Low Quality Sequence: 11
                  contiguous PHRED high quality bases following vector sequence. Very
                  Low Quality Sequence: Trace file contained 15 contiguous distinct
                  peaks following vector sequence. Polyadenylation: Based upon the
                  presence of a XhoI site followed by a run of 14 or more T residues
                  at the beginning of the sequence, this cDNA insert was
                  polyadenylated.
                  Plate: LLCM8 row: N column: 22
                  High quality sequence stop: 11.

FEATURES         source
                  1..15
                  /organism="Homo sapiens"
                  /mol_type="mRNA"
                  /db_xref="taxon:9606"
                  /clone="IMAGE:2822229"
                  /tissue_type="small cell carcinoma"
                  /cell_line="MGC3"
                  /lab_host="DH10B (phage-resistant)"
                  /clone_lib="NIH_MGC_7"
                  /note="Organ: lung; Vector: pOTB7; Site:1: XhoI; Site:2:
                  EcoRI; cDNA made by oligo-dT priming. Directionally
                  cloned into EcoRI/XhoI sites using the following 5'
                  adaptor: GGACGAG(G). Size-selected >500bp for average
                  insert size 1.8kb. Library constructed by Ling Hong in
                  the laboratory of Gerald M. Rubin (University of
                  California, Berkeley) using ZAP-cDNA synthesis kit
                  (Stratagene) and Superscript II RT (Life Technologies)."
```

```

Query Match      0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 9.7;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 68 TTTTTCAGAT 81
Db 2 TTTTTCAGAT 15
```

```

RESULT 116
BG673623/c
LOCUS           BG673623
DEFINITION      BG673623 Rat DRG Library Rattus norvegicus cDNA clone DRNAQC09
                  5', mRNA sequence.
ACCESSION       BG673623
VERSION         BG673623.1 GI:13895722
KEYWORDS        EST.
SOURCE          Rattus norvegicus (Norway rat)
ORGANISM        Rattus norvegicus
```

```

REFERENCE        1 (bases 1 to 17)
AUTHORS          Xiao,H.S., Huang,Q.H., Zhang,F.X., Bao,L., Lu,Y.J., Guo,C.,
                  Yang,L., Huang,W.J., Fu,G., Xu,S.H., Cheng,X.P., Yan,Q., Zhu,Z.D.,
                  Zhang,X., Chen,Z., Han,Z.G. and Zhang,X.
TITLE            Identification of gene expression profile of dorsal root ganglion
                  in the rat peripheral axotomy model of neuropathic pain
JOURNAL          Proc. Natl. Acad. Sci. U.S.A. 99 (12), 8360-8366 (2002)
MEDLINE          22056133
PUBMED          12060780
COMMENT          Contact: Zhang Xu
                  Laboratory of Sensory System
                  Institute of Neuroscience
                  320 Yue Yang Road, Shanghai 200031, P.R.China
                  Tel: 86-21-64748700-121
                  Fax: 86-21-64713446
                  Email: xu.zhang@ion.ac.cn
                  This clone is also available at Chinese National Human Genome
                  Center at Shanghai, 351 Guo Shoujing Road, Zhangjiang Hi-Tech Park,
                  Pudong New Area, P.R.China. Please contact with Zhang Xu
                  (xu.zhang@ion.ac.cn) or Han Zeguang (hanzg@chgc.sh.cn)
                  PCR Primers
                  FORWARD: T3
                  BACKWARD: T7
                  Seq primer: T3
                  POLYA-No.

FEATURES         source
                  1..17
                  /organism="Rattus norvegicus"
                  /mol_type="mRNA"
                  /strain="Sprague-Dawley"
                  /db_xref="taxon:10116"
                  /clone="DRNAQC09"
                  /sex="male"
                  /tissue_type="dorsal root ganglion"
                  /dev_stage="adult"
                  /clone_lib="Rat DRG Library"

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 33;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2577 TTTTCTGAAA 2593
Db 17 TTTTCTGAAA 1

RESULT 117
CF297251
LOCUS           CF297251
DEFINITION      CF297251 17 bp mRNA linear EST 14-AUG-2003
                  30DGS--07-P12.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
                  sativa (japonica cultivar-group) cDNA clone 30DGS--07-P12, mRNA
                  sequence.
ACCESSION       CF297251
VERSION         CF297251.1 GI:33666284
KEYWORDS        EST.
SOURCE          Oryza sativa (japonica cultivar-group)
ORGANISM        Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE        1 (bases 1 to 17)
AUTHORS          Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
                  Song,S.I., Kim,J.K., Kim,Y.-K. and Nam,B.H.
TITLE            Large-scale Sequencing Analysis of Rice ESTs
JOURNAL          Unpublished (2003)
COMMENT          Contact: Nam B.H.
                  Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
                  of Bioscience and Bioinformatics, Myongji University
                  Yongin, Kyeonggi, Korea
                  Tel: 82 31 330 6193
```

Qy 2572 TCCTCTTTTTTTTCT 2588

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

Location/Qualifiers

1..17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="ABP-08-P19"
/tissue_type="leaf"
/dev_stages="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="ABF3-overexpressing transgenic rice plasmid
cDNA library (ABF)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; Leaf was dried
for 2hrs. Oligo-capped mRNA was reverse transcribed and
then used for PCR. mRNA was prepared from ABA-responsive
element binding transcription factor 3 overexpression
line."

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 33;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTTTTCCTTTTTC 2587

Db 1 TTTTTCCTTTTTCCTTTTTC 17

RESULT 121

AL048754/c

LOCUS

DEFINITION DKFP2566L173 r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
EST.

ACCESSION AL048754

VERSION AL048754.1

KEYWORDS GI:4727825

SOURCE EST.

ORGANISM Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 18)

AUTHORS Koehrer, K., Beyer, A., Mewes, H.W., Gassenhuber, J. and Wiemann, S.

TITLE EST (Koehrer, et al.)

JOURNAL Unpublished (1999)

COMMENT Contact: MIPS

Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.

FEATURES

source

Location/Qualifiers

1..18

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="DKFP2566L173"

/tissue_type="kidney"

/dev_stages="fetal"

/lab_host="Xl-2blue"

/clone_lib="566 (synonym: hfkd2)"

/note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

Query Match

Best Local Similarity 0.4%; Score 13.8; DB 1; Length 18;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2574 TTCTTTTTCCTTTTCGGA 2590

Db 17 TTTTTCCTTTTTCCTTTTCGGA 1

RESULT 122

AW246505

LOCUS

DEFINITION

2821585.3prime NIH MGC_7 Homo sapiens cDNA clone IMAGE:2821585 3',

mRNA sequence.

ACCESSION AW246505

VERSION AW246505.1

KEYWORDS GI:6589498

SOURCE EST.

ORGANISM Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 18)

AUTHORS NIH-MGC http://mgi.nci.nih.gov/.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT Other ESTs: 2821585.5prime

Contact: Robert Strausberg, Ph.D.

Email: gqaps-r@mail.nih.gov

Tissue Procurement: DCTD/DTP cDNA Library Preparation: Ling

Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E.

Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing

Project Clone distribution: MGC clone distribution information can

be found through the I.M.A.G.E. Consortium/LLNL at:

www-bio.llnl.gov/bbrp/image/image.html Base Calling / Quality

Scores: PHRED from University of Washington Genome Center. Vector

Trimming: cross_match from University of Washington Genome Center

PHRAP suite. Poly-I identification: patmatch.pl from Berkeley

Drosophila Genome Project. University of Washington Genome Center:

http://www.genome.washington.edu Low Quality Sequence: 18

contiguous PHRED high quality bases followed vector sequence. Very

Low Quality Sequence: Trace file contained 18 contiguous distinct

peaks following vector sequence. Polyadenylation: Based upon the

presence of a XhoI site followed by a run of 14 or more T residues

at the beginning of the sequence, this cDNA insert was

polyadenylated.

Plate: L1CM7 row: D column: 2

High quality sequence stop: 18.

FEATURES

source

Location/Qualifiers

1..18

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:2821585"

/tissue_type="small cell carcinoma"

/cell_line="MGC3"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH MGC 7"

/notes="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2:

EcoRI; cDNA made by oligo-dT priming. Directionally _

cloned into EcoRI/XhoI sites using the following 5'

adaptor: GGACGAG(G). Size-selected >500bp for average

insert size 1.8kb. Library constructed by Ling Hong in

the laboratory of Gerald M. Rubin (University of

California, Berkeley) using ZAP-cDNA synthesis kit

(Stratagene) and Superscript II RT (Life Technologies)."

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 53;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3479 TTTTTCCTTTTCATATTT 3495

Db 2 TTTTTCCTTTTCCTTTTATTT 18

RESULT 123

CF301057

LOCUS

DEFINITION

7LEAF--05-M05.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza

sativa (japonica cultivar-group) cDNA clone 7LEAF--05-M05, mRNA

sequence.

ACCESSION CF301057

18 bp mRNA linear EST 15-AUG-2003
7LEAF--05-M05.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
sativa (japonica cultivar-group) cDNA clone 7LEAF--05-M05, mRNA
sequence.
CF301057

CF301057.1 GI:33672818
EST.
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 18)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1. .18
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-M05"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 53;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TCTCTCTTTTCTTTTCT 2587
DB 2 TTTTCTTTTCTTTTCT 18

RESULT 124
CF320418
LOCUS
DEFINITION
HD--11-E22.g1 OshDAC1-overexpressing transgenic rice plasmid cDNA
library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
HD--11-E22, mRNA sequence.
CF320418.1 GI:33692179
EST.
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 18)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1. .18
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-M05"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library (NACL)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 53;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TCTCTCTTTTCTTTTCT 2587
DB 2 TTTTCTTTTCTTTTCT 18

RESULT 124
CF320418
LOCUS
DEFINITION
HD--11-E22.g1 OshDAC1-overexpressing transgenic rice plasmid cDNA
library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
HD--11-E22, mRNA sequence.
CF320418.1 GI:33692179
EST.
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 18)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1. .18
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-M05"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library (NACL)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 53;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TCTCTCTTTTCTTTTCT 2587
DB 2 TTTTCTTTTCTTTTCT 18

RESULT 125
CF329285
LOCUS
DEFINITION
NACL--04-I22.b1 Rice callus plasmid cDNA library (NACL) Oryza
sativa (japonica cultivar-group) cDNA clone NACL--04-I22, mRNA
sequence.
CF329285.1 GI:33806806
EST.
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 18)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1. .18
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--04-I22"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 53;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2572 TCTCTCTTTTCTTTTCT 2588
DB 1 TTTTCTTTTCTTTTCT 17

```

RESULT 126
AZ345540/c
LOCUS      21 bp      DNA      linear      GSS 29-SEP-2000
DEFINITION  clone UUGC1M0080P05 F, genomic survey sequence.
ACCESSION  AZ345540
VERSION    AZ345540
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
REFERENCE  1 (bases 1 to 21)
AUTHORS    Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
            Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
            Reilly, M., Rose, R., Stokes, R., Tingey, A., von
            Niederhausern, A., and Wright, D., Weiss, R.
TITLE      Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL    Unpublished (2000)
COMMENT    Contact: Robert B. Weiss
            University of Utah Genome Center
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0080 row: P column: 05
            Seq primer: CGTTGTAACGACGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES   source
            1..21
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"
                /db_xref="taxon:10090"
                /clone="UUGC1M0080P05"
                /sex="Male"
                /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                /clone_lib="Mouse 10kb plasmid UUGC1M library"
                /note="Vector: PWD42nv; Purified genomic DNA from M.
            musculus C57BL/6J (male) was obtained from the Jackson
            Laboratory Mouse DNA Resource
            (http://www.jax.org/resources/documents/dnares/). The DNA
            was hydrodynamically sheared by repeated passage through a
            0.005 inch orifice at constant velocity. The sheared DNA
            was blunt end-repaired with T4 DNA polymerase and T4
            polynucleotide kinase. Adaptor oligonucleotides were
            ligated to the blunt ends in high molar excess. The
            adaptor DNA was purified and size-selected for a 9.5 to
            10.5 kb range using preparative agarose gel
            electrophoresis. Vector DNA was prepared from a derivative
            of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
            inducible derivative of plasmid R1. The vector was ligated
            with adaptors complementary to the insert adaptors and
            purified. The sheared, adaptor mouse DNA was annealed to
            adaptor vector DNA, and transformed into
            chemically-competent E. coli XL10-Gold (Stratagene) cells
            and selected for ampicillin resistance."
Query Match      0.4%; Score 13.4; DB 1; Length 21;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2589 GAAGAAAGGAAAAAG 2603
        |||||||
        15 GAAGAAAGGAAAAAG 1

Db
;

RESULT 127
AZ345540/c
LOCUS      21 bp      DNA      linear      GSS 29-SEP-2000
DEFINITION  clone UUGC1M0080P05 F, genomic survey sequence.
ACCESSION  AZ345540
VERSION    AZ345540
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
REFERENCE  1 (bases 1 to 21)
AUTHORS    Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
            Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
            Reilly, M., Rose, R., Stokes, R., Tingey, A., von
            Niederhausern, A., and Wright, D., Weiss, R.
TITLE      Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL    Unpublished (2000)
COMMENT    Contact: Robert B. Weiss
            University of Utah Genome Center
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0080 row: P column: 05
            Seq primer: CGTTGTAACGACGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES   source
            1..21
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"
                /db_xref="taxon:10090"
                /clone="UUGC1M0080P05"
                /sex="Male"
                /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                /clone_lib="Mouse 10kb plasmid UUGC1M library"
                /note="Vector: PWD42nv; Purified genomic DNA from M.
            musculus C57BL/6J (male) was obtained from the Jackson
            Laboratory Mouse DNA Resource
            (http://www.jax.org/resources/documents/dnares/). The DNA
            was hydrodynamically sheared by repeated passage through a
            0.005 inch orifice at constant velocity. The sheared DNA
            was blunt end-repaired with T4 DNA polymerase and T4
            polynucleotide kinase. Adaptor oligonucleotides were
            ligated to the blunt ends in high molar excess. The
            adaptor DNA was purified and size-selected for a 9.5 to
            10.5 kb range using preparative agarose gel
            electrophoresis. Vector DNA was prepared from a derivative
            of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
            inducible derivative of plasmid R1. The vector was ligated
            with adaptors complementary to the insert adaptors and
            purified. The sheared, adaptor mouse DNA was annealed to
            adaptor vector DNA, and transformed into
            chemically-competent E. coli XL10-Gold (Stratagene) cells
            and selected for ampicillin resistance."
Query Match      0.4%; Score 13.4; DB 1; Length 21;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2589 GAAGAAAGGAAAAAG 2603
        |||||||
        15 GAAGAAAGGAAAAAG 1

Db
;


```

```

CF293087/c
LOCUS      21 bp      mRNA      linear      EST 14-AUG-2003
DEFINITION  30DGS--02-C07.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--02-C07, mRNA
            sequence.
ACCESSION  CF293087
VERSION    CF293087
KEYWORDS   EST.
SOURCE     Oryza sativa (japonica cultivar-group)
ORGANISM   Oryza sativa (japonica cultivar-group)
REFERENCE  1 (bases 1 to 21)
AUTHORS    Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
            Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
            Large-scale Sequencing Analysis of Rice ESTs
            Unpublished (2003)
TITLE      Large-scale Sequencing Analysis of Rice ESTs
JOURNAL    Unpublished (2003)
COMMENT    Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, Myongji University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES   source
            1..21
                /organism="Oryza sativa (japonica cultivar-group)"
                /mol_type="mRNA"
                /cultivar="Nackdong"
                /db_xref="taxon:39947"
                /clone="30DGS--02-C07"
                /tissue_type="leaf"
                /dev_stage="30 days after germination"
                /lab_host="E.coli DH10B"
                /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                /note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
            with oligoribonucleotides and then used as templates for
            RT-PCR."
Query Match      0.4%; Score 13; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      2582 TTTTCTGAAAAAGGAAAAA 2602
        |||||
        21 TTGTCAAAAAAAGAAAAA 1

Db
;

RESULT 128
AI564678/c
LOCUS      16 bp      mRNA      linear      EST 14-MAY-1999
DEFINITION  tq78903.x1 NCI CGAP U11 Homo sapiens cDNA clone IMAGE:2214964 3,
            similar to TR:Q15214 Q15214 SALLIVARY PROLINE-RICH PROTEIN 1
            ;contains element MSRI repetitive element ;, mRNA sequence.
ACCESSION  AI564678
VERSION    AI564678.1 GI:4523135
KEYWORDS   EST.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 16)
AUTHORS    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      1 (bases 1 to 16)
JOURNAL    NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
            National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
            Unpublished (1997)
COMMENT    Contact: Robert Strausberg, Ph.D.
            Email: cgapsb-x@mail.nih.gov
            Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
            cDNA Library Preparation: Life Technologies, Inc.
            cDNA Library Arrayed by: Greg Lennon, Ph.D.

```

```

COMMENT
Contact: Weissehaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weissehaar@mpiz-koeln.mpg.de
Insert Length: 16 Std Error: 0.00
Plate: 19 Row: K Column: 18
Seq primer: T7; GTAATACGACTCATTATAGGC.
Location/Qualifiers
1. .16
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding
line)"
/db_xref="GABI:189955"
/db_xref="taxon:161934"
FEATURES
source

```

FEATURES
SOURCE


```

VERSION      B0595717.1  GI:26125300
KEYWORDS
SOURCE
ORGANISM      Beta vulgaris
               Beta vulgaris
REFERENCE
AUTHORS      Herwig,R., Schulz,B., Weishaar,B., Hennig,S., Steinfath,M.,
               Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
               and Radloff,U.
TITLE        Construction of a 'unigene' cDNA clone set by oligonucleotide
               fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL      Plant J. 32 (5), 845-857 (2002)
MEDLINE
PUBMED      22362189
12472698
COMMENT      Contact: Weishaar B
               ADIS DNA core facility at MPIZ
               Max-Planck-Institute for Plant Breeding Research
               Carl-von-Linne Weg 10, 50829 Koeln, Germany
               Fax: 00492215062851
               Email: weishaar@mpiz-koeln.mpg.de
               Insert Length: 16 Std Error: 0.00
               Plate: 22 row: H column: 07
               Seq primer: SP6: CATACGATTAGTGACACTATAG.
               Location/Qualifiers
               1..16
               /organism="Beta vulgaris"
               /mol_type="mRNA"
               /cultivar="KWS2320 (double haploid, monogerm breeding
               line)"
               /db_xref="GABI:191134"
               /db_xref="taxon:161934"
               /clone="024-022-H07"
               /tissue_type="developing root"
               /lab_host="EMDH10B"
               /clone_lib="MPI2-ADIS-024-developing root"
               /note="Vector: PCMVSPORT6; Site 1: Sali; Site 2: NotI;
               cDNA library from sugar beet, library provided by KWS
               Kleinwanzlebener Saatzzucht AG Einbeck, Germany, contact:
               b.schulz@kws.de; cloning sites Sali-NotI, primer sites and
               orientation:
               SP6-Sali-CCACGCGTCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
               Sequencing granted in the context of the GABI-Beet
               project, local PI: Dr. Katharina Schneider, coordinator:
               Prof. Christian Jung; Sequence submission managed by
               RZPD/GABI-Primary database: http://gabi.rzpd.de"
               Query Match      0.3%; Score 12.8; DB 1; Length 16;
               Best Local Similarity 87.5%; Pred. No. 38;
               Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2571  TTCTTCTTTTTTTTTT 2586
Db      16  TTTTCTTTTTTTTTTT 1

RESULT 134
CF279325
LOCUS      14ETL--05-J09.g1 Rice etiolated leaf plasmid cDNA library (14ETL)
DEFINITION      Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--05-J09,
               mRNA sequence.
ACCESSION      CF279325
VERSION      CF279325.1  GI:33656711
KEYWORDS      EST.
SOURCE      Oryza sativa (japonica cultivar-group)
ORGANISM      Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
               Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
               Ehrhartoideae; Oryzaceae; Oryza.
               1 (bases 1 to 16)
               Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
               Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
               Large-scale Sequencing Analysis of Rice ESTs
               Unpublished (2003)
               Contact: Nahm B.H.
               Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
               of Bioscience and Bioinformatics, Myongji University
               Yongin, Kyeonggi, Korea
               Tel: 82 31 330 6193
               Fax: 82 31 321 6355
               Email: bhnaahm@bio.com, bhnaahm@bio.myongji.ac.kr.
               Location/Qualifiers
               1..16
               /organism="Oryza sativa (japonica cultivar-group)"
               /mol_type="mRNA"
               /cultivar="Nackdong"
               /db_xref="taxon:39947"
               /clone="ABF--06-C03"
               /tissue_type="leaf"
               /dev_stage="14 days after germination"
               /lab_host="E.coli DH10B"
               /clone_lib="ABF3-overexpressing transgenic rice plasmid
               cDNA library (ABF)"

REFERENCE
AUTHORS      Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
               Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
               Large-scale Sequencing Analysis of Rice ESTs
               Unpublished (2003)
               Contact: Nahm B.H.
               Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
               of Bioscience and Bioinformatics, Myongji University
               Yongin, Kyeonggi, Korea
               Tel: 82 31 330 6193
               Fax: 82 31 321 6355
               Email: bhnaahm@bio.com, bhnaahm@bio.myongji.ac.kr.
               Location/Qualifiers
               1..16
               /organism="Oryza sativa (japonica cultivar-group)"
               /mol_type="mRNA"
               /cultivar="Nackdong"
               /db_xref="taxon:39947"
               /clone="ABF--06-C03"
               /tissue_type="leaf"
               /dev_stage="14 days after germination"
               /lab_host="E.coli DH10B"
               /clone_lib="ABF3-overexpressing transgenic rice plasmid
               cDNA library (ABF)"

```

```

Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnaahm@bio.com, bhnaahm@bio.myongji.ac.kr.
Location/Qualifiers
1..16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="14ETL--05-J09"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice etiolated leaf plasmid cDNA library
(14ETL)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."
Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2571  TTCTTCTTTTTTTTTT 2586
Db      1  TTTTCTTTTTTTTTTT 16

RESULT 135
CF311057
LOCUS      16 bp mRNA linear EST 15-AUG-2003
DEFINITION      ABF--06-C03.g1 ABF3-overexpressing transgenic rice plasmid cDNA
               library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
               ABF--06-C03, mRNA sequence.
ACCESSION      CF311057
VERSION      CF311057.1  GI:33682818
KEYWORDS      EST.
SOURCE      Oryza sativa (japonica cultivar-group)
ORGANISM      Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
               Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
               Ehrhartoideae; Oryzaceae; Oryza.
               1 (bases 1 to 16)
               Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
               Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
               Large-scale Sequencing Analysis of Rice ESTs
               Unpublished (2003)
               Contact: Nahm B.H.
               Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
               of Bioscience and Bioinformatics, Myongji University
               Yongin, Kyeonggi, Korea
               Tel: 82 31 330 6193
               Fax: 82 31 321 6355
               Email: bhnaahm@bio.com, bhnaahm@bio.myongji.ac.kr.
               Location/Qualifiers
               1..16
               /organism="Oryza sativa (japonica cultivar-group)"
               /mol_type="mRNA"
               /cultivar="Nackdong"
               /db_xref="taxon:39947"
               /clone="ABF--06-C03"
               /tissue_type="leaf"
               /dev_stage="14 days after germination"
               /lab_host="E.coli DH10B"
               /clone_lib="ABF3-overexpressing transgenic rice plasmid
               cDNA library (ABF)"

```



```

Email: bhnamhggbio.com, bhnamhggbio.myongji.ac.kr.
Location/Qualifiers
1. .16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--04-N10"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OshDAC1-overexpressing transgenic rice plasmid
cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
treated with ABA(20um) for 1hr. Oligo-capped mRNA was
reverse transcribed and then used for PCR. mRNA was
derived from rice Histone Deacetylase overexpression
line."

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTTTT 2586
DB 1 TTTT 16

RESULT 139
CF316056
LOCUS
DEFINITION
HD--05-D07.b1 OshDAC1-overexpressing transgenic rice plasmid cDNA
library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
HD--05-D07, mRNA sequence.
CF316056
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 16)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnamhggbio.com, bhnamhggbio.myongji.ac.kr.
Location/Qualifiers
1. .16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--07-105"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/clone_lib="OshDAC1-overexpressing transgenic rice plasmid
cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
treated with ABA(20um) for 1hr. Oligo-capped mRNA was
reverse transcribed and then used for PCR. mRNA was
derived from rice Histone Deacetylase overexpression
line."

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTTTT 2586
DB 1 TTTT 16

RESULT 140
CF317718
LOCUS
DEFINITION
HD--07-105.g1 OshDAC1-overexpressing transgenic rice plasmid cDNA
library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
HD--07-105, mRNA sequence.
CF317718
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 16)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnamhggbio.com, bhnamhggbio.myongji.ac.kr.
Location/Qualifiers
1. .16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--07-105"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/clone_lib="OshDAC1-overexpressing transgenic rice plasmid
cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
treated with ABA(20um) for 1hr. Oligo-capped mRNA was
reverse transcribed and then used for PCR. mRNA was
derived from rice Histone Deacetylase overexpression
line."

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTTTT 2586
DB 1 TTTT 16

RESULT 141
CF318894
LOCUS
DEFINITION
HD--09-D06.g1 OshDAC1-overexpressing transgenic rice plasmid cDNA
library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
HD--09-D06, mRNA sequence.
CF318894
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

```

```

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 16)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--09-D06"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OshDAC1-overexpressing transgenic rice plasmid
cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
treated with ABA(20um) for 1hr. Oligo-capped mRNA was
reverse transcribed and then used for PCR. mRNA was
derived from rice Histone Deacetylase overexpression
line."

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2574 TTCTCTTTTTCG 2589
|||
1 TTTTTCCTTTTTCG 16

Db

RESULT 142
CF320356
LOCUS
DEFINITION
16 bp mRNA linear EST 15-AUG-2003
HD--11-D14.b1 OshDAC1-overexpressing transgenic rice plasmid cDNA
library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
HD--11-D14, mRNA sequence.
CF320356
VERSION
KEYWORDS
SOURCE
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 16)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"

REFERENCE
AUTHORS
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 16)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"

FEATURES
source

```

```

/clone="HD--11-D14"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OshDAC1-overexpressing transgenic rice plasmid
cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
treated with ABA(20um) for 1hr. Oligo-capped mRNA was
reverse transcribed and then used for PCR. mRNA was
derived from rice Histone Deacetylase overexpression
line."

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTTCG 2586
|||
1 TTTTTCCTTTTTCG 16

Db

RESULT 143
CF327722
LOCUS
DEFINITION
16 bp mRNA linear EST 18-AUG-2003
NACL--02-F06.b1 Rice callus plasmid cDNA library (NACL) Oryza
sativa (japonica cultivar-group) cDNA clone NACL--02-F06, mRNA
sequence.
CF327722
VERSION
KEYWORDS
SOURCE
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 16)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--02-F06"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTTCG 2586
|||
1 TTTTTCCTTTTTCG 16

Db

RESULT 144
CF327923

```



```

LOCUS       CF327923                16 bp    mRNA    linear    EST 18-AUG-2003
DEFINITION  NACL--02-J18.g1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--02-J18, mRNA
            sequence.
ACCESSION   CF327923
VERSION     CF327923.1    GI:33804096
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
            Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE       Large-scale Sequencing Analysis of Rice ESTs
JOURNAL     Unpublished (2003)
COMMENT     Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, Myongji University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES             Location/Qualifiers
     source           1..16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--03-A10"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2574 TTCTTTTCTTTTCTG 2589
      ||| ||||| |||
Db 1 TTTTCTTTTCTTTTCTG 16

RESULT 146
CF328223     CF328223/c
LOCUS        CF328223                16 bp    mRNA    linear    EST 18-AUG-2003
DEFINITION  JMT--02-E05.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--02-E05, mRNA sequence.
ACCESSION   CF328223
VERSION     CF328223.1    GI:33815044
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
            Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE       Large-scale Sequencing Analysis of Rice ESTs
JOURNAL     Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, Myongji University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES             Location/Qualifiers
     source           1..16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--02-E05"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site 1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     prepared from Arabidopsis Jasmonate Carboxyl
                     methyltransferase overexpression line."

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 38;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTCTTTT 2586
      ||| ||||| |||

```


orientation:
 SP6-Sali-CCACGCGTCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
 Sequencing granted in the context of the GABI-Beet
 project, local PI: Dr. Katharina Schneider, coordinator:
 Prof. Christian Jung; Sequence submission managed by
 RZPD/GABI-Primary database: <http://gabi.rzpd.de>

Query Match 0.3%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 63;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
 Db 1 TTTT

RESULT 152
 BQ591588
 LOCUS
 DEFINITION BQ591588 17 bp mRNA linear EST 06-DEC-2002
 E012616-024-017-C15-SP6 MP1Z-ADIS-024-storage root Beta vulgaris
 CDNA clone 024-017-C15 5-PRIME, mRNA sequence.

ACCESSION BQ591588.1 GI:26121171
 VERSION
 KEYWORDS
 SOURCE

ORGANISM Beta vulgaris
 Beta vulgaris
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Caryophyllales; Amaranthaceae; Beta.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Herwig, R., Schulz, B., Weishaar, B., Hennig, S., Steinfath, M.,
 Drungowski, M., Stahl, D., Wruck, W., Menze, A., O'Brien, J., Lehrach, H.
 and Radelof, U.

TITLE Construction of a 'unigenes' cDNA clone set by oligonucleotide
 fingerprinting allows access to 25 000 potential sugar beet genes

JOURNAL Plant J. 32 (5), 845-857 (2002)
 MEDLINE 22362189
 PUBMED 12472698

COMMENT Contact: Weishaar B
 ADIS DNA core facility at MP1Z
 Max-Planck-Institute for Plant Breeding Research
 Carl-von-Linne Weg 10, 50829 Koeln, Germany
 Fax: 00492215062851
 Email: weishaar@mpiz-koeln.mpg.de
 Insert Length: 17 Std Error: 0.00
 Plate: 17 row: C column: 15
 Seq primer: SP6; CATACGATTGATGACACTATAG.

FEATURES
 source
 1..17
 /organism="Beta vulgaris"
 /mol_type="mRNA"
 /cultivar="KWS2320 (double haploid, monogerm breeding line)"
 /db_xref="GABI:188532"
 /db_xref="taxon:161934"
 /clone="024-017-C15"
 /tissue_type="storage root"
 /lab_host="EMDR10B"
 /clone_lib="MP1Z-ADIS-024-storage root"
 /note="Vector: pCMVSPORT6; Site 1: Sali; Site 2: NotI;
 cDNA library from sugar beet, library provided by KWS
 Kleinzanleber Saatzzucht AG Einbeck, Germany, contact:
 b.schulz@kws.de; cloning sites Sali-NotI, primer sites and
 orientation:
 SP6-Sali-CCACGCGTCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
 Sequencing granted in the context of the GABI-Beet
 project, local PI: Dr. Katharina Schneider, coordinator:
 Prof. Christian Jung; Sequence submission managed by
 RZPD/GABI-Primary database: <http://gabi.rzpd.de>

Query Match 0.3%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 63;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
 Db 1 TTTT

RESULT 153

CF290854 17 bp mRNA linear EST 14-AUG-2003
 LOCUS 14ROOT--01-A21.b1 Rice root plasmid cDNA library (14ROOT) Oryza
 DEFINITION sativa (japonica cultivar-group) cDNA clone 14ROOT--01-A21, mRNA
 sequence.

ACCESSION CF290854
 VERSION
 KEYWORDS
 SOURCE

ORGANISM Oryza sativa (japonica cultivar-group)
 Oryza sativa (japonica cultivar-group)
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzeae; Oryza.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
 Song, S.I., Kim, J.K., Kim, I.-K. and Nahm, B.H.

TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)

COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 320 6193
 Fax: 82 31 321 6355
 Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.

FEATURES
 source
 1..17
 /organism="Oryza sativa (japonica cultivar-group)"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:39947"
 /clone="14ROOT--01-A21"
 /tissue_type="root"
 /dev_stage="14 days after germination"
 /lab_host="E.coli DH10B"
 /clone_lib="Rice root plasmid cDNA library (14ROOT)"
 /note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
 with oligoribonucleotides and then used as templates for
 RT-PCR."

Query Match 0.3%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 63;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
 Db 1 TTTT

RESULT 154

CF294668 17 bp mRNA linear EST 14-AUG-2003
 LOCUS 30DGS--04-E17.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
 DEFINITION sativa (japonica cultivar-group) cDNA clone 30DGS--04-E17, mRNA
 sequence.

ACCESSION CF294668
 VERSION
 KEYWORDS
 SOURCE

ORGANISM Oryza sativa (japonica cultivar-group)
 Oryza sativa (japonica cultivar-group)
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzeae; Oryza.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
 Song, S.I., Kim, J.K., Kim, I.-K. and Nahm, B.H.

REFERENCE
AUTHORS Ehrhartoidae; Oryzae; Oryza.
1 (bases 1 to 17)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
COMMENT Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 321 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source

```
1. .17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--01-K24"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."
```

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 63;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2574 TTCTTTCTTTTCTG 2589
||| |||||
Db 1 TTTTCTTTTCTG 16

RESULT 158
CF298589
LOCUS 17 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--02-A18.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
sativa (japonica cultivar-group) cDNA clone 7LEAF--02-A18, mRNA
sequence.

ACCESSION CF298589
VERSION CF298589.1 GI:33670350
KEYWORDS EST.

SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoidae; Oryzae; Oryza.

REFERENCE 1 (bases 1 to 17)
AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 321 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source

```
1. .17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--02-A18"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
```

/clone lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 63;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTCTTTT 2586
||| |||||
Db 1 TTTTCTTTTCTTTT 16

RESULT 159
CF299639

LOCUS 17 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--03-L20.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
sativa (japonica cultivar-group) cDNA clone 7LEAF--03-L20, mRNA
sequence.

ACCESSION CF299639
VERSION CF299639.1 GI:33671400
KEYWORDS EST.

SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoidae; Oryzae; Oryza.

REFERENCE 1 (bases 1 to 17)
AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 321 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source

```
1. .17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--03-L20"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."
```

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 63;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTCTTTT 2586
||| |||||
Db 1 TTTTCTTTTCTTTT 16

RESULT 160
CF310219

LOCUS 17 bp mRNA linear EST 15-AUG-2003
DEFINITION ABF--04-M02.g1 ABF3-overexpressing transgenic rice plasmid cDNA
library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
ABF--04-M02, mRNA sequence.

ACCESSION CF310219
VERSION CF310219.1 GI:33681980
KEYWORDS EST.

Search completed: November 2, 2004, 09:39:47
Job time : 7 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 2, 2004, 09:49:50 : Search time 21 Seconds

(without alignments)
3.684 Million cell updates/sec

Title: US-10-003-354-3

Perfect score: 3713

Sequence: 1 attaacaggccgtggttagg.....aaactttaagtattatta 3713

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 580 seqs, 10417 residues

Total number of hits satisfying chosen parameters: 1160

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 583 summaries

Database : fetch3rge.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20.4	0.5	22	1	AX921363
2	20.4	0.5	22	1	AX921365
3	19.4	0.5	24	1	AX377075
4	18.2	0.5	23	1	CQ788046
5	17.4	0.5	22	1	AX921540
6	17.4	0.5	22	1	AX922714
7	17.2	0.5	22	1	I49874
8	17.2	0.5	22	1	AX686399
9	16.8	0.5	20	1	AR016163
10	16.8	0.5	20	1	AR016175
11	16.8	0.5	20	1	AR019161
12	16.8	0.5	20	1	AR019173
13	16.8	0.5	20	1	AR099479
14	16.8	0.5	20	1	AR178760
15	16.8	0.5	20	1	E08847
16	16.8	0.5	20	1	AX055666
17	16.4	0.4	18	1	AR092040
18	16.4	0.4	18	1	AR112175
19	16.4	0.4	18	1	AR149217
20	16.4	0.4	19	1	AR082444
21	16.4	0.4	19	1	AR139000
22	16.4	0.4	20	1	AX394643
23	16.4	0.4	21	1	AB087734
24	16.2	0.4	21	1	AR054040
25	16.2	0.4	21	1	AX225073
26	16.2	0.4	21	1	AR077048
27	16.2	0.4	21	1	AX201409
28	16.2	0.4	21	1	AX211599
29	16.2	0.4	21	1	AX825119
30	16.2	0.4	21	1	AX825148
31	16.2	0.4	21	1	AX825162
32	16.2	0.4	21	1	AX825165
33	16	0.4	21	1	AX095505
C					ACCESSION:AX095505
					ACCESSION:AX921363
					ACCESSION:AX921365
					ACCESSION:AX377075
					ACCESSION:CQ788046
					ACCESSION:AX921540
					ACCESSION:AX922714
					ACCESSION:I49874
					ACCESSION:AX686399
					ACCESSION:AR016163
					ACCESSION:AR016175
					ACCESSION:AR019161
					ACCESSION:AR019173
					ACCESSION:AR099479
					ACCESSION:AR178760
					ACCESSION:E08847
					ACCESSION:AX055666
					ACCESSION:AR092040
					ACCESSION:AR112175
					ACCESSION:AR149217
					ACCESSION:AR082444
					ACCESSION:AR139000
					ACCESSION:AX394643
					ACCESSION:AB087734
					ACCESSION:AR054040
					ACCESSION:AR225073
					ACCESSION:AR077048
					ACCESSION:AX201409
					ACCESSION:AX211599
					ACCESSION:AX825119
					ACCESSION:AX825148
					ACCESSION:AX825162
					ACCESSION:AX825165
					ACCESSION:AX095505
					ACCESSION:AX132145
					ACCESSION:AR129621
					ACCESSION:AR130764
					ACCESSION:AR150284
					ACCESSION:AR163864
					ACCESSION:BD228157
					ACCESSION:CQ784182
					ACCESSION:E15988
					ACCESSION:E15990
					ACCESSION:AR314719
					ACCESSION:AR373074
					ACCESSION:AX495922
					ACCESSION:BD128106
					ACCESSION:AR029929
					ACCESSION:AR481860
					ACCESSION:AR481870
					ACCESSION:AX657389
					ACCESSION:BD105846
					ACCESSION:BD105856
					ACCESSION:BD259457
					ACCESSION:AX217117
					ACCESSION:AX218301
					ACCESSION:AX531757
					ACCESSION:AX531758
					ACCESSION:AX726240
					ACCESSION:AX757732
					ACCESSION:AR294845
					ACCESSION:BD230637
					ACCESSION:I31463
					ACCESSION:AX039816
					ACCESSION:AR1336
					ACCESSION:AR126728
					ACCESSION:AR136424
					ACCESSION:AR163897
					ACCESSION:AR168583
					ACCESSION:CQ785680
					ACCESSION:CQ802004
					ACCESSION:AR224579
					ACCESSION:AR271155
					ACCESSION:AR294505
					ACCESSION:AR342848
					ACCESSION:AX557158
					ACCESSION:AR011654
					ACCESSION:AR064875
					ACCESSION:AR080000
					ACCESSION:AR085926
					ACCESSION:AR086392
					ACCESSION:AR087520
					ACCESSION:AR093312
					ACCESSION:AR118970
					ACCESSION:AR121692
					ACCESSION:AR122379
					ACCESSION:AR123335
					ACCESSION:AR136425
					ACCESSION:AR141070
					ACCESSION:AR144242
					ACCESSION:AR154115
					ACCESSION:AR164658
					ACCESSION:AR172953
					ACCESSION:BD218101
					ACCESSION:BD225114
					ACCESSION:CQ798982
					ACCESSION:E13676
					ACCESSION:E22412
					ACCESSION:I19766
					ACCESSION:I36180
					ACCESSION:AR209924
					ACCESSION:AR213738
					ACCESSION:AR222466
					ACCESSION:AR236083
					ACCESSION:AR266134
					ACCESSION:AR274394


```
c 545 13.4 0.4 17 1 AX692621
c 546 13.4 0.4 17 1 AX692622
c 547 13.4 0.4 17 1 AX704873
c 548 13.4 0.4 17 1 AX704874
c 549 13.4 0.4 17 1 AX704875
c 550 13.4 0.4 17 1 AX722359
c 551 13.4 0.4 17 1 AX722987
c 552 13.4 0.4 17 1 AX725263
c 553 13.4 0.4 17 1 AX725688
c 554 13.4 0.4 17 1 AX727549
c 555 13.4 0.4 17 1 AX727552
c 556 13.4 0.4 17 1 AX729279
c 557 13.4 0.4 17 1 AX730015
c 558 13.4 0.4 17 1 AX730406
c 559 13.4 0.4 17 1 AX730974
c 560 13.4 0.4 17 1 AX732253
c 561 13.4 0.4 17 1 AX732936
c 562 13.4 0.4 17 1 AX733356
c 563 13.4 0.4 17 1 AX733384
c 564 13.4 0.4 17 1 AX734479
c 565 13.4 0.4 17 1 AX734751
c 566 13.4 0.4 17 1 AX734993
c 567 13.4 0.4 17 1 AX736330
c 568 13.4 0.4 17 1 AX736447
c 569 13.4 0.4 17 1 AX737433
c 570 13.4 0.4 17 1 AX738493
c 571 13.4 0.4 17 1 AX739445
c 572 13.4 0.4 17 1 AX754437
c 573 13.4 0.4 17 1 AX757592
c 574 13.4 0.4 17 1 AX757892
c 575 13.4 0.4 17 1 AX757931
c 576 13.4 0.4 17 1 AX758169
c 577 13.4 0.4 17 1 AX758323
c 578 13.4 0.4 17 1 AX759441
c 579 13.4 0.4 17 1 AX781825
c 580 13.4 0.4 17 1 AX781826
c 581 13.4 0.4 17 1 AX781827
c 582 13.4 0.4 17 1 BD067501
c 583 12.8 0.3 17 1 AX218302
```

ACCESSION:AX692621
ACCESSION:AX692622
ACCESSION:AX704873
ACCESSION:AX704874
ACCESSION:AX704875
ACCESSION:AX722359
ACCESSION:AX722987
ACCESSION:AX725263
ACCESSION:AX725688
ACCESSION:AX727549
ACCESSION:AX727552
ACCESSION:AX729279
ACCESSION:AX730015
ACCESSION:AX730406
ACCESSION:AX730974
ACCESSION:AX732253
ACCESSION:AX732936
ACCESSION:AX733356
ACCESSION:AX733384
ACCESSION:AX734479
ACCESSION:AX734751
ACCESSION:AX734993
ACCESSION:AX736330
ACCESSION:AX736447
ACCESSION:AX737433
ACCESSION:AX738493
ACCESSION:AX739445
ACCESSION:AX754437
ACCESSION:AX757592
ACCESSION:AX757892
ACCESSION:AX757931
ACCESSION:AX758169
ACCESSION:AX758323
ACCESSION:AX759441
ACCESSION:AX781825
ACCESSION:AX781826
ACCESSION:AX781827
ACCESSION:BD067501
ACCESSION:AX218302

RESULT 1
AX921363
LOCUS AX921363
DEFINITION Sequence 356 from Patent WO02068652.
ACCESSION AX921363
VERSION AX921363.1 GI:40214984
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Nov-x proteins and nucleic acids encoding same
TITLE Patent: WO 02068652-A 356 06-SEP-2002;
JOURNAL Location/Qualifiers
FEATURES
source
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: oligonucleotide primer"

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1743 AAAAGTTTCGGTCATC 1764
Db 1 AAAAGTTTCGGTCATC 22

ALIGNMENTS

RESULT 1
AX921363
LOCUS AX921363
DEFINITION Sequence 356 from Patent WO02068652.
ACCESSION AX921363
VERSION AX921363.1 GI:40214984
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Nov-x proteins and nucleic acids encoding same
TITLE Patent: WO 02068652-A 356 06-SEP-2002;
JOURNAL Location/Qualifiers
FEATURES
source
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: oligonucleotide primer"

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1743 AAAAGTTTCGGTCATC 1764
Db 1 AAAAGTTTCGGTCATC 22

RESULT 2
AX921365/c
LOCUS AX921365
DEFINITION Sequence 358 from Patent WO02068652.
ACCESSION AX921365
VERSION AX921365.1 GI:40214986
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Nov-x proteins and nucleic acids encoding same
TITLE Patent: WO 02068652-A 358 06-SEP-2002;
JOURNAL Location/Qualifiers
FEATURES
source
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: oligonucleotide primer"

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1801 CATTACTTACGCGTCGTC 1822
Db 22 CATTACTTACGCGTCGTC 1

RESULT 3
AX377075
LOCUS AX377075
DEFINITION Sequence 33 from Patent WO0212557.
ACCESSION AX377075
VERSION AX377075.1 GI:19573369
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Cailloux, F. and Gobron, S.
TITLE Method for detecting known mutations in tube
JOURNAL Patent: WO 0212557-A 33 14-FEB-2002;
Nucleica (FR)
FEATURES
Location/Qualifiers
source
1..24
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Amorce pour la detection de mutations responsables de la mucoviscidose."

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2566 CTTTCTTCTCTCTTTT 2586
Db 1 CTTTCTTCTCTCTTTT 21

RESULT 4
CQ788046
LOCUS CQ788046
DEFINITION Sequence 352 from Patent WO2004020664.
ACCESSION CQ788046
VERSION CQ788046.1 GI:45722998
KEYWORDS

Qy 1743 AAAAGTTTCGGTCATC 1764
Db 1 AAAAGTTTCGGTCATC 22

```

SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE       Geldermann,H., Preuss,S. and Han,Y.
JOURNAL     Polymorphous microsatellite loci in genes for pre-diagnostic
FEATURES    purposes
SOURCE      Patent: WO 2004020664-A 352 11-MAR-2004;
            Universitaet Hohenheim (DE)
            Location/Qualifiers
              1..23
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
            satellite
              repeat_unit
                1..4
                  /note="M11, Allel A (PrP-Gen)"
              repeat_unit
                8..11
                  /note="Anzahl der Wiederholungen: 7"
              repeat_unit
                16..19
                  /note="Anzahl der Wiederholungen: 2"
              repeat_unit
                /note="Anzahl der Wiederholungen: 1"

Query Match      0.5%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 47;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2566 CTTTCTCTCTCTTTTCTTTCT 2588
Db 1 CTTTCTCTCTTTCTTTCTTTT 23

RESULT 5
AX921540
LOCUS       AX921540                22 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 533 from Patent WO02068652.
ACCESSION  AX921540
VERSION     AX921540.1 GI:40215161
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE   1
AUTHORS     Nov-x proteins and nucleic acids encoding same
TITLE       Patent: WO 02068652-A 533 06-SEP-2002;
JOURNAL     Location/Qualifiers
FEATURES    source
              1..22
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Description of Artificial Sequence: oligonucleotide primer"

Query Match      0.5%; Score 17.4; DB 1; Length 22;
Best Local Similarity 94.7%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 140 GGGGAAAGTATCCCTGTG 158
Db 1 GGGGAAAGTATCCTCTGTG 19

RESULT 6
AX922714
LOCUS       AX922714                22 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1054 from Patent WO02068649.
ACCESSION  AX922714
VERSION     AX922714.1 GI:40215673
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           ORGANISM
REFERENCE   1
AUTHORS     Shinkets,R.A., Patturajan,M., Vernet,C.A., Casman,S.J.,
            Malyankar,U., Shenoy,S., Spytek,K.A., Gangolli,E., Miller,C.,
            Boldog,F., Li,L., Taupier,R.J., Kekuda,R., Smithson,G.,
            Zerkusen,B.D., Liu,X., Colman,S.D., Tchernev,V., Si,J., Edinger,S.,
            Stone,D., Sclore,P., Millet,I. and Rothenberg,M.
            Human nucleic acids and polypeptides and methods of use thereof
            Patent: WO 02059315-A 208 01-AUG-2002;
            Curagen Corporation (US)
            Location/Qualifiers
              1..22
                /organism="synthetic construct"

```

```

artificial sequences.
REFERENCE   1
AUTHORS     Patent: WO 02068649-A 1054 06-SEP-2002;
            Curagen Corporation (US)
FEATURES    Location/Qualifiers
            source
              1..22
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Description of Artificial Sequence: Ag3010 Forward"

Query Match      0.5%; Score 17.4; DB 1; Length 22;
Best Local Similarity 94.7%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 140 GGGGAAAGTATCCCTGTG 158
Db 1 GGGGAAAGTATCCTCTGTG 19

RESULT 7
I49874/c
LOCUS       I49874                22 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 65 from patent US 5641663.
ACCESSION  I49874
VERSION     I49874.1 GI:2472094
KEYWORDS   .
SOURCE     Unknown.
           Unknown.
           ORGANISM
REFERENCE   1 (bases 1 to 22)
AUTHORS     Garvin,R.T. and Malek,L.T.
TITLE       Expression system for the secretion of bioactive human granulocyte
            macrophage colony stimulating factor (GM-CSF) and other
            heterologous proteins from steptomyces
            Patent: US 5641663-A 65 24-JUN-1997;
            Location/Qualifiers
              1..22
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.5%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 69;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 408 CGGCCTCTCCGGCGCCGTCGTC 429
Db 22 CGGCCTCTCCGGCGCCGTCGTC 1

RESULT 8
AX86399/c
LOCUS       AX86399                22 bp DNA linear PAT 29-MAR-2003
DEFINITION Sequence 208 from Patent WO02059315.
ACCESSION  AX86399
VERSION     AX86399.1 GI:29372138
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE   1
AUTHORS     Shinkets,R.A., Patturajan,M., Vernet,C.A., Casman,S.J.,
            Malyankar,U., Shenoy,S., Spytek,K.A., Gangolli,E., Miller,C.,
            Boldog,F., Li,L., Taupier,R.J., Kekuda,R., Smithson,G.,
            Zerkusen,B.D., Liu,X., Colman,S.D., Tchernev,V., Si,J., Edinger,S.,
            Stone,D., Sclore,P., Millet,I. and Rothenberg,M.
            Human nucleic acids and polypeptides and methods of use thereof
            Patent: WO 02059315-A 208 01-AUG-2002;
            Curagen Corporation (US)
            Location/Qualifiers
              1..22
                /organism="synthetic construct"

```

```
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR Primer sequence"

Query Match      0.5%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 69;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 490 TGGAAATCAAGAGACCCATGGCA 511
      |||||
Db 22 TGGAAATCAAGAGACTCAGGGTA 1

RESULT 9
AR016163/c
LOCUS AR016163 20 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 51 from patent US 5776682.
ACCESSION AR016163
VERSION AR016163.1 GI:3972440
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS First,M.Kent., Agoulnik,A.I. and Muallem,A.
TITLE Male infertility Y-deletion detection battery
JOURNAL Patent: US 5776682-A 51 07-JUL-1998;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGTTCCAGCGCTTCATGTG 1698
      |||||
Db 20 CAGTTCCAGTGTTCATGTG 1

RESULT 10
AR016175/c
LOCUS AR016175 20 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 63 from patent US 5776682.
ACCESSION AR016175
VERSION AR016175.1 GI:3972452
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS First,M.Kent., Agoulnik,A.I. and Muallem,A.
TITLE Male infertility Y-deletion detection battery
JOURNAL Patent: US 5776682-A 63 07-JUL-1998;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGTTCCAGCGCTTCATGTG 1698
      |||||
Db 20 CAGTTCCAGTGTTCATGTG 1

RESULT 11
AR019161/c
LOCUS AR019161 20 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 51 from patent US 5783390.

/mol_type="unassigned DNA"

Query Match      0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGTTCCAGCGCTTCATGTG 1698
      |||||
Db 20 CAGTTCCAGTGTTCATGTG 1

RESULT 12
AR019173/c
LOCUS AR019173 20 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 63 from patent US 5783390.
ACCESSION AR019173
VERSION AR019173.1 GI:3974287
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS First,M.Kent. and Agoulnik,A.I.
TITLE Male infertility Y-deletion detection battery
JOURNAL Patent: US 5783390-A 63 21-JUL-1998;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGTTCCAGCGCTTCATGTG 1698
      |||||
Db 20 CAGTTCCAGTGTTCATGTG 1

RESULT 13
AR099479/c
LOCUS AR099479 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 6 from patent US 6077833.
ACCESSION AR099479
VERSION AR099479.1 GI:12809245
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Vickers,T.A.
TITLE Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
JOURNAL Patent: US 6077833-A 6 20-JUN-2000;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.5%; Score 16.8; DB 1; Length 20;
```

Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3669 AAGTGATATATGGTTTAAAT 3688
|||||
Db 20 AAGTGATACATGTTTAAAT 1

RESULT 14
AR178760/c
LOCUS AR178760 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 6 from patent US 6319906.
ACCESSION AR178760
VERSION AR178760.1 GI:20219898
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett, C. Frank. and Vickers, T. A.
TITLE Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
JOURNAL Patent: US 6319906-A 6 20-NOV-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3669 AAGTGATATATGGTTTAAAT 3688
|||||
Db 20 AAGTGATACATGTTTAAAT 1

RESULT 15
E08847
LOCUS E08847 20 bp DNA linear PAT 29-SEP-1997
DEFINITION PCR primer to detect polymorphism of Histamine H1 receptor gene.
ACCESSION E08847
VERSION E08847.1 GI:2176951
KEYWORDS JP 1995067654-A/5.
SOURCE unidentified
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Shimizu, S., Shimazu, M., Habano, W. and Hayashi, T.
TITLE HUMAN HISTAMINE H1 RECEPTOR GENE AND ITS UTILIZATION
JOURNAL Patent: JP 1995067654-A 5 14-MAR-1995;
COMMENT MITSUBISHI KAGAKU B C L:KK
OS None
OC Artificial sequences.
PN JP 1995067654-A/5
PD 14-MAR-1995
PF 03-SEP-1993 JP 1993219544
PI SHIMIZU SHOICHI, SHIMAZU MITSUNOBU, HABANO WATARU, PI
HAYASHI TOMOKO
PC C12N15/09, C12Q1/68;
CC strandedness: Single;
CC topology: Linear;
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

FEATURES source
1..20
/organism="Artificial sequences".

Query Match 0.5%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1687 GCGCTTCATGTGCAACACAG 1706
|||||
Db 1 GCGGTTTCATGTGCAACCCAG 20

RESULT 16
AX055666
LOCUS AX055666 20 bp DNA linear PAT 13-JAN-2001
DEFINITION Sequence 24 from Patent WO0073499.
ACCESSION AX055666
VERSION AX055666.1 GI:12228806
KEYWORDS Emericella nidulans (anamorph: Aspergillus nidulans)
SOURCE Emericella nidulans
ORGANISM Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; Emericella.
REFERENCE 1
AUTHORS Smith, T., Maher, M., Martin, C., Jannes, G., Rossau, R. and van der Weide, M.
TITLE Nucleic acid probes and methods for detecting clinically important fungal pathogens
JOURNAL Patent: WO 0073499-A 24 07-DEC-2000;
INNOGENETICS N.V. (BE) ; Enterprise Ireland (trading as Bioresearch Ireland) (IE)
FEATURES Location/Qualifiers
source 1..20
/organism="Emericella nidulans"
/mol_type="unassigned DNA"
/db_xref="taxon:162425"

Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 655 GAGCCTGAGTACCACCAACCAG 674
|||||
Db 1 GAGCCTGAATACCAATCAG 20

RESULT 17
AR092040
LOCUS AR092040 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 64 from patent US 5998141.
ACCESSION AR092040
VERSION AR092040.1 GI:10018794
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Acton, S. Laurene.
TITLE Intronic and polymorphic SR-BI nucleic acids and uses therefor
JOURNAL Patent: US 5998141-A 64 07-DEC-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
|||||
Db 1 TTGAGGCTGAAGGAATGA 18

RESULT 18
AR112175
LOCUS AR112175 18 bp DNA linear PAT 16-MAY-2001


```
DEFINITION Sequence 64 from patent US 6130041.
ACCESSION AR112175
VERSION AR112175.1 GI:14092075
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 18;
    Best Local Similarity 94.4%; Pred. No. 67;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2774 TTAAGGCTGAAGGAATGA 2791
    Db 1 TTGAGGCTGAAGGAATGA 18

RESULT 19
LOCUS AR149217 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 64 from patent US 6228581.
ACCESSION AR149217
VERSION AR149217.1 GI:15113808
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 18;
    Best Local Similarity 94.4%; Pred. No. 67;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2774 TTAAGGCTGAAGGAATGA 2791
    Db 1 TTGAGGCTGAAGGAATGA 18

RESULT 20
LOCUS AR082444 19 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 3 from patent US 5972901.
ACCESSION AR082444
VERSION AR082444.1 GI:10009170
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 18;
    Best Local Similarity 94.4%; Pred. No. 67;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2774 TTAAGGCTGAAGGAATGA 2791
    Db 1 TTGAGGCTGAAGGAATGA 18

DEFINITION Sequence 64 from patent US 6130041.
ACCESSION AR112175
VERSION AR112175.1 GI:14092075
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 19;
    Best Local Similarity 94.4%; Pred. No. 75;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2568 TTCTTCTCTCTTTTCTTTT 2585
    Db 2 TTCTTCTCTCTTTTCTTTT 19

RESULT 21
LOCUS AR139000 19 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 3 from patent US 6200801.
ACCESSION AR139000
VERSION AR139000.1 GI:14481345
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 19;
    Best Local Similarity 94.4%; Pred. No. 75;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2568 TTCTTCTCTCTTTTCTTTT 2585
    Db 2 TTCTTCTCTCTTTTCTTTT 19

RESULT 22
LOCUS AX394643 20 bp DNA linear PAT 18-MAY-2002
DEFINITION Sequence 13 from Patent WO0218639.
ACCESSION AX394643
VERSION AX394643.1 GI:21065756
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 19;
    Best Local Similarity 94.4%; Pred. No. 75;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2568 TTCTTCTCTCTTTTCTTTT 2585
    Db 2 TTCTTCTCTCTTTTCTTTT 19

DEFINITION Sequence 64 from patent US 6228581.
ACCESSION AR149217
VERSION AR149217.1 GI:15113808
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 18;
    Best Local Similarity 94.4%; Pred. No. 67;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2774 TTAAGGCTGAAGGAATGA 2791
    Db 1 TTGAGGCTGAAGGAATGA 18

RESULT 19
LOCUS AR149217 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 64 from patent US 6228581.
ACCESSION AR149217
VERSION AR149217.1 GI:15113808
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 18;
    Best Local Similarity 94.4%; Pred. No. 67;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2774 TTAAGGCTGAAGGAATGA 2791
    Db 1 TTGAGGCTGAAGGAATGA 18

RESULT 20
LOCUS AR082444 19 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 3 from patent US 5972901.
ACCESSION AR082444
VERSION AR082444.1 GI:10009170
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 18;
    Best Local Similarity 94.4%; Pred. No. 67;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2774 TTAAGGCTGAAGGAATGA 2791
    Db 1 TTGAGGCTGAAGGAATGA 18

DEFINITION Sequence 64 from patent US 6130041.
ACCESSION AR112175
VERSION AR112175.1 GI:14092075
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 19;
    Best Local Similarity 94.4%; Pred. No. 75;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2568 TTCTTCTCTCTTTTCTTTT 2585
    Db 2 TTCTTCTCTCTTTTCTTTT 19

RESULT 21
LOCUS AR139000 19 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 3 from patent US 6200801.
ACCESSION AR139000
VERSION AR139000.1 GI:14481345
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 19;
    Best Local Similarity 94.4%; Pred. No. 75;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2568 TTCTTCTCTCTTTTCTTTT 2585
    Db 2 TTCTTCTCTCTTTTCTTTT 19

RESULT 22
LOCUS AX394643 20 bp DNA linear PAT 18-MAY-2002
DEFINITION Sequence 13 from Patent WO0218639.
ACCESSION AX394643
VERSION AX394643.1 GI:21065756
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 19;
    Best Local Similarity 94.4%; Pred. No. 75;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 2568 TTCTTCTCTCTTTTCTTTT 2585
    Db 2 TTCTTCTCTCTTTTCTTTT 19

DEFINITION Homo sapiens gene for beta-globin, intron, partial sequence, CTTT
ACCESSION AB087734
VERSION AB087734
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    Query Match 0.4%; Score 16.4; DB 1; Length 20;
    Best Local Similarity 94.4%; Pred. No. 83;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 1720 TCCCTTGAAGCCTTCTCC 1737
    Db 3 TCCATTGAAGCCTTCTCC 20

RESULT 23
LOCUS AB087734 21 bp DNA linear PRI 08-JAN-2003
DEFINITION Homo sapiens gene for beta-globin, intron, partial sequence, CTTT
```

```

deletion at IVS 2.
ACCESSION AB087734
VERSION AB087734.1 GI:27544745
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
TITLE Phanaagaoakar,S., Colah,R., Mohanty,D. and Kiyama,R.
JOURNAL Three novel polymorphisms found in the Indian Thalassemia patients
AUTHORS Unpublished
REFERENCE
AUTHORS 2 (bases 1 to 21)
Nadkarni,A., Sakaguchi,T., Takaku,H., Gorakshakar,A.,
Phanaagaoakar,S., Colah,R., Mohanty,D. and Kiyama,R.
Submitted (05-JUL-2002) Ryoiti Kiyama, National Institute of
Advanced Industrial Science and Technology, Research Center for
Glycoscience, AIST Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki
305-8566, Japan (E-mail:kiyama.royaist.go.jp, Tel:81-298-61-6189,
Fax:81-298-61-6190)
FEATURES
source
1..21
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="Indian Thalassemia patient"
/db_xref="taxon:9606"
<1..>21
/note="Sequence containing a CTTT deletion at IVS 2
#200-203 from an Indian Thalassemia patient
beta-globin"
intron
Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3468 AATCTTGCTATTTT 3485
Db 3 AATCTTGCTATTTT 20
RESULT 24
AR054040
LOCUS 21 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 18 from patent US 5834310.
ACCESSION AR054040
VERSION AR054040.1 GI:5978902
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS 1 (bases 1 to 21)
Moss,J., Okazaki,I., Zolkiewska,A. and Nightingale,M.S.
TITLE Mammalian muscle NAD: arginine ADP-ribosyltransferase
JOURNAL Patent: US 5834310-A 18 10-NOV-1998;
FEATURES
source
1..21
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 885 GCTCTGAGCTAGTGGTTCC 905
Db 1 GCTCTAGAACTAGTGGATCCC 21
RESULT 25
AR225073/c
LOCUS 21 bp DNA linear PAT 26-SEP-2002

```

```

Sequence 39 from patent US 6441156.
ACCESSION AR225073
VERSION AR225073.1 GI:23334208
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS 1 (bases 1 to 21)
Lerman,M.I., Latif,F., Wei,M.-H., Duh,F.-M., Minna,J.D., Sekido,Y.
and Gao,B.
TITLE Calcium channel compositions and methods of use thereof
JOURNAL Patent: US 6441156-A 39 27-AUG-2002;
FEATURES
source
1..21
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2305 CGGATTTTCAACTGGCCAACC 2325
Db 21 CGTATGTTCAACTGGCCATCC 1
RESULT 26
AX077048/c
LOCUS 21 bp DNA linear PAT 22-FEB-2001
DEFINITION Sequence 36 from Patent WO0105972.
ACCESSION AX077048
VERSION AX077048.1 GI:13121674
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 artificial sequences.
AUTHORS Ashkenazi,A.J., Baker,K.P., Fong,S., Goddard,A., Godowski,P.J.,
Gurney,A.L., Hillan,K.J., Mark,M.R., Marsters,S.A., Pitti,R.M.,
Tumas,D., Watanabe,C.K. and Wood,W.I.
TITLE Compositions and methods for the treatment of immune related
diseases
JOURNAL Patent: WO 0105972-A 36 25-JAN-2001;
Genentech, Inc. (US)
FEATURES
source
1..21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR cloning oligonucleotide"
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 612 CCTTGAAGGTGCGCATCCAGT 632
Db 21 CATGGAAGCGCCATCCAGT 1
RESULT 27
AX201409/c
LOCUS 21 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 88 from Patent WO0153486.
ACCESSION AX201409
VERSION AX201409.1 GI:15391213
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 artificial sequences.
AUTHORS Ashkenazi,A.J., Goddard,A., Godowski,P.J., Gurney,A.L.,
Hillan,K.J., Marsters,S.A., Pan,J., Pitti,R.M., Roy,M.A., Smith,V.,

```

TITLE
JOURNAL
Compositions and methods for the treatment of tumour
Patent: WO 0153486-A 88 28-JUL-2001;
Genentech, Inc. (US)

FEATURES
source
1. .21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic Oligonucleotide Probe."

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 612 CCTGAAAGGTGCCATCCAGT 632
| | | | | | | | | | | | | | | | | | | | |
Db 21 CATGAAAGGCCCATCCAGT 1

RESULT 28
AX2111599/c
LOCUS AX2111599 21 bp DNA linear PAT 06-SEP-2001
DEFINITION Sequence 4 from Patent WO0159100.
ACCESSION AX2111599

VERSION AX2111599.1 GI:15523843
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS Gurney,A.L., Kirchhofer,D.K. and Wood,W.I.
TITLE Inhibitor of hepatocyte growth factor activator for use in
modulation of angiogenesis and cardiovascularization
JOURNAL Patent: WO 0159100-A 4 16-AUG-2001;
Genentech, Inc. (US)

FEATURES
source
1. .21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="reverse PCR primer"

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 612 CCTGAAAGGTGCCATCCAGT 632
| | | | | | | | | | | | | | | | | | | | |
Db 21 CATGAAAGGCCCATCCAGT 1

RESULT 29
AX825119
LOCUS AX825119 21 bp DNA linear PAT 11-DEC-2003
DEFINITION Sequence 17 from Patent WO03072818.
ACCESSION AX825119

VERSION AX825119.1 GI:39750848
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS Boekenkamp,D., Dieck,T.H. and Hoppe,H.U.
TITLE Method for sorting single-stranded nucleic acids
JOURNAL Patent: WO 03072818-A 17 04-SEP-2003;
Degussa Bioactives GmbH (DE)

FEATURES
source
1. .21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen

Sequenz: Capture-Oligonukleotid"

misc_binding 1 /bound_moiety="Biotin"
modified_base 3 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 6 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 9 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 12 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 15 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 18 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2571 TTCTTCTTTTTTTTCTGAA 2591
| | | | | | | | | | | | | | | | | | | | |
Db 1 TTTTCTTTTTTTTTTTTGAA 21

RESULT 30
AX825148
LOCUS AX825148 21 bp DNA linear PAT 11-DEC-2003
DEFINITION Sequence 46 from Patent WO03072818.
ACCESSION AX825148

VERSION AX825148.1 GI:39750877
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS Boekenkamp,D., Dieck,T.H. and Hoppe,H.U.
TITLE Method for sorting single-stranded nucleic acids
JOURNAL Patent: WO 03072818-A 46 04-SEP-2003;
Degussa Bioactives GmbH (DE)

FEATURES
source
1. .21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen
Sequenz: Capture-Oligonukleotid"

misc_binding 1 /bound_moiety="Biotin"
modified_base 3 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 6 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 9 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 12 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 15 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER
modified_base 18 /note="LNA-T (Locked Nucleic Acid)"
/mod_base=OTHER

Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1e+02; 3; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2569 TCTCTCTCTCTCTCTCTCTCTG 2589
 Db 1 TTTTCTCTCTCTCTCTCTCTCTG 21

RESULT 31
 AX825162
 LOCUS AX825162 21 bp DNA linear PAT 11-DEC-2003
 DEFINITION Sequence 60 from Patent WO03072818.
 ACCESSION AX825162
 VERSION AX825162.1 GI:39750891
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM artificial sequences.

REFERENCE 1
 Boekenkamp, D., Dieck, T.H. and Hoppe, H.U.
 Method for sorting single-stranded nucleic acids
 TITLE Patent: WO 03072818-A 60 04-SEP-2003;
 JOURNAL Degussa Bioactives GmbH (DE)
 FEATURES
 source Location/Qualifiers
 1..21
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Beschreibung der kuenstlichen Sequenz: Capture-Oligonukleotid"

misc_binding 1 /bound_moiety="Biotin"
 modified_base 3 /note="LNA-T (Locked Nucleic Acid)"
 modified_base 6 /mod_base=OTHER
 modified_base 9 /note="LNA-T (Locked Nucleic Acid)"
 modified_base 12 /mod_base=OTHER
 modified_base 15 /note="LNA-T (Locked Nucleic Acid)"
 modified_base 18 /mod_base=OTHER
 modified_base 18 /note="LNA-T (Locked Nucleic Acid)"
 /mod_base=OTHER

Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1e+02; 3; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2568 TCTCTCTCTCTCTCTCTCTCTG 2588
 Db 1 TTTTCTCTCTCTCTCTCTCTCTG 21

RESULT 32
 AX825165
 LOCUS AX825165 21 bp DNA linear PAT 11-DEC-2003
 DEFINITION Sequence 63 from Patent WO03072818.
 ACCESSION AX825165
 VERSION AX825165.1 GI:39750894
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM artificial sequences.

REFERENCE 1

AUTHORS Boekenkamp, D., Dieck, T.H. and Hoppe, H.U.
 TITLE Method for sorting single-stranded nucleic acids
 JOURNAL Patent: WO 03072818-A 63 04-SEP-2003;
 Degussa Bioactives GmbH (DE)
 FEATURES
 source Location/Qualifiers
 1..21
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Beschreibung der kuenstlichen Sequenz: Capture-Oligonukleotid"

misc_binding 1 /bound_moiety="Biotin"
 modified_base 3 /note="LNA-T (Locked Nucleic Acid)"
 modified_base 6 /mod_base=OTHER
 modified_base 9 /note="LNA-T (Locked Nucleic Acid)"
 modified_base 12 /mod_base=OTHER
 modified_base 15 /note="LNA-T (Locked Nucleic Acid)"
 modified_base 18 /mod_base=OTHER
 modified_base 18 /note="LNA-T (Locked Nucleic Acid)"
 /mod_base=OTHER

Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1e+02; 3; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTCTCTCTCTCTTC 2587
 Db 1 TTTTCTCTCTCTCTCTCTCTCTTC 21

RESULT 33
 AX095505/c
 LOCUS AX095505 21 bp DNA linear PAT 30-MAR-2001
 DEFINITION Sequence 683 from Patent WO0118250.
 ACCESSION AX095505
 VERSION AX095505.1 GI:13511708
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 Lander, E.S., Gargill, M., Ireland, J.S., Bolck, S., Daley, G.Q. and
 McCarthy, J.J.
 Single nucleotide polymorphisms in genes
 TITLE Patent: WO 0118250-A 683 15-MAR-2001;
 JOURNAL WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
 Pharmaceuticals, Inc. (US)

FEATURES
 source Location/Qualifiers
 1..21
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 16; DB 1; Length 21;
 Best Local Similarity 88.9%; Pred. No. 1.1e+02;
 Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2562 CCAGCTTCTCTCTCTCTT 2579
 Db 21 CCAGCTTCTCTCTCTT 4

```
RESULT 34
AXI32145
LOCUS AXI32145 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 3363 from Patent WO0130362.
ACCESSION AXI32145
VERSION AXI32145.1 GI:14138450
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL
PATENT: WO 0130362-A 3363 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3441 CTGCCATGTTTATTCAG 3459
Db 1 CTGCCATGTTTATTCAG 19

RESULT 35
ARI29621
LOCUS ARI29621 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 25 from patent US 6187545.
ACCESSION ARI29621
VERSION ARI29621.1 GI:14117518
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS McKay, R., Butler, M.M., Wyatt, J. and Cowse, L.M.
TITLE Antisense modulation of peptidocytotoxic expression
JOURNAL Patent: US 6187545-A 25 13-FEB-2001;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 959 GAGGCGGAATTTCTGCAGA 977
Db 2 GAGGCGGAATTTCTGCAGA 20

RESULT 36
ARI30764/c
LOCUS ARI30764 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 15 from patent US 6190869.
ACCESSION ARI30764
VERSION ARI30764.1 GI:14119089
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS
```

```
Bennett, C. Frank, and Cowse, L.M.
TITLE Antisense inhibition of protein kinase C-theta expression
JOURNAL Patent: US 6190869-A 15 20-FEB-2001;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3272 TCCTCCACTCTTGTTCAG 3290
Db 19 TCCTCCACTCTTGTTCAG 1

RESULT 37
ARI50284/c
LOCUS ARI50284 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 360 from patent US 6228642.
ACCESSION ARI50284
VERSION ARI50284.1 GI:15114875
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Baker, B.F., Bennett, C. Frank., Butler, M.M. and Shanahan, W.R. Jr.
TITLE Antisense oligonucleotide modulation of tumor necrosis
factor- (alpha.) (TNF- alpha.) expression
JOURNAL Patent: US 6228642-A 360 08-MAY-2001;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 486 CATCTGGAATCAAGAGACC 504
Db 20 CATCTGGAATCTGGAGACC 2

RESULT 38
ARI63864
LOCUS ARI63864 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 62 from patent US 6271030.
ACCESSION ARI63864
VERSION ARI63864.1 GI:16234659
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Monia, B.P., Butler, M.M. and Wyatt, J.
TITLE Antisense inhibition of C/EBP beta expression
JOURNAL Patent: US 6271030-A 62 07-AUG-2001;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2182 AGCTGCTCTCCATCTTCT 2200
Db 1 AGCTGCTCTCCATCTTCT 19
```

```

RESULT 39
BD228157/c
LOCUS
DEFINITION Antisense oligonucleotide regulation of expression of tumor
necrosis factor-alpha (TNF-alpha).
ACCESSION BD228157
VERSION BD228157.1 GI:33037927
KEYWORDS JP 2002526125-A/360.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Bennett,F.C., Butler,M.M. and Jr,W.J.S.
TITLE Antisense oligonucleotide regulation of expression of tumor
necrosis factor-alpha (TNF-alpha)
JOURNAL Patent: JP 2002526125-A 360 20-AUG-2002;
ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002526125-A/360
PD 20-AUG-2002
PF 05-OCT-1999 JP 2000574737
PR 05-OCT-1998 US 09/166186,18-MAY-1999 US 09/313932 PI
BRENDA F BAKER, FRANK C BENNETT, MADELINE M BUTLER, WILLIAM J PI
SHANAHAN JR
PC C12N15/09,A61K31/7115,A61K31/712,A61K31/7125,A61K48/00,A61P1/
PC 00,A61P1/16,
PC A61P1/18,A61P3/10,A61P17/00,A61P17/04,A61P29/00,A61P31/00, PC
C07H21/02,
PC C07H21/04,C12N15/00
CC Synthetic Location/Qualifiers
FH Key 1..20
FT source /organism='Artificial Sequence'.
FEATURES
source
1..20
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 486 CATCTGGAATCAAGAGACC 504
DB 20 CATCTGGAATCGGAGACC 2

RESULT 40
CQ784182
LOCUS
DEFINITION Sequence 4322 from Patent EP1396543.
ACCESSION CQ784182
VERSION CQ784182.1 GI:45538670
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga, H.
TITLE Primers for synthesizing full length cDNA clones and their use
JOURNAL Patent: EP 1396543-A 4322 10-MAR-2004;
Research Association for Biotechnology (JP)
FEATURES
source
1..20
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/note='Description of Artificial Sequence: an artificially
synthesized primer se q uence'

```

```

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1752 GGTCTGGCTCATCTTCTC 1770
DB 2 GGTCTGGCTCATCTTCTC 20

RESULT 41
E15988/c
LOCUS
DEFINITION Oligonucleotide which modulates expression,production or reception
of hepatocyte growth factor or expression of c-Met.
ACCESSION E15988
VERSION E15988.1 GI:5710671
KEYWORDS JP 1998127286-A/13.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Ishikawa,T., Shigematsu,T. and Yamamoto,A.
TITLE OLIGONUCLEOTIDE FOR SUPPRESSING PRODUCTION OF HGF
JOURNAL Patent: JP 1998127286-A 13 19-MAY-1998;
TERUMO CORP
COMMENT OS None
OC Artificial sequences.
PN JP 1998127286-A/13
PD 19-MAY-1998
PF 01-NOV-1996 JP 1996291499
PI ISHIKAWA TETSUYA, SHIGEMATSU TAKASHI, YAMAMOTO AKIHIRO PC
C12N15/09,A61K31/70,A61K31/70,C07H21/04;
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
FH Key Location/Qualifiers
FT source 1..20
/organism='Artificial sequences'.
FEATURES
source
1..20
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2214 CTTTCTCTCTCTCTCTTC 2232
DB 19 CTTTCTCTCTCTCTTC 1

RESULT 42
E15990
LOCUS
DEFINITION Oligonucleotide which modulates expression,production or reception
of hepatocyte growth factor or expression of c-Met.
ACCESSION E15990
VERSION E15990.1 GI:5710673
KEYWORDS JP 1998127286-A/15.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Ishikawa,T., Shigematsu,T. and Yamamoto,A.
TITLE OLIGONUCLEOTIDE FOR SUPPRESSING PRODUCTION OF HGF
JOURNAL Patent: JP 1998127286-A 15 19-MAY-1998;
TERUMO CORP
COMMENT OS None
OC Artificial sequences.

```

```
PN JP 1998127286-A/15
PD 19-MAY-1998
PF 01-NOV-1998 JP 1996291499
PI ISHIKAWA TETSUYA, SHIGEMATSU TAKASHI, YAMAMOTO AKIHIRO PC
C12N15/09,A61K31/70,A61K31/70,C07H21/04;
CC strandedness: Single;
CC topology: linear;
CC hypothetical: No;
FH key Location/Qualifiers
FT
FT source 1..20
FT /organism='Artificial sequences'.
FT Location/Qualifiers
FT 1..20
FT /organism='unidentified'
FT /mol_type='genomic DNA'
FT /db_xref='taxon:3264'

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 CCTCTCTCCTTCCTTC 2232
Db 2 CCTTTCTCCTTCCTTC 20

RESULT 43
AR314719
LOCUS AR314719 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 5256 from patent US 6559294.
ACCESSION AR314719
VERSION AR314719.1 GI:31708145
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths,R., Hoibeth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 5256 06-MAY-2003;
FEATURES
source
1..20
/organism='unknown'
/mol_type='genomic DNA'

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 966 AATTCTGCAGAGCTGCT 984
Db 2 AAATCTGCAGAGCTGCT 20

RESULT 44
AR373074/c
LOCUS AR373074 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 3 from patent US 6602674.
ACCESSION AR373074
VERSION AR373074.1 GI:40075017
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS O'Brien,T.J., Underwood,L.J., Tanimoto,H. and Shigemasa,K.
TITLE Uses of antileukoprotease in carcinoma
JOURNAL Patent: US 6602674-A 3 05-AUG-2003;
FEATURES
source
1..20
/organism='unknown'
```

```
/mol_type='genomic DNA'

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1904 CAGACTCCACCTTGGAGG 1922
Db 19 CAGACTCCAGCTTGAAGG 1

RESULT 45
AX495922/c
LOCUS AX495922 20 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 1687 from Patent WO02059256.
ACCESSION AX495922
VERSION AX495922.1 GI:23341532
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Tuijnder,M., Telerman,A., Amson,R. and Susini,L.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 02059256-A 1687 01-AUG-2002;
FEATURES
source
1..20
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTT 2586
Db 20 TTTNTCTCTCTCTCTCTT 1

RESULT 46
BD128106
LOCUS BD128106 20 bp DNA linear PAT 18-SEP-2002
DEFINITION Primer for synthesizing full-length cDNA and use thereof.
ACCESSION BD128106
VERSION BD128106.1 GI:23223051
KEYWORDS JP 2002017375-A/3537.
SOURCE unidentified
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga,H.
TITLE Primer for synthesizing full-length cDNA and use thereof
JOURNAL Patent: JP 2002017375-A 3537 22-JAN-2002;
COMMENT HELIX RESEARCH INSTITUTE
OS Unidentified
PN JP 2002017375-A/3537
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO
PI ISHII,
PI YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI,HISASHI KOGA
PC
C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
10,
```

```
PC C12P21/02,C12Q1/69//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
Description of Artificial Sequence: an artificially CC
synthesized primer
CC sequence
FH Key 1..20 Location/Qualifiers
FT source 1..20 /organism='Unidentified'.
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1752 GGTCTGGCTCATCTTCTC 1770
||||| ||||| ||||| |||||
Db 2 GGTCTGGCTCATCTTCTTC 20

RESULT 47
AR029929
LOCUS 21 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 118 from patent US 5861244.
ACCESSION AR029929
VERSION AR029929.1 GI:5943143
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Wang,C.-G. and Hepburn,A.G.
TITLE Genetic sequence assay using DNA triple strand formation
JOURNAL Patent: US 5861244-A 118 19-JAN-1999;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTTCTCTCTTTTCTTCTTC 2587
||||| ||||| ||||| |||||
Db 3 TCTTCTCTTTTCTTCTTCTTC 21

RESULT 48
AR481860
LOCUS 21 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 23 from patent US 6699838.
ACCESSION AR481860
VERSION AR481860.1 GI:47243576
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Davidson,D.J.
TITLE Antiangiogenic peptides
JOURNAL Patent: US 6699838-A 23 02-MAR-2004;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2995 GAGATTTTTTGTCTCTTC 3013
||||| ||||| ||||| |||||
Db 2 GGGCTTTTTTGTCTCTTC 20

RESULT 49
AR481870/c
LOCUS 21 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 33 from patent US 6699838.
ACCESSION AR481870
VERSION AR481870.1 GI:47243586
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Davidson,D.J.
TITLE Antiangiogenic peptides
JOURNAL Patent: US 6699838-A 33 02-MAR-2004;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2995 GAGATTTTTTGTCTCTTC 3013
||||| ||||| ||||| |||||
Db 20 GGGCTTTTTTGTCTCTTC 2

RESULT 50
AX657389/c
LOCUS 21 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 102 from Patent WO02100896.
ACCESSION AX657389
VERSION AX657389.1 GI:29160129
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS dalla Venezia,N.L., Magnard,C.M., Lenoir,G.M. and Sinelnikova-Erard,O.
TITLE Method for diagnosing cancer susceptibility
JOURNAL Patent: WO 02100896-A 102 19-DEC-2002;
FEATURES
source
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2079 GATTCTGCCATCTCTGTGA 2097
||||| ||||| ||||| |||||
Db 20 GATTCTGCCCTCTCTGTGA 2

RESULT 51
BD105846
LOCUS 21 bp DNA linear PAT 18-SEP-2002
DEFINITION Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis.
ACCESSION BD105846
VERSION BD105846.1 GI:23200664
```


KEYWORDS JP 2002502235-A/20.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Davidson,D.J., Wang,J. and Gubbins,E.J.
TITLE Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
JOURNAL Patent: JP 2002502235-A 20 22-JAN-2002;
COMMENT ABBOTT LABORATORIES
PN JP 2002502235-A/20
PD 22-JAN-2002
PF 05-MAY-1997 JP 1997540162
PR 03-MAY-1996 US 08/643219
PI DONALD J DAVIDSON, JIEYI WANG, EARL J GUBBINS
PC A61K
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers.
FEATURES source
1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2995 GAGATTTTTCCTCTTC 3013
DB 2 GGGCTTTTTCCTCTTC 20
RESULT 52
BD105856/c
LOCUS 21 bp DNA linear PAT 18-SEP-2002
DEFINITION Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis.
ACCESSION BD105856
VERSION BD105856.1 GI:23200674
KEYWORDS JP 2002502235-A/30.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Davidson,D.J., Wang,J. and Gubbins,E.J.
TITLE Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
JOURNAL Patent: JP 2002502235-A 30 22-JAN-2002;
COMMENT ABBOTT LABORATORIES
PN JP 2002502235-A/30
PD 22-JAN-2002
PF 05-MAY-1997 JP 1997540162
PR 03-MAY-1996 US 08/643219
PI DONALD J DAVIDSON, JIEYI WANG, EARL J GUBBINS
PC A61K
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers.
FEATURES source
1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2995 GAGATTTTTCCTCTTC 3013
DB 20 GGGCTTTTTCCTCTTC 2

RESULT 53
BD259457
LOCUS 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD259457
VERSION BD259457.1 GI:33069227
KEYWORDS JP 2002541795-A/7250.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 7250 10-DEC-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/7250
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN
PC C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02, PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
FT /organism='Eukaryote'.
FEATURES source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 95;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 231 GAGCTGTCAGGAGCC 247
DB 1 GAGCTGTCAGGAGCC 17
RESULT 54
AX217117
LOCUS 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2559 from Patent WO0159103.
ACCESSION AX217117
VERSION AX217117.1 GI:15527178
KEYWORDS synthetic construct
SOURCE synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 2559 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match
Best Local Similarity 0.4%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3640 ATTGTCAGAAATGCCA 3656
Db 1 ATTATTCAGAAATGCCA 17

RESULT 55
AX218301
LOCUS AX218301 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3743 from Patent WO0159103.
ACCESSION AX218301
VERSION AX218301.1 GI:15528362
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3743 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match
Best Local Similarity 0.4%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 337 TCCGAGAGAGGAGAA 353
Db 1 TCCAGAGAGAGGAGAA 17

RESULT 56
AX531757/c
LOCUS AX531757 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1266 from Patent EPI239051.
ACCESSION AX531757
VERSION AX531757.1 GI:25255293
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon, M.
TITLE Human pox-like protein 1
JOURNAL Patent: EP 1239051-A 1266 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.4%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2845 CATGGGCTGGGAGATCA 2861
Db 17 CATGGGCTGGGTGATCA 1

RESULT 57
AX531758/c
LOCUS AX531758 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1267 from Patent EPI239051.
ACCESSION AX531758
VERSION AX531758.1 GI:25255295
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon, M.
TITLE Human pox-like protein 1
JOURNAL Patent: EP 1239051-A 1267 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.4%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2844 CCATGGGCTGGGAGATC 2860
Db 17 CCATGGGCTGGGTGATC 1

RESULT 58
AX726240
LOCUS AX726240 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3927 from Patent WO03025176.
ACCESSION AX726240
VERSION AX726240.1 GI:30505583
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3927 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match
Best Local Similarity 0.4%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2980 GATCATTCTCCAGAGCA 2996
Db 1 GATCATTCTCCAAAGCA 17

RESULT 59
AX757732/c
LOCUS AX757732 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 1053 from Patent WO03040369.
ACCESSION AX757732
VERSION AX757732.1 GI:32252348
KEYWORDS
SOURCE Homo sapiens (human)

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1053 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="caxon:9606"

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 95;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2967 CAAATGAATTTTAGATC 2983
|||||
Db 17 CAAATGAATTTGAGATC 1

RESULT 60
AR294845/c 18 bp DNA linear PAT 12-JUN-2003
LOCUS AR294845
DEFINITION Sequence 6580 from patent US 6537751.
ACCESSION AR294845
VERSION AR294845.1 GI:31682129
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 6580 25-MAR-2003;
FEATURES
source 1..18
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 11e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 468 CCTGTACCTTGTCTCA 484
|||||
Db 18 CCTGTACCTTGTCTTA 2

RESULT 61
BD230637 19 bp DNA linear PAT 17-JUL-2003
LOCUS BD230637
DEFINITION Total genome radiation hybrid map of canine genome and its use for
identification of interesting genes.
ACCESSION BD230637
VERSION BD230637.1 GI:33040407
KEYWORDS JP 2002530091-A/506.
SOURCE Canis familiaris (dog)
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1 (bases 1 to 19)
AUTHORS Galibert,F. and Andre,C.
TITLE Total genome radiation hybrid map of canine genome and its use for
identification of interesting genes
JOURNAL Patent: JP 2002530091-A 506 17-SEP-2002;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
COMMENT OS Canis familiaris (dog)

```

```

PN JP 2002530091-A/506
PD 17-SEP-2002
PF 15-NOV-1999 JP 2000582596
PR 13-NOV-1998 US 60/108193
PI FRANCIS GALIBERT,CATHERINE ANDRE
PC C12N15/09,C12Q1/68,C12M15/00
CC M13150
FH Key Location/Qualifiers
FT source 1..19
/organism="Canis familiaris (dog)"
/Location/Qualifiers
1..19
/organism="Canis familiaris"
/mol_type="genomic DNA"
/db_xref="taxon:9615"

FEATURES
source 1..19
Location/Qualifiers
1..19
/organism="Canis familiaris"
/mol_type="genomic DNA"
/db_xref="taxon:9615"

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1613 TCTTGAAGCCCTGGT 1629
|||||
Db 2 TCTTGAAGCCCTGGT 18

RESULT 62
I31463 19 bp DNA linear PAT 06-FEB-1997
LOCUS I31463
DEFINITION Sequence 375 from patent US 5582979.
ACCESSION I31463
VERSION I31463.1 GI:1822254
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Weber,J.L.
TITLE Length polymorphisms in (dc-da).sub.n.(dg-dt).sub.n sequences and
method of using the same
JOURNAL Patent: US 5582979-A 375 10-DEC-1996;
FEATURES
source 1..19
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2057 AGCCTCAGAGACCTGG 2073
|||||
Db 2 AGCCTCAGAGACCTGG 18

RESULT 63
AX039816/c 19 bp DNA linear PAT 18-NOV-2000
LOCUS AX039816
DEFINITION Sequence 205 from Patent WO0063441.
ACCESSION AX039816
VERSION AX039816.1 GI:11229845
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Herznstadt,C. and Davis,R.E.
TITLE Single nucleotide polymorphisms in mitochondrial genes that segreg
ate with alzheimer's disease
JOURNAL Patent: WO 0063441-A 205 26-OCT-2000;
MITOKOR (US)
FEATURES
source 1..19
Location/Qualifiers
/organism="synthetic construct"

```



```
disequilibrium map of the human genome
Patent: US 6537751-A 6240 25-MAR-2003;
LOCUS      Location/Qualifiers
FEATURES   source
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1918 GGAGGAATCAGTCAGG 1934
      |||||
Db 18 GGAGGAATCAGAGG 2

RESULT 74
AR342848/c
LOCUS      AR342848      20 bp      DNA      linear      PAT 17-AUG-2003
DEFINITION Sequence 14 from patent US 6576742.
ACCESSION  AR342848
VERSION     AR342848.1 GI:33738121
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Piletz,J.B. and Ivanov,T.R.
TITLE       DNA sequence encoding a human imidazoline receptor and method for
            cloning the same
JOURNAL     Patent: US 6576742-A 14 10-JUN-2003;
FEATURES    Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1756 TGGCTCACPCTTTCTCTC 1772
      |||||
Db 19 TGGCTCACCTTCTCTC 3

RESULT 75
AX657158
LOCUS      AX657158      20 bp      DNA      linear      PAT 22-MAR-2003
DEFINITION Sequence 4 from Patent WO03000896.
ACCESSION  AX657158
VERSION     AX657158.1 GI:29159938
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Escary,J.L.
TITLE       Polynucleotides and polypeptides of the ifnalpha-5 gene
JOURNAL     Patent: WO 03000896-A 4 03-JAN-2003;
            GenOdysee (FR)
FEATURES    Location/Qualifiers
            source
            1..20
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2637 CAGAACTCAGAGTGT 2653
      |||||
```

```
Db 3 CAGAACTCAAGAAGTGT 19

RESULT 76
A40129/c
LOCUS      A40129      20 bp      DNA      linear      PAT 05-MAR-1997
DEFINITION Sequence 5 from Patent WO9423026.
ACCESSION  A40129
VERSION     A40129.1 GI:2296287
KEYWORDS    .
SOURCE      unidentified
            unclassified.
ORGANISM    1 (bases 1 to 20)
REFERENCE   Vasseur,M., Blumenfeld,M., Meguenni,S. and Poddevin,B.
            STAPLE AND SEMI-STAPLE OLIGONUCLEOTIDES, METHOD OF PREPARATION AND
            APPLICATIONS
            GENSET (FR)
JOURNAL     Patent: WO 9423026-A 5 13-OCT-1994;
            Other publication AU 6432094 941024
            Other publication FR 2703053 940930.
COMMENT     Other publication FR 2703053 940930.
FEATURES    Location/Qualifiers
            source
            1..20
            /organism="unidentified"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32644"

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2565 GCCTTCTCTCTCTCTTTT 2584
      |||||
Db 20 GCCTTCTATTTTCTTTT 1

RESULT 77
AR011654
LOCUS      AR011654      20 bp      DNA      linear      PAT 04-DEC-1998
DEFINITION Sequence 4 from patent US 5763165.
ACCESSION  AR011654
VERSION     AR011654.1 GI:3969644
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Boon-Falleur,I., Weynants,P., Lethe,B., Brasseur,F., Marchand,M.,
            Desmet,C., Lurquin,C., van der Bruggen,P. and Deplaen,E.
            Method for determining lung adenocarcinomas by assaying for one or
            more of MAGE-1, MAGE-2 and MAGE-3
            Patent: US 5763165-A 4 09-JUN-1998;
JOURNAL     Location/Qualifiers
FEATURES    Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 342 GAAGAGGAGAACCGGATTG 361
      |||||
Db 1 GAAGAGGAGAACGCGTCTG 20

RESULT 78
AR064875
LOCUS      AR064875      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 5 from patent US 5849480.
ACCESSION  AR064875
VERSION     AR064875.1 GI:5995091
KEYWORDS    .
```

[illegible]

[illegible]


```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 586 AACATATAAAGACAACCT 605
Db 20 AACATATGAAATACAACTT 1

RESULT 94
BD218101/c
LOCUS      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Compositions derived from mycobacterium vaccae and methods for
their use.
ACCESSION  BD218101
VERSION     BD218101.1 GI:33027871
KEYWORDS   JP 2002514385-A/26.
SOURCE     synthetic construct
ORGANISM   synthetic construct
artificial sequences.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Tan, P., Watson, J., Visser, E.S., Skinner, M.A. and Prestid, R.L.
TITLE      Compositions derived from mycobacterium vaccae and methods for
their use.
JOURNAL    Patent: JP 2002514385-A 26 21-MAY-2002;
GENESIS RESEARCH AND DEVELOPMENT CORP LTD
OS Artificial Sequence
PN JP 2002514385-A/26
PD 21-MAY-2002
PF 23-DEC-1998 JP 2000525553
PR 23-DEC-1997 US 08/997362,23-DEC-1997 US 08/997080 PR
23-DEC-1997 US 08/996624,11-JUN-1998 US 09/095855 PR
17-SEP-1998 US 09/156181,04-DEC-1998 US 09/205426 PI PAUL
TAN, JAMES WATSON, ELIZABETH S VISSER, MARGOT A SKINNER, ROSS
PI L PRESTIDGE
PC C12N15/09,A61K31/711,A61K39/04,A61K48/00,A61P11/00,A61P11/06,
PC A61P17/00,
PC A61P17/06,A61P31/00,A61P31/06,A61P37/04,C07K14/35,C07K16/12,
PC C07K19/00,
PC C12N1/19,C12N1/21,C12N5/10,C12P21/08,C12Q1/02,G01N33/569, PC
G01N33/68//
PC C12N15/09,C12R1:32),C12N15/00,C12N5/00,(C12N15/00,C12R1:32)
CC Made in a lab
FH Key
FT source      1..20
Location/Qualifiers
/organism="Artificial Sequence".

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTCTCTCTTTTTTTT 2586
Db 20 TTTTCTCTCTCTTTTTTTT 1

RESULT 95
BD225114
LOCUS      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Antisense modulation of expression of tumor necrosis factor
receptor-associated factor (TRAF).
ACCESSION  BD225114
VERSION     BD225114.1 GI:33034884
KEYWORDS   JP 2002526095-A/249.
SOURCE     synthetic construct
artificial sequences.

/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2364 CTTTCATGCTGGAATGGAT 2383
Db 20 CTTTCAGCTGGACTTGGAT 1

RESULT 97
E12676
LOCUS      20 bp      DNA      linear      PAT 27-APR-1998
DEFINITION Anti-HTLV-1 antisense oligonucleotide.
ACCESSION  E12676
VERSION     E12676.1 GI:3251508
SOURCE     E12676.1 GI:3251508
artificial sequences.

```

```

ORGANISM      synthetic construct
artificial sequences.
REFERENCE      1 (bases 1 to 20)
AUTHORS        Baker,B.F., Cowser,L.M., Monia,B.P. and Xu,X.S.
TITLE          Antisense modulation of expression of tumor necrosis factor
receptor-associated factor (TRAF)
JOURNAL        Patent: JP 2002526095-A 249 20-AUG-2002;
ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002526095-A/249
PD 20-AUG-2002
PF 05-OCT-1999 JP 2000574546
PR 06-OCT-1998 US 09/167109
PI BRENDA F BAKER, LEX M COWSERT, BRETT P MONIA, XIAOXING S XU PC
C12N15/09,A61K31/7105,A61K48/00,A61P29/00,A61P35/04,C12N15/00 CC
antisense sequence
FH Key
FT source      1..20
Location/Qualifiers
/organism="Artificial Sequence".

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2724 CTCGCGCAGAGCAGCTCCT 2743
Db 1 CTCAGCGCAGAGCTTCTCCT 20

RESULT 96
CQ798982/c
LOCUS      20 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 63 from Patent WO2004031412.
ACCESSION  CQ798982
VERSION     CQ798982.1 GI:46847995
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    synthetic construct
artificial sequences.
REFERENCE    1
AUTHORS      Nakamura, Y. and Katagiri, T.
TITLE        Method for diagnosing pancreatic cancer
JOURNAL      Patent: WO 2004031412-A 63 15-APR-2004;
Oncotherapy Science, Inc. (JP); Japan as represented by the
president of the university of Tokyo (JP)
FT source      1..20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Artificially synthesized primer sequence for
RT-PCR"

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2364 CTTTCATGCTGGAATGGAT 2383
Db 20 CTTTCAGCTGGACTTGGAT 1

RESULT 97
E12676
LOCUS      20 bp      DNA      linear      PAT 27-APR-1998
DEFINITION Anti-HTLV-1 antisense oligonucleotide.
ACCESSION  E12676
VERSION     E12676.1 GI:3251508
SOURCE     E12676.1 GI:3251508
artificial sequences.

```

KEYWORDS	JP 1997052898-A/10.
SOURCE	unidentified
ORGANISM	unidentified
REFERENCE	unclassified.
AUTHORS	1 (bases 1 to 20)
TITLE	Mzuyuch, M., Kurosaki, N., Makino, K., Koyanagi, Y. and Yamamoto, N.
JOURNAL	ANTI-HELV-I ANTI-SENSE OLIGONUCLEOTIDE
COMMENT	Patent: JP 1997052898-A 10 25-FEB-1997; SOFARU GIUTSU KENKYUSHO:KK
OS	None
OC	Artificial sequences.
PN	JP 1997052898-A/10
PD	25-FEB-1997
PF	09-AUG-1995 JP 1995224606
PI	MIZUGUCHI MASATSUGU, KUROSAKI NAOKO, MAKINO KEISUKE, PI
KEYWORDS	KOYANAGI YOSHIO, YAMAMOTO NAOKI
PC	C07H21/04//A61K31/70;
CC	strandedness: Single;
CC	topology: linear;
CC	hypothetical: No;
CC	anti-sense: Yes;
PH	Key
FT	Location/Qualifiers
FEATURES	FT source 1..20 /organism='artificial sequences', Location/Qualifiers 1..20 /organism="unidentified" /mol_type="genomic DNA" /db_xref="taxon:32644"
Query Match	0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
OY	2567 TTCTCTCTCTTTT 2586
DB	1 TTTT TTTT TTTT TTTT TTTT
RESULT 98	
LOCUS	E22412 20 bp DNA linear PAT 18-JUN-2001
E22412/c	
DEFINITION	Antisense nucleic acid compound.
ACCESSION	E22412
VERSION	E22412.1 GI:13024055
KEYWORDS	JP 1999042091-A/14. unidentified unclassified
SOURCE	unclassified.
ORGANISM	1 (bases 1 to 20)
REFERENCE	Kinya, K., Yoko, M. and Kiyoshi, U.
AUTHORS	Antisense nucleic acid compound
TITLE	Patent: JP 1999042091-A 14 16-FEB-1999;
JOURNAL	TOGOSHI CHEM IND CO LTD
COMMENT	OS Unidentified PN JP 1999042091-A/14 PD 16-FEB-1999 PF 25-JUL-1997 JP 1997213838
PR	
PC	KINYA KAMIYA, YOKO MATSUDA, KIYOSHI UCHIDA
PI	C12N15/09, A61K31/70, A61K48/00, C12Q1/68, C12N15/00 CC
Strandedness: Single;	
CC Topology: linear;	
PH Key	Location/Qualifiers
FT source 1..20 /organism='unidentified', Location/Qualifiers 1..20 /organism="unidentified" /mol_type="genomic DNA" /db_xref="taxon:32644"	
FEATURES	
SOURCE	

Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;	
Best Local Similarity	85.0%;	Pred. No. 1.5e+02;			
Matches 17;	Conservative	0;	Mismatches 3;	Indels	0; Gaps 0;
Oy	2216	TTCTCTCTCTCTCTCTCTC	2235		
Db	20	TTCTCTCTCTCTCTCTCTC	CCCC 1		
RESULT 99					
LOCUS	119766		20 bp	DNA	PAT 07-OCT-1996
DEFINITION	Sequence 6 from patent US 5512444.				
ACCESSION	119766				
VERSION	119766.1	GI:1600121			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
TITLE	Patard,J.-J., Brasseur,F. and Boon-Falleur,T. Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4				
JOURNAL	Patent: US 5512444-A 6 30-APR-1996;				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;	
Best Local Similarity	85.0%;	Pred. No. 1.5e+02;			
Matches 17;	Conservative	0;	Mismatches 3;	Indels	0; Gaps 0;
Oy	342	GAAGAGGAGACCGGATTG	361		
Db	1	GAAGAGGAGAGCGGCTG	20		
RESULT 100					
LOCUS	136180		20 bp	DNA	PAT 13-MAY-1997
DEFINITION	Sequence 16 from patent US 5605662.				
ACCESSION	136180				
VERSION	136180.1	GI:2086693			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
TITLE	Heller,M.J. and Tu,E. Active programmable electronic devices for molecular biological analysis and diagnostics				
JOURNAL	Patent: US 5605662-A 16 25-FEB-1997;				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;	
Best Local Similarity	85.0%;	Pred. No. 1.5e+02;			
Matches 17;	Conservative	0;	Mismatches 3;	Indels	0; Gaps 0;
Oy	2567	TTTCTCTCTCTCTCTCTTTT	2586		
Db	1	TTTTTTTTTTTTTTTTTTTTT	20		
RESULT 101					
LOCUS	AR209924		20 bp	DNA	PAT 20-JUN-2002
DEFINITION	Sequence 4 from patent US 6387630.				
ACCESSION	AR209924				

VERSION AR209924.1 GI:21512021
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Van Baren,N., Brasseur,F. and Boon-Falleur,T.
TITLE Methods for diagnosing multiple myeloma by determining rejection
antigen precursors
JOURNAL Patent: US 6387630-A 4 14-MAY-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 342 GAAGAGAGAACCGGATTG 361
Db 1 GAAGAGAGAGAACCGGCTTG 20
|||||
|||||

RESULT 102
AR213738/c AR213738 20 bp DNA linear PAT 25-SEP-2002
LOCUS AR213738
DEFINITION Sequence 83 from patent US 6406704.
ACCESSION AR213738
VERSION AR213738.1 GI:23311025
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Tan,P., Viesser,E., Prestidge,R. and Watson,J.D.
TITLE Compounds and methods for treatment and diagnosis of mycobacterial
infections
JOURNAL Patent: US 6406704-A 83 18-JUN-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCT 1
|||||
|||||

RESULT 103
AR222466/c AR222466 20 bp DNA linear PAT 26-SEP-2002
LOCUS AR222466
DEFINITION Sequence 26 from patent US 6423300.
ACCESSION AR222466
VERSION AR222466.1 GI:23239997
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kurtz,M., Lohse,P. and Wagner,R.
TITLE Peptide acceptor ligation methods
JOURNAL Patent: US 6429300-A 26 06-AUG-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCT 1
|||||
|||||

RESULT 104
AR236083 AR236083 20 bp DNA linear PAT 20-DEC-2002
LOCUS AR236083
DEFINITION Sequence 1 from patent US 6462184.
ACCESSION AR236083
VERSION AR236083.1 GI:27279782
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Waier,M.A.
TITLE Compounds, processes and intermediates for synthesis of mixed
backbone oligomeric compounds
JOURNAL Patent: US 6462184-A 1 08-OCT-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCT 20
|||||
|||||

RESULT 105
AR266134 AR266134 20 bp DNA linear PAT 10-APR-2003
LOCUS AR266134
DEFINITION Sequence 33 from patent US 6492172.
ACCESSION AR266134
VERSION AR266134.1 GI:29694980
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F., Busch,H. and Wyatt,J.
TITLE Antisense modulation of GU protein expression
JOURNAL Patent: US 6492172-A 33 10-DEC-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2137 TCCTCTACTGTGCATCAAA 2156
Db 1 TCTTCCACTGTATCAGCAAA 20
|||||
|||||

RESULT 106
AR274394/c AR274394 20 bp DNA linear PAT 10-APR-2003
LOCUS AR274394
DEFINITION Sequence 55 from patent US 6506564.
ACCESSION AR274394
VERSION AR274394.1 GI:29706840
KEYWORDS
SOURCE Unknown.

Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCT 1
|||||
|||||

RESULT 104
AR236083 AR236083 20 bp DNA linear PAT 20-DEC-2002
LOCUS AR236083
DEFINITION Sequence 1 from patent US 6462184.
ACCESSION AR236083
VERSION AR236083.1 GI:27279782
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Waier,M.A.
TITLE Compounds, processes and intermediates for synthesis of mixed
backbone oligomeric compounds
JOURNAL Patent: US 6462184-A 1 08-OCT-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCT 20
|||||
|||||

RESULT 105
AR266134 AR266134 20 bp DNA linear PAT 10-APR-2003
LOCUS AR266134
DEFINITION Sequence 33 from patent US 6492172.
ACCESSION AR266134
VERSION AR266134.1 GI:29694980
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F., Busch,H. and Wyatt,J.
TITLE Antisense modulation of GU protein expression
JOURNAL Patent: US 6492172-A 33 10-DEC-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2137 TCCTCTACTGTGCATCAAA 2156
Db 1 TCTTCCACTGTATCAGCAAA 20
|||||
|||||

RESULT 106
AR274394/c AR274394 20 bp DNA linear PAT 10-APR-2003
LOCUS AR274394
DEFINITION Sequence 55 from patent US 6506564.
ACCESSION AR274394
VERSION AR274394.1 GI:29706840
KEYWORDS
SOURCE Unknown.

Source	Unknown.
Organism	Unclassified.
Reference	1 (bases 1 to 20)
Authors	Mitkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghanian,R. and Taton,T.A.
Title	Nanoparticles having oligonucleotides attached thereto and uses therefor
Journal	Patent: US 6645721-A 55 11-NOV-2003;
Features	Location/Qualifiers
Source	1..20 /organism="unknown" /mol_type="genomic DNA"
Query Match	0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred.No.1.5e+02;
Matches	17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Cy	2567 TTTCCTCTCTCTTTT 2586
Db	20 TTTT TTTT TTTT TTTT TTTT 1
RESULT 112	
LOCUS	AR447441 20 bp DNA linear PAT 20-FEB-2004
DEFINITION	Sequence 55 from patent US 6673548.
ACCESSION	AR447441
VERSION	AR447441.1 GI:42675765
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Mitkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghanian,R. and Taton,T.A.
TITLE	Nanoparticles having oligonucleotides attached thereto and uses therefor
Journal	Patent: US 6673548-A 55 06-JAN-2004;
Features	Location/Qualifiers
Source	1..20 /organism="unknown" /mol_type="genomic DNA"
Query Match	0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred.No.1.5e+02;
Matches	17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Cy	2567 TTTCCTCTCTTTT 2586
Db	20 TTTT TTTT TTTT TTTT 1
RESULT 113	
LOCUS	AR451990 20 bp DNA linear PAT 20-FEB-2004
DEFINITION	Sequence 55 from patent US 6677122.
ACCESSION	AR451990
VERSION	AR451990.1 GI:42683297
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Mitkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghanian,R. and Taton,T.A.
TITLE	Nanoparticles having oligonucleotides attached thereto and uses therefor
Journal	Patent: US 6677122-A 55 13-JAN-2004;
Features	Location/Qualifiers
Source	1..20 /organism="unknown" /mol_type="genomic DNA"

Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 1.5e+02;		
Matches 17;	Conservative	0;	Mismatches 3;	Indels 0;
Oy	2567	TTTCCTCTCTCTTTTTTTT	2586	
Db	20	TTTTTTTTTTTTTTTTTTTTT	1	
RESULT 114				
LOCUS	AR454776	20 bp	DNA	linear
DEFINITION	Sequence 55 from patent US 6682895.			PAT 20-FEB-2004
ACCESSION	AR454776			
VERSION	AR454776.1			
KEYWORDS	GI:42688297			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 20)			
AUTHORS	Winkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghanian,R. and Tatom,T.A.			
TITLE	Nanoparticles having oligonucleotides attached thereto and uses thereof			
JOURNAL	Patent: US 6682895-A 55 27-JAN-2004;			
FEATURES	Location/Qualifiers			
SOURCE	1..20			
	/organism="unknown"			
	/mol_type="genomic DNA"			
Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 1.5e+02;		
Matches 17;	Conservative	0;	Mismatches 3;	Indels 0;
Oy	2567	TTTCCTCTCTCTTTTTTTT	2586	
Db	20	TTTTTTTTTTTTTTTTTTTTT	1	
RESULT 115				
LOCUS	AR489044	20 bp	DNA	linear
DEFINITION	Sequence 55 from patent US 6709825.			PAT 15-MAY-2004
ACCESSION	AR489044			
VERSION	AR489044.1			
KEYWORDS	GI:47255475			
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	Unclassified.			
AUTHORS	1 (bases 1 to 20)			
TITLE	Mikkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghanian,R. and Tatom,T.A.			
JOURNAL	Nanoparticles having oligonucleotides attached thereto and uses thereof			
FEATURES	Patent: US 6709825-A 55 23-MAR-2004;			
SOURCE	Location/Qualifiers			
	1..20			
	/organism="unknown"			
	/mol_type="genomic DNA"			
Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 1.5e+02;		
Matches 17;	Conservative	0;	Mismatches 3;	Indels 0;
Oy	2567	TTTCCTCTCTCTTTTTTTT	2586	
Db	20	TTTTTTTTTTTTTTTTTTTTT	1	
RESULT 116				
LOCUS	AR490959	20 bp	DNA	linear
				PAT 15-MAY-2004

DEFINITION Sequence 53 from patent US 6713300.
ACCESSION AR490959
VERSION AR490959.1 GI:47258492
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Allikmeers,R., Anderson,K.L., Dean,M., Leppert,M., Lewis,R.A., Li,Y., Lupski,J.R., Nathans,J., Rattner,A., Shroyer,N.F., Singh,N., Smallwood,P. and Sun,H.
TITLE Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter
JOURNAL Patent: US 6713300-A 53 30-MAR-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1296 GTTGTGCTGCAGAGCTTC 1315
DB 20 GCTGTGTCAGAGAGCTTC 1
RESULT 117
LOCUS AR494116 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 55 from patent US 6720147.
ACCESSION AR494116
VERSION AR494116.1 GI:47266895
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storchhoff,J.J., Elghanian,R. and Taton,T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL Patent: US 6720147-A 55 13-APR-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCCTCTCTCTTTT 2586
DB 20 TTTTCTTTTCTTTT 1
RESULT 118
LOCUS AR494728 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 55 from patent US 6720411.
ACCESSION AR494728
VERSION AR494728.1 GI:47269581
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storchhoff,J.J., Elghanian,R. and Taton,T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor

therefor
JOURNAL Patent: US 6720411-A 55 13-APR-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCCTCTCTCTTTT 2586
DB 20 TTTTCTTTTCTTTT 1
RESULT 119
LOCUS AX004876 20 bp DNA linear PAT 24-AUG-2000
DEFINITION Sequence 5 from Patent WO910527.
ACCESSION AX004876
VERSION AX004876.1 GI:9928276
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Bayer,E. and Schweltz,J.
TITLE Method for isolating anionic organic substances from aqueous systems using cationic polymer nanoparticles
JOURNAL Patent: WO 910527-A 5 04-MAR-1999;
SUEDEUTSCHE KALKSTICKSTOFF (DE); BAYER ERNST (DE)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="phosphorothioate oligonucleotide"
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCCTCTCTCTTTT 2586
DB 1 TTTTCTTTTCTTTT 20
RESULT 120
LOCUS AX006757 20 bp DNA linear PAT 06-SEP-2000
DEFINITION Sequence 6 from Patent WO0003013.
ACCESSION AX006757
VERSION AX006757.1 GI:9994799
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Leegwater,A.C., Van der Vliet,H.N., Chamuleau,R.A. and Groenink,M.
TITLE Gene and protein involved in liver regeneration
JOURNAL Patent: WO 0003013-A 6 20-JAN-2000;
LEEGWATER ADAM CORNELIS JOSEF (NL); VLIET HENDRIK NIEUS V D (NL); AMSTERDAM MOLECULAR THERAPEUTI (NL); CHAMULEAU ROBERT ANTOINE FRANC (NL); GROENINK MARTIJN (NL)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer F971RAP"
Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2279 CCCCTCCACTCCAGAGTTGG 2298

Db 1 CGCCTTCGCTCCAGAGTTGG 20

RESULT 121

AX045779 20 bp DNA linear PAT 24-NOV-2000
LOCUS AX045779
DEFINITION Sequence 9 from Patent WO0067023.
ACCESSION AX045779
VERSION AX045779.1 GI:11344146
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Noll, B.O., Schetter, C. and Krieg, A.M.
TITLE Screening for immunostimulatory dna functional modifiers
JOURNAL Patent: WO 0067023-A 9 09-NOV-2000;
CPG Immunopharmaceuticals GmbH (DE) ; UNIVERSITY OF IOWA RESEARCH
FOUNDATION (US)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

misc_feature 1
/note="modified with digoxigenin"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTTTT 2586

Db 1 TTTTCTCTCTCTTTT 20

RESULT 122

AX045787 20 bp DNA linear PAT 24-NOV-2000
LOCUS AX045787
DEFINITION Sequence 17 from Patent WO0067023.
ACCESSION AX045787
VERSION AX045787.1 GI:11344154
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Noll, B.O., Schetter, C. and Krieg, A.M.
TITLE Screening for immunostimulatory dna functional modifiers
JOURNAL Patent: WO 0067023-A 17 09-NOV-2000;
CPG Immunopharmaceuticals GmbH (DE) ; UNIVERSITY OF IOWA RESEARCH
FOUNDATION (US)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

misc_feature 1..20
/note="phosphorothioate backbone"
misc_feature 1
/note="modified with digoxigenin"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTTTT 2586

Db 1 TTTTCTCTCTTTT 20

RESULT 123
AX045790 20 bp DNA linear PAT 24-NOV-2000
LOCUS AX045790
DEFINITION Sequence 20 from Patent WO0067023.
ACCESSION AX045790
VERSION AX045790.1 GI:11344157
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Noll, B.O., Schetter, C. and Krieg, A.M.
TITLE Screening for immunostimulatory dna functional modifiers
JOURNAL Patent: WO 0067023-A 20 09-NOV-2000;
CPG Immunopharmaceuticals GmbH (DE) ; UNIVERSITY OF IOWA RESEARCH
FOUNDATION (US)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTTTT 2586

Db 1 TTTTCTCTCTTTT 20

RESULT 124
AX104034 20 bp DNA linear PAT 30-APR-2001
LOCUS AX104034
DEFINITION Sequence 226 from Patent WO0122972.
ACCESSION AX104034
VERSION AX104034.1 GI:13920231
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Krieg, A.M., Schetter, C. and Vollmer, J.C.
TITLE Immunostimulatory nucleic acids
JOURNAL Patent: WO 0122972-A 226 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
GmbH (DE)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTTTT 2586

Db 1 TTTTCTCTCTTTT 20

RESULT 125
AX104364 20 bp DNA linear PAT 30-APR-2001
LOCUS AX104364
DEFINITION Sequence 556 from Patent WO0122972.
ACCESSION AX104364

VERSION	AXI04364.1	GI:13920561
KEYWORDS	.	
SOURCE	synthetic construct	
ORGANISM	synthetic construct artificial sequences.	
REFERENCE	1	
AUTHORS	Krieg,A.M., Schetter,C. and Vollmer,J.C.	
TITLE	Immunostimulatory nucleic acids	
JOURNAL	Patent: WO 0122972-A 556 05-APR-2001; UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical GmbH (DE)	
FEATURES	Location/Qualifiers	
source	1..20 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630"	
Query Match	0.4%; Score 15.2; DB 1;	Length 20;
Best Local Similarity	85.0%; Pred.No.1.5e+02;	
Matches	17; Conservative 0; Mismatches 3;	Indels 0; Gaps 0;
OY	2567 TTCTCTCTCTTTTTTTT 2586	
Dn	1 TTTTTTTTTTTTTTTTTT 20	
RESULT 126		
LOCUS	AXI04368	20 bp DNA linear PAT 30-APR-2001
DEFINITION	Sequence 560 from Patent WO0122972.	
ACCESSION	AXI04368	
VERSION	AXI04368.1 GI:13920565	
KEYWORDS	.	
ORGANISM	synthetic construct	
SOURCE	synthetic construct artificial sequences.	
REFERENCE	1	
AUTHORS	Krieg,A.M., Schetter,C. and Vollmer,J.C.	
TITLE	Immunostimulatory nucleic acids	
JOURNAL	Patent: WO 0122972-A 560 05-APR-2001; UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical GmbH (DE)	
FEATURES	Location/Qualifiers	
source	1..20 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630"	
Query Match	0.4%; Score 15.2; DB 1;	Length 20;
Best Local Similarity	85.0%; Pred.No.1.5e+02;	
Matches	17; Conservative 0; Mismatches 3;	Indels 0; Gaps 0;
OY	2567 TTCTCTCTCTTTTTTTT 2586	
Dn	20 TTTTTTTTTTTTTTTTTT 1	
RESULT 127		
LOCUS	AXI96224/c	20 bp DNA linear PAT 28-AUG-2001
DEFINITION	Sequence 55 from Patent WO0151665.	
ACCESSION	AXI96224	
VERSION	AXI96224.1 GI:15386427	
KEYWORDS	.	
SOURCE	synthetic construct	
ORGANISM	synthetic construct artificial sequences.	
REFERENCE	1	
AUTHORS	Micklin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghamhan,R., Tateon,T.A. and Li,Z.	
TITLE	Nanoparticles having oligonucleotides attached thereto and uses therefor	
JOURNAL	Patent: WO 0151665-A 55 19-JUL-2001;	

```

FEATURES             Nanosphere, Inc. (US)
                    Location/Qualifiers
     source           1..20
                        /organism="synthetic construct"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:32630"
                        /note="random synthetic sequence"

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2567 TTTCCTCTCTTTT 2586
            ||| ||||| ||||| |||
Db       20 TTTTTTTTTTTTTTTT 1

RESULT 128
LOCUS AX196239/c                20 bp    DNA        linear   PAT 28-AUG-2001
DEFINITION Sequence 70 from Patent WO0151665.
ACCESSION AX196239
VERSION AX196239.1 GI:15386442
KEYWORDS .
SOURCE synthetic construct
         artificial sequences.
ORGANISM
REFERENCE
AUTHORS 1 Mitkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J.,
         Elghanian,R., Taton,T.A. and Li,Z.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: WO 0151665-A 70 19-JUL-2001;
Nanosphere, Inc. (US)
FEATURES
source location/Qualifiers
     1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="random synthetic sequence"

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2567 TTTCCTCTCTTTT 2586
            ||| ||||| ||||| |||
Db       20 TTTTTTTTTTTTTTTT 1

RESULT 129
LOCUS AX293534                20 bp    DNA        linear   PAT 22-NOV-2001
DEFINITION Sequence 5296 from Patent WOO179548.
ACCESSION AX293534
VERSION AX293534.1 GI:17055217
KEYWORDS .
SOURCE synthetic construct
         artificial sequences.
ORGANISM
REFERENCE
AUTHORS 1 Barany,F., Zilvay,M., Gerry,N.P., Favis,R. and Kliman,R.
TITLE Method of designing addressable array for detection of nucleic acid
Sequence differences using ligase detection reaction
Patent: WO 0179548-A 5296 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
source location/Qualifiers
     1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Hypothetical Probe Sequence"

```

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 98 GCAAGTCCCGACGACGAC 117
 DB 1 GCAAGTATCTGCACGACG 20

RESULT 130
 LOCUS AX298795 20 bp DNA linear PAT 26-NOV-2001
 DEFINITION Sequence 429 from Patent WO0183749.
 ACCESSION AX298795
 VERSION AX298795.1 GI:17128785
 KEYWORDS
 SOURCE Mus sp.
 ORGANISM Mus sp.
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
 Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
 TITLE Gene and sequence variation associated with sensing carbohydrate
 compounds and other sweeteners
 JOURNAL Patent: WO 0183749-A 429 08-NOV-2001;
 WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
 (US)
 FEATURES
 source 1..20
 /organism="Mus sp."
 /mol_type="unassigned DNA"
 /db_xref="taxon:10095"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2068 ACCTGGAACAGATTCTGCG 2087
 DB 1 ACATGGAACAGATTCTGCG 20

RESULT 131
 LOCUS AX354974 20 bp DNA linear PAT 06-FEB-2002
 DEFINITION Sequence 2 from Patent WO0197843.
 ACCESSION AX354974
 VERSION AX354974.1 GI:18619641
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 Weiner,G. and Hartmann,G.
 AUTHORS Weiner,G. and Hartmann,G.
 TITLE Methods for enhancing antibody-induced cell lysis and treating
 JOURNAL Patent: WO 0197843-A 2 27-DEC-2001;
 UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
 FEATURES
 source 1..20
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Synthetic oligonucleotide-phosphodiester backbone"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTT 2586
 DB 20 TTTTCTCTCTTTT 1

RESULT 132
 LOCUS AX355810 20 bp DNA linear PAT 06-FEB-2002
 DEFINITION Sequence 838 from Patent WO0197843.
 ACCESSION AX355810
 VERSION AX355810.1 GI:18620478
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 ORGANISM artificial sequences.

REFERENCE 1 Weiner,G. and Hartmann,G.
 AUTHORS Weiner,G. and Hartmann,G.
 TITLE Methods for enhancing antibody-induced cell lysis and treating
 JOURNAL Patent: WO 0197843-A 838 27-DEC-2001;
 UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
 FEATURES
 source 1..20
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Synthetic oligonucleotide-phosphorothioate
 backbone"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTT 2586
 DB 1 TTTTCTCTCTTTT 20

RESULT 133
 LOCUS AX355811 20 bp DNA linear PAT 06-FEB-2002
 DEFINITION Sequence 839 from Patent WO0197843.
 ACCESSION AX355811
 VERSION AX355811.1 GI:18620479
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 ORGANISM artificial sequences.

REFERENCE 1 Weiner,G. and Hartmann,G.
 AUTHORS Weiner,G. and Hartmann,G.
 TITLE Methods for enhancing antibody-induced cell lysis and treating
 JOURNAL Patent: WO 0197843-A 839 27-DEC-2001;
 UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
 FEATURES
 source 1..20
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Synthetic oligonucleotide-phosphodiester backbone"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTT 2586
 DB 1 TTTTCTCTCTTTT 20

RESULT 134
 LOCUS AX417659 20 bp DNA linear PAT 18-JUN-2002
 DEFINITION Sequence 19 from Patent WO0231144.
 ACCESSION AX417659
 VERSION AX417659.1 GI:21522821

KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS Butzke, D., Machuy, N., Meyer, T.F. and Rudel, T.
TITLE Identification of a new cytotoxic activity from the ink of *Aplysia punctata*
JOURNAL Patent: WO 0231144-A 19 18-APR-2002;
MAX PLANCK GESELLSCHAFT (DE)

FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide primer"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 908 TTCTATGTCGACGACGA 927
Db 20 TTCTCGTGTCCGACGACA 1

RESULT 135
LOCUS AX440125 55 from Patent WO0173123. 20 bp DNA linear PAT 28-JUN-2002
DEFINITION Sequence AX440125
ACCESSION AX440125
VERSION AX440125.1 GI:21664936
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS 1 Mirkin, C.A., Letsinger, R.L., Mucic, R.C., Storchhoff, J.J.,
Elghanian, R., Taton, T.A., Park, S.J. and Li, Z.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
JOURNAL Patent: WO 0173123-A 55 04-OCT-2001;
Nanosphere, Inc. (US)

FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="random synthetic sequence"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTTTT 2586
Db 20 TTTTCTTTTCTTTT 1

RESULT 136
LOCUS AX440140 20 bp DNA linear PAT 28-JUN-2002
DEFINITION Sequence 70 from Patent WO0173123.
ACCESSION AX440140
VERSION AX440140.1 GI:21664951
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS 1 Mirkin, C.A., Letsinger, R.L., Mucic, R.C., Storchhoff, J.J.,
Elghanian, R., Taton, T.A., Park, S.J. and Li, Z.
TITLE Nanoparticles having oligonucleotides attached thereto and uses

therefor
JOURNAL Patent: WO 0173123-A 70 04-OCT-2001;
Nanosphere, Inc. (US)

FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="random synthetic sequence"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTTTT 2586
Db 20 TTTTCTTTTCTTTT 1

RESULT 137
LOCUS AX465311/C 20 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence AX465311
ACCESSION AX465311
VERSION AX465311.1 GI:21899674
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS 1 Mirkin, C.A., Letsinger, R.L., Mucic, R.C., Storchhoff, J.J.,
Elghanian, R., Taton, T.A., Garimella, V., Li, Z. and Park, S.J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
JOURNAL Patent: WO 0218643-A 55 07-MAR-2002;
Nanosphere, Inc. (US)

FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="random synthetic sequence"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTTTT 2586
Db 20 TTTTCTTTTCTTTT 1

RESULT 138
LOCUS AX465326/C 20 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 70 from Patent WO0218643.
ACCESSION AX465326
VERSION AX465326.1 GI:21899689
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS 1 Mirkin, C.A., Letsinger, R.L., Mucic, R.C., Storchhoff, J.J.,
Elghanian, R., Taton, T.A., Garimella, V., Li, Z. and Park, S.J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
JOURNAL Patent: WO 0218643-A 70 07-MAR-2002;
Nanosphere, Inc. (US)

FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"

SOURCE	synthetic construct
ORGANISM	synthetic construct
LOCUS	artificial sequences.
REFERENCE	1
AUTHORS	Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghanian,R., Taton,T.A., Garimella,V., Li,Z. and Park,S.J.
TITLE	Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL	Patent: WO 0246472-A 55 13-JUN-2002;
FEATURES	
source	Location/Qualifiers 1..20 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630" /note="Random synthetic sequence"
Query Match	0.4%; Score 15.2; DB 1; Length 20; Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches	17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	2567 TTCTCTCTCTTTT 2586 20 TTTTTTTTTTTTTTTT 1
RESULT 144	
LOCUS	AX556139 20 bp DNA linear PAT 27-NOV-2002
DEFINITION	Sequence 70 from Patent WO0246472.
ACCESSION	AX556139
VERSION	AX556139.1 GI:25899521
KEYWORDS	.
SOURCE	synthetic construct
ORGANISM	synthetic construct
REFERENCE	artificial sequences. 1
AUTHORS	Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storchoff,J.J., Elghanian,R., Taton,T.A., Garimella,V., Li,Z. and Park,S.J.
TITLE	Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL	Patent: WO 0246472-A 70 13-JUN-2002;
FEATURES	
source	Location/Qualifiers 1..20 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630" /note="Random synthetic sequence"
Query Match	0.4%; Score 15.2; DB 1; Length 20; Best Local Similarity 85.0%; Pred.No.1.5e+02;
Matches	17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	2567 TTCTCTCTCTTTT 2586 20 TTTTTTTTTTTTTTTT 1
DB	
RESULT 145	
LOCUS	AX565515 20 bp DNA linear PAT 29-NOV-2002
DEFINITION	Sequence 4 from Patent WO02077228.
ACCESSION	AX565515
VERSION	AX565515.1 GI:26000865
KEYWORDS	.
SOURCE	synthetic construct
ORGANISM	synthetic construct
REFERENCE	artificial sequences. 1
AUTHORS	de Villaray,J.P., Moshous,D. and Fischer,A.
TITLE	Gene involved in V(d)J recombination and/or dna repair
JOURNAL	Patent: WO 02077228-A 4 03-OCT-2002;

```

FEATURES
source
INSERM (E.P.S.T.) (FR)
Location/Qualifiers
1..20
/mol_type="synthetic construct"
/db_xref="taxon:32630"
/note="Primer 169P"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2514 TGTATCTCTGTAAGTTT 2533
1 ||| ||||| |||||
1 TGTATCTCTGTGCAGGTTT 20

RESULT 146
AX573350 20 bp DNA linear PAT 29-NOV-2002
LOCUS
DEFINITION Sequence 4 from Patent WO02077026.
ACCESSION AX573350
VERSION AX573350.1 GI:26005233
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS de Villatray,J.P., Moshou,D. and Fischer,A.
TITLE Gene involved in v(d) recombination and/or dna repair
JOURNAL Patent: WO 02077026-A 4 03-OCT-2002;
INSITUUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
(FR)

FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer 169P"

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2514 TGTATCTCTGTAAGTTT 2533
1 ||| ||||| |||||
1 TGTATCTCTGTGCAGGTTT 20

Db 1 TGTATCTCTGTGCAGGTTT 20

RESULT 147
AX663044/C 20 bp DNA linear PAT 22-MAR-2003
LOCUS
DEFINITION Sequence 1 from Patent WO02066989.
ACCESSION AX663044
VERSION AX663044.1 GI:29163589
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Kaufman,S.J.
TITLE Diagnostics, assay methods and amelioration of muscular dystrophy
JOURNAL symptoms
PATENT: WO 02066989-A 1 23-AUG-2002;
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US)
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide useful as a primer"

FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide useful as a primer"

Query Match 0.4%; Score 15.2; DB 1; Length 20;

```


REFERENCE	1	artificial sequences.
AUTHORS		Kirteem,N.V., Hyldig-Nielsen,J.V. and Williams,B.F.
TITLE		Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid
JOURNAL		Patent: WO 03027328-A 26 03-APR-2003;
FEATURES		Boston Probe, Inc. (US) ; DakoCytomation Denmark A/S (DK)
source		Location/Qualifiers
	1..20	
	/organism="synthetic construct"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:32630"	
	/note="Description of Combined DNA/RNA Molecule:Synthetic Oligomer Sequence-Synthetic Probe Sequence"	
Query Match		0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%;	Pred.No.1.5e+02;
Matches	17; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
QY	2567	TTTCTTCTTCTTTTCTTTT 2586
Db	20	TTTTTTTTTTTTTTTTTTT 1
RESULT 153		
LOCUS	AX804730	20 bp DNA linear PAT 25-NOV-2003
DEFINITION	Sequence 898 from Patent WO03060160.	
ACCESSION	AX804730	
VERSION	AX804730.1	GI:38521871
KEYWORDS		
SOURCE		
ORGANISM		Oreochromis niloticus (Nile tilapia)
		Oreochromis niloticus
		Eutariota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
		Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
		Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
		Labroidae; Cichlidae; Oreochromis.
REFERENCE	1	
AUTHORS		Lie,Y., Sletten,A., Hoeyum,M. and Lingaas,F.
TITLE		Verification of food origin based on nucleic acid pattern recognition
JOURNAL		Patent: WO 03060160-A 898 24-JUL-2003;
FEATURES		Genomat ASA (NO)
source		Location/Qualifiers
	1..20	
	/organism="Oreochromis niloticus"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:8128"	
Query Match		0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%;	Pred.No.1.5e+02;
Matches	17; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
QY	1287	AGCGTACTGTTTGTCGTG 1306
Db	20	AGTGTGCTGTTTGTCGTG 1
RESULT 154		
LOCUS	AX804813	20 bp DNA linear PAT 25-NOV-2003
DEFINITION	Sequence 981 from Patent WO03060160.	
ACCESSION	AX804813	
VERSION	AX804813.1	GI:38521954
KEYWORDS		
SOURCE		
ORGANISM		Oreochromis niloticus (Nile tilapia)
		Oreochromis niloticus
		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
		Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
		Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
		Labroidae; Cichlidae; Oreochromis.
REFERENCE	1	

```

AUTHORS      life.Y., Sletten,A., Hoeyum,M. and Lingaas,F.
TITLE        Verification of food origin based on nucleic acid pattern
JOURNAL      recognition
              Patent: WO 03060160-A 981 24-JUL-2003;
              Genomar ASA (NO)
FEATURES
  source      location/Qualifiers
              1..20
              /organism="Oreochromis niloticus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:8128"

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3095 ATCTGTGAGGCCAGCAATA 3114
Db      1 ATCTGGAGGCGCAGAAATA 20

RESULT 155
AX937865/c      20 bp DNA linear PAT 06-JAN-2004
LOCUS
DEFINITION      Sequence 133 from Patent WO03091381.
ACCESSION      AX937865
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  AUTHORS      Rappold,G.A. and Kirsch,S.
  TITLE        Height-related gene
  JOURNAL      Patent: WO 03091381-A 133 06-NOV-2003;
              Rappold, Gudrun A. (DE)
FEATURES
  source      location/Qualifiers
              1..20
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="RT-PCR primer for exon trap clone: eta2 reverse"

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1222 ACAAGACATCCCTGATGTC 1241
Db      20 AGAAGACACCCCTGATGTC 1

RESULT 156
BD008523/c      20 bp DNA linear PAT 31-JAN-2002
LOCUS
DEFINITION      Compounds and methods for treatment and diagnosis of Mycobacterial
              infections.
ACCESSION      BD008523
VERSION      BD008523.1 GI:18636896
KEYWORDS      JP 2001503969-A/26.
SOURCE      unidentified
ORGANISM      unidentified
              unclassified.
              1 (baae 1 to 20)
              Tan,P., Hiyana,O., Visser,E.S., Skinner,M.A., Scott,L.M. and
              Priestidge,R.L.
              Compounds and methods for treatment and diagnosis of Mycobacterial
              infections
              Patent: JP 2001503969-A 26 27-MAR-2001;
              GENESIS RESEARCH & DEVELOPMENT CO LTD
              OS      Unidentified
              PN      JP 2001503969-A/26
              PD      27-MAR-2001
              PF      28-AUG-1997 JP 1998511516

JOURNAL
COMMENT

```

	PI	PAUL TAN,JUN HIYAMA,ELIZABETH S VISSER,MARGOT A SKINNER, PI LINDA M SCOTT,
	PI	ROSS U FRESTIDGE
	PC	A6IKJ9/04,A6IKJ5/74,C07KI4/35,C12NI5/63
	CC	Strandedness: Single;
	CC	Topology: Linear;
	FH	Key
	FT	Location/Qualifiers
	FT	source 1..20 /organism='unidentified'.
		location/Qualifiers
		1..20
		/organism="unidentified"
		/mol_type="genomic DNA"
		/db_xref="taxon:32644"
Query Match		0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity		85.0%; Pred.No.1.5e+02;
Matches 17; Conservative		0; Mismatches 3; Indels 0; Gaps 0;
Oy	2567	TTCCTCCTCTTTTTTTT 2586 TTTTTTTTTTTTTTTTTT 1
Dn	20	TTTTTTTTTTTTTTTTTT 1
RESULT 157		
	BD080522	20 bp RNA linear PAT 27-AUG-2002
LOCUS	BD080522	Ribonucleoside-derivative and method for preparing the same.
DEFINITION	BD080522	
ACCESSION	BD080522	GI:22626125
VERSION	JP 2001515087-A/1.	
KEYWORDS		synthetic construct
SOURCE		artificial sequences.
ORGANISM		1 (bases 1 to 20)
REFERENCE		Pitsch,S., Weiss,P.A. and Jenny,I.
AUTHORS		Ribonucleoside-derivative and method for preparing the same
TITLE		Patent: JP 2001515087-A 1 18-SEP-2001;
JOURNAL		STEFAN PITTSCH,PATRICK A WEISS,LUZI JENNY
COMMENT		OS Artificial Sequence
	PN	JP 2001515087-A/1
	PD	18-SEP-2001
	PP	17-AUG-1998 JP 2000509723
	PR	18-AUG-1997 CH 1931/97
	PI	STERFAN PITTSCH,PATRICK A WEISS,LUZI JENNY
	PC	C07HI19/06,C07F7/18,C07HI19/16,C07H21/02,C07H23/00 CC
	Key	Description of Artificial sequence:synthetic polynucleotide FH
	FT	Location/Qualifiers
	FT	source 1..20 /organism='Artificial Sequence'.
		location/Qualifiers
		1..20
		/organism="synthetic construct"
		/mol_type="genomic RNA"
		/db_xref="taxon:32630"
Query Match		0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity		85.0%; Pred.No.1.5e+02;
Matches 17; Conservative		0; Mismatches 3; Indels 0; Gaps 0;
Oy	2567	TTCCTCCTCTTTTTTTT 2586 TTTTTTTTTTTTTTTTTT 20
Dn	1	TTTTTTTTTTTTTTTTTT 20
RESULT 158		
	BD089333	20 bp DNA linear PAT 27-AUG-2002
LOCUS	BD089333	A method of arraying genome clone.
DEFINITION	BD089333	
ACCESSION	BD089333	GI:22634943
VERSION	JP 2001321190-A/1577.	
KEYWORDS		

ORGANISM	synthetic construct
SOURCE	synthetic construct
REFERENCE	1 (bases 1 to 20)
AUTHORS	Soeda,E.
TITLE	A method of arraying genome clone
JOURNAL	Patent: JP 2001321190-A 1577 20-NOV-2001; THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
COMMENT	GENOTEC
OS	Artificial Sequence
PN	JP 2001321190-A/1577
PD	20-NOV-2001
PF	12-MAR-2001 JP 2001068285
PI	EIICHI SOEDA
PC	C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566,PC
PC	C12N15/00,
CC	Description of Artificial Sequence:Synthetic DNA FH
FT	Location/Qualifiers
source	1..20 /Organism='Artificial Sequence', /organization='synthetic construct' /mol_type='genomic DNA' /db_xref='taxon:32630'
FEATURES	
source	1..20 Location/Qualifiers
Query Match	0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. No. 1.5e+02;
Matches	17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy	3360 GCCTTGATATATGTTAGCC 3379
Db	1 GCCTTGAGAAATATTTTAGCC 20
RESULT 159	
LOCUS	BD107450 20 bp DNA linear PAT 18-SEP-2002
DEFINITION	Method of detecting single base polymorphism.
ACCESSION	BD107450
VERSION	BD107450.1 GI:23202268
KEYWORDS	JP 2002034599-A/9.
SOURCE	synthetic construct
ORGANISM	artificial construct
REFERENCE	1 (bases 1 to 20)
AUTHORS	Segawa,M., Takarada,H., Aono,T. and Yoshiga,S.
TITLE	Method of detecting single base polymorphism
JOURNAL	Patent: JP 2002034599-A 9 05-FEB-2002; TOYOBO CO LTD
COMMENT	OS Artificial Sequence
PN	JP 2002034599-A/9
PD	05-FEB-2002
PF	26-JUL-2000 JP 2000225354
PI	MASUYA SEGAWA,HIROSHI TAKARADA,TOSHIYA AONO,SATOKO YOSHIGA PC
CC	C12Q1/68,C12N15/09,C12N15/00
CC	Description of Artificial Sequence:primer
FH	Key Location/Qualifiers
FT	1..20 /Organism='Artificial Sequence', /organization='synthetic construct' /mol_type='genomic DNA' /db_xref='taxon:32630'
FEATURES	
source	1..20 Location/Qualifiers
Query Match	0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. No. 1.5e+02;
Matches	17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy	2567 TTTCCTCTCTTTTCTTTT 2566
Db	TTTCCTCTCTTTTCTTTT

Db 1 TTTT TTTT TTTT TTTT TTTT 20

RESULT 160
BD255546 17 bp DNA linear PAT 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
DEFINITION BD255546
ACCESSION BD255546.1 GI:33065316
VERSION JP 2002541795-A/3339.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 3339 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/3339
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91)
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source 1..17
Location/Qualifiers
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2926 TGAATATATTCTCG 2940
|||||
3 TGAATATATTCTCG 17

Db

RESULT 161
BD255547 17 bp DNA linear PAT 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
DEFINITION BD255547
ACCESSION BD255547.1 GI:33065317
VERSION JP 2002541795-A/3340.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 3340 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/3340
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC

C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91)
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source 1..17
Location/Qualifiers
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3095 ATCTGTGAGGCCAGC 3109
|||||
15 ATCTGTGAGGCCAGC 1

Db

RESULT 162
BD259223 17 bp DNA linear PAT 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
DEFINITION BD259223
ACCESSION BD259223.1 GI:33068993
VERSION JP 2002541795-A/7016.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 7016 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/7016
PD 10-DEC-2002 JP 2000611654
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91)
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source 1..17
Location/Qualifiers
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 3134 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2914 TATTTGCAATTTGA 2928
Db 17 TATTTGCAATTTGA 3

RESULT 168
LOCUS A97837 18 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 114 from Patent WO9914377.
ACCESSION A97837
VERSION A97837.1 GI:6781075
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Quint, W. and Kleier, B.
TITLE DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND TYPE-SPECIFIC REVERSE HYBRIDIZATION
JOURNAL Patent: WO 9914377-A 114 25-MAR-1999;
FEATURES INNOGENETICS NV (BE); DELFTS DIAGNOSTIC LAB B V (NL)
source Location/Qualifiers
1.18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3698 TTTAATGAGTTATTT 3712
Db 4 TTTAATGAGTTATTT 18

RESULT 169
LOCUS AR254830 18 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 114 from patent US 6482588.
ACCESSION AR254830
VERSION AR254830.1 GI:27303878
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Van Doorn, L.-J., Quint, W., Kleier, B. and Tersmette, J.
TITLE Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization
JOURNAL Patent: US 6482588-A 114 19-NOV-2002;
FEATURES Location/Qualifiers
1.18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3698 TTTAATGAGTTATTT 3712
Db 4 TTTAATGAGTTATTT 18

RESULT 170
LOCUS AX428715 18 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 114 from Patent EP1201771.
ACCESSION AX428715
VERSION AX428715.1 GI:21538626
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Van Doorn, L.-J., Kleier, B. and Tersmette, J.
TITLE Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization
JOURNAL Patent: EP 1201771-A 114 02-MAY-2002;
FEATURES INNOGENETICS N.V. (BE); DELFTS Diagnostic Laboratory B.V. (NL)
source Location/Qualifiers
1.18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3698 TTTAATGAGTTATTT 3712
Db 4 TTTAATGAGTTATTT 18

RESULT 171
LOCUS AX296645 20 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 8407 from Patent WO0179548.
ACCESSION AX296645
VERSION AX296645.1 GI:17058334
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Barany, F., Zivni, M., Gerry, N.P., Favis, R. and Kliman, R.
TITLE Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction
JOURNAL Patent: WO 0179548-A 8407 25-OCT-2001;
FEATURES CORNELL RESEARCH FOUNDATION, INC. (US)
source Location/Qualifiers
1.20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2172 AAGTGAGGGGAGCTG 2186
Db 19 AAGTGAGGGGAGCTG 5

RESULT 172
LOCUS AX816429 20 bp DNA linear PAT 09-DEC-2003

DEFINITION Sequence 18 from Patent WO03066900.
ACCESSION AX816429
VERSION AX816429.1 GI:39646903
KEYWORDS Capsicum annuum
SOURCE Capsicum annuum
ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids; lamiales; Solanales; Solanaceae; Capsicum.
REFERENCE 1
AUTHORS Caranta,C., Ruffel,S., Bendahmane,A., Palloix,A.M. and Robaglia,C.
TITLE Bifide gene mutations and potyvirus resistance
JOURNAL Patent: WO 03066900-A 18 14-AUG-2003;
Genoplante-Valor (FR)
FEATURES
source Location/Qualifiers
1..20
/organism="Capsicum annuum"
/mol_type="unassigned DNA"
/db_xref="taxon:4072"
Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2599 AAAAGCACACGAC 2613
DB 1 AAAAGCACACGAC 15
RESULT 173
LOCUS AR173675 18 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 84 from patent US 6306588.
ACCESSION AR173675
VERSION AR173675.1 GI:17913995
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Solus,J., Yang,S. and Chatterjee,D.K.
TITLE Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof
JOURNAL Patent: US 6306588-A 84 23-OCT-2001;
FEATURES
source Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1442 TCCACAGCCATGTAATCC 1459
DB 1 TCCACAGCCATGTAATCC 18
RESULT 174
LOCUS CQ797008 18 bp DNA linear PAT 19-APR-2004
DEFINITION Sequence 25 from Patent WO2004027066.
ACCESSION CQ797008
VERSION CQ797008.1 GI:46408584
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified.
REFERENCE 1
AUTHORS Letourneur,O.
TITLE Chimeric recombinant protein and in vitro diagnosis
JOURNAL Patent: WO 2004027066-A 25 01-APR-2004;
Biomerieux (FR)

FEATURES
source Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="artificial sequence"
Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2567 TTCTTCCTCTTTTCTTTT 2584
DB 18 TTCTTCCTCTTTTCTTTT 1
RESULT 175
LOCUS BD057109 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof.
ACCESSION BD057109
VERSION BD057109.1 GI:22602715
KEYWORDS JP 2001511018-A/60.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 18)
AUTHORS Chatterjee,D.K., Solus,J. and Yang,S.
TITLE Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof
JOURNAL Patent: JP 2001511018-A 60 07-AUG-2001;
LIFE TECHNOLOGIES INC
COMMENT
PN JP 2001511018-A/60
PD 07-AUG-2001
PF 09-FEB-1998 JP 1998535069
PR 07-FEB-1997 US 60/037393
PI DEB K CHATTERJEE JOSSEPH SOLUS SHUWEI YANG
PC C12Q1/68,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/12,C12N15/00
PC C12N5/00
CC Strandedness: Both;
CC Topology: Both;
FH Key
FEATURES
source Location/Qualifiers
1..18
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1442 TCCACAGCCATGTAATCC 1459
DB 1 TCCACAGCCATGTAATCC 18
RESULT 176
LOCUS A02071 19 bp DNA linear PAT 19-MAR-1993
DEFINITION Artificial sequence for oligonucleotide No.1.
ACCESSION A02071
VERSION A02071.1 GI:344560
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS
TITLE PRODUCTION OF HUMAN INTERFERON- alpha

JOURNAL Patent: WO 8502862-A 2 04-JUL-1985;
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAGGCTGAAGCATGA 2791
DB 18 TTAAGAGAGAGCATGA 1
|||||
|||||

RESULT 177
AR279300/c 19 bp DNA linear PAT 10-APR-2003
LOCUS Sequence 59 from patent US 6514697.
DEFINITION AR279300
ACCESSION AR279300
VERSION AR279300.1 GI:297114028
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 19)
AUTHORS Petersen,C., Barnes,D.A., Nelson,R.C. and Gut,J.
TITLE Methods for detection of Cryptosporidium species and isolates and
for diagnosis of Cryptosporidium infections
JOURNAL Patent: US 6514697-A 59 04-FEB-2003;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3257 TGCTTTCCATCGATCC 3274
DB 18 TGCTTTCATATGATCC 1
|||||
|||||

RESULT 178
AR428324 19 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 1 from patent US 6642000.
DEFINITION AR428324
ACCESSION AR428324
VERSION AR428324.1 GI:40187789
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 19)
AUTHORS Strishkov,B., Tiliib,S., Mikhailovich,V. and Mirzabekov,A.
TITLE PCR amplification on microarrays of gel immobilized
oligonucleotides
JOURNAL Patent: US 6642000-A 1 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3361 CCTTGATATATGTTAGC 3378
DB 2 CCTTGATATATCTTACC 19
|||||
|||||

RESULT 179
AX130000/c 19 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 1218 from Patent WO0130362.
DEFINITION AX130000
ACCESSION AX130000
VERSION AX130000.1 GI:14136305
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Homo sapiens; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 Robbins,J.M. and Tritz,R.
Ribozyne therapy for the treatment of proliferative skin and eye
diseases
JOURNAL Patent: WO 0130362-A 1218 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cdk-we-hu ribozyme binding site"

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2984 ATTCTCAGAGGAGATT 3001
DB 18 ATTCTCAGAGCGCATTT 1
|||||
|||||

RESULT 180
AX131776 19 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 2994 from Patent WO0130362.
DEFINITION AX131776
ACCESSION AX131776
VERSION AX131776.1 GI:14138081
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Homo sapiens; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 Robbins,J.M. and Tritz,R.
Ribozyne therapy for the treatment of proliferative skin and eye
diseases
JOURNAL Patent: WO 0130362-A 2994 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin A1 ribozyme binding site"

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2559 CTCGCCAGCTTCTCTTC 2576
DB 1 CTCGCCAGATTGCTCTTC 18
|||||
|||||

RESULT 181
AX132146 19 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 3364 from Patent WO0130362.
DEFINITION AX132146
ACCESSION AX132146
VERSION AX132146.1 GI:14138451

KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	1 Robbins,J.M. and Tritz,R.				
AUTHORS	Ribozyme therapy for the treatment of proliferative skin and eye diseases				
TITLE	Patent: WO 0130362-A 3364 03-MAY-2001;				
JOURNAL	IMMUSOL, INC. (US)				
FEATURES	Location/Qualifiers				
source	1..19				
	/organism="Homo sapiens"				
	/mol type="unassigned DNA"				
	/db xref="taxon:9606"				
	/note="Cyclin B1 ribozyme binding site"				
Qy	3442	TGCCATGTTTATTCACAG	3459		
	1				
Db	1	TGCCATGTTTATTCACAG	18		
RESULT 182					
LOCUS	AX132502	19 bp	DNA	linear	PAT 15-MAY-2001
DEFINITION	Sequence 3720 from Patent WO0130362.				
ACCESSION	AX132502				
VERSION	AX132502.1	GI:14138807			
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	1 Robbins,J.M. and Tritz,R.				
AUTHORS	Ribozyme therapy for the treatment of proliferative skin and eye diseases				
TITLE	Patent: WO 0130362-A 3720 03-MAY-2001;				
JOURNAL	IMMUSOL, INC. (US)				
FEATURES	Location/Qualifiers				
source	1..19				
	/organism="Homo sapiens"				
	/mol type="unassigned DNA"				
	/db xref="taxon:9606"				
	/note="Cdc25 hs ribozyme binding site"				
Query Match	0.4%;	Score 14.8;	DB 1;	Length 19;	
Best Local Similarity	88.9%;	Pred. No. 1.6e+02;			
Matches	16;	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0;	
Qy	2194	ATCTTCTTCGAGAGAG	2211		
	1				
Db	2	AACCTCTTCTGAGAGAG	19		
RESULT 183					
LOCUS	AX132503	19 bp	DNA	linear	PAT 15-MAY-2001
DEFINITION	Sequence 3721 from Patent WO0130362.				
ACCESSION	AX132503				
VERSION	AX132503.1	GI:14138808			
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	1 Robbins,J.M. and Tritz,R.				

TITLE	Ribozyme therapy for the treatment of proliferative skin and eye diseases			
JOURNAL	Patent: WO 0130362-A 3721 03-MAY-2001;			
IMMUSOL, INC. (US)	Location/Qualifiers			
1. .19	/organism="Homo sapiens"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:9606"			
/note="Cdc25 hs ribozyme binding site"				
Query Match	0.4%;	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%;	Pred. No. 1.6e+02;		
Matches 16;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Oy	2194	ATCTTCTCCTGAAGANG	2211	
Db	1	AACCTCTTCTGAAGANG	18	
RESULT 184				
LOCUS	AX193517	19 bp	DNA	linear
DEFINITION	Sequence 1 from Patent WO0134842.			
ACCESSION	AX193517			
VERSION	AX193517.1	GI:15211451		
KEYWORDS	.			
SOURCE	synthetic construct			
ORGANISM	synthetic construct			
REFERENCE	1			
AUTHORS	Mikhailovich, V., Mirzabekov, A., Strizhkov, B.N. and Tiliib, S.			
TITLE	PCR amplification on microarrays of gel immobilized oligonucleotides			
JOURNAL	Patent: WO 0134842-A 1 17-MAY-2001;			
THE UNIVERSITY OF CHICAGO (US)	Location/Qualifiers			
1. .19	/organism="synthetic construct"			
	/mol_type="unassigned DNA"			
/db_xref="taxon:12630"	/note="Primer"			
Query Match	0.4%;	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%;	Pred. No. 1.6e+02;		
Matches 16;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Oy	3361	CCTGATATATGTTAGC	3378	
Db	2	CCTGATATATCTTACC	19	
RESULT 185				
LOCUS	AX802546	19 bp	DNA	linear
DEFINITION	Sequence 56 from Patent WO03057914.			
ACCESSION	AX802546			
VERSION	AX802546.1	GI:38501244		
KEYWORDS	.			
SOURCE	synthetic construct			
ORGANISM	synthetic construct			
REFERENCE	1			
AUTHORS	Karlsen, F.			
TITLE	Method for detecting human papillomavirus mRNA			
JOURNAL	Patent: WO 0305791-A 56 17-JUL-2003;			
NORCHIP A/S (NO)	Location/Qualifiers			
1. .19	/organism="synthetic construct"			
	/mol_type="unassigned DNA"			
/db_xref="taxon:32630"	/note="HPV probe"			
FEATURES	source			

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3253 GTTGTGCTTTCATCTG 3270
 Db 18 GTTGTGCTTTCATCTG 1

RESULT 186
 AX803061/c 19 bp DNA linear PAT 24-NOV-2003
 LOCUS Sequence 93 from Patent WO03057927.
 DEFINITION AX803061
 ACCESSION AX803061
 VERSION AX803061.1 GI:38501726
 KEYWORDS
 SOURCE Human papillomavirus
 ORGANISM Human papillomavirus
 Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;
 Papillomavirus.
 REFERENCE 1
 AUTHORS Karlsson, F.
 TITLE Detection of human papillomavirus e6 mRNA
 JOURNAL Patent: WO 03057927-A 93 17-JUL-2003;
 Norchip A/S (NO)
 FEATURES
 source Location/Qualifiers
 1.19
 /organism="Human papillomavirus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10566"

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3253 GTTGTGCTTTCATCTG 3270
 Db 18 GTTGTGCTTTCATCTG 1

RESULT 187
 ATH521258/c 19 bp DNA linear PLN 29-MAR-2003
 LOCUS Arabidopsis thaliana T-DNA flanking sequence, right border, clone
 DEFINITION 263H10.
 ACCESSION AJ521258
 VERSION AJ521258.1 GI:26789494
 KEYWORDS right border; T-DNA flanking sequence.
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eustosids II; Brassicales; Brassicaceae; Arabidopsids.
 1
 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
 Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
 Lepoint, L., Caboche, M. and Lecharny, A.
 T-DNA integration into the Arabidopsis genome depends on sequences
 of pre-insertion sites
 EMBO Rep. 3 (12), 1152-1157 (2002)
 JOURNAL
 MEDLINE 22363535
 PUBMED 12446565
 REFERENCE 2 (bases 1 to 19)
 AUTHORS Balzerque, S.
 TITLE Direct Submission
 JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
 Gaston Cremieux, 91057 Evry cedex, FRANCE
 COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
 plants from INRA (Versailles). The DNA fragment(s) resulting from
 the PCR were directly sequenced from the left or the right border
 to determine the genomic sequence flanking the insertion. T-DNA
 derived sequences were removed. Information to order the

corresponding mutant line and a link to a database providing a
 graphical display of the insertion site are available at
<http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has
 been generated in the framework of the French plant genomics
 program 'genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.infobiogen.fr>).

FEATURES
 source Location/Qualifiers
 1.19
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultiivar="waasillewskija"
 /db_xref="taxon:3702"
 /clone="263H10"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"

misc_feature
 1.19
 /note="T-DNA flanking sequence
 right border"

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3486 TTCATATTACTATTTA 3503
 Db 18 TTCATATTACTATTTA 1

RESULT 188
 AR271155/c 20 bp DNA linear PAT 10-APR-2003
 LOCUS Sequence 98 from patent US 6503152.
 DEFINITION AR271155
 ACCESSION AR271155
 VERSION AR271155.1 GI:29702458
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Pelz, D.T.
 TITLE Putting trainer
 JOURNAL Patent: US 6503152-A 98 07-JAN-2003;
 FEATURES
 source Location/Qualifiers
 1.20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 1.7e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 410 GCCTCCTCCGGCCGCTG 427
 Db 20 GCCTCCTCCGGCCGCTG 3

RESULT 189
 A95837/c 16 bp DNA linear PAT 26-JAN-2000
 LOCUS Sequence 10 from Patent WO9924608.
 DEFINITION A95837
 ACCESSION A95837
 VERSION A95837.1 GI:6779773
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 16)
 AUTHORS Lev, Z. and Herzog, R.
 TITLE METHOD FOR LABELING POLYNUCLEOTIDES
 JOURNAL Patent: WO 9924608-A 10 20-MAY-1999;
 (TECHNION RES & DEV FOUNDATION (IL); LEV ZEEV (IL)
 FEATURES
 source Location/Qualifiers
 1.16
 /organism="unidentified"

/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1731 CTTCTCTTCCAAAA 1746
DB 16 CTTCTCTTCAAAAA 1

RESULT 190
LOCUS AR101754 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 16 from patent US 6083702.
ACCESSION AR101754
VERSION AR101754.1 GI:12812552
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Mitchell, L.G. and Garcia-Bianco, M.A.
TITLE Methods and compositions for use in spliceosome mediated RNA
trans-splicing
JOURNAL Patent: US 6083702-A 16 04-JUL-2000;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2573 CTTCTCTTTTCTCT 2588
DB 1 CTTCTCTTTTCTCT 16

RESULT 191
LOCUS AR166243 17 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 16 from patent US 6280978.
ACCESSION AR166243
VERSION AR166243.1 GI:16241478
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Mitchell, L.G. and Garcia-Bianco, M.A.
TITLE Methods and compositions for use in spliceosome mediated RNA
trans-splicing
JOURNAL Patent: US 6280978-A 16 28-AUG-2001;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2573 CTTCTCTTTTCTCT 2588
DB 1 CTTCTCTTTTCTCT 16

RESULT 192
LOCUS BD258358 17 bp DNA linear PAT 17-JUL-2003

DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD258358
VERSION BD258358.1 GI:33068128
KEYWORDS JP 2002541795-A/6151.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and McSwiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 6151 10-DEC-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/6151
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN
PC C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02, A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism="Eukaryote".
FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2485 TTTCTCTGTGACTCCT 2500
DB 2 TTTCTCTGTGACACT 17

RESULT 193
LOCUS I37405 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 418 from patent US 5612215.
ACCESSION I37405
VERSION I37405.1 GI:2085365
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and
Stinchcomb, D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 418 18-MAR-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2002 TACAACCTTGAAAG 2017
DB 1 TACAACCTTGAAAG 16


```

RESULT 194
LOCUS 194255 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 418 from patent US 5731295.
ACCESSION 194255
VERSION 194255.1 GI:3938725
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1..17
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
    0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2002 TACAACCTTGAAAG 2017
Db 1 TACAACCTTGAAAG 16
|||||
|||||

RESULT 195
LOCUS AR327747 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5149 from patent US 6566127.
ACCESSION AR327747
VERSION AR327747.1 GI:33713555
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1..17
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match
    0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2590 AAAAAAGAAAAAGCA 2605
Db 1 AAAAAAGCAAAAAAGCA 16
|||||
|||||

RESULT 196
LOCUS AR328884 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6286 from patent US 6566127.
ACCESSION AR328884
VERSION AR328884.1 GI:33714692
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1..17
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match
    0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

JOURNAL Patent: US 6566127-A 6286 20-MAY-2003;
FEATURES
source
    1..17
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match
    0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2139 TTCTACTTGTCATCA 2154
Db 17 TTCTCTTGTCATCA 2
|||||
|||||

RESULT 197
LOCUS AR328885 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6287 from patent US 6566127.
ACCESSION AR328885
VERSION AR328885.1 GI:33714693
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1..17
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match
    0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2139 TTCTACTTGTCATCA 2154
Db 16 TTCTCTTGTCATCA 1
|||||
|||||

RESULT 198
LOCUS AX055672 17 bp DNA linear PAT 13-JAN-2001
DEFINITION Sequence 30 from Patent WO0073499.
ACCESSION AX055672
VERSION AX055672.1 GI:12228812
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1..17
        /organism="Pneumocystis carinii"
        /mol_type="unassigned DNA"
        /db_xref="taxon:4754"

Query Match
    0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 718 CTTCTTCCAGTGAA 733
 |||||
 Db 16 CTTCTTCCAGCGAA 1

RESULT 199
 LOCUS AX215793 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 1235 from Patent WO0159103.
 ACCESSION AX215793
 VERSION AX215793.1 GI:15525836
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Blatt, L., McSwiggen, J. and Chowrira, B.M.
 AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
 TITLE nogo gene expression
 JOURNAL Patent: WO 0159103-A 1235 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
 McSwiggen, James (US); Chowrira, Bharat M. (US)
 FEATURES
 source 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3640 ATTGTTCAAGATGCG 3655
 |||||
 Db 2 ATTATTCAGAAATGCG 17

RESULT 200
 LOCUS AX216730 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2172 from Patent WO0159103.
 ACCESSION AX216730
 VERSION AX216730.1 GI:15526791
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Blatt, L., McSwiggen, J. and Chowrira, B.M.
 AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
 TITLE nogo gene expression
 JOURNAL Patent: WO 0159103-A 2172 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
 McSwiggen, James (US); Chowrira, Bharat M. (US)
 FEATURES
 source 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTT 2586
 |||||
 Db 17 TTCTTCTATTTT 2

RESULT 201
 LOCUS AX531756/C

LOCUS AX531756 17 bp DNA linear PAT 22-NOV-2002
 DEFINITION Sequence 1265 from Patent EP1239051.
 ACCESSION AX531756
 VERSION AX531756.1 GI:25255291
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Homo sapiens (human)
 AUTHORS Homo sapiens
 TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 JOURNAL Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 FEATURES
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2846 ATGGGCTGGAGATCA 2861
 |||||
 Db 17 ATGGGCTGGATGATCA 2

RESULT 202
 LOCUS AX531759 17 bp DNA linear PAT 22-NOV-2002
 DEFINITION Sequence 1268 from Patent EP1239051.
 ACCESSION AX531759
 VERSION AX531759.1 GI:25255297
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Homo sapiens (human)
 AUTHORS Homo sapiens
 TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 JOURNAL Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 FEATURES
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCATGGCTGGAGAT 2859
 |||||
 Db 16 CCATGGCTGGAT 1

RESULT 203
 LOCUS AX532428 17 bp DNA linear PAT 22-NOV-2002
 DEFINITION Sequence 1937 from Patent EP1239051.
 ACCESSION AX532428
 VERSION AX532428.1 GI:25256631
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Homo sapiens (human)
 AUTHORS Homo sapiens
 TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 JOURNAL Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 FEATURES
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1937 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GCTGAGGGGAGGGGG 392
17 GCTGAGGGGAGGGAGG 2

RESULT 204
AX532429/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 1938 from Patent EP1239051.
DEFINITION AX532429
ACCESSION AX532429
VERSION AX532429.1 GI:25256633
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1938 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GCTGAGGGGAGGGGG 392
16 GCTGAGGGGAGGGAGG 1

RESULT 205
AX671966/c 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 411 from Patent WO03004526.
DEFINITION AX671966
ACCESSION AX671966
VERSION AX671966.1 GI:29330314
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 411 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3660 ACAATATATAAAGTGAT 3675
17 ACATATATAAAGTGAT 2

RESULT 206
AX672749/c 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 1194 from Patent WO03004526.
DEFINITION AX672749
ACCESSION AX672749
VERSION AX672749.1 GI:29331097
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1194 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2061 TCAGAAAGCTGGAAC 2076
16 TCAGAAAGCTGGAATC 1

RESULT 207
AX674379/c 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 2824 from Patent WO03004526.
DEFINITION AX674379
ACCESSION AX674379
VERSION AX674379.1 GI:29332727
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 2824 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 CTGCCAGAGCAGCTC 2741
16 CTGCCAGAGCAGATC 1

RESULT 208
AX691781/c
LOCUS AX691781 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4513 from Patent EP1281758.
ACCESSION AX691781
VERSION AX691781.1 GI:29414722
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
PATENT: EP 1281758-A 4513 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2049 AAGCGCAAGCCTCAG 2064
Db 17 AAGCGCAAGCCTTAG 2

RESULT 209
AX691782/c
LOCUS AX691782 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4514 from Patent EP1281758.
ACCESSION AX691782
VERSION AX691782.1 GI:29414723
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
PATENT: EP 1281758-A 4514 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2049 AAGCGCAAGCCTCAG 2064
Db 16 AAGCGCAAGCCTTAG 1

RESULT 210
AX692522
LOCUS AX692522 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5254 from Patent EP1281758.
ACCESSION AX692522
VERSION AX692522.1 GI:29415480
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
PATENT: EP 1281758-A 5254 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2571 TTCTTTCTTTTCTTTT 2586
Db 2 TTCTTTCTTTTCTTTT 17

RESULT 211
AX692523
LOCUS AX692523 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5255 from Patent EP1281758.
ACCESSION AX692523
VERSION AX692523.1 GI:29415481
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
PATENT: EP 1281758-A 5255 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2571 TTCTTTCTTTTCTTTT 2586
Db 1 TTCTTTCTTTTCTTTT 16

RESULT 212
AX725807
LOCUS AX725807 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3494 from Patent WO03025176.
ACCESSION AX725807
VERSION AX725807.1 GI:30505150
KEYWORDS
SOURCE
ORGANISM Mus musculus (house mouse)
REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
JOURNAL Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025176-A 3494 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2980 GATCATTTCTCCAGAG 2995
Db 1 GATCATTTCTCCAAAG 16

RESULT 213
AX727110 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 4797 from Patent WO03025176.
DEFINITION AX727110
ACCESSION AX727110.1 GI:30506453
VERSION
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 4797 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3543 AGGGGTGGAGGGAAT 3558
Db 17 AGGGGTGGAGGGAAT 2

RESULT 214
AX729159 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 793 from Patent WO03025175.
DEFINITION AX729159
ACCESSION AX729159.1 GI:30508502
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 793 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2634 GATCAGAACTCCAGAA 2649
Db 1 GATCAGAACTCCAAWA 16

RESULT 215
AX733382 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 5016 from Patent WO03025175.
DEFINITION AX733382
ACCESSION AX733382
VERSION AX733382.1 GI:30512725
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5016 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3095 ATCTGTGAGCCACGA 3110
Db 2 ATCTGTGAGCCACGA 17

RESULT 216
AX735559 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 1149 from Patent WO03025177.
DEFINITION AX735559
ACCESSION AX735559
VERSION AX735559.1 GI:30514836
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 1149 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2135 TTTCCTACTTGTC 2150
|||||

Db 16 TTCTCTACTGATC 1

RESULT 217
LOCUS AX739681 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5271 from Patent WO03025177.
ACCESSION AX739681
VERSION AX739681.1 GI:30518978
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Teلمان, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 5271 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3660 ACAATATAAGTGAT 3675
Db 17 ACATTATAAGTGAT 2

RESULT 218
LOCUS AX754438 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 785 from Patent WO03037931.
ACCESSION AX754438
VERSION AX754438.1 GI:32167135
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 785 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2209 AAGAACCTTCTCTCT 2224
Db 17 AAGAACCTTCTCTCT 2

RESULT 219
LOCUS AX754439 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 786 from Patent WO03037931.
ACCESSION AX754439
VERSION AX754439.1 GI:32167136

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 786 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2209 AAGAACCTTCTCTCT 2224
Db 16 AAGAACCTTCTCTCT 1

RESULT 220
LOCUS AX757451 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 772 from Patent WO03040369.
ACCESSION AX757451
VERSION AX757451.1 GI:32252067
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Teلمان, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 772 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2726 CTGCCAGAGCAGCTC 2741
Db 16 CTGCCAGAGCAGATC 1

RESULT 221
LOCUS AX760563 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 384 from Patent WO03040369.
ACCESSION AX760563
VERSION AX760563.1 GI:32255179
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Teلمان, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as

JOURNAL Medicines
Patent: WO 03040369-A 3884 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
Source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2135 TTTCTTCTACTGTGTC 2150
|||||
16 TTTCTTCTACTGTGATC 1

RESULT 222
LOCUS AX761627 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 4948 from Patent WO03040369.
ACCESSION AX761627
VERSION AX761627.1 GI:32256243
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 4948 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
Source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2726 CTGCCGAGCAGCTC 2741
|||||
16 CTGCCGAGCAGATC 1

RESULT 223
LOCUS AX761781 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 5102 from Patent WO03040369.
ACCESSION AX761781
VERSION AX761781.1 GI:32256397
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 5102 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
Source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2061 TCAGAGACCTGGAAC 2076
|||||
16 TCAGAGACCTGATC 1

RESULT 224
LOCUS AR095852 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 73 from patent US 6004814.
ACCESSION AR095852
VERSION AR095852.1 GI:10024114
KEYWORDS
SOURCE
ORGANISM
Unknown.

REFERENCE
AUTHORS 1 (bases 1 to 18)
TITLE Bennett, C., Frank, and Cowser, L.M.
Antisense modulation of CD71 expression
JOURNAL Patent: US 6004814-A 73 21-DEC-1999;
FEATURES Location/Qualifiers
Source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 358 ATTGAAGAGAGCCAG 373
|||||
18 ATTGAAGAGAGCCAG 3

RESULT 225
LOCUS AR299605 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 11340 from patent US 6537751.
ACCESSION AR299605
VERSION AR299605.1 GI:31686889
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE
AUTHORS 1 (bases 1 to 18)
TITLE Cohen, D., Chumakov, I. and Blumenfeld, M.
Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 11340 25-MAR-2003;
FEATURES Location/Qualifiers
Source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1072 GAACATTCGATGTG 1087
|||||
16 GAACATTCGATGTG 1

RESULT 226
LOCUS AX127893 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 1132 from Patent WO0130848.
ACCESSION AX127893

VERSION AX127893.1 GI:14134525
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Deneffe, P., Rosier-Montus, M.F., Arnold-Reguigne, I., Prades, C., Naudin, L., Lemoine, C., Duverger, N., Jaye, M., Searfoss, G.H., Remaley, A., Brewer, H.B. and Dean, M.
TITLE Nucleic acids of the human abcl gene and their therapeutic and diagnostic application
JOURNALS Patent: WO 0130848-A 132 03-MAY-2001;
Aventis Pharma S.A. (FR)
FEATURES
source location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer Oligonucleotide"

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2469 ATCCCTACCTTAGTTC 2484
DB 16 ATCCCTCCCTTAGTTC 1
|||||
16 ATCCCTCCCTTAGTTC 1

RESULT 227
AX131240 19 bp DNA linear PAT 15-MAY-2001
LOCUS AX131240
DEFINITION Sequence 2458 from Patent WO0130362.
ACCESSION AX131240
VERSION AX131240.1 GI:14137545
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Carnivora; Hominoidea; Homo.
REFERENCE 1
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNALS Patent: WO 0130362-A 2458 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source location/Qualifiers
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin F ribozyme binding site"

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 324 GGAAGATTTCGATTC 339
DB 2 GGAAGATTTCGATTC 17
|||||
2 GGAAGATTTCGATTC 17

RESULT 228
AX131241 19 bp DNA linear PAT 15-MAY-2001
LOCUS AX131241
DEFINITION Sequence 2459 from Patent WO0130362.
ACCESSION AX131241
VERSION AX131241.1 GI:14137546
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Carnivora; Hominoidea; Homo.

REFERENCE 1
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNALS Patent: WO 0130362-A 2459 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source location/Qualifiers
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin F ribozyme binding site"

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 324 GGAAGATTTCGATTC 339
DB 1 GGAAGATTTCGATTC 16
|||||
1 GGAAGATTTCGATTC 16

RESULT 229
AX139880 19 bp DNA linear PAT 30-MAY-2001
LOCUS AX139880/c
DEFINITION Sequence 132 from Patent EP1096012.
ACCESSION AX139880
VERSION AX139880.1 GI:14275447
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Deneffe, P., Rosier-Montus, M.F., Arnold-Reguigne, I., Prades, C., Naudin, L., Lemoine, C., Duverger, N., Jaye, M., Searfoss, G.H., Remaley, A., Brewer, H.B. and Dean, M.
TITLE Nucleic acids of the human abcl gene and their therapeutic and diagnostic application
JOURNALS Patent: EP 1096012-A 132 02-MAY-2001;
Aventis Pharma S.A. (FR)
FEATURES
source location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer Oligonucleotide"

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2469 ATCCCTACCTTAGTTC 2484
DB 16 ATCCCTCCCTTAGTTC 1
|||||
16 ATCCCTCCCTTAGTTC 1

RESULT 230
AX244257/c 19 bp DNA linear PAT 28-SEP-2001
LOCUS AX244257
DEFINITION Sequence 19 from Patent WO0165569.
ACCESSION AX244257
VERSION AX244257.1 GI:15859305
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Melvin, W.T., Breeman, S., and Jabus, M.B.
TITLE Viral antigen and vaccine against leav (infectious salmon anaemia virus)
JOURNALS Patent: WO 0165569-A 19 13-SEP-2001;
The University Court of The University of Aberdeen (GB)
FEATURES
source location/Qualifiers

source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1567 CATTGACATCTTACAG 1582
|||||
17 CATTGACATCTTACAG 2

RESULT 231
LOCUS AX923652 19 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 87 from Patent WO03080638.
ACCESSION AX923652
VERSION AX923652.1 GI:40216668
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Lacasse, E., McManus, D. and Durkin, J.P.
TITLE Antisense iap nucleobase oligomers and uses thereof
JOURNAL Patent: WO 03080638-A 87 02-OCT-2003;
Aegera Therapeutics Inc. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Based on Homo sapiens. Each nucleobase may be part
of a ribonucleotide, deoxyribonucleotide, or nucleotide
analog-n = T or U"

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTCTG 2589
|||||
19 TTTCCTTTTCTG 1

RESULT 232
LOCUS AX298795 20 bp DNA linear PAT 26-NOV-2001
DEFINITION Sequence 429 from Patent WO0183749.
ACCESSION AX298795
VERSION AX298795.1 GI:17128785
KEYWORDS
SOURCE Mus sp.
ORGANISM Mus sp.
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE Bachmanov, A.A., Beauchamp, G.K., Chatterjee, A., de Jong, P.J., Li, S.,
Li, X., Ohmen, J.D., Reed, D.R., Ross, D. and Tordoff, M.G.
JOURNAL Gene and sequence variation associated with sensing carbohydrate
compounds and other sweeteners
PATENT: WO 0183749-A 429 08-NOV-2001;
WARNER-LAMBERT COMPANY (US); The Moneill Chemical Senses Center
(US)
FEATURES
source
1. .20
/organism="Mus sp."
/mol_type="unassigned DNA"
/db_xref="taxon:10095"

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2874 GGCAGAACTCTGTCACTG 2892
|||||
20 GCCAGAACTCTGTCCATG 2

RESULT 233
LOCUS AX040870 15 bp DNA linear PAT 23-NOV-2000
DEFINITION Sequence 15 from Patent WO0065090.
ACCESSION AX040870
VERSION AX040870.1 GI:11340492
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Lok, S. and Whitmore, T.E.
TITLE The insulin receptor-related receptor gene sequence for diagnosis
JOURNAL of human obesity and diabetic disorders
PATENT: WO 0065090-A 15 02-NOV-2000;
ZymoGenetics, Inc. (US)
FEATURES
source
1. .15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 644 CACACTGTGGGAG 657
|||||
14 CACACTGTGGGAG 1

RESULT 234
LOCUS BD254271 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254271
VERSION BD254271.1 GI:33064041
KEYWORDS JP 2002541795-A/2064.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and McSwiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2064 10-DEC-2002;
RIBOTIME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2064
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PT LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/00, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91)
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1. .17

FEATURES FT /organism='Eukaryote'.
source 1..17 Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 345 GAGGAAGAACCGGA 358
DB 16 GAGGAAGAACCGGA 3

RESULT 235
BD254272/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254272
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254272.1 GI:33064042
VERSION BD254272.1 JP 2002541795-A/2065.
KEYWORDS JP 2002541795-A/2065.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2065 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
PN JP 2002541795-A/2065
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PI 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
CC Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 345 GAGGAAGAACCGGA 358
DB 15 GAGGAAGAACCGGA 2

RESULT 236
BD257470/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD257470
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD257470
VERSION BD257470.1 GI:33067240
KEYWORDS JP 2002541795-A/5263.
SOURCE unidentified
ORGANISM unidentified

REFERENCE unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
JOURNAL Regulation of repressor genes using nucleic acid molecules
Patent: JP 2002541795-A 5263 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
PN JP 2002541795-A/5263
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PI 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
CC Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 380 GAGGGGAGGGGGC 393
DB 15 GAGGGGAGGGGGC 2

RESULT 237
CO616210/c 17 bp DNA linear PAT 02-FEB-2004
LOCUS CO616210
DEFINITION Sequence 950 from Patent WO0192524.
ACCESSION CO616210
VERSION CO616210.1 GI:41666428
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 950 06-DEC-2001;
Aeomica, Inc. (US)

FEATURES source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3428 CTGCCCTGCTTTGC 3441
DB 17 CTGCCCTGCTTTGC 4

RESULT 238
CO616211/c

```

LOCUS       CQ616211               17 bp    DNA             PAT 02-FEB-2004
DEFINITION   Sequence 951 from Patent WO0192524.
ACCESSION    CQ616211
VERSION      CQ616211.1 GI:41666429
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 951 06-DEC-2001;
              Aeonica, Inc. (US)
FEATURES
  source     1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3428 CTGCGCTGCTTTGC 3441
Db      15 CTGCGCTGCTTTGC 2

RESULT 239
LOCUS       CQ616212               17 bp    DNA             PAT 02-FEB-2004
DEFINITION   Sequence 952 from Patent WO0192524.
ACCESSION    CQ616212
VERSION      CQ616212.1 GI:41666430
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 952 06-DEC-2001;
              Aeonica, Inc. (US)
FEATURES
  source     1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3428 CTGCGCTGCTTTGC 3441
Db      15 CTGCGCTGCTTTGC 2

RESULT 240
LOCUS       CQ616213               17 bp    DNA             PAT 02-FEB-2004
DEFINITION   Sequence 953 from Patent WO0192524.
ACCESSION    CQ616213
VERSION      CQ616213.1 GI:41666431
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

```

```

REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 953 06-DEC-2001;
              Aeonica, Inc. (US)
FEATURES
  source     1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3428 CTGCGCTGCTTTGC 3441
Db      14 CTGCGCTGCTTTGC 1

RESULT 241
LOCUS       AR329203               17 bp    RNA             PAT 17-AUG-2003
DEFINITION   Sequence 6605 from patent US 6566127.
ACCESSION    AR329203
VERSION      AR329203.1 GI:33715011
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unknown.
              Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 6605 20-MAY-2003;
              Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1818 CGGTCTGTGGGAA 1831
Db      17 CGGTCTGTGGGAA 4

RESULT 242
LOCUS       AR329204               17 bp    RNA             PAT 17-AUG-2003
DEFINITION   Sequence 6606 from patent US 6566127.
ACCESSION    AR329204
VERSION      AR329204.1 GI:33715012
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unknown.
              Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 6606 20-MAY-2003;
              Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy 1818 CGGCTCTGGGGA 1831
Db 16 CGGCTCTGGGGA 3

RESULT 243
LOCUS AR457273/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 950 from patent US 6686188.
ACCESSION AR457273
VERSION AR457273.1 GI:42692330
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 950 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Gaps 0;

Qy 3428 CTGCTGTCTTGC 3441
Db 17 CTGCTGTCTTGC 4

RESULT 244
LOCUS AR457274/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 951 from patent US 6686188.
ACCESSION AR457274
VERSION AR457274.1 GI:42692331
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 951 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Gaps 0;

Qy 3428 CTGCTGTCTTGC 3441
Db 16 CTGCTGTCTTGC 3

RESULT 245
LOCUS AR457275/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 952 from patent US 6686188.
ACCESSION AR457275
VERSION AR457275.1 GI:42692332
KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 952 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Gaps 0;

Qy 3428 CTGCTGTCTTGC 3441
Db 15 CTGCTGTCTTGC 2

RESULT 246
LOCUS AR457276/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 953 from patent US 6686188.
ACCESSION AR457276
VERSION AR457276.1 GI:42692333
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 953 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Gaps 0;

Qy 3428 CTGCTGTCTTGC 3441
Db 14 CTGCTGTCTTGC 1

RESULT 247
LOCUS AX217118 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2560 from Patent WO0159103.
ACCESSION AX217118
VERSION AX217118.1 GI:15527179
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., McSwigen,J. and Chowrita,B.M.
TITLE Method and reagent for the modulation and diagnosis of cdt20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 2560 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwigen, James (US); Chowrita, Bharat M. (US)
FEATURES Location/Qualifiers
1..17
/organism="synthetic construct"

/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3645 TCAGAAATGCGAAA 3658
|||||
1 TCAGAAATGCGAAA 14

RESULT 248
AX265975/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS AX265975
DEFINITION Sequence 3366 from Patent WO0173002.
ACCESSION AX265975
VERSION AX265975.1 GI:16514774
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Kmiec, E.B., Gampert, H.B. and Rice, M.C.
JOURNAL Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3366 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 CTTTCCAGTGAG 734
|||||
14 CTTTCCAGTGAG 1

RESULT 249
AX265976 17 bp DNA linear PAT 26-OCT-2001
LOCUS AX265976
DEFINITION Sequence 3367 from Patent WO0173002.
ACCESSION AX265976
VERSION AX265976.1 GI:16514775
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Kmiec, E.B., Gampert, H.B. and Rice, M.C.
JOURNAL Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3367 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 CTTTCCAGTGAG 734

|||||
4 CTTTCCAGTGAG 17

RESULT 250
AX673535 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX673535
DEFINITION Sequence 1980 from Patent WO03004526.
ACCESSION AX673535
VERSION AX673535.1 GI:29331883
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijnder, M.
JOURNAL Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 1980 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3270 GATCCTTCACCTCT 3283
|||||
1 GATCCTTCACCTCT 14

RESULT 251
AX674166 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX674166
DEFINITION Sequence 2611 from Patent WO03004526.
ACCESSION AX674166
VERSION AX674166.1 GI:29332514
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijnder, M.
JOURNAL Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 2611 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 68 TTTTTCAGAT 81
|||||
15 TTTTTCAGAT 2

RESULT 252
AX723346/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX723346

```

DEFINITION Sequence 1033 from Patent WO03025176.
ACCESSION AX723346
VERSION AX723346.1 GI:30423847
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1033 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3280 CTCTGTGTCAGGGGA 3293
DB 16 CTCTGTGTCAGGGGA 3

RESULT 253
AX727217/c AX727217 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4904 from Patent WO03025176.
ACCESSION AX727217
VERSION AX727217.1 GI:30506560
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 4904 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3260 TTTTCATCTGATC 3273
DB 14 TTTTCATCTGATC 1

RESULT 254
AX727807/c AX727807 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 5494 from Patent WO03025176.
ACCESSION AX727807
VERSION AX727807.1 GI:30507150
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5494 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

```

```

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5494 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2014 AAAGCTGAGTTG 2027
DB 17 AAAGCTGAGTTG 4

RESULT 255
AX728123 AX728123 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 5810 from Patent WO03025176.
ACCESSION AX728123
VERSION AX728123.1 GI:30507466
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5810 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2575 TCTTTTCTTTTCT 2588
DB 3 TCTTTTCTTTTCT 16

RESULT 256
AX754440/c AX754440 17 bp DNA linear PAT 23-JUN-2003
LOCUS
DEFINITION Sequence 787 from Patent WO03037931.
ACCESSION AX754440
VERSION AX754440.1 GI:32167137
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 787 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source Location/Qualifiers

```

```
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2209 AAGAACCTTCTC 2222
Db 15 AAGAACCTTCTC 2

RESULT 257
AX754441/c 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 788 from Patent WO03037931.
ACCESSION AX754441
VERSION AX754441.1 GI:32167138
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Shannon,M. and Phan,T.
1 Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 788 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2209 AAGAACCTTCTC 2222
Db 14 AAGAACCTTCTC 1

RESULT 258
AR292922/c 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 4657 from patent US 6537751.
ACCESSION AR292922
VERSION AR292922.1 GI:31680206
KEYWORDS
SOURCE
ORGANISM Unknown.
1 Unclassified.
REFERENCE Cohen,D., Chumakov,I. and Blumenfeld,M.
1 (bases 1 to 18)
AUTHORS Ballelic markers for use in constructing a high density
TITLE disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 4657 25-MAR-2003;
FEATURES
source
1. .18
Location/Qualifiers
/mol_type="genomic DNA"

Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 ACCTTCTCTCCTC 2226
Db 17 ACCTTCTCTCCTC 4
```

```
RESULT 259
AR337684/c 18 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 19 from patent US 6566514.
ACCESSION AR337684
VERSION AR337684.1 GI:33724252
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS Wright,J.A., Young,A.H. and Lee,Y.S.
1 (bases 1 to 18)
TITLE Oligonucleotide sequences complementary to thioredoxin or
thioredoxin reductase genes and methods of using same to modulate
cell growth
JOURNAL Patent: US 6566514-A 19 20-MAY-2003;
FEATURES
source
1. .18
Location/Qualifiers
/mol_type="genomic DNA"

Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2011 GGAAAAGCTTGAG 2024
Db 16 GGAAAAGCTTGAG 3

RESULT 260
BD131957/c 18 bp DNA linear PAT 18-SEP-2002
DEFINITION Oligonucleotide sequence complementary to thioredoxin gene or
thioredoxin reductase gene and utilization thereof for controlling
cell proliferation.
ACCESSION BD131957
VERSION BD131957.1 GI:23226902
KEYWORDS JP 2002501743-A/19.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 18)
TITLE Wright,J.A., Young,A.H. and Lee,Y.S.
JOURNAL Oligonucleotide sequence complementary to thioredoxin gene or
thioredoxin reductase gene and utilization thereof for controlling
GENESENSE TECHNOLOGIES INC
OS Homo sapiens (human)
PN JP 2002501743-A/19
PD 22-JAN-2002
PF 29-JAN-1999 JP 200529423
PR 30-JAN-1998 US 60/073196
PI JIM A WRIGHT, AIPING H YOUNG, YOON S LEE
PC C12N15/09,A61K31/711,A61K48/00,A61P35/00,A61P35/04,C07H21/04//
PC (A61K31/711,A61K45:00), (A61K48/00,A61K45:00), C12N15/00 CC
Oligonucleotide sequence complementary to thioredoxin gene or
thioredoxin
CC reductase gene and utilization thereof for controlling cell
proliferation
CC Key Location/Qualifiers
FT source 1. .18
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2011 GGAAGCTTGAAG 2024
|||||
16 GGAAAGCTTGAAG 3

RESULT 261
BD202774/c 17 bp RNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Method and reagent for treating diseases or conditions concerning
BD202774 molecule participating in vasculogenic response.
ACCESSION BD202774.1 GI:33012544
VERSION JP 2002509721-A/5800.
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 17)
REFERENCE Pavco, P.A., Roberts, E., Jarvis, T., Coeshott, C. and Mcswigen, J.A.
AUTHORS Method and reagent for treating diseases or conditions concerning
TITLE molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 5800 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/5800
PD 02-APR-2002 JP 2000541291
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC C12N15/09, A61K31/7088, A61K31/7125, A61K48/00, A61P3/10, A61P17/06, PC
A61P29/00,
PC A61P3/00, A61P43/00, C12N5/10, C12N9/00//A61K35/76, C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
location/Qualifiers
1..17
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 3204 GAAATTGGAATGGCG 3220
|||||
17 GAAATTGGAATGGCG 1

RESULT 262
BD254257 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
BD254257
ACCESSION BD254257.1 GI:33064027
VERSION JP 2002541795-A/2050.
KEYWORDS unclassified
SOURCE unclassified
ORGANISM unclassified.
1 (bases 1 to 17)
REFERENCE Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
AUTHORS Regulation of repressor genes using nucleic acid molecules
TITLE Patent: JP 2002541795-A 2050 10-DEC-2002;
JOURNAL RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
PN JP 2002541795-A/2050
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 2998 ATTTTGTGCTCTCT 3014
|||||
1 ATTATTTGCTCTGT 17

RESULT 263
BD254430 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
BD254430
ACCESSION BD254430.1 GI:33064200
VERSION JP 2002541795-A/2223.
KEYWORDS unclassified
SOURCE unclassified
ORGANISM unclassified.
1 (bases 1 to 17)
REFERENCE Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
AUTHORS Regulation of repressor genes using nucleic acid molecules
TITLE Patent: JP 2002541795-A 2223 10-DEC-2002;
JOURNAL RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/2223
PD 10-DEC-2002 JP 2000611654
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02, (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1771 TCGGCGAGGAGGCTCCA 1787
DB 17 TCGACGAGGAGGCTCCA 1

RESULT 264
BD258354 17 bp DNA linear PAT 17-JUL-2003

LOCUS BD258354
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD258354
VERSION BD258354.1 GI:33068124
KEYWORDS JP 2002541795-A/6147.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 6147 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT

OS Eukaryote
PN JP 2002541795-A/6147
PD 10-DEC-2002
PE 11-APR-2000 JP 200611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN
PC C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
Location/Qualifiers
1..17
/organism='Eukaryote'.
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2478 TTAGTCTTCTCTCTG 2494
DB 1 TTATTTTCTCTCTG 17

RESULT 265

BD258355 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD258355
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD258355
VERSION BD258355.1 GI:33068125
KEYWORDS JP 2002541795-A/6148.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 6148 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT

OS Eukaryote
PN JP 2002541795-A/6148

PD 10-DEC-2002
PF 11-APR-2000 JP 200611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN
PC C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
Location/Qualifiers
1..17
/organism='Eukaryote'.
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES

source 1..17
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2479 TAGTCTTCTCTCTGA 2495
DB 1 TTATTTTCTCTCTGA 17

RESULT 266

BD258356 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD258356
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD258356
VERSION BD258356.1 GI:33068126
KEYWORDS JP 2002541795-A/6149.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 6149 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT

OS Eukaryote
PN JP 2002541795-A/6149
PD 10-DEC-2002
PE 11-APR-2000 JP 200611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN
PC C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
Location/Qualifiers
1..17
/organism='Eukaryote'.
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES

source 1..17
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2480 AGTCTTCTCTCTGAC 2496
 DB 1 ATTTTCTCTCTGAC 17

RESULT 267
 BD258357 17 bp DNA linear PAT 17-JUL-2003
 LOCUS Regulation of repressor genes using nucleic acid molecules.
 DEFINITION BD258357
 ACCESSION BD258357.1 GI:33068127
 VERSION JP 2002541795-A/6150.
 KEYWORDS unclassified
 SOURCE unclassified
 ORGANISM unclassified

REFERENCE
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 6150 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT
 OS Eukaryote
 PN JP 2002541795-A/6150
 PD 10-DEC-2002
 PR 11-APR-2000 JP 200611654
 PI 12-APR-1999 US 60/129390
 P1 LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
 C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91),
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 Key Location/Qualifiers
 FT source 1. .17
 FT /organism='Eukaryote'.
 Location/Qualifiers
 1. .17
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2;

QY 2482 TTCTTCTCTCTGACTC 2498
 DB 1 TTTTCTCTCTGACAC 17

RESULT 268
 BD259637 17 bp DNA linear PAT 17-JUL-2003
 LOCUS Regulation of repressor genes using nucleic acid molecules.
 DEFINITION BD259637
 ACCESSION BD259637.1 GI:33069407
 VERSION JP 2002541795-A/7430.
 KEYWORDS unclassified
 SOURCE unclassified
 ORGANISM unclassified

REFERENCE
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 7430 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT
 OS Eukaryote
 PN JP 2002541795-A/7430
 PD 10-DEC-2002
 PR 11-APR-2000 JP 200611654

PR 12-APR-1999 US 60/129390
 P1 LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91),
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 Key Location/Qualifiers
 FT source 1. .17
 FT /organism='Eukaryote'.
 Location/Qualifiers
 1. .17
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2;

QY 2572 TCTTCTTTTCTTCT 2588
 DB 17 TCTTTTCTTTTCTTCT 1

RESULT 269
 COG16436 17 bp DNA linear PAT 02-FEB-2004
 LOCUS Sequence 1176 from Patent WO0192524.
 DEFINITION COG16436
 ACCESSION COG16436
 VERSION COG16436.1 GI:4166654
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
 Shannon, M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 1176 06-DEC-2001;
 Aeomica, Inc. (US)

FEATURES
 source Location/Qualifiers
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2;

QY 20 GAAGGACGAGAGGGG 36
 DB 1 GAAGGACAAAGAGGGG 17

RESULT 270
 COG16840 17 bp DNA linear PAT 02-FEB-2004
 LOCUS Sequence 1580 from Patent WO0192524.
 DEFINITION COG16840
 ACCESSION COG16840
 VERSION COG16840.1 GI:41667058
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 TITLE

```
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 1580 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES
  source      1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match  0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          2981 ATCATCTCCAGAGAG 2997
DB          17 ATCTTCTCCAGAGCAG 1

RESULT 271
LOCUS       CQ617530                17 bp    DNA          linear    PAT 02-FEB-2004
DEFINITION  Sequence 2270 from Patent WO0192524.
ACCESSION   CQ617530
VERSION     CQ617530.1  GI:41667748
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 2270 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES
  source      1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match  0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          413 TCCTCCGGGCGCTCGTC 429
DB          1 TCCTCCGGGCGCTTCGC 17

RESULT 272
LOCUS       CQ617531                17 bp    DNA          linear    PAT 02-FEB-2004
DEFINITION  Sequence 2271 from Patent WO0192524.
ACCESSION   CQ617531
VERSION     CQ617531.1  GI:41667749
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 2271 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES
  source      1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match  0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          1173 AGAAGAGCGAGAGAG 1189
DB          1 AGAAGCAGCGAGAGAG 17

RESULT 274
LOCUS       CQ622116                17 bp    DNA          linear    PAT 02-FEB-2004
DEFINITION  Sequence 6856 from Patent WO0192524.
ACCESSION   CQ622116
VERSION     CQ622116.1  GI:41672334
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 6856 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES
  source      1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match  0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          1174 GAAAGAGCGAGAGAGC 1190
DB          1 GAAAGCAGCGAGAGAGC 17

RESULT 275
LOCUS       CQ622115                17 bp    DNA          linear    PAT 02-FEB-2004
DEFINITION  Sequence 6855 from Patent WO0192524.
ACCESSION   CQ622115
VERSION     CQ622115.1  GI:41672333
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 6855 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES
  source      1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match  0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          414 CCTCCGGGCGCTCGCT 430
DB          1 CCTCCGGGCGCTTCGCT 17
```

RESULT 275
CO622189/c
LOCUS Sequence 6929 from Patent WO0192524.
DEFINITION CO622189
ACCESSION CO622189.1 GI:41672407
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,W.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6929 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3318 AGATTGTGAATTCCTG 3334
DB 17 AGCTTCTGATTCCTG 1

RESULT 276
CO622190/c
LOCUS Sequence 6930 from Patent WO0192524.
DEFINITION CO622190
ACCESSION CO622190.1 GI:41672408
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,W.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6930 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3317 CAGATTGTTGAATTCCT 3333
DB 17 CAGCTTCTGATTCCT 1

RESULT 277
CO623376
LOCUS Sequence 8116 from Patent WO0192524.
DEFINITION CO623376
ACCESSION CO623376.1 GI:41673594
VERSION
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,W.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8116 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 CTGCCAGAGCGCTCC 2742
DB 1 CTGCCAGAGCGCTTC 17

RESULT 278
CO623714
LOCUS Sequence 8454 from Patent WO0192524.
DEFINITION CO623714
ACCESSION CO623714.1 GI:41673932
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,W.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8454 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1357 AGATCATGCACACGAG 1373
DB 1 AGAGCATGCACACGAG 17

RESULT 279
CO624133/c
LOCUS Sequence 8873 from Patent WO0192524.
DEFINITION CO624133
ACCESSION CO624133.1 GI:41674351
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,W.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8873 06-DEC-2001;

FEATURES
source
Aeomica, Inc. (US)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2182 ACCTGCTCTCCATCTT 2198
|||||
17 ACCTCTCTCCCATCTT 1

RESULT 280
LOCUS CQ625578 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10318 from Patent WO0192524.
ACCESSION CQ625578
VERSION CQ625578.1 GI:41675796
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10318 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1764 CTTTCTCTCGCGAGCA 1780
|||||
1 CTTTCTCTCGCGATCA 17

RESULT 281
LOCUS AR187058 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2546 from patent US 6346398.
ACCESSION AR187058
VERSION AR187058.1 GI:20233023
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
METHOD and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6346398-A 2546 12-FEB-2002;
JOURNAL Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTTCTTCTTTT 2585

Db
1 TCTACTTTT 17
|||||

RESULT 282
LOCUS AR187059 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2547 from patent US 6346398.
ACCESSION AR187059
VERSION AR187059.1 GI:20233024
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
METHOD and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6346398-A 2547 12-FEB-2002;
JOURNAL Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTCTTCTTTT 2586
|||||
1 CTACTTTT 17

RESULT 283
LOCUS AR187062 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2550 from patent US 6346398.
ACCESSION AR187062
VERSION AR187062.1 GI:20233027
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
METHOD and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6346398-A 2550 12-FEB-2002;
JOURNAL Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTTCTTTT 2586
|||||
1 CTTTCTTTT 17

RESULT 284
LOCUS AR187063 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2551 from patent US 6346398.
ACCESSION AR187063
VERSION AR187063.1 GI:20233028
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2551 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTCTTTTTC 2587
Db 1 TTTTCTTTTTC 17

RESULT 285
AR190277/c 17 bp DNA linear PAT 20-APR-2002
LOCUS AR190277
DEFINITION Sequence 5765 from patent US 6346398.
ACCESSION AR190277
VERSION AR190277.1 GI:20236242
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5765 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 TTCTGAGAGCTGCTT 985
Db 17 TTCTGAGAGCTTCTT 1

RESULT 286
AR190455/c 17 bp DNA linear PAT 20-APR-2002
LOCUS AR190455
DEFINITION Sequence 5943 from patent US 6346398.
ACCESSION AR190455
VERSION AR190455.1 GI:20236420
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5943 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 AAAATGATCAAT 1133
Db 1117 AAAATGATCAAT 1133

Db 17 AAAATGATCAAT 1

RESULT 287
AR192328/c 17 bp DNA linear PAT 20-APR-2002
LOCUS AR192328
DEFINITION Sequence 7816 from patent US 6346398.
ACCESSION AR192328
VERSION AR192328.1 GI:20238293
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7816 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2590 AAAAGAGAAAAGCAC 2606
Db 17 AAAAGAGAAAAGCAC 1

RESULT 288
AR286349 17 bp RNA linear PAT 10-APR-2003
LOCUS AR286349
DEFINITION Sequence 721 from patent US 6528640.
ACCESSION AR286349
VERSION AR286349.1 GI:29723945
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Beigelman, L., Burgin, A., Beaudry, A., Karpelisky, A.,
Matulic-Adamic, J., Sweedler, D. and Zimen, S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 721 04-MAR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 365 GAGAGCCAGCCGCTGA 381
Db 1 GAGAGCCAGCCCTCTGA 17

RESULT 289
AR323668 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR323668
DEFINITION Sequence 1070 from patent US 6566127.
ACCESSION AR323668
VERSION AR323668.1 GI:33709476
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 1070 20-MAY-2003;

FEATURES

source 1. .17 /organism="unknown" /mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 2e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTTCTCTTTTCTTTT 2585
|||||
1 TCTACTTTTCTTTTCTTT 17

RESULT 290

AR323669 AR323669 17 bp RNA linear PAT 17-AUG-2003

LOCUS Sequence 1071 from patent US 6566127.

DEFINITION AR323669

ACCESSION AR323669

VERSION AR323669.1 GI:33709477

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE Unclassified.

AUTHORS 1 (bases 1 to 17)

TITLE Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

JOURNAL Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

FEATURES Patent: US 6566127-A 1071 20-MAY-2003;

source 1. .17 /organism="unknown" /mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 2e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTCTCTCTTTTCTTTT 2586
|||||
1 CTACTTTTCTTTTCTTTT 17

RESULT 291

AR323672 AR323672 17 bp RNA linear PAT 17-AUG-2003

LOCUS Sequence 1074 from patent US 6566127.

DEFINITION AR323672

ACCESSION AR323672

VERSION AR323672.1 GI:33709480

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE Unclassified.

AUTHORS 1 (bases 1 to 17)

TITLE Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

JOURNAL Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

FEATURES Patent: US 6566127-A 1074 20-MAY-2003;

source 1. .17 /organism="unknown" /mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 2e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTCTCTCTTTTCTTTT 2586
|||||
1 CTCTTTTCTTTTCTTTT 17

RESULT 292

AR323673 AR323673 17 bp RNA linear PAT 17-AUG-2003

LOCUS Sequence 1075 from patent US 6566127.

DEFINITION AR323673

ACCESSION AR323673

VERSION AR323673.1 GI:33709481

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE Unclassified.

AUTHORS 1 (bases 1 to 17)

TITLE Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

JOURNAL Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

FEATURES Patent: US 6566127-A 1075 20-MAY-2003;

source 1. .17 /organism="unknown" /mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 2e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTCTTTTCTT 2587
|||||
1 TTTTCTTTTCTTTTCTT 17

RESULT 293

AR325242 AR325242 17 bp RNA linear PAT 17-AUG-2003

LOCUS Sequence 2644 from patent US 6566127.

DEFINITION AR325242

ACCESSION AR325242

VERSION AR325242.1 GI:33711050

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE Unclassified.

AUTHORS 1 (bases 1 to 17)

TITLE Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

JOURNAL Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

FEATURES Patent: US 6566127-A 2644 20-MAY-2003;

source 1. .17 /organism="unknown" /mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 2e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 TTCTGCAAGAGCTGCTT 985
|||||
17 TTCTGCAAGAGCTGCTT 1

RESULT 294

AR325378 AR325378 17 bp RNA linear PAT 17-AUG-2003

LOCUS Sequence 2780 from patent US 6566127.

DEFINITION AR325378

ACCESSION AR325378

VERSION AR325378.1 GI:33711186

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE Unclassified.

AUTHORS 1 (bases 1 to 17)

TITLE Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

JOURNAL Method and reagent for the treatment of diseases or conditions

related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 2780 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 AAAAATGCATATCAAT 1133
Db 17 AAAAATGAAATCAAT 1

RESULT 295
AR326198/c AR326198 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 3600 from patent US 6566127.
ACCESSION AR326198
VERSION AR326198.1 GI:33712006
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3600 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2590 AAAAAAGAAAAAGCAC 2606
Db 17 AAAAAACAATAAGCAC 1

RESULT 296
AR327229/c AR327229 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4631 from patent US 6566127.
ACCESSION AR327229
VERSION AR327229.1 GI:33713037
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4631 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2931 TATATTCGTGTTGTTT 2947
Db 17 TATTTGTGTTGTTT 1

RESULT 297
AR328172 AR328172 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 5574 from patent US 6566127.
ACCESSION AR328172
VERSION AR328172.1 GI:33713980
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5574 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1733 TCTCCTTCGAAAAAGTT 1749
Db 1 TCTCCTTCGATTAATTT 17

RESULT 298
AR328173 AR328173 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 5575 from patent US 6566127.
ACCESSION AR328173
VERSION AR328173.1 GI:33713981
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5575 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1734 CTCCTTCGAAAAAGTT 1750
Db 1 CTCCTTCGATTAATTT 17

RESULT 299
AR328737 AR328737 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 6139 from patent US 6566127.
ACCESSION AR328737
VERSION AR328737.1 GI:33714545
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 6139 20-MAY-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 585 CAACATATAAAGACA 601
 |||||
 1 CAGCATACAAAGACA 17

RESULT 300
 AR398339 AR398339 17 bp RNA linear PAT 18-DEC-2003
 LOCUS Sequence 720 from patent US 6617438.
 DEFINITION AR398339
 ACCESSION AR398339
 VERSION AR398339.1 GI:40136072
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Beigelman, L., Burgin, A.B., Beaudry, A., Karpelsky, A.,
 Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
 TITLE Oligoribonucleotides with enzymatic activity
 JOURNAL Patent: US 6617438-A 720 09-SEP-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 365 GAGAGCCAGCGCGCTGA 381
 |||||
 1 GAGAGCCAGCGCTCTGA 17

RESULT 301
 AR402469 AR402469 17 bp DNA linear PAT 18-DEC-2003
 LOCUS Sequence 809 from patent US 6623962.
 DEFINITION AR402469
 ACCESSION AR402469
 VERSION AR402469.1 GI:40149919
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Akhtar, S., Fell, P. and McSwiggen, J.A.
 TITLE Enzymatic nucleic acid treatment of diseases of conditions related
 JOURNAL Patent: US 6623962-A 809 23-SEP-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1586 TACAGCTTGTAAAGAA 1602
 |||||
 1 TACAGCATTTTAAGAA 17

RESULT 302
 AR429797 AR429797 17 bp DNA linear PAT 18-DEC-2003
 LOCUS Sequence 5 from patent US 6645748.
 DEFINITION AR429797
 ACCESSION AR429797
 VERSION AR429797.1 GI:40190163
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Wood, K.W., Sakowicz, R., Goldstein, L.S.B. and Cleveland, D.W.
 TITLE Plus end-directed microtubule motor required for chromosome
 JOURNAL Patent: US 6645748-A 5 11-NOV-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1164 GGGCTTCCCGAAGAG 1180
 |||||
 1 GGGCTGCCCGAAGAG 17

RESULT 303
 AR433773 AR433773 17 bp DNA linear PAT 18-DEC-2003
 LOCUS Sequence 196 from patent US 6656700.
 DEFINITION AR433773
 ACCESSION AR433773
 VERSION AR433773.1 GI:40196616
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu, Y. and Shannon, M.E.
 TITLE Isoforms of human pregnancy-associated protein-E
 JOURNAL Patent: US 6656700-A 196 02-DEC-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2916 TTTTGCAATTGAATA 2932
 |||||
 1 TTTTGCAATTTAATA 17

RESULT 304
 AR434060 AR434060 17 bp DNA linear PAT 18-DEC-2003
 LOCUS Sequence 483 from patent US 6656700.
 DEFINITION AR434060
 ACCESSION AR434060
 VERSION AR434060.1 GI:40196903
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu, Y. and Shannon, M.E.
 TITLE Isoforms of human pregnancy-associated protein-E
 JOURNAL Patent: US 6656700-A 483 02-DEC-2003;
 FEATURES Location/Qualifiers
 source 1..17

```

Query Match
Best Local Similarity 0.4%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTTCTTTTTC 2587
Db 17 TTCTTCTTTTTC 1

/organism="unknown"
/mol_type="genomic DNA"

RESULT 305
AR434352 17 bp DNA linear PAT 18-DEC-2003
LOCUS AR434352/c
DEFINITION Sequence 775 from patent US 6656700.
ACCESSION AR434352
VERSION AR434352.1 GI:40197195
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 (bases 1 to 17)
Gu.Y. and Shannon,M.E.
Isoforms of human pregnancy-associated protein-E
Patent: US 6656700-A 775 02-DEC-2003;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 TGAGTACCAACGAG 676
Db 17 TGAGTACCAACGAG 1

/organism="unknown"
/mol_type="genomic DNA"

RESULT 306
AR434353 17 bp DNA linear PAT 18-DEC-2003
LOCUS AR434353/c
DEFINITION Sequence 776 from patent US 6656700.
ACCESSION AR434353
VERSION AR434353.1 GI:40197196
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 (bases 1 to 17)
Gu.Y. and Shannon,M.E.
Isoforms of human pregnancy-associated protein-E
Patent: US 6656700-A 776 02-DEC-2003;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 659 CTGAGTACCAACGAG 675
Db 17 CTGAGTACCAACGAG 1

/organism="unknown"
/mol_type="genomic DNA"

RESULT 307
AR457499 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR457499
DEFINITION Sequence 1176 from patent US 6686188.
ACCESSION AR457499

```

```

VERSION AR457499.1 GI:42692556
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 1176 03-FEB-2004;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 20 GAAGGACGAGAGCGG 36
Db 1 GAAGGACGAGAGCGG 17

/organism="unknown"
/mol_type="genomic DNA"

RESULT 308
AR457903 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR457903/c
DEFINITION Sequence 1580 from patent US 6686188.
ACCESSION AR457903
VERSION AR457903.1 GI:42692960
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 1580 03-FEB-2004;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2981 ATCATTCCTCCAGAG 2997
Db 17 ATCTTCTCCAGAGCAG 1

/organism="unknown"
/mol_type="genomic DNA"

RESULT 309
AR458593 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR458593/c
DEFINITION Sequence 2270 from patent US 6686188.
ACCESSION AR458593
VERSION AR458593.1 GI:42693650
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 2270 03-FEB-2004;
Location/Qualifiers
1..17

```

```
/organism="unknown"  
/mol_type="genomic DNA"
```

Query Match	0.4%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 2e+02;		
Matches	15;	Conservative	0;	Mismatches 2;
			Indels	0;
			Gaps	0;

QY	413	TCCTCCGGGCGCTGTC	423
Db	1	TCCTCCGGGCGCTGCGC	17

RESULT 310
AR458594
17 1- 1:00:00 PM 20-FEB-2000

LOCUS	AR458594	17 bp	DNA	linear	PAT 20-FEB-2004
DEFINITION	Sequence 2271 from patent US 6686188.				
ACCESSION	AR458594				
VERSION	AR458594.1	GI: 42693651			
KEYWORDS					
SOURCE	Unknown.				

REFERENCE	(bases 1 to 17)
AUTHORS	Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE	Poly nucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 2271 03-FEB-2004;
FEATURES	Location/Qualifiers
Source	1..17

```

/organism="unknown"
/mol_type="genomic DNA"

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0

OY      414 CCTCGGGGCGTCGCT 430
      |||||
db      1 CCTCGGGGCTTCGACT 17

```

	RESULT 311				
AR463178					
LOCUS	AR463178	17 bp	DNA		linear
DEFINITION	Sequence 6855 from patent US 6686188.				
ACCESSION	AR463178				
VERSION	AR463178.1	GI:42698235			

REFERENCE	1 (bases 1 to 17)
AUTHORS	Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 6855 03-FEB-2004;
FEATURES	location/Qualifiers

```
/organism="unknown"
/mol_type="genomic DNA"
```

Query Match	0.48	Score 13.8	DB 1	Length 17
Best Local Similarity	88.2%	Pred. No. 2e+02		
Matches 15, Conservative	0	Mismatches 2	Indels 0	Gaps 0

QY 1173 AGAAGAGCGAGAGAAG 1189
||| |||||
Db 1 AGAAGCAGCGAGAGAAG 17

RESULT 312

AR463179	AR463179	17 bp	DNA	linear	PAT 20-FEB-2004
LOCUS	Sequence	6856	from patent US 6686186.		
DEFINITION	Sequence	6856	from patent US 6686186.		

VERSION	AR463179.1	GI:42698236
KEYWORDS		
SOURCE	Unknown.	

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and

TITLE	polynucleotide encoding a human myosin-11k polypeptide expressed
JOURNAL	predominantly in heart and muscle
FEATURES	Patent: US 6686188-A 6856 03-FEB-2004;
	Location/Qualifiers

```
1. .17
/organism="unknown"
/mol_type="genomic DNA"
```

Query Match	0.4%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 2e+02;		
Matches 15; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

QY	1174	GAAAGAGCCGAGAGAAGC	1190
Db	1	GAAGCAGCCGAGAGAAGC	17

	PAT	20-FEB-2004
DNA	linear	
bp	17	
Locus	AR6J252	
RESULT 313		
AR6J252/c		

VERSION	AR463252.1	GI:42698309
KEYWORDS		
SOURCE	Unknown.	

REFERENCE
AUTHORS

1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and

TITLE	Journal	Location/Qualifiers
Polyelectrode encoding a human myosin-like polypeptide expressed predominantly in heart and muscle	JOURNAL	
Patent: US 6686188-A 6929 03-FEB-2004;		

```
1..17
/organism="unknown"
/mol_type="genomic DNA"
```

Query Match	0.4%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%	Pred. No. 2e+02;		
Matches 15; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

```

QY      3318 AGATTGTTGAATTCCTG 3334
          ||| ||||| |||||
Db      17  AGCTTCTTGAATTCCTG 1

```

RESULT 314			
AR463253/C			
LOCUS	17 bp	DNA	linear
AR463253			PAT 20-FEB-2004

VERSION	AR463253.1	GI:42698310
KEYWORDS		
SOURCE	Unknown.	

ORGANISM Unknown.
unclassified.

REFERENCE
AUTHORS
1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed

Journal Patent: US 6686188-A 6930 03-FEB-2004;
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3317 CAGATGTTGAATTCCT 3333
DB 17 CAGCTTCTGAATTCCT 1

RESULT 315
LOCUS AR464439 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8116 from patent US 6686188.
ACCESSION AR464439
VERSION AR464439.1 GI:42699496
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8116 03-FEB-2004;
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 CTGCCAGAGCAGCTCC 2742
DB 1 CTGCCAGAGCGGCTTC 17

RESULT 316
LOCUS AR464777 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8454 from patent US 6686188.
ACCESSION AR464777
VERSION AR464777.1 GI:42699834
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8454 03-FEB-2004;
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1357 AGATCATGCACACAGAG 1373
DB 1 AGATCATGCACACAGAG 17

DB 1 AGAGCATGCACACAGAG 17

RESULT 317
LOCUS AR465196/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8873 from patent US 6686188.
ACCESSION AR465196
VERSION AR465196.1 GI:42700253
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8873 03-FEB-2004;
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2182 AGCTGCTCTCCATCTT 2198
DB 17 AGCTCTCTCCCATCTT 1

RESULT 318
LOCUS AR466641 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10318 from patent US 6686188.
ACCESSION AR466641
VERSION AR466641.1 GI:42701698
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10318 03-FEB-2004;
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1764 CTTTCTCTCGGCGAGCA 1780
DB 1 CTTTCTCTCGGCGATCA 17

RESULT 319
LOCUS AX214795/c 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 237 from Patent WO0159103.
ACCESSION AX214795
VERSION AX214795.1 GI:15524838
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 237 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
 source
 1. .17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTTCTCTCTTTT 2585
 DB 17 TTTCTCTCTATTTT 1

RESULT 320
 AX216329 17 bp RNA linear PAT 07-SEP-2001
 LOCUS Sequence 1771 from Patent WO0159103.
 DEFINITION AX216329
 ACCESSION AX216329
 VERSION AX216329.1 GI:15526390
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 location/Qualifiers

REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 1771 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
 source
 1. .17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3431 CCTGCTTCTGCTGCAT 3447
 DB 1 CTGCTTCTGCTGCAT 17

RESULT 321
 AX216879 17 bp RNA linear PAT 07-SEP-2001
 LOCUS Sequence 2321 from Patent WO0159103.
 DEFINITION AX216879
 ACCESSION AX216879
 VERSION AX216879.1 GI:15526940
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 location/Qualifiers

REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2321 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
 source
 1. .17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3432 CTGCTTCTGCTGCATG 3448
 DB 1 CTGCTTCTGCTGCATG 17

RESULT 322
 AX217019 17 bp RNA linear PAT 07-SEP-2001
 LOCUS Sequence 2461 from Patent WO0159103.
 DEFINITION AX217019
 ACCESSION AX217019
 VERSION AX217019.1 GI:15527080
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 location/Qualifiers

REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2461 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
 source
 1. .17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2568 TTCTTCTCTTTT 2584
 DB 17 TTCTTCTCTTTT 1

RESULT 323
 AX217020 17 bp RNA linear PAT 07-SEP-2001
 LOCUS Sequence 2462 from Patent WO0159103.
 DEFINITION AX217020
 ACCESSION AX217020
 VERSION AX217020.1 GI:15527081
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 location/Qualifiers

REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2462 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
 source
 1. .17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2215 CTTCTCTCTCTCTCTT 2231
DB 17 CTTCTCTCTCTCTCTT 1

RESULT 324
LOCUS AX217966 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3408 from Patent WO0159103.
ACCESSION AX217966
VERSION AX217966.1 GI:15528027
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL Patent: WO 0159103-A 3408 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3435 TCTTTGCTGCCATGTTT 3451
DB 1 TCTTTGCTGCCATTTCT 17

RESULT 325
LOCUS AX263144 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 535 from Patent WO0173002.
ACCESSION AX263144
VERSION AX263144.1 GI:16511943
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1
JOURNAL Kmiec, E.B., Gamper, H.B. and Rice, M.C.
targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 535 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGTTGTTTCTTA 2951
DB 17 TTCTAGTTGTTTCTTA 1

RESULT 326
LOCUS AX263145 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 536 from Patent WO0173002.
ACCESSION AX263145
VERSION AX263145.1 GI:16511944
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1
JOURNAL Kmiec, E.B., Gamper, H.B. and Rice, M.C.
targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 536 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCGAGCTTCTCTTC 2576
DB 17 TCTCAGCCTCTCTCTC 1

RESULT 328
LOCUS AX265772 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3163 from Patent WO0173002.
ACCESSION AX265772
VERSION AX265772.1 GI:16514571
KEYWORDS
SOURCE Homo sapiens (human)

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGTTGTTTCTTA 2951
DB 1 TTCTAGTTGTTTCTTA 17

RESULT 327
LOCUS AX265771 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3162 from Patent WO0173002.
ACCESSION AX265771
VERSION AX265771.1 GI:16514570
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1
JOURNAL Kmiec, E.B., Gamper, H.B. and Rice, M.C.
targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3162 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1
Kmetz, B., Gampel, H.B. and Rice, M.C.
JOURNAL Targeted chromosomal genomic alterations with modified single
STRANDS Targeted oligonucleotides
PATENT: WO 0173002-A 3163 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCGAGCTTCTTCTTC 2576
1 TCTCAGCTTCTTCTTC 17
Db

RESULT 329
AX278602 17 bp DNA linear PAT 02-NOV-2001
LOCUS Sequence 139 from Patent WO0177372.
ACCESSION AX278602
VERSION AX278602.1 GI:16606056
KEYWORDS
SOURCE
ORGANISM
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisens 1C Primer"

JOURNAL Facultes Universitaires Notre-Dame de la Paix (BE)
TITLE Identification of biological (micro) organisms by detection of the
AUTHORS Remacle, J., Hamels, S., Zammatteo, N., Lockman, L., Dufour, S.,
Alexandre, I. and de Longueville, F.
JOURNAL Identification of biological (micro) organisms by detection of the
STRANDS Identification of biological (micro) organisms by detection of the
PATENT: WO 0177372-A 139 18-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisens 1C Primer"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2392 TTGGCAGCTTCTTCTTC 2408
1 TTGGAGCTTCTTCTTC 17
Db

RESULT 330
AX278607 17 bp DNA linear PAT 02-NOV-2001
LOCUS Sequence 144 from Patent WO0177372.
ACCESSION AX278607
VERSION AX278607.1 GI:16606061
KEYWORDS
SOURCE
ORGANISM
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisens 1C Primer"

JOURNAL Facultes Universitaires Notre-Dame de la Paix (BE)
TITLE Identification of biological (micro) organisms by detection of the
AUTHORS Remacle, J., Hamels, S., Zammatteo, N., Lockman, L., Dufour, S.,
Alexandre, I. and de Longueville, F.
JOURNAL Identification of biological (micro) organisms by detection of the
STRANDS Identification of biological (micro) organisms by detection of the
PATENT: WO 0177372-A 144 18-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisens 1C Primer"

```

```

FEATURES Facultes Universitaires Notre-Dame de la Paix (BE)
LOCATION/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisens 2C Primer"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2392 TTGGCAGCTTCTTCTTC 2408
1 TTGGAGCTTCTTCTTC 17
Db

RESULT 331
AX361606 17 bp DNA linear PAT 15-FEB-2002
LOCUS Sequence 24 from Patent WO0208461.
ACCESSION AX361606
VERSION AX361606.1 GI:18694225
KEYWORDS
SOURCE
ORGANISM
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Double-stranded product DNA"

JOURNAL Linmarsson, S.G., Ernfor, P.G. and Bauren, G.G.
TITLE A method and an algorithm for mRNA expression analysis
AUTHORS Patent: WO 0208461-A 24 31-JAN-2002;
JOURNAL Global Genomics AB (SE)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Double-stranded product DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTCTTCTTCTTC 2587
1 TTTTCTTCTTCTTCTTC 17
Db

RESULT 332
AX391870 17 bp DNA linear PAT 23-MAR-2002
LOCUS Sequence 20 from Patent WO0216618.
ACCESSION AX391870
VERSION AX391870.1 GI:19700450
KEYWORDS
SOURCE
ORGANISM
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Double-stranded product DNA"

JOURNAL Aspergillus niger
TITLE Aspergillus niger
AUTHORS Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
Basten, D., Dekker, P.J., Schuurhuizen, P.W., Schaap, P.J. and
Visser, J.
JOURNAL Aspergillus niger
TITLE Aspergillus niger
AUTHORS Patent: WO 0216618-A 20 28-FEB-2002;
JOURNAL DSM N.V. (NL)
FEATURES Location/Qualifiers
source 1..17
/organism="Aspergillus niger"
/mol_type="unassigned DNA"
/db_xref="taxon:5061"
/note="CBS 120.49"
/note="Reverse primer (APSC 19)"

```

Query Match 0.4%; Score 13.8; DB 1; Length 17;
AX500607/c
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 98 GCAAGTCCAGCAGCC 114
|||||
17 GCAAGATCCAGAGCC 1

RESULT 333

AX423732 17 bp RNA linear PAT 18-JUN-2002

LOCUS AX423732
DEFINITION Sequence 2068 from Patent WO0188124.
ACCESSION AX423732
VERSION AX423732.1 GI:21527114
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Jarvis,T., von Carlwiltz,I., Moswigen,U.A., McLaughlin,F.G. and Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 2068 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2595 AGGAAAAGCAGCAGC 2611
|||||
1 AGGAGAAAAGCAGCAGC 17

RESULT 334

AX500606/c 17 bp DNA linear PAT 27-SEP-2002

LOCUS AX500606
DEFINITION Sequence 1913 from Patent EP1229046.
ACCESSION AX500606
VERSION AX500606.1 GI:23382899
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1913 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 587 ACATATATAAAGACAC 603
|||||
17 ACATATATAAAGACTAC 1

RESULT 335
AX500607/c 17 bp DNA linear PAT 27-SEP-2002
LOCUS AX500607
DEFINITION Sequence 1914 from Patent EP1229046.
ACCESSION AX500607
VERSION AX500607.1 GI:23382900
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1914 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 586 AACATATATAAAGACAA 602
|||||
17 AACATATATAAAGACTA 1

RESULT 336
AX500609/c 17 bp DNA linear PAT 27-SEP-2002
LOCUS AX500609
DEFINITION Sequence 1916 from Patent EP1229046.
ACCESSION AX500609
VERSION AX500609.1 GI:23382902
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1916 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 584 ACAACATATATAAAGAC 600
|||||
17 AAAACATATATAAAGAC 1

RESULT 337
AX531754/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX531754
DEFINITION Sequence 1263 from Patent EP1239051.
ACCESSION AX531754
VERSION AX531754.1 GI:25255287
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1263 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
SOURCE location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2848 GGGCTGGAGATCATAG 2864
Db 17 GGGCTGGAGTACAG 1

RESULT 338
AX531755/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 1264 from Patent EP1239051.
ACCESSION AX531755
VERSION AX531755.1 GI:25255289
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1264 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
SOURCE location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2847 TGGGCTGGAGATCATTA 2863
Db 17 TGGGCTGGAGTACACA 1

RESULT 339
AX532359/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 1868 from Patent EP1239051.
ACCESSION AX532359
VERSION AX532359.1 GI:25256497
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1868 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
SOURCE location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3569 GGGCTGGCTTTAGGA 3585
Db 17 GGGCTGGCTTGAAGGA 1

RESULT 340
AX532430/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 1939 from Patent EP1239051.
ACCESSION AX532430
VERSION AX532430.1 GI:25256634
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1939 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
SOURCE location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 375 CCGCTGAGGGAGGGG 391
Db 17 CCGCTGAGGGAGGAG 1

RESULT 341
AX578461/c 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 299 from Patent WO0211674.
ACCESSION AX578461
VERSION AX578461.1 GI:27647663
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grude,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 299 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
SOURCE location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2230 TTCTCATGATGGCC 2246
Db 17 TTCTCATGATGAAGGCC 1

RESULT 342
LOCUS AX579591 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1429 from Patent WO0211674.
ACCESSION AX579591
VERSION AX579591.1 GI:27648793
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grube,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 1429 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2964 TACCAATGAAATTTAG 2980
Db 1 TACTTAATGATTTAG 17
RESULT 343
LOCUS AX580236 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 2074 from Patent WO0211674.
ACCESSION AX580236
VERSION AX580236.1 GI:27649438
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grube,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 2074 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2086 CCATCTCTGTATCCCA 2102
Db 1 CCTTCTCTGGATCCCA 17
RESULT 344
LOCUS AX649485 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1325 from Patent EP1273660.

ACCESSION AX649485
VERSION AX649485.1 GI:29152303
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1325 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3225 ATATGCCCTCTCCGCC 3241
Db 1 ATATGCCCTCTCCGCC 17
RESULT 345
LOCUS AX672043 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 488 from Patent WO03004526.
ACCESSION AX672043
VERSION AX672043.1 GI:29330391
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Telemann,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 488 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3257 TGGTTTCATCTGATC 3273
Db 1 TGGTCTCATCTGATC 1
RESULT 346
LOCUS AX687419 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 151 from Patent EP1281758.
ACCESSION AX687419
VERSION AX687419.1 GI:29410113
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Shannon,M., Gu,Y. and Nguyen,C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL mdz12 Patent: EP 1281758-A 151 05-FEB-2003;

FEATURES Aeomica, Inc. (US)

SOURCE location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 2078 AGATTCTGCCATCTCTG 2094

Db 17 AGCTTCGCCATCTCTG 1

RESULT 347

LOCUS AX687485 17 bp DNA linear PAT 31-MAR-2003

DEFINITION Sequence 217 from Patent EP1281758.

ACCESSION AX687485

VERSION AX687485.1 GI:29410179

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL mdz12 Patent: EP 1281758-A 217 05-FEB-2003;

FEATURES Aeomica, Inc. (US)

SOURCE location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 2222 CCTTCTCTTCTCTCATG 2238

Db 17 CCTTCTCTGCCCCATG 1

RESULT 348
LOCUS AX691783 17 bp DNA linear PAT 31-MAR-2003

DEFINITION Sequence 4515 from Patent EP1281758.

ACCESSION AX691783

VERSION AX691783.1 GI:29414724

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL mdz12 Patent: EP 1281758-A 4515 05-FEB-2003;

FEATURES Aeomica, Inc. (US)

SOURCE location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2;

QY 2047 TTAAGCGCAAGCCTCA 2063

Db 17 TGAAGCGCAAGCCTTA 1

RESULT 349

LOCUS AX692524 17 bp DNA linear PAT 31-MAR-2003

DEFINITION Sequence 5256 from Patent EP1281758.

ACCESSION AX692524

VERSION AX692524.1 GI:29415482

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL mdz12 Patent: EP 1281758-A 5256 05-FEB-2003;

FEATURES Aeomica, Inc. (US)

SOURCE location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 2569 TCTTCTCTCTTTT 2585

Db 1 TCTTTTCTTTT 17

RESULT 350

LOCUS AX692525 17 bp DNA linear PAT 31-MAR-2003

DEFINITION Sequence 5257 from Patent EP1281758.

ACCESSION AX692525

VERSION AX692525.1 GI:29415483

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL mdz12 Patent: EP 1281758-A 5257 05-FEB-2003;

FEATURES Aeomica, Inc. (US)

SOURCE location/Qualifiers

1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 2570 CTCTCTCTTTT 2586

Db 1 CTCTTTT 17

RESULT 351
 AX692527 17 bp DNA linear PAT 31-MAR-2003
 LOCUS AX692527
 DEFINITION Sequence 5259 from Patent EP1281758.
 ACCESSION AX692527
 VERSION AX692527.1 GI:29415485
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
 JOURNAL Patent: EP 1281758-A 5259 05-FEB-2003;
 Aeomica, Inc. (US)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2574 TTCTTTTCTTTCTGCA 2590
 Db 1 TTTTCTTTTCTTTCTGCA 17

RESULT 352
 AX693080 17 bp DNA linear PAT 31-MAR-2003
 LOCUS AX693080/c
 DEFINITION Sequence 5812 from Patent EP1281758.
 ACCESSION AX693080
 VERSION AX693080.1 GI:29416044
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
 JOURNAL Patent: EP 1281758-A 5812 05-FEB-2003;
 Aeomica, Inc. (US)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3026 ACAGTGTCTCTGTTT 3042
 Db 17 ACATGTCTCTGCTTT 1

RESULT 353
 AX693187 17 bp DNA linear PAT 31-MAR-2003
 LOCUS AX693187
 DEFINITION Sequence 5919 from Patent EP1281758.
 ACCESSION AX693187
 VERSION AX693187.1 GI:29416151
 KEYWORDS
 SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
 JOURNAL Patent: EP 1281758-A 5919 05-FEB-2003;
 Aeomica, Inc. (US)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1450 CATGGAATCCATCCAGG 1466
 Db 1 CATGGAACCTTCCAGG 17

RESULT 354
 AX722595 17 bp DNA linear PAT 08-MAY-2003
 LOCUS AX722595/c
 DEFINITION Sequence 282 from Patent WO03025176.
 ACCESSION AX722595
 VERSION AX722595.1 GI:30423096
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
 AUTHORS Teلمان,A., Amson,R. and Tuijinder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 282 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 76 TCAGTGTGGCTTGTC 92
 Db 17 TCAGTGTGGCTTGATC 1

RESULT 355
 AX725191 17 bp DNA linear PAT 08-MAY-2003
 LOCUS AX725191
 DEFINITION Sequence 2878 from Patent WO03025176.
 ACCESSION AX725191
 VERSION AX725191.1 GI:30504534
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
 AUTHORS Teلمان,A., Amson,R. and Tuijinder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025176-A 2878 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2186 GCTCTCCATCTTCTTC 2202
Db 1 GATCCCTCATCTTCCCTC 17

RESULT 356 AX727162 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX727162/c
DEFINITION Sequence 4849 from Patent WO03025176.
ACCESSION AX727162
VERSION AX727162.1 GI:30506505
KEYWORDS
SOURCE
ORGANISM Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 4849 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3257 TGCTTTCCATCTGCATC 3273
Db 17 TGGTTATCATCTGCATC 1

RESULT 357 AX727443 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX727443/c
DEFINITION Sequence 5130 from Patent WO03025176.
ACCESSION AX727443
VERSION AX727443.1 GI:30506786
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 5130 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2168 ATGAGTGGAGGAGGAGC 2184
Db 17 ATGAGAGGAGGAGGATC 1

RESULT 358 AX728656 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX728656/c
DEFINITION Sequence 290 from Patent WO03025175.
ACCESSION AX728656
VERSION AX728656.1 GI:30507999
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 290 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2341 TGAATTTTTCGACC 2357
Db 17 TGAATTTTTCGATC 1

RESULT 359 AX728907 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX728907/c
DEFINITION Sequence 541 from Patent WO03025175.
ACCESSION AX728907
VERSION AX728907.1 GI:30508250
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 541 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3257 TGCTTTCCATCTGCATC 3273
Db 17 TGGTTATCATCTGCATC 1

Db 17 TGTTCCTCACTGATC 1

RESULT 360
AX730515/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS AX730515
DEFINITION Sequence 2149 from Patent WO03025175.
ACCESSION AX730515
VERSION AX730515.1 GI:30509858
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2149 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1642 CACTGCTTCAGTCATC 1658
17 CACTGCTTCAGTCATC 1

RESULT 361
AX736991/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS AX736991
DEFINITION Sequence 2581 from Patent WO03025177.
ACCESSION AX736991
VERSION AX736991.1 GI:30516279
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2581 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 TTTTCATCCTTTGATC 455
17 TTTTCATCCTTTGATC 1

RESULT 362
AX738895/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS AX738895
DEFINITION Sequence 4485 from Patent WO03025177.

ACCESSION AX738895
VERSION AX738895.1 GI:30518185
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4485 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 TTTTCATCCTTTGATC 455
17 TTTTCATCCTTTGATC 1

RESULT 363
AX757960 17 bp DNA linear PAT 25-JUN-2003

LOCUS AX757960
DEFINITION Sequence 1281 from Patent WO03040369.
ACCESSION AX757960
VERSION AX757960.1 GI:32252576
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in tumoral suppression, tumoural reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1281 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1090 GATGACCAATCTTAC 1106
1 GATGACCAATCTTAC 17

RESULT 364
AX758113 17 bp DNA linear PAT 25-JUN-2003

LOCUS AX758113
DEFINITION Sequence 1434 from Patent WO03040369.
ACCESSION AX758113
VERSION AX758113.1 GI:32252729
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 1434 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2997 GATTTTTCCTTC 3013
17 bp DNA linear PAT 25-JUN-2003
1 GATCTTTTCTCTTC 17

RESULT 365
AX759943/c 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 3264 from Patent WO03040369.
DEFINITION AX759943
ACCESSION AX759943
VERSION AX759943.1 GI:32254559
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1
1 Telerman,A., Amson,R. and Tuijinder,M.
Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 3264 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2967 CAAATGATTTTAGATC 2983
17 bp DNA linear PAT 04-OCT-2003
17 CAGCTGAATTTTAGATC 1

RESULT 366
AX796711 17 bp DNA linear PAT 04-OCT-2003
LOCUS Sequence 85 from Patent EP123835.
DEFINITION AX796711
ACCESSION AX796711
VERSION AX796711.1 GI:37517366
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS artificial sequences.
1 Yano,H., Nishida,M. and Suzuki,O.
TITLE Method for determining biospecies contained in test specimen and kit used for the same
JOURNAL Patent: EP 132835-A 85 02-JUL-2003;
Nishinbo Industries, Inc. (JP)
FEATURES
source Location/Qualifiers
1.17

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer: amplify cytochrome B gene"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3545 GGGTGGAGGGAATATT 3561
17 bp DNA linear PAT 05-DEC-2003
1 GGGTGGAGGGAATATT 17

RESULT 367
AX814938 17 bp DNA linear PAT 05-DEC-2003
LOCUS Sequence 24 from Patent WO03064691.
DEFINITION AX814938
ACCESSION AX814938
VERSION AX814938.1 GI:39104076
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS artificial sequences.
1 Linmarson,S., Ennfors,P., Bauren,G., Metsis,A., Pihlak,A. and Montellius,A.
TITLE Methods and means for manipulating nucleic acid
JOURNAL Patent: WO 03064691-A 24 07-AUG-2003;
Global Genomics AB (SE)
FEATURES
source Location/Qualifiers
1.17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Double-stranded product DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTTC 2587
17 bp RNA linear PAT 27-AUG-2002
1 TTTTCTTTTTC 17

RESULT 368
BD067969 17 bp RNA linear PAT 27-AUG-2002
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.
DEFINITION BD067969
ACCESSION BD067969
VERSION BD067969.1 GI:22613572
KEYWORDS JP 2001511003-A/809.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1 (bases 1 to 17)
TITLE Akhtar,S., Fell,P. and Mcswigen,J.A.
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 809 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC./ASTON UNIV
COMMENT
OS Unidentified
PN JP 2001511003-A/809
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476.04-DEC-1997 US
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
Topology: Linear;

CC Enzymatic nucleic acid treatment of diseases or conditions CC

related to

CC levels of epidermal growth factor receptors

PH location/Qualifiers

FT source 1..17

FEATURES /organism='Unidentified',

source 1..17

/organism="unidentified"

/mol_type="genomic DNA"

/db_xref="taxon:32644"

Query Match 0.4%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1586 TACAGCTTGTAAAGA 1602

DB 1 TACAGCATTGTAAAGA 17

RESULT 369

BD105676 17 bp DNA linear PAT 27-AUG-2002

LOCUS Plus end-directed microtubule motor required for chromosome

DEFINITION congression.

ACCESSION BD105676

VERSION BD105676.1 GI:22651250

KEYWORDS JP 2001526881-A/2;

SOURCE JP 2001526881-A/2;

ORGANISM synthetic construct

artificial sequences.

1 (bases 1 to 17)

REFERENCE Wood,K.W., Sakowicz,R., Goldstein,L.S.B. and Cleveland,D.W.

AUTHORS Plus end-directed microtubule motor required for chromosome

TITLE Patent: JP 2001526881-A 2 25-DEC-2001;

JOURNAL THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

COMMENT OS Artificial Sequence

PN JP 2001526881-A/2

PD 25-DEC-2001

PF 10-SEP-1998 JP 2000510850

PR 11-SEP-1997 US 60/058645

PI KENNETH W WOOD,ROMAN SAKOWICZ,LAWRENCE S B GOLDSTEIN, DON W PI

CLEVELAND

PC C12N9/16,C07K16/40,C12N15/09,C12Q1/42,C12N15/00 CC

DEFINITION Description of Artificial Sequence:primer

PH Key location/Qualifiers

FT source 1..17

FEATURES /organism='Artificial Sequence',

source 1..17

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1164 GGGCTTCCGGAAGAG 1180

DB 1 GGGCTGCCGGAAGAG 17

RESULT 370

A87993 18 bp DNA linear PAT 22-JAN-2000

LOCUS Sequence 141 from Patent WO9833904.

DEFINITION A87993

ACCESSION A87993

VERSION A87993.1 GI:6736563

KEYWORDS

SOURCE unidentified

ORGANISM unidentified

unclassified.

1 (bases 1 to 18)

REFERENCE Brysch,W. and Schlingensiepen,K.

AUTHORS AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD

TITLE Patent: WO 9833904-A 141 06-AUG-1998;

JOURNAL BIOLOGISTIK GBS (DE); BRYSCH WOLFGANG (DE)

FEATURES location/Qualifiers

source 1..18

/organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 GGGCCGAGGGGGCGG 284

DB 2 GGGCAGAGGGGGGCTGG 18

RESULT 371

A89960 18 bp DNA linear PAT 22-JAN-2000

LOCUS Sequence 141 from Patent EP0856579.

DEFINITION A89960

ACCESSION A89960

VERSION A89960.1 GI:6738474

KEYWORDS

SOURCE unidentified

ORGANISM unidentified

unclassified.

1 (bases 1 to 18)

REFERENCE Brysch,W.D. and Schlingensiepen,K.D.

AUTHORS An antisense oligonucleotide preparation method

TITLE Patent: EP 0856579-A 141 05-AUG-1998;

JOURNAL BIOLOGISTIK GBS (DE)

FEATURES location/Qualifiers

source 1..18

/organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 GGGCCGAGGGGGCGG 284

DB 2 GGGCAGAGGGGGGCTGG 18

RESULT 372

A96909 18 bp DNA linear PAT 26-JAN-2000

LOCUS Sequence 5 from Patent WO9923252.

DEFINITION A96909

ACCESSION A96909

VERSION A96909.1 GI:6780350

KEYWORDS

SOURCE unidentified

ORGANISM unidentified

unclassified.

1 (bases 1 to 18)

REFERENCE Bakkenist,C.U. and McGee,J.O.

AUTHORS CANCER GENE

TITLE Patent: WO 9923252-A 5 14-MAY-1999;

JOURNAL BAKKENIST CHRISTOPHER JAMES (GB); MCGEE JAMES O DONNELL (GB)

FEATURES location/Qualifiers

source 1..18

/organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1863 TGGAGCCAGGCGCTTAC 1879
Db 2 TGGAGCCAGGCGCTTAC 18

RESULT 373
AR042339/c 18 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 1129 from patent US 5811300.
DEFINITION AR042339
ACCESSION AR042339.1 GI:5962835
VERSION AR042339.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 18)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- α ha. ribozymes
JOURNAL Patent: US 5811300-A 1129 22-SEP-1998;
FEATURES Location/Qualifiers
1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 554 GGCCATAGAACTGTGA 570
Db 18 GGCCATAGAACTGATGA 2

RESULT 374
AR069552/c 18 bp DNA linear PAT 18-FEB-2000
LOCUS AR069552
DEFINITION Sequence 26 from patent US 5891671.
ACCESSION AR069552
VERSION AR069552.1 GI:7220440
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 18)
AUTHORS Suzuki,T., Magoca,K. and Maunda,T.
TITLE Method for cleaving chimeric protein using processing enzyme
JOURNAL Patent: US 5891671-A 26 06-APR-1999;
FEATURES Location/Qualifiers
1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2562 CCAGCTTCTTCTTCTT 2578
Db 17 CCAGGCTTCTTCTTCTT 1

RESULT 375
AR095824 18 bp DNA linear PAT 08-SEP-2000
LOCUS AR095824
DEFINITION Sequence 45 from patent US 6004814.
ACCESSION AR095824
VERSION AR095824.1 GI:10024058
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.,Frank. and Cowser,L.M.
TITLE Antisense modulation of CD71 expression
JOURNAL Patent: US 6004814-A 45 21-DEC-1999;
FEATURES Location/Qualifiers
1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2014 AAAGCTTGAAGTGCAG 2030
Db 1 AAACCTGAAGTGCCTG 17

RESULT 376
AR121128/c 18 bp DNA linear PAT 16-MAY-2001
LOCUS AR121128
DEFINITION Sequence 24 from patent US 6159697.
ACCESSION AR121128
VERSION AR121128.1 GI:14104704
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 18)
AUTHORS Monia,B.P. and Cowser,L.M.
TITLE Antisense modulation of Smad7 expression
JOURNAL Patent: US 6159697-A 24 12-DEC-2000;
FEATURES Location/Qualifiers
1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1537 AGGGGAAGGCTTCGC 1553
Db 18 AGGGGAAGGCTTTGC 2

RESULT 377
BD175407/c 18 bp DNA linear PAT 18-MAR-2003
LOCUS BD175407
DEFINITION Secretary and transmembrane polypeptide and nucleic acid encoding
the same.
ACCESSION BD175407
VERSION BD175407.1 GI:29121103
KEYWORDS JP 2002253280-A/189.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J.
TITLE Secretary and transmembrane polypeptide and nucleic acid encoding
the same
JOURNAL Patent: JP 2002253280-A 189 10-SEP-2002;
COMMENT GENENTECH INC
OS Artificial Sequence
PN JP 2002253280-A/189
PD 10-SEP-2002 JP 2001385319
PF 18-DEC-2001 JP 2001385319
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR

18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
31-OCT-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066134 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,A61K45/00,A61P1/00,A61P13/12,A61P17/00,A61P17/06, PC
A61P25/00,
PC A61P25/16,A61P25/28,A61P31/12,A61P35/00,C07K14/47,C07K16/18,
PC C07K19/00,
PC C12N1/19,C12N1/21,C12N5/10//A61K38/00,A61K39/395,A61K39/395,
PC A61P43/00,
PC C12P21/08,(C12N1/19,C12R1:645),(C12N1/21,C12R1:19),(C12N5/10,
PC C12R1:91),
PC C12N15/00,C12N5/00,A61K37/02,(C12N5/00,C12R1:91) CC
Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1. .18
/organism='Artificial Sequence'.
Location/Qualifiers
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 150 TCCTCTGTGGAAGCGG 166
17 TCCTCTGTGGAAGCGG 1
Db

RESULT 378
BD190553 18 bp DNA linear PAT 17-JUL-2003
LOCUS BD190553
DEFINITION Secretory proteins and polynucleotides encoding the same.
ACCESSION BD190553
VERSION BD190553.1 GI:33000292
KEYWORDS JP 2002515753-A/12.
SOURCE
ORGANISM Rattus
Rattus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae.
1 (bases 1 to 18)
Jacobs,K., Mccoy,J.M., Lavallie,E.R., Racie,L.A., Merberg,D.,
Treacy,M., Spaulding,V. and Agostino,M.J.
Secretory proteins and polynucleotides encoding the same
Patent: JP 2002515753-A 12 28-MAY-2002;
JOURNAL GENETICS INSTITUTE INC
PN JP 2002515753-A/12
PD 28-MAY-2002
PF 31-OCT-1997 JP 1998521609
PR 01-NOV-1996 US 08/724973

PI KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A RACIE, PI
DAVID MERBERG,
PI MAURICE TREACY, VIKKI SPAULDING, MICHAEL J AGOSTINO PC
C12N1/12,C12N5/10,C07K14/47,C12Q1/68,A61K38/17 CC Strandedness:
Double;
CC Topology: Linear;
FH Key Location/Qualifiers.
Location/Qualifiers
1. .18
/organism="Rattus"
/mol_type="genomic DNA"
/db_xref="taxon:10114"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2571 TTCTCTTTTCTTTTC 2587
17 TTTTCTTTTCTTTTC 1
Db

RESULT 379
CQ788654/c 18 bp DNA linear PAT 24-MAR-2004
LOCUS CQ788654/c
DEFINITION Sequence 2 from Patent WO2004018696.
ACCESSION CQ788654
VERSION CQ788654.1 GI:45723411
KEYWORDS
SOURCE Bos sp.
Bos sp.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovinae; Bos.
1
Prinzberg,E.M. and Erhardt,G.
Method for determining the allelic state of the 5'-end of the
gf(a)1-casein gene
Patent: WO 2004018696-A 2 04-MAR-2004;
Transmit Gesellschaft fuer Technologie transfer mbH (DE);
Justus-Liebig- Universitat Giessen (DE)
JOURNAL Location/Qualifiers
1. .18
/organism="Bos sp."
/mol_type="unassigned DNA"
/db_xref="taxon:29061"
/note="Primer 2"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2562 CCAGCTTCTTCTTCTT 2578
18 CCAGCTTCTGCTTCTT 2
Db

RESULT 380
CQ797868/c 18 bp DNA linear PAT 20-APR-2004
LOCUS CQ797868
DEFINITION Sequence 13 from Patent WO2004029289.
ACCESSION CQ797868
VERSION CQ797868.1 GI:46426365
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Bugawan,T., Erlich,A.H. and Ching,J.C.
Detection of susceptibility to autoimmune diseases
Patent: WO 2004029289-A 13 08-APR-2004;
Roche Diagnostics GmbH (DE); F.HOFFMANN-LA ROCHE AG (CH)
JOURNAL Location/Qualifiers

source

1. 18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Artificial Sequence Type: Probe for HLA-C
Allele-Sequence attaches to BSA at Position 1 on 5' end"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 366 AGAGCCAGCCCGCTGNG 382
DB 17 AGAGCGAGCCCGCTGAG 1

RESULT 381

LOCUS CQ799823 18 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 473 from Patent WO2004031413.
ACCESSION CQ799823
VERSION CQ799823.1 GI:46848770
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

1
Nakamura, Y., Daigo, Y. and Nakatsuru, S.
Method for diagnosing non-small cell lung cancers
Patent: WO 2004031413-A 473 15-APR-2004; represented by the
Oncotherapy Science, Inc. (JP); Japan as president by the
president of the university of Tokyo (JP)
Location/Qualifiers
1. 18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Artificially synthesized S-oligonucleotide sequence
for antisense method"

FEATURES

source
1. 18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Artificially synthesized S-oligonucleotide sequence
for antisense method"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1443 CCACAGCATGATCC 1459
DB 17 CCACAGCATGATTCG 1

RESULT 382

LOCUS E32455 18 bp DNA linear PAT 18-JUN-2001
DEFINITION Mammal-derived tissue specific physiologically active protein.
ACCESSION E32455
VERSION E32455.1 GI:13018691
KEYWORDS
SOURCE
ORGANISM

1 (bases 1 to 18)
Jun, N., Yunque, N. and Toshihiro, T.
Mammal-derived tissue specific physiologically active protein
Patent: JP 2000037190-A 15 08-FEB-2000;
JAPAN TOBACCO INC

REFERENCE
AUTHORS
TITLE
JOURNAL

COMMENT

OS Artificial Sequence
PN JP 2000037190-A/15
PD 08-FEB-2000
PF 23-JUL-1998 JP 1998225228
PR JUN NISHIU, YUSUKE NAKAMURA, TOSHIHIRO TANAKA
PC C12N15/09, C07K14/47, C07K16/18, C12N1/19, C12N1/21, C12N5/10, PC
C12N15/02,
PC C12P21/02, C12P21/08// (C12N5/10, C12R1:91), (C12P21/08, C12R1:91),

PC C12N15/00,
PC C12N5/00, C12N15/00, (C12N5/00, C12R1:91)

CC
FH Key Location/Qualifiers
FT primer_bind (1)..(18).

FEATURES

1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTTTTTCT 2588
DB 2 TTTTCTTTTTTTTCT 18

RESULT 383

LOCUS E32457 18 bp DNA linear PAT 18-JUN-2001
DEFINITION Mammal-derived tissue specific physiologically active protein.
ACCESSION E32457
VERSION E32457.1 GI:13018693
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL

COMMENT

OS Artificial Sequence
PN JP 2000037190-A/17
PD 08-FEB-2000
PF 23-JUL-1998 JP 1998225228
PR JUN NISHIU, YUSUKE NAKAMURA, TOSHIHIRO TANAKA
PC C12N15/09, C07K14/47, C07K16/18, C12N1/19, C12N1/21, C12N5/10, PC
C12N15/02,
PC C12P21/02, C12P21/08// (C12N5/10, C12R1:91), (C12P21/08, C12R1:91),
PC C12N5/00, C12N15/00, (C12N5/00, C12R1:91)
CC
CC
FH Key Location/Qualifiers
FT primer_bind (1)..(18).

FEATURES

1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2574 TTTTCTTTTTTTTGA 2590
DB 2 TTTTCTTTTTTTTGA 18

RESULT 384

LOCUS I57035 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 36 from patent US 5650553.
ACCESSION I57035
VERSION I57035.1 GI:2477448
KEYWORDS
SOURCE
ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Ecker,J., Rothenberg,M., Lehman,A. and Roman,G.
TITLE Plant genes for sensitivity to ethylene and pathogens
JOURNAL Patent: US 5650553-A 36 22-JUL-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGTGTCAGG 243
DB 18 CCAGGAGCTGTGTCAGG 2

RESULT 385
ARI92833 18 bp DNA linear PAT 20-APR-2002
LOCUS AR192833
DEFINITION Sequence 8321 from patent US 6346398.
ACCESSION AR192833
VERSION AR192833.1 GI:20238798
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Payco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 8321 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2488 CTCTCTGACTCCTTGAA 2504
DB 2 CTCTCAGACCTCTTGAA 18

RESULT 386
AR201811 18 bp DNA linear PAT 20-APR-2002
LOCUS AR201811
DEFINITION Sequence 26 from patent US 6361941.
ACCESSION AR201811
VERSION AR201811.1 GI:20256350
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Todd,A.V., Puery,C.J. and Cairns,M.J.
TITLE Catalytic nucleic acid-based diagnostic methods
JOURNAL Patent: US 6361941-A 26 26-MAR-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3642 TGTTCAGAAATGGCAA 3658
DB 1 TGTTCAGAAATGGCAA 17

DB 1 TGTTCAGAAATGGCAA 17

RESULT 387
AR208427 18 bp DNA linear PAT 20-JUN-2002
LOCUS AR208427
DEFINITION Sequence 7 from patent US 6383754.
ACCESSION AR208427
VERSION AR208427.1 GI:21509578
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Kaufman,J.C., Roth,M.E., Lizardi,P.M., Feng,L. and Latimer,D.R.
TITLE Binary encoded sequence tags
JOURNAL Patent: US 6383754-A 7 07-MAY-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTCTTTTCTTC 2587
DB 1 TTTTCTTTTCTTTTCTTC 17

RESULT 388
AR295387 18 bp DNA linear PAT 12-JUN-2003
LOCUS AR295387
DEFINITION Sequence 7122 from patent US 6537751.
ACCESSION AR295387
VERSION AR295387.1 GI:31682671
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 7122 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3338 TATCCCTTCTCTATCCC 3354
DB 2 TATACCTTCCTATCCC 18

RESULT 389
AR295906 18 bp DNA linear PAT 12-JUN-2003
LOCUS AR295906
DEFINITION Sequence 7641 from patent US 6537751.
ACCESSION AR295906
VERSION AR295906.1 GI:31683190
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density

disequilibrium map of the human genome
Patent: US 6537751-A 7641 25-MAR-2003;
JOURNAL
FEATURES
source
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2033 TCAGAGTTCACCCATTA 2049
Db 1 TCAGAGTTCACCCATTA 17

RESULT 390
LOCUS AR297870 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 9605 from patent US 6537751.
ACCESSION AR297870
VERSION AR297870.1 GI:31685154
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL disequilibrium map of the human genome
FEATURES Patent: US 6537751-A 9605 25-MAR-2003;
source Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3581 AGCGAAGGATGGGGA 3597
Db 17 AGAGAGAGGATGGGGA 1

RESULT 391
LOCUS AR326577 18 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3979 from patent US 6566127.
ACCESSION AR326577
VERSION AR326577.1 GI:33712385
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwigen,J.A., Stinchcomb,D.T. and Becobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
FEATURES Patent: US 6566127-A 3979 20-MAY-2003;
source Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2488 CTCTGAGCTCTGGAA 2504
Db 2 CTCTGAGCTCTGGAA 18

RESULT 392
LOCUS AR339664 18 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 4 from patent US 6569671.
ACCESSION AR339664
VERSION AR339664.1 GI:33726576
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Okamoto,T., Yamamoto,N. and Suzuki,T.
TITLE Pattern exposure method, exposure device, formation of nucleic acid
JOURNAL array, and formation of peptide array
FEATURES Patent: US 6569671-A 4 27-MAY-2003;
source Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3441 CTGCCATCTTTTACA 3457
Db 2 CTGCCATCTTTTACA 18

RESULT 393
LOCUS AR362564 18 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 7 from patent US 5175384.
ACCESSION AR362564
VERSION AR362564.1 GI:34422799
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Krimpenfort,P.J.A. and Berns,A.J.M.
TITLE Transgenic mice depleted in mature T-cells and methods for making
JOURNAL transgenic mice
FEATURES Patent: US 5175384-A 7 29-DEC-1992;
source Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 380 GAGGGGAGGGGCTGC 396
Db 1 GAGGGGAGGGGCTGC 17

RESULT 394
LOCUS AR410785 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 229 from patent US 6635468.
ACCESSION AR410785
VERSION AR410785.1 GI:40162285
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Ashkenazi,A., Botstein,D., Desnoyers,L., Eaton,D.L., Ferrara,N.,
Filvaroff,E., Fong,S., Gao,W.-O., Gerber,H., Grittsen,M.E.,
Goddard,A., Godowski,P.J., Grimaldi,J.C., Gurney,A.L., Hillan,K.J.,

TITLE Kljavin, I.J., Mather, J.P., Pan, J., Paoni, N.F., Roy, M.A., Stewart, T.A., Tumas, D., Williams, P.M. and Wood, W.I.
Secreted and transmembrane polypeptides and nucleic acids encoding the same

JOURNAL Patent: US 6635468-A 229 21-OCT-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCG 166
17 TCCCTGTGACGACG 1

RESULT 395
LOCUS AR439149 18 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 229 from patent US 6664376.
ACCESSION AR439149
VERSION AR439149.1 GI:42664998
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 18)
Ashkenazi, A., Botstein, D., Desnoyers, L., Eaton, D.L., Ferrara, N., Filvaroff, E., Fong, S., Gao, W.-Q., Gerber, H., Gertlisen, M.E., Goddard, A., Godowski, P.J., Grimaldi, J.C., Gurney, A.L., Hillan, K.J., Kljavin, I.J., Mather, J.P., Pan, J., Paoni, N.F., Roy, M.A., Stewart, T.A., Tumas, D., Williams, P.M. and Wood, W.I.

TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same

JOURNAL Patent: US 6664376-A 229 16-DEC-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCG 166
17 TCCCTGTGACGACG 1

RESULT 396
LOCUS AR473169 18 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 229 from patent US 6664451.
ACCESSION AR473169
VERSION AR473169.1 GI:42708544
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 18)
Desnoyers, L., Goddard, A., Godowski, P.J., Gurney, A.L., Mather, J.P., Williams, P.M. and Wood, W.I.

TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same

JOURNAL Patent: US 6664451-A 229 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCG 166
17 TCCCTGTGACGACG 1

RESULT 397
LOCUS AR490943 18 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 37 from patent US 6713300.
ACCESSION AR490943
VERSION AR490943.1 GI:47258476
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 18)
Allikmets, R., Anderson, K.L., Dean, M., Leppert, M., Lewis, R.A., Li, Y., Lupski, J.R., Nathans, J., Ratner, A., Shroyer, N.F., Singh, N., Smallwood, P. and Sun, H.

TITLE Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter

JOURNAL Patent: US 6713300-A 37 30-MAR-2004;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 205 CCATGCCAGCGCAATGG 221
18 CCATGACGCGCAATGG 2

RESULT 398
LOCUS AX028844 18 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 28 from Patent W09732023.
ACCESSION AX028844
VERSION AX028844.1 GI:10189947
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1
Brugliera, F., Holton, T.A. and Michael, M.Z.

TITLE Genetic sequences encoding flavonoid pathway enzymes and uses therefor

JOURNAL Patent: WO 9732023-A 28 04-SEP-1997;
FEATURES FIORIGENE LIMITED (AU) ; BRUGLIERA FILIPPA (AU) ; HOLTON TIMOTHY ALBERT (AU) ; MICHAEL MICHAEL ZENON (AU)
Location/Qualifiers
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTCTTC 2587
2 TTTTCTTTTCTTC 18

RESULT 399
AX085253 18 bp DNA PAT 09-MAR-2001
LOCUS Sequence 7 from Patent WO0112855.
DEFINITION AX085253
ACCESSION AX085253.1 GI:13275311
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Kaufman,J.C., Roth,M.E., Lizardi,P.M., Feng,L. and Latimer,D.R.
TITLE Binary encoded sequence tags
JOURNAL Patent: WO 0112855-A 7 22-FEB-2001;
YALE UNIVERSITY (US)
FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTTC 2587
Db 1 TTTTTC 17

RESULT 400
AX114425 18 bp DNA PAT 11-MAY-2001
LOCUS Sequence 94 from Patent WO0129257.
DEFINITION AX114425
ACCESSION AX114425
VERSION AX114425.1 GI:14031389
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Schork,N. and Skierczynski,B.
TITLE Methods of genetic cluster analysis and use thereof
JOURNAL Patent: WO 0129257-A 94 26-APR-2001;
GENSET (FR)
FEATURES
source 1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="upstream amplification primer 5-15 for SEQ 31"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2783 AAGGAATGAAGAGTG 2799
Db 17 AAGGAATGATGAGTG 1

RESULT 401
AX133069 18 bp DNA PAT 15-MAY-2001
LOCUS Sequence 4287 from Patent WO0130362.
DEFINITION AX133069
ACCESSION AX133069.1 GI:14139379
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source 1..18
/organism="Homo sapiens (human)"

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Robbins,J.M. and Trltz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL diseases
Patent: WO 0130362-A 4287 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source 1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Hammerhead ribozyme recognition site for cdc 2
kinase"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2637 CAGAACTCCAGAGTGT 2653
Db 2 CAGATCTCCAGAGTAT 18

RESULT 402
AX318812 18 bp DNA PAT 14-DEC-2001
LOCUS Sequence 28 from Patent WO0172957.
DEFINITION AX318812
ACCESSION AX318812
VERSION AX318812.1 GI:17901094
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Itoh,N.
TITLE Fibroblast growth factor-like molecules and uses thereof
JOURNAL Patent: WO 0172957-A 28 04-OCT-2001;
Itoh, Nobuyuki (JP)
FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2058 GCCTCAGAGACCTGA 2074
Db 1 GCCTCAGAGACCAAGA 17

RESULT 403
AX361600 18 bp DNA PAT 15-FEB-2002
LOCUS Sequence 18 from Patent WO0208461.
DEFINITION AX361600
ACCESSION AX361600
VERSION AX361600.1 GI:18694219
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Linnarsson,S.G., Ernfor,P.G. and Bauren,G.G.
TITLE A method and an algorithm for mra expression analysis
JOURNAL Patent: WO 0208461-A 18 31-JAN-2002;
Global Genomics AB (SE)
FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"

Db 18 AGGGGAATGCTTTTC 2

RESULT 408
AX754829/c
LOCUS AX754829 18 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 24 from Patent WO03037368.
ACCESSION AX754829
VERSION AX754829.1 GI:32167259
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 Steinbrecher, A., Giegerich, G., Kleiter, I., Horn, M., Apfel, R., Kreutzer, R., Limmer, S. and Vornlocher, H.P.
TITLE Smad7 inhibitors for the treatment of cns diseases
JOURNAL Patent: WO 03037368-A 24 08-MAY-2003;
Steinbrecher, Andreas (DE) ; Ribopharma AG (DE)
FEATURES
source 1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1537 AGGGGAATGCTTTTC 1553
Db 18 AGGGGAATGCTTTTC 2

RESULT 409
AX754842/c
LOCUS AX754842 18 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 37 from Patent WO03037368.
ACCESSION AX754842
VERSION AX754842.1 GI:32167272
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
1 Steinbrecher, A., Giegerich, G., Kleiter, I., Horn, M., Apfel, R., Kreutzer, R., Limmer, S. and Vornlocher, H.P.
TITLE Smad7 inhibitors for the treatment of cns diseases
JOURNAL Patent: WO 03037368-A 37 08-MAY-2003;
Steinbrecher, Andreas (DE) ; Ribopharma AG (DE)
FEATURES
source 1..18
/organism="Rattus norvegicus"
/mol_type="unassigned DNA"
/db_xref="taxon:10116"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1537 AGGGGAATGCTTTTC 1553
Db 18 AGGGGAATGCTTTTC 2

RESULT 410
AX814932
LOCUS AX814932 18 bp DNA linear PAT 05-DEC-2003
DEFINITION Sequence 18 from Patent WO03064691.
ACCESSION AX814932

VERSION AX814932.1 GI:39104070
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS artificial sequences.
1 Linmarsson, S., Enfors, P., Bauren, G., Metsis, A., Pihlak, A. and Montellius, A.
TITLE Methods and means for manipulating nucleic acid
JOURNAL Patent: WO 03064691-A 18 07-AUG-2003;
Global Genomics AB (SE)
FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Double-stranded product DNA"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTCTTTTC 2587
Db 1 TTTTCTTTTCTTTTC 17

RESULT 411
AX838262
LOCUS AX838262 18 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 5386 from Patent EP1347046.
ACCESSION AX838262
VERSION AX838262.1 GI:39921954
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS unclassified.
1 Isogai, T., Sugiyama, T., Otsuka, T., Wakamatsu, A., Sato, H., Ishii, S., Yamamoto, D., I., Isono, Y., Hio, Y., Otsuka, K., Nagai, K., Irie, R., Tamechika, I., Seki, N., Yoshikawa, T., Otsuka, M., Nagahari, K. and Masuko, Y.
TITLE Full-length cDNA sequences
JOURNAL Patent: EP 1347046-A 5386 24-SEP-2003;
Research Association for Biotechnology (JP)
FEATURES
source 1..18
/organism="unclassified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Description of Artificial Sequence: an artificially synthesized primer se q"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2562 CCAGCTTTCTTCTTCTT 2578
Db 1 CCAGCTTTCTTCTTCTT 17

RESULT 412
AX838323
LOCUS AX838323 18 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 5447 from Patent EP1347046.
ACCESSION AX838323
VERSION AX838323.1 GI:39922015
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS unclassified.

REFERENCE
AUTHORS
1
Isegai, T., Sugiyama, T., Otsuki, T., Wakamatsu, A., Sato, H., Ishii, S., Yamamoto, J. I., Isono, Y., Hio, Y., Otsuka, K., Nagai, K., Irie, R., Tamechika, I., Seki, N., Yoshikawa, T., Otsuka, M., Nagahari, K. and Masuno, Y.
TITLE
Full-length cDNA sequences
JOURNAL
Patent: EP 1347046-A 5447 24-SEP-2003;
Research Association for Biotechnology (JP)
FEATURES
source
1. .18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Description of Artificial Sequence: an artificially synthesized primer se q"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1240 TCTTTTGGATGCTG 1256
||||| |||||||
18 TCTTTGATGATGCTG 2

RESULT 413
LOCUS BD065506 18 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065506
VERSION BD065506.1 GI:22611109
KEYWORDS JP 2001511000-A/141.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Schlingensiepen, K. H. and Brysch, W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 141 07-AUG-2001;
BIOCHEMISTRIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/141
PD 07-AUG-2001
PR 30-JAN-1998 JP 1998532533
PI 31-JAN-1997 EP 97101531.8
PC KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC C12N15/11, C07H21/04, A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1. .18
/organism='Unknown'.
Location/Qualifiers
1. .18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 268 GGGCCGAGGGGGCGG 284
||||| |||||||
2 GGGCAGAGGGGGCTGG 18

RESULT 414
LOCUS BD075556/c 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Secretory and transmembrane polypeptide and nucleic acid encoding the same.
ACCESSION BD075556
VERSION BD075556.1 GI:22621159

KEYWORDS
SOURCE JP 2001516580-A/189.
ORGANISM synthetic construct
ARTIFICIAL SEQUENCE
REFERENCE
AUTHORS 1 (bases 1 to 18)
TITLE Wood, W. I., Gurney, A. L., Goddard, A., Penica, D., Chen, J. and Yuan, J.
JOURNAL Secretory and transmembrane polypeptide and nucleic acid encoding the same
Patent: JP 2001516580-A 189 02-OCT-2001;
GENENTECH INC
COMMENT
OS Artificial Sequence
PN JP 2001516580-A/189
PD 02-OCT-2001
PR 16-SEP-1998 JP 2000511667
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
PR 17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR
PR 17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
PR 17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
PR 18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR
PR 17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
PR 21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
PR 24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR
PR 24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR
PR 24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
PR 27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
PR 28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR
PR 28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR
PR 28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063546 PR
PR 28-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
PR 29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR
PR 29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/063735 PR
PR 29-OCT-1997 US 60/064103, 31-OCT-1997 US 60/063870 PR
PR 03-OCT-1997 US 60/064248, 07-NOV-1997 US 60/065846 PR
PR 12-NOV-1997 US 60/065186, 17-NOV-1997 US 60/065846 PR
PR 18-NOV-1997 US 60/065693, 21-NOV-1997 US 60/065120 PR
PR 21-NOV-1997 US 60/066364, 24-NOV-1997 US 60/065772 PR
PR 24-NOV-1997 US 60/066466, 24-NOV-1997 US 60/066770 PR
PR 25-NOV-1997 US 60/066511, 24-NOV-1997 US 60/066453 PR
PR 60/066840
PI WILLIAM I WOOD, AUSTIN L GURNEY, AUDLEY GODDARD, DIANE PENICA, PI
JEAN CHEN,
PI JEAN YUAN
PC C12N15/09, C07K14/47, C07K14/705, C07K16/18, C07K19/00,
PC C12N15/19,
PC C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/02, C12P21/08, PC
C12R1/91)
PC C12N15/00, C12N5/00
CC Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1. .18
/organism='Artificial Sequence'.
Location/Qualifiers
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 150 TCCCTGTGAAAGCGG 166
||||| |||||||
17 TCCCTGTGACAGCAG 1

RESULT 415
LOCUS BD172416/c 18 bp DNA linear PAT 18-FEB-2003
DEFINITION Secreted and transmembrane polypeptides and nucleic acids encoding the same.
ACCESSION BD172416
VERSION BD172416.1 GI:28413716

KEYWORDS JP 2002223786-A/189.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood, W. I., Gurney, A. L., Goddard, A., Pennica, D., Zheng, J. and Yuan, J.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same
JOURNAL Patent: JP 2002223786-A 189 13-AUG-2002;
GENENTECH INC
COMMENT OS Artificial Sequence
PN JP 2002223786-A/189
PD 13-AUG-2002
PR 18-DEC-2001 JP 2001385135
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/052125 PR
17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
60/062814, 24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063564 PR
28-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064103 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064248 PR
29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064175 PR
31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065168 PR
17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065364 PR
21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09, C07K14/47, C07K16/18, C07K19/00, C12N1/19, C12N1/21, PC
C12N5/10,
PC C12P21/02//C12P21/08, (C12P21/02, C12R1:19), (C12P21/02, C12R1:91), PC
(C12P21/02, C12R1:645), C12N15/00, C12N5/00
CC Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1..18 /organism='Artificial Sequence'.
FEATURES
source 1..18 Location/Qualifiers
1..18 /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAACGCG 166
17 TCCCTGTGACACGAG 1

Db 17 TCCCTGTGACACGAG 1

RESULT 416
BD172735 18 bp DNA linear PAT 18-FEB-2003
LOCUS Secreted and transmembrane polypeptides and nucleic acids encoding
DEFINITION the same.
ACCESSION BD172735

VERSION BD172735.1 GI:28414039
KEYWORDS JP 2002238586-A/189.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood, W. I., Gurney, A. L., Goddard, A., Pennica, D., Zheng, J. and Yuan, J.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same
JOURNAL Patent: JP 2002238586-A 189 27-AUG-2002;
GENENTECH INC
COMMENT OS Artificial Sequence
PN JP 2002238586-A/189
PD 27-AUG-2002
PR 18-DEC-2001 JP 2001385205
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/062814, 24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063564 PR
28-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064103 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064248 PR
29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064175 PR
31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065168 PR
17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065364 PR
21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09, C07K14/47, C07K16/18, C07K19/00, C12N1/19, C12N1/21, PC
C12N5/10,
PC C12P21/02//C12P21/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19), PC
(C12N15/10, C12R1:91), (C12P21/02, C12R1:91), (C12P21/02, C12R1:645), PC
(C12P21/02, C12R1:19), (C12P21/08, C12R1:91), C12N15/00, C12N5/00, PC
(C12N5/00, C12R1:91)
CC Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1..18 /organism='Artificial Sequence'.
FEATURES
source 1..18 Location/Qualifiers
1..18 /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAACGCG 166
17 TCCCTGTGACACGAG 1

Db 17 TCCCTGTGACACGAG 1

RESULT 417
BD173054 18 bp DNA linear PAT 18-FEB-2003
LOCUS Secreted and transmembrane polypeptides and nucleic acids encoding
DEFINITION the same.
ACCESSION BD173054

DEFINITION Secreted and transmembrane polypeptides and nucleic acids encoding the same.

ACCESSION BD173373

VERSION BD173373.1 GI:28414360

KEYWORDS JP 2002238587-A/189.

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1 (bases 1 to 18)

AUTHORS Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and Yuan, J.

TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same

JOURNAL Patent: JP 2002238587-A 189 27-AUG-2002;

COMMENT OS Artificial Sequence

PN JP 2002238587-A/189

PD 27-AUG-2002

PF 18-DEC-2001 JP 2001385248

PR 17-SEP-1997 US 60/059112, 17-SEP-1997 US 60/059117 PR

17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR

17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR

18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR

17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR

21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR

24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063121 PR

24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063128 PR

27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR

28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR

28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR

28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063544 PR

29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR

29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR

29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR

29-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR

31-OCT-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR

07-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR

17-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR

21-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066466 PR

24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR

24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI

WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI

JIAN ZHENG,

PI JEAN YUAN

PC C12N15/09, C07K14/47, C07K16/18, C12N1/19, C12N1/21, C12N5/10, PC C12N15/02,

PC C12P21/02, C12P21/08, (C12P21/02, C12R1:91), (C12P21/02, C12R1:19), PC (C12P21/02, C12R1:645), C12N15/00, C12N5/00, C12N15/00 CC

Description of Artificial Sequence: Synthetic FH Key

Location/Qualifiers

FT source 1..18 /organism='Artificial Sequence'.

FEATURES

source 1..18 Location/Qualifiers

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCGTGTGAAGCGG 166

DB 17 TCCCGTGTGAAGCGG 1

LOCUS BD173373 18 bp DNA linear PAT 18-FEB-2003

DEFINITION Secreted and transmembrane polypeptides and nucleic acids encoding the same.

ACCESSION BD173373

VERSION BD173373.1 GI:28414684

KEYWORDS JP 2002238588-A/189.

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1 (bases 1 to 18)

AUTHORS Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and Yuan, J.

TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same

JOURNAL Patent: JP 2002238588-A 189 27-AUG-2002;

COMMENT OS Artificial Sequence

PN JP 2002238588-A/189

PD 27-AUG-2002

PF 18-DEC-2001 JP 2001385315

PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR

17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR

17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR

17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR

18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR

17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR

21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/063127 PR

24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063121 PR

24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063128 PR

27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR

28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR

28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR

28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063544 PR

29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR

29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR

29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064335 PR

29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR

29-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR

31-OCT-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR

07-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR

17-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR

21-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066466 PR

24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR

24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI

WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI

JIAN ZHENG,

PI JEAN YUAN

PC C12N15/09, C07K14/435, C07K16/18, C07K19/00, C12N1/19, C12N1/21, PC C12N5/10,

PC C12P21/02, C12P21/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19), PC (C12N5/10, C12R1:91), C12N15/00, C12N5/00, C12N15/00, C12R1:91) CC

Description of Artificial Sequence: Synthetic FH Key

Location/Qualifiers

FT source 1..18 /organism='Artificial Sequence'.

FEATURES

source 1..18 Location/Qualifiers

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCGTGTGAAGCGG 166

DB 17 TCCCGTGTGAAGCGG 1

LOCUS ATH524527 18 bp DNA linear PLN 29-MAR-2003
 DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 076F06.
 ACCESSION AJ524527
 VERSION AJ524527.1 GI:26792763
 KEYWORDS left border; T-DNA flanking sequence.
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
 AUTHORS 1 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Criaud, C., Derose, R., Pelletier, G., Lepoint, L., Caboche, M. and Lecharny, A.
 T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
 JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
 MEDLINE 22363535
 PUBMED 12446565
 REFERENCE 2 (bases 1 to 18)
 AUTHORS Balzerque, S.
 TITLE Direct Submission
 JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
 PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.inbio.gen.fr>).
 FEATURES
 source location/Qualifiers
 1..18
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Massillwsktja"
 /db_xref="taxon:3702"
 /clone="076F06"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 /note="T-DNA flanking sequence
 left border"

misc_feature
 1..18
 /note="T-DNA flanking sequence
 left border"

Query Match 0.4%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3478 ATTTTTCATATT 3494
 Db 2 ATGTTTTCATGATT 18

RESULT 420
 AR008498 17 bp DNA linear PAT 04-DEC-1998
 LOCUS AR008498
 DEFINITION Sequence 27 from patent US 5753492.
 ACCESSION AR008498
 VERSION AR008498.1 GI:3967607
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE Unclassified.
 AUTHORS 1 (bases 1 to 17)
 Schnepl,H.Ernest., Schwab,G.E., Payne,J., Narva,K.E. and Foncecrada,L.
 TITLE Genes encoding nematode-active toxins from Bacillus thuringiensis strains
 JOURNAL Patent: US 5753492-A 27 19-MAY-1998;

FEATURES location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.2e+02;
 Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTCAACC 2008
 Db 2 AAYTACAAGCWCACACC 17

RESULT 421
 AR049950 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR049950
 DEFINITION Sequence 24 from patent US 5824792.
 ACCESSION AR049950
 VERSION AR049950.1 GI:5971942
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE Unclassified.
 AUTHORS 1 (bases 1 to 17)
 Payne,J.M., Kennedy,M.Keith., Randall,J.Brookes., Meier,H., Uick,H.Jane., Foncecrada,L., Schnepl,H.Ernest., Schwab,G.E. and Fu,J.
 TITLE Bacillus thuringiensis toxins active against hymenopteran pests
 JOURNAL Patent: US 5824792-A 24 20-OCT-1998;
 FEATURES location/Qualifiers
 1..17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.2e+02;
 Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTCAACC 2008
 Db 2 AAYTACAAGCWCACACC 17

RESULT 422
 AR099636 17 bp DNA linear PAT 14-FEB-2001
 LOCUS AR099636
 DEFINITION Sequence 24 from patent US 6077937.
 ACCESSION AR099636
 VERSION AR099636.1 GI:12809402
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE Unclassified.
 AUTHORS 1 (bases 1 to 17)
 Payne,J.M., Kennedy,M.Keith., Randall,J.Brookes., Meier,H., Uick,H.Jane., Foncecrada,L., Schnepl,H.Ernest., Schwab,G.E. and Fu,J.
 TITLE Bacillus thuringiensis toxins active against hymenopteran pests
 JOURNAL Patent: US 6077937-A 24 20-JUN-2000;
 FEATURES location/Qualifiers
 1..17
 /organism="unknown"
 /mol_type="unassigned DNA"

```

RESULT 423
LOCUS 113741 17 bp DNA linear PAT 26-SEP-1995
DEFINITION Sequence 17 from patent US 5439881.
ACCESSION 113741
VERSION 113741.1 GI:996807
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1. .17
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 81.2%; Score 13.6; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTCAAGTACACACC 2008
Db 2 AAYTACAGCWCACACC 17

RESULT 424
LOCUS 1134530 17 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 24 from patent US 5596071.
ACCESSION 1134530
VERSION 1134530.1 GI:1825321
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1. .17
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 81.2%; Score 13.6; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTCAAGTACACACC 2008
Db 2 AAYTACAGCWCACACC 17

RESULT 425
LOCUS 1139800 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 24 from patent US 5616495.
ACCESSION 1139800
VERSION 1139800.1 GI:2084280
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1. .17
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 81.2%; Score 13.6; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTCAAGTACACACC 2008
Db 2 AAYTACAGCWCACACC 17

```

```

JOURNAL Patent: US 5616495-A 24 01-APR-1997;
FEATURES
source
    1. .17
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 81.2%; Score 13.6; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTCAAGTACACACC 2008
Db 2 AAYTACAGCWCACACC 17

RESULT 426
LOCUS AR409126 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 27 from patent US 6632792.
ACCESSION AR409126
VERSION AR409126.1 GI:40159616
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1. .17
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 81.2%; Score 13.6; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTCAAGTACACACC 2008
Db 2 AAYTACAGCWCACACC 17

RESULT 427
LOCUS AR172755/c 18 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 74 from patent US 6303344.
ACCESSION AR172755
VERSION AR172755.1 GI:17912246
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    1. .18
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 72.2%; Score 13.6; DB 1; Length 18;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGATGA 2791
Db 18 TTAAGAGKAGAGAWTGA 1

RESULT 428
LOCUS AR178699/c
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

```

LOCUS AR178699 18 bp DNA PAT 20-APR-2002
DEFINITION Sequence 74 from patent US 6319713.
ACCESSION AR178699
VERSION AR178699.1 GI:20219837
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Paten,P.A. and Stemmer,W.P.C.
TITLE Methods and compositions for polypeptide engineering
JOURNAL Patent: US 6319713-A 74 20-NOV-2001;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGGATGA 2791
Db 18 TTAAGAGKAGAGAWTGA 1
|||||:|||||:|||||
|:|:|:|:|:|:|:|:|:|

RESULT 429
AR181270/c AR181270 18 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 74 from patent US 6335160.
DEFINITION AR181270
ACCESSION AR181270.1 GI:20223484
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Paten,P.A. and Stemmer,W.P.C.
TITLE Methods and compositions for polypeptide engineering
JOURNAL Patent: US 6335160-A 74 01-JAN-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGGATGA 2791
Db 18 TTAAGAGKAGAGAWTGA 1
|||||:|||||:|||||
|:|:|:|:|:|:|:|:|:|

RESULT 430
AR199951/c AR199951 18 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 74 from patent US 6355484.
DEFINITION AR199951
ACCESSION AR199951.1 GI:20250025
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Paten,P.A. and Stemmer,W.P.C.
TITLE Methods and compositions for polypeptides engineering
JOURNAL Patent: US 6355484-A 74 12-MAR-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGGATGA 2791
Db 18 TTAAGAGKAGAGAWTGA 1
|||||:|||||:|||||
|:|:|:|:|:|:|:|:|:|

RESULT 431
AR231899 AR231899/c AR231899 18 bp DNA linear PAT 20-DEC-2002
LOCUS Sequence 74 from patent US 6455253.
DEFINITION AR231899
ACCESSION AR231899.1 GI:27273480
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Paten,P.A. and Stemmer,W.P.C.
TITLE Methods and compositions for polypeptide engineering
JOURNAL Patent: US 6455253-A 74 24-SEP-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGGATGA 2791
Db 18 TTAAGAGKAGAGAWTGA 1
|||||:|||||:|||||
|:~:~:~:~:~:~:~:~:~

RESULT 432
AR343374/c AR343374 18 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 74 from patent US 6579678.
DEFINITION AR343374
ACCESSION AR343374.1 GI:3378903
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Paten,P.A. and Stemmer,W.P.C.
TITLE Methods and compositions for polypeptide engineering
JOURNAL Patent: US 6579678-A 74 17-JUN-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGGATGA 2791
Db 18 TTAAGAGKAGAGAWTGA 1
|||||:|||||:|||||
|:~:~:~:~:~:~:~:~:~

RESULT 433
AR349692/c AR349692 18 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 74 from patent US 6586182.
DEFINITION AR349692
ACCESSION AR349692.1 GI:33750490
VERSION
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Patten,P.A. and Stemmer,W.P.C.
TITLE Methode and compositions for polypeptide engineering
JOURNAL Patent: US 656182-A 74 01-JUL-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGAAATGA 2791
DB 18 TTAAGAGKAAAGAAWTGA 1
|||||:|:|||||:|

RESULT 434
AR431606/c 18 bp DNA linear PAT 18-DEC-2003
LOCUS AR431606
DEFINITION Sequence 74 from patent US 6653072.
ACCESSION AR431606
VERSION AR431606.1 GI:40193710
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Patten,P.A. and Stemmer,W.P.C.
TITLE Methode and compositions for polypeptide engineering
JOURNAL Patent: US 6653072-A 74 25-NOV-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGAAATGA 2791
DB 18 TTAAGAGKAAAGAAWTGA 1
|||||:|:|||||:|

DB 18 TTAAGAGKAAAGAAWTGA 1
|||||:|:|||||:|

RESULT 436
BD062888/c 18 bp DNA linear PAT 27-AUG-2002
LOCUS BD062888
DEFINITION Methode and compositions for polypeptide engineering.
ACCESSION BD062888
VERSION BD062888.1 GI:22608491
KEYWORDS JP 2001506855-A/74.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Patten,P.A. and Stemmer,W.P.C.
TITLE Methode and compositions for polypeptide engineering
JOURNAL Patent: JP 2001506855-A 74 29-MAY-2001;
COMMENT MAXYGEN INC
OS Artificial Sequence
PN JP 2001506855-A/74
PD 29-MAY-2001
PF 17-DEC-1997 JP 1998528054
PR 18-DEC-1996 US 08/769062
PI PHILLIP A PATTEN,WILHEM P C STEMMER
PC C12Q1/68,C12P19/34,G01N33/53,C12N9/12,C12N9/50,C12N9/56,C12N15/PC
63, C07K14/435
CC Description of Artificial Sequence: degenerate oligonucleotide
CC used for
CC alpha interferon shuffling
FH key Location/Qualifiers.
FEATURES 1..18
source /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGCTGAAGAAATGA 2791
DB 18 TTAAGAGKAAAGAAWTGA 1
|||||:|:|||||:|

RESULT 437
A88529 15 bp DNA linear PAT 22-JAN-2000
LOCUS A88529
DEFINITION Sequence 677 from Patent WO9833904.
ACCESSION A88529
VERSION A88529.1 GI:6737099
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Brysch,W. and Schlingensiefen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 677 06-AUG-1998;
FEATURES BIOLOGISTIK GBS (DE); BRYSCH WOLFGANG (DE)
Location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```

Qy      3113 TATTTCTTAACCTC 3127
Db      15 TATTTTATTAACCTC 1

RESULT 438
LOCUS   A90496      15 bp      DNA      linear      PAT 22-JAN-2000
DEFINITION   Sequence 677 from Patent EP0856579.
ACCESSION    A90496
VERSION      A90496.1 GI:6739010
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Brysch W.D. and Schlingensiepen,K.D.
  An antisense oligonucleotide preparation method
  Patent: EP 0856579-A 677 05-AUG-1998;
  BIOGNOSTIK GES (DE)
  Location/Qualifiers
  1..15
  /organism="unidentified"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32644"

Query Match      0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      3113 TATTTCTTAACCTC 3127
Db      15 TATTTTATTAACCTC 1

RESULT 439
LOCUS   A98763      15 bp      DNA      linear      PAT 26-JAN-2000
DEFINITION   Sequence 1 from Patent WO9910362.
ACCESSION    A98763
VERSION      A98763.1 GI:6781785
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Southern,E.M. and Shchepnov,M.S.
  BRANCHED DENDRIMERIC STRUCTURES
  Patent: WO 9910362-A 1 04-MAR-1999;
  SOUTHERN EDWIN MELLOR (GB); ISIS INNOVATION (GB)
  Location/Qualifiers
  1..15
  /organism="unidentified"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32644"

Query Match      0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2569 TCTTCTTCTTTT 2583
Db      1 TCTTCTTCTTCTTT 15

RESULT 440
LOCUS   AR035564      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION   Sequence 9 from patent US 5871918.
ACCESSION    AR035564
VERSION      AR035564.1 GI:5952232
KEYWORDS
SOURCE
  Unknown.

Query Match      0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

ORGANISM   Unknown.
REFERENCE
  1 (bases 1 to 15)
  Thorp,H.Holden., Johnston,D.H., Napier,M.E., Loomis,C.R.,
  SISTARE,M.F. and Kim,J.
  Electrochemical detection of nucleic acid hybridization
  Patent: US 5871918-A 9 16-FEB-1999;
  Location/Qualifiers
  1..15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      3656 AATATCAATATATAAA 3670
Db      15 AATATATATATATAAA 1

RESULT 441
LOCUS   AR056088      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION   Sequence 292 from patent US 5837542.
ACCESSION    AR056088
VERSION      AR056088.1 GI:5981665
KEYWORDS
SOURCE
  Unknown.
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
  Draper,K.G.
  Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  Patent: US 5837542-A 292 17-NOV-1998;
  Location/Qualifiers
  1..15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      278 GCGCGGAGGTGGC 292
Db      15 GCGTGGGAGGTGGC 1

RESULT 442
LOCUS   AR113846      15 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION   Sequence 292 from patent US 6132967.
ACCESSION    AR113846
VERSION      AR113846.1 GI:14094168
KEYWORDS
SOURCE
  Unknown.
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
  Draper,K.G.
  Ribozyme treatment of diseases or conditions related to levels of
  intercellular adhesion molecule-1 (ICAM-1)
  Patent: US 6132967-A 292 17-OCT-2000;
  Location/Qualifiers
  1..15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;

```

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 278 GGGCGGGAGGTGGC 292

Db 15 GGGTGGGAGGTGGC 1

RESULT 443
AR116014/c AR116014 15 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 9 from patent US 6132971.
DEFINITION AR116014
ACCESSION AR116014
VERSION AR116014.1 GI:14096336
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Thorp,H.Holden., Johnston,D.H., Napier,M.E., Loomis,C.R.,
Sistare,M.F. and Kim,J.
TITLE Microelectronic device
JOURNAL Patent: US 6132971-A 9 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3656 AATACATATATAA 3670

Db 15 AATATATAATAA 1

RESULT 444

BD272133 15 bp DNA linear PAT 17-JUL-2003
LOCUS Novel antisense-oligo having improved stability and antisense
DEFINITION effect.
ACCESSION BD272133
VERSION BD272133.1 GI:33081901
KEYWORDS JP 2002540813-A/1.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 15)
AUTHORS Park,J.G.
TITLE Novel antisense-oligo having improved stability and antisense
JOURNAL Patent: JP 2002540813-A 1 03-DEC-2002;
COMMENT JONG GU PARK
OS Homo sapiens (human)
PN JP 2002540813-A/1
PD 03-DEC-2002 JP 2000610864
PF 04-APR-2000 JP 2000610864
PR 08-APR-1999 KR 1999/12297
PI JONG GU PARK
PC C12N15/09,A61K9/127,A61K48/00,A61P31/00,A61P35/00,A61P35/02,
PC A61P37/00,
CC C12Q1/68,C12N15/00
CC Novel antisense-oligo having improved stability and antisense
effect
CC Key Location/Qualifiers
FH 1..15
FT source 1..15
/organism='Homo sapiens (human)'.
FEATURES Location/Qualifiers
source 1..15
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 435 TCGGTTTTCATCCT 449

Db 1 TCAGTTTTCATCCT 15

RESULT 445

AR231732 15 bp DNA linear PAT 20-DEC-2002
LOCUS AR231732
DEFINITION Sequence 1 from patent US 6455071.
ACCESSION AR231732
VERSION AR231732.1 GI:27273073
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Shchepinov,M.S. and Southern,E.M.
TITLE Branched dendrimeric structures
JOURNAL Patent: US 6455071-A 1 24-SEP-2002;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2569 TCTTCTTCTTTT 2583

Db 1 TCTTCTTCTTCT 15

RESULT 446

AX633156/c 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX633156
DEFINITION Sequence 295 from Patent EP1260586.
ACCESSION AX633156
VERSION AX633156.1 GI:28468770
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Swedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
JOURNAL genes
PATENT Patent: EP 1260586-A 295 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 278 GGGCGGGAGGTGGC 292

Db 15 GGGTGGGAGGTGGC 1

```

RESULT 447
BD066042/c 15 bp DNA linear PAT 27-AUG-2002
LOCUS BD066042
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066042
VERSION BD066042.1 GI:22611645
KEYWORDS JP 2001511000-A/677.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Schlingensiepen,K.H. and Brysch,W
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 677 07-AUG-2001;
BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/677
PD 07-AUG-2001
PE 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source
FT 1. .15
Location/Qualifiers
FEATURES
source 1. .15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3113 TATTTCTTAACCTC 3127
DB 15 TATTTATTAACCTC 1
RESULT 448
A88530/c 16 bp DNA linear PAT 22-JAN-2000
LOCUS A88530
DEFINITION Sequence 678 from Patent WO9833904.
ACCESSION A88530
VERSION A88530.1 GI:6737100
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 678 06-AUG-1998;
BIOLOGISTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source 1. .16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3113 TATTTCTTAACCTC 3127
DB 16 TATTTATTAACCTC 2
RESULT 449
A90497/c

```

```

LOCUS A90497 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 678 from Patent EP0856579.
ACCESSION A90497
VERSION A90497.1 GI:6739011
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 678 05-AUG-1998;
BIOLOGISTIK GES (DE)
FEATURES
source 1. .16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 3113 TATTTCTTAACCTC 3127
DB 16 TATTTATTAACCTC 2
RESULT 450
AR021039 16 bp DNA linear PAT 05-DEC-1998
LOCUS AR021039/c
DEFINITION Sequence 72 from patent US 5789245.
ACCESSION AR021039
VERSION AR021039.1 GI:3975654
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Dubensky,T.W. Jr., Polo,J.M., Ibanez,C.E., Chang,S.M.W., Jolly,D.J.
and Driver,D.A.
TITLE Alphavirus structural protein expression cassettes
JOURNAL Patent: US 5789245-A 72 04-AUG-1998;
FEATURES
source 1. .16
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2737 ACCTCCTGTTAAAC 2751
DB 16 ACCTCCTGTTAAAC 2
RESULT 451
AR043454 16 bp DNA linear PAT 29-SEP-1999
LOCUS AR043454/c
DEFINITION Sequence 72 from patent US 5814482.
ACCESSION AR043454
VERSION AR043454.1 GI:5964462
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Dubensky,T.W. Jr., Polo,J.M., Jolly,D.J. and Driver,D.A.
TITLE Eukaryotic layered vector initiation systems
JOURNAL Patent: US 5814482-A 72 29-SEP-1998;
FEATURES
source 1. .16
Location/Qualifiers

```

```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
Db 16 AGCTCCTGTTTAAAC 2

RESULT 452
AR062369/c AR062369 16 bp DNA linear PAT 29-SEP-1999
LOCUS DEFINITION Sequence 72 from patent US 5843723.
ACCESSION AR062369
VERSION AR062369.1 GI:5990060
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Dubensky,T.W. Jr., Polo,J.M., Ibanez,C.E., Chang,S.M.W.,
TITLE Jolly,D.J., Driver,D.A. and Belli,B.A.
JOURNAL Alphavirus vector constructs
FEATURES Patent: US 5843723-A 72 01-DEC-1998;
source Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
Db 16 AGCTCCTGTTTAAAC 2

RESULT 453
E51106 E51106 16 bp DNA linear PAT 31-JAN-2002
LOCUS DEFINITION Method for detecting virus.
ACCESSION E51106
VERSION E51106.1 GI:18622180
KEYWORDS JP 2000312589-A/10.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 16)
AUTHORS Okamura,K., Kondo,S., Sase,I., Kan,T., Furusawa,I., Mise,K.,
TITLE Watanabe,Y. and Kawakami,S.
JOURNAL Method for detecting virus
FEATURES Patent: JP 2000312589-A 10 14-NOV-2000;
source BUNSHI BIO HOTONIKUSU KENKYUSHO
OS Artificial Sequence
PN JP 2000312589-A/10
PD 14-NOV-2000
PF 16-JUL-1999 JP 1999203474
PR Koji OKAMURA,SATOSHI KONDO,ICHIRO SASE,TAKAYUKI KAN, PI IMAO
FURUSAWA,
PI KAZUYUKI MISE,YUICHIRO WATANABE,SHIGEKI KAWAKAMI PC
C12N15/09,C12N7/00,C12Q1/70,C12N15/00
CC
FH Key location/Qualifiers
FT source 1..16
/organism='Artificial Sequence'.
FEATURES location/Qualifiers
1..16
source /organism="synthetic construct"
```

```

/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match      0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3626 TGCCTCACTTGTGA 3640
Db 2 TGCATCACTTGTGA 16

RESULT 454
AR183828/c AR183828 16 bp DNA linear PAT 20-APR-2002
LOCUS DEFINITION Sequence 72 from patent US 6342372.
ACCESSION AR183828
VERSION AR183828.1 GI:20227797
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Dubensky,T.W. Jr., Polo,J.M. and Driver,D.A.
TITLE Eukaryotic layered vector initiation systems for production of
JOURNAL recombinant proteins
FEATURES Patent: US 6342372-A 72 29-JAN-2002;
source Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
Db 16 AGCTCCTGTTTAAAC 2

RESULT 455
AR368211/c AR368211 16 bp DNA linear PAT 12-SEP-2003
LOCUS DEFINITION Sequence 72 from patent US 6376236.
ACCESSION AR368211
VERSION AR368211.1 GI:34601885
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Dubensky,T.W. Jr., Polo,J.M., Ibanez,C.E. and Driver,D.A.
TITLE Recombinant alphavirus particles
JOURNAL Patent: US 6376236-A 72 23-APR-2002;
FEATURES Location/Qualifiers
1..16
source /organism="unknown"
/mol_type="genomic DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
Db 16 AGCTCCTGTTTAAAC 2

RESULT 456
BD066043/c BD066043 16 bp DNA linear PAT 27-AUG-2002
LOCUS DEFINITION An antisense oligonucleotide preparation method.
```

```

ACCESSION   BD066043.1 GI:22611646
VERSION     JP 2001511000-A/678.
KEYWORDS    unidentified
SOURCE      unidentified
ORGANISM    unidentified.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Schlingensiepen,K.H. and Brysch,W.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: JP 2001511000-A 678 07-AUG-2001;
            BIOLOGISCH GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT     OS Unknown
            PN JP 2001511000-A/678
            PD 07-AUG-2001
            PF 30-JAN-1998 JP 1998532533
            PR 31-JAN-1997 EP 97101531.8
            PI KARL HERMANN SCHLINGENSIEPEN WOLFGANG BRYSCH
            PC C12N15/11,C07H21/04,A61K31/70
            CC An antisense oligonucleotide preparation method FH Key
            Location/Qualifiers
            FT source
            /organism='Unknown'.

FEATURES
  source          Location/Qualifiers
  1..16           /organism="unidentified"
                  /mol_type="genomic DNA"
                  /db_xref="taxon:32644"

Query Match      0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3113 TATTTCTTAAGTC 3127
Db      16 TATTTATTTAACTC 2

RESULT 457
A24327/c      A24327      17 bp      DNA      linear      PAT 09-MAR-1995
LOCUS         SK30 primer.
DEFINITION   A24327
ACCESSION    A24327.1 GI:904438
KEYWORDS     SOURCE
ORGANISM     synthetic construct
              synthetic construct
              artificial sequences.
REFERENCE    1 (bases 1 to 17)
AUTHORS     TYPE C-LIKE HUMAN RETROVIRUS LINKED TO MULTIPLE SCLEROSIS (MS)
TITLE       Patent: WO 9307259-A 12 15-APR-1993;
JOURNAL     Location/Qualifiers
FEATURES     1..17
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2672 TAGAGTTCCTCAGA 2686
Db      17 TAGGATCCCTCAGA 3

RESULT 458
AR029907/c    AR029907      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS         Sequence 96 from patent US 5861244.
DEFINITION   AR029907
ACCESSION    AR029907.1 GI:5943121
KEYWORDS     SOURCE

```

```

SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Wang,C.-G. and Hepburn,A.G.
TITLE       Genetic sequence assay using DNA triple strand formation
JOURNAL     Patent: US 5861244-A 96 19-JAN-1999;
            Location/Qualifiers
FEATURES     1..17
              /organism="Unknown"
              /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      276 GGGGGCGGGGAGGTG 290
Db      15 GGGGGCGGGGAGGCG 1

RESULT 459
AR046642      AR046642      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS         Sequence 1435 from patent US 5817796.
DEFINITION   AR046642
ACCESSION    AR046642.1 GI:5968107
KEYWORDS     SOURCE
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE       C-myd ribozymes having 2'-5'-linked adenylyate residues
JOURNAL     Patent: US 5817796-A 1435 06-OCT-1998;
            Location/Qualifiers
FEATURES     1..17
              /organism="Unknown"
              /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      634 AGGCATTACCAAC 648
Db      3 AGGCATTACCAAC 17

RESULT 460
AR046644      AR046644      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS         Sequence 1437 from patent US 5817796.
DEFINITION   AR046644
ACCESSION    AR046644
VERSION      AR046644.1 GI:5968109
KEYWORDS     SOURCE
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE       C-myd ribozymes having 2'-5'-linked adenylyate residues
JOURNAL     Patent: US 5817796-A 1437 06-OCT-1998;
            Location/Qualifiers
FEATURES     1..17
              /organism="Unknown"
              /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      634 AGGCATTACCAAC 648

```

Db 2 AGGCATTACCAACAC 16

RESULT 461
BD197628/c
LOCUS BD197628
DEFINITION BD197628 17 bp RNA linear PAT 17-JUL-2003
Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD197628
VERSION BD197628.1 GI:33007398
KEYWORDS JP 2002509721-A/654.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A. Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
Patent: JP 2002509721-A 654 02-Apr-2002;
JOURNAL RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/654
PD 02-Apr-2002
PR 24-MAR-1999 JP 2000541291
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT, JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00, A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'.
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3544 GGGGTGGAGGGAAT 3558
Db 16 GGGGTAGGAGGGAAT 2

RESULT 462
BD244485/c
LOCUS BD244485 17 bp DNA linear PAT 17-JUL-2003
DEFINITION BD244485
New triplex forming oligonucleotides and their use in anti-HBV.
ACCESSION BD244485
VERSION BD244485.1 GI:33054255
KEYWORDS JP 2002511384-A/3.
SOURCE JP 2002511384-A/3.
ORGANISM JP 2002511384-A/3.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
New triplex forming oligonucleotides and their use in anti-HBV
Patent: JP 2002511384-A 3 16-Apr-2002;
JOURNAL SHANGHAI INSTITUTE OF BIOCHEMISTRY CHINESE ACADEMY OF SCIENCES
COMMENT OS Artificial Sequence
PN JP 2002511384-A/3
PD 16-Apr-2002

PF 19-OCT-1998 JP 2000516982
PR 21-OCT-1997 CN 97 1 06667.1
PI CHANGDE LU
PC A61K31/711,A61K48/00,A61P31/20,C12N15/09,C12N15/00 CC
Description of Artificial Sequence: Triplex forming CC oligonucleotide
CC This oligo may or may not be 3'-monophosphorylated FH Key
Location/Qualifiers
FT source 1..17
FT /organism='Artificial Sequence'.
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 CTCCTTCTCTTCTT 2234
Db 16 CTCCTTCTCTTCTT 2

RESULT 463
BD254255
LOCUS BD254255 17 bp DNA linear PAT 17-JUL-2003
DEFINITION BD254255
Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254255
VERSION BD254255.1 GI:33064025
KEYWORDS JP 2002541795-A/2048.
SOURCE JP 2002541795-A/2048.
ORGANISM JP 2002541795-A/2048.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J. Regulation of repressor genes using nucleic acid molecules
Patent: JP 2002541795-A 2048 10-DEC-2002;
JOURNAL RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/2048
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN
PC C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00, PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH Key
Location/Qualifiers
FT source 1..17
FT /organism='Eukaryote'.
FEATURES
source 1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2998 ATTTTGTGCTCTT 3012
Db 3 ATTTTGTGCTCTT 17

```
RESULT 464
BD254256 17 bp DNA linear PART 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254256
VERSION BD254256.1 GI:33064026
KEYWORDS JP 2002541795-A/2049.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2049 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/2049
PD 10-DEC-2002 JP 200611654
PR 11-APR-2000 JP 200611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGEN PC
C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02.
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2998 ATTTTTCCTCTT 3012
|||||
2 ATTATTTCCTCTT 16

RESULT 465
BD256435 17 bp DNA linear PART 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD256435
VERSION BD256435.1 GI:33066205
KEYWORDS JP 2002541795-A/4228.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 4228 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/4228
PD 10-DEC-2002 JP 200611654
PR 11-APR-2000 JP 200611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
```

```
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,C12R1:91)
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2979 AGATCATTCACGA 2993
|||||
1 AGATTAATTCACGA 15

RESULT 467
BD256883 17 bp DNA linear PART 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD256883
VERSION BD256883.1 GI:33066206
KEYWORDS JP 2002541795-A/4229.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 4229 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/4229
PD 10-DEC-2002 JP 200611654
PR 11-APR-2000 JP 200611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,C12R1:91)
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source
Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2979 AGATCATTCACGA 2993
|||||
1 AGATTAATTCACGA 15
```

LOCUS BD256883 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD256883.1 GI:33066653
VERSION BD256883.1
KEYWORDS JP 2002541795-A/4676.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 4676 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/4676
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source 1..17
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2979 AGATCATTTCTCCAGA 2993
|||||
2 AGATAATTCTCCAGA 16
DB
RESULT 468
LOCUS BD256884 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD256884
VERSION BD256884.1 GI:33066654
KEYWORDS JP 2002541795-A/4677.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 4677 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/4677
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12N15/00, C12N5/00,
PC A61K37/02, (C12P21/02, C12R1:91), (C12P21/02, C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source 1..17
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source 1..17
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2979 AGATCATTTCTCCAGA 2993
|||||
1 AGATAATTCTCCAGA 15
DB
RESULT 469
LOCUS BD257462/c 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD257462
VERSION BD257462.1 GI:33067232
KEYWORDS JP 2002541795-A/5255.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 5255 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/5255
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12N15/00, C12N5/00, C12N5/00,
PC A61K37/02, (C12P21/02, C12R1:91), (C12P21/02, C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source 1..17
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1772 CGGCGAGGAGGCTCC 1786
|||||
17 CGGCGAGGAGGCTCC 3
DB
RESULT 470
LOCUS C0617528 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2268 from Patent WO0192524.

ACCESSION CQ617528
VERSION CQ617528.1 GI:41667746
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2268 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 413 TCCTCCGGCGCGCTCG 427
Db 3 TCCTCCGGCGCGCTCG 17
RESULT 471
LOCUS CQ617529 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2269 from Patent WO0192524.
ACCESSION CQ617529
VERSION CQ617529.1 GI:41667747
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2269 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 413 TCCTCCGGCGCGCTCG 427
Db 2 TCCTCCGGCGCGCTCG 16
RESULT 472
LOCUS CQ623374 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8114 from Patent WO0192524.
ACCESSION CQ623374
VERSION CQ623374.1 GI:41673592
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8114 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2726 CTGCCAGAACGAGCT 2740
Db 3 CTGCCAGAACGAGCT 17
RESULT 473
LOCUS CQ623375 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8115 from Patent WO0192524.
ACCESSION CQ623375
VERSION CQ623375.1 GI:41673593
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8115 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2726 CTGCCAGAACGAGCT 2740
Db 2 CTGCCAGAACGAGCT 16
RESULT 474
LOCUS CQ624850 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9590 from Patent WO0192524.
ACCESSION CQ624850
VERSION CQ624850.1 GI:41675068
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9590 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2388 GGACTGGCAGCTTT 2402
|||||
17 GGACTGGCAGCTTT 3

RESULT 475
LOCUS CQ624851 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9591 from Patent WO0192524.
ACCESSION CQ624851
VERSION CQ624851.1 GI:41675069
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9591 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2388 GGACTGGCAGCTTT 2402
|||||
16 GGACTGGCAGCTTT 2

RESULT 476
LOCUS CQ624852 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9592 from Patent WO0192524.
ACCESSION CQ624852
VERSION CQ624852.1 GI:41675070
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9592 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2388 GGACTGGCAGCTTT 2402
|||||
15 GGACTGGCAGCTTT 1

RESULT 477
LOCUS I53694 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1435 from patent US 5646042.
ACCESSION I53694
VERSION I53694.1 GI:2474897
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1435 08-JUL-1997;
Location/Qualifiers
1. 17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 634 AGGCATTACCCACAC 648
|||||
3 AGGCATTACCCACAC 17

RESULT 478
LOCUS I53696 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1437 from patent US 5646042.
ACCESSION I53696
VERSION I53696.1 GI:2474899
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1437 08-JUL-1997;
Location/Qualifiers
1. 17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 634 AGGCATTACCCACAC 648
|||||
2 AGGCATTACCCACAC 16

RESULT 479
LOCUS ARI86443 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1931 from patent US 6346398.
ACCESSION ARI86443
VERSION ARI86443.1 GI:20232408
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1931 12-FEB-2002;
Location/Qualifiers


```

/organism="unknown"
/mol_type="unassigned DNA"
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3276 TCCACTCTGTCAGG 3290
      |||||
Db      3 TCCACTCCTGTCAGG 17

RESULT 485
ARI96418/C      ARI96418      17 bp      DNA      linear      PAT 20-APR-2002
LOCUS      Sequence 883 from patent US 6350934.
ACCESSION      ARI96418
VERSION      ARI96418.1 GI:20245855
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
      Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
TITLE      Nucleic acid encoding delta-9 desaturase
JOURNAL      Patent: US 6350934-A 883 26-FEB-2002;
FEATURES
      source
      1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3656 AAATACATATATAA 3670
      |||||
Db      17 AAATACAAATATAA 3

RESULT 486
ARI96419/C      ARI96419      17 bp      DNA      linear      PAT 20-APR-2002
LOCUS      Sequence 884 from patent US 6350934.
ACCESSION      ARI96419
VERSION      ARI96419.1 GI:20245856
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
      Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
TITLE      Nucleic acid encoding delta-9 desaturase
JOURNAL      Patent: US 6350934-A 884 26-FEB-2002;
FEATURES
      source
      1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3656 AAATACATATATAA 3670
      |||||
Db      16 AAATACAAATATAA 2

RESULT 487
ARI96420/C      ARI96420      17 bp      DNA      linear      PAT 20-APR-2002
LOCUS

```

```

DEFINITION      Sequence 885 from patent US 6350934.
ACCESSION      ARI96420
VERSION      ARI96420.1 GI:20245857
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
      Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
TITLE      Nucleic acid encoding delta-9 desaturase
JOURNAL      Patent: US 6350934-A 885 26-FEB-2002;
FEATURES
      source
      1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3656 AAATACATATATAA 3670
      |||||
Db      15 AAATACAAATATAA 1

RESULT 488
ARI23074/C      ARI23074      17 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      Sequence 476 from patent US 6566127.
ACCESSION      ARI23074
VERSION      ARI23074.1 GI:33708882
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Payco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
      related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 476 20-MAY-2003;
FEATURES
      source
      1..17
      /organism="unknown"
      /mol_type="unassigned RNA"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1968 TAGTTGGAGAGACTT 1982
      |||||
Db      17 TAGTTGGAGAGACTT 3

RESULT 489
ARI23075/C      ARI23075      17 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      Sequence 477 from patent US 6566127.
ACCESSION      ARI23075
VERSION      ARI23075.1 GI:33708883
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Payco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
      related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 477 20-MAY-2003;
FEATURES
      source
      1..17
      /organism="unknown"

```

/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1968 TAGTTGAGAGACTT 1982
DB 15 TAGTTGAGAGACTT 1

RESULT 490
AR323666 AR323666 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 1068 from patent US 6566127.
DEFINITION AR323666
ACCESSION AR323666
VERSION AR323666.1 GI:33709474
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1068 20-MAY-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTTTTTTT 2586
DB 3 TCTACTTTTTTTTTT 17

RESULT 491
AR323667 AR323667 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 1069 from patent US 6566127.
DEFINITION AR323667
ACCESSION AR323667
VERSION AR323667.1 GI:33709475
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1069 20-MAY-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTTTTTTT 2586
DB 2 TCTACTTTTTTTTTT 16

RESULT 492
AR324698 AR324698 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 2100 from patent US 6566127.
DEFINITION

ACCESSION AR324698
VERSION AR324698.1 GI:33710506
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2100 20-MAY-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2677 TTCCTCAGAGAGC 2691
DB 3 TTGCCTCAGAGAGC 17

RESULT 493
AR325507 AR325507 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 2909 from patent US 6566127.
DEFINITION AR325507
ACCESSION AR325507
VERSION AR325507.1 GI:33711315
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2909 20-MAY-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3276 TCCACTCTTGACG 3290
DB 3 TCCACTCCTGTCAGG 17

RESULT 494
AR327364 AR327364 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4766 from patent US 6566127.
DEFINITION AR327364
ACCESSION AR327364
VERSION AR327364.1 GI:33713172
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4766 20-MAY-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1968 TAGTGGAGAGACTT 1982
|||
16 TAGTTGGAGAGATT 2

RESULT 495
AR328091/C AR328091 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR328091 Sequence 5493 from patent US 6566127.
DEFINITION AR328091
ACCESSION AR328091.1 GI:33713899
VERSION AR328091.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 5493 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3645 TCAGAAATGGCAAT 3659
|||
17 TCATTAATGGCAAT 3

RESULT 496
AR328092/C AR328092 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR328092 Sequence 5494 from patent US 6566127.
DEFINITION AR328092
ACCESSION AR328092.1 GI:33713900
VERSION AR328092.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 5494 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3645 TCAGAAATGGCAAT 3659
|||
16 TCATTAATGGCAAT 2

RESULT 497
AR329458 AR329458 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR329458 Sequence 6860 from patent US 6566127.
DEFINITION AR329458

VERSION AR329458.1 GI:33715266
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 6860 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2677 TTCCCTCAGAGAGC 2691
|||
2 TTGCTCTCAGAGAGC 16

RESULT 498
AR402001/C AR402001 17 bp DNA linear PAT 18-DEC-2003
LOCUS AR402001 Sequence 341 from patent US 6623962.
DEFINITION AR402001
ACCESSION AR402001.1 GI:40149451
VERSION AR402001.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar, S., Fell, P. and McSwiggen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors

JOURNAL Patent: US 6623962-A 341 23-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 256 GTGCTGAGGAGGC 270
|||
15 GTGGCTGAGGAGGC 1

RESULT 499
AR454916/C AR454916 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR454916 Sequence 3 from patent US 6682930.
DEFINITION AR454916
ACCESSION AR454916.1 GI:42688952
VERSION AR454916.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Lu, C.
TITLE Triplex forming oligonucleotides and their use in anti-HBV

JOURNAL Patent: US 6682930-A 3 27-JAN-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2220 CTCCTTCTCTCTCT 2234
Db 16 CTCCTTCTCTCTCT 2

RESULT 500

AR458591 17 bp DNA PAT 20-FEB-2004
LOCUS AR458591
DEFINITION Sequence 2268 from patent US 6686188.
ACCESSION AR458591
VERSION AR458591.1 GI:42693648
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2268 03-FEB-2004;
FEATURES
source Location/Qualifiers
1.17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 413 TCCTCCGGGCGCTCG 427
Db 3 TCCTCCGGGCGCTTCG 17

RESULT 501

AR458592 17 bp DNA PAT 20-FEB-2004
LOCUS AR458592
DEFINITION Sequence 2269 from patent US 6686188.
ACCESSION AR458592
VERSION AR458592.1 GI:42693649
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2269 03-FEB-2004;
FEATURES
source Location/Qualifiers
1.17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 413 TCCTCCGGGCGCTCG 427
Db 2 TCCTCCGGGCGCTTCG 16

RESULT 502

AR464437 17 bp DNA PAT 20-FEB-2004
LOCUS AR464437
DEFINITION Sequence 8114 from patent US 6686188.
ACCESSION AR464437

VERSION AR464437.1 GI:42699494
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8114 03-FEB-2004;
FEATURES
source Location/Qualifiers
1.17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2726 CTGCCAGAACGCT 2740
Db 3 CTGCCAGAACGCGCT 17

RESULT 503

AR464438 17 bp DNA PAT 20-FEB-2004
LOCUS AR464438
DEFINITION Sequence 8115 from patent US 6686188.
ACCESSION AR464438
VERSION AR464438.1 GI:42699495
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8115 03-FEB-2004;
FEATURES
source Location/Qualifiers
1.17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2726 CTGCCAGAACGCT 2740
Db 2 CTGCCAGAACGCGCT 16

RESULT 504

AR465913 17 bp DNA PAT 20-FEB-2004
LOCUS AR465913/c
DEFINITION Sequence 9590 from patent US 6686188.
ACCESSION AR465913
VERSION AR465913.1 GI:42700970
KEYWORDS
SOURCE Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9590 03-FEB-2004;
FEATURES
source Location/Qualifiers
1.17

```

      /organism="unknown"
      /mol_type="genomic DNA"
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2388 GGACTTGGCAGCTTT 2402
      |||||
      17 GGACTGGGCGAGCTTT 3

RESULT 505
LOCUS      AR465914      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION      Sequence 9591 from patent US 6686188.
ACCESSION      AR465914
VERSION      AR465914.1 GI:42700971
KEYWORDS
SOURCE      .
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE      Polynucleotide encoding a human myosin-like polypeptide expressed
              predominantly in heart and muscle
              Patent: US 6686188-A 9591 03-FEB-2004;
              Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="genomic DNA"
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2388 GGACTTGGCAGCTTT 2402
      |||||
      16 GGACTGGGCGAGCTTT 2

RESULT 506
LOCUS      AR465915/c      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION      Sequence 9592 from patent US 6686188.
ACCESSION      AR465915
VERSION      AR465915.1 GI:42700972
KEYWORDS
SOURCE      .
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE      Polynucleotide encoding a human myosin-like polypeptide expressed
              predominantly in heart and muscle
              Patent: US 6686188-A 9592 03-FEB-2004;
              Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="genomic DNA"
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2388 GGACTTGGCAGCTTT 2402
      |||||
      15 GGACTGGGCGAGCTTT 1

RESULT 507
```

```

AX099952/c      17 bp      DNA      linear      PAT 02-APR-2001
LOCUS      AX099952
DEFINITION      Sequence 12 from Patent WO0120034.
ACCESSION      AX099952
VERSION      AX099952.1 GI:13538962
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM      Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      1
AUTHORS      Voss,J. and Timm,J.
TITLE      Methods and compositions for the screening of cell cycle modulators
              Patent: WO 0120034-A 12 22-MAR-2001;
              BASF AKTENSENSELCHAFT (DE)
JOURNAL
FEATURES
source      1..17
              /organism="Mus musculus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:10090"
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3106 CAGCAATATTTCT 3120
      |||||
      15 CAGCAACATTTCT 1

RESULT 508
LOCUS      AX214916      17 bp      RNA      linear      PAT 07-SEP-2001
DEFINITION      Sequence 358 from Patent WO0159103.
ACCESSION      AX214916
VERSION      AX214916.1 GI:15524959
KEYWORDS
SOURCE      .
ORGANISM      synthetic construct
              synthetic construct
              artificial sequences.
REFERENCE      1
AUTHORS      Blatt,L., Mcswigen,J. and Chowrira,B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
              Patent: WO 0159103-A 358 16-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
              Mcswigen, James (US) ; Chowrira, Bharat M. (US)
JOURNAL
FEATURES
source      1..17
              /organism="synthetic construct"
              /mol_type="unassigned RNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3640 ATTGTCGAATG 3654
      |||||
      3 ATTATTCGAATG 17

RESULT 509
LOCUS      AX216750/c      17 bp      RNA      linear      PAT 07-SEP-2001
DEFINITION      Sequence 2192 from Patent WO0159103.
ACCESSION      AX216750
VERSION      AX216750.1 GI:15526811
KEYWORDS
SOURCE      .
ORGANISM      synthetic construct
              synthetic construct
              artificial sequences.
              1.
```


REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 2192 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3478 ATTTTTCATTA 3492
Db 16 ATTTTTCATTA 2

RESULT 510
AX217712 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 3154 from Patent WO0159103.
ACCESSION AX217712
VERSION AX217712.1 GI:15527773
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 3154 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3435 TCTTGCTGCATGT 3449
Db 2 TCTTGCTGCATTT 16

RESULT 511
AX218200/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 3642 from Patent WO0159103.
ACCESSION AX218200
VERSION AX218200.1 GI:15528261
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 3642 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3473 TTGCTATTTT 3487
Db 15 TTGCTATTTT 1

RESULT 512
AX218292/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 3734 from Patent WO0159103.
ACCESSION AX218292
VERSION AX218292.1 GI:15528353
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 3734 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2570 CTCTCTCTTTT 2584
Db 15 CTCTCTCTTTT 1

RESULT 513
AX218302 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 3744 from Patent WO0159103.
ACCESSION AX218302
VERSION AX218302.1 GI:15528363
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 3744 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 339 CGAGAGAGAGAGAA 353
 DB 1 CAAGAGAGAGAGAA 15

RESULT 514
 LOCUS AX227722 17 bp RNA linear PAT 10-SEP-2001
 DEFINITION Sequence 1094 from Patent WO0157206.
 ACCESSION AX227722
 VERSION AX227722.1 GI:15556863
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2700 TTATGAGAGAGAG 2714
 DB 2 TTCTGAGAGAGAG 16

RESULT 515
 LOCUS AX266079 17 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 3470 from Patent WO0173002.
 ACCESSION AX266079
 VERSION AX266079.1 GI:16514878
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2184 CTGCTCCTCCAGCTT 2198
 DB 17 CTGCTCCTCCAGCTT 3

RESULT 516

AX266080 17 bp DNA linear PAT 26-OCT-2001
 LOCUS AX266080
 DEFINITION Sequence 3471 from Patent WO0173002.
 ACCESSION AX266080
 VERSION AX266080.1 GI:16514879
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2184 CTGCTCCTCCAGCTT 2198
 DB 1 CTGCTCCTCCAGCTT 15

RESULT 517
 LOCUS AX272661 17 bp RNA linear PAT 29-OCT-2001
 DEFINITION Sequence 230 from Patent WO0162911.
 ACCESSION AX272661
 VERSION AX272661.1 GI:16545398
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned RNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1377 CCTTAGCAGTGAAA 1391
 DB 17 CCTGAGCAGTGAAA 3

RESULT 518
 LOCUS AX272933 17 bp RNA linear PAT 29-OCT-2001
 DEFINITION Sequence 502 from Patent WO0162911.
 ACCESSION AX272933
 VERSION AX272933.1 GI:16545670
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned RNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1377 CCTTAGCAGTGAAA 1391
 DB 17 CCTGAGCAGTGAAA 3

REFERENCE Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1
AUTHORS Jarvis, T., von Carlowitz, I., Meswigen, J.A., Hamblin, P.A. and Ellis, J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 502 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1377 CCTAAGCAGTGAAA 1391
DB 16 CCTGAAGCAGTGAAA 2
RESULT 519
AX500608/c 17 bp DNA linear PAT 27-SEP-2002
LOCUS AX500608 Sequence 1915 from Patent EP1229046.
DEFINITION AX500608
ACCESSION AX500608
VERSION AX500608.1 GI:23382901
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1915 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 586 AACATATATAAGAC 600
DB 16 AACATATATAAGAC 2
RESULT 520
AX531760/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX531760 Sequence 1269 from Patent EP1239051.
DEFINITION AX531760
ACCESSION AX531760
VERSION AX531760.1 GI:25255299
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1269 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2844 CCATGGGCTGGGAGA 2858
DB 15 CCATGGGCTGGGAGA 1
RESULT 521
AX531845 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX531845 Sequence 1354 from Patent EP1239051.
DEFINITION AX531845
ACCESSION AX531845
VERSION AX531845.1 GI:25255465
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1354 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1440 ATTCCACAGCCGATGG 1454
DB 3 ATTCCACAGCCGATGG 17
RESULT 522
AX531846 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX531846 Sequence 1355 from Patent EP1239051.
DEFINITION AX531846
ACCESSION AX531846
VERSION AX531846.1 GI:25255467
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1355 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1440 ATTCCACAGCCGATGG 1454
DB 2 ATTCCACAGCCGATGG 16

```
RESULT 523
AX531847      AX531847      17 bp      DNA      linear      PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1356 from Patent EP1239051.
ACCESSION AX531847
VERSION AX531847.1 GI:25255469
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 1356 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
OY 1440 ATTCCAGCGCATGG 1454
Db 1 ATTCACAGCCCTGG 15

RESULT 524
AX532427      AX532427      17 bp      DNA      linear      PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1936 from Patent EP1239051.
ACCESSION AX532427
VERSION AX532427.1 GI:25256629
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 1936 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
OY 378 CTGAGGGGGAGGGG 392
Db 17 CTGAGGGGGAGGAGG 3

RESULT 525
AX532431      AX532431      17 bp      DNA      linear      PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1940 from Patent EP1239051.
ACCESSION AX532431
VERSION AX532431.1 GI:25256636
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 1940 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
OY 375 CCGCTGAGGGGAGG 389
Db 16 CGGCTGAGGGGAGG 2

RESULT 526
AX532432      AX532432      17 bp      DNA      linear      PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1941 from Patent EP1239051.
ACCESSION AX532432
VERSION AX532432.1 GI:25256638
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 1941 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1;
OY 375 CCGCTGAGGGGAGG 389
Db 16 CGGCTGAGGGGAGG 2

RESULT 527
AX578684      AX578684      17 bp      RNA      linear      PAT 10-JAN-2003
LOCUS
DEFINITION Sequence 522 from Patent WO0211674.
ACCESSION AX578684
VERSION AX578684.1 GI:27647866
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.B.
            and Grube,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
            channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 522 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES
source location/Qualifiers
            1..17
            /organism="Homo sapiens"
```

/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2341 TGAATTTTTCAGA 2355
|||||
Db 3 TGAATTTTTCAGA 17

RESULT 528

AX578685 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 523 from Patent WO0211674.
ACCESSION AX578685
VERSION AX578685.1 GI:27647887
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
AUTHORS Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grube, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 523 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2341 TGAATTTTTCAGA 2355
|||||
Db 2 TGAATTTTTCAGA 16

RESULT 529

AX578686 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 524 from Patent WO0211674.
ACCESSION AX578686
VERSION AX578686.1 GI:27647888
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
AUTHORS Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grube, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 524 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2341 TGAATTTTTCAGA 2355
|||||
Db 1 TGAATTTTTCAGA 15

RESULT 530
AX580139 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 1977 from Patent WO0211674.
ACCESSION AX580139
VERSION AX580139.1 GI:27649341
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
AUTHORS Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grube, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 1977 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1726 GAAGCTTCTCCCTTC 1740
|||||
Db 17 GAAGCTTCTCCCTTC 3

RESULT 531
AX649283 17 bp DNA linear PAT 22-MAR-2003
LOCUS Sequence 1123 from Patent EP1273660.
ACCESSION AX649283
VERSION AX649283.1 GI:29152101
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Human sodium-hydrogen exchanger like protein 1
Gu, Y.
TITLE Patent: EP 1273660-A 1123 08-JAN-2003;
JOURNAL Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2462 GCACATTATCCCTAC 2476
|||||
Db 3 GCACATTATCCCTAC 17

RESULT 532

AX649284
LOCUS AX649284 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1124 from Patent EP1273660.
ACCESSION AX649284
VERSION AX649284.1 GI:29152102
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Gu. Y.
JOURNAL Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 1124 08-JUN-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2462 GCACATTTATCCTTAC 2476
DB 2 GCACATTTATCCTTAC 16
|||||

RESULT 533
AX649285 17 bp DNA linear PAT 22-MAR-2003
LOCUS AX649285
DEFINITION Sequence 1125 from Patent EP1273660.
ACCESSION AX649285
VERSION AX649285.1 GI:29152103
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Gu. Y.
JOURNAL Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 1125 08-JUN-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2462 GCACATTTATCCTTAC 2476
DB 1 GCACATTTATCCTTAC 15
|||||

RESULT 534
AX672705/c 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX672705/c
DEFINITION Sequence 1150 from Patent WO03004526.
ACCESSION AX672705
VERSION AX672705.1 GI:29331053
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1

AUTHORS Teلمان, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1150 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2376 AATGGATTTGCTGGA 2390
DB 17 AGTGGATTTGCTGGA 3
|||||

RESULT 535
AX673410 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX673410
DEFINITION Sequence 1855 from Patent WO03004526.
ACCESSION AX673410
VERSION AX673410.1 GI:29331758
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Teلمان, A., Amson, R. and Tuijinder, M.
JOURNAL Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 1855 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2436 TTAATTTCTTCAGGA 2450
DB 17 TGAATTTCTTCAGGA 3
|||||

RESULT 536
AX673805/c 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX673805/c
DEFINITION Sequence 2250 from Patent WO03004526.
ACCESSION AX673805
VERSION AX673805.1 GI:29332153
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Teلمان, A., Amson, R. and Tuijinder, M.
JOURNAL Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 2250 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers

```
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2969 AATGAATTTAGATC 2983
15 AATGAACCTTAGATC 1

RESULT 537
AX674135 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX674135
DEFINITION Sequence 2580 from Patent WO03004526.
ACCESSION AX674135
VERSION AX674135.1 GI:29332483
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 2580 16-JAN-2003;
FEATURES
source Molecular Engines Laboratories (FR)
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2487 TCTCTGTACTCTG 2501
3 TCTCTGTACTCTG 17

RESULT 538
AX674636 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX674636
DEFINITION Sequence 3081 from Patent WO03004526.
ACCESSION AX674636
VERSION AX674636.1 GI:29332984
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3081 16-JAN-2003;
FEATURES
source Molecular Engines Laboratories (FR)
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTCTTTT 2586
3 TCTTCTTTTCTTTT 17

RESULT 539
AX674764 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX674764
DEFINITION Sequence 3209 from Patent WO03004526.
ACCESSION AX674764
VERSION AX674764.1 GI:29333112
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3209 16-JAN-2003;
FEATURES
source Molecular Engines Laboratories (FR)
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1732 TTCTCTTCCAAA 1746
17 TTCTCTTCCAAA 3

RESULT 540
AX691780 17 bp DNA linear PAT 31-MAR-2003
LOCUS AX691780
DEFINITION Sequence 4512 from Patent EP1281758.
ACCESSION AX691780
VERSION AX691780.1 GI:29414721
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 4512 05-FEB-2003;
FEATURES
source Aecomica, Inc. (US)
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2050 AGCGCAAGCTCAG 2064
17 AGCGCAAGCTCAG 3

RESULT 541
```

```
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTCTTTT 2586
3 TCTTCTTTTCTTTT 17

RESULT 539
AX674764 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX674764
DEFINITION Sequence 3209 from Patent WO03004526.
ACCESSION AX674764
VERSION AX674764.1 GI:29333112
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3209 16-JAN-2003;
FEATURES
source Molecular Engines Laboratories (FR)
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1732 TTCTCTTCCAAA 1746
17 TTCTCTTCCAAA 3

RESULT 540
AX691780 17 bp DNA linear PAT 31-MAR-2003
LOCUS AX691780
DEFINITION Sequence 4512 from Patent EP1281758.
ACCESSION AX691780
VERSION AX691780.1 GI:29414721
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 4512 05-FEB-2003;
FEATURES
source Aecomica, Inc. (US)
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2050 AGCGCAAGCTCAG 2064
17 AGCGCAAGCTCAG 3

RESULT 541
```

AX691784/c
LOCUS AX691784 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4516 from Patent EP1281758.
ACCESSION AX691784
VERSION AX691784.1 GI:29414725
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 4516 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2047 TTAAAGCGCAAGCCT 2061
DB 16 TGAAGCGCAAGCCT 2
RESULT 542
AX691785/c
LOCUS AX691785 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4517 from Patent EP1281758.
ACCESSION AX691785
VERSION AX691785.1 GI:29414726
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 4517 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2047 TTAAGCGCAAGCCT 2061
DB 15 TGAAGCGCAAGCCT 1
RESULT 543
AX692521
LOCUS AX692521 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5253 from Patent EP1281758.
ACCESSION AX692521
VERSION AX692521.1 GI:29415479
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 5253 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTCTT 2585
DB 3 TTCTTCTTTTCTT 17
RESULT 544
AX692620/c
LOCUS AX692620 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5352 from Patent EP1281758.
ACCESSION AX692620
VERSION AX692620.1 GI:29415578
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Eukaryota; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 5352 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 211 CAGGCGAATGCTG 225
DB 17 CAGGCGAATGCTG 3
RESULT 545
AX692621/c
LOCUS AX692621 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5353 from Patent EP1281758.
ACCESSION AX692621
VERSION AX692621.1 GI:29415579
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 5353 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17


```
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      211 CAGCGCAATGCTGTG 225
      |||||
      16 CAGGAGAAATGCTGTG 2

RESULT 546
LOCUS      AX692622                17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 5354 from Patent EP1281758.
ACCESSION  AX692622
VERSION     AX692622.1 GI:29415580
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE    1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS      Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE         mdz12
JOURNAL      Patent: EP 1281758-A 5354 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES
            Location/Qualifiers
            source
            1.17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      211 CAGCGCAATGCTGTG 225
      |||||
      15 CAGGAGAAATGCTGTG 1

RESULT 547
LOCUS      AX704873                17 bp      DNA      linear      PAT 04-APR-2003
DEFINITION Sequence 49 from Patent EP1285963.
ACCESSION  AX704873
VERSION     AX704873.1 GI:29561534
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE    1 Shannon,M.
AUTHORS      Human zzap1 protein
TITLE         Patent: EP 1285963-A 49 26-FEB-2003;
JOURNAL      Aeomica, Inc. (US)
FEATURES
            Location/Qualifiers
            source
            1.17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3453 TTACAAGAGGAAG 3467
      |||||
      3453 TTACAAGAGGAAG 3467
```

```
DB      3 TTACAAGAGTAAG 17

RESULT 548
LOCUS      AX704874                17 bp      DNA      linear      PAT 04-APR-2003
DEFINITION Sequence 50 from Patent EP1285963.
ACCESSION  AX704874
VERSION     AX704874.1 GI:29561535
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE    1 Shannon,M.
AUTHORS      Human zzap1 protein
TITLE         Patent: EP 1285963-A 50 26-FEB-2003;
JOURNAL      Aeomica, Inc. (US)
FEATURES
            Location/Qualifiers
            source
            1.17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3453 TTACAAGAGGAAG 3467
      |||||
      1 TTACAAGAGTAAG 15

RESULT 550
LOCUS      AX722359                17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 46 from Patent WO03025176.
ACCESSION  AX722359
VERSION     AX722359.1 GI:30422860
KEYWORDS
SOURCE      Mus musculus (house mouse)
```

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 46 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2777 AGGCTGAAGGAATGA 2791
DB 17 AGGCTGAATGAATGA 3

RESULT 551
LOCUS AX722987 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 674 from Patent WO03025176.
ACCESSION AX722987
VERSION AX722987.1 GI:30423488
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 674 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2560 TCCGAGCTTCTTCT 2574
DB 3 TCCGAGCTCTTCT 17

RESULT 552
LOCUS AX725263 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2950 from Patent WO03025176.
ACCESSION AX725263
VERSION AX725263.1 GI:30504606
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as

JOURNAL Patent: WO 03025176-A 2950 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1732 TTCTCTTCGAAANA 1746
DB 17 TTCTCTTCGAAAGA 3

RESULT 553
LOCUS AX725688 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3375 from Patent WO03025176.
ACCESSION AX725688
VERSION AX725688.1 GI:30505031
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3375 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2569 TCTTCTCTTTTGT 2583
DB 3 TCTTCTCTTTTGT 17

RESULT 554
LOCUS AX727549 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5236 from Patent WO03025176.
ACCESSION AX727549
VERSION AX727549.1 GI:30506892
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5236 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"

/db_xref="taxon:10090"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1171 CCAGAAAGAGCGAGA 1185
 |||||
 |||||
 Db 17 CCAGAAAGAGCGAGA 3

RESULT 555
 AX727552 17 bp DNA linear PAT 08-MAY-2003
 LOCUS Sequence 5239 from Patent WO03025176.
 DEFINITION AX727552
 ACCESSION AX727552
 VERSION AX727552.1 GI:30506895
 KEYWORDS Mus musculus (house mouse)
 SOURCE Mus musculus
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 JOURNAL Patent: WO 03025176-A 5239 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. 17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3643 GTTCAGAAATGGCAA 3657
 |||||
 |||||
 Db 1 GATCAGAAATGGCAA 15

RESULT 556
 AX729279 17 bp DNA linear PAT 08-MAY-2003
 LOCUS Sequence 913 from Patent WO03025175.
 DEFINITION AX729279
 ACCESSION AX729279
 VERSION AX729279.1 GI:30508622
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 JOURNAL Patent: WO 03025175-A 913 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. 17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2277 ATCCCTCCTCACTCA 2291
 |||||
 |||||
 Db 17 ATCCCTCCTCACTCA 2291

Db 2 ATCCCTCCTCCTCA 16

RESULT 557
 AX730015/c 17 bp DNA linear PAT 08-MAY-2003
 LOCUS Sequence 1649 from Patent WO03025175.
 DEFINITION AX730015
 ACCESSION AX730015
 VERSION AX730015.1 GI:30509358
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 JOURNAL Patent: WO 03025175-A 1649 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. 17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2969 AATGAATTTAGATC 2983
 |||||
 |||||
 Db 15 AATGAATTTAGATC 1

RESULT 558
 AX730406 17 bp DNA linear PAT 08-MAY-2003
 LOCUS Sequence 2040 from Patent WO03025175.
 DEFINITION AX730406
 ACCESSION AX730406
 VERSION AX730406.1 GI:30509749
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 JOURNAL Patent: WO 03025175-A 2040 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. 17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2707 GAGAGATGATGAT 2721
 |||||
 |||||
 Db 16 GAGAGATGATGAT 2

RESULT 559
 AX730974/c 17 bp DNA linear PAT 08-MAY-2003
 LOCUS AX730974

DEFINITION Sequence 2608 from Patent WO03025175.
ACCESSION AX730974
VERSION AX730974.1 GI:30510317
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2608 27-MAR-2003;
FEATURES
source
1. 17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2577 TTTTCTTTCTGAA 2591
DB 17 TTTTCTTTCTGCA 3
RESULT 560
AX732253 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX732253
DEFINITION Sequence 3887 from Patent WO03025175.
ACCESSION AX732253
VERSION AX732253.1 GI:30511596
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3887 27-MAR-2003;
FEATURES
source
1. 17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2376 AATGGATTGCTGGA 2390
DB 17 AGTGGATTGCTGCA 3
RESULT 561
AX732936 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX732936
DEFINITION Sequence 4570 from Patent WO03025175.
ACCESSION AX732936
VERSION AX732936.1 GI:30512279
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE
1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4570 27-MAR-2003;
FEATURES
source
1. 17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1732 TTCTCTTCCAAA 1746
DB 17 TTCTCTTCCAAA 3
RESULT 562
AX733356 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX733356
DEFINITION Sequence 4990 from Patent WO03025175.
ACCESSION AX733356
VERSION AX733356.1 GI:30512699
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4990 27-MAR-2003;
FEATURES
source
1. 17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 3687 ATGTAATTAACCTTA 3701
DB 2 ATGTAATTAACCTTA 16
RESULT 563
AX733384 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX733384
DEFINITION Sequence 5018 from Patent WO03025175.
ACCESSION AX733384
VERSION AX733384.1 GI:30512727
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5018 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 TCCGAGACGAGCTC 2741
|||||
15 TCCGAGACGAGATC 1

RESULT 564
LOCUS AX734479 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 69 from Patent WO03025177.
ACCESSION AX734479
VERSION AX734479.1 GI:30513756
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 69 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2085 GCCATCTGTGATC 2039
|||||
15 GCCATCTTGTGATC 1

RESULT 565
LOCUS AX734751 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 341 from Patent WO03025177.
ACCESSION AX734751
VERSION AX734751.1 GI:30514028
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 341 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2634 GATCAGAACTCCAGA 2648
|||||
1 GATCAAACTCCAGA 15

RESULT 566
LOCUS AX734993 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 583 from Patent WO03025177.
ACCESSION AX734993
VERSION AX734993.1 GI:30514270
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 583 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1732 TTCTCTTCGAAAA 1746
|||||
17 TTCTCTTCGAAAA 3

RESULT 567
LOCUS AX736330 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1920 from Patent WO03025177.
ACCESSION AX736330
VERSION AX736330.1 GI:30515607
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 1920 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1733 TCTCTTCGAAAAAG 1747
|||||
3 TCTCTTCGAAAAAG 17

RESULT 568
AX736447 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX736447
DEFINITION Sequence 2037 from Patent WO03025177.
ACCESSION AX736447
VERSION AX736447.1 GI:30515735
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2037 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2569 TCTTCTCTCTTTT 2583
DB 3 TCTTTTCTTTT 17
RESULT 569
AX737433 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX737433
DEFINITION Sequence 3023 from Patent WO03025177.
ACCESSION AX737433
VERSION AX737433.1 GI:30516721
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3023 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2569 TCTTCTCTCTTTT 2583
DB 3 TCTTCTCTTTTGT 17
RESULT 570
AX738493 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX738493
DEFINITION Sequence 4083 from Patent WO03025177.
ACCESSION AX738493

VERSION AX738493.1 GI:30517781
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4083 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2572 TCTTCTCTCTTTT 2586
DB 3 TCTTATTTTTTTT 17
RESULT 571
AX739445 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX739445
DEFINITION Sequence 5035 from Patent WO03025177.
ACCESSION AX739445
VERSION AX739445.1 GI:30518742
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 5035 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2572 TCTTCTCTCTTTT 2586
DB 3 TCTTATTTTTTTT 17
RESULT 572
AX754437 17 bp DNA linear PAT 23-JUN-2003
LOCUS AX754437/c
DEFINITION Sequence 784 from Patent WO03037931.
ACCESSION AX754437
VERSION AX754437.1 GI:32167134
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1

AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 784 08-MAY-2003;
Amer sham Biosciences SV Corp. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2210 AGAAGCTTCTCTCTT 2224
17 AGAAGCTTCTCTCTT 3

RESULT 573
AX757592 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 913 from Patent WO03040369.
DEFINITION AX757592
ACCESSION AX757592
VERSION AX757592.1 GI:32252208
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 913 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 542 ATCAGAAATATAGGC 556
2 ATCAGAAATATAGGC 16

RESULT 574
AX757892 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 1213 from Patent WO03040369.
DEFINITION AX757892
ACCESSION AX757892
VERSION AX757892.1 GI:32252508
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1213 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTCTTTT 2586
3 TCTTCTTTTCTTTT 17

RESULT 575
AX757931 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 1252 from Patent WO03040369.
DEFINITION AX757931
ACCESSION AX757931
VERSION AX757931.1 GI:32252547
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1252 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 607 ATCAGCTTGAAGG 621
2 ATCAGCTTGAAGG 16

RESULT 576
AX758169 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 1490 from Patent WO03040369.
DEFINITION AX758169
ACCESSION AX758169
VERSION AX758169.1 GI:32252785
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1490 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy	3016 ATCTTTTCCAAAGT	3030
Dd	 2 ATCTGTTCCAACGT	16
RESULT 577		
LOCUS	AX758323	17 bp DNA
DEFINITION	Sequence 1644 from Patent WO03040369.	linear PAT 25-JUN-2003
ACCESSION	AX758323	
VERSION	AX758323.1 GI:32252939	
KEYWORDS		
SOURCE		
ORGANISM	Homo sapiens (human)	
REFERENCE	Eukaryotes; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
AUTHORS	1 Telerman,A., Amson,R. and Tuijinder,M.	
TITLE	Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines	
JOURNAL	Patent: WO 03040369-A 1644 15-MAY-2003;	
FEATURES	Molecular Engines Laboratories (FR) Location/Qualifiers	
source	1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /_db_xref="taxon:9606"	
Query Match	0.4%; Score 13.4; DB 1;	Length 17;
Best Local Similarity	93.3%; Pred. No. 2.4e+02;	
Matches	14; Conservative 0; Mismatches 1;	Indels 0; Gaps 0;
Oy	2569 TCCTCTCTTTTTT	2583
Dd	 3 TCCTGTTCTTTTTT	17
RESULT 578		
LOCUS	AX759441	17 bp DNA
DEFINITION	Sequence 2762 from Patent WO03040369.	linear PAT 25-JUN-2003
ACCESSION	AX759441	
VERSION	AX759441.1 GI:32254057	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	Eukaryotes; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
AUTHORS	1 Telerman,A., Amson,R. and Tuijinder,M.	
TITLE	Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines	
JOURNAL	Patent: WO 03040369-A 2762 15-MAY-2003;	
FEATURES	Molecular Engines Laboratories (FR) Location/Qualifiers	
source	1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /_db_xref="taxon:9606"	
Query Match	0.4%; Score 13.4; DB 1;	Length 17;
Best Local Similarity	93.3%; Pred. No. 2.4e+02;	
Matches	14; Conservative 0; Mismatches 1;	Indels 0; Gaps 0;
Oy	2572 TCCTCTTTTTTTT	2586
Dd	 3 TCCTCTTTCTTTTTT	17
RESULT 579		
LOCUS	AX781825	

LOCUS	AX781825		17 bp	DNA	linear	PAT 17-JUL-2003
DEFINITION	Sequence 156 from Patent WO03050284.					
ACCESSION	AX781825					
VERSION	AX781825.1	GI:32949659				
KEYWORDS						
SOURCE						
ORGANISM	Homo sapiens (human)					
AUTHORS	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.					
JOURNAL						
FEATURES						
source	1..17	/organism="Homo sapiens"				
		/mol_type="unassigned DNA"				
		/db_xref="taxon:9606"				
Query Match		0.4%; Score 13.4; DB 1;	Length 17;			
Best Local Similarity	93.3%; Pred. No. 2.4e+02;					
Matches	14; Conservative	0; Mismatches	1; Indels	0; Gaps	0;	
Oy	340 GAGAAAGGGAAGAAC	354				
Db						
	3 GACAAGAGGAAGAAC	17				
RESULT 580						
LOCUS	AX781826		17 bp	DNA	linear	PAT 17-JUL-2003
DEFINITION	Sequence 157 from Patent WO03050284.					
ACCESSION	AX781826					
VERSION	AX781826.1	GI:32949660				
KEYWORDS						
SOURCE						
ORGANISM	Homo sapiens (human)					
AUTHORS	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.					
JOURNAL						
FEATURES						
source	1..17	/organism="Homo sapiens"				
		/mol_type="unassigned DNA"				
		/db_xref="taxon:9606"				
Query Match		0.4%; Score 13.4; DB 1;	Length 17;			
Best Local Similarity	97.3%; Pred. No. 2.4e+02;					
Matches	14; Conservative	0; Mismatches	1; Indels	0; Gaps	0;	
Oy	340 GAGAAAGGGAAGAAC	354				
Db						
	2 GACAAGAGGAAGAAC	16				
RESULT 581						
LOCUS	AX781827		17 bp	DNA	linear	PAT 17-JUL-2003
DEFINITION	Sequence 158 from Patent WO03050284.					
ACCESSION	AX781827					
VERSION	AX781827.1	GI:32949661				
KEYWORDS						
SOURCE						
ORGANISM	Homo sapiens (human)					
AUTHORS	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.					
JOURNAL						
REFERENCE						
AUTHORS	Guo,J.					
TITLE	Human prostate cancer candidate protein 1					
JOURNAL	Patent: WO 03050284-A 157 19-JUN-2003;					
	Amer sham Biosciences (SV) Corp. (US)					
	Location/Qualifiers					
	1..17	/organism="Homo sapiens"				
		/mol_type="unassigned DNA"				
		/db_xref="taxon:9606"				

TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 158 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)

FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 340 GAGAGAGGAGAGAC 354
Db 1 GACNAGAGGAGAGAC 15

RESULT 582
BD067501/c 17 bp RNA linear PAT 27-AUG-2002
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to levels of epidermal growth factor receptors.
ACCESSION BD067501
VERSION BD067501.1 GI:22613104
KEYWORDS JP 2001511003-A/341.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswigen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL to levels of epidermal growth factor receptors
PATENT: JP 2001511003-A 341 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/341
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHR AKHTAR, PATRICIA FELL, JAMES A MCSWIGEN PC
CI2N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to

CC levels of epidermal growth factor receptors
FH Key location/Qualifiers
FT source 1..17
FT /organism='Unidentified'.
Location/Qualifiers

FEATURES
source 1..17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 256 GTGCTGAGGAGGC 270
Db 15 GTGCTGAGGAGGC 1

RESULT 583
AX218302/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS Sequence 3744 from Patent W00159103.
DEFINITION AX218302
ACCESSION AX218302.1 GI:15528363
KEYWORDS
SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Blatt,L., Mcswigen,J. and Chowitra,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 3744 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
MCSWIGEN, James (US) ; Chowitra, Bharat M. (US)

FEATURES
source location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2219 TCTCCTTCCTTCCT 2234
Db 17 TCTTCTCCTTCCT 2

Search completed: November 2, 2004, 09:50:14
Job time : 24 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 2, 2004, 09:45:01 ; Search time 29 Seconds
(without alignment)
3.553 Million cell updates/sec

Title: US-10-003-354-3
Perfect score: 3713
Sequence: 1 attaacagccgtggttagg.....aaactttaatgagttattta 3713

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 709 seqs, 13877 residues

Total number of hits satisfying chosen parameters: 1418

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 715 summaries

Database : fetch3rng.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	26	0.7	26	ABT43754	Human phosphatidyl
2	22	0.6	22	ABT43753	Human phosphatidyl
3	20.6	0.6	27	AAZ23570	Deletion sequence
4	20.4	0.5	22	ADH49072	NOV33 PCR primer,
5	20.4	0.5	22	ADH49074	NOV33 PCR primer,
6	20	0.5	20	ABT43802	Human PIP5Kia anti
7	20	0.5	20	ABT43803	Human PIP5Kia anti
8	20	0.5	20	ABT43833	Human PIP5Kia anti
9	20	0.5	20	ABT43771	Human PIP5Kia anti
10	20	0.5	20	ABT43780	Human PIP5Kia anti
11	20	0.5	20	ABT43788	Human PIP5Kia anti
12	20	0.5	20	ABT43794	Human PIP5Kia anti
13	20	0.5	20	ABT43760	Human PIP5Kia anti
14	20	0.5	20	ABT43766	Human PIP5Kia anti
15	20	0.5	20	ABT43792	Human PIP5Kia anti
16	20	0.5	20	ABT43801	Human PIP5Kia anti
17	20	0.5	20	ABT43822	Human PIP5Kia anti
18	20	0.5	20	ABT43828	Human PIP5Kia anti
19	20	0.5	20	ABT43762	Human PIP5Kia anti
20	20	0.5	20	ABT43764	Human PIP5Kia anti
21	20	0.5	20	ABT43809	Human PIP5Kia anti
22	20	0.5	20	ABT43768	Human PIP5Kia anti
23	20	0.5	20	ABT43770	Human PIP5Kia anti
24	20	0.5	20	ABT43782	Human PIP5Kia anti
25	20	0.5	20	ABT43804	Human PIP5Kia anti
26	20	0.5	20	ABT43814	Human PIP5Kia anti
27	20	0.5	20	ABT43824	Human PIP5Kia anti
28	20	0.5	20	ABT43832	Human PIP5Kia anti
29	20	0.5	20	ABT43793	Human PIP5Kia anti
30	20	0.5	20	ABT43807	Human PIP5Kia anti
31	20	0.5	20	ABT43815	Human PIP5Kia anti
32	20	0.5	20	ABT43817	Human PIP5Kia anti
33	20	0.5	20	ABT43817	Human PIP5Kia anti

34	20	0.5	20	1	ABT43819	Human PIP5Kia anti
35	20	0.5	20	1	ABT43759	Human PIP5Kia anti
36	20	0.5	20	1	ABT43773	Human PIP5Kia anti
37	20	0.5	20	1	ABT43783	Human PIP5Kia anti
38	20	0.5	20	1	ABT43795	Human PIP5Kia anti
39	20	0.5	20	1	ABT43835	Human PIP5Kia anti
40	20	0.5	20	1	ABT43772	Human PIP5Kia anti
41	20	0.5	20	1	ABT43774	Human PIP5Kia anti
42	20	0.5	20	1	ABT43775	Human PIP5Kia anti
43	20	0.5	20	1	ABT43778	Human PIP5Kia anti
44	20	0.5	20	1	ABT43797	Human PIP5Kia anti
45	20	0.5	20	1	ABT43830	Human PIP5Kia anti
46	20	0.5	20	1	ABT43758	Human PIP5Kia anti
47	20	0.5	20	1	ABT43763	Human PIP5Kia anti
48	20	0.5	20	1	ABT43787	Human PIP5Kia anti
49	20	0.5	20	1	ABT43761	Human PIP5Kia anti
50	20	0.5	20	1	ABT43786	Human PIP5Kia anti
51	20	0.5	20	1	ABT43791	Human PIP5Kia anti
52	20	0.5	20	1	ABT43811	Human PIP5Kia anti
53	20	0.5	20	1	ABT43818	Human PIP5Kia anti
54	20	0.5	20	1	ABT43785	Human PIP5Kia anti
55	20	0.5	20	1	ABT43826	Human PIP5Kia anti
56	20	0.5	20	1	ABT43827	Human PIP5Kia anti
57	20	0.5	20	1	ABT43777	Human PIP5Kia anti
58	20	0.5	20	1	ABT43805	Human PIP5Kia anti
59	20	0.5	20	1	ABT43813	Human PIP5Kia anti
60	20	0.5	20	1	ABT43767	Human PIP5Kia anti
61	20	0.5	20	1	ABT43776	Human PIP5Kia anti
62	20	0.5	20	1	ABT43799	Human PIP5Kia anti
63	20	0.5	20	1	ABT43820	Human PIP5Kia anti
64	20	0.5	20	1	ABT43796	Human PIP5Kia anti
65	20	0.5	20	1	ABT43816	Human PIP5Kia anti
66	20	0.5	20	1	ABT43825	Human PIP5Kia anti
67	20	0.5	20	1	ABT43829	Human PIP5Kia anti
68	20	0.5	20	1	ABT43765	Human PIP5Kia anti
69	20	0.5	20	1	ABT43769	Human PIP5Kia anti
70	20	0.5	20	1	ABT43779	Human PIP5Kia anti
71	20	0.5	20	1	ABT43781	Human PIP5Kia anti
72	20	0.5	20	1	ABT43789	Human PIP5Kia anti
73	20	0.5	20	1	ABT43790	Human PIP5Kia anti
74	20	0.5	20	1	ABT43800	Human PIP5Kia anti
75	20	0.5	20	1	ABT43808	Human PIP5Kia anti
76	20	0.5	20	1	ABT43810	Human PIP5Kia anti
77	20	0.5	20	1	ABT43784	Human PIP5Kia anti
78	20	0.5	20	1	ABT43806	Human PIP5Kia anti
79	20	0.5	20	1	ABT43812	Human PIP5Kia anti
80	20	0.5	20	1	ABT43821	Human PIP5Kia anti
81	20	0.5	20	1	ABT43823	Human PIP5Kia anti
82	20	0.5	20	1	ABT43831	Human PIP5Kia anti
83	20	0.5	20	1	ABT43834	Human PIP5Kia anti
84	19.8	0.5	25	1	ACK09575	Human microarray D
85	19.4	0.5	24	1	ABL56411	PCR primer F used
86	18.8	0.5	24	1	AAH44623	Human FD 17 PCR pr
87	18.4	0.5	23	1	AAH91823	Human inflammatory
88	18.2	0.5	24	1	ADP71410	Giardia intestinal
89	18.2	0.5	24	1	ADP71404	Giardia intestinal
90	17.8	0.5	21	1	AAZ26403	Human polymorphic
91	17.6	0.5	23	1	ADC66134	Human CFTF exon 21
92	17.4	0.5	20	1	AAZ05507	PCR primer used to
93	17.4	0.5	22	1	ADH49249	NOV88 PCR primer
94	17.4	0.5	22	1	ADH49249	Forward PCR primer
95	17.4	0.5	22	1	ADN42607	Human NOV16b RTQ-P
96	17.2	0.5	22	1	ABT08600	Human novel protei
97	17.2	0.5	22	1	ADO09965	Human NOVX probe #
98	17	0.5	22	1	ABT43752	Human phosphatidyl
99	16.8	0.5	20	1	AAQ87918	Human histamine H1
100	16.8	0.5	20	1	AAAT68349	Loc1-specific prim
101	16.8	0.5	20	1	AAAT68404	Loc1-specific prim
102	16.8	0.5	20	1	AAV47967	Human B7-2 target
103	16.8	0.5	20	1	AAZ21462	Human BUR1 PCR pr
104	16.8	0.5	20	1	AAF32809	Human B7-2 mRNA an
105	16.8	0.5	20	1	AAH27401	PCR primer #70. H
106	16.8	0.5	20	1	AAH43108	Human ERbeta gene,

C 691 14 0.4 17 1 ARN00960
 C 692 14 0.4 17 1 ARN00961
 C 693 14 0.4 17 1 ARN00958
 C 694 14 0.4 17 1 ARN00959
 C 695 14 0.4 17 1 ACN00982
 C 696 14 0.4 17 1 ACN00981
 C 697 14 0.4 17 1 ACN02765
 C 698 14 0.4 17 1 ACN02766
 C 699 14 0.4 17 1 ACN14564
 C 700 14 0.4 17 1 ACN14565
 C 701 14 0.4 17 1 ACC68247
 C 702 14 0.4 17 1 ACC63786
 C 703 14 0.4 17 1 ACC67657
 C 704 14 0.4 17 1 ACC68563
 C 705 14 0.4 17 1 ADC38438
 C 706 14 0.4 17 1 ADC38439
 C 707 14 0.4 17 1 ACC53213
 C 708 14 0.4 17 1 ACC53844
 C 709 14 0.4 18 1 AAZ00496
 C 710 14 0.4 18 1 AAZ070301
 C 711 14 0.4 18 1 AA80684
 C 712 14 0.4 18 1 ADA27154
 C 713 14 0.4 18 1 ADE43436
 C 714 14 0.4 18 1 ADH53914
 C 715 14 0.4 18 1 ADP08093

ALIGNMENTS

RESULT 1
 ABT43754
 ID ABT43754 standard; DNA; 26 BP.
 XX
 AC ABT43754;
 XX
 XX
 DT 16-OCT-2003 (first entry)
 XX
 DE Human phosphatidylinositol-4-phosphate 5-kinase probe Seq ID6.
 XX
 KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5KIalpa;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; probe; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 FH
 FH Key Location/Qualifiers
 FT Modified_base 1 /*tag= a
 FT /*mod_base= OTHER
 FT /note= "OTHER= Labelled with FAM; FAM= 6-
 FT carboxyfluorescein"
 FT 26
 FT Modified_base /*tag= a
 FT /*mod_base= OTHER
 FT /note= "OTHER= Labelled with TAMRA; TAMRA= N,N,N,N-
 FT tetramethyl-6-carboxyrhodamine"
 XX
 FN WO2003050309-A1.
 XX
 XX 19-JUN-2003.
 XX
 XX 04-DEC-2002; 2002WO-US038615.
 XX
 PR 06-DEC-2001; 2001US-00003354.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Freier SM;
 XX
 XX WPI; 2003-627257/59.

XX
 PT New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Example 13; Page 80; 117pp; English.
 XX
 CC This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5Kia such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5Kia expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of probe Seq ID6 which
 CC is a probe used during real time analysis of human phosphatidylinositol-4-
 CC -phosphate 5-kinase Ialpa (PIP5Kia) mRNA levels in example 13 of the
 CC specification
 XX
 SQ Sequence 26 BP; 5 A; 4 C; 11 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 3.5;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 301 CGCGGGTTCTGTAAAGAGACGTTGGG 326
 DB 1 CGCGGGTTCTGTAAAGAGACGTTGGG 26
 RESULT 2
 ABT43753/c
 ID ABT43753 standard; DNA; 22 BP.
 XX
 AC ABT43753;
 XX
 DT 16-OCT-2003 (first entry)
 XX
 DE Human phosphatidylinositol-4-phosphate 5-kinase primer Seq ID5.
 XX
 KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5KIalpa;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2003050309-A1.
 XX
 XX 19-JUN-2003.
 XX
 XX 04-DEC-2002; 2002WO-US038615.
 XX
 PR 06-DEC-2001; 2001US-00003354.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Bennett CF, Freier SM;
 XX
 XX WPI; 2003-627257/59.
 XX
 XX New antisense compound useful for treating diseases such as
 XX PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Example 13; Page 80; 117pp; English.
 XX
 CC This invention relates to the novel antisense compounds, particularly

antisense oligonucleotides, for the modulation of phosphatidylinositol-4-phosphate 5-kinase α (PIP5K α) expression. The oligonucleotides of the invention may have antiinflammatory, antitumor or cytostatic activities through use in a gene therapy method. As a result the antisense oligonucleotides may be of use for the treatment of an animal having a disease associated with PIP5K α such as a hyperproliferative or inflammatory disorder through inhibition of PIP5K α expression. The oligonucleotides of the invention may also be used prophylactically to prevent or delay infection, inflammation or tumour formation. They may also be useful for diagnostics, therapeutics, prevention, as research reagents and kits or for distinguishing functions of various members of a biological pathway. The present sequence is that of PCR primer Seq ID5 which is a reverse primer used for amplification of the human phosphatidylinositol-4-phosphate 5-kinase α (PIP5K α) gene during real time analysis of mRNA levels in example 13 of the specification

XX SQ Sequence 22 BP; 4 A; 7 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 15; Mismatches 0; Indels 0; Gaps 0;
Matches 22; Conservative 0;

Qy 328 AGATTTCGATTCCGAGAGAGGA 349
|||||
Db 22 AGATTTCGATTCCGAGAGAGGA 1

RESULT 3
AA23570
ID AAX23570 standard; DNA; 27 BP.

XX AC AAX23570;

XX DT 18-JUN-1999 (first entry)

XX DE Deletion sequence oligonucleotide 23.

XX KW Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
XX KW probe; cellular adhesion modulator; cellular proliferation modulator;
XX KW human retrovirus; human immunodeficiency virus; non-human retrovirus;
XX KW HIV; primer; ss.

XX OS Synthetic.

XX PN WO9911820-A1.

XX PD 11-MAR-1999.

XX PF 01-SEP-1998; 98WO-US018084.

XX PR 02-SEP-1997; 97US-00923771.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Chen D, Srivatsa GS;

XX DR WPI; 1999-205198/17.

XX PT New compositions comprising sensor arrays made up of unique probe
XX PT oligonucleotides - useful for characterizing a sample of target deletion
XX PT oligonucleotides.

XX PS Example 1; Page 97; 163pp; English.

XX CC This invention describes a novel composition comprising a number of
XX CC sensor arrays, where each array comprises a unique probe oligonucleotide,
XX CC which is the reverse complement of part of a unique target
XX CC oligonucleotide present in a mixture of target deletion sequence
XX CC oligonucleotides. The compositions form a method for characterizing a
XX CC sample of target deletion oligonucleotides which are labelled and
XX CC hybridize with the probe oligonucleotides of the sensor arrays. Such
XX CC oligonucleotides and their targets are represented in AAX23548-X23709.
XX CC Oligonucleotides characterized by the method form pharmaceutical

CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides

XX SQ Sequence 27 BP; 8 A; 1 C; 3 G; 15 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.6; DB 1; Length 27;

Best Local Similarity 85.2%; Pred. No. 41;

Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 2574 TTCTTTTTTTTCTGAAAAAGGAAA 2600
|||||
Db 1 TTTTTTTTTTTTGAAGAAAGCAAA 27

RESULT 4

ADH49072

ID ADH49072 standard; DNA; 22 BP.

XX AC ADH49072;

XX DT 25-MAR-2004 (first entry)

XX DE NOV33 PCR primer, SEQ ID 356.

XX KW Human; NOVX; atherosclerosis; hypertension; obesity; cancer; cytostatic;
XX KW hypotensive; antiarteriosclerotic; anorectic; gene therapy; NOV33; PCR;
XX KW primer; ss.

XX OS Homo sapiens.

XX PN WO200268652-A2.

XX PD 06-SEP-2002.

XX PF 26-FEB-2002; 2002WO-US005910.

XX PR 26-FEB-2001; 2001US-0271646P.

XX PR 27-FEB-2001; 2001US-0271840P.

XX PR 28-FEB-2001; 2001US-0272404P.

XX PR 28-FEB-2001; 2001US-0272405P.

XX PR 28-FEB-2001; 2001US-0272410P.

XX PR 28-FEB-2001; 2001US-0272414P.

XX PR 02-MAR-2001; 2001US-0272787P.

XX PR 02-MAR-2001; 2001US-0272922P.

XX PR 02-MAR-2001; 2001US-0273048P.

XX PR 16-MAR-2001; 2001US-0273300P.

XX PR 20-MAR-2001; 2001US-0276401P.

XX PR 20-MAR-2001; 2001US-0277324P.

XX PR 30-MAR-2001; 2001US-0280039P.

XX PR 30-MAR-2001; 2001US-0280234P.

XX PR 02-APR-2001; 2001US-0280818P.

XX PR 12-APR-2001; 2001US-0283443P.

XX PR 23-APR-2001; 2001US-0285754P.

XX PR 24-APR-2001; 2001US-0286096P.

XX PR 03-MAY-2001; 2001US-0286353P.

XX PR 17-MAY-2001; 2001US-0291703P.

XX PR 31-MAY-2001; 2001US-0294834P.

XX PR 20-JUN-2001; 2001US-0295959P.

XX PR 21-JUN-2001; 2001US-0295845P.

XX PR 05-JUL-2001; 2001US-0303242P.

XX PR 13-AUG-2001; 2001US-0311981P.

XX PR 16-AUG-2001; 2001US-0312858P.

XX PR 17-AUG-2001; 2001US-0313280P.

```

PR 29-AUG-2001; 2001US-0315614P.
PR 17-SEP-2001; 2001US-0322818P.
PR 25-FEB-2002; 2002US-00322818.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Alsbrook JP, Anderson DW, Ballinger RA, Boldog FL, Burgess CE;
PI Casman SJ, Ellerman KE, Gangolli EA, Gerlach VL, Gilbert JA;
PI Gorman L, Guo X, Gusev VV, Kekuda R, Li L, Liu X, Malyankar UM;
PI Miller CE, Millet I, Padigaru M, Patturajan M, Pena CEA, Peyman JA;
PI Rastelli L, Shenoy SG, Shimkets RA, Smithson G, Spytek KA, Stone DJ;
PI Taupier RJ, Tchernev VT, Vernet CAM, Zerhusen BD;
XX
DR WPI; 2002-698672/75.
XX
XX New NOVX polypeptides or polynucleotides, useful for preventing or
PT treating disorders or syndromes e.g., atherosclerosis, hypertension,
PT obesity or cancer.
XX
PS Example 2; Page 694; 923pp; English.
XX
CC The present invention relates to novel human NOVX proteins, where X is
CC any number from 1 to 91 and their coding sequences (see ADH48717-
CC ADH48930). The proteins and coding sequences are useful for preventing or
CC treating disorders or syndromes e.g. atherosclerosis, hypertension,
CC obesity or cancer. The present sequence was used in an example from the
CC invention.
XX
SQ Sequence 22 BP; 5 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 31;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1743 AAAAGTTTCGGTCTGGCTCATC 1764
DB 1 AAAAGTTTCGGTCTGGCTTATC 22
XX
RESULT 5
ADH49074/c
ID ADH49074 standard; DNA; 22 BP.
XX
AC ADH49074;
XX
DT 25-MAR-2004 (first entry)
XX
DE NOV33 PCR primer, SEQ ID 358.
XX
KW Human; NOVX; atherosclerosis; hypertension; obesity; cancer; cytostatic;
KW hypotensive; antiarteriosclerotic; anorectic; gene therapy; NOV33; PCR;
KW primer; ss.
XX
OS Homo sapiens.
XX
XX WO200268652-A2.
XX
XX 06-SEP-2002.
XX
XX 26-FEB-2002; 2002WO-US005910.
XX
XX 26-FEB-2001; 2001US-0271646P.
XX 27-FEB-2001; 2001US-0271840P.
XX 28-FEB-2001; 2001US-0272404P.
XX 28-FEB-2001; 2001US-0272405P.
XX 28-FEB-2001; 2001US-0272410P.
XX 28-FEB-2001; 2001US-0272414P.
XX 02-MAR-2001; 2001US-0272787P.
XX 02-MAR-2001; 2001US-0272922P.
XX 02-MAR-2001; 2001US-0273048P.
XX 02-MAR-2001; 2001US-0273300P.
XX 16-MAR-2001; 2001US-0276401P.
XX 20-MAR-2001; 2001US-0277324P.

```

```

PR 20-MAR-2001; 2001US-0278660P.
PR 30-MAR-2001; 2001US-0280039P.
PR 30-MAR-2001; 2001US-0280234P.
PR 02-APR-2001; 2001US-0280818P.
PR 12-APR-2001; 2001US-0283443P.
PR 23-APR-2001; 2001US-0285754P.
PR 24-APR-2001; 2001US-0286096P.
PR 03-MAY-2001; 2001US-0288353P.
PR 17-MAY-2001; 2001US-0291703P.
PR 31-MAY-2001; 2001US-0294834P.
PR 20-JUN-2001; 2001US-0296959P.
PR 21-JUN-2001; 2001US-0298459P.
PR 05-JUL-2001; 2001US-0303242P.
PR 13-AUG-2001; 2001US-0311981P.
PR 16-AUG-2001; 2001US-0312858P.
PR 17-AUG-2001; 2001US-0313280P.
PR 29-AUG-2001; 2001US-0315614P.
PR 17-SEP-2001; 2001US-0322818P.
PR 25-FEB-2002; 2002US-00322818.
XX
PA (CURA-) CURAGEN CORP.
XX
XX Alsbrook JP, Anderson DW, Ballinger RA, Boldog FL, Burgess CE;
XX Casman SJ, Ellerman KE, Gangolli EA, Gerlach VL, Gilbert JA;
XX Gorman L, Guo X, Gusev VV, Kekuda R, Li L, Liu X, Malyankar UM;
XX Miller CE, Millet I, Padigaru M, Patturajan M, Pena CEA, Peyman JA;
XX Rastelli L, Shenoy SG, Shimkets RA, Smithson G, Spytek KA, Stone DJ;
XX Taupier RJ, Tchernev VT, Vernet CAM, Zerhusen BD;
XX
DR WPI; 2002-698672/75.
XX
XX New NOVX polypeptides or polynucleotides, useful for preventing or
PT treating disorders or syndromes e.g., atherosclerosis, hypertension,
PT obesity or cancer.
XX
PS Example 2; Page 694; 923pp; English.
XX
XX The present invention relates to novel human NOVX proteins, where X is
XX any number from 1 to 91 and their coding sequences (see ADH48717-
XX ADH48930). The proteins and coding sequences are useful for preventing or
XX treating disorders or syndromes e.g. atherosclerosis, hypertension,
XX obesity or cancer. The present sequence was used in an example from the
XX invention.
XX
SQ Sequence 22 BP; 7 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 31;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1801 CATTACTTACCAGCCATCGGTC 1822
DB 22 CATTACTTACCAGCCATGGTC 1
XX
RESULT 6
ABT43802/c
ID ABT43802 standard; DNA; 20 BP.
XX
AC ABT43802;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID54.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
XX
XX

```


DR WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits

PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX

PS Claim 3; Page 83; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly

CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-

CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of

CC the invention may have antiinflammatory, antitumour or cytostatic

CC activities through use in a gene therapy method. As a result the

CC antisense oligonucleotides may be of use for the treatment of an animal

CC having a disease associated with PIP5K1a such as a hyperproliferative or

CC inflammatory disorder through inhibition of PIP5K1a expression. The

CC oligonucleotides of the invention may also be used prophylactically to

CC prevent or delay infection, inflammation or tumour formation. They may

CC also be useful for diagnostics, therapeutics, prevention, as research

CC reagents and kits or for distinguishing functions of various members of a

CC biological pathway. The present sequence is that of an antisense

CC oligonucleotide of the invention. The oligonucleotide is a chimeric

CC phosphorothioate oligonucleotide which has five nucleotide 2'-

CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.

CC The oligonucleotide backbone is phosphorothioate throughout

XX

SQ Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 31;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3520 TTTATTAAAGGACAGAGTTCT 3539

DB 20 TTTATTAAAGGACAGAGTTCT 1

RESULT 9

ABT43771/c

ID ABT43771 standard; DNA; 20 BP.

XX

AC ABT43771;

XX

DT 16-OCT-2003 (first entry)

XX

DE Human PIP5K1a antisense oligonucleotide Seq ID23.

XX

KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;

KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;

KW antisense oligonucleotide; hyperproliferative disorder;

KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;

KW 2'-MOE wing; phosphorothioate backbone; ss.

XX

OS Homo sapiens.

XX

PN WO2003050309-A1.

XX

PD 19-JUN-2003.

XX

PF 04-DEC-2002; 2002WO-US038615.

XX

PR 06-DEC-2001; 2001US-00003354.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Bennett CF, Freier SM;

XX

DR WPI; 2003-627257/59.

XX

PT New antisense compound useful for treating diseases such as

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits

PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX

PS Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly

CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-

CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of

CC the invention may have antiinflammatory, antitumour or cytostatic

CC activities through use in a gene therapy method. As a result the

CC antisense oligonucleotides may be of use for the treatment of an animal

CC having a disease associated with PIP5K1a such as a hyperproliferative or

CC inflammatory disorder through inhibition of PIP5K1a expression. The

CC oligonucleotides of the invention may also be used prophylactically to

CC prevent or delay infection, inflammation or tumour formation. They may

CC also be useful for diagnostics, therapeutics, prevention, as research

CC reagents and kits or for distinguishing functions of various members of a

CC biological pathway. The present sequence is that of an antisense

CC oligonucleotide of the invention. The oligonucleotide is a chimeric

CC phosphorothioate oligonucleotide which has five nucleotide 2'-

CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.

CC The oligonucleotide backbone is phosphorothioate throughout

XX

SQ Sequence 20 BP; 6 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 31;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGCCCATAGAGTGTGATT 572

DB 20 AGCCCATAGAGTGTGATT 1

RESULT 10

ABT43780/c

ID ABT43780 standard; DNA; 20 BP.

XX

AC ABT43780;

XX

DT 16-OCT-2003 (first entry)

XX

DE Human PIP5K1a antisense oligonucleotide Seq ID32.

XX

KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;

KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;

KW antisense oligonucleotide; hyperproliferative disorder;

KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;

KW 2'-MOE wing; phosphorothioate backbone; ss.

XX

OS Homo sapiens.

XX

PN WO2003050309-A1.

XX

PD 19-JUN-2003.

XX

PF 04-DEC-2002; 2002WO-US038615.

XX

PR 06-DEC-2001; 2001US-00003354.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Bennett CF, Freier SM;

XX

DR WPI; 2003-627257/59.

XX

PT New antisense compound useful for treating diseases such as

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits

PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX

PS Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly

CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-

CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of

CC the invention may have antiinflammatory, antitumour or cytostatic

CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout

XX Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 GCTGCTTCAGGATACATACA 998
DB 20 GCTGCTTCAGGATACATACA 1

RESULT 11

ABT43788/c
ID ABT43788 standard; DNA; 20 BP.

XX AC ABT43788;

XX DT 16-OCT-2003 (first entry)

XX DE Human PIP5K1a antisense oligonucleotide Seq ID40.

XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO2003050309-A1.

XX PD 19-JUN-2003.

XX PF 04-DEC-2002; 2002WO-US038615.

XX PR 06-DEC-2001; 2001US-00003354.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Freier SM;

XX DR WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may

CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout

XX Sequence 20 BP; 6 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1285 GCAGCGTGACTGTTGGTGC 1304

DB 20 GCAGCGTGACTGTTGGTGC 1

RESULT 12

ABT43794/c

ID ABT43794 standard; DNA; 20 BP.

XX AC ABT43794;

XX DT 16-OCT-2003 (first entry)

XX DE Human PIP5K1a antisense oligonucleotide Seq ID46.

XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO2003050309-A1.

XX PD 19-JUN-2003.

XX PF 04-DEC-2002; 2002WO-US038615.

XX PR 06-DEC-2001; 2001US-00003354.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Freier SM;

XX DR WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.

CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 2 A; 8 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1526 CGGAATAGTAAAGGGGAAG 1545
Dbb 20 CGGAATAGTAAAGGGGAAG 1

RESULT 13
ABT43760/C
ID ABT43760 standard; DNA; 20 BP.

XX AC ABT43760;
XX
XX
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID12.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO2003050309-A1.

XX PD 19-JUN-2003.

XX PF 04-DEC-2002; 2002WO-US038615.

XX PR 06-DEC-2001; 2001US-00003354.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Freier SM;

XX PS WPI; 2003-627257/59.

XX
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.

PS Claim 3; Page 82; 117pp; English.

XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout

SQ Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 215 CGAATGGTGGCCTTGAGC 234
Dbb 20 CGAATGGTGGCCTTGAGC 1

RESULT 14

ABT43766/C

ID ABT43766 standard; DNA; 20 BP.

XX AC ABT43766;

XX
XX 16-OCT-2003 (first entry)

XX Human PIP5K1a antisense oligonucleotide Seq ID18.

XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO2003050309-A1.

XX PD 19-JUN-2003.

XX PF 04-DEC-2002; 2002WO-US038615.

XX PR 06-DEC-2001; 2001US-00003354.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Freier SM;

XX PS WPI; 2003-627257/59.

XX
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.

PS Claim 3; Page 82; 117pp; English.

XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout

SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CATCTGGAATCAAGAGACCC 505

Dbb 20 CATCTGGAATCAAGAGACCC 1

```
RESULT 15
ABT43792/c
ID ABT43792 standard; DNA; 20 BP.
XX
XX AC
XX ABT43792;
XX
XX DT 16-OCT-2003 (first entry)
XX
XX DE Human PIP5K1a antisense oligonucleotide Seq ID44.
XX
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2003050309-A1.
XX
XX PD 19-JUN-2003.
XX
XX PF 04-DEC-2002; 2002WO-US038615.
XX
XX PR 06-DEC-2001; 2001US-00003354.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX PT New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX
XX PS Claim 3; Page 82; 117pp; English.
XX
XX CC This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antiinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense
XX oligonucleotide of the invention. The oligonucleotide is a chimeric
XX phosphorothioate oligonucleotide which has five nucleotide 2'-
XX methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
XX SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 31;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1452 TGGATCCATCCAGGAGAG 1471
DB 20 TGGATCCATCCAGGAGAG 1

RESULT 16
ABT43801/c
ID ABT43801 standard; DNA; 20 BP.
XX
XX AC
XX ABT43801;
XX
```

```
XX
XX DT 16-OCT-2003 (first entry)
XX
XX DE Human PIP5K1a antisense oligonucleotide Seq ID53.
XX
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2003050309-A1.
XX
XX PD 19-JUN-2003.
XX
XX PF 04-DEC-2002; 2002WO-US038615.
XX
XX PR 06-DEC-2001; 2001US-00003354.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX PT New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX
XX PS Claim 3; Page 82; 117pp; English.
XX
XX CC This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antiinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense
XX oligonucleotide of the invention. The oligonucleotide is a chimeric
XX phosphorothioate oligonucleotide which has five nucleotide 2'-
XX methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
XX SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 31;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1786 CAGTGGCAACTCCTGCATTA 1805
DB 20 CAGTGGCAACTCCTGCATTA 1

RESULT 17
ABT43822/c
ID ABT43822 standard; DNA; 20 BP.
XX
XX AC
XX ABT43822;
XX
XX DT 16-OCT-2003 (first entry)
XX
XX DE Human PIP5K1a antisense oligonucleotide Seq ID74.
XX
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
```

KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
OS Homo sapiens.
XX
XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Claim 3; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5Kia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5Kia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2448 GGACAGACTAGCTGGCAGAT 2467
DB 20 GGACAGACTAGCTGGCAGAT 1

RESULT 18
ABT43828/C
ID ABT43828 standard; DNA; 20 BP.
XX
XX ABT43828;
XX
XX 16-OCT-2003 (first entry)
XX
XX Human PIP5Kia antisense oligonucleotide Seq IB80.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5Kialpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.

XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Example 15; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5Kia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5Kia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3301 GGCCTGGTATCTCAGGCAGA 3320
DB 20 GGCCTGGTATCTCAGGCAGA 1

RESULT 19
ABT43762/C
ID ABT43762 standard; DNA; 20 BP.
XX
XX ABT43762;
XX
XX 16-OCT-2003 (first entry)
XX
XX Human PIP5Kia antisense oligonucleotide Seq ID14.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5Kialpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
XX
XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.


```
XX PR 06-DEC-2001; 2001US-00003354.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Freier SM;
XX DR WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 82; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase (PIP5K) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 254 ACGTGCTCTGAGGAGGCCG 273
DB 20 ACGTGCTCTGAGGAGGCCG 1
|||||
RESULT 20
ABT43764/c
ID ABT43764 standard; DNA; 20 BP.
XX
XX AC ABT43764;
XX
XX DT 16-OCT-2003 (first entry)
XX
XX DE Human PIP5K antisense oligonucleotide Seq ID16.
XX
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2003050309-A1.
XX
XX PD 19-JUN-2003.
XX
XX PF 04-DEC-2002; 2002WO-US038615.
XX
XX PR 06-DEC-2001; 2001US-00003354.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Bennett CF, Freier SM;
```

```
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 82; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpha (PIP5K) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 2 A; 6 C; 4 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 336 TTCGAGAGGAGGAGGACC 355
DB 20 TTCGAGAGGAGGAGGACC 1
|||||
RESULT 21
ABT43809/c
ID ABT43809 standard; DNA; 20 BP.
XX
XX AC ABT43809;
XX
XX DT 16-OCT-2003 (first entry)
XX
XX DE Human PIP5K antisense oligonucleotide Seq ID61.
XX
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2003050309-A1.
XX
XX PD 19-JUN-2003.
XX
XX PF 04-DEC-2002; 2002WO-US038615.
XX
XX PR 06-DEC-2001; 2001US-00003354.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
```

XX PS Claim 3; Page 83; 117pp; English.

CC This invention relates to the novel antisense compounds, particularly

CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-

CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of

CC the invention may have antiinflammatory, antitumour or cytostatic

CC activities through use in a gene therapy method. As a result the

CC antisense oligonucleotides may be of use for the treatment of an animal

CC having a disease associated with PIP5Kia such as a hyperproliferative or

CC inflammatory disorder through inhibition of PIP5Kia expression. The

CC oligonucleotides of the invention may also be used prophylactically to

CC prevent or delay infection, inflammation or tumour formation. They may

CC also be useful for diagnostics, therapeutics, prevention, as research

CC reagents and kits or for distinguishing functions of various members of a

CC biological pathway. The present sequence is that of an antisense

CC oligonucleotide of the invention. The oligonucleotide is a chimeric

CC phosphorothioate oligonucleotide which has five nucleotide 2'-

CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.

CC The oligonucleotide backbone is phosphorothioate throughout

XX SQ Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 31;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2011 GGAAAGCTTGAAGTTGCAG 2030

DB 20 GGAAAGCTTGAAGTTGCAG 1

RESULT 22

ABT43768/c

ID ABT43768 standard; DNA; 20 BP.

XX AC ABT43768;

XX AC ABT43768;

DT 16-OCT-2003 (first entry)

XX Human PIP5Kia antisense oligonucleotide Seq ID20.

XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5KiaIalpa;

KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;

KW antisense oligonucleotide; hyperproliferative disorder;

KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;

KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX WO2003050309-A1.

PN 19-JUN-2003.

PD 04-DEC-2002; 2002WO-US038615.

XX 06-DEC-2001; 2001US-00003354.

XX (ISIS-) ISIS PHARM INC.

PA Bennett CF, Freier SM;

PI WPI; 2003-627257/59.

DR New antisense compound useful for treating diseases such as

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits

PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

PS Example 15; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly

CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-

CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of

CC the invention may have antiinflammatory, antitumour or cytostatic

CC activities through use in a gene therapy method. As a result the

CC antisense oligonucleotides may be of use for the treatment of an animal

CC having a disease associated with PIP5Kia such as a hyperproliferative or

CC inflammatory disorder through inhibition of PIP5Kia expression. The

CC oligonucleotides of the invention may also be used prophylactically to

CC prevent or delay infection, inflammation or tumour formation. They may

CC also be useful for diagnostics, therapeutics, prevention, as research

CC reagents and kits or for distinguishing functions of various members of a

CC biological pathway. The present sequence is that of an antisense

CC oligonucleotide of the invention. The oligonucleotide is a chimeric

CC phosphorothioate oligonucleotide which has five nucleotide 2'-

CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.

CC The oligonucleotide backbone is phosphorothioate throughout

XX SQ Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 31;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 514 TGAGTGCCCTTATGCCTCTG 533

DB 20 TGAGTGCCCTTATGCCTCTG 1

RESULT 23

ABT43770/c

ID ABT43770 standard; DNA; 20 BP.

XX AC ABT43770;

XX AC ABT43770;

DT 16-OCT-2003 (first entry)

XX Human PIP5Kia antisense oligonucleotide Seq ID22.

XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5KiaIalpa;

KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;

KW antisense oligonucleotide; hyperproliferative disorder;

KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;

KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX WO2003050309-A1.

PN 19-JUN-2003.

PD 04-DEC-2002; 2002WO-US038615.

XX 06-DEC-2001; 2001US-00003354.

XX (ISIS-) ISIS PHARM INC.

PA Bennett CF, Freier SM;

PI WPI; 2003-627257/59.

DR New antisense compound useful for treating diseases such as

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits

PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

PS Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly

CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-

CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of

CC the invention may have antiinflammatory, antitumour or cytostatic

CC activities through use in a gene therapy method. As a result the

CC antisense oligonucleotides may be of use for the treatment of an animal

CC having a disease associated with PIP5Kia such as a hyperproliferative or

CC inflammatory disorder through inhibition of PIP5Kia expression. The

CC oligonucleotides of the invention may also be used prophylactically to

CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 3 A; 3 C; 5 G; 9 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 540 CCATCAAGAAATAGGCCAT 559
Db 20 CCATCAAGAAATAGGCCAT 1
RESULT 24
ABT43782/c
ID ABT43782 standard; DNA; 20 BP.
XX
AC ABT43782;
XX
DT 16-OCT-2003 (first entry)
DE Human PIP5K1a antisense oligonucleotide Seq ID34.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
PS WPI; 2003-627257/59.
XX
PT New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX
PS Claim 3; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX

CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 2 A; 3 C; 9 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1002 ACCTCAACCAAGACCCCTCGG 1021
Db 20 ACCTCAACCAAGACCCCTCGG 1
RESULT 25
ABT43798/c
ID ABT43798 standard; DNA; 20 BP.
XX
AC ABT43798;
XX
DT 16-OCT-2003 (first entry)
DE Human PIP5K1a antisense oligonucleotide Seq ID50.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
PS WPI; 2003-627257/59.
XX
PT New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX
PS Claim 3; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX
SQ Sequence 20 BP; 7 A; 1 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;

```
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1730 CCTTCTCTTCCAAAGATT 1749
Db 20 CCTTCTCTTCCAAAGATT 1

RESULT 26
ABT43804/c
ID ABT43804 standard; DNA; 20 BP.
XX
AC ABT43804;
XX
XX Human PIP5K1a antisense oligonucleotide Seq ID56.
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID56.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5K1alpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Claim 3; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 9 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1884 GTCGTCCTGATGTTTACCT 1903
Db 20 GTCGTCCTGATGTTTACCT 1

RESULT 28
ABT43824/c
ID ABT43824 standard; DNA; 20 BP.
XX
```

```
RESULT 27
ABT43814/c
ID ABT43814 standard; DNA; 20 BP.
XX
AC ABT43814;
XX
XX 16-OCT-2003 (first entry)
XX
XX Human PIP5K1a antisense oligonucleotide Seq ID66.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5K1alpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Claim 3; Page 83; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2092 CTGTGATCCCAAGATGTCAG 2111
Db 20 CTGTGATCCCAAGATGTCAG 1

RESULT 28
ABT43824/c
ID ABT43824 standard; DNA; 20 BP.
XX
```

AC ABT43824;
 XX
 DT 16-OCT-2003 (first entry)
 XX
 XX Human PIP5K1a antisense oligonucleotide Seq ID76.
 DE
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
 KW antiinflammatory; antitumour; cytosstatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2003050309-A1.
 FN
 XX 19-JUN-2003.
 PD
 XX 04-DEC-2002; 2002WO-US038615.
 PF
 XX 06-DEC-2001; 2001US-00003354.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Freier SM;
 PI
 XX WPI; 2003-627257/59.
 DR
 XX New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Claim 3; Page 83; 117pp; English.
 XX
 XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3124 ACTCATGGGGAGACACAGCA 3143
 DB 20 ACTCATGGGGAGACACAGCA 1
 RESULT 29
 ID ABT43832/c
 XX
 XX Human PIP5K1a antisense oligonucleotide Seq ID84.
 AC ABT43832;
 XX
 XX 16-OCT-2003 (first entry)
 DT
 XX Human PIP5K1a antisense oligonucleotide Seq ID84.
 DE
 XX

KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2003050309-A1.
 FN
 XX 19-JUN-2003.
 PD
 XX 04-DEC-2002; 2002WO-US038615.
 PF
 XX 06-DEC-2001; 2001US-00003354.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Freier SM;
 PI
 XX WPI; 2003-627257/59.
 DR
 XX New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Example 15; Page 83; 117pp; English.
 XX
 XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 7 A; 1 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3386 CCAATAACTGCTCTATATTA 3405
 DB 20 CCAATAACTGCTCTATATTA 1
 RESULT 30
 ABT43793/c
 ID ABT43793 standard; DNA; 20 BP.
 XX
 XX AC ABT43793;
 XX
 XX DT 16-OCT-2003 (first entry)
 XX
 XX Human PIP5K1a antisense oligonucleotide Seq ID45.
 DE
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX

OS Homo sapiens.
XX WO2003050309-A1.
PN
XX
PD 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
PF
XX 06-DEC-2001; 2001US-00003354.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Bennett CF, Freier SM;
PI
XX WPI; 2003-627257/59.
DR
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Example 15; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1480 GGGTGGTACCATGGAGACTG 1499
DB 20 GGGTGGTACCATGGAGACTG 1
RESULT 31
ABT43807/c
ID ABT43807 standard; DNA; 20 BP.
XX
AC ABT43807;
XX
XX 16-OCT-2003 (first entry)
DT
XX Human PIPSKia antisense oligonucleotide Seq ID59.
DE
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIPSKiaIalpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
XX WO2003050309-A1.
PN
XX
PD 19-JUN-2003.
XX

PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Bennett CF, Freier SM;
PI
XX WPI; 2003-627257/59.
DR
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Example 15; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 6 A; 2 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1980 CTTTGCAATGCTAACTACA 1999
DB 20 CTTTGCAATGCTAACTACA 1
RESULT 32
ABT43815/c
ID ABT43815 standard; DNA; 20 BP.
XX
AC ABT43815;
XX
XX 16-OCT-2003 (first entry)
DT
XX Human PIPSKia antisense oligonucleotide Seq ID67.
DE
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIPSKiaIalpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
XX WO2003050309-A1.
PN
XX 19-JUN-2003.
PD
XX
XX 04-DEC-2002; 2002WO-US038615.
PF
XX 06-DEC-2001; 2001US-00003354.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX

PI Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 7 A; 1 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2209 AAGAACCTTCTCTCCTCTCT 2228
DB 20 AAGAACCTTCTCTCCTCTCT 1
RESULT 33
ABT43817/C
ID ABT43817 standard; DNA; 20 BP.
XX
XX ABT43817;
XX
XX 16-OCT-2003 (first entry)
XX
XX Human PIPSKia antisense oligonucleotide Seq ID69.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIPSKialpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
XX
XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits

PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2231 TCCTCATGATGGCCTTAG 2250
DB 20 TCCTCATGATGGCCTTAG 1
RESULT 34
ABT43819/C
ID ABT43819 standard; DNA; 20 BP.
XX
XX AC ABT43819;
XX
XX 16-OCT-2003 (first entry)
XX
XX Human PIPSKia antisense oligonucleotide Seq ID71.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIPSKialpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
XX
XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-

phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of the invention may have antiinflammatory, antitumour or cytostatic activities through use in a gene therapy method. As a result the antisense oligonucleotides may be of use for the treatment of an animal having a disease associated with PIP5Kia such as a hyperproliferative or inflammatory disorder through inhibition of PIP5Kia expression. The oligonucleotides of the invention may also be used prophylactically to prevent or delay infection, inflammation or tumour formation. They may also be useful for diagnostics, therapeutics, prevention, as research reagents and kits or for distinguishing functions of various members of a biological pathway. The present sequence is that of an antisense oligonucleotide of the invention. The oligonucleotide is a chimeric phosphorothioate oligonucleotide which has five nucleotide 2'-methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap. The oligonucleotide backbone is phosphorothioate throughout

XX
SQ Sequence 20 BP; 8 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2388 GGACTTGGCAGCTTCTTC 2407
|||||
Db 20 GGACTTGGCAGCTTCTTC 1

RESULT 35
ABT43759/c
ID ABT43759 standard; DNA; 20 BP.
XX
AC ABT43759;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5Kia antisense oligonucleotide Seq ID11.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5KiaIalpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
DR WPI; 2003-627257/59.
XX
PT New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Claim 3; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5Kia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5Kia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout

CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout

XX
SQ Sequence 20 BP; 2 A; 8 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 TGGGCGCAAGGTCCACGAG 112
|||||
Db 20 TGGGCGCAAGGTCCACGAG 1

RESULT 36
ABT43773/c
ID ABT43773 standard; DNA; 20 BP.
XX
AC ABT43773;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5Kia antisense oligonucleotide Seq ID25.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5KiaIalpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
DR WPI; 2003-627257/59.
XX
PT New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Claim 3; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5Kia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5Kia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5Kia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric

CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 649 TGTGGGACCTGAGTACCA 668
 DB 20 TGTGGGACCTGAGTACCA 1
 RESULT 37
 ABT43783/c
 ID ABT43783 standard; DNA; 20 BP.
 XX ABT43783;
 AC
 DT 16-OCT-2003 (first entry)
 XX Human PIP5K1a antisense oligonucleotide Seq ID35.
 DE
 KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003050309-A1.
 XX
 PD 19-JUN-2003.
 XX
 PF 04-DEC-2002; 2002WO-US038615.
 XX
 PR 06-DEC-2001; 2001US-00003354.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Freier SM;
 XX
 PS WPI; 2003-627257/59.
 DR
 XX New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
 XX
 PS Claim 3; Page 82; 117pp; English.
 XX
 CC This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1043 GGACTGTACTGTGTGCAGGC 1062
 DB 20 GGACTGTACTGTGTGCAGGC 1
 RESULT 38
 ABT43795/c
 ID ABT43795 standard; DNA; 20 BP.
 XX ABT43795;
 AC
 DT 16-OCT-2003 (first entry)
 XX Human PIP5K1a antisense oligonucleotide Seq ID47.
 DE
 KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003050309-A1.
 XX
 PD 19-JUN-2003.
 XX
 PF 04-DEC-2002; 2002WO-US038615.
 XX
 PR 06-DEC-2001; 2001US-00003354.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Freier SM;
 XX
 PS WPI; 2003-627257/59.
 DR
 XX New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
 XX
 PS Example 15; Page 82; 117pp; English.
 XX
 CC This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 9 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1552 GCTTTATATTGGCATCATTTG 1571
 |||||||||||||||||||||

```
Db      20 GCATTATATGGCATCTTG 1
RESULT 39
ABT43835/c
ID   ABT43835 standard; DNA; 20 BP.
XX
XX   ABT43835;
AC
XX
XX   16-OCT-2003 (first entry)
DT
XX
XX   Human PIP5K1a antisense oligonucleotide Seq ID87.
DE
XX
XX   Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
KW   antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW   antisense oligonucleotide; hyperproliferative disorder;
KW   inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW   2'-MOE wing; phosphorothioate backbone; ss.
XX
XX   Homo sapiens.
OS
XX
XX   WO2003050309-A1.
PN
XX
XX   19-JUN-2003.
PD
XX
XX   04-DEC-2002; 2002WO-US038615.
PF
XX
XX   06-DEC-2001; 2001US-00003354.
PR
XX
XX   (ISIS-) ISIS PHARM INC.
PA
XX
XX   Bennett CF, Freier SM;
PI
XX
XX   WPI; 2003-627257/59.
DR
XX
XX   New antisense compound useful for treating diseases such as
PT   hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT   nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX   Example 15; Page 83; 117pp; English.
PS
XX
XX   This invention relates to the novel antisense compounds, particularly
CC   antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC   phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
CC   the invention may have antiinflammatory, antitumour or cytostatic
CC   activities through use in a gene therapy method. As a result the
CC   antisense oligonucleotides may be of use for the treatment of an animal
CC   having a disease associated with PIP5K1a such as a hyperproliferative or
CC   inflammatory disorder through inhibition of PIP5K1a expression. The
CC   oligonucleotides of the invention may also be used prophylactically to
CC   prevent or delay infection, inflammation or tumour formation. They may
CC   also be useful for diagnostics, therapeutics, prevention, as research
CC   reagents and kits or for distinguishing functions of various members of a
CC   biological pathway. The present sequence is that of an antisense
CC   oligonucleotide of the invention. The oligonucleotide is a chimeric
CC   phosphorothioate oligonucleotide which has five nucleotide 2'-
CC   methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC   The oligonucleotide backbone is phosphorothioate throughout
XX
XX   Sequence 20 BP; 6 A; 4 C; 2 G; 8 T; 0 U; 0 Other;
SQ
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3640 ATTGTTTCAGAAATGGCAAAAT 3659
DB      20 ATTGTTTCAGAAATGGCAAAAT 1
|||||
RESULT 40
ABT43772/c
ID   ABT43772 standard; DNA; 20 BP.
XX
XX   16-OCT-2003 (first entry)
DT
XX
XX   Human PIP5K1a antisense oligonucleotide Seq ID26.
DE
```

```
XX
AC   ABT43772;
XX
XX   16-OCT-2003 (first entry)
DT
XX
XX   Human PIP5K1a antisense oligonucleotide Seq ID24.
DE
XX
XX   Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
KW   antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW   antisense oligonucleotide; hyperproliferative disorder;
KW   inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW   2'-MOE wing; phosphorothioate backbone; ss.
XX
XX   Homo sapiens.
OS
XX
XX   WO2003050309-A1.
PN
XX
XX   19-JUN-2003.
PD
XX
XX   04-DEC-2002; 2002WO-US038615.
PF
XX
XX   06-DEC-2001; 2001US-00003354.
PR
XX
XX   (ISIS-) ISIS PHARM INC.
PA
XX
XX   Bennett CF, Freier SM;
PI
XX
XX   WPI; 2003-627257/59.
DR
XX
XX   New antisense compound useful for treating diseases such as
PT   hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT   nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX   Example 15; Page 82; 117pp; English.
PS
XX
XX   This invention relates to the novel antisense compounds, particularly
CC   antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC   phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
CC   the invention may have antiinflammatory, antitumour or cytostatic
CC   activities through use in a gene therapy method. As a result the
CC   antisense oligonucleotides may be of use for the treatment of an animal
CC   having a disease associated with PIP5K1a such as a hyperproliferative or
CC   inflammatory disorder through inhibition of PIP5K1a expression. The
CC   oligonucleotides of the invention may also be used prophylactically to
CC   prevent or delay infection, inflammation or tumour formation. They may
CC   also be useful for diagnostics, therapeutics, prevention, as research
CC   reagents and kits or for distinguishing functions of various members of a
CC   biological pathway. The present sequence is that of an antisense
CC   oligonucleotide of the invention. The oligonucleotide is a chimeric
CC   phosphorothioate oligonucleotide which has five nucleotide 2'-
CC   methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC   The oligonucleotide backbone is phosphorothioate throughout
XX
XX   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      633 TAGGCATTACCCACACTGTG 652
DB      20 TAGGCATTACCCACACTGTG 1
|||||
RESULT 41
ABT43774/c
ID   ABT43774 standard; DNA; 20 BP.
XX
XX   ABT43774;
AC
XX
XX   16-OCT-2003 (first entry)
DT
XX
XX   Human PIP5K1a antisense oligonucleotide Seq ID26.
DE
```

```

XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5K1alpha;
KW antinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
OS Homo sapiens.
XX WO2003050309-A1.
XX 19-JUN-2003.
XX 04-DEC-2002; 2002WO-US038615.
XX 06-DEC-2001; 2001US-00003354.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX Claim 3; Page 82; 117pp; English.
XX This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase Ialpa (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense
XX oligonucleotide of the invention. The oligonucleotide is a chimeric
XX phosphorothioate oligonucleotide which has five nucleotide 2'-
XX methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 678 GTGATGTCCTCATGCAAGAT 697
DB 20 GTGATGTCCTCATGCAAGAT 1
RESULT 42
ABT43775/C
ID ABT43775 standard; DNA; 20 BP.
XX
XX ABT43775;
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID27.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5K1alpha;
XX antinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.

```

```

XX Homo sapiens.
XX WO2003050309-A1.
XX 19-JUN-2003.
XX 04-DEC-2002; 2002WO-US038615.
XX 06-DEC-2001; 2001US-00003354.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX Claim 3; Page 82; 117pp; English.
XX This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase Ialpa (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense
XX oligonucleotide of the invention. The oligonucleotide is a chimeric
XX phosphorothioate oligonucleotide which has five nucleotide 2'-
XX methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX Sequence 20 BP; 7 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 771 TTCGTTTCAAGACCTATGCA 790
DB 20 TTCGTTTCAAGACCTATGCA 1
RESULT 43
ABT43778/C
ID ABT43778 standard; DNA; 20 BP.
XX
XX ABT43778;
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID30.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5K1alpha;
XX antinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX Homo sapiens.
XX WO2003050309-A1.
XX 19-JUN-2003.

```

```

XX PF 04-DEC-2002; 2002WO-US038615.
XX PR 06-DEC-2001; 2001US-00003354.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Freier SM;
XX DR WPI; 2003-627257/59.
XX XX
XX PT New antisense compound useful for treating diseases such as
XX PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX PS Claim 3; Page 82; 117pp; English.
XX CC
XX CC This invention relates to the novel antisense compounds, particularly
XX CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
XX CC the invention may have antiinflammatory, antitumour or cytostatic
XX CC activities through use in a gene therapy method. As a result the
XX CC antisense oligonucleotides may be of use for the treatment of an animal
XX CC having a disease associated with PIP5K1a such as a hyperproliferative or
XX CC inflammatory disorder through inhibition of PIP5K1a expression. The
XX CC oligonucleotides of the invention may also be used prophylactically to
XX CC prevent or delay infection, inflammation or tumour formation. They may
XX CC also be useful for diagnostics, therapeutics, prevention, as research
XX CC reagents and kits or for distinguishing functions of various members of a
XX CC biological pathway. The present sequence is that of an antisense
XX CC oligonucleotide of the invention. The oligonucleotide is a chimeric
XX CC phosphorothioate oligonucleotide which has five nucleotide 2'-
XX CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX CC The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 868 GCTGATTGAACCTCTGTAGCT 887
DB 20 GCTGATTGAACCTCTGTAGCT 1

RESULT 44
ABT43797/c
ID ABT43797 standard; DNA; 20 BP.
AC ABT43797;
XX XX
XX DT 16-OCT-2003 (first entry)
XX DE Human PIP5K1a antisense oligonucleotide seq ID49.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX KW 2'-MOE wing; phosphorothioate backbone; ss.
XX OS Homo sapiens.
XX XX
XX PN WO2003050309-A1.
XX XX
XX PD 19-JUN-2003.
XX XX
XX PF 04-DEC-2002; 2002WO-US038615.
XX XX
XX PR 06-DEC-2001; 2001US-00003354.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Freier SM;
XX DR WPI; 2003-627257/59.
XX PT New antisense compound useful for treating diseases such as
XX PF 04-DEC-2002; 2002WO-US038615.
XX PR 06-DEC-2001; 2001US-00003354.
XX PA (ISIS-) ISIS PHARM INC.

Bennett CF, Freier SM;
WPI; 2003-627257/59.

New antisense compound useful for treating diseases such as
hyperproliferative or inflammatory disorders, hybridizes and inhibits
nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

Claim 3; Page 82; 117pp; English.

This invention relates to the novel antisense compounds, particularly
antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
the invention may have antiinflammatory, antitumour or cytostatic
activities through use in a gene therapy method. As a result the
antisense oligonucleotides may be of use for the treatment of an animal
having a disease associated with PIP5K1a such as a hyperproliferative or
inflammatory disorder through inhibition of PIP5K1a expression. The
oligonucleotides of the invention may also be used prophylactically to
prevent or delay infection, inflammation or tumour formation. They may
also be useful for diagnostics, therapeutics, prevention, as research
reagents and kits or for distinguishing functions of various members of a
biological pathway. The present sequence is that of an antisense
oligonucleotide of the invention. The oligonucleotide is a chimeric
phosphorothioate oligonucleotide which has five nucleotide 2'-
methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
The oligonucleotide backbone is phosphorothioate throughout

Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1591 GTTTGTTAAGAGCTGAGC 1610
DB 20 GTTTGTTAAGAGCTGAGC 1

RESULT 45
ABT43830/c
ID ABT43830 standard; DNA; 20 BP.
XX XX
XX AC ABT43830;
XX XX
XX DT 16-OCT-2003 (first entry)
XX DE Human PIP5K1a antisense oligonucleotide Seq ID82.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX KW 2'-MOE wing; phosphorothioate backbone; ss.
XX OS Homo sapiens.
XX XX
XX PN WO2003050309-A1.
XX XX
XX PD 19-JUN-2003.
XX XX
XX PF 04-DEC-2002; 2002WO-US038615.
XX XX
XX PR 06-DEC-2001; 2001US-00003354.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Freier SM;
XX DR WPI; 2003-627257/59.
XX PT New antisense compound useful for treating diseases such as

```

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Example 15; Page 83; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIPSKia) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5Kia such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5Kia expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX

SQ Sequence 20 BP; 7 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3355 ACCCTGCCCTTGATATATGCT 3374
 DB 20 ACCCTGCCCTTGATATATGCT 1
 |||||

RESULT 46

ABT43758/c
 ID ABT43758 standard; DNA; 20 BP.
 XX
 AC ABT43758;
 XX
 DT 16-OCT-2003 (first entry)
 DE Human PIP5Kia antisense oligonucleotide Seq ID10.
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5Kialpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.

XX Homo sapiens.

OS WO2003050309-A1.

PN 19-JUN-2003.

PD 04-DEC-2002; 2002WO-US038615.

PF 06-DEC-2001; 2001US-00003354.

PR (ISIS-) ISIS PHARM INC.

PA Bennett CF, Freier SM;

PI WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly

CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIPSKia) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5Kia such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5Kia expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX

SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 83 TGGCTTGGCTCTGGCGCAAG 102
 DB 20 TGGCTTGGCTCTGGCGCAAG 1
 |||||

RESULT 47

ABT43763/c
 ID ABT43763 standard; DNA; 20 BP.

XX AC ABT43763;

XX DT 16-OCT-2003 (first entry)

XX DE Human PIP5Kia antisense oligonucleotide Seq ID15.

XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5Kialpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.

XX Homo sapiens.

OS WO2003050309-A1.

PN 19-JUN-2003.

PD 04-DEC-2002; 2002WO-US038615.

PF 06-DEC-2001; 2001US-00003354.

PR (ISIS-) ISIS PHARM INC.

PA Bennett CF, Freier SM;

PI WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as

PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIPSKia) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5Kia such as a hyperproliferative or

CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX

XX Sequence 20 BP; 6 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 322 TTGGGAGATTCGATTCGA 341
DB 20 TTGGGAGATTCGATTCGA 1

RESULT 48
ABT43787/c
ID ABT43787 standard; DNA; 20 BP.

XX AC ABT43787;
XX
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID39.
XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.

XX Homo sapiens.

XX WO2003050309-A1.
XX 19-JUN-2003.
XX 04-DEC-2002; 2002WO-US038615.
XX 06-DEC-2001; 2001US-00003354.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Freier SM;

XX WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antiinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense

CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX

XX Sequence 20 BP; 6 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1218 TCTTACAAGACATCCCTGAT 1237
DB 20 TCTTACAAGACATCCCTGAT 1

RESULT 49
ABT43761/c
ID ABT43761 standard; DNA; 20 BP.

XX AC ABT43761;

XX 16-OCT-2003 (first entry)

XX Human PIP5K1a antisense oligonucleotide Seq ID13.

XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.

XX Homo sapiens.

XX WO2003050309-A1.

XX 19-JUN-2003.

XX 04-DEC-2002; 2002WO-US038615.

XX 06-DEC-2001; 2001US-00003354.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Freier SM;

XX WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX Claim 3; Page 82; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antiinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense
XX oligonucleotide of the invention. The oligonucleotide is a chimeric
XX phosphorothioate oligonucleotide which has five nucleotide 2'-
XX methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout

XX Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

```
Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 236 GGTCCAGGAGCGGCTCGAC 255
      |||||
DB 20 GGTCCAGGAGCGGCTCGAC 1

RESULT 50
ABT43786/c
ID ABR43786 standard; DNA; 20 BP.
XX
AC ABR43786;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID38.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
WPI; 2003-627257/59.
XX
New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX
Claim 3; Page 82; 117pp; English.
XX
This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1213 AGACTTCTTACAGACATCC 1232
      |||||
DB 20 AGACTTCTTACAGACATCC 1

RESULT 52
ABT43811/c
```

```
DB 20 AGACTTCTTACAGACATCC 1
      |||||
QY 1380 TAAGCAGTGAACACAGTAC 1399
      |||||
DB 20 TAAGCAGTGAACACAGTAC 1

RESULT 51
ABT43791/c
ID ABR43791 standard; DNA; 20 BP.
XX
AC ABR43791;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID43.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
WPI; 2003-627257/59.
XX
New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX
Claim 3; Page 82; 117pp; English.
XX
This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
Sequence 20 BP; 3 A; 4 C; 4 G; 9 T; 0 U; 0 Other;

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 TAAGCAGTGAACACAGTAC 1399
      |||||
DB 20 TAAGCAGTGAACACAGTAC 1

RESULT 52
ABT43811/c
```

```
ID AC ABT43811 standard; DNA; 20 BP.
XX AC ABT43811;
XX DT 16-OCT-2003 (first entry)
XX DE Human PIP5K1a antisense oligonucleotide Seq ID63.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX KW 2'-MOE wing; phosphorothioate backbone; ss.
XX OS Homo sapiens.
XX PN WO2003050309-A1.
XX PD 19-JUN-2003.
XX PF 04-DEC-2002; 2002WO-US038615.
XX PR 06-DEC-2001; 2001US-00003354.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Freier SM;
XX DR WPI; 2003-627257/59.
XX PT New antisense compound useful for treating diseases such as
XX PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX PS Claim 3; Page 83; 117pp; English.
XX CC This invention relates to the novel antisense compounds, particularly
XX CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
XX CC the invention may have antiinflammatory, antitumour or cytostatic
XX CC activities through use in a gene therapy method. As a result the
XX CC having a disease associated with PIP5K1a such as a hyperproliferative or
XX CC inflammatory disorder through inhibition of PIP5K1a expression. The
XX CC oligonucleotides of the invention may also be used prophylactically to
XX CC prevent or delay infection, inflammation or tumour formation. They may
XX CC also be useful for diagnostics, therapeutics, prevention, as research
XX CC reagents and kits or for distinguishing functions of various members of a
XX CC biological pathway. The present sequence is that of an antisense
XX CC oligonucleotide of the invention. The oligonucleotide is a chimeric
XX CC phosphorothioate oligonucleotide which has five nucleotide 2'-
XX CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX CC The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2039 TTCACCCATTAAAGGCGCAAG 2058
DB 20 TTCACCCATTAAAGGCGCAAG 1
RESULT 53
ABT43818/c
ID ABT43818 standard; DNA; 20 BP.
XX AC ABT43818;
XX DT 16-OCT-2003 (first entry)
XX KW Human PIP5K1a antisense oligonucleotide Seq ID37.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
```

```
DE Human PIP5K1a antisense oligonucleotide Seq ID70.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX KW 2'-MOE wing; phosphorothioate backbone; ss.
XX OS Homo sapiens.
XX PN WO2003050309-A1.
XX PD 19-JUN-2003.
XX PF 04-DEC-2002; 2002WO-US038615.
XX PR 06-DEC-2001; 2001US-00003354.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Freier SM;
XX DR WPI; 2003-627257/59.
XX PT New antisense compound useful for treating diseases such as
XX PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX PS Claim 3; Page 83; 117pp; English.
XX CC This invention relates to the novel antisense compounds, particularly
XX CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
XX CC the invention may have antiinflammatory, antitumour or cytostatic
XX CC activities through use in a gene therapy method. As a result the
XX CC having a disease associated with PIP5K1a such as a hyperproliferative or
XX CC inflammatory disorder through inhibition of PIP5K1a expression. The
XX CC oligonucleotides of the invention may also be used prophylactically to
XX CC prevent or delay infection, inflammation or tumour formation. They may
XX CC also be useful for diagnostics, therapeutics, prevention, as research
XX CC reagents and kits or for distinguishing functions of various members of a
XX CC biological pathway. The present sequence is that of an antisense
XX CC oligonucleotide of the invention. The oligonucleotide is a chimeric
XX CC phosphorothioate oligonucleotide which has five nucleotide 2'-
XX CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX CC The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2365 TTCATGCTGGAATGGGATT 2384
DB 20 TTCATGCTGGAATGGGATT 1
RESULT 54
ABT43785/c
ID ABT43785 standard; DNA; 20 BP.
XX AC ABT43785;
XX DT 16-OCT-2003 (first entry)
XX DE Human PIP5K1a antisense oligonucleotide Seq ID37.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
```


KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX Homo sapiens.
 OS WO2003050309-A1.
 XX 19-JUN-2003.
 PD 04-DEC-2002; 2002WO-US038615.
 XX 06-DEC-2001; 2001US-00003354.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Freier SM;
 PI WPI; 2003-627257/59.
 DR New antisense compound useful for treating diseases such as
 XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX Claim 3; Page 82; 117pp; English.
 XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIPK5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX Sequence 20 BP; 5 A; 2 C; 5 G; 8 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1205 AAAGACCTAGACTTCTTACA 1224
 DB |||||||||||||||||||
 20 AAAGACCTAGACTTCTTACA 1
 RESULT 55
 ABT43826/c
 ID ABT43826 standard; DNA; 20 BP.
 XX AC ABT43826;
 XX 16-OCT-2003 (first entry)
 DT Human PIP5K1a antisense oligonucleotide Seq ID78.
 DE Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
 XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX Homo sapiens.
 OS WO2003050309-A1.
 XX 19-JUN-2003.
 PD 04-DEC-2002; 2002WO-US038615.
 XX 06-DEC-2001; 2001US-00003354.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Freier SM;
 PI WPI; 2003-627257/59.
 DR New antisense compound useful for treating diseases such as
 XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX Claim 3; Page 82; 117pp; English.
 XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIPK5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX Sequence 20 BP; 5 A; 2 C; 5 G; 8 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PD 19-JUN-2003.
 XX 04-DEC-2002; 2002WO-US038615.
 XX 06-DEC-2001; 2001US-00003354.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Freier SM;
 PI WPI; 2003-627257/59.
 DR New antisense compound useful for treating diseases such as
 XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX Claim 3; Page 83; 117pp; English.
 XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIPK5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3192 TCTTCATGCAGGGAAGTTGG 3211
 DB |||||||||||||||||||
 20 TCTTCATGCAGGGAAGTTGG 1
 RESULT 56
 ABT43827/c
 ID ABT43827 standard; DNA; 20 BP.
 XX AC ABT43827;
 XX 16-OCT-2003 (first entry)
 DT Human PIP5K1a antisense oligonucleotide Seq ID79.
 DE Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
 XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX Homo sapiens.
 OS WO2003050309-A1.
 XX 19-JUN-2003.
 PD 04-DEC-2002; 2002WO-US038615.
 XX 06-DEC-2001; 2001US-00003354.

PA (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Freier SM;
 XX WPI; 2003-627257/59.
 XX
 PT New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Claim 3; Page 83; 117pp; English.
 XX
 CC This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5Kia) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5Kia such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5Kia expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 7 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3242 CGTCTACAAGAGTTGTGTT 3261
 DB 20 CGTCTACAAGAGTTGTGTT 1
 RESULT 57
 ABT43777/c
 ID ABT43777 standard; DNA; 20 BP.
 AC ABT43777;
 XX
 XX 16-OCT-2003 (first entry)
 DT Human PIP5Kia antisense oligonucleotide Seq ID29.
 DE
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5KiaIalpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2003050309-A1.
 PN 19-JUN-2003.
 XX
 XX 04-DEC-2002; 2002WO-US038615.
 PF 06-DEC-2001; 2001US-00003354.
 PR (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Freier SM;
 XX WPI; 2003-627257/59.
 XX
 PT New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Claim 3; Page 82; 117pp; English.
 XX
 CC This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5Kia) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5Kia such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5Kia expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 7 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3242 CGTCTACAAGAGTTGTGTT 3261
 DB 20 CGTCTACAAGAGTTGTGTT 1
 RESULT 57
 ABT43777/c
 ID ABT43777 standard; DNA; 20 BP.
 AC ABT43777;
 XX
 XX 16-OCT-2003 (first entry)
 DT Human PIP5Kia antisense oligonucleotide Seq ID29.
 DE
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5KiaIalpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2003050309-A1.
 PN 19-JUN-2003.
 XX
 XX 04-DEC-2002; 2002WO-US038615.
 PF 06-DEC-2001; 2001US-00003354.
 PR (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Freier SM;
 XX WPI; 2003-627257/59.
 XX

PT New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Claim 3; Page 82; 117pp; English.
 XX
 CC This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5Kia) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5Kia such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5Kia expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 807 ACTTCGGGAGCTATTGTT 826
 DB 20 ACTTCGGGAGCTATTGTT 1
 RESULT 58
 ABT43805/c
 ID ABT43805 standard; DNA; 20 BP.
 XX ABT43805;
 AC ABT43805;
 XX
 XX 16-OCT-2003 (first entry)
 DT Human PIP5Kia antisense oligonucleotide Seq ID57.
 DE
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5KiaIalpha;
 KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2003050309-A1.
 PN 19-JUN-2003.
 XX
 XX 04-DEC-2002; 2002WO-US038615.
 PF 06-DEC-2001; 2001US-00003354.
 PR (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Freier SM;
 XX WPI; 2003-627257/59.
 XX
 PT New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 XX
 PS Claim 3; Page 82; 117pp; English.
 XX

CC This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1914 CTTTGGAGGAATCAGTGAG 1933
 DB 20 CTTTGGAGGAATCAGTGAG 1
 |||||
 RESULT 59
 ABT43813/c
 ID ABT43813 standard; DNA; 20 BP.
 AC ABT43813;
 XX
 XX Human PIP5K1a antisense oligonucleotide Seq ID65.
 DT 16-OCT-2003 (first entry)
 DE Human PIP5K1a antisense oligonucleotide Seq ID65.
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
 XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2003050309-A1.
 PN
 XX 19-JUN-2003.
 PD
 XX 04-DEC-2002; 2002WO-US038615.
 PF
 XX 06-DEC-2001; 2001US-00003354.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Freier SM;
 PI
 XX WPI; 2003-627257/59.
 DR
 XX
 XX New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 PS Example 15; Page 83; 117pp; English.
 XX
 XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a
 CC biological pathway. The present sequence is that of an antisense
 CC oligonucleotide of the invention. The oligonucleotide is a chimeric
 CC phosphorothioate oligonucleotide which has five nucleotide 2'-
 CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
 CC The oligonucleotide backbone is phosphorothioate throughout
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2063 AGAAGACCTGGACACAGATT 2082
 DB 20 AGAAGACCTGGACACAGATT 1
 |||||
 RESULT 60
 ABT43767/c
 ID ABT43767 standard; DNA; 20 BP.
 XX ABT43767;
 AC ABT43767;
 XX
 DT 16-OCT-2003 (first entry)
 DE Human PIP5K1a antisense oligonucleotide Seq ID19.
 XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
 XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
 KW antisense oligonucleotide; hyperproliferative disorder;
 KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
 KW 2'-MOE wing; phosphorothioate backbone; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2003050309-A1.
 PN
 XX 19-JUN-2003.
 PD
 XX 04-DEC-2002; 2002WO-US038615.
 PF
 XX 06-DEC-2001; 2001US-00003354.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Freier SM;
 PI
 XX WPI; 2003-627257/59.
 DR
 XX
 XX New antisense compound useful for treating diseases such as
 PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
 PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
 PS Example 15; Page 82; 117pp; English.
 XX
 XX This invention relates to the novel antisense compounds, particularly
 CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
 CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
 CC the invention may have antiinflammatory, antitumour or cytostatic
 CC activities through use in a gene therapy method. As a result the
 CC antisense oligonucleotides may be of use for the treatment of an animal
 CC having a disease associated with PIP5K1a such as a hyperproliferative or
 CC inflammatory disorder through inhibition of PIP5K1a expression. The
 CC oligonucleotides of the invention may also be used prophylactically to
 CC prevent or delay infection, inflammation or tumour formation. They may
 CC also be useful for diagnostics, therapeutics, prevention, as research
 CC reagents and kits or for distinguishing functions of various members of a

CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 500 AGACCCATGGCATCTGAGGT 519
DB 20 AGACCCATGGCATCTGAGGT 1
|||||

RESULT 61
ABT43776/C
ID ABT43776 standard; DNA; 20 BP.
XX
AC ABT43776;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID28.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
PS WPI; 2003-627257/59.
XX
PT New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Claim 3; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 780 AGACCTATGCACCTGTTGCC 799
DB 20 AGACCTATGCACCTGTTGCC 1
|||||

RESULT 62
ABT43799/C
ID ABT43799 standard; DNA; 20 BP.
XX
AC ABT43799;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID51.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
PS WPI; 2003-627257/59.
XX
PT New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Claim 3; Page 82; 117pp; English.
XX
CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 8 A; 4 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OY 1755 CTGGCTCATCTTCTCTCGG 1774
DB |||||||||||||||||||
20 CTGGCTCATCTTCTCTCGG 1

RESULT 63
ID ABT43820/c
XX ABT43820 standard; DNA; 20 BP.
AC ABT43820;
XX
XX
XX 16-OCT-2003 (first entry)
XX
XX Human PIP5K1a antisense oligonucleotide Seq ID72.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
XX
XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antiinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense
XX oligonucleotide of the invention. The oligonucleotide is a chimeric
XX phosphorothioate oligonucleotide which has five nucleotide 2'-
XX methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 31;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 2424 GGAACCGGACTCTTAATTC 2443
DB |||||||||||||||||||
20 GGAACCGGACTCTTAATTC 1

RESULT 64
```

```
ABT43796/c
ID ABT43796 standard; DNA; 20 BP.
XX
XX
XX ABT43796;
XX
XX 16-OCT-2003 (first entry)
XX
XX Human PIP5K1a antisense oligonucleotide Seq ID48.
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
XX
XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 82; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
XX antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
XX phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
XX the invention may have antiinflammatory, antitumour or cytostatic
XX activities through use in a gene therapy method. As a result the
XX antisense oligonucleotides may be of use for the treatment of an animal
XX having a disease associated with PIP5K1a such as a hyperproliferative or
XX inflammatory disorder through inhibition of PIP5K1a expression. The
XX oligonucleotides of the invention may also be used prophylactically to
XX prevent or delay infection, inflammation or tumour formation. They may
XX also be useful for diagnostics, therapeutics, prevention, as research
XX reagents and kits or for distinguishing functions of various members of a
XX biological pathway. The present sequence is that of an antisense
XX oligonucleotide of the invention. The oligonucleotide is a chimeric
XX phosphorothioate oligonucleotide which has five nucleotide 2'-
XX methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 31;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1580 CAGTCTTACAGTTTGTAA 1599
DB |||||||||||||||||||
20 CAGTCTTACAGTTTGTAA 1

RESULT 65
ID ABT43816/c
XX ABT43816 standard; DNA; 20 BP.
XX
XX ABT43816;
XX
XX 16-OCT-2003 (first entry)
```

XX DE Human PIP5K1a antisense oligonucleotide Seq ID68.

XX KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO2003050309-A1.

XX PD 19-JUN-2003.

XX PF 04-DEC-2002; 2002WO-US038615.

XX PR 06-DEC-2001; 2001US-00003354.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Freier SM;

XX DR WPI; 2003-627257/59.

XX PT New antisense compound useful for treating diseases such as

XX PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX PS Example 15; Page 83; 117pp; English.

XX CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout

XX SQ Sequence 20 BP; 8 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2220 CTCCTTCCTCTCCATCA 2239

DB 20 CTCCTTCCTCTCCATCA 1

RESULT 66

ABT43825/c

ID ABT43825 standard; DNA; 20 BP.

XX AC ABT43825;

XX DT 16-OCT-2003 (first entry)

DE Human PIP5K1a antisense oligonucleotide Seq ID77.

XX KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;

KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO2003050309-A1.

XX PD 19-JUN-2003.

XX PF 04-DEC-2002; 2002WO-US038615.

XX PR 06-DEC-2001; 2001US-00003354.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Freier SM;

XX DR WPI; 2003-627257/59.

XX PT New antisense compound useful for treating diseases such as
XX PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX PS Claim 3; Page 83; 117pp; English.

XX CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout

XX SQ Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3160 GTCATTGCTGTCATATGT 3179

DB 20 GTCATTGCTGTCATATGT 1

RESULT 67

ABT43829/c

ID ABT43829 standard; DNA; 20 BP.

XX AC ABT43829;

XX DT 16-OCT-2003 (first entry)

DE Human PIP5K1a antisense oligonucleotide Seq ID81.

XX KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
XX KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX KW antisense oligonucleotide; hyperproliferative disorder;
XX KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX KW 2'-MOE wing; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO2003050309-A1.

```

XX 19-JUN-2003.
PD
XX
XX 04-DEC-2002; 2002WO-US038615.
PF
XX
XX 06-DEC-2001; 2001US-00003354.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Bennett CF, Freier SM;
PI
XX
XX WPI; 2003-627257/59.
DR
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Example 15; Page 83; 117pp; English.
PS
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 9 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3317 CAGATTGTTGAATTCCTGTT 3336
DB 20 CAGATTGTTGAATTCCTGTT 1
|||||
RESULT 69
ABT43765/c
ID ABT43765 standard; DNA; 20 BP.
XX
XX ABT43765;
AC
XX
XX 16-OCT-2003 (first entry)
DT
XX
XX Human PIP5Kia antisense oligonucleotide Seq ID17.
DE
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIPSKialpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2003050309-A1.
PN
XX
XX 19-JUN-2003.
PD
XX
XX 04-DEC-2002; 2002WO-US038615.
PF
XX
XX 06-DEC-2001; 2001US-00003354.
PR

```

```

XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Bennett CF, Freier SM;
PI
XX
XX WPI; 2003-627257/59.
DR
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 82; 117pp; English.
PS
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 7 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 458 GCGGTCCCTTCCTGTACCTT 477
DB 20 GCGGTCCCTTCCTGTACCTT 1
|||||
RESULT 69
ABT43769/c
ID ABT43769 standard; DNA; 20 BP.
XX
XX ABT43769;
AC
XX
XX 16-OCT-2003 (first entry)
DT
XX
XX Human PIP5Kia antisense oligonucleotide Seq ID21.
DE
XX
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIPSKialpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2003050309-A1.
PN
XX
XX 19-JUN-2003.
PD
XX
XX 04-DEC-2002; 2002WO-US038615.
PF
XX
XX 06-DEC-2001; 2001US-00003354.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Bennett CF, Freier SM;
PI
XX
XX WPI; 2003-627257/59.
DR

```

XX PT New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX PS Claim 3; Page 82; 117pp; English.
XX CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX CC The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 526 TGCCTCTGGCATGCCCATCA 545
DB 20 TGCCTCTGGCATGCCCATCA 1
RESULT 70
ABT43779/c
ID ABT43779 standard; DNA; 20 BP.
AC ABT43779;
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID31.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX OS Homo sapiens.
XX WO2003050309-A1.
XX 19-JUN-2003.
XX 04-DEC-2002; 2002WO-US038615.
XX 06-DEC-2001; 2001US-00003354.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX Claim 3; Page 82; 117pp; English.

XX CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX CC The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 955 TAAAGAGGCGGAATTTCTGC 974
DB 20 TAAAGAGGCGGAATTTCTGC 1
RESULT 71
ABT43781/c
ID ABT43781 standard; DNA; 20 BP.
XX AC ABT43781;
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID33.
XX KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha;
XX antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
XX antisense oligonucleotide; hyperproliferative disorder;
XX inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX OS Homo sapiens.
XX WO2003050309-A1.
XX 19-JUN-2003.
XX 04-DEC-2002; 2002WO-US038615.
XX 06-DEC-2001; 2001US-00003354.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX New antisense compound useful for treating diseases such as
XX hyperproliferative or inflammatory disorders, hybridizes and inhibits
XX nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX Claim 3; Page 82; 117pp; English.
XX CC This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX CC The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 955 TAAAGAGGCGGAATTTCTGC 974
DB 20 TAAAGAGGCGGAATTTCTGC 1

antisense oligonucleotides may be of use for the treatment of an animal having a disease associated with PIP5K1a such as a hyperproliferative or inflammatory disorder through inhibition of PIP5K1a expression. The oligonucleotides of the invention may also be used prophylactically to prevent or delay infection, inflammation or tumour formation. They may also be useful for diagnostics, therapeutics, prevention, as research reagents and kits or for distinguishing functions of various members of a biological pathway. The present sequence is that of an antisense oligonucleotide of the invention. The oligonucleotide is a chimeric phosphorothioate oligonucleotide which has five nucleotide 2'-methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap. The oligonucleotide backbone is phosphorothioate throughout

Sequence 20 BP; 2 A; 2 C; 8 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 997 CATGAACCTCAACCAACC 1016
DB 20 CATGAACCTCAACCAACC 1

RESULT 72
ABT43789/c
ID ABT43789 standard; DNA; 20 BP.
XX AC ABT43789;
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID41.
XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX Homo sapiens.
XX WO2003050309-A1.
XX 19-JUN-2003.
XX 04-DEC-2002; 2002WO-US038615.
XX 06-DEC-2001; 2001US-00003354.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX Claim 3; Page 82; 117pp; English.
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research

reagents and kits or for distinguishing functions of various members of a biological pathway. The present sequence is that of an antisense oligonucleotide of the invention. The oligonucleotide is a chimeric phosphorothioate oligonucleotide which has five nucleotide 2'-methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap. The oligonucleotide backbone is phosphorothioate throughout

Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1321 AATGATTACAGCCTCTTGA 1340
DB 20 AATGATTACAGCCTCTTGA 1

RESULT 73
ABT43790/c
ID ABT43790 standard; DNA; 20 BP.
XX AC ABT43790;
XX 16-OCT-2003 (first entry)
XX Human PIP5K1a antisense oligonucleotide Seq ID42.
XX Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX Homo sapiens.
XX WO2003050309-A1.
XX 19-JUN-2003.
XX 04-DEC-2002; 2002WO-US038615.
XX 06-DEC-2001; 2001US-00003354.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
XX Claim 3; Page 82; 117pp; English.
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC The oligonucleotide backbone is phosphorothioate throughout

```
XX SQ Sequence 20 BP; 4 A; 4 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1354 TATAGATCATGCACACGAG 1373
Db 20 TATAGATCATGCACACGAG 1

RESULT 74
ABT43800/c
ID ABT43800 standard; DNA; 20 BP.
XX
AC ABT43800;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID52.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
DR WPI; 2003-627257/59.
XX
New antisense compound useful for treating diseases such as
hyperproliferative or inflammatory disorders, hybridizes and inhibits
nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
Claim 3; Page 82; 117pp; English.
XX
This invention relates to the novel antisense compounds, particularly
antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
the invention may have antiinflammatory, antitumour or cytostatic
activities through use in a gene therapy method. As a result the
antisense oligonucleotides may be of use for the treatment of an animal
having a disease associated with PIP5K1a such as a hyperproliferative or
inflammatory disorder through inhibition of PIP5K1a expression. The
oligonucleotides of the invention may also be used prophylactically to
prevent or delay infection, inflammation or tumour formation. They may
also be useful for diagnostics, therapeutics, prevention, as research
reagents and kits or for distinguishing functions of various members of a
biological pathway. The present sequence is that of an antisense
oligonucleotide of the invention. The oligonucleotide is a chimeric
phosphorothioate oligonucleotide which has five nucleotide 2'-
methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2001 GTACACCTTGGAAAGCTT 2020
Db 20 GTACACCTTGGAAAGCTT 1

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1766 TTCTCTCGCGAGCAGGCTC 1785
Db 20 TTCTCTCGCGAGCAGGCTC 1

RESULT 75
ABT43808/c
ID ABT43808 standard; DNA; 20 BP.
XX
AC ABT43808;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID60.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
DR WPI; 2003-627257/59.
XX
New antisense compound useful for treating diseases such as
hyperproliferative or inflammatory disorders, hybridizes and inhibits
nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
Claim 3; Page 82; 117pp; English.
XX
This invention relates to the novel antisense compounds, particularly
antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
the invention may have antiinflammatory, antitumour or cytostatic
activities through use in a gene therapy method. As a result the
antisense oligonucleotides may be of use for the treatment of an animal
having a disease associated with PIP5K1a such as a hyperproliferative or
inflammatory disorder through inhibition of PIP5K1a expression. The
oligonucleotides of the invention may also be used prophylactically to
prevent or delay infection, inflammation or tumour formation. They may
also be useful for diagnostics, therapeutics, prevention, as research
reagents and kits or for distinguishing functions of various members of a
biological pathway. The present sequence is that of an antisense
oligonucleotide of the invention. The oligonucleotide is a chimeric
phosphorothioate oligonucleotide which has five nucleotide 2'-
methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
The oligonucleotide backbone is phosphorothioate throughout
XX SQ Sequence 20 BP; 5 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2001 GTACACCTTGGAAAGCTT 2020
Db 20 GTACACCTTGGAAAGCTT 1

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
RESULT 76
ABT43810/c
ID ABT43810 standard; DNA; 20 BP.
XX
AC ABT43810;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID62.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
WPI; 2003-627257/59.
XX
New antisense compound useful for treating diseases such as
hyperproliferative or inflammatory disorders, hybridizes and inhibits
nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
Claim 3; Page 83; 117pp; English.
XX
This invention relates to the novel antisense compounds, particularly
antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
the invention may have antiinflammatory, antitumour or cytostatic
activities through use in a gene therapy method. As a result the
antisense oligonucleotides may be of use for the treatment of an animal
having a disease associated with PIP5K1a such as a hyperproliferative or
inflammatory disorder through inhibition of PIP5K1a expression. The
oligonucleotides of the invention may also be used prophylactically to
prevent or delay infection, inflammation or tumour formation. They may
also be useful for diagnostics, therapeutics, prevention, as research
reagents and kits or for distinguishing functions of various members of a
biological pathway. The present sequence is that of an antisense
oligonucleotide of the invention. The oligonucleotide is a chimeric
phosphorothioate oligonucleotide which has five nucleotide 2'-
methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2026 TGCAGAGTCAGAGTTCACCC 2045
DB 20 TGCAGAGTCAGAGTTCACCC 1
RESULT 77
ABT43784/c
ID ABT43784 standard; DNA; 20 BP.
XX
AC ABT43784;
XX
```

```
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID36.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
WPI; 2003-627257/59.
XX
New antisense compound useful for treating diseases such as
hyperproliferative or inflammatory disorders, hybridizes and inhibits
nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, 1 alpha.
Claim 3; Page 82; 117pp; English.
XX
This invention relates to the novel antisense compounds, particularly
antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
phosphate 5-kinase 1alpha (PIP5K1a) expression. The oligonucleotides of
the invention may have antiinflammatory, antitumour or cytostatic
activities through use in a gene therapy method. As a result the
antisense oligonucleotides may be of use for the treatment of an animal
having a disease associated with PIP5K1a such as a hyperproliferative or
inflammatory disorder through inhibition of PIP5K1a expression. The
oligonucleotides of the invention may also be used prophylactically to
prevent or delay infection, inflammation or tumour formation. They may
also be useful for diagnostics, therapeutics, prevention, as research
reagents and kits or for distinguishing functions of various members of a
biological pathway. The present sequence is that of an antisense
oligonucleotide of the invention. The oligonucleotide is a chimeric
phosphorothioate oligonucleotide which has five nucleotide 2'-
methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
The oligonucleotide backbone is phosphorothioate throughout
XX
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1178 GAGCGAGAGAGCCCTCTTCC 1197
DB 20 GAGCGAGAGAGCCCTCTTCC 1
RESULT 78
ABT43806/c
ID ABT43806 standard; DNA; 20 BP.
XX
AC ABT43806;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5K1a antisense oligonucleotide Seq ID58.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase 1alpha; PIP5K1alpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
```

KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 82; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX Sequence 20 BP; 6 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1967 CTAGTTGGAGAGACTTTGCA 1986
DB 20 CTAGTTGGAGAGACTTTGCA 1
RESULT 79
ABT43812/c
ID ABT43812 standard; DNA; 20 BP.
XX
XX ABT43812;
XX
XX 16-OCT-2003 (first entry)
DT Human PIP5K1a antisense oligonucleotide Seq ID64.
DE
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5K1alpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS

PN WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX
XX 06-DEC-2001; 2001US-00003354.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM;
XX WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Claim 3; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpa (PIP5K1a) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIP5K1a such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIP5K1a expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
XX Sequence 20 BP; 1 A; 5 C; 6 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2050 AGCGCAAGCCTCAGAAGAC 2069
DB 20 AGCGCAAGCCTCAGAAGAC 1
RESULT 80
ABT43821/c
ID ABT43821 standard; DNA; 20 BP.
XX
XX ABT43821;
XX
XX 16-OCT-2003 (first entry)
DT Human PIP5K1a antisense oligonucleotide Seq ID73.
DE
XX Human; phosphatidylinositol-4-phosphate 5-kinase Ialpa; PIP5K1alpa;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
XX 2'-MOE wing; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS
XX WO2003050309-A1.
XX
XX 19-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038615.
XX

PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
DR WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
PS Claim 3; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpha (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
SQ Sequence 20 BP; 6 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2435 CTTAATTTCTCAGGACAGA 2454
DB 20 CTTAATTTCTCAGGACAGA 1
|||||
RESULT 81
ABT43823/c
ID ABT43823 standard; DNA; 20 BP.
XX
AC ABT43823;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5Kia antisense oligonucleotide Seq ID75.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIPSKiaIalpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
DR WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

DR WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
XX Example 15; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly
CC antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC phosphate 5-kinase Ialpha (PIPSKia) expression. The oligonucleotides of
CC the invention may have antiinflammatory, antitumour or cytostatic
CC activities through use in a gene therapy method. As a result the
CC antisense oligonucleotides may be of use for the treatment of an animal
CC having a disease associated with PIPSKia such as a hyperproliferative or
CC inflammatory disorder through inhibition of PIPSKia expression. The
CC oligonucleotides of the invention may also be used prophylactically to
CC prevent or delay infection, inflammation or tumour formation. They may
CC also be useful for diagnostics, therapeutics, prevention, as research
CC reagents and kits or for distinguishing functions of various members of a
CC biological pathway. The present sequence is that of an antisense
CC oligonucleotide of the invention. The oligonucleotide is a chimeric
CC phosphorothioate oligonucleotide which has five nucleotide 2'-
CC methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
XX The oligonucleotide backbone is phosphorothioate throughout
SQ Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3119 CTTAAACTCATGGGAGACA 3138
DB 20 CTTAAACTCATGGGAGACA 1
|||||
RESULT 82
ABT43831/c
ID ABT43831 standard; DNA; 20 BP.
XX
AC ABT43831;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human PIP5Kia antisense oligonucleotide Seq ID83.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIPSKiaIalpha;
KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
DR WPI; 2003-627257/59.
XX
XX New antisense compound useful for treating diseases such as
PT hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

Claim 3; Page 83; 117pp; English.

This invention relates to the novel antisense compounds, particularly antisense oligonucleotides, for the modulation of phosphatidylinositol-4-phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of the invention may have antiinflammatory, antitumour or cytostatic activities through use in a gene therapy method. As a result the antisense oligonucleotides may be of use for the treatment of an animal having a disease associated with PIP5K1a such as a hyperproliferative or inflammatory disorder through inhibition of PIP5K1a expression. The oligonucleotides of the invention may also be used prophylactically to prevent or delay infection, inflammation or tumour formation. They may also be useful for diagnostics, therapeutics, prevention, as research reagents and kits or for distinguishing functions of various members of a biological pathway. The present sequence is that of an antisense oligonucleotide of the invention. The oligonucleotide is a chimeric phosphorothioate oligonucleotide which has five nucleotide 2'-methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap. The oligonucleotide backbone is phosphorothioate throughout

Sequence 20 BP; 8 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3363 TTGATAATATGTTAGCCCAT 3382
DB 20 TTGATAATATGTTAGCCCAT 1

RESULT 83
ABT43834/c
ID ABT43834 standard; DNA; 20 BP.
XX
AC ABT43834;
XX
DT 16-OCT-2003 (first entry)
DE Human PIP5K1a antisense oligonucleotide Seq ID86.
XX
KW Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5K1alpha; antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW antisense oligonucleotide; hyperproliferative disorder;
KW inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW 2'-MOE wing; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX
PN WO2003050309-A1.
XX
PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038615.
XX
PR 06-DEC-2001; 2001US-00003354.
XX
PA (ISIS-). ISIS PHARM INC.
XX
PI Bennett CF, Freier SM;
XX
XX WPI; 2003-627257/59.
XX
PT New antisense compound useful for treating diseases such as hyperproliferative or inflammatory disorders, hybridizes and inhibits nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS Example 15; Page 83; 117pp; English.
XX
XX This invention relates to the novel antisense compounds, particularly antisense oligonucleotides, for the modulation of phosphatidylinositol-4-phosphate 5-kinase Ialpha (PIP5K1a) expression. The oligonucleotides of the invention may have antiinflammatory, antitumour or cytostatic

activities through use in a gene therapy method. As a result the antisense oligonucleotides may be of use for the treatment of an animal having a disease associated with PIP5K1a such as a hyperproliferative or inflammatory disorder through inhibition of PIP5K1a expression. The oligonucleotides of the invention may also be used prophylactically to prevent or delay infection, inflammation or tumour formation. They may also be useful for diagnostics, therapeutics, prevention, as research reagents and kits or for distinguishing functions of various members of a biological pathway. The present sequence is that of an antisense oligonucleotide of the invention. The oligonucleotide is a chimeric phosphorothioate oligonucleotide which has five nucleotide 2'-methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap. The oligonucleotide backbone is phosphorothioate throughout

Sequence 20 BP; 9 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3631 CTACTTTGTATTGTTTCAGAA 3650
DB 20 CTACTTTGTATTGTTTCAGAA 1

RESULT 84
ACK09575/c
ID ACK09575 standard; DNA; 25 BP.
XX
AC ACK09575;
XX
DT 14-OCT-2003 (first entry)
XX
DE Human microarray DNA oligonucleotide SEQ ID NO 109556.
XX
KW EST; ss; probe; expressed sequence tag; microarray; gene expression; genetic variation; biallelic marker; polymorphism; human; cross-species comparison.
XX
OS Homo sapiens.
XX
PN US2003104410-A1.
XX
PD 05-JUN-2003.
XX
PF 15-MAR-2002; 2002US-00098263.
XX
PR 16-MAR-2001; 2001US-0276759P.
XX
PA (AFFY-) AFFYMETRIX INC.
XX
PI Mittmann MP;
XX
XX WPI; 2003-567953/53.
XX
PT New array of nucleic acid probes, useful for in situ hybridization, in Southern, Northern or dot-blot hybridization to identify or detect the sequence or specific mutations of any gene.
XX
PS Claim 1; SEQ ID NO 109556; 9pp; English.
XX
XX The invention discloses a microarray comprising a plurality of nucleic acid probes including one of 2,018,500 fully defined sequences, or its perfect match, perfect mismatch, antisense match or antisense mismatch. Also disclosed is a method of gene expression analysis. The array is used in monitoring gene expression levels by hybridisation to a DNA library, in analysis of genetic variation or in hybridisation of tag-labelled compounds. The nucleic acid probes are specifically designed for analysis of at least one target sequence. The method of analysis comprises hybridising at least one or more nucleic acids to at least two or more nucleic acid probes and detecting the hybridisation. The nucleic acid probes are attached to a solid support. The analysis comprises monitoring gene expression levels, identifying biallelic markers or polymorphisms,

or family members of a gene and a cross-species comparison. Each of the nucleic acids further comprises a tag sequence. The array of nucleic acid probes is useful in situ hybridisation, in Southern, Northern or dot-blot hybridisation to identify or detect the sequence or specific mutations of any gene, in mapping the 5' termini of mRNA molecules by primer extensions or in screening cDNA or genomic libraries or subclones for additional subclones containing segments of DNA that have been isolated and previously sequenced. The sequence presented is one of the nucleic acid probes incorporated in the microarray. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

Sequence 25 BP; 8 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 51;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 415 CTCGGCGCGCTGCTCTCGGTGC 437

DB 24 CTCGGCCAGTCGTCTTCGGTGC 2

RESULT 85

ABL56411
ID ABL56411 standard; DNA; 24 BP.

XX AC ABL56411;

XX 22-JUL-2002 (first entry)

XX PCR primer F used to detect mutation N1303K causing cystic fibrosis.

XX Mutation; solid phase amplification; haemochromatosis; cancer;
KW sickle-cell anaemia; beta-thalassemia; alpha-thalassemia; polymorphism;
KW cystic fibrosis; haemophilia; neurodegeneration; PCR; primer; ss.

XX Homo sapiens.

OS WO200212557-A1.

PN 14-FEB-2002.

PD 08-AUG-2001; 2001WO-FR002574.

PF 08-AUG-2000; 2000FR-00010425.

XX (NUCL-) NUCLEICA.

XX Cailloux F, Gobron S;

XX WPI; 2002-269096/31.

XX Detecting mutations in nucleic acid, useful e.g. for diagnosing
PT hemochromatosis, by solid phase amplification to incorporate exonuclease
PT resistant nucleotide.

XX Example 3; Fig 3; 43pp; French.

XX PCR primers ABL56411-12 and probe ABL56413 were used to detect a mutation
XX responsible for cystic fibrosis. The primers and probe are used to
XX demonstrate the method of the invention. The specification describes a
XX method for detecting a mutation at position n in a target nucleic acid by
XX solid phase amplification process. The region of interest is amplified on
XX at least two separate supports (A, B) using at least one primer linked,
XX at its 5'-end, to the supports. The DNA strands are then separated and
XX strands in the suspension removed by washing. Bound DNA sequences are
XX hybridized to a probe, the 3'-end of which hybridizes up to, at most,
XX position n-1. The probe is elongated by adding complementary nucleotides
XX in the 5' to 3' direction, using a DNA polymerase and a nucleotide
XX derivative (dNTP*) that is resistant to exonuclease. The dNTP* used is
XX complementary to the mutation for support A but to the wild type for
XX support B. Products are digested with an exonuclease so that only probes

CC elongated by dNTP* are not degraded. The supports are then washed and non
CC degraded probes detected (in)directly. The method is used to detect
CC mutations associated with disease, especially haemochromatosis; sickle-
CC cell anaemia; alpha or beta-thalassemia; cystic fibrosis; haemophilia;
CC neurodegeneration and cancer. The method is also used to study
CC polymorphisms of gene or an entire genetic region and for detecting
CC and/or identifying genetically modified organisms

XX Sequence 24 BP; 0 A; 6 C; 1 G; 17 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 57;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2566 CTTTCTCTCTCTTTTCTTTT 2586

DB 1 CTTTCTCTCTCTTTTCTTTT 21

RESULT 86

AAH44623
ID AAH44623 standard; DNA; 24 BP.

XX AC AAH44623;

XX 16-NOV-2001 (first entry)

XX Human FD 17 PCR primer 2 SEQ ID NO:4.

XX Human; FD 17; cytostatic; virucidal; immunomodulatory; haemostatic;
KW antiinflammatory; gene therapy; malignant tumour; haemopathy;
KW human immunodeficiency virus infection; HIV infection;
KW immunological disease; inflammation; PCR primer; ss.

XX Homo sapiens.

XX WO200164729-A1.

XX 07-SEP-2001.

XX 26-FEB-2001; 2001WO-CN000221.

XX 02-MAR-2000; 2000CN-0011868.

XX (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.

XX Mao Y, Xie Y;

XX WPI; 2001-550164/61.

XX New human polypeptide PD 17 for diagnosing and treating malignant tumor,
PT hemopathy, human immunodeficiency virus (HIV) infection, immunological
PT diseases and inflammations.

XX Example 2; Page 11; 36pp; Chinese.

XX The present invention describes the human PD 17 protein (I). (I) has
XX cytostatic, virucidal, immunomodulatory, antiinflammatory and haemostatic
XX activities. The polynucleotide encoding (I) can be used in gene therapy.
XX (I) and the polynucleotide encoding it are applicable in the diagnosis
XX and treatment of malignant tumour, haemopathy, human immunodeficiency
XX virus (HIV) infection, immunological diseases and various inflammations.
XX The present sequence represents a PCR primer for human PD 17, which is
XX used in an example from the present invention

XX Sequence 24 BP; 0 A; 2 C; 1 G; 21 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.8; DB 1; Length 24;

Best Local Similarity 90.9%; Pred. No. 73;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTTTTCTTTTCT 2588

||||| ||||||| |||||

```
Db 1 TTTCTTTTCTTTTTTTTTTTTT 22

RESULT 87
AAH91823
ID AAH91823 standard; DNA; 23 BP.
XX
XX AC AAH91823;
XX
XX DT 09-OCT-2001 (first entry)
XX
XX DE Human inflammatory bowel disease associated polymorphic site #898.
XX
XX KW Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
XX single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
XX chromosome 5q31-33; forensic test; gene therapy; ds.
XX
XX OS Homo sapiens.
XX
XX FH Key Location/Qualifiers
XX misc_feature 11
XX /*tag= a
XX /*note= "SNP, optionally T or A at this position"
XX
XX PN WO200142511-A2.
XX
XX PD 14-JUN-2001.
XX
XX PF 11-DEC-2000; 2000WO-US033632.
XX
XX PR 10-DEC-1999; 99US-0170257P.
XX
XX PR 10-APR-2000; 2000US-0196046P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX (ELLI-) ELLIPSIS BIOTHERAPEUTICS CORP.
XX
XX PI Daly M, Hudson TJ, Lander ES, Rioux J, Siminovitch K;
XX
XX WPI; 2001-367874/38.
XX
XX Testing for the presence of polymorphisms associated with inflammatory
XX bowel disease, using a hybridization assay.
XX
XX Claim 1; Page 76; 463pp; English.
XX
XX The present invention describes a method for detecting the presence of
XX polymorphisms associated with inflammatory bowel diseases such as
XX ulcerative colitis and Crohn's disease. The methods can be used to detect
XX the presence of genetic polymorphisms associated with inflammatory bowel
XX disease and correlating their occurrence with disease states. They may be
XX used in this way for phenotypic correlations, forensics, paternity
XX testing, medicine and genetic analysis. The present sequence is a
XX polymorphic site described in the exemplification of the invention
XX
XX Sequence 23 BP; 0 A; 4 C; 0 G; 18 T; 0 U; 1 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2568 TTCTTCTTCTTTTTTTTTTCT 2588
Db 2 TTCTTCTTCTTTTTTTTTTTT 22

RESULT 88
ADP71410
ID ADP71410 standard; DNA; 24 BP.
XX
XX AC ADP71410;
XX
XX DT 12-AUG-2004 (first entry)
XX
```

```
DE
XX
KW Giardia intestinalis detection-related PCR primer SeqID20.
KW pathogenic microbe detection; microbe pathogenicity; total coliform;
KW toxigenic; microbial sample; drinking water; sewage; waste water;
KW treated water; disinfected water; irrigation water; well water;
KW river water; lake water; recreational water; swimming pool; food; fruit;
KW vegetable; meat; slaughter line; meat surface; environmental surface;
KW slaughter house; meat preparation facility; soil; clinical sample;
KW veterinary sample; stool; biopsy; PCR; primer; ss.
XX
XX Giardia intestinalis.
XX
XX CA24448098-A1.
XX
XX 26-MAY-2004.
XX
XX 26-NOV-2003; 2003CA-02448098.
XX
XX 26-NOV-2002; 2002US-0428914P.
XX
XX (GUYR/) GUY R A.
XX (HORG/) HORGEN P A.
XX (TAMI/) TAM I V.
XX
XX Guy RA, Horgen PA, Tam IV;
XX
XX WPI; 2004-488366/47.
XX
XX Detecting pathogenic microbe e.g., Escherichia coli in environmental and
XX clinical specimens, by amplifying DNA by PCR using primers that produce
XX detectable amplicon from pathogenicity gene of microbe and measuring
XX amplicon.
XX
XX Claim 17; SEQ ID NO 20; 65pp; English.
XX
XX This invention relates to a novel method of detecting a pathogenic
XX microbe, which involves subjecting DNA extracted from microbe or its
XX equivalent cDNA, to PCR comprising primers adapted to produce a
XX detectable amplicon from a gene responsible for the pathogenicity of the
XX microbe and measuring in real time the accumulation of amplicon during
XX reaction. The invention is useful for detecting pathogenic microbes such
XX as total coliforms, E coli, E coli O157:H7, toxigenic, M aeruginosa, G
XX lamblia and C parvum. The invention is useful for analysis of a wide
XX array of microbial samples such as finished drinking water, sewage, waste
XX water, treated water, disinfected water, irrigation water, and water
XX obtained from wells, rivers, lakes and recreational waters such as
XX swimming pools. The method is also useful for analysing food (fruits,
XX vegetables, meat and prepared food items), swabs taken from slaughter
XX lines, and meat surface, as well as swabs taken from environmental
XX surfaces such as slaughter houses, and meat preparation facilities, soil
XX and clinical and veterinary sample including stool and biopsy samples.
XX The invention allows rapid, sensitive and selective detection, in real
XX time, of a variety of pathogenic microbes in both environmental and
XX clinical specimens. The present sequence is that of a PCR primer which
XX may be used in the method of the invention.
XX
XX Sequence 24 BP; 4 A; 8 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 95;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2182 AGCTGCTCTCCCATCTTCTTCT 2204
Db 1 AGCTGGTCATACATCTTCTTCT 23

RESULT 89
ADP71404
ID ADP71404 standard; DNA; 24 BP.
XX
XX AC ADP71404;
```



```
DT 12-AUG-2004 (first entry)
XX Giardia intestinalis detection-related PCR primer SeqID14.
DE pathogenic microbe detection; microbe pathogenicity; total coliform;
XX toxigenic; microbial sample; drinking water; sewage; waste water;
KW treated water; disinfected water; irrigation water; well water;
KW river water; lake water; recreational water; swimming pool; food; fruit;
KW vegetable; meat; slaughter line; meat surface; environmental surface;
KW slaughter house; meat preparation facility; soil; clinical sample;
XX veterinary sample; stool; biopsy; PCR; primer; ss.
XX Giardia intestinalis.
OS
XX
XX CA2448098-A1.
XX
XX
XX 26-MAY-2004.
XX
XX 26-NOV-2003; 2003CA-02448098.
XX
XX 26-NOV-2002; 2002US-0428914P.
XX
XX (GUYR/) GUY R A.
XX (HORG/) HORG P A.
XX (TAMI/) TAM I V.
XX
XX Guy RA, Horgen PA, Tam IV;
XX
XX WPI; 2004-488366/47.
XX
XX Detecting pathogenic microbe e.g., Escherichia coli in environmental and
XX clinical specimens, by amplifying DNA by PCR using primers that produce
XX detectable amplicon from pathogenicity gene of microbe and measuring
XX amplicon.
XX
XX Claim 10; SEQ ID NO 14; 65pp; English.
XX
XX This invention relates to a novel method of detecting a pathogenic
XX microbe, which involves subjecting DNA extracted from microbe or its
XX equivalent cDNA, to PCR comprising primers adapted to produce a
XX detectable amplicon from a gene responsible for the pathogenicity of the
XX microbe and measuring in real time the accumulation of amplicon during
XX reaction. The invention is useful for detecting pathogenic microbes such
XX as total coliforms, E coli, E coli O157:H7, toxigenic, M aeruginosa, G
XX lamblia and C parvum. The invention is useful for analysis of a wide
XX array of microbial samples such as finished drinking water, sewage, waste
XX water, treated water, disinfected water, irrigation water, and water
XX obtained from wells, rivers, lakes and recreational waters such as
XX swimming pools. The method is also useful for analysing food (fruit,
XX vegetables, meat and prepared food items), swabs taken from slaughter
XX lines, and meat surface, as well as swabs taken from environmental
XX surfaces such as slaughter houses, and meat preparation facilities, soil
XX and clinical and veterinary sample including stool and biopsy samples.
XX The invention allows rapid, sensitive and selective detection, in real
XX time, of a variety of pathogenic microbes in both environmental and
XX clinical specimens. The present sequence is that of a PCR primer which
XX may be used in the method of the invention.
XX
XX Sequence 24 BP; 3 A; 7 C; 4 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 18.2; DB 1; Length 24;
XX Best Local Similarity 87.0%; Pred. No. 95;
XX Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 2182 AGCTGCTCCTCCATCTTCTTCT 2204
XX 1 AGCTGCTCGTACATCTTCTTCT 23
XX
XX RESULT 90
XX AA226403/c
XX ID AA226403 standard; DNA; 21 BP.
XX
```

```
AC AA226403;
XX 30-NOV-1999 (first entry)
XX Human polymorphic region 592.
XX Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
XX cell viability; loss of heterozygosity; precancerous condition; ASI;
XX allele specific inhibitor; somatic cell; diagnosis; prevention;
XX atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
XX dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
XX graft versus host disease; malignant cell removal; bone marrow; ss.
XX Homo sapiens.
XX WO9841648-A2.
XX 24-SEP-1998.
XX 19-MAR-1998; 98WO-US005419.
XX 20-MAR-1997; 97US-0041057P.
XX (VARI-) VARIAGENICS INC.
XX Housman D, Ledley PD, Stanton VP;
XX WPI, 1998-521232/44.
XX
XX Identifying target genes for allele-specific drugs - used for diagnosis,
XX prevention and treatment of, e.g. cancers, atherosclerotic plaque,
XX dysplastic lesions, endometriosis or graft versus host disease.
XX Disclosure; Fig 7; 605pp; English.
XX
XX This invention describes a novel method for identifying an inhibitor
XX potentially useful for treatment of cancer, where the inhibitor is active
XX on a gene vital for cell growth or viability, and where the gene is
XX subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is
XX used for preventing the development of cancer in a patient having a
XX precancerous condition, by administering to the patient a first allele
XX specific inhibitor (ASI) targeted to an allele of a first essential gene
XX present in cells of the precancerous condition, where the normal somatic
XX cells of the patient are heterozygous for the first gene, the inhibitor
XX is active on at least one but less than all allelic forms of the gene
XX present in a population and targets only one allelic form present in the
XX normal somatic cells, and the first gene. The products and methods can be
XX used in the diagnosis, prevention and treatment of LOH disorders, e.g.
XX cancers, atherosclerotic plaques, premalignant metaplastic or dysplastic
XX lesions, benign tumours, endometriosis, polycystic kidney disease, and
XX graft versus host disease. The method can also be used to remove
XX malignant cells from bone marrow transplants. AA225812-226825 represent
XX human polymorphic sites described in the method of the invention
XX
XX Sequence 21 BP; 12 A; 2 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 17.8; DB 1; Length 21;
XX Best Local Similarity 90.5%; Pred. No. 89;
XX Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2578 TTTTCTTTCTGAAAAAGGA 2598
XX 21 TTTTCTTTCTTAAAAAGGA 1
XX
XX RESULT 91
XX ADC66134
XX ID ADC66134 standard; DNA; 23 BP.
XX
XX ADC66134;
XX
XX 18-DEC-2003 (first entry)
XX
```

DE Human CFTR exon 21 PCR primer #1.
XX typing; variable site; cystic fibrosis; human;
KW cystic fibrosis transmembrane conductance regulator; CFTR; PCR primer;
KW ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO2003074737-A1.
DN
XX 12-SEP-2003.
XX
XX 07-MAR-2003; 2003WO-SE000394.
PF
XX 07-MAR-2002; 2002SE-00000695.
PR
XX (PYRO-) PYROSEQUENCING AB.
PA
XX Schiller A, Dunker J;
XX
XX WPI; 2003-731684/69.
DR
XX
XX Typing at least two variable sites of at least one nucleic acid molecule
PT related to cystic fibrosis by simultaneously or sequentially performing
PT primer extension reactions and determining the pattern of nucleotide
PT incorporation.
XX
XX Example 2; Page 29; 69pp; English.
FS
XX The present invention describes a method for typing at least two variable
CC sites of at least one nucleic acid molecule related to cystic fibrosis.
CC The method comprises: (a) providing at least one nucleic acid molecule of
CC a gene related to cystic fibrosis; (b) providing at least one extension
CC primer, which binds to different predetermined sites in the nucleic acid
CC molecules, where at least one extension primer is designed to extend over
CC at least two potential variable sites in the nucleic acid molecule, and
CC nucleotide; (c) simultaneously or sequentially performing primer
CC extension reactions; and (d) determining the pattern of nucleotide
CC incorporation to obtain a test pattern; optionally (e) comparing the test
CC pattern of step (c) with one or more reference patterns, in order to type
CC the variable sites of the nucleic acid molecules. Also described: (1)
CC diagnosing the genetic predisposition of states, diseases and drug
CC response related to the human cystic fibrosis transmembrane conductance
CC regulator (CFTR) gene; and (2) a kit for use in the method for typing
CC comprising at least one extension primer. The method is useful for typing
CC at least two variable sites of at least one nucleic acid molecule related
CC to cystic fibrosis. The present sequence represents a PCR primer for
CC human CFTR, which is used in the exemplification of the present
CC invention.
XX
XX Sequence 23 BP; 0 A; 5 C; 1 G; 16 T; 0 U; 1 Other;
SQ
Query Match 0.5%; Score 17.6; DB 1; Length 23;
Best Local Similarity 90.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 2567 TTTCTTCTCTCTTTTCTTTT 2586
Dd :|||||
1 BTCTCTCTCTTTCTTTT 20
RESULT 92
AAZ05607/C
ID AAZ05607 standard; DNA; 20 BP.
XX
AC AAZ05607;
XX
XX 07-OCT-1999 (first entry)
DT
XX PCR primer used to amplify an ORF of Chlamydia trachomatis.
DE
XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW

KW paratrachoma; inclusion conjunctivitis; genital disease; perithenarthritis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartholinitis; pneumonia; venereal lymphogranulomatosis; ss.
XX
OS Synthetic.
OS Chlamydia trachomatis.
XX
XX WO9928475-A2.
DN
XX 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
XX
XX 28-NOV-1997; 97FR-00015041.
PR
XX 17-DEC-1997; 97FR-00016034.
PR
XX 04-NOV-1998; 98US-0107077P.
XX
XX (GIST) GENSET.
PA
XX Griffais R;
XX
XX WPI; 1999-371125/31.
DR
XX
XX Genome sequence of Chlamydia trachomatis.
PT
XX Disclosure; Page 1784; 1755pp; English.
PS
XX PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as
CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis,
CC epididymitis, cervicitis, salpingitis, perithenarthritis, bartholinitis;
CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
XX
XX Sequence 20 BP; 4 A; 9 C; 1 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 97;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2160 GGAGTCTAATAGAGTGTAG 2178
Dd :|||||
19 GGAGTCTAATAGAGTGTAG 1
RESULT 93
ADH49249
ID ADH49249 standard; DNA; 22 BP.
XX
AC ADH49249;
XX
XX 25-MAR-2004 (first entry)
DT
XX NOV88 PCR primer, SEQ ID 533.
DE
XX Human; NOVX; atherosclerosis; hypertension; obesity; cancer; cytostatic;
KW hypotensive; antiarteriosclerotic; anorectic; gene therapy; NOV88; PCR;
KW primer; ss.
XX
XX Homo sapiens.
OS
XX WO200268652-A2.
PN
XX 06-SEP-2002.
PD
XX 26-FEB-2002; 2002WO-US005910.
PF
XX

26-FEB-2001; 2001US-0271646P.
 PR 27-FEB-2001; 2001US-0271840P.
 PR 28-FEB-2001; 2001US-0272404P.
 PR 28-FEB-2001; 2001US-0272405P.
 PR 28-FEB-2001; 2001US-0272410P.
 PR 28-FEB-2001; 2001US-0272414P.
 PR 02-MAR-2001; 2001US-0272787P.
 PR 02-MAR-2001; 2001US-0272922P.
 PR 02-MAR-2001; 2001US-0273048P.
 PR 02-MAR-2001; 2001US-0273300P.
 PR 16-MAR-2001; 2001US-0276401P.
 PR 20-MAR-2001; 2001US-0277324P.
 PR 20-MAR-2001; 2001US-0278660P.
 PR 30-MAR-2001; 2001US-0280039P.
 PR 30-MAR-2001; 2001US-0280234P.
 PR 02-APR-2001; 2001US-0280818P.
 PR 12-APR-2001; 2001US-0283443P.
 PR 23-APR-2001; 2001US-0285754P.
 PR 24-APR-2001; 2001US-0286096P.
 PR 03-MAY-2001; 2001US-0288353P.
 PR 17-MAY-2001; 2001US-0291703P.
 PR 31-MAY-2001; 2001US-0294834P.
 PR 20-JUN-2001; 2001US-0299695P.
 PR 21-JUN-2001; 2001US-0299845P.
 PR 05-JUL-2001; 2001US-0303242P.
 PR 13-AUG-2001; 2001US-0311981P.
 PR 16-AUG-2001; 2001US-0311858P.
 PR 17-AUG-2001; 2001US-0313280P.
 PR 29-AUG-2001; 2001US-0315614P.
 PR 17-SEP-2001; 2001US-0322818P.
 PR 25-FEB-2002; 2002US-00322818.
 PR
 PA (CURA-) CURAGEN CORP.
 XX
 PI Alsobrook JP, Anderson DW, Ballinger RA, Boldog FL, Burgess CE;
 PI Casman SJ, Ellerman KE, Gangolli EA, Gerlach VL, Gilbert JA;
 PI Gorman L, Guo X, Gusev VY, Kekuda R, Li L, Liu X, Malyankar UM;
 PI Miller CE, Millet I, Padigaru M, Patturajan M, Pena CE, Peyman JA;
 PI Rastelli L, Shenoy SG, Shinkets RA, Smithson G, Spytek KA, Stone DJ;
 PI Taupier RJ, Tchernev VT, Vernet CAM, Zerhusen BD;
 XX
 DR WPI; 2002-698672/75.
 XX
 XX New NOVX polypeptides or polynucleotides, useful for preventing or
 PT treating disorders or syndromes e.g., atherosclerosis, hypertension,
 PT obesity or cancer.
 XX
 PS Example 2; Page 890; 923pp; English.
 XX
 CC The present invention relates to novel human NOVX proteins, where X is
 CC any number from 1 to 91 and their coding sequences (see ADH48717-
 CC ADH48930). The proteins and coding sequences are useful for preventing or
 CC treating disorders or syndromes e.g. atherosclerosis, hypertension,
 CC obesity or cancer. The present sequence was used in an example from the
 CC invention.
 XX
 XX Sequence 22 BP; 4 A; 3 C; 7 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 17.4; DB 1; Length 22;
 Best Local Similarity 94.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 140 GGGGAAGTATCCCTGTG 158
 DB 1 GGGGAAGTATCCCTGTG 19
 RESULT 94
 ADI17518
 ID ADI17518 standard; DNA; 22 BP.
 XX
 AC ADI17518;
 XX

15-APR-2004 (first entry)
 Forward PCR primer used to amplify human NOVX DNA SeqID1054.
 PCR; ss; NOVX; metabolic disorder; diabetes; anorexia; cancer;
 cardiovascular; infectious; neurodegenerative; immune;
 haematopoietic disease; dyslipidaemia; anorectic; nootropic;
 antiinflammatory; neuroprotective; antilipemic; anabolic; cardiant;
 neogenesis; wound healing; angiogenesis; chromosome mapping;
 tissue typing; preventive medicine; pharmacogenomic; primer; human.
 XX Homo sapiens.
 OS
 XX WO200268649-A2.
 PN
 XX 06-SEP-2002.
 PD
 XX
 XX 31-JAN-2002; 2002WO-US002785.
 PF
 XX 31-JAN-2001; 2001US-0265395P.
 PR 31-JAN-2001; 2001US-0265412P.
 PR 31-JAN-2001; 2001US-0265514P.
 PR 31-JAN-2001; 2001US-0265517P.
 PR 02-FEB-2001; 2001US-0266406P.
 PR 05-FEB-2001; 2001US-0266767P.
 PR 07-FEB-2001; 2001US-0266975P.
 PR 07-FEB-2001; 2001US-0267057P.
 PR 08-FEB-2001; 2001US-0267459P.
 PR 09-FEB-2001; 2001US-0267823P.
 PR 15-FEB-2001; 2001US-0268974P.
 PR 26-FEB-2001; 2001US-0271664P.
 PR 27-FEB-2001; 2001US-0271839P.
 PR 27-FEB-2001; 2001US-0271855P.
 PR 02-MAR-2001; 2001US-0272788P.
 PR 02-MAR-2001; 2001US-0273046P.
 PR 14-MAR-2001; 2001US-0275925P.
 PR 14-MAR-2001; 2001US-0275947P.
 PR 14-MAR-2001; 2001US-0275950P.
 PR 15-MAR-2001; 2001US-0275989P.
 PR 15-MAR-2001; 2001US-0276448P.
 PR 15-MAR-2001; 2001US-0276450P.
 PR 16-MAR-2001; 2001US-0276397P.
 PR 16-MAR-2001; 2001US-0276768P.
 PR 20-MAR-2001; 2001US-0278652P.
 PR 26-MAR-2001; 2001US-0278775P.
 PR 26-MAR-2001; 2001US-0278778P.
 PR 29-MAR-2001; 2001US-0279882P.
 PR 29-MAR-2001; 2001US-0279884P.
 PR 30-MAR-2001; 2001US-0280147P.
 PR 11-APR-2001; 2001US-0282992P.
 PR 11-APR-2001; 2001US-0283083P.
 PR 20-APR-2001; 2001US-0285133P.
 PR 23-APR-2001; 2001US-0285749P.
 PR 03-MAY-2001; 2001US-0288327P.
 PR 03-MAY-2001; 2001US-0288504P.
 PR 29-MAY-2001; 2001US-0294047P.
 PR 30-MAY-2001; 2001US-0294733P.
 PR 08-JUN-2001; 2001US-0296964P.
 PR 18-JUN-2001; 2001US-0298959P.
 PR 19-JUN-2001; 2001US-0299324P.
 PR 13-AUG-2001; 2001US-0312020P.
 PR 16-AUG-2001; 2001US-0312889P.
 PR 16-AUG-2001; 2001US-0312908P.
 PR 21-AUG-2001; 2001US-0313390P.
 PR 28-AUG-2001; 2001US-0315470P.
 PR 31-AUG-2001; 2001US-0316447P.
 PR 07-SEP-2001; 2001US-0318118P.
 PR 07-SEP-2001; 2001US-0318118P.
 PR 12-SEP-2001; 2001US-0318740P.
 PR 19-SEP-2001; 2001US-0323379P.
 PR 18-OCT-2001; 2001US-0330245P.
 PR 18-OCT-2001; 2001US-0330308P.
 PR 14-NOV-2001; 2001US-0332701P.
 PR

```
XX PA (CURA-) CURAGEN CORP.
XX PA Tchernev VT, Spytek KA, Zethusen BD, Patturajan M, Shinkets RA;
XX PI Li L, Gangolli EA, Padigar M, Anderson DW, Rastelli L, Miller CE;
XX PI Gerlach VU, Taupier RU, Gusev VY, Colman SD, Wolenc AR, Pena CE;
XX PI Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;
XX DR WPI; 2002-706998/76.
XX XX
XX PT New NOVX polypeptides and nucleic acids, useful for preventing or
XX PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy,
XX PT atherosclerosis, or diabetes, and in chromosome mapping, tissue typing or
XX PT pharmacogenomics.
XX PS Example 2; SEQ ID NO 1054; 1498bp; English.
XX CC This invention relates to a novel nucleic acids, and encoded polypeptides
XX CC thereof, which have properties related to the stimulation of biochemical
XX CC or physiological responses in a cell, tissue, organ or organism.
XX CC Specifically, it refers to the use of biologically active fragments for
XX CC diagnostic and prognostic assays and furthermore in the treatment of
XX CC diverse pathological conditions. The present invention describes novel
XX CC human and murine NOVX proteins, as well as methods to modulate their
XX CC expression using antisense oligos, ribozymes and peptide nucleic acids.
XX CC The polypeptides, nucleic acid molecules and antibodies are useful in the
XX CC manufacture of a medicament for treating metabolic disorders, diabetes,
XX CC anorexia, cancer, cardiovascular, infectious, neurodegenerative, immune
XX CC and haematopoietic diseases as well as various dyslipidaemias.
XX CC Accordingly, these molecules have many activities including anorectic,
XX CC virucide, nootropic, antiinflammatory, neuroprotective, antilipaeamic,
XX CC anabolic and cardiant. Furthermore, they are useful in screening assays
XX CC to identify small molecules that modulate or inhibit, for example,
XX CC neurogenesis, wound healing and angiogenesis. The nucleic acids are also
XX CC used as in chromosome mapping, tissue typing, preventive medicine and
XX CC pharmacogenomics. This oligonucleotide is a PCR primer used to amplify
XX CC human NOVX DNA of the invention.
XX SQ Sequence 22 BP; 4 A; 3 C; 7 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.4; DB 1; Length 22;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 140 GGGGAAAGTATCCCTCTGTG 158
Db 1 GGGGAAAGTATCCCTCTGTG 19
|||||
|||||
RESULT 95
ADN42607
ID ADN42607 standard; DNA; 22 BP.
XX AC
XX AC ADN42607;
XX DT
XX DT 17-JUN-2004 (first entry)
XX DE Human NOV16b RTQ-PCR forward primer #2.
XX KW Human; ss; NOVX; cancer; diabetes; cardiomyopathy; atherosclerosis; PCR;
XX KW primer; RTQ PCR; real time quantitative PCR.
XX XX
XX OS Homo sapiens.
XX XX US2004033493-A1.
XX PN
XX PD 19-FEB-2004.
XX XX
XX XX 31-JAN-2002; 2002US-00072012.
XX PF
XX XX 31-JAN-2001; 2001US-0265395P.
XX PR 31-JAN-2001; 2001US-0265412P.
XX PR 31-JAN-2001; 2001US-0265514P.
PR 31-JAN-2001; 2001US-0265517P.
PR 02-FEB-2001; 2001US-0266406P.
PR 05-FEB-2001; 2001US-0266767P.
PR 07-FEB-2001; 2001US-0266975P.
PR 08-FEB-2001; 2001US-0267057P.
PR 09-FEB-2001; 2001US-0267459P.
PR 15-FEB-2001; 2001US-0267823P.
PR 26-FEB-2001; 2001US-0268974P.
PR 27-FEB-2001; 2001US-0271664P.
PR 27-FEB-2001; 2001US-0271839P.
PR 27-FEB-2001; 2001US-0271855P.
PR 02-MAR-2001; 2001US-0272788P.
PR 02-MAR-2001; 2001US-0273046P.
PR 14-MAR-2001; 2001US-0275925P.
PR 14-MAR-2001; 2001US-0275947P.
PR 14-MAR-2001; 2001US-0275950P.
PR 14-MAR-2001; 2001US-0275989P.
PR 15-MAR-2001; 2001US-0276448P.
PR 15-MAR-2001; 2001US-0276450P.
PR 16-MAR-2001; 2001US-0276397P.
PR 16-MAR-2001; 2001US-0276768P.
PR 20-MAR-2001; 2001US-0278652P.
PR 26-MAR-2001; 2001US-0278775P.
PR 26-MAR-2001; 2001US-0278778P.
PR 29-MAR-2001; 2001US-0279882P.
PR 29-MAR-2001; 2001US-0279884P.
PR 30-MAR-2001; 2001US-0280147P.
PR 11-APR-2001; 2001US-0282392P.
PR 11-APR-2001; 2001US-0283083P.
PR 20-APR-2001; 2001US-0285133P.
PR 23-APR-2001; 2001US-0285749P.
PR 03-MAY-2001; 2001US-0288327P.
PR 03-MAY-2001; 2001US-0288504P.
PR 29-MAY-2001; 2001US-0294047P.
PR 30-MAY-2001; 2001US-0294473P.
PR 08-JUN-2001; 2001US-0296964P.
PR 18-JUN-2001; 2001US-0298959P.
PR 19-JUN-2001; 2001US-0299324P.
PR 13-AUG-2001; 2001US-0312020P.
PR 16-AUG-2001; 2001US-0312889P.
PR 16-AUG-2001; 2001US-0312908P.
PR 21-AUG-2001; 2001US-0313930P.
PR 28-AUG-2001; 2001US-0315470P.
PR 31-AUG-2001; 2001US-0316447P.
PR 07-SEP-2001; 2001US-0318115P.
PR 07-SEP-2001; 2001US-0318118P.
PR 12-SEP-2001; 2001US-0318740P.
PR 19-SEP-2001; 2001US-0323379P.
PR 18-OCT-2001; 2001US-0330245P.
PR 18-OCT-2001; 2001US-0330308P.
PR 14-NOV-2001; 2001US-0332701P.
XX XX
XX PA (TCHE/) TCHERNEV V T.
XX PA (SPYT/) SPYTEK K A..
XX PA (ZERH/) ZERHUSEN B D.
XX PA (PATT/) PATTURAJAN M.
XX PA (SHIM/) SHINKETS R A.
XX PA (LILL/) LI L.
XX PA (GANG/) GANGOLLI E A.
XX PA (PADI/) PADIGARU M.
XX PA (ANDE/) ANDERSON D W.
XX PA (RAST/) RASTELLI L.
XX PA (MILL/) MILLER C E.
XX PA (GERL/) GERLACH V.
XX PA (TAUP/) TAUPIER R J.
XX PA (GUSE/) GUSEV V Y.
XX PA (COLM/) COLMAN S D.
XX PA (WOLE/) WOLENC A R.
XX PA (PENA/) PENNA C E A.
XX PA (FURT/) FURTAK K.
XX PA (GROS/) GROSSE W M.
XX PA (ALSO/) ALSOBROOK J P.
XX PA (LEPL/) LEPLEY D M.
```

PA (RIEG//) RIEGER D K.
 PA (BURG//) BURGESS C E.
 XX
 XX Tchernev VT, Spytek KA, Zerhusen BD, Patturajan M, Shimkets RA;
 PI Li L, Gangolli EA, Padigara M, Anderson DM, Rastelli L, Miller CE;
 PI Gerlach V, Taupier RJ, Gusev VY, Colman SD, Wolenc AR, Pena CE;
 PI Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;
 XX WPI; 2004-180039/17.
 DR
 XX Isolated NOVX polypeptides and polynucleotides, useful for preventing
 PT diagnosing and/or treating cancer, diabetes, cardiomyopathy and
 PT atherosclerosis.
 PT
 XX Example 2; SEQ ID NO 1054; 1309pp; English.
 PS
 XX The invention relates isolated 162 NOVX polypeptides (NOV1-NOV99,
 CC including splice variants) and the nucleic acids (NA) that encode them.
 CC Also included are the mature NOVX proteins (NA) that encode them.
 CC polynucleotides), a vector comprising NOVX NA, a cell comprising the
 CC vector, an antibody that binds immunospecifically to NOVX, determining
 CC the presence or amount of NOVX in a sample, determining the presence or
 CC amount of NOVX NA in a sample, identifying an agent that binds to NOVX,
 CC modulating the activity of NOVX, treating or preventing a NOVX-associated
 CC disorder, determining the presence of or predisposition to a disease
 CC associated with altered levels of NOVX and treating a pathological state
 CC in a mammal comprising administering a polypeptide which is at least 95%
 CC identical to NOVX (or fragment). NOVX and NA may be used in the
 CC prevention, treatment and diagnosis of diseases associated with
 CC inappropriate expression and activity of NOVX (e.g. cancer, diabetes,
 CC cardiomyopathy and/or atherosclerosis). The anti-NOVX antibodies and
 CC antagonists may also be used to down regulate expression and activity of
 CC NOVX. The anti-NOVX antibodies may also be used as diagnostic agents for
 CC detecting the presence of NOVX in samples (e.g. by enzyme linked
 CC immunosorbant assay (ELISA)). The agents and methods may be used in this
 CC way to prevent, diagnose and treat cancer, diabetes, cardiomyopathy
 CC and/or atherosclerosis. The present sequence is a real time quantitative
 CC PCR (RTQ PCR) primer for tissue specific expression studies for a NOVX
 CC gene.
 XX
 XX Sequence 22 BP; 4 A; 3 C; 7 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 17.4; DB 1; Length 22;
 Best Local Similarity 94.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 140 GGGGAAAGTATCCCTGTG 158
 DB 1 GGGGAAAGTATCTCTGTG 19
 RESULT 96
 ABT08600/c
 ID ABT08600 standard; DNA; 22 BP.
 XX
 AC ABT08600;
 XX
 XX 28-NOV-2002 (first entry)
 DT
 XX Human novel protein coding sequence NOVX PCR primer SEQ ID NO: 208.
 DE
 XX Human; NOVX; single nucleotide polymorphism; SNP; anti-HIV; cytostatic;
 XX antartiosclerotic; antidiabetic; antisthmatic; antinflammatory;
 KW haemostatic; hypotensive; neuroprotective; anorectic; nootropic;
 KW antidepressant; immunosuppressive; antibacterial; antiparasitic;
 KW virucide; tranquilizer; anticonvulsant; osteopathic; analgesic;
 KW antiparkinsonian; dermatological; antinfertility; cerebroprotective;
 KW antiaddictive; PCR; primer; probe; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200259315-A2.
 PN
 XX

01-AUG-2002.
 PD
 XX 19-DEC-2001; 2001WO-US0500076.
 PF
 XX 19-DEC-2000; 2000US-0256619P.
 PR 19-JAN-2001; 2001US-0262959P.
 PR 28-FEB-2001; 2001US-0272408P.
 PR 20-APR-2001; 2001US-0285189P.
 PR 26-JUL-2001; 2001US-0308039P.
 PR 09-AUG-2001; 2001US-0311266P.
 XX (CURA-) CURAGEN CORP.
 XX
 XX Shimkets RA, Patturajan M, Vernet CAM, Casman SJ, Malyankar U;
 PI Shenoy S, Spytek KA, Gangolli E, Miller C, Boldog F, Li L;
 PI Taupier RJ, Kekuda R, Smithson G, Zerhusen BD, Liu X, Colman SD;
 PI Rothenberg M;
 PI Edinger S, Stone D, Sciore P, Millet I;
 XX WPI; 2002-666903/71.
 XX New isolated NOVX polypeptides and polynucleotides, useful for
 PT preventing, diagnosing or treating NOVX-associated disorders e.g.
 PT diabetes, Crohn's disease, atherosclerosis, cancer, Huntington's disease
 PT or Alzheimer's disease.
 XX Example 2; Page 342; 363pp; English.
 PS
 XX The present invention provides the protein and coding sequences of
 CC several novel human proteins, designated NOVX. These can be used in the
 CC treatment of diseases such as cancers, Hodgkin's disease, Von Hippel-
 CC Lindau syndrome, Alzheimer's disease, stroke, tuberosus sclerosis,
 CC hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral
 CC palsy, epilepsy, Leisch-Nyhan syndrome, multiple sclerosis, ataxia
 CC telangiectasia, leukodystrophies, addiction, anxiety, depression, pain,
 CC obesity, Crohn's disease, osteoporosis, inflammatory bowel disease,
 CC infertility, atherosclerosis, hypertension, scleroderma, haemophilia,
 CC diabetes, pancreatitis, autoimmune disease, asthma, arthritis,
 CC immunodeficiencies, HIV, viral, bacterial or parasitic infections, or
 CC graft-versus-host disease. The present sequence is an oligonucleotide
 CC used to isolate a coding sequence of the invention
 XX
 XX Sequence 22 BP; 4 A; 7 C; 3 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 1.3e+02;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 490 TGGATCAAGAGACCCATGGCA 511
 DB 22 TGGATCAAGAGACTCAGGTA 1
 RESULT 97
 ADO09965/c
 ID ADO09965 standard; DNA; 22 BP.
 XX
 AC ADO09965;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 XX Human NOVX probe #25.
 DE
 XX human; NOVX; immunogen; vaccine; cancer; diabetes; Alzheimer's disease;
 XX Parkinson's disease; Huntington's disease; asthma; allergy; emphysema;
 KW bronchitis; autoimmune disease; graft-versus-host disease; arthritis;
 KW scleroderma; systemic lupus erythematosus; bacterial infection;
 KW cystic fibrosis; coronary artery disease; stroke; hypertension;
 KW myocardial infarction; haemophilia; idiopathic thrombocytopenic purpura;
 KW hyperlipidaemia; obesity; cirrhosis; inflammatory bowel disease;
 KW Crohn's disease; ulcers; muscular dystrophy; myasthenia gravis;
 KW endometriosis; psoriasis; alopecia; uveitis;
 KW amytrophic lateral sclerosis; osteoporosis; osteoarthritis;

KW liver disease; epilepsy; multiple sclerosis; anxiety; pain; fertility;
KW glomerulonephritis; polycystic kidney disease; ss; probe.

OS Homo sapiens.

PN US2004018970-A1.

XX 29-JAN-2004.

PD 27-MAR-2002; 2002US-00107782.

XX 19-DEC-2000; 2000US-0256619P.

XX 19-JAN-2001; 2001US-0262959P.

PR 28-FEB-2001; 2001US-0272408P.

PR 28-MAR-2001; 2001US-0279344P.

PR 20-APR-2001; 2001US-0285189P.

PR 26-JUL-2001; 2001US-0308039P.

PR 09-AUG-2001; 2001US-0311266P.

PR 19-DEC-2001; 2001US-00028248.

XX (SHIM/) SHIMKETS R A.

PA (PATT/) PATTURAJAN M.

PA (VERN/) VERNET C A M.

PA (CASM/) CASMAN S J.

PA (MALY/) MALYANKAR U M.

PA (SHEN/) SHENOY S G.

PA (SPYT/) SPYTEK K A.

PA (GANG/) GANGOLLI E A.

PA (MILL/) MILLER C E.

PA (BOLD/) BOLDOG F L.

PA (LILL/) LI L.

PA (TAUP/) TAUPIER R J.

PA (KEKU/) KEKUDA R.

PA (SMIT/) SMITHSON G.

PA (ZERH/) ZERHUSEN B D.

PA (LIUX/) LIU X.

PA (COLM/) COLMAN S D.

PA (TCHE/) TCHERNEV V T.

PA (SIJ/) SI J.

PA (EDIN/) EDINGER S R.

PA (STON/) STONE D J.

PA (SCIO/) SCIORE P.

PA (MILL/) MILLET I.

PA (ROTH/) ROTHENBERG M E.

XX Shimkets RA, Patturajan M, Vernet CAM, Casman SJ, Malyankar UM;

PI Shenoy SG, Spytek KA, Gangolli EA, Miller CE, Boldog FL, Li L;

PI Taupier RJ, Kekuda R, Smithson G, Zerhusen BD, Liu X, Colman SD;

PI Tchernev VT, Si J, Edinger SR, Stone DJ, Sciore P, Millet I;

PI Rothenberg ME;

XX WPI; 2004-122080/12.

New NOVX polypeptides and nucleic acid molecules, useful for diagnosing, preventing or treating NOVX-associated disorders e.g. cancer, diabetes, Alzheimer's disease, stroke, arthritis, hypertension or myocardial infarction.

Example 1; SEQ ID NO 208; 240pp; English.

The invention relates to an isolated NOVX polypeptide. A therapeutic, i.e. the NOVX polypeptide, nucleic acid and antibody, is useful for manufacturing a medicament for treating a syndrome associated with a human disease, e.g. a NOVX-associated disorder. The NOVX polypeptides can be used as immunogens or as vaccines. The NOVX polypeptide, nucleic acid or antibody is useful for diagnosing, treating or preventing a NOVX-associated disorder, e.g. cancer, diabetes, Alzheimer's disease, Parkinson's disease, Huntington's disease, asthma, allergies, emphysema, bronchitis, autoimmune disease, graft-versus-host disease, arthritis, scleroderma, systemic lupus erythematosus, bacterial infections, cystic fibrosis, coronary artery disease, stroke, hypertension, myocardial infarction, haemophilia, idiopathic thrombocytopenic purpura, hyperlipidaemia, obesity, cirrhosis, inflammatory bowel disease, Crohn's

CC disease, ulcers, muscular dystrophy, myasthenia gravis, endometriosis, psoriasis, alopecia, uveitis, amyotrophic lateral sclerosis, CC osteoporosis, osteoarthritis, liver disease, epilepsy, multiple CC sclerosis, anxiety, pain, fertility, glomerulonephritis, or polycystic CC kidney disease. The NOVX polypeptides and nucleic acid molecules are useful for determining the presence of or predisposition to a disease CC associated with altered levels of the NOVX polypeptide or the nucleic CC acid molecule, or for screening for molecules that inhibit or enhance CC NOVX activity or function. The nucleic acids may be used as hybridisation CC probes, in chromosome mapping, tissue typing, preventive medicine, or CC pharmacogenomics. The present sequence represents a human NOVX protein CC probe.

SQ Sequence 22 BP; 4 A; 7 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. NO. 1.3e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 490 TGGATCAAGAGACCCATGGCA 511

|||||

Db 22 TGGATCAAGAGACTCAGGTA 1

RESULT 98

ABT43752

ID ABT43752 standard; DNA; 17 BP.

XX ABT43752;

DT 16-OCT-2003 (first entry)

DE Human phosphatidylinositol-4-phosphate 5-kinase primer Seq ID4.

XX Human; phosphatidylinositol-4-phosphate 5-kinase lalpha; PIP5Klalpha;

KW antiinflammatory; antitumour; cytostatic; gene therapy; tumour;

KW antisense oligonucleotide; hyperproliferative disorder;

KW inflammatory disorder; infection; inflammation; PCR; primer; ss.

XX Homo sapiens.

XX WO2003050309-A1.

XX 19-JUN-2003.

XX 04-DEC-2002; 2002WO-US038615.

XX 06-DEC-2001; 2001US-00003354.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Freier SM;

XX WPI; 2003-627257/59.

XX New antisense compound useful for treating diseases such as hyperproliferative or inflammatory disorders, hybridizes and inhibits nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.

XX Example 13; Page 80; 117pp; English.

XX This invention relates to the novel antisense compounds, particularly antisense oligonucleotides, for the modulation of phosphatidylinositol-4-phosphate 5-kinase lalpha (PIP5Klalpha) expression. The oligonucleotides of the invention may have antiinflammatory, antitumour or cytostatic activities through use in a gene therapy method. As a result the antisense oligonucleotides may be of use for the treatment of an animal having a disease associated with PIP5Klalpha such as a hyperproliferative or inflammatory disorder through inhibition of PIP5Klalpha expression. The oligonucleotides of the invention may also be used prophylactically to prevent or delay infection, inflammation or tumour formation. They may also be useful for diagnostics, therapeutics, prevention, as research reagents and kits or for distinguishing functions of various members of a

```
CC biological pathway. The present sequence is that of PCR primer Seq ID4
CC which is a forward primer used for amplification of the human
CC phosphatidylinositol-4-phosphate 5-kinase Ialpha (PIPSK1a) gene during
CC real time analysis of mRNA levels in example 13 of the specification
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 86;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 283 GGGAGGTGGCCACACAGA 299
DB 1 GGGAGGTGGCCACACAGA 17
RESULT 99
AAQ87918
ID AAQ87918 standard; DNA; 20 BP.
XX
AC AAQ87918;
XX
DT 29-NOV-1995 (first entry)
DE Human histamine H1 receptor PCR primer.
XX
XX Human histamine H1 receptor; polymorphism detection; treatments;
KW drug design; PCR primer; ss.
XX Synthetic.
XX JP07067654-A.
PN 14-MAR-1995.
PD
XX
PF 03-SEP-1993; 93JP-00219544.
XX
PR 03-SEP-1993; 93JP-00219544.
XX
PA (MITP ) MITSUBISHI YUKA BCL KK.
XX
XX WPI; 1995-143848/19.
DR
XX Human histamine H1 receptor gene and protein - used in a method for the
PT detection of histamine polymorphism.
PS Claim 3; Page 2; 13pp; Japanese.
XX
XX AAQ87917 and AAQ87918 are a pair of primers for the PCR amplification of
CC AAQ87915, which encodes AAR1909 the human histamine H1 receptor. The DNA
CC fragment can be used in a new method for the detection of histamine
CC polymorphisms, it may also be used in the development of drugs for the
CC treatment of histamine associated conditions
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1687 GCGCTTCATGTGCAACACAG 1706
DB 1 GCGCTTCATGTGCAACCCAG 20
RESULT 100
AAT68349/C
ID AAT68349 standard; DNA; 20 BP.
XX
AC AAT68349;
XX
DT 11-AUG-1997 (first entry)
XX
```

```
DE Loci-specific primer for assessing integrity of human Y chromosome.
XX Y chromosome; integrity; chromosome locus; primer; amplification; PCR;
XX polymerase chain reaction; fertility; azoospermia; oligospermia;
KW infertile; diagnosis; DYS209; DYP43S1; DYS210; DYS211; DYS33; DYS1; SMCX;
KW DAZ(1); DYS218; DYS219; DYS212; DYS215; DYS216; DYS217; DYS218; DYS219;
KW DYS241; DYS198; SRY; DYS197; DYS196; DYS240; DYS271; DYS221; KAL182;
KW DAZ(2); DYS224; DYS222; DYS227; DYS229; DYS21; DYS230; DAZ(3);
KW DAZ(4); DAZ(5); SMCY; DYS217; DYS220; DYS223; DYS7; DYS237; DYS215; DYS7;
KW DYS237; DAZ(6); DAZ(7); DAZ(8); DAZ(9); DAZ(10); DAZ(11); YRRM1; 2FY;
KW BKM; ss.
XX
XX Homo sapiens.
OS
XX WO9641007-A1.
PN
XX 19-DEC-1996.
PD
XX 06-JUN-1996; 96WO-US009421.
PF
XX 07-JUN-1995; 95US-00472416.
PR
XX 18-SEP-1995; 95US-00531556.
PR
XX (PROM-) PROMEGA CORP.
PA
XX First MK, Agoulunik AI, Muallem A;
XX
XX WPI; 1997-099942/09.
DR
XX
XX Assessing integrity of Y chromosome - by amplification of selected human
XX chromosome loci by multiplex PCR and comparison with normal control DNA.
XX Claim 2; Page 56; 111pp; English.
XX
XX AAT68347-T68354 are a set of primers used in a method for assessing the
CC integrity of a Y chromosome. The primers are capable of priming the
CC chromosome loci: DYS224, DYS226, DYS227 and MIC2. The method can
CC be used to rapidly and reproducibly assess the integrity of specific
CC regions of the Y chromosome that are associated with male fertility. It
CC can be used to assess the integrity of the Y chromosome in males
CC exhibiting azoospermia or oligospermia (no or very little spermatozoa in
CC the semen) or to assess the genotype of infants of phenotypically
CC ambiguous sexuality. The method can also be used in diagnosis and quality
CC control
XX
XX Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1679 CGGTTCCAGCGCTTCATGTG 1698
DB 20 CAGTTCCAGTGTTCATGTG 1
RESULT 101
AAT68404/C
ID AAT68404 standard; DNA; 20 BP.
XX
XX AAT68404;
XX
XX 11-AUG-1997 (first entry)
DT
XX
XX Loci-specific primer for assessing integrity of human Y chromosome.
XX Y chromosome; integrity; chromosome locus; primer; amplification; PCR;
XX polymerase chain reaction; fertility; azoospermia; oligospermia;
KW infertile; diagnosis; DYS209; DYP43S1; DYS210; DYS211; DYS33; DYS1; SMCX;
KW DAZ(1); DYS218; DYS219; DYS212; DYS215; DYS216; DYS217; DYS218; DYS219;
KW DYS241; DYS198; SRY; DYS197; DYS196; DYS240; DYS271; DYS221; KAL182;
KW DAZ(2); DYS224; DYS222; DYS227; DYS229; DYS21; DYS230; DAZ(3);
KW DAZ(4); DAZ(5); SMCY; DYS217; DYS220; DYS223; DYS7; DYS237; DYS215; DYS7;
KW DAZ(6); DAZ(7); DAZ(8); DAZ(9); DAZ(10); DAZ(11); YRRM1; 2FY;
KW BKM; ss.
```

```
KW DYS237; DAZ(6); DAZ(7); DAZ(8); DAZ(9); DAZ(10); DAZ(11); YRRM1; ZFY;
KW BKM; SS.
XX
OS Homo sapiens.
XX
PN WO9641007-A1.
XX
XX 19-DEC-1996.
XX
XX 06-JUN-1996; 96WO-US009421.
XX
XX 07-JUN-1995; 95US-00472416.
XX
XX 18-SEP-1995; 95US-00531556.
XX
XX (PROM-) PROMEGA CORP.
XX
XX First MK, Agoulnik AI, Muallem A;
XX
XX WPI; 1997-099942/09.
XX
XX Assessing integrity of Y chromosome - by amplification of selected human
XX chromosome loci by multiplex PCR and comparison with normal control DNA.
XX
XX Disclosure; Page 60; 111pp; English.
XX
XX AAT68402-T68409 are PCR primers used in a method for assessing the
XX integrity of a Y chromosome. The primers are capable of priming the
XX chromosome loci: DYS331, DYS229, DYZ1, DYS230, DAZ(3), DAZ(4), DAZ(5)
XX and MIC2. The method can be used to rapidly and reproducibly assess the
XX integrity of specific regions of the Y chromosome that are associated
XX with male fertility. It can be used to assess the integrity of the Y
XX chromosome in males exhibiting azoospermia or oligospermia (no or very
XX little spermatozoa in the semen) or to assess the genotype of infants of
XX phenotypically ambiguous sexuality. The method can also be used in
XX diagnosis and quality control
XX
XX Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 16.8; DB 1; Length 20;
XX Best Local Similarity 90.0%; Pred. No. 1.3e+02;
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1679 CGGTTCCAGCGCTTCATGTG 1698
XX | | | | | | | | | | | | | | | |
XX 20 CAGTTCAGTGCCTTCATGTG 1
XX
XX
XX RESULT 102
XX AAV47967/c
XX ID AAV47967 standard; DNA; 20 BP.
XX
XX AC AAV47967;
XX
XX 19-OCT-1998 (first entry)
XX
XX Human B7-2 targetted oligonucleotide 9136.
XX
XX ss; human; B7; T cell; inflammation; autoimmune disease; cell activation;
XX cell proliferation.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /*note= "Phosphorothioate linkages"
XX
XX WO9829124-A1.
XX
XX 09-JUL-1998.
XX
XX 16-DEC-1997; 97WO-US023270.
```

```
XX 31-DEC-1996; 96US-00777266.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Vickers TA;
XX
XX WPI; 1998-387783/33.
XX
XX New oligo:nucleotide(s) that modulate expression of B7 proteins - used
XX for, e.g. controlling activation and proliferation of T cells,
XX particularly for treatment, diagnosis and prevention of inflammation.
XX
XX Example 1; Page 37; 120pp; English.
XX
XX The oligonucleotides which specifically hybridise to B7 modulate its
XX expression (and thus T cell activation and proliferation). This is
XX particularly useful for treatment and prevention of inflammation and
XX autoimmune diseases, e.g. asthma, (juvenile) diabetes, myaesthesia gravis,
XX Grave's disease, rheumatoid arthritis, allograft rejection, psoriasis,
XX (systemic) lupus erythematosus, multiple sclerosis, contact dermatitis,
XX rhinitis, allergy, cancer and metastases. The oligonucleotides may also
XX be used to manipulate T cell activation ex vivo; to determine or detect
XX B7 protein expression; for diagnosis; as assay and purification reagents,
XX and to study physiological roles of B7 proteins
XX
XX Sequence 20 BP; 9 A; 3 C; 1 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 16.8; DB 1; Length 20;
XX Best Local Similarity 90.0%; Pred. No. 1.3e+02;
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 3669 AAGTGATATATGCTTTTAAT 3688
XX | | | | | | | | | | | | | | | |
XX 20 AAGTGATACATGTTTTTAAT 1
XX
XX
XX RESULT 103
XX AAZ21462/c
XX ID AAZ21462 standard; DNA; 20 BP.
XX
XX AC AAZ21462;
XX
XX 02-DEC-1999 (first entry)
XX
XX Human BURB1 PCR primer #4.
XX
XX Human; BUR1; BURB1; hBUR1; hBUR1; mutation; mitosis; diagnosis;
XX microsatellite instability; MIN; tumour; mismatch repair; CIN;
XX chromosomal instability; detection; cell proliferative disorder;
XX neoplasm; breast cancer; colorectal cancer; fibrotic disorder;
XX benign hyperplasia; neoplasia; PCR primer; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX WO9947638-A2.
XX
XX 23-SEP-1999.
XX
XX 16-MAR-1999; 99WO-US005692.
XX
XX 16-MAR-1998; 98US-0078196P.
XX
XX (UWJO ) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
XX Vogelstein B, Kinzler KW, Cahill D, Lengaver C;
XX
XX WPI; 1999-562100/47.
XX
XX Use of mitotic checkpoint genes for developing methods for the diagnosis
XX and treatment of cell proliferative disorders or for increasing the
XX proliferation of cells.
```


XX PS Example; Page 34; 56pp; English.

XX CC The present invention describes the use of mitotic check point genes (MCPGs) in the diagnosis and treatment of cell proliferative disorders. A method has been developed for diagnosing a cell proliferative disorder in a subject associated with a MCPG, by determining the presence of a mutant MCPG in the sample where the presence of a mutant MCPG in the sample is indicative of a cell proliferative disorder. The method can be used for diagnosing a cell proliferative disorder such as a neoplasm, e.g. breast or colorectal neoplasm. It can also be used for treating a cell proliferative disorder, e.g. a fibrotic disorder, benign hyperplasia or neoplasia, particularly colon or breast cancer. It can also be used for treating disorders associated with insufficient cell proliferation or undesirable cell degeneration. The present sequence represents a PCR primer used to amplify human BUBR1, in an example from the present invention. Loss of a MCPG is associated with the mutational inactivation of the human BUB1 gene

XX CC Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

XX PS Query Match 0.5%; Score 16.8; DB 1; Length 20;

XX CC Best Local Similarity 90.0%; Pred. No. 1.3e+02;

XX PS Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GCCAGAGCAGCTCTCTTT 2747

DB 20 GCCAGAGCAGCTCTCTTT 1

RESULT 104

AAF32809/c

ID AAF32809 standard; DNA; 20 BP.

XX AC AAF32809;

XX DT 23-MAR-2001 (first entry)

XX DE Human B7-2 mRNA antisense oligonucleotide SEQ ID NO: 6.

XX KW Human; mouse; B7-1; B7-2; antisense; PCR primer; inflammation;

XX KW autoimmune disorder; phosphorothioate backbone; ss.

XX OS Homo sapiens.

XX PN WO200074687-A1.

XX PD 14-DEC-2000.

XX PF 25-MAY-2000; 2000WO-US014471.

XX PR 04-JUN-1999; 99US-00326186.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Vickers TA, Karras JG;

XX DR WPI; 2001-049991/06.

XX PT Novel compound for diagnosing, preventing and treating immune disorders, comprising an oligonucleotide that specifically hybridizes with a nucleic acid sequence encoding B7 protein.

XX PS Example 1; Page 50; 162pp; English.

XX CC The present invention provides sequences of antisense oligonucleotides targeted at the murine and human B7-1 and B7-2 coding and mRNA sequences. The antisense sequences have phosphorothioate backbones and some nucleotides are 2'-methoxyethoxy residues. The sequences can be used in the treatment of inflammatory and autoimmune disorders, including asthma, juvenile diabetes mellitus, myasthenia gravis, Graves' disease, rheumatoid arthritis, allograft rejection, inflammatory bowel disease, multiple sclerosis, psoriasis, systemic lupus erythematosus, contact

CC dermatitis, rhinitis, allergies and cancer

XX SQ Sequence 20 BP; 9 A; 3 C; 1 G; 7 T; 0 U; 0 Other;

XX CC Query Match 0.5%; Score 16.8; DB 1; Length 20;

XX CC Best Local Similarity 90.0%; Pred. No. 1.3e+02;

XX PS Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3669 AAGTGATATATGTTTAAAT 3688

DB 20 AAGTGATATGTTTAAAT 1

RESULT 105

AAH27401

ID AAH27401 standard; DNA; 20 BP.

XX AC AAH27401;

XX DT 08-AUG-2001 (first entry)

XX DE PCR primer #70.

XX KW Tumour suppressor gene 16; TSG16; immune response modulator;

XX KW inflammatory response modulator; signal transduction activator;

XX KW cytokine inhibitor; gene therapy; anticancer; anti-inflammatory;

XX KW autoimmune disorder; infection; chromosome 16q24.3; human;

XX KW cellular proliferation suppressor; PCR primer; ss.

XX OS Homo sapiens.

XX PN WO200132861-A1.

XX PD 10-MAY-2001.

XX PF 30-OCT-2000; 2000WO-AU001329.

XX PR 29-OCT-1999; 99AU-00003771.

XX PA (WOME-) WOMEN'S & CHILDREN'S HOSPITAL.

XX PI Callen DF, Whitmore SA, Kremmidiotis G, Kochetkova M, Crawford J;

XX DR WPI; 2001-316439/33.

XX PT New nucleic acid representing the human tumor suppressor gene TSG16, useful e.g. for diagnosis and treatment of tumors, inflammatory and immunological disorders.

XX PS Disclosure; Page 200; 215pp; English.

XX CC The present invention relates to human tumour suppressor gene 16 (TSG16; see AAH23688). TSG16 was isolated from chromosome 16q24.3. TSG16 suppresses cellular proliferation. TSG16 is useful for treating disorders associated with decreased expression or activity of TSG16, e.g. cancer, (auto)immune disorders, inflammation, complications of wound healing and infections (by viruses, bacteria, fungi, parasites, protozoa or helminths). The present sequence is a PCR primer, which was used in the present invention

XX SQ Sequence 20 BP; 1 A; 9 C; 1 G; 9 T; 0 U; 0 Other;

XX PS Query Match 0.5%; Score 16.8; DB 1; Length 20;

XX CC Best Local Similarity 90.0%; Pred. No. 1.3e+02;

XX PS Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2184 CTGCTCCCTCCATCTCTTCC 2203

DB 1 CTGCTCCCTCCATCTCTTCC 20

RESULT 106

AAS43108/c

KW cardiovascular disease; oestrogen receptor; ds.
XX Homo sapiens.
OS WO200162969-A2.
PN XX
PD 30-AUG-2001.
XX
XX 20-FEB-2001; 2001WO-US005358.
PF 22-FEB-2000; 2000US-0183756P.
PR 20-OCT-2000; 2000US-00692414.
PR 24-JAN-2001; 2001US-00768184.
XX
XX (PEKE) PE CORP NY.
PA
PI Kalush F, Cassel MJ, Hwang SS, Winn-Deen ES;
PI WPI; 2002-041152/05.
DR
XX Novel variant of estrogen receptor alpha polypeptide useful for
PT determining the biological activity of a protein for high throughput
PT screening and for raising antibodies that elicit an immune response in
PT host.
XX
PS Example; Page 56; 333pp; English.
XX
CC The present invention describes an isolated peptide (I) consisting of an
CC amino acid sequence selected from: (a) the amino acid sequence of a
CC variant of the oestrogen receptor alpha (ESR-alpha) protein in AAG68251;
CC or (b) a fragment comprising at least 10 contiguous amino acids of the
CC protein in AAG68251. (I) has cytostatic, osteopathic, cardiant and
CC vasotropic activities, and can be used in gene therapy and vaccine
CC production. (I) is useful for identifying an agent that binds to (I), by
CC contacting (I) with an agent and assaying the contacted mixture to
CC determine whether a complex is formed with the agent bound to the
CC peptide. A polynucleotide (II), encoding (I), is useful in the
CC development of diagnostics and therapies for diseases and disorders
CC mediated/modulated by an oestrogen receptor (ER). (II) is also useful in
CC gene therapy for treating cancer, osteoporosis and cardiovascular
CC diseases. The human ESR-alpha gene is located on chromosome 6. ABA89779
CC to ABA89828 represent oligonucleotides covering human ER exon-intron
CC boundaries, and ABA89829 to ABA89868 represent oligonucleotides covering
CC human synaptic nuclei expressed gene 2 exon-intron boundaries, which are
CC used in an example from the present invention
XX
SQ Sequence 20 BP; 15 A; 1 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2567 TTTCTTCTCTCTTTTCTTTT 2586
DB 20 TTTCTTCTCTCTTTTCTTTT 1
RESULT 109
ADE27744/c
ID ADE27744 standard; DNA; 20 BP.
XX
XX ADE27744;
AC ADE27744;
XX
XX 29-JAN-2004 (first entry)
DT
XX Human B7-2 mRNA targeted oligonucleotide SEQ ID 6.
DE
XX ss; human; B7-2; inflammatory skin disorder; antisense; psoriasis;
KW contact dermatitis; atopic dermatitis; seborrheic dermatitis;
KW nummular dermatitis; Generalised exfoliative dermatitis; eczema;
KW critical costimulatory molecule.
XX
XX Synthetic.
OS

OS Homo sapiens.
XX US2003176374-A1.
PN
XX 18-SEP-2003.
PD
XX 09-MAY-2001; 2001US-00851871.
XX
XX 31-DEC-1996; 96US-00777266.
PR 04-JUN-1999; 99US-00326186.
PR 25-MAY-2000; 2000WO-US014471.
XX
XX (BENN/) BENNETT C F.
PA (VICK/) VICKERS T A.
PA (KARR/) KARRAS J G.
XX
XX Bennett CF, Vickers TA, Karras JG;
FI WPI; 2003-863863/80.
DR
XX Treating an inflammatory skin disorder such as psoriasis comprises
PT topically applying an antisense compound targeted to the nucleic acid
PT encoding human B7 protein.
XX
XX Example 1; SEQ ID NO 6; 88pp; English.
XX
CC The invention relates to a method of treating an inflammatory skin
CC disorder in an individual by topically applying an antisense compound
CC targeted to a nucleic acid molecule encoding a human B7 protein. The
CC invention is for treating an inflammatory skin disorder in individual.
CC The skin disorder is psoriasis, contact dermatitis, atopic dermatitis,
CC seborrheic dermatitis, nummular dermatitis, generalised exfoliative
CC dermatitis or eczema. The invention effectively modulates critical
CC costimulatory molecules such as the B7 protein. The present sequence
CC represents a human B7-2 targeted oligonucleotide.
XX
SQ Sequence 20 BP; 9 A; 3 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3669 AAGTGATATATGTTTAAAT 3688
DB 20 AAGTGATACATGTTTAAAT 1
RESULT 110
ADJ54186/c
ID ADJ54186 standard; DNA; 20 BP.
XX
XX ADJ54186;
AC ADJ54186;
XX
XX 06-MAY-2004 (first entry)
DT
XX Human B7-2 DNA antisense oligonucleotide #4.
DE
XX
XX Airway hyperresponsiveness; pulmonary inflammation;
KW antisense oligonucleotide; human; B7 protein; B7-2; asthma;
KW antiasthmatic; antiinflammatory; ss.
XX
XX Homo sapiens.
OS
XX US2004023917-A1.
PN
XX 05-FEB-2004.
PD
XX 23-MAY-2003; 2003US-00444206.
PF
XX 31-DEC-1996; 96US-00777266.
PR 04-JUN-1999; 99US-00326186.
PR 25-MAY-2000; 2000WO-US014471.
PR 09-MAY-2001; 2001US-00851871.
PR

XX (BENN/) BENNETT C F.
 PA (VICK/) VICKERS T A.
 PA (KARR/) KARRAS J G.
 PI Bennett CF, Vickers TA, Karras JG;
 XX WPI; 2004-132608/13.
 XX Treating airway hyperresponsiveness or pulmonary inflammation comprises
 PT administering an antisense compound targeted to a nucleic acid molecule
 PT encoding a human B7 protein to the individual.
 XX Example 1; SEQ ID NO 6; 182pp; English.
 PS The invention relates to a method for treating airway hyperresponsiveness
 CC or pulmonary inflammation in an individual comprising administering an
 CC antisense compound targeted to a nucleic acid molecule encoding a human
 CC B7 protein. The invention also relates to a method of inhibiting
 CC expression of a nucleic acid molecule encoding B7-1 or B7-2. The
 CC antisense compound is an antisense oligonucleotide which has a modified
 CC sugar moiety and nucleobase. The human B7 protein is human B7-1 or B7-2
 CC protein or both. The compound is useful for treating airway
 CC hyperresponsiveness or pulmonary inflammation, which is associated with
 CC asthma, by inhibiting expression of human B7 protein. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX Sequence 20 BP; 9 A; 3 C; 1 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.5%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.3e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3669 AAGTGATATGCTTTTAAT 3688
 DB 20 AAGTGATACATGTTTAAAT 1

RESULT 111
 ADK77343/c
 ID ADK77343 standard; DNA; 20 BP.
 XX AC ADK77343;
 XX 20-MAY-2004 (first entry)
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4677.
 XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX Synthetic.
 OS WO2004016754-A2.
 FN 26-FEB-2004.
 PD 14-AUG-2003; 2003WO-US025465.
 PF 14-AUG-2002; 2002US-0403416P.
 XX (PHAA) PHARMACIA CORP.
 PA Roberds SL;
 PI WPI; 2004-203785/19.
 DR New antisense compound targeted to a nucleic acid molecule encoding
 XX Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX

PS Claim 4; SEQ ID NO 4677; 417pp; English.
 XX The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.
 XX Sequence 20 BP; 3 A; 4 C; 3 G; 10 T; 0 U; 0 Other;
 SQ

Query Match 0.5%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.3e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 951 AACATAAGAGCGGAATTT 970
 DB 20 AACATAAGAGCGGAATTT 1

RESULT 112
 ADK78202/c
 ID ADK78202 standard; DNA; 20 BP.
 XX AC ADK78202;
 XX 20-MAY-2004 (first entry)
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5536.
 XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX Synthetic.
 OS WO2004016754-A2.
 FN 26-FEB-2004.
 PD 14-AUG-2003; 2003WO-US025465.
 PF 14-AUG-2002; 2002US-0403416P.
 XX (PHAA) PHARMACIA CORP.
 PA Roberds SL;
 PI WPI; 2004-203785/19.
 DR New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX Claim 4; SEQ ID NO 5536; 417pp; English.
 PS The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate

CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 957 AGAGCGCGAATTCTGCAG 976
DB 20 AAGAGCGCGAATTCTGCAG 1

RESULT 113

ADK78057/c
ID ADK78057 standard; DNA; 20 BP.

XX
AC ADK78057;

XX 20-MAY-2004 (first entry)

XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5391.

XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.

XX Synthetic.

XX WO2004016754-A2.

XX 26-FEB-2004.

XX 14-AUG-2003; 2003WO-US025465.

XX 14-AUG-2002; 2002US-0403416P.

XX (PHAA) PHARMACIA CORP.

XX Roberds SL;

XX WPI; 2004-203785/19.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.

XX Claim 4; SEQ ID NO 5391; 417pp; English.

XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.3e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 958 AGAGCGCGAATTCTGCAG 977
DB 20 AGAGCGCGAATTCTGCAG 1

RESULT 114

ADK77138/c

ID ADK77138 standard; DNA; 20 BP.

XX
AC ADK77138;

XX 20-MAY-2004 (first entry)

XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4472.

XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.

XX Synthetic.

XX WO2004016754-A2.

XX 26-FEB-2004.

XX 14-AUG-2003; 2003WO-US025465.

XX 14-AUG-2002; 2002US-0403416P.

XX (PHAA) PHARMACIA CORP.

XX Roberds SL;

XX WPI; 2004-203785/19.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.

XX Claim 4; SEQ ID NO 4472; 417pp; English.

XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX Sequence 20 BP; 3 A; 4 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 952 ACATAAAGAGCGCGAATTTC 971
DB 20 ACAAAGAGCGCGAATTTC 1

RESULT 115

ADK78574/c

ID ADK78574 standard; DNA; 20 BP.
XX AC ADK78574;
XX DT 20-MAY-2004 (first entry)
XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5908.
XX KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX KW diabetic neuropathy; arthritic pain; migraine headache;
XX KW infantile epilepsy; ataxia; ss.
XX OS Synthetic.
XX XX WO2004016754-A2.
XX PD 26-FEB-2004.
XX PF 14-AUG-2003; 2003WO-US025465.
XX PR 14-AUG-2002; 2002US-0403416P.
XX PA (PHAA) PHARMACIA CORP.
XX PI Roberts SL;
XX XX WPI; 2004-203785/19.
XX DR New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX PS Claim 4; SEQ ID NO 5908; 417pp; English.
XX XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'WOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX XX Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. NO. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 956 AAAGAGCGGATTTCTGCA 975
DB 20 AAAGAGCGGATTTCTGCA 1
RESULT 116
AAQ75768
ID AAQ75768 standard; DNA; 21 BP.
XX AC AAQ75768;
XX DT 04-AUG-1995 (first entry)
XX DE Reverse transcription primer used in cDNA analysis technique.
XX XX Analysis; gene expression; reverse transcription; primer; cDNA;
KW aggregate; restriction enzyme; ss.

XX OS Synthetic.
XX XX JP06303997-A.
XX PD 01-NOV-1994.
XX PF 16-APR-1993; 93JP-00112515.
XX PR 16-APR-1993; 93JP-00112515.
XX PA (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.
XX XX WPI; 1995-018287/03.
XX DR Analysis of cDNA and gene expression - by amplification of mRNA followed
PT by digestion with restriction enzymes.
XX PS Disclosure; Page 9; 11pp; Japanese.
XX CC A method for the analysis of cDNA comprises (a) preparing an aggregate of
CC double-stranded cDNAs by using an aggregate of mRNAs and a plural type of
CC labelled reverse transcription primers (GENESEQ files AAQ7547-Q75798)
CC and using the aggregate of mRNAs as the template for each reverse
CC transcription primer; (b) digesting each of the prepared aggregates of
CC the double-stranded cDNAs with restriction enzyme and; (c)
CC electrophoresing the digested aggregate of cDNAs in separate lanes. The
CC method can be used to analyse gene expression rapidly and easily
XX XX Sequence 21 BP; 1 A; 1 C; 1 G; 18 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. NO. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2571 TTCTCTTTTTTTTTCTGCA 2590
DB 2 TTTTTTTTTTTTTTCTGCA 21
RESULT 117
AAZ46103/C
ID AAZ46103 standard; DNA; 21 BP.
XX AC AAZ46103;
XX DE PCR primer used to isolate human NIT1 cDNA sequences.
XX KW NIT1 gene; nitrlase; tumour suppressor gene; FHIT; chromosome 3p14.2;
XX KW FRA3B; cancer; genome allele inactivation; PCR primer; ss.
XX OS Homo sapiens.
XX XX WO200003685-A2.
XX PD 27-JAN-2000.
XX PF 20-JUL-1999; 99WO-US016366.
XX PR 20-JUL-1998; 98US-0093350P.
XX PA (UYJE-) UNIV JEFFERSON THOMAS.
XX PI Croce CM;
XX XX WPI; 2000-171195/15.
XX PT Novel nitrlase homologs used as diagnostic and therapeutic reagents for
XX the detection and treatment of cancer.
XX PS Disclosure; Page 6; 25pp; English.

XX PCR primers AAX246102-03 were used to isolate the human NIT1 gene cDNA
CC sequence. The human and mouse NIT1 genes are members of an
CC uncharacterised mammalian gene family with homology to bacterial and
CC plant nitrilases. The tumour suppressor gene FHIT in D. melanogaster and
CC C. elegans code for fusion proteins in which the Phit domain is fused
CC with a Nit domain. In mouse and humans, FHIT and NIT are encoded by two
CC different genes, localised on chromosomes 3 and 1 in human and 14 and 1
CC in mouse. The human FHIT gene at chromosome 3p14.2, spanning the
CC constitutive chromosomal fragile site FRA3B, is often altered in most
CC common forms of human cancer. The Nit1 protein overcomes the mutated
CC inactivation of the genome alleles. The NIT1 genes, encoded polypeptides,
CC derivatives and analogues of them, and antibodies are used as diagnostic
CC and therapeutic reagents for the detection and treatment of cancers
XX
SQ Sequence 21 BP; 4 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2172 AAGTGAGGGGAGCTGTCTCT 2191
Db |||||
21 AAGTGAGGGGAGCTGTGCT 2
RESULT 118
AAX24533
ID AAX24533 standard; DNA; 18 BP.
AC AAX24533;
XX
XX 20-MAR-2003 (revised)
DT 21-JUN-1999 (first entry)
XX
XX Human SR-BI gene exon 12 primer 3e100srbl.
DE
XX SR-BI; human; polymorphism; cardiovascular disorder; ischaemia;
KW restenosis; congestive heart failure; atherosclerosis; cholesterol;
KW low density lipoprotein; LDL; high density lipoprotein; HDL; diagnosis;
KW body mass index; obesity; cachexia; gallstone; PCR; primer; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX WO9902735-A2.
PN
XX 21-JAN-1999.
PD
XX 10-JUL-1998; 98WO-US014354.
PF
XX 10-JUL-1997; 97US-00890979.
PR
XX 27-FEB-1998; 98US-00031626.
XX
XX (MILL-) MILLENNIUM PHARM INC.
PA (TUFT) UNIV TUFTS.
XX
XX Acton SL, Ordovas JM;
PI
XX WPI; 1999-120935/10.
XX
XX Detecting genetic predisposition for body mass disorders - by identifying
PT allelic variants of a polymorphic region of the SR-BI gene.
XX
XX Example 2; Page 68; 102pp; English.
PS
XX Primer 3e100srbl is used with primer 5e112srbl (see AAX24532) in the PCR
CC amplification of exon 12 (see AAX24509) of the human SR-BI gene. The
CC invention is based on the discovery of the genomic structure of the human
CC SR-BI gene (see AAX24498-509) and on the identification of polymorphic
CC regions within the gene which are associated with abnormal body mass
CC index (BMI) and abnormal lipoprotein levels and hence with disorders such
CC as obesity, cachexia, cardiovascular disorders and gallstone formation.
XX

CC Primers (see AAX24510-35) are provided for amplification of the exons,
CC introns and promoter region of the SR-BI gene for detection of
CC polymorphisms and mutations. The invention provides methods for
CC determining whether a subject has, or is at risk of developing, a disease
CC associated with a specific allele of a polymorphic region of an SR-BI
CC gene. Kits comprising the relevant probe or primer are claimed. (Updated
CC on 20-MAR-2003 to correct PA field.)
XX
SQ Sequence 18 BP; 6 A; 1 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2774 TTAAGGCTGAAGGAATGA 2791
Db |||||
1 TTGAGGCTGAAGGAATGA 18
RESULT 119
AAX24625
ID AAX24625 standard; DNA; 18 BP.
XX
XX AAX24625;
AC
XX
XX 21-JUN-1999 (first entry)
DT
XX Human SR-BI gene exon 12 primer 3e100srbl.
DE
XX SR-BI; human; polymorphism; cardiovascular disorder; ischaemia;
KW restenosis; congestive heart failure; atherosclerosis; cholesterol;
KW low density lipoprotein; LDL; high density lipoprotein; HDL; diagnosis;
KW body mass index; obesity; cachexia; gallstone; PCR; primer; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX WO9902736-A2.
PN
XX 21-JAN-1999.
PD
XX 10-JUL-1998; 98WO-US014359.
PF
XX 10-JUL-1997; 97US-00890980.
PR
XX 27-FEB-1998; 98US-00032894.
XX
XX (MILL-) MILLENNIUM PHARM INC.
PA
XX Acton SL;
PI
XX WPI; 1999-120936/10.
XX
XX New nucleic acids comprising intronic sequence of a human scavenger
PT receptor-BI (SR-BI) gene - useful for prognosis, diagnosis and treatment
PT of SR-BI associated diseases or conditions.
XX
XX Claim 10; Page 67; 103pp; English.
PS
XX Primer 3e100srbl is used with primer 5e100srbl (see AAX24624) in the PCR
CC amplification of exon 12 (see AAX24601) of the human SR-BI gene. The
CC invention is based on the discovery of the genomic structure of the human
CC SR-BI gene (see AAX24590-601) and on the identification of polymorphic
CC regions within the gene which are associated with abnormal body mass
CC index (BMI) and abnormal lipoprotein levels and hence with disorders such
CC as obesity, cachexia, cardiovascular disorders and gallstone formation.
CC Claimed primers (see AAX24602-25) are used for the amplification of the
CC exons, introns and promoter region of the SR-BI gene for detection of
CC polymorphisms and mutations. The invention provides methods for
CC determining whether a subject has, or is at risk of developing, a disease
CC associated with a specific allele of a polymorphic region of an SR-BI
CC gene. Kits comprising the relevant probe or primer are claimed
XX
XX Sequence 18 BP; 6 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

CC conditions associated with expression of phosphodiesterase 4D, e.g.
 CC cancer, cardiovascular disease or inflammation. The antisense compounds
 CC are also useful as research reagents and kits, or in diagnostic,
 CC therapeutic and prophylaxis applications, e.g. to prevent or delay
 CC infection, inflammation or tumour formation. This sequence represents a
 CC human phosphodiesterase 4D antisense oligonucleotide.

XX
 SQ Sequence 20 BP; 6 A; 1 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3635 TTTGTATTGTCAGAAAT 3652
 |||||
 DB 2 TTTGTATTGATCAGAAAT 19

RESULT 124
 ABK65666
 ID ABK65666 standard; DNA; 21 BP.
 XX AC
 XX ABK65666;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human single nucleotide polymorphism #286.
 XX
 KW Human; single nucleotide polymorphism; SNP; sickle cell anaemia;
 KW agammaglobulinaemia; diabetes insipidus; Lesch-Nyhan syndrome;
 KW muscular dystrophy; Wiskott-Aldrich syndrome; Fabry's disease;
 KW familial hypercholesterolaemia; polycystic kidney disease; cancer;
 KW hereditary spherocytosis; Von Willebrand's disease; tuberous sclerosis;
 KW hereditary haemorrhagic telangiectasia; familial colonic polyposis;
 KW Ehlers-Danlos syndrome; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; inflammation; nervous system disorder;
 KW infection; rheumatoid arthritis; multiple sclerosis; diabetes;
 KW systemic lupus erythematosus; Graves disease; longevity; obesity;
 KW baldness; fertility; forensic; paternity testing; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002037508-A1.
 XX
 PD 28-MAR-2002.
 XX
 PF 18-JAN-2001; 2001US-00765081.
 XX
 PR 19-JAN-2000; 2000US-0176861P.
 XX
 PA (CARG/) CARGILL M.
 PA (IREL/) IRELAND J. S.
 PA (LAND/) LANDER E. S.
 XX
 XX Cargill M, Ireland JS, Lander ES;
 PI
 XX WPI; 2002-315108/35.
 XX
 DR
 XX Nucleic acid comprising single nucleotide polymorphisms, useful in
 PT forensics, paternity testing and diagnosis of disease.
 PT
 XX
 PS Claim 1; Page 71; 96pp; English.

CC The invention relates to a nucleic acid comprising single nucleotide
 CC polymorphisms (SNPs) associated with diseases. The nucleic acids
 CC comprising the SNPs and probes and primers for detecting them may be used
 CC in assays for the diagnosis of diseases associated with SNPs (such as
 CC sickle cell anaemia, agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan
 CC syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
 CC familial hypercholesterolaemia, polycystic kidney disease, hereditary
 CC spherocytosis, Von Willebrand's disease, tuberous sclerosis, hereditary
 CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
 CC syndrome, osteogenesis imperfecta, and acute intermittent porphyria,

CC symptoms of, or susceptibility to, multifactorial diseases of which a
 CC component is or may be genetic, such as autoimmune diseases,
 CC inflammation, cancer, diseases of the nervous system, and infection by
 CC pathogenic microorganisms, autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes (insulin-dependent and non-
 CC independent), systemic lupus erythematosus and Graves disease, cancers
 CC including cancers of the bladder, brain, breast, colon, oesophagus,
 CC kidney, leukaemia, liver, lung, oral cavity, ovary, pancreas, prostate,
 CC skin, stomach and uterus, longevity, appearance (e.g., baldness,
 CC obesity), strength, speed, endurance, fertility, and susceptibility or
 CC receptivity to particular drugs or therapeutic treatments), in forensics
 CC and in paternity testing. ABK65381-ABK65841 represent human single
 CC nucleotide polymorphisms of the invention

XX
 SQ Sequence 21 BP; 3 A; 9 C; 2 G; 6 T; 0 U; 1 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 21;
 Best Local Similarity 85.0%; Pred. No. 1.6e+02;
 Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1723 CTTGAAGCCTTCTCCTTCCA 1742
 |||||
 DB 1 CTTTAAGCCTKCTCTGCCA 20

RESULT 125
 ABQ81102
 ID ABQ81102 standard; DNA; 21 BP.
 XX AC
 XX ABQ81102;
 XX
 DT 25-NOV-2002 (first entry)
 XX
 DE Rat HNF1-alpha sense PCR primer.
 XX
 XX Multipotent adult stem cell; MSC; cell replacement therapy; cytostatic;
 KW cardiant; cardiovascular; hepatotropic; haemostatic; antidiabetic;
 KW virucide; antiinflammatory; vasotropic; antianaemic; neuroprotective;
 KW cerebroprotective; immunosuppressive; antibacterial; rat; hepatocyte;
 KW HNF1-alpha; PCR; primer; ss.
 XX
 OS Rattus sp.
 XX
 PN WO200264748-A2.
 XX
 PD 22-AUG-2002.
 XX
 PF 14-FEB-2002; 2002WO-US004652.
 XX
 PR 14-FEB-2001; 2001US-0268786P.
 PR 15-FEB-2001; 2001US-0269062P.
 PR 07-AUG-2001; 2001US-0310625P.
 PR 25-OCT-2001; 2001US-0343386P.
 XX
 XX (ANON) ANONYMOUS.
 PA
 XX
 XX WPI; 2002-667000/71.
 XX
 DR
 XX New multipotent adult stem cells that can be induced to differentiate to
 PT form a cell type of mesodermal, ectodermal or endodermal origin, useful
 PT for treating e.g. cancer, diabetes, hepatitis, hemophilia, ischemia or
 PT inflammation.
 PT
 XX
 PS Example 11; Page 70; 117pp; English.

CC The present sequence comprises a sense primer for rat HNF1-alpha, a late
 CC marker of hepatocyte differentiation. Quantitative RT-PCR of early and
 CC late markers of hepatocyte differentiation was performed to demonstrate
 CC that fibroblast growth factor 4 (FGF4) and hepatocyte growth factor (HGF)
 CC induce differentiation of rat multipotent adult stem cells (MASC) into
 CC hepatocytes. HNF1-alpha mRNA expression increased between days 7 and 14
 CC following treatment of rat MASC with FGF4 and HGF. The invention relates
 CC to methods of obtaining, maintaining and differentiating MASC. The MASC

are derived from a non-embryonic organ or tissue, such as bone marrow, muscle, brain, umbilical cord blood or placenta, and have the capacity to be induced to differentiate to a cell type of mesodermal, ectodermal or endodermal origin, including osteoblast, chondrocyte, adipocyte, fibroblast, marrow stroma, skeletal muscle, smooth muscle, cardiac muscle, endothelial, epithelial, liver, pancreas, haematopoietic, glial, neuronal or oligodendrocyte cell types. MSC constitutively express oct4 and high levels of telomerase and are negative for CD44. MHC class I and MHC class II expression. Teratomas are not formed when MSC are administered to a patient. MSC or their progeny are particularly useful for treating cancer, cardiovascular disease, metabolic disease, liver disease, diabetes, hepatitis, haemophilia, degenerative or traumatic neurological conditions, autoimmune disease, genetic deficiency, connective tissue disorders, anaemia, infectious disease, transplant rejection, ischaemia or inflammation. Treatment may be directed to abdominal aortic aneurysm, cardiac bypass surgery, peripheral vascular disease, or coronary vascular disease (all claimed)

Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 1.6e-02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2182 AGCTGCTCTCCATCTTC 2199
|||||
Db 1 AGCTGCTCTCCATCATC 18

RESULT 126
ADE36639/c
ID ADE36639 standard; DNA; 21 BP.

AC ADE36639;
XX
XX
XX 29-JAN-2004 (first entry)
XX Human ERG gene PCR primer.
XX foetal aneuploidy; foetal allele; detection; foetal DNA; prenatal;
KW chromosome aberration; chromosome mutation; PCR primer; human; ERG gene;
KW chromosome 21; ss.

XX Synthetic.
OS Homo sapiens.

PN WO2003062441-A1.

XX 31-JUL-2003.

XX 17-JAN-2003; 2003WO-US001551.

XX 18-JAN-2002; 2002US-0349877P.

XX (GENZ) GENZYME CORP.

XX Landes GM, Michalowsky L, Miller G, Weber W;

XX WPI; 2003-902657/82.

XX Detecting fetal aneuploidies or alleles of a gene of interest in fetal DNA by determining the ratio of methylated and unmethylated DNA in maternal serum is useful for prenatal detection of chromosome aberrations and mutations.

XX Example 4; Page 17; 31pp; English.

XX The present invention describes methods for detecting foetal aneuploidies, alleles of a gene of interest in foetal DNA and imprinted genes in a subject. Also described: (1) detecting foetal aneuploidies comprising treating DNA from maternal serum with a reagent that differentially modifies methylated and non-methylated DNA and performing quantitative PCR using one primer pair on a potentially aneuploid

CC chromosome and a on a non-aneuploid chromosome with an different primer
CC pair and comparing the ratio of the quantity of the two PCR products; (2)
CC detecting alleles of a gene of interest in foetal DNA, comprising
CC treating DNA isolated from maternal serum with bisulfite, performing PCR
CC with a primer pair that amplifies the gene of interest and analysing the
CC PCR product to identify the allele of the gene of interest; (3) detecting
CC imprinted genes in a subject comprises treating DNA isolated from the
CC subject with bisulfite, performing PCR with a primer pair for a
CC polymorphic region that only amplifies bisulfite-treated unmethylated DNA
CC and analysing the PCR product to identify the polymorphism thereby
CC detecting imprinted genes. The invention is used for prenatal detection
CC of chromosome aberrations and mutations. The present sequence represents
CC a PCR primer for the human ERG gene, which is used in an example from the
CC present invention. The human ERG gene is located on chromosome 21 within
CC the Down's critical region.

XX Sequence 21 BP; 4 A; 0 C; 10 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 1.6e-02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 993 ACTACATGAACCTCAACC 1010
|||||
Db 20 ACTACATGAACCTCAACC 3

RESULT 127

AAQ40984
ID AAQ40984 standard; DNA; 21 BP.

AC AAQ40984;

XX 17-DEC-2001 (revised)

DT 06-OCT-1993 (first entry)

XX Rabbit mono ADP-ribosyltransferase gene PCR primer BSC2.

XX Antisense technology; gene therapy; structure/function studies;
KW production; preparation; prodn; prepn; antibody; NAD; arginine;
KW polymerase chain reaction; ss.

XX Synthetic.

XX USN7985698-N.

XX 01-MAY-1993.

XX 30-NOV-1992; 92US-00985698.

XX 30-NOV-1992; 92US-00985698.

XX (USSH) US DEPT HEALTH & HUMAN SERVICE.

XX Moss J, Zolkiewska A, Okazaki I, Nightingale MS;

XX WPI; 1993-188869/23.

XX Gene sequences encoding mono-ADP-ribosyl:transferase - specifically from rabbit skeletal muscle and human form, useful in antisense technology.

XX Example; Page 45; 46pp; English.

XX The sequence is that of the PCR primer BSC2 which was used in a PCR for the generation of partial ADP-ribosyltransferase sequences from a rabbit skeletal muscle cDNA library. (Note: Revised entry submitted to correct the patent number format of US Government-owned NTIS applications to prevent clashes with ongoing US granted patent numbers. For further information please visit the Derwent web site at www.derwent.com/dwpi/updates/ntis_us.html.)

XX Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

```
Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      885 GCTCTGAGCTAGTGGTTCCC 905
      ||||| ||||| ||||| |||||
Db      1 GCTCTAGAACTAGTGGATCCC 21

RESULT 128
AAQ75628
ID      AAQ75628 standard; DNA; 21 BP.
XX
AC      AAQ75628;
XX
DT      04-AUG-1995 (first entry)
XX
DE      Reverse transcription primer used in cDNA analysis technique.
XX
KW      Analysis; Gene expression; reverse transcription; primer; cDNA;
KW      aggregate; restriction enzyme; ss.
XX
OS      Synthetic.
XX
PN      JP06303997-A.
XX
PD      01-NOV-1994.
XX
PF      16-APR-1993; 93JP-00112515.
XX
PR      16-APR-1993; 93JP-00112515.
XX
PA      (NITE ) NIPPON TELEGRAPH & TELEPHONE CORP.
XX
DR      WPI; 1995-018287/03.
XX
PT      Analysis of cDNA and gene expression - by amplification of mRNA followed
PT      by digestion with restriction enzymes.
XX
PS      Disclosure; Page 6; 11pp; Japanese.
XX
CC      A method for the analysis of cDNA comprises (a) preparing an aggregate of
CC      double-stranded cDNAs by using an aggregate of mRNAs and a plural type of
CC      labelled reverse transcription primers (GENESQ files AAQ75547-Q75798)
CC      and using the aggregate of mRNAs as the template for each reverse
CC      transcription primer; (b) digesting each of the prepared aggregates of
CC      the double-stranded cDNAs with restriction enzyme and; (c)
CC      electrophoresing the digested aggregate of cDNAs in separate lanes. The
CC      method can be used to analyse gene expression rapidly and easily
XX
SQ      Sequence 21 BP; 3 A; 0 C; 1 G; 17 T; 0 U; 0 Other;

Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2572 TCTTCTTTTCTTTTCTGAAA 2592
      ||||| ||||| ||||| |||||
Db      1 TTTTCTTTTCTTTTCTGAAA 21

RESULT 129
AAZ26823
ID      AAZ26823 standard; DNA; 21 BP.
XX
AC      AAZ26823;
XX
DT      30-NOV-1999 (first entry)
XX
DE      Human polymorphic region 1012.
XX
KW      Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
KW      cell viability; loss of heterozygosity; precancerous condition; ASI;

allele specific inhibitor; somatic cell; diagnosis; prevention;
atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
graft versus host disease; malignant cell removal; bone marrow; ss.
Homo sapiens.
WO9841648-A2.
24-SEP-1998.
19-MAR-1998; 98WO-US005419.
20-MAR-1997; 97US-0041057P.
(VARI-) VARIAGENICS INC.
Housman D, Ledley FD, Stanton VP;
WPI; 1998-521232/44.
Identifying target genes for allele-specific drugs - used for diagnosis,
prevention and treatment of, e.g. cancers, atherosclerotic plaque,
dysplastic lesions, endometriosis or graft versus host disease.
Disclosure; Fig 7; 605pp; English.
This invention describes a novel method for identifying an inhibitor
potentially useful for treatment of cancer, where the inhibitor is active
on a gene vital for cell growth or viability, and where the gene is
subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is
used for preventing the development of cancer in a patient having a
precancerous condition, by administering to the patient a first allele
specific inhibitor (ASI) targeted to an allele of a first essential gene
present in cells of the precancerous condition, where the normal somatic
cells of the patient are heterozygous for the first gene, the inhibitor
is active on at least one but less than all allelic forms of the gene
present in a population and targets only one allelic form present in the
normal somatic cells, and the first gene. The products and methods can be
used in the diagnosis, prevention and treatment of LOH disorders, e.g.
cancers, atherosclerotic plaques, premalignant metaplastic or dysplastic
lesions, benign tumours, endometriosis, polycystic kidney disease, and
graft versus host disease. The method can also be used to remove
malignant cells from bone marrow transplants. AAZ25812-226825 represent
human polymorphic sites described in the method of the invention
XX
SQ      Sequence 21 BP; 9 A; 0 C; 1 G; 11 T; 0 U; 0 Other;

Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2579 TTTTCTTTCTGAAAAGGAA 2599
      ||||| ||||| ||||| |||||
Db      1 TTTTCTTTCTTAAAAAGAAA 21

RESULT 130
AAV63068
ID      AAV63068 standard; DNA; 21 BP.
XX
AC      AAV63068;
XX
DT      19-JAN-1999 (first entry)
XX
DE      Human ADP-ribosyltransferase PCR primer BSC2.
XX
KW      ADP-ribosyltransferase; intracellular protein activity; primer; probe;
KW      diagnostic reagent; enzyme; identification; inhibitor; activator; ss.
XX
OS      Synthetic.
OS      Homo sapiens.
XX
```

```

PN US5934310-A.
XX
PD 10-NOV-1998.
XX
PF 18-JUL-1997; 97US-00896410.
XX
PR 30-NOV-1992; 92US-00985698.
PR 30-MAY-1995; 95US-00454556.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Nightingale MS, Zolkiewska A, Okazaki I, Moss J;
XX WPI; 1999-008730/01.
DR
XX
PT New isolated ADP-ribosyl transferase nucleic acids - used to study the
PT effects and functions of ADP-ribosyltransferases, and to develop products
PT for diagnosis and therapy.
XX
PS Example 3; Col 39-40; 28pp; English.
XX
CC AAV63055-V63086 are PCR primers and probes used in the amplification of a
CC human and rabbit ADP-ribosyltransferase which can be used to study its
CC effect in cells and effect on intracellular protein activity. The
CC products permit the isolation of the protein in amounts suitable for
CC purification for antibody production, the development of diagnostic
CC reagents, sensitive tests to detect the activity of this enzyme in cell
CC lysates and for identifying inhibitors and activators
XX
SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 885 GCTCTGGAGCTAGTGTTCCC 905
DB 1 GCTCTAGAACTAGTGGATCCC 21

RESULT 131
AAF30072/c
ID AAF30072 standard; DNA; 21 BP.
XX
AC AAF30072;
XX
DT 30-APR-2001 (first entry)
XX
DE Human PRO256 DNA reverse PCR primer.
XX
XX PRO256; UNQ223; human; immune disease; autoimmune disease; antirheumatic;
KW antarthritic; antiinflammatory; antinaemic; immunosuppressive;
KW antithyroid; antidiabetic; neutroprotective; hepatotropic; virucide;
KW dermatological; antiporiatic; antiasthmatic; antiallergic;
KW immunostimulant; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX WO200105972-A1.
PN
XX 25-JAN-2001.
PD
XX
XX 15-MAR-2000; 2000WO-US006884.
PF
XX
XX 20-JUL-1999; 99US-0144758P.
PR
XX
PA (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Fong S, Goddard A, Godowski PJ;
PI Gurney AL, Hillan KJ, Mark MR, Marsters SA, Pitti RM, Tumas D;
PI Watanabe CK, Wood WI;
XX WPI; 2001-103149/11.
DR

```

```

XX New PRO polypeptides, nucleic acids and (ant)agonists, useful for
PT diagnosing and treating immune-related disorders, such as multiple
PT sclerosis, rheumatoid arthritis and diabetes.
XX
XX Example 1.F; Page 93; 127pp; English.
XX
XX This oligonucleotide is based on consensus sequence DNA28725, assembled
CC from expressed sequence tag clones following human cDNA screening in
CC yeast transformants. It was used as reverse primer to identify by PCR a
CC cDNA library that contained human PRO256 cDNA. A positive library,
CC constructed from human placenta tissue RNA, was then screened to obtain
CC full-length cDNA (see AAF30055) for PRO256 (see AAB20113). PRO256 is 1 of
CC 13 novel proteins of the invention involved in immunomodulation. Methods
CC are provided for using these proteins, nucleic acids encoding them,
CC agonists, antagonists and antibodies in the diagnosis and treatment of
CC immune-related disorders
XX
SQ Sequence 21 BP; 3 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 612 CCTTGAAGAGTGCCATCCAGT 632
DB 21 CATGMAAGGCGCCATCCAGT 1

RESULT 132
AAD16723/c
ID AAD16723 standard; DNA; 21 BP.
XX
AC AAD16723;
XX
DT 19-NOV-2001 (first entry)
XX
DE Reverse PCR primer to isolate human PRO256 cDNA clone.
XX
XX Human; PRO256 protein; cardiovascular; endothelial; angiogenic disorder;
KW cardiac hypertrophy; trauma; cardiac; age-related macular degeneration;
KW gene therapy; angiogenesis; prostate activity; hepatocyte growth factor;
KW peripheral vascular disease; hepatic; renal injury; nephrotropic; tumour;
KW restinosis; tranquilizer; vulnerary; cytostatic; hepatotropic;
KW PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200159100-A2.
PN
XX 16-AUG-2001.
PD
XX 19-DEC-2000; 2000WO-US034756.
XX
XX 11-FEB-2000; 2000WO-US003565.
PR
XX 15-MAR-2000; 2000WO-US006884.
PR
XX 28-NOV-2000; 2000US-0253665P.
XX
XX (GETH ) GENENTECH INC.
PA
XX Gurney AL, Kirchhofer DK, Wood WI;
PI
XX WPI; 2001-541567/60.
DR
XX
XX An isolated polypeptide designated PRO256 useful for treating a
PT cardiovascular, endothelial, or angiogenic disorder.
XX
XX Example 1; Page 100; 124pp; English.
PS
XX
XX The present invention relates to PRO256 or its agonist/antagonist may be
CC used to treat a cardiovascular, endothelial, or angiogenic disorder in a
CC mammal, especially a human with cardiac hypertrophy, trauma, a type of
CC tumour or age-related macular degeneration. PRO256 may be administered
CC

```

CC together with a cardiovascular, endothelial, or angiogenic agent, a
 CC chemotherapeutic agent, a growth inhibitory agent, or a cytotoxic agent.
 CC PRO256 may also be used to treat the disorders above, preferably through
 CC administration via *ex vivo* gene therapy. PRO256 or its agonist may be
 CC used to inhibit endothelial cell growth, angiogenesis or protease
 CC activity of a hepatocyte growth factor, whereas an antagonist of PRO256
 CC may be used to stimulate endothelial cell growth, angiogenesis or
 CC protease activity of a hepatocyte growth factor. Stimulation or
 CC inhibition of the protease activity of a hepatocyte growth factor is
 CC preferably carried out where a mammal has a cardiovascular, endothelial,
 CC or angiogenic disorder selected from peripheral vascular disease, hepatic
 CC or renal injury or a restenosis disorder. The present sequence is human
 CC hepatocyte growth factor activator inhibitor, PRO256 cDNA clone isolating
 CC reverse PCR primer
 XX
 XX Sequence 21 BP; 3 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 612 CCTTGAAGGTGCCATCCAGT 632
 DB 21 CATGGAAGGCGCCATCCAGT 1

RESULT 133
 ABK40306/c
 ID ABK40306 standard; DNA; 21 BP.

XX AC ABK40306;
 XX DT 15-JUL-2002 (first entry)
 XX DE Reverse PCR primer for human PRO256 DNA.

XX Human; PRO; benign tumour; malignant tumour; lymphoid malignancy;
 KW leukaemia; neuronal disorder; stromal disorder; blastocoele disorder;
 KW inflammatory disorder; immune disorder; angiogenic disorder; cytostatic;
 KW neuroprotective; PCR; primer; ss.

XX Homo sapiens.

XX WO200153486-A1.

XX 26-JUL-2001.

XX PF 11-FEB-2000; 2000WO-US003365.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 11-MAR-1999; 99US-0123972P.

XX PR 11-MAY-1999; 99US-0133459P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 22-JUN-1999; 99US-0140650P.

XX PR 20-JUL-1999; 99US-0144758P.

XX PR 26-JUL-1999; 99US-0145698P.

XX PR 28-JUL-1999; 99US-0146222P.

XX PR 17-AUG-1999; 99US-0149385P.

XX PR 31-AUG-1999; 99US-0151689P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 01-DEC-1999; 99WO-US028301.

XX PR 01-DEC-1999; 99WO-US028634.

XX PR 05-JAN-2000; 2000WO-US000219.

(GETH) GENENTECH INC.

XX Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;

XX Marsters SA, Pan J, Pitti RM, Roy MA, Smith V, Stone DM;

XX Watanabe CK, Wood WI;

DR WPI; 2002-205567/26.

XX Thirty five nucleic acids encoding PRO polypeptides, useful for treating
 PT benign or malignant tumors, leukemias and lymphoid malignancies,
 PT inflammatory, angiogenic and immunologic disorders.

XX Example 8; Page 116; 302pp; English.

XX The present invention relates to the isolation of novel human PRO
 CC polypeptides (AAU86128-AAU86162) and the polynucleotide sequences
 CC encoding them. The PRO polypeptides, agonists, antagonists or anti-PRO
 CC antibodies are useful for treating benign or malignant tumours (e.g.
 CC renal, kidney, bladder, breast, etc), leukemias and lymphoid
 CC malignancies, other disorders such as neuronal, glial, astrocytal,
 CC hypothalamic, glandular, macrophagal, stromal and blastocoele disorders,
 CC inflammatory, immune and angiogenic disorders. The polynucleotide
 CC sequences are also useful in gene therapy. The present sequence
 CC represents a PCR primer used in the methods of the present invention
 XX
 XX Sequence 21 BP; 3 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 612 CCTTGAAGGTGCCATCCAGT 632
 DB 21 CATGGAAGGCGCCATCCAGT 1

RESULT 134

ABST74302/c

ID ABS74302 standard; DNA; 21 BP.

XX AC ABS74302;

XX DT 09-DEC-2002 (first entry)

XX DE Human calcium channel alpha2delta SSCP PCR primer #26.

XX Human; ss; primer; calcium channel alpha2delta; splice isoform; CACNA2D2;
 KW gene therapy; Lambert-Eaton myasthenic syndrome; LEMS; PCR;
 KW autoimmune disease; epilepsy; migraine; episodic ataxia; cancer; stroke;
 KW brain trauma; Alzheimer's disease; multiinfarct dementia; convulsion;
 KW Korea-koff's disease; amyotrophic lateral sclerosis; seizure;
 KW Huntington's disease; amnesia; cardiac arrhythmia; angina pectoris;
 KW hypoxia; ischaemia; myocardial infarction; congestive heart failure;
 KW muscular dystrophy; hypertension; chromosome 3p21.3; lung cancer;
 KW breast cancer; preneoplastic lesion; hyperplasia; dysplasia; carcinoma;
 KW SSCP; single strand change polymorphism.

XX Homo sapiens.

XX US6441156-B1.

XX 27-AUG-2002.

XX 22-DEC-1999; 99US-00470443.

XX 30-DEC-1998; 98US-0114359P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Lerman MI, Latif F, Wei M, Duh F, Minna JD, Sekido Y, Gao B;

XX WPI; 2002-730574/79.

XX Novel purified nucleic acid sequence encoding human calcium channel
 PT alpha2delta subunit protein, useful for detecting, preventing and
 PT treating cancer, stroke, brain trauma, Huntington's disease, myocardial
 PT infarction.

XX Example 7; Col 47; 77pp; English.

XX The invention relates to a purified nucleic acid sequence (referred as
CC CACNA2D2 gene which encodes human calcium channel alpha2delta-2 subunit
CC protein) comprising a fully defined alpha2delta splice isoform 1, 2 or 3
CC nucleic acid sequence, or its complement and the encoded proteins. Also
CC include are: (1) a method of producing a calcium channel protein which
CC involves introducing a recombinant expression vector comprising the
CC CACNA2D2 nucleic acids and encoding the calcium channel protein, into a
CC cultured host cell under conditions such that the host cell expresses the
CC amino acid sequences; and (2) a method for co-expressing calcium channel
CC proteins, comprising carrying out the method of (1), but with one or more
CC than one expression vector comprising one or more nucleic acid sequences
CC encoding the splice variants. CACNA2D2 nucleic acid is useful for
CC producing a calcium channel protein. The recombinantly expressed
CC polypeptide is useful for treating patients with Lambert-Eaton myasthenic
CC syndrome (LEMS) (an autoimmune disease) and for identifying compounds
CC useful for treating other diseases associated with abnormal calcium
CC channel protein activity (e.g. epilepsy, migraine, episodic ataxia,
CC cancer, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia,
CC Korsakoff's disease, amyotrophic lateral sclerosis, convulsions,
CC seizures, Huntington's disease, amnesia, cardiac arrhythmia, angina
CC pectoris, hypoxic damage to the cardiovascular system, ischaemic damage
CC to the cardiovascular system, myocardial infarction, congestive heart
CC failure, muscular dystrophy and hypertension) CACNA2D2 nucleic acid is
CC useful as primers and probes for detecting presence of nucleic acid
CC sequence encoding at least a portion of calcium channel protein, in
CC detection, identification and isolation of alpha2delta sequences
CC diagnosing and typing of preneoplasias and cancers, since genetic
CC disruption of 3p21.3 region (in which the alpha 2delta gene is located)
CC is common in cancer (e.g. lung cancer and breast cancer) and
CC preneoplastic lesion (e.g. hyperplasia, dysplasia, carcinoma in situ).
CC The present is an SSCP (single strand change polymorphism) PCR primer
CC used to detect polymorphisms in sequences encoding a human calcium
CC channel alpha2delta splice isoform protein
XX

XX SQ Sequence 21 BP; 6 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2305 CGGATTTTCAACTGGCCAAACC 2325
Db 21 CGTATGTTCAACTGGCCATCC 1
|||||
|||||

RESULT 135
ACD25700/c
ID ACD25700 standard; DNA; 21 BP.
XX
XX ACD25700;
XX
XX 26-AUG-2003 (first entry)
XX
XX Human calcium channel alpha2delta SSCP primer MJE8R.
XX
XX Human; ss; PCR; calcium channel alpha2delta; chromosome 3p21.3; primer;
XX transgenic; cancer; lung cancer; small cell carcinoma; epilepsy; stroke;
XX non-small cell carcinoma; breast cancer; nasopharyngeal cancer;
XX cervical cancer; head and neck cancer; neurological disease;
XX brain trauma; Alzheimer's disease; multiinfarct dementia; seizure;
XX amyotrophic lateral sclerosis; convulsions; Huntington's disease;
XX amnesia; cardiovascular disease; cardiac arrhythmia; angina pectoris;
XX hypoxic damage; ischaemia; myocardial infarction; SSCP;
XX congestive heart failure; Lambert-Eaton myasthenic syndrome;
XX single strand conformation polymorphism.
XX
XX Homo sapiens.
OS
XX US2003044911-A1.
PN
XX
XX 06-MAR-2003.
PD
XX

PF 05-APR-2002; 2002US-00116949.
XX 30-DEC-1998; 98US-0114359P.
PR 22-DEC-1999; 99US-00470443.
XX (LERM/) LERMAN M I.
PA (LATI/) LATIF F.
PA (WEIM/) WEI M.
PA (DUHF/) DUH F.
PA (MINN/) MINNA J D.
PA (SEKI/) SEKIDO Y.
PA (GAOB/) GAO B.
PI Lerman MI, Latif F, Wei M, Duh F, Minna JD, Sekido Y, Gao B;
XX WPI; 2003-492262/46.
DR New substantially pure human calcium channel alpha2delta subunit splice
XX isoform 1, 2 and 3 sequence useful in preventing, treating and diagnosing
PT cancer, neurological disorders and cardiovascular disease.
PT
XX Example 7; Page 25; 79pp; English.
PS The invention relates to a substantially purified amino acid sequence
XX comprising at least a portion of human calcium channel alpha2delta
CC subunit splice isoform 1, splice isoform 2 sequence or splice isoform 3,
CC or their variants, and their encoding nucleic acids (or their
CC complements, variants, or homologues). Also included are screening a test
CC compound for modulating calcium channel activity, an antibody which binds
CC to the calcium channel or its variants and producing a transgenic non-
CC human animal (where the animal expresses a reduced level of calcium
CC channel alpha 2delta subunit relative to a corresponding wild-type
CC animal. The calcium channel proteins are useful for generating an
CC antibody (which is useful for detecting the proteins or their portions).
CC The transgenic animal (preferably a rodent e.g. mouse) is useful for
CC identifying a therapeutic compound for treating a transgenic animal
CC having cancer, especially lung cancer (small cell carcinoma or non-small
CC cell carcinoma), breast cancer, nasopharyngeal cancer, cervical cancer,
CC head and neck cancer, a neurological disease, especially epilepsy,
CC stroke, brain trauma, Alzheimer's disease, multiinfarct dementia,
CC amyotrophic lateral sclerosis, convulsions, seizures, Huntington's
CC disease, and amnesia, a cardiovascular disease, especially cardiac
CC arrhythmia, angina pectoris, hypoxic damage to the cardiovascular system,
CC ischaemic damage to the cardiovascular system, myocardial infarction, and
CC congestive heart failure; or Lambert-Eaton myasthenic syndrome. The
CC proteins and nucleic acids are useful in the diagnosis, prevention and
CC treatment of the above mentioned diseases. The human gene for the calcium
CC channel is located on chromosome 3p21.3. The present sequence is an SSCP
CC (single strand conformation polymorphism) primer used to detect
CC polymorphisms in the calcium channel alpha2delta subunit gene
XX
XX SQ Sequence 21 BP; 6 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2305 CGGATTTTCAACTGGCCAAACC 2325
Db 21 CGTATGTTCAACTGGCCATCC 1
|||||
|||||

RESULT 136
ADU37369/c
ID ADU37369 standard; DNA; 21 BP.
XX
XX AC ADU37369;
XX
XX 22-APR-2004 (first entry)
XX
XX Tumour therapy associated PRO256 primer seq id 88.
DE
XX
XX cytostatic; gene therapy; PRO; PRO197; PRO207; PRO226; PRO232; PRO243;
KW

KW PRO256; PRO259; PRO274; PRO304; PRO339; PRO1558; PRO779; PRO1185;
KW PRO1245; PRO1759; PRO5775; PRO7133; PRO7168; PRO5725; PRO202; PRO206;
KW PRO264; PRO313; PRO542; PRO773; PRO861; PRO1216; PRO1686;
KW PRO1800; PRO3562; PRO9850; PRO4316; PRO4980; cancer; tumour;
KW neoplastic cell growth; neoplastic cell proliferation; carcinoma;
KW lymphoma; blastoma; sarcoma; leukaemia; primer; ss.
XX Homo sapiens.
OS
XX
XX US2003211096-A1.
XX
XX 13-NOV-2003.
XX
XX 02-AUG-2002; 2002US-00211858.
XX
XX 31-AUG-1999; 99US-0151689P.
XX 11-FEB-2000; 2000WO-US003565.
XX 09-AUG-2001; 2001US-00927796.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
PI Marsters SA, Pan J, Pitti RM, Roy MA, Smith V, Stone DM;
PI Watanabe CK, Wood WI;
XX
XX WPI; 2003-901564/82.
DR
XX
XX New isolated PRO polypeptides, useful as targets for the diagnosis,
PT prevention and treatment of cancers, e.g. lymphoma, blastoma, sarcoma or
PT leukemia, and as predictors of the prognosis of tumor treatment.
XX
XX Example 8; SEQ ID NO 88; 307pp; English.
PS
XX
XX The invention describes an isolated PRO polypeptide. The PRO polypeptide:
CC has at least 80% amino acid sequence identity to: (1) any one of 35 fully
CC defined sequences of 104-954 amino acids (designated P1-P35) given in the
CC specification, with or without its associated signal peptide; (2) an
CC extracellular domain of any one of the polypeptides of P1-P35, with or
CC without its associated signal peptide; or (3) an amino acid sequence
CC encoded by the full-length coding sequence of the DNA deposited under
CC ATCC accession number 209284, 209358, 203376, 209250, 209508, 209379,
CC 209397, 209786, 209482, 209490, 203312, 55820, 203096, 203155, 203465,
CC PTA-255, PTA-618, PTA-545, PTA-256, 203538, 203661, 203835 or PTA-43; or
CC scores at least 80% positives when compared to any one of the sequences
CC of P1-P35. Specifically claimed are 35 PRO polypeptides, i.e. PRO197,
CC PRO207, PRO226, PRO232, PRO243, PRO256, PRO269, PRO274, PRO304, PRO339,
CC PRO1558, PRO779, PRO1185, PRO1245, PRO1759, PRO5775, PRO7133, PRO7168,
CC PRO5725, PRO202, PRO206, PRO264, PRO313, PRO342, PRO342, PRO773, PRO861,
CC PRO1216, PRO1686, PRO1800, PRO3562, PRO9850, PRO539, PRO4316 and PRO4980
CC polypeptides. The PRO polypeptides are useful as targets for the
CC diagnosis, prevention and treatment of cancers, and as predictors of the
CC prognosis of tumour treatment. The nucleic acid molecules, antibodies and
CC antagonists are useful for diagnosing and treating neoplastic cell growth
CC and proliferation, e.g. carcinoma, lymphoma, blastoma, sarcoma or
CC leukaemia. The antibodies may be used in screening assays for drug
CC candidates. This sequence represents a primer used in the isolation of
CC DNA encoding a PRO protein useful in the treatment of cancers.
XX
XX
SQ Sequence 21 BP; 3 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 612 CTTGAAGAGGTGCCATCCAGT 632
DB 21 CATGGAAGAGGCGCCATCCAGT 1
RESULT 137
ADI00299/c
ID ADI00299 standard; DNA; 21 BP.
XX

AC ADI00299;
XX
XX 22-APR-2004 (first entry)
DT
XX PCR primer SEQ ID 79 used to amplify human PKD-1 exon 11C DNA.
DE
XX mutation analysis; PKD; polycystic kidney disease; human; PKD-1; ss; PCR;
KW primer.
XX
XX Homo sapiens.
OS
XX US2003152936-A1.
XX
XX 14-AUG-2003.
XX
XX 26-FEB-2002; 2002US-00083246.
XX
XX 12-OCT-2001; 2001US-0328739P.
XX
XX (ATHE-) ATHENA DIAGNOSTICS INC.
XX
XX Jones JG, Hennigan AM, Curran JA, Allen SK, Robichaud NJ, Wang J;
PI Flynn KE, Garces JA, Palatucci CM;
XX
XX WPI; 2003-897708/82.
DR
XX
XX Analyzing mutations of a target nucleic acid by detecting heteroduplexes
PT from generated duplexes, useful for diagnosing patients affected with
PT polycystic kidney disease.
XX
XX Disclosure; SEQ ID NO 79; 126pp; English.
PS
XX
XX The invention relates to a novel method of mutation analysis of a target
CC nucleic acid which comprises incubating a sample having the target
CC nucleic acid in a reaction mixture, in the presence of at least one first
CC and second nucleic acid, where incubation produces amplified products,
CC generating duplexes in the amplified products and detecting the presence
CC or absence of a heteroduplex from the duplexes, where its presence
CC indicates a potential mutation in the target nucleic acid and its absence
CC indicates the absence of mutation in the target nucleic acid. The method
CC and compositions of the invention may be useful for analysing mutation
CC and diagnosing patients affected with PKD (polycystic kidney disease).
CC The current sequence is that of a PCR primer of the invention which was
CC used to amplify human polycystic kidney disease PKD-1 DNA.
XX
XX
SQ Sequence 21 BP; 3 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 723 TTCCCAAGTGAAGGAGCAACC 743
DB 21 TTCCCAAGTGAAGGAGCAAGCC 1
RESULT 138
ADK01340
ID ADK01340 standard; DNA; 21 BP.
XX
XX ADK01340;
XX
XX 06-MAY-2004 (first entry)
DT
XX
XX Rat DNA microarray capture oligonucleotide #60.
DE
XX ss; hybridisation; capture oligonucleotide; pattern; mucosal; hair root;
KW blood; nerve; germ cell; food additive; food supplement.
XX
XX Rattus sp.
OS
XX
XX DE10208794-A1.
XX

PD 04-SEP-2003.
 XX 28-FEB-2002; 2002DE-01008794.
 XX 28-FEB-2002; 2002DE-01008794.
 XX (DEGS) DEGUSSA BIOACTIVES GMBH.
 XX Boekenkamp D, Dieck HT, Hoppe H;
 XX WPI; 2003-714082/68.
 XX Sorting single-stranded nucleic acid, useful for analyzing expression
 XX patterns and screening active agents, uses capture agent with variable
 XX and constant regions.
 XX Example; Page 6; 8pp; German.
 XX This invention describes a novel method for sorting single-stranded
 XX nucleic acids by isolation and hybridisation of nucleic acid pools, then
 XX reading out, where the nucleic acids are selectively bound using capture
 XX agents that are (a) immobilised on the surface of a solid matrix and (b)
 XX comprise variable and non-variable regions. The capture oligonucleotides
 XX have a 5'-invariable anchor region, the complement of which is present at
 XX least once in each nucleic acid and a 3'-variable, discriminatory region
 XX that comprises all possible combinations of up to 10 nucleotides to allow
 XX binding of particular sorts of single stranded nucleic acids. The capture
 XX agents are particularly locked nucleic acids (LNA) and the anchor region
 XX comprises a sequence of 10-50, particularly 15-25, T residues. The
 XX capture oligonucleotides are biotinylated and immobilised on a surface by
 XX interaction with streptavidin. The matrix is of plastic, ceramic, glass,
 XX metal, resin, gel, crystalline material and/or membrane, having semi-
 XX conducting properties and especially in the form of a chip. Its surface
 XX is particularly a layer of (bio)molecular filaments and binding of single
 XX stranded nucleic acids to the surface is (quasi)covalent, supramolecular,
 XX physical, stimulated by an electrical field or through a molecular sieve.
 XX The method is used (i) for analysis of patterns, especially in mucosal,
 XX hair root, blood, nerve or germ cells and (ii) for determining the
 XX activity of pharmaceuticals and/or nutritional compounds, e.g. food
 XX additives or supplements, especially minerals, trace elements, organic
 XX acids (amino, carboxylic or fatty acid) or their derivatives, salts and
 XX mixtures. The method provides rapid, inexpensive and reproducible
 XX representation of differences in pools of nucleic acids from cells. It
 XX allows imaging of the complete pattern of all nucleic acid in a cell, and
 XX can detect very small differences in the nucleic acid pool. Since the
 XX method is based on comparison of nucleic acid pools, not individual
 XX genes, matrix miniaturisation is possible. ADK01281-ADK01344 represent
 XX capture probes used in the method of the invention.
 XX Sequence 21 BP; 0 A; 1 C; 0 G; 20 T; 0 U; 0 Other;
 XX
 Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. NO. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2568 TTCTTCTTTCTTTTCTTCT 2588
 DB 1 TTTTCTTTTCTTTTCTTCT 21
 RESULT 139
 ADK01297
 ID ADK01297 standard; DNA; 21 BP.
 XX
 XX ADK01297;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 XX Rat DNA microarray capture oligonucleotide #17.
 XX
 XX ss; hybridisation; capture oligonucleotide; pattern; mucosal; hair root;
 XX blood; nerve; germ cell; food additive; food supplement.

OS Rattus sp.
 XX DE10208794-A1.
 XX
 XX 04-SEP-2003.
 XX 28-FEB-2002; 2002DE-01008794.
 XX 28-FEB-2002; 2002DE-01008794.
 XX (DEGS) DEGUSSA BIOACTIVES GMBH.
 XX Boekenkamp D, Dieck HT, Hoppe H;
 XX WPI; 2003-714082/68.
 XX Sorting single-stranded nucleic acid, useful for analyzing expression
 XX patterns and screening active agents, uses capture agent with variable
 XX and constant regions.
 XX Example; Page 5; 8pp; German.
 XX This invention describes a novel method for sorting single-stranded
 XX nucleic acids by isolation and hybridisation of nucleic acid pools, then
 XX reading out, where the nucleic acids are selectively bound using capture
 XX agents that are (a) immobilised on the surface of a solid matrix and (b)
 XX comprise variable and non-variable regions. The capture oligonucleotides
 XX have a 5'-invariable anchor region, the complement of which is present at
 XX least once in each nucleic acid and a 3'-variable, discriminatory region
 XX that comprises all possible combinations of up to 10 nucleotides to allow
 XX binding of particular sorts of single stranded nucleic acids. The capture
 XX agents are particularly locked nucleic acids (LNA) and the anchor region
 XX comprises a sequence of 10-50, particularly 15-25, T residues. The
 XX capture oligonucleotides are biotinylated and immobilised on a surface by
 XX interaction with streptavidin. The matrix is of plastic, ceramic, glass,
 XX metal, resin, gel, crystalline material and/or membrane, having semi-
 XX conducting properties and especially in the form of a chip. Its surface
 XX is particularly a layer of (bio)molecular filaments and binding of single
 XX stranded nucleic acids to the surface is (quasi)covalent, supramolecular,
 XX physical, stimulated by an electrical field or through a molecular sieve.
 XX The method is used (i) for analysis of patterns, especially in mucosal,
 XX hair root, blood, nerve or germ cells and (ii) for determining the
 XX activity of pharmaceuticals and/or nutritional compounds, e.g. food
 XX additives or supplements, especially minerals, trace elements, organic
 XX acids (amino, carboxylic or fatty acid) or their derivatives, salts and
 XX mixtures. The method provides rapid, inexpensive and reproducible
 XX representation of differences in pools of nucleic acids from cells. It
 XX allows imaging of the complete pattern of all nucleic acid in a cell, and
 XX can detect very small differences in the nucleic acid pool. Since the
 XX method is based on comparison of nucleic acid pools, not individual
 XX genes, matrix miniaturisation is possible. ADK01281-ADK01344 represent
 XX capture probes used in the method of the invention.
 XX Sequence 21 BP; 2 A; 0 C; 1 G; 18 T; 0 U; 0 Other;
 XX
 Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. NO. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2571 TTCTTCTTTTCTTTTCTGAA 2591
 DB 1 TTTTCTTTTCTTTTCTGAA 21
 RESULT 140
 ADK01343
 ID ADK01343 standard; DNA; 21 BP.
 XX
 XX ADK01343;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 XX Rat DNA microarray capture oligonucleotide #63.

```
XX KW ss; hybridisation; capture oligonucleotide; pattern; mucosal; hair root;
XX KW blood; nerve; germ cell; food additive; food supplement.
XX OS Rattus sp.
XX PN DE10208794-A1.
XX PD 04-SEP-2003.
XX PF 28-FEB-2002; 2002DE-01008794.
XX PR 28-FEB-2002; 2002DE-01008794.
XX PA (DEGS ) DEGUSSA BIOACTIVES GMBH.
XX PI Boekenkamp D, Dieck HT, Hoppe H;
XX DR WPI; 2003-714082/68.
XX PT Sorting single-stranded nucleic acid, useful for analyzing expression
XX PT patterns and screening active agents, uses capture agent with variable
XX PT and constant regions.
XX PS Example; Page 6; 8pp; German.
XX CC This invention describes a novel method for sorting single-stranded
XX CC nucleic acids by isolation and hybridisation of nucleic acid pools, then
XX CC reading out, where the nucleic acids are selectively bound using capture
XX CC agents that are (a) immobilised on the surface of a solid matrix and (b)
XX CC comprise variable and non-variable regions. The capture oligonucleotides
XX CC have a 5'-invariable anchor region, the complement of which is present at
XX CC least once in each nucleic acid and a 3'-variable, discriminatory region
XX CC that comprises all possible combinations of up to 10 nucleotides to allow
XX CC binding of particular sorts of single stranded nucleic acids. The capture
XX CC agents are particularly locked nucleic acids (LNA) and the anchor region
XX CC comprises a sequence of 10-50, particularly 15-25, T residues. The
XX CC capture oligonucleotides are biotinylated and immobilised on a surface by
XX CC interaction with streptavidin. The matrix is of plastic, ceramic, glass,
XX CC metal, resin, gel, crystalline material and/or membrane, having semi-
XX CC conducting properties and especially in the form of a chip. Its surface
XX CC is particularly a layer of (bio)molecular filaments and binding of single
XX CC stranded nucleic acids to the surface is (quasi)covalent, supramolecular,
XX CC physical, stimulated by an electrical field or through a molecular sieve.
XX CC The method is used (i) for analysis of patterns, especially in mucosal,
XX CC hair root, blood, nerve or germ cells and (ii) for determining the
XX CC activity of pharmaceuticals and/or nutritional compounds, e.g. food
XX CC additives or supplements, especially minerals, trace elements, organic
XX CC acids (amino, carboxylic or fatty acid) or their derivatives, salts and
XX CC mixtures. The method provides rapid, inexpensive and reproducible
XX CC representation of differences in pools of nucleic acids from cells. It
XX CC allows imaging of the complete pattern of all nucleic acid in a cell, and
XX CC can detect very small differences in the nucleic acid pool. Since the
XX CC method is based on comparison of nucleic acid pools, not individual
XX CC genes, matrix miniaturisation is possible. ADK01281-ADK01344 represent
XX CC capture probes used in the method of the invention.
XX SQ Sequence 21 BP; 0 A; 1 C; 0 G; 20 T; 0 U; 0 Other;
XX Query Match 0.4%; Score 16.2; DB 1; Length 21;
XX Best Local Similarity 85.7%; Pred. No. 1.8e+02;
XX Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 2567 TTTCTCTCTCTTTTCTTCTG 2587
DB 1 TTTTCTCTCTCTTTTCTTCTG 21
RESULT 141
ADK01326
ID ADK01326 standard; DNA; 21 BP.
XX AC ADK01326;
```

```
XX DT 06-MAY-2004 (first entry)
XX DE Rat DNA microarray capture oligonucleotide #46.
XX KW ss; hybridisation; capture oligonucleotide; pattern; mucosal; hair root;
XX KW blood; nerve; germ cell; food additive; food supplement.
XX OS Rattus sp.
XX PN DE10208794-A1.
XX PD 04-SEP-2003.
XX PF 28-FEB-2002; 2002DE-01008794.
XX PR 28-FEB-2002; 2002DE-01008794.
XX PA (DEGS ) DEGUSSA BIOACTIVES GMBH.
XX PI Boekenkamp D, Dieck HT, Hoppe H;
XX DR WPI; 2003-714082/68.
XX PT Sorting single-stranded nucleic acid, useful for analyzing expression
XX PT patterns and screening active agents, uses capture agent with variable
XX PT and constant regions.
XX PS Example; Page 5; 8pp; German.
XX CC This invention describes a novel method for sorting single-stranded
XX CC nucleic acids by isolation and hybridisation of nucleic acid pools, then
XX CC reading out, where the nucleic acids are selectively bound using capture
XX CC agents that are (a) immobilised on the surface of a solid matrix and (b)
XX CC comprise variable and non-variable regions. The capture oligonucleotides
XX CC have a 5'-invariable anchor region, the complement of which is present at
XX CC least once in each nucleic acid and a 3'-variable, discriminatory region
XX CC that comprises all possible combinations of up to 10 nucleotides to allow
XX CC binding of particular sorts of single stranded nucleic acids. The capture
XX CC agents are particularly locked nucleic acids (LNA) and the anchor region
XX CC comprises a sequence of 10-50, particularly 15-25, T residues. The
XX CC capture oligonucleotides are biotinylated and immobilised on a surface by
XX CC interaction with streptavidin. The matrix is of plastic, ceramic, glass,
XX CC metal, resin, gel, crystalline material and/or membrane, having semi-
XX CC conducting properties and especially in the form of a chip. Its surface
XX CC is particularly a layer of (bio)molecular filaments and binding of single
XX CC stranded nucleic acids to the surface is (quasi)covalent, supramolecular,
XX CC physical, stimulated by an electrical field or through a molecular sieve.
XX CC The method is used (i) for analysis of patterns, especially in mucosal,
XX CC hair root, blood, nerve or germ cells and (ii) for determining the
XX CC activity of pharmaceuticals and/or nutritional compounds, e.g. food
XX CC additives or supplements, especially minerals, trace elements, organic
XX CC acids (amino, carboxylic or fatty acid) or their derivatives, salts and
XX CC mixtures. The method provides rapid, inexpensive and reproducible
XX CC representation of differences in pools of nucleic acids from cells. It
XX CC allows imaging of the complete pattern of all nucleic acid in a cell, and
XX CC can detect very small differences in the nucleic acid pool. Since the
XX CC method is based on comparison of nucleic acid pools, not individual
XX CC genes, matrix miniaturisation is possible. ADK01281-ADK01344 represent
XX CC capture probes used in the method of the invention.
XX SQ Sequence 21 BP; 0 A; 1 C; 1 G; 19 T; 0 U; 0 Other;
XX Query Match 0.4%; Score 16.2; DB 1; Length 21;
XX Best Local Similarity 85.7%; Pred. No. 1.8e+02;
XX Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 2569 TCTCTCTCTCTTTTCTTCTG 2589
DB 1 TTTTCTCTCTCTTTTCTTCTG 21
RESULT 142
```

```

ADG68293/c
ID ADG68293 standard; DNA; 21 BP.
XX
AC ADG68293;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO polypeptide PCR primer #7.
XX
KW neoplastic tumour; lung; colon; breast; prostate; rectal; cervical;
KW liver; gene therapy; Human; ss; primer; PCR.
XX
OS Homo sapiens.
XX
PN US2003170228-A1.
XX
PD 11-SEP-2003.
XX
PF 02-AUG-2002; 2002US-00210951.
XX
PR 31-AUG-1999; 99US-0151689P.
XX
PR 11-FEB-2000; 2000WO-US003565.
XX
PR 09-AUG-2001; 2001US-00927796.
XX
PA (GETH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
PI Marsters SA, Pan J, Pitti RM, Roy MA, Smith V, Stone DM;
PI Watanabe CK, Wood WI;
XX
DR WPI; 2004-020650/02.
XX
XX New isolated antibodies binding PRO polypeptides, useful for diagnosing,
PT prognosticating and/or treating neoplastic tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and liver tumors.
XX
PS Example 8; SEQ ID NO 88; 308pp; English.
XX
CC The invention relates to an isolated antibody that binds to a PRO
CC polypeptide. The methods and compositions of the present invention are
CC useful for diagnosing, prognosticating and/or treating neoplastic
CC tumors, such as lung, colon, breast, prostate, rectal, cervical and
CC liver tumors. The PRO polypeptides are also useful as molecular weight
CC markers, or for chromosome identification. The PRO genes are useful as
CC hybridisation probes, or for screening libraries of Human cDNA, genomic
CC DNA or mRNA. The PRO genes may also be used in gene therapy, particularly
CC for replacing a defective gene. The present sequence is used in the
CC exemplification of the invention.
XX
SQ Sequence 21 BP; 3 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 612 CTTGAAAGTCCTCCAGT 632
DB 21 CATGGAAGCGCCATCCAGT 1

RESULT 143
ADL61618
ID ADL61618 standard; RNA; 21 BP.
XX
AC ADL61618;
XX
DT 03-JUN-2004 (first entry)
XX
DE Antisense RNAi DNA-RNA hybrid oligo 1 targeted to human epha2-1.
XX
KW predictor set; protein tyrosine kinase biomarker; cytostatic;
KW antiangiogenic; vasotrophic; vulnerable; pharmacogenomic; drug sensitivity;
KW breast cancer; hypervascular disease; angiogenesis; wound healing scar;

ADG68293/c
KW human; ss; antisense; RNAi; interfering RNA; DNA-RNA hybrid; epha2-1.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_feature 20..21
FT /*tag= a
FT /note= "Deoxyribonucleotide (thymine)"
XX
PN WO2004020583-A2.
XX
PD 11-MAR-2004.
XX
PF 26-AUG-2003; 2003WO-US026491.
XX
PR 27-AUG-2002; 2002US-0406385P.
XX
PA (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX
PI Huang F, Han X, Reeves KA, Amler L, Fairchild CR, Lee FY;
PI Shaw P;
XX
DR WPI; 2004-239171/22.
XX
XX New predictor sets with a plurality of polynucleotides and/or
PT polypeptides whose expression pattern predicts cell response to a
PT compound that modulates protein tyrosine kinase activity, useful in
PT treating breast cancer.
XX
PS Example 5; SEQ ID NO 542; 649pp; English.
XX
CC The invention relates to a novel predictor set comprising a plurality of
CC polynucleotides and/or polypeptides whose expression pattern is
CC predictive of the response of cells to treatment with a compound that
CC modulates protein tyrosine kinase activity or members of the protein
CC tyrosine kinase pathway. The molecules of the invention demonstrate
CC cytostatic, antiangiogenic, vasotrophic and vulnerary activities and may
CC be useful in the field of pharmacogenomics, in particular for determining
CC drug sensitivity and in treating breast cancer, hypervascular diseases,
CC angiogenesis and scars in wound healing. The current sequence is that of
CC an antisense RNAi (interfering RNA) DNA-RNA hybrid oligonucleotide which
CC was targeted to a human protein tyrosine kinase biomarker polynucleotide
CC of the invention.
XX
SQ Sequence 21 BP; 4 A; 3 C; 8 G; 2 T; 4 U; 0 Other;

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.8e+02;
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 2373 GGAAATGGGATTGCTGACTT 2393
DB 1 GGAAGUGGACUGCGGACTT 21

RESULT 144
ADN75686
ID ADN75686 standard; RNA; 21 BP.
XX
AC ADN75686;
XX
DT 01-JUL-2004 (first entry)
XX
DE Murine PTP1B siRNA oligonucleotide mPTP1B1.4.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW -cytostatic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss;
KW DNA-RNA hybrid.
XX
OS Mus musculus.
XX

```

PN WO2004016735-A2.
 XX 26-FEB-2004.
 XX 23-MAY-2003; 2003WO-US016632.
 XX 23-MAY-2002; 2002US-0383249P.
 PR 14-APR-2003; 2003US-0462942P.
 XX (CEPT-) CEPTVR INC.
 PA (COLD-) COLD SPRING HARBOR LAB.
 XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 PI WPI; 2004-203773/19.
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX Example 5; SEQ ID NO 511; 392pp; English.
 PS This invention describes novel small interfering RNA (siRNA)
 XX polynucleotides capable of interfering with expression of a polypeptide
 CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
 CC invention have cytostatic, immunomodulator, antimicrobial,
 CC antiinflammatory, antidiabetic and anorectic activity. The methods and
 CC compositions of the present invention are useful for treating diseases or
 CC conditions associated with aberrant expression or activity of the protein
 CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
 CC inflammation, diabetes and obesity. This sequence represents a siRNA
 CC directed against dual specificity phosphatase (DSP) expression.
 XX Sequence 21 BP; 4 A; 6 C; 6 G; 2 T; 3 U; 0 Other;
 SQ

Query Match 0.4%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 71.4%; Pred. No. 1.8e+02;
 Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 2096 GATCCCAAGATGTCAGCCCTT 2116
 DB 1 GGUACCGAGAGUCAGCCCTT 21

RESULT 145
 AAA85777
 ID AAA85777 standard; DNA; 19 BP.
 XX
 AC AAA85777;
 DT 04-DEC-2000 (first entry)
 DE
 DE Cyclin B1 ribozyme binding site #106.
 XX
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
 OS Mammalia.
 XX
 PN WO200032765-A2.
 XX
 PD 08-JUN-2000.
 XX
 PF 06-DEC-1999; 99WO-US028772.
 PR
 PR 04-DEC-1998; 98US-0110954P.
 XX
 PA (IMMU-) IMMUSOL INC.
 XX
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;
 PI WPI; 2000-412314/35.
 DR
 XX

PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 XX PCNA and Cyclin B1.
 XX Disclosure; Page 97; 109pp; English.
 XX The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 CC Representative examples of ribozyme recognition sites are given for
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells. The
 CC ribozyme is resistant to endonuclease activity and hence is efficient in
 CC restenosis treatment
 XX Sequence 19 BP; 4 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.8e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3441 CTGCCATGTTTTTACAG 3459
 DB 1 CTGCCATGTTATTGCAAG 19

RESULT 146
 AAH60939
 ID AAH60939 standard; DNA; 19 BP.
 XX
 AC AAH60939;
 XX
 DT 10-SEP-2001 (first entry)
 DE
 DE Cyclin B1 ribozyme binding site SEQ ID NO:3363.
 XX
 KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antisking; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200130362-A2.
 XX
 PD 03-MAY-2001.
 XX
 XX 26-OCT-2000; 2000WO-US029500.
 PF
 XX 26-OCT-1999; 99US-0161532P.
 PR
 XX (IMMU-) IMMUSOL INC.
 XX
 XX Robbins JM, Tritz R;
 PI WPI; 2001-300427/31.
 DR
 XX Treating proliferative skin or eye diseases and scarring, using ribozymes
 PT that cleave RNA encoding cytokines involved in inflammation, matrix
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.
 XX
 PS Example 1; Page 316; 408pp; English.
 XX The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in

CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antiproliferative,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, anti-itching,
 CC ophthalmological, vulvular, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62999 represent sequences used in the
 CC exemplification of the present invention
 XX
 SQ Sequence 19 BP; 4 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.8e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3441 CTGCCATGTTTTCACAG 3459
 DB 1 CTGCCATGTTTTCACAG 19

RESULT 147
 ADA25494/c
 ID ADA25494 standard; RNA; 19 BP.
 XX
 AC ADA25494;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PKC-alpha short interfering nucleic acid SEQ ID NO:225.
 XX
 DE short interfering nucleic acid; siRNA; protein kinase C alpha; PKC-alpha;
 KW RNA interference; cytostatic; vasotropic; nephrotropic; modulation;
 KW inhibition; cancer; breast cancer; ovarian cancer; lung cancer;
 KW prostate cancer; glioblastoma; proliferative disease; restenosis;
 KW polycystic kidney disease; human; ribozyme; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS WO2003070983-A1.
 PN
 XX
 PD 28-AUG-2003.
 PF 11-FEB-2003; 2003WO-US004034.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 18-SEP-2002; 2002US-0411707P.
 PR 15-JAN-2003; 2003US-0440129P.

XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA
 XX Mcswiggen J, Beigelman L;
 XX WPI; 2003-679891/64.
 XX
 XX New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer and restenosis, downregulates expression of the
 PT protein kinase C-alpha gene.
 XX
 XX Example 3; Page 120; 143pp; English.

XX The present invention describes a short interfering nucleic acid (siRNA)
 CC that downregulates expression of a protein kinase C-alpha (PKC-alpha)
 CC gene by RNA interference. Also described: (1) a siRNA that modulates
 CC expression and/or activity of genes for other isoforms of PKC or genes
 CC involved in the PKC pathway; (2) kits for in vitro or in vivo delivery of
 CC siRNA; (3) conjugates and/or complexes of siRNA; and (4) vectors that
 CC express siRNA. The siRNA sequences have cytostatic, vasotropic and
 CC nephrotropic activities, and can be used in the modulation (inhibition)
 CC of expression of the PKC-alpha gene by RNA interference. The siRNA can be
 CC used to modulate expression of PKC-alpha genes. They are potentially
 CC useful in treating a variety of cancers including e.g. breast cancer,
 CC cancers of the head and neck, ovarian cancer, lung cancer, prostate
 CC cancer, and glioblastoma and for treating other proliferative diseases
 CC and conditions, such as restenosis and polycystic kidney disease. The
 CC siRNA may also be useful for diagnosis, drug screening, target
 CC identification and validation, genetic engineering, studying gene
 CC function, and for gene mapping (e.g. of single-nucleotide polymorphisms).
 CC The present sequence represents a human PKC-alpha siRNA, which is used in
 CC the exemplification of the present invention.
 XX
 SQ Sequence 19 BP; 1 A; 12 C; 1 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.8e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 GAGGGGTCGGGACGTGA 196
 DB 19 GAGGGGTCGGGACGTGA 1

RESULT 148
 ADA25369
 ID ADA25369 standard; RNA; 19 BP.
 XX
 AC ADA25369;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PKC-alpha short interfering nucleic acid target SEQ ID NO:100.
 XX
 DE short interfering nucleic acid; siRNA; protein kinase C alpha; PKC-alpha;
 KW RNA interference; cytostatic; vasotropic; nephrotropic; modulation;
 KW inhibition; cancer; breast cancer; ovarian cancer; lung cancer;
 KW prostate cancer; glioblastoma; proliferative disease; restenosis;
 KW polycystic kidney disease; human; ribozyme; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS WO2003070983-A1.
 PN
 XX
 PD 28-AUG-2003.
 PF 11-FEB-2003; 2003WO-US004034.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 18-SEP-2002; 2002US-0411707P.
 PR 15-JAN-2003; 2003US-0440129P.

XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA
 XX Mcswiggen J, Beigelman L;
 XX WPI; 2003-679891/64.
 XX
 XX New short interfering nucleic acid, useful e.g. for treatment and

PT diagnosis of cancer and restenosis, downregulates expression of the
PT protein kinase C-alpha gene.
XX Example 3; Page 120; 143pp; English.
PS
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a protein kinase C-alpha (PKC-alpha)
CC gene by RNA interference. Also described: (1) a siNA that modulates
CC expression and/or activity of genes for other isoforms of PKC or genes
CC involved in the PKC pathway; (2) kits for in vitro or in vivo delivery of
CC siNA; (3) conjugates and/or complexes of siNA; and (4) vectors that
CC express siNA. The siNA sequences have cytostatic, vasotropic and
CC nephrotropic activities, and can be used in the modulation (inhibition)
CC of expression of the PKC-alpha gene by RNA interference. The siNA can be
CC used to modulate expression of PKC-alpha genes. They are potentially
CC useful in treating a variety of cancers including e.g. breast cancer,
CC cancers of the head and neck, ovarian cancer, lung cancer, prostate
CC cancer, and glioblastoma and for treating other proliferative diseases
CC and conditions, such as restenosis and polycystic kidney disease. The
CC siNA may also be useful for diagnosis, drug screening, target
CC identification and validation, genetic engineering, studying gene
CC function, and for gene mapping (e.g. of single-nucleotide polymorphisms).
CC The present sequence represents a human PKC-alpha siNA target, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 5 A; 1 C; 12 G; 0 T; 1 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.8e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 178 GAGGGGGTGGCGGACGTGA 196
Db 1 GAGGGGGAGAGGACGUGA 19
||||| |||||:|
RESULT 149
ADCS6895/c
ID ADCS6895 standard; DNA; 19 BP.
XX
AC ADCS6895;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PCR primer (SeqID 1) used to detect SNPs in the CYP2C8 gene.
XX
XX metabolic activity; haemoprotein; cytochrome P450; CYP;
KW oxidation metabolism; single nucleotide polymorphism detection; CYP2C8;
KW paclitaxel; PCR; primer; ss; human.
XX
OS Homo sapiens.
XX
PN JP2003093068-A.
XX
PD 02-APR-2003.
XX
PF 25-SEP-2001; 2001JP-00291004.
XX
PR 25-SEP-2001; 2001JP-00291004.
XX
XX (KOKU-) KOKURITSU IYAKUHIN SHOKUHIN EISEI KENKYU.
PA (IYAK-) IYAKUHIN FUKUSAYO HIGAI KYUSAI KENKYU SH.
PA (GENO-) GENOX SOYAKU KENKYUSHO KK.
XX
XX WPI; 2003-590921/56.
XX
XX Testing metabolic activity of medicine metabolized by hemoprotein and
PT cytochrome P450, CYP2C8, by detecting polymorphism of 2CCYP8 gene which
PT decreases 2C8 amount of CYPs.
XX
XX Example 2; SEQ ID NO 1; 39pp; Japanese.
PS
XX This invention relates to a novel method for testing metabolic activity

CC with respect to the medicine metabolised by haemoprotein and cytochrome
CC P450 (CYP), which catalyses oxidation metabolism. Specifically, it refers
CC to a method comprising the detection of a single nucleotide polymorphism
CC of the CYP2C8 gene, which correlates to a decrease in CYP activity.
CC Furthermore, the present invention describes testing metabolic activity
CC with respect to the medicine metabolised by CYP2C8, where the medicine is
CC paclitaxel. This novel screening method also controls the dosage of the
CC medicine metabolised by CYP2C8 and avoids adverse side reactions. This
CC oligonucleotide sequence is the human PCR primer (SeqID 1) used to detect
CC novel single nucleotide polymorphisms in the CYP2C8 gene that influence
CC metabolic activity, in an exemplification of the invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1715 AAGATTCCCTTGAAGCCTT 1733
Db 19 AAGTTCCATTGAAGCCTT 1
||||| |||||
RESULT 150
ADM00615
ID ADM00615 standard; RNA; 19 BP.
XX
AC ADM00615;
XX
DT 20-MAY-2004 (first entry)
XX
DE Hepatitis B virus short interfering nucleic acid (siNA) #1031.
XX
XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
OS Hepatitis B virus.
XX
PN US2003206887-A1.
XX
XX 06-NOV-2003.
XX
PF 16-SEP-2002; 2002US-00244647.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00533025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358860P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002WO-US009187.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX
XX (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX
XX Morrissey D, Mcswiggen JA, Beigelman L;
PI WPI; 2003-901032/82.
XX
XX New short interfering nucleic acid molecules which down-regulates
PT expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for

characterizing gene function.

Claim 11; Page 46; 72pp; English.

The invention relates to a short interfering nucleic acid (siNA) molecule that down-regulates expression of a hepatitis B virus (HBV) gene by RNA interference or that inhibits HBV replication. Also disclosed are the following: (i) a method of modulating the expression of a HBV gene in a tissue explant; (ii) a method of generating a library of siNA constructs having predetermined complexity; (iii) a cell containing one or more siNA molecules; (iv) a kit containing a siNA molecule which can be used to modulate the expression of a HBV target gene in a cell, tissue or organism; and (v) a method for synthesizing a siNA molecule. The siNA molecule is adapted for use to treat HBV infection, and comprises a sense and an antisense region, where the antisense region comprises sequence complementary to an RNA sequence encoding HBV and the sense region comprises sequence complementary to the antisense region. The siNA molecule is assembled from 2 nucleic acid fragments, where one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule, where sense region and the antisense region comprise separate oligonucleotides, and are covalently connected via a linker molecule. The linker molecule is a polynucleotide linker or a non-nucleotide linker. The sense region comprises a 3'-terminal overhang and the antisense region comprises a 3'-terminal overhang. The 3'-terminal overhangs each comprise about 2 nucleotides. The antisense region 3'-terminal overhang is complementary to RNA encoding HBV. The siNA is useful for treating human hepatitis B virus infections, and for characterizing pathways of gene function, e.g. to inhibit activity of target genes in a pathway to determine the function of uncharacterised genes in gene function analysis. The siNA molecules may also be used in clinical, industrial, environmental, agricultural and/or research settings. The present sequence represents 1 of 1504 HBV siNA molecules of the invention.

Sequence 19 BP; 6 A; 2 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.8e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2643 TCCAGAGTGTTCACAAGA 2661
DB 1 UCCGGAGUGUAGAAGA 19

RESULT 151
ADL99968/c
ID ADL99968 standard; RNA; 19 BP.
XX ADL99968;
AC ADL99968;
DT 20-MAY-2004 (first entry)
XX Hepatitis B virus short interfering nucleic acid (siNA) #385.
XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid; siNA; hepatitis B virus; HBV; RNA interference.
XX Hepatitis B virus.
XX US2003206887-A1.
XX 06-NOV-2003.
XX 16-SEP-2002; 2002US-00244647.
XX 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.

08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002WO-US0009187.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX (MORR/) MORRISSEY D.
FA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.
XX Morrissey D, Mcswiggen JA, Beigelman L;
PI WPI; 2003-901032/82.
DR New short interfering nucleic acid molecules which down-regulates
XX expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for
PT characterizing gene function.
XX Claim 11; Page 46; 72pp; English.
XX The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesizing a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises sequence
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC linker or a non-nucleotide linker. The sense region comprises a 3'-
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
XX The antisense region 3'-terminal overhang is complementary to RNA
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterizing pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.
XX Sequence 19 BP; 5 A; 6 C; 2 G; 0 T; 6 U; 0 Other;
QY Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2643 TCCAGAGTGTTCACAAGA 2661
DB 19 TCCGAGAGTGTTCATAAGA 1
XX RESULT 152
ADN00625
ID ADM00625 standard; RNA; 19 BP.
XX ADM00625;
AC ADM00625;
XX

DT 20-MAY-2004 (first entry)

DE Hepatitis B virus short interfering nucleic acid (siNA) #1041.

XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;

KW siNA; hepatitis B virus; HBV; RNA interference.

XX Hepatitis B virus.

XX US2003206887-A1.

XX 06-NOV-2003.

XX 16-SEP-2002; 2002US-00244647.

XX 14-MAY-1992; 92US-00882712.

XX 07-FEB-1994; 94US-00193627.

XX 08-NOV-1999; 99US-00436430.

XX 20-MAR-2000; 2000US-00531025.

XX 09-AUG-2000; 2000US-00636385.

XX 24-OCT-2000; 2000US-00696347.

XX 08-JUN-2001; 2001US-00877478.

XX 08-JUN-2001; 2001US-0296876P.

XX 24-OCT-2001; 2001US-0335059P.

XX 05-DEC-2001; 2001US-0337055P.

XX 24-OCT-2001; 2001US-0296876P.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 26-MAR-2002; 2002US-0363124P.

XX 06-JUN-2002; 2002US-0386782P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX (MORR/) MORRISSEY D.

PA (MCSW/) MCSWIGGEN J A.

PA (BEIG/) BEIGELMAN L.

XX Morrissey D, Mcswiggen JA, Beigelman L;

XX WPI; 2003-901032/82.

XX New short interfering nucleic acid molecules which down-regulates

PT expression of a hepatitis B virus (HBV) or which inhibits HBV

PT replication, useful for treating human HBV infections or for

PT characterizing gene function.

XX Claim 11; Page 46; 72pp; English.

XX The invention relates to a short interfering nucleic acid (siNA) molecule

CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA

CC interference or that inhibits HBV replication. Also disclosed are the

CC following: (i) a method of modulating the expression of a HBV gene in a

CC tissue explant; (ii) a method of generating a library of siNA constructs

CC having predetermined complexity; (iii) a cell containing one or more siNA

CC molecules; (iv) a kit containing a siNA molecule which can be used to

CC modulate the expression of a HBV target gene in a cell, tissue or

CC organism; and (v) a method for synthesizing a siNA molecule. The siNA

CC molecule is adapted for use to treat HBV infection, and comprises a sense

CC and an antisense region, where the antisense region comprises a sense

CC complementary to an RNA sequence encoding HBV and the sense region

CC comprises sequence complementary to the antisense region. The siNA

CC molecule is assembled from 2 nucleic acid fragments, where one fragment

CC comprises the sense region and the second fragment comprises the

CC antisense region of the siNA molecule, where sense region and the

CC antisense region comprise separate oligonucleotides, and are covalently

CC connected via a linker molecule. The linker molecule is a polynucleotide

CC linker or a non-nucleotide linker. The sense region comprises a 3'-

CC terminal overhang and the antisense region comprises a 3'-terminal

CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.

CC The antisense region 3'-terminal overhang is complementary to RNA

CC encoding HBV. The siNA is useful for treating human hepatitis B virus

CC infections, and for characterizing pathways of gene function, e.g. to

CC inhibit activity of target genes in a pathway to determine the function

CC of uncharacterised genes in gene function analysis. The siNA molecules

CC may also be used in clinical, industrial, environmental, agricultural

CC and/or research settings. The present sequence represents 1 of 1504 HBV

CC siNA molecules of the invention.

XX Sequence 19 BP; 6 A; 2 C; 6 G; 0 T; 5 U; 0 Other;

XX Query Match 0.4%; Score 15.8; DB 1; Length 19;

XX Best Local Similarity 68.4%; Pred. NO. 1.8e+02; Indels 0; Gaps 0;

XX Matches 13; Conservative 4; Mismatches 2;

QY 2644 CCAGAAAGTGTGACAAAGAT 2652

DB 1 CCGAAGUGUGAUAAGAU 19

RESULT 153

ADL99978/c

ID ADL99978 standard; RNA; 19 BP.

XX AC ADL99978;

XX 20-MAY-2004 (first entry)

XX Hepatitis B virus short interfering nucleic acid (siNA) #395.

XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;

KW siNA; hepatitis B virus; HBV; RNA interference.

XX Hepatitis B virus.

XX US2003206887-A1.

XX 06-NOV-2003.

XX 16-SEP-2002; 2002US-00244647.

XX 14-MAY-1992; 92US-00882712.

XX 07-FEB-1994; 94US-00193627.

XX 08-NOV-1999; 99US-00436430.

XX 20-MAR-2000; 2000US-00531025.

XX 09-AUG-2000; 2000US-00636385.

XX 24-OCT-2000; 2000US-00696347.

XX 08-JUN-2001; 2001US-00877478.

XX 08-JUN-2001; 2001US-0296876P.

XX 24-OCT-2001; 2001US-0335059P.

XX 05-DEC-2001; 2001US-0337055P.

XX 24-OCT-2001; 2001US-0296876P.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 26-MAR-2002; 2002US-0363124P.

XX 06-JUN-2002; 2002US-0386782P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX (MORR/) MORRISSEY D.

PA (MCSW/) MCSWIGGEN J A.

PA (BEIG/) BEIGELMAN L.

XX Morrissey D, Mcswiggen JA, Beigelman L;

XX WPI; 2003-901032/82.

XX New short interfering nucleic acid molecules which down-regulates

PT expression of a hepatitis B virus (HBV) or which inhibits HBV

PT replication, useful for treating human HBV infections or for

PT characterizing gene function.

XX Claim 11; Page 46; 72pp; English.

XX The invention relates to a short interfering nucleic acid (siNA) molecule

CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA

CC interference or that inhibits HBV replication. Also disclosed are the

CC following: (i) a method of modulating the expression of a HBV gene in a

CC tissue explant; (ii) a method of generating a library of siNA constructs

CC having predetermined complexity; (iii) a cell containing one or more siNA

CC molecules; (iv) a kit containing a siNA molecule which can be used to

CC modulate the expression of a HBV target gene in a cell, tissue or

CC organism; and (v) a method for synthesizing a siNA molecule. The siNA

CC molecule is adapted for use to treat HBV infection, and comprises a sense

CC and an antisense region, where the antisense region comprises a sense

CC complementary to an RNA sequence encoding HBV and the sense region

CC comprises sequence complementary to the antisense region. The siNA

CC molecule is assembled from 2 nucleic acid fragments, where one fragment

CC comprises the sense region and the second fragment comprises the

CC antisense region of the siNA molecule, where sense region and the

CC antisense region comprise separate oligonucleotides, and are covalently

CC connected via a linker molecule. The linker molecule is a polynucleotide

CC linker or a non-nucleotide linker. The sense region comprises a 3'-

CC terminal overhang and the antisense region comprises a 3'-terminal

CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.

CC The antisense region 3'-terminal overhang is complementary to RNA

CC encoding HBV. The siNA is useful for treating human hepatitis B virus

CC infections, and for characterizing pathways of gene function, e.g. to

CC inhibit activity of target genes in a pathway to determine the function

CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siRNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesising a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises a sense
CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC linker or a non-nucleotide linker. The sense region comprises a 3'-
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterising pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.

XX Sequence 19 BP; 5 A; 6 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2644 CCAGAAAGTGTGACAAAGAT 2662
DB 19 CCGGAAGTGTGTAAGAT 1

RESULT 154

AAQ75599
ID AAQ75599 standard; DNA; 20 BP.

XX AAQ75599;

DT 04-AUG-1995 (first entry)

XX Reverse transcription primer used in cDNA analysis technique.

DE Analysis; gene expression; reverse transcription; primer; cDNA;

KW aggregate; restriction enzyme; ss.

XX Synthetic.

XX JP06303997-A.

XX 01-NOV-1994.

XX 16-APR-1993; 93JP-00112515.

XX 16-APR-1993; 93JP-00112515.

XX (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.

XX WPI; 1995-018287/03.

XX Analysis of cDNA and gene expression - by amplification of mRNA followed
PT by digestion with restriction enzymes.

XX Disclosure; Page 5; 11pp; Japanese.

XX A method for the analysis of cDNA comprises (a) preparing an aggregate of
CC double-stranded cDNAs by using an aggregate of mRNAs and a plural type of
CC labelled reverse transcription primers (GENSEQ files AAQ75547-Q75798)

CC and using the aggregate of mRNAs as the template for each reverse
CC transcription primer; (b) digesting each of the prepared aggregates of
CC the double-stranded cDNAs with restriction enzyme and; (c)
CC electrophoresing the digested aggregate of cDNAs in separate lanes. The
XX method can be used to analyse gene expression rapidly and easily

SQ Sequence 20 BP; 0 A; 1 C; 1 G; 18 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTCTCTCTCTCTCTCTG 2589
DB 2 TTTTCTCTCTCTCTCTCTCTCTG 20

RESULT 155

AAV11921/c
ID AAV11921 standard; DNA; 20 BP.

XX AAV11921;

XX 13-AUG-1998 (first entry)

DE Hepatocyte growth factor inhibiting oligonucleotide #13.

KW Hepatocyte growth factor; HGF; c-Met; modulator; inhibitor;
KW antitumour agent; anti-metastasis agent; primer; ss.

XX Synthetic.

XX JP10127286-A.

XX 19-MAY-1998.

XX 01-NOV-1996; 96JP-00291499.

XX 01-NOV-1996; 96JP-00291499.

XX (TERU) TERUMO CORP.

XX WPI; 1998-340665/30.

XX Oligo-nucleotide inhibiting HGF production - useful as antitumour and
PT anti-metastatic agent.

XX Claim 8; Page 10; 15pp; Japanese.

XX AAV11909-V11925, AAV11927 and AAV11928 are oligonucleotide primers used
CC to identify sequences which modulate or inhibit expression, production or
CC reception of hepatocyte growth factor (HGF) or expression of c-Met. Such
CC oligonucleotides are useful as antitumour or anti-metastasis agents

SQ Sequence 20 BP; 9 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 CCTTCTCTCTCTCTCTCTTC 2232
DB 19 CCTTCTCTCTCTCTCTCTTC 1

RESULT 156

AAV11923
ID AAV11923 standard; DNA; 20 BP.

XX AAV11923;

XX 13-AUG-1998 (first entry)

XX

```

DE Hepatocyte growth factor inhibiting oligonucleotide #15.
XX Hepatocyte growth factor; HGF; c-Met; modulator; inhibitor;
KW antitumour agent; anti-metastasis agent; primer; ss.
XX Synthetic.
OS
XX JPI0127286-A.
PN
XX 19-MAY-1998.
XX
XX 01-NOV-1996; 96JP-00291499.
PF
XX 01-NOV-1996; 96JP-00291499.
PR
XX (TERU ) TERUMO CORP.
PA
XX WPI; 1998-340665/30.
DR
XX Oligo-nucleotide inhibiting HGF production - useful as antitumour and
PT anti-metastatic agent.
PT
XX Claim 8; Page 10; 15pp; Japanese.
PS
XX
XX AAV11909-V11925, AAV11927 and AAV11928 are oligonucleotide primers used
CC to identify sequences which modulate or inhibit expression, production or
CC reception of hepatocyte growth factor (HGF) or expression of c-Met. Such
CC oligonucleotides are useful as antitumour or anti-metastasis agents
XX
XX Sequence 20 BP; 0 A; 11 C; 0 G; 9 T; 0 U; 0 Other;
SQ
    Query Match          0.4%; Score 15.8; DB 1; Length 20;
    Best Local Similarity 89.5%; Pred. No. 1.9e+02;
    Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 CCTTCTCTCTCTCTCTTC 2232
Db 2 CCTTTCTCTCTCTCTCTTC 20

RESULT 157
AAZ03648
ID AAZ03648 standard; DNA; 20 BP.
XX
XX AAZ03648;
AC
XX 07-OCT-1999 (first entry)
DT
XX PCR primer used to amplify an ORF of Chlamydia trachomatis.
DE
XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW paratrachoma; inclusion conjunctivitis; genital disease; peritriepatitis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
XX Synthetic.
OS Chlamydia trachomatis.
OS
XX WO9928475-A2.
PN
XX 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
PF
XX 28-NOV-1997; 97FR-00015041.
PR 17-DEC-1997; 97FR-00016034.
PR 04-NOV-1998; 98US-0107077P.
XX
XX (GEST ) GENSET.
PA
XX Griffais R;
XX
XX WPI; 1999-371125/31.
XX
XX 27-NOV-1998; 98WO-IB001939.
PF
XX 28-NOV-1997; 97FR-00015041.
PR 17-DEC-1997; 97FR-00016034.
PR 04-NOV-1998; 98US-0107077P.
XX
XX (GEST ) GENSET.
PA
XX Griffais R;
XX
XX WPI; 1999-371125/31.
XX

Genome sequence of Chlamydia trachomatis.
Disclosure; Page 1624; 1755pp; English.
PCR primers AAZ01426-Z06209 were used to amplify open reading frames
(ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
against Chlamydia trachomatis. Antisense and ribozyme sequences can also
be used to control growth of the microorganism. Chlamydia trachomatis is
responsible for a large number of diseases, e.g. eye diseases such as
conjunctivitis; genital diseases such as nongonococcal urethritis,
epididymitis, cervicitis, salpingitis, peritriepatitis, bartholinitis,
pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
The polypeptides of the invention may be of use in treating these
diseases
XX
XX Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
SQ
    Query Match          0.4%; Score 15.8; DB 1; Length 20;
    Best Local Similarity 89.5%; Pred. No. 1.9e+02;
    Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1790 GGCAACTCTCTGCAATTA 1808
Db 1 GGCAACTCTCTGCAATTA 19

RESULT 158
AAZ02359/c
ID AAZ02359 standard; DNA; 20 BP.
XX
XX AAZ02359;
AC
XX 07-OCT-1999 (first entry)
DT
XX PCR primer used to amplify an ORF of Chlamydia trachomatis.
DE
XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW paratrachoma; inclusion conjunctivitis; genital disease; peritriepatitis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
XX Synthetic.
OS Chlamydia trachomatis.
OS
XX WO9928475-A2.
PN
XX 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
PF
XX 28-NOV-1997; 97FR-00015041.
PR 17-DEC-1997; 97FR-00016034.
PR 04-NOV-1998; 98US-0107077P.
XX
XX (GEST ) GENSET.
PA
XX Griffais R;
XX
XX WPI; 1999-371125/31.
XX
XX Genome sequence of Chlamydia trachomatis.
Disclosure; Page 1518; 1755pp; English.
PCR primers AAZ01426-Z06209 were used to amplify open reading frames
(ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
against Chlamydia trachomatis. Antisense and ribozyme sequences can also
be used to control growth of the microorganism. Chlamydia trachomatis is
responsible for a large number of diseases, e.g. eye diseases such as

```

CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
 CC conjunctivitis; genital diseases such as nongonococcal urethritis,
 CC epididymitis, cervicitis, salpingitis, perihepatitis, Bartholinitis;
 CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
 CC The polypeptides of the invention may be of use in treating these
 CC diseases
 XX
 SQ Sequence 20 BP; 8 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2395 GCAGCTTTCTTCCCTCG 2413
 DB 19 GCAGCTTTCTTTCATCG 1
 RESULT 159
 AAX95930
 ID AAX95930 standard; DNA; 20 BP.
 XX
 AC AAX95930;
 XX
 DT 13-SEP-1999 (first entry)
 XX
 DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.
 XX
 KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KW neutralising epitope; PCR primer; ss.
 XX
 OS Synthetic.
 OS Chlamydothila pneumoniae.
 OS
 PN WO9927105-A2.
 XX
 PD 03-JUN-1999.
 XX
 PF 20-NOV-1998; 98WO-IB001890.
 XX
 PR 21-NOV-1997; 97FR-00014673.
 PR 04-NOV-1998; 98US-0107078P.
 XX
 PA (GEST) GENSET.
 XX
 PI Griffais R;
 XX
 DR WPI; 1999-357842/30.
 XX
 PT Genome sequence of Chlamydia pneumoniae.
 XX
 PS Page 1786; Disclosure; 1912pp; English.
 XX
 CC AAX91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotides sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae
 XX
 SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 966 AATTTCTGCAGAGCTGCT 984

DB 2 AATCCTGCAGAGCTGCT 20
 RESULT 160
 AAA41119/C
 ID AAA41119 standard; DNA; 20 BP.
 XX
 AC AAA41119;
 XX
 DT 16-AUG-2000 (first entry)
 XX
 DE Human TNFalpha antisense oligonucleotide ISIS# 104764.
 XX
 KW Antisense oligonucleotide; phosphorothioate; TNFalpha; cytokine; inhibit;
 KW tumour necrosis factor alpha; inflammatory bowel disease; diabetes;
 KW rheumatoid arthritis; infectious disease; multiple sclerosis; hepatitis;
 KW pancreatitis; atopic dermatitis; allograft rejection; autoimmune disease;
 KW inflammatory disease; ss.
 XX
 OS Synthetic.
 XX
 PN WO200020645-A1.
 XX
 PD 13-APR-2000.
 XX
 PF 05-OCT-1999; 99WO-US023205.
 XX
 PR 05-OCT-1998; 98US-00166186.
 PR 18-MAY-1999; 99US-00313932.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Baker BP, Bennett CF, Butler MM, Shanahan WJ;
 XX
 DR WPI; 2000-303808/26.
 XX
 PT Oligonucleotide for treating diseases associated with human tumor
 PT necrosis factor-alpha (TNF-alpha) such as, diabetes and rheumatoid
 PT arthritis, comprises nucleotide sequence complementary to intron of
 PT nucleic acid encoding TNF-alpha.
 XX
 PS Example 22; Page 103; 283pp; English.
 XX
 CC This sequence represents an antisense oligonucleotide sequence which
 CC targets a region of the human tumor necrosis factor alpha (TNFalpha)
 CC nucleotide sequence. TNFalpha is an important cytokine that plays a role
 CC in host defence. It is produced mainly in macrophages and monocytes in
 CC response to infection, invasion, injury or inflammation. Overexpression
 CC of TNFalpha can result in disease states, particularly in infectious,
 CC inflammatory and autoimmune diseases. The invention relates to antisense
 CC oligonucleotides, such as that represented by the present sequence which
 CC are capable of modulating the TNFalpha gene expression. The
 CC oligonucleotides optionally have a phosphorothioate backbone, and may
 CC also optionally contain at least one 2'-O-methoxyethyl modification. The
 CC oligonucleotides are useful for modulating the expression of human
 CC TNFalpha in cells and tissues, reducing a human cell inflammatory
 CC response, reducing the blood glucose level in a human and treating a
 CC human having a disease or condition associated with TNFalpha. Examples of
 CC diseases associated with TNFalpha include diabetes, inflammatory bowel
 CC disease, multiple sclerosis, pancreatitis, rheumatoid arthritis,
 CC infectious disease, hepatitis, atopic dermatitis or allograft rejection.
 CC The antisense oligonucleotides are also useful for modulating the
 CC function of a selected nucleic acid sequence in adipose tissue
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 486 CATCTGGAATCAAGAGACC 504

Db 20 CATCTGGAATCTGGAGACC 2

RESULT 161

AAK95077

ID AAK95077 standard; DNA; 20 BP.

XX AAK95077;

XX 06-NOV-2001 (first entry)

XX Human cDNA clone-specific primer, SEQ ID NO: 4322.

XX Human; full length cDNA; cDNA synthesis; oligo-capping; PCR primer; ss.

XX Homo sapiens.

XX EP1130094-A2.

XX 05-SEP-2001.

XX 07-JUL-2000; 2000EP-00114089.

XX 08-JUL-1999; 99JP-00194486.

XX 11-JAN-2000; 2000JP-00118774.

XX 02-MAY-2000; 2000JP-00183765.

XX (HELI-) HELIX RES INST.

XX Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;

PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;

XX WPI; 2001-524255/58.

XX 830 Primers useful for synthesizing full length cDNA clones and their use

PT in genetic manipulation.

XX Example 18; Page 130; 1380pp + Sequence Listing; English.

XX The invention relates to primers for synthesizing full length cDNA

CC clones. 830 cDNA molecules encoding a human protein have been isolated

CC and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have

CC been determined. Primers for synthesizing the full length cDNA are useful

CC for clarifying the function of the protein encoded by the cDNA. The full

CC length clones were obtained by construction of full length enriched cDNA

CC libraries that were synthesised by the oligo-capping method. The primers

CC enable the production of the full length cDNA easily without any special

CC methods. The present sequence is a primer used to amplify a human cDNA

CC clone provided in the invention

XX Sequence 20 BP; 1 A; 8 C; 3 G; 8 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 1.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1752 GGTCTGGCTCACTCTTCTC 1770

Db 2 GGTCTGGCTCACTCTTCTC 20

RESULT 162

AAK59822/C

ID AAK59822 standard; DNA; 20 BP.

XX AAK59822;

XX 04-MAY-2001 (first entry)

XX Human protein kinase C-theta antisense oligonucleotide, SEQ ID NO:15.

XX Human protein kinase C-theta; PKCT; PRKCT; nPKC-theta; PRKCO;

XX isozyme; serine/threonine protein kinase; signal transduction;

KW calcium-independent function; JNK/SAPK pathway upstream activator;

KW Jun N-terminal kinase/stress-activated protein kinase;

KW T-cell signalling pathway; cell cycle control; cellular activation;

KW AP1 transcription factor activation; AIDS aetiology; apoptosis;

KW cytoskeletal arrangement; proliferation; wound healing disorder;

KW angiogenesis; insulin signalling; chromosome 10p15;

KW expression inhibition; antisense; cancer; inflammation; diabetes;

KW phosphorothioate; 2'-MOE gapmer; ss.

XX Homo sapiens.

XX US6190869-B1.

XX 20-FEB-2001.

XX 26-OCT-1999; 99US-00429322.

XX 26-OCT-1999; 99US-00429322.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Cowsett LM;

XX WPI; 2001-210378/21.

XX Novel antisense compound 8-30 nucleobases in length targeted to a nucleic

PT acid molecule encoding human protein kinase C-theta useful for inhibiting

PT expression of human protein kinase C-theta in human cells.

XX Claim 3; Col 41-42; 40pp; English.

XX Sequences AAF59817-AAF59896 represent phosphorothioate 2'-MOE gapmer

CC antisense targeted to the human protein kinase C-theta gene, which

CC inhibit its expression. The antisense oligonucleotides were designed to

CC target different regions of the human protein kinase C-theta RNA, and

CC were analysed for their effect on protein kinase C-theta mRNA levels by

CC quantitative real-time PCR. Protein kinase C-theta (also known as PKC-

CC theta, PKCT, PRKCT, nPKC-theta and PRKCO) is one of several protein

CC kinase C isozymes and is ubiquitously expressed, with the highest levels

CC being found in haematopoietic cell lines. It has been shown to function

CC in a calcium-independent fashion, and it is involved in a variety of

CC signal transduction pathways, for example, it is an upstream activator of

CC the JNK/SAPK (Jun N-terminal kinase/stress-activated protein kinase)

CC pathway. Protein kinase C-theta is also involved in T-cell signalling

CC pathways, cell cycle control, cellular activation, AP1 transcription

CC factor activation and the aetiology of AIDS, and has also been implicated

CC in apoptosis, cytoskeletal arrangement, proliferation, and angiogenesis

CC and wound repair. It is additionally involved in insulin signalling and

CC is thought to play a role in the development of diabetes in humans. The

CC oligonucleotides of the invention are useful for diagnosis, prevention

CC and treatment of conditions associated with protein kinase C-theta

CC expression, such as inflammation, cancer, wound healing disorders and

CC diabetes

XX Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 1.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3272 TCCTTCCACTCTTGTCTCAGG 3290

Db 19 TCCTGCCAGTCTTGTCTCAGG 1

RESULT 163

AAF62869

ID AAF62869 standard; DNA; 20 BP.

XX AAF62869;

XX 08-MAY-2001 (first entry)

```
DE Human PEPCK-cytosolic antisense oligonucleotide ISIS 108037.
XX
KW Human; antiinflammatory; cytostatic; antisense gene therapy;
KW phosphoenol pyruvate carboxykinase-cytosolic; PEPCK-cytosolic; infection;
KW inflammation; tumour formation; phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PN US6187545-B1.
XX
PD 13-FEB-2001.
XX
PF 21-JAN-2000; 2000US-00488671.
XX
PR 21-JAN-2000; 2000US-00488671.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI McKay R, Butler MM, Wyatt J, Cowsett LM;
XX
DR WPI; 2001-190979/19.
XX
PT Antisense compound capable of modulating the expression of phosphoenol
PT pyruvate carboxykinase-cytosolic, useful for preventing or delaying
PT infection, inflammation or tumor formation.
XX
PS Claim 1; Col 42; 64pp; English.
XX
CC The present sequence is one of a number of antisense compounds of up to
CC 30 nucleobases in length that are capable of inhibiting the expression of
CC phosphoenol pyruvate carboxykinase-cytosolic (PEPCK-cytosolic). The
CC antisense compounds are useful for inhibiting the expression of PEPCK-
CC cytosolic in cells or tissues. They are commonly used as research
CC reagents and in diagnostics, e.g. to elucidate the function of particular
CC genes. They are also useful for distinguishing between functions of
CC various members of a biological pathway and for research use. The
CC antisense compounds are also useful prophylactically, e.g. to prevent or
CC delay infection, inflammation or tumor formation. The present sequence
CC is a chimeric phosphorothioate oligonucleotide with 2'-MOE wings and a
CC deoxy gap
XX
SQ Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 959 GAGCGGGAATTTCTGCAGA 977
DB 2 GAGGAGGCATTTCTGCAGA 20
RESULT 164
AAH23849/c
ID AAH23849 standard; DNA; 20 BP.
XX
AC AAH23849;
XX
DT 07-AUG-2001 (first entry)
XX
DE Human antileukoprotease (ALP) forward PCR primer, SEQ ID NO:3.
XX
KW Antileukoprotease; ALP; secretory leukocyte proteinase; SLP; human;
KW cancer marker; ovarian tumour; ovarian-derived metastatic tumour;
KW overexpression; low malignant potential tumour; ovarian carcinoma;
KW serous carcinoma; mucinous carcinoma; endometrioid carcinoma;
KW clear cell carcinoma; cancer; diagnosis; cytostatic;
KW quantitative PCR primer; ss.
XX
OS Homo sapiens.
XX
PN W0200128500-A2.
XX
```

```
PD 26-APR-2001.
XX
PF 18-OCT-2000; 2000WO-US041306.
XX
PR 18-OCT-1999; 99US-0159972P.
XX
PA (UYAR-) UNIV ARKANSAS.
XX
PI O'Brien TJ, Tanimoto H, Underwood LJ, Shigemasa K;
XX
DR WPI; 2001-290812/30.
XX
PT Detecting tumor growth in an individual, particularly ovarian and ovarian
PT -derived metastatic tumors, comprises measuring antileukoprotease levels.
XX
PS Example 3; Page 10; 45pp; English.
XX
CC The invention relates to methods for the diagnosis and treatment of
CC ovarian tumors or ovarian-derived metastatic tumors in an individual.
CC The diagnostic method involves measuring the level of antileukoprotease
CC (ALP) in a sample (e.g., a blood sample, tissue biopsy or ovarian
CC secretion) from an individual. If the level of ALP exceeds the mean basal
CC level of ALP in non-diseased individuals by 2 or more standard
CC deviations, the individual is likely to have an ovarian or ovarian-
CC derived tumour. ALP, also known as secretory leukocyte proteinase (SLP),
CC is a small (approximately 100 amino acids) secreted protease inhibitor
CC which specifically inhibits the activity of stratum corneum chymotryptic
CC enzyme, and is also able to inhibit leukocyte elastase, cathepsin G,
CC chymotrypsin and trypsin. It is significantly overexpressed in carcinomas
CC and potential tumors of ovarian origin. The invention also provides
CC methods of treating ovarian or ovarian-derived tumors, or preventing
CC ovarian tumour metastasis, via the administration of ALP. Methods of the
CC invention are useful for the diagnosis, prevention and treatment of
CC ovarian and ovarian-derived metastatic tumors, particularly low
CC malignant potential tumors or ovarian carcinomas such as serous carcinoma,
CC mucinous carcinoma, endometrioid carcinoma and clear cell carcinoma.
CC Sequences AAH23847-AAH23850 represent PCR primers used in quantitative
CC PCR in an exemplification of the invention to determine levels of ALP
CC mRNA from normal and cancerous ovarian tissue
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1904 CAGACTCCACCTTTGGAGG 1922
DB 19 CAGACTCCAGCTTTGAAGG 1
RESULT 165
AAS05714/c
ID AAS05714 standard; DNA; 20 BP.
XX
AC AAS05714;
XX
DT 09-SEP-2004 (revised)
DT 07-SEP-2001 (first entry)
XX
DE Aminopurine substituted region of an RP-TFO.
XX
KW Reverse phase triplex forming oligonucleotide; RP-TFO;
KW protected nucleic acid sequence; PNAS; single nucleotide polymorphism;
KW SNP; short tandem repeat; cancer; Factor V Leiden SNP; ss.
XX
OS Synthetic.
XX
FH Key modified_base 1 Location/Qualifiers
FT /*tag= a
FT /mod_base= OTHER
FT /note= "A is aminopurine substituted"
```


RESULT 168
 ABO96037/c
 ID: "ABO96037 standard; DNA; 20 BP.
 XX'
 AC ABO96037;
 XX
 28-OCT-2002 (first entry)
 XX
 Tumour suppression-related oligonucleotide #1688.
 XX
 Tumour; cytostatic; antiviral; neuroprotective; nootropic; neuroleptic;
 XX
 tumour suppression; tumour reversion; apoptosis; viral resistance; human;
 XX
 viral infection; cell degeneration disease; neurodegeneration; ds;
 XX
 Alzheimer's disease; schizophrenia; immune disease; inflammatory disease.
 XX
 Homo sapiens.
 OS
 FR2819824-Al.
 PN
 26-JUL-2002.
 XX
 23-JAN-2001; 2001FR-00000899.
 XX
 23-JAN-2001; 2001FR-00000899.
 XX
 (MOLE-) MOLECULAR ENGINES LAB SA.
 XX
 Telerman A, Amson R, Tuijnder M, Susini L;
 XX
 WPI; 2002-610803/66.
 XX
 New nucleic acid implicated e.g. in tumor suppression, useful for
 XX
 diagnosis of tumors, viral infection and cellular degeneration and for
 XX
 drug screening.
 XX
 Claim 1; Page 468; 623pp; French.
 XX
 The present invention relates to novel human nucleic acid sequences (I).
 XX
 The present sequence is one such nucleic acid sequence. Expression of (I)
 XX
 are implicated in tumour suppression or reversion and apoptosis and viral
 XX
 resistance. (I) are useful as probes or primers for detecting,
 XX
 identifying, measuring and/or amplifying nucleic acid sequences, as
 XX
 antisense reagents and for recombinant production of polypeptides. (I),
 XX
 polypeptides (II) encoded by (I), vector containing (I), cells containing
 XX
 these vectors and antibodies (Ab) against (II) are all useful for
 XX
 treatment/prevention of viral, tumour and cell degeneration diseases
 XX
 (especially neurodegeneration, such as Alzheimer's disease and
 XX
 schizophrenia). Analysing the expression of (I) is also useful for
 XX
 diagnosis and/or prognosis of such diseases. Transgenic animals carrying
 XX
 (I) are used for studying the aetiology of these diseases (also immune
 XX
 and inflammatory diseases). Note: In the present specification, SEQ ID 1
 XX
 to 2280 are claimed in Claim 1, however only SEQ ID 1 to 2270 are shown
 XX
 in the specification
 XX
 SQ Sequence 20 BP; 17 A; 1 C; 1 G; 0 T; 0 U; 1 Other;
 XX
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 XX
 Best Local Similarity 85.0%; Pred. No. 1.9e+02;
 XX
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0
 XX
 QY 2567 TTCTCTCTCTCTTTTTTTT 2586
 XX
 DB 20 TTNTTCTTTTTTTGTTTT 1
 XX
 RESULT 169
 ABL94296
 ID ABL94296 standard; DNA; 20 BP.
 XX
 XX ABL94296;
 XX
 XX 29-JUL-2002 (first entry)
 XX
 XX

Human C/EBP beta phosphorothioate antisense oligonucleotide, SEQ ID:62.

Human; C/EBP beta; CCAAT/enhancer-binding protein beta; C/EBP2; LAP; TCF5; CRP2; NFIL6; IL6BP; NF-M; AGP/EBP; Apc/EBP; transcription factor; tissue development; cellular function; proliferation; differentiation; hormone responsiveness; oxidative stress response; IL-6 signalling mediator; interleukin-6; carbohydrate metabolism; immunity; Th1 response; female fertility; gluconeogenesis; ovarian cancer; tumour formation; type II diabetes; infection; inflammation; expression inhibition; phosphorothioate; antisense oligonucleotide; ss.

Homo sapiens.

Key modified_base 1..20 Location/Qualifiers

FT FT /mod_base= a

FT FT /mod_base= OTHER

FT FT /note= "Phosphorothioate linkages"

FT FT 1..15

FT FT /mod_base= b

FT FT /mod_base= OTHER

FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE cytosines are 5-methylcytosine"

FT FT 16..20

FT FT /mod_base= c

FT FT /mod_base= OTHER

FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE cytosines are 5-methylcytosine"

PN US6271030-B1.

PD 07-AUG-2001.

PP 14-JUN-2000; 2000US-00593711.

PP 14-JUN-2000; 2000US-00593711.

PA (ISIS-) ISIS PHARM INC.

PI Monia BP, Butler MM, Wyatt J;

PI WPI; 2002-214451/27.

PT Novel antisense compound targeted to nucleic acids encoding human or mouse CCAAT/enhancer binding protein (C/EBP) beta, useful in vitro for inhibiting expression of human or mouse C/EBP beta in cells/tissues.

PS Claim 1; Col 43-44; 69pp; English.

XX Sequences ABL94252-ABL94476 represent antisense oligonucleotides targeted to the human or mouse CCAAT/enhancer-binding protein alpha (C/EBP alpha) gene, which inhibit its expression. The antisense oligonucleotides were designed to target different regions of the human and/or mouse C/EBP alpha RNA, and were analysed for their effect on C/EBP alpha mRNA levels by quantitative real-time PCR. The C/EBP family of proteins are a family of transcription factors which regulate the expression of a wide range of genes that control normal tissue development, cellular function, cellular proliferation and functional differentiation. C/EBP beta (also known as C/EBP2, LAP, TCF5, CRP2, NFIL6, IL6BP, NF-M, AGP/EBP and Apc/EBP) primarily regulates hormone responsiveness and oxidative stress responses and is a mediator of IL-6 (interleukin-6) signalling. C/EBP beta is thought to be involved in carbohydrate metabolism, immunity, the Th1 response, female fertility and gluconeogenic pathways. C/EBP beta is expressed in the liver, lung, spleen, kidney, brain, and testis, with the highest expression found in the lung. It is also expressed at a higher level in malignant ovarian tissue compared with normal ovarian tissue, and its expression in pancreas is upregulated in response to chronically elevated levels of glucose, indicating that it is involved in the impairment of insulin secretion in type II diabetes. The oligonucleotides of the invention are useful for diagnosis, prevention and treatment of conditions associated with C/EBP beta expression, such as cancer (particularly ovarian cancer), tumour formation, diabetes (particularly type II diabetes), infection, or inflammation

XX SQ Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 1.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY : 2182 AGCTGCTCTCCATCTTCT 2200

DB 1 AGCTGCTCCACCTTCTTCT 19

RESULT 170

ACD05347/C

ID ACD05347 standard; DNA; 20 BP.

XX

AC ACD05347;

XX

DT 05-AUG-2003 (first entry)

XX

DE Tumour necrosis factor alpha antisense oligonucleotide #350.

XX

KW Tumour necrosis factor alpha; TNF-alpha; antiinflammatory; antirheumatic; antiarthritic; antidiabetic; dermatological; hepatotropic; antiaethmatic; inflammatory disorder; inflammatory bowel disease; Crohn's disease; colitis; rheumatoid arthritis; diabetes; pancreatitis;

KW multiple sclerosis; atopic dermatitis; asthma; hepatitis;

KW antisense technology; ss.

XX

OS Synthetic.

XX

PN US2003022848-A1.

XX

DD 30-JAN-2003.

XX

PF 02-APR-2001; 2001US-00824322.

XX

PR 05-OCT-1998; 98US-00165186.

PR 18-MAY-1999; 99US-00313932.

XX

PA (BAKE/) BAKER B F.

PA (BENN/) BENNETT C F.

PA (BUTL/) BUTLER M M.

PA (SHAN/) SHANAHAN W R.

XX

PI Baker BF, Bennett CF, Butler MM, Shanahan WR;

XX

WPI; 2003-447433/42.

XX

PT Treating inflammatory disorders such as inflammatory bowel disease, Crohn's disease or rheumatoid arthritis, in a subject, by administering oligonucleotide which inhibits expression of human tumour necrosis factor alpha.

XX

PS Example 24; Page 39; 142pp; English.

XX

CC The invention describes a method of treating an inflammatory disorder in an individual, comprising administering to the individual an oligonucleotide upto 30 nucleotides in length complementary to a nucleic acid molecule encoding human tumour necrosis factor (TNF)-alpha. The method is useful for treating an inflammatory disorder such as inflammatory bowel disease, Crohn's disease, colitis or rheumatoid arthritis, in an individual. The method is also useful for treating diabetes, pancreatitis, multiple sclerosis, atopic dermatitis, asthma, and hepatitis in an individual. This sequence represents an antisense oligonucleotide used to modulate expression of tumour necrosis factor alpha (TNF-alpha)

XX

SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 1.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 486 CATCTGGAATCAAGAGACC 504
DB 20 CATCTGGAATCTGGAGACC 2

RESULT 171
ABZ85659/C
ID ABZ85659 standard; DNA; 20 BP.

XX AC ABZ85659;

XX DT 17-OCT-2003 (first entry)

XX DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Claim 15; SEQ ID NO 901; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3442 TGCCATGCTTTTACAGA 3460
DB 20 TGCCATGCTTTTACAGA 2

RESULT 172
ABZ88617/C
ID ABZ88617 standard; DNA; 20 BP.

XX AC ABZ88617;

XX DT 17-OCT-2003 (first entry)

XX DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Disclosure; SEQ ID NO 3859; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 13 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2577 TTTTCTGAAAAA 2595
 |||||
 db 19 TTTTCTGAAAAA 1
 |||||

RESULT 173
ABZ87303
ID ABZ87303 standard; DNA; 20 BP.

AC ABZ87303:

DT 17-OCT-2003 (first entry)

Human oligonucleotide sequence.

Human; antiseize; lung dysfunction; nasal airway dysfunction;
 antiinflammatory steroid; ubiquinone; antiinflammatory; anti allergic;
 antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 antiseize gene therapy; respiratory; lung; adenosine sensitivity;
 adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 lung inflammation; respiratory disease; ds.

Homo sapiens.

PN WO200285308-A2.

31-OCT-2002

23-APR-2002: 2002WO-US013135.

24-APR-2001: 2001US-0286137P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

xx
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI

WPT: 2003-229219/22.

pharmaceutical composition for treating ailments associated with impaired
respiration, has oligo(s) antisense to specific gene(s) or its
corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
ubiquinone.

PS Disclosure: SEO ID NO 2545: 872pp: English:

The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of 5' and 3' intron-exon junctions, or polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, for reducing levels of adenosine or, or reducing bronchodilation, increasing levels of ubiquinone or receptor, producing bronchodilation, increasing levels of ubiquinone or lung surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published pct sequences

Sequence 20 BP: 7 A: 3 C: 1 G: 9 T: 0 U: 0 Other: 0

Query Match	0.4%	Score 15.8;	DB 1;	Length 20;
Best Local Similarity	89.5%;	Pred. No. 1.9e+02;		
Matches 17:	Conservative	0;	Mismatches 2;	Indels 0;
	Gaps	0;		

2814 CTTTATCCCTTTGTAAA 2832
QY ||||| ||||| ||||| |||||
2 CTTTATACCTTTGTAAA 20
Dp

RESULT 174

ABZ87232

ID ABZ87232 standard; DNA; 20 BP.

AC ABZ87232;

17-OCT-2003 (first entry)

Human oligonucleotide sequence.

Human; antisense; lung dysfunction; nasal airway dysfunction;
antiinflammatory steroid; ubiquinone; antiinflammatory; anti-
allergic; antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
antisense gene therapy; lung; adenosine sensitivity;
adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
lung inflammation; respiratory diseases; ds.

Homo sapiens.

PN WO200285308-A2.

31-OCT-2002.

23-APR-2002: 2002WO-US013135.

24-APR-2001: 2001US-0286137P.

XX PA (EPTG-) EPTGENESIS PHARM INC.

XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

WPT: 2003-229219/22.

xx pharmaceutical composition for treating ailments associated with impaired
xx respiration, has oligo(s) antisense to specific gene(s) or its
xx corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
xx ubinimone.

XX
PS
Claim 15: SEQ ID NO 2474: 872pp: English.

The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, for reducing levels of adenosine or receptor, producing bronchodilation, increasing levels of ubiquinone or surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at http://www.int/pub/published/pct_sequences

XX
sequence 20 BP: 0 A: 7 C: 1 G: 12 T: 0 U: 0 Other:

Query Match	0.4;	Score 15.8;	DB 1;	Length 20;
Best Local Similarity	89.5%;	Pred. No. 1.9e+02;		
Matches 17.	Conservative	0: Mismatches 2;	Indels 0;	Gaps 0;

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 0 A; 7 C; 1 G; 12 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TTCTCTCTCTCTCTCTCT 2234

Db 1 TTCTTTCTCTCTCTCTCT 19

RESULT 177

ABD24847/C

ID ABD24847 standard; DNA; 20 BP.

AC ABD24847;

DT 29-JUL-2004 (first entry)

XX AI092623-derived oligonucleotide SEQ ID 3859.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013143.

PF 24-APR-2001; 2001US-0286036P.

PR (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 FT oligonucleotide containing less percentage of adenosine, targeted to
 FT nucleic acids associated with lung airway or lung dysfunction, and
 FT bronchodilating agent.

XX Claim 15; SEQ ID NO 3859; 763pp; English.

XX

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 13 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2577 TTTTCTTTCTGAAAAA 2595

Db 19 TTTTCTTTCTGAAAAA 1

RESULT 178

ABD23533

ID ABD23533 standard; DNA; 20 BP.

XX ABD23533;

XX 29-JUL-2004 (first entry)

XX Human myosin X-derived oligonucleotide SEQ ID 2545.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013143.

PF 24-APR-2001; 2001US-0286036P.

PR (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nvce JW, Li Y, Sandraagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093059/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 2545; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposcretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 7 A; 3 C; 1 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2814 CTTATCCCTTTGTGTA 2832
DB 2 CTTATACCTTTGTGTA 20
RESULT 179
ADG72145/C
ID ADG72145 standard; DNA; 20 BP.
XX
AC ADG72145;
XX
DT 11-MAR-2004 (first entry)
XX
XX Mouse SREBP-1 antisense oligonucleotide ISIS 219690.
DE
XX Sterol regulatory element-binding protein-1; SREBP-1; ss; mouse;
XX antisense gene therapy;
KW sterol regulatory element-binding transcription factor; SREBP;
KW metabolic disorder; diabetes; cardiovascular disorder; atherosclerosis;
KW hyperlipidaemia.
XX
OS Mus musculus.
XX
FH Key Location/Qualifiers

FT modified_base 1. 20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytidines are 5-
methylycytidines"
FT modified_base 1. 5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residues"
FT modified_base 16. 20
FT /*tag= C
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residues"
XX
XX US2003224515-A1.
XX
XX 04-DEC-2003.
XX
XX 04-JUN-2002; 2002US-00161996.
XX
XX 04-JUN-2002; 2002US-00161996.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Baker BF, Dobie KW;
XX WPI; 2004-022079/02.
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding sterol regulatory element-binding protein-1, useful
PT for treating diabetes, atherosclerosis or hyperlipidemia.
XX
XX Example 16; SEQ ID NO 140; 112pp; English.
XX
XX The invention relates to a compound 8-80 nucleobases in length targeted
CC to, and which specifically hybridises with a nucleic acid molecule
CC encoding sterol regulatory element-binding protein-1 (SREBP-1), also known
CC as sterol regulatory element-binding transcription factor, SREBF), and
CC inhibits the expression of SREBP-1, i.e. is an antisense oligonucleotide.
CC Also included are a compound 8-80 nucleobases in length that specifically
CC hybridises with at least an 8-nucleobase portion of an active site on a
CC nucleic acid molecule encoding sterol regulatory element-binding protein-
CC 1, a composition comprising the compound and a carrier or diluent,
CC inhibiting the expression of sterol regulatory element-binding protein-1
CC in cells or tissues (by contacting the cells or tissues with the compound
CC so that expression of sterol regulatory element-binding protein-1 is
CC inhibited) and treating an animal having a disease or condition
CC associated with sterol regulatory element-binding protein-1 by
CC administering to the animal a therapeutic or prophylactic amount of the
CC compound so that expression of sterol regulatory element-binding protein-
CC 1 is inhibited. The antisense oligonucleotide comprises at least one
CC modified internucleoside linkage (preferably a phosphorothioate linkage),
CC at least one modified sugar moiety (preferably 2'-O-methoxyethyl sugar
CC moiety) or at least one modified nucleobase (preferably 5-
CC methylcytosine). The compound, composition and methods are useful for
CC treating a disease or condition associated with sterol regulatory element
CC -binding protein-1, such as a metabolic disorder e.g. diabetes, or a
CC cardiovascular disorder, e.g. atherosclerosis or hyperlipidaemia. They
CC are also useful in research and diagnostics for modulating the expression
CC of sterol regulatory element-binding protein-1. The present sequence is
CC an antisense oligonucleotide targeting mouse SREBP-1.
XX
SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1776 GAGCAGGCTCCAGTGGCAA 1794
DB 20 GGCAGGTTCCAGTGGCAA 2

RESULT 180
ADG72265
ID ADG72265 standard; CDNA; 20 BP.
XX AC ADG72265;
XX DT 11-MAR-2004 (first entry)
XX DE Mouse SREBP-1 target site #34.
XX KW Sterol regulatory element-binding protein-1; SREBP-1; ss; mouse;
XX KW antisense gene therapy;
KW sterol regulatory element-binding transcription factor; SREBF;
KW metabolic disorder; diabetes; cardiovascular disorder; atherosclerosis;
KW hyperlipidaemia.
XX OS Mus musculus.
XX FN US2003224515-A1.
XX PD 04-DEC-2003.
XX PF 04-JUN-2002; 2002US-00161996.
XX PR 04-JUN-2002; 2002US-00161996.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Baker BF, Dobie KW;
XX WPI; 2004-022079/02.
XX PT New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding sterol regulatory element-binding protein-1, useful
PT for treating diabetes, atherosclerosis or hyperlipidemia.
XX PS Example 16; SEQ ID NO 260; 112pp; English.
XX CC The invention relates to a compound 8-80 nucleobases in length targeted
CC to, and which specifically hybridises with a nucleic acid molecule
CC encoding sterol regulatory element-binding protein-1 (SREBP-1, also known
CC as sterol regulatory element-binding transcription factor, SREBF), and
CC inhibits the expression of SREBP-1, i.e. is an antisense oligonucleotide.
CC Also included are a compound 8-80 nucleobases in length that specifically
CC hybridises with at least an 8-nucleobase portion of an active site on a
CC nucleic acid molecule encoding sterol regulatory element-binding protein-
CC 1, a composition comprising the compound and a carrier or diluent,
CC inhibiting the expression of sterol regulatory element-binding protein-1
CC in cells or tissues (by contacting the cells or tissues with the compound
CC so that expression of sterol regulatory element-binding protein-1 is
CC inhibited) and treating an animal having a disease or condition
CC associated with sterol regulatory element-binding protein-1 by
CC administering to the animal a therapeutic or prophylactic amount of the
CC compound so that expression of sterol regulatory element-binding protein-
CC 1 is inhibited. The antisense oligonucleotide comprises at least one
CC modified internucleoside linkage (preferably a phosphorothioate linkage),
CC at least one modified sugar moiety (preferably 2'-O-methoxyethyl sugar
CC moiety) or at least one modified nucleobase (preferably 5-
CC methylcytosine). The compound, composition and methods are useful for
CC treating a disease or condition associated with sterol regulatory element
CC -binding protein-1, such as a metabolic disorder e.g. diabetes, or a
CC cardiovascular disorder, e.g. atherosclerosis or hyperlipidaemia. They
CC are also useful in research and diagnostics for modulating the expression
CC of sterol regulatory element-binding protein-1. The present sequence is a
CC mouse SREBP-1 target region for the antisense oligonucleotides.
XX SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1776 GAGCAGGTCACAGTGGCAA 1794

Db 1 GG3CAGGTTCCAGTGGCAA 19
RESULT 181
ADH67583
ID ADH67583 standard; DNA; 20 BP.
XX AC ADH67583;
XX DT 25-MAR-2004 (first entry)
XX DE Human glucocorticoid receptor-specific antisense oligonucleotide #4417.
XX KW antisense oligonucleotide; glucocorticoid receptor; infection;
KW inflammation; tumour formation; diabetes; obesity;
KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; ss;
KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX OS Homo sapiens.
XX FN WO2003099215-A2.
XX PD 04-DEC-2003.
XX PF 20-MAY-2003; 2003WO-US016084.
XX PR 20-MAY-2002; 2002US-0381857P.
XX PA (PHAA) PHARMACIA CORP.
XX PI Crosby SD, Nalseth AE;
XX WPI; 2004-035034/03.
XX PT New antisense compound targeted to a nucleic acid molecule encoding
PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX PS Claim 4; SEQ ID NO 4417; 985pp; English.
XX CC The invention comprises an antisense oligonucleotides that are targeted
CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC antisense oligonucleotides of the invention are useful for preventing or
CC delaying infection, inflammation or tumour formation. The antisense
CC oligonucleotides are also useful for treating diabetes, obesity. The
CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC present DNA sequence represents an antisense oligonucleotide that targets
CC the human glucocorticoid receptor gene. NOTE: The present sequence
CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX SQ Sequence 20 BP; 7 A; 1 C; 0 G; 12 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2575 TCCTTTTCTTTCTGAAA 2593
Db 2 TATTTTCTTTCTGAAA 20
RESULT 182
ADH44476
ID ADH44476 standard; DNA; 20 BP.
XX AC ADH44476;
XX DT 25-MAR-2004 (first entry)
XX DE Extracellular-signal-regulated kinase-6, antisense oligonucleotide #2.
XX KW Antisense therapy; human; extracellular-signal-regulated kinase-6;

KW hyperproliferative disorder; cancer; inflammatory disorder;
 KW neurodegenerative disorder; Alzheimer's disease; infection; inflammation;
 KW tumour formation; cytostatic; antiinflammatory; neuroprotective;
 KW neutropic; antibacterial; phosphorothioate; ss.
 OS Homo sapiens.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5',
 FT and 3' ends, which are 5 nucleotides in length at each
 FT end. All cytidine residues are 5-methylcytidines"
 XX
 PN US2003232772-A1.
 XX
 XX 18-DEC-2003.
 PD
 XX 17-JUN-2002; 2002US-00174465.
 PF
 XX 17-JUN-2002; 2002US-00174465.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Dobie KW;
 PI
 XX WPI; 2004-052189/05.
 DR
 XX
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT extracellular-signal-regulated kinase-6, useful for modulating expression
 PT of extracellular-signal-regulated kinase-6 or treating cancer.
 XX
 XX Example 15; SEQ ID NO 12; 45pp; English.
 PS
 XX The present invention relates to antisense compounds targeted to a
 CC nucleic acid encoding extracellular-signal-regulated kinase-6. The
 CC antisense compound comprises an antisense oligonucleotide that
 CC specifically hybridises with the nucleic acid and inhibits the expression
 CC of extracellular-signal-regulated kinase-6. The antisense oligonucleotide
 CC is a chimeric oligonucleotide. The antisense oligonucleotide comprises at
 CC least one modified internucleoside linkage, preferably a phosphorothioate
 CC linkage. It also comprises at least one modified sugar moiety, preferably a 5-
 CC 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide
 CC further comprises at least one modified nucleobase, preferably a 5-
 CC methylcytosine. The antisense oligonucleotides are useful for the
 CC treatment of diseases such as hyperproliferative disorders, preferably
 CC cancer, inflammatory disorders, and neurodegenerative disorders,
 CC preferably Alzheimer's disease. The antisense compound can also be used
 CC as prophylaxis, e.g. to prevent or delay infection, inflammation or
 CC tumour formation. The present sequence represents an antisense
 CC oligonucleotide used in the examples of the present invention.
 XX
 SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 227 CCTTGAGCTGGTCCAGGAG 245
 DB |||||
 2 CCTTGAGCTGGTCCAGGTG 20
 RESULT 183
 ADH44512/C
 ID ADH44512 standard; DNA; 20 BP.
 XX
 XX ADH44512;
 AC
 XX 25-MAR-2004 (first entry)
 DT
 XX

DE Human extracellular-signal-regulated kinase-6 DNA target sequence #1.
 XX
 XX Antisense therapy; human; extracellular-signal-regulated kinase-6;
 KW hyperproliferative disorder; cancer; inflammatory disorder;
 KW neurodegenerative disorder; Alzheimer's disease; infection; inflammation;
 KW tumour formation; cytostatic; antiinflammatory; neuroprotective;
 KW neutropic; antibacterial; ds.
 OS Homo sapiens.
 XX
 XX US2003232772-A1.
 PN
 XX 18-DEC-2003.
 PD
 XX 17-JUN-2002; 2002US-00174465.
 PF
 XX 17-JUN-2002; 2002US-00174465.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Dobie KW;
 PI
 XX WPI; 2004-052189/05.
 DR
 XX
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT extracellular-signal-regulated kinase-6, useful for modulating expression
 PT of extracellular-signal-regulated kinase-6 or treating cancer.
 XX
 XX Example 15; SEQ ID NO 48; 45pp; English.
 PS
 XX The present invention relates to antisense compounds targeted to a
 CC nucleic acid encoding extracellular-signal-regulated kinase-6. The
 CC antisense compound comprises an antisense oligonucleotide that
 CC specifically hybridises with the nucleic acid and inhibits the expression
 CC of extracellular-signal-regulated kinase-6. The antisense oligonucleotide
 CC is a chimeric oligonucleotide. The antisense oligonucleotide comprises at
 CC least one modified internucleoside linkage, preferably a phosphorothioate
 CC linkage. It also comprises at least one modified sugar moiety, preferably a 5-
 CC 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide
 CC further comprises at least one modified nucleobase, preferably a 5-
 CC methylcytosine. The antisense oligonucleotides are useful for the
 CC treatment of diseases such as hyperproliferative disorders, preferably
 CC cancer, inflammatory disorders, and neurodegenerative disorders,
 CC preferably Alzheimer's disease. The antisense compound can also be used
 CC as prophylaxis, e.g. to prevent or delay infection, inflammation or
 CC tumour formation. The present sequence represents a human extracellular-
 CC signal-regulated kinase-6 DNA target sequence for an antisense
 CC oligonucleotide.
 XX
 SQ Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 227 CCTTGAGCTGGTCCAGGAG 245
 DB |||||
 19 CCTTGAGCTGGTCCAGGTG 1
 RESULT 184
 ADJ32619
 ID ADJ32619 standard; DNA; 20 BP.
 XX
 XX ADJ32619;
 AC
 XX 22-APR-2004 (first entry)
 DT
 XX Human ERK-6 specific antisense oligo, ISIS 157012.
 DE
 XX Extracellular-signal-regulated kinase-6; ERK-6;
 KW hyperproliferative disorder; cancer; inflammatory disorder;
 KW neurodegenerative disorder; Alzheimer's disease; angiogenesis;
 KW

KW tubular formation; matrix degradation; human; antisense;
KW phosphorothioate backbone; therapy; ss.
OS Homo sapiens.
OS Synthetic.

Key Location/Qualifiers
modified_base 1..20
/*tag= b
/mod_base= OTHER
/note= "Phosphorothioate backbone in which all cytidines
are 5-methylcytidines"
modified_base 1..5
/*tag= a
/mod_base= OTHER
/note= "2'-methoxyethyl residues"
modified_base 16..20
/*tag= c
/mod_base= OTHER
/note= "2'-methoxyethyl residues"

US2003232778-A1.

PD 18-DEC-2003.

17-JAN-2003; 2003US-00348431.

17-JUN-2002; 2002US-00174465.

(MARC/) MARCUSSEN E G.

(BENN/) BENNETT C F.

(DOBI/) DOBIE K W.

Marcusson EG, Bennett CF, Dobie KW;

WPI; 2004-061312/06.

New compound targeted to a nucleic acid molecule encoding extracellular-
signal-regulated kinase-6, useful for treating angiogenic,
hyperproliferative (cancer), inflammatory or neurodegenerative disorders
(Alzheimer's disease).

Example 15; SEQ ID NO 12; 47pp; English.

The invention relates to antisense compounds, compositions and methods
for modulating the expression of extracellular-signal-regulated kinase-6
(ERK-6). The compound is useful in treating an animal having a disease or
condition associated with ERK-6, e.g. a hyperproliferative disorder
(especially cancer), an inflammatory disorder or a neurodegenerative
disorder (especially Alzheimer's disease). It is also useful for
inhibiting angiogenesis, for preventing tubular formation of blood
vessels, and for preventing degradation of extracellular matrix for new
blood vessel formation. The present sequence is an antisense
oligonucleotide targetted towards human ERK-6 DNA. This sequence is used
to illustrate the method of the invention.

Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245

DB 2 CCTTCAGCTGGTCCAGGTG 20

RESULT 185

ADJ32655/C

ID ADJ32655 standard; DNA; 20 BP.

XX

XX ADJ32655;

XX

DT 22-APR-2004 (first entry)

XX Human ERK-6 target DNA fragment #1.

XX Extracellular-signal-regulated kinase-6; ERK-6;
KW hyperproliferative disorder; cancer; inflammatory disorder;
KW neurodegenerative disorder; Alzheimer's disease; angiogenesis;
KW tubular formation; matrix degradation; human; therapy; ds.

OS Homo sapiens.

XX US2003232778-A1.

PD 18-DEC-2003.

17-JAN-2003; 2003US-00348431.

17-JUN-2002; 2002US-00174465.

(MARC/) MARCUSSEN E G.

(BENN/) BENNETT C F.

(DOBI/) DOBIE K W.

Marcusson EG, Bennett CF, Dobie KW;

WPI; 2004-061312/06.

New compound targeted to a nucleic acid molecule encoding extracellular-
signal-regulated kinase-6, useful for treating angiogenic,
hyperproliferative (cancer), inflammatory or neurodegenerative disorders
(Alzheimer's disease).

Example 15; SEQ ID NO 48; 47pp; English.

The invention relates to antisense compounds, compositions and methods
for modulating the expression of extracellular-signal-regulated kinase-6
(ERK-6). The compound is useful in treating an animal having a disease or
condition associated with ERK-6, e.g. a hyperproliferative disorder
(especially cancer), an inflammatory disorder or a neurodegenerative
disorder (especially Alzheimer's disease). It is also useful for
inhibiting angiogenesis, for preventing tubular formation of blood
vessels, and for preventing degradation of extracellular matrix for new
blood vessel formation. The present sequence is human ERK-6 target DNA
fragment. This sequence is used to illustrate the method of the
invention.

Sequence 20 BP; 6 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245

DB 19 CCTTCAGCTGGTCCAGGTG 1

RESULT 186

ADK67452/C

ID ADK67452 standard; DNA; 20 BP.

XX

XX ADK67452;

XX

DT 06-MAY-2004 (first entry)

XX Electrochemical detection intercalator-related DNA 2.

XX intercalator; electrochemical detection; mismatch; ss.

XX

OS Synthetic.

XX

PN JP2004024114-A.

XX

PD 29-JAN-2004.
 XX
 PF 26-JUN-2002; 2002JP-00185555.
 XX
 XX 26-JUN-2002; 2002JP-00185555.
 PR (TAKE/) TAKENAKA S.
 PA (TUMK-) TUM KENKYUSHO KK.
 XX
 XX WPI; 2004-207136/20.
 DR
 XX Novel intercalator, useful as electrochemical double stranded DNA
 PT detection reagent.
 PT
 XX
 PS Example 1; Page 23; 24pp; Japanese.
 XX
 CC The invention relates to a novel intercalator having a specific formula.
 CC The intercalator of the invention may be useful for the electrochemical
 CC detection of a gene, as an electrochemical double stranded DNA detection
 CC reagent and as an intercalator for inhibiting the influence of mismatch
 CC DNA and single stranded DNA. The intercalator enables the transmission of
 CC electronic transition between two base pairs to occur efficiently. The
 CC current sequence is that of the electrochemical detection intercalator-
 CC related DNA 2 of the invention.
 XX
 XX Sequence 20 BP; 19 A; 0 C; 1 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2567 TTTCTTCTCTTTT 2585
 DB 19 TTTTCTTCTTTT 1
 RESULT 187
 ADK78484/c
 ID ADK78484 standard; DNA; 20 BP.
 XX
 AC ADK78484;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5818.
 DE
 XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX
 OS Synthetic.
 XX
 PN WO2004016754-A2.
 XX
 PD 26-FEB-2004.
 XX
 PF 14-AUG-2003; 2003WO-US025465.
 XX
 PR 14-AUG-2002; 2002US-0403416P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Robert's SL;
 XX
 DR WPI; 2004-203785/19.
 XX
 PT New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX
 PS Claim 4; SEQ ID NO 5818; 417pp; English.
 XX

CC The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'NOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.
 XX
 XX Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 959 GAGGCGGAATTCGACGA 977
 DB 20 GAGGCGGAATTCGACGA 2
 RESULT 188
 ADK78101/c
 ID ADK78101 standard; DNA; 20 BP.
 XX
 AC ADK78101;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5435.
 DE
 XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX
 OS Synthetic.
 XX
 PN WO2004016754-A2.
 XX
 PD 26-FEB-2004.
 XX
 PF 14-AUG-2003; 2003WO-US025465.
 XX
 PR 14-AUG-2002; 2002US-0403416P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Robert's SL;
 XX
 DR WPI; 2004-203785/19.
 XX
 PT New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX
 PS Claim 4; SEQ ID NO 5435; 417pp; English.
 XX
 CC The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present

CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 3 A; 4 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 953 CATAAAGAGCGGAATTC 971
 |||||
 Db 20 CAAAAGAGCGCGAATTC 2

RESULT 189
 ADK78246/C
 ID ADK78246 standard; DNA; 20 BP.

XX AC ADK78246;

XX DT 20-MAY-2004 (first entry)

XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5580.

XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.

XX OS Synthetic.

XX PN WO2004016754-A2.

XX PD 26-FEB-2004.

XX PF 14-AUG-2003; 2003WO-US025465.

XX PR 14-AUG-2002; 2002US-0403416P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Roberds SL;

XX DR WPI; 2004-203785/19.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.

XX PS Claim 4; SEQ ID NO 5580; 417pp; English.

XX The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 956 AAAGAGCGGAATTCGC 974
 |||||
 Db 19 AAAGAGCGCGAATTCAGC 1

RESULT 190

ADK77091/C

ID ADK77091 standard; DNA; 20 BP.

XX AC ADK77091;

XX DT 20-MAY-2004 (first entry)

XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4425.

XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.

XX OS Synthetic.

XX PN WO2004016754-A2.

XX PD 26-FEB-2004.

XX PF 14-AUG-2003; 2003WO-US025465.

XX PR 14-AUG-2002; 2002US-0403416P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Roberds SL;

XX DR WPI; 2004-203785/19.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.

XX PS Claim 4; SEQ ID NO 4425; 417pp; English.

XX The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 2 A; 5 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 951 AACATAAGAGCGGAATT 969
 |||||
 Db 19 AACAAAAGAGCGGAATT 1

RESULT 191

ADL32289

ID ADL32289 standard; DNA; 20 BP.

XX

```

AC ADL32289;
XX
DT 20-MAY-2004 (first entry)
XX
DE Clone specific PCR primer to amplify human full length cDNA seqID 4322.
XX
DE human; medicine; signal transduction; glycoprotein; transcription;
XX
KW oligo-capping method; ss; PCR; primer.
XX
OS Homo sapiens.
XX
PN EPI396543-A2.
XX
PD 10-MAR-2004.
XX
PF 07-JUL-2000; 2003EP-00025638.
XX
PR 08-JUL-1999; 99JP-00194486.
XX
PR 11-JAN-2000; 2000JP-00118774.
XX
PR 02-MAY-2000; 2000JP-00183865.
XX
PR 07-JUL-2000; 2000EP-00114089.
XX
PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI Ota T, Nishikawa T, Isogai T, Hayashi K, Iehii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otauki T, Koga H;
XX
DR WPI; 2004-204755/20.
XX
PT New oligonucleotide primers (830 cDNAs) useful for synthesizing full
PT length human cDNAs.
XX
PS Example 18; SEQ ID NO 4322; 1340pp; English.
XX
CC This invention relates to a novel primers useful for synthesizing full
CC length cDNA molecules that encode human proteins. Specifically, it refers
CC to secretory or membrane proteins that are potential therapeutic agents/
CC target molecules in the field of medicine, and in particular genes
CC encoding proteins that are associated with signal transduction,
CC glycoproteins and transcription. The present invention describes a method
CC for efficiently cloning a full length human cDNA from both the 5' and 3'
CC ends using the oligo-capping method. This oligonucleotide sequence is a
CC human clone specific PCR primer used in an exemplification of the
CC invention.
XX
SQ Sequence 20 BP; 1 A; 8 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1752 GGTCTGGCTCATCTTTCTC 1770
Db 2 GGTCTGGCTCATCTTTCTC 20

RESULT 192
AD016416/c
ID AD016416 standard; DNA; 20 BP.
XX
AC AD016416;
XX
DT 29-JUL-2004 (first entry)
XX
DE 4 synthesis-period of neuroblastoma related primer, SEQ ID 678.
XX
KW Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
XX
OS Synthetic.
XX
PN WO2004039975-A1.
XX
PD 13-MAY-2004.
XX

```

```

XX 30-OCT-2003; 2003WO-JP013932.
XX
PR 30-OCT-2002; 2002JP-00316586.
XX
PA (HISM) HISAMITSU PHARM CO LTD.
PA (CHIB-) CHIBA PREFECTURE.
XX
PI Nakagawara A, Ohira M;
XX
DR WPI; 2004-390323/36.
XX
PT Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
PT cells useful for prognosing and determining progress stage of
PT neuroblastomas.
XX
PS Claim 8; SEQ ID NO 678; 455pp; Japanese.
XX
CC The present invention relates to human nucleic acid sequences (I;
CC AD015739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC neuroblastoma cell. (I) is useful for prognosing and determining the
CC progress stage of 4 synthesis-period of neuroblastoma. The present
CC sequence is a primer, used to illustrate the invention.
XX
SQ Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2835 AGGAGGCGAGCCATGGGCTG 2853
Db 20 AGGAGGCGAGCATGAGCTG 2

RESULT 193
ADP79249
ID ADP79249 standard; DNA; 20 BP.
XX
AC ADP79249;
XX
DT 12-AUG-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide #3048.
XX
KW GFAT; Antidiabetic; Cardiant;
KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW reperfusion; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..4
FT /tag= a
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
FT modified_base 17..20 b
FT /tag= b
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
XX
PN WO2004035763-A2.
XX
PD 29-APR-2004.
XX
PF 02-OCT-2003; 2003WO-US033332.
XX
PR 17-OCT-2002; 2002US-0419268P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Broschat KO, Crosby SD;
XX

```

DR WPI; 2004-348453/32.

XX New compounds, particularly antisense oligonucleotides targeted to a

PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase

PT (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,

PT ischemia/reperfusion injury.

XX Claim 4; SEQ ID NO 3048; 175pp; English.

XX The present invention relates to a compound which specifically hybridizes

CC with a nucleic acid molecule encoding GFAT, and inhibits the expression

CC of GFAT. Specifically claimed are antisense oligonucleotides capable of

CC modulating the expression of GFAT, and which comprise any of the 3063

CC sequences of 20 base pairs, given in the specification. The compound,

CC composition and methods are useful for treating a disease or condition

CC associated with GFAT, such as a disease or condition, e.g. diabetes, a

CC cardiovascular or neurological disorder, ischemia/reperfusion injury.

CC They are also useful in research and diagnostics for modulating the

CC expression of GFAT. The present sequence represents a chimeric

CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these

CC oligonucleotides inhibit human GFAT expression.

XX Sequence 20 BP; 12 A; 3 C; 3 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 1.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2594 AAGGAAAAGCACACAGCA 2612

Db 1 AAGGAAAAGCAACATCA 19

RESULT 194

ADP79253

ID ADP79253 standard; DNA; 20 BP.

XX AC ADP79253;

XX 12-AUG-2004 (first entry)

XX Chimeric phosphorothioate oligonucleotide #3052.

XX GFAT; Antidiabetic; Cardiant;

XX Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;

XX reperfusion; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..4

FT /*tag= a

FT /mod_base= other

FT /note= "2-methoxyethyl wing"

FT modified_base 17..20

FT /*tag= b

FT /mod_base= other

FT /note= "2-methoxyethyl wing"

XX WO2004035763-A2.

XX 29-APR-2004.

XX 02-OCT-2003; 2003WO-US033332.

XX 17-OCT-2002; 2002US-0419268P.

XX (PHAA) PHARMACIA CORP.

XX Broschat KO, Crosby SD;

XX WPI; 2004-348453/32.

PT New compounds, particularly antisense oligonucleotides targeted to a

PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase

PT (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,

PT ischemia/reperfusion injury.

XX Claim 4; SEQ ID NO 3052; 175pp; English.

XX The present invention relates to a compound which specifically hybridizes

CC with a nucleic acid molecule encoding GFAT, and inhibits the expression

CC of GFAT. Specifically claimed are antisense oligonucleotides capable of

CC modulating the expression of GFAT, and which comprise any of the 3063

CC sequences of 20 base pairs, given in the specification. The compound,

CC composition and methods are useful for treating a disease or condition

CC associated with GFAT, such as a disease or condition, e.g. diabetes, a

CC cardiovascular or neurological disorder, ischemia/reperfusion injury.

CC They are also useful in research and diagnostics for modulating the

CC expression of GFAT. The present sequence represents a chimeric

CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these

CC oligonucleotides inhibit human GFAT expression.

XX Sequence 20 BP; 12 A; 3 C; 3 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 1.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2594 AAGGAAAAGCACACAGCA 2612

Db 2 AAGGAAAAGCAACATCA 20

RESULT 195

ADP78439/c

ID ADP78439 standard; DNA; 20 BP.

XX AC ADP78439;

XX 12-AUG-2004 (first entry)

XX Chimeric phosphorothioate oligonucleotide #2238.

XX GFAT; Antidiabetic; Cardiant;

XX Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;

XX reperfusion; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..4

FT /*tag= a

FT /mod_base= other

FT /note= "2-methoxyethyl wing"

FT modified_base 17..20

FT /*tag= b

FT /mod_base= other

FT /note= "2-methoxyethyl wing"

XX WO2004035763-A2.

XX 29-APR-2004.

XX 02-OCT-2003; 2003WO-US033332.

XX 17-OCT-2002; 2002US-0419268P.

XX (PHAA) PHARMACIA CORP.

XX Broschat KO, Crosby SD;

XX WPI; 2004-348453/32.

XX New compounds, particularly antisense oligonucleotides targeted to a

PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase

PT (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT ischemia/reperfusion injury.
PS Claim 4; SEQ ID NO 2238; 175pp; English.
XX
XX The present invention relates to a compound which specifically hybridizes
CC with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC modulating the expression of GFAT, and which comprise any of the 3063
CC sequences of 20 base pairs, given in the specification. The compound,
CC associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC They are also useful in research and diagnostics for modulating the
CC expression of GFAT. The present sequence represents a chimeric
CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC oligonucleotides inhibit human GFAT expression.
XX
XX Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3130 GGGGAGACGACGATTCCTT 3148
DB |||||||||||||
20 GGTGAGACGACGATCCTT 2
RESULT 196
ADP78685/c
ID ADP78685 standard; DNA; 20 BP.
XX
XX
AC ADP78685;
XX
XX 12-AUG-2004 (first entry)
XX
XX Chimeric phosphorothioate oligonucleotide #2484.
DE
XX GFAT; Antidiabetic; Cardiant;
KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW reperfusion; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..4
FT /tag= a
FT /mod_base= other
FT /note="2-methoxyethyl wing"
FT modified_base 17..20
FT /tag= b
FT /mod_base= other
FT /note="2-methoxyethyl wing"
FT
FT
XX WO2004035763-A2.
XX
XX 29-APR-2004.
XX
XX 02-OCT-2003; 2003WO-US033332.
XX
XX 17-OCT-2002; 2002US-0419268P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Broschat KO, Crosby SD;
XX
XX WPI; 2004-348453/32.
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT ischemia/reperfusion injury.

XX Claim 4; SEQ ID NO 2484; 175pp; English.
PS
XX The present invention relates to a compound which specifically hybridizes
CC with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC modulating the expression of GFAT, and which comprise any of the 3063
CC sequences of 20 base pairs, given in the specification. The compound,
CC associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC They are also useful in research and diagnostics for modulating the
CC expression of GFAT. The present sequence represents a chimeric
CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC oligonucleotides inhibit human GFAT expression.
XX
XX Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3130 GGGGAGACGACGATTCCTT 3148
DB |||||||||||||
19 GGTGAGACGACGATCCTT 1
RESULT 197
ADO48050/c
ID ADO48050 standard; DNA; 20 BP.
XX
XX ADO48050;
XX
XX 12-AUG-2004 (first entry)
XX
XX Human HIP-1 antisense oligonucleotide ISIS 251705.
XX ss: Huntingtin interacting protein 1; HIP-1; HIP-1 protein interactor;
KW apoptosis dysregulation; antisense.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX US2004096834-A1.
XX
XX 20-MAY-2004.
XX
XX 19-NOV-2002; 2002US-00300263.
XX
XX 19-NOV-2002; 2002US-00300263.
XX (ISIS-) ISIS PHARM INC.
XX
XX Dobie KW;
XX
XX WPI; 2004-389149/36.
XX
XX New compounds targeted to a nucleic acid molecule encoding HIP-1 protein
PT interactor, useful for treating an animal having a disease or condition
PT associated with HIP-1 protein interactor, such as dysregulation of
PT apoptosis.
XX
XX Example 15; SEQ ID NO 60; 76pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding Huntingtin interacting protein 1 (HIP-1) protein interactor. The
CC compound is useful for treating an animal having a disease or condition
CC associated with HIP-1 protein interactor, such as dysregulation of
CC apoptosis. The compound may also be used for diagnostics, therapeutics,
CC prophylaxis and as research agents and kits; or to elucidate the function
CC of particular genes or to distinguish between functions of various
CC members of a biological pathway. The present sequence represents a human
CC HIP-1 antisense oligonucleotide.

```
XX SQ Sequence 20 BP; 8 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 968 TTCTGCGAGAGCTGCTTC 986
Db 20 TTCTGCGAGATGCTGCTGC 2

RESULT 198
ADO48119
ID ADO48119 standard; DNA; 20 BP.
XX AC ADO48119;
XX DT 12-AUG-2004 (first entry)
XX DE Human HIP-1 target sequence ISIS 168221.
XX KW ss: Huntingtin interacting protein 1; HIP-1; HIP-1 protein interactor;
XX KW apoptosis dysregulation.
XX OS Homo sapiens.
XX PN US2004096834-A1.
XX PD 20-MAY-2004.
XX PF 19-NOV-2002; 2002US-00300263.
XX PR 19-NOV-2002; 2002US-00300263.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Dobie KW;
XX DR WPI; 2004-389149/36.
XX PT New compounds targeted to a nucleic acid molecule encoding HIP-1 protein
PT interactor, useful for treating an animal having a disease or condition
PT associated with HIP-1 protein interactor, such as dysregulation of
PT apoptosis.
XX PS Example 15; SEQ ID NO 129; 76pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding Huntingtin interacting protein 1 (HIP-1) protein interactor. The
CC compound is useful for treating an animal having a disease or condition
CC associated with HIP-1 protein interactor, such as dysregulation of
CC apoptosis. The compound may also be used for diagnostics, therapeutics,
CC prophylaxis and as research agents and kits; or to elucidate the function
CC of particular genes or to distinguish between functions of various
CC members of a biological pathway. The present sequence represents a human
CC HIP-1 antisense oligonucleotide target sequence.
XX SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 968 TTCTGCGAGAGCTGCTTC 986
Db 1 TTCTGCGAGATGCTGCTGC 19

RESULT 199
AAQ33214
ID AAQ33214 standard; DNA; 21 BP.
XX KW Analysis; gene expression; reverse transcription; primer; cDNA;
```

```
AC AAQ33214;
XX 25-MAR-2003 (revised)
DT 28-JAN-1993 (first entry)
XX DE PCR primer #38 to identify subtle DP2.5 mutations.
XX KW neoplasm; cancer; oncogene; tumour; growth; detection; diagnosis;
XX KW prognosis; treatment; sporadic colorectal carcinomas; ss.
XX OS Synthetic.
XX PN WO9213103-A1.
XX PD 06-AUG-1992.
XX PF 16-JAN-1992; 92WO-US000376.
XX PR 16-JAN-1991; 91GB-00000963.
XX PR 08-AUG-1991; 91US-00741940.
XX XX (UYJO ) UNIV JOHNS HOPKINS.
XX PA (ICIL ) IMPERIAL CHEM IND PLC.
XX PA (UTAH ) UNIV UTAH.
XX PA (CANC-) CANCER INST.
XX KW Kinzler KW, Vogelstein B, Anand R, Hedge PJ, Markham AP;
XX PI Albertsen H, Carlson ML, Groden JL, Joslyn G, Thliveris A, White RL;
XX PI Nakamura Y;
XX DR WPI; 1992-284685/34.
XX PT Detection of somatic and germ-line alterations of human APC gene - used
XX PT to diagnose, treat and study familial adenomatous polyposis and sporadic
XX PT colorectal cancer.
XX PS Example 8; Table 3; 132pp; English.
XX CC This PCR primer was used to detect subtle mutations in the DP2.5 gene. It
XX CC was used with AAQ33213. To obtain DNA sequence adjacent to the exons of
XX CC the gene, sequencing substrate was obtained by inverse PCR amplification
XX CC of DNAs from two YACs 310D8 and 183H12 that span the deletions. Ligation
XX CC at low concentration cyclized the restriction enzyme digested YAC DNAs.
XX CC Oligonucleotides with sequencing tails designed in inverse orientation at
XX CC intervals along the cDNAs primed PCR amplification from the cyclised
XX CC templates. Comparison of these DNA sequences with the cDNA sequences as
XX CC placed exon boundaries at the divergence points. NOTE: The sequence as
XX CC given in the specification is barely legible. See also AAQ33158-253.
XX CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-MAR-2003 to
XX CC correct PI field.)
XX SQ Sequence 21 BP; 1 A; 7 C; 3 G; 10 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1748 TTTCGGTCTGGCTCAGCTT 1766
Db 3 TTTCGGTCTGGCTCAGCTT 21

RESULT 200
AAQ75767
ID AAQ75767 standard; DNA; 21 BP.
XX AC AAQ75767;
XX DT 04-AUG-1995 (first entry)
XX DE Reverse transcription primer used in cDNA analysis technique.
XX KW Analysis; gene expression; reverse transcription; primer; cDNA;
```

KW aggregate; restriction enzyme; ss.
 XX Synthetic.
 OS
 XX JP06303997-A.
 PN
 XX 01-NOV-1994.
 PD
 XX 16-APR-1993; 93JP-00112515.
 XX
 XX 16-APR-1993; 93JP-00112515.
 PR
 XX (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.
 PA
 XX WPI; 1995-018287/03.
 DR
 XX Analysis of cDNA and gene expression - by amplification of mRNA followed
 PT by digestion with restriction enzymes.
 PT
 XX Disclosure; Page 9; 11pp; Japanese.
 PS
 XX
 CC A method for the analysis of cDNA comprises (a) preparing an aggregate of
 CC double-stranded cDNAs by using an aggregate of mRNAs and a plural type of
 CC labelled reverse transcription primers (GENESEQ files AAQ75547-Q75798)
 CC and using the aggregate of mRNAs as the template for each reverse
 CC transcription primer; (b) digesting each of the prepared aggregates of
 CC the double-stranded cDNAs with restriction enzyme and; (c)
 CC electrophoresing the digested aggregate of cDNAs in separate lanes. The
 CC method can be used to analyse gene expression rapidly and easily
 CC
 XX Sequence 21 BP; 0 A; 1 C; 2 G; 18 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2571 TTCTTCTTTTTTTTCTG 2589
 DB 2 TTTTCTTTTTTTTCTG 20
 XX
 RESULT 201
 AAQ75769
 ID AAQ75769 standard; DNA; 21 BP.
 XX
 XX AAQ75769;
 AC
 XX 04-AUG-1995 (first entry)
 DT
 XX Reverse transcription primer used in cDNA analysis technique.
 DE
 XX Analysis; gene expression; reverse transcription; primer; cDNA;
 KW aggregate; restriction enzyme; ss.
 XX Synthetic.
 XX
 XX JP06303997-A.
 PN
 XX 01-NOV-1994.
 PD
 XX 16-APR-1993; 93JP-00112515.
 XX
 XX 16-APR-1993; 93JP-00112515.
 PR
 XX (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.
 PA
 XX WPI; 1995-018287/03.
 DR
 XX Analysis of cDNA and gene expression - by amplification of mRNA followed
 PT by digestion with restriction enzymes.
 PT
 XX Disclosure; Page 9; 11pp; Japanese.
 PS
 XX

CC A method for the analysis of cDNA comprises (a) preparing an aggregate of
 CC double-stranded cDNAs by using an aggregate of mRNAs and a plural type of
 CC labelled reverse transcription primers (GENESEQ files AAQ75547-Q75798)
 CC and using the aggregate of mRNAs as the template for each reverse
 CC transcription primer; (b) digesting each of the prepared aggregates of
 CC the double-stranded cDNAs with restriction enzyme and; (c)
 CC electrophoresing the digested aggregate of cDNAs in separate lanes. The
 CC method can be used to analyse gene expression rapidly and easily
 CC
 XX Sequence 21 BP; 0 A; 1 C; 1 G; 19 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2571 TTCTTCTTTTTTTTCTG 2589
 DB 2 TTTTCTTTTTTTTCTG 20
 XX
 RESULT 202
 AAQ75770
 ID AAQ75770 standard; DNA; 21 BP.
 XX
 XX AAQ75770;
 AC
 XX 04-AUG-1995 (first entry)
 DT
 XX Reverse transcription primer used in cDNA analysis technique.
 DE
 XX Analysis; gene expression; reverse transcription; primer; cDNA;
 KW aggregate; restriction enzyme; ss.
 XX Synthetic.
 XX
 XX JP06303997-A.
 PN
 XX 01-NOV-1994.
 PD
 XX 16-APR-1993; 93JP-00112515.
 XX
 XX 16-APR-1993; 93JP-00112515.
 PR
 XX (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.
 PA
 XX WPI; 1995-018287/03.
 DR
 XX Analysis of cDNA and gene expression - by amplification of mRNA followed
 PT by digestion with restriction enzymes.
 PT
 XX Disclosure; Page 9; 11pp; Japanese.
 PS
 XX
 CC A method for the analysis of cDNA comprises (a) preparing an aggregate of
 CC double-stranded cDNAs by using an aggregate of mRNAs and a plural type of
 CC labelled reverse transcription primers (GENESEQ files AAQ75547-Q75798)
 CC and using the aggregate of mRNAs as the template for each reverse
 CC transcription primer; (b) digesting each of the prepared aggregates of
 CC the double-stranded cDNAs with restriction enzyme and; (c)
 CC electrophoresing the digested aggregate of cDNAs in separate lanes. The
 CC method can be used to analyse gene expression rapidly and easily
 CC
 XX Sequence 21 BP; 0 A; 2 C; 1 G; 18 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2571 TTCTTCTTTTTTTTCTG 2589
 DB 2 TTTTCTTTTTTTTCTG 20
 XX
 RESULT 203
 AAQ75770
 ID AAQ75770 standard; DNA; 21 BP.
 XX
 XX AAQ75770;
 AC
 XX 04-AUG-1995 (first entry)
 DT
 XX Reverse transcription primer used in cDNA analysis technique.
 DE
 XX Analysis; gene expression; reverse transcription; primer; cDNA;
 KW aggregate; restriction enzyme; ss.
 XX Synthetic.
 XX
 XX JP06303997-A.
 PN
 XX 01-NOV-1994.
 PD
 XX 16-APR-1993; 93JP-00112515.
 XX
 XX 16-APR-1993; 93JP-00112515.
 PR
 XX (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.
 PA
 XX WPI; 1995-018287/03.
 DR
 XX Analysis of cDNA and gene expression - by amplification of mRNA followed
 PT by digestion with restriction enzymes.
 PT
 XX Disclosure; Page 9; 11pp; Japanese.
 PS
 XX

```

AAT93205/c
ID  AAT93209 standard; DNA; 21 BP.
XX  AC
XX  AAT93209;
XX  DT
XX  14-MAY-1998 (first entry)
XX  DE
XX  Primer used in kringle 5 expression vector construction.
XX  KW
XX  PCR primer; Kringle 5 peptide; anti-angiogenesis agent; cancer;
XX  metastatic solid tumour; carcinoma; sarcoma; lymphoma; haemangioma;
XX  psoriasis; arthritis; macular degeneration; diabetic retinopathy;
XX  autoimmune disease; ocular disease; capillary proliferation; therapy;
XX  kringle 5 receptor; ss.
XX  OS
XX  Synthetic.
XX  OS
XX  Homo sapiens.
XX  PN
XX  WO9741824-A2.
XX  PD
XX  13-NOV-1997.
XX  PF
XX  05-MAY-1997; 97WO-US007700.
XX  PR
XX  03-MAY-1996; 96US-00643219.
XX  PR
XX  03-APR-1997; 97US-00832087.
XX  PA
XX  (ABBO ) ABBOTT LAB.
XX  XX
XX  Davidson DJ, Wang J, Gubbins EJ;
XX  PI
XX  WPI; 1997-558670/51.
XX  DR
XX  New kringle 5 peptide(s) and fusion proteins derived from plasminogen -
XX  useful as anti-angiogenesis agents for treating cancer, psoriasis,
XX  arthritis etc., including gene therapy.
XX  PT
XX  Example 20; Page 56; 78pp; English.
XX  PS
XX  This sequence is a primer used in the construction of a kringle 5 (K5)
XX  peptide expression vector. The K5 peptide is used in the compounds of the
XX  invention. K5 peptide fragments are anti-angiogenesis agents,
XX  specifically for treating or preventing cancer, particularly primary or
XX  metastatic solid tumours, carcinomas, sarcomas, lymphomas, haemangiomas.
XX  They can also be used for treating or preventing psoriasis, arthritis,
XX  macular degeneration and diabetic retinopathy. The fragments can also be
XX  used to treat autoimmune or ocular diseases, capillary proliferation
XX  within atherosclerotic plaque, haemophilic joints, wound granulation,
XX  ulcers etc., also as contraceptives that inhibit ovulation and
XX  establishment of the placenta. K5 antisera or (ant)agonists can be used
XX  similarly, optionally coupled to cytotoxic agents. Antagonists may be
XX  used to induce angiogenesis, e.g. for wound healing. The K5 peptides are
XX  also used to raise specific antibodies (Ab), for diagnosis and for
XX  affinity purification of K5 receptors. The K5 receptors may then be
XX  expressed in tumour cells to increase their response to the peptides or
XX  used for identification of smaller antagonists. The Ab are used to
XX  detect/quantify the peptides in biological samples. The K5 peptides (and
XX  K5 fusion proteins) selectively inhibit proliferation of endothelial
XX  cells with low toxicity against normal cells. Typically they have 800-
XX  times greater inhibitory activity against bovine capillary cells in vitro
XX  than kringle 1-4 peptides
XX  SQ
XX  Sequence 21 BP; 11 A; 4 C; 5 G; 1 T; 0 U; 0 Other;
XX  Query Match 0.4%; Score 15.8; DB 1; Length 21;
XX  Best Local Similarity 89.5%; Pred. No. 2.1e+02;
XX  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2995 GAGATTTTTCCTCTTC 3013
DB 20 GGGCTTTTTCCTCTTC 2

AAT93201
ID  AAT93201 standard; DNA; 21 BP.
XX  AC
XX  AAT93201;
XX  DT
XX  14-MAY-1998 (first entry)
XX  DE
XX  Primer used in kringle 5 expression vector construction.
XX  KW
XX  PCR primer; Kringle 5 peptide; anti-angiogenesis agent; cancer;
XX  metastatic solid tumour; carcinoma; sarcoma; lymphoma; haemangioma;
XX  psoriasis; arthritis; macular degeneration; diabetic retinopathy;
XX  autoimmune disease; ocular disease; capillary proliferation; therapy;
XX  kringle 5 receptor; ss.
XX  OS
XX  Synthetic.
XX  OS
XX  WO9741824-A2.
XX  PN
XX  PD
XX  13-NOV-1997.
XX  PF
XX  05-MAY-1997; 97WO-US007700.
XX  PR
XX  03-MAY-1996; 96US-00643219.
XX  PR
XX  03-APR-1997; 97US-00832087.
XX  PA
XX  (ABBO ) ABBOTT LAB.
XX  XX
XX  Davidson DJ, Wang J, Gubbins EJ;
XX  PI
XX  WPI; 1997-558670/51.
XX  DR
XX  New kringle 5 peptide(s) and fusion proteins derived from plasminogen -
XX  useful as anti-angiogenesis agents for treating cancer, psoriasis,
XX  arthritis etc., including gene therapy.
XX  PT
XX  Example 20; Page 56; 78pp; English.
XX  PS
XX  This sequence is a primer used in the construction of a kringle 5 (K5)
XX  peptide expression vector. The K5 peptide is used in the compounds of the
XX  invention. K5 peptide fragments are anti-angiogenesis agents,
XX  specifically for treating or preventing cancer, particularly primary or
XX  metastatic solid tumours, carcinomas, sarcomas, lymphomas, haemangiomas.
XX  They can also be used for treating or preventing psoriasis, arthritis,
XX  macular degeneration and diabetic retinopathy. The fragments can also be
XX  used to treat autoimmune or ocular diseases, capillary proliferation
XX  within atherosclerotic plaque, haemophilic joints, wound granulation,
XX  ulcers etc., also as contraceptives that inhibit ovulation and
XX  establishment of the placenta. K5 antisera or (ant)agonists can be used
XX  similarly, optionally coupled to cytotoxic agents. Antagonists may be
XX  used to induce angiogenesis, e.g. for wound healing. The K5 peptides are
XX  also used to raise specific antibodies (Ab), for diagnosis and for
XX  affinity purification of K5 receptors. The K5 receptors may then be
XX  expressed in tumour cells to increase their response to the peptides or
XX  used for identification of smaller antagonists. The Ab are used to
XX  detect/quantify the peptides in biological samples. The K5 peptides (and
XX  K5 fusion proteins) selectively inhibit proliferation of endothelial
XX  cells with low toxicity against normal cells. Typically they have 800-
XX  times greater inhibitory activity against bovine capillary cells in vitro
XX  than kringle 1-4 peptides
XX  SQ
XX  Sequence 21 BP; 1 A; 5 C; 4 G; 11 T; 0 U; 0 Other;
XX  Query Match 0.4%; Score 15.8; DB 1; Length 21;
XX  Best Local Similarity 89.5%; Pred. No. 2.1e+02;
XX  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2995 GAGATTTTTCCTCTTC 3013
DB 2 GGGCTTTTTCCTCTTC 20

```



```
RESULT 205
AA14731
ID AA14731 standard; DNA; 21 BP.
XX
AC AA14731;
XX
DT 24-MAR-1999 (first entry)
XX
DE Triple helix third strand of Beta-globin gene nucleotides 917-937.
XX
KW Triplex formation; DNA detection; triple helix; identification; bacteria;
KW oncogene; virus; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5861244-A.
XX
PD 19-JAN-1999.
XX
PF 22-DEC-1993; 93US-00173489.
XX
PR 29-OCT-1992; 92US-00968436.
XX
PA (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
PI Hepburn AG, Wang C;
XX
WPI; 1999-130384/11.
XX
PT Assay of genetic sequences based on triplex formation from double
PT stranded analyte - and hybrid of anchor and reporter sequences, with
PT reporter released if triplex formation occurs, used e.g. to identify
PT bacteria.
XX
PS Disclosure; Col 17-18; 168pp; English.
XX
CC The present sequence represents a polynucleotide that is able to form a
CC triple helix with a double stranded sequence. Cytosine bases in the
CC present can be replaced with 5-methylcytosine for increased triplex
CC stability. The present sequence is used in the assay of the invention,
CC where it can be part of the anchor DNA or reporter DNA sequence. The
CC assay comprises adding a sample containing double-stranded DNA test
CC sequences to an aqueous medium containing at least one complex of anchor
CC DNA, attached to a solid support, and reporter DNA, where either a part
CC of the anchor DNA or reporter DNA is designed to form a triple-strand
CC structure with part of the test sequence. Triplex formation results in
CC displacement of the reporter DNA which is detected as an indication of
CC the presence of the DNA test sequence. The method is used to detect DNA
CC sequences, particularly for identification of bacteria (by detecting
CC genes for ribosomal RNA) in clinical samples, but also detection of
CC oncogenes and Hepatitis B virus
XX
SQ Sequence 21 BP; 0 A; 6 C; 0 G; 15 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2569 TCCTCTCTCTCTCTCTCTCTCTC 2587
DB 3 TCCTCTCTCTCTCTCTCTCTCTC 21
RESULT 206
AA14731
ID AA14731 standard; DNA; 21 BP.
XX
AC AA14731;
XX
DT 24-MAR-1999 (first entry)
XX
DE Triple helix third strand of Beta-globin gene nucleotides 917-937.
XX
KW Triplex formation; DNA detection; triple helix; identification; bacteria;
KW oncogene; virus; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5861244-A.
XX
PD 19-JAN-1999.
XX
PF 22-DEC-1993; 93US-00173489.
XX
PR 29-OCT-1992; 92US-00968436.
XX
PA (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
PI Hepburn AG, Wang C;
XX
WPI; 1999-130384/11.
XX
PT Assay of genetic sequences based on triplex formation from double
PT stranded analyte - and hybrid of anchor and reporter sequences, with
PT reporter released if triplex formation occurs, used e.g. to identify
PT bacteria.
XX
PS Disclosure; Col 17-18; 168pp; English.
XX
CC The present sequence represents a polynucleotide that is able to form a
CC triple helix with a double stranded sequence. Cytosine bases in the
CC present can be replaced with 5-methylcytosine for increased triplex
CC stability. The present sequence is used in the assay of the invention,
CC where it can be part of the anchor DNA or reporter DNA sequence. The
CC assay comprises adding a sample containing double-stranded DNA test
CC sequences to an aqueous medium containing at least one complex of anchor
CC DNA, attached to a solid support, and reporter DNA, where either a part
CC of the anchor DNA or reporter DNA is designed to form a triple-strand
CC structure with part of the test sequence. Triplex formation results in
CC displacement of the reporter DNA which is detected as an indication of
CC the presence of the DNA test sequence. The method is used to detect DNA
CC sequences, particularly for identification of bacteria (by detecting
CC genes for ribosomal RNA) in clinical samples, but also detection of
CC oncogenes and Hepatitis B virus
XX
SQ Sequence 21 BP; 0 A; 6 C; 0 G; 15 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2569 TCCTCTCTCTCTCTCTCTCTCTC 2587
DB 3 TCCTCTCTCTCTCTCTCTCTCTC 21
```

```
XX Plasminogen; human; kringle 5 domain; endothelial cell proliferation;
KW angiogenesis; antiproliferative; antiarteriosclerotic; cytostatic;
KW antiproliferative; antinflammatory; antiulcer; antirheumatic; antiarthritic;
KW antiangiogenic; cancer; tumour; autoimmune disease; Escherichia coli;
KW recombinant expression; vector construction; PCR primer; ss.
XX Synthetic.
XX US6057122-A.
XX 02-MAY-2000.
XX 05-MAY-1997; 97US-00851350.
XX 03-MAY-1996; 96US-00643219.
XX 03-APR-1997; 97US-00832087.
XX (ABBO ) ABBOTT LAB.
XX Davidson DJ;
XX WPI; 2000-349573/30.
XX Preparation of Kringle five peptide fragment for treating various
XX disorders such as angiogenic, ocular, skin diseases and cancer, involves
XX mixing mammalian plasminogen and elastase followed by incubation and
XX isolation.
XX Example 20; Col 48; 48pp; English.
XX The invention relates to a method of preparing plasminogen kringle 5
XX peptide fragments. The method comprises mixing mammalian plasminogen and
XX elastase in the ratio 1:100-1:300, followed by incubating and isolating
XX the fragment. The kringle 5 peptides are inhibitors of angiogenesis and
XX endothelial cell proliferation and migration. The peptides are useful for
XX treating angiogenic diseases, primary and metastatic solid tumours and
XX carcinomas of various organs such as breast, genital tract, endocrine
XX glands, skin, tumours of the brain and eyes and solid tumours arising
XX from haematopoietic malignancies such as leukaemias and lymphomas. They
XX are also used for the prophylaxis of various autoimmune diseases (e.g.,
XX rheumatoid arthritis), ocular diseases, skin diseases (e.g., psoriasis),
XX blood vessel diseases (e.g. haemangiomas, Osler-Weber Syndrome),
XX diseases caused by excessive or abnormal stimulation of endothelial cells
XX (e.g., Crohn's disease, atherosclerosis), diseases which have
XX angiogenesis as a pathologic consequence (e.g., cat scratch disease and
XX ulcers). The peptides are also useful as a birth control agent which
XX inhibits ovulation and establishment of the placenta. Sequences AA52294-
XX A52304 represent PCR primers used in the construction of Escherichia coli
XX expression vectors for recombinant expression of various human
XX plasminogen kringle 5 fragments
XX
SQ Sequence 21 BP; 1 A; 5 C; 4 G; 11 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2995 GAGATTTTTTTTGTCTTC 3013
DB 2 GGGCTTTTTTTTGTCTTC 20
RESULT 207
AA52304/c
ID AA52304 standard; DNA; 21 BP.
XX
AC AA52304;
XX
DT 18-SEP-2000 (first entry)
XX
DE PCR primer used to construct UpEt-Ubi vector, SEQ ID NO:33.
XX
```

KW plasminogen; human; kringle 5 domain; endothelial cell proliferation;
KW angiogenesis; antiproliferative; antiarteriosclerotic; cytostatic;
KW antiproliferative; antiinflammatory; antiulcer; antirheumatic; antiarthritic;
KW antiangiogenic; cancer; tumour; autoimmune disease; Escherichia coli;
KW recombinant expression; vector construction; PCR primer; ss.
XX
XX Synthetic.
XX
XX US6057122-A.
XX
XX 02-MAY-2000.
XX
XX 05-MAY-1997; 97US-00851350.
XX
XX 03-MAY-1996; 96US-00643219.
XX
XX 03-APR-1997; 97US-00832087.
XX
XX (ABBO) ABBOTT LAB.
XX
XX Davidson DJ;
XX
XX WPI; 2000-349573/30.
XX
XX Preparation of Kringle five peptide fragment for treating various
XX disorders such as angiogenic, ocular, skin diseases and cancer, involves
XX mixing mammalian plasminogen and elastase followed by incubation and
XX isolation.
XX
XX Example 20; Col 50; 48pp; English.
XX
XX The invention relates to a method of preparing plasminogen kringle 5
XX peptide fragments. The method comprises mixing mammalian plasminogen and
XX elastase in the ratio 1:100-1:300, followed by incubating and isolating
XX the fragment. The kringle 5 peptides are inhibitors of angiogenesis and
XX endothelial cell proliferation and migration. The peptides are useful for
XX treating angiogenic diseases, primary and metastatic solid tumours and
XX carcinomas of various organs such as breast, genital tract, endocrine
XX glands, skin, tumours of the brain and eyes and solid tumours arising
XX from haematopoietic malignancies such as leukaemias and lymphomas. They
XX are also used for the prophylaxis of various autoimmune diseases (e.g.,
XX rheumatoid arthritis), ocular diseases, skin diseases (e.g., psoriasis),
XX blood vessel diseases (e.g. haemangiomas, Osler-Webber Syndrome),
XX diseases caused by excessive or abnormal stimulation of endothelial cells
XX (e.g., Crohn's disease, atherosclerosis), diseases which have
XX angiogenesis as a pathologic consequence (e.g., cat scratch disease and
XX ulcers). The peptides are also useful as a birth control agent which
XX inhibits ovulation and establishment of the placenta. Sequences AAA52294-
XX A52304 represent PCR primers used in the construction of Escherichia coli
XX expression vectors for recombinant expression of various human
XX plasminogen kringle 5 fragments
XX
XX Sequence 21 BP; 11 A; 4 C; 5 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 2.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2995 GAGATTTTTTTCCTCTTC 3013
XX 20 GGGCTTTTTTTCCTCTTC 2
XX
XX
XX RESULT 208
XX AAA91630/C
XX ID AAA91630 standard; DNA; 21 BP.
XX
XX AAA91630;
XX
XX 12-JAN-2001 (first entry)
XX
XX Caenorhabditis elegans DNA sequence #3.
XX
XX Caenorhabditis elegans; daf-7; daf-18; insulin signalling pathway; daf-2;

KW age-1; insulin receptor; PI 3-kinase; PKB kinase; PTEN lipid phosphatase;
KW antidiabetic; anorectic; obesity; diabetes; ds.
XX
XX Caenorhabditis elegans.
XX
XX WO200033068-A1.
XX
XX 08-JUN-2000.
XX
XX 02-DEC-1999; 99WO-US028529.
XX
XX 03-DEC-1998; 98US-00205658.
XX
XX (GEHO) GEN HOSPITAL CORP.
XX
XX Ruvkun G, Ogg S;
XX
XX WPI; 2000-423022/36.
XX
XX Diagnosing and treating obesity and impaired glucose tolerance using
XX modulators of daf-18 expression and/or activity.
XX
XX Disclosure; Page 397; 402pp; English.
XX
XX The present sequence is a DNA sequence from Caenorhabditis elegans. A
XX number of C. elegans genes have been identified that have mammalian
XX homologues acting in the insulin signalling pathway. The C. elegans age-1
XX gene encodes a homologue of the mammalian PI 3-kinase whilst daf-2
XX encodes a homologue of the mammalian insulin receptor. The C. elegans AKT
XX kinase and PKB kinase act downstream of daf-2 and age-1, just as their
XX mammalian homologues act downstream of insulin signalling. The C. elegans
XX PTEN lipid phosphatase homologue, DAF-18, has been found to act upstream
XX of AKT in the pathway. This discovery has enabled mammalian PTEN action
XX to be mapped to the insulin signalling pathway. Conserved DAF motifs can
XX be used to design probes to identify mammalian DAF homologues and thus to
XX identify individuals with a predisposition towards the development of
XX glucose intolerance conditions, such as obesity and diabetes
XX
XX Sequence 21 BP; 2 A; 8 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 2.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 333 CGATTCCGAGAGAGGAAG 351
XX 19 CGATTCCGAGAGAGGAAG 1
XX
XX
XX RESULT 209
XX ABS98019
XX ID ABS98019 standard; DNA; 21 BP.
XX
XX ABS98019;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human urokinase gene (uPA) polymorphic sequence #8.
XX
XX Human; ds; cytochrome P450 A1; UGT2B4; MDR1;
XX cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
XX adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
XX aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
XX cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
XX epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
XX glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
XX HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
XX NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
XX UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7; STM;
XX UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
XX multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
XX multidrug resistance associated protein 3; cancer; prostate;
XX acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;

KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological; SNP;
 KW single nucleotide polymorphism.
 XX Homo sapiens.
 XX WO200257410-A2.
 XX 25-JUL-2002.
 XX 28-NOV-2001; 2001WO-US044838.
 XX 28-NOV-2000; 2000US-00724389.
 XX (DNAS-) DNA SCI LAB INC.
 XX Guida M, Hall J;
 XX WPI; 2002-698522/75.
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.
 XX Example 21; Page 140; 714pp; English.
 XX This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome p450 A1 (CYP450A1), cytochrome p450 A2 (CYP450A2),
 CC cytochrome p450 02E1 (CYP45002E1), adrenergic receptor betai (ADBR1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 CC transferase (HNMT), kallikrein 2 (KLK2), nicotinamide -N-methyl
 CC sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 CC transferase (UGT2B15), urokinase receptor (UPA), multidrug resistance 1
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 CC (MRP3), orphan nuclear receptor (NRL12), or acetylcholine muscarinic
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 CC The polymorphisms in the human genes cited in the invention are useful as
 CC genetic linkage markers for locating and characterizing the genes that
 CC are responsible for specific traits within the genome and eventually
 CC traits as a result of their e.g., overexpression, constitutive
 CC expression, mutation or underexpression, which may be used in diagnosing
 CC and/or treating the disorders. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1, AHR,
 CC ARNT, EPHX2, GST12, HNMT, NOQ2, NRL12, STM, UGT2B4, UGT2B7, UGT2B15,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 CC used to screen for altered cardiovascular function, in COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HNMT for altered pulmonary,
 CC immunological or haematological function, in KLK2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a
 CC polymorphic DNA sequence of the invention.
 XX Sequence 21 BP; 4 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 714 GTATCTTCTTCCACAGTGA 732
 |||||

Db 2 GTATCTTCTTCCACAGTGA 20
 RESULT 210
 ABS98020
 ID ABS98020 standard; DNA; 21 BP.
 XX ABS98020;
 AC ABS98020;
 XX 23-DEC-2002 (first entry)
 DT
 XX Human urokinase gene (UPA) polymorphic sequence #9.
 DE
 XX Human; ds; cytochrome p450 A1; CYP450A1A1; UGT2B4; MDR1;
 KW cytochrome p450 A2; CYP450A2; cytochrome p450 02E; CYP45002E1; LTF;
 KW adrenergic receptor betai; ADRB1; aryl hydrocarbon; AHR; MRP3; NRL12;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NOQ2; sulfoltransferase thermolabile; STM;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; UPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological; SNP;
 KW single nucleotide polymorphism.
 XX Homo sapiens.
 XX WO200257410-A2.
 XX 25-JUL-2002.
 PD 28-NOV-2001; 2001WO-US044838.
 XX 28-NOV-2000; 2000US-00724389.
 XX (DNAS-) DNA SCI LAB INC.
 XX Guida M, Hall J;
 XX WPI; 2002-698522/75.
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.
 XX Example 21; Page 140; 714pp; English.
 XX This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome p450 A1 (CYP450A1), cytochrome p450 A2 (CYP450A2),
 CC cytochrome p450 02E1 (CYP45002E1), adrenergic receptor betai (ADBR1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 CC transferase (HNMT), kallikrein 2 (KLK2), nicotinamide -N-methyl
 CC sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 CC transferase (UGT2B15), urokinase receptor (UPA), multidrug resistance 1
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 CC (MRP3), orphan nuclear receptor (NRL12), or acetylcholine muscarinic
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 CC The polymorphisms in the human genes cited in the invention are useful as
 CC genetic linkage markers for locating and characterizing the genes that
 CC are responsible for specific traits within the genome and eventually
 CC traits as a result of their e.g., overexpression, constitutive
 CC expression, mutation or underexpression, which may be used in diagnosing
 CC and/or treating the disorders. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1, AHR,
 CC ARNT, EPHX2, GST12, HNMT, NOQ2, NRL12, STM, UGT2B4, UGT2B7, UGT2B15,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 CC used to screen for altered cardiovascular function, in COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HNMT for altered pulmonary,
 CC immunological or haematological function, in KLK2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a
 CC polymorphic DNA sequence of the invention.
 XX Sequence 21 BP; 4 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 2.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 714 GTATCTTCTTCCACAGTGA 732
 |||||

DT 20-MAY-2004

The present invention relates to human acetyl-Coenzyme A-carboxylase- α (ACC- α ; see AB279442), which can be used for in vitro diagnosis of cancer (or of an increased risk of developing it), by detecting ACC- α gene mutations or polymorphisms, or altered ACC- α protein expression, relative to a control population. The method is particularly used to diagnose cancer, especially of breast or ovary, or for assessing

```
XX PET expression vector, PCR primer #3.
DE Cytostatic; Antiarthritic; Antidiabetic; Ophthalmological; kringle 5;
KW angiogenesis; cancer; arthritis; macular degeneration;
KW diabetic retinopathy; human; plasminogen; ss; primer.
OS Synthetic.
XX US6699838-B1.
PN
XX
PD
XX
PD 02-MAR-2004.
XX
XX 05-SEP-1997; 97US-00924287.
XX
XX 03-MAY-1996; 96US-00643219.
PR 03-APR-1997; 97US-00832087.
PR 05-MAY-1997; 97US-00851350.
XX
XX (ABBO ) ABBOTT LAB.
PA
XX
XX Davidson DJ;
PI
XX
XX WPI; 2004-224006/21.
XX
XX Novel compound e.g., kringle 5 fusion protein useful for treating
PT diseases e.g., cancer, arthritis, macular degeneration and diabetic
PT retinopathy.
XX
XX Example 20; SEQ ID NO 23; 47pp; English.
XX
XX The invention relates to a new compound coupled to another protein to
CC form a conjugate. The compound is a kringle 5 (K5) fusion protein. The
CC compound is useful for inhibiting angiogenic diseases and for treating
CC diseases such as cancer, arthritis, macular degeneration and diabetic
CC retinopathy. The present sequence represents a PET vector PCR primer used
CC to clone and express the K5 region of human plasminogen.
XX
XX Sequence 21 BP; 1 A; 5 C; 4 G; 11 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 2.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2995 GAGATTTTTCCTCTTC 3013
XX | | | | | | | | | |
XX 2 GGGCTTTTTCCTCTTC 20
XX
XX
XX RESULT 214
XX ADK23686/c
XX ID ADK23686 standard; DNA; 21 BP.
XX
XX AC ADK23686;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human stromelysin, PCR primer #5.
XX
XX Cytostatic; Antiarthritic; Antidiabetic; Ophthalmological; kringle 5;
KW angiogenesis; cancer; arthritis; macular degeneration;
KW diabetic retinopathy; human; plasminogen; ss; primer.
XX
XX Homo sapiens.
XX
XX US6699838-B1.
XX
XX 02-MAR-2004.
XX
XX 05-SEP-1997; 97US-00924287.
XX
XX 03-MAY-1996; 96US-00643219.
PR 03-APR-1997; 97US-00832087.
XX
XX 03-MAY-1996; 96US-00643219.
PR 03-APR-1997; 97US-00832087.
XX
```

```
PR 05-MAY-1997; 97US-00851350.
XX
XX (ABBO ) ABBOTT LAB.
XX
XX Davidson DJ;
PI
XX
XX WPI; 2004-224006/21.
XX
XX Novel compound e.g., kringle 5 fusion protein useful for treating
PT diseases e.g., cancer, arthritis, macular degeneration and diabetic
PT retinopathy.
XX
XX Example 20; SEQ ID NO 33; 47pp; English.
XX
XX The invention relates to a new compound coupled to another protein to
CC form a conjugate. The compound is a kringle 5 (K5) fusion protein. The
CC compound is useful for inhibiting angiogenic diseases and for treating
CC diseases such as cancer, arthritis, macular degeneration and diabetic
CC retinopathy. The present sequence represents a human stromelysin PCR
CC primer used to clone and express the K5 region of human plasminogen.
XX
XX Sequence 21 BP; 11 A; 4 C; 5 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.4%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 2.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2995 GAGATTTTTCCTCTTC 3013
XX | | | | | | | | | |
XX 20 GGGCTTTTTCCTCTTC 2
XX
XX
XX RESULT 215
XX AAF07259
XX ID AAF07259 standard; DNA; 17 BP.
XX
XX AC AAF07259;
XX
XX 16-FEB-2001 (first entry)
XX
XX Hammerhead ribozyme substrate #3516.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
XX Homo sapiens.
XX
XX WO200061729-A2.
XX
XX 19-OCT-2000.
XX
XX 11-APR-2000; 2000WO-US009721.
XX
XX 12-APR-1999; 99US-0129390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
XX Claim 54; Page 136; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
```

CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha

XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 1.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 231 GAGCTGGTCCAGGACC 247

|||||

1 GAGCTGGTCCAGGACC 17

RESULT 216

ABK02559

ID ABK02559 standard; RNA; 17 BP.

XX AC ABK02559;

XX DT 12-MAR-2002 (first entry)

XX DE Human NOGO Amberzyme #231.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX Homo sapiens.

OS Synthetic.

XX WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US004273.

XX 11-FEB-2000; 2000US-0181797P.

XX 28-FEB-2000; 2000US-0185516P.

XX 06-MAR-2000; 2000US-0187128P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (CHOW/) CHOWRIRA B M.

XX Blatt L, Mcswiggen J, Chowrira BM;

XX WPI; 2001-607195/69.

XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.

XX Claim 88; Page 135; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA

CC with a VGY motif). The CD20-targetting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapis. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an amberzyme molecule of the invention

XX Sequence 17 BP; 7 A; 2 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;

Best Local Similarity 64.7%; Pred. No. 1.7e+02;

Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 3640 ATTGTTTCAGAAATGGCA 3656

|||||

1 AUUAUUCAGAAUUGGCA 17

RESULT 217

ABK03743

ID ABK03743 standard; RNA; 17 BP.

XX AC ABK03743;

XX DT 12-MAR-2002 (first entry)

XX DE Human CD20 Amberzyme #92.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX Homo sapiens.

OS Synthetic.

XX WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US004273.

XX 11-FEB-2000; 2000US-0181797P.

XX 28-FEB-2000; 2000US-0185516P.

XX 06-MAR-2000; 2000US-0187128P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
XX Claim 30; Page 168; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NGO). The
XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX the cell and treat a patient having a condition associated with the level
XX of CD20. The treatment may further comprise the use of one or more
XX therapies. In particular, the CD20 targeting nucleic acid may be used to
XX treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX immune thrombocytopenia, and inflammatory arthropathy. The NGO-
XX targeting nucleic acid is used to cleave RNA of the NGO gene in the
XX presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
XX nucleic acid may be contacted with a cell to reduce NGO activity of the
XX cell and treat a patient having a condition associated with the level of
XX NGO. The treatment may further comprise the use of one or more
XX therapies. In particular, the NGO-targeting nucleic acid may be used to
XX treat central nervous system (CNS) injury and cerebrovascular accident
XX (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NGO expression. The present
XX sequence is an amberyzyme molecule of the invention
XX
XX Sequence 17 BP; 9 A; 2 C; 5 G; 0 T; 1 U; 0 Other;
XX
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 1.7e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 337 TCCGAGAGAGGAGAA 353
Db : |||||
1 UCCAGAGAGGAGAA 17
RESULT 218
ID ABV90554/C
XX
XX AC ABV90554;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1267.
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX

XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US0000663.
XX 30-JAN-2001; 2001WO-US0000664.
XX 30-JAN-2001; 2001WO-US0000665.
XX 30-JAN-2001; 2001WO-US0000666.
XX 30-JAN-2001; 2001WO-US0000667.
XX 30-JAN-2001; 2001WO-US0000668.
XX 30-JAN-2001; 2001WO-US0000669.
XX 30-JAN-2001; 2001WO-US0000670.
XX 23-MAY-2001; 2001US-00864761.
XX 10-OCT-2001; 2001US-0328205P.
XX (ABOM-) ABOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
XX -1, useful for treating disorders associated with decreased expression or
XX activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 1267; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (S1, AB383999), a sequence having 65% sequence identity to (S1),
XX (S1) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX downstream components of the signal transduction pathway. (I) is useful
XX for identifying a specific binding partner. (I) and nucleic acids (II)
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they are useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention. Note: The present sequence did not form part of the
XX printed specification, but is based on sequence information supplied to
XX Derwent by the European Patent Office
XX
XX Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. NO. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2844 CCATGGGCTGGGAGATC 2860
Db |||||
17 CCATGGGCTGGGTGATC 1
RESULT 219
ID ABV90553/C
XX
XX AC ABV90553;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1266.
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX

KW Gene therapy; transgenic; ss.
 OS Homo sapiens.
 XX EPI239051-A2.
 PN 11-SEP-2002.
 XX 28-JAN-2002; 2002EP-00001165.
 XX 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX (AEOM-) AEOMICA INC.
 XX Shannon M;
 PI WPI; 2002-684061/74.
 XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX Example 2; SEQ ID NO 1266; 60pp + Sequence Listing; English.
 XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoded (II) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 XX Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.7e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2845 CATGGGCTGGGAGATCA 2861
 Db 17 CATGGGCTGGGTGATCA 1
 RESULT 220
 ACC66680
 ID ACC66680 standard; DNA; 17 BP.
 XX ACC66680;
 AC 01-JUL-2003 (first entry)
 DT Murine oligonucleotide associated with tumour suppression, SEQ ID 3927.
 DE

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX Mus musculus.
 OS WO2003025176-A2.
 PN 27-MAR-2003.
 XX 17-SEP-2002; 2002WO-IB004210.
 PR 17-SEP-2001; 2001EP-00011979.
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-333167/31.
 DR New isolated nucleic acid, useful for treating viral diseases associated
 XX with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 PT Disclosure; Page 490; 738pp; French.
 PS The present invention relates to murine oligonucleotides (ACC62754-
 XX ACC68806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.7e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2980 GATCATTCCTCCAGAGA 2996
 Db 1 GATCATTCCTCCAAAGGA 17
 RESULT 221
 ADB40730/C
 ID ADB40730 standard; DNA; 17 BP.
 XX ADB40730;
 AC 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)
 XX Tumour suppression/reversion associated nucleotide #1053.
 DE cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX Homo sapiens.
 OS WO2003040369-A2.
 PN 15-MAY-2003.
 PD 17-SEP-2002; 2002WO-IB004219.
 XX


```
XX 17-SEP-2001; 2001FR-00011981.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Anson R, Tuijnder M;
XX WPI; 2003-441574/41.
XX New nucleic acid encoding human prostate membrane-specific antigen,
XX useful e.g. for treatment of tumors and viral infection, also related
XX polypeptide and antibodies.
XX Disclosure; Page 155; 771pp; French.
XX The invention relates to the isolation of 6327 nucleotide sequences,
XX fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX sequence having at least 80% identity, after optimal alignment, with the
XX nucleotides, a sequence that hybridizes under stringent conditions with
XX the nucleotides, or the complement, or corresponding RNA, of the
XX nucleotides. The nucleotides are used as probes or primers for detecting,
XX identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX sense and antisense sequences, of nucleotides involved in tumour
XX suppression or reversion, apoptosis and or viral resistance, to produce
XX recombinant polypeptides, and to prepare transgenic animals, as
XX experimental models. The nucleotides (also vectors containing them and
XX cells containing the vectors), the encoded polypeptides and antibodies
XX (Ab) against the polypeptide are useful for prevention and/or treatment
XX of viral infections or diseases characterized by development of tumours
XX or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX Analysis of the expression of the nucleotides can be used for diagnosis
XX and/or prognosis of these diseases. The nucleotides and polypeptides can
XX also be used to screen for their specific interactive molecules.
XX potentially useful for treating diseases associated with abnormal
XX expression of the nucleotides.
XX Sequence 17 BP; 5 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2967 CAAATGAATTTAGATC 2983
DB 17 CAAATGAATTTAGATC 1
RESULT 222
AAZ72224/C
ID AAZ72224 standard; DNA; 18 BP.
XX AC AAZ72224;
XX DT 10-SEP-2001 (first entry)
XX DE Human biallelic marker upstream amplification primer SEQ ID NO:6580.
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation;
XX amplification; single nucleotide polymorphism; SNP; PCR primer;
XX diagnosis; ss.
XX OS Homo sapiens.
XX PN WO954500-A2.
XX PD 28-OCT-1999.
XX PF 21-APR-1999; 99WO-1B000822.
XX PR 21-APR-1998; 98US-0082614P.
XX PR 23-NOV-1998; 98US-0109732P.
```

```
XX (GEST ) GENSET.
XX Cohen D, Blumenfeld M, Chumakov I;
XX WPI; 2000-013267/01.
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX Claim 9; Page 1633; 2745pp; English.
XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3221, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX Sequence 18 BP; 7 A; 2 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 468 CCTGTACCTTGTCTCA 484
DB 18 CCTGTACCTTGTCTCA 2
RESULT 223
AAAT66033
ID AAT66033 standard; DNA; 19 BP.
XX AC AAT66033;
XX DT 25-MAR-2003 (revised)
XX DT 18-JUN-1997 (first entry)
XX DE Primer #2 to amplify repeat sequence marker Mfd118.
XX Polymorphism; repeat sequence; Genetic marker; primer; amplification;
XX PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
XX linkage analysis; Genetic disease; animal; plant; breeding; locus;
XX hybridisation; chromosome; ds.
XX OS Synthetic.
XX PN US5582979-A.
XX PD 10-DEC-1996.
XX PF 04-APR-1994; 94US-00222177.
XX PR 21-APR-1989; 89US-00341562.
XX PR 05-SEP-1991; 91US-00754351.
XX (MARS-) MARSHFIELD CLINIC.
XX Weber JL;
XX WPI; 1997-042299/04.
XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
```

PT using novel nucleic acid mols. as primers.

PS Claim 7; Col 13-14; 186pp; English.

XX The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dc-da)n.(dG-dT)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g. paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. Clones containing the
 CC repeat sequences were isolated by hybridisation of chromosome-specific
 CC phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
 CC repeat blocks were isolated. The primers AAT65798-T66047 were used to PCR
 CC amplify the inserts from the isolated clones containing the repeat
 CC sequences. The primers AAT66032-3 were used to amplify the repeat
 CC sequence marker clone Mfd118 (AAT65789). (Updated on 25-MAR-2003 to
 CC correct PF field.)

XX SQ Sequence 19 BP; 6 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2057 AGCCTCAGACACCTGG 2073
 ||| |||||
 Db 2 AGCATCAGACACCTGG 18

RESULT 224

AAA66644

ID AAA66644 standard; DNA; 19 BP.

XX AC AAA66644;

XX DT 09-OCT-2000 (first entry)

XX DE Dog genomic marker oligonucleotide sequence SEQ ID NO:506.

XX KW Dog; genome; genomic marker; radiation hybrid map; identification;
 KW chromosome location; gene marker; polymorphic microsatellite marker;
 KW phenotype; behaviour; pedigree; ss.

XX OS Canis familiaris.

XX PN WO200029615-A2.

XX PD 25-MAY-2000.

XX PF 15-NOV-1999; 99WO-IB001907.

XX PR 13-NOV-1998; 98US-0108193P.

XX PA (CNRS) CNRS CENT NAT RECH SCI.

XX PI Galibert F, Andre C;

XX WPI; 2000-387821/33.

XX New radiation hybrid map of the dog, Canine familiaris, genome, useful
 PT for e.g. identifying genes implicated in phenotypic and behavioral traits
 PT or in genetic diseases and for studying dog pedigrees.

XX Claim 1; Page 75; 87pp; English.

XX The present invention describes a radiation hybrid map of the dog (Canine
 CC familiaris) genome comprising the genome location of a marker selected
 CC from AAG66139 to AAG66942. The radiation hybrid map is useful for
 CC identifying and localising dog genes, since it covers approximately 80 %
 CC of the dog genome and provides a dense map integrating different types
 CC (i.e. Type I and Type II) of markers. The map and the dog genome markers
 CC (or complementary sequences) are especially useful to identify genes
 CC responsible for phenotypic and behavioural traits in dogs, to identify

CC morbid genes, to analyse diseases and identify implicated genes in such
 CC diseases and their alleles, and to study dog pedigrees. They may also be
 CC useful for isolating corresponding human gene sequences e.g. genes
 CC involved in genetic diseases

XX SQ Sequence 19 BP; 4 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1613 TCTTGGAAAGCCCTGGT 1629
 ||| |||||
 Db 2 TCTTGGAAAGCCCTGGT 18

RESULT 225

AAC67494/c

ID AAC67494 standard; DNA; 19 BP.

XX AC AAC67494;

XX DT 14-FEB-2001 (first entry)

XX DE Alzheimer's disease-linked mitochondrial SNP PCR primer #194.

XX KW Human; mitochondrial genome; single nucleotide polymorphism; SNP;

XX KW Alzheimer's disease; mtDNA; PCR primer; ss.

XX OS Homo sapiens.

XX PN WO200063441-A2.

XX PD 26-OCT-2000.

XX PF 19-APR-2000; 2000WO-US010906.

XX PR 20-APR-1999; 99US-0130447P.

XX PA (MITO-) MITOKOR.

XX PI Herrnsstadt C, Davis RE;

XX WPI; 2000-672748/65.

XX Diagnosing a subject at the risk for or having Alzheimer's disease
 PT comprises determining at least one single nucleotide polymorphism in
 PT mitochondrial DNA associated with the disease in the sample from the
 PT subject.

XX Example 9; Page 50; 89pp; English.

XX The present invention describes a novel method for determining the risk
 CC of or diagnosing Alzheimer's disease using single nucleotide
 CC polymorphisms (SNPs) present in an individual's mitochondrial DNA
 CC (mtDNA). In addition, the SNPs identified can be used to identify agents
 CC suitable for use in treating Alzheimer's disease. Sequences AAC67301-
 CC C67610 are PCR primers used to demonstrate the method of the invention

XX SQ Sequence 19 BP; 6 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 2.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 ACAGGTTTGTAAAGAG 1603
 ||| |||||
 Db 19 ACAGGTTTGTAAAGATG 3

RESULT 226

ADD3417/c

```
ID ADD43417 standard; DNA; 19 BP.
XX
AC ADD43417;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human mitochondrial DNA (mtDNA) PCR primer SEQ ID NO:591.
XX
KW mitochondrial haplogroup; mitochondrial DNA; mtDNA;
KW single nucleotide polymorphism; SNP; genetic relationship; antidiabetic;
KW neotrophic; neuroprotective; cytosatic; gene therapy; genealogy;
KW forensic; Alzheimer's disease; cancer; type 2 diabetes mellitus; human;
KW PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003046225-A1.
XX
PD 05-JUN-2003.
XX
XX 25-NOV-2002; 2002WO-US038276.
XX
XX 26-NOV-2001; 2001US-0333622P.
XX
PR 28-MAR-2002; 2002US-0369131P.
PR
PR 01-APR-2002; 2002US-0369539P.
XX
XX (MITO-) MITOKOR.
XX
XX Herrnstadt C;
XX
XX WPI; 2003-505214/47.
XX
XX Determining single nucleotide polymorphisms in mtDNA or homoplasmic mtDNA
XX mutations, useful for diagnosing and treating diseases, such as
XX Alzheimer's disease, cancer and type 2 diabetes mellitus.
XX
XX Example 2; SEQ ID NO 591; 193pp; English.
XX
XX The present invention describes a method (M1) for determining the
XX mitochondrial haplogroup of a subject, comprising determining in a
XX biological sample with mitochondrial DNA (mtDNA) from a subject, the
XX presence or absence of at least one mitochondrial single nucleotide
XX polymorphism (SNP) that is associated with a mitochondrial haplogroup.
XX Also described: (1) determining a genetic relationship between two
XX subjects; (2) determining a genetic relationship between an unknown
XX source or biological subject from which an unidentified sample is
XX obtained, and a known source or biological subject from an identified
XX sample is obtained; and (3) determining the presence of or the risk of
XX having a disease associated with a mtDNA SNP. Mitochondrial DNA can have
XX antidiabetic, neotrophic, neuroprotective and cytosatic activities, and
XX can be used in gene therapy. M1 and compositions of the present invention
XX are useful for detecting the presence or risk of diseases, treating such
XX diseases, determining the haplogroup of an individual, and establishing
XX genetic relationships between individuals for genealogical and forensic
XX purposes. The diseases include Alzheimer's disease, cancer and type 2
XX diabetes mellitus. The present sequence represents a PCR primer used in
XX the amplification of human mtDNA in an example from the present
XX invention.
XX
XX Sequence 19 BP; 6 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1587 ACAGGTTTGTAGAG 1603
DB |||||||
19 ACAGGTTTGTAGAG 3
XX
RESULT 227
ADN97135/c
XX
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 3425 TGGCTGCCTGCTTTGC 3441
DB |||||||
17 TGGCTGCCTGCTTTAC 1
XX
RESULT 228
ADN97173/c
XX
ID ADN97173 standard; DNA; 19 BP.
XX
AC ADN97173;
XX
DT 01-JUL-2004 (first entry)
XX
DE Primer of the invention #5.
XX
KW DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
KW forensic identification; marijuana; primer; ss.
XX
OS Unidentified.
OS
XX
PN WO2004008841-A2.
XX
PD 29-JAN-2004.
XX
XX 21-JUL-2003; 2003WO-US022887.
XX
PR 19-JUL-2002; 2002US-0397179P.
XX
XX (UYAR-) UNIV ARIZONA.
XX (KEIM/) KEIM P S.
XX (ZINN/) ZINNAMON K.
XX
XX Keim PS, Zinnamon K;
XX
XX WPI; 2004-143139/14.
XX
XX New isolated nucleic acid for amplification of a short tandem repeat
XX located in DNA isolated from Cannabis sativa L species, useful for
XX forensic identification of marijuana or for linking a marijuana sample to
XX its plant source.
XX
XX Claim 1; SEQ ID NO 2; 79pp; English.
XX
XX The present invention relates to DNA fingerprinting for Cannabis Sativa
XX using short tandem repeat markers. The nucleic acid is useful for
XX forensic identification of marijuana or for linking a marijuana sample to
XX its plant source. The present sequence represents a Cannabis sativa
XX primer of the invention.
XX
XX Sequence 19 BP; 7 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 3425 TGGCTGCCTGCTTTGC 3441
DB |||||||
17 TGGCTGCCTGCTTTAC 1
XX
RESULT 228
ADN97173/c
XX
ID ADN97173 standard; DNA; 19 BP.
XX
AC ADN97173;
XX
DT 01-JUL-2004 (first entry)
XX
DE Primer of the invention #5.
XX
KW DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
KW forensic identification; marijuana; primer; ss.
XX
OS Unidentified.
OS
XX
PN WO2004008841-A2.
XX
PD 29-JAN-2004.
XX
XX 21-JUL-2003; 2003WO-US022887.
XX
PR
```

```

XX PR 19-JUL-2002; 2002US-0397179P.
XX PA (UYAR-) UNIV ARIZONA.
XX PA (KEIM/) KEIM P S.
XX PA (ZINN/) ZINNAMON K.
XX
XX Keim PS, Zinnamon K;
XX WPI; 2004-143139/14.
XX
XX New isolated nucleic acid for amplification of a short tandem repeat
XX located in DNA isolated from Cannabis sativa L species, useful for
XX forensic identification of marijuana or for linking a marijuana sample to
XX its plant source.
XX
XX Example 1; SEQ ID NO 40; 79pp; English.
XX
XX The present invention relates to DNA fingerprinting for Cannabis Sativa
XX using short tandem repeat markers. The nucleic acid is useful for
XX forensic identification of marijuana or for linking a marijuana sample to
XX its plant source. The present sequence represents a primer of the
XX invention.
XX
XX Sequence 19 BP; 7 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 2.1e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 3425 TGGCTGCTGCTTTGC 3441
XX | | | | | | | | | |
XX DB 17 TGGCTGCTGCTTTAC 1
XX
XX RESULT 229
XX ID ADN97175 standard; DNA; 19 BP.
XX AC ADN97175;
XX
XX DT 01-JUL-2004 (first entry)
XX DE Primer of the invention #7.
XX
XX DNA fingerprinting; Cannabis sativa; short tandem repeat marker;
XX forensic identification; marijuana; primer; ss.
XX
XX Unidentified.
XX
XX WO2004008841-A2.
XX
XX PD 29-JAN-2004.
XX
XX PF 21-JUL-2003; 2003WO-US022887.
XX
XX PR 19-JUL-2002; 2002US-0397179P.
XX
XX PA (UYAR-) UNIV ARIZONA.
XX PA (KEIM/) KEIM P S.
XX PA (ZINN/) ZINNAMON K.
XX
XX Keim PS, Zinnamon K;
XX WPI; 2004-143139/14.
XX
XX New isolated nucleic acid for amplification of a short tandem repeat
XX located in DNA isolated from Cannabis sativa L species, useful for
XX forensic identification of marijuana or for linking a marijuana sample to
XX its plant source.
XX
XX Example 1; SEQ ID NO 42; 79pp; English.
XX
XX The present invention relates to DNA fingerprinting for Cannabis Sativa
XX using short tandem repeat markers. The nucleic acid is useful for
XX forensic identification of marijuana or for linking a marijuana sample to
XX its plant source. The present sequence represents a primer of the
XX invention.
XX
XX Sequence 19 BP; 2 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 2.1e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 3425 TGGCTGCTGCTTTGC 3441
XX | | | | | | | | | |
XX DB 3 TGGCTGCTGCTTTAC 19
XX
XX RESULT 230
XX ID AAZ71884/c
XX ID AAZ71884 standard; DNA; 20 BP.
XX AC AAZ71884;
XX
XX DT 10-SEP-2001 (first entry)
XX DE Human biallelic marker upstream amplification primer SEQ ID NO:6240.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation;
XX amplification; single nucleotide polymorphism; SNP; PCR primer;
XX diagnosis; ss.
XX
XX Homo sapiens.
XX
XX WO9954500-A2.
XX
XX PD 28-OCT-1999.
XX
XX PF 21-APR-1999; 99WO-1B000822.
XX
XX PR 21-APR-1998; 98US-0082614P.
XX PR 23-NOV-1998; 98US-0109732P.
XX
XX (GEST ) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX
XX WPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 9; Page 1561; 2745pp; English.
XX
XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX
XX Sequence 20 BP; 1 A; 10 C; 1 G; 8 T; 0 U; 0 Other;

```

```
Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1918 GGAGGAATCAGTGAGG 1934
DB 18 GGAGGAATCAGAGAGG 2

RESULT 231
AAF73056
ID AAF73056 standard; DNA; 20 BP.
XX
AC AAF73056;
XX
DT 24-APR-2001 (first entry)
XX
DE Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:157.
XX
KW Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
KW Fas binding protein; CENP-C binding protein; dap6; EAP; cytosstatic;
KW antiinflammatory; death associated protein 6; Bts-1 associated protein;
KW infection; inflammation; tumour formation; ss.
XX
OS Homo sapiens.
XX
PN US6180353-B1.
XX
PD 30-JAN-2001.
XX
PF 24-JAN-2000; 2000US-00490692.
XX
PR 24-JAN-2000; 2000US-00490692.
XX
PA (ISIS-) ISIS PHARM INC.
PI Dean NM, Cowseert LM;
XX
WPI; 2001-217744/22.
XX
Novel antisense compounds capable of modulating expression of daxx useful
for diagnosis, prophylaxis and treatment of diseases associated with
expression of daxx.
XX
Example 16; Col 49; 59pp; English.
XX
The present invention describes an antisense compound (I) up to 30
nucleobases in length, where (I) inhibits expression of daxx (also known
as Fas binding protein, CENP-C binding protein, dap6 for death associated
protein 6 and EAP for Ets-1 associated protein). (I) has cytosstatic and
antiinflammatory activity, and can be used in antisense therapy and as a
modulator of daxx. (I) is useful for inhibiting the expression of daxx in
cells or tissues in vitro. (I) can be utilised for diagnostics,
therapeutics for the treatment of diseases associated with the expression
of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
tumour formation and as research reagent. The present sequence represents
an inhibitory human daxx antisense phosphorothioate oligonucleotide which
is used in the exemplification of the present invention
XX
Sequence 20 BP; 1 A; 10 C; 0 G; 9 T; 0 U; 0 Other;

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 CTCCTTCCTCTCTCTCA 2236
DB 4 CTCCTTCCTCTCTCTCA 20

RESULT 232
AAC67699
ID AAC67699 standard; DNA; 20 BP.
```

```
XX AAC67699;
AC
DT 16-FEB-2001 (first entry)
XX
DE Oligonucleotide #10 ISIS #116878.
XX
KW Antiinflammatory; cytosstatic; antibacterial; methionine aminopeptidase 2;
KW inhibitor; MetAP2; eukaryotic initiation factor associated protein; p67;
KW eIF-2; protein synthesis; antisense oligonucleotide; infection; human;
KW inflammation; tumour; phosphorothioate; 2-methoxyethyl wing; ss.
XX
OS Homo sapiens.
XX
PN US6136604-A.
XX
PD 24-OCT-2000.
XX
PF 27-OCT-1999; 99US-00428584.
XX
PR 27-OCT-1999; 99US-00428584.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt J;
XX
WPI; 2001-030942/04.
XX
New antisense compounds which specifically hybridize with and inhibit
human methionine aminopeptidase 2 expression, useful for treating
methionine aminopeptidase 2 related disorders and preventing inflammation
or tumor formation.
XX
Example 15; Col 41-42; 39pp; English.
XX
Methionine aminopeptidase 2 (also known as MetAP2 and eukaryotic
initiation factor [eIF-2] associated protein, p67) is a cellular
glycoprotein that promotes protein synthesis in the presence of active
eIF-2 kinases by protecting the eIF-2 alpha subunit from phosphorylation.
XX
The present invention relates to antisense oligonucleotides (AAC67690-
C67767) which inhibit human methionine aminopeptidase 2 coding sequence
expression (see AAC67683). The present sequence is one such antisense
oligonucleotide. The present sequence may be used for treating a patient
suspected of having or being prone to a disease or condition associated
with expression of MetAP2. In addition, the present sequence can also be
used as research reagents, diagnostics and to distinguish between
functions of various members of a biological pathway. The antisense
oligonucleotide may further be used prophylactically, e.g. to prevent or
delay infection, inflammation or tumour formation. Note: the present
sequence may have a phosphorothioate backbone and 2-methoxyethyl (2'-MOE)
wings
XX
Sequence 20 BP; 0 A; 6 C; 0 G; 14 T; 0 U; 0 Other;

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2568 TTCCTTCCTCTCTCTTTT 2584
DB 3 TTCCTTCCTCTCTTTCTT 19

RESULT 233
AAS09080
ID AAS09080 standard; DNA; 20 BP.
XX
AC AAS09080;
XX
DT 26-SEP-2001 (first entry)
XX
DE Human MEKK2 antisense oligonucleotide 113886.
XX
```

KW Human; mitogen-activated protein kinase kinase kinase 2; MAP; MEK2;
KW MEK kinase 2; MAP/ERK kinase kinase 2; immunological disorder;
KW inflammatory disorder; hyperproliferative disorder; cancer; antisense;
KW phosphorothioate; ss.
XX Homo sapiens.
XX
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /mod_base= a
XX /tag= a
XX /note= "OTHER= phosphorothioate internucleotide linkages.
XX Some bases especially bases 1-5 and bases 16-20 are 2'-
XX methoxyethyl (2'-MOE) bases, bases 6-15 are 2'-
XX deoxynucleotides and all cytidine bases are 5'-
XX methylcytidines"
XX
XX WO200152863-A1.
XX
XX
XX PD 26-JUL-2001.
XX
XX PF 16-JAN-2001; 2001WO-US001361.
XX
XX PR 20-JAN-2000; 2000US-00488744.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Monia BP, Gaarde WA, Ward DT, Freier SM, Wyatt JR;
XX
XX WPI; 2001-442246/47.
XX
XX Antisense compound 8 to 30 nucleobases in length targeted to a nucleic
XX acid molecule encoding MEK2, useful for the treatment of an
XX immunological, inflammatory of hyperproliferative disorder.
XX
XX Example 15; Page 79; 105pp; English.
XX
XX The present sequence for human MEK2 antisense oligonucleotide 113886 is
XX 1 of various novel human mitogen-activated protein (MAP) kinase kinase
XX kinase 2 (MEK2), also known as MEK kinase 2 and MAP/ERK kinase 2)
XX antisense oligonucleotides (AAS09045-AAS09122) which specifically
XX hybridize with and inhibit the expression of MEK2. The antisense
XX oligonucleotides can be used in a composition to modulate the expression
XX of MEK2 (AAU03598). The antisense oligonucleotides are useful for
XX inhibiting the expression of MEK2 in the treatment of immunological
XX disorders, inflammatory disorders and hyperproliferative disorders e.g.
XX cancer
XX
XX Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 2.3e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1311 GCTTCAAGTAATGGAT 1327
XX
XX Db 2 GCTTAAAGTAATGGAT 18
XX
XX
XX RESULT 234
XX ABA82442/c
XX ID ABA82442 standard; DNA; 20 BP.
XX
XX AC ABA82442;
XX
XX DT 25-JAN-2002 (first entry)
XX
XX DE Zmax1 gene region physical map preparation STS marker #401.
XX
XX Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11; 11q13.3;
XX sequence tagged site; STS; osteoporosis; osteopathic; gene therapy;
KW antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.

XX Homo sapiens.
OS Synthetic.
XX WO200177327-A1.
XX
XX PD 18-OCT-2001.
XX
XX PF 21-JUN-2000; 2000WO-US016951.
XX
XX PR 05-APR-2000; 2000US-00543771.
XX PR 05-APR-2000; 2000US-00544398.
XX
XX PA (GENO-) GENOME THERAPEUTICS CORP.
XX
XX PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
XX WPI; 2001-657171/75.
XX
XX New high bone mass (HBM) and Zmax1 genes and proteins useful for
XX modulating bone mass for the treatment of e.g. osteoporosis.
XX
XX Disclosure; Page 36; 443pp; English.
XX
XX The present invention describes the human Zmax1 gene and the high bone
XX mass (HBM) gene, which are found on chromosome 11q13.3. The Zmax1 and HBM
XX genes have osteopathic activities. The genes can be used in gene therapy,
XX antisense therapy and in the production of vaccines. They can be used in
XX the diagnosis and treatment of bone disorders including osteoporosis,
XX Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
XX ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
XX the exemplification of the present invention
XX
XX Sequence 20 BP; 11 A; 3 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 2.3e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2997 GATTTTTCCTCTTC 3013
XX
XX Db 18 GATTTTTCCTCTTC 2
XX
XX
XX RESULT 235
XX ABK23239/c
XX ID ABK23239 standard; DNA; 20 BP.
XX
XX AC ABK23239;
XX
XX DT 09-APR-2002 (first entry)
XX
XX DE Human Zmax1 cDNA forward PCR primer #201.
XX
XX KW Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;
XX lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
KW osteoporosis; arteriosclerosis; diabetic atherosclerosis; plaque build-up;
KW neurovascular condition; wound healing; gene therapy; PCR primer; probe;
KW bone development disorder; arteriosclerotic; cardiovascular;
KW osteopathic; cerebroprotective.
XX
XX OS Homo sapiens.
XX
XX PN WO200192891-A2.
XX
XX PD 06-DEC-2001.
XX
XX PF 25-MAY-2001; 2001WO-US016946.
XX
XX PR 26-MAY-2000; 2000US-00578900.
XX
XX PA (GENO-) GENOME THERAPEUTICS CORP.
XX (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.

```
XX Carulli JP, Little RD, Recker RR, Johnson ML;
XX WPI; 2002-097784/13.
XX Identifying molecules involved in lipid regulation, useful for
XX diagnosing, treating or preventing e.g., arteriosclerosis, comprises
XX identifying a molecule that binds to high bone mass gene or its
XX corresponding wild type gene.
XX Disclosure; Page 41; 409pp; English.
XX The invention relates to a method for identifying a molecule involved in
XX lipid regulation comprising identifying a molecule that binds to or
XX inhibits binding of a molecule to high bone mass (HBM) or its wild type
XX gene, Zmax1. Compounds identified by the method are useful for treating,
XX diagnosing, preventing or screening for normal and abnormal lipid-
XX associated conditions, including arteriosclerosis, cardiovascular
XX disease, stroke, and osteoporosis. The compounds may also be used in the
XX treatment or prevention of diabetic atherosclerosis, neurovascular
XX conditions caused by plaque build-up, poor circulation due to plaque
XX build-up and associated poor wound healing. The methods may be used in
XX gene therapy, pharmaceutical development, and diagnostic assays for bone
XX development disorders. Molecules identified by comparison of Zmax1 and
XX HBM systems can be used as surrogate markers in pharmaceutical
XX development, in diagnosis of human or animal bone disease, and in the
XX treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
XX molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
XX and adapters of the invention
XX Sequence 20 BP; 11 A; 3 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 2.3e+02;
XX Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2997 GATTTTTCCTTC 3013
XX DB 18 GATTATTTCCTTC 2
XX
XX RESULT 236
XX ABL94329
XX ID ABL94329 standard; DNA; 20 BP.
XX AC ABL94329;
XX
XX 29-JUL-2002 (first entry)
XX
XX Human C/EBP beta phosphorothioate antisense oligonucleotide, SEQ ID:95.
XX
XX Human; C/EBP beta; CCAAT/enhancer-binding protein beta; C/EBP2; LAP;
XX TCF5; CRP2; NFIL6; IL6DBP; NF-M; AGP/EBP; transcription factor;
XX tissue development; cellular function; proliferation; differentiation;
XX hormone responsiveness; oxidative stress response;
XX IL-6 signalling mediator; interleukin-6; carbohydrate metabolism;
XX immunity; Th1 response; female fertility; gluconeogenesis; ovarian;
XX cancer; tumour formation; type II diabetes; infection; inflammation;
XX expression inhibition; phosphorothioate; antisense oligonucleotide; ss.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages"
XX
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
XX cytosines are 5-methylcytosine"
XX modified_base 16..20
XX
XX FT /tag= c
XX FT /mod_base= OTHER
XX FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
XX cytosines are 5-methylcytosine"
XX
XX US6271030-B1.
XX 07-AUG-2001.
XX 14-JUN-2000; 2000US-00593711.
XX 14-JUN-2000; 2000US-00593711.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Butler MM, Wyatt J;
XX WPI; 2002-214451/27.
XX Novel antisense compound targeted to nucleic acids encoding human or
XX mouse CCAAT/enhancer binding protein (C/EBP) beta, useful in vitro for
XX inhibiting expression of human or mouse C/EBP beta in cells/tissues.
XX Example 15; Col 45-46; 69pp; English.
XX Sequences ABL94252-ABL94476 represent antisense oligonucleotides targeted
XX to the human or mouse CCAAT/enhancer-binding protein alpha (C/EBP alpha)
XX gene, which inhibit its expression. The antisense oligonucleotides were
XX designed to target different regions of the human and/or mouse C/EBP
XX alpha RNA, and were analysed for their effect on C/EBP alpha mRNA levels
XX by quantitative real-time PCR. The C/EBP family of proteins are a family
XX of transcription factors which regulate the expression of a wide range of
XX genes that control normal tissue development, cellular function, cellular
XX proliferation and functional differentiation. C/EBP beta (also known as
XX C/EBP2, LAP, TCF5, CRP2, NFIL6, IL6DBP, NF-M, AGP/EBP and Apc/EBP)
XX is primarily regulator of hormone responsiveness and oxidative stress responses
XX and is a mediator of IL-6 (interleukin-6) signalling. C/EBP beta is
XX thought to be involved in carbohydrate metabolism, immunity, the Th1
XX response, female fertility and gluconeogenic pathways. C/EBP beta is
XX expressed in the liver, lung, spleen, kidney, brain, and testis, with the
XX highest expression found in the lung. It is also expressed at a higher
XX level in malignant ovarian tissue compared with normal ovarian tissue
XX and its expression in pancreas is upregulated that it is involved in the
XX elevated levels of glucose, indicating that it is involved in the
XX impairment of insulin secretion in type II diabetes. The oligonucleotides
XX of the invention are useful for diagnosis, prevention and treatment of
XX conditions associated with C/EBP beta expression, such as cancer
XX (particularly ovarian cancer), tumour formation, diabetes (particularly
XX type II diabetes), infection, or inflammation
XX Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 2.3e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1423 CCCCCAAAAGGCTCTGT 1439
XX DB 4 CCCCCAAAAGGCTTGT 20
XX
XX RESULT 237
XX ABS65083/c
XX ID ABS65083 standard; DNA; 20 BP.
XX AC ABS65083;
XX 15-NOV-2002 (first entry)
XX Human casein kinase 2-beta antisense oligonucleotide #21.
XX ss; antisense; casein kinase2-beta; human; antisense gene therapy;
XX cytostatic; antidiabetic; antiinflammatory; diabetes; cancer; tumour;
```

KW hyperproliferative disorder; breast cancer; prostate cancer;
XX liver cancer.
XX

OS Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /tag= a

FT /mod_base= OTHER

FT /note= "All cytidines are 5-methylcytidines"

FT modified_base 1..20

FT /tag= b

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

FT modified_base 1..5

FT /tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl residues"

FT modified_base 16..20

FT /tag= d

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl residues"

XX WO200262954-A2.

PN 15-AUG-2002.

PD 31-JAN-2002; 2002WO-US003159.

PF 08-FEB-2001; 2001US-00780175.

PR (ISIS-) ISIS PHARM INC.

XX McKay R, Freier SM, Wyatt JR;

XX WPI; 2002-643409/69.

XX New antisense oligonucleotides targeted to nucleic acid encoding Casein
PT kinase 2-beta, useful in diagnostic and research applications, or for
PT treating a disease or condition associated with the expression of Casein
PT kinase 2-beta.
XX

PS Example 15; Page 91; 142pp; English.

XX The invention relates to a compound that is 8 - 50 nucleobases in length
CC targeted to a nucleic acid molecule encoding Casein kinase 2-beta, and
CC which specifically hybridizes with and inhibits the expression of Casein
CC kinase 2-beta, or which specifically hybridizes with an 8-nucleobase
CC portion of an active site on a nucleic acid molecule encoding Casein
CC kinase 2-beta. Also included are: (1) a composition comprising the
CC compound, and a carrier or diluent; (2) inhibiting the expression of
CC Casein kinase 2-beta in cells or tissues by contacting the cells or
CC tissues with the compound so that the expression of Casein kinase 2-beta
CC is inhibited; and (3) treating an animal having a disease or condition
CC associated with Casein kinase 2-beta by administering to the animal the
CC new compound so that the expression of Casein kinase 2-beta is inhibited.
CC The antisense compounds are useful for modulating the expression of
CC Casein kinase 2-beta and for treating diseases or conditions associated
CC with expression of Casein kinase 2-beta, e.g. diabetes or
CC hyperproliferative disorders, particularly cancer, such as breast cancer,
CC prostate cancer, or liver cancer. The antisense compounds are also useful
CC for diagnostics, therapeutics, prophylaxis, e.g. to prevent or delay
CC infection, inflammation or tumour formation, as research reagents and
CC kits, and in distinguishing between functions of various members of a
CC biological pathway. The present sequence is an antisense oligonucleotide
CC of the invention targeting human casein kinase 2-beta
XX

XX Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 CTCCTCCGGCGCGTCGT 428
Db |||||

20 CTCCTCCGGCGCGTCGT 4

RESULT 238

ACC45822/c

ID ACC45822 standard; DNA; 20 BP.

XX ACC45822;

XX 02-JUN-2003 (first entry)

XX Human HBM STS marker forward primer #201.

XX Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
KW gene therapy; bone density modulation; bone strength; trabecular number;
KW bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
KW osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.

XX Homo sapiens.

XX WO200292764-A2.

XX 21-NOV-2002.

XX 13-MAY-2002; 2002WO-US014876.

XX 11-MAY-2001; 2001US-0290071P.

XX 17-MAY-2001; 2001US-0291311P.

XX 01-FEB-2002; 2002US-0353058P.

XX 04-MAR-2002; 2002US-0361293P.

XX (GENO-) GENOME THERAPEUTICS CORP.

XX (AMHP) WYETH.

XX Babij P, Bex FJ, Yaworsky PJ, Bodine PV;

XX WPI; 2003-129278/12.

XX New transgenic animals (e.g. mice), useful as models for studying bone
PT density modulation, developing drugs for treating or preventing bone
PT diseases (e.g. osteoporosis), or diagnosing diseases characterized by
PT reduced bone density.
XX

XX Disclosure; Page 57; 603pp; English.

XX The invention relates to novel transgenic animals expressing the high
CC bone mass (HBM) gene, expressing the corresponding wild type HBM gene,
CC comprising an alteration of the gene encoding LRP5 or LRP6, or expressing
CC an LRP5 that is modulated by an altered gene control sequence introduced
CC by homologous or non-homologous recombination. The transgenic animals are
CC for the study of bone density modulation or bone mass modulation. The
CC invention has osteopathic and cytostatic activity. The polynucleotides of
CC the invention may have a use in gene therapy. The transgenic animals and
CC nucleic acids are for the study of bone density modulation, where the
CC bone mass is modulated relative to non-transgenic animals of the same
CC species in more than one parameter selected from bone density, bone
CC strength, trabecular number, bone size, or bone tissue connectivity. The
CC transgenic animals, nucleic acids and methods are useful for identifying
CC molecules involved in bone development, and for developing pharmaceutical
CC compositions, which may be employed for treating or preventing bone
CC diseases, e.g. osteoporosis, osteomalacia, rickets, Paget's disease, or
CC neoplasms of the bone. The transgenic animals and nucleic acids are also
CC useful in methods for diagnosing diseases involved in bone development,
CC or characterised by reduced bone density or mass. The present sequence is
CC used in the exemplification of the invention
XX

XX Sequence 20 BP; 11 A; 3 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```
QY 2997 GATTTTTCCTCTTC 3013
DB 18 GATTATTTCCTCTTC 2

RESULT 239
ACFS7337
ID ACF57337 standard; DNA; 20 BP.
AC ACF57337;
XX
XX
XX 16-OCT-2003 (first entry)
XX
XX Human atlastin exon 10 intronic acceptor splice site.
XX
XX Human; atlastin; chromosome 14; 14q22.1; hereditary spastic paraplegia;
KW HSP; neuroprotective; gene therapy; intronic splice site; gene; ds.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX WO2003026566-A2.
XX
XX 03-APR-2003.
XX
XX 13-SEP-2002; 2002WO-US029165.
XX
XX 21-SEP-2001; 2001US-0323997P.
PR 12-SEP-2002; 2002US-00242008.
XX
XX (UNMI ) UNIV MICHIGAN.
PA
XX
XX Fink JK, Zhao X;
XX
XX WPI; 2003-371871/35.
XX
XX New atlastin gene, useful for preparing a composition for treating
PT Hereditary Spastic Paraplegia (HSP) or for identifying subjects who have,
PT or at risk of developing, HSP.
XX
XX Example 6; Page 102; 11pp; English.
XX
XX The present invention describes human atlastin, which is located to
XX chromosome 14 (more specifically to 14q22.1). Also described: (1) an
XX isolated atlastin polypeptide; (2) identifying subjects who have, or are
XX at risk of developing, hereditary spastic paraplegia (HSP); (3) a kit for
XX determining if a subject has, or at risk of developing, HSP; (4) a
XX computer readable medium encoding a representation of the atlastin
XX nucleic acid sequence or polypeptide; (6) identifying subjects at risk of
XX carrying an allele for HSP; and (7) treating a patient with HSP. Atlastin
XX has neuroprotective activity and can be used in gene therapy. The
XX atlastin nucleic acid is useful for preparing a composition for treating
XX HSP or for identifying subjects who have, or at risk of developing, HSP.
XX The present sequence represents an atlastin intronic splice site
XX oligonucleotide, which is given in an example from the present invention
XX
XX
XX Sequence 20 BP; 2 A; 2 C; 1 G; 15 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2569 TCTTCTCTTTTTCCTTC 2585
DB 2 TCTTCTCTTTTTCCTTC 18

RESULT 240
ADB98520/C
ID ADB98520 standard; DNA; 20 BP.
XX
XX ADB98520;
AC
```

```
XX 04-DEC-2003 (first entry)
DT
XX
XX Sequence tagged site #401 used to prepare Zmax1 (LRP5) gene region map.
DE
XX
XX Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW bone mass modulation; osteoporosis; STS; sequence tagged site; ds.
KW
XX Homo sapiens.
OS
XX WO200292000-A2.
XX
XX 21-NOV-2002.
XX
XX 13-MAY-2002; 2002WO-US014877.
XX
XX 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
XX (GENO-) GENOME THERAPEUTICS CORP.
PA (AMHP ) WYETH.
PA
XX Allen K, Anisowicz A, Graham JR, Morales A, Yaworsky PJ, Liu W;
XX
XX WPI; 2003-129214/12.
XX
XX New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT diagnosing a HBM-like phenotype in a subject and for preparing a
PT composition for modulating bone mass and/or lipid levels in a subject
PT suffering from e.g. osteoporosis.
XX
XX Example 2; Page 64; 629pp; English.
XX
XX The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
XX LRP6 mutants, which results in a HBM-like phenotype when expressed in a
XX cell. The HBM-like phenotype results in bone mass modulation and/or lipid
XX level modulation. The invention is useful for diagnosing a HBM-like
XX phenotype in a subject and for preparing a composition for modulating
XX bone mass and/or lipid levels in a subject suffering from e.g.
XX osteoporosis. The present sequence is a sequence tagged site (STS)
XX marker, which was used to prepare a physical map of the Zmax1 (LRP5) gene
XX region.
XX
XX Sequence 20 BP; 11 A; 3 C; 4 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2997 GATTTTTCCTCTTC 3013
DB 18 GATTATTTCCTCTTC 2

RESULT 241
ADC65802
ID ADC65802 standard; DNA; 20 BP.
XX
XX ADC65802;
AC
XX
XX 18-DEC-2003 (first entry)
DT
XX
XX Mouse TGF-beta receptor II targeted antisense oligonucleotide #1.
DE
XX
XX mouse; antisense oligonucleotide;
KW transforming growth factor beta receptor II; TGF-beta receptor II;
KW hyperproliferative disorder; breast cancer; autoimmune disorder;
KW rheumatoid arthritis; 2'-O-methoxyethyl gapper;
KW phosphorothioate backbone; ss; murine.
XX
XX Mus musculus.
OS
```

```
XX PN WO2003000656-A2.
XX PF
XX PD 03-JAN-2003.
XX PF
XX PR 19-JUN-2002; 2002WO-US019665.
XX PF
XX PR 21-JUN-2001; 2001US-00888361.
XX PA
XX PA (ISIS-) ISIS PHARM INC.
XX PI
XX PI Murray SF, Wyatt JR;
XX PI WPI; 2003-175279/17.
XX DR
XX XX New compound having a sequence targeted to a nucleic acid encoding
PT Transforming growth factor beta-receptor II, useful for preparing a
PT composition for treating hyperproliferative disorder e.g., lung, liver,
PT colon or gastric cancer.
XX PT
XX PS Example 15; SEQ ID NO 98; 141pp; English.
XX CC
XX CC The invention comprises antisense oligonucleotides that are targeted to
CC the nucleic acid encoding transforming growth factor beta (TGF-beta)
CC receptor II. The antisense oligonucleotides of the invention are useful
CC for treating: hyperproliferative disorders (e.g. breast cancer), or an
CC autoimmune disorder (e.g. rheumatoid arthritis). The present DNA sequence
CC represents a 2'-O-methoxyethyl gapped oligonucleotide with a
XX phosphorothioate backbone that is targeted to mouse TGF-beta receptor II.
XX SQ
XX SQ Sequence 20 BP; 3 A; 6 C; 10 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 265 GGAGGCCCGGAGGGGC 281
Db 4 GGAGGCCCGGAGGGGC 20
RESULT 242
ADG6355/c
ID ADC66355 standard; DNA; 20 BP.
XX AC
XX AC ADC66355;
XX DT
XX DT 18-DEC-2003 (first entry)
XX DE
XX DE Human collapsin response mediator protein 2 gene antisense oligo #138023.
XX KW neuroprotective; nootropic; neuroleptic; gene therapy;
KW human collapsin response mediator protein 2; neurodegenerative disease;
KW Alzheimer's disease; Down syndrome; schizophrenia; H-ras; ss; antisense.
XX OS
XX OS Synthetic.
XX OS Homo sapiens.
XX FH
XX FH Key Location/Qualifiers
FT misc_difference 1..20
FT /*tag= b
FT /note= "contains phosphorothioate internucleotide
FT linkages; all cytidine nucleotides are 5-methylcytidine
FT residues"
FT misc_difference 1..5
FT /*tag= a
FT /note= "2'-O-methoxyethyl modified nucleotides"
FT misc_difference 16..20
FT /*tag= c
FT /note= "2'-O-methoxyethyl modified nucleotides"
XX PN WO2003040320-A2.
XX
```

```
PD 15-MAY-2003.
XX PF
XX PF 04-NOV-2002; 2002WO-US035323.
XX PR
XX PR 08-NOV-2001; 2001US-00006911.
XX PA
XX PA (ISIS-) ISIS PHARM INC.
XX PI
XX PI Gaarde WA, Watt AT;
XX PI WPI; 2003-449447/42.
XX DR
XX XX New compound, having a sequence targeted to a nucleic acid encoding human
PT collapsin response mediator protein 2, useful for preparing a composition
PT for treating neurodegenerative disease, e.g., Alzheimer's disease.
XX PT
XX PS Claim 3; SEQ ID NO 33; 102pp; English.
XX CC
XX CC The invention relates to a new compound having a sequence comprising 8-50
CC bp targeted to a nucleic acid encoding human collapsin response mediator
CC protein 2 which specifically hybridizes with the nucleic acid encoding
CC human collapsin response mediator protein 2 and inhibits its expression.
XX CC The compound is useful for preparing a composition for treating
CC neurodegenerative disease, e.g., Alzheimer's disease, Down syndrome or
CC schizophrenia. This sequence represents the human collapsin response
CC mediator protein 2 gene intron 1 sequence against which the antisense
CC oligonucleotides may be targeted.
XX SQ
XX SQ Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3281 TCTTGTACAGGGGAAGAA 3297
Db 18 TCTTATCAGGGGAAGAA 2
RESULT 243
ADG32515
ID ADG32515 standard; DNA; 20 BP.
XX AC
XX AC ADG32515;
XX DT
XX DT 26-FEB-2004 (first entry)
XX DE
XX DE Transposon Tn10 primer to select transposon insertion mutants SeqID 98.
XX KW ss; attenuated gram negative bacteria; immunogenic; vaccine;
KW bacterial infection; Pasteurellaceae; immunogen; allergen; growth factor;
KW cytokine; antibacterial; transposon insertion site; PCR; primer; Tn10.
XX OS
XX OS Transposon Tn10.
XX PN
XX PN WO2003086277-A2.
XX PD
XX PD 23-OCT-2003.
XX XX
XX XX 04-APR-2003; 2003WO-US010308.
XX PF
XX PF 05-APR-2002; 2002US-0370282P.
XX PR
XX PR 03-APR-2003; 2003US-00406686.
XX XX
XX PA (MERI-) MERIAL LLC.
XX XX
XX XX Crooke HR, Shea JE, Feldman RG, Coutbroze SG, Legros F;
XX WPI; 2003-845250/78.
XX DR
XX XX New mutant gram negative bacterium having attenuated virulence, useful
PT for preparing a composition or vaccine for preventing bacterial
PT infections.
```

XX Example 5; SEQ ID NO 98; 170pp; English.

PS This invention relates to novel live attenuated gram negative bacteria

XX useful for immunogenic compositions and in vaccines to prevent bacterial

CC infections. Specifically, it refers to a mutant gram negative bacterium

CC from the Pasteurellaceae family, having a mutation in a first nucleotide

CC sequence that codes for a first polypeptide, and results in the bacterium

CC having attenuated virulence. This mutation can be a deletion, insertion

CC or replacement of nucleic acids in a regulatory element or coding

CC sequence of a gene that encodes an immunogen such as a viral, parasitic

CC or bacterial agent, allergen, growth factor, therapeutic protein or

CC cytokine. The present invention describes a method for attenuating live

CC bacteria that reduces or abolishes pathogenicity, decreases bacterial

CC growth rate and thereby prevents cell death. Accordingly, these

CC compositions have antibacterial activity and can be administered in an

CC antibody preparation. This oligonucleotide sequence is a transposon Tn10

CC PCR primer used to select transposon insertion mutants of the invention.

XX Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

SEQ

Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3266 ATCTGATCCTTCAACTC 3282

DB 1 ATCTGATCCTTCAACTC 17

RESULT 244

ID ADF87543 standard; DNA; 20 BP.

XX ADF87543;

XX 26-FEB-2004 (first entry)

DE Single nucleotide polymorphism detection primer, SEQ ID NO 1126.

XX human; single nucleotide polymorphism; microarray; side effect; ss;

KW primer; PCR.

XX Synthetic.

OS Homo sapiens.

XX JP2003235571-A.

PN 26-AUG-2003.

XX 12-FEB-2002; 2002JP-00034717.

PF 12-FEB-2002; 2002JP-00034717.

XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

PA WPI; 2003-820454/77.

DR

XX Novel polynucleotide useful for detecting single nucleotide polymorphisms

PT in human gene.

XX Claim 2; SEQ ID NO 1126; 704pp; Japanese.

PS

XX The invention relates to a novel polynucleotide isolated and purified

CC from a human gene having any one of 935 fully defined sequences as given

CC in specification, or a sequence having a base substitution. The invention

CC further relates to: an oligonucleotide containing single nucleotide

CC polymorphisms; a PCR primer set chosen from the combination of two DNA

CC fragments from any one of 1220 fully defined sequences as given in

CC specification; a labelling probe containing the SNP containing oligo; and

CC a microarray equipped with the SNP containing oligo. The isolated human

CC gene of the invention is useful for detecting the single nucleotide

CC polymorphisms in human gene. The isolated human gene is also useful for

CC diagnosis of disease and determination of side effect to a medical agent.

CC The isolated human gene is also effective in detecting single nucleotide

CC polymorphisms in a human gene. This polynucleotide sequence represents

CC one of the PCR primers used in the single nucleotide polymorphism

CC detection method of the invention.

XX Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

SEQ

Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 2.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TTGGGACTTTTCATGCC 64

DB 4 TTGGGACTTTTCATGCC 20

RESULT 245

ID ABZ97832 standard; DNA; 20 BP.

XX ABZ97832;

XX 17-OCT-2003 (first entry)

DE Human eotaxin oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cycostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

OS WO200285308-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

PR (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

DR

XX Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubiquinone.

XX Disclosure; SEQ ID NO 13074; 872pp; English.

PS

XX The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, and

CC immunosuppressive, and cycostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 665 ACCAAACCAGAGCCTGA 681
|||||
Db 17 ACCAAACCAGAGCCTGA 1

RESULT 246

ABZ70353
ID ABZ70353 standard; DNA; 20 BP.

XX
AC ABZ70353;

XX
DT 25-APR-2003 (first entry)

XX
DE Human interferon alpha 5 PCR primer #2.

XX
KW Human; antiviral; cytostatic; neuroprotective;
KW immunosuppressive; anti-HIV; anti-inflammatory;
KW interferon alpha 5; IFNalpha-5; cancer; cardiovascular disorder;
KW metabolic disease; infectious disease; pneumonia; ulcerative colitis;
KW central nervous system disorder; AIDS; Alzheimer's disease;
KW schizophrenia; depression; graft rejection; anaemia; allergy; asthma;
KW multiple sclerosis; osteoporosis; psoriasis; rheumatoid arthritis;
KW Crohn's disease; autoimmune disease; wound healing; Kaposi's sarcoma;
KW gastrointestinal disorder; leukaemia; Parkinson's disease;
KW cell signalling; PCR; primer; ss.

XX
OS Homo sapiens.

XX
FN FR2824333-A1.

XX
PD 08-NOV-2002.

XX
PF 03-MAY-2001; 2001FR-00005919.

XX
PR 03-MAY-2001; 2001FR-00005919.

XX
PA (GENO-) GENODYSEE SA.

XX
PI Escary JL;

XX
WPI; 2003-142460/14.

XX
PT New interferon alpha 5 polynucleotides containing single nucleotide
PT polymorphisms are useful to prevent and treat a variety of disorders and
PT diseases including cancer and immune disorders.

XX
PS Claim 12; Page 66; 69pp; French.

XX
CC The present invention relates to human interferon alpha 5 (IFNalpha-5)
CC coding sequence (see ABZ70351). The coding sequence has the single
CC nucleotide polymorphisms (SNPs) c641g and/or g798c. The coding sequence
CC is useful for preventing or treating cancer, cardiovascular or metabolic
CC disease not related to the immune system or obesity, infectious disease
CC particularly viral, pneumonia, ulcerative colitis, disease of the central
CC nervous system, AIDS, Alzheimer's disease, schizophrenia, depression,
CC graft rejection, anaemia, particularly in dialysis patients, allergies,
CC asthma, multiple sclerosis, osteoporosis, psoriasis, rheumatoid
CC arthritis, Crohn's disease, autoimmune diseases and disorders, wound
CC healing, gastrointestinal disorders, genital or venereal warts, or
CC disorders arising from chemotherapy. A particular use is to prevent or
CC treat leukaemia such as chronic myeloid leukaemia, multiple myelomas,

CC follicular lymphomas, malignant melanomas, renal carcinomas metastases,
CC Alzheimer's disease, Parkinson's disease and tumours which arise due to
CC an immune system deficiency, particularly Kaposi's sarcoma in AIDS. The
CC present sequence is a PCR primer, which was used in an example from the
CC invention

XX
SQ Sequence 20 BP; 7 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2637 CAGAACTCCAGAGTGT 2653
|||||
Db 3 CAGAACTCCAGAGTGT 19

RESULT 247

ABD30863/C
ID ABD30863 standard; DNA; 20 BP.

XX
AC ABD30863;

XX
DT 29-JUL-2004 (first entry)

XX
DE Human eotaxin-derived oligonucleotide SEQ ID 13074.

XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

XX
OS Homo sapiens.

XX
FN WO200285309-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013143.

XX
PR 24-APR-2001; 2001US-0286036P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

XX
WPI; 2003-093058/08.

XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX
PS Claim 15; SEQ ID NO 13074; 763pp; English.

XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it

XX
SQ Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 665 ACCAAACACGAGCGTGA 681
DB 17 ACCAAACACGAGCGTGA 1

RESULT 248
ADH27256/C
ID ADH27256 standard; DNA; 20 BP.
XX
AC ADH27256;
XX
DT 11-MAR-2004 (first entry)
XX
DE Ferritin related oligonucleotide Bin#3 structure 7.
XX
KW detection; conserved structure; RNA structural element; fitness; ss.

XX Synthetic.
XX WO2003104478-A2.
XX
PD 18-DEC-2003.
XX
PF 10-JUN-2003; 2003WO-US018573.
XX
PR 10-JUN-2002; 2002US-0387342P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Sampath R, Ecker DJ, Griffey RH, Fogel GB, Porto VW;
XX
XX WPI; 2004-062371/06.
XX
PT Detecting a conserved structures in an RNA sequence by generating an
PT offspring group from the parent group and selecting at least one group
PT from the parent and offspring groups with the highest fitness.
XX
PS Example 1; Fig 11; 52pp; English.

XX The present invention describes a method for detecting a conserved
CC structure in an RNA sequence. The method comprises: (a) placing 2
CC structures from RNA sequences generated for 2 RNA sequences from 2 organisms
CC into a parent group; (b) generating an offspring group from the parent
CC group; (c) determining fitness of the parent and offspring groups; (d)
CC comparing the fitness of the parent and offspring groups; and (e)
CC selecting at least one group from the parent and offspring groups with
CC the highest fitness, where the conserved structure in the RNA is present
CC within the at least one group. The method is useful for detecting a
CC conserved structure in an RNA sequence. The present sequence is used in

CC the exemplification of the present invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2178 GGGGAGCTGCTCTCCA 2194
DB 18 GTGGAGCTGCTCTCCA 2

RESULT 249
ADH18212
ID ADH18212 standard; DNA; 20 BP.
XX
AC ADH18212;

XX
DT 11-MAR-2004 (first entry)
XX
DE 2'-MOE gapmer antisense oligo targeted to human ApoB DNA 1 - SEQ ID 201.
XX
KW apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
KW human; ss.

XX Homo sapiens.

XX WO2003097662-A1.

XX PD 27-NOV-2003.

XX PF 15-MAY-2003; 2003WO-US015493.

XX PR 15-MAY-2002; 2002US-00147196.

XX PR 13-NOV-2002; 2002US-0426324P.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Crooke RM, Graham MJ;

XX DR WPI; 2004-022840/02.

XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidemia or cardiovascular disease.

XX Claim 1; SEQ ID NO 201; 405pp; English.

XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC MOE) gapmer antisense oligo of the invention which has 2'-MOE 'wings', a
CC phosphorothioate backbone throughout and in which all cytidine residues
CC are 5-methylcytidines.

XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2203 CTGAGAGAACCTTCT 2219
|||||||

Db 3 CTGAAGAGACCTCTCT 19

RESULT 250
ADH18580/c
ID ADH18580 standard; DNA; 20 BP.

XX
AC ADH18580;
XX
DT 11-MAR-2004 (first entry)
XX
DS Human apolipoprotein B antisense inhibition target DNA - SEQ ID 569.
XX
KW apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense inhibition target; human; ds.
XX
OS Homo sapiens.
XX
FN WO2003097662-A1.
XX
PD 27-NOV-2003.
XX
PF 15-MAY-2003; 2003WO-US015493.
XX
PR 15-MAY-2002; 2002US-00147196.
PR 13-NOV-2002; 2002US-0426324P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
XX WPI; 2004-022840/02.
XX
DS New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidemia or cardiovascular disease.
XX
PS Claim 1; SEQ ID NO 569; 405pp; English.
XX
CC The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the human ApoB antisense
CC inhibition target DNA of the invention.
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2203 CTGAAGAGACCTCTCT 2219
Db 18 CTGAAGAGACCTCTCT 2

RESULT 251
ADJ59691/c
ID ADJ59691 standard; DNA; 20 BP.
XX
AC ADJ59691;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to Botaxin D49372 #18.
XX

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
FN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
DS Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 547; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 665 ACCAACCAGAGCGTGA 681
Db 17 ACCAACCAGAGCGTGA 1

RESULT 252
ADM41295
ID ADM41295 standard; DNA; 20 BP.
XX
AC ADM41295;
XX
DT 03-JUN-2004 (first entry)
XX
DE Rat EDG receptor 4 5' PCR primer.
XX
KW Rat; plasticity-related gene-1; PRG-1; lipid phosphate phosphatase;
KW enzyme; nootropic; neuroprotective; cerebroprotective; gene therapy; EDG;
KW receptor; PCR; primer; ss.
XX
OS Rattus norvegicus.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT PT asthma.

XX PS Claim 2; SEQ ID NO 547; 174pp; English.

XX CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICM, VCM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICM, VCM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 665 ACCAAACAGAGCGTGA 681
|||||
DB 17 ACCAAACAGAGCGCTGA 1

RESULT 255
AD054692/c
ID AD054692 standard; DNA; 20 BP.
XX AC AD054692;
XX DT 15-JUL-2004 (first entry)
XX DE Farnesoid X receptor gene expression antisense inhibitory oligo #2065.
XX KW ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.

XX OS Homo sapiens.
XX FN WO2004030750-A1.
XX PD 15-APR-2004.
XX PF 25-SEP-2003; 2003WO-US030353.
XX PR 25-SEP-2002; 2002US-0413588P.
XX PA (PHAA) PHARMACIA CORP.
XX PI Kane CD;
XX DR WPI; 2004-347928/32.

PA (PHAA) PHARMACIA CORP.
XX Kane CD;
XX WPI; 2004-347928/32.
XX PT New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.

XX PS Claim 4; SEQ ID NO 2065; 150pp; English.

XX CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 13 A; 1 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2577 TTTTCTTTCTGAAAA 2593
|||||
DB 20 TTTTCTTTCTGAAAA 4

RESULT 256
AD054593/c
ID AD054593 standard; DNA; 20 BP.
XX AC AD054593;
XX DT 15-JUL-2004 (first entry)
XX DE Farnesoid X receptor gene expression antisense inhibitory oligo #1966.
XX KW ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.

XX OS Homo sapiens.
XX FN WO2004030750-A1.
XX PD 15-APR-2004.
XX PF 25-SEP-2003; 2003WO-US030353.
XX PR 25-SEP-2002; 2002US-0413588P.
XX PA (PHAA) PHARMACIA CORP.
XX PI Kane CD;
XX DR WPI; 2004-347928/32.

XX New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
XX
PS Claim 4; SEQ ID NO 1966; 150pp; English.
XX
CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 10 A; 2 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2577 TTTTCTTTCTGAAAA 2593
DB 17 TTTTCTTTCTGAAAA 1
RESULT 257
AD054663/C
ID AD054663 standard; DNA; 20 BP.
XX
AC AD054663;
XX
XX 15-JUL-2004 (first entry)
XX Farnesoid X receptor gene expression antisense inhibitory oligo #2036.
DE ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS Homo sapiens.
XX
XX WO2004030750-A1.
XX
XX 15-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030353.
XX
XX 25-SEP-2002; 2002US-0413588P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Kane CD;
XX
XX WPI; 2004-347928/32.
XX
XX New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
PT

XX
PS Claim 4; SEQ ID NO 2036; 150pp; English.
XX
CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 12 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2577 TTTTCTTTCTGAAAA 2593
DB 19 TTTTCTTTCTGAAAA 3
RESULT 258
AD054594/C
ID AD054594 standard; DNA; 20 BP.
XX
AC AD054594;
XX
XX 15-JUL-2004 (first entry)
XX Farnesoid X receptor gene expression antisense inhibitory oligo #1967.
DE ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS Homo sapiens.
XX
XX WO2004030750-A1.
XX
XX 15-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030353.
XX
XX 25-SEP-2002; 2002US-0413588P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Kane CD;
XX
XX WPI; 2004-347928/32.
XX
XX New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
XX
PS Claim 4; SEQ ID NO 1967; 150pp; English.
XX
CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 12 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2577 TTTTCTTTCTGAAAA 2593
DB 19 TTTTCTTTCTGAAAA 3
RESULT 258
AD054594/C
ID AD054594 standard; DNA; 20 BP.
XX
AC AD054594;
XX
XX 15-JUL-2004 (first entry)
XX Farnesoid X receptor gene expression antisense inhibitory oligo #1967.
DE ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS Homo sapiens.
XX
XX WO2004030750-A1.
XX
XX 15-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030353.
XX
XX 25-SEP-2002; 2002US-0413588P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Kane CD;
XX
XX WPI; 2004-347928/32.
XX
XX New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
XX

CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.

XX Sequence 20 BP; 11 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2577 TTTTCTTTTCTGAAA 2593
Db 18 TTTTCTTTTCTGAAA 2

RESULT 259
ADO33121/c
ID ADO33121 standard; DNA; 20 BP.

XX ADO33121;

XX 12-AUG-2004 (first entry)

XX Human apolipoprotein B (ApoB) antisense therapy target DNA - SEQ 569.

XX apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
KW antilipemic; antidiabetic; anorectic; cardiant; vasotropic; hypotensive;
KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;
KW neuroprotective; nontropic; lipid; cholesterol metabolism;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
KW obesity; atherosclerosis; human; chromosome 2p23-2p24; ds;
KW antisense target.

XX Homo sapiens.

XX WO2004044181-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036411.

XX 13-NOV-2002; 2002US-0426234P.

XX 15-MAY-2003; 2003WO-US015493.

XX (ISIS-) ISIS PHARM INC.

XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;

XX WPI; 2004-420321/39.

XX Antisense oligonucleotide compound that inhibits expression of mRNA
PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
PT syndrome.

XX Example 36; SEQ ID NO 569; 483pp; English.

XX The invention relates to a novel antisense compound where the compound
CC hybridises to and inhibits expression of mRNA encoding human
CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%

CC confluent HepG2 cells in culture at a concentration of 150 nM. The
CC compound of the invention demonstrates cardiovascular,
CC antiarteriosclerotic, antilipemic, antidiabetic, anorectic, cardiant,
CC vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
CC endocrine, vasotropic, neuroprotective and nontropic activities and may
CC be useful for inhibiting the expression of apolipoprotein B in cells or
CC tissues in vivo in order to address a condition associated with abnormal
CC lipid or cholesterol metabolism. The compound may be useful for
CC decreasing circulating lipoprotein levels, triglyceride levels,
CC cholesterol levels, lipid levels, fatty acid levels, acute phase
CC reactants and chylomicrons and thus may be utilised during treatment of
CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC diabetes, obesity and atherosclerosis. The current sequence is that of a
CC human apolipoprotein B (ApoB) antisense therapy target DNA of the
CC invention. The human ApoB gene is located at chromosome 2p23-2p24.

XX Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

XX Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2203 CTGAAGAAGAACCTTCT 2219

Db 18 CTGAAGAAGAACCTTCT 2

RESULT 260

ADO32753

ID ADO32753 standard; DNA; 20 BP.

XX ADO32753;

XX 12-AUG-2004 (first entry)

XX Antisense 2'-MOE gapmer oligo targeted to human ApoB RNA - SEQ 201.

XX apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
KW antilipemic; antidiabetic; anorectic; cardiant; vasotropic; hypotensive;
KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;
KW neuroprotective; nontropic; lipid; cholesterol metabolism;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
KW obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;
KW phosphorothioate backbone; human; chromosome 2p23-2p24; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX modified_base 1..20

XX /tag= a

XX /mod_base= OTHER

XX /note= "OTHER = Phosphorothioate backbone, bases 1-5 and

XX 16-20 2'-MOE wing bases, all cytidine residues are 5-

XX methylethyldines"

XX WO2004044181-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036411.

XX 13-NOV-2002; 2002US-0426234P.

XX 15-MAY-2003; 2003WO-US015493.

XX (ISIS-) ISIS PHARM INC.

```
XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
PI WPI; 2004-420321/39.
XX
XX Antisense oligonucleotide compound that inhibits expression of mRNA
XX encoding human apolipoprotein B, useful for treating hyperlipidemia,
XX diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
XX syndrome.
XX
XX Example 29; SEQ ID NO 201; 483pp; English.
XX
XX The invention relates to a novel antisense compound where the compound
XX hybridises to and inhibits expression of mRNA encoding human
XX apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
XX confluent HepG2 cells in culture at a concentration of 150 nM. The
XX compound of the invention demonstrates cardiovascular,
XX antiarteriosclerotic, antilipemic, antidiabetic, anorectic, cardiant,
XX vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
XX endocrine, vasotropic, neuroprotective and neurotropic activities and may
XX be useful for inhibiting the expression of apolipoprotein B in cells or
XX tissues in vivo in order to address a condition associated with abnormal
XX lipid or cholesterol metabolism. The compound may be useful for
XX decreasing circulating lipoprotein levels, triglyceride levels,
XX cholesterol levels, lipid levels, fatty acid levels, acute phase
XX reactants and chylomicrons and thus may be utilised during treatment of
XX hyperlipoproteinemia, hyperlipidaemia, hypercholesterolaemia,
XX cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
XX syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
XX anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
XX impotence, obstructive liver disease, Alzheimer's disease, dementia,
XX diabetes, obesity and atherosclerosis. The current sequence is that of an
XX antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is
XX targeted to human ApoB RNA.
XX
XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2203 CTGAGAGAGAACTCTCT 2219
DB 3 CTGAGAGAGAACTCTCT 19
|||||
|||||

RESULT 261
AAQ25565
ID AAQ25565 standard; DNA; 20 BP.
XX
XX AAQ25565;
AC
XX
XX 25-MAR-2003 (revised)
DT 02-DEC-1992 (first entry)
XX
XX Dye-coupled 3'-amino modified oligonucleotide.
DE
XX
XX DNA synthesis; RNA; antisense strands; detection; ss.
KW
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 20
FT /*tag= a
FT /*note= "3-amino modified"
XX
XX EP490281-A1.
PN
XX
XX 17-JUN-1992.
PD
XX
XX 06-DEC-1991; 91EP-00120935.
PF
XX
XX 11-DEC-1990; 90DE-04039488.
PR
```

```
XX (FARH ) HOECHST AG.
PA
XX Engels J, Herrlein M, Konrad R, Mag M;
PI
XX WPI; 1992-201578/25.
XX
XX New dye-coupled modified nucleosides, nucleotides and oligonucleotides -
XX useful for synthesis of antisense DNA and RNA strands in presence of
XX template, also for in-vivo and in-vitro detection of genetic material.
XX
XX Example; Page 9; 17pp; German.
XX
XX The sequence is an example of a dye coupled 3'-amino modified oligo-
XX nucleotide, it can be used in the synthesis of DNA and RNA nucleosides,
XX nucleotides and oligonucleotides and for the synthesis of opposite
XX strands in the presence of a template strand and in fluorescence
XX microscopic and macroscopic detection in vivo and in vitro of genetic
XX material. It is labelled with a fluorescent dye. See also AAQ25566 and
XX AAQ25567. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTTCTCTCTCTCTTT 2586
DB 1 TTTTCTCTCTCTCTCTCTTT 20
|||||
|||||

RESULT 262
AAQ33554
ID AAQ33554 standard; DNA; 20 BP.
XX
XX AAQ33554;
AC
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
XX Microsatellite sequence from clone AGLA247.
DE
XX
XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX genetic mapping; traits; amplification; ss.
XX
XX Bos taurus.
OS
XX
XX WO9213102-A1.
PN
XX
XX 06-AUG-1992.
PD
XX
XX 15-JAN-1992; 92WO-US0000340.
PF
XX
XX 15-JAN-1991; 91US-00642342.
PR
XX
XX (GENW-) GENMARK.
PA
XX
XX Georges M, Massey JM;
PI
XX
XX WPI; 1992-284684/34.
DR
XX
XX Polymorphic bovine DNA markers - used in genetic identification, gene
XX mapping, and selective breeding.
FT
XX
XX Table 7; Page 150; 517pp; English.
XX
XX The sequence is that of a bovine microsatellite sequence obtd. by
XX screening a library of bovine MboI DNA fragments of between 250 and 500
XX bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
XX clones cross-hybridised. Assuming independent distribution of
XX microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
XX in the bovine genome is estimated at >100, 000. The sequence information
XX
```



```

RESULT 265
AAQ58578/c
ID AAQ58578 standard; RNA; 20 BP.
XX
AC AAQ58578;
XX
XX 25-MAR-2003 (revised)
DT 21-AUG-1994 (first entry)
XX
XX Sequence of synthetic RNA oligo which is a target nucleotide for a novel
DE receptor.
XX
XX Novel receptor; nucleic acid; transcript; oligo; ss.
XX
XX Synthetic.
OS
XX
XX WO9404194-A1.
PN
XX
PD 03-MAR-1994.
XX
PF 13-AUG-1993; 93WO-US007603.
XX
PR 14-AUG-1992; 92US-00930087.
XX
PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI Usman N, Rebek J, De Mendoza J;
XX
XX WPI; 1994-082846/10.
DR
XX
XX Transport of nucleic acid deriva. across membranes - using new receptors
PT which use salt bridging, aromatic stacking, hydrogen bonding and
PT chelation.
XX
XX Example; Table 1, page 38; 103pp; English.
XX
XX The inventors claim a method of transporting a nucleic acid deriv. across
CC a membrane which comprises using a receptor that uses salt bridg,
CC aromatic stacking, H bonding and chelation to recognise the nucleic acid
CC deriv. AAQ56305, AAQ58577-86 are nucleic acid derivs used in the
CC examples. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ
    Query Match      0.4%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. NO. 2.4e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2567 TTTCTCTCTCTTTT 2586
    |||||
    Db 20 TTTTCTCTCTCTTTT 1

RESULT 266
AAQ94205
ID AAQ94205 standard; DNA; 20 BP.
XX
XX
AC AAQ94205;
XX
XX 25-MAR-2003 (revised)
DT 24-AUG-1995 (first entry)
XX
XX Alpha-anomeric oligonucleotide ligand 1803 for oestradiol hapten.
DE
XX Oligonucleotide ligand; steroid hormone; hapten; immobilisation;
KW immunodetection; estradiol; alpha-anomer; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH misc_feature 1..21
FT /tag= b
FT /note= "the glycosidic bonds between nucleotides are all
in the alpha-anomer form"
    modified_base 20
    /tag= a
    /mod_base= OTHER
    /note= "carries a group derived ffrom aminopropanediol"

FT
FT
FT
FT
XX
XX WO9429723-A1.
PN
XX
PD 22-DEC-1994.
XX
XX 10-JUN-1994; 94WO-FR000689.
PF
XX
PR 11-JUN-1993; 93FR-00007093.
XX
XX (CROS/) CROS P.
PA (KURF/) KURFURST R.
PA (BATT/) BATTAIL N.
PA (PIGA/) PIGA N.
XX
XX CROS P, Kurfurst R, Battail N, Piga N;
PI
XX
XX WPI; 1995-036665/05.
DR
XX
XX Assay device for hapten or its specific antibodies - comprises support
PT having competitive reagent immobilised via nucleic acid ligand to improve
PT orientation and accessibility.
XX
XX Example 1; Page 10; 39pp; French.
PS
XX
XX Oligonucleotides (AAQ94201-Q94205) were synthesised for use as ligands.
CC The ligands are covalently linked to a hapten (esp. a steroid hormone) to
CC form a conjugate which is then immobilised on a solid support for
CC interaction with antibodies against the hapten. Nucleic acid ligands are
CC less likely to be recognised by the antibodies than are peptide ligands
CC and nucleic acids are also less likely to undergo intramolecular
CC organisation which interferes with accessibility of the hapten to the
CC antibodies. For immunodiagnosis of oestradiol, the active hapten
CC oestradiol-6-carboxymethoxime-N- hydroxysuccinimide ester was used.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ
    Query Match      0.4%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. NO. 2.4e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2567 TTTCTCTCTCTTTT 2586
    |||||
    Db 1 TTTTCTCTCTCTTTT 20

RESULT 267
AAQ75564
ID AAQ75564 standard; DNA; 20 BP.
XX
XX
AC AAQ75564;
XX
XX 04-AUG-1995 (first entry)
DT
XX
XX Reverse transcription primer used in cDNA analysis technique.
DE
XX Analysis; gene expression; reverse transcription; primer; cDNA;
KW aggregate; restriction enzyme; ss.
XX
XX Synthetic.
OS
XX
XX JP06303997-A.
PN
XX
PD 01-NOV-1994.
XX
XX 16-APR-1993; 93JP-00112515.
PF
XX
PR 16-APR-1993; 93JP-00112515.

```


DE	PCR primer ABCR.EXON01:R for ABCR coding sequence.
XX	ATP binding cassette; ABC transporter; ABCR; Stargardt Disease; therapy;
KW	Fundus Flavimaculatus; age-related macular degeneration; diagnosis;
KW	PCR primer; ss.
XX	
OS	Synthetic.
OS	Homo sapiens.
XX	
PN	WO9837764-A1.
XX	
XX	03-SEP-1998.
XX	
XX	27-FEB-1998; 98WO-US003895.
PF	
XX	
XX	27-FEB-1997; 97US-0039388P.
PR	
XX	
PA	(BAYU) BAYLOR COLLEGE MEDICINE.
PA	(UJUV) UNIV JOHNS HOPKINS.
PA	(USSH) US DEPT HEALTH & HUMAN SERVICES.
PA	(UTAH) UNIV UTAH.
XX	
XX	Allikmets R, Anderson KL, Dean M, Leppart M, Lewis RA, Li Y;
PI	Lupski JR, Nathans J, Rattner A, Shroyer NF, Singh N, Smallwood PW;
PI	Sun H;
XX	
DR	WPI; 1998-495375/42.
XX	
XX	Retina-specific ATP-binding cassette transporter and DNA - useful for,
PT	e.g. diagnosis and treatment of macular degeneration, such as in
PT	Stargardt Disease, Fundus Flavimaculatus and age-related degeneration.
XX	
PS	Claim 41; Page 29; 79pp; English.
XX	
CC	This sequence represents a PCR primer for DNA encoding the human retina
CC	specific ATP binding cassette transporter (ABCR) of the invention. ABCR
CC	may be used in compositions for screening agents that alters ABCR. The
CC	agent can inhibit Stargardt Disease, Fundus Flavimaculatus and age-
CC	related macular degeneration (MD). Primers (such as this sequence) and
CC	probes for the ABCR DNA can be used in a diagnostic kit for detecting MD
XX	
XX	Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
XX	
XX	Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX	Best Local Similarity 85.0%; Pred. NO. 2.4e+02;
XX	Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps
Qy	: 1296 GTTTGGTGTGCGAGAGCTTC 1315
Db	20 GCTTGTGTCGAGAGAGCTTC 1
RESULT 272	
AAT86606	
ID	AAT86606 standard; DNA; 20 BP.
XX	
AC	AAT86606;
XX	
DT	04-JUN-1998 (first entry)
XX	
DE	Oligonucleotide separated by capillary affinity gel electrophoresis.
XX	
KW	Capillary affinity gel electrophoresis; separation; polymer-gel;
KW	polyacrylamide; ss.
XX	
XX	Synthetic.
OS	
PN	WO9745721-A1.
XX	
PD	04-DEC-1997.
XX	
XX	23-MAY-1997; 97WO-EP002647.
XX	

```

RESULT 270
AAV34591/c
ID AAV34591 standard; DNA; 20 BP.
XX
XX AAV34591;
XX
XX AC
XX AC
XX 25-AUG-1998 (first entry)
XX
XX M. vaccae antigenic sequence hybridising oligo AD12.
XX
XX Mycobacterium vaccae; antigen; therapy; prevention; cytokine production;
XX M. avium; M. tuberculosis; immune response enhancer; cell proliferation;
XX mycobacteria infection; vaccine; cancer; ss.
XX
XX Synthetic.
XX OS Mycobacterium vaccae.
XX WO9808542-A2.
XX
XX 05-MAR-1998.
XX
XX 28-AUG-1997; 97WO-NZ000105.
XX
XX 29-AUG-1996; 96US-00705347.
XX 12-JUN-1997; 97US-00873970.
XX
XX (GENE-) GENESIS RES & DEV CORP.
XX PA
XX Tan P, Hiyama J, Visser E, Skinner MA, Scott LM, Prestidge RL;
XX WPI; 1998-216926/19.
XX
XX Mycobacterium vaccae polypeptides - used to develop products for use in
XX detection, therapy and prevention of mycobacteria infections or as immune
XX response enhancers.
XX
XX Example 8; Page 99; 153pp; English.
XX
XX This oligonucleotide is used in the DNA cloning strategies of the
XX Mycobacterium vaccae antigens. The invention provides M. vaccae
XX polypeptides that comprise an immunogenic portion of a soluble M. vaccae
XX antigen, or a variant, where the antigen induces an immune response in
XX patients previously exposed to a mycobacterium. Such M. vaccae
XX polypeptides can be used in methods for enhancing non-specific immune
XX response. The methods and products can be used for the detection,
XX treatment and prevention of infectious diseases caused by mycobacteria
XX such as M. vaccae, M. avium or M. tuberculosis. The products also have
XX the ability to induce cell proliferation and cytokine production (e.g. B
XX interferon-gamma and interleukin-12 production) in T cells, NK cells, B
XX cells, or macrophages. They can be used for enhancing immune responses
XX for use in vaccines or immunotherapy of infectious diseases and cancers
XX
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e-02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0
Qy 2567 TTTCTCTCTCTTTTCTTTT 2586
Db 20 TTTTCTTTTCTTTTCTTTT 1
RESULT 271
AAV08230/c
ID AAV08230 standard; DNA; 20 BP.
XX
XX AAV08230;
XX
XX AC
XX AC
XX 27-JAN-1999 (first entry)
XX
XX

```

```

PR 24-MAY-1996; 96CH-00001320.
XX (NOVS ) NOVARTIS AG.
XX
XX Muscate A, Paulus A, Natt F;
XX WPI; 1998-041763/04.
XX
XX Separation of electrically charged target molecules - by capillary
PT affinity gel electrophoresis using polymer-gel to which receptors for
PT target molecules are bound.
XX
XX Example D3; Page 25; 41pp; English.
XX
XX A mixture of oligonucleotides (AAT8604-7) were separated by a new
CC process using capillary affinity gel electrophoresis. The invention
CC relates to selective separation of electrically charged target molecules
CC in an analytical mixture. It comprises capillary affinity gel
CC electrophoresis using a capillary tube which is at least partly filled
CC with a polymer gel. Receptors for target molecules are covalently bound
CC to the polymer. An electric field of at least 50 volts/cm is applied. The
CC capillary tube is charged with the analytical mixture. In a first
CC separation stage, the target molecules in the mixture are bound to the
CC receptors and the remaining components are eluted, optionally whilst
CC splitting open. In a second stage, the elution conditions are changed,
CC optionally in stages, so that the affinity of the target molecules for
CC the receptor is eliminated and the target molecules are eluted and
CC detected, optionally whilst splitting open. The process is useful for
CC selective separation and/or determination of charged organic compounds,
CC such as oligonucleotides, peptides or carbonydrates. It may be used, e.g.
CC for isolation of specific proteins and DNA molecules, purification of
CC antibodies, analysis of antisense compounds or screening for enzyme
CC inhibitors. The process achieves higher resolution and selectivity than
CC prior art processes, especially in the case of complex biological
CC analytical mixtures. It has high sensitivity, even with small amounts of
CC samples. The derivatised polymers may be synthesised specifically using
CC standard methods
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0
QY 2567 TTCTCTCTCTCTCTCTCTCTTTT 2586
Db ||| ||| ||| ||| ||| ||| |||
1 TTTTCTCTCTCTCTCTCTCTCTTTT 20
RESULT 273
AAK15776
ID AAK15776 standard; cDNA to mRNA; 20 BP.
XX
XX AAK15776;
XX
XX 07-MAY-1999 (first entry)
DT
XX
XX Antisense oligonucleotide targeted to upstream sequence of VEGF.
DE
XX Vascular endothelial cell growth factor; VEGF; antisense oligonucleotide;
KW solid tumor growth; anticancer agent; rheumatic arthritis;
KW diabetic retinitis; ss.
XX
XX Synthetic.
OS
XX JP11042091-A.
XX PN
XX 16-FEB-1999.
PD
XX 25-JUL-1997; 97JP-00213838.
XX PF
XX 25-JUL-1997; 97JP-00213838.
XX PR
XX

```



```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2216 TTCTCTCTCTCTCTCTCTCTC 2235
Db 20 TTCTCTCTCTCTCTCTCTCTC 1

RESULT 275
AAZ02574/C
ID AAZ02574 standard; RNA; 20 BP.
XX
AC AAZ02574;
XX
DT 07-OCT-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW paratrachoma; inclusion conjunctivitis; genital disease; perihhepatitis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS Synthetic.
OS Chlamydia trachomatis.
XX
PN WO9928475-A2.
XX
PD 10-JUN-1999.
XX
PF 27-NOV-1998; 98WO-IB001939.
XX
PR 28-NOV-1997; 97FR-00015041.
PR 17-DEC-1997; 97FR-00016034.
PR 04-NOV-1998; 98US-0107077P.
XX
PA (GEST ) GENSET.
XX
PI Griffais R;
XX
DR WPI; 1999-371125/31.
XX
PT Genome sequence of Chlamydia trachomatis.
XX
PS Disclosure; Page 1536; 1755pp; English.
XX
CC PCR primers AAZ01426-206209 were used to amplify open reading frames
CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as
CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis;
CC epididymitis, cervicitis, salpingitis, perihhepatitis, bartholinitis;
CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
XX
SQ Sequence 20 BP; 6 A; 10 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3283 TTGTCAGGGGGAAGAGGGGG 3302
Db 20 TTGTTAGGGGAAGTATGGG 1

RESULT 277
AAZ04587
ID AAZ04587 standard; DNA; 20 BP.
XX
AC AAZ04587;
XX
DT 07-OCT-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
```

```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2216 TTCTCTCTCTCTCTCTCTCTC 2235
Db 20 TTCTCTCTCTCTCTCTCTCTC 1

RESULT 275
AAZ27533
ID AAX27533 standard; RNA; 20 BP.
XX
AC AAX27533;
XX
DT 27-MAY-1999 (first entry)
XX
DE Synthetic RNA sequence produced by the method of the invention.
XX
KW silyloxymethyl; phosphonate; silyloxymethyl halide; diagnosis; ss;
KW cyanoethyl phosphoramidate coupling; isomerisation; steric hindrance.
XX
OS Synthetic.
XX
PN WO9909044-A1.
XX
PD 25-FEB-1999.
XX
PF 17-AUG-1998; 98WO-BF005215.
XX
PR 18-AUG-1997; 97CH-00001931.
XX
PA (PITS/) PITSCH S.
PA (WEIS/) WEISS P A.
PA (JENN/) JENNY L.
XX
PI Pitsch S, Weiss PA, Jenny L;
XX
DR WPI; 1999-180963/15.
XX
PT 2-silyloxymethyl ribonucleosides and their phosphonate derivatives - have
PT high purity, use in machine synthesis of ribonucleic acids, enable longer
PT oligonucleotide chain construction, and larger amounts.
XX
PS Example 6; Page 25; 38pp; English.
XX
CC The invention relates to silyloxymethyl protected D- or L-ribonucleosides
CC and their phosphonates (I), and silyloxymethyl halides (II). (I) are
CC intermediates for synthesis of RNA-oligonucleotides with predetermined
CC nucleotide sequence, particularly by machine synthesis. The groups
CC specified above, apart from those on silyl, are those particularly for
CC the cyanoethyl phosphoramidate coupling. Uses of the oligoribonucleotide
CC products in diagnosis, therapy, and as research tools, are well known,
CC and are not dealt with in detail. (II) is an intermediate for (I). The
CC silyloxymethyl halide reagent is easy to prepare, and yields are high.
CC Introduction of the silyloxymethyl group into the ribonucleoside is
CC simple and rapid, and the acetal bond formed does not migrate,
CC eliminating particularly the prior art problem of 2' to 3' isomerisation.
CC The methylenedioxy group spacer between the silyl group and nucleoside
CC ring results in less steric hindrance than bulky direct silyloxy
CC linkages, enabling first, a range of choices for the silyl substituents,
CC to provide, e.g., acid or base stability; and second, higher yields in
CC coupling. Purer products are therefore obtained than in prior art.
CC enabling larger quantities and longer chains of oligoribonucleotides to
CC be synthesised successfully, and in shorter times
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 0 T; 20 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 2.4e+02;
Matches 0; Conservative 17; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db 1 UUUUUUUUUUUUUUUUUUUU 20
```

XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW paratrachoma; inclusion conjunctivitis; genital disease; perihhepatitis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX Synthetic.
OS Chlamydia trachomatis.
XX WO9928475-A2.
XX 10-JUN-1999.
XX 27-NOV-1998; 98WO-IB001939.
XX 28-NOV-1997; 97FR-00015041.
XX 17-DEC-1997; 97FR-00016034.
XX 04-NOV-1998; 98US-0107077P.
XX (GBST) GENSET.
XX Griffais R;
XX WPI; 1999-371125/31.
XX Genome sequence of Chlamydia trachomatis.
XX Disclosure; Page 1701; 1755pp; English.
XX PCR primers AA201426-206209 were used to amplify open reading frames
CC (ORFs) of the genome of Chlamydia trachomatis (see AA201425). These ORFs
CC encode polypeptides (see AA36754-Y37949) which can be used as vaccines
CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as
CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis,
CC epididymitis, cervicitis, salpingitis, perihhepatitis, bartholinitis;
CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
XX
XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1371 GAGAGCCCTTAAGCAGTGAA 1390
Db 1 GTGAGCTCCTTAAGCAGTGAA 20

RESULT 278
AA211326/C
ID AA211326 standard; DNA; 20 BP.
XX
XX AA211326;
AC
XX
XX 25-OCT-1999 (first entry)
DT
XX
DE Mycobacterial 16S rRNA specific oligo AD12.
XX
XX Mycobacterium vaccae protein; antigen; T cell activation; cytokine;
KW dendritic cell maturation; infectious disease; immune disorder; cancer;
KW respiratory system; mycobacterial infection; allergy; tuberculosis;
KW leprosy; sarcoidosis; lung cancer; asthma; skin disorder; psoriasis;
KW dermatitis; eczema; alopecia areata; skin cancer; basal carcinoma;
KW squamous cell carcinoma; melanoma; PCR primer; ss.
XX
XX Synthetic.
OS Mycobacterium vaccae.
XX

PN WO9932634-A2.
XX
PD 01-JUL-1999.
XX
XX 23-DEC-1998; 98WO-NZ000189.
XX
PR 23-DEC-1997; 97US-00996624.
PR 23-DEC-1997; 97US-00997080.
PR 23-DEC-1997; 97US-00997382.
PR 11-JUN-1998; 98US-00095855.
PR 17-SEP-1998; 98US-00156181.
PR 04-DEC-1998; 98US-00205426.
XX
XX (GENE-) GENESIS RES & DEV CORP LTD.
XX
XX Tan P, Watson J, Visser ES, Skinner MA, Prestidge RL;
XX WPI; 1999-430163/36.
XX
XX Enhancing immune response to an antigen.
XX
XX Example 15; Page 177; 243pp; English.
XX
XX The invention provides heat-killed Mycobacterium vaccae, or recombinant
CC M. vaccae proteins. The M. vaccae proteins may be employed to activate T
CC cells and natural killer cells, to stimulate the production of cytokines,
CC to enhance the expression of co-stimulatory molecules on dendritic cells
CC and monocytes, and to enhance dendritic cell maturation and function. The
CC proteins can be expressed by standard recombinant methodology.
CC Pharmaceutical compositions comprising the proteins or nucleic acid
CC sequences encoding the proteins can be used for the treatment,
CC prevention, and detection of disorders including infectious diseases,
CC immune disorders and cancer. In particular, the compounds and methods are
CC used for treatment of diseases of the respiratory system, such as
CC mycobacterial infections, asthma, allergies, tuberculosis, leprosy,
CC sarcoidosis and lung cancers, and disorders of the skin such as
CC psoriasis, atopic dermatitis, eczema, allergic contact dermatitis, cell
CC alopecia areata, and skin cancers such as basal carcinoma, squamous cell
CC carcinoma and melanoma
XX
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTTCTTCTTCTTCTTCTT 2586
Db 20 TTTTCTTCTTCTTCTTCTTCTTCTT 1

RESULT 279
AA238193
ID AA238193 standard; DNA; 20 BP.
XX
XX AA238193;
AC
XX
XX 04-JUN-1999 (first entry)
DT
XX
DE Primer SEQ ID NO:349.
XX
XX Human; histocompatibility locus antigen; HLA; determination; allele;
KW HLA-B typing; PCR; HLA class I; cis/trans linkage resolution; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9907883-A1.
XX
XX 18-FEB-1999.
XX
XX 11-AUG-1998; 98WO-CA000768.
XX

PR 11-AUG-1997; 97US-00909290.
 XX (VISI-) VISIBLE GENETICS INC.
 PA (BLAS/) BLASZYK R H.
 XX Blaszcyk RH, Leushner J;
 DR WPI; 1999-167446/14.
 XX Determination of HLA class I group type of a subject - using group
 PT specific untranslated region primer pair.
 XX Example; Page 35; 195pp; English.
 XX The present invention describes a method using novel primers involving
 CC the PCR-based determination of histocompatibility locus antigen B (HLA-B)
 CC Class I group type. Determining the HLA-B Class I group type of a subject
 CC comprises: (i) combining a group-specific untranslated region primer pair
 CC with a target DNA sample from the subject under conditions such that
 CC primer-based amplification of the target DNA may occur; and (ii)
 CC determining whether a nucleic acid product is produced by the
 CC amplification; where the ability of the primer pair to produce a nucleic
 CC acid product is associated with a particular HLA group type. The method
 CC can be used for HLA-B typing. In the method, the initial group specific
 CC amplification allows a PCR based separation of haplotypes in 95% of
 CC patient samples. It permits the resolution of cis/trans linkages of
 CC heterozygote sequencing results which cannot be achieved with other
 CC protocols. AAX37845 to AAX38286 represent DNA sequence used in the
 CC exemplification of the present invention
 XX Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2191 TCCATCTTCTTCTCGAAGA 2210
 DB 1 TCCATGTCTCTCTCGAAGCA 20
 RESULT 280
 AAZ45859
 ID AAZ45859 standard; DNA; 20 BP.
 XX AAZ45859;
 AC AAZ45859;
 XX 25-APR-2000 (first entry)
 DT PCR primer F971RAP used to amplify a portion of the RAP3 gene.
 DE RAP3; regeneration association protein 3; liver regeneration;
 KW liver proliferation; PCR primer; ss.
 XX Homo sapiens.
 OS WO200003013-A2.
 XX 20-JAN-2000.
 PD 12-JUL-1999; 99WO-EP004938.
 XX 10-JUL-1998; 98EP-00202336.
 PR (AMST-) AMSTERDAM MOLECULAR THERAPEUTICS BV.
 PA Chamuleau RAFM, Groenink M, Van Der Vliet HN, Leegwater ACJ;
 PI WPI; 2000-147615/13.
 DR Isolated RAP3 gene, protein and antibody useful for diagnosing liver
 XX regeneration and/or cell proliferation.
 PT

PS Disclosure; Page 3; 42pp; English.
 XX AAZ45854-71 represent PCR primers, derived from the human RAP3 cDNA
 CC sequence. The RAP3 (regeneration association protein 3) gene is involved
 CC in regeneration processes of the liver. The RAP3 gene was found to be
 CC upregulated 6 hours after partial hepatectomy, after which it is
 CC downregulated. The PCR primers are useful for detecting nucleotide
 CC sequences in a source material. The RAP3 cDNA sequence is useful as a
 CC marker of liver proliferation. The RAP3 protein is useful for the
 CC diagnosis of liver regeneration and liver cell proliferation. RAP3
 CC antibodies, PCR primers and probes are useful for detecting the
 CC occurrence of liver cell proliferation in a patient. The RAP3 protein is
 CC also useful for enhancing the growth of regeneration of liver tissue
 CC comprising treating the liver tissue such as extracorporeal or
 CC intracorporeal
 XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2279 CCCCTCCATCTCCAGAGTTGG 2298
 DB 1 CGCCTTCGCTCCAGAGTTGG 20
 RESULT 281
 AAA40449/C
 ID AAA40449 standard; DNA; 20 BP.
 XX AAA40449;
 AC AAA40449;
 XX 13-NOV-2000 (first entry)
 DT Electrochemical detection method sample DNA target.
 DE Electrochemical detection; glucose; cholesterol; urea nitrogen;
 KW bilirubin; uric acid; haemoglobin; lactic acid; body fluid; blood;
 KW plasma; serum; urine; lymph diagnosis; ss.
 XX Synthetic.
 OS EPI018646-A2.
 XX 12-JUL-2000.
 PD 07-JAN-2000; 2000EP-00100126.
 PF 06-JAN-1999; 99JP-00001111.
 PR 24-MAY-1999; 99JP-00143599.
 XX (FUJF) FUJIFILM CO LTD.
 PA Ogawa M, Takenaka S, Takagi M;
 PI WPI; 2000-444372/39.
 DR Quantitative analysis of a biochemical compound such as glucose, in body
 XX a body fluid such as blood, comprising detecting enhanced electron
 PT transfer between an oxidase and a DNA-immobilized electrode, useful for
 PT diagnosis of disease.
 XX Example 1; Page 8; 14pp; English.
 PS This invention describes a novel method for quantitatively analysing a
 CC biochemical compound (I) which comprises contacting (I) with double
 CC stranded DNA fixed to the surface of an electrode at their terminals in
 CC which electrochemically active threading intercalators are intercalated,
 CC in an aqueous medium under application of electric potential to the
 CC electrode in the presence of an oxidase which oxidizes the biochemical
 CC compound and becomes reduced, and detecting electric current flowing
 CC between the electrode and a second electrode in the aqueous medium. The

method is useful for detection of biochemical compounds such as glucose, cholesterol, urea nitrogen, bilirubin, uric acid, haemoglobin and lactic acid in body fluids such as whole blood, plasma, serum, urine, and lymph for diagnosis of various diseases. The method allows detection of biochemical compounds quickly and easily with a high sensitivity using a simple apparatus. This sequence represents DNA fragment used as a target sample in the method of the invention

SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels

Qy	2567	TTTCTCTCTCTTTT	2586
pB	20	TTTTTTTTTTTTTTTT	1

RESULT 282

AAA40448
ID AAA40448 standard: DNA: 20 BP.

XX
AC
AAA40448:XX
DT 13-NOV-2000 (first entry)XX
DE
Electrochemical detection method fixed probe DNA.

Electrochemical detection; glucose; cholesterol; urea nitrogen; bilirubin; uric acid; haemoglobin; lactic acid; body fluid; blood; plasma; serum; urine; lymph diagnosis; probe; ss.

XX	Synthetic.
OS	Synthetic.

PN EP1018646-A2

12-JUL-2000.

07-JAN-2000; 2000EP-0010012

PR 06-JAN-1999; 99JP-00001111.

PR 24-MAY-1999; 99JP-00143599.

PA (FUJF) FUJI PHOTO FILM CO LTD.

PI Ogawa M, Takenaka S, Takagi M;

DR WPI; 2000-444372/39.

Quantitative analysis of a biochemical compound such as glucose, in body
a body fluid such as blood, comprising detecting enhanced electron
transfer between an oxidase and a DNA-immobilized electrode, useful for
diagnosis of disease.

PS Example 1: Page 7: 14pp: English.

This invention describes a novel method for quantitatively analysing a biochemical compound (I) which comprises contacting (I) with double stranded DNA fixed to the surface of an electrode at their terminals in which electrochemically active threading intercalators are intercalated, in an aqueous medium under application of electric potential to the electrode in the presence of an oxidase which oxidizes the biochemical compound and becomes reduced, and detecting electric current flowing between the electrode and a second electrode in the aqueous medium. The method is useful for detection of biochemical compounds such as glucose, cholesterol, urea nitrogen, bilirubin, uric acid, haemoglobin and lactic acid in body fluids such as whole blood, plasma, serum, urine, and lymph for diagnosis of various diseases. The method allows detection of biochemical compounds quickly and easily with a high sensitivity using a simple apparatus. This sequence represents DNA fragment used as fixed probe DNA in the method of the invention

33X

SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 3; Indels

Qy 2567 TTTCTCTCTCTTTTTTTT 2586
pB 1 TTTTTTTTTTTTTTTTTTTT 20

RESULT 283

AAA55738
ID AAA55738 standard; DNA; 20 BP.

AA
AC AAA55738:

30-AUG-2000 (first entry)

XX DE TRAF1 antisense oligonucleotide ISIS# 101889.

XX Tumour necrosis factor receptor-associated factor; TRAF; human;
KW antisense oligonucleotide; phosphorothioate; antiproliferative;
KW anti-inflammatory; E-selectin; jun kinase; ss.
KW

XX
QS
synthetic

XX PN WO200020435-A1.

XX
PD
13-APR-2000.

AA 05-OCT-1999: 99WO-US023171.

PR 06-OCT-1998: 98US-00167109.

PA (ISIS-) ISIS PHARM INC.

PI Baker BF, Cowsert LM, Monia BP, Xu XS;

DR WPI; 2000-303732/26.

Antisense oligonucleotides targeted to nucleic acids encoding human tumor necrosis factor receptor-associated factor (TRAF), useful for treating diseases associated with TRAF expression such as inflammatory diseases.

XX
PS Example 33: Page 100; 170pp; English.

CC The present invention relates to antisense oligonucleotides (see ARA55496
CC A55757) which are targeted to nucleic acids encoding a human tumour
CC antisense factor receptor-associated factor (TRAF). The antisense
CC sequences comprise at least one modified internucleotide linkage, which
CC is a phosphorothioate linkage. The oligonucleotides also include at least
CC one modified sugar moiety such as a 2'-O-methoxyethyl sugar moiety.
CC Sequences ARA55490-A55495 represent nucleotide sequences encoding human
CC TRAF1-6. Included in the invention is a method for treating a human
CC having a disease associated with the expression of TRAF comprising
CC administering an antisense oligonucleotide. The reduction of jun kinase
CC activation in cells comprises contacting the cells with an antisense
CC oligonucleotide targeted to TRAF-6. A method for the reduction of E-
CC selectin expression in cells or tissues comprises contacting the cells or
CC tissues with an antisense oligonucleotide targeted to TRAF-2 or TRAF-6.
CC The antisense oligonucleotides have antiproliferative and anti-
CC inflammatory activity and are useful for treating disorders associated
CC with cell proliferation and inflammation. The antisense oligonucleotides
CC may also be used as a diagnostic probe for studying gene function

Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other; 0 X

Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 2.4e+02;		
Matches 17:	Conservative	0;	Mismatches 3;	Indels

Qy 2724 CTCTGCCAGAAGCAGCTCCT 2743

PR	29-APR-1999;	99US-0131830P.
PPR	03-MAR-2000;	2000US-0186845P.
XX		
XX	(CPGI-) CPG IMMUNOPHARMACEUTICALS GMBH.	
PPA	(IOWA) UNIV IOWA RES FOUND.	
PPA		
XX		
XX	Noll BO, Schetter C, Krieg AM;	
PI	WPI; 2001-016002/02.	
XX		
DR		
XX		
PPT	Immunostimulatory DNA binding proteins to identify immunostimulatory DNA functional modifiers, immunostimulatory DNA binding competitors and to optimize immunostimulatory oligodeoxynucleotides for stimulation.	
PT		
PT		
XX	Example 1; Page 45; 95pp; English.	
PS		
XX	The invention relates to the use of an immunostimulatory single-stranded DNA-binding protein in screening assays to identify compounds which bind to it and thereby act as functional modifiers of immunostimulatory oligodeoxynucleotide (ODN) activity. Such modifiers of ODN activity consist of immunostimulatory DNA binding inhibitors, immunostimulatory DNA mimics, and immunostimulatory DNA agonists and antagonists.	
CC	Immunostimulatory DNA-binding proteins can also be used in screening methods to identify immunostimulatory DNA binding competitors, and to optimize an immunostimulatory ODN for immune stimulation. Isolated complexes of an immunostimulatory DNA-binding protein bound to an immunostimulatory ODN can additionally be used to screen a panel of candidate target molecules to identify the cellular target molecules of the immunostimulatory ODN. The immunostimulatory DNA-binding proteins used in the methods of the invention are the RNA-binding proteins nucleolin, hnRNP D, AUF1, hnRNP A1 and lupus La protein. The screening methods are useful for identifying a compound that inhibits interaction between immunostimulatory DNA and an immunostimulatory DNA-binding protein and for identifying agonists useful in immunotherapy. The complex is useful in screening for immunostimulatory DNA cellular target molecules. The candidate immunostimulatory ODN competitors allow the investigation of structure/activity relationships of immunostimulatory DNA-binding proteins and immunostimulatory ODNs. The present sequence represents an oligonucleotide used in an exemplification of the invention	
XX	Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;	
SQ		
	Query Match 0.4%; Score 15.2; DB 1; Length 20;	
	Best Local Similarity 85.0%; Pred. No. 2.4e+02;	
	Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
QY	2567 TTCTCTTCTTTTTTTT 2586	
DB	1 TTTTTTTTTTTTTTTTTT 20	
RESULT 291		
AAS10402		
ID	AAS10402 standard; DNA; 20 BP.	
XX		
AC	AAS10402;	
XX		
DT	24-OCT-2001 (first entry)	
XX		
DE	DNA template for 3' end labeling of an RNA molecule, #14.	
DE	3' RNA end labeling; DNA template; Okazaki fragment; 5' overhang; ss.	
XW	Synthetic.	
XX		
OS	US6238865-B1.	
XX		
PN	29-MAY-2001.	
XX		
PD	16-OCT-1998; 98US-00173936.	
XX		
PF	17-OCT-1997; 97US-0063757P.	
PR		
XX		

CC	(II)), by preparing (A') containing a reactive function at the position
CC	'at which (B') is to be bonded, preparing (B') and reacting (A') and (B');
CC	and (ii) the use of aryl groups (II) (optionally bonded via a chemical
CC	group) for transporting (A) across biological membranes. The products of
CC	the invention have cytostatic, virucide, vasotropic, dermatological,
CC	antiporiatic and antiasthmatic activity and can be used for gene
CC	therapy. Conjugation of (A) with (B) is useful for transporting (A)
CC	across biological membranes or into eukaryotic or prokaryotic cells
CC	(specifically bacterial, yeast or mammalian cells, including human cells,
CC	particularly tumor cells). Medicaments, diagnostic agents and test kits
CC	containing (I) are also claimed. Typically (I) are antisense
CC	oligonucleotide derivatives for tumor therapy; oligonucleotide drugs for
CC	treating viral infections or diseases associated with integrins or cell-
CC	cell interactions (e.g. restenosis, vitiligo, psoriasis or asthma); or
CC	labeled oligonucleotides for in vivo diagnostic use, e.g. by in situ
CC	hybridization. Conjugation with (B) markedly improves the cellular uptake
CC	of (A), e.g. in tumor cells. (B) include fluorescein derivative residues,
CC	in which case the conjugates (I) are fluorescently labeled, allowing
CC	macroscopic monitoring of cellular uptake etc. The cellular uptake of (I)
CC	is superior to that obtained using other conjugated groups related to
CC	(II); e.g. oligonucleotides conjugated with fluorescein diacetate (within
CC	the scope of (B)) have superior uptake to corresponding fluorescein
CC	conjugates
XX	
SQ	Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
	Query Match 0.4%; Score 15.2; DB 1; Length 20;
	Best Local Similarity 85.0%; Pred. No. 2.4e+02;
	Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0
Qy	2567 TTCTTCTTTCTTTTTTTTTTTT 2586
Db	
	20 TTTTNTTTTTTTTTTTTTTTTTT 1
RESULT 294	
AASG3428/c	
ID	AASG3428 standard; DNA; 20 BP.
XX	
AC	AASG3428;
XX	
DT	29-JAN-2002 (first entry)
XX	
DE	Oligonucleotide-nanoparticle probe #52.
XX	
KW	Oligonucleotide-nanoparticle probe; diagnostic; forensic analysis;
KW	nucleic acid detection; nanostructure; biochip; biofilter; drug delivery;
KW	ss.
OS	Synthetic.
XX	
PN	WO200173123-A2.
XX	
PD	04-OCT-2001.
XX	
Pf	28-MAR-2001; 2001WO-US010071.
XX	
PR	28-MAR-2000; 2000US-0192699P.
FR	26-APR-2000; 2000US-0200161P.
PR	26-JUN-2000; 2000US-00603830.
PR	26-JUN-2000; 2000US-0213906P.
PR	08-DEC-2000; 2000US-0254392P.
PR	11-DEC-2000; 2000US-0255235P.
PR	12-JAN-2001; 2001US-00760500.
PR	28-MAR-2001; 2001US-00820279.
PA	(NANO-) NANOSPHERE INC.
XX	
PI	Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
PI	Taton TA, Park S, Li Z;
XX	
DR	WPI; 2001-656926/75.
XX	

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 342 GAAGAGGAAGACCGGATTG 361
DB 1 GAAGAGGAAGACCGGCTGTG 20

RESULT 297
AAS10578/c
ID AAS10578 standard; DNA; 20 BP.
XX
AC AAS10578;
XX
DT 24-OCT-2001 (first entry)
XX
DE Human caspase 3 antisense oligonucleotide 108902.
XX
KW Human; caspase 3; apoptosis; hyperproliferative disorder; hepatitis;
KW viral infection; haematopoietic disorder; autoimmune disorder;
KW atherosclerosis; neurological disorder; antisense; phosphorothioate; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate internucleotide linkages.
FT Some bases especially bases 1-5 and bases 16-20 are 2'-
FT methoxyethyl (2'-MOE) bases, bases 6-15 are 2'-
FT deoxynucleotides and all cytidine bases are 5'-
FT methylcytidines"
XX
XX WO200153310-A1.
XX
XX 26-JUL-2001.
XX
XX 11-JAN-2001; 2001WO-US000888.
XX
XX 18-JAN-2000; 2000US-00484617.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Zhang H, Cowser LM;
XX
XX WPI; 2001-442252/47.
XX
XX New antisense compound to inhibit caspase 3 is useful for treating
XX hepatitis and atherosclerosis.
XX
XX Claim 3; Page 84; 127pp; English.
XX
XX The present sequence for human caspase 3 antisense oligonucleotide 108902
XX is 1 of various novel antisense oligonucleotides (AAS10517-AAS10676)
XX described in the present invention. Also described are methods of using
XX these compounds for the modulation of caspase 3 expression. The caspase 3
XX antisense oligonucleotides specifically hybridise with and inhibit the
XX expression of caspase 3. Antisense compounds targeted to caspase 3 are
XX useful to inhibit caspase 3 expression in cells or tissues and to
XX modulate apoptosis. The caspase 3 antisense oligonucleotides are useful
XX for treating disorders associated with expression of caspase 3. Such
XX disorders include hyperproliferative disorders (e.g. cancer), viral
XX infections (e.g. hepatitis), haematopoietic disorders, autoimmune
XX disorders, atherosclerosis and neurological disorders (e.g. Alzheimer's
XX disease)
XX
SQ Sequence 20 BP; 5 A; 1 C; 3 G; 11 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 586 AACATATATAAAGACAACT 605
DB 20 AACATATGAAATACAACTT 1

RESULT 298
AAS10371/c
ID AAS10371 standard; DNA; 20 BP.
XX
AC AAS10371;
XX
DT 24-OCT-2001 (first entry)
XX
DE Oligonucleotide-cyclic disulphide linker, d.
XX
KW Nanoparticle; cyclic disulphide-oligonucleotide; DNA detection;
KW DNA isolation; genetic disease; bacterial disease; viral disease;
KW forensic science; paternity testing; gene therapy; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1
FT /*tag= a
FT /note= "A is covalently linked to a cyclic-disulphide
FT moiety"
XX
XX WO200151665-A2.
XX
XX 19-JUL-2001.
XX
XX 12-JAN-2001; 2001WO-US001190.
XX
XX 13-JAN-2000; 2000US-0176409P.
XX 26-APR-2000; 2000US-0200161P.
XX 26-JUN-2000; 2000US-00603830.
XX 12-JAN-2001; 2001US-00760500.
XX
XX (NANO-) NANOSPHERE INC.
XX
XX Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
XX Taton TA, Li Z;
XX
XX WPI; 2001-451868/48.
XX
XX Detecting a nucleic acid useful in e.g. diagnosing genetic, bacterial or
XX viral diseases, by contacting the nucleic acid with oligonucleotides
XX attached to nanoparticles and having sequences complementary a portion of
XX the nucleic acid.
XX
XX Example 24; Fig 44; 323pp; English.
XX
XX The sequence represents a cyclic disulphide linked oligonucleotide which
XX may be coupled with colloidal gold particles (nanoparticles) and used to
XX demonstrate the method of the invention. The invention relates to
XX isolating or detecting a nucleic acid of interest, in a mixture of
XX nucleic acids, by binding it to 2 or more complimentary nucleotides which
XX have a nanoparticle attached to their 5' ends. The nanoparticles (e.g.
XX colloidal gold) are used to both isolate and detect (e.g. by linking the
XX particle to a fluorescent probe) the resultant complex. The methods are
XX useful for detecting nucleic acids, natural or synthetic, and modified or
XX unmodified. The methods may also be applied in the diagnosis of genetic,
XX bacterial and viral diseases, in forensics, in DNA sequencing, for
XX paternity testing, for cell line authentication, and for monitoring gene
XX therapy. The methods are further useful in research and analytical
XX laboratories in DNA sequencing, in the field to detect the presence of
XX specific pathogens, for quick identification of an infection to assist in
XX drug prescription, and in homes and health centres for inexpensive first-
XX line screening. The methods, which are based on observing colour change
XX with the naked eye, are cheap, fast, simple, robust (reagents are
XX stable), do not require specialised or expensive equipment, and little or


```

XX AAF99431;
AC
XX 12-JUN-2001 (first entry)
DT
XX Immunostimulatory nucleic acid #547.
DE
XX Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW immunostimulatory; tumour; viral infection; bacterial infection;
KW fungal infection; parasitic infection; cancer; asthma;
KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX Synthetic.
OS
XX WO200122972-A2.
PN
XX 05-APR-2001.
PD
XX 25-SEP-2000; 2000WO-US026383.
PF
XX 25-SEP-1999; 99US-0156113P.
PR
XX 27-SEP-1999; 99US-0156135P.
PR
XX 23-AUG-2000; 2000US-0227436P.
XX
XX (IOWA ) UNIV IOWA RES FOUND.
PA (COLE-) COLEY PHARM GMBH.
XX
XX Krieg AM, Schetter C, Vollmer J;
PI
XX WPI; 2001-273485/28.
DR
XX Vaccinating against tumors, infectious diseases, allergies and asthma
PT using immunostimulatory Py-rich and TG nucleic acids.
XX
XX Claim 101; Page 49; 338pp; English.
PS
XX The present invention relates to a method for stimulating an immune
CC response. The method comprises administering an immunostimulatory nucleic
CC acid to a non-rodent subject in sufficient quantity to stimulate an
CC immune response. The present sequence is one such immunostimulatory
CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC also useful for preventing cancer, asthma, infectious disease, allergy or
CC immune deficiency. The present sequence can also be used to redirect a
CC Th2 to a Th1 immune response and to activate immune cells. Note: the
CC present sequence may have a phosphorothioate backbone
XX
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTTTT 2586
DB 20 TTTTCTTTTCTTTT 1

RESULT 302
AAH46465
ID AAH46465 standard; DNA; 20 BP.
XX
AC AAH46465;
XX
DT 14-SEP-2001 (first entry)
XX
DE Oligonucleotide #13.
XX
KW Phosphorothioate; anti-viral therapy; stereochemical pathway; ss.

```

```

XX Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT modified_base 1
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Modified with 2'-O-methyl"
XX
XX US6242591-B1.
PN
XX 05-JUN-2001.
PD
XX 11-JAN-2000; 2000US-00481486.
PF
XX 15-OCT-1997; 97US-00950779.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Cole DL, Ravikumar VT, Cheruvallath ZS;
PI WPI; 2001-407218/43.
DR
XX Preparing sulfurized 2' substituted phosphorothioate oligonucleotides
PT useful in biological research, comprises phosphorylating the 5'-hydroxyl
PT of a nucleic acid having a nucleoside with a 2' modification.
XX
XX Example 23; Col 11; 7pp; English.
PS
XX The present invention relates to a method for preparing phosphorothioate
CC oligonucleotides having at least one nucleoside with a 2' modification.
CC The method comprises phosphorylating the 5'-hydroxyl of a nucleic acid
CC group having at least one nucleoside with a 2' modification in an
CC acetonitrile. The present sequence was used to illustrate the method of
CC the present invention. The method is useful for synthesising sulphurised
CC 2' substituted phosphorothioate oligonucleotides, which may be used in
CC molecular biological research, in applications such as anti-viral
CC therapy, and for determining the stereochemical pathways of certain
CC enzymes which recognise nucleic acids
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTTTT 2586
DB 1 TTTTCTTTTCTTTT 20

RESULT 303
AAH78547/c
ID AAH78547 standard; cDNA; 20 BP.
XX
AC AAH78547;
XX
DT 10-DEC-2001 (first entry)
XX
DE Nucleotide sequence of a cDNA sequence.
KW Nucleic acid identification; DNA library screening; ss.
XX Synthetic.
OS
XX US6274321-B1.
PN
XX 14-AUG-2001.
PD
XX

```



```
Qy 342 GAAGAGGAGAACCGGATTG 361
Db |||||
1 GAAGAGGAGGAGAACCGGCTG 20

RESULT 308
AAS97819
ID AAS97819 standard; DNA; 20 BP.
XX
AC AAS97819;
XX
DT 12-MAR-2002 (first entry)
XX
DE Murine SAC1 gene-specific oligonucleotide PCR primer #386.
XX
KW Human; mouse; SAC1; carbohydrate; sweetener; ethanol; alcoholism; ss;
KW obesity; diabetes; transgenic embryo; body tissue; body fluid; pancreas;
KW blood; tongue; PCR primer; anorectic; antidiabetic; gene therapy;
KW protein replacement therapy.
XX
OS Mus sp.
XX
FN WO200183749-A2.
XX
PD 08-NOV-2001.
XX
PF 25-APR-2001; 2001WO-US013387.
XX
PR 28-APR-2000; 2000US-0200794P.
XX
PR 28-JUL-2000; 2000US-0221419P.
XX
PR 10-NOV-2000; 2000US-0247443P.
XX
PA (WARN ) WARNER LAMBERT CO.
PA (MONE-) MONELL CHEM SENSES CENT.
XX
PI Bachmanov AA, Beauchamp GK, Chatterjee A, De Jong PJ, Li S, Li X;
PI Ohmen JD, Reed DR, Ross D, Tordoff MG;
XX
DR WPI; 2002-075162/10.
XX

Novel isolated polypeptide comprising variant form of mouse or human SAC1
PT polypeptide, and is associated with altered preference for carbohydrates
PT or other sweeteners, useful for preventing obesity, diabetes, alcoholism.
XX
PS Claim 14; Page 89; 239pp; English.
XX
CC The invention relates to an isolated polypeptide, comprising a variant
CC form of mouse or human SAC1 polypeptide. The variant form is associated
CC with altered preference for carbohydrates, other sweeteners or ethanol.
CC The polypeptide and its associated DNA sequence can be produced by
CC recombinant techniques and is useful for preventing obesity, diabetes or
CC alcoholism associated with SAC1 expression. The sequences are useful in
CC screening for drugs and sweeteners. Recombinant cell lines and transgenic
CC embryos may be used in screening for and identifying agents that induce
CC or repress function of SAC1. Predisposition to diabetes, obesity or
CC alcoholism can be ascertained by testing any fluid or tissue of a human
CC (such as blood, pancreas or tongue) for sequence variations of the SAC1
CC gene. A sequence variation of the SAC1 locus may indicate a
CC predisposition to diabetes, obesity and/or alcoholism and may provide a
CC diagnostic mark. The polynucleotide can be detected in a biological
CC sample by contacting the DNA with a probe to form a hybridisation complex
CC which is then detected. The sequences represent cDNA encoding human and
CC mouse SAC1 polypeptides and PCR primers specific for the SAC1 genes
XX
SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2068 ACCTGGACACGATTCTGCC 2087
Db |||||
1 ACATGGACACGATTCTGGC 20

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
RESULT 309
ABS77742
ID ABS77742 standard; DNA; 20 BP.
XX
AC ABS77742;
XX
DT 13-DEC-2002 (first entry)
XX
DE Angiogenesis inhibitory oligonucleotide #226.
XX
KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophilic joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
FN WO200253141-A2.
XX
PD 11-JUL-2002.
XX
PF 14-DEC-2001; 2001WO-US048458.
XX
PR 14-DEC-2000; 2000US-025534P.
XX
PA (COLE-) COLEY PHARM GROUP INC.
XX
PI Bratzler RL;
XX
DR WPI; 2002-566690/60.
XX
PT Inhibiting angiogenesis in a subject, involves administering at least one
PT antiangiogenic nucleic acid molecule to the subject.
XX
PS Claim 2; Page 23; 276pp; English.
XX
CC The invention relates to inhibiting angiogenesis in a subject, comprising
CC administering at least one antiangiogenic nucleic acid molecule. Also
CC included is a kit comprising a first container housing the antiangiogenic
CC nucleic acids, and instructions for administering them to a subject
CC having a condition characterised by unwanted angiogenesis. The method is
CC useful for inhibiting angiogenesis associated with solid tumour growth,
CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC acid of the invention
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCT 2586
Db |||||
1 TTTTCTCTCTCTCTCTCTCT 20

RESULT 310
ABS78072
ID ABS78072 standard; DNA; 20 BP.
XX
AC ABS78072;
```


XX The present invention relates to methods for treating or preventing
CC cancer, involving administering to a subject having or at risk of
CC developing cancer immunostimulatory nucleic acids that induce expression
CC of cell surface antigens and antibodies. The methods are useful for
CC treating or preventing cancer such as basal cell carcinoma, bladder
CC cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC breast cancer, cervical cancer, colon and rectum cancer, connective
CC tissue cancer, esophageal cancer, eye cancer, kidney cancer, larynx
CC cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC present sequence is an immunostimulatory oligonucleotide described in the
CC exemplification of the invention
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 315
ABL54775
ID ABL54775 standard; DNA; 20 BP.
XX
AC ABL54775;
XX
DT 10-JUN-2002 (first entry)
XX
DE CD14 receptor PCR primer SEQ ID NO 9.
XX
KW Angiotensin-I converting enzyme; ACE; CD14; receptor; SNP;
KW single-nucleotide polymorphism; PCR; primer; ss.
XX
OS Synthetic.
XX
PN JP2002034599-A.
XX
PD 05-FEB-2002.
XX
PF 26-JUL-2000; 2000JP-00225354.
XX
PR 26-JUL-2000; 2000JP-00225354.
XX
PA (TOYM) TOYOBO KK.
XX
DR WPI; 2002-275727/32.
XX
PT Detecting 1 base polymorphism on a sequence of a chromosome or it's
PT fragment.
XX
PS Example 2; Page 10; 10pp; Japanese.
XX
CC The invention relates to a method for detecting 1 base polymorphism on
CC the sequence of a chromosome or its fragment in which a sample nucleic
CC acid is reacted with a reaction liquor containing a nucleic acid primer
CC having a base adjacent to the polymorphic base at its 3'-end, one
CC dideoxynucleotide corresponding to a polymorphic base having a
CC distinguishable feature or its mixture, DNA polymerase and a composition
CC required for its activity expression to detect the presence of taking
CC dideoxynucleotide in the nucleic acid primer and to detect the type of
CC the base to be specified. The method is used for detecting 1 base
CC polymorphism on the sequence of a chromosome or its fragment. The present
CC sequence is that of a PCR primer, useful in examples of the invention
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 316
ABK5035/C
ID ABK5035 standard; DNA; 20 BP.
XX
AC ABK5035;
XX
DT 02-JUL-2002 (first entry)
XX
DE Nanoparticle-oligonucleotide #55.
XX
KW Nanoparticle-oligonucleotide; nanofabrication; nucleic acid detection;
KW ss.
XX
OS Synthetic.
XX
PN WO200218643-A2.
XX
PD 07-MAR-2002.
XX
PF 10-AUG-2001; 2001WO-US025237.
XX
PR 11-AUG-2000; 2000US-0224631P.
PR 08-DEC-2000; 2000US-0254392P.
PR 11-DEC-2000; 2000US-0255235P.
PR 12-JAN-2001; 2001US-00760500.
PR 28-MAR-2001; 2001US-00820279.
XX
PA (NANO-) NANOSPHERE INC.
XX
PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
PI Taton TA, Garimella V, Li Z, Park S;
XX
DR WPI; 2002-258024/30.
XX
PT Detecting nucleic acid, useful for diagnosis of genetic, viral or
PT bacterial disease, comprises hybridizing nanoparticles with attached
PT oligonucleotides to nucleic acid and detecting change brought about by
PT hybridization.
XX
PS Example 18; Page 410; 412pp; English.
XX
CC The invention relates to a method of detecting a nucleic acid (NA) having
CC at least 2 portions comprising: (a) providing nanoparticles (NP) with
CC attached oligonucleotides (OGN), where OGN has a sequence complementary
CC to the sequence of NA; (b) contacting NA and NP under conditions
CC effective to allow hybridisation of OGN with NA; and (c) observing a
CC detectable change brought about by hybridisation of OGN with NA. The
CC method is useful for detecting a nucleic acid, separating a selected
CC nucleic acid from others and methods of nanofabrication. Detecting
CC analytes such as nucleic acids and proteins are useful for the diagnosis
CC of genetic, bacterial and viral diseases. The OGN-NP conjugates that use
CC cyclic disulphide linkers improve the sensitivity of diagnostic assays.
CC In particular assays using OGN-NP conjugates prepared using linkers
CC comprising a steroid residue attached to a cyclic disulphide have been
CC found to be approximately 10 times more sensitive than assays employing
CC conjugates prepared using alkanethiols or acyclic disulphides as the
CC linker. The OGN-NP conjugates are stable allowing them to be used
CC directly in PCR solutions. Therefore conjugates added as probes to a DNA
CC target to be PCR amplified can be carried through the 30 or 40 heating
CC cooling cycles of the PCR and are still able to detect the amplicons
CC without opening the tubes and causing contamination. ABK64981-ABK65055
CC represent nanoparticle-oligonucleotides of the invention
XX
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match	0.4%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 2.4e+02;		
Matches	17;	Conservative	0;	Mismatches 3; Indels 0; Gaps 0;

QY	2567	TTTCTTCTCTCTTTTTTTTTTT	2586
Db	20	TTTTTTTTTTTTTTTTTTTTTT	1

RESULT 317	
ABK65050/c	
ID ABK65050	standard; DNA; 20 BP.
XX AC	ABK65050;
XX AC	
DT 02-JUL-2002	(first entry)
DE Nanoparticle-oligonucleotide #70.	
XX KW	Nanoparticle-oligonucleotide; nanofabrication; nucleic acid detection;
XX KW	ss.
OS Synthetic.	
OS Synthetic.	
PN WO200218643-A2.	
XX PD	07-MAR-2002.
XX PF	10-AUG-2001; 2001WO-US025237.
XX PR	11-AUG-2000; 2000US-0224631P.
PR 08-DEC-2000;	2000US-0254392P.
PR 11-DEC-2000;	2000US-0255235P.
PR 12-JAN-2001;	2001US-00760500.
PR 28-MAR-2001;	2001US-00820279.
XX PA	(NANO-) NANOSPHERE INC.
XX PI	Mirkin CA, Letsinger RU, Mucic RC, Storhoff JJ, Elghanian R;
PI Taton TA, Garimella V, Li Z, Park S;	
XX WPI;	2002-258024/30.
XX	
PT Detecting nucleic acid, useful for diagnosis of genetic, viral or	
PT bacterial disease, comprises hybridizing nanoparticles with attached	
PT oligonucleotides to nucleic acid and detecting change brought about by	
PT hybridization.	
XX	
PS Example 24; Fig 44; 412pp; English.	
XX	
CC The invention relates to a method of detecting a nucleic acid (NA) having	
CC at least 2 portions comprising: (a) providing nanoparticles (NP) with	
CC attached oligonucleotides (OGN), where OGN has a sequence complementary	
CC to the sequence of NA; (b) contacting NA and NP under conditions	
CC effective to allow hybridization of OGN with NA; and (c) observing a	
CC detectable change brought about by hybridization of OGN with NA. The	
CC method is useful for detecting a nucleic acid, separating a selected	
CC nucleic acid from others and methods of nanofabrication. Detecting	
CC analytes such as nucleic acids and proteins are useful for the diagnosis	
CC of genetic, bacterial and viral diseases. The OGN-NP conjugates that use	
CC cyclic disulphide linkers improve the sensitivity of diagnostic assays.	
CC In particular assays using OGN-NP conjugates prepared using linkers	
CC comprising a steroid residue attached to a cyclic disulphide have been	
CC found to be approximately 10 times more sensitive than assays employing	
CC conjugates prepared using alkanethiols or acyclic disulphides as the	
CC linker. The OGN-NP conjugates are stable allowing them to be used	
CC directly in PCR solutions. Therefore conjugates added as probes to a DNA	
CC target to be PCR amplified can be carried through the 30 or 40 heating	
CC cooling cycles of the PCR and are still able to detect the amplicons	
CC without opening the tubes and causing contamination. ABK64981-ABK65055	
CC represent nanoparticle-oligonucleotides of the invention	
XX	

CC then used to produce transgenic mdx/utr(-/-) mice. Primers ABQ80571 and
CC ABQ80572 used to amplify between the MCK promoter and the alpha1 integrin
CC CDNA resulted in a 455bp amplicon only in transgenic mice
XX

SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1864 GGAGCCAGGCGTTCACCTTG 1883
DB 20 GGACCCAGGCGTGACGCTTG 1

RESULT 326
ABI93576
ID ABI93576 standard; DNA; 20 BP.

XX AC ABI93576;

XX DT 15-FEB-2002 (first entry)

XX DE Capture oligonucleotide Zip ID#663 oligo #9.

XX KW Human; K-ras; PCR primer; probe; capture probe; mutation detection;
XX KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
XX KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
XX KW oncogene; tumour suppressor; human papillomavirus; forensic;
XX KW environmental monitoring; food industry; feed industry; ss.

XX OS Synthetic.

XX PN WO200179548-A2.

XX PD 25-OCT-2001.

XX PF 04-APR-2001; 2001WO-US010958.

XX PR 14-APR-2000; 2000US-0197271P.

XX PA (CORR) CORNELL RES FOUND INC.

XX PI Barany F, Zirvi M, Gerry NP, Favis R, Kliman R;

XX DR WPI; 2002-034366/04.

XX PT Designing capture oligonucleotide probes for use on a support to which
XX PT complementary oligonucleotides hybridize with little mismatch.

XX PS Example 5; Fig 29; 30pp; English.

XX CC The present invention describes a method (M1) for designing capture
XX CC oligonucleotide probes (I) for use on a support to which complementary
XX CC oligonucleotide probes (II) will hybridize with little mismatch, where
XX CC (I) have melting temperatures within a narrow range. The method is useful
XX CC for detecting infectious diseases caused by bacterial infectious agents
XX CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
XX CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
XX CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
XX CC Epstein-Barr virus and polio virus, and parasitic infectious agents
XX CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
XX CC medineis. The method is also useful for detecting genetic diseases such
XX CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
XX CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
XX CC involved in DNA amplification, replication, recombination or repair, the
XX CC cancer is specifically associated with a gene selected from BRCA1 gene,
XX CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
XX CC method is also used for environmental monitoring, forensics and the food
XX CC and feed industry, detecting comprises scanning (using e.g. a scanning
XX CC electron microscope and infrared microscope) the support at the
XX CC particular sites and identifying if ligation of the oligonucleotide probe
XX CC sets occurred and correlating (using a computer) identified ligation to a

CC presence or absence of the target nucleotide sequences. ABI82074 to
CC ABI97546 represent oligonucleotide sequences used in the exemplification
CC of the present invention

SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 98 GCAAGGTCCAGCAGCCAGC 117
DB 1 GCAAGGTATCTGCAGCCAGC 20

RESULT 327

ABN86931

ID ABN86931 standard; DNA; 20 BP.

XX AC ABN86931;

XX DT 29-JUL-2002 (first entry)

XX DE Human NOV2c reverse PCR primer SEQ ID NO:50.

XX KW Human; NOVX; cytostatic; antiarteriosclerotic; cardiovascular; lymphoma;
XX KW anti-diabetic; immunosuppressive; neuroprotective; gene therapy; cancer;
XX KW cardiomyopathy; atherosclerosis; cell signal processing; diabetes; AIDS;
XX KW metabolic pathway modulation; neoplastic; neurological disorder; asthma;
XX KW adenocarcinoma; prostate cancer; uterus cancer; immune response;
XX KW Crohn's disease; multiple sclerosis; Graft versus host disease;
XX KW PCR primer; ss.

XX OS Homo sapiens.

XX PN WO200230974-A2.

XX PD 18-APR-2002.

XX PF 12-OCT-2001; 2001WO-US031922.

XX PR 12-OCT-2000; 2000US-0240113P.

XX PR 16-OCT-2000; 2000US-0240625P.

XX PR 16-OCT-2000; 2000US-0240637P.

XX PR 16-OCT-2000; 2000US-0240648P.

XX PR 16-OCT-2000; 2000US-0240662P.

XX PR 16-OCT-2000; 2000US-0240669P.

XX PR 16-OCT-2000; 2000US-0240703P.

XX PR 16-OCT-2000; 2000US-0240732P.

XX PR 16-OCT-2000; 2000US-0241190P.

XX PR 18-JAN-2001; 2001US-0262455P.

XX CC (CURA-) CURAGEN CORP.

XX CC (MILL/) MILLET I.

XX PI Grosse WM, Alsobrook JP, Lepley DM, Burgess CE, Mishra V;

XX PI Kekuda R, Li L, Padigaru M, Shinkets RA, Zehusen BD, Spytek KA,

XX PI Edinger S, Gerlach V, Macdougall J, Stone D, Gunther E, Ellerman K;

XX DR WPI; 2002-444172/47.

XX PT New NOVX polypeptides and polynucleotides, useful for treating or

XX PT preventing a NOVX-associated disorder or a pathological state in a

XX PT subject, particularly a human, e.g. cardiomyopathy, atherosclerosis,

XX PT cancer or diabetes.

XX PS Example 2; Page 156; 227pp; English.

XX CC The present invention describes novel human proteins designated NOVX

XX CC (where X is 1, 2a, 2b, 2c, 2d, 3, 4, 5, 6a, 6b, 7, 8, or 9). NOV1 is a

XX CC tyrosine-protein kinase 6-like protein; NOV2a-d are keratin 4-like

XX CC proteins; NOV3 is a collagen-like protein; NOV4 is a cystatin B-like

XX CC protein; NOV5 is a serotonin receptor-like protein; NOV6a and NOV65v are

CC cold inducible glycoprotein 30-like proteins; NOV7 is a matrilin-2-like
CC protein; NOV8 is a leukocyte surface antigen (CD53)-like protein; and
CC NOV9 is a tyrosine kinase-like protein. NOVX sequences have cytostatic, and
CC antiarteriosclerotic, cardiovascular, antidiabetic, immunosuppressive and
CC neuroprotective activities, and can be used in gene therapy. The NOVX
CC sequences can be used in therapeutics, particularly for treating,
CC preventing or alleviating a NOVX-associated disorder or a pathological
CC state in a subject, particularly a human. These disorders include
CC cardiomyopathy, atherosclerosis, a disorder related to cell signal
CC processing and metabolic pathway modulation or diabetes. The NOVX
CC sequences are also useful for determining the presence of or
CC predisposition to a disease associated with altered levels of NOVX
CC polypeptide or nucleic acid, particularly cancer. The NOVX sequences are
CC especially useful in therapeutic or prophylactic applications for
CC neoplastic or neurological disorders, and in the treatment of
CC adenocarcinoma, lymphoma, prostate cancer, uterus cancer, immune
CC response, AIDS, asthma, Crohn's disease, multiple sclerosis or Graft
CC versus host disease. The present sequence represents a PCR primer for
CC human NOV2c, which is used in an example from the present invention
XX
SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 467 TCCTGTACCTTGTCTCAGC 486
Db 1 TACTGTGCTTGACCTCAGC 20
||||| ||||| ||||| |||||

RESULT 328
ABN87103
ID ABN87103 standard; DNA; 20 BP.
XX
AC ABN87103;
XX
DT 30-JUL-2002 (first entry)
XX
DE Capture probe CP5' SEQ ID NO:23.
XX
KW Protein scaffold; antibody; binding protein; immunoglobulin;
KW tumour necrosis factor alpha; TNF-alpha; protein framework; probe; ss.
XX
OS Synthetic.
XX
PN WO200232925-A2.
XX
PD 25-APR-2002.
XX
PF 16-OCT-2001; 2001WO-US032233.
XX
PR 16-OCT-2000; 2000US-00688566.
XX
PA (PHYL-) PHYLLOS INC.
XX
PI Lipovsek D, Wagner RW, Kuimelis RG;
XX
DR WPI; 2002-444238/47.
XX

PT New non-antibody proteins having an immunoglobulin fold, useful in
PT research, therapeutic or diagnostic fields, particularly as scaffolds for
PT designing proteins with specific properties, e.g. for binding any antigen
PT of interest.
XX

PS Disclosure; Page 58; 94pp; English.

XX The present invention describes a non-antibody protein, comprising a
CC domain having an immunoglobulin-like fold, derived from a reference
CC protein having a mutated amino acid sequence, where the non-antibody
CC protein binds with a Kd at least as tight as 10 nM to a compound that is
CC not bound as tightly by the reference protein. The non-antibody protein
CC is useful as scaffolds for selecting or designing a protein framework

CC with specific and favourable properties, e.g. for binding any antigen of
CC interest, or for destroying or inactivating antibody molecules. The non-
CC antibody protein is also useful in all areas where antibodies are used,
CC e.g. research, therapeutic or diagnostic fields, and for screening novel
CC binding proteins useful in the above-mentioned fields. The present
CC proteins have thermodynamic properties superior to those of natural
CC antibodies, and can be evolved rapidly in vitro. The present proteins or
CC antibody mimics exhibit improved biophysical properties, such as
CC stability under reducing conditions and solubility at high
CC concentrations. In addition, these molecules are readily expressed and
CC folded in prokaryotic systems (e.g. Escherichia coli), in eukaryotic
CC systems (e.g. yeast), or in in vitro translation systems (e.g. rabbit
CC reticulocyte lysate system). Furthermore, these proteins are extremely
CC amenable to affinity maturation techniques involving multiple cycles of
CC selection, e.g. in vitro selection using RNA-protein fusion technology,
CC phage display or yeast display systems. The present sequence is used in
CC the exemplification of the present invention
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTCTTTTTTTT 2586
Db 1 TTTTCTTCTCTCTTTTTTTT 20
||||| ||||| ||||| |||||

RESULT 329
AAL61645/c
ID AAL61645 standard; DNA; 20 BP.
XX
AC AAL61645;
XX
DT 22-SEP-2003 (first entry)
XX
DE Thiol-modified oligo #4 used in the nucleic acid detection method.
XX
KW Nucleic acid detection; fabrication; ss.
XX
OS Unidentified.
XX
PN WO2003035829-A2.
XX
PD 01-MAY-2003.
XX

PF 08-OCT-2002; 2002WO-US032088.

PR 09-OCT-2001; 2001US-0327864P.

PR 07-DEC-2001; 2001US-00008978.

PA (NANO-) NANOSPHERE INC.

PI Park S, Taton TA, Mirkin CA;

DR WPI; 2003-430409/40.

XX
PT Detecting nucleic acid having two portions, by providing nanoparticles
PT having oligonucleotides attached to it, contacting nucleic acid and
PT nanoparticles to allow hybridization, and observing detectable change.

PS Example 18; Page 179; 467pp; English.

XX The invention relates to a method of detecting a nucleic acid having two
CC portions. The method involves providing nanoparticles having
CC oligonucleotides attached to it which has a sequence complementary to
CC sequence of two portions of nucleic acid, contacting nucleic acid and
CC nanoparticles to allow hybridisation of oligonucleotides with two or more
CC portions of nucleic acid and observing a detectable change brought about
CC by hybridisation. The method and aggregate probes are useful for
CC detecting two or more nucleic acids (from a biological source) having at
CC least two portions such as viral RNA, bacterial or fungal DNA, a gene


```

RESULT 332
ABX79181/c
ID ABX79181 standard; DNA; 20 BP.
AC ABX79181;
XX
DT 15-APR-2003 (first entry)
DE Thio-modified 20dA oligonucleotide.
KW Nanoparticle; ss; nucleic acid detection; viral disease; probe;
KW human immunodeficiency virus infection; hepatitis virus infection;
KW herpes virus infection; cytomegalovirus infection; forensic science;
KW Epstein-Barr virus infection; bacterial disease; gene therapy;
KW sexually transmitted disease; inherited disorder; DNA sequencing;
KW paternity testing; cell line authentication.
XX
OS Synthetic.
XX
PN US2002155462-A1.
XX
PD 24-OCT-2002.
XX
PF 12-OCT-2001; 2001US-00976577.
XX
PR 29-JUL-1996; 96US-0031809P.
PR 21-JUL-1997; 97WO-US012783.
PR 29-JAN-1999; 99US-00240755.
PR 25-JUN-1999; 99US-00344667.
PR 26-APR-2000; 2000US-0200161P.
PR 26-JUN-2000; 2000US-00601830.
XX
PA (NANO-) NANOSPHERE INC.
XX
PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
PI Taton TA;
XX
DR WPI; 2003-198491/19.
XX
PT Detecting nucleic acids having at least 2 portions comprises use of
PT nanoparticles which have oligonucleotides attached to them that are
PT complementary to portions of the nucleic acid sequence.
XX
PS Example 18; Page 44; 130pp; English.
XX
CC The invention relates to detecting a nucleic acid (NA) having at least 2
CC portions, comprises providing a type of nanoparticles (NP) having
CC attached to oligonucleotides (O) (O) on each NP has a sequence
CC complementary to sequence of at least 2 portions of NA, contacting NA
CC and NP to allow hybridisation of (O) on NP with 2 or more portions of NA,
CC and observing a detectable change brought about by hybridisation of (O)
CC on NP with NA. The nanoparticle is useful for separating a selected
CC nucleic acid having at least 2 portions, from other nucleic acids, and
CC for detecting nucleic acids having at least 2 portions. The method of
CC using NP is useful for detecting any type of nucleic acids which may be
CC used for diagnosis of disease and in sequencing of nucleic acids.
CC Preferably, the method is useful for detecting nucleic acids for
CC diagnosis and/or monitoring of viral diseases (human immunodeficiency
CC virus, hepatitis virus, herpes virus, cytomegalovirus and Epstein-Barr
CC virus), bacterial diseases, sexually transmitted diseases, inherited
CC disorders, in forensics, in DNA sequencing, for paternity testing, for
CC cell line authentication and for monitoring gene therapy. The method is
CC useful in research and analytical laboratories in DNA sequencing and in
CC the field to detect the presence of specific pathogens. Detecting nucleic
CC acids based on observing a colour change with the naked eye is cheap,
CC fast, simple and robust, and do not require specialised expensive
CC equipment. The present sequence is a nanoparticle (e.g. gold particles)
CC labelled probe used to demonstrate the method of the invention
XX
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTCTTTTTTTTTT 2586
Db 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 333
AAD47532
ID AAD47532 standard; DNA; 20 BP.
XX
AC AAD47532;
XX
DT 24-FEB-2003 (first entry)
DE Human Artemis full-length cDNA amplifying PCR primer, 169F1.
KW Human; ARTEMIS protein; V(D)J recombination; DNA repair; gene therapy;
KW severe combined immunodeficiency; SCID; cancer; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200277026-A2.
XX
PD 03-OCT-2002.
XX
PF 21-MAR-2002; 2002WO-IB001737.
XX
PR 22-MAR-2001; 2001WO-IB000546.
XX
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI De Villartay J, Moshous D, Fischer A;
XX
DR WPI; 2003-018886/01.
XX
PT New ARTEMIS nucleic acid coding for a protein involved in V(D)J
PT recombination and/or DNA repair, useful for treating and diagnosing
PT severe combined immunodeficiencies (SCID) or cancer.
XX
PS Example 1; Page 65; 71pp; English.
XX
CC The invention relates to an Artemis nucleic acid coding for a protein
CC involved in V(D)J recombination and/or DNA repair. Sequences of the
CC invention are useful for treating severe combined immunodeficiencies
CC (SCID) or cancer. They are also useful for diagnosing a patient,
CC including a prenatal diagnosis with SCID, a predisposition to cancer, an
CC immune deficiency or a carriage of a mutation increasing the risk of
CC progeny to have such a disease. Peptides of the invention are used for
CC preparing antibodies. The invention is useful in gene therapy. The
CC present sequence is a PCR primer used to amplify human Artemis full-
CC length cDNA
XX
SQ Sequence 20 BP; 2 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2514 TGTATATCTCTGTAAAGGTTT 2533
Db 1 TGTATATCTCTGTGAGGTTT 20

RESULT 334
ABX92177/c
ID ABX92177 standard; DNA; 20 BP.
XX
AC ABX92177;
XX
DT 12-MAY-2003 (first entry)
```

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0

[illegible]

CC involves detecting nucleic acids based on observing a colour change with
CC the naked eye so is cheap, fast, simple and robust, and does not require
CC specialised expensive equipment. The present sequence represents a thiol
CC modified oligonucleotide sequence used to demonstrate the method of the
CC invention

XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTTCTTTTTTTTTT 2586
||| ||| ||| ||| ||| |||
Dd 20 TTTTTTTTTTTTTTTTTT 1

RESULT 337
ACD27125/c

ID ACD27125 standard; DNA; 20 BP.

XX AC ACD27125;

XX DT 15-OCT-2003 (first entry)

XX DE Nanotechnology nucleic acid detection method oligonucleotide #54.

XX KW Nanotechnology; nucleic acid detection; nanoparticle; ss; forensic;
KW DNA sequencing; paternity testing; cell line authentication.
XX OS Synthetic.

XX FH Key Location/Qualifiers

FT modified_base 1 /tag= a
FT /mod_base= OTHER
FT /note= "Thiol modified" "

XX US2002164605-A1.

XX PD 07-NOV-2002.

XX PF 28-SEP-2001; 2001US-00966312.

XX PR 29-JUL-1996; 96US-0031809P.
PR 21-JUL-1997; 97MO-US012783.
PR 29-JAN-1999; 99US-00240755.
PR 25-JUN-1999; 99US-00344667.
PR 26-APR-2000; 2000US-0200161P.
PR 26-JUN-2000; 2000US-00603830.

PA (NANO-) NANOSPHERE INC.

XX PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
PI Taton TA;

XX DR WPI; 2003-247253/24.

XX PT Detecting nucleic acid having two portions, by providing nanoparticles
PT having oligonucleotides attached to it, contacting nucleic acid and
PT nanoparticles to allow hybridization, and observing detectable change,
PT useful in forensics.

XX PS Example 18; Page 44; 130pp; English.

XX CC This invention relates to a novel method for detecting nucleic acid
CC sequences having two portions. The method involves providing
CC nanoparticles having oligonucleotides attached to them, which has a
CC sequence complementary to sequence of two portions of nucleic acid,
CC contacting nucleic acid and nanoparticles, to allow hybridisation of
CC oligonucleotides with two or more portions of nucleic acid, and observing
CC a detectable change brought about by hybridisation. The method of the
CC invention and the aggregate probes are useful for detecting two or more

CC This invention relates to a novel method for detecting a nucleic acid by

This invention relates to a novel method for detecting a nucleic acid by contacting nucleic acid with at least two types of nanoparticles having oligonucleotides, allowing hybridisation of the oligonucleotides on the nanoparticles, and observing a detectable change. The oligonucleotides on each nanoparticle have a sequence complementary to its respective portion of the sequence of the nucleic acid. The method of the invention may be used for the detection of a nucleic acid used in, e.g. research and analytical laboratories in DNA sequencing, in the field to detect the presence of specific pathogens, in the doctor's office for quick identification of an infection to assist in prescribing a drug for treatment, and in homes and health centres for inexpensive first-line screening. The inventive method of detecting nucleic acids based on observing a colour change with the naked eye are cheap, fast, simple, robust (the reagents are stable), do not require specialised or expensive equipment, and little or no instrumentation is required. The present sequence represents a thiol modified oligonucleotide sequence used to demonstrate the method of the invention

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0

Qy 2567 TTTCTCTCTCTTTTTTTT 2586
pB 20 TTTCTCTCTCTTTTTTTT 1

RESULT 340
ACD27060/c
ID ACD27060 standard: DNA: 20 BP.

XX	ACD27060;
AC	
XX	
DT	15-OCT-2003 (first entry)

XX
DE Nanotechnology nucleic acid detection method oligonucleotide #54.

XX Nanotechnology: nucleic acid detection: nanofabrication: nanoprobe; ss.

OS Synthetic.

AA	Key	Location/Qualifiers
FT	modified_base	1
FT		/*tag= a
FT		/mod_base= OTHER
PT		/notes="OTHER= This

XX PN US2003044805-A1.

XX
PD
06-MAR-2003

15-OCT-2001: 2001US-00981344.

XX
PP 29-III-1996. 96US-0031809P.

PR 21-JUL-1997; 97WO-US012783.
PR 20-JAN-1999; 99US-00240755

PR 25-JUN-1999; 99US-00344667.
PR 25-JUN-1999; 99US-00344667.
PR 25-JUN-1999; 99US-00344667.

PR 26-JUN-2000; 2000US-00603830.

PA (NANO-) NANOSPHERE INC.

PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Eghanian R;
PI Taton TA;

DR WPI; 2003-521746/49.

PT Detection of nucleic acid having -2 portions used to prepare biomaterials
PT and in nanofabrication methods, comprises providing nanoparticles,
PT contacting nucleic acid and nanoparticles, and observing change.

PS Example 18: Page 44; 130pp; English.

This invention relates to a novel method for detecting nucleic acids. The method comprises providing nanoparticles with oligonucleotides attached to them, which have a sequence complementary to a sequence of two portions of nucleic acid, contacting the nucleic acid and nanoparticles to allow hybridisation of the oligonucleotides with two or more portions of the nucleic acid, and observing a detectable change brought about by the hybridisation. The nucleic acid to be detected must have at least two portions and the distances between these are chosen so that when the nanoparticle-oligonucleotide conjugate binds the target sequence a detectable change occurs. The method of the invention is useful for detecting two or more nucleic acids (from a biological source) having at least two portions, such as viral RNA, bacterial or fungal DNA, a gene associated with a disease, synthetic, or structurally-modified natural or synthetic RNA or DNA, or a product of a polymerase chain reaction amplification. Nanoparticle-oligonucleotide conjugates of the invention are useful for preparing a nanoprobe conjugate for detecting an analyte, and for detecting a nucleic acid bound to an electrode surface. Nanoparticles and nanoparticle conjugates of the invention are useful for nanofabrication and for separating a selected nucleic acid having two portions from other nucleic acids. Diagnostic assays employing nanoparticle-oligonucleotide conjugates improve the sensitivity of nucleic acid detection methods and can be used to detect nucleic acids that are present in only small amounts in a sample. The invention also provides highly detectable nanoparticle-oligonucleotide conjugates. These conjugates are stable with tailored hybridisation abilities. The present sequence represents a thiol modified oligonucleotide sequence used to demonstrate the method of the invention.

XX
SQ
sequence 20 BP: 20 A: 0 C: 0 G: 0 T: 0 U: 0 Other:

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;

2567 TTCTCTCTCTTTTCTTTT 2586

100

RESULT 341

RESOL 341
ACH00064/C
ID ACH00064 standard: DNA: 20 BP.

XX ACH00064:

XX DT 15-OCT-2003 (first entry)

XX
DE Nanotechnology nucleic acid detection method oligonucleotide #54:

XX Nanotechnology: nucleic acid detection; nanoprobe; ss:

3	3
XX	XX

XX	Key	Location/Qualifiers
FH		
FT	modified base 1	

```

FT      /mod_base= OTHER
FT      /note= "OTHER= Thiol modified" "

```

PN US2003049631-A1.

XX
PD
13-MAR-2003

XX
PE
10-OCT-2001: 2001US-00974500-

XX 29-III-1996. 96US-0031809P

PR 21-JUL-1997; 97WO-US012783.
PR 22-JAN-1998; 98US-00240755
PR 22-JAN-1998; 98US-00240755

PR 25-JUN-1999; 99US-00344667.

PR 26-JUN-2000; 2000US-00603830.

DT 15-JAN-2004 (first entry)
 XX Oreochromis niloticus microsatellite primer SEQ ID NO:981.
 DE single nucleotide polymorphism; SNP; fish; Salmo salar;
 XX Oreochromis niloticus; Atlantic halibut; microsatellite; cod;
 KW polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;
 KW detection; primer; ss.
 XX Synthetic.
 OS Oreochromis niloticus.
 XX WO2003060160-A2.
 XX 24-JUL-2003.
 PD 17-JAN-2003; 2003WO-IB000112.
 XX 18-JAN-2002; 2002US-0349950P.
 PR 16-AUG-2002; 2002US-0404200P.
 XX (GENO-) GENOMAR ASA.
 PA Lie O, Slettan A, Hoyum M, Lingaas F;
 XX WPI; 2003-627388/59.
 DR Novel isolated nucleic acid molecule comprising single nucleotide
 XX polymorphism associated with fish, useful for forming PCR primers which
 PT are used for detecting single nucleotide polymorphisms in fish nucleic
 PT acids.
 XX Claim 18; SEQ ID NO 981; 233pp; English.
 PS The present invention describes an isolated nucleic acid (I) comprising a
 CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of
 CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;
 CC and (ii) a nucleic acid having nucleotide sequence that hybridises to
 CC (i), or its complement under highly stringent hybridisation conditions.
 CC Also described: (1) an isolated oligonucleotide (II) comprising at least
 CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.
 CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
 CC polymorphic sites and seabass polymorphic sites, or their complement; (2)
 CC a primer pair (III) suitable for use in PCR, comprising two (II) capable
 CC of amplifying a nucleotide sequence chosen from S. salar SNPs and, O.
 CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
 CC polymorphic sites and seabass polymorphic sites; and determining (M1) the
 CC origin of fish sample comprising providing a parentage genotype database
 CC comprising a collection of candidate parent genotypes, where each of the
 CC candidate parent genotype represents a distinct origin, and comparing a
 CC sample genotype to the parentage genotype database, where a match between
 CC the sample genotype and one of the candidate parent genotype identifies
 CC to the origin of the sample. (M1) is useful for determining the origin of
 CC a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus,
 CC rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for
 CC detecting nucleic acid molecule comprising SNP in a sample, which
 CC involves contacting the sample containing nucleic acids with one or more
 CC (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus
 CC SNPs, and identifying nucleic acid that hybridises to (II). (II) is
 CC useful for detecting nucleic acid molecule comprising a polymorphic
 CC sequence in a sample, comprising contacting the sample containing nucleic
 CC acids with one or more (II) which is derived from O. niloticus
 CC microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic
 CC sites or seabass polymorphic sites, and identifying a nucleic acid that
 CC hybridises to (II). (III) is useful for detecting nucleic acid molecule
 CC comprising a microsatellite sequence in sample. The present invention is
 CC used in the exemplification of the present invention.
 XX Sequence 20 BP; 7 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QV 3095 ATCTGTGAGCGCAGCAATA 3114
 ||||| ||||| ||||| |||||
 Db 1 ATCTGGGAGGCGCAGCAATA 20
 RESULT 353
 ADD20263/c
 ID ADD20263 standard; DNA; 20 BP.
 XX ADD20263;
 AC 15-JAN-2004 (first entry)
 DT Oreochromis niloticus microsatellite primer SEQ ID NO:898.
 DE single nucleotide polymorphism; SNP; fish; Salmo salar;
 KW Oreochromis niloticus; Atlantic halibut; microsatellite; cod;
 KW polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;
 KW detection; primer; ss.
 XX Synthetic.
 OS Oreochromis niloticus.
 XX WO2003060160-A2.
 XX 24-JUL-2003.
 PD 17-JAN-2003; 2003WO-IB000112.
 XX 18-JAN-2002; 2002US-0349950P.
 PR 16-AUG-2002; 2002US-0404200P.
 XX (GENO-) GENOMAR ASA.
 PA Lie O, Slettan A, Hoyum M, Lingaas F;
 XX WPI; 2003-627388/59.
 DR Novel isolated nucleic acid molecule comprising single nucleotide
 XX polymorphism associated with fish, useful for forming PCR primers which
 PT are used for detecting single nucleotide polymorphisms in fish nucleic
 PT acids.
 XX Claim 18; SEQ ID NO 898; 233pp; English.
 PS The present invention describes an isolated nucleic acid (I) comprising a
 CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of
 CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;
 CC and (ii) a nucleic acid having nucleotide sequence that hybridises to
 CC (i), or its complement under highly stringent hybridisation conditions.
 CC Also described: (1) an isolated oligonucleotide (II) comprising at least
 CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.
 CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
 CC polymorphic sites and seabass polymorphic sites, or their complement; (2)
 CC a primer pair (III) suitable for use in PCR, comprising two (II) capable
 CC of amplifying a nucleotide sequence chosen from S. salar SNPs and, O.
 CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
 CC polymorphic sites and seabass polymorphic sites; and determining (M1) the
 CC origin of fish sample comprising providing a parentage genotype database
 CC comprising a collection of candidate parent genotypes, where each of the
 CC candidate parent genotype represents a distinct origin, and comparing a
 CC sample genotype to the parentage genotype database, where a match between
 CC the sample genotype and one of the candidate parent genotype identifies
 CC to the origin of the sample. (M1) is useful for determining the origin of
 CC a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus,
 CC rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for
 CC detecting nucleic acid molecule comprising SNP in a sample, which
 CC involves contacting the sample containing nucleic acids with one or more
 CC (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus
 CC SNPs, and identifying nucleic acid that hybridises to (II). (II) is
 CC useful for detecting nucleic acid molecule comprising a polymorphic
 CC sequence in a sample, comprising contacting the sample containing nucleic
 CC acids with one or more (II) which is derived from O. niloticus
 CC microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic
 CC sites or seabass polymorphic sites, and identifying a nucleic acid that
 CC hybridises to (II). (III) is useful for detecting nucleic acid molecule
 CC comprising a microsatellite sequence in sample. The present invention is
 CC used in the exemplification of the present invention.
 XX Sequence 20 BP; 7 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

CC acids with one or more (II) which is derived from *O. niloticus*
CC microsatellite, *O. niloticus* SNPs, Atlantic halibut SNPs, cod polymorphic
CC sites or seabass polymorphic sites, and identifying a nucleic acid that
CC hybridises to (II). (III) is useful for detecting nucleic acid molecule
CC comprising a microsatellite sequence in sample. The present sequence is
CC used in the exemplification of the present invention.

XX SQ Sequence 20 BP; 9 A; 8 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1287 AGCGTGACTTTGGTGCTG 1306

DB 20 AGTGTGCTGTTGGTGCTG 1

RESULT 354

ACF04849

ID ACF04849 standard; DNA; 20 BP.

XX AC ACF04849;

XX DT 12-FEB-2004 (first entry)

XX DE Barley HGGT PCR primer #3.

XX KW Tocotrienol; seed tocol content; transgenic; plant; HGGT; HPT;

XX KW homogenitase geranylgeranyl transferase; PCR; primer;

XX KW homogenitase phytyltransferase; ss.

XX OS Hordeum vulgare.

XX PN WO2003082899-A2.

XX PD 09-OCT-2003.

XX PF 11-MAR-2003; 2003WO-US007599.

XX PR 22-MAR-2002; 2002US-0366757P.

XX PA (DUPO) DU PONT DE NEMOURS & CO E. I.

XX PI Cahoon EB, Coughlan SJ, Cahoon RE, Butler KH;

XX DR WPI; 2003-804022/75.

XX PT New isolated polynucleotide encoding a polypeptide that alters
XX PT tocotrienol content, useful for transforming plants to manipulate the
XX PT synthetic pathway for tocol compounds.

XX PS Example 2; Page 110; Opp; English.

XX CC The present invention provides the protein and coding sequences of
XX CC several homogenitase geranylgeranyl transferases. These are capable of
XX CC altering the tocol content of seeds. The methods of the invention are
XX CC useful for altering tocotrienol as compared to a wild-type, and altering
XX CC tocols as compared to a wild-type. The polynucleotides and polypeptides
XX CC are useful for altering tocol and tocotrienol content in seeds. The
XX CC compositions are useful for transforming plants to manipulate the
XX CC synthetic pathway for tocol compounds. The transformed plants are useful
XX CC for improving grain or seed characteristics, e.g. antioxidant level or
XX CC activity. The present sequence is a PCR primer shown in the
XX CC exemplification of the invention

XX SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 886 CTCTGGAGCTAGTGGTTCCC 905

DB 1 CTCTAGACTAGTGGATCCC 20

RESULT 355

ADF09421/c

ID ADF09421 standard; DNA; 20 BP.

XX AC ADF09421;

XX DT 12-FEB-2004 (first entry)

XX DE Linking oligonucleotide #55.

XX KW Linking oligonucleotide; ss; nucleic acid detection;
XX KW nanoparticle-oligonucleotide conjugate.

XX OS Synthetic.

XX PN US2003148282-A1.

XX PD 07-AUG-2003.

XX PF 12-OCT-2001; 2001US-00976968.

XX PR 29-JUL-1996; 96US-0031809P.

XX PR 21-JUL-1997; 97WO-US012783.

XX PR 29-JAN-1999; 99US-00240755.

XX PR 25-JUN-1999; 99US-00344667.

XX PR 26-APR-2000; 2000US-0200161P.

XX PR 26-JUN-2000; 2000US-00603830.

XX PA (NANO-) NANOSPHERE INC.

XX PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
XX PI Taton TA;

XX DR WPI; 2003-897536/82.

XX PT Detection of nucleic acid having at least two portions comprises
XX PT contacting the nucleic acid and nanoparticles under conditions to allow
XX PT hybridization of the oligonucleotides, and observing detectable change
XX PT brought by hybridization.

XX PS Example 18; SEQ ID NO 55; 129pp; English.

XX CC The invention relates to a method of detecting a nucleic acid with at
XX CC least two portions by providing a type of nanoparticle-oligonucleotide
XX CC conjugate, contacting the nucleic acid and nanoparticles to allow
XX CC hybridisation of the oligonucleotides with the two or more portions of
XX CC the nucleic acid and observing a detectable change brought about by
XX CC hybridisation. The oligonucleotides have a sequence complementary to the
XX CC sequence of at least two portions of the nucleic acid. Hybridisation of
XX CC the oligonucleotides on the nanoparticles with the nucleic acid results
XX CC in a detectable change. This sequence represents a linking
XX CC oligonucleotide of the invention.

XX SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2567 TTTCTTCTTCTTTTTTTTTT 2586

DB 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 356

ADF65655/c

ID ADF65655 standard; DNA; 20 BP.

XX AC ADF65655;


```
PR 21-JUL-1997; 97WO-US012783.
PR 29-JAN-1999; 99US-00240755.
PR 25-JUN-1999; 99US-00344667.
PR 26-APR-2000; 2000US-0200161P.
PR 26-JUN-2000; 2000US-00603830.
PA (NANO-) NANOSPHERE INC.
XX
XX Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
PI Taton TA;
XX
XX WPI; 2003-810979/76.
XX
PT Detection of nucleic acid useful for, e.g. research and analytical
PT laboratories in deoxyribonucleic acid sequencing, comprises contacting
PT nucleic acid with at least two types of nanoparticles attached with
PT oligonucleotides.
XX
XX Example 18; SEQ ID NO 55; 130pp; English.
XX
CC The invention relates to a method of detecting a nucleic acid with at
CC least two portions by providing a type of nanoparticle-oligonucleotide
CC conjugate, contacting the nucleic acid and nanoparticles to allow
CC hybridisation of the oligonucleotides with the two or more portions of
CC the nucleic acid and observing a detectable change brought about by
CC hybridisation. The oligonucleotides have a sequence complementary to the
CC sequence of at least two portions of the nucleic acid. Hybridisation of
CC the oligonucleotides on the nanoparticles with the nucleic acid results
CC in a detectable change. This sequence represents a linking
CC oligonucleotide of the invention.
XX
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTTTT 2586
Db 20 TTTTCTCTCTCTTTT 1

RESULT 359
ADH63095
ID ADH63095 standard; DNA; 20 BP.
XX
AC ADH63095;
XX
XX 25-MAR-2004 (first entry)
XX
DE FGF receptor 2 antisense oligonucleotide, ISIS143355, SEQ ID 49.
XX
XX Cytostatic; Vulnuary; Gene Therapy; Antisense;
KW fibroblast growth factor receptor 2; FGF receptor 2;
KW hyperproliferative disorder; cancer; developmental disorder;
KW wound healing; ss; phosphorothioate.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidine"
XX
XX WO2003024987-A1.
XX
XX 27-MAR-2003.
XX
XX 12-SEP-2002; 2002WO-US029149.
XX
```

```
XX
XX 14-SEP-2001; 2001US-00954556.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM, Cooper SR;
XX
XX WPI; 2003-354582/33.
XX
XX New antisense oligonucleotides for modulating expression of genes
PT encoding fibroblast growth factor receptor 2, useful for treating
PT hyperproliferative (e.g. cancer of the colon, lung, breast or skin) or
PT developmental disorders.
XX
XX Claim 3; SEQ ID NO 49; 200pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADH63077-
CC ADH63154) targeted to fibroblast growth factor (FGF) receptor 2 coding
CC sequences (ADH63049 and ADH63056), which specifically hybridize with and
CC inhibit FGF receptor 2 expression. The antisense oligonucleotides are
CC useful for treating or preventing diseases or conditions associated with
CC FGF receptor 2 in an animal, e.g. hyperproliferative disorders
CC (particularly cancer of the colon, lung, breast or skin), or
CC developmental disorders. The antisense compound may also be used in wound
CC healing. The antisense compounds are useful for diagnostics,
CC therapeutics, prophylaxis, or as research reagents or kits.
XX
XX Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2738 GCTCCTCTTTAACTCTCC 2757
Db 1 GCTCCTGCTTAAACTCTTC 20

RESULT 360
ADH59608
ID ADH59608 standard; DNA; 20 BP.
XX
AC ADH59608;
XX
XX 25-MAR-2004 (first entry)
XX
DE Non-nucleotide probe of the invention #12.
XX
XX non-nucleotide probe; Bacterial Artificial Chromosome clone; BAC; ss;
KW probe.
XX
OS Synthetic.
XX
XX WO2003027328-A2.
XX
XX 03-APR-2003.
XX
XX 24-SEP-2002; 2002WO-US030573.
XX
XX 24-SEP-2001; 2001US-0324499P.
XX
XX (BOST-) BOSTON PROBES INC.
XX
XX (DAKO-) DAKOCYTOMATION DENMARK AS.
XX
XX Kirteen NV, Hyldig-Nielsen JJ, Williams BF;
XX
XX WPI; 2003-421160/39.
XX
XX Non-nucleotide probe for suppressing binding of detectable nucleic acid
PT probes to undesired sequences, has aggregate nucleobase sequence
PT homologous to randomly distributed repeat sequence of genomic nucleic
PT acid.
XX
```


KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 8226; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 10 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3494 TTACTATTATGATGATTT 3513
DB 20 TTACTATTAAATGATTT 1
RESULT 367
ABZ97424
ID ABZ97424 standard; DNA; 20 BP.
XX
AC ABZ97424;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human IL4-R oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 12666; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 231 GAGCTGCTCCAGGACGCGC 250
DB 1 GAGCAGGTCAGGACAGGC 20
RESULT 368
ABZ88816/c
ID ABZ88816 standard; DNA; 20 BP.
XX
AC ABZ88816;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 5992; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTCTTCTCTCTTTTTC 2586
DB 20 TTTTCTTTTCTTTTTC 1

RESULT 375
ABZ99050
ID ABZ99050 standard; DNA; 20 BP.
XX
XX ABZ99050;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human PDE4C oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 14292; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 0 A; 1 C; 0 G; 19 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2568 TTCTTCTCTCTTTTTC 2587
DB 1 TTTTCTTTTCTTTTTC 20

RESULT 376
ABZ88815/C
ID ABZ88815 standard; DNA; 20 BP.
XX
XX ABZ88815;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 677; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTCTTTTTTTT 2586
DB 1 TTTTCTTTTTTTTTTTTTT 20

RESULT 379
ABZ88817/c
ID ABZ88817 standard; DNA; 20 BP.
XX
AC ABZ88817;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 4059; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTCTTTTTTTT 2586
DB 20 TTTTCTTTTTTTTTTTTTT 1

RESULT 380
ABZ88939/c
ID ABZ88939 standard; DNA; 20 BP.
XX
AC ABZ88939;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 6474; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 6 A; 1 C; 11 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3577 TCTTAGGGAACGATGGG 3596
DB 1 TCTGAGGGAGAGGAAGGG 20
RESULT 383
ABZ87681
ID ABZ87681 standard; DNA; 20 BP.
XX AC ABZ87681;
XX 17-OCT-2003 (first entry)
XX Human oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 2923; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 0 A; 1 C; 0 G; 19 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2568 TTCTTCTCTCTTTTTC 2587
DB 1 TTTTCTTTTCTTTTTC 20
RESULT 384
ABZ88566/c
ID ABZ88566 standard; DNA; 20 BP.
XX AC ABZ88566;
XX 17-OCT-2003 (first entry)
XX Human oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 4683; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCTCTCTCTTTTCTTTT 2586
DB 20 TTTTCTTTTCTTTTCTTTT 1
RESULT 391
ABZ90183
ID ABZ90183 standard; DNA; 20 BP.
XX ABZ90183;
XX 17-OCT-2003 (first entry)
XX Human oligonucleotide sequence.
DE Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 5425; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1396 GTACTCAGTTGATCTCGAA 1415
DB 1 GTACACAGTTGATATCCAA 20
RESULT 392
ABZ85535/c
ID ABZ85535 standard; DNA; 20 BP.
XX ABZ85535;
XX 17-OCT-2003 (first entry)
XX Human oligonucleotide sequence.
DE Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
PF 24-APR-2001; 2001US-0286137P.
XX
PR (EPIG-) EPIGENESIS PHARM INC.
XX
PA
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 4362; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTTCTTTTCTTTT 2586
DB 20 TTTTCTTCTCTTTTCTTTTCTTTT 1

RESULT 395
ABZ89592/C
ID ABZ89592 standard; DNA; 20 BP.
XX
AC ABZ89592;
XX
XX 17-OCT-2003 (first entry)
DT
DE Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
PF 24-APR-2001; 2001US-0286137P.
XX
PR (EPIG-) EPIGENESIS PHARM INC.
XX
PA
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 4834; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2579 TTTTCTTCTGAAAAAGGA 2598
DB 20 TTTTCTTCTGAAAAAGGA 1

RESULT 396
ABZ89704/C
ID ABZ89704 standard; DNA; 20 BP.
XX
AC ABZ89704;
XX
XX 17-OCT-2003 (first entry)
DT
DE Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 4946; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTTTTTTTTTT 2586
DB 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 397
ABZ90289
ID ABZ90289 standard; DNA; 20 BP.
XX
AC ABZ90289;
XX
DT 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 5531; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 2 C; 2 G; 12 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2575 TCTTTTTTTTTTCTGAAAAA 2594
DB 1 TCTTTTTTTTTTCAGGAATA 20

RESULT 398
ABZ76038
ID ABZ76038 standard; DNA; 20 BP.
XX
AC ABZ76038;
XX
DT 29-MAY-2003 (first entry)
XX
XX Mammalian cruciform forming replication origin sequence.
XX
XX Cruciform; DNA replication; antigen; antibacterial; virucide; fungicide;
KW protozoazide; antihelminthic; anti-HIV; cytostatic; gene therapy; ds.
XX

```
OS Synthetic.
XX WO2003012097-A2.
XX
XX
XX
XX 13-FEB-2003.
XX
XX 30-JUL-2002; 2002WO-IB003667.
XX
XX 30-JUL-2001; 2001US-0308636P.
XX
XX (PRIC/) PRICE G B.
XX (ZANN/) ZANNIS-HADJOPOULOS M.
XX
XX Price GB, Zannis-Hadjopoulos M;
XX
XX WPI; 2003-248179/24.
XX
XX Inhibiting DNA replication or cell proliferation, useful for treating
XX tumors, comprises contacting a DNA molecule with a nucleic acid antigen
XX that specifically hybridizes to a portion of the DNA molecule having dyad
XX symmetry.
XX
XX Disclosure; Page 14; 54pp; English.
XX
XX The invention relates to inhibiting DNA replication and involves
XX contacting a DNA molecule with a nucleic acid antigen comprising at
XX least 12 nucleobases selected from natural nucleobases, modified
XX nucleobases, and their mixture. The antigen specifically hybridizes to a
XX portion of the DNA molecule having dyad symmetry. The method is useful in
XX inhibiting DNA replication and, thus, inhibiting the growth of bacteria,
XX virus (e.g. HIV), fungi, protozoa, helminths and insects. The method is
XX also useful in inhibiting cell proliferation of tumour cells. Sequences
XX AB276034-49 represent mammalian cruciform forming replication origin
XX sequences
XX
XX Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 2180 GGAGCTGCTCCATCTTC 2199
XX | | | | |
XX 1 GAAGGTTCTCTCCATCTTC 20
XX
XX RESULT 399
XX ACD27320/c
XX ID ACD27320 standard; DNA; 20 BP.
XX
XX AC ACD27320;
XX
XX 15-OCT-2003 (first entry)
XX
XX Nanotechnology nucleic acid detection method associated #54.
XX
XX Nanotechnology; ss; nucleic acid detection; nanoparticle;
XX virus detection; human immunodeficiency virus; HIV; hepatitis; herpes;
XX cytomegalovirus; Epstein-Barr virus; bacterial disease; DNA sequencing;
XX sexually transmitted disease; inherited disorder; forensic;
XX paternity testing; cell line authentication.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1
XX /*tag= a
XX /mod_base= OTHER
XX /note= "OTHER= Thiol modified"
XX
XX US2002155461-A1.
XX
XX 24-OCT-2002.
```

```
XX 12-OCT-2001; 2001US-00976378.
XX
XX 29-JUL-1996; 96US-0031809P.
XX 21-JUL-1997; 97WO-US012783.
XX 29-JAN-1999; 99US-00240755.
XX 25-JUN-1999; 99US-00344667.
XX 26-APR-2000; 2000US-0200161P.
XX 26-JUN-2000; 2000US-00603830.
XX
XX (NANO-) NANOSPHERE INC.
XX
XX Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
XX Taton TA;
XX
XX WPI; 2003-228115/22.
XX
XX Detecting nucleic acids having 2 portions e.g. for detecting disease,
XX comprises use of nanoparticles which have oligonucleotides attached to
XX them that are complementary to portions of the nucleic acid sequence.
XX
XX Example 18; Page 44; 130pp; English.
XX
XX This invention relates to a novel method for detecting a nucleic acid
XX having 2 portions. The method comprises providing nanoparticles having
XX oligonucleotides attached, where the oligonucleotide on each nanoparticle
XX has a sequence complementary to a sequence of 2 portions of nucleic acid.
XX The nucleic acid and nanoparticle are contacted to allow hybridisation of
XX the oligonucleotide on the nanoparticle with two or more portions of
XX the nucleic acid and observing a detectable change brought about by the
XX hybridisation. The method of the invention is useful for separating a
XX selected nucleic acid having 2 portions, from other nucleic acids, and
XX for detecting nucleic acids having 2 portions. The method of the
XX invention is useful for detecting any type of nucleic acids which may be
XX used for diagnosis of disease and in sequencing of nucleic acids.
XX Preferably, the method is useful for detecting nucleic acids for
XX diagnosis and/or monitoring of viral diseases (human immunodeficiency
XX virus, hepatitis virus, herpes virus, cytomegalovirus and Epstein-Barr
XX virus), bacterial diseases, sexually transmitted diseases, inherited
XX disorders, in forensics, in DNA sequencing, for paternity testing, for
XX cell line authentication, for monitoring gene therapy, etc. This method
XX involves detecting nucleic acids based on observing a colour change with
XX the naked eye so is cheap, fast, simple and robust, and does not require
XX specialised expensive equipment. The present sequence represents a thiol
XX modified oligonucleotide sequence used to demonstrate the method of the
XX invention
XX
XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 2567 TTCTCTCTCTCTCTCTCTCT 2586
XX | | | | |
XX 20 TTTTCTCTCTCTCTCTCTCTCT 1
XX
XX RESULT 400
XX ADA66526
XX ID ADA66526 standard; DNA; 20 BP.
XX
XX AC ADA66526;
XX
XX 20-NOV-2003 (first entry)
XX
XX Transforming growth factor-beta 3 antisense oligonucleotide, SEQ ID 85.
XX
XX Cytostatic; antirheumatic; antiarthritic; gynecological;
XX antiarteriosclerotic; Transforming Growth Factor beta-3; TGF beta-3;
XX hyperproliferative disorder; cancers; atherosclerosis;
XX rheumatoid arthritis; preeclampsia; fibrosis; phosphorothioate; ss.
XX
```

```

OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
XX WO2003008544-A2.
XX PN
XX PD
XX PP 30-JAN-2003.
XX PR 12-JUL-2002; 2002WO-US022423.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX WPI; 2003-229569/22.
XX
XX Novel antisense compound which is targeted to nucleic acid encoding
XX transforming growth factor beta-3, and inhibits expression of TGF-beta 3,
XX useful for treating a condition associated with TGF-beta 3, e.g. cancer.
XX
XX Example 15; Page 88; 154pp; English.
XX
XX The present invention relates to antisense oligonucleotides (ADA66459-
XX ADA6609), which inhibit Transforming Growth Factor (TGF) beta-3
XX expression. The oligonucleotides are useful for inhibiting the expression
XX of TGF-beta3 in cells or tissues, and for treating an animal having a
XX disease condition associated with TGF-beta3, e.g. a hyperproliferative
XX disorder such as cancers of lung, liver, colon, oesophagus, pancreas,
XX breast, skin or hematopoietic, atherosclerosis, rheumatoid arthritis,
XX preclampsia and fibrosis.
XX
XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 972 TGCAGAGCTGCTCCAGGA 991
Db 1 TGTAGCACCTGCTTCAGGA 20
||| ||||| ||||| |||||
1 TGTAGCACCTGCTTCAGGA 20
RESULT 401
ACC62213
ID ACC62213 standard; DNA; 20 BP.
XX
XX ACC62213;
XX
XX 20-JUN-2003 (first entry)
XX
XX Mouse alipoprotein B antisense oligonucleotide SEQ ID NO: 102.
XX
XX alipoprotein B; ApoB; antilipemic; antiarteriosclerotic; antidiabetic;
XX anorectic; cardiovascular; gene therapy; lipid metabolism;
XX cholesterol metabolism; atherosclerosis; hyperlipidaemia; diabetes;
XX type 2 diabetes; obesity; atherosclerosis; cardiovascular disease;
XX glucose; antisense oligonucleotide; ss.
XX
XX Synthetic.
XX
XX WO2003011887-A2.
XX PN
XX PD
XX PP 13-FEB-2003.
XX PR

```

```

PP 30-JUL-2002; 2002WO-US024247.
XX
XX 01-AUG-2001; 2001US-00920033.
XX 30-APR-2002; 2002US-00135985.
XX 15-MAY-2002; 2002US-00147196.
XX (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ;
XX WPI; 2003-268105/26.
XX
XX New antisense oligonucleotides for modulating apolipoprotein B,
XX especially for preventing or treating atherosclerosis, hyperlipidemia or
XX diabetes, or for modulating glucose, cholesterol, lipoprotein or
XX triglyceride levels.
XX
XX Example 17; Page 99; 160pp; English.
XX
XX The invention relates to a novel compound that is 8-50 nucleotides in
XX length that is targeted to a nucleic acid molecule encoding
XX apolipoprotein B (ApoB), and specifically hybridises with and inhibits
XX the expression of a nucleic acid molecule encoding ApoB; or which
XX specifically hybridises with at least an 8-nucleotide portion of an
XX active site on a nucleic acid molecule encoding ApoB. A compound of the
XX invention has antilipemic, antiarteriosclerotic, antidiabetic,
XX anorectic, and cardiovascular activity. The compound may have a use in
XX gene therapy. The antisense oligonucleotide is useful for treating an
XX animal having a disease or conditions associated with ApoB, e.g. a
XX condition involving abnormal lipid metabolism, a condition involving
XX abnormal cholesterol metabolism, atherosclerosis, or a condition
XX involving an abnormal metabolic condition (e.g. hyperlipidaemia, diabetes
XX (specifically Type 2 diabetes), obesity, atherosclerosis or
XX cardiovascular disease). The new compound or the antisense
XX oligonucleotide is also useful for modulating glucose levels
XX (particularly plasma or serum glucose levels) in a human or diabetic
XX animal, or for modulating serum cholesterol levels, lipoprotein levels
XX (specifically VLDL, HDL or LDL) or serum triglyceride levels,
XX particularly in a human. The antisense compound is also useful for
XX preventing or delaying the onset of a disease or condition associated
XX with ApoB, or the onset of an increase in glucose levels in the animal or
XX human. The present sequence is used in the exemplification of the
XX invention
XX
XX Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3461 AGGAAGAAATCTTGCTATT 3480
Db 1 AGGAAGAACTCTTGATATT 20
||||| ||||| ||||| |||||
1 AGGAAGAACTCTTGATATT 20
RESULT 402
ABV72388
ID ABV72388 standard; DNA; 20 BP.
XX
XX ABV72388;
XX
XX 29-JAN-2003 (first entry)
XX
XX PCR primer used to amplify Human Artemis gene cDNA.
XX
XX Human; Artemis gene; DNA repair factor; metallo beta-lactamase; RS-SCID;
XX chromosome 10; severe combined immunodeficiency; SCID1; cancer; PCR;
XX primer; ss.
XX
XX Homo sapiens.
XX
XX WO200277228-A1.
XX

```

XX New isolated nucleic acid molecule of the Artemis gene, useful for
PT diagnosing or treating SCID or cancer.
XX
PS Example 1; Page 35; 71pp; English.

[illegible]

AC	ABZ22916;
XX	'
XX	08-APR-2003 (first entry)
DI	
XX	phosphorothioate 20-mer oligonucleotide #1.
DE	
XX	Chiral; phosphorothioate; oligonucleotide synthesis; enantiomer; ss.
KW	
XX	Synthetic.
OS	

DT	08-APR-2003 (first entry)
XX	
DE	phosphorothioate 20-mer oligonucleotide #1.
XX	
KW	Chiral; phosphorothioate; oligonucleotide synthesis; enantiomer; ss.
XX	
OS	synthetic.
OS	

Chiral; phosphorothioate; oligonucleotide synthesis; enantiomer; ss.
 KW
 XX
 OS Synthetic.

```
FT modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
```

XXIX

XXXXXX

XX

XX

XX

XX
XX

XX
XX

XX

PT enantiomer, by coupling a synthon with 2'-substituted nucleoside in

PT enantiomer.

PS Example 1; Page 31; 65pp; English.

CC The present invention describes a method (M1) for preparing an

CC enantiomer between a synthon having a hydroxyl moiety at the 5' position
CC and a 2'-substituted nucleoside having an activated phosphate moiety at
CC the 3'-position, comprising coupling a synthon with a 2'-substituted
CC nucleoside in the presence of coupling agent that is selected to enhance
CC either the Rp or Sp enantiomer according to its pKa. This method is⁵

CC either the Rp or Sp enantiomer according to its pKa. This method is

CC internucleotide linkages that is enhanced in the Sp or Rp enantiomer,

CC position or a growing oligonucleotide chain having a hydroxyl moiety at

CC the 5'-position, coupling the nucleotide or growing oligonucleotide chain
 CC to a 2'-substituted nucleoside having an activated phosphate moiety at
 CC the 3' position in the presence of the coupling agent, and repeating the
 CC coupling step until the desired number of linkages is established. The
 CC oligonucleotide having a region of internucleotide linkages that is
 CC enhanced in the S_p enantiomer is further processed to include another
 CC region of internucleotide linkages that is enhanced in the S_p and/or R_p
 CC enantiomer. Oligonucleotides prepared by the method lead to improved
 CC drugs, diagnostics and research reagents. The present sequence represents
 CC an oligonucleotide used in the exemplification of the present invention
 XX
 SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTCTTTTTTTT 2586

DB 1 TTTTCTTTTTTTTTTTTT 20

RESULT 405
 ABD27462
 ID ABD27462 standard; DNA; 20 BP.

XX ABD27462;

XX 29-JUL-2004 (first entry)

DE H37989-derived oligonucleotide SEQ ID 6474.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

PN 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 6474; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 6 A; 1 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3577 TCTTAGGGAAGGAATGGG 3596

DB 1 TCTGAGGAGAGGAAGGGG 20

RESULT 406

ABD30455

ID ABD30455 standard; DNA; 20 BP.

XX ABD30455;

XX 29-JUL-2004 (first entry)

XX Human IL4-R derived oligonucleotide SEQ ID 12666.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

PN 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2569 TCTTCTCTCTCTCTCTCTCTCT 2598
 Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 410
 ABD29214/c

ID ABD29214 standard; DNA; 20 BP.
 XX
 AC ABD29214;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE AA150500-derived oligonucleotide SEQ ID 8236.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 8226; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX
 SQ Sequence 20 BP; 10 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3494 TTACTATTTATGATGATTTT 3513
 Db 20 TTACTATTAATAATGATTTT 1

RESULT 411
 ABD25316/c

ID ABD25316 standard; DNA; 20 BP.
 XX
 AC ABD25316;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE AI092429-derived oligonucleotide SEQ ID 4328.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 4328; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,

CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2567 TTTCTTCTCTTTTTTTTTT 2586

DB 20 TTTTCTTCTCTTTTTTTTTT 1

RESULT 412

ID ABD21763/c

ABD21763 standard; DNA; 20 BP.

XX ABD21763;

AC ABD21763;

XX 29-JUL-2004 (first entry)

DE Human stanniocalcin-derived oligo SEQ ID 775.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

PN 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (BPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

DR Pharmaceuical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 775; 763pp; English.

PS This invention describes a novel composition (a) a first active agent,
 XX comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction of cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2567 TTTCTTCTCTTTTTTTTTT 2586

DB 20 TTTTCTTCTCTTTTTTTTTT 1

RESULT 413

ABD25246/c

ID ABD25246 standard; DNA; 20 BP.

XX ABD25246;

AC ABD25246;

XX 29-JUL-2004 (first entry)

DE AI051839-derived oligonucleotide SEQ ID 4258.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

```
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX FI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX XX
XX DR WPI; 2003-093058/08.
XX XX
XX PT Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX PS Claim 15; SEQ ID NO 4258; 763pp; English.
XX XX
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes a kit, that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX CC prevent any unwanted effects due to it
XX SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 2567 TTTCTCTCTCTTTTTTTT 2586
XX DB 20 TTTTCTCTCTCTTTTTTTT 1
XX
XX RESULT 414
XX ABD24849/C
XX ID ABD24849 standard; DNA; 20 BP.
XX XX
XX AC ABD24849;
XX XX
XX DT 29-JUL-2004 (first entry)
XX DE AI092623-derived oligonucleotide SEQ ID 3861.
XX XX
XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
```

```
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX OS Homo sapiens.
XX PN WO200285309-A2.
XX XX
XX PD 31-OCT-2002.
XX XX
XX PF 23-APR-2002; 2002WO-US013143.
XX XX
XX PR 24-APR-2001; 2001US-0286036P.
XX XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX XX
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX XX
XX DR WPI; 2003-093058/08.
XX XX
XX PT Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX PS Claim 15; SEQ ID NO 3861; 763pp; English.
XX XX
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes a kit, that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC inflammation, allergies, asthma, impeded respiration, respiratory
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX CC prevent any unwanted effects due to it
XX SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 2567 TTTCTCTCTCTTTTTTTT 2586
XX DB 20 TTTTCTCTCTCTTTTTTTT 1
XX
XX RESULT 415
XX ABD21665
XX ID ABD21665 standard; DNA; 20 BP.
XX XX
```

AC ABD21665;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human stanniocalcin-derived oligo SEQ ID 677.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 677; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2567 TTTCTTCTCTCTTTTTTTTTT 2586
Db 1 TTTTTTTTTTTTTTTTTTTT 20

RESULT 416

ABD24796/C
ID ABD24796 standard; DNA; 20 BP.
XX
AC ABD24796;
XX
DT 29-JUL-2004 (first entry)
XX
DE A112689-derived oligonucleotide SEQ ID 3808.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 3808; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP: 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

```
Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 2567 TTTCTTCTTCTTTT 2586

Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 417
ABD25045/C
ID ABD25045 standard; DNA; 20 BP.

AC ABD25045;

DT 29-JUL-2004 (first entry)

DE AI128305-derived oligonucleotide SEQ ID 4057.

KW Human; antihense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; allergic; antiinflammatory; antisthmatic;
KW analgesic; hypertensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

PN WO200285309-A2.

31-OCT-2002.

23-APR-2002; 2002WO-US013143.

24-APR-2001: 2001US-0286036P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX
PI Nvce JW. Li Y. Sandrasaqa A, Katz E, Pabalan J, Aguilar D;

PI Nyce SW, Li 1, Shahabuddin S;
PI Miller S, Tang L, Shahabuddin S;

DR WPI: 2003-093058/08.

pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

PS Claim 15: SEO ID NO 4057; 763pp: English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c)

instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match	0.4%	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%	Pred. No. 2.4e+02;		
Matches 17: Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

2567 TTTCTTCTTCTTTT 2586

Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 418

ABD25350/c

ID ABD25350 standard; DNA; 20 BP.

AC ABD25350;

29-JUL-2004 (first entry)

DE AI096522-derived oligonucleotide SEQ ID 4362.

Human; antitense; bronchoconstriction; allergy; hyposecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
surfactant depletion; allergic; antiinflammatory; antisthmatic;
analgesic; hypotensive; immunosuppressive; cystostatic; cystic fibrosis;
beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection; cancer; ss; primer.

XX Homo sapiens.

XX PN WO200285309-A2.

31-OCT-2002

XX
PF 23-APR-2002: 2002WO-US013143.XX
PP 24-APR-2001: 2001US-0286036P.

XX PA (EPTG-) EPIGENESIS PHARM INC.

XX
PT Niyce JW I; V. Sandrasagra A. Katz E. Pabalan J. Aquilar D;

PI Miller S, Tang L, Shahabuddin S;
yy

DR WPI; 2003-093058/08.

PT pharmaceutical composition for treating asthma, has an active
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XXI

CC	hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC	transplantation rejection, pulmonary infections, bronchitis or cancer.
CC	The reduced adenosine content of the anti-sense oligos corresponding to
CC	thymidines present in the target RNA serves to prevent the breakdown of
CC	the oligonucleotides into products that free adenosine into the system
CC	e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC	prevent any unwanted effects due to it
XX	
SQ	Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
	Query Match 0.4%; Score 15.2; DB 1; Length 20;
	Best Local Similarity 85.0%; Pred. No. 2.4e+02;
	Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	2567 TTCTCTCTCTTTTTTTTTT 2586
Dd	20 TTTTTTTTTTTTTTTTTTTT 1
RESULT 423	
ABD25934/c	
ID ABD25934 standard; DNA; 20 BP.	
AC ABD25934;	
XX	
DT 29-JUL-2004 (first entry)	
XX	
DE AA505075-derived oligonucleotide SEQ ID 4946.	
XX	
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;	
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;	
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;	
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;	
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;	
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;	
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;	
KW pulmonary transplantation rejection; ss; primer.	
OS Homo sapiens.	
XX	
XX WO200285309-A2.	
XX	
PD 31-OCT-2002.	
XX	
Pf 23-APR-2002; 2002WO-US013143.	
XX	
PR 24-APR-2001; 2001US-0286036P.	
XX	
PA (EPIG-) EPTGENESIS PHARM INC.	
XX	
PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;	
PI Miller S, Tang L, Shahabuddin S;	
XX	
DR WPI; 2003-093058/08.	
XX	
PT Pharmaceutical composition for treating asthma, has antisense	
PT oligonucleotide containing less percentage of adenosine, targeted to	
PT nucleic acids associated with lung airway or lung dysfunction, and	
PT bronchodilating agent.	
XX	
PS Claim 15; SEQ ID NO 4946; 763pp; English.	
XX	
CC This invention describes a novel composition (a) a first active agent,	
CC comprising oligonucleotides, effective for alleviating	
CC bronchoconstriction, respiratory tract inflammation, allergies and	
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,	
CC surfactant depletion or hyposecretion, when administered to a mammal.	
CC Oligonucleotides are derived from a gene encoding or regulating	
CC expression of a target polypeptide associated with lung airway or lung	
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.	
CC The invention also describes a kit, that comprises: (a) a delivery	
CC device, in separate containers, (b) the oligonucleotides, (c)	
CC instructions for adding a carrier and for use of the kit.	
CC The composition	

PS Claim 15: SEO ID NO 4947; 763pp; English.

DT	29-JUL-2004 (first entry)	
XX	S100 calcium binding protein A2-derived oligo SEQ ID 553.	
XX	Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;	
XX	respiratory tract inflammation; adenosine sensitivity; lung; cancer;	
XX	surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;	
KW	analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;	
KW	beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;	
KW	respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;	
KW	emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;	
KW	pulmonary transplantation rejection; ss; primer.	
XX	Homo sapiens.	
OS	WO200285309-A2.	
FN	31-OCT-2002.	
PD	23-APR-2002; 2002WO-US013143.	
PF	24-APR-2001; 2001US-0286036P.	
PP	(EPIG-) EPIGENESIS PHARM INC.	
PR	Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;	
PR	Miller S, Tang L, Shahabuddin S;	
XX	WPI; 2003-093058/08.	
DR	Pharmaceutical composition for treating asthma, has antisense	
XX	oligonucleotide containing less percentage of adenosine, targeted to	
PT	nucleic acids associated with lung airway or lung dysfunction, and	
PT	bronchodilating agent.	
XX	Claim 15; SEQ ID NO 553; 763pp; English.	
XX	This invention describes a novel composition (a) a first active agent,	
CC	comprising oligonucleotides, effective for alleviating	
CC	bronchoconstriction, respiratory tract inflammation, allergies and	
CC	reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors.	
CC	surfactant depletion or hyposecretion, when administered to a mammal. The	
CC	oligonucleotides are derived from a gene encoding or regulating	
CC	expression of a target polypeptide associated with lung airway or lung	
CC	dysfunction or cancer and can be anti-sense to the corresponding mRNA.	
CC	The invention also describes a kit, that comprises: (a) a delivery	
CC	device, in separate containers, (b) the oligonucleotides, (c)	
CC	of the invention has anti-allergic, anti-inflammatory, antiasthmatic,	
CC	analgesic, hypotensive, immunosuppressive and cytostatic activity, is a	
CC	beta-adrenergic agonist. The composition is useful for preventing or	
CC	treating a respiratory, lung or malignant disease. The administered	
CC	composition comprises oligo and is administered to reduce the production	
CC	or availability, or to increase the degradation of the target mRNA or to	
CC	reduce the amount of target polypeptide present in the lungs. The	
CC	pulmonary obstruction, and/or bronchoconstriction and/or lung	
CC	inflammation, allergies and/or surfactant hypoproduction are associated	
CC	with a disease or condition such as pulmonary vasoconstriction,	
CC	inflammation, allergies, asthma, impeded respiration, respiratory	
CC	distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary	
CC	hypertension, emphysema, chronic obstructive pulmonary disease, cancer.	
CC	The reduced adenosine content of the anti-sense oligos corresponding to	
CC	thymidines present in the target RNA serves to prevent the breakdown of	
CC	the oligonucleotides into products that free adenosine into the system	
CC	e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to	
CC	prevent any unwanted effects due to it	
XX	Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;	
XX	Query Match 0.4%; Score 15.2; DB 1; Length 20;	
XX	Best Local Similarity 85.0%; Pred. No. 2.4e+02;	
XX	Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	

CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2567 TTTCTTCTCTTTTCTTTT 2586
 DB 20 TTTTCTTTTCTTTTCTTTT 1
 RESULT 429
 ABD26413
 ID ABD26413 standard; DNA; 20 BP.
 AC
 XX ABD26413;
 DT 29-JUL-2004 (first entry)
 XX
 DE AA487557-derived oligonucleotide SEQ ID 5425.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIC-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 5425; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1396 GTACTCAGTTGATCTCGAA 1415

DB 1 GTACACAGTTGATCTCCAA 20

RESULT 430

ABD21765/c

ID ABD21765 standard; DNA; 20 BP.

XX

AC ABD21765;

XX

DT 29-JUL-2004 (first entry)

XX

DE Human stanniocalcin-derived oligo SEQ ID 777.

XX

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX

PN WO200285309-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013143.

XX

PR 24-APR-2001; 2001US-0286036P.

XX

PA (EPIC-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

PI

DR WPI; 2003-093058/08.

XX

PT Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX

PS Claim 15; SEQ ID NO 777; 763pp; English.

XX

CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypo-production are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
CC
XX Sequence 20 BP; 18 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

```
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

	2567	2586
Qy	TTTTCTCTCTCTTTTTTT	TTTTCTCTCTCTTTTTTT
pb		
	20	20

RESULT 431
ABD26519
ID ABD26519 standard; DNA: 20 BP.

AC ABD26519;

DT 29-JUL-2004 (first entry)

DE AI313387-derived oligonucleotide SEQ ID 5531.

Human, antiense; bronchoconstriction; allergy; hyposecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
surfactant depletion; allergic; antiinflammatory; antisthmaic;
analgesic; hypertensive; immunosuppressive; cystostatic; cystic fibrosis;
beta-adrenergic agonist; respiratory disease; pulmonary vasodilation;
respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX PN WO200285309-A2.

31-OCT-2002.

23-APR-2002: 2002WO-US013143.

24-APR-2001: 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XXII

PI	Nyce JW, Li Y, Sandraseagra A, Katz E, Pabalan J, Aguilar D;
PI	Miller S, Tang L, Shahabuddin S;
XX	WPI; 2003-093058/08.
DR	
XX	Pharmaceutical composition for treating asthma, has antisense
PT	oligonucleotide containing less percentage of adenosine, targeted to
PT	nucleic acids associated with lung airway or lung dysfunction, and
PT	bronchodilating agent.

PS Claim 15: SEO ID NO 5531; 763pp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating allergies and bronchoconstriction, respiratory tract inflammation, (A) or (A) receptors, reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating lung expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA.

The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it.

Sequence 20 BP: 4 A; 2 C; 2 G; 12 T; 0 U; 0 Other; XX SO

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches	17: Conservative	0: Mismatches	3; Indels	0; Gaps
Matches	17: Conservative	0: Mismatches	3; Indels	0; Gaps

2575 TCCTTTTCTGAAAA 2594

1 TCTTTTTCAGGAATA 20

RESULT 432

RESOL 432
ABD26880/C

ABD26880/ C
ID ABD26880 standard: DNA: 20 BP.

XX

AC ABD26880;

29-JUL-2004 (first entry)

AA
DE
AA278764-derived oligonucleotide SEQ ID 5892.[illegible]

CC	The reduced adenosine content of the anti-sense oligos corresponding to
CC	thymidines present in the target RNA serves to prevent the breakdown of
CC	the oligonucleotides into products that free adenosine into the system
CC	e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC	prevent any unwanted effects due to it
XX	
SEQ	Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
	Query Match 0.4%; Score 15.2; DB 1; Length 20;
	Best Local Similarity 85.0%; Pred. No. 2.4e+02;
	Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	2579 TTTTCTTCTGAAAAAGGA 2598
Db	20 TTTTCTTCTGAAAAAGGA 1
RESULT 435	
ABD25532/c	
ID	ABD25532 standard; DNA; 20 BP.
XX	
AC	
XX	ABD25532;
XX	
DT	29-JUL-2004 (first entry)
XX	
XX	A1125651-derived oligonucleotide SEQ ID 4544.
DE	
XX	
KW	Human, antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW	respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW	surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW	analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW	beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW	respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW	emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW	pulmonary transplantation rejection; ss; primer.
XX	
OS	Homo sapiens.
XX	
XX	WO200285309-A2.
PN	
XX	
FD	31-OCT-2002.
XX	
XX	23-APR-2002; 2002WO-US013143.
PF	
XX	
XX	24-APR-2001; 2001US-0286036P.
PR	
XX	
PA	(EPIG-) EPIGENESIS PHARM INC.
XX	
XX	Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI	Miller S, Tang L, Shahabuddin S;
PI	
XX	
DR	WPI; 2003-093058/08.
XX	
PT	Pharmaceutical composition for treating asthma, has antisense
PT	oligonucleotide containing less percentage of adenosine, targeted to
PT	nucleic acids associated with lung airway or lung dysfunction, and
PT	bronchodilating agent.
XX	
PS	Claim 15; SEQ ID NO 4544; 763pp; English.
XX	
CC	This invention describes a novel composition (a) a first active agent,
CC	comprising oligonucleotides, effective for alleviating
CC	bronchoconstriction, respiratory tract inflammation, allergies and
CC	reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC	surfactant depletion or hyposecretion, when administered to a mammal. The
CC	oligonucleotides are derived from a gene encoding or regulating
CC	expression of a target polypeptide associated with lung airway or lung
CC	dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC	The invention also describes a kit, that comprises: (a) a delivery
CC	device, in separate containers, (b) the oligonucleotides, (c)
CC	instructions for adding a carrier and for use of the kit. The composition
CC	of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC	analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTT 2586

DB 20 TTTTCTTCTTCTTTT 1

RESULT 436

ABD25046/C

ID ABD25046 standard; DNA; 20 BP.

AC ABD25046;

DT 29-JUL-2004 (first entry)

DE A1128305-derived oligonucleotide SEQ ID 4058.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 XX pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 4058; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTT 2586

DB 20 TTTTCTTCTTCTTTT 1

RESULT 437

ABD23911

ID ABD23911 standard; DNA; 20 BP.

XX ABD23911;

XX 29-JUL-2004 (first entry)

XX Human calmodulin 2-derived oligonucleotide SEQ ID 2923.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 XX pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PT treating diseases associated with beta-site APP-cleaving enzyme, e.g.
 PT neurodegeneration.
 XX
 PS Example 15; SEQ ID NO 41; 58pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding a beta-site amyloid precursor protein (APP)-cleaving enzyme. The
 CC antisense oligonucleotides and compounds are useful for inhibiting the
 CC expression of beta-site amyloid precursor protein (APP)-cleaving enzyme,
 CC modulating amyloid deposition in neurons, altering the expression of a
 CC splice variant of beta-site APP-cleaving enzyme, and for treating
 CC diseases or conditions associated with expression of beta-site APP-
 CC cleaving enzyme e.g. neurodegeneration or Alzheimer's disease. The
 CC antisense compounds are also useful as research reagents and kits, or in
 CC diagnostic, therapeutic and prophylaxis applications, e.g. to prevent or
 CC delay infection, inflammation or tumour formation. The present sequence
 CC represents a human APP-cleaving enzyme antisense oligonucleotide.
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2618 TTTCAGCCATTTTCAGATC 2637
 |||||
 DB 1 TTGCAGTCCATTTTCAGATC 20

RESULT 444
 ADH0814/C
 ID ADH0814 standard; DNA; 20 BP.
 XX
 AC ADH0814;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Nanotechnology nucleic acid detection method associated #54.
 XX
 KW Linking oligonucleotide; ss; nucleic acid detection;
 KW nanoparticle-oligonucleotide conjugate.
 XX
 OS Synthetic.
 XX
 XX US2002137072-A1.
 XX
 PD 26-SEP-2002.
 XX
 PF 12-OCT-2001; 2001US-00976617.
 XX
 PR 29-JUL-1996; 96US-0031809P.
 PR 21-JUL-1997; 97WO-US012783.
 PR 29-JAN-1999; 99US-00240755.
 PR 25-JUN-1999; 99US-00344667.
 PR 26-APR-2000; 2000US-0200161P.
 PR 26-JUN-2000; 2000US-00603830.
 XX
 PA (NANO-) NANOSPHERE INC.
 XX
 PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
 PI Taton TA;
 XX
 DR WPI; 2004-059020/06.
 XX
 CC Detecting nucleic acid used for e.g. diagnosis of diseases, forensics and
 CC DNA sequencing, comprises observing detectable change caused by
 CC hybridization of nucleic acid with substrate or particle bound
 CC oligonucleotides.
 XX
 XX Example 18; SEQ ID NO 55; 130pp; English.
 XX
 PS The invention relates to a method of detecting a nucleic acid with at
 CC least two portions by providing a type of nanoparticle-oligonucleotide

CC conjugate, contacting the nucleic acid and nanoparticles to allow
 CC hybridisation of the oligonucleotides with the two or more portions of
 CC the nucleic acid and observing a detectable change brought about by
 CC hybridisation. The oligonucleotides have a sequence complementary to the
 CC sequence of at least two portions of the nucleic acid. Hybridisation of
 CC the oligonucleotides on the nanoparticles with the nucleic acid results
 CC in a detectable change. This sequence represents a linking
 CC oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCT 2586
 |||||
 DB 20 TTTTCTCTCTCTCTCTCTCTCT 1

RESULT 445
 ADH08749/C
 ID ADH08749 standard; DNA; 20 BP.
 XX
 AC ADH08749;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Nanotechnology nucleic acid detection method associated #54.
 XX
 KW Linking oligonucleotide; ss; nucleic acid detection;
 KW nanoparticle-oligonucleotide conjugate.
 XX
 OS Synthetic.
 XX
 XX US2002137071-A1.
 XX
 PD 26-SEP-2002.
 XX
 PF 10-OCT-2001; 2001US-00974007.
 XX
 PR 29-JUL-1996; 96US-0031809P.
 PR 21-JUL-1997; 97WO-US012783.
 PR 29-JAN-1999; 99US-00240755.
 PR 25-JUN-1999; 99US-00344667.
 PR 26-APR-2000; 2000US-0200161P.
 PR 26-JUN-2000; 2000US-00603830.
 XX
 PA (NANO-) NANOSPHERE INC.
 XX
 PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;
 PI Taton TA;
 XX
 DR WPI; 2004-059019/06.
 XX
 CC Detecting nucleic acid used for e.g. diagnosis of diseases, forensics and
 CC DNA sequencing, comprises observing detectable change caused by
 CC hybridization of nucleic acid with substrate or particle bound
 CC oligonucleotides.
 XX
 XX Example 18; SEQ ID NO 55; 130pp; English.
 XX
 CC The invention relates to a method of detecting a nucleic acid with at
 CC least two portions by providing a type of nanoparticle-oligonucleotide
 CC conjugate, contacting the nucleic acid and nanoparticles to allow
 CC hybridisation of the oligonucleotides with the two or more portions of
 CC the nucleic acid and observing a detectable change brought about by
 CC hybridisation. The oligonucleotides have a sequence complementary to the
 CC sequence of at least two portions of the nucleic acid. Hybridisation of
 CC the oligonucleotides on the nanoparticles with the nucleic acid results
 CC in a detectable change. This sequence represents a linking
 CC oligonucleotide of the invention.

```
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTTCTCTTTTTTTTTT 2586
||| ||| ||| ||| ||| ||| |||
Db 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 446
ADH14417
ID ADH14417 standard; DNA; 20 BP.
XX
AC ADH14417;
XX
DT 11-MAR-2004 (first entry)
XX
DE Mouse retinoblastoma 1 (RB1CC1) cDNA PCR primer MINT23-S.
XX
KW cell nucleus; transcription; gene expression; retinoblastoma-1; RB1CC1;
XX diagnosis; cancer; primer; ss.
XX
OS Mus sp.
XX
PN WO2003102028-A1.
XX
PD 11-DEC-2003.
XX
PF 30-JAN-2003; 2003WO-JP000882.
XX
PR 03-JUN-2002; 2002JP-00161400.
XX
PR 24-JUL-2002; 2002JP-00214978.
XX
PA (OKAB//) OKABE H.
XX (IKEG//) IKEGAWA S.
XX (CHAN//) CHANO T.
XX
PI Chano T;
XX
DR WPI; 2004-081932/08.
XX
PT Protein in the nuclei of human and animal cells associated with
PT expression of retinoblastoma-1 gene for diagnosis of cancer.
XX
PS Disclosure; SEQ ID NO 131; 113pp; Japanese.
XX
CC The invention relates to a protein or polypeptide found in the nuclei of
CC human and animal cells that are associated with transcription and/or
CC induction of expression of retinoblastoma-1 gene (RB1CC1). The detection
CC of RB1CC1 gene and its protein is useful for the diagnosis of cancer. The
CC human RB1CC1 cDNA is 6.6 kb containing a 4782 bp ORF, encoding a 180 kD
CC 1594 amino acid protein. This sequence corresponds to a PCR primer used
CC to amplify and isolate the mouse RB1CC1 cDNA sequence (ADH14290) from
CC genomic DNA.
XX
SQ Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3572 CTGGGTCTTAGGGAAGAA 3591
||| ||| ||| ||| ||| |||
Db 1 CTGGGTCTTAGGGAAGTAA 20

RESULT 447
ADG64299/c
ID ADG64299 standard; DNA; 20 BP.
XX
AC ADG64299;

SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1222 ACAAGACATCCCTGATGTC 1241
||| ||| ||| ||| ||| |||
Db 20 AGAAGACACCCCTGATGTC 1

RESULT 448
ADH18113
ID ADH18113 standard; DNA; 20 BP.
XX
AC ADH18113;
XX
DT 11-MAR-2004 (first entry)
XX
```

XX 11-MAR-2004 (first entry)

DT Y chromosome exon trap clone reverse RT-PCR primer eta2.

DE Y chromosome; chromosome Y; SKY1; sY83; Y-specific growth gene; GCY;

XX primer; sex-related height difference; height; reverse transcriptase;

KW PCR primer; ss.

KW Synthetic.

XX Homo sapiens.

OS WO2003091381-A2.

XX 06-NOV-2003.

XX 25-APR-2003; 2003WO-EP004546.

XX 26-APR-2002; 2002GB-00009640.

PR 01-JUL-2002; 2002GB-00015188.

XX (RAPP//) RAPPOLD G A.

PA Rappold GA, Kirsch S;

XX WPI; 2004-108240/11.

XX An isolated region of the Y chromosome between SKY1 and sY83 which

PT encompasses the Y-specific growth gene GCY, for identifying the presence

PT or absence of a GCY gene associated with height.

XX Claim 10; Page 33; 54pp; English.

PS The present invention describes an isolated region of the Y chromosome

CC between SKY1 and sY83 which encompasses the Y-specific growth gene GCY.

CC Also described: (1) an isolated GCY protein, encoded by a region of the Y

CC chromosome within the interval SKY1 and sY83; (2) a nucleic acid primer

CC having a nucleic acid sequence selected from a nucleic acid sequence as

CC shown in Tables 2.5, 6.7A, 7B, 7C or 8 given in the specification; (3)

CC studying GCY localisation or identifying a GCY gene associated with

CC height comprising the use of a primer in (2) to selectively amplify or

CC detect a region of a nucleic acid molecule; (4) an isolated protein

CC having greater than 65% homology to the GCY protein of (1), and which

CC contributes to the sex-related height difference in humans; and (5) use

CC of a nucleic acid molecule comprising at least a portion of the isolated

CC region of the Y chromosome between markers SKY8 and sY83, or a sequence

CC complementary to it, to identify the presence or absence of a GCY gene

CC associated with height. The isolated region of the Y chromosome between

CC SKY1 and sY83, or a sequence complementary to it, is used to identify the

CC presence or absence of a GCY gene associated with height. The primer is

CC used for studying GCY localisation or identifying a GCY gene associated

CC with height by selective amplification. The present sequence is used in

CC the exemplification of the present invention.

XX

SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1222 ACAAGACATCCCTGATGTC 1241

||| ||| ||| ||| ||| |||

Db 20 AGAAGACACCCCTGATGTC 1

RESULT 448

ADH18113

ID ADH18113 standard; DNA; 20 BP.

XX

AC ADH18113;

XX

DT 11-MAR-2004 (first entry)

XX

DE 2'-MOE gapmer antisense oligo targeted to murine ApoB - SEQ ID 102.
XX apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
XX mouse; murine; ss.
XX Mus musculus.
OS
XX
XX WO2003097662-A1.
PN
XX
XX 27-NOV-2003.
PD
XX
XX 15-MAY-2003; 2003WO-US015493.
XX
PF 15-MAY-2002; 2002US-00147196.
XX
PR 13-NOV-2002; 2002US-0426324P.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Crooke RM, Graham MJ;
XX
PI WPI; 2004-022840/02.
XX
DR
XX
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidaemia or cardiovascular disease.
XX
XX Example 17; SEQ ID NO 102; 405pp; English.
PS
XX
XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC MOE) gapmer antisense oligo of the invention which has 2'-MOE 'wings', a
CC phosphorothioate backbone throughout and in which all cytidine residues
CC are 5-methylcytidines.
XX
XX Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3461 AGGAAGAATTTCTGTATT 3480
DB 1 AGGAGGAACTCTGTATT 20
RESULT 449
ADH18566
ID ADH18566 standard; DNA; 20 BP.
XX
XX ADH18566;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX Human apolipoprotein B antisense inhibition target DNA - SEQ ID 555.
DE
XX
XX apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense inhibition target; human; ds.
XX
XX Homo sapiens.
OS
XX
XX WO2003097662-A1.
PN

XX 27-NOV-2003.
PD
XX
XX 15-MAY-2003; 2003WO-US015493.
XX
PF 15-MAY-2002; 2002US-00147196.
XX
PR 13-NOV-2002; 2002US-0426324P.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Crooke RM, Graham MJ;
XX
PI WPI; 2004-022840/02.
XX
DR
XX
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidaemia or cardiovascular disease.
XX
XX Claim 1; SEQ ID NO 555; 405pp; English.
PS
XX
XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the human ApoB antisense
CC inhibition target DNA of the invention.
XX
XX Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2190 CTCATCTTCTTCTCTGAAGA 2209
DB 1 CTGCAGCTTCATCTCTGAAGA 20
RESULT 450
ADH18198/c
ID ADH18198 standard; DNA; 20 BP.
XX
XX ADH18198;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX 2'-MOE gapmer antisense oligo targeted to human ApoB DNA 1 - SEQ ID 187.
DE
XX
XX apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
XX human; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2003097662-A1.
PN
XX
XX 27-NOV-2003.
PD
XX
XX 15-MAY-2003; 2003WO-US015493.
XX
PF 15-MAY-2002; 2002US-00147196.
XX
PR 13-NOV-2002; 2002US-0426324P.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Crooke RM, Graham MJ;
XX
PI
XX

[illegible]


```
DT 25-MAR-2004 (first entry)
DE Human glucocorticoid receptor-specific antisense oligonucleotide #4234.
KW antisense oligonucleotide; glucocorticoid receptor; infection;
KW inflammation; tumour formation; diabetes; obesity;
KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
OS Homo sapiens.
PN WO2003099215-A2.
XX 04-DEC-2003.
XX 20-MAY-2003; 2003WO-US016084.
XX 20-MAY-2002; 2002US-0381857P.
XX (PHAA ) PHARMACIA CORP.
XX Crosby SD, Nalseth AE;
XX WPI; 2004-035034/03.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT cardiovascular disorder, hyperlipidaemia or Cushing's syndrome.
XX Claim 4; SEQ ID NO 4234; 985pp; English.
XX The invention comprises an antisense oligonucleotides that are targeted
CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC antisense oligonucleotides of the invention are useful for preventing or
CC delaying infection, inflammation or tumour formation. The antisense
CC oligonucleotides are also useful for treating diabetes, obesity,
CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC present DNA sequence represents an antisense oligonucleotide that targets
CC the human glucocorticoid receptor gene. NOTE: The present sequence
CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX Sequence 20 BP; 1 A; 0 C; 1 G; 18 T; 0 U; 0 Other;
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTCTTCTCTGA 2590
DB 1 TTTTCTTTTCTTTTCTGA 20
RESULT 456
ADH67409
ID ADH67409 standard; DNA; 20 BP.
XX ADH67409;
XX 25-MAR-2004 (first entry)
XX Human glucocorticoid receptor-specific antisense oligonucleotide #4243.
XX antisense oligonucleotide; glucocorticoid receptor; infection;
KW inflammation; tumour formation; diabetes; obesity;
KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
OS Homo sapiens.
XX WO2003099215-A2.
XX 04-DEC-2003.
XX 20-MAY-2003; 2003WO-US016084.
XX 20-MAY-2002; 2002US-0381857P.
XX (PHAA ) PHARMACIA CORP.
XX Crosby SD, Nalseth AE;
XX WPI; 2004-035034/03.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT cardiovascular disorder, hyperlipidaemia or Cushing's syndrome.
XX Claim 4; SEQ ID NO 4234; 985pp; English.
XX The invention comprises an antisense oligonucleotides that are targeted
CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC antisense oligonucleotides of the invention are useful for preventing or
CC delaying infection, inflammation or tumour formation. The antisense
CC oligonucleotides are also useful for treating diabetes, obesity,
CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC present DNA sequence represents an antisense oligonucleotide that targets
CC the human glucocorticoid receptor gene. NOTE: The present sequence
CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX Sequence 20 BP; 1 A; 0 C; 1 G; 18 T; 0 U; 0 Other;
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTCTTCTCTGA 2590
DB 1 TTTTCTTTTCTTTTCTGA 20
RESULT 456
ADH67409
ID ADH67409 standard; DNA; 20 BP.
XX ADH67409;
XX 25-MAR-2004 (first entry)
XX Human glucocorticoid receptor-specific antisense oligonucleotide #4243.
XX antisense oligonucleotide; glucocorticoid receptor; infection;
KW inflammation; tumour formation; diabetes; obesity;
KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
OS Homo sapiens.
XX WO2003099215-A2.
XX 04-DEC-2003.
XX 20-MAY-2003; 2003WO-US016084.
XX 20-MAY-2002; 2002US-0381857P.
XX (PHAA ) PHARMACIA CORP.
XX Crosby SD, Nalseth AE;
XX WPI; 2004-035034/03.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT cardiovascular disorder, hyperlipidaemia or Cushing's syndrome.
XX Claim 4; SEQ ID NO 4243; 985pp; English.
XX The invention comprises an antisense oligonucleotides that are targeted
CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC antisense oligonucleotides of the invention are useful for preventing or
CC delaying infection, inflammation or tumour formation. The antisense
CC oligonucleotides are also useful for treating diabetes, obesity,
CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC present DNA sequence represents an antisense oligonucleotide that targets
CC the human glucocorticoid receptor gene. NOTE: The present sequence
CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX Sequence 20 BP; 1 A; 1 C; 1 G; 17 T; 0 U; 0 Other;
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2564 AGCTTCTTCTTCTTCTTTT 2583
DB 1 AGCTTCTTCTTCTTCTTTT 20
RESULT 457
AD134492/C
ID AD134492 standard; DNA; 20 BP.
XX AD134492;
XX 22-APR-2004 (first entry)
XX Nucleotide sequence of a da20 oligonucleotide.
XX Nucleic acid amplification; RNA transcription; RNA polymerase; ss; T7.
XX Synthetic.
XX WO2003102243-A1.
XX 11-DEC-2003.
XX 30-MAY-2003; 2003WO-US017103.
XX 31-MAY-2002; 2002US-0384454P.
XX (JANC ) JANSSEN PHARM NV.
XX Kamme FC, Zhu JY;
XX WPI; 2004-035466/03.
XX Amplifying for RNA in a sample, useful for improving RNA polymerase based
PT RNA transcription from a polynucleotide template, comprises eliminating
PT single-stranded oligonucleotide from the transcription sample.
XX Example 2; SEQ ID NO 11; 26pp; English.
XX The invention relates to amplifying for RNA in a sample comprises
CC eliminating single-stranded oligonucleotide from the transcription
```

```
PF 20-MAY-2003; 2003WO-US016084.
XX 20-MAY-2002; 2002US-0381857P.
XX (PHAA ) PHARMACIA CORP.
XX Crosby SD, Nalseth AE;
XX WPI; 2004-035034/03.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT cardiovascular disorder, hyperlipidaemia or Cushing's syndrome.
XX Claim 4; SEQ ID NO 4243; 985pp; English.
XX The invention comprises an antisense oligonucleotides that are targeted
CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC antisense oligonucleotides of the invention are useful for preventing or
CC delaying infection, inflammation or tumour formation. The antisense
CC oligonucleotides are also useful for treating diabetes, obesity,
CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC present DNA sequence represents an antisense oligonucleotide that targets
CC the human glucocorticoid receptor gene. NOTE: The present sequence
CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX Sequence 20 BP; 1 A; 1 C; 1 G; 17 T; 0 U; 0 Other;
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2564 AGCTTCTTCTTCTTCTTTT 2583
DB 1 AGCTTCTTCTTCTTCTTTT 20
RESULT 457
AD134492/C
ID AD134492 standard; DNA; 20 BP.
XX AD134492;
XX 22-APR-2004 (first entry)
XX Nucleotide sequence of a da20 oligonucleotide.
XX Nucleic acid amplification; RNA transcription; RNA polymerase; ss; T7.
XX Synthetic.
XX WO2003102243-A1.
XX 11-DEC-2003.
XX 30-MAY-2003; 2003WO-US017103.
XX 31-MAY-2002; 2002US-0384454P.
XX (JANC ) JANSSEN PHARM NV.
XX Kamme FC, Zhu JY;
XX WPI; 2004-035466/03.
XX Amplifying for RNA in a sample, useful for improving RNA polymerase based
PT RNA transcription from a polynucleotide template, comprises eliminating
PT single-stranded oligonucleotide from the transcription sample.
XX Example 2; SEQ ID NO 11; 26pp; English.
XX The invention relates to amplifying for RNA in a sample comprises
CC eliminating single-stranded oligonucleotide from the transcription
```

Claim 1; SEQ ID NO 18; 48pp; English.

The present invention is directed to antisense oligonucleotides targeted to a nucleic acid encoding amyloid beta protein precursor and which modulates the expression of amyloid beta protein precursor. The invention is useful for treating a disease or condition associated with amyloid beta protein precursor such as a neurodegenerative disorder e.g. Alzheimer's disease or a disease or condition involving aberrant apoptosis. They are also useful in research and diagnostics for modulating the expression of amyloid beta protein precursor. The present sequence is human amyloid beta protein precursor antisense oligonucleotide.

Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

```

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2721  TTGCTCTGCCAGAGCAGCT 2740
Db      1      TTGCTCTCTTGAAGCAGCT 20

```

RESULT 459
ADJ31781/c
ID ADJ31781 standard; DNA; 20 BP.
XX
XX
XX AC ADJ31781;
XX ADJ31781;
DT 22-APR-2004 (first entry)

DE	Human amyloid beta precursor target oligonucleotide #7.
DE	
XX	
KW	Amyloid beta protein precursor; neurodegenerative disorder;
KW	Alzheimer's disease; apoptosis; diagnosis; therapy; human; ss.
XX	
OS	Homo sapiens.
OS	
XX	

XX	18-DEC-2003.	
PD		
XX		
XX	14-JUN-2002; 2002US-00173208.	
PF		
XX		
XX	14-JUN-2002; 2002US-00173208.	
PR		
XX		
XX	(ISIS-) ISIS PHARM INC.	
PA		
XX		
XX	Dobie KW;	
PI		
XX		
XX	WPI; 2004-061283/06.	
DR		
XX		
XX		
PT	New compounds, particularly antisense oligonucleotides targeted to a	
PT	nucleic acid encoding an amyloid beta protein precursor, useful for	
PT	treating Alzheimer's disease or a disease involving aberrant apoptosis.	
PT		

PS	Example 15; SEQ ID NO 54; 48pp; English.		
XX			
CC	The present invention is directed to antisense oligonucleotides targetted		
CC	to a nucleic acid encoding amyloid beta protein precursor and which		
CC	modulates the expression of amyloid beta protein precursor. The invention		
CC	is useful for treating a disease or condition associated with amyloid		
CC	beta protein precursor such as a neurodegenerative disorder e.g.		
CC	Alzheimer's disease or a disease or condition involving aberrant		
CC	apoptosis. They are also useful in research and diagnostics for		
CC	modulating the expression of amyloid beta protein precursor. The present		
CC	sequence is human amyloid beta protein precursor target oligonucleotide.		
XX			
SQ	Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;	0.4%;	Score 15.2; DB 1; Length 20;
	Query Match		

```
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2721 TTGCTCTGCCAAGACGAGCT 2740
Db 20 TTGCTCTTCTGAAGCAGCT 1

RESULT 460
AD147212/c
ID AD147212 standard; DNA; 20 BP.
XX
AC AD147212;
XX
DT 22-APR-2004 (first entry)
XX
DE Molecule analysing microchannel method related probe #2.
XX
KW laminar flow; micro channel; complex; selectively promoted; fluorescence;
KW probe; ss.
XX
OS Unidentified.
XX
PN WO2004010140-A1.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-JP009142.
XX
PR 19-JUL-2002; 2002JP-00211462.
XX
PA (NAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.
XX
PI Yamashita K, Maeda H, Shimizu H, Miyazaki M, Nakamura H;
PI Yamaguchi Y;
XX
DR WPI; 2004-180318/17.
XX
PT Analysis of sample molecules such as DNA fragment, by using micro channel
PT to form laminar flow of specimen molecule-containing solution and complex
PT forming molecule containing solution.
XX
PS Example 1; Page 9; 19pp; Japanese.
XX
CC The invention relates to a novel method involving forming a laminar flow,
CC by passing into a micro channel, a solution containing the specimen
CC molecules, and a solution containing probe molecules capable of forming a
CC complex with the specimen molecules. The dispersion of the formed complex
CC is selectively promoted, based on their affinity, and the degree of
CC dispersion of the complex formed between the specimen molecules and the
CC probe molecules is detected and analysed. The probe molecules are capable
CC of producing fluorescence. This polynucleotide sequence represents an
CC oligo used in the exemplification of the invention.
XX
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTCTCTCTTTTTTTTTT 2586
Db 20 TTTCTCTCTCTTTTTTTTTT 1

RESULT 461
AD127582
ID AD127582 standard; DNA; 20 BP.
XX
AC AD127582;
XX
DT 22-APR-2004 (first entry)
XX
```

```
DE Human DRAK1 DNA, antisense oligonucleotide #60.
XX
KW Antisense therapy; human;
KW death-associated protein kinase-related apoptosis-inducing;
KW protein kinase 1; DRAK1; hyperproliferative disorder; cancer;
KW neurological disorder; infection; inflammation; tumour formation;
KW cytostatic; antiinflammatory; neuroprotective; antimicrobial;
KW phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length at each
FT end. All cytidine residues are 5-methylcytidines"
XX
PN US2003232773-A1.
XX
PD 18-DEC-2003.
XX
PF 17-JUN-2002; 2002US-00174559.
XX
PR 17-JUN-2002; 2002US-00174559.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Freier SM, Dobie KW;
XX
DR WPI; 2004-061310/06.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding death
PT -associated protein kinase-related apoptosis-inducing protein kinase 1
PT (DRAK1), useful for modulating expression of DRAK1 or for treating
PT cancer.
XX
PS Example 15; SEQ ID NO 74; 56pp; English.
XX
CC The present invention relates to antisense compounds targeted to a
CC nucleic acid encoding death-associated protein kinase-related apoptosis-
CC inducing protein kinase 1 (DRAK1). The antisense compound comprises an
CC antisense oligonucleotide that specifically hybridises with the nucleic
CC acid and inhibits the expression of DRAK1. The antisense oligonucleotide
CC is a chimeric oligonucleotide. The antisense oligonucleotide comprises at
CC least one modified internucleoside linkage, preferably a phosphorothioate
CC linkage. It also comprises at least one modified sugar moiety, preferably
CC a 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide
CC further comprises at least one modified nucleobase, preferably a 5-
CC methylcytosine. The antisense oligonucleotides are useful for the
CC treatment of diseases such as hyperproliferative disorders, preferably
CC cancer, and neurological disorders. The antisense compound can also be
CC used as prophylaxis, e.g. to prevent or delay infection, inflammation or
CC tumour formation. The present sequence represents an antisense
CC oligonucleotide used in the examples of the present invention.
XX
SQ Sequence 20 BP; 5 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1215 ACTTCTTACAGACATCCCT 1234
Db 1 ACTTCTTCCAGACTTACCT 20

RESULT 462
ADJ51142
ID ADJ51142 standard; DNA; 20 BP.
XX
```


the invention relates to phosphorothioate oligonucleotides having nucleoside with 240 modification are prepared by phosphorylating 5'-hydroxyl of a nucleic acid moiety having a nucleoside with 2'-modification in an acetonitrile containing phosphate intermediate with an acetyl disulfide in an acetonitrile for a time to effect conversion of the phosphate intermediate to phosphorothioate. The invented method achieves high yields and greater efficiency. The present sequence is

XX Roberds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 2303; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCTCTCTCTTTT 2586
DB 1 TTTTCTTTTCTTTT 20
RESULT 473
ADK78622/C
ID ADK78622 standard; DNA; 20 BP.
XX
XX
AC ADK78622;
XX
XX 20-MAY-2004 (first entry)
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5956.
DE
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
XX Synthetic.
OS
XX WO2004016754-A2.
XX
XX 26-FEB-2004.
XX
XX 14-AUG-2003; 2003WO-US025465.
XX
XX 14-AUG-2002; 2002US-0403416P.
XX
XX (PHAA) PHARMACIA CORP.
PA
XX Roberds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX

PS Claim 4; SEQ ID NO 5956; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 962 GCGGAATTTTCGAGAAGCT 981
DB 20 GCCGAATTTTCAGCAGATGCT 1
RESULT 474
ADK74889
ID ADK74889 standard; DNA; 20 BP.
XX
XX
AC ADK74889;
XX
XX 20-MAY-2004 (first entry)
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2223.
DE
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
XX Synthetic.
OS
XX WO2004016754-A2.
XX
XX 26-FEB-2004.
XX
XX 14-AUG-2003; 2003WO-US025465.
XX
XX 14-AUG-2002; 2002US-0403416P.
XX
XX (PHAA) PHARMACIA CORP.
PA
XX Roberds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
XX Claim 4; SEQ ID NO 2223; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX

ID ADK79423 standard; DNA; 20 BP.
XX
AC ADK79423;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #6757.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
FN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPT; 2004-203785/19.
XX
PF New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 6757; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3650 AATGGCAATACATATATAA 3669
DB 1 AAAGGCAATATAATATCA 20

RESULT 478
ADK74838
ID ADK74838 standard; DNA; 20 BP.
XX
AC ADK74838;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2172.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;

KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
FN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPT; 2004-203785/19.
XX
PF New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 2172; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 1 A; 1 C; 1 G; 17 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2564 AGCTTCTCTCTCTCTCTCTT 2583
DB 1 AGCTTTTCTTTTCTTTTCTT 20

RESULT 479
ADK78442/C
ID ADK78442 standard; DNA; 20 BP.
XX
AC ADK78442;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5776.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
FN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX

```
PR 14-AUG-2002; 2002US-0403416P.
XX (PHAA ) PHARMACIA CORP.
XX Roberds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 5776; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 954 ATAAAGAGCGGAATTTCTG 973
DB 20 AAAAGAGCGGAATTTCTAG 1
RESULT 480
ADK80069/C
ID ADK80069 standard; DNA; 20 BP.
XX AC ADK80069;
XX 20-MAY-2004 (first entry)
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #7403.
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX diabetic neuropathy; arthritic pain; migraine headache;
XX infantile epilepsy; ataxia; ss.
XX Synthetic.
XX WO2004016754-A2.
XX 26-FEB-2004.
XX 14-AUG-2003; 2003WO-US025465.
XX 14-AUG-2002; 2002US-0403416P.
XX (PHAA ) PHARMACIA CORP.
XX Roberds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 2548; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 960 AGGCGGAATTTCTGCAGAG 979
DB 20 AGGCGGAATTTCTGCAGATG 1
RESULT 481
ADK75214
ID ADK75214 standard; DNA; 20 BP.
XX AC ADK75214;
XX 20-MAY-2004 (first entry)
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2548.
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX diabetic neuropathy; arthritic pain; migraine headache;
XX infantile epilepsy; ataxia; ss.
XX Synthetic.
XX WO2004016754-A2.
XX 26-FEB-2004.
XX 14-AUG-2003; 2003WO-US025465.
XX 14-AUG-2002; 2002US-0403416P.
XX (PHAA ) PHARMACIA CORP.
XX Roberds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 2548; 417pp; English.
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 960 AGGCGGAATTTCTGCAGAG 979
DB 20 AGGCGGAATTTCTGCAGATG 1
```

CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 1 A; 2 C; 1 G; 16 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2563 CAGCTTTCTCTCTCTTTT 2582
DB 1 CAGCTTTCTCTCTCTTTT 20

RESULT 482
ADL33726
ID ADL33726 standard; DNA; 20 BP.
XX
AC ADL33726;
XX
DT 03-JUN-2004 (first entry)
XX
DE LNA oligomer #5.
XX
KW Detection; isolation; locked nucleic acid; LNA; ss.
XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally LNA nucleotides"
FT modified_base 1
FT /tag= a
FT /mod_base= OTHER
FT /note= "Optionally biotinylated or 5' AQ2-HEG3, where AQ
FT is anthraquinone and HEG is hexa-ethylene glycol"
XX
PN WO2004020575-A2.

XX
PD 11-MAR-2004.
XX
PF 20-JUN-2003; 2003WO-IB006354.
XX
PR 24-JUN-2002; 2002US-0390928P.
XX
PS (EXIQ-) EXIQON AS.
XX
PI Kauppinen S, Jacobsen N;
XX
DR WPI; 2004-315512/29.

XX
PT Detecting and/or isolating nucleic acid molecule having homopolymeric
PT sequence or repetitive element or conserved nucleotide sequence involves
PT treating sample containing nucleic acid compounds with locked nucleic
PT acid oligonucleotide.

XX
PS Claim 22; Page 51; 104pp; English.
XX
CC The present invention relates to a method (M1) for detecting and/or
CC isolating a nucleic acid having a homopolymeric sequence or repetitive
CC element or conserved nucleotide sequence. (M1) comprises treating a
CC sample containing nucleic acid compounds with an locked nucleic acid
CC (LNA) oligonucleotide (LO) to thereby detect and/or isolate a nucleic
CC acid having the homopolymeric sequence or repetitive element or conserved

CC nucleotide sequence. (M1) is useful for detecting and isolating nucleic
CC acids released from a lysed complex biological mixture comprising nucleic
CC acids. The present sequence is a LNA oligomer, used to illustrate the
CC invention.

XX SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTTCTCTCTCTTTT 2586
DB 1 TTCTTCTCTCTCTTTT 20

RESULT 483
ADM92426/c
ID ADM92426 standard; DNA; 20 BP.
XX
AC ADM92426;
XX
DT 01-JUL-2004 (first entry)
XX
DE Pancreatic cancer related RT-PCR forward primer SEQ ID NO:63.
XX
KW Pancreatic cancer; diagnosis; pancreatic cancer-associated gene;
KW cytostatic; vaccine; gene therapy; human; reverse transcription; PCR;
KW primer; ss; semi-quantitative RT-PCR experiment.

XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004031412-A2.
XX
PD 15-APR-2004.
XX
PF 17-SEP-2003; 2003WO-JP011817.
XX
PR 30-SEP-2002; 2002US-0414872P.
PR 28-FEB-2003; 2003US-0450899P.
XX
PA (ONCO-) ONCOTHERAPY SCI INC.
PA (UVTY) UNIV TOKYO.
XX
PI Nakamura Y, Katagiri T;
XX
DR WPI; 2004-330205/30.

XX
PT Diagnosing pancreatic cancer (PNC) comprises determining a level of
PT expression of a PNC-associated gene in a patient derived biological
PT sample.

XX
PS Example 1; SEQ ID NO 63; 152pp; English.
XX
CC The present invention describes a method for diagnosing pancreatic cancer
CC (PNC) or a predisposition to developing PNC in a subject. The method
CC comprises determining a level of expression of a PNC-associated gene in a
CC patient derived biological sample, where an increase or decrease of the
CC level compared to a normal control level of the gene indicates that the
CC subject suffers from or is at risk of developing PNC. Also described: (1)
CC a PNC reference expression profile, comprising a pattern of gene
CC expression of two or more genes, i.e. PNC 1-605 or PNC 850-866 and PNC
CC 894-906; (2) a method of screening for a compound for treating or
CC preventing PNC or malignant PNC; (3) a kit comprising a detection reagent
CC which binds to two or more nucleic acid sequences, i.e. PNC 1-605 or PNC
CC 850-866 and PNC 894-906 or the encoded polypeptides; (4) an array
CC comprising two or more nucleic acids which bind to one or more nucleic
CC acid sequences, i.e. PNC 1-605 or PNC 850-866 and PNC 894-906; (5) a
CC method of treating or preventing PNC in a subject; (6) a composition, for
CC treating or preventing PNC, comprising a pharmaceutical amount of: (a) an
CC antisense polynucleotide or small interfering RNA against a
CC polynucleotide, i.e. PNC 1-259, PNC 606-640 and PNC 682-741 or PNC 850-

CC 933; (b) an antibody or antibody fragment that binds to a protein encoded
 CC by any one gene, i.e. PNC 1-259, PNC 606-640 and PNC 682-741 or PNC 850-
 CC 993; or (c) the compound obtained by the method of (2) as an active
 CC ingredient and a pharmaceutical carrier; and (7) a method of predicting
 CC recurrence of PNC. The compounds have cytostatic activity, and can be
 CC used in vaccines and in gene therapy. The method is useful in diagnosing
 CC PNC or a predisposition to developing PNC in a subject. The methods,
 CC compounds and compositions are useful in treating or preventing PNC. The
 CC polypeptides are useful as vaccines against PNC. The present sequence
 CC represents a reverse transcription (RT) PCR primer used in semi-
 CC quantitative RT-PCR experiments related to the diagnosis of PNC, which is
 CC used in an example from the present invention.

XX Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. NO. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2364 CTTTCATGCTGGAATGGGAT 2383
 DB 20 CTTTCACGCTGGACTTGGGAT 1

RESULT 484
 ADM13992
 ID ADM13992 standard; DNA; 20 BP.

XX ADM13992;

XX 01-JUL-2004 (first entry)

DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:179.

XX Chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"

FT modified_base 1..5

FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"

XX WO2004028458-A2.

PN 08-APR-2004.

XX 25-SEP-2003; 2003WO-US030374.

XX 25-SEP-2002; 2002US-0413549P.

XX (PHAA) PHARMACIA CORP.

XX Gierse JK;

XX WPI; 2004-305094/28.
 DR New antisense compound, having a sequence targeted to a nucleic acid
 XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

PS Claim 4; SEQ ID NO 179; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. NO. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTTTTCTTTTCTTTT 2586

DB 1 TTTTCTTTTCTTTTCTTTTCTTTT 20

RESULT 485
 ADM13994
 ID ADM13994 standard; DNA; 20 BP.

XX ADM13994;

XX 01-JUL-2004 (first entry)

DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:181.

XX Chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"

FT modified_base 1..5

FT /tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

```
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
FN WO2004028458-A2.
XX
PD 08-APR-2004.
XX
PP 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 181; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCTTCTCTCTTTT 2586
DB 1 TTTTCTTTTCTTTT 20
RESULT 486
ADMI3999
ID ADMI3999 standard; DNA; 20 BP.
XX
XX ADMI3999;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:186.
DE
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
```

```
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 186; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCTTCTCTCTTTT 2586
DB 1 TTTTCTTTTCTTTT 20
RESULT 487
```


ADMI14008	ADMI14008 standard; DNA; 20 BP.
XX	
XX	
AC	ADMI14008;
XX	
DT	01-JUL-2004 (first entry)
DE	Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:195.
XX	
KW	chimeric; antisense oligonucleotide; phosphorothioate; human;
KW	microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW	microsomal prostaglandin E2 synthase inhibitor; cytotostatic; antiidiabetic;
KW	immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW	neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW	immunomodulatory; cardiovascular; gene therapy; inflammation;
KW	Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW	reperfusion injury; ophthalmic disorder; immunological disorder;
KW	cardiovascular disorder; neurological disorder; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
XX	
FH	Key Location/Qualifiers
FT	modified_base 1..20
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "phosphorothioate linkages and all cytidine
FT	residues are 5-methylcytidines"
FT	
FT	modified_base 1..5
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
FT	
FT	modified_base 16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
XX	
XX	WO2004028458-A2.
XX	
XX	
PD	08-APR-2004.
XX	
XX	
PF	25-SEP-2003; 2003WO-US030374.
XX	
PR	25-SEP-2002; 2002US-0413549P.
XX	
XX	(PHAA) PHARMACIA CORP.
PA	
XX	
XX	Gierse JK;
PI	
XX	WPI; 2004-305094/28.
DR	
XX	
PT	New antisense compound, having a sequence targeted to a nucleic acid
PT	encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT	inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT	ischemia.
XX	
PS	Claim 4; SEQ ID NO 195; 132pp; English.
XX	
CC	The present sequence represents a chimeric antisense oligonucleotide
CC	targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC	human mPGES-1 gene is located on chromosome 9, more specifically to
CC	9q34.3. The present invention also describes: (1) antisense compounds,
CC	having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC	mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC	inhibits its expression; (2) a method of inhibiting the expression of
CC	mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC	having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC	antisense oligonucleotides and antisense compounds have cytostatic,
CC	antiidiabetic, immunomodulator, cardiant, neuroprotective,
CC	antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC	ophthalmological, immunomodulatory and cardiovascular activities, and can
CC	be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC	can be used for preparing a composition for treating a disease or

CC	condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC	disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC	ophthalmic, immunological, cardiovascular or neurological disorder.
XX	
SQ	Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match	0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. No. 2.e+02;
Matches 17; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
QY	2567 TTCTCTCTCTTTTTTTT 2586
DB	1 TTTTTTTTTTTTTTTT 20
RESULT 488	
ADMI4002	
ID	ADM14002 standard; DNA; 20 BP.
XX	
AC	ADM14002;
XX	
XX	01-JUL-2004 (first entry)
DE	
DE	Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:189.
XX	
KW	chimeric; antisense oligonucleotide; phosphorothioate; human;
KW	microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW	microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW	immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW	neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
KW	immunomodulatory; cardiovascular; gene therapy; inflammation;
KW	Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW	reperfusion injury; ophthalmic disorder; immunological disorder;
KW	cardiovascular disorder; neurological disorder; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	modified_base 1..20
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "phosphorothioate linkages and all cytidine residues are 5-methylcytidines"
FT	modified_base 1..5
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
FT	modified_base 16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
XX	
PN	WO2004028458-A2.
XX	
PD	08-APR-2004.
XX	
PF	25-SEP-2003; 2003WO-US030374.
XX	
PR	25-SEP-2002; 2002US-0413549P.
XX	
PA	(PHAA) PHARMACIA CORP.
XX	
PI	Gierse JK;
XX	
DR	WPI; 2004-305094/28.
XX	
PT	New antisense compound, having a sequence targeted to a nucleic acid
PT	encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT	inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT	ischaemia.
XX	
PS	Claim 4; SEQ ID NO 189; 132pp; English.

```

XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTCTCTCTTTTCTTTT 2586
Db 1 TTTTCTTTTCTTTTCTTTT 20

RESULT 499
ADM14090
ID ADM14090 standard; DNA; 20 BP.
XX
AC ADM14090;
XX
DT 01-JUL-2004 (first entry)
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:277.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
PD 08-APR-2004.
XX

```

```

PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
XX
PT New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 277; 132pp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTCTCTCTTTTCTTTT 2586
Db 1 TTTTCTTTTCTTTTCTTTT 20

RESULT 490
ADM14151
ID ADM14151 standard; DNA; 20 BP.
XX
AC ADM14151;
XX
DT 01-JUL-2004 (first entry)
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:338.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT

```



```
Qy 2567 TTTCTCTCTCTCTCTCTCTTTT 2586
Db 1 TTTCTCTCTCTCTCTCTCTTTT 20

RESULT 492
ADM14017
ID ADM14017 standard; DNA; 20 BP.
XX
AC ADM14017;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:204.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW immunomodulator; cardiant; neuroprotective; cytosstatic; antidiabetic;
KW neuroprotective; nootropic; antiarthritic; vasotrophic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
PD 08-APR-2004.
XX
PP 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
XX
PT New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 204; 132pp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
```

```
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotrophic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTCTCTCTCTCTCTCTTTT 2586
Db 1 TTTCTCTCTCTCTCTCTCTTTT 20

RESULT 493
ADM14018
ID ADM14018 standard; DNA; 20 BP.
XX
AC ADM14018;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:205.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW immunomodulator; cardiant; neuroprotective; cytosstatic; antidiabetic;
KW neuroprotective; nootropic; antiarthritic; vasotrophic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
PD 08-APR-2004.
XX
PP 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
```

```
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 205; 132pp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antiinflammatory, neuroprotective, cardiant, neuroprotective,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCTTCTCTTTTTTTTTT 2586
Db 1 TTTTCTTTTTTTTTTTTTTT 20
RESULT 494
ADM14088
ID ADM14088 standard; DNA; 20 BP.
XX
AC ADM14088;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:275.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
```

```
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX WO2004028458-A2.
XX 08-APR-2004.
XX 25-SEP-2003; 2003WO-US030374.
XX 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
XX Gierse JK;
XX WPI; 2004-305094/28.
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX Claim 4; SEQ ID NO 275; 132pp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTTCTTCTCTTTTTTTTTT 2586
Db 1 TTTTCTTTTTTTTTTTTTTT 20
RESULT 495
ADM14257
ID ADM14257 standard; DNA; 20 BP.
XX
AC ADM14257;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:444.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
```

```

XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key
XX FT modified_base
XX FT Location/Qualifiers
XX FT 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate linkages and all cytidine
XX FT residues are 5-methylcytidines"
XX FT modified_base
XX FT 1..5
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "2'-O-methoxyethyls"
XX FT modified_base
XX FT 16..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "2'-O-methoxyethyls"
XX FT
XX FT
XX PN WO2004028458-A2.
XX PD 08-APR-2004.
XX PD
XX PF 25-SEP-2003; 2003WO-US030374.
XX PF
XX PR 25-SEP-2002; 2002US-0413549P.
XX PR
XX PA (PHAA ) PHARMACIA CORP.
XX PA
XX PI Gierse JK;
XX PI
XX XX
XX DR WPI; 2004-305094/28.
XX XX
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX PT ischemia.
XX PS Claim 4; SEQ ID NO 444; 132pp; English.
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX CC human mPGES-1 gene is located on chromosome 9, more specifically to
XX CC 9q34.3. The present invention also describes: (1) antisense compounds,
XX CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX CC inhibits its expression; (2) a method of inhibiting the expression of
XX CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX CC antisense oligonucleotides and antisense compounds have cytostatic,
XX CC anti-diabetic, immunomodulator, cardiant, neuroprotective,
XX CC anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX CC ophthalmological, immunomodulatory and cardiovascular activities, and can
XX CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX CC can be used for preparing a composition for treating a disease or
XX CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 2567 TTCTCTCTCTCTCTCTCTTTT 2586
XX Db 1 TTTTCTCTCTCTCTCTCTCTTTT 20
XX
XX RESULT 496
XX ADM14000
XX ID ADM14000 standard; DNA; 20 BP.

```

```

XX AC ADM14000;
XX DT 01-JUL-2004 (first entry)
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:187.
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
XX KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX KW microsomal prostaglandin E2 synthase inhibitor; cycostatic; antidiabetic;
XX KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX KW immunomodulatory; cardiovascular; gene therapy; inflammation;
XX KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX KW reperfusion injury; ophthalmic disorder; immunological disorder;
XX KW cardiovascular disorder; neurological disorder; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key
XX FT modified_base
XX FT Location/Qualifiers
XX FT 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate linkages and all cytidine
XX FT residues are 5-methylcytidines"
XX FT modified_base
XX FT 1..5
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "2'-O-methoxyethyls"
XX FT modified_base
XX FT 16..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "2'-O-methoxyethyls"
XX FT
XX FT
XX PN WO2004028458-A2.
XX XX
XX PD 08-APR-2004.
XX PD
XX PF 25-SEP-2003; 2003WO-US030374.
XX PF
XX PR 25-SEP-2002; 2002US-0413549P.
XX PR
XX PA (PHAA ) PHARMACIA CORP.
XX PA
XX PI Gierse JK;
XX PI
XX DR WPI; 2004-305094/28.
XX XX
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX PT ischemia.
XX PS Claim 4; SEQ ID NO 187; 132pp; English.
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX CC human mPGES-1 gene is located on chromosome 9, more specifically to
XX CC 9q34.3. The present invention also describes: (1) antisense compounds,
XX CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX CC inhibits its expression; (2) a method of inhibiting the expression of
XX CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX CC antisense oligonucleotides and antisense compounds have cytostatic,
XX CC anti-diabetic, immunomodulator, cardiant, neuroprotective,
XX CC anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX CC ophthalmological, immunomodulatory and cardiovascular activities, and can
XX CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX CC can be used for preparing a composition for treating a disease or
XX CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX CC ophthalmic, immunological, cardiovascular or neurological disorder.

```



```
PR 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
PA
XX
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 201; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTCTCTTCTCTTTT 2586
Db 1 TTTT 20
RESULT 499
ADM14020
ID ADM14020 standard; DNA; 20 BP.
XX
XX ADM14020;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:207.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 207; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTCTCTTCTCTTTT 2586
Db 1 TTTT 20
RESULT 500
ADM13991
ID ADM13991 standard; DNA; 20 BP.
XX
XX ADM13991;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:178.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
```


KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 178; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antiinflammatory, neuroprotective, cardiant, neuroprotective,
XX immunomodulatory, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX 2567 TTCTCTCTCTTTTTTTTTT 2586

Db . ||||| 1 ||||| 20
. TTTTTTTTTTTTTTTTTT
RESULT 501
ADMI4003
ID ADMI4003 standard; DNA; 20 BP.
XX
XX ADMI4003;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:190.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 190; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antiinflammatory, neuroprotective, cardiant, neuroprotective,
XX immunomodulatory, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX 2567 TTCTCTCTCTTTTTTTTTT 2586

XX New antisense compound having a sequence targeted to a nucleic acid

PR 25-SEP-2002; 2002US-0413549P.

```

FT modified base 1. .5
FT residues are 5-methylcytidines"

```

```

FT      /*tag= a
FT      /mod_base= OTHER
FT      /note= "2'-O-methoxyethyls"
FT      16..20
FT      modified_base
FT      /*tag= c
FT      /mod_base= OTHER
FT      /note= "2'-O-methoxyethyls"
FT
FT
PN      WO2004028458-A2.
XX
XX      08-APR-2004.
XX
XX      25-SEP-2003; 2003WO-US030374.
XX
XX      25-SEP-2002; 2002US-0413549P.
XX      (PHAA ) PHARMACIA CORP.
XX
XX      Gierse JK;
XX
XX      WPI; 2004-305094/28.
XX
XX      New antisense compound, having a sequence targeted to a nucleic acid
XX      encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX      inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX      ischemia.
XX
XX      Claim 4; SEQ ID NO 276; 132pp; English.
XX
XX      The present sequence represents a chimeric antisense oligonucleotide
XX      targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX      human mPGES-1 gene is located on chromosome 9, more specifically to
XX      9q34.3. The present invention also describes: (1) antisense compounds,
XX      having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX      mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX      inhibits its expression; (2) a method of inhibiting the expression of
XX      mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX      having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX      antisense oligonucleotides and antisense compounds have cytostatic,
XX      antidiabetic, immunomodulator, cardiant, neuroprotective,
XX      antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX      ophthalmological, immunomodulatory and cardiovascular activities, and can
XX      be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX      can be used for preparing a composition for treating a disease or
XX      condition associated with mPGES-1 e.g.; inflammation, Alzheimer's
XX      disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX      ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX      Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
XX      Query Match          0.4%; Score 15.2; DB 1; Length 20;
XX      Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX      Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY      2567 TTCTCTCTCTCTCTCTCTTTT 2586
DB      1 TTTTCTCTCTCTCTCTCTCTTTT 20

RESULT 509
ADM14016
ID      ADM14016 standard; DNA; 20 BP.
XX
XX      ADM14016;
XX
XX      01-JUL-2004 (first entry)
XX
XX      Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:203.
XX
XX      chimeric; antisense oligonucleotide; phosphorothioate; human;
XX      microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX      microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX      immunomodulator; cardiant; neuroprotective; antiinflammatory;

```

```

KW      neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW      immunomodulatory; cardiovascular; gene therapy; inflammation;
KW      Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW      reperfusion injury; ophthalmic disorder; immunological disorder;
KW      cardiovascular disorder; neurological disorder; ss.
XX
XX      Homo sapiens.
OS      Synthetic.
XX
XX      Key          Location/Qualifiers
FT      modified_base 1..20
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "phosphorothioate linkages and all cytidine
FT      residues are 5-methylcytidines"
FT      modified_base 1..5
FT      /*tag= a
FT      /mod_base= OTHER
FT      /note= "2'-O-methoxyethyls"
FT      modified_base 16..20
FT      /*tag= c
FT      /mod_base= OTHER
FT      ;
FT      /note= "2'-O-methoxyethyls"
XX
XX      WO2004028458-A2.
XX
XX      08-APR-2004.
XX
XX      25-SEP-2003; 2003WO-US030374.
XX
XX      25-SEP-2002; 2002US-0413549P.
XX      (PHAA ) PHARMACIA CORP.
XX
XX      Gierse JK;
XX
XX      WPI; 2004-305094/28.
XX
XX      New antisense compound, having a sequence targeted to a nucleic acid
XX      encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX      inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX      ischemia.
XX
XX      Claim 4; SEQ ID NO 203; 132pp; English.
XX
XX      The present sequence represents a chimeric antisense oligonucleotide
XX      targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX      human mPGES-1 gene is located on chromosome 9, more specifically to
XX      9q34.3. The present invention also describes: (1) antisense compounds,
XX      having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX      mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX      inhibits its expression; (2) a method of inhibiting the expression of
XX      mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX      having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX      antisense oligonucleotides and antisense compounds have cytostatic,
XX      antidiabetic, immunomodulator, cardiant, neuroprotective,
XX      antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX      ophthalmological, immunomodulatory and cardiovascular activities, and can
XX      be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX      can be used for preparing a composition for treating a disease or
XX      condition associated with mPGES-1 e.g.; inflammation, Alzheimer's
XX      disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX      ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX      Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
XX      Query Match          0.4%; Score 15.2; DB 1; Length 20;
XX      Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX      Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY      2567 TTCTCTCTCTCTCTCTCTTTT 2586
DB      1 TTTTCTCTCTCTCTCTCTCTTTT 20

```


ischemia.

Claim 4; SEQ ID NO 376; 132pp; English.

The present sequence represents a chimeric antisense oligonucleotide targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The human mPGES-1 gene is located on chromosome 9, more specifically to 9q34.3. The present invention also describes: (1) antisense compounds, having a sequence comprising 8-30 bp targeted to a nucleic acid encoding mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and inhibits its expression; (2) a method of inhibiting the expression of mPGES-1 in cells or tissues; and (3) a method of treating an animal having a disease or condition associated with mPGES-1. mPGES-1 chimeric antisense oligonucleotides and antisense compounds have cytostatic, antidiabetic, immunomodulator, cardiant, neuroprotective, antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic, antihypertensive, immunomodulatory and cardiovascular activities, and can be used as mPGES-1 inhibitors and in gene therapy. The antisense compound can be used for preparing a composition for treating a disease or condition associated with mPGES-1 e.g. inflammation, Alzheimer's disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or ophthalmic, immunological, cardiovascular or neurological disorder.

Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0

Qy 2567 TTTCTTCTCTCTTTTTTTT 2586
||||| ||| ||| ||| ||| |||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 512
ADM13996

ID ADM13996 standard; DNA; 20 BP.

AC ADM13996;

XX 01-JUL-2004 (first entry)

XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:183.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antiinflammatory;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.

OS Homo sapiens.
OS Synthetic.

XX

FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX

PN WO2004028458-A2.


```

PH Key      Location/Qualifiers
FT modified_base 1..20
FT *tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT *tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT *tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT
FT
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 188; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 2567 TTCTCTCTCTCTCTCTCTTT 2586
XX ||||| ||||| ||||| |||||
XX 1 TTTTCTCTCTCTCTCTCTCTTT 20
XX
XX RESULT 514
XX ADM14004
XX ID ADM14004 standard; DNA; 20 BP.
XX
XX AC ADM14004;
XX
XX 01-JUL-2004 (first entry)
XX

```

```

XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:191.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key      Location/Qualifiers
XX modified_base 1..20
XX *tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX modified_base 1..5
XX *tag= a
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX modified_base 16..20
XX *tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 191; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
XX

```

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 515
ADM14012
ID ADM14012 standard; DNA; 20 BP.
XX
AC ADM14012;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:199.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.

Key Location/Qualifiers
modified_base 1..20
/tag= b
/mod_base= OTHER
/note= "phosphorothioate linkages and all cytidine residues are 5-methylcytidines"
modified_base 1..5
/tag= a
/mod_base= OTHER
/note= "2'-O-methoxyethyls"
modified_base 16..20
/tag= c
/mod_base= OTHER
/note= "2'-O-methoxyethyls"
WO2004028458-A2.
08-APR-2004.
25-SEP-2003; 2003WO-US030374.
25-SEP-2002; 2002US-0413549P.
(PHAA) PHARMACIA CORP.
Gierse JK;
WPI; 2004-305094/28.
New antisense compound, having a sequence targeted to a nucleic acid encoding mPGES-1, useful for preparing a composition for treating e.g., inflammation, Alzheimer's disease, arthritis, diabetes, cancer or ischemia.
Claim 4; SEQ ID NO 199; 132pp; English.
The present sequence represents a chimeric antisense oligonucleotide targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The human mPGES-1 gene is located on chromosome 9, more specifically to 9q34.3. The present invention also describes: (1) antisense compounds, having a sequence comprising 8-30 bp targeted to a nucleic acid encoding

CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and inhibits its expression; (2) a method of inhibiting the expression of mPGES-1 in cells or tissues; and (3) a method of treating an animal having a disease or condition associated with mPGES-1. mPGES-1 chimeric antisense oligonucleotides and antisense compounds have cytosolic, antidiabetic, immunomodulator, cardiant, neuroprotective, antiinflammatory, immunomodulatory and cardiovascular activities, and can be used as mPGES-1 inhibitors and in gene therapy. The antisense compound can be used for preparing a composition for treating a disease or condition associated with mPGES-1 e.g., inflammation, Alzheimer's disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 516
ADM14015
ID ADM14015 standard; DNA; 20 BP.
XX
AC ADM14015;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:202.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.

Key Location/Qualifiers
modified_base 1..20
/tag= b
/mod_base= OTHER
/note= "phosphorothioate linkages and all cytidine residues are 5-methylcytidines"
modified_base 1..5
/tag= a
/mod_base= OTHER
/note= "2'-O-methoxyethyls"
modified_base 16..20
/tag= c
/mod_base= OTHER
/note= "2'-O-methoxyethyls"
WO2004028458-A2.
08-APR-2004.
25-SEP-2003; 2003WO-US030374.
25-SEP-2002; 2002US-0413549P.
(PHAA) PHARMACIA CORP.

CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2567 TTTCTCTCTCTTTTTTTT 2586
 DB 1 TTTTTTTTTTTTTTTTTT 20
 RESULT 520
 ADM14019
 ID ADM14019 standard; DNA; 20 BP.
 XX
 AC ADM14019;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:206.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 PN WO2004028458-A2.
 XX
 PD 08-APR-2004.
 XX
 PF 25-SEP-2003; 2003WO-US030374.
 XX
 PR 25-SEP-2002; 2002US-0413549P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Gierse JK;
 XX
 DR WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 PT

PS
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds;
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2567 TTTCTCTCTCTTTTTTTT 2586
 DB 1 TTTTTTTTTTTTTTTTTT 20
 RESULT 521
 ADM14087
 ID ADM14087 standard; DNA; 20 BP.
 XX
 AC ADM14087;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:274.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 PN WO2004028458-A2.
 XX
 PD 08-APR-2004.


```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0
Qy " 2567 TTTCTTCTCTTTTTTTTT 2586
Db 1 TTTTTTTTTTTTTTTTTTTT 20

RESULT 524
ADM13998
ID ADM13998 standard; DNA; 20 BP.
XX
XX ADM13998;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:185.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1. .20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX modified_base 1. .5
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX modified_base 16. .20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 185; 132pp; English.
XX
XX *The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of

```

CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiac, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

```
Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy	2567	TTTTCTCTCTCTTTTTTTTT	2586
Db	1	TTTTTTTTTTTTTTTTTTTT	20

RESULT 525
ADM14007
ID ADM14007 standard; DNA; 20 BP.

XX
AC ADM14007;

01-JUL-2004 (first entry)

DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:194.

KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; neurotic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.

OS Homo sapiens.
OS Synthetic.

XX	Key	Location/Qualifiers
FH	modified base	1. .20
FT		

```

FI
FT
FT
FT
FT

```

```
FT modified_base 1..5
```

```

Z1      /*cag= a
FT      /mod base= OTHER

```

```

FI modified base 16. .20
FT modified base 16. .20
/note= "2'-O-methoxyethyl"

```

```
FT /wtag= C
FT /mod_base= OTHER
FT /note= "2',-O-methoxyethyl"s"
```

XX
PN
WO2004028458-A2

XX PD 08-APR-2004.

XX
PF
25-SEP-2003: 2003WO-US030374.

XX
PR 25-SEP-2002: 2002US-0413549P.

XX
PA (PHAA) PHARMACIA CORP.

XX PI Gierse JK:

XX

WPI; 2004-305094/28.

New antisense compound, having a sequence targeted to a nucleic acid encoding mPGES-1, useful for preparing a composition for treating e.g., inflammation, Alzheimer's disease, arthritis, diabetes, cancer or ischemia.

Claim 4; SEQ ID NO 194; 132pp; English.

The present sequence represents a chimeric antisense oligonucleotide targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The human mPGES-1 gene is located on chromosome 9, more specifically to 9q34.3. The present invention also describes: (1) antisense compounds, having a sequence comprising 8-30 bp targeted to a nucleic acid encoding mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and inhibits its expression; (2) a method of inhibiting the expression of mPGES-1 in cells or tissues; and (3) a method of treating an animal having a disease or condition associated with mPGES-1. mPGES-1 chimeric antisense oligonucleotides and antisense compounds have cytostatic, antidiabetic, immunomodulatory, cardiant, neuroprotective, antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic, ophthalmological, immunomodulatory and cardiovascular activities, and can be used as mPGES-1 inhibitors and in gene therapy. The antisense compound can be used for preparing a composition for treating a disease or condition associated with mPGES-1 e.g., inflammation, Alzheimer's disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or ophthalmic, immunological, cardiovascular or neurological disorder.

Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other:

Query Match	0.4%	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 2.4e+02;		
Matches 17; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0

Qy 2567 TTTCTCTCTCTCTTTTTTTT 2586
Db 1 TTTTTTTTTTTTTTTTTTTTTTTT 20

RESULT 526

ADM14124
ID ADM14124 standard; DNA; 20 BP.

XX
AC ADM14124:XX
DT 01-JUL-2004 (first entry)

XX DE Human mpGES-1 chimeric antisense oligonucleotide SEO ID NO:311.

xx chimeric; antisense oligonucleotide; phosphorothioate; human;
 kw microsonal prostaglandin E2 synthase; mPGEs-1; mPGEs-1 inhibitor;
 kw microsonal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 kw immunomodulator; cardiant; neuroprotective; antiinflammatory;
 kw neuroprotective; nootropic; antiarrhythmic; vasotropic; ophthalmological;
 kw immunomodulatory; cardiovascular; gene therapy; inflammation;
 kw Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 kw reperfusion injury; ophthalmic disorder; immunological disorder;
 kw cardiovascular disorder; neurologic disorder; ss.

XX Homo sapiens.
OS

OS Synthetic.

XX	Key	Location/Qualifiers
FH		

```
FT modified_base 1.:20
FT /*tag= b
```

```
FT /mod_base= OTHER
FT /note= "phosphor"
```

FT modified base 1.5
residues are 5-methylcytidines"

 $\frac{f}{x_0} \quad \frac{f}{x_1}$

FT modified base 16...20 /note= "2'-O-methoxyethyls"


```
FT      /*tag= c
FT      /mod_base= OTHER
FT      /note= "2'-O-methoxyethyls"
XX
PN      WO2004028458-A2.
PD      08-APR-2004.
XX
XX      25-SEP-2003; 2003WO-US030374.
PF
XX      25-SEP-2002; 2002US-0413549P.
PR
XX      (PHAA ) PHARMACIA CORP.
PA
XX      Gierse JK;
XX
PI      WPI; 2004-305094/28.
XX
XX      New antisense compound, having a sequence targeted to a nucleic acid
XX      encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX      inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX      ischemia.
XX
PS      Claim 4; SEQ ID NO 311; 132pp; English.
XX
CC      The present sequence represents a chimeric antisense oligonucleotide
CC      targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC      human mPGES-1 gene is located on chromosome 9, more specifically to
CC      9q34.3. The present invention also describes: (1) antisense compounds,
CC      having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC      mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC      inhibits its expression; (2) a method of inhibiting the expression of
CC      mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC      having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC      antisense oligonucleotides and antisense compounds have cytostatic,
CC      antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC      antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC      ophthalmological, immunomodulatory and cardiovascular activities, and can
CC      be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC      can be used for preparing a composition for treating a disease or
CC      condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC      disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC      ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ      Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

      Query Match      0.4%; Score 15.2; DB 1; Length 20;
      Best Local Similarity 85.0%; Pred. No. 2.4e+02;
      Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2567 TTCTCTCTCTCTCTCTCTTTT 2586
      ||| ||| ||| ||| ||| ||| |||
      1 TTTTCTCTCTCTCTCTCTCTTTT 20

Db

RESULT 527
ADM14216
ID      ADM14216 standard; DNA; 20 BP.
XX
XX      ADM14216;
AC
XX
XX      01-JUL-2004 (first entry)
DT
XX
XX      Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:403.
DE
XX
XX      chimeric; antisense oligonucleotide; phosphorothioate; human;
KW      microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW      microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW      immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW      neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW      immunomodulatory; cardiovascular; gene therapy; inflammation;
KW      Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW      reperfusion injury; ophthalmic disorder; immunological disorder;
```

```
KW      cardiovascular disorder; neurological disorder; ss.
XX
XX      Homo sapiens.
OS
OS      Synthetic.
XX
XX      Key      Location/Qualifiers
FH      modified_base 1..20
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "phosphorothioate linkages and all cytidine
FT      residues are 5-methylcytidines"
FT      modified_base 1..5
FT      /*tag= a
FT      /mod_base= OTHER
FT      modified_base 16..20
FT      /*tag= c
FT      /mod_base= OTHER
FT      /note= "2'-O-methoxyethyls"
XX
XX      WO2004028458-A2.
PN
XX      08-APR-2004.
PD
XX
XX      25-SEP-2003; 2003WO-US030374.
PF
XX
XX      25-SEP-2002; 2002US-0413549P.
PR
XX      (PHAA ) PHARMACIA CORP.
PA
XX      Gierse JK;
XX
XX      WPI; 2004-305094/28.
XX
XX      New antisense compound, having a sequence targeted to a nucleic acid
XX      encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX      inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX      ischemia.
XX
PS      Claim 4; SEQ ID NO 403; 132pp; English.
XX
CC      The present sequence represents a chimeric antisense oligonucleotide
CC      targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC      human mPGES-1 gene is located on chromosome 9, more specifically to
CC      9q34.3. The present invention also describes: (1) antisense compounds,
CC      having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC      mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC      inhibits its expression; (2) a method of inhibiting the expression of
CC      mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC      having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC      antisense oligonucleotides and antisense compounds have cytostatic,
CC      antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC      antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC      ophthalmological, immunomodulatory and cardiovascular activities, and can
CC      be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC      can be used for preparing a composition for treating a disease or
CC      condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC      disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC      ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX      Sequence 20 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 0 Other;

      Query Match      0.4%; Score 15.2; DB 1; Length 20;
      Best Local Similarity 85.0%; Pred. No. 2.4e+02;
      Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 2567 TTCTCTCTCTCTCTCTTTT 2586

Db 1 TTTTCTCTCTCTCTCTCTTTT 20

RESULT 528
ADO44733

ID XX AC ADO44733 standard; DNA; 20 BP.
XX AC ADO44733;
DT 15-JUL-2004 (first entry)
XX DE Human oligonucleotide #99.
XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
XX KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
XX KW asthma; lung allergy; inflammation; inflammatory disease;
XX KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
XX KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
XX KW acute respiratory distress syndrome; pulmonary hypertension;
XX KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX OS Homo sapiens.
XX FN US2004049022-A1.
XX PD 11-MAR-2004.
XX PF 25-JUL-2003; 2003US-00627930.
XX XX 23-APR-2002; 2002WO-US013135.
XX PR 23-APR-2002; 2002WO-US013143.
XX XX (NYCE/) NYCE J W.
XX PA (SAND/) SANDRASAGRA A.
XX PA (TANG/) TANG L.
XX PA (AGUI/) AGUILAR D.
XX PA (MILL/) MILLER S.
XX PA (SHAH/) SHAHABUDDIN S.
XX PA (LUHH/) LU H.
XX PA (CONG/) CONG H.
XX XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;
XX XX WPI; 2004-293804/27.
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
XX PT asthma.
XX PS Claim 2; SEQ ID NO 99; 174pp; English.
XX CC The invention relates to oligonucleotides anti-sense to an initiation
XX CC codon, coding region, 5' or 3' intron-exon junction, intron or region
XX CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
XX CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
XX CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
XX CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
XX CC also relates to a method of screening a candidate compound that binds to
XX CC one or more nucleic acid target(s) or expressed product(s), for the
XX CC prevention and/or treatment of a respiratory or lung disease. The
XX CC oligonucleotides are useful for reducing or inhibiting expression of a
XX CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
XX CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
XX CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
XX CC useful for preventing or treating a respiratory or lung disease. The
XX CC respiratory or lung disease is associated with hyper-responsiveness to
XX CC and/or increased levels of, adenosine and/or levels of adenosine A
XX CC receptor(s), and/or asthma and/or lung allergies associated with
XX CC inflammation or an inflammatory disease. The respiratory or lung disease
XX CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
XX CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
XX CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
XX CC hypertension, lung inflammation, bronchitis, airway obstruction or
XX CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.
XX XX Sequence 20 BP; 6 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 231 GAGCTGGTCCAGGCGGC 250
Db 1 GAGCAGGTCAGGACAGGC 20
AD046424
AD046424 standard; DNA; 20 BP.
XX AC ADO46424;
XX DT 15-JUL-2004 (first entry)
XX DE Human oligonucleotide #1790.
XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
XX KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
XX KW asthma; lung allergy; inflammation; inflammatory disease;
XX KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
XX KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
XX KW acute respiratory distress syndrome; pulmonary hypertension;
XX KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX OS Homo sapiens.
XX XX US2004049022-A1.
XX XX 11-MAR-2004.
XX XX 25-JUL-2003; 2003US-00627930.
XX XX 23-APR-2002; 2002WO-US013135.
XX XX 23-APR-2002; 2002WO-US013143.
XX XX (NYCE/) NYCE J W.
XX PA (SAND/) SANDRASAGRA A.
XX PA (TANG/) TANG L.
XX PA (AGUI/) AGUILAR D.
XX PA (MILL/) MILLER S.
XX PA (SHAH/) SHAHABUDDIN S.
XX PA (LUHH/) LU H.
XX PA (CONG/) CONG H.
XX XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;
XX XX WPI; 2004-293804/27.
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
XX PT asthma.
XX PS Claim 2; SEQ ID NO 1791; 174pp; English.
XX CC The invention relates to oligonucleotides anti-sense to an initiation
XX CC codon, coding region, 5' or 3' intron-exon junction, intron or region
XX CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
XX CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
XX CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
XX CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
XX CC also relates to a method of screening a candidate compound that binds to
XX CC one or more nucleic acid target(s) or expressed product(s), for the

PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.

PS Claim 4; SEQ ID NO 1802; 150pp; English.

XX The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurochemical disorders, or ischemia/reperfusion injury. In addition, the
CC neurological disorders, or as research reagents
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2211 GAACCTTCTCTCTCTCTCTCT 2230

DB 1 GAAGCTTCTCTACTGCTCTCT 20

RESULT 532

AD053172/c

ID AD053172 standard; DNA; 20 BP.

XX AC AD053172;

XX DT 15-JUL-2004 (first entry)

XX DE Farnesoid X receptor gene expression antisense inhibitory oligo #545.

XX ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.

XX OS Homo sapiens.

XX PN WO2004030750-A1.

XX PD 15-APR-2004.

XX PF 25-SEP-2003; 2003WO-US030353.

XX PR 25-SEP-2002; 2002US-0413588P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Kane CD;

XX DR WPI; 2004-347928/32.

XX New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.

XX Claim 4; SEQ ID NO 545; 150pp; English.

XX PS

CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurochemical disorders, or ischemia/reperfusion injury. In addition, the
CC neurological disorders, or as research reagents
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 10 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1752 GGTCTGGCTCATCTTCTCT 1771

DB 20 GGTCTAGCTCCTTTTCTCT 1

RESULT 533

AD053011/c

ID AD053011 standard; DNA; 20 BP.

XX AC AD053011;

XX DT 15-JUL-2004 (first entry)

XX DE Farnesoid X receptor gene expression antisense inhibitory oligo #384.

XX ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.

XX OS Homo sapiens.

XX PN WO2004030750-A1.

XX PD 15-APR-2004.

XX PF 25-SEP-2003; 2003WO-US030353.

XX PR 25-SEP-2002; 2002US-0413588P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Kane CD;

XX DR WPI; 2004-347928/32.

XX New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.

XX Claim 4; SEQ ID NO 384; 150pp; English.

XX The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or

CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 10 A; 2 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1753 GTCTGCTCATCTTCTCTC 1772
Db 20 GTCTAGCTCCTTTCTCTC 1

RESULT 534

ADO03711/c

ID ADO03711 standard; DNA; 20 BP.

XX ADO03711;

XX 29-JUL-2004 (first entry)

XX SERS-based analyte detection oligonucleotide seqid 31.

XX Raman label; specific binding member; surface-enhanced Raman scattering;
KW SERS; ss.

XX Synthetic.

XX US2004086897-A1.

XX 06-MAY-2004.

XX 07-MAY-2003; 2003US-00431341.

XX 07-MAY-2002; 2002US-0378538P.

XX 28-MAY-2002; 2002US-0383630P.

XX 14-JUN-2002; 2002US-0017428.

XX (MIRK/) MIRKIN C A.

XX (CAOY/) CAO Y.

XX (JINR/) JIN R.

XX Mirkin CA, Cao Y, Jin R;

XX WPI; 2004-418413/39.

XX Reagent, useful for detecting target analyte e.g., nucleic acid,
PT comprising particle having bound to at least one Raman label, which can
PT be activated to provide surface-enhanced Raman scattering effect, and
PT specific binding member.

XX Disclosure; SEQ ID NO 31; 55pp; English.

XX The invention describes a reagent (I) comprising a particle bound to at
CC least one Raman label and a specific binding member, where the Raman
CC label can be activated to provide a surface-enhanced Raman scattering
CC (SERS) effect or comprising a specific binding member having two or more
CC different Raman labels bound to it. Also described are: a test kit (II),
CC comprising (I) in one container and a silver, gold or copper Raman
CC enhancer stain in another container; and a fibre optic detection device
CC (III), having a bundle of optical fibres terminating with ends of the
CC optical fibre, where a several of the optical fibres have (I) located at
CC the ends of the optical fibre. (II) is useful for: detecting for the
CC presence or absence of one or more target analytes in a sample, the
CC target analytes having at least two binding sites; detecting the presence

CC or absence of one or more target nucleic acid in a sample, the sequence
CC of the nucleic acid having at least two portions; and for screening one
CC or more molecules to determine whether the molecule is a ligand to one or
CC more specific receptors. This sequence represents an oligonucleotide
XX associated with the SERS-based detection analyte detection method.

SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTCTTTT 2586
Db 20 TTTTCTTTTCTTTTCTTTT 1

RESULT 535

ADN48670/c

ID ADN48670 standard; DNA; 20 BP.

XX ADN48670;

XX 12-AUG-2004 (first entry)

XX Human Notch3 DNA antisense oligonucleotide target region #36.

XX Human; Notch3; ss; antisense oligonucleotide; phosphorothioate linkage;

KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; cytostatic.

XX Homo sapiens.

XX US2004102390-A1.

XX 27-MAY-2004.

XX 21-NOV-2002; 2002US-00301832.

XX 21-NOV-2002; 2002US-00301832.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;

XX WPI; 2004-399720/37.

XX New compounds, particularly oligonucleotides targeted to a nucleic acid
PT encoding Notch3, useful for treating diseases associated with Notch3,
PT e.g. hyperproliferative disorders.

XX Example 15; SEQ ID NO 125; 74pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding the human Notch3 polypeptide. The compound is an antisense
CC oligonucleotide that specifically hybridizes with the nucleic acid and
CC inhibits expression of the polypeptide. The antisense oligonucleotide
CC comprises at least one modified internucleoside linkage i.e. a
CC phosphorothioate linkage, at least one modified sugar moiety, preferably
CC a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC comprising a 5-methylcytosine. The antisense compounds are useful for
CC modulating the expression of the human Notch3 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents a human Notch3 DNA antisense
XX oligonucleotide target region of the invention.

SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 669 AACGAGCGTGATGCTCTC 688

QY 2190 CTCGATCTTCTCTCTGAAGA 2209
 DB 20 CTGCAGCTTTCATCTCTGAAGA 1

RESULT 538
 ADO33107
 ID ADO333107 standard; DNA; 20 BP.
 AC ADO333107;
 XX
 XX 12-AUG-2004 (first entry)
 XX
 XX Human apolipoprotein B (ApoB) antisense therapy target DNA - SEQ 555.
 DE
 XX
 KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
 KW antilipaeamic; antidiabetic; anorectic; cardiant; vasotropic; hypotensive;
 KW anabolic; eating disorder; cytotatic; endocrine; vasotropic;
 KW neuroprotective; nootropic; lipid; cholesterol metabolism;
 KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
 KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
 KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
 KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
 KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
 KW obesity; atherosclerosis; human; chromosome 2p23-2p24; ds;
 KW antisense target.
 XX
 XX Homo sapiens.
 OS
 PN WO2004044181-A2.
 XX
 XX 27-MAY-2004.
 PD
 PF 13-NOV-2003; 2003WO-US036411.
 XX
 XX 13-NOV-2002; 2002US-0426234P.
 PR 15-MAY-2003; 2003WO-US015493.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
 PI WPI; 2004-420321/39.
 XX
 XX Antisense oligonucleotide compound that inhibits expression of mRNA
 PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
 PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
 PT syndrome.
 XX
 XX Example 36; SEQ ID NO 555; 483pp; English.
 PS
 XX The invention relates to a novel antisense compound where the compound
 XX hybridises to and inhibits expression of mRNA encoding human
 CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
 CC confluent HepG2 cells in culture at a concentration of 150 nM. The
 CC compound of the invention demonstrates cardiovascular,
 CC antiarteriosclerotic, antilipaeamic, antidiabetic, anorectic, cardiant,
 CC vasotropic, hypotensive, anabolic, eating disorder-related, cytotatic,
 CC endocrine, vasotropic, neuroprotective and nootropic activities and may
 CC be useful for inhibiting the expression of apolipoprotein B in cells or
 CC tissues in vivo in order to address a condition associated with abnormal
 CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilised during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia, Cushing's
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and atherosclerosis. The current sequence is that of a
 CC human apolipoprotein B (ApoB) antisense therapy target DNA of the

CC invention. The human ApoB gene is located at chromosome 2p23-2p24.
 XX
 XX Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2190 CTCGATCTTCTCTCTGAAGA 2209
 DB 1 CTGCAGCTTTCATCTCTGAAGA 20

RESULT 539
 ADO32654
 ID ADO32654 standard; DNA; 20 BP.
 AC ADO32654;
 XX
 XX 12-AUG-2004 (first entry)
 DE Antisense 2'-MOE gapmer oligo targeted to murine ApoB RNA - SEQ 102.
 XX
 KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
 KW antilipaeamic; antidiabetic; anorectic; cardiant; vasotropic; hypotensive;
 KW anabolic; eating disorder; cytotatic; endocrine; vasotropic;
 KW neuroprotective; nootropic; lipid; cholesterol metabolism;
 KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
 KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
 KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
 KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
 KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
 KW obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;
 KW phosphorothioate backbone; murine; mouse; ss.
 XX
 XX Mus sp.
 OS
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = Phosphorothioate backbone, bases 1-5 and
 FT 16-20 2'-MOE wing bases, all cytidine residues are 5-
 FT methylecytidines"
 FT
 XX WO2004044181-A2.
 PN
 XX 27-MAY-2004.
 PD
 XX 13-NOV-2003; 2003WO-US036411.
 PF
 XX 13-NOV-2002; 2002US-0426234P.
 PR 15-MAY-2003; 2003WO-US015493.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
 PI WPI; 2004-420321/39.
 XX
 XX Antisense oligonucleotide compound that inhibits expression of mRNA
 PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
 PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
 PT syndrome.
 XX
 XX Example 17; SEQ ID NO 102; 483pp; English.
 PS
 XX The invention relates to a novel antisense compound where the compound
 CC hybridises to and inhibits expression of mRNA encoding human
 CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
 CC confluent HepG2 cells in culture at a concentration of 150 nM. The
 CC compound of the invention demonstrates cardiovascular,
 CC antiarteriosclerotic, antilipaeamic, antidiabetic, anorectic, cardiant,
 CC vasotropic, hypotensive, anabolic, eating disorder-related, cytotatic,
 CC endocrine, vasotropic, neuroprotective and nootropic activities and may
 CC be useful for inhibiting the expression of apolipoprotein B in cells or
 CC tissues in vivo in order to address a condition associated with abnormal
 CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilised during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia, Cushing's
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and atherosclerosis. The current sequence is that of a
 CC human apolipoprotein B (ApoB) antisense therapy target DNA of the

CC vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
CC endocrine, vasotropic, neuroprotective and nootropic activities and may
CC be useful for inhibiting the expression of apolipoprotein B in cells or
CC tissues in vivo in order to address a condition associated with abnormal
CC lipid or cholesterol metabolism. The compound may be useful for
CC decreasing circulating lipoprotein levels, triglyceride levels,
CC cholesterol levels, lipid levels, fatty acid levels, acute phase
CC reactants and chylomicrons and thus may be utilised during treatment of
CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
CC syndrome, sexual atretic dwarfism, hyperthyroidism, hypertension,
CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC diabetes, obesity and atherosclerosis. The current sequence is that of an
CC antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is
CC targeted to murine ApoB RNA.

XX Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3461 AGGAAGAAATCTTGCTATT 3480
Db 1 AGGAAGGAATCTTGATATT 20

RESULT 540
ADP20152/c
ID ADP20152 standard; DNA; 20 BP.

XX AC ADP20152;

XX DT 26-AUG-2004 (first entry)

XX DE Nucleic acid detection method linking oligonucleotide #66.

XX KW Nucleic acid detection; nanoparticle-oligonucleotide conjugate;
KW genetic disease; bacterial infection; viral infection; forensic;
KW DNA sequencing; paternity testing; linking oligonucleotide; ss.

XX OS Synthetic.

XX PN US2004110220-A1.

XX PD 10-JUN-2004.

XX PF 18-NOV-2003; 2003US-00716829.

XX PR 29-JUL-1996; 96US-0031809P.

XX PR 21-JUL-1997; 97WO-US012783.

XX PR 29-JAN-1999; 99US-00240755.

XX PR 25-JUN-1999; 99US-00344667.

XX PR 13-JAN-2000; 2000US-0176409P.

XX PR 26-APR-2000; 2000US-0200161P.

XX PR 26-JUN-2000; 2000US-00603830.

XX PR 12-JAN-2001; 2001US-00760500.

XX PA (NANO-) NANOSPHERE INC.

XX PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;

XX PI Taton TA, Garimella V, Li Z;

XX DR WPI; 2004-440357/41.

XX PT Nanoparticles useful for detection and separation of nucleic acids e.g.
PT genes associated with disease, in a diagnostic assay, comprise several
PT oligonucleotides attached to them.

XX PS Example 24; SEQ ID NO 70; 142pp; English.

XX XX

CC The invention relates to a method of detecting a nucleic acid with at
CC least two portions by providing a type of nanoparticle-oligonucleotide
CC conjugate, contacting the nucleic acid and nanoparticles to allow
CC hybridisation of the oligonucleotides with the two or more portions of
CC the nucleic acid and observing a detectable change brought about by
CC hybridisation. The oligonucleotides have a sequence complementary to the
CC sequence of at least two portions of the nucleic acid. Hybridisation of
CC the oligonucleotides on the nanoparticles with the nucleic acid results
CC in a detectable change. The method is used for detection and separation
CC of nucleic acids (e.g. viral DNA, a gene associated with a disease, DNA
CC bacterial DNA, fungal DNA, synthetic DNA, structurally-modified DNA, DNA
CC from biological sources or PCR products) for diagnosis of various
CC diseases (such as genetic diseases, bacterial infections and viral
CC infections) and for forensics, DNA sequencing, paternity testing and
CC monitoring gene therapy. This sequence represents a linking
CC oligonucleotide of the invention.

XX SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTTTT 2586
Db 20 TTTTCTCTCTCTCTCTTTT 1

RESULT 541
ADP20137/c

ID ADP20137 standard; DNA; 20 BP.

XX AC ADP20137;

XX DT 26-AUG-2004 (first entry)

XX DE Nucleic acid detection method linking oligonucleotide #54.

XX KW Nucleic acid detection; nanoparticle-oligonucleotide conjugate;
KW genetic disease; bacterial infection; viral infection; forensic;
KW DNA sequencing; paternity testing; linking oligonucleotide; ss.

XX OS Synthetic.

XX PN US2004110220-A1.

XX PD 10-JUN-2004.

XX PF 18-NOV-2003; 2003US-00716829.

XX PR 29-JUL-1996; 96US-0031809P.

XX PR 21-JUL-1997; 97WO-US012783.

XX PR 29-JAN-1999; 99US-00240755.

XX PR 25-JUN-1999; 99US-00344667.

XX PR 13-JAN-2000; 2000US-0176409P.

XX PR 26-APR-2000; 2000US-0200161P.

XX PR 26-JUN-2000; 2000US-00603830.

XX PR 12-JAN-2001; 2001US-00760500.

XX PA (NANO-) NANOSPHERE INC.

XX PI Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ, Elghanian R;

XX PI Taton TA, Garimella V, Li Z;

XX DR WPI; 2004-440357/41.

XX PT Nanoparticles useful for detection and separation of nucleic acids e.g.
PT genes associated with disease, in a diagnostic assay, comprise several
PT oligonucleotides attached to them.

XX PS Example 18; SEQ ID NO 55; 142pp; English.

XX XX

CC The invention relates to a method of detecting a nucleic acid with at
 CC least two portions by providing a type of nanoparticle-oligonucleotide
 CC conjugate, contacting the nucleic acid and nanoparticles to allow
 CC hybridisation of the oligonucleotides with the two or more portions of
 CC the nucleic acid and observing a detectable change brought about by
 CC hybridisation. The oligonucleotides have a sequence complementary to the
 CC sequence of at least two portions of the nucleic acid. Hybridisation of
 CC the oligonucleotides on the nanoparticles with the nucleic acid results
 CC in a detectable change. The method is used for detection and separation
 CC of nucleic acids (e.g. viral DNA, a gene associated with a disease,
 CC bacterial DNA, fungal DNA, synthetic DNA, structurally-modified DNA, DNA
 CC from biological sources or PCR products) for diagnosis of various
 CC diseases (such as genetic diseases, bacterial infections and viral
 CC infections) and for forensics, DNA sequencing, paternity testing and
 CC monitoring gene therapy. This sequence represents a linking
 CC oligonucleotide of the invention.

XX Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTCTCTCTTTTTTTT 2586
 |||||
 DB 20 TTTTCTCTCTCTTTTTTTT 1

RESULT 542
 ADP64800/C
 ID ADP64800 standard; DNA; 20 BP.

XX AC ADP64800;

XX DT 26-AUG-2004 (first entry)

XX DE Drosophila Na+-coupled citrate transporter protein gene primer #1.

XX KW ss; primer; sodium-coupled citrate transporter;
 KW transmembrane citrate transporter; lifespan; weight reduction;
 KW weight gain prevention; blood cholesterol; triglyceride;
 KW low density lipopolysaccharide; glucose; obesity; hyperlipidemia;
 KW hypercholesterolemia; INDY protein.

XX OS Drosophila melanogaster.

XX PN WO2004048925-A2.

XX PD 10-JUN-2004.

XX PF 20-NOV-2003; 2003WO-US037054.

XX PR 22-NOV-2002; 2002US-0428469P.

XX PR 01-APR-2003; 2003US-045941P.

XX PA (MEDI-) MEDICAL COLLEGE GEORGIA RES INST.
 PA (GANA/) GANAPATHY V.
 PA (INOI/) INOUE K.
 PA (FEIY/) FEI Y.

XX PI Ganapathy V, Inoue K, Fei Y;

XX WP1; 2004-460797/43.

XX New isolated polynucleotide encoding a Na+-coupled citrate transporter
 PT (Nact) polypeptide, useful as a drug target for the treatment of obesity,
 PT hyperlipidemia, and hypercholesterolemia.

XX Example 1; SEQ ID NO 15; 186pp; English.

XX The invention relates to novel Na+-coupled citrate transporter proteins
 CC and their encoding genes. Inhibitors of transmembrane citrate
 CC transporters are useful for extending the lifespan, reducing weight,

CC preventing weight gain or lowering blood cholesterol, triglyceride, LDL
 CC or glucose levels in a subject. The Nact polypeptide is useful as a drug
 CC target for the treatment of obesity, hyperlipidemia, and
 CC hypercholesterolemia. This sequence corresponds to a PCR primer to
 CC amplify the drosophila INDY gene encoding an Na+-coupled citrate
 CC transporter protein.

XX Sequence 20 BP; 4 A; 9 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1590 GCTTTGTTAAGAGCTTGGAG 1609
 |||||
 DB 20 GCTTAGCGAGAGCTTGGAG 1

RESULT 543

ADP69222

ID ADP69222 standard; DNA; 20 BP.

XX AC ADP69222;

XX DT 09-SEP-2004 (first entry)

XX DE Human mitonEET-specific antisense oligonucleotide #116.

XX KW human; antisense oligonucleotide; mitochondrial membrane;
 KW insulin sensitising antidiabetic thiazolidinediones; mitonEET; diabetes;
 KW immunological disorder; cardiovascular disorder; including hypertension;
 KW neurological disorders; ischaemia; reperfusion; ss;
 KW 2'-methoxyethyl gapmer; 2'-MOE gapmer; phosphorothioate backbone.

XX OS Homo sapiens.

XX PN WO2004053060-A2.

XX PD 24-JUN-2004.

XX PF 25-NOV-2003; 2003WO-US037621.

XX PR 06-DEC-2002; 2002US-0431529P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Colca JR;

XX WP1; 2004-468836/44.

XX New antisense oligonucleotides encoding mitonEET, useful for modulating
 PT mitonEET expression or for treating diseases associated with mitonEET,
 PT e.g. diabetes, immunological disorders or cardiovascular disorders.

XX Claim 4; SEQ ID NO 116; 226pp; English.

XX The invention comprises antisense oligonucleotides that are targeted to
 CC the nucleic acids encoding a family of human proteins from mitochondrial
 CC membranes, which bind insulin sensitising, antidiabetic
 CC thiazolidinediones (referred to as: mitonEET). The antisense
 CC oligonucleotides of the invention are useful for modulating mitonEET
 CC expression and for treating diseases or conditions associated with
 CC mitonEET, such as: diabetes, immunological disorders, cardiovascular
 CC disorders including hypertension, neurological disorders, and
 CC ischaemia/reperfusion injuries. The present DNA sequence represents a
 CC -mitonEET-specific antisense oligonucleotide of the invention. NOTE: The
 CC present sequence is a 2'-methoxyethyl (2'-MOE) gapmer with a
 CC phosphorothioate backbone.

XX Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2939 GGTGTTTCTTCTAAATGTGA 2958
 ||||| ||||| |||||
 Db 1 GGTGTCTTCTGATGTGA 20

RESULT 544
 ADP69317
 ID ADP69317 standard; DNA; 20 BP.
 AC ADP69317;
 XX
 XX 09-SEP-2004 (first entry)
 DE Human mitoNEET-specific antisense oligonucleotide #211.
 KW human; antisense oligonucleotide; mitochondrial membrane;
 KW insulin sensitising antidiabetic thiazolidinediones; mitoNEET; diabetes;
 KW immunological disorder; cardiovascular disorder; including hypertension;
 KW neurological disorders; ischaemia; reperfusion; ss;
 KW 2'-methoxyethyl gapmer; 2'-MOE gapmer; phosphorothioate backbone.
 XX
 OS Homo sapiens.
 XX
 XX WO2004053060-A2.
 PN 24-JUN-2004.
 PD
 XX 25-NOV-2003; 2003WO-US037621.
 PF
 XX 06-DEC-2002; 2002US-0431529P.
 PR
 XX (PHAA) PHARMACIA CORP.
 PA Colca JR;
 PI
 XX WPI; 2004-468836/44.
 DR
 XX New antisense oligonucleotides encoding mitoNEET, useful for modulating
 PT mitoNEET expression or for treating diseases associated with mitoNEET,
 PT e.g. diabetes, immunological disorders or cardiovascular disorders.
 XX
 PS Claim 4; SEQ ID NO 211; 226pp; English.
 XX The invention comprises antisense oligonucleotides that are targeted to
 CC the nucleic acids encoding a family of human proteins from mitochondrial
 CC membranes, which bind insulin sensitising, antidiabetic
 CC thiazolidinediones (referred to as: mitoNEET). The antisense
 CC oligonucleotides of the invention are useful for modulating mitoNEET
 CC expression and for treating diseases or conditions associated with
 CC mitoNEET, such as: diabetes, immunological disorders, cardiovascular
 CC disorders including hypertension, neurological disorders, and
 CC ischaemia/reperfusion injuries. The present DNA sequence represents a
 CC mitoNEET-specific antisense oligonucleotide of the invention. NOTE: The
 CC present sequence is a 2'-methoxyethyl (2'-MOE) gapmer with a
 CC phosphorothioate backbone.
 XX
 SQ Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2941 TTGTTTCTTCTAAAGTGAAG 2960
 ||||| ||||| |||||
 Db 1 TTGTCTTCTGATGTGAAG 20

RESULT 545
 ADP69234
 ID ADP69234 standard; DNA; 20 BP.
 XX

AC ADP69234;
 XX
 DT 09-SEP-2004 (first entry)
 XX
 DE Human mitoNEET-specific antisense oligonucleotide #128.
 XX
 KW human; antisense oligonucleotide; mitochondrial membrane;
 KW insulin sensitising antidiabetic thiazolidinediones; mitoNEET; diabetes;
 KW immunological disorder; cardiovascular disorder; including hypertension;
 KW neurological disorders; ischaemia; reperfusion; ss;
 KW 2'-methoxyethyl gapmer; 2'-MOE gapmer; phosphorothioate backbone.
 XX
 OS Homo sapiens.
 XX
 XX WO2004053060-A2.
 PN 24-JUN-2004.
 PD
 XX 25-NOV-2003; 2003WO-US037621.
 PF
 XX 06-DEC-2002; 2002US-0431529P.
 PR
 XX (PHAA) PHARMACIA CORP.
 PA Colca JR;
 PI
 XX WPI; 2004-468836/44.
 DR
 XX New antisense oligonucleotides encoding mitoNEET, useful for modulating
 PT mitoNEET expression or for treating diseases associated with mitoNEET,
 PT e.g. diabetes, immunological disorders or cardiovascular disorders.
 XX
 PS Claim 4; SEQ ID NO 128; 226pp; English.
 XX The invention comprises antisense oligonucleotides that are targeted to
 CC the nucleic acids encoding a family of human proteins from mitochondrial
 CC membranes, which bind insulin sensitising, antidiabetic
 CC thiazolidinediones (referred to as: mitoNEET). The antisense
 CC oligonucleotides of the invention are useful for modulating mitoNEET
 CC expression and for treating diseases or conditions associated with
 CC mitoNEET, such as: diabetes, immunological disorders, cardiovascular
 CC disorders including hypertension, neurological disorders, and
 CC ischaemia/reperfusion injuries. The present DNA sequence represents a
 CC mitoNEET-specific antisense oligonucleotide of the invention. NOTE: The
 CC present sequence is a 2'-methoxyethyl (2'-MOE) gapmer with a
 CC phosphorothioate backbone.
 XX
 SQ Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2940 GTTGTCTTCTAAATGTGAA 2959
 ||||| ||||| |||||
 Db 1 GTTGTCTTCTGATGTGAA 20

RESULT 546
 AAF07025/c
 ID AAF07025 standard; DNA; 17 BP.
 XX
 AC AAF07025;
 XX
 XX 16-FEB-2001 (first entry)
 DT
 XX Hammerhead ribozyme substrate #3282.
 DE
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 OS Homo sapiens.
 XX

PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes.
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 54; Page 131; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3095 ATCTGTGAGGCCAGC 3109
DB 15 ATCTGTGAGGCCAGC 1
RESULT 547
AAF03348
ID AAF03348 standard; DNA; 17 BP.
XX
AC AAF03348;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #1643.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX

PS Claim 37; Page 93; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 7 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2926 TGAATATATATCTGG 2940
DB 3 TGAATATATATCTGG 17
RESULT 548
AAF03349
ID AAF03349 standard; DNA; 17 BP.
XX
AC AAF03349;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #1644.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 93; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2926 TGAATATATATCTGG 2940

[illegible]

CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 9 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2914 TATTTGCAATTGA 2928
 DB 17 TATTTGCAATTGA 3

RESULT 551
 ADB41701
 ID ADB41701 standard; DNA; 17 BP.
 XX AC ADB41701;
 XX DT 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)
 XX DE Tumour suppression/reversion associated nucleotide #2024.
 XX KW cytostatic; antiviral; neuroprotective; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX OS Homo sapiens.
 OS WO2003040369-A2.
 PN 15-MAY-2003.
 XX PD 17-SEP-2002; 2002WO-IB004219.
 XX PF 17-SEP-2001; 2001FR-00011981.
 XX PR (MOLE-) MOLECULAR ENGINES LAB.
 XX PA Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-441574/41.
 XX PI New nucleic acid encoding human prostate membrane-specific antigen,
 XX useful e.g. for treatment of tumors and viral infection, also related
 XX polypeptide and antibodies.
 XX PS Disclosure; Page 268; 771pp; French.

XX The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and/or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours

CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.

SQ Sequence 17 BP; 1 A; 2 C; 1 G; 13 T; 0 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTCTTTT 2586
 DB 3 TCTTCTTTTCTTTT 17

RESULT 552
 ADB42811/c
 ID ADB42811 standard; DNA; 17 BP.
 XX AC ADB42811;
 XX DT 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)
 XX DE Tumour suppression/reversion associated nucleotide #3134.
 XX KW cytostatic; antiviral; neuroprotective; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX OS Homo sapiens.
 OS WO2003040369-A2.
 PN 15-MAY-2003.
 XX PD 17-SEP-2002; 2002WO-IB004219.
 XX PF 17-SEP-2001; 2001FR-00011981.
 XX PR (MOLE-) MOLECULAR ENGINES LAB.
 XX PA Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-441574/41.
 XX PI New nucleic acid encoding human prostate membrane-specific antigen,
 XX useful e.g. for treatment of tumors and viral infection, also related
 XX polypeptide and antibodies.
 XX PS Disclosure; Page 398; 771pp; French.

XX The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and/or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours

or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
Analysis of the expression of the nucleotides can be used for diagnosis
and/or prognosis of these diseases. The nucleotides and polypeptides can
also be used to screen for their specific interactive molecules,
potentially useful for treating diseases associated with abnormal
expression of the nucleotides.

Sequence 17 BP; 9 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2914 TATTTTGCATTTGA 2928
|||||
DB 17 TATTTGCAATTTGA 3

RESULT 553
ADI47616/c
ID ADI47616 standard; DNA; 17 BP.

AC ADI47616;

DT 15-APR-2004 (first entry)

DE Human tumour suppression/reversion-related DNA sequence SeqID119.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

XX WO2003025177-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004523.

XX 17-SEP-2001; 2001PR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.

PS Disclosure; SEQ ID NO 119; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC nootropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 9 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2914 TATTTTGCATTTGA 2928
|||||
DB 17 TATTTGCAATTTGA 3

RESULT 554

AAx61962

ID AAX61962 standard; DNA; 18 BP.

XX AAX61962;

XX 31-AUG-1999 (first entry)

XX Type-specific HPV probe MM7.

XX PCR primer; probe; human papillomavirus; HPV; A region; B region;
KW C region; D region; detection; HPV genotype; cervical cancer; ss.

XX Synthetic.

OS Human papillomavirus.

XX WO9914377-A2.

XX 25-MAR-1999.

XX 14-SEP-1998; 98WO-EP005829.

XX 16-SEP-1997; 97EP-00870136.

XX (INNO-) INNOGENETICS NV.

XX (DELF-) DELFTS DIAGNOSTIC LAB BV.

XX Van Doorn L, Quint W, Kleter B, Ter Schegget J;

XX WPI; 1999-244048/20.

XX Detection and identification of human papillomavirus.

XX Claim 8; Page 32; 78pp; English.

XX AAX61849-X61982 and AAX62002-X62093 represent PCR primers and probes used
CC for detecting and/or identifying human papillomavirus (HPV) present in a
CC biological sample. The method comprises amplification of a polynucleic
CC acid fragment of HPV using a 5'-primer specifically hybridizing to the A
CC region or B region of the genome of at least one HPV type, and a 3'-
CC primer specifically hybridizing to the C region of at least one HPV type,
CC and hybridisation of the amplified fragments with at least one probe
CC capable of specific hybridization with the D region of at least one HPV
CC type. The primers individually or as a combination of 5'-primer and 3'-
CC primer, and the probes are used in the detection and/or identification of
CC HPV present in a biological sample. An isolated HPV polynucleotide, or
CC fragment, can also be used as a primer in a method for detection and/or
CC identification of HPV present in a sample. Identification of the
CC different HPV genotypes may have great clinical and epidemiological
CC importance. The presence of high-risk HPV types is a prognostic marker
CC for development and detection of cervical cancer

XX Sequence 18 BP; 4 A; 0 C; 4 G; 10 T; 0 U; 0 Other;
Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3698 TTTAATGAGTTATTT 3712
|||||
DB 4 TTTAATGAGTTATTT 18

KW primer.
 OS Capsicum annuum.
 XX WO2003066900-A2.
 PN 14-AUG-2003.
 PD 07-FEB-2003; 2003WO-FR000397.
 XX 08-FEB-2002; 2002FR-00001583.
 PF 31-OCT-2002; 2002FR-00013678.
 PR (GENO-) GENOPLANTE-VALOR.
 XX Caranta C, Ruffel S, Bendahmane A, Palloix A, Robaglia C;
 PI WPI; 2003-663604/62.
 DR Selecting plants, e.g. solanaceous plants resistant to potyvirus,
 PT comprises detecting the presence of mutant eIF4E protein, or its nucleic
 PT acid, and absence of the wild-type.
 XX Example 3; SEQ ID NO 18; 59pp; French.
 PS The invention relates to a process of selecting plants (A) resistant to
 XX potyvirus by detecting the presence or absence of a wild-type translation
 CC factor eIF4E protein (I) or its nucleic acid (II) and mutant eIF4E
 CC protein (Ia) or its nucleic acid (IIa), where plants are selected if (Ia)
 CC or (IIa) is detected and if (I) or (II) is absent. The method is
 CC especially applied to selection of solanaceous plants that are resistant
 CC to potyvirus or can be used to prepare these plants. This sequence
 CC represents a primer used to amplify the pepper translation factor eIF4E
 CC cDNA which is detected in the method of the invention.
 XX Sequence 20 BP; 11 A; 7 C; 2 G; 0 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2599 AAAAGCACACGAC 2613
 DB 1 AAAAGCACACGAC 15
 RESULT 558
 ABZ85668
 ID ABZ85668 standard; DNA; 20 BP.
 XX AC ABZ85668;
 XX 17-OCT-2003 (first entry)
 DT Human oligonucleotide sequence.
 DE Human; antisense; lung dysfunction; nasal airway dysfunction;
 XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX Homo sapiens.
 OS WO200285308-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013135.
 PF 24-APR-2001; 2001US-0286137P.
 XX

PA (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX Claim 15; SEQ ID NO 910; 872pp; English.
 PS The invention relates to a novel pharmaceutical composition, which has a
 XX first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of ubiquinone or
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 20 BP; 0 A; 3 C; 0 G; 17 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2574 TTCTTTTCTTTTCT 2588
 DB 4 TTCTTTTCTTTTCT 18
 RESULT 559
 ABZ84835/C
 ID ABZ84835 standard; DNA; 20 BP.
 XX AC ABZ84835;
 XX 17-OCT-2003 (first entry)
 DT Human oligonucleotide sequence.
 DE Human; antisense; lung dysfunction; nasal airway dysfunction;
 XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX Homo sapiens.
 OS WO200285308-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013135.
 PF 24-APR-2001; 2001US-0286137P.
 XX


```

PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Claim 15; SEQ ID NO 77; 872bp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, anti-allergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine or
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: the sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 979 GCTGCTTCCAGGATA 993
Db 17 GCTGCTTCCAGGATA 3

RESULT 560
ABD21065/c
ID ABD21065 standard; DNA; 20 BP.
XX
XX ABD21065;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human transglutaminase-derived oligo SEQ ID 77.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.
XX
XX
XX
XX 23-APR-2002; 2002WO-US011143.
XX

```

```

PR 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 77; 763bp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer,
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 979 GCTGCTTCCAGGATA 993
Db 17 GCTGCTTCCAGGATA 3

RESULT 561
ABD21898
ID ABD21898 standard; DNA; 20 BP.
XX
XX ABD21898;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human stanniocalcin-derived oligo SEQ ID 910.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.
XX
XX
XX
XX 23-APR-2002; 2002WO-US011143.
XX

```

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX Nvce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
PS Claim 15; SEQ ID NO 910; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 0 A; 3 C; 0 G; 17 T; 0 U; 0 Other;
Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2574 TTCTTTTCTTCT 2588
DB 4 TTCTTTTCTTCT 18
RESULT 562
ADJ19106/c
ID ADJ19106 standard; DNA; 20 BP.

XX ADJ19106;
XX 20-MAY-2004 (first entry)
XX Antisense 2-MOE gapmer oligo targeted to human IGF2 - SEQ ID 61.
XX insulin-like growth factor 2; IGF2; cytostatic; antiarthritic;
KW antirheumatic; antisense; gene therapy; hyperproliferative disorder;
KW cancer; autoimmune disorder; rheumatoid arthritis; 2-MOE wing;
KW 2'-methoxyethyl gapmer; ss; human; phosphorothioate backbone.
XX Homo sapiens.
XX US2004006220-A1.
XX 08-JAN-2004.
XX 02-JUL-2002; 2002US-00188777.
XX 02-JUL-2002; 2002US-00188777.
XX (ISIS-) ISIS PHARM INC.
XX Bhanot S, Dobie KW;
XX WPI; 2004-081750/08.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT insulin-like growth factor 2, useful for modulating expression of insulin
PT -like growth factor 2 or for treating cancer or rheumatoid arthritis.
XX Example 15; SEQ ID NO 61; 70pp; English.
XX The invention relates to a novel compound 8 to 80 nucleobases in length
CC targeted to a nucleic acid molecule encoding insulin-like growth factor 2
CC (IGF2) which specifically hybridises with the nucleic acid molecule
CC encoding insulin-like growth factor 2 and thus inhibits its expression.
CC The nucleic acid of the invention demonstrates cytostatic, antiarthritic
CC and antirheumatic activities and may be useful in modulating the
CC expression of insulin-like growth factor 2, via antisense gene therapy,
CC in order to treat diseases or conditions associated with insulin-like
CC growth factor 2, preferably a hyperproliferative disorder such as cancer,
CC or an autoimmune disorder such as rheumatoid arthritis. The current
CC sequence is that of an antisense 2-MOE (2'-methoxyethyl) gapmer oligo
CC targeted to human IGF2 of the invention. The oligonucleotide has central
CC "gap" region flanked on both sides by 2-MOE "wings". The backbone
CC linkages are phosphorothioate and all cytidine residues are 5-
CC methylcytidines.
XX
SQ Sequence 20 BP; 1 A; 2 C; 8 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2602 AGCACACGACACACA 2616
DB 19 AGCACACGACACACA 5
RESULT 563
ADJ19166
ID ADJ19166 standard; DNA; 20 BP.
XX
XX ADJ19166;
XX 20-MAY-2004 (first entry)
XX Human IGF2 DNA targeted for antisense therapy - SEQ ID 121.
XX insulin-like growth factor 2; IGF2; cytostatic; antiarthritic;
KW antirheumatic; antisense; gene therapy; hyperproliferative disorder;

CC that modulate Emil function or that mimic Emil activity, and the agents
CC are used for enhancing APC in a proliferating cell. The Emil is useful
CC for modulating the cycling of cells, e.g. for treating hyperproliferative
CC conditions, in diseases involving tissues where there is a high rate of
CC cell turnover, and in modulating oocyte activation. Emil proteins may
CC also be used in screening and research methods for determining specific
CC analogues, agonists, antagonists and mimetics. Nucleic acid compositions
CC are useful in identifying homologous or related genes, in producing the
CC encoded protein, in producing compositions that modulate the expression
CC or function of its encoded protein, for gene therapy, mapping functional
CC regions of the protein, and in studying associated physiological pathways
XX
SQ Sequence 18 BP; 5 A; 1 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3231 CCTCTCCTCCCGCTAC 3248
Dbb ||||| ||||| ||||| |||||
18 CCTCTCCTCCCGATCTAC 1

RESULT 566
ADB98970/c
ID ADB98970 standard; DNA; 18 BP.
XX
AC ADB98970;
XX
DT 04-DEC-2003 (first entry)
XX
DE LRP5 mutagenic PCR primer #89.
XX
XX Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW bone mass modulation; osteoporosis; PCR; primer; ss.
XX
OS Synthetic.
XX
EN WO200292000-A2.
XX
PD 21-NOV-2002.
XX
PF 13-MAY-2002; 2002WO-US014877.
XX
PR 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (AMHP) WYETH.
XX
PI Allen K, Anisowicz A, Graham JR, Morales A, Yaworsky PJ, Liu W;
XX
FI WPI; 2003-129214/12.
DR
XX New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT diagnosing a HBM-like phenotype in a subject and for preparing a
PT composition for modulating bone mass and/or lipid levels in a subject
PT suffering from e.g. osteoporosis.
XX
XX Disclosure; Page 53; 629pp; English.
PS
XX The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC level modulation. The invention is useful for diagnosing a HBM-like
CC phenotype in a subject and for preparing a composition for modulating
CC bone mass and/or lipid levels in a subject suffering from e.g.
CC osteoporosis. The present sequence was used to illustrate the invention.
XX
SQ Sequence 18 BP; 4 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 127 CTCTCTGTGAAAGGGA 144
Dbb ||||| ||||| ||||| |||||
18 CTCATCTGTGAAACGGGA 1
RESULT 567
ADM80162/c
ID ADM80162 standard; DNA; 18 BP.
XX
AC ADM80162;
XX
DT 03-JUN-2004 (first entry)
XX
DE Hexalysine encoding DNA SEQ ID NO:25.
XX
KW ds; gene; in vitro diagnosis; virus-related disease; HIV-1; HIV-2;
KW hexalysine.
XX
OS Synthetic.
XX
PH Key Location/Qualifiers
FT CDS 1..18
FT /*tag= a
FT /partial
FT /note= "No start/stop codon given"
XX
PN FR2844519-A1.
XX
PD 19-MAR-2004.
XX
PF 17-SEP-2002; 2002FR-00011485.
XX
PR 17-SEP-2002; 2002FR-00011485.
XX
PA (INMR) BIO MERIEUX.
XX
PI Letourneur O;
XX
DR WPI; 2004-259482/25.
DR P-PSDB; ADM80163.
XX
PT New recombinant DNA encoding chimeric protein, useful for in vitro
PT diagnosis of viral infections, comprises sequences encoding epitopic
PT regions, a linker and a binding region.
XX
PS Claim 10; SEQ ID NO 25; 33pp; French.
XX
CC The invention relates to a novel recombinant DNA (I) encoding a
CC recombinant chimeric protein (II). The protein consists of at least two
CC nucleotide fragments, each encoding an epitopic region of at least one
CC microorganism; at least one sequence encoding a linker, and at least one
CC sequence encoding a binding region. The DNA and/or protein are used for
CC in vitro diagnosis, especially of virus-related diseases, specifically
CC HIV-1 or -2 infections. The protein is easy to purify and synthesize, and
CC has strong immunoreactivity with sera from virus-infected subjects. The
CC present sequence encodes hexalysine peptide.
XX
SQ Sequence 18 BP; 15 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2567 TTCTCTCTCTCTTTT 2584
Dbb ||||| ||||| ||||| |||||
18 TTCTCTCTCTCTTTCTT 1

RESULT 568

```
ADO79780
ID ADO79780 standard; DNA; 18 BP.
XX
AC ADO79780;
XX
DT 26-AUG-2004 (first entry)
XX
XX DPF3 extend primer #33.
DE
XX
KW Cytostatic; Gene therapy; breast cancer; human; DLG1; KIAA0783; DPF3;
KW CENPC1; SNP; single nucleotide polymorphism;
KW D4, zinc and double PHD fingers, family 3; CERD4; cer-d4; FLJ14079;
KW 2810403B03Rik; Rho family guanine-nucleotide exchange factor;
KW chromosome 14q24.3-q31.1; extend; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004047514-A2.
XX
PD 10-JUN-2004.
XX
PF 25-NOV-2003; 2003WO-US037943.
XX
PR 25-NOV-2002; 2002US-0429136P.
XX
PR 24-JUL-2003; 2003US-0490234P.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441037/41.
XX
PT Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the DLG1, KIAA0783, DPF3 or CENPC1 regions
PT which are associated with breast cancer in a nucleic acid sample from a
PT subject.
XX
PS Example 5; Page 84; 227pp; English.
XX
CC The present invention relates to a method for identifying a subject at
CC risk of breast cancer. The method comprising detecting the presence or
CC absence of one or more polymorphic variations associated with breast
CC cancer in a nucleic acid sample from a subject. The nucleic acid sample
CC comprises the DLG1 region (ADO79402), KIAA0783 region (ADO79403), DPF3
CC region (ADO79404) or CENPC1 region (ADO79405). The gene DLG1 (discs,
CC large homolog 1 (Drosophila)) is also known as synapse-associated protein
CC 97, hdlg or SAP97. DLG1 has been mapped to chromosomal position 3q29. The
CC gene KIAA0783 is also known as PHF14 and PHD finger protein 14. KIAA0783
CC has been mapped to chromosomal position 7p21.3. The KIAA0783 protein is a
CC novel gene with unknown function, however, being a zinc finger protein,
CC it likely to be a transcription factor. The gene DPF3 (D4, zinc and
CC double PHD fingers, family 3) is also known as CERD4, cer-d4, FLJ14079
CC and 2810403B03Rik. DPF3 is a Rho family guanine-nucleotide exchange
CC factor. DPF3 has been mapped to chromosomal position 14q24.3-q31.1. The
CC gene CENPC1 (centromere protein C1) is also known as Centromere
CC autoantigen C1. CENPC1 has been mapped to chromosomal position 4q12-
CC q13.3. CENPC1 is a centromere autoantigen and a component of the inner
CC kinetochore plate. The CENPC1 protein is required for maintaining proper
CC kinetochore size and a timely transition to anaphase. The method is
CC useful for identifying a subject at risk of breast cancer, for early
CC diagnosis, prevention and treatment of breast cancer, to analyze and
CC predict a response to a breast cancer treatment, and in clinical drug
CC trials. The present sequence was used in an example from the invention.
XX
SQ Sequence 18 BP; 6 A; 1 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3578 CTTAGGGAAGGATGGG 3595
DB 1 CATAGGGATGAATGGG 18

RESULT:569
AAQ75557
ID AAQ75557 standard; DNA; 19 BP.
XX
AC AAQ75557;
XX
DT 04-AUG-1995 (first entry)
XX
DE Reverse transcription primer used in cDNA analysis technique.
XX
KW Analysis; Gene expression; reverse transcription; primer; cDNA;
KW aggregate; restriction enzyme; ss.
XX
OS Synthetic.
XX
PN JP06303997-A.
XX
PD 01-NOV-1994.
XX
PF 16-APR-1993; 93JP-00112515.
XX
PR 16-APR-1993; 93JP-00112515.
XX
PA (NITE ) NIPPON TELEGRAPH & TELEPHONE CORP.
XX
DR WPI; 1995-018287/03.
XX
PT Analysis of cDNA and gene expression - by amplification of mRNA followed
PT by digestion with restriction enzymes.
XX
PS Disclosure; Page 5; 11pp; Japanese.
XX
CC A method for the analysis of cDNA comprises (a) preparing an aggregate of
CC double-stranded cDNAs by using an aggregate of mRNAs and a plural type of
CC labelled reverse transcription primers (GENESEQ files AAQ75547-Q75798)
CC and using the aggregate of mRNAs as the template for each reverse
CC transcription primer; (b) digesting each of the prepared aggregates of
CC the double-stranded cDNAs with restriction enzyme and; (c)
CC electrophoresing the digested aggregate of cDNAs in separate lanes. The
CC method can be used to analyse gene expression rapidly and easily
XX
SQ Sequence 19 BP; 0 A; 1 C; 0 G; 18 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTCT 2588
DB 2 TTTTTTTTTTTTTTCT 19

RESULT 570
AAA86135
ID AAA86135 standard; DNA; 19 BP.
XX
AC AAA86135;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cdc 25 hs ribozyme binding site #243.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
```

```
XX 04-DEC-1998; 98US-0110954P.
XX (IMMU-) IMMUSOL INC.
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX WPI; 2000-412314/35.
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX Disclosure; Page 103; 109pp; English.
XX The present invention relates to a hairpin or hammerhead ribozyme,
XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX Representative examples of ribozyme recognition sites are given in
XX AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX inhibiting restenosis by introduction of the ribozyme into cells. The
XX ribozyme is resistant to endonuclease activity and hence is efficient in
XX restenosis treatment
XX Sequence 19 BP; 6 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2194 ATCTTCTTCTGGAAGAAG 2211
DB 1 AACTTCTTCTGGAAGAAG 18
RESULT 571
AAA85778
ID AAA85778 standard; DNA; 19 BP.
XX AAA85778;
XX 04-DEC-2000 (first entry)
XX Cyclin B1 ribozyme binding site #107.
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX Mammalia.
XX WO200032765-A2.
XX 08-JUN-2000.
XX 06-DEC-1999; 99WO-US028772.
XX 04-DEC-1998; 98US-0110954P.
XX (IMMU-) IMMUSOL INC.
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX WPI; 2000-412314/35.
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX Disclosure; Page 97; 109pp; English.
XX The present invention relates to a hairpin or hammerhead ribozyme,
XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX Representative examples of ribozyme recognition sites are given in
XX AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX inhibiting restenosis by introduction of the ribozyme into cells. The
XX ribozyme is resistant to endonuclease activity and hence is efficient in
XX restenosis treatment
XX Sequence 19 BP; 6 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2194 ATCTTCTTCTGGAAGAAG 2211
DB 1 AACTTCTTCTGGAAGAAG 18
RESULT 571
AAA85778
ID AAA85778 standard; DNA; 19 BP.
XX AAA85778;
XX 04-DEC-2000 (first entry)
XX Cyclin B1 ribozyme binding site #107.
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX Mammalia.
XX WO200032765-A2.
XX 08-JUN-2000.
XX 06-DEC-1999; 99WO-US028772.
XX 04-DEC-1998; 98US-0110954P.
XX (IMMU-) IMMUSOL INC.
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX WPI; 2000-412314/35.
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX Disclosure; Page 97; 109pp; English.
XX The present invention relates to a hairpin or hammerhead ribozyme,
XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX Representative examples of ribozyme recognition sites are given in
```

```
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX Sequence 19 BP; 4 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3442 TGCCATGTTTTTTTACAAG 3459
DB 1 TGCCATGTTTTTATGCAAG 18
RESULT 572
AAA85408
ID AAA85408 standard; DNA; 19 BP.
XX AAA85408;
XX 04-DEC-2000 (first entry)
XX Cyclin A1 ribozyme binding site #30.
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX Mammalia.
XX WO200032765-A2.
XX 08-JUN-2000.
XX 06-DEC-1999; 99WO-US028772.
XX 04-DEC-1998; 98US-0110954P.
XX (IMMU-) IMMUSOL INC.
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX WPI; 2000-412314/35.
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX Disclosure; Page 92; 109pp; English.
XX The present invention relates to a hairpin or hammerhead ribozyme,
XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX Representative examples of ribozyme recognition sites are given in
XX AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX inhibiting restenosis by introduction of the ribozyme into cells. The
XX ribozyme is resistant to endonuclease activity and hence is efficient in
XX restenosis treatment
XX Sequence 19 BP; 2 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2559 CTCCGAGCTTTCTCTTC 2576
DB 1 CTCCGAGTTTCGTCTTC 18
RESULT 573
AAA86134
ID AAA86134 standard; DNA; 19 BP.
```


XX PS Example 1; Page 316; 408pp; English.

XX CC The present invention describes a method for treating a proliferative

XX CC skin or eye disease and scarring. The method involves administering a

XX CC ribozyme (I) which cleaves RNA encoding a cytokine involved in

XX CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle

XX CC dependent kinase, growth factor or a reductase, or administering a

XX CC nucleic acid molecule (II) comprising a promoter operably linked to a

XX CC nucleic acid segment encoding (I). (I) can have antipsoriatic,

XX CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,

XX CC ophthalmological, vulnery, keratolytic and virucide activities, and

XX CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used

XX CC in gene therapy. (I) and (II) are useful for treating proliferative skin

XX CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,

XX CC squamous or basal cell carcinoma and viral or seborrheic wart. They can

XX CC also be used for treating proliferative eye diseases such as diabetic

XX CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of

XX CC prematurity and retinal detachment, and for treating and preventing

XX CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn

XX CC scar. AAH57577 to AAH62099 represent sequences used in the

XX CC exemplification of the present invention

XX SQ Sequence 19 BP; 4 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 2.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3442 TGCCATGTTTATTGCAAG 3459

DB 1 TGCCATGTTTATTGCAAG 18

RESULT 576

AAH58794/C

ID AAH58794 standard; DNA; 19 BP.

AC AAH58794;

XX 10-SEP-2001 (first entry)

DT Cdk-we-hu ribozyme binding site SEQ ID NO:1218.

DE Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;

XX recognition site; target; ribozyme binding site; eye disease; vulnery;

KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;

KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;

KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;

KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;

KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;

KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;

KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;

KW sickle cell retinopathy; ss.

XX Homo sapiens.

OS Synthetic.

XX WO200130362-A2.

XX 03-MAY-2001.

XX 26-OCT-2000; 2000WO-US029500.

XX 26-OCT-1999; 99US-0161532P.

XX (IMMU-) IMMUSOL INC.

XX Robbins JM, Tritz R;

XX WPI; 2001-300427/31.

XX Treating proliferative skin or eye diseases and scarring, using ribozymes

PT that cleave RNA encoding cytokines involved in inflammation, matrix

PT metalloproteinases, growth factors and cell-cycle dependent kinases.

XX Example 1; Page 160; 408pp; English.

XX PS The present invention describes a method for treating a proliferative

XX CC skin or eye disease and scarring. The method involves administering a

XX CC ribozyme (I) which cleaves RNA encoding a cytokine involved in

XX CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle

XX CC dependent kinase, growth factor or a reductase, or administering a

XX CC nucleic acid molecule (II) comprising a promoter operably linked to a

XX CC nucleic acid segment encoding (I). (I) can have antipsoriatic,

XX CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,

XX CC ophthalmological, vulnery, keratolytic and virucide activities, and

XX CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used

XX CC in gene therapy. (I) and (II) are useful for treating proliferative skin

XX CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,

XX CC squamous or basal cell carcinoma and viral or seborrheic wart. They can

XX CC also be used for treating proliferative eye diseases such as diabetic

XX CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of

XX CC prematurity and retinal detachment, and for treating and preventing

XX CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn

XX CC scar. AAH57577 to AAH62099 represent sequences used in the

XX CC exemplification of the present invention

XX SQ Sequence 19 BP; 6 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 2.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2984 ATTCTCCAGAGGAGATT 3001

DB 18 ATTCTCCAGAGCGGATT 1

RESULT 577

AAH60570

ID AAH60570 standard; DNA; 19 BP.

XX AAH60570;

XX 10-SEP-2001 (first entry)

DT Cyclin A1 ribozyme binding site SEQ ID NO:2994.

DE Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;

XX recognition site; target; ribozyme binding site; eye disease; vulnery;

KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;

KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;

KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;

KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;

KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;

KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;

KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;

KW sickle cell retinopathy; ss.

XX Homo sapiens.

OS Synthetic.

XX WO200130362-A2.

XX 03-MAY-2001.

XX 26-OCT-2000; 2000WO-US029500.

XX 26-OCT-1999; 99US-0161532P.

XX (IMMU-) IMMUSOL INC.

XX Robbins JM, Tritz R;

XX WPI; 2001-300427/31.

XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 289; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiscikling,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
XX Sequence 19 BP; 2 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2559 CTCACGCTTTCTCTTC 2576
Db ||||| ||||| |||||
1 CTCACGATTCGCTCTTC 18
RESULT 578
AAH61296
ID AAH61296 standard; DNA; 19 BP.
XX
XX AAH61296;
XX
XX 10-SEP-2001 (first entry)
XX
XX Cdc25 hs ribozyme binding site SEQ ID NO:3720.
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antiscikling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;

XX WPI; 2001-300427/31.
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 342; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiscikling,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
XX Sequence 19 BP; 6 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2194 ATCTTCTCTCTGAAGAAG 2211
Db ||||| ||||| |||||
2 AACTTCTTCTGAAGAAG 19
RESULT 579
AAH61297
ID AAH61297 standard; DNA; 19 BP.
XX
XX AAH61297;
XX
XX 10-SEP-2001 (first entry)
XX
XX Cdc25 hs ribozyme binding site SEQ ID NO:3721.
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antiscikling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;

XX Robbins JM, Tritz R;
 XX WPI; 2001-300427/31.
 XX Treating proliferative skin or eye diseases and scarring, using ribozymes
 XX that cleave RNA encoding cytokines involved in inflammation, matrix
 XX metalloproteinases, growth factors and cell-cycle dependent kinases.
 XX Example 1; Page 342; 408pp; English.
 XX The present invention describes a method for treating a proliferative
 XX skin or eye disease and scarring. The method involves administering a
 XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
 XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 XX dependent kinase, growth factor or a reductase, or administering a
 XX nucleic acid molecule (II) comprising a promoter operably linked to a
 XX nucleic acid segment encoding (I). (I) can have antipsoriatic,
 XX dermatological, cytostatic, antieborrheic, antidiabetic, antisickling,
 XX ophthalmological, vulvar, keratolytic and virucide activities, and
 XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 XX in gene therapy. (I) and (II) are useful for treating proliferative skin
 XX diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 XX squamous or basal cell carcinoma and viral or seboreic wart. They can
 XX also be used for treating proliferative eye diseases such as diabetic
 XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 XX prematurity and retinal detachment, and for treating and preventing
 XX scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 XX scar. AAH57577 to AAH62099 represent sequences used in the
 XX exemplification of the present invention
 XX Sequence 19 BP; 6 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2194 ATCTTCTCTCTGAGAG 2211
 Db 1 AACTTCTTCTGAGAG 18
 RESULT 580
 AAH27175
 ID AAH27175 standard; DNA; 19 BP.
 XX
 AC AAH27175;
 XX
 DT 08-AUG-2001 (first entry)
 XX
 DE PCR primer lef-F specific for lethal factor (lef) gene.
 XX
 KW PCR amplification; gel pad; PCR primer; anthrax toxin; lethal factor;
 KW lef; ss.
 XX
 OS Bacillus anthracis.
 XX
 PN WO200134842-A2.
 XX
 PD 17-MAY-2001.
 XX
 PF 09-NOV-2000; 2000WO-US030835.
 XX
 PR 12-NOV-1999; 99US-0165029P.
 PR 25-APR-2000; 2000US-00559306.
 XX
 PA (UYCH-) UNIV CHICAGO.
 XX
 PI Mikhailovich V, Mirzabekov A, Strizhkov BN, Tillib S;
 XX
 DR WPI; 2001-335947/35.
 XX
 PT Performing polymerase chain reaction in a microarray of gel pads, useful

PT for detecting bacterial toxin genes, uses immobilized primers that can be
 PT modulated selectively.
 XX Example 2; Page 16; 73pp; English.
 XX This invention relates to several methods for performing PCR
 CC amplification combined with the detection and analysis of the PCR
 CC products on a microchip. In one method PCR amplification takes place
 CC within gel pads on a microchip, with the pads surrounded by a hydrophobic
 CC liquid which separates the individual gel pads. In a second method the
 CC amplification occurs both outside in the solution surrounding the gel and
 CC within the gel pads themselves on a microchip, with at least one
 CC oligonucleotide primer immobilised in a gel pad. The method is used for
 CC detection and mutational analysis of microorganisms (e.g. anthrax/shiga
 CC toxin genes, plasmid-borne beta-lactamase or rifamycin-resistance
 CC mutations in Mycobacterium tuberculosis) also for detecting the bract
 CC gene. The present sequence represents a PCR primer specific for the
 CC lethal factor (lef) gene. The primer is used in an example illustrating
 CC the method of the invention for the detection of the anthrax toxin genes
 XX Sequence 19 BP; 5 A; 6 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3361 CCTTGATAATATCTTACC 3378
 Db 2 CCTTGATAATATCTTACC 19
 RESULT 581
 ABT04817/C
 ID ABT04817 standard; DNA; 19 BP.
 XX
 AC ABT04817;
 XX
 DT 27-SBP-2002 (first entry)
 XX
 DE C parvum GP900 gene PCR primer SEQ ID NO: 59.
 XX
 KW Cryptosporidium detection; GP900; P68; cryptopain; cryptosporidiosis;
 KW PCR; primer; ss.
 XX
 OS Cryptosporidium parvum.
 XX
 PN WO200194631-A1.
 XX
 PD 13-DEC-2001.
 XX
 PF 14-MAY-2001; 2001WO-US015624.
 XX
 PR 06-JUN-2000; 2000US-00588995.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Petersen C, Barnes DA, Nelson RG, Gut J;
 XX
 DR WPI; 2002-566447/60.
 XX
 PT Detecting Cryptosporidium in biological and environmental samples and
 PT diagnosis of cryptosporidiosis involves, contacting the sample with
 PT Cryptosporidium GP900, P68 or cryptopain antigen, antibody, DNA or RNA.
 XX Example 12; Page 137; 157pp; English.
 XX The present invention relates to a method of detecting Cryptosporidium in
 CC biological and environmental samples, and of diagnosing
 CC cryptosporidiosis. This involves obtaining a sample and contacting it
 CC with Cryptosporidium GP900, P68 or cryptopain antigen, antibody, DNA or
 CC RNA, or its variant, mutant or fragment. The method is also useful for
 CC detecting and identifying individual Cryptosporidium isolates based on
 CC the genetic characteristics, and for diagnosis of prior or concurrent

CC Cryptosporidium infection. The present sequence is a PCR primer for a C.
CC parvum coding sequence used in the exemplification of the invention
XX
SQ Sequence 19 BP; 7 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3257 TGGTTTTCATGATGCC 3274
Db 18 TGGTTTGCATATGATCC 1
RESULT 582
ADD36943/C
ID ADD36943 standard; DNA; 19 BP.
XX
AC ADD36943;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human papillomavirus E6 gene-specific PCR primer/probe Seq ID56.
XX
KW cervical carcinoma; L1 gene; E6 gene; HPV16; HPV18; HPV; cervical cancer;
KW cervical cell; cervix; PCR; primer; probe; ss.
XX
OS Human papillomavirus.
XX
PN WO2003057914-A2.
XX
PD 17-JUL-2003.
XX
PF 07-JAN-2003; 2003WO-GB0000034.
XX
PR 07-JAN-2002; 2002GB-00000239.
PR 19-JUN-2002; 2002GB-00014124.
XX
XX (NORC-) NORCHIP AS.
PA (ALLA/) ALLARD S J.
XX
XX Karlse F;
XX
XX WPI; 2003-587136/55.
XX
PT An in vitro method of screening human subjects to assess their risk of
PT developing cervical carcinoma, comprises screening the subject for
PT expression of mRNA transcripts from the L1 gene and the E6 gene of human
PT papillomavirus.
XX
PS Disclosure; SEQ ID NO 56; 102pp; English.
XX
CC This invention relates to a novel method for the detection of human
CC papillomavirus mRNA for use in the screening of human female subjects to
CC assess their risk of developing cervical carcinoma. The invention
CC comprises screening the subject for expression of mRNA transcripts from
CC the L1 gene and the E6 gene of human papillomavirus, where subjects
CC positive for expression of L1 and/or E6 mRNA are scored as being at risk
CC of developing cervical carcinoma. The presence of the human
CC papillomavirus (in particular HPV16 and HPV18) has been associated with
CC cervical cancer in numerous epidemiological studies. The methods of the
CC invention are useful for screening human subjects to assess their risk of
CC developing cervical carcinoma, or for identifying human subjects having
CC abnormal cell changes in the cervix. The present sequence is that of a
CC PCR primer (which may also be suitable as a probe) which may be used to
CC amplify the E6 gene of human papillomavirus in the method of the
CC invention.
XX
SQ Sequence 19 BP; 8 A; 6 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3253 GTTGTGCTTTCATCTG 3270
Db 18 GTTGTGCTTTCATCTG 1
RESULT 584
ADD22001/C

QY 3253 GTTGTGCTTTCATCTG 3270
Cc
Db 18 GTTGTGCTTTCATCTG 1
RESULT 583
ADD36586/C
ID ADD36586 standard; DNA; 19 BP.
XX
AC ADD36586;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human papillomavirus E6 gene-specific preferred PCR primer/probe 66.
XX
KW cervical carcinoma; L1 gene; E6 gene; HPV16; HPV18; HPV; cervical cancer;
KW cervical cell; cervix; PCR; primer; probe; ss.
XX
OS Human papillomavirus.
XX
PN WO2003057914-A2.
XX
PD 17-JUL-2003.
XX
PF 07-JAN-2003; 2003WO-GB0000034.
XX
PR 07-JAN-2002; 2002GB-00000239.
PR 19-JUN-2002; 2002GB-00014124.
XX
XX (NORC-) NORCHIP AS.
PA (ALLA/) ALLARD S J.
XX
XX Karlse F;
XX
XX WPI; 2003-587136/55.
XX
PT An in vitro method of screening human subjects to assess their risk of
PT developing cervical carcinoma, comprises screening the subject for
PT expression of mRNA transcripts from the L1 gene and the E6 gene of human
PT papillomavirus.
XX
PS Disclosure; Page 47; 102pp; English.
XX
CC This invention relates to a novel method for the detection of human
CC papillomavirus mRNA for use in the screening of human female subjects to
CC assess their risk of developing cervical carcinoma. The invention
CC comprises screening the subject for expression of mRNA transcripts from
CC the L1 gene and the E6 gene of human papillomavirus, where subjects
CC positive for expression of L1 and/or E6 mRNA are scored as being at risk
CC of developing cervical carcinoma. The presence of the human
CC papillomavirus (in particular HPV16 and HPV18) has been associated with
CC cervical cancer in numerous epidemiological studies. The methods of the
CC invention are useful for screening human subjects to assess their risk of
CC developing cervical carcinoma, or for identifying human subjects having
CC abnormal cell changes in the cervix. The present sequence is that of a
CC preferred PCR primer (which may also be suitable as a probe) which may be
CC used to amplify the E6 gene of human papillomavirus in the method of the
CC invention.
XX
SQ Sequence 19 BP; 8 A; 6 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3253 GTTGTGCTTTCATCTG 3270
Db 18 GTTGTGCTTTCATCTG 1
RESULT 584
ADD22001/C

ID ADD22001 standard; DNA; 19 BP.
XX
AC ADD22001;
XX
DT 15-JAN-2004 (first entry)
XX
DE HPV E6 gene transcribed mRNA detecting oligonucleotide, SEQ ID NO 40.
XX
KW E6; human papillomavirus; HPV; NASBA; probe; PCR; ss.
XX
OS Human papillomavirus type 33.
XX
PN WO2003057927-A2.
XX
PD 17-JUL-2003.
XX
XX 07-JAN-2003; 2003WO-GB000030.
XX
PF (NORC-) NORCHIP AS.
XX
PR (ALLA/) ALLARD S J.
XX
PA Karlsten F;
XX
PI WPI; 2003-587141/55.
XX
DR New oligonucleotide primer and probe for detecting the presence of mRNA
PT transcripts from the E6 gene of a human papillomavirus in clinical
PT samples.
XX
PS Claim 1; SEQ ID NO 40; 28pp; English.
XX
CC The invention relates to a novel oligonucleotide molecule used for
CC detecting mRNA transcribed from the E6 gene of a human papillomavirus
CC (HPV). The oligonucleotide comprises any of the 133 fully defined
CC sequences having 17-26 bp given in the specification. The invention
CC further provides the detection of HPV mRNA in a test sample suspected of
CC containing HPV, comprising performing an amplification reaction on a
CC preparation of a nucleic acid isolated from the test sample to amplify a
CC portion of the mRNA transcribed from the E6 gene of HPV, where the
CC amplification reaction is performed using the primer-pair of
CC oligonucleotide cited above. The invention also provides: a reagent kit
CC for use in the detection of HPV by NASBA, comprising an oligonucleotide
CC primer-pair and, optionally, an enzyme mixture comprising an RNA directed
CC DNA polymerase, a ribonuclease that hydrolyzes the RNA strand of an RNA-
CC DNA hybrid without hydrolyzing single or double stranded RNA or DNA, and
CC an RNA polymerase that recognises the promoter sequence present in at
CC least one NASBA P1 primer oligonucleotide included in the reagent kit.
CC The oligonucleotide of the invention is useful in detecting mRNA
CC transcripts from the E6 gene of HPV in clinical samples. This
CC polynucleotide sequence represents one of the 133 oligonucleotides used
CC for detecting mRNA transcribed from the E6 gene of a human papillomavirus
CC (HPV) of the invention.
XX
SQ Sequence 19 BP; 8 A; 6 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3253 GTTGTGTTTTCATCTG 3270
Db 18 GTTGTGTTTTCATCTG 1
RESULT 585
ADD22164/c
ID ADD22164 standard; DNA; 19 BP.
XX
AC ADD22164;
XX
DT 15-JAN-2004 (first entry)

XX HPV E6 gene transcribed mRNA detecting NASBA primer/probe #66.
DE
XX E6; human papillomavirus; HPV; NASBA; primer; probe; PCR; ss.
KW
XX Human papillomavirus type 33.
OS
XX WO2003057927-A2.
PN
XX 17-JUL-2003.
XX
XX 07-JAN-2003; 2003WO-GB000030.
XX
PF 07-JAN-2002; 2002GB-00000258.
XX
PR (NORC-) NORCHIP AS.
XX
PA (ALLA/) ALLARD S J.
XX
PI Karlsten F;
XX
PI WPI; 2003-587141/55.
DR
XX New oligonucleotide primer and probe for detecting the presence of mRNA
PT transcripts from the E6 gene of a human papillomavirus in clinical
PT samples.
XX
PS Disclosure; Page 20; 28pp; English.
XX
CC The invention relates to a novel oligonucleotide molecule used for
CC detecting mRNA transcribed from the E6 gene of a human papillomavirus
CC (HPV). The oligonucleotide comprises any of the 133 fully defined
CC sequences having 17-26 bp given in the specification. The invention
CC further provides the detection of HPV mRNA in a test sample suspected of
CC containing HPV, comprising performing an amplification reaction on a
CC preparation of a nucleic acid isolated from the test sample to amplify a
CC portion of the mRNA transcribed from the E6 gene of HPV, where the
CC amplification reaction is performed using the primer-pair of
CC oligonucleotide cited above. The invention also provides: a reagent kit
CC for use in the detection of HPV by NASBA, comprising an oligonucleotide
CC primer-pair and, optionally, an enzyme mixture comprising an RNA directed
CC DNA polymerase, a ribonuclease that hydrolyzes the RNA strand of an RNA-
CC DNA hybrid without hydrolyzing single or double stranded RNA or DNA, and
CC an RNA polymerase that recognises the promoter sequence present in at
CC least one NASBA P1 primer oligonucleotide included in the reagent kit.
CC The oligonucleotide of the invention is useful in detecting mRNA
CC transcripts from the E6 gene of HPV in clinical samples. This
CC polynucleotide sequence represents an oligonucleotide used for detecting
CC mRNA transcribed from the E6 gene of a human papillomavirus (HPV) of the
CC invention.
XX
SQ Sequence 19 BP; 8 A; 6 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3253 GTTGTGTTTTCATCTG 3270
Db 18 GTTGTGTTTTCATCTG 1
RESULT 586
ADE27120/c
ID ADE27120 standard; RNA; 19 BP.
XX
AC ADE27120;
XX
XX 29-JAN-2004 (first entry)
DT
DE Stearoyl-CoA desaturase siNA oligonucleotide SEQ ID NO:64.
XX
KW short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;

KW antiarteriosclerotic; cytostatic; virucide; obesity; diabetes;
 KW atherosclerosis; cancer; viral infection; drug screening;
 KW genetic engineering; pharmacogenomic; gene mapping; ss.

XX Synthetic.

XX WO2003070885-A2.

XX 28-AUG-2003.

XX 13-FEB-2003; 2003WO-US004317.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 06-JUN-2002; 2002US-0386782P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX 20-SEP-2002; 2002US-0412304P.

XX 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Thompson J;

XX WPI; 2003-721687/68.

XX New short interfering nucleic acid, useful e.g. for treatment and

XX diagnosis of obesity or diabetes, downregulates expression of the

XX stearyl-CoA desaturase gene.

XX Example 3; SEQ ID NO 64; 139pp; English.

XX The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
 CC by RNA interference. Also described: (1) modulating expression of SCD
 CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
 CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
 CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
 CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
 CC virucide activities. The siNAs can be used to modulate expression of SCD
 CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
 CC diabetes (types I and II); atherosclerosis; cancer and viral infections.
 CC They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents an SCD siNA, which is
 CC used in the exemplification of the present invention.

XX Sequence 19 BP; 4 A; 8 C; 1 G; 0 T; 6 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 2.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3577 TCCTAGGGAAGGATGG 3594

DB 19 TCATAGGGAAGGATGG 2

RESULT 587

ADE27410

ID ADE27410 standard; RNA; 19 BP.

XX ADE27410;

XX 29-JAN-2004 (first entry)

XX Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:354.

XX short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
 KW stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
 KW antiarteriosclerotic; cytostatic; virucide; obesity; diabetes;

KW atherosclerosis; cancer; viral infection; drug screening;
 KW genetic engineering; pharmacogenomic; gene mapping; ss.

XX Synthetic.

XX WO2003070885-A2.

XX 28-AUG-2003.

XX 13-FEB-2003; 2003WO-US004317.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 06-JUN-2002; 2002US-0386782P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX 20-SEP-2002; 2002US-0412304P.

XX 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Thompson J;

XX WPI; 2003-721687/68.

XX New short interfering nucleic acid, useful e.g. for treatment and

XX diagnosis of obesity or diabetes, downregulates expression of the

XX stearyl-CoA desaturase gene.

XX Example 3; SEQ ID NO 354; 139pp; English.

XX The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
 CC by RNA interference. Also described: (1) modulating expression of SCD
 CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
 CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
 CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
 CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
 CC virucide activities. The siNAs can be used to modulate expression of SCD
 CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
 CC diabetes (types I and II); atherosclerosis; cancer and viral infections.
 CC They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents an SCD siNA, which is
 CC used in the exemplification of the present invention.

XX Sequence 19 BP; 6 A; 1 C; 8 G; 0 T; 4 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;

Best Local Similarity 72.2%; Pred. No. 2.6e+02;

Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 3577 TCCTAGGGAAGGATGG 3594

DB 1 UCAUAGGGAAGGAGUGG 18

RESULT 588

ADE29541/c

ID ADE29541 standard; RNA; 19 BP.

XX ADE29541;

XX 29-JAN-2004 (first entry)

XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:163.

XX short interfering nucleic acid; siNA; downregulation; inhibition;
 KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
 KW cytostatic; anorectic; antidiabetic; antiinflammatory; antiarthritic;
 KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;

antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
 inflammatory disease; asthma; septic shock; rheumatoid arthritis;
 psoriasis; inflammatory bowel disease; drug screening;
 genetic engineering; pharmacogenomic; gene mapping; ss.

OS Synthetic.

XX WO2003072590-A1.

XX 04-SEP-2003.

XX 28-JAN-2003; 2003WO-US002510.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 06-JUN-2002; 2002US-0386782P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX 15-JAN-2003; 2003US-0440129P.

XX (SIRN-) SIRNA THERAPEUTICS INC.

PI Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;

XX WPI; 2003-689980/65.

XX New short interfering nucleic acid, useful e.g. for treatment and
 diagnosis of cancer, downregulates expression of mitogen-activated
 protein kinase genes.

XX Example 3; SEQ ID NO 163; 164pp; English.

XX The present invention describes a short interfering nucleic acid (siNA)
 that downregulates expression of a mitogen-activated protein kinase
 (MAPK) genes by RNA interference. Also described: (1) a method for
 modulating expression of MAPK genes in cells, tissue explants or
 organisms by introduction of siNA; (2) kits for in vitro or in vivo
 delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
 vectors that express siNA and cells containing these vectors. MAPK siNAs
 have cytostatic, anorectic, antidiabetic, antiinflammatory,
 antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
 antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
 siNAs can be used to modulate the expression of MAPK genes, in cells,
 tissue explants or organisms, e.g. for treating obesity; diabetes types I
 and II; a wide range of tumours, and inflammatory diseases (asthma,
 septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
 disease). They can also be used for drug screening; diagnosis; target
 identification and validation; genetic engineering; pharmacogenomics;
 studying gene function and gene mapping (e.g. of single-nucleotide
 polymorphisms). The present sequence represents a MAPK siNA which is used
 in the exemplification of the present invention.

XX Sequence 19 BP; 16 A; 1 C; 0 G; 0 T; 2 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 2.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2574 TTCCTTTTTCCTTCGAA 2591

DB 18 TTTTTCCTTTTTCCTTCGAA 1

RESULT 599

ADE29406

ID ADE29406 standard; RNA; 19 BP.

XX ADE29406;

XX ADE29406;

DT 29-JAN-2004 (first entry)

XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:28.

XX

short interfering nucleic acid; siNA; downregulation; inhibition;
 mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
 cytosstatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
 immunosuppressive; antibacterial; antirheumatic; antiarthritic;
 antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
 inflammatory disease; asthma; septic shock; rheumatoid arthritis;
 psoriasis; inflammatory bowel disease; drug screening;
 genetic engineering; pharmacogenomic; gene mapping; ss.

XX Synthetic.

XX WO2003072590-A1.

XX 04-SEP-2003.

XX 28-JAN-2003; 2003WO-US002510.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 06-JUN-2002; 2002US-0386782P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX 15-JAN-2003; 2003US-0440129P.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;

XX WPI; 2003-689980/65.

XX New short interfering nucleic acid, useful e.g. for treatment and
 diagnosis of cancer, downregulates expression of mitogen-activated
 protein kinase genes.

XX Example 3; SEQ ID NO 28; 164pp; English.

XX The present invention describes a short interfering nucleic acid (siNA)
 that downregulates expression of a mitogen-activated protein kinase
 (MAPK) genes by RNA interference. Also described: (1) a method for
 modulating expression of MAPK genes in cells, tissue explants or
 organisms by introduction of siNA; (2) kits for in vitro or in vivo
 delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
 vectors that express siNA and cells containing these vectors. MAPK siNAs
 have cytostatic, anorectic, antidiabetic, antiinflammatory,
 antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
 antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
 siNAs can be used to modulate the expression of MAPK genes, in cells,
 tissue explants or organisms, e.g. for treating obesity; diabetes types I
 and II; a wide range of tumours, and inflammatory diseases (asthma,
 septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
 disease). They can also be used for drug screening; diagnosis; target
 identification and validation; genetic engineering; pharmacogenomics;
 studying gene function and gene mapping (e.g. of single-nucleotide
 polymorphisms). The present sequence represents a MAPK siNA which is used
 in the exemplification of the present invention.

XX Sequence 19 BP; 7 A; 3 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 55.6%; Pred. No. 2.6e+02;
 Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

OY 1559 ATTGGCATCATTCGACATT 1576

DB 2 AUGGGAUCAUGACAUU 19

RESULT 590

ADE29704

ID ADE29704 standard; RNA; 19 BP.

XX

```

AC ADE29704;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:326.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition;
KW short interfering nucleic acid; siNA; downregulation; inhibition;
KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003072590-A1.
XX
XX 04-SEP-2003.
XX
PD 28-JAN-2003; 2003WO-US002510.
XX
PF 20-FEB-2002; 2002US-0358580P.
XX
PR 11-MAR-2002; 2002US-0363124P.
XX
PR 06-JUN-2002; 2002US-0386782P.
XX
PR 29-AUG-2002; 2002US-0406784P.
XX
PR 05-SEP-2002; 2002US-0408378P.
XX
PR 09-SEP-2002; 2002US-0409293P.
XX
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
XX
DR WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
PS Example 3; SEQ ID NO 326; 164pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNA can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 2 A; 0 C; 1 G; 0 T; 16 U; 0 Other;
XX
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 16.7%; Pred. No. 2.6e+02;
Matches 3; Conservative 13; Mismatches 2; Indels 0; Gaps 0;
QY 2574 TTCTTTTTCCTGAA 2591
DB 2 UUUUUUUUUUUUUGNA 19

```

```

RESULT 591
ADE29569/C
ID ADE29569 standard; RNA; 19 BP.
XX
XX ADE29569;
AC
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:191.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition;
KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003072590-A1.
XX
XX 04-SEP-2003.
XX
PD 28-JAN-2003; 2003WO-US002510.
XX
PF 20-FEB-2002; 2002US-0358580P.
XX
PR 11-MAR-2002; 2002US-0363124P.
XX
PR 06-JUN-2002; 2002US-0386782P.
XX
PR 29-AUG-2002; 2002US-0406784P.
XX
PR 05-SEP-2002; 2002US-0408378P.
XX
PR 09-SEP-2002; 2002US-0409293P.
XX
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
XX
DR WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
PS Example 3; SEQ ID NO 191; 164pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNA can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 6 A; 3 C; 3 G; 0 T; 7 U; 0 Other;
XX
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 1559 ATTGGCATCATGACATT 1576
||||| ||||| ||||| |||||
Db 18 ATTGGAATCAATGACATT 1

RESULT 592
ADF47984
ID ADF47984 standard; RNA; 19 BP.
XX
AC ADF47984;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human Myc siRNA lower strand, SEQ ID 121.
XX
KW Human; Myc; Myb; cancer; proliferative disease; restenosis;
KW polycystic kidney disease; RNA interference;
KW short interfering nucleic acid; siRNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; cytostatic; vasotropic;
KW nephrotropic; ss.
XX
OS Homo sapiens.
XX
PN WO2003070917-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005326.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-OCT-2002; 2002US-0418655P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
XX WPI; 2003-689784/65.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of Myc or Myb genes.
XX
PS Example 7; Page 126; 161pp; English.
XX
CC The invention relates to short interfering nucleic acids (siRNA) which
CC downregulate expression of the human Myc or Myb genes by RNA
CC interference. The siRNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siRNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siRNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
CC and/or complexes of siRNA; and vectors that express siRNA. The siRNAs are
CC used to modulate expression of the Myc or Myb genes in cells, tissue
CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC transplants for the treatment of a variety of conditions. They may be
CC used for treating cancers and other proliferative diseases, such as
CC restenosis and polycystic kidney disease. The siRNAs are also useful for
CC drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).

CC The present sequence represents the lower strand of a human Myc-targeted
CC double-stranded siRNA.
XX Sequence 19 BP; 5 A; 3 C; 11 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1854 AGGCAGAGTGGAGCCAG 1871
||||| ||||| ||||| |||||
Db 2 AGGCAGAGGGGAGCCAG 19

RESULT 593
ADF47866/C
ID ADF47866 standard; RNA; 19 BP.
XX
AC ADF47866;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human Myc transcript target sequence/siRNA upper strand, SEQ ID 3.
XX
KW Human; Myc; Myb; cancer; proliferative disease; restenosis;
KW polycystic kidney disease; RNA interference;
KW short interfering nucleic acid; siRNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; cytostatic; vasotropic;
KW nephrotropic; ss.
XX
OS Homo sapiens.
XX
PN WO2003070917-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005326.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-OCT-2002; 2002US-0418655P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
XX WPI; 2003-689784/65.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of Myc or Myb genes.
XX
PS Example 7; Page 126; 161pp; English.
XX
CC The invention relates to short interfering nucleic acids (siRNA) which
CC downregulate expression of the human Myc or Myb genes by RNA
CC interference. The siRNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siRNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siRNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
CC and/or complexes of siRNA; and vectors that express siRNA. The siRNAs are
CC used to modulate expression of the Myc or Myb genes in cells, tissue
CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC transplants for the treatment of a variety of conditions. They may be
CC used for treating cancers and other proliferative diseases, such as
CC restenosis and polycystic kidney disease. The siRNAs are also useful for
CC drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).

used to modulate expression of the Myc or Myb genes in cells, tissue explants or organisms (e.g., by ex vivo gene therapy), or in grafts and transplants for the treatment of a variety of conditions. They may be used for treating cancers and other proliferative diseases, such as restenosis and polycystic kidney disease. The siRNAs are also useful for drug screening, diagnosis, therapeutic target identification and validation, genetic engineering, pharmacogenomics, studying gene function, and gene mapping (e.g., of single nucleotide polymorphisms). The present sequence represents the upper strand of a human Myc-targeted double-stranded siRNA, which is identical to the Myc transcript target sequence.

Sequence 19 BP; 0 A; 11 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1854 AGGCAGAGTGGAGCCAG 1871
DB 18 AGGCAGAGTGGAGCCAG 1

RESULT 594
ADF31613/C
ID ADF31613 standard; RNA; 19 BP.
AC ADF31613;
XX
DT 12-FEB-2004 (first entry)
DE Human IGF-1R siRNA lower strand, SEQ ID NO:278.
XX
XX RNA interference; short interfering nucleic acid; siRNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW proliferative disease; restenosis; polycystic kidney disease;
KW inflammatory disease; allergic disease; autoimmune disease;
KW transplant rejection; cytostatic; vasotropic; nephrotropic;
KW antiinflammatory; antiallergic; immunosuppressive; human;
KW insulin-like growth factor 1 receptor; IGF-1R; ss.
XX
OS Homo sapiens.
XX
XX WO2003070911-A2.
PN
XX
PD 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US0005044.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcswiggen J, Beigelman L, Chowira B;
PI
XX WPI; 2003-721691/68.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the insulin-like growth
PT factor-1 receptor gene.
PT
XX
XX Example 3; SEQ ID NO 278; 147pp; English.
PS
XX The invention relates to short interfering nucleic acids (siRNA) which

downregulate expression of the human insulin-like growth factor 1 receptor (IGF-1R) gene by RNA interference. The siRNAs may or may not comprise ribonucleotides and may be double or single stranded. They further comprise sense and antisense regions, or alternatively are assembled from a sense oligonucleotide and an antisense oligonucleotide. Specifically, the siRNAs include short interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siRNAs can be unmodified or chemically modified, can contain deoxyribonucleotides, and can be chemically synthesised, expressed from a vector or enzymatically synthesised. The invention also relates to kits for the in vitro or in vivo delivery of siRNA; conjugates and/or complexes of siRNA; and vectors that express siRNA. The siRNAs are used to modulate expression of the IGF-1R gene in cells, tissue explants or organisms (e.g., by ex vivo gene therapy), or in grafts and transplants for the treatment of a variety of conditions. They may be used for treating cancer and other proliferative diseases (e.g., restenosis and polycystic kidney disease), inflammatory and/or allergic diseases, autoimmune diseases and transplant rejection. The siRNAs are also useful for drug screening, diagnosis, therapeutic target identification and validation, genetic engineering, pharmacogenomics, studying gene function, and gene mapping (e.g., of single nucleotide polymorphisms). The present sequence represents the lower strand of a human IGF-1R-targeted double-stranded siRNA.

Sequence 19 BP; 12 A; 3 C; 0 G; 0 T; 4 U; 0 Other;

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2577 TTTTCTTTCTGAAAA 2594
DB 19 TTTTCTTTCTGAGAAA 2

RESULT 595
ADF31336
ID ADF31336 standard; RNA; 19 BP.
XX
AC ADF31336;
XX
DT 12-FEB-2004 (first entry)
DE Human IGF-1R transcript target sequence/siRNA upper strand, SEQ ID NO:1.
XX
XX RNA interference; short interfering nucleic acid; siRNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW proliferative disease; restenosis; polycystic kidney disease;
KW inflammatory disease; allergic disease; autoimmune disease;
KW transplant rejection; cytostatic; vasotropic; nephrotropic;
KW antiinflammatory; antiallergic; immunosuppressive; human;
KW insulin-like growth factor 1 receptor; IGF-1R; target sequence; ss.
XX
OS Homo sapiens.
XX
XX WO2003070911-A2.
PN
XX
PD 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US0005044.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA

```

XX PI Mcswiggen J, Beigelman L, Chowrira B;
XX WPI; 2003-721691/68.
XX
XX PT New short interfering nucleic acid, useful e.g. for treatment and
XX PT diagnosis of cancer, downregulates expression of the insulin-like growth
XX PT factor-1 receptor gene.
XX
XX PS Example 3; SEQ ID NO 1; 147pp; English.
XX
XX CC The invention relates to short interfering nucleic acids (siNA) which
XX CC downregulate expression of the human insulin-like growth factor 1
XX CC receptor (IGF-1R) gene by RNA interference. The siNAs may or may not
XX CC comprise ribonucleotides and may be double or single stranded. They
XX CC further comprise sense and antisense regions, or alternatively are
XX CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
XX CC Specifically, the siNAs include short interfering RNA (siRNA), double-
XX CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
XX CC can be unmodified or chemically modified, can contain
XX CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
XX CC vector or enzymatically synthesised. The invention also relates to kits
XX CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
XX CC of siNA; and vectors that express siNA. The siNAs are used to modulate
XX CC expression of the IGF-1R gene in cells, tissue explants or organisms
XX CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
XX CC treatment of a variety of conditions. They may be used for treating
XX CC cancer and other proliferative diseases (e.g., restenosis and polycystic
XX CC kidney disease), inflammatory and/or allergic diseases, autoimmune
XX CC diseases and transplant rejection. The siNAs are also useful for drug
XX CC screening, diagnosis, therapeutic target identification and validation,
XX CC genetic engineering, pharmacogenomics, studying gene function, and gene
XX CC mapping (e.g., of single nucleotide polymorphisms). The present sequence
XX CC represents the upper strand of a human IGF-1R-targeted double-stranded
XX CC siNA, which is identical to the IGF-1R transcript target sequence.
XX
XX SQ Sequence 19 BP; 4 A; 0 C; 3 G; 0 T; 12 U; 0 Other;

Query Match          0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 27.8%; Pred. No. 2.6e+02;
Matches 5; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY 2577 TTTTTCCTCTGAAAAA 2594
Db 1 UUUUUUUUUUGAGAAA 18

RESULT 596
ADE95707/c
ID ADE95707 standard; DNA; 19 BP.
XX AC ADE95707;
XX
XX DT 12-FEB-2004 (first entry)
XX
XX DE Human NOVX protein-related PCR primer Ag5917 forward.
XX
XX KW NOVX protein; biochemical stimulation; physiological stimulation;
XX KW cardiant; antiarteriosclerotic; hypotensive; cytostatic; anorectic;
XX KW antirheumatic; antiarthritic; antidiabetic; nephrotropic; dermatological;
XX KW immunosuppressive; anti-HIV; antiinflammatory; neuroprotective;
XX KW nootropic; antipsoriatic; antiparkinsonian; antiasthmatic; neuroleptic;
XX KW antidepressant; antiallergic; gynaecological; gene therapy; vaccine;
XX KW NOVX-associated disorder; cardiomyopathy; atherosclerosis; hypertension;
XX KW cancer; obesity; rheumatoid arthritis; diabetes; glomerulonephritis;
XX KW psoriasis; skin disorder; AIDS; inflammation; multiple sclerosis;
XX KW Alzheimer's disease; Parkinson's disease; asthma; schizophrenia;
XX KW depression; allergy; fertility disorder; PCR; primer; ss; Ag5917 forward.
XX
XX OS Homo sapiens.
XX
XX OS WO2003050245-A2.
XX

```

```

PD 19-JUN-2003.
XX
XX PF 03-DEC-2002; 2002WO-US038594.
XX
XX PR 05-DEC-2001; 2001US-0336600P.
XX PR 07-DEC-2001; 2001US-0338285P.
XX PR 12-DEC-2001; 2001US-0341346P.
XX PR 17-DEC-2001; 2001US-0341477P.
XX PR 17-DEC-2001; 2001US-0341540P.
XX PR 20-DEC-2001; 2001US-0342592P.
XX PR 27-DEC-2001; 2001US-0344297P.
XX PR 31-DEC-2001; 2001US-0344903P.
XX PR 17-APR-2002; 2002US-0373288P.
XX PR 15-MAY-2002; 2002US-0380981P.
XX PR 17-MAY-2002; 2002US-0381495P.
XX PR 28-MAY-2002; 2002US-0383534P.
XX PR 28-MAY-2002; 2002US-0383744P.
XX PR 29-MAY-2002; 2002US-0383829P.
XX PR 29-MAY-2002; 2002US-0384024P.
XX PR 07-AUG-2002; 2002US-0401788P.
XX PR 26-AUG-2002; 2002US-0406353P.
XX PR 31-OCT-2002; 2002US-00401788.
XX PR 02-DEC-2002; 2002US-00406353.
XX
XX PA (CURA-) CURAGEN CORP.
XX
XX PI Alsbrook JP, Anderson DW, Boldog FL, Burgess CE, Chillakuru RA;
XX PI Reinger SR, Gerlach VL, Gorman L, Gould-Rothberg BE, Guo X;
XX PI Jeffers ME, Ji W, Li L, Malyankar UM, Miller CE, Murphy R;
XX PI Pattarajan M, Peyman JA, Rastelli L, Rieger DK, Shenoy SG;
XX PI Smithson G, Starling G, Taupier RJ, Voss EZ, Zhong H, Zhong M;
XX WPI; 2003-513974/48.
XX
XX PT New NOVX polypeptides and nucleic acids, useful for preventing or
XX PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy,
XX PT atherosclerosis or diabetes, and in chromosome mapping, tissue typing or
XX PT pharmacogenomics.
XX
XX PS Example B; SEQ ID NO 239; 211pp; English.
XX
XX CC This invention relates to novel NOVX proteins, and the DNA sequence which
XX CC encode them, having properties related to stimulation of biochemical or
XX CC physiological responses in a cell, a tissue, an organ or an organism.
XX CC Compounds which modulate the proteins of the invention may have cardiant,
XX CC antiarteriosclerotic, hypotensive, cytostatic, anorectic, antirheumatic,
XX CC antiarthritic, antidiabetic, nephrotropic, dermatological,
XX CC immunosuppressive, anti-HIV, antiinflammatory, neuroprotective,
XX CC nootropic, antipsoriatic, antiparkinsonian, antiasthmatic, neuroleptic,
XX CC antidepressant, antiallergic or gynaecological activities. The DNA
XX CC sequences of the invention may be useful for gene therapy whilst the
XX CC protein sequences may allow the development of a vaccine. The protein is
XX CC useful in the manufacture of a medicament for treating a syndrome
XX CC associated with a human disease. The invention may be useful in
XX CC diagnosing, treating or preventing NOVX-associated disorders, for example
XX CC cardiomyopathy, atherosclerosis, hypertension, cancer, obesity,
XX CC rheumatoid arthritis, diabetes, glomerulonephritis, psoriasis, skin
XX CC disorders, AIDS, inflammation, multiple sclerosis, Alzheimer's disease,
XX CC Parkinson's disease, asthma, schizophrenia, depression, allergies or
XX CC fertility disorders. The nucleic acids may further be used as
XX CC hybridisation probes, in chromosome mapping, tissue typing, preventive
XX CC medicine, and pharmacogenomics. The present sequence is that of PCR
XX CC primer Ag5917 forward which was used for the amplification of a human
XX CC gene sequence during the analysis of gene expression in the
XX CC exemplification of the invention.
XX
XX SQ Sequence 19 BP; 2 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match          0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 363 AAGAGAGCCAGGCCGCTG 380

```

Db 19 AAGAGAGCCAGATGCTG 2
RESULT 597
ADL99971/c
ID ADL99971 standard; RNA; 19 BP.
XX
AC ADL99971;
XX
DT 20-MAY-2004 (first entry)
XX
DE Hepatitis B virus short interfering nucleic acid (siNA) #388.
XX
KW Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
OS Hepatitis B virus.
XX
PN US2003206887-A1.
XX
PD 06-NOV-2003.
XX
PF 16-SEP-2002; 2002US-00244647.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 09-SEP-2002; 2002US-0408378P.
XX
XX (MORRISSEY D.
PA (MCSWIGGEN J A.
PA (BEIGELMAN L.
XX
XX Morrissey D, Mcswiggen JA, Beigelman L;
XX WPI; 2003-901032/82.
XX
XX New short interfering nucleic acid molecules which down-regulate
PT expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for
PT characterizing gene function.
XX
XX Claim 11; Page 46; 72pp; English.
XX
XX The invention relates to a short interfering nucleic acid (siNA) molecule
XX that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
XX interference or that inhibits HBV replication. Also disclosed are the
XX following: (i) a method of modulating the expression of a HBV gene in a
XX tissue explant; (ii) a method of generating a library of siNA constructs
XX having predetermined complexity; (iii) a cell containing one or more siNA
XX molecules; (iv) a kit containing a siNA molecule which can be used to
XX modulate the expression of a HBV target gene in a cell, tissue or
XX organism; and (v) a method for synthesizing a siNA molecule. The siNA
XX molecule is adapted for use to treat HBV infection, and comprises a sense
XX and an antisense region, where the antisense region comprises a sense
XX complementary to an RNA sequence encoding HBV and the sense region
XX comprises a sequence complementary to the antisense region. The siNA
XX molecule is assembled from 2 nucleic acid fragments, where one fragment
XX comprises the sense region and the second fragment comprises the

antisense region of the siNA molecule, where sense region and the
antisense region comprise separate oligonucleotides, and are covalently
connected via a linker molecule. The linker molecule is a polynucleotide
linker or a non-nucleotide linker. The sense region comprises a 3'-
terminal overhang and the antisense region comprises a 3'-terminal
overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
The antisense region 3'-terminal overhang is complementary to RNA
encoding HBV. The siNA is useful for treating human hepatitis B virus
infections, and for characterising pathways of gene function, e.g. to
inhibit activity of target genes in a pathway to determine the function
of uncharacterised genes in gene function analysis. The siNA molecules
may also be used in clinical, industrial, environmental, agricultural
and/or research settings. The present sequence represents 1 of 1504 HBV
siNA molecules of the invention.
XX
SQ Sequence 19 BP; 5 A; 6 C; 1 G; 0 T; 7 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2645 CAGBAGTGTTCACAAGAT 2662
DB 19 CGGAAGTGTTCATAAGAT 2
RESULT 598
ADM00618
ID ADM00618 standard; RNA; 19 BP.
XX
AC ADM00618;
XX
DT 20-MAY-2004 (first entry)
XX
DE Hepatitis B virus short interfering nucleic acid (siNA) #1034.
XX
KW Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
OS Hepatitis B virus.
XX
PN US2003206887-A1.
XX
PD 06-NOV-2003.
XX
PF 16-SEP-2002; 2002US-00244647.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 09-SEP-2002; 2002US-0408378P.
XX
XX (MORRISSEY D.
PA (MCSWIGGEN J A.
PA (BEIGELMAN L.
XX
XX Morrissey D, Mcswiggen JA, Beigelman L;
XX WPI; 2003-901032/82.
XX

XX ADM00789;
 XX 20-MAY-2004 (first entry)
 XX Hepatitis B virus short interfering nucleic acid (siNA) #1205.
 XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
 KW siNA; hepatitis B virus; HBV; RNA interference.
 XX Hepatitis B virus.
 XX US2003206887-A1.
 XX 06-NOV-2003.
 XX 16-SEP-2002; 2002US-00244647.
 XX 14-MAY-1992; 92US-00882712.
 PR 07-FEB-1994; 94US-00193627.
 PR 08-NOV-1999; 99US-00436430.
 PR 20-MAR-2000; 2000US-00531025.
 PR 09-AUG-2000; 2000US-00636385.
 PR 24-OCT-2000; 2000US-00696347.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-02968769.
 PR 24-OCT-2001; 2001US-03350599.
 PR 05-DEC-2001; 2001US-03370559.
 PR 20-FEB-2002; 2002US-03585809.
 PR 11-MAR-2002; 2002US-03631249.
 PR 26-MAR-2002; 2002WO-US009187.
 PR 06-JUN-2002; 2002US-03867829.
 PR 29-AUG-2002; 2002US-04067849.
 PR 05-SEP-2002; 2002US-04083789.
 PR 09-SEP-2002; 2002US-04092939.
 XX (MORRISSEY D.
 PA (MCSWIGG J A.
 PA (BEIGIG) BEIGELMAN L.
 XX Morrissey D, Mcswiggen JA, Beigelman L;
 XX WPI; 2003-901032/82.
 XX New short interfering nucleic acid molecules which down-regulate
 PT expression of a hepatitis B virus (HBV) or which inhibits HBV
 PT replication, useful for treating human HBV infections or for
 PT characterizing gene function.
 XX Claim 11; Page 48; 72pp; English.

CC encoding HBV. The siNA is useful for treating human hepatitis B virus
 CC infections, and for characterising pathways of gene function, e.g. to
 CC inhibit activity of target genes in a pathway to determine the function
 CC of uncharacterised genes in gene function analysis. The siNA molecules
 CC may also be used in clinical, industrial, environmental, agricultural
 CC and/or research settings. The present sequence represents 1 of 1504 HBV
 CC siNA molecules of the invention.
 XX Sequence 19 BP; 5 A; 2 C; 6 G; 0 T; 6 U; 0 Other;
 SQ
 Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 66.7%; Pred. No. 2.6e+02;
 Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 2643 TCCAGAGTGTGTGACAG 2660
 :|||:||||:|||||
 Db 2 UCCGGAGUGUGAUAAG 19
 RESULT 601
 ADN34584
 ID ADN34584 standard; RNA; 19 BP.
 XX
 AC ADN34584;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE siNA upper strand target sequence #85.
 XX
 KW short interfering nucleic acid; siNA; multidrug resistance; MDR;
 KW P-glycoprotein; Cytostatic; cancer; drug screening; genetic engineering;
 KW pharmacogenomics; gene mapping; ss.
 XX Homo sapiens.
 OS
 XX WO2003070884-A2.
 PN
 XX 28-AUG-2003.
 XX
 PP 13-FEB-2003; 2003WO-US004250.
 XX
 PR 20-FEB-2002; 2002US-03585809.
 PR 11-MAR-2002; 2002US-03631249.
 PR 06-JUN-2002; 2002US-03867829.
 PR 29-AUG-2002; 2002US-04067849.
 PR 05-SEP-2002; 2002US-04083789.
 PR 09-SEP-2002; 2002US-04092939.
 PR 26-SEP-2002; 2002US-04137149.
 PR 15-JAN-2003; 2003US-04401299.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Beigelman L, Thompson J;
 XX WPI; 2003-697605/66.
 XX New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancers, downregulates expression of the multidrug
 PT resistance gene.
 XX
 PS Example 3; SEQ ID NO 85; 143pp; English.
 XX
 CC The present invention relates to short interfering nucleic acid (siNA)
 CC that downregulates expression of a multidrug resistance (MDR; P-
 CC glycoprotein) gene by RNA interference, modulating expression of MDR
 CC genes in cells, tissue explants or organisms by introduction of siNA;
 CC kits for in vitro or in vivo delivery of siNA; conjugates and/or
 CC complexes of siNA; and vectors that express siNA. The method relates to
 CC the modulation (inhibition) of expression or activity of RNA
 CC interference, siNA target mRNA, RNA splice variants, post-
 CC transcriptionally modified RNA, pre-RNA and/or RNA templates. siNA are
 CC used to modulate expression of MDR genes, in cells, tissue explants or
 CC organisms, e.g. for treating multidrug-resistant cancers but also for

CC drug screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping
CC (e.g. of single-nucleotide polymorphisms).The present sequence represents
CC the upper strand of human MDR targeted double stranded siNA which is
CC identical to the MDR transcript target sequence.

XX
SQ Sequence 19 BP; 8 A; 2 C; 2 G; 0 T; 7 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 2.6e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1312 CTTCAAGATAATGGATTA 1329

Db 2 CUUCAAGAUAAUUGAUA 19

RESULT 602

ADN34842/c

ID ADN34842 standard; RNA; 19 BP.

XX

AC ADN34842;

XX

DT 01-JUL-2004 (first entry)

XX

DE siNA lower strand target sequence #85.

XX

KW short interfering nucleic acid; siNA; multidrug resistance; MDR;
KW P-glycoprotein; Cytostatic; cancer; drug screening; genetic engineering;
KW pharmacogenomics; gene mapping; ss.

XX

OS Homo sapiens.

XX

FN WO20003070884-A2.

XX

PD 28-AUG-2003.

XX

PF 13-FEB-2003; 2003WO-US004250.

XX

PR 20-FEB-2002; 2002US-0358580P.

XX

PR 11-MAR-2002; 2002US-0363124P.

XX

PR 06-JUN-2002; 2002US-0386782P.

XX

PR 29-AUG-2002; 2002US-0406784P.

XX

PR 05-SEP-2002; 2002US-0408378P.

XX

PR 09-SEP-2002; 2002US-0409293P.

XX

PR 26-SEP-2002; 2002US-0433714P.

XX

PR 15-JAN-2003; 2003US-0440129P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Mcswiggen J, Beigelman L, Thompson J;

XX

XX WPI; 2003-697605/66.

DR

PT New short interfering nucleic acid, useful e.g. for treatment and

XX

PT diagnosis of cancers, downregulates expression of the multidrug

XX

PT resistance gene.

XX

PS Example 3; SEQ ID NO 343; 143pp; English.

XX

CC The present invention relates to short interfering nucleic acid (siNA)
CC that downregulates expression of a multidrug resistance (MDR; P-
CC glycoprotein) gene by RNA interference, modulating expression of MDR
CC genes in cells, tissue explants or organisms by introduction of siNA;
CC kits for in vitro or in vivo delivery of siNA; conjugates and/or
CC complexes of siNA; and vectors that express siNA. The method relates to
CC the modulation (inhibition) of expression or activity of MDR by RNA
CC interference, siNA target mRNA, RNA splice variants, post-
CC transcriptionally modified RNA, pre-RNA and/or RNA templates. siNA are
CC used to modulate expression of MDR genes, in cells, tissue explants or
CC organisms, e.g. for treating multidrug-resistant cancers but also for
CC drug screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping

CC (e.g. of single-nucleotide polymorphisms).The present sequence represents
CC the lower strand of human MDR targeted double stranded siNA.

XX
SQ Sequence 19 BP; 7 A; 2 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1312 CTTCAAGATAATGGATTA 1329

Db 18 CTTCAAGATAATGTGATA 1

RESULT 603

ADO58242

ID ADO58242 standard; DNA; 19 BP.

XX

AC ADO58242;

XX

DT 15-JUL-2004 (first entry)

XX

DE Hepatitis A genome DNA isolated from Korean patients PCR primer #22.

XX

KW ss; PCR; hepatitis A virus; Korean; vaccine; primer.

XX

OS Hepatitis A virus.

XX

FN KR2002078708-A.

XX

PD 19-OCT-2002.

XX

PF 10-APR-2001; 2001KR-00018829.

XX

PR 10-APR-2001; 2001KR-00018829.

XX

PA (BUKW-) BUKWANG PHARM CO LTD.

XX

PA (SONG/) SONG J W.

XX

PI Byun GS, Kim JH, Song GJ, Song JW;

XX

XX WPI; 2003-338963/32.

XX

XX Nucleotide sequence of the total genomic DNA of hepatitis A virus

XX

XX isolated from Korean patients.

XX

PS Disclosure; SEQ ID NO 24; 26pp; Korean.

XX

CC The invention relates to a nucleotide sequence of the total genomic DNA
CC of hepatitis A virus isolated from Korean patients is provided, thereby
CC diagnosing Korean hepatitis A virus can be more correctly and preparing
CC an improved vaccine for hepatitis A virus. The present sequence
CC represents a hepatitis A genome DNA isolated from Korean patients PCR
CC primer.

XX

SQ Sequence 19 BP; 8 A; 6 C; 5 G; 0 T; 0 U; 0 Other;

XX

Query Match 0.4%; Score 14.8; DB 1; Length 19;

XX

Best Local Similarity 88.9%; Pred. No. 2.6e+02;

XX

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 338 CCGAGAGAGGAAGAAC 355

Db 2 CCGAAAGAGGAAGAAC 19

RESULT 604

ADJ97246/c

ID ADJ97246 standard; DNA; 19 BP.

XX

AC ADJ97246;

XX

DT 06-MAY-2004 (first entry)

XX Human VEGF DNA sequence, a target for siRNA inhibition SeqID 19.
DE human; ss; short interfering RNA; siRNA; angiogenesis;
XX vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antiangiogenic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-0029422B.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
XX WPI; 2004-203472/19.
DR
XX
XX Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
XX Disclosure; SEQ ID NO 19; 218pp; English.
PS
XX This invention relates to novel compositions that comprise short
XX interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human VEGF DNA oligo,
CC a target for siRNA inhibition of the invention.
XX
XX Sequence 19 BP; 6 A; 9 C; 3 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3144 TTCTTGCCTGGTGAGGT 3161
DB 18 TGCTGGCCTGGTGAGGT 1
RESULT 605
ADC65802/c
ID ABC65802 standard; DNA; 20 BP.
XX
AC ADC65802;
XX
DT 18-DEC-2003 (first entry)
XX

DE Mouse TGF-beta receptor II targeted antisense oligonucleotide #1.
XX mouse; antisense oligonucleotide;
KW transforming growth factor beta receptor II; TGF-beta receptor II;
KW hyperproliferative disorder; breast cancer; autoimmune disorder;
KW rheumatoid arthritis; 2'-O-methoxyethyl gapmer;
KW phosphorothioate backbone; ss; murine.
OS Mus musculus.
XX
PN WO2003000656-A2.
XX
PD 03-JAN-2003.
XX
PF 19-JUN-2002; 2002WO-US019665.
XX
PR 21-JUN-2001; 2001US-00888361.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Murray SF, Wyatt JR;
XX
XX WPI; 2003-175279/17.
DR
XX New compound having a sequence targeted to a nucleic acid encoding a
PT transforming growth factor beta-receptor II, useful for preparing a
PT composition for treating hyperproliferative disorder e.g., lung, liver,
PT colon or gastric cancer.
XX
XX Example 15; SEQ ID NO 98; 141pp; English.
PS
XX The invention comprises antisense oligonucleotides that are targeted to
CC the nucleic acid encoding transforming growth factor beta (TGF-beta)
CC receptor II. The antisense oligonucleotides of the invention are useful
CC for treating: hyperproliferative disorders (e.g. breast cancer), or an
CC autoimmune disorder (e.g. rheumatoid arthritis). The present DNA sequence
CC represents a 2'-O-methoxyethyl gapmer oligonucleotide with a
CC phosphorothioate backbone that is targeted to mouse TGF-beta receptor II.
XX
XX Sequence 20 BP; 3 A; 6 C; 10 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 410 GCCTCCTCGGCGCGTCG 427
DB 20 GCCTCCTCGGCGCGTCG 3
RESULT 606
AAX23570/c
ID AAX23570 standard; DNA; 27 BP.
XX
XX AAX23570;
XX
DT 18-JUN-1999 (first entry)
XX
DE Deletion sequence oligonucleotide 23.
XX
KW Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KW probe; cellular adhesion modulator; cellular proliferation modulator;
KW human retrovirus; human immunodeficiency virus; non-human retrovirus;
KW HIV; primer; ss.
XX
XX Synthetic.
XX
PN WO9911820-A1.
XX
PD 11-MAR-1999.
XX
PF 01-SEP-1998; 98WO-US018084.
XX

```
PR 02-SEP-1997; 97US-00923771.
PA (ISIS-) ISIS PHARM INC.
XX
XX Chen D, Srivatesa GS;
XX
XX WPI; 1999-205198/17.
XX
XX New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.
XX
XX Example 1; Page 97; 163pp; English.
XX
XX This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.
CC oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides
XX
XX Sequence 27 BP; 8 A; 1 C; 3 G; 15 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14.8; DB 1; Length 27;
Best Local Similarity 73.1%; Pred. No. 4.4e+02;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 2577 TTTTCTTTCTGAAAAAGGAAAAA 2602
||| ||| ||| ||| ||| ||| |||
Db 26 TTGCTTTCTTCAAAAAAAGAAAAA 1

RESULT 607
ADM16445
ID ADM16445 standard; RNA; 19 BP.
XX
XX ADM16445;
XX
XX 17-JUN-2004 (first entry)
XX
XX RNA intron poly-pyrimidine tract, seq id 2.
XX
XX Cytostatic; antimicrobial; virucide; gene therapy; RNA intron; cancer;
XX viral; microbial; infection; poly-pyrimidine tract; ds.
XX
XX Unidentified.
XX
XX Key Location/Qualifiers
FH misc_feature 2..4
FT /*tag= a
FT /note= "optionally between 1-3 bases at this position"
FT misc_feature 5
FT /*tag= b
FT /note= "optionally absent base"
FT misc_feature 6..17
FT /*tag= c
FT /note= "optionally between 7-12 bases at this position"
FT misc_feature 19
FT /*tag= d
```

```
FT
XX
XX WO2004024940-A2.
XX
XX 25-MAR-2004.
XX
XX 16-SEP-2003; 2003WO-US029274.
XX
XX 16-SEP-2002; 2002US-0411062P.
XX 12-OCT-2002; 2002US-0418405P.
XX
XX (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX
XX Lin S, Ying S;
XX
XX WPI; 2004-270056/25.
XX
XX New isolated RNAs comprising an intron RNA that is released in a cell,
PT thus modulating the function of a target gene, useful for treating and
PT preventing diseases such as cancer and viral/microbial infections.
XX
XX Claim 2; SEQ ID NO 2; 54pp; English.
XX
XX The invention relates to isolated RNAs comprising an intron RNA that is
CC released in a cell, thus modulating the function of a target gene. Also
CC disclosed is a DNA template for the isolated RNA, an expression vector
CC comprising the DNA, and a composition comprising one or more agents that
CC induce RNA-mediated modulation of the functions of two or more target
CC genes in a cell, such as a mammalian cell. The isolated RNAs and
CC compositions are useful for modulating the function of a target gene in a
CC cell, e.g. to inhibit a cancer-related gene, potential viral gene, and
CC microbe-related gene, and thus useful for treating and preventing
CC diseases such as cancer and viral/microbial infections. The current
CC sequence represents a potential poly-pyrimidine tract of the artificial
CC RNA intron.
XX
XX Sequence 19 BP; 0 A; 3 C; 0 G; 0 T; 13 U; 3 Other;
SQ
Query Match 0.4%; Score 14.6; DB 1; Length 19;
Best Local Similarity 10.5%; Pred. No. 2.9e+02;
Matches 2; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

Qy 2569 TCTTCTCTTTTTCCTTC 2597
||||| :||| :||| :||| :|||
Db 1 UYUUCUUUUUUUUUUUCC 19

RESULT 608
AAX82073/c
ID AAX82073 standard; DNA; 16 BP.
XX
XX AAX82073;
XX
XX 10-SEP-1999 (first entry)
XX
XX Normal tailer #885 used in restriction site polymorphism.
XX
XX Restriction site polymorphism; RSP; nucleic acid hybridisation; ss;
XX gel mobility shift assay; DNA cloning; DNA mutation; mutated cancer cell.
XX
XX Synthetic.
XX
XX WO9924608-A1.
XX
XX 20-MAY-1999.
XX
XX 21-OCT-1998; 98WO-IL000513.
XX
XX 10-NOV-1997; 97IL-00122147.
XX
XX (TECR ) TECHNION RES & DEV FOUND LTD.
XX
XX Lev Z, Herzog R;
```



```
XX WPI; 1999-418431/35.
DR Labeling of the single stranded 3' end of a target polynucleotide.
PT Disclosure; Page 16; 53pp; English.
XX
XX The invention describes a method for labeling single stranded 3' end of a
CC target polynucleotide, and subsequently detecting specific restriction
CC sites in a sequence. The method comprises (a) preparing an
CC oligonucleotide whose 3' end is complementary to the 3' end of the target
CC polynucleotide, and which comprises a nucleotide sequence (termed the
CC tailing sequence) located on the 5' side of the 3' end; (b) incubating
CC the oligonucleotide and the target polynucleotide under extending
CC conditions; (c) adding a polymerase and labeled tri-phosphate nucleotides
CC (which are complementary to the tailing sequence) to the incubation
CC mixture, and allowing the labeled nucleotides to extend the 3' end of the
CC target polynucleotide; (d) optionally removing unincorporated labeled
CC nucleotides from the mixture; and (e) optionally dissociating the
CC oligonucleotide from the target polynucleotide. The method, designated
CC restriction site polymorphism (RSP), can be used to end-label DNA for use
CC in nucleic acid hybridization assays, gel mobility shift assays,
CC molecular markers, DNA cloning, polynucleotide probes, and so on. The
CC methods can be used to detect any DNA mutation which creates a
CC restriction site, and for detecting mutated cancer cells in the presence
CC of a large excess of normal cells. The methods may also be used for the
CC large-scale screening of populations at risk for inherited or sporadic
CC mutations for early detection of various diseases. The methods can also
CC be used to distinguish between mutated heterozygous and homozygous
CC individuals
XX
SQ Sequence 16 BP; 5 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1731 CTTCTCCTTCCAAAAA 1746
DB 16 CTTCTCCTTCCAAAAA 1

RESULT 609
AAAG3786
ID AAG3786 standard; RNA; 17 BP.
XX
AC AAG3786;
XX
DT 20-JUL-1999 (first entry)
DE Rabbit stromelysin hammerhead target SEQ ID NO:418.
XX
DE Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
XX Oryctolagus cuniculus.
XX
XX WO9618736-A2.
PN
XX
PD 20-JUN-1996.
XX
XX 22-NOV-1995; 95US-00315516.
XX
XX 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
```

```
PR 07-JUL-1995; 95US-0000951P.
PR 07-JUL-1995; 95US-0000974P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-005411365.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI Mcswigen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Karpelsky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX
XX Example 1; Page 153; 307pp; English.
XX
XX The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX
SQ Sequence 17 BP; 9 A; 3 C; 2 G; 0 T; 3 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 2002 TACAACCTTGGAAG 2017
DB 1 UACRACCUUGAAG 16

RESULT 610
AAT76503
ID AAT76503 standard; DNA; 17 BP.
XX
AC AAT76503;
XX
DT 16-SEP-1997 (first entry)
XX
DE Endothelial nitric oxide antisense oligonucleotide.
XX
XX Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW chronic obstructive pulmonary disease; bronchitis; ss.
XX
XX Synthetic.
XX
XX WO9640162-A1.
XX
XX 19-DEC-1996.
XX
XX 06-JUN-1996; 96WO-US009306.
XX
XX 07-JUN-1995; 95US-00474497.
XX
XX (UYEC-) UNIV EAST CAROLINA.
PA
```

XX PI Nyce JW, Metzger WJ;
 XX DR WPI; 1997-051871/05.
 XX PT Treatment of airway diseases such as asthma - by topically applying
 XX PT adenosine-free antisense oligo:nucleotide to airway epithelium of
 XX PT subject.
 XX PS Example 5; Page 42; 71pp; English.
 XX CC A method for treating airway disease in a subject has been produced,
 XX CC which involves the topical administration of an essentially adenosine
 XX CC free antisense oligonucleotide (ON) to the airway epithelium of the
 XX CC subject. The present sequence is an antisense oligonucleotide specific
 XX CC for endothelial nitric oxide. The method can be used to treat airway
 XX CC diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary
 XX CC disease, bronchitis and other airway diseases characterised by an
 XX CC inflammatory response. By eliminating adenosine from the antisense ON,
 XX CC its liberation upon antisense degradation is prevented, thereby
 XX CC preventing adenosine-induced bronchoconstriction in patients with hyper-
 XX CC reactive airways
 XX CC Sequence 17 BP; 0 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 2.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 409 GGCCTCTCTCCGGCGC 424
 DB 1 GGCCTCTCTCGGCG 16
 RESULT 611
 AAV93275/C
 ID AAV93275 standard; RNA; 17 BP.
 XX AC AAV93275;
 XX DT 18-FEB-1999 (first entry)
 XX DE Human B-raf substrate nucleotide position 17.
 XX KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
 KW screening; identification; synthesis; deprotection; purification; cancer;
 KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
 KW restenosis; rheumatoid arthritis; ss.
 XX OS Homo sapiens.
 XX FN WO9805030-A2.
 XX PD 12-NOV-1998.
 XX PF 05-MAY-1998; 98WO-US009249.
 XX PR 09-MAY-1997; 97US-0046059P.
 XX PR 09-JUN-1997; 97US-0049002P.
 XX PR 03-JUL-1997; 97US-0051718P.
 XX PR 22-AUG-1997; 97US-0056808P.
 XX PR 02-OCT-1997; 97US-0061321P.
 XX PR 02-OCT-1997; 97US-0061324P.
 XX PR 05-NOV-1997; 97US-0064866P.
 XX PR 19-DEC-1997; 97US-0068212P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
 PI Parry T, Bergelman L, Mcswiggen JA, Karpeisky A, Burgin A;
 PI Thompson J, Workman CT, Beaudry A, Sweedler D;
 XX

DR WPI; 1999-009494/01.
 XX Identifying new catalytic nucleic acid that modulates selected processes
 XX PT - especially ribozymes that cleave Raf RNA for treating cancer,
 XX PT restenosis, and also new ribozymes and modified nucleoside triphosphates
 XX PT used as antiviral agents and synthons.
 XX PS Claim 177; Page 165; 259pp; English.
 XX CC A method has been developed for the identification of a nucleic acid
 XX CC capable of modulating a process in a biological system. The method
 XX CC comprises: (a) introducing into the system a random library of nucleic
 XX CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 XX CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 XX CC in systems where modulation has occurred and/or determining the sequence
 XX CC of at least part of the SBDs in such systems. Nucleic acid molecules with
 XX CC endonuclease activity and catalytic activity, from the present invention,
 XX CC are used to modulate gene expression in plant and mammalian cells and to
 XX CC cleave target nucleic acid, particularly for treating systemic diseases
 XX CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
 XX CC ascites and infection. They may also be used to detect genetic drift and
 XX CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
 XX CC with RNA-cleaving activity that modulate expression of the Raf gene, are
 XX CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
 XX CC generally any condition associated with the level of c-raf. Introduction
 XX CC of sugar/phosphate modifications increases stability against nuclease and
 XX CC activity, AAV90922 to AAV93877 represent NACs that can be used in the
 XX CC method, specifically for modulating the expression of a Raf gene
 XX CC Sequence 17 BP; 0 A; 12 C; 4 G; 0 T; 1 U; 0 Other;
 Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 2.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 278 GCGCGGGAGGTGGCC 293
 DB 16 GCGCGGGAGGGGGCC 1
 RESULT 612
 AAX54294
 ID AAX54294 standard; DNA; 17 BP.
 XX AC AAX54294;
 XX DT 05-JUL-1999 (first entry)
 XX DE Endothelial nitric oxide synthase antisense oligonucleotide.
 XX KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; pain; cystic fibrosis;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX OS Synthetic.
 XX FN WO9913886-A1.
 XX PD 25-MAR-1999.
 XX PF 17-SEP-1998; 98WO-US019419.
 XX PR 17-SEP-1997; 97US-0059160P.
 XX PR 09-JUN-1998; 98US-00093972.
 XX PA (UYEC-) UNIV EAST CAROLINA.

XX NYce JW;
 PI WPI; 1999-229400/19.
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction.
 PT Disclosure; Page 61; 120pp; English.
 PS
 XX The specification describes antisense oligonucleotides (AA52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene initiation
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3',
 CC end and the juxta-section between coding and non-coding regions and all
 CC segments of RNAs encoding proteins associated with one or more diseases,
 CC conditions or mixtures. The antisense oligonucleotides may be derived
 CC from sequences AAX55272-74. These multiple target oligonucleotides
 CC (specifically AAX55180-271) can be used for the antisense treatment of
 CC diseases and conditions. Typical diseases and conditions are those
 CC associated with impaired respiration and inflammation, including lung
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
 CC acute asthma, allergies, asthma, impaired respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
 CC well as all types of cancers which may metastasize or have metastasized
 CC to the lungs, including breast and prostate cancer
 XX
 SQ Sequence 17 BP; 0 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 2.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 409 GGCCTCTCTCGGCGC 424
 DB 1 GGCCTCTCTCTCGGCG 16
 RESULT 613
 AA33738
 ID AAA33738 standard; DNA; 17 BP.
 XX
 AC AAA33738;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1427.
 XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytotatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 XX 03-AUG-1999; 99WO-US017712.
 XX
 PR 03-AUG-1998; 98US-0095212P.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.

PI NYce JW;
 DR WPI; 2000-205971/18.
 XX
 PT New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers.
 XX
 PS Claim 18; Page 443; 1343pp; English.
 XX
 CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytotatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 XX
 SQ Sequence 17 BP; 0 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 2.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 409 GGCCTCTCTCGGCGC 424
 DB 1 GGCCTCTCTCTCGGCG 16
 RESULT 614
 AA319860
 ID AA319860 standard; DNA; 17 BP.
 XX
 AC AA319860;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 DE Human endothelial nitric oxide synthase polynucleotide fragment #1427.
 XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytotatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200062736-A2.

```
PD XX 26-OCT-2000.
PF XX 24-MAR-2000; 2000WO-US008020.
XX XX
PR XX 06-APR-1999; 99US-0127958P.
XX XX
XX XX (UYEC-) UNIV EAST CAROLINA.
PA XX (NYCE/) NYCE J W.
XX XX
PI XX Nyce JW;
XX XX
DR XX WPI; 2000-679539/66.
XX XX
XX XX Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX XX
PS XX Claim 14; Page 251; 1592pp; English.
XX XX
CC XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system peptide
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention
XX XX
SQ Sequence 17 BP; 0 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 409 GGCCTCCTCCGGCGC 424
DB 1 GGCCTCCTCCTGGCGC 16
RESULT 615
AAF06160
ID AAF06160 standard; DNA; 17 BP.
XX XX
XX XX AAF06160;
XX XX
XX XX 16-FEB-2001 (first entry)
DT XX
DE XX Hammerhead ribozyme substrate #2957.
XX XX
XX XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX interferon alpha; ss.
XX XX
```

```
OS Homo sapiens.
XX WO200061729-A2.
PN XX
XX 19-OCT-2000.
XX XX
XX 11-APR-2000; 2000WO-US009721.
PF XX
XX 12-APR-1999; 99US-0129390P.
PR XX
XX (RIBO-) RIBOZYME PHARM INC.
PA XX
XX Blatt L, Zwick M, Pavco P, Mctswiggen J;
PI WPI; 2000-647423/62.
XX XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX XX
XX Claim 42; Page 123; 164pp; English.
XX XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX XX
SQ Sequence 17 BP; 2 A; 6 C; 1 G; 0 T; 8 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 2.6e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
QY 2485 TTCTCTCTGACTCTCT 2500
DB 2 UUUUCUCUGACACCU 17
RESULT 616
ABK02172/c
ID ABK02172 standard; RNA; 17 BP.
XX XX
XX ABK02172;
XX 12-MAR-2002 (first entry)
DT XX
XX Human NOGO DNazyme #84.
XX XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX XX
XX Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US004273.
XX PF
```


QY	718	CTTCTTTCCCACTGNA	733
		Best Local Similarity	93.8%;
		pred. No. 2.6e+02;	
		0: Mismatches 1;	Indels
		Marches 15: Conservative	0: Gaps

OY 377 GCTGAGGGGAGGGGG 392
 DB 16 GCTGAGGGGAGGGAGG 1
 RESULT 620
 ABV90552/c
 ID ABV90552 standard; DNA; 17 BP.
 AC ABV90552;
 XX 23-DEC-2002 (first entry)
 DT Human POSHL1 scanning oligonucleotide SEQ ID NO 1265.
 DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX Homo sapiens.
 OS EP1239051-A2.
 PN 11-SEP-2002.
 PD 28-JAN-2002; 2002EP-00001165.
 XX 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX (AEOM-) AEOMICA INC.
 PA Shannon M;
 PI WPI; 2002-684061/74.
 DR Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX Example 2; SEQ ID NO 1265; 60pp + Sequence Listing; English.
 PS The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 XX Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 2.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2846 ATGGGCTGGGAGATCA 2861
 DB 17 ATGGGCTGGGATCA 2
 RESULT 621
 ABV90555/c
 ID ABV90555 standard; DNA; 17 BP.
 AC ABV90555;
 XX 23-DEC-2002 (first entry)
 DT Human POSHL1 scanning oligonucleotide SEQ ID NO 1268.
 DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX Homo sapiens.
 OS EP1239051-A2.
 PN 11-SEP-2002.
 PD 28-JAN-2002; 2002EP-00001165.
 XX 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX (AEOM-) AEOMICA INC.
 PA Shannon M;
 PI WPI; 2002-684061/74.
 DR Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX Example 2; SEQ ID NO 1268; 60pp + Sequence Listing; English.
 PS The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 XX Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
 SQ

```
XX SQ Sequence 17 BP; 5 A; 7 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2844 CCATGGGCTGGGAGAT 2859
Db 16 CCATGGGCTGGGTGAT 1

RESULT 622
ABV91224/C
ID ABV91224 standard; DNA; 17 BP.
XX AC ABV91224;
XX DT 23-DEC-2002 (first entry)
XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1937.
XX KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX OS Homo sapiens.
XX PN EP1239051-A2.
XX PD 11-SEP-2002.
XX PF 28-JAN-2002; 2002EP-00001165.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 10-OCT-2001; 2001US-0328205P.
XX PA (ABOM-) ABOMICA INC.
XX PI Shannon M;
XX WPI; 2002-684061/74.
XX PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX PS Example 2; SEQ ID NO 1937; 60pp + Sequence Listing; English.
XX CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention. Note: The present sequence did not form part of the
XX printed specification, but is based on sequence information supplied to
XX derwent by the European Patent Office
XX SQ Sequence 17 BP; 1 A; 12 C; 1 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 377 GCTGAGGGGAGGGG 392
Db 17 GCTGAGGGGAGGAGG 2

RESULT 623
ACN09263
ID ACN09263 standard; RNA; 17 BP.
XX AC ACN09263;
XX DT 22-APR-2004 (first entry)
XX DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9266.
XX KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX OS West Nile Virus.
XX PN WO200268637-A2.
XX PD 06-SEP-2002.
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-024211P.
XX PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX CC New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX PS Claim 23; SEQ ID NO 9266; 495pp; English.
XX CC The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 3780
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX SQ Sequence 17 BP; 2 A; 8 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
```



```
Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2109 CAGCCCTTGCCCCAGC 2124
Db 2 CAGCCGUGGCCAGC 17
||||| :|||||

RESULT 624
ACN13459
ID ACN13459 standard; RNA; 17 BP.
XX
AC ACN13459;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Zinzyne substrate SEQ ID NO 13462.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 13462; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2109 CAGCCCTTGCCCCAGC 2124
Db 1 CAGCCGUGGCCAGC 16
||||| :|||||

Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2109 CAGCCCTTGCCCCAGC 2124
Db 1 CAGCCGUGGCCAGC 16
||||| :|||||
```

```
RESULT 625
ACN01642/c
ID ACN01642 standard; RNA; 17 BP.
XX
AC ACN01642;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Inozyme substrate SEQ ID NO 1632.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 1632; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2109 CAGCCCTTGCCCCAGC 2124
Db 16 CAGCCGUGGCCAGC 1
||||| :|||||

RESULT 626
ABT35156
ID ABT35156 standard; DNA; 17 BP.
XX
AC ABT35156;
XX
```

DT 12-JUN-2003 (first entry)
XX Tumour suppression related human fukutin oligo SEQ ID NO 793.
DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizoprenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX Homo sapiens.
OS
XX WO2003025175-A2.
XX 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004208.
PF 17-SEP-2001; 2001FR-00011978.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijnder M;
PI WPI; 2003-313353/30.
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX Disclosure; Page 125; 720pp; French.
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizoprenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
SQ Sequence 17 BP; 7 A; 5 C; 2 G; 2 T; 0 U; 1 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 2634 GATCAGAACTCCAGAA 2649
|||||
Db 1 GATCAGAACTCCAWAA 16
RESULT 627
ABT39379
ID ABT39379 standard; DNA; 17 BP.
XX
AC ABT39379;
XX
DT 12-JUN-2003 (first entry)
XX

DE Tumour suppression related human fukutin oligo SEQ ID No 5016.
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizoprenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX Homo sapiens.
XX WO2003025175-A2.
XX 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004208.
PF 17-SEP-2001; 2001FR-00011978.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijnder M;
PI WPI; 2003-313353/30.
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX Disclosure; Page 620; 720pp; French.
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizoprenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 3095 ACTGTGAGCCAGCA 3110
|||||
Db 2 ATCTGTGAGCCAGGA 17
RESULT 628
ADB04268
ID ADB04268 standard; DNA; 17 BP.
XX
AC ADB04268;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ7 scanning oligonucleotide SEQ ID 5254.
XX

KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX Homo sapiens.
XX EP1281758-A2.
XX 05-FEB-2003.
XX 30-JUL-2002; 2002EP-00016874.
XX 02-AUG-2001; 2001US-00922181.
XX (AEOM-) AEOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX New zinc finger-containing proteins and nucleic acids, useful in
XX manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MDZ12, e.g. cancer.
XX Example 8; SEQ ID NO 5254; 103pp; English.
XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MDZ12. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MDZ12 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MDZ12, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MDZ12. The nucleic
XX acids can also be used as probes to detect and characterize gross
XX alterations in MD23, MD24, MD27, or MDZ12 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 1 A; 1 C; 0 G; 15 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTTTTTTT 2586
Db 2 TTCTTTTTTTTTTTTT 17
RESULT 629
ADB04269
ID ADB04269 standard; DNA; 17 BP.
XX ADB04269;
XX 20-NOV-2003 (first entry)
XX Human MD27 scanning oligonucleotide SEQ ID 5255.
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX Homo sapiens.
XX EP1281758-A2.

XX 05-FEB-2003.
XX 30-JUL-2002; 2002EP-00016874.
XX 02-AUG-2001; 2001US-00922181.
XX (AEOM-) AEOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX New zinc finger-containing proteins and nucleic acids, useful in
XX manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MDZ12, e.g. cancer.
XX Example 8; SEQ ID NO 5255; 103pp; English.
XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MDZ12. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MDZ12 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MDZ12, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MDZ12, or MDZ12. The nucleic
XX acids can also be used as probes to detect and characterize gross
XX alterations in MD23, MD24, MDZ12, or MDZ12 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 0 A; 1 C; 0 G; 16 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTTTTTTT 2586
Db 1 TTCTTTTTTTTTTTTT 16
RESULT 630
ADB03527/c
ID ADB03527 standard; DNA; 17 BP.
XX ADB03527;
XX 20-NOV-2003 (first entry)
XX Human MD27 scanning oligonucleotide SEQ ID 4513.
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX Homo sapiens.
XX EP1281758-A2.
XX 05-FEB-2003.
XX 30-JUL-2002; 2002EP-00016874.
XX 02-AUG-2001; 2001US-00922181.
XX (AEOM-) AEOMICA INC.

XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
XX Example 8; SEQ ID NO 4513; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
XX Sequence 17 BP; 2 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2049 AAGCGCAAAGCCTCAG 2064
DB 17 AAGCGCAAAGCCTTAG 2
RESULT 631
ADB03528/c
ID ADB03528 standard; DNA; 17 BP.
XX
XX ADB03528;
AC
XX 20-NOV-2003 (first entry)
DT
XX Human MDZ7 scanning oligonucleotide SEQ ID 4514.
DE
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX EP1281758-A2.
PN
XX 05-FEB-2003.
PD
XX 30-JUL-2002; 2002EP-00016874.
PF
XX 02-AUG-2001; 2001US-00922181.
PR
XX (AEOM-) AEOMICA INC.
PA
XX Shannon M, Gu Y, Nguyen C;
PI
XX WPI; 2003-423107/40.
DR
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT

PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
XX Example 8; SEQ ID NO 4514; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
XX Sequence 17 BP; 2 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2049 AAGCGCAAAGCCTCAG 2064
DB 16 AAGCGCAAAGCCTTAG 1
RESULT 632
ACD52714/c
ID ACD52714 standard; RNA; 17 BP.
XX
XX ACD52714;
AC
XX 24-SEP-2003 (first entry)
DT
XX HBV inozyme substrate sequence #538.
DE
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis B virus.
OS
XX WO200281494-A1.
PN
XX 17-OCT-2002.
PD
XX 26-MAR-2002; 2002WO-US009187.
PF
XX 26-MAR-2001; 2001US-00817879.
PR
XX 08-JUN-2001; 2001US-00877478.
PR
XX 08-JUN-2001; 2001US-0296876P.
PR
XX 24-OCT-2001; 2001US-0335059P.
PR
XX 05-DEC-2001; 2001US-0337055P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX (BLAT) BLATT L.
PA (MACE) MACEJAK D.
PA (MCSW) MCSWIGGEN J.
PA (MORR) MORRISSEY D.
PA (PASC) PAVCO P.
PA (LEEP) LEE P.
PA (DRAP) DRAPER K.
PA (ROBE) ROBERTS E.
PA

```

XX PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX PI Draper K, Roberts E;
XX DR WPI; 2003-229207/22.
XX PT Novel compound useful for treating cirrhosis, liver failure,
XX PT hepatocellular carcinoma, or condition associated with hepatitis C virus
XX PT infection.
XX PS Example 1; Page 160; 387pp; English.
XX CC The present invention relates to nucleic acid molecules which modulate
XX CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
XX CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX CC as oligonucleotides that specifically bind the Enhancer I region of HBV
XX CC DNA. The nucleic acids may be used to modulate the expression of HBV
XX CC genes and HBV viral replication. Also disclosed is a method for screening
XX CC compounds and/or potential therapies directed against HBV, and compounds
XX CC that modulate the expression and/or replication of HCV. The compounds and
XX CC methods of the invention are useful for the treatment of degenerative and
XX CC disease states related to HBV and HCV infection, replication and gene
XX CC expression such as cirrhosis, liver failure, and hepatocellular
XX CC carcinoma. The present sequence represents a substrate for one of the HBV
XX CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
XX CC disclosed in the present invention
XX SQ Sequence 17 BP; 5 A; 6 C; 0 G; 0 T; 6 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
DB 16 GAAGTGTTCAGTAAGAT 1

RESULT 633
ACD51279/C
ID ACD51279 standard; RNA; 17 BP.
XX AC ACD51279;
XX DT 23-SEP-2003 (first entry)
XX DE HBV hammerhead ribozyme substrate sequence #490.
XX CC Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX KW RNA stability; RNA expression; RNA synthesis; antisense;
XX KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
XX KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX KW HBV reverse transcriptase; Enhancer I region; viral replication;
XX KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX KW virucide; antiinflammatory; substrate; ss.
XX OS Hepatitis B virus.
XX PN WO200281494-A1.
XX PD 17-OCT-2002.
XX PF 26-MAR-2002; 2002WO-US0009187.
XX PR 26-MAR-2001; 2001US-00817879.
XX PR 08-JUN-2001; 2001US-00877478.
XX PR 08-JUN-2001; 2001US-0296876P.
XX PR 24-OCT-2001; 2001US-0335059P.

```

```

PR 05-DEC-2001; 2001US-0337055P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX PI Draper K, Roberts E;
XX DR WPI; 2003-229207/22.
XX PT Novel compound useful for treating cirrhosis, liver failure,
XX PT hepatocellular carcinoma, or condition associated with hepatitis C virus
XX PT infection.
XX PS Example 1; Page 145; 387pp; English.
XX CC The present invention relates to nucleic acid molecules which modulate
XX CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
XX CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX CC as oligonucleotides that specifically bind the Enhancer I region of HBV
XX CC DNA. The nucleic acids may be used to modulate the expression of HBV
XX CC genes and HBV viral replication. Also disclosed is a method for screening
XX CC compounds and/or potential therapies directed against HBV, and compounds
XX CC that modulate the expression and/or replication of HCV. The compounds and
XX CC methods of the invention are useful for the treatment of degenerative and
XX CC disease states related to HBV and HCV infection, replication and gene
XX CC expression such as cirrhosis, liver failure, and hepatocellular
XX CC carcinoma. The present sequence represents a substrate for one of the HBV
XX CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
XX CC disclosed in the present invention
XX SQ Sequence 17 BP; 5 A; 5 C; 0 G; 0 T; 7 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
DB 17 GAAGTGTTCAGTAAGAT 2

RESULT 634
ACD67550/C
ID ACC67550 standard; DNA; 17 BP.
XX AC ACC67550;
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4797.
XX KW Cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW .schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.

```

XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX PS Disclosure; Page 591; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX SQ Sequence 17 BP; 2 A; 11 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3543 AGGGGTGGGAGGGAAT 3558
DB 17 AGGGGTGGGAGGGAAT 2
|||||||

RESULT 635
ACC66247
ID ACC66247 standard; DNA; 17 BP.
XX AC ACC66247;
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 3494.
XX KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.

XX PS Disclosure; Page 439; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX SQ Sequence 17 BP; 5 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2980 GATCATTCTCCAGAGG 2995
DB 1 GATCATTCTCCAAAGG 16
|||||||

RESULT 636
ADB40449/C
ID ADB40449 standard; DNA; 17 BP.
XX AC ADB40449;
XX DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX DE Tumour suppression/reversion associated nucleotide #772.
XX KW cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX OS Homo sapiens.
XX PN WO2003040369-A2.
XX PD 15-MAY-2003.
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-441574/41.
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX PS Disclosure; Page 122; 771pp; French.
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as

CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX Sequence 17 BP; 2 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 CTGCCAGAGCAGCTC 2741
DB 16 CTGCCAGAGCAGATC 1

RESULT 637
ADB43561/c
ID ADB43561 standard; DNA; 17 BP.
XX ADB43561;
AC ADB43561;
XX 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX Tumour suppression/reversion associated nucleotide #3884.
DE cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX Homo sapiens.
OS WO2003040369-A2.
XX 15-MAY-2003.
PD 17-SEP-2002; 2002WO-IB004219.
XX 17-SEP-2001; 2001FR-00011981.
XX (MOLE-) MOLECULAR ENGINES LAB.
PA Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumours and viral infection, also related
PT polypeptide and antibodies.
XX Disclosure; Page 486; 771pp; French.
PS The invention relates to the isolation of 6327 nucleotide sequences.
XX fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment

CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX Sequence 17 BP; 9 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2135 TTCTTCTACTTGCTC 2150
DB 16 TTCTTCTACTTGATC 1

RESULT 638
ADC38437/c
ID ADC38437 standard; DNA; 17 BP.
XX ADC38437;
AC ADC38437;
XX 18-DEC-2003 (first entry)
DT Human AMLP1b scanning 17-mer oligonucleotide SEQ ID NO:786.
XX human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1b; ss.
XX Synthetic.
OS Homo sapiens.
XX WO2003037931-A2.
PN 08-MAY-2003.
XX 01-NOV-2002; 2002WO-US035129.
XX 01-NOV-2001; 2001US-0334773P.
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
PA Shannon M, Phan T;
XX WPI; 2003-430501/40.
XX New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX Example 2; SEQ ID NO 786; 172pp; English.
PS The present invention describes the human angiominotin-like protein 1
XX (AMLP1). human AMLP1 has cytostatic activity, and can be used in Gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1b, which is used in an example from the
CC present invention.
XX Sequence 17 BP; 6 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2209 AAGAACCTTCTCTCT 2224
DB 16 AAGAACCTTCTCTCT 1

```

RESULT 639
ADC38436/C
ID   ADC38436 standard; DNA; 17 BP.
XX
AC   ADC38436;
XX
DT   18-DEC-2003 (first entry)
XX
DE   Human AMLP1b scanning 17-mer oligonucleotide SEQ ID NO:785.
XX
KW   human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX   AMLP1b; ss.
XX
OS   Synthetic.
XX   Homo sapiens.
XX
PN   WO2003037931-A2.
XX
PD   08-MAY-2003.
XX
PF   01-NOV-2002; 2002WO-US035129.
XX
PR   01-NOV-2001; 2001US-0334773P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Shannon M, Phan T;
XX
DR   WPI; 2003-430501/40.
XX
PT   New isolated nucleic acid molecule encoding a human angiominotin-like
XX   protein, useful for treating or preventing a disorder associated with
XX   decreased or increased expression or activity of AMLP1.
XX
PS   Example 2; SEQ ID NO 785; 172pp; English.
XX
CC   The present invention describes the human angiominotin-like protein 1
XX   (AMLP1). Human AMLP1 has cytostatic activity, and can be used in gene
XX   therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
XX   compositions of the present invention can be used for treating or
XX   preventing a disorder associated with decreased or increased expression
XX   or activity of AMLP1. The present sequence represents a scanning
XX   oligonucleotide for human AMLP1b, which is used in an example from the
XX   present invention.
XX
SQ   Sequence 17 BP; 6 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
      Query Match      0.4%; Score 14.4; DB 1; Length 17;
      Best Local Similarity 93.8%; Pred. No. 2.6e+02;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY   2209 AAGAACCTTCTCTCTCT 2224
      |||||
DB   17 AAGAACCTTCTCTCTCT 2

RESULT 640
ADB44625/C
ID   ADB44625 standard; DNA; 17 BP.
XX
AC   ADB44625;
XX
DT   18-DEC-2003 (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #4948.
XX
KW   cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;
XX   primer; probe; tumour suppression; tumour reversion; apoptosis;
XX   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX   diagnosis.
XX

```

```

OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A, Amson R, Tuijnder M;
XX   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
XX   useful e.g. for treatment of tumors and viral infection, also related
XX   polypeptide and antibodies.
XX
PS   Disclosure; Page 610; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
XX   fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX   sequence having at least 80% identity, after optimal alignment, with the
XX   nucleotides, a sequence that hybridizes under stringent conditions with
XX   the nucleotides, or the complement, or corresponding RNA, of the
XX   nucleotides. The nucleotides are used as probes or primers for detecting,
XX   identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX   sense and antisense sequences, of nucleotides involved in tumour
XX   suppression or reversion, apoptosis and or viral resistance, to produce
XX   recombinant polypeptides, and to prepare transgenic animals, as
XX   experimental models. The nucleotides (also vectors containing them and
XX   calls containing the vectors), the encoded polypeptides and antibodies
XX   (Ab) against the polypeptide are useful for prevention and/or treatment
XX   of viral infections or diseases characterized by development of tumours
XX   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX   Analysis of the expression of the nucleotides can be used for diagnosis
XX   and/or prognosis of these diseases. The nucleotides and polypeptides can
XX   also be used to screen for their specific interactive molecules,
XX   potentially useful for treating diseases associated with abnormal
XX   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
      Query Match      0.4%; Score 14.4; DB 1; Length 17;
      Best Local Similarity 93.8%; Pred. No. 2.6e+02;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY   2726 CTGCCAGACGAGCTC 2741
      |||||
DB   16 CTGCCAGACGAGATC 1

RESULT 641
ADB44779/C
ID   ADB44779 standard; DNA; 17 BP.
XX
AC   ADB44779;
XX
DT   18-DEC-2003 (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #5102.
XX
KW   cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;
XX   primer; probe; tumour suppression; tumour reversion; apoptosis;
XX   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX

```


PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 628; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and/or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2061 TCAGAAGACCTGGAAC 2076
Db 16 TCAGAAGACCTGGATC 1
RESULT 642
ADI48646/c
XX ADI48646 standard; DNA; 17 BP.
XX
AC ADI48646;
XX
XX 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID1149.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX WPI; 2003-313354/30.

PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313354/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; SEQ ID NO 1149; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC nontropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterized by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 9 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2135 TTTCTTCTACTTGTC 2150
Db 16 TTTCTTCTACTTGATC 1
RESULT 643
ADI52768/c
XX ADI52768 standard; DNA; 17 BP.
XX
AC ADI52768;
XX
XX 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID5271.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.

PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
XX

PS Disclosure; SEQ ID NO 5271; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumor suppression, tumor reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virocidic, neuroprotective,
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterized by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences

XX SQ Sequence 17 BP; 5 A; 2 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3660 ACAATATAAAAGTGAT 3675
||| ||||| |||||
Db 17 ACATATATAAAAGTGAT 2

RESULT 644

ABZ95554

ID ABZ95554 standard; DNA; 17 BP.

AC ABZ95554;

XX 17-OCT-2003 (first entry)

XX Human endothelial nitric oxide synthase antisense fragment no.1418.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200295308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shanabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

PS Disclosure; SEQ ID NO 10796; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine or
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 17 BP; 0 A; 9 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 409 GGCCTCTCTCCGGCCG 424
||||| ||||| |||||
Db 1 GGCCTCTCTCCGGCCG 16

RESULT 645

ACC52427/c

ID ACC52427 standard; DNA; 17 BP.

AC ACC52427;

XX 27-JUN-2003 (first entry)

XX Human tumour suppressor sequence #1194.

XX ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.

XX Homo sapiens.

XX PR2826373-A1.

XX 27-DEC-2002.

XX 20-JUN-2001; 2001FR-00008139.

XX 20-JUN-2001; 2001FR-00008139.

XX (MOLE-) MOLECULAR ENGINES LAB SA.

XX Tuijnder M, Telerman A, Anson R;

XX WPI; 2003-250498/25.

XX New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.

XX Claim 1; Page 316; 798pp; French.

XX This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%

RESULT 647
ACC54057/C

```

XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX DR WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 2303; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
      Query Match 0.4%; Score 14.4; DB 1; Length 17;
      Best Local Similarity 93.8%; Pred. No. 2.6e+02;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 846 TGTATTCCTCTGCAG 861
DB 17 TGTACTCCTCTGCAG 2

RESULT 649
ADL49404
ID ADL49404 standard; RNA; 17 BP.
XX AC ADL49404;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #518.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

```

```

XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX DR WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 2937; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX SQ Sequence 17 BP; 1 A; 1 C; 0 G; 0 T; 15 U; 0 Other;
      Query Match 0.4%; Score 14.4; DB 1; Length 17;
      Best Local Similarity 6.2%; Pred. No. 2.6e+02;
      Matches 1; Conservative 14; Mismatches 1; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTCTTTT 2586
DB 1 UUAUUCUUUUUUUUU 16

RESULT 650
ADL48771/c
ID ADL48771 standard; RNA; 17 BP.
XX AC ADL48771;
XX DT 20-MAY-2004 (first entry)
XX DE Human IKK-gamma substrate sequence #1281.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.

```

```

XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX DR WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 2304; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
    Query Match 0.4%; Score 14.4; DB 1; Length 17;
    Best Local Similarity 93.8%; Pred. No. 2.6e+02;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 846 TGTATTCCTCTGCAG 861
DB 16 TGTACTCCTCTGCAG 1
RESULT 651
ADL49406
ID ADL49406 standard; RNA; 17 BP.
XX AC ADL49406;
XX AC ADL49406;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #520.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.

```

```

XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX DR WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 2939; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human PKR
XX CC substrate sequence.
XX SQ Sequence 17 BP; 1 A; 1 C; 0 G; 0 T; 15 U; 0 Other;
    Query Match 0.4%; Score 14.4; DB 1; Length 17;
    Best Local Similarity 6.2%; Pred. No. 2.6e+02;
    Matches 1; Conservative 14; Mismatches 1; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTCTTTT 2586
DB 2 UUCUUUUUUUUUUU 17
RESULT 652
ADL49403
ID ADL49403 standard; RNA; 17 BP.
XX AC ADL49403;
XX AC ADL49403;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #517.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.

```

XX OS Unidentified.
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX DR WPI; 2003-058513/05.

XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX PS Claim 59; SEQ ID NO 2936; 317pp; English.

XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.

XX SQ Sequence 17 BP; 1 A; 1 C; 0 G; 0 T; 15 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 6.2%; Pred. No. 2.6e+02;
 Matches 1; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2571 TTCTCTCTTTT TTTT 2586

Db 2 UUAUUCUUUUUUUUU 17

RESULT 653

ADL49407

ID ADL49407 standard; RNA; 17 BP.

XX AC ADL49407;

XX DT 20-MAY-2004 (first entry)

XX DE Human PKR substrate sequence #521.

XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX OS Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX DR WPI; 2003-058513/05.

XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 59; SEQ ID NO 2940; 317pp; English.

XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.

XX SQ Sequence 17 BP; 0 A; 1 C; 0 G; 0 T; 16 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 6.2%; Pred. No. 2.6e+02;
 Matches 1; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2571 TTCTCTCTTTT TTTT 2586

Db 1 UUCUUUUUUUUUUU 16

RESULT 654

ADL51485

ID ADL51485 standard; RNA; 17 BP.

XX AC ADL51485;

XX DT 20-MAY-2004 (first entry)

XX DE Human PTGDR substrate sequence #604.

XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
 KW substrate; ds.

```

XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013143.
XX PR 24-APR-2001; 2001US-0286036P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX NYce JW, Li Y, Sandrasaga A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 10796; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX SQ Sequence 17 BP; 0 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3467 GAATTCCTGCTATTTT 3482
Db 1 GAAUUCUGGCUAUUUU 16
||||:||||:|
3467 GAATTCCTGCTATTTT 3482
1 GAAUUCUGGCUAUUUU 16
RESULT 655
ABD19704
ID ABD19704 standard; DNA; 17 BP.
XX AC ABD19704;
XX 29-JUL-2004 (first entry)
XX Human endothelial nitric oxide synthase fragment 1418.
DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ds.
XX Homo sapiens.
XX OS

```

```
DE Hepatitis B virus (HBV) RNA target sequence #523.
XX
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX Hepatitis B virus.
XX
XX US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX 15-JAN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
XX 07-FEB-1994; 94US-00193627.
XX 08-NOV-1999; 99US-00436430.
XX 20-MAR-2000; 2000US-00531025.
XX 09-AUG-2000; 2000US-00636385.
XX 24-OCT-2000; 2000US-00696347.
XX 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 523; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 5 A; 5 C; 0 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 0.4%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 2.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2647 GAAGTGTGTGACAAAGAT 2662
XX 17 GAAGTGTGTGATAAGAT 2
XX
XX RESULT 657
XX ADM59105/c
XX ID ADM59105 standard; RNA; 17 BP.
XX
XX ADM59105;
XX
XX 03-JUN-2004 (first entry)
XX
XX Hepatitis B virus (HBV) RNA target sequence #1239.
XX
```

```
XX
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX Hepatitis B virus.
XX
XX US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX 15-JAN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
XX 07-FEB-1994; 94US-00193627.
XX 08-NOV-1999; 99US-00436430.
XX 20-MAR-2000; 2000US-00531025.
XX 09-AUG-2000; 2000US-00636385.
XX 24-OCT-2000; 2000US-00696347.
XX 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 523; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 5 A; 5 C; 0 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 0.4%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 2.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2647 GAAGTGTGTGACAAAGAT 2662
XX 17 GAAGTGTGTGATAAGAT 2
XX
XX RESULT 657
XX ADM59105/c
XX ID ADM59105 standard; RNA; 17 BP.
XX
XX ADM59105;
XX
XX 03-JUN-2004 (first entry)
XX
XX Hepatitis B virus (HBV) RNA target sequence #1239.
XX
```

```
XX
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX Hepatitis B virus.
XX
XX US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX 15-JAN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
XX 07-FEB-1994; 94US-00193627.
XX 08-NOV-1999; 99US-00436430.
XX 20-MAR-2000; 2000US-00531025.
XX 09-AUG-2000; 2000US-00636385.
XX 24-OCT-2000; 2000US-00696347.
XX 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 1239; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 5 A; 6 C; 0 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 0.4%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 2.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2647 GAAGTGTGTGACAAAGAT 2662
XX 16 GAAGTGTGTGATAAGAT 1
XX
XX RESULT 658
XX AAZ65422/c
XX ID AAZ65422 standard; DNA; 18 BP.
XX
XX AAZ65422;
XX
XX 10-APR-2000 (first entry)
XX
XX Human CD71 phosphorothioate antisense oligonucleotide SEQ ID NO:73.
XX
```


KW Human; CD71; transferrin receptor; antisense; phosphorothioate;
KW antiproliferative; anticancer; anti-inflammatory; gene therapy; ss.
XX
OS Homo sapiens.
XX
XX US6004814-A.
XX
XX 21-DEC-1999.
XX
XX 25-SEP-1998; 98US-00161244.
XX
XX 25-SEP-1998; 98US-00161244.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Cowsett LM;
XX
XX WPI; 2000-105082/09.
XX
XX Antisense oligonucleotides targeted to genes encoding CD71, useful for
XX preventing, diagnosing and treating inflammatory disorders and tumors.
XX
XX Example 15; Col 28; 34pp; English.
XX
XX Sequences AAZ65357-265440 represent novel phosphorothioate antisense
XX oligonucleotides targeted against the human CD71 gene, which encodes the
XX CD71 transferrin receptor. Upon uptake in the small intestine, iron
XX immediately combines with the ubiquitous serum protein transferrin, the
XX primary vehicle by which iron is transported around the body. The uptake
XX of circulating iron-transferrin complexes is mediated by the transferrin
XX receptor, CD71. The requirement of both iron-transferrin complexes and
XX CD71 for cell proliferation suggests that inhibition of iron utilisation
XX could represent a strategy for the treatment of cancer. The
XX oligonucleotides may be used in the treatment of an animal suspected of
XX having a disease or disorder which can be treated by inhibition of CD71
XX expression. Use of the antisense compounds and methods of the invention
XX may also be useful prophylactically to prevent or delay infection,
XX inflammation or tumour formation. The antisense compounds may
XX additionally be useful for research and as diagnostic tools. The
XX antisense oligonucleotides provide a tool for effectively downregulating
XX CD71 expression. Prior art methods utilised antibodies specific for CD71
XX proteins; however, this resulted in the development of resistant tumour
XX cells, due to the development of mutations in CD71 which altered the
XX epitope recognised by the antibodies
XX
XX Sequence 18 BP; 4 A; 4 C; 2 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 358 ATTGAAGAGAGCCAG 373
DB 18 ATTGAAGAGAGCCAG 3
XX
RESULT 659
AAZ76984/C
ID AAZ76984 standard; DNA; 18 BP.
XX
XX AAZ76984;
XX
XX 10-SEP-2001 (first entry)
XX
XX Human biallelic marker downstream amplification primer SEQ ID NO:11340.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation;
XX amplification; single nucleotide polymorphism; SNP; PCR primer;
XX diagnosis; ss.
XX
XX Homo sapiens.

XX WO9954500-A2.
XX 28-OCT-1999.
XX
XX 21-APR-1999; 99WO-IB000822.
XX
XX 21-APR-1998; 98US-0082614P.
XX 23-NOV-1998; 98US-0109732P.
XX (GEST) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX WPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 9; Page 2648; 2745pp; English.
XX
XX AAZ65554 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. the SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX
XX Sequence 18 BP; 6 A; 6 C; 2 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1072 GAACATTCGATTG 1087
DB 16 GAACATTCGATTG 1
XX
RESULT 660
ADE14090
ID ADE14090 standard; DNA; 18 BP.
XX
XX ADE14090;
XX
XX 29-JAN-2004 (first entry)
XX
XX Optineurin promoter motif, repeat element or regulatory region #199.
XX
XX Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
XX SNP; glaucoma; progressive ocular hypertensive disorder;
XX glaucoma related disorder; motif; repeat element; regulatory region.
XX
XX Homo sapiens.
XX
XX US2003190617-A1.
XX
XX 09-OCT-2003.
XX
XX 06-MAR-2002; 2002US-00091281.
XX
XX 06-MAR-2002; 2002US-00091281.
XX
XX (SIEE/) SI E.

PA (RAYM/) RAYMOND V.
PA (MORI/) MORISSETTE J.
XX
XX
XX Raymond V, Morissette J, Si E;
XX
XX WPI; 2003-864168/80.
XX
XX New nucleic acid sequences of the optineurin gene are useful to detect
PT polymorphisms particularly single nucleotide polymorphisms in the
PT optineurin promoter to diagnose, prognose and treat glaucoma and related
PT disorders.
XX
XX Claim 11; SEQ ID NO 201; 159pp; English.
XX
XX The invention relates to an isolated nucleic acid (NU) comprising at
CC least 20 but not more than 1500 consecutive nucleotides of the optineurin
CC promoter appearing as ADE13890. Also included are the optineurin promoter
CC operably linked to a heterologous nucleic acid, a nucleic acid capable of
CC detecting a single nucleotide polymorphism (SNP) in the optineurin
CC promoter, a host cell comprising the promoter operably linked to a
CC heterologous sequence, diagnosing or prognosing glaucoma in a sample
CC obtained from a cell or bodily fluid (comprising detecting a polymorphism
CC in a promoter region of the optineurin gene, associated with a glaucoma
CC phenotype), detecting a SNP sequence variation in a sample containing
CC DNA, detecting the presence of an optineurin promoter sequence variation
CC in a sample containing DNA, determining the presence or increased
CC susceptibility to glaucoma or to a progressive ocular hypertensive
CC disorder resulting in loss of visual field in a patient (or the severity
CC or progression of glaucoma in a patient, comprising providing
CC amplification reaction primers that direct amplification of a selected
CC nucleic acid region containing the variation within the optineurin
CC promoter and amplifying the DNA) and detecting a polymorphism (comprising
CC obtaining a sample containing human genomic DNA, providing a nucleic acid
CC capable of detecting a SNP located within an optineurin promoter, and
CC detecting the polymorphism). The invention is used to diagnose and
CC prognose glaucoma and also to treat glaucoma related disorders. The
CC present sequence is an optineurin promoter motif, repeat element or
CC putative regulatory region.
XX
XX Sequence 18 BP; 9 A; 3 C; 5 G; 1 T; 0 U; 0 Other;
SQ

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1827 GGGAAACACACAGGCACA 1842
DB 2 GGGAAACACACAGGCACA 17
|||||
RESULT 661
AAA84872
ID AAA84872 standard; DNA; 19 BP.
XX
XX AAA84872;
XX
XX 04-DEC-2000 (first entry)
XX
XX Cyclin F ribozyme binding site #140.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX Mammalia.
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US028772.
XX
XX 04-DEC-1998; 98US-0110954P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX
XX Disclosure; Page 83; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
XX Sequence 19 BP; 5 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
SQ

XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX
XX Disclosure; Page 83; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
XX Sequence 19 BP; 5 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
SQ

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 324 GGGAGAGATTCGATTC 339
DB 2 GGGAGAGATTCGAGTCC 17
|||||
RESULT 662
AAA84873
ID AAA84873 standard; DNA; 19 BP.
XX
XX AAA84873;
XX
XX 04-DEC-2000 (first entry)
XX
XX Cyclin F ribozyme binding site #141.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX Mammalia.
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US028772.
XX
XX 04-DEC-1998; 98US-0110954P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX
XX Disclosure; Page 83; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX

```

XX SQ Sequence 19 BP; 5 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 324 GGGAGATTCGATTC 339
Db |||||
1 GGGAGATTCGATTC 16

RESULT 663
AAH43421/c
ID AAH43421 standard; DNA; 19 BP.
XX
AC AAH43421;
XX
DT 04-DEC-2001 (first entry)
XX
DE ISA3 reverse primer.
XX
KW European; infectious Salmon anaemia; ISA; antigen; RNA segment 3; virus;
KW ISA; nucleoprotein; vaccine; fish; infection; primer; amplify;
KW polymerase chain reaction; PCR; ss.
XX
OS Synthetic.
XX
PN WO200166569-A1.
XX
PD 13-SEP-2001.
XX
PF 08-MAR-2001; 2001WO-GB001013.
XX
PR 08-MAR-2000; 2000GB-00005457.
PR 14-MAR-2000; 2000GB-00005960.
PR 01-DEC-2000; 2000GB-00029409.
XX
PA (UYAB-) UNIV ABERDEEN.
XX
PI Melvin WT, Breeman S, Labus MB;
XX
DR WPI; 2001-589927/66.
XX
PT Vaccinating fish against Infectious Salmon Anemia (ISA) virus infection
PT using European ISA virus antigen polypeptides.
XX
PS Claim 34; Page 34; 41pp; English.
XX
CC The sequences given in AAH43407-21 are primers which were used in the
CC amplification and cloning of the cDNA encoding the European infectious
CC Salmon anaemia (ISA) antigen polypeptide. The antigen is cloned from RNA
CC segment 3 of ISA virus (ISAV) and is believed to be a major cell culture
CC antigen of the virus, which may be a nucleoprotein. The ISA antigen, or a
CC fragment of it, may be used to vaccinate fish against ISA infection. It
CC may also be used to screen fish for ISA virus infection
XX
SQ Sequence 19 BP; 5 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1567 CATTGACATTCAC 1582
Db |||||
17 CATTGACATTCAC 2

RESULT 664
AAS05869/c
ID AAS05869 standard; DNA; 19 BP.
XX
AC AAS05869;

XX SQ Sequence 19 BP; 6 A; 1 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2469 ATCCCTACCTTAGTTC 2484
Db |||||
16 ATCCCTCCCTTAGTTC 1

RESULT 665
AAH60034
ID AAH60034 standard; DNA; 19 BP.
XX
AC AAH60034;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin F ribozyme binding site SEQ ID NO:2458.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulvular;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;

```

```

XX 12-SEP-2001 (first entry)
XX
DE PCR primer #14, used to amplify human ABC1 gene fragments.
XX
KW Human; ABC1 gene; atherosclerosis; reverse transport; cholesterol;
KW cardiovascular; neurological; Tangier disease; LCAT deficiency;
KW lecithin-cholesterol acetyltransferase; malaria; diabetes; ss;
KW PCR primer.
XX
OS Homo sapiens.
XX
PN WO200130848-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-EP010886.
XX
PR 26-OCT-1999; 99EP-00402668.
PR 01-MAR-2000; 2000US-0186260P.
XX
PA (AVET) AVENTIS PHARMA SA.
XX
PI Deneffe P, Rosier-Montus M, Arnould-Reguigne I, Prades C;
PI Naudin L, Lemoine C, Duverger N, Jaye M, Searfoss GH, Remaley A;
PI Brewer HB, Dean M;
XX
DR WPI; 2001-316327/33.
XX
PT New human ABC1 nucleic acids and polypeptides for treating
PT atherosclerosis, malaria and diabetes.
XX
PS Claim 14; Page 360; 368pp; English.
XX
CC The sequence represents PCR primer #14, used to amplify human ABC1 gene
CC fragments. The ABC1 nucleic acid sequence, primers and probes derived
CC from the sequence, and polypeptides and vectors are useful for the
CC prevention of atherosclerosis in a subject affected by a dysfunction in
CC the reverse transport of cholesterol. The polypeptide encoded by the ABC1
CC gene is useful for screening for an active ingredient for the prevention
CC or treatment of a disease resulting from dysfunction in the reverse
CC transport of cholesterol. The nucleic acids and polypeptides are also
CC useful for treating and preventing cardiovascular and neurological
CC pathologies, and other diseases e.g. Tangier disease, lecithin-
CC cholesterol (LCAT) deficiency, malaria and diabetes
XX
SQ Sequence 19 BP; 6 A; 1 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2469 ATCCCTACCTTAGTTC 2484
Db |||||
16 ATCCCTCCCTTAGTTC 1

RESULT 665
AAH60034
ID AAH60034 standard; DNA; 19 BP.
XX
AC AAH60034;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin F ribozyme binding site SEQ ID NO:2458.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulvular;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;

```

KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200130362-A2.
 XX 03-MAY-2001.
 XX 26-OCT-2000; 2000WO-US029500.
 XX 26-OCT-1999; 99US-0161532P.
 XX (IMMU-) IMMUSOL INC.
 XX Robbins JM, Tritz R;
 XX WPI; 2001-300427/31.
 XX Treating proliferative skin or eye diseases and scarring, using ribozymes
 PT that cleave RNA encoding cytokines involved in inflammation, matrix
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.
 XX Example 1; Page 250; 408pp; English.
 XX The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
 CC ophthalmological, vulnery, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention
 XX Sequence 19 BP; 5 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 3.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 324 GGGAGAGATTCGATCC 339
 |||||
 DB 2 GGGAGAGATTCGATCC 17
 |||||
 RESULT 666
 AAH60035
 ID AAH60035 standard; DNA; 19 BP.
 XX
 AC AAH60035;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Cyclin F ribozyme binding site SEQ ID NO:2459.
 XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnery;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;

KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200130362-A2.
 XX 03-MAY-2001.
 XX 26-OCT-2000; 2000WO-US029500.
 XX 26-OCT-1999; 99US-0161532P.
 XX (IMMU-) IMMUSOL INC.
 XX Robbins JM, Tritz R;
 XX WPI; 2001-300427/31.
 XX Treating proliferative skin or eye diseases and scarring, using ribozymes
 PT that cleave RNA encoding cytokines involved in inflammation, matrix
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.
 XX Example 1; Page 250; 408pp; English.
 XX The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
 CC ophthalmological, vulnery, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention
 XX Sequence 19 BP; 5 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 3.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 324 GGGAGAGATTCGATCC 339
 |||||
 DB 1 GGGAGAGATTCGATCC 16
 |||||
 RESULT 667
 ACD06398/c
 ID ACD06398 standard; DNA; 19 BP.
 XX
 AC ACD06398;
 XX
 DT 06-AUG-2003 (first entry)
 XX
 DE Forward RT-PCR primer for human NOV30c.
 XX Human; ss; PCR; NOVX; cardiomyopathy; atherosclerosis; hypertension;
 KW congenital heart defect; prostate cancer; diabetes; metabolic disorder;

KW neoplasm; graft versus host disease; AIDS; bronchial asthma; primer;
 KW Crohn's disease; multiple sclerosis; infectious disease; anorexia;
 KW cancer-associated cachexia; neurodegenerative disorder; RT-PCR;
 KW Alzheimer's disease; Parkinson's disease; immune disorder;
 KW haematopoietic disorder; dyslipidaemia; wasting disorder; gene therapy;
 KW reverse transcriptase PCR.
 XX
 OS Homo sapiens.
 XX
 PN WO2003023008-A2.
 XX
 PD 20-MAR-2003.
 XX
 PF 09-SEP-2002; 2002WO-US028596.
 XX
 PR 07-SEP-2001; 2001US-0318120P.
 PR 07-SEP-2001; 2001US-0318130P.
 PR 10-SEP-2001; 2001US-0318430P.
 PR 12-SEP-2001; 2001US-0318765P.
 PR 17-SEP-2001; 2001US-0322781P.
 PR 17-SEP-2001; 2001US-0322816P.
 PR 19-SEP-2001; 2001US-0323519P.
 PR 20-SEP-2001; 2001US-0323631P.
 PR 20-SEP-2001; 2001US-0323636P.
 PR 25-SEP-2001; 2001US-0324969P.
 PR 25-SEP-2001; 2001US-0325091P.
 PR 26-SEP-2001; 2001US-0324990P.
 PR 15-FEB-2002; 2002US-0357303P.
 PR 28-FEB-2002; 2002US-0360973P.
 PR 20-MAR-2002; 2002US-0366131P.
 PR 25-MAR-2002; 2002US-0367753P.
 PR 02-APR-2002; 2002US-0369479P.
 PR 10-MAY-2002; 2002US-0379532P.
 PR 17-MAY-2002; 2002US-0381664P.
 PR 17-MAY-2002; 2002US-0381672P.
 PR 28-MAY-2002; 2002US-0383651P.
 PR 29-MAY-2002; 2002US-0384012P.
 PR 19-JUN-2002; 2002US-0390155P.
 PR 06-SEP-2002; 2002US-00390155.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Zhong M, Li L, Gorman L, Spytek KA, Kekuda R, Taupier RJ;
 PI Anderson DW, Vernet CAM, Catterton E, Miller CE, Shenoy SG;
 PI Patturajan M, Pena CE, Tchernev VT, Padigaru M, Gusev VI;
 PI Malvankar UM, Burgess CE, Gerlach VL, Casman SJ, Rieger DK;
 PI Grose WM, Smithson G, Peyman JA, Starling G, Rothenberg ME;
 PI Larochelle WJ, Shimkets RA, Crabtree J, Rastelli L, Voss EZ;
 PI Boldog FL, Edinger SR, Millet I, Macdougall JR, Ellerman K;
 PI Chapoval A;
 DR WPI; 2003-313246/30.
 XX
 XX New polypeptides and polynucleotides having properties related to
 PT stimulation of biochemical or physiological responses in a cell or
 PT tissue, useful for diagnosing or preventing e.g. atherosclerosis,
 PT hypertension, prostate cancer.
 XX
 PS Example C; Page 411; 849pp; English.
 XX
 CC The invention relates to an isolated polypeptide comprising one of 127
 CC sequences (appearing as ABO1288-ABO1414) designated as NOVX, a mature
 CC form of NOVX, an amino acid sequence which is at least 95% identical to
 CC NOVX or an amino acid sequence comprising one or more conservative
 CC substitutions in NOVX. Also included are nucleic acids encoding NOVX
 CC proteins, determining the presence or amount of NOVX or NOVX DNA in a
 CC sample (by introducing the sample to an antibody that binds
 CC immunospecifically to the polypeptide, and determining the presence or
 CC amount of antibody bound to the polypeptide), determining the presence of
 CC or predileposition to a disease associated with altered levels of
 CC expression of NOVX or NOVX DNA in a first mammalian subject, identifying
 CC an agent that binds to NOVX, identifying a potential therapeutic agent
 CC for treatment of a pathology related to aberrant expression or aberrant

CC physiological interactions of NOVX, screening for a modulator of activity
 CC of or of latency or predileposition to a pathology associated with NOVX, a
 CC vector comprising NOVX DNA, a cell comprising the vector (used to produce
 CC NOVX) and an anti-NOVX antibody. The NOVX nucleic acids and polypeptides
 CC are useful as a marker for cell or tissue type, and in diagnosing and
 CC treating pathologies, diseases, conditions or disorders associated with
 CC NOVX sequences, including cardiomyopathy, atherosclerosis, hypertension,
 CC congenital heart defects, prostate cancer, diabetes, metabolic disorders,
 CC neoplasm, graft versus host disease, AIDS, bronchial asthma, Crohn's
 CC disease, multiple sclerosis, infectious diseases, anorexia, cancer-
 CC associated cachexia, neurodegenerative disorders (e.g. Alzheimer's
 CC disease or Parkinson's disease), immune disorders, haematopoietic
 CC disorders, dyslipidaemias, and wasting disorders associated with chronic
 CC diseases. These may also be used to screen for molecules which inhibit or
 CC enhance NOVX activity or function, and for detecting specific cell types.
 CC These may also be used in chromosome mapping, gene therapy, tissue
 CC typing, and in forensic biology. The present sequence is a reverse
 CC transcriptase (RT)-PCR primer used to assess the tissue specific
 CC expression of mRNA encoding a NOVX protein
 XX
 SQ Sequence 19 BP; 6 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 3.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2457 AGCTGGCACATTATCC 2472

Db 17 AGCTGGCACCTTATCC 2

RESULT 668

ADF68242/C

ID ADF68242 standard; DNA; 19 BP.

AC ADF68242;

DT 12-FEB-2004 (first entry)

DE Human antisense XIAP nucleobase oligomer SEQ ID NO:87.

KW nucleobase oligomer; inhibitor-of apoptosis inhibitor; IAP inhibitor;
 KW cytosolic; antisense therapy; apoptosis enhancer; cancer;
 KW lymphoproliferative disorder; leukaemia; myelodysplastic syndrome;
 KW polycythemia vera; lymphoma; Hodgkin's disease;
 KW Waldenstrom's macroglobulinemia; breast cancer; basal cell carcinoma;
 KW lung carcinoma; melanoma; retinoblastoma; human; ss.

OS Synthetic.

OS Homo sapiens.

XX Key Location/Qualifiers

FT misc_feature 1..19

FT /tag= a

FT /note= "N = T or U where each nucleobase may be part of a
 FT ribonucleotide, deoxyribonucleotide, or nucleotide
 FT analogue"

XX WO2003080638-A2.

XX 02-OCT-2003.

XX 27-MAR-2003; 2003WO-IB001670.

XX 27-MAR-2002; 2002US-0367853P.

XX (AEGE-) AEGERA THERAPEUTICS INC.

XX Lacasse E, Mcmanus D, Durkin JP;

XX WPI; 2003-779241/73.

XX New nucleobase oligomers that inhibit expression of inhibitor of

PT apoptosis gene, useful for treating cancer and other lymphoproliferative
 XX disorders by inducing apoptosis.
 PS Claim 54; SEQ ID NO 87; 259pp; English.

XX The present invention describes a substantially pure nucleobase oligomer

CC (I) of up to 30 nucleobases in length or comprising eleven DNA residues
 CC flanked on each side by four 2'-O-methyl RNA residues that inhibits the
 CC expression of an inhibitor-of apoptosis (IAP) in the cell. Also
 CC described: (1) a pharmaceutical composition (I) comprising (I) and a
 CC carrier; (2) a catalytic RNA molecule (III) capable of cleaving XIAP,
 CC HIAP1, or HIAP2 mRNA; (3) an expression vector (IV) comprising a nucleic
 CC acid encoding one or more (III) positioned for expression in a mammalian
 CC cell; (4) a double-stranded RNA molecule (IV) consisting of 21-29
 CC nucleobases, comprising at least eight consecutive nucleobases
 CC corresponding to a sequence comprising 19 nucleotides, as given in
 CC specification; (5) a double-stranded hairpin RNA molecule (V) consisting
 CC of 50-70 nucleobases, comprising a first domain of 21-29 nucleobases that
 CC comprise at least eight consecutive nucleobases corresponding to a
 CC sequence fully defined in the specification, comprising, e.g. 19
 CC nucleotides, and a second domain complementary to the first domain, and a
 CC loop domain situated between the first and the second domains such that
 CC the first domain and the second domain are capable of duplexing to form
 CC the double-stranded hairpin RNA molecule; and (6) an expression vector
 CC (VI) comprising a nucleic acid molecule encoding the double stranded RNA
 CC molecule positioned for expression in a mammalian cell. (I) has
 CC cytosolic activity, and can be used in antisense therapy. (I) is useful
 CC for enhancing the apoptosis of a cell in an animal, preferably human
 CC where (I) inhibits the expression of an IAP in the cell. (I) is also
 CC useful for treating an animal having a cancer or lymphoproliferative
 CC disorder. The cancer includes acute leukaemia, acute myeloblastic leukaemia,
 CC leukaemia, acute myelocytic leukaemia, acute myelomonocytic leukaemia, acute
 CC acute promyelocytic leukaemia, acute erythroleukaemia, chronic leukaemia, chronic
 CC monocytic leukaemia, acute erythroleukaemia, chronic lymphocytic
 CC myelocytic leukaemia, myelodysplastic syndrome, chronic lymphocytic
 CC leukaemia, polycythemia vera, lymphoma, Hodgkin's disease, Waldenstrom's
 CC macroglobulinemia, breast cancer, basal cell carcinoma, lung carcinoma,
 CC melanoma and retinoblastoma. The present sequence is used in the
 CC exemplification of the present invention.

SQ Sequence 19 BP; 12 A; 1 C; 3 G; 0 T; 0 U; 3 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred NO. 3.1e+02;
 Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTCTTTTCTG 2589

DB 19 TTNTCCNTTTTCTTCTG 1

RESULT 669

ADE95680

ID ADE95680 standard; DNA; 19 BP.

AC ADE95680;

XX 12-FEB-2004 (first entry)

XX Human NOVX protein-related PCR primer Ag7845 forward.

XX NOVX protein; biochemically stimulation; physiological stimulation;
 KW cardiant; antiarteriosclerotic; hypotensive; cytostatic; anorectic;
 KW antirheumatic; antiarthritic; antidiabetic; nephrotropic; dermatological;
 KW immunosuppressive; anti-HIV; antiinflammatory; neuroprotective;
 KW neutropic; antiparkinsonian; antiasthmatic; neuroleptic;
 KW antidepressant; antiallergic; gynaecological; gene therapy; vaccine;
 KW NOVX-associated disorder; cardiomyopathy; atherosclerosis; hypertension;
 KW cancer; obesity; rheumatoid arthritis; diabetes; glomerulonephritis;
 KW psoriasis; skin disorder; AIDS; inflammation; multiple sclerosis;
 KW Alzheimer's disease; Parkinson's disease; asthma; schizophrenia;
 KW depression; allergy; fertility disorder; PCR; primer; ss; Ag7845 forward.

OS Homo sapiens.

XX WO2003050245-A2.

XX 19-JUN-2003.

XX 03-DEC-2002; 2002WO-US038594.

XX 05-DEC-2001; 2001US-0336600P.

XX 07-DEC-2001; 2001US-0338285P.

XX 12-DEC-2001; 2001US-0341346P.

XX 17-DEC-2001; 2001US-0341477P.

XX 17-DEC-2001; 2001US-0341540P.

XX 20-DEC-2001; 2001US-0342592P.

XX 27-DEC-2001; 2001US-0344297P.

XX 31-DEC-2001; 2001US-0344903P.

XX 17-APR-2002; 2002US-0373288P.

XX 15-MAY-2002; 2002US-0380981P.

XX 17-MAY-2002; 2002US-0381495P.

XX 28-MAY-2002; 2002US-0383534P.

XX 28-MAY-2002; 2002US-0383744P.

XX 29-MAY-2002; 2002US-0383829P.

XX 07-AUG-2002; 2002US-0384024P.

XX 26-AUG-2002; 2002US-0406353P.

XX 31-OCT-2002; 2002US-00401788.

XX 02-DEC-2002; 2002US-00406353.

XX (CURA-) CURAGEN CORP.

XX Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Chillakuru RA;

PI Edinger SR, Gerlach VL, Gorman L, Malyankar UM, Miller CE, Murphy R;

PI Jeffers ME, Ji W, Li L, Rastelli L, Rieger DK, Shenoy SG;

PI Patturajan M, Peyman JA, Rastelli L, Rieger DK, Shenoy SG;

PI Pitturajan G, Scarling G, Taupier RJ, Voss EZ, Zhong H, Zhong M;

XX WPI; 2003-513974/48.

XX New NOVX polypeptides and nucleic acids, useful for preventing or
 PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy,
 PT atherosclerosis or diabetes, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.

XX Example B; SEQ ID NO 212; 211pp; English.

XX This invention relates to novel NOVX proteins, and the DNA sequence which
 CC encode them, having properties related to stimulation of biochemical or
 CC physiological responses in a cell, a tissue, an organ or an organism.
 CC Compounds which modulate the proteins of the invention may have cardiant,
 CC antiarteriosclerotic, hypotensive, cytostatic, anorectic, antirheumatic,
 CC antiarthritic, antidiabetic, nephrotropic, dermatological,
 CC immunosuppressive, anti-HIV, antiinflammatory, neuroprotective,
 CC neutropic, antiparkinsonian, antiasthmatic, neuroleptic,
 CC antidepressant, antiallergic or gynaecological activities. The DNA
 CC sequences of the invention may be useful for gene therapy whilst the
 CC protein sequences may allow the development of a vaccine. The protein is
 CC useful in the manufacture of a medicament for treating a syndrome
 CC associated with a human disease. The invention may be useful in
 CC diagnosing, treating or preventing NOVX-associated disorders, for example
 CC cardiomyopathy, atherosclerosis, hypertension, cancer, obesity, skin
 CC rheumatoid arthritis, diabetes, glomerulonephritis, psoriasis, skin
 CC disorders, AIDS, inflammation, multiple sclerosis, Alzheimer's disease,
 CC Parkinson's disease, asthma, schizophrenia, depression, allergies or
 CC fertility disorders. The nucleic acids may further be used as
 CC hybridisation probes, in chromosome mapping, tissue typing, preventive
 CC medicine, and pharmacogenomics. The present sequence is that of PCR
 CC primer Ag7845 forward which was used for the amplification of a human
 CC gene sequence during the analysis of gene expression in the
 CC exemplification of the invention.

XX Sequence 19 BP; 3 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

XX Query Match

0.4%; Score 14.4; DB 1; Length 19;

Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 221 GTGTGCGCTTGAGCTG 236
Db |||||||
2 GTGTGCGCTTGAGCAG 17

RESULT 670

ADM08181

ID ADM08181 standard; DNA; 19 BP.

XX AC

XX ADM08181;

XX DT

XX 20-MAY-2004 (first entry)

XX DE

XX PCR primer 1 used to amplify canine IgGH variable domain cDNA.

XX DE

XX canine; dog; heavy; immunoglobulin; antibody light chain variable domain;

XX KW

XX antiallergic; allergy; IgE; gene therapy; PCR; primer; ss; IgGH.

XX XX

XX Canis familiaris.

XX OS

XX WO2003060080-A2.

XX PN

XX 24-JUL-2003.

XX PD

XX 20-DEC-2002; 2002WO-US041362.

XX PF

XX 21-DEC-2001; 2001US-0344874P.

XX PR

XX (IDEX-) IDEX LAB INC.

XX PA

XX Krah ER, Guo H, Aiyappa A, Lawton R;

XX PI

XX WPI; 2003-598521/56.

XX DR

XX New canine heavy and light chain variable domain polypeptides, useful for

XX PT

XX treating canine allergy.

XX PS

XX Example 1; Page 41; 130pp; English.

XX XS

XX The invention relates to a novel canine heavy or light chain variable

XX CC

XX domain polypeptide. The protein of the invention demonstrates

XX CC

XX antiallergic activity and may be useful for treating canine allergy.

XX CC

XX possibly via gene therapy. The current sequence is that of an PCR primer

XX CC

XX which was used in the exemplification of the invention.

XX CC

XX Sequence 19 BP; 4 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

XX SQ

QY 233 GCTGTCCAGGAGCCG 248

Db 4 GCTGTCCAGGAGCCG 19

RESULT 671

ADL99975/C

ID ADL99975 standard; RNA; 19 BP.

XX AC

XX ADL99975;

XX XX

XX 20-MAY-2004 (first entry)

XX DT

XX Hepatitis B virus short interfering nucleic acid (siNA) #392.

XX DE

XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;

XX KW

XX siNA; hepatitis B virus; HBV; RNA interference.

XX XX

XX Hepatitis B virus.

XX OS

XX US2003206887-A1.
XX 06-NOV-2003.
XX PF 16-SEP-2002; 2002US-00244647.
XX XX

XX 14-MAY-1992; 92US-00882712.
XX 07-FEB-1994; 94US-00193627.
XX PR 08-NOV-1999; 99US-00436430.
XX PR 20-MAR-2000; 2000US-00531025.
XX PR 09-AUG-2000; 2000US-00636385.
XX PR 24-OCT-2000; 2000US-00696347.
XX PR 08-JUN-2001; 2001US-00877478.
XX PR 08-JUN-2001; 2001US-0296876P.
XX PR 24-OCT-2001; 2001US-0335059P.
XX PR 05-DEC-2001; 2001US-0337055P.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 26-MAR-2002; 2002WO-US009187.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.

XX (MORR/) MORRISSEY D.
XX (MCSW/) MCSWIGGEN J A.
XX (BEIG/) BEIGELMAN L.

XX Morrissey D, Mcswiggen JA, Beigelman L;

XX WPI; 2003-901032/82.

XX New short interfering nucleic acid molecules which down-regulates

XX expression of a hepatitis B virus (HBV) or which inhibits HBV

XX replication, useful for treating human HBV infections or for

XX characterizing gene function.

XX Claim 11; Page 46; 72pp; English.

XX The invention relates to a short interfering nucleic acid (siNA) molecule

XX that down-regulates expression of a hepatitis B virus (HBV) gene by RNA

XX interference or that inhibits HBV replication. Also disclosed are the

XX following: (i) a method of modulating the expression of a HBV gene in a

XX tissue explant; (ii) a method of generating a library of siNA constructs

XX having predetermined complexity; (iii) a cell containing one or more siNA

XX molecules; (iv) a kit containing a siNA molecule which can be used to

XX modulate the expression of a HBV target gene in a cell, tissue or

XX organism; and (v) a method for synthesizing a siNA molecule. The siNA

XX molecule is adapted for use to treat HBV infection, and comprises a sense

XX and an antisense region, where the antisense region comprises a sense

XX complementary to an RNA sequence encoding HBV and the sense region

XX comprises sequence complementary to the antisense region. The siNA

XX molecule is assembled from 2 nucleic acid fragments, where one fragment

XX comprises the sense region and the second fragment comprises the

XX antisense region of the siNA molecule, where sense region and the

XX antisense region comprise separate oligonucleotides, and are covalently

XX connected via a linker molecule. The linker molecule is a polynucleotide

XX linker or a non-nucleotide linker. The sense region comprises a 3'-

XX terminal overhang and the antisense region comprises a 3'-terminal

XX overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.

XX The antisense region 3'-terminal overhang is complementary to RNA

XX encoding HBV. The siNA is useful for treating human hepatitis B virus

XX infections, and for characterising pathways of gene function, e.g. to

XX inhibit activity of target genes in a pathway to determine the function

XX of uncharacterised genes in gene function analysis. The siNA molecules

XX may also be used in clinical, industrial, environmental, agricultural

XX and/or research settings. The present sequence represents 1 of 1504 HBV

XX siNA molecules of the invention.

XX Sequence 19 BP; 5 A; 7 C; 0 G; 0 T; 7 U; 0 Other;

XX SQ

Query Match 0.4%; Score 14.4; DB 1; Length 19;

Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTGACAGAT 2662
19 GAAGTGTGATAGAT 4

Db

RESULT 672
ADM00622
ID ADM00622 standard; RNA; 19 BP.
XX
AC ADM00622;
XX
XX
DT 20-MAY-2004 (first entry)
XX
DE Hepatitis B virus short interfering nucleic acid (siNA) #1038.
XX
KW Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
OS Hepatitis B virus.
XX
PN US2003206887-A1.
XX
PD 06-NOV-2003.
XX
PF 16-SEP-2002; 2002US-00244647.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 26-MAR-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX
PA (MORR/) MORRISSEY D.
PA (MCSW/) MCSWIGGEN J A.
PA (BEIG/) BEIGELMAN L.

PI Morrissey D, Mcswiggen JA, Beigelman L;
XX
XX
DR WPI; 2003-901032/82.
XX
XX
PT New short interfering nucleic acid molecules which down-regulates
PT expression of a hepatitis B virus (HBV) or which inhibits HBV
PT replication, useful for treating human HBV infections or for
PT characterizing gene function.
XX
XX
PS Claim 11; Page 46; 72pp; English.

XX
XX
CC The invention relates to a short interfering nucleic acid (siNA) molecule
CC that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
CC interference or that inhibits HBV replication. Also disclosed are the
CC following: (i) a method of modulating the expression of a HBV gene in a
CC tissue explant; (ii) a method of generating a library of siNA constructs
CC having predetermined complexity; (iii) a cell containing one or more siNA
CC molecules; (iv) a kit containing a siNA molecule which can be used to
CC modulate the expression of a HBV target gene in a cell, tissue or
CC organism; and (v) a method for synthesizing a siNA molecule. The siNA
CC molecule is adapted for use to treat HBV infection, and comprises a sense
CC and an antisense region, where the antisense region comprises sequence

CC complementary to an RNA sequence encoding HBV and the sense region
CC comprises sequence complementary to the antisense region. The siNA
CC molecule is assembled from 2 nucleic acid fragments, where one fragment
CC comprises the sense region and the second acid fragment comprises the
CC antisense region of the siNA molecule, where sense region and the
CC antisense region comprise separate oligonucleotides, and are covalently
CC connected via a linker molecule. The linker molecule is a polynucleotide
CC linker or a non-nucleotide linker. The sense region comprises a 3'-
CC terminal overhang and the antisense region comprises a 3'-terminal
CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
CC The antisense region 3'-terminal overhang is complementary to RNA
CC encoding HBV. The siNA is useful for treating human hepatitis B virus
CC infections, and for characterising pathways of gene function, e.g. to
CC inhibit activity of target genes in a pathway to determine the function
CC of uncharacterised genes in gene function analysis. The siNA molecules
CC may also be used in clinical, industrial, environmental, agricultural
CC and/or research settings. The present sequence represents 1 of 1504 HBV
CC siNA molecules of the invention.
XX
SQ Sequence 19 BP; 7 A; 0 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 68.8%; Pred. No. 3.1e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTGACAGAT 2662
19 GAAGUGUGUAAGAU 16

Db

RESULT 673
ADM00624
ID ADM00624 standard; RNA; 19 BP.
XX
AC ADM00624;
XX
XX
DT 20-MAY-2004 (first entry)
XX
DE Hepatitis B virus short interfering nucleic acid (siNA) #1040.
XX
KW Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
KW siNA; hepatitis B virus; HBV; RNA interference.
XX
OS Hepatitis B virus.
XX
XX
PN US2003206887-A1.
XX
PD 06-NOV-2003.
XX
XX
PF 16-SEP-2002; 2002US-00244647.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 26-MAR-2002; 2002US-0386782P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
XX
XX (MORR/) MORRISSEY D.
XX (MCSW/) MCSWIGGEN J A.
XX (BEIG/) BEIGELMAN L.

PI Morrissey D, Mcswiggen JA, Beigelman L;
 XX WPI; 2003-901032/82.
 DR New short interfering nucleic acid molecules which down-regulates
 PT expression of a hepatitis B virus (HBV) or which inhibits HBV
 PT replication, useful for treating human HBV infections or for
 PT characterizing gene function.
 XX Claim 11; Page 46; 72pp; English.
 PS The invention relates to a short interfering nucleic acid (siNA) molecule
 XX that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
 CC interference or that inhibits HBV replication. Also disclosed are the
 CC following: (i) a method of modulating the expression of a HBV gene in a
 CC tissue explant; (ii) a method of generating a library of siNA constructs
 CC having predetermined complexity; (iii) a cell containing one or more siNA
 CC molecules; (iv) a kit containing a siNA molecule which can be used to
 CC modulate the expression of a HBV target gene in a cell, tissue or
 CC organism; and (v) a method for synthesising a siNA molecule. The siNA
 CC molecule is adapted for use to treat HBV infection, and comprises a sense
 CC and an antisense region, where the antisense region comprises a sense
 CC complementary to an RNA sequence encoding HBV and the sense region
 CC comprises sequence complementary to the antisense region. The siNA
 CC molecule is assembled from 2 nucleic acid fragments, where one fragment
 CC comprises the sense region and the second fragment comprises the
 CC antisense region of the siNA molecule, where sense region and the
 CC antisense region comprise separate oligonucleotides, and are covalently
 CC connected via a linker molecule. The linker molecule is a polynucleotide
 CC linker or a non-nucleotide linker. The sense region comprises a 3'-
 CC terminal overhang and the antisense region comprises a 3'-terminal
 CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
 CC The antisense region 3'-terminal overhang is complementary to RNA
 CC encoding HBV. The siNA is useful for treating human hepatitis B virus
 CC infections, and for characterising pathways of gene function, e.g. to
 CC inhibit activity of target genes in a pathway to determine the function
 CC of uncharacterised genes in gene function analysis. The siNA molecules
 CC may also be used in clinical, industrial, environmental, agricultural
 CC and/or research settings. The present sequence represents 1 of 1504 HBV
 CC siNA molecules of the invention.
 XX Sequence 19 BP; 7 A; 0 C; 7 G; 0 T; 5 U; 0 Other;
 SQ Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 68.8%; Pred. No. 3.1e+02;
 Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 2647 GAAGTGTTCACAGAT 2662
 DB 2 GAAGUGUGAUAAGAU 17
 RESULT 674
 ID ADL99977/c
 XX ADL99977 standard; RNA; 19 BP.
 AC ADL99977;
 XX 20-MAY-2004 (first entry)
 DT Hepatitis B virus short interfering nucleic acid (siNA) #394.
 XX Virucide; Hepatotropic; Gene therapy; ss; short interfering nucleic acid;
 KW siNA; hepatitis B virus; HBV; RNA interference.
 XX Hepatitis B virus.
 OS US2003206887-A1.
 PN 06-NOV-2003.
 PD 16-SEP-2002; 2002US-00244647.
 XX

PR 14-MAY-1992; 92US-00882712.
 PR 07-FEB-1994; 94US-00193627.
 PR 08-NOV-1999; 99US-00436430.
 PR 09-MAR-2000; 2000US-00531025.
 PR 09-AUG-2000; 2000US-00636385.
 PR 24-OCT-2000; 2000US-00696347.
 PR 08-JUN-2001; 2001US-00877478.
 PR 24-OCT-2001; 2001US-0296876P.
 PR 05-DEC-2001; 2001US-0335059P.
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363114P.
 PR 26-MAR-2002; 2002WO-US009187.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 XX (MORRISSEY D.
 PA (MCSW/ MCSSWIGGEN J A.
 PA (BEIG/ BEIGELMAN L.
 XX Morrissey D, Mcswiggen JA, Beigelman L;
 PI WPI; 2003-901032/82.
 XX New short interfering nucleic acid molecules which down-regulates
 PT expression of a hepatitis B virus (HBV) or which inhibits HBV
 PT replication, useful for treating human HBV infections or for
 PT characterizing gene function.
 XX Claim 11; Page 46; 72pp; English.
 PS The invention relates to a short interfering nucleic acid (siNA) molecule
 XX that down-regulates expression of a hepatitis B virus (HBV) gene by RNA
 CC interference or that inhibits HBV replication. Also disclosed are the
 CC following: (i) a method of modulating the expression of a HBV gene in a
 CC tissue explant; (ii) a method of generating a library of siNA constructs
 CC having predetermined complexity; (iii) a cell containing one or more siNA
 CC molecules; (iv) a kit containing a siNA molecule which can be used to
 CC modulate the expression of a HBV target gene in a cell, tissue or
 CC organism; and (v) a method for synthesising a siNA molecule. The siNA
 CC molecule is adapted for use to treat HBV infection, and comprises a sense
 CC and an antisense region, where the antisense region comprises a sense
 CC complementary to an RNA sequence encoding HBV and the sense region
 CC comprises sequence complementary to the antisense region. The siNA
 CC molecule is assembled from 2 nucleic acid fragments, where one fragment
 CC comprises the sense region and the second fragment comprises the
 CC antisense region of the siNA molecule, where sense region and the
 CC antisense region comprise separate oligonucleotides, and are covalently
 CC connected via a linker molecule. The linker molecule is a polynucleotide
 CC linker or a non-nucleotide linker. The sense region comprises a 3'-
 CC terminal overhang and the antisense region comprises a 3'-terminal
 CC overhang. The 3'-terminal overhangs each comprise about 2 nucleotides.
 CC The antisense region 3'-terminal overhang is complementary to RNA
 CC encoding HBV. The siNA is useful for treating human hepatitis B virus
 CC infections, and for characterising pathways of gene function, e.g. to
 CC inhibit activity of target genes in a pathway to determine the function
 CC of uncharacterised genes in gene function analysis. The siNA molecules
 CC may also be used in clinical, industrial, environmental, agricultural
 CC and/or research settings. The present sequence represents 1 of 1504 HBV
 CC siNA molecules of the invention.
 XX Sequence 19 BP; 5 A; 7 C; 0 G; 0 T; 7 U; 0 Other;
 SQ Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 3.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2647 GAAGTGTTCACAGAT 2662
 DB 18 GAAGTGTTCACAGAT 3

RESULT 675
ADM93029
ID ADM93029 standard; DNA; 19 BP.
XX
XX ADM93029;
AC
DT
XX
XX 03-JUN-2004 (first entry)
DE
XX SNP-containing cardiovascular associated gene primer #360.
XX
XX SNP; single nucleotide polymorphism; cardiovascular associated gene;
KW allelic variation; atherosclerosis; ischemia; reperfusion; hypertension;
KW restenosis; arterial inflammation; myocardial infarction; stroke; primer;
KW ss.
XX
XX Homo sapiens.
OS
XX WO2003057911-A2.
FN
XX 17-JUL-2003.
PD
XX
XX 07-JAN-2003; 2003WO-EP000060.
PF
XX 08-JAN-2002; 2002EP-00000153.
PR
XX (FARB) BAYER AG.
PA
XX
XX Stropp U, Schwes S, Kallabis H;
PI
XX WPI; 2003-577532/54.
DR
XX
XX New isolated polynucleotides comprising single nucleotide polymorphisms
PT of the cardiovascular gene, useful for assessing predisposition or
PT susceptibility to a cardiovascular disease, e.g. atherosclerosis,
PT restenosis or stroke.
XX
XX Disclosure; Page 82; 187pp; English.
PS
XX The invention relates an isolated polynucleotide (I) encoded by a
CC cardiovascular associated (CA) gene, having allelic variation contained
CC in a functional surrounding like full length cDNA for CA gene
CC polypeptide, and with or without the CA gene promoter sequence. (I) is a
CC polynucleotide comprising single nucleotide polymorphisms predicting
CC cardiovascular disease. The polynucleotides are useful for assessing
CC predisposition or susceptibility to a cardiovascular disease, e.g.
CC atherosclerosis, ischemia/reperfusion, hypertension, restenosis, arterial
CC inflammation, myocardial infarction, and stroke. These may also be used
CC to predict personal medication schemes omitting adverse drug reactions,
CC or as probes for detecting genetic polymorphisms and as templates for the
CC recombinant production of normal or variant peptides/polypeptides encoded
CC by the genes. This sequence corresponds to a PCR primer to amplify one of
CC the genes of the invention.
XX
XX Sequence 19 BP; 2 A; 3 C; 8 G; 6 T; 0 U; 0 Other;
SQ

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. NO. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 388 GGGGGCTGCTAAGATG 403
Db 2 GGGGGCTGCTTAGATG 17
|||||
|||||
RESULT 676
ADM47357
ID ADM47357 standard; DNA; 19 BP.
XX
XX ADM47357;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX

DE NOVX oligonucleotide forward primer, SEQ ID NO 190.
XX
XX NOVX; cytostatic; gene therapy; vaccine; cancer; chromosome mapping;
KW primer; ss.
XX
XX Unidentified.
XX
XX WO2003083039-A2.
PN
XX 09-OCT-2003.
PD
XX 03-JUL-2002; 2002WO-US021485.
XX
XX 05-JUL-2001; 2001US-0303046P.
PF
XX 09-JUL-2001; 2001US-0303828P.
PR
XX 11-JUL-2001; 2001US-0304502P.
PR
XX 12-JUL-2001; 2001US-0305011P.
PR
XX 13-JUL-2001; 2001US-0305262P.
PR
XX 16-JUL-2001; 2001US-0305673P.
PR
XX 17-JUL-2001; 2001US-0306085P.
PR
XX 24-JUL-2001; 2001US-0307536P.
PR
XX 27-JUL-2001; 2001US-0308228P.
PR
XX 30-JUL-2001; 2001US-0308877P.
PR
XX 14-AUG-2001; 2001US-0312203P.
PR
XX 17-SEP-2001; 2001US-0322640P.
PR
XX 19-SEP-2001; 2001US-0323484P.
PR
XX 21-SEP-2001; 2001US-0323821P.
PR
XX 21-SEP-2001; 2001US-0323948P.
PR
XX 25-SEP-2001; 2001US-0324711P.
PR
XX 09-OCT-2001; 2001US-0327893P.
PR
XX 21-NOV-2001; 2001US-0331768P.
PR
XX 21-FEB-2002; 2002US-0359191P.
PR
XX 22-FEB-2002; 2002US-0358939P.
PR
XX 28-FEB-2002; 2002US-0360923P.
PR
XX 01-MAR-2002; 2002US-0360830P.
PR
XX 01-MAR-2002; 2002US-0361178P.
PR
XX 05-MAR-2002; 2002US-0361748P.
PR
XX 12-MAR-2002; 2002US-0363429P.
PR
XX 12-MAR-2002; 2002US-0363683P.
PR
XX 12-APR-2002; 2002US-0372141P.
PR
XX 16-APR-2002; 2002US-0372967P.
PR
XX 16-APR-2002; 2002US-0373051P.
PR
XX 16-APR-2002; 2002US-0373063P.
PR
XX 17-APR-2002; 2002US-0373280P.
PR
XX 19-APR-2002; 2002US-0373287P.
PR
XX 19-APR-2002; 2002US-0373881P.
PR
XX 02-JUL-2002; 2002US-00187975.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Li L, Shenoy SG, Patturajan M, Ellerman K, Gorman L, Zhong M;
XX Catterton E, Spytek KA, Miller CE, Edinger SR, Hjal T, Gerlach VL;
PI Shimkets RA, Taupier RJ, Anderson DW, Guo X, Baumgartner JC;
PI Padigaru M, Peyman JA, Smithson G, Casman SJ, Voss EZ, Boldog FL;
PI Pena CE, Chapoval A, Rastelli L, Kekuda R, Vernet CAM;
XX
XX WPI; 2003-812538/76.
DR
XX New NOVX polypeptide, useful for preparing a composition for treating or
PT preventing e.g. cancer or for chromosome mapping.
PT
XX
XX Example C; SEQ ID NO 190; 433pp; English.
XX
XX The invention relates to a novel isolated polypeptide, designated NOVX.
CC The novel polypeptide comprises a sequence comprising 109-1671 amino
CC acids, or its mature form, a sequence that is at least 95% identical to
CC the 109-1671 amino acid polypeptide; or a sequence comprising one or more
CC conservative substitutions in the 109-1671 amino acid polypeptide. The
CC invention further comprises: a composition; a kit comprising the
CC composition; a method for determining the presence or amount of the
CC polypeptide or nucleic acid molecule in a sample; determining the
CC presence of, or predisposition to, a disease associated with the altered
CC levels of nucleic acid or of expression of the polypeptide in a first

CC mammalian subject; identification of an agent that binds to the
 CC polypeptide; identification of a potential therapeutic agent for treating
 CC a pathology related to aberrant expression or physiological interactions
 CC of the polypeptide; a method of screening for a modulator of activity or
 CC latency of, or predisposition to, a pathology associated with the
 CC polypeptide; a method for modulating the activity of the polypeptide;
 CC treating or preventing a pathology associated with the polypeptide;
 CC treating a pathological state in a mammal; an isolated nucleic acid
 CC molecule; a vector comprising the nucleic acid molecule; a cell
 CC comprising the vector; an antibody that immunospecifically binds to the
 CC polypeptide; and a method for producing the polypeptide. The NOVX
 CC polypeptide and its encoding nucleic acid have cytostatic activity. The
 CC NOVX polynucleotide can be used in gene therapy to treat disorders. The
 CC NOVX polypeptide can be used to create a vaccine. The polypeptide is
 CC useful for preparing a composition for treating or preventing a
 CC pathological state in a mammal, e.g., cancer, or for chromosome mapping.
 CC This polynucleotide sequence represents a primer used in the
 CC exemplification of the invention.

XX SQ Sequence 19 BP; 5 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 3.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1437 TGTATTCACAGCCAT 1452

DB 4 TGAATTCACAGCCAT 19

RESULT 677

ADN96294/C

ID ADN96294 standard; DNA; 19 BP.

XX AC ADN96294;

DT 01-JUL-2004 (first entry)

XX DE Human NOVX PCR primer #69.

XX Human; NOVX; PCR; ss; metabolic disorder; diabetes; obesity;
 KW infectious disease; anorexia; cancer; neurodegenerative disorder;
 KW Alzheimer's disease; Parkinson's disease; immune disorder;
 KW haematopoietic disorder; antidiabetic; anorectic; antimicrobial;
 KW anabolic; eating disorder; cytostatic; neuroprotective; nontropic;
 KW antiparkinsonian; antianaemic; primer.

XX OS Homo sapiens.

XX US2004067490-A1.

XX PD 08-APR-2004.

XX PF 06-SEP-2002; 2002US-00236392.

XX PR 07-SEP-2001; 2001US-0318120P.

PR 07-SEP-2001; 2001US-0318130P.

PR 10-SEP-2001; 2001US-0318219P.

PR 10-SEP-2001; 2001US-0318430P.

PR 12-SEP-2001; 2001US-0318765P.

PR 17-SEP-2001; 2001US-0322781P.

PR 17-SEP-2001; 2001US-0322816P.

PR 19-SEP-2001; 2001US-032319P.

PR 20-SEP-2001; 2001US-0323631P.

PR 20-SEP-2001; 2001US-0323636P.

PR 25-SEP-2001; 2001US-0324969P.

PR 25-SEP-2001; 2001US-0325091P.

PR 26-SEP-2001; 2001US-0324990P.

PR 15-FEB-2002; 2002US-0357303P.

PR 28-FEB-2002; 2002US-0360973P.

PR 20-MAR-2002; 2002US-0366131P.

PR 25-MAR-2002; 2002US-0367753P.

PR 02-APR-2002; 2002US-0369479P.

PR 10-MAY-2002; 2002US-0379532P.
 PR 17-MAY-2002; 2002US-0381664P.
 PR 17-MAY-2002; 2002US-0381672P.
 PR 28-MAY-2002; 2002US-0383651P.
 PR 29-MAY-2002; 2002US-0384012P.
 PR 19-JUN-2002; 2002US-0390155P.

XX (ZHON/) ZHONG M.
 PA (LILL/) LI L.
 PA (GORM/) GORMAN L.
 PA (SPYT/) SPYTEK K A.
 PA (KEKU/) KEKUDA R.
 PA (TAUP/) TAUPIER R J.
 PA (ANDE/) ANDERSON D W.
 PA (VERN/) VERNET C A M.
 PA (CATT/) CATTERTON E.
 PA (MILL/) MILLER C E.
 PA (SHEN/) SHENOY S G.
 PA (PATT/) PATTURAJAN M.
 PA (PENA/) PENA C E A.
 PA (TCHE/) TCHERNEV V T.
 PA (PADI/) PADIGARU M.
 PA (GUSE/) GUSEV V Y.
 PA (MALY/) MALYANKAR U M.
 PA (BURG/) BURGESS C E.
 PA (GERL/) GERLACH V.
 PA (CASM/) CASMAN S J.
 PA (RIEG/) RIEGER D K.
 PA (GROS/) GROSSE W M.
 PA (SMIT/) SMITHSON G.
 PA (PEYM/) PEYMAN J A.
 PA (STAR/) STARLING G.
 PA (ROTH/) ROTHENBERG M E.
 PA (LARO/) LAROCHELLE W J.
 PA (SHIM/) SHIMKETS R A.
 PA (CRAB/) CRABTREE J.
 PA (RAST/) RASTELLI L.
 PA (VOSS/) VOSS E Z.
 PA (BOLD/) BOLDOG F L.
 PA (EDIN/) EDINGER S R.
 PA (MILL/) MILLET I.
 PA (MACD/) MACDOUGALL J R.
 PA (ELLE/) ELLERMAN K.
 PA (CHAP/) CHAPOVAL A.

XX Zhong M, Li L, Gorman L, Spytke KA, Kekuda R, Taupier RJ;
 PI Anderson DM, Vernet CAM, Catterton E, Miller CE, Shenoy SG;
 PI Patturajan M, Pena CEA, Tchernev VT, Padigaru M, Gusev VI;
 PI Malyankar UM, Burgess CE, Gerlach V, Casman SJ, Rieger DK;
 PI Grosse WM, Smithson G, Peyman JA, Starling G, Rothenberg ME;
 PI Larochelle WJ, Shinkets RA, Crabtree J, Rastelli L, Voss EZ;
 PI Boldog FL, Edinger SR, Millet I, Macdougall JR, Ellerman K;
 PI Chapoval A;

XX WPI; 2004-355290/33.

XX New isolated polypeptide, useful for treating or preventing a pathology
 PT associated with the polypeptide, e.g. diabetes, infectious disease,
 PT cancer, neurodegenerative disorders or Alzheimer's disease.

XX Example C; SEQ ID NO 357; 552pp; English.

XX The invention relates to human NOVX polypeptides and polynucleotides. The
 CC isolated nucleic acids can be used to express the novel proteins, to
 CC detect novel mRNA or a genetic lesion in a novel gene and to modulate its
 CC activity. It can also be used in gene therapy for treating or preventing
 CC a pathology associated with the protein or nucleic acid. The disorders
 CC include metabolic disorders, diabetes, obesity, infectious diseases,
 CC anorexia, cancer, neurodegenerative disorders, Alzheimer's disease,
 CC Parkinson's disease, immune disorders and haematopoietic disorders. This
 CC sequence represents a PCR primer used in analysis of expression of a
 CC human NOVX polynucleotide of the invention.

SQ Sequence 19 BP; 6 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels

QY 2457 AGCTGGCACATTATCC 2472
|||
Db 17 AGCTGGCACCTTATCC 2

RESULT 678
AAS97819/C
ID AAS97819 standard: DNA: 20 BP.

AA
AC
AAS97819;

DT 12-MAR-2002 (first entry)

DE Murine SAC1 gene-specific oligonucleotide PCR primer #386.

Human, mouse; SACL1; carbohydrate; sweetener; ethanol; alcoholism; ss;
 KW obesity; diabetes; transgenic embryo; body tissue; body fluid; pancreas;
 KW blood; tongue; PCR primer; anorectic; antidiabetic; gene therapy;
 KW protein replacement therapy.
 KW

OS Mus sp.

PN WO200183749-A2.

PD 08-NOV-2001.

25-APR-2001; 2001WO-US013387.

PR 28-APR-2000; 2000US-0200794P.

PR 10-NOV-2000; 2000US-0247443P.

PA (WARN) WARNER LAMBERT CO.

XX Bachmanov AA, Beauchamp GK, Ch
PI Ohmen JD, Reed DR, Ross D, To

DR WPI; 2002-075162/10.

Novel isolated polypeptide comprising variant form of mouse or human SACL polypeptide, and is associated with altered preference for carbohydrates or other sweeteners, useful for preventing obesity, diabetes, alcoholism.

PS Claim 14; Page 89; 239pp; English.

CC The invention relates to an isolated polypeptide, comprising a variant
CC form of mouse or human SACL polypeptide. The variant form is associated
CC with altered preference for carbohydrates, other sweeteners or ethanol.
CC The polypeptide and its associated DNA sequence can be produced by
CC recombinant techniques and is useful for preventing obesity, diabetes or
CC alcoholism associated with SACL expression. The sequences are useful in
CC screening for drugs and sweeteners. Recombinant cell lines and transgenic
CC embryos may be used in screening for and identifying agents that induce
CC or repress function of SACL. Predisposition to diabetes, obesity or
CC alcoholism can be ascertained by testing any fluid or tissue of a human
CC (such as blood, pancreas or tongue) for sequence variations of the SACL
CC gene. A sequence variation of the SACL locus may indicate a
CC predisposition to diabetes, obesity and/or alcoholism and may provide a
CC diagnostic mark. The polynucleotide can be detected in a biological
CC sample by contacting the DNA with a probe to form a hybridisation complex
CC which is then detected. The sequences represent cDNA encoding human and
CC mouse SACL polypeptides and PCR primers specific for the SACL genes

Sequence 20 BP: 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other; 0 X

Query Match 0.4%; Score 14.2; DB 1; Length 20;

Best Local Similarity 84.2%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 3

Qy 2874 GGCAGAAATCCTGTTCACTG 2892
| | | | | | | | | |
pb 20 GCCAGAAATCCTGTTCCATG 2

RESULT 679
ABZ89592

ID ABZ89592 standard; DNA; 20 BP.

AC ABZ89592;

DT 17-OCT-2003 (first entry)

DE Human oligonucleotide sequence.

Human; antisense; lung dysfunction; nasal airway dysfunction;
antiinflammatory steroid; ubiquinone; antiinflammatory;
antiallergic; antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
antisense gene therapy; respiratory; lung; adenosine sensitivity;
adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
lung inflammation; respiratory disease; ds.

OS Homo sapiens.

PN WO200285308-A2.

PD 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013135.

24-APR-2001: 2001US-0286137P.

PA (EPIG-) EPIGENESIS PHARM INC.

XX NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI: 2003-329219/22.
DR

Pharmaceutical composition for treating ailments associated with impaired PT respiration, has oligo(s) antisense to specific gene(s) or its corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or PT ubiguinone.

PS Disclosure: SEO ID NO 4834: 872pp: English: XX

The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine or receptor, producing bronchodilation, increasing levels of ubiquinone or lung surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published/pct_sequences

Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other; 22

Query Match 0.4%; Score 14.2; DB 1; Length 20;

Best Local Similarity 84.2%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2577 TTTTTCGAAAAA 2595
| | | | | | | | | |
Db 1 TCTTTTCTAAAAA 19

RESULT 680
ABD25822
ID ABD25822 standard; DNA; 20 BP.
AC ABD25822;
XX
XX 29-JUL-2004 (first entry)
DE AI085559-derived oligonucleotide SEQ ID 4834.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX 31-OCT-2002.
PD
XX 23-APR-2002; 2002WO-US013143.
PF
XX 24-APR-2001; 2001US-0286036P.
PR
XX (EPITG-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX WPI; 2003-093058/08.
DR
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15, SEQ ID NO 4834; 763pp; English.
PS
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it

XX Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2577 TTTTTCGAAAAA 2595

Db 1 TCTTTTCTAAAAA 19

RESULT 681

ADM16159/c

ID ADM16159 standard; DNA; 20 BP.

XX ADM16159;

XX 15-JUL-2004 (first entry)

XX Murine SAC1 DNA PCR primer #386.

XX Mouse; SAC1; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
KW diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
KW primer.

XX Mus musculus.

XX US2004081964-A1.

XX 29-APR-2004.

XX 25-OCT-2002; 2002US-00280183.

XX 25-OCT-2002; 2002US-00280183.

XX (BACH/) BACHMANOV A A.

XX (BEAU/) BEAUCHAMP G K.

XX (LISS/) LI S.

XX (LIXX/) LI X.

XX (REED/) REED D R.

XX (TORD/) TORDOFF M G.

XX (ROSS/) ROSS D A.

XX (OHNA/) OHMAN J D.

XX (CHAT/) CHATTERJEE A.

XX (DJON/) DE JONG P J.

XX Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;

XX Ross DA, Ohman JD, Chatterjee A, De Jong PJ;

XX WPI; 2004-340133/31.

XX New isolated polynucleotides for sensing carbohydrates, other sweeteners,
PT ethanol, useful for screening drugs for inhibition or restoration of
PT gene function as antidiabetic, antioesity or antialcohol consumption
PT therapies.

XX Example 12; SEQ ID NO 429; 148pp; English.

XX The invention relates to SAC1 polypeptides and the polynucleotides
XX encoding them. The polynucleotides contain a variation associated with
XX sensing carbohydrates, other sweeteners or ethanol. The invention also
XX relates to a method for analysing a biomolecule in a biological sample,
XX comprising altering SAC1 activity in the sample and measuring the
XX activity, a method for analysing a polynucleotide in a biological sample,


```
XX DT 27-SEP-2002 (first entry)
XX DE Human neuropeptide Y allele specific probe SEQ ID NO: 10.
XX KW Human; neuropeptide Y; NPY; isogene; SNP; atherosclerosis; obesity;
XX KW psychological disorder; single nucleotide polymorphism; alcoholism;
XX KW antiarteriosclerotic; anorectic; probe; ss.
XX OS Homo sapiens.
XX PN WO200251857-A1.
XX PD 04-JUL-2002.
XX PF 21-DEC-2000; 2000WO-US034758.
XX PR 21-DEC-2000; 2000WO-US034758.
XX PA (GENA-) GENAISANCE PHARM INC.
XX PI Chew A, Denton RR, Lanz EM, Nandabalan K, Stephens JC;
XX WI WPI; 2002-566671/60.
XX PT New genetic variants of the human Neuropeptide Y (NPY) gene useful for
XX PT treating disorders affected by abnormal expression or function of NPY
XX PT isogene e.g., atherosclerosis or obesity.
XX PS Claim 11; Page 16; 80pp; English.
XX CC The present invention provides the human neuropeptide Y (NPY) gene and
XX CC single nucleotide polymorphisms (SNPs) identified therein. The sequence
XX CC can be used in the treatment of disorders associated with NPY, including
XX CC atherosclerosis, obesity, psychological disorders and alcoholism. The
XX CC present sequence is an allele specific probe used to isolate the human
XX CC NPY coding sequence
XX SQ Sequence 15 BP; 1 A; 12 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 382 GGGGAGGGGGCTG 395
DB 14 GGGGAGGGGGCTG 1

RESULT 685
AAF02074/c
ID AAF02074 standard; DNA; 17 BP.
XX AC AAF02074;
XX DT 16-FEB-2001 (first entry)
XX DE Hammerhead ribozyme substrate #369.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US009721.
XX PR 12-APR-1999; 99US-0129390P.
XX PA (RIBO-) RIBOZYME PHARM INC.

XX DT 27-SEP-2002 (first entry)
XX DE Human neuropeptide Y allele specific probe SEQ ID NO: 10.
XX KW Human; neuropeptide Y; NPY; isogene; SNP; atherosclerosis; obesity;
XX KW psychological disorder; single nucleotide polymorphism; alcoholism;
XX KW antiarteriosclerotic; anorectic; probe; ss.
XX OS Homo sapiens.
XX PN WO200251857-A1.
XX PD 04-JUL-2002.
XX PF 21-DEC-2000; 2000WO-US034758.
XX PR 21-DEC-2000; 2000WO-US034758.
XX PA (GENA-) GENAISANCE PHARM INC.
XX PI Chew A, Denton RR, Lanz EM, Nandabalan K, Stephens JC;
XX WI WPI; 2002-566671/60.
XX PT New genetic variants of the human Neuropeptide Y (NPY) gene useful for
XX PT treating disorders affected by abnormal expression or function of NPY
XX PT isogene e.g., atherosclerosis or obesity.
XX PS Claim 11; Page 16; 80pp; English.
XX CC The present invention provides the human neuropeptide Y (NPY) gene and
XX CC single nucleotide polymorphisms (SNPs) identified therein. The sequence
XX CC can be used in the treatment of disorders associated with NPY, including
XX CC atherosclerosis, obesity, psychological disorders and alcoholism. The
XX CC present sequence is an allele specific probe used to isolate the human
XX CC NPY coding sequence
XX SQ Sequence 15 BP; 1 A; 12 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 382 GGGGAGGGGGCTG 395
DB 14 GGGGAGGGGGCTG 1

RESULT 685
AAF02074/c
ID AAF02074 standard; DNA; 17 BP.
XX AC AAF02074;
XX DT 16-FEB-2001 (first entry)
XX DE Hammerhead ribozyme substrate #369.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US009721.
XX PR 12-APR-1999; 99US-0129390P.
XX PA (RIBO-) RIBOZYME PHARM INC.
```

```
XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX WI WPI; 2000-647423/62.
XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX PT useful for producing e.g. granulocyte colony stimulating factor protein,
XX PT interferon alpha and erythropoietin.
XX PS Claim 37; Page 64; 164pp; English.
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX CC molecules that act as inhibitors of the expression of repressor genes
XX CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
XX CC Inhibition of the repressors removes prevents inhibition (and
XX CC consequently increases expression of) genes involved in the production of
XX CC erythropoietin, granulocyte colony stimulating factor protein and
XX CC interferon alpha
XX SQ Sequence 17 BP; 0 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 345 GAGGAAGAACCGGA 358
DB 15 GAGGAAGAACCGGA 2

RESULT 686
AAF02073/c
ID AAF02073 standard; DNA; 17 BP.
XX AC AAF02073;
XX DT 16-FEB-2001 (first entry)
XX DE Hammerhead ribozyme substrate #368.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US009721.
XX PR 12-APR-1999; 99US-0129390P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX WI WPI; 2000-647423/62.
XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX PT useful for producing e.g. granulocyte colony stimulating factor protein,
XX PT interferon alpha and erythropoietin.
XX PS Claim 37; Page 64; 164pp; English.
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX CC molecules that act as inhibitors of the expression of repressor genes
XX CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
XX CC Inhibition of the repressors removes prevents inhibition (and
XX CC consequently increases expression of) genes involved in the production of
XX CC erythropoietin, granulocyte colony stimulating factor protein and
```


CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC parkinson's disease, ataxia, huntington's disease, creutzfeldt-jacob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an ambzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 8 A; 2 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 85.7%; Pred. No. 3.1e-02;
 Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 3645 TCAGAAATGGCAA 3658
 Db 1 UCAGAAAGGCCAA 14
 RESULT 689
 ID ABA80520/c
 XX ABA80520 standard; DNA; 17 BP.
 AC ABA80520;
 DT 24-JAN-2002 (first entry)
 XX
 DE MSH6 mutation correcting oligonucleotide SEQ ID NO: 3366.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 229; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 721 CTTTCCCGAGTGAAG 734
 Db 14 CTTTCCCGAGTGAAG 1
 RESULT 690
 ID ABA80521
 XX ABA80521 standard; DNA; 17 BP.
 AC ABA80521;
 DT 24-JAN-2002 (first entry)
 XX
 DE MSH6 mutation correcting oligonucleotide SEQ ID NO: 3367.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 229; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

CC (UCT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention

XX SQ Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 721 CTTTCCAGTGAAG 734
 |||||
 Db 4 CTTTCCAGTGAAG 17

RESULT 691
 ABN00960/c
 ID ABN00960 standard; DNA; 17 BP.
 AC ABN00960;
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:952.
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 952; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3428 CTGCCTGTCTTTC 3441
 |||||
 Db 15 CTGCCTGTCTTTC 2

RESULT 692
 ABN00961/c
 ID ABN00961 standard; DNA; 17 BP.
 XX
 AC ABN00961;
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:953.
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX
PS Disclosure; SEQ ID NO 953; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3428 CTGCCTGCTCTTGC 3441
DB 14 CTGCCTGCTCTTGC 1
RESULT 693
ABN00958/c
ID ABN00958 standard; DNA; 17 BP.
XX
XX ABN00958;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:950.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US016981.
PF
XX 26-MAY-2000; 2000US-0207456P.
PR
XX 21-SEP-2000; 2000US-0234687P.
PR
XX 27-SEP-2000; 2000US-0236359P.
PR
XX 04-OCT-2000; 2000GB-00024263.
PR
XX 30-JAN-2001; 2001WO-US000661.
PR
XX 30-JAN-2001; 2001WO-US000662.
PR
XX 30-JAN-2001; 2001WO-US000663.
PR
XX 30-JAN-2001; 2001WO-US000664.
PR
XX 30-JAN-2001; 2001WO-US000665.
PR
XX 30-JAN-2001; 2001WO-US000666.

30-JAN-2001; 2001WO-US000667.
PR
30-JAN-2001; 2001WO-US000668.
PR
30-JAN-2001; 2001WO-US000669.
PR
30-JAN-2001; 2001WO-US000670.
PR
05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI
XX WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 950; 214pp; English.
PS The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 7 A; 3 C; 7 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3428 CTGCCTGCTCTTGC 3441
DB 17 CTGCCTGCTCTTGC 4
RESULT 694
ABN00959/c
ID ABN00959 standard; DNA; 17 BP.
XX
XX ABN00959;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:951.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US016981.
PF

XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-02336359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX XX
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX XX
XX DR WPI; 2002-179446/23.
XX XX
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PS
XX PS Disclosure; SEQ ID NO 951; 214pp; English.
XX XX
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption/ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX XX
XX SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3428 CTGCTGTCTTTGC 3441
Db 16 CTGCTGTCTTTGC 3
RESULT 695
ACN00982/C
ID ACN00982 standard; RNA; 17 BP.
XX AC
XX AC ACN00982;
XX XX
XX DT 22-APR-2004 (first entry)
XX DE WNV Hammerhead Ribozyme substrate SEQ ID NO 972.
XX XX

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyne; ss.
XX OS
XX XX West Nile Virus.
XX XX
XX XX W0200268637-A2.
XX XX
XX XX 06-SEP-2002.
XX XX
XX XX 19-OCT-2001; 2001WO-US048350.
XX XX
XX XX 20-OCT-2000; 2000US-0242411P.
XX XX
XX XX (RIBO-) RIBOZYME PHARM INC.
XX XX (BLAT/) BLATT L.
XX XX (MCSW/) MCSWIGGEN J A.
XX XX
XX XX Blatt L, Mcswiggen JA;
XX XX
XX XX WPI; 2002-706994/76.
XX XX
XX XX New nucleic acid molecule that modulates replication of West Nile Virus
XX PT (WNV), useful for treating a condition related to WNV infection e.g.
XX PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX XX
XX PS Claim 23; SEQ ID NO 972; 495pp; English.
XX XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC treating a condition related to WNV infection e.g. pancreatitis,
XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC molecule is selected from the group of ribozymes consisting of
XX CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
XX CC nucleic acid molecules further comprise at least five ribose residues, at
XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC in the specification. The present sequence is that of a nucleic acid
XX CC molecule of the invention
XX XX
XX SQ Sequence 17 BP; 3 A; 6 C; 1 G; 0 T; 7 U; 0 Other;
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2153 CAAAAAGGAGTGT 2166
Db 14 CAAAAAGGAGTGT 1
RESULT 696
ACN00981/C
ID ACN00981 standard; RNA; 17 BP.
XX XX
XX AC ACN00981;
XX XX
XX XX 22-APR-2004 (first entry)
XX XX
XX XX WNV Hammerhead Ribozyme substrate SEQ ID NO 971.
XX XX
XX XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX XX Amberzyme; Zinzyne; ss.
XX XX
XX XX West Nile Virus.
XX OS

XX WPI; 2002-706994/76.
 XX
 PT New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 PS Claim 23; SEQ ID NO 2769; 495pp; English.
 XX
 CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 XX Sequence 17 BP; 3 A; 6 C; 1 G; 0 T; 7 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2153 CAAAAAGGAGTGT 2166
 Db 15 CAAAAAGGAGTGT 2
 |||||
 RESULT 699
 ACN14564
 ID ACN14564 standard; RNA; 17 BP.
 XX
 AC ACN14564;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV minus strand Amberzyme substrate SEQ ID NO 14567.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 DR WPI; 2002-706994/76.
 XX
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX

PS Claim 23; SEQ ID NO 14567; 495pp; English.
 XX
 CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 XX Sequence 17 BP; 7 A; 1 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 85.7%; Pred. No. 3.1e+02;
 Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 2153 CAAAAAGGAGTGT 2166
 Db 2 CAAAAAGGAGUGU 15
 |||||
 RESULT 700
 ACN14565
 ID ACN14565 standard; RNA; 17 BP.
 XX
 AC ACN14565;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV minus strand Amberzyme substrate SEQ ID NO 14568.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 DR WPI; 2002-706994/76.
 XX
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 PS Claim 23; SEQ ID NO 14568; 495pp; English.
 XX
 CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule of the invention

CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Ambenzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 85.7%; Pred. No. 3.1e+02;
 Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2153 CAAAAAGGAGTGT 2166
 Db 1 CAAAAAGGAGUGU 14

RESULT 701
 ACC68247/c
 ID ACC68247 standard; DNA; 17 BP.
 XX
 AC ACC68247;
 XX
 DT 01-JUL-2003 (first entry)
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5494.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.

XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001FR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-333167/31.

XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 673; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC68806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration.
 CC specifically cancer but also Alzheimer's disease and schizophrenia

XX
 SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;

QY 3280 CTCTTGTCAGGGGA 3293
 Db 16 CTCTTGTCAGGGGA 3

RESULT 703
 ACC67657/c
 ID ACC67657 standard; DNA; 17 BP.
 XX
 AC ACC67657;
 XX
 DT 01-JUL-2003 (first entry)

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2014 AAAGCTTGAAGTTG 2027
 Db 17 AAAGCTTGAAGTTG 4

RESULT 702
 ACC63786/c
 ID ACC63786 standard; DNA; 17 BP.
 XX
 AC ACC63786;
 XX
 DT 01-JUL-2003 (first entry)
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1033.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.

XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001FR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-333167/31.

XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 151; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC68806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration.
 CC specifically cancer but also Alzheimer's disease and schizophrenia

XX
 SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3280 CTCTTGTCAGGGGA 3293
 Db 16 CTCTTGTCAGGGGA 3

RESULT 703
 ACC67657/c
 ID ACC67657 standard; DNA; 17 BP.
 XX
 AC ACC67657;
 XX
 DT 01-JUL-2003 (first entry)

```
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4904.
XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX XX 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX XX
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX XX
XX XX New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 604; 738pp; French.
XX XX
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX SQ Sequence 17 BP; 9 A; 1 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3260 TTTTCCATCTGATC 3273
Db 14 TTTTCCATCTGATC 1

RESULT 704
ACC68563
ID ACC68563 standard; DNA; 17 BP.
XX AC ACC68563;
XX XX
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5810.
XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX XX 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX XX
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX XX
XX XX New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 604; 738pp; French.
XX XX
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX SQ Sequence 17 BP; 9 A; 1 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3260 TTTTCCATCTGATC 3273
Db 14 TTTTCCATCTGATC 1

RESULT 704
ACC68563
ID ACC68563 standard; DNA; 17 BP.
XX AC ACC68563;
XX XX
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5810.
XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX XX 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX XX
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX XX
XX XX New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 710; 738pp; French.
XX XX
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX SQ Sequence 17 BP; 2 A; 2 C; 1 G; 12 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2575 TCTTTTTTTTTTCT 2588
Db 3 TCTTTTTTTTTTCT 16

RESULT 705
ADC38438/c
ID ADC38438 standard; DNA; 17 BP.
XX AC ADC38438;
XX XX
XX DT 18-DEC-2003 (first entry)
XX DE Human AMLP1b scanning 17-mer oligonucleotide SEQ ID NO:787.
XX KW human; angiomotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX KW AMLP1b; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO2003037931-A2.
XX XX
XX PD 08-MAY-2003.
XX XX
XX PF 01-NOV-2002; 2002WO-US035129.
XX PR 01-NOV-2001; 2001US-0334773P.
XX XX
XX PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX XX Shannon M, Phan T;
XX XX WPI; 2003-430501/40.
XX XX
XX PT New isolated nucleic acid molecule encoding a human angiomotin-like
XX PT protein, useful for treating or preventing a disorder associated with
XX PT decreased or increased expression or activity of AMLP1.
XX XX Example 2; SEQ ID NO 787; 172pp; English.
```



```
XX The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1b, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0;
QY 2209 AAGAACCTTCTCTC 2222
Db 15 AAGAACCTTCTCTC 2
RESULT 706
ADC38439/c
ID ADC38439 standard; DNA; 17 BP.
XX
AC ADC38439;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1b scanning 17-mer oligonucleotide SEQ ID NO:788.
XX
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1b; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
PS Example 2; SEQ ID NO 788; 172pp; English.
XX
CC The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1b, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0;
QY 2209 AAGAACCTTCTCTC 2222
```

```
Db 14 AAGAACCTTCTCTC 1
RESULT 707
ACC53213
ID ACC53213 standard; DNA; 17 BP.
XX
AC ACC53213;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #1980.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Amson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 497; 798pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0;
QY 3270 GATCCTTCCACTCT 3283
Db 1 GATCCTTCCACTCT 14
RESULT 708
ACC53844/c
ID ACC53844 standard; DNA; 17 BP.
XX
AC ACC53844;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #2611.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
```

OS Homo sapiens.
XX
PN FR2826373-A1.
XX
XX 27-DEC-2002.
PD
XX 20-JUN-2001; 2001FR-00008139.
PF
XX 20-JUN-2001; 2001FR-00008139.
PR
XX (MOLE-) MOLECULAR ENGINES LAB SA.
PA
XX Tuijnder M, Telerman A, Amson R;
PI
XX WPI; 2003-250498/25.
DR
XX
XX New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
PT
XX Claim 1; Page 643; 798pp; French.
PS
XX This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
CC
XX Sequence 17 BP; 12 A; 1 C; 2 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 68 TTTTTCAGAT 81
DB 15 TTTTTCAGAT 2
RESULT 709
AAZ00496/c
ID AAZ00496 standard; DNA; 18 BP.
XX
XX AAZ00496;
AC
XX 06-OCT-1999 (first entry)
DT
XX Human thioresoxin DNA binding antisense oligonucleotide 2619.
DE
XX Thioresoxin; thioresoxin reductase; human; antisense; primer; metastasis;
KW cytosolic; tumour growth inhibitor; detection; nuclease resistant;
KW phosphorothioate linkage; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
OS
XX WO9938963-A1.
PN
XX 05-AUG-1999.
PD
XX 29-JAN-1999; 99WO-CA000077.
PF
XX 30-JAN-1998; 98US-0073196P.
PR
XX (GENE-) GENESENSE TECHNOLOGIES INC.
PA
XX Wright JA, Young AH, Lee YS;
PI
XX WPI; 1999-469328/39.
DR
XX Antisense oligonucleotides against thioresoxin and thioresoxin reductase
PT

PT genes, useful for inhibiting tumor growth and metastasis.
XX
XX Claim 1; Page 19; 88pp; English.
XX
XX This invention describes novel antisense oligonucleotides against
CC thioresoxin and thioresoxin reductase gene which have cytostatic activity
CC and are useful for inhibiting tumour growth and metastasis in mammals.
CC They may also be used as hybridization probes to detect the presence of
CC the thioresoxin and thioresoxin reductase mRNAs in mammalian cells. They
CC may also be used as molecular weight markers. The antisense of
CC oligonucleotides are nuclease resistant due to the presence of
CC phosphorothioate internucleotide linkages. AAZ00478-200503 represent
CC oligonucleotide primers capable of binding to human thioresoxin mRNA
XX
XX Sequence 18 BP; 2 A; 5 C; 3 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2011 GGAAAGCTTGAG 2024
DB 16 GGAAAGCTTGAG 3
RESULT 710
AAZ70301/c
ID AAZ70301 standard; DNA; 18 BP.
XX
XX AAZ70301;
AC
XX 10-SEP-2001 (first entry)
DT
XX Human biallelic marker upstream amplification primer SEQ ID NO:4657.
DE
XX Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
XX Homo sapiens.
OS
XX WO9954500-A2.
PN
XX 28-OCT-1999.
PD
XX 21-APR-1999; 99WO-IB000822.
PF
XX 21-APR-1998; 98US-0082614P.
PR
XX 23-NOV-1998; 98US-0109732P.
PR
XX (GEST) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
PI
XX WPI; 2000-013267/01.
DR
XX Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
PT
XX Claim 8; Page 1224; 2745pp; English.
PS
XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the

CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX
 SQ Sequence 18 BP; 7 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2213 ACCTTCTCTCCTTC 2226
 |||||
 DB 17 ACCTTCTCTCCTTC 4
 RESULT 711
 AAA80684/c
 ID AAA80684 standard; DNA; 18 BP.
 XX
 AC AAA80684;
 XX
 DT 21-NOV-2000 (first entry)
 XX
 DE PCR primer for human alpha interin cDNA amplification.
 XX
 KW Secreted protein; immunosuppressant; anti-inflammatory; antiarthritic;
 KW antirheumatic, dermatological; antiproliferative; antiarteriosclerotic;
 KW anticancer; vulnery; antiviral; antibacterial; antifungal;
 KW immune disorder; Addison's disease; rheumatoid arthritis; dermatitis;
 KW multiple sclerosis; inflammatory disorder; inflammatory bowel disease;
 KW Crohn's disease; nephritis; hyperproliferative disorder;
 KW cardiovascular disorder; coronary arteriosclerosis; myocarditis; cancer;
 KW melanoma; lymphoma; wound healing; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200029435-A1.
 XX
 PD 25-MAY-2000.
 XX
 PF 27-OCT-1999; 99WO-US025031.
 XX
 PR 28-OCT-1998; 98US-0105971P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Ni J, Ruben SM, Olsen HS, Young PE, Kenny JJ, Moore PA, Wei Y;
 PI Greene JM;
 XX
 DR WPI; 2000-387742/33.
 XX
 PT Isolated nucleic acid molecules encoding human secreted proteins are used
 PT for the prevention, amelioration and treatment of autoimmune,
 PT inflammatory, hyperproliferative and cardiovascular disorders, cancer,
 PT wounds, and infectious diseases.
 XX
 PS Example 53; Page 562; 803pp; English.
 XX
 CC The present invention relates to 12 secreted human proteins and the
 CC nucleotide sequences encoding them. The polynucleotide sequences given in
 CC AAA80606-A80623 encode the 12 secreted protein sequences given in
 CC AAB25576-B25593. The human secreted proteins have various activities
 CC dependent on the tissues in which they are expressed. Examples of the
 CC activities of the proteins include: immunosuppressant; anti-inflammatory;
 CC antiarthritic; antirheumatic, dermatological; antiproliferative;
 CC antiarteriosclerotic; anticancer; vulnery; antiviral; antibacterial;
 CC and antifungal activity. The proteins, polypeptides, agonists and
 CC antagonists may be used to treat prevent and/or diagnose various disease,
 CC disorders and conditions examples of which include: immune disorders e.g.
 CC Addison's disease, rheumatoid arthritis, dermatitis, and multiple
 CC sclerosis; inflammatory disorders e.g. inflammatory bowel disease,

CC Crohn's disease and nephritis; hyperproliferative disorders such as
 CC paraproteinemia and purpura; cardiovascular disorders e.g. coronary
 CC arteriosclerosis and myocarditis; cancer e.g. melanoma and lymphoma. The
 CC proteins and polynucleotide sequences may also be used in wound healing
 CC and the treatment of infectious diseases. Sequences AAA80597-A80605 are
 CC used in the identification of the nucleotide and protein sequences of the
 CC invention, so are AAB25575 and AAA80684-A80687
 XX
 SQ Sequence 18 BP; 3 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 14; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1511 GGTGGCATCCCTGC 1524
 |||||
 DB 14 GGTGGCATCCCTGC 1
 RESULT 712
 ADA27154/c
 ID ADA27154 standard; DNA; 18 BP.
 XX
 AC ADA27154;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human integrin alpha 11 subunit PCR primer KL120.
 XX
 KW cytostatic; antiinflammatory; immunomodulator; neuroprotective;
 KW hemostatic; gene therapy; cancer; inflammation; immune disorder;
 KW neurological disorder; blood clotting disorder; food additive;
 KW preservative; human; ss; secreted protein; PCR; primer;
 KW integrin alpha 11; chromosome 15 q22.3-23.
 XX
 OS Homo sapiens.
 XX
 PN US2003055231-A1.
 XX
 PD 20-MAR-2003.
 XX
 PF 29-OCT-2001; 2001US-00984130.
 XX
 PR 28-OCT-1998; 98US-0105971P.
 PR 27-OCT-1999; 99WO-US025031.
 PR 19-APR-2000; 2000US-0198407P.
 PR 30-OCT-2000; 2000US-0243792P.
 PR 18-APR-2001; 2001US-00836353.
 XX
 PA (NIJ/) NI J.
 PA (YOUN/) YOUNG P E.
 PA (KENN/) KENNY J J.
 PA (OLSE/) OLSEN H S.
 PA (MOOR/) MOORE P A.
 PA (WEI/) WEI Y.
 PA (GREE/) GREENE J M.
 PA (RUBS/) RUBEN S M.
 PA (LIUD/) LIU D.
 PA (CROC/) CROCKER P R.
 XX
 PI Ni J, Young PE, Kenny JJ, Olsen HS, Moore PA, Wei Y, Greene JM;
 PI Ruben SM, Liu D, Crocker PR;
 XX
 DR WPI; 2003-567103/53.
 XX
 PT New human secreted nucleic acid molecules and polypeptides, useful for
 PT preventing, treating, or ameliorating a medical condition, such as
 PT cancer, inflammation, immune disorders, neurological and blood clotting
 PT disorders.
 XX
 PS Example 53; Page 256; 454pp; English.
 XX
 CC The invention relates to an isolated nucleic molecule that is at least

95% identical to 18 human cDNA sequences representing 12 novel genes encoding secreted proteins or a polynucleotide fragment of the cDNA sequence contained in American Type Culture Collection (ATCC) deposit No. defined in the specification, its species homologue, a variant or allelic variant of the polynucleotide having a polynucleotide capable of hybridizing under conditions the polynucleotide, where the polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A or T residues. Also included are recombinant vectors, host cells (for producing the polypeptide), the secreted polypeptide (comprising a sequence that is at least 95% identical to a polypeptide fragment, domain, epitope, full-length protein, variant, allelic variant or species homologue), antibodies that specifically bind to the polypeptides, diagnosing, treating, preventing or ameliorating a medical condition by administering the polynucleotide or the polypeptide, the gene corresponding to the cDNA sequence and identifying an activity in a biological assay (by expressing the cDNA sequence in a cell, isolating the supernatant, and detecting an activity in a biological assay and identifying the protein in the supernatant having the activity). The polypeptides, nucleic acids and antibodies are useful for diagnosing a pathological condition or a susceptibility to a pathological condition, for preventing, treating, or ameliorating a medical condition, such as cancer, inflammation and other immune disorders, neurological and blood clotting disorders (many examples are given in the specification). The nucleic acids are also useful for chromosome identification, radiation hybrid mapping or long-range restriction mapping. The polypeptides and antibodies are useful for providing immunological probes for differential identification of the tissues immunohistochemistry assays. The polypeptide, polynucleotide, agonist or antagonist may also be used as a food additive or preservative to increase or decrease storage capabilities, fat content or other nutritional components. Novel gene 7 has been identified as encoding integrin alpha 11 subunit. The present sequence is a PCR primer used to assess the tissue distribution of the expression of gene 7.

Sequence 18 BP; 3 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1511 GGTGGCATCCTCGC 1524

Db 14 GGTGGCATCCTCGC 1

RESULT 713
ADE43436

ID ADE43436 standard; DNA; 18 BP.

AC ADE43436;

DT 29-JAN-2004 (first entry)

DE Human SNCG sequencing primer, SEQ ID 41.

Human neurodegenerative disease; uPA; SNCG; IDE; KNSL1; LIPA; TNFRSF6;

Neurodegenerative disease; uPA; SNCG; IDE; KNSL1; LIPA; TNFRSF6;

Alzheimer's disease; neuroprotective; nontropic; gene therapy;

Chromosome 10; PCR; primer; ss.

OS Homo sapiens.

PN WO2003054143-A2.

XX 03-JUL-2003.

PD 25-OCT-2002; 2002WO-US034679.

PF 25-OCT-2001; 2001US-0339525P.

PR 08-NOV-2001; 2001US-0336929P.

PR 08-NOV-2001; 2001US-0338010P.

PR 09-NOV-2001; 2001US-0338363P.

PR 04-DEC-2001; 2001US-0337052P.

PR 28-MAR-2002; 2002US-0368919P.

XX (NEUR-) NEUROGENETICS INC.
PA (GEHO) GEN HOSPITAL CORP.

XX Becker KD, Velicelebi G, Elliott KJ, Wang X, Tanzi RE, Bertram L;

PI Saunders AJ, Mullin KM, Sampson AJ, Blacker DL;

XX WPI; 2003-559131/52.

XX Determining a predisposition for or the occurrence of neurodegenerative

PT disease, e.g. Alzheimer's disease by detecting in a target nucleic acid

PT the presence or absence of an allelic variant of one or more polymorphic

PT regions.

XX Example 2; Page 266; 848pp; English.

XX The present invention relates to a method (M1) for determining a

CC predisposition for or the occurrence of neurodegenerative disease in a

CC subject. The method comprises detecting in a target nucleic acid obtained

CC from the subject the presence or absence of an allelic variant of one or

CC more polymorphic regions of one or more genes selected from uPA

CC (urokinase plasminogen activator), SNCG (gamma-synuclein), IDE (insulin-

CC degrading enzyme), KNSL1 (Kinesin-like protein 1), LIPA (lysosomal acid

CC lyase), and TNFRSF6 (Tumour Necrosis Factor Receptor-SF6), where the

CC presence of at least one of the allelic variant of one or more

CC polymorphic regions is indicative of a predisposition for or the

CC occurrence of neurodegenerative disease. The genes are all located on

CC chromosome 10. M1 is useful for determining a predisposition for or the

CC occurrence of, and for treating neurodegenerative disease, particularly

CC Alzheimer's disease. The present sequence is a PCR primer, which was used

CC in the method of the invention.

XX Sequence 18 BP; 5 A; 8 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 14; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.3e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1901 CCTCAGACTCCACC 1914

Db 5 CCTCAGACTCCACC 18

RESULT 714

ADH53914

ID ADH53914 standard; DNA; 18 BP.

XX AC ADH53914;

XX 25-MAR-2004 (first entry)

XX Human neurodegenerative disease-related sequencing primer SeqID41.

DE human; neurodegenerative disease; urokinase plasminogen activator; uPA;

human; neurodegenerative disease; urokinase plasminogen activator; uPA;

gamma-synuclein; SNCG; insulin degrading enzyme; IDE;

kinesin-like protein 1; KNSL1; lysosomal acid lipase; LIPA;

tumour necrosis factor receptor SF6; TNFRSF6; Alzheimer's disease; PCR;

primer; ss; sequencing.

XX Homo sapiens.

OS US2003224380-A1.

PN 04-DEC-2003.

XX 25-OCT-2002; 2002US-00282174.

PF 25-OCT-2001; 2001US-0339525P.

PR 02-OCT-2001; 2001US-0348065P.

PR 25-NOV-2001; 2001US-0336983P.

PR 08-NOV-2001; 2001US-0336929P.

PR 08-NOV-2001; 2001US-0338010P.

PR 09-NOV-2001; 2001US-0338363P.

```
PR 04-DEC-2001; 2001US-0337052P.
PR 28-MAR-2002; 2002US-0368919P.
XX
PA (GCHO ) GEN HOSPITAL CORP.
XX
PI Becker KD, Velicelebi G, Elliott KJ, Wang X, Tanzi RE;
PI Bertram L, Saunders AJ, Mullin KM, Sampson AJ;
XX
XX WPI; 2004-060538/06.
XX
XX Determining a predisposition for or the occurrence of neurodegenerative
PT disease, particularly Alzheimer's disease, comprises determining the
PT presence of a polymorphism in the UPA, SNCG, IDE, KNSL1, LIPA or TNFRSF6
PT gene.
XX
XX Example 2; SEQ ID NO 41; 205pp; English.
XX
XX This invention relates to a novel method of determining a predisposition
CC for or the occurrence of neurodegenerative disease comprising detecting
CC in a target nucleic acid obtained from the subject the presence of an
CC allelic variant of polymorphic regions of human genes selected from
CC urokinase plasminogen activator (uPA), gamma-synuclein (SNCG), insulin
CC degrading enzyme (IDE), kinesin-like protein 1 (KNSL1), lysosomal acid
CC lipase (LIPA) and tumour necrosis factor receptor SF6 (TNFRSF6). The
CC method is useful in determining the presence or predisposition to a
CC neurodegenerative disease, particularly Alzheimer's disease. The present
CC sequence is that of a sequencing primer which was used for sequencing of
CC a region of the human SNCG gene in the exemplification of the invention.
XX
XX Sequence 18 BP; 5 A; 8 C; 3 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0;
QY 1901 CCTCAGACTCCACC 1914
DB 5 CCTCAGACTCCACC 18
RESULT 715
ADP08093/C
ID ADP08093 standard; DNA; 18 BP.
XX
XX AC ADP08093;
XX
XX 26-AUG-2004 (first entry)
XX
XX Human RAD21 primer #8.
XX
XX Cytostatic; Gene Therapy; breast cancer; RAD21; human; chromosome 8q24;
KW primer; ss.
XX
XX Homo sapiens.
XX
XX WO2004048546-A2.
XX
XX 10-JUN-2004.
XX
XX 25-NOV-2003; 2003WO-US037949.
XX
XX 25-NOV-2002; 2002US-0429136P.
PR 24-JUL-2003; 2003US-0490234P.
PR 18-SEP-2003; 2003US-0504258P.
XX
XX (SEQU-) SEQUENOM INC.
XX
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Denissenko MF;
PI Reneland R, Atienza JM;
XX
XX WPI; 2004-450365/42.
XX
XX Identifying subject at risk of breast cancer, useful for diagnosing,
PT
```

```
PT treating, or preventing breast cancer, comprises detecting the presence
PT or absence of a polymorphic variation associated with breast cancer in a
PT nucleic acid sample.
XX
XX Example 3; Page 75; 125pp; English.
XX
XX The present invention relates to methods for identifying a subject at
CC risk of breast cancer. The method comprises detecting the presence or
CC absence of one or more polymorphic variations associated with breast
CC cancer in a nucleic acid sample comprising the RAD21 nucleotide sequence
CC (ADP07906 and ADP07907) from a subject. The RAD21 sequences are useful
CC for diagnostic purposes for detection and control of polypeptide
CC expression and for diagnosing, treating, or preventing breast cancer. The
CC chromosomal location for the RAD21 gene is chromosome 8q24. RAD21 is
CC intimately involved in breast cell proliferation by maintaining genomic
CC stability during the cell cycle. RAD21 plays a role in DNA repair and in
CC the proper segregation of chromatids during mitosis. The present primer
XX was used in an example from the invention.
XX
XX Sequence 18 BP; 2 A; 9 C; 0 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0;
QY 1533 GTAAAGGGGAAAGG 1546
DB 18 GTAAAGGGGAAAGG 5
Search completed: November 2, 2004, 09:45:34
Job time : 33 secs
```


107	16.2	0.4	21	1	US-10-444-795B-511	Sequence 511, App	C 180	15.2	0.4	20	1	US-09-966-312-55	Sequence 55, Appl
108	16.2	0.4	21	1	US-10-648-593-542	Sequence 542, App	C 181	15.2	0.4	20	1	US-09-927-777A-55	Sequence 55, Appl
109	16.2	0.4	21	1	US-10-733-890-4	Sequence 4, Appl	C 182	15.2	0.4	20	1	US-09-927-777A-70	Sequence 70, Appl
110	15.8	0.4	19	1	US-10-224-005-59	Sequence 59, Appl	C 183	15.2	0.4	20	1	US-09-966-491A-55	Sequence 55, Appl
111	15.8	0.4	19	1	US-10-224-005-220	Sequence 220, App	C 184	15.2	0.4	20	1	US-09-976-971A-55	Sequence 55, Appl
112	15.8	0.4	19	1	US-10-244-647-395	Sequence 395, App	C 185	15.2	0.4	20	1	US-09-880-505-83	Sequence 83, Appl
113	15.8	0.4	19	1	US-10-244-647-385	Sequence 385, App	C 186	15.2	0.4	20	1	US-09-820-279B-55	Sequence 55, Appl
114	15.8	0.4	19	1	US-10-244-647-1031	Sequence 1031, App	C 187	15.2	0.4	20	1	US-09-888-326-2	Sequence 2, Appl
115	15.8	0.4	19	1	US-10-244-647-1041	Sequence 1041, App	C 188	15.2	0.4	20	1	US-09-888-326-838	Sequence 838, App
116	15.8	0.4	20	1	US-09-824-322B-360	Sequence 360, App	C 189	15.2	0.4	20	1	US-09-888-326-839	Sequence 839, App
117	15.8	0.4	20	1	US-10-408-969-3	Sequence 3, Appl	C 190	15.2	0.4	20	1	US-09-981-344-55	Sequence 55, Appl
118	15.8	0.4	20	1	US-10-161-936-140	Sequence 140, App	C 191	15.2	0.4	20	1	US-09-957-318A-55	Sequence 55, Appl
119	15.8	0.4	20	1	US-10-161-996-260	Sequence 260, App	C 192	15.2	0.4	20	1	US-09-974-500A-55	Sequence 55, Appl
120	15.8	0.4	20	1	US-10-174-465-12	Sequence 12, Appl	C 193	15.2	0.4	20	1	US-09-975-376A-55	Sequence 55, Appl
121	15.8	0.4	20	1	US-10-174-465-48	Sequence 48, Appl	C 194	15.2	0.4	20	1	US-09-957-313A-55	Sequence 55, Appl
122	15.8	0.4	20	1	US-10-348-431-12	Sequence 12, Appl	C 195	15.2	0.4	20	1	US-09-912-014-16	Sequence 16, Appl
123	15.8	0.4	20	1	US-10-348-431-48	Sequence 48, Appl	C 196	15.2	0.4	20	1	US-09-997-672-40	Sequence 40, Appl
124	15.8	0.4	20	1	US-10-289-762-5256	Sequence 5256, App	C 197	15.2	0.4	20	1	US-09-976-863A-55	Sequence 55, Appl
125	15.8	0.4	20	1	US-10-380-195A-6	Sequence 6, Appl	C 198	15.2	0.4	20	1	US-09-881-535-2	Sequence 2, Appl
126	15.8	0.4	20	1	US-10-380-195A-50	Sequence 50, Appl	C 199	15.2	0.4	20	1	US-09-906-158-85	Sequence 85, Appl
127	15.8	0.4	20	1	US-10-300-263-60	Sequence 60, Appl	C 200	15.2	0.4	20	1	US-09-954-556-49	Sequence 49, Appl
128	15.8	0.4	20	1	US-10-300-263-129	Sequence 129, App	C 201	15.2	0.4	20	1	US-09-776-479-226	Sequence 226, App
129	15.8	0.4	20	1	US-10-688-706-2238	Sequence 2238, App	C 202	15.2	0.4	20	1	US-09-776-479-226	Sequence 226, App
130	15.8	0.4	20	1	US-10-688-706-2484	Sequence 2484, App	C 203	15.2	0.4	20	1	US-09-776-479-556	Sequence 556, App
131	15.8	0.4	20	1	US-10-688-706-3052	Sequence 3052, App	C 204	15.2	0.4	20	1	US-09-776-479-556	Sequence 556, App
132	15.8	0.4	20	1	US-10-688-706-3052	Sequence 3052, App	C 205	15.2	0.4	20	1	US-09-776-479-560	Sequence 560, App
133	15.8	0.4	20	1	US-10-652-795-360	Sequence 360, App	C 206	15.2	0.4	20	1	US-09-776-479-560	Sequence 560, App
134	15.8	0.4	20	1	US-10-647-918-360	Sequence 360, App	C 207	15.2	0.4	20	1	US-09-920-033-102	Sequence 102, App
135	15.8	0.4	20	1	US-10-412-137-40	Sequence 40, Appl	C 208	15.2	0.4	20	1	US-09-953-047-25	Sequence 25, Appl
136	15.8	0.4	20	1	US-10-723-947-40	Sequence 40, Appl	C 209	15.2	0.4	20	1	US-09-976-601A-55	Sequence 55, Appl
137	15.8	0.4	21	1	US-09-205-658-321	Sequence 321, App	C 210	15.2	0.4	20	1	US-09-975-059A-55	Sequence 55, Appl
138	15.8	0.4	21	1	US-09-963-693-321	Sequence 321, App	C 211	15.2	0.4	20	1	US-09-976-968A-55	Sequence 55, Appl
139	15.8	0.4	21	1	US-10-418-182-106	Sequence 106, App	C 212	15.2	0.4	20	1	US-09-976-782-50	Sequence 50, Appl
140	15.8	0.4	21	1	US-10-418-182-122	Sequence 122, App	C 213	15.2	0.4	20	1	US-09-994-701B-5	Sequence 5, Appl
141	15.8	0.4	21	1	US-10-753-646-23	Sequence 23, Appl	C 214	15.2	0.4	20	1	US-10-081-885A-1	Sequence 1, Appl
142	15.8	0.4	21	1	US-10-753-646-33	Sequence 33, Appl	C 215	15.2	0.4	20	1	US-10-051-643-83	Sequence 83, Appl
143	15.8	0.4	21	1	US-10-786-720-1376	Sequence 1376, App	C 216	15.2	0.4	20	1	US-10-176-055-11	Sequence 11, Appl
144	15.4	0.4	17	1	US-09-780-533A-2559	Sequence 2559, App	C 217	15.2	0.4	20	1	US-10-176-267-1	Sequence 1, Appl
145	15.4	0.4	17	1	US-09-780-164-1042	Sequence 1042, App	C 218	15.2	0.4	20	1	US-10-112-653-218	Sequence 218, App
146	15.4	0.4	17	1	US-10-061-201-1266	Sequence 1266, App	C 219	15.2	0.4	20	1	US-10-112-653-533	Sequence 533, App
147	15.4	0.4	17	1	US-10-061-201-1267	Sequence 1267, App	C 220	15.2	0.4	20	1	US-10-112-653-537	Sequence 537, App
148	15.4	0.4	18	1	US-10-349-143-6580	Sequence 6580, App	C 221	15.2	0.4	20	1	US-10-077-383-5	Sequence 5, Appl
149	15.4	0.4	19	1	US-10-308-264-591	Sequence 591, App	C 222	15.2	0.4	20	1	US-10-077-383-6	Sequence 6, Appl
150	15.4	0.4	20	1	US-09-898-361-98	Sequence 98, Appl	C 223	15.2	0.4	20	1	US-10-017-995-226	Sequence 226, App
151	15.4	0.4	20	1	US-09-898-361-98	Sequence 98, Appl	C 224	15.2	0.4	20	1	US-10-017-995-556	Sequence 556, App
152	15.4	0.4	20	1	US-10-181-846-157	Sequence 157, App	C 225	15.2	0.4	20	1	US-10-017-995-560	Sequence 560, App
153	15.4	0.4	20	1	US-10-1006-911-33	Sequence 33, Appl	C 226	15.2	0.4	20	1	US-10-194-138-32	Sequence 32, Appl
154	15.4	0.4	20	1	US-10-420-845-13	Sequence 13, Appl	C 227	15.2	0.4	20	1	US-10-181-107-78	Sequence 78, Appl
155	15.4	0.4	20	1	US-10-181-856-46	Sequence 46, Appl	C 228	15.2	0.4	20	1	US-10-008-978-55	Sequence 55, Appl
156	15.4	0.4	20	1	US-10-421-783-14	Sequence 14, Appl	C 229	15.2	0.4	20	1	US-10-008-978-55	Sequence 55, Appl
157	15.4	0.4	20	1	US-10-364-748-60	Sequence 60, Appl	C 230	15.2	0.4	20	1	US-10-188-404-66	Sequence 66, Appl
158	15.4	0.4	20	1	US-10-349-143-6240	Sequence 6240, App	C 231	15.2	0.4	20	1	US-10-234-764-10	Sequence 10, Appl
159	15.4	0.4	20	1	US-10-458-939-23	Sequence 23, Appl	C 232	15.2	0.4	20	1	US-10-355-434-14	Sequence 14, Appl
160	15.4	0.4	20	1	US-10-406-686A-98	Sequence 98, Appl	C 233	15.2	0.4	20	1	US-10-255-434-26	Sequence 26, Appl
161	15.4	0.4	20	1	US-10-304-125-50	Sequence 50, Appl	C 234	15.2	0.4	20	1	US-10-278-047-1	Sequence 1, Appl
162	15.4	0.4	20	1	US-10-304-125-117	Sequence 117, App	C 235	15.2	0.4	20	1	US-10-371-066-16	Sequence 16, Appl
163	15.4	0.4	20	1	US-10-698-402-4	Sequence 4, Appl	C 236	15.2	0.4	20	1	US-10-340-097-53	Sequence 53, Appl
164	15.4	0.4	20	1	US-10-731-739-467	Sequence 467, App	C 237	15.2	0.4	20	1	US-10-336-219-53	Sequence 53, Appl
165	15.2	0.4	20	1	US-09-726-096A-1	Sequence 1, Appl	C 238	15.2	0.4	20	1	US-10-336-219-53	Sequence 53, Appl
166	15.2	0.4	20	1	US-09-916-369A-1	Sequence 1, Appl	C 239	15.2	0.4	20	1	US-10-410-324-55	Sequence 55, Appl
167	15.2	0.4	20	1	US-09-973-788A-55	Sequence 55, Appl	C 240	15.2	0.4	20	1	US-10-410-324-55	Sequence 55, Appl
168	15.2	0.4	20	1	US-09-973-638A-55	Sequence 55, Appl	C 241	15.2	0.4	20	1	US-10-266-983-55	Sequence 55, Appl
169	15.2	0.4	20	1	US-09-974-007-55	Sequence 55, Appl	C 242	15.2	0.4	20	1	US-10-266-983-70	Sequence 70, Appl
170	15.2	0.4	20	1	US-09-976-617A-55	Sequence 55, Appl	C 243	15.2	0.4	20	1	US-10-314-578-226	Sequence 226, App
171	15.2	0.4	20	1	US-09-961-949A-55	Sequence 55, Appl	C 244	15.2	0.4	20	1	US-10-314-578-556	Sequence 556, App
172	15.2	0.4	20	1	US-09-263-959-894	Sequence 894, App	C 245	15.2	0.4	20	1	US-10-314-578-560	Sequence 560, App
173	15.2	0.4	20	1	US-09-760-500A-55	Sequence 55, Appl	C 246	15.2	0.4	20	1	US-10-181-200-10	Sequence 10, Appl
174	15.2	0.4	20	1	US-09-967-409A-55	Sequence 55, Appl	C 247	15.2	0.4	20	1	US-10-181-200-15	Sequence 15, Appl
175	15.2	0.4	20	1	US-09-975-062A-55	Sequence 55, Appl	C 248	15.2	0.4	20	1	US-10-147-196-102	Sequence 102, App
176	15.2	0.4	20	1	US-09-976-378A-55	Sequence 55, Appl	C 249	15.2	0.4	20	1	US-10-159-942-41	Sequence 41, Appl
177	15.2	0.4	20	1	US-09-976-577-55	Sequence 55, Appl	C 250	15.2	0.4	20	1	US-10-159-942-108	Sequence 108, App
178	15.2	0.4	20	1	US-09-771-554-5	Sequence 5, Appl	C 251	15.2	0.4	20	1		
179	15.2	0.4	20	1	US-09-975-498-55	Sequence 55, Appl	C 252	15.2	0.4	20	1		

253	15.2	0.4	20	1	US-10-162-846-81	Sequence 81, Appl	326	15	0.4	18	1	US-10-241-780-114	Sequence 114, App
254	15.2	0.4	20	1	US-10-388-263-534	Sequence 534, App	c 327	15	0.4	20	1	US-10-188-777-61	Sequence 61, Appl
255	15.2	0.4	20	1	US-10-388-263-638	Sequence 638, App	328	15	0.4	20	1	US-10-188-777-121	Sequence 121, App
256	15.2	0.4	20	1	US-10-173-208-18	Sequence 18, Appl	329	14.8	0.4	18	1	US-09-831-332A-84	Sequence 84, Appl
c 257	15.2	0.4	20	1	US-10-173-208-54	Sequence 54, Appl	c 330	14.8	0.4	19	1	US-10-244-647-388	Sequence 388, App
258	15.2	0.4	20	1	US-10-174-559-74	Sequence 74, Appl	c 331	14.8	0.4	19	1	US-10-244-647-559	Sequence 559, App
259	15.2	0.4	20	1	US-10-373-406B-26	Sequence 26, Appl	332	14.8	0.4	19	1	US-10-244-647-1034	Sequence 1034, Ap
c 260	15.2	0.4	20	1	US-10-630-401-25	Sequence 25, Appl	333	14.8	0.4	19	1	US-10-244-647-1205	Sequence 1205, Ap
c 261	15.2	0.4	20	1	US-10-640-618-55	Sequence 55, Appl	c 334	14.8	0.4	19	1	US-10-294-328-19	Sequence 19, Appl
c 262	15.2	0.4	20	1	US-10-280-183A-429	Sequence 429, App	c 335	14.8	0.4	19	1	US-10-309-290-239	Sequence 239, App
c 263	15.2	0.4	20	1	US-10-431-341-31	Sequence 31, Appl	c 336	14.8	0.4	20	1	US-09-888-361-98	Sequence 98, Appl
c 264	15.2	0.4	20	1	US-10-399-241A-19	Sequence 19, Appl	c 337	14.8	0.4	20	1	US-09-756-095-16	Sequence 16, Appl
c 265	15.2	0.4	20	1	US-10-399-241A-28	Sequence 28, Appl	338	14.4	0.4	17	1	US-09-941-492-16	Sequence 16, Appl
c 266	15.2	0.4	20	1	US-10-301-832-49	Sequence 49, Appl	339	14.4	0.4	17	1	US-09-730-289B-880	Sequence 880, App
c 267	15.2	0.4	20	1	US-10-301-832-125	Sequence 125, App	c 340	14.4	0.4	17	1	US-09-780-533A-1235	Sequence 1235, Ap
c 268	15.2	0.4	20	1	US-10-653-416-25	Sequence 55, Appl	341	14.4	0.4	17	1	US-09-780-533A-2112	Sequence 2112, Ap
c 269	15.2	0.4	20	1	US-10-716-825-55	Sequence 178, App	c 342	14.4	0.4	17	1	US-09-877-478-523	Sequence 523, App
c 270	15.2	0.4	20	1	US-10-671-395-178	Sequence 179, App	c 343	14.4	0.4	17	1	US-09-838-858-16	Sequence 16, Appl
271	15.2	0.4	20	1	US-10-671-395-179	Sequence 180, App	345	14.4	0.4	17	1	US-10-156-306-517	Sequence 517, App
272	15.2	0.4	20	1	US-10-671-395-180	Sequence 181, App	346	14.4	0.4	17	1	US-10-156-306-518	Sequence 518, App
273	15.2	0.4	20	1	US-10-671-395-181	Sequence 182, App	347	14.4	0.4	17	1	US-10-156-306-520	Sequence 520, App
274	15.2	0.4	20	1	US-10-671-395-182	Sequence 183, App	348	14.4	0.4	17	1	US-10-156-306-521	Sequence 521, App
275	15.2	0.4	20	1	US-10-671-395-183	Sequence 184, App	349	14.4	0.4	17	1	US-10-156-306-7025	Sequence 7025, Ap
276	15.2	0.4	20	1	US-10-671-395-184	Sequence 185, App	350	14.4	0.4	17	1	US-10-156-306-7026	Sequence 7026, Ap
277	15.2	0.4	20	1	US-10-671-395-185	Sequence 186, App	c 351	14.4	0.4	17	1	US-10-061-201-1265	Sequence 1265, Ap
278	15.2	0.4	20	1	US-10-671-395-186	Sequence 187, App	c 352	14.4	0.4	17	1	US-10-061-201-1268	Sequence 1268, Ap
279	15.2	0.4	20	1	US-10-671-395-187	Sequence 188, App	c 353	14.4	0.4	17	1	US-10-061-201-1937	Sequence 1937, Ap
280	15.2	0.4	20	1	US-10-671-395-188	Sequence 189, App	c 354	14.4	0.4	17	1	US-10-061-201-1938	Sequence 1938, Ap
281	15.2	0.4	20	1	US-10-671-395-189	Sequence 190, App	c 355	14.4	0.4	17	1	US-10-230-006-1207	Sequence 1207, Ap
282	15.2	0.4	20	1	US-10-671-395-190	Sequence 191, App	c 356	14.4	0.4	17	1	US-10-342-902-523	Sequence 523, App
283	15.2	0.4	20	1	US-10-671-395-191	Sequence 192, App	357	14.4	0.4	17	1	US-10-342-902-1239	Sequence 1239, Ap
284	15.2	0.4	20	1	US-10-671-395-192	Sequence 193, App	c 358	14.4	0.4	17	1	US-10-138-674-5149	Sequence 5149, Ap
285	15.2	0.4	20	1	US-10-671-395-193	Sequence 194, App	c 359	14.4	0.4	17	1	US-10-138-674-6286	Sequence 6286, Ap
286	15.2	0.4	20	1	US-10-671-395-194	Sequence 195, App	360	14.4	0.4	17	1	US-10-138-674-6287	Sequence 6287, Ap
287	15.2	0.4	20	1	US-10-671-395-195	Sequence 196, App	c 361	14.4	0.4	17	1	US-10-287-949A-5149	Sequence 5149, Ap
288	15.2	0.4	20	1	US-10-671-395-196	Sequence 197, App	c 362	14.4	0.4	17	1	US-10-287-949A-6286	Sequence 6286, Ap
289	15.2	0.4	20	1	US-10-671-395-197	Sequence 198, App	363	14.4	0.4	17	1	US-10-287-949A-6287	Sequence 6287, Ap
290	15.2	0.4	20	1	US-10-671-395-198	Sequence 199, App	c 364	14.4	0.4	17	1	US-10-712-672-68	Sequence 68, Appl
291	15.2	0.4	20	1	US-10-671-395-199	Sequence 200, App	c 365	14.4	0.4	17	1	US-10-712-672-685	Sequence 685, App
292	15.2	0.4	20	1	US-10-671-395-200	Sequence 201, App	c 366	14.4	0.4	17	1	US-10-669-841-523	Sequence 523, App
293	15.2	0.4	20	1	US-10-671-395-201	Sequence 202, App	c 367	14.4	0.4	17	1	US-10-669-841-1239	Sequence 1239, Ap
294	15.2	0.4	20	1	US-10-671-395-202	Sequence 203, App	c 368	14.4	0.4	17	1	US-09-969-373-2495	Sequence 2495, Ap
295	15.2	0.4	20	1	US-10-671-395-203	Sequence 204, App	c 369	14.4	0.4	18	1	US-10-091-281-201	Sequence 201, App
296	15.2	0.4	20	1	US-10-671-395-204	Sequence 205, App	370	14.4	0.4	18	1	US-10-349-143-11340	Sequence 11340, A
297	15.2	0.4	20	1	US-10-671-395-205	Sequence 206, App	c 371	14.4	0.4	18	1	US-10-224-005-315	Sequence 315, App
298	15.2	0.4	20	1	US-10-671-395-206	Sequence 207, App	c 372	14.4	0.4	19	1	US-10-400-382-87	Sequence 87, Appl
299	15.2	0.4	20	1	US-10-671-395-207	Sequence 208, App	c 373	14.4	0.4	19	1	US-10-244-647-392	Sequence 392, App
300	15.2	0.4	20	1	US-10-671-395-208	Sequence 209, App	c 374	14.4	0.4	19	1	US-10-244-647-394	Sequence 394, App
301	15.2	0.4	20	1	US-10-671-395-209	Sequence 210, App	c 375	14.4	0.4	19	1	US-10-244-647-1038	Sequence 1038, Ap
302	15.2	0.4	20	1	US-10-671-395-210	Sequence 211, App	c 376	14.4	0.4	19	1	US-10-244-647-1040	Sequence 1040, Ap
303	15.2	0.4	20	1	US-10-671-395-211	Sequence 212, App	c 377	14.4	0.4	19	1	US-10-187-975-190	Sequence 190, App
304	15.2	0.4	20	1	US-10-671-395-212	Sequence 213, App	378	14.4	0.4	19	1	US-10-309-290-212	Sequence 212, App
305	15.2	0.4	20	1	US-10-671-395-213	Sequence 214, App	379	14.4	0.4	19	1	US-10-236-392-357	Sequence 357, App
306	15.2	0.4	20	1	US-10-671-395-214	Sequence 215, App	380	14.4	0.4	19	1	US-10-327-588-823	Sequence 823, App
307	15.2	0.4	20	1	US-10-671-395-215	Sequence 216, App	c 382	14.4	0.4	19	1	US-10-280-183A-429	Sequence 429, App
308	15.2	0.4	20	1	US-10-671-395-216	Sequence 217, App	c 383	14.4	0.4	20	1	US-09-866-108-950	Sequence 950, App
309	15.2	0.4	20	1	US-10-671-395-217	Sequence 218, App	c 384	14.2	0.4	17	1	US-09-866-108-951	Sequence 951, App
310	15.2	0.4	20	1	US-10-671-395-218	Sequence 219, App	c 385	14	0.4	17	1	US-09-866-108-952	Sequence 952, App
311	15.2	0.4	20	1	US-10-671-395-219	Sequence 220, App	c 386	14	0.4	17	1	US-09-866-108-953	Sequence 953, App
312	15.2	0.4	20	1	US-10-671-395-220	Sequence 221, App	c 387	14	0.4	17	1	US-09-818-875-3366	Sequence 3366, Ap
313	15.2	0.4	20	1	US-10-671-395-221	Sequence 222, App	c 388	14	0.4	17	1	US-09-818-875-3367	Sequence 3367, Ap
314	15.2	0.4	20	1	US-10-671-395-222	Sequence 223, App	c 389	14	0.4	17	1	US-10-209-787-3366	Sequence 3366, Ap
315	15.2	0.4	20	1	US-10-671-395-223	Sequence 224, App	390	14	0.4	17	1	US-10-261-185-3366	Sequence 3366, Ap
316	15.2	0.4	20	1	US-10-671-395-224	Sequence 225, App	391	14	0.4	17	1	US-10-261-185-3367	Sequence 3367, Ap
c 317	15.2	0.4	20	1	US-10-661-088-12	Sequence 12, Appl	c 392	14	0.4	17	1	US-10-138-674-6605	Sequence 6605, Ap
c 318	15.2	0.4	20	1	US-10-661-088-15	Sequence 15, Appl	c 393	14	0.4	17	1	US-10-138-674-6606	Sequence 6606, Ap
c 319	15.2	0.4	20	1	US-10-661-088-18	Sequence 18, Appl	394	14	0.4	17	1	US-10-287-949A-6605	Sequence 6605, Ap
320	15.2	0.4	20	1	US-10-661-088-21	Sequence 21, Appl	c 395	14	0.4	17	1		
c 321	15.2	0.4	20	1	US-10-661-088-24	Sequence 24, Appl	396	14	0.4	17	1		
322	15.2	0.4	20	1	US-10-661-088-27	Sequence 27, Appl	397	14	0.4	17	1		
c 323	15.2	0.4	20	1	US-10-661-088-30	Sequence 30, Appl	c 398	14	0.4	17	1		
324	15.2	0.4	20	1	US-10-661-088-33	Sequence 33, Appl	c 399	14	0.4	17	1		
325	15.2	0.4	17	1	US-09-780-533A-2213	Sequence 2213, Ap							

C 399	14	0.4	17	1	US-10-287-949A-6606	Sequence 6606, Ap	472	13.8	0.4	17	1	US-10-333-461-24	Sequence 24, Appl
C 400	14	0.4	17	1	US-10-723-361-950	Sequence 950, App	C 473	13.8	0.4	17	1	US-10-061-201-1263	Sequence 1263, Ap
C 401	14	0.4	17	1	US-10-723-361-951	Sequence 951, App	C 474	13.8	0.4	17	1	US-10-061-201-1264	Sequence 1264, Ap
C 402	14	0.4	17	1	US-10-723-361-952	Sequence 952, App	C 475	13.8	0.4	17	1	US-10-061-201-1868	Sequence 1868, Ap
C 403	14	0.4	17	1	US-10-723-361-953	Sequence 953, App	C 476	13.8	0.4	17	1	US-10-061-201-1939	Sequence 1939, Ap
C 404	14	0.4	17	1	US-10-681-074-3366	Sequence 3366, Ap	C 477	13.8	0.4	17	1	US-10-352-253A-24	Sequence 24, Appl
C 405	14	0.4	17	1	US-10-681-074-3367	Sequence 3367, Ap	C 478	13.8	0.4	17	1	US-10-056-229-132	Sequence 132, App
C 406	14	0.4	17	1	US-10-282-174-411	Sequence 411, Appl	C 479	13.8	0.4	17	1	US-10-056-229-137	Sequence 137, App
C 407	14	0.4	18	1	US-10-349-143-4657	Sequence 4657, Ap	C 480	13.8	0.4	17	1	US-10-430-882-164	Sequence 164, App
C 408	13.8	0.4	17	1	US-09-866-108-1176	Sequence 1176, Ap	C 481	13.8	0.4	17	1	US-10-352-255A-24	Sequence 24, Appl
C 409	13.8	0.4	17	1	US-09-866-108-1580	Sequence 1580, Ap	C 482	13.8	0.4	17	1	US-10-209-787-535	Sequence 535, App
C 410	13.8	0.4	17	1	US-09-866-108-2270	Sequence 2270, Ap	C 483	13.8	0.4	17	1	US-10-209-787-536	Sequence 536, App
C 411	13.8	0.4	17	1	US-09-866-108-2271	Sequence 2271, Ap	C 484	13.8	0.4	17	1	US-10-209-787-3162	Sequence 3162, Ap
C 412	13.8	0.4	17	1	US-09-866-108-6855	Sequence 6855, Ap	C 485	13.8	0.4	17	1	US-10-209-787-3163	Sequence 3163, Ap
C 413	13.8	0.4	17	1	US-09-866-108-6856	Sequence 6856, Ap	C 486	13.8	0.4	17	1	US-10-261-185-535	Sequence 535, App
C 414	13.8	0.4	17	1	US-09-866-108-6929	Sequence 6929, Ap	C 487	13.8	0.4	17	1	US-10-261-185-536	Sequence 536, App
C 415	13.8	0.4	17	1	US-09-866-108-6930	Sequence 6930, Ap	C 488	13.8	0.4	17	1	US-10-261-185-3162	Sequence 3162, Ap
C 416	13.8	0.4	17	1	US-09-866-108-8116	Sequence 8116, Ap	C 489	13.8	0.4	17	1	US-10-261-185-3163	Sequence 3163, Ap
C 417	13.8	0.4	17	1	US-09-866-108-8454	Sequence 8454, Ap	C 490	13.8	0.4	17	1	US-10-344-741-20	Sequence 20, Appl
C 418	13.8	0.4	17	1	US-09-866-108-8873	Sequence 8873, Ap	C 491	13.8	0.4	17	1	US-10-342-902-1240	Sequence 1240, Ap
C 419	13.8	0.4	17	1	US-09-866-108-10318	Sequence 10318, A	C 492	13.8	0.4	17	1	US-10-342-902-2087	Sequence 2087, Ap
C 420	13.8	0.4	17	1	US-09-827-998-196	Sequence 196, App	C 493	13.8	0.4	17	1	US-10-342-902-2088	Sequence 2088, Ap
C 421	13.8	0.4	17	1	US-09-827-998-483	Sequence 483, App	C 494	13.8	0.4	17	1	US-10-675-685-196	Sequence 196, App
C 422	13.8	0.4	17	1	US-09-827-998-775	Sequence 775, App	C 495	13.8	0.4	17	1	US-10-675-685-483	Sequence 483, App
C 423	13.8	0.4	17	1	US-09-827-998-776	Sequence 776, App	C 496	13.8	0.4	17	1	US-10-675-685-483	Sequence 775, App
C 424	13.8	0.4	17	1	US-09-817-014-131	Sequence 131, App	C 497	13.8	0.4	17	1	US-10-675-685-776	Sequence 776, App
C 425	13.8	0.4	17	1	US-09-817-014-136	Sequence 136, App	C 498	13.8	0.4	17	1	US-10-138-674-1070	Sequence 1070, Ap
C 426	13.8	0.4	17	1	US-09-864-785-551	Sequence 551, App	C 499	13.8	0.4	17	1	US-10-138-674-1071	Sequence 1071, Ap
C 427	13.8	0.4	17	1	US-09-825-805-720	Sequence 720, App	C 500	13.8	0.4	17	1	US-10-138-674-1074	Sequence 1074, Ap
C 428	13.8	0.4	17	1	US-09-818-875-535	Sequence 535, App	C 501	13.8	0.4	17	1	US-10-138-674-1075	Sequence 1075, Ap
C 429	13.8	0.4	17	1	US-09-818-875-536	Sequence 536, App	C 502	13.8	0.4	17	1	US-10-138-674-2644	Sequence 2644, Ap
C 430	13.8	0.4	17	1	US-09-818-875-3162	Sequence 3162, Ap	C 503	13.8	0.4	17	1	US-10-138-674-2780	Sequence 2780, Ap
C 431	13.8	0.4	17	1	US-09-818-875-3163	Sequence 3163, Ap	C 504	13.8	0.4	17	1	US-10-138-674-3600	Sequence 3600, Ap
C 432	13.8	0.4	17	1	US-09-780-533A-237	Sequence 237, App	C 505	13.8	0.4	17	1	US-10-138-674-4631	Sequence 4631, Ap
C 433	13.8	0.4	17	1	US-09-780-533A-1771	Sequence 1771, Ap	C 506	13.8	0.4	17	1	US-10-138-674-5574	Sequence 5574, Ap
C 434	13.8	0.4	17	1	US-09-780-533A-2321	Sequence 2321, Ap	C 507	13.8	0.4	17	1	US-10-138-674-5575	Sequence 5575, Ap
C 435	13.8	0.4	17	1	US-09-780-533A-2461	Sequence 2461, Ap	C 508	13.8	0.4	17	1	US-10-138-674-6139	Sequence 6139, Ap
C 436	13.8	0.4	17	1	US-09-780-533A-2462	Sequence 2462, Ap	C 509	13.8	0.4	17	1	US-10-138-674-7992	Sequence 7992, Ap
C 437	13.8	0.4	17	1	US-09-927-046-299	Sequence 299, App	C 510	13.8	0.4	17	1	US-10-138-674-8417	Sequence 8417, Ap
C 438	13.8	0.4	17	1	US-09-927-046-1429	Sequence 1429, Ap	C 511	13.8	0.4	17	1	US-10-138-674-9161	Sequence 9161, Ap
C 439	13.8	0.4	17	1	US-09-927-046-2074	Sequence 2074, Ap	C 512	13.8	0.4	17	1	US-10-287-949A-1070	Sequence 1070, Ap
C 440	13.8	0.4	17	1	US-09-877-478-1240	Sequence 1240, Ap	C 513	13.8	0.4	17	1	US-10-287-949A-1071	Sequence 1071, Ap
C 441	13.8	0.4	17	1	US-09-877-478-2087	Sequence 2087, Ap	C 514	13.8	0.4	17	1	US-10-287-949A-1074	Sequence 1074, Ap
C 442	13.8	0.4	17	1	US-09-877-478-2088	Sequence 2088, Ap	C 515	13.8	0.4	17	1	US-10-287-949A-1075	Sequence 1075, Ap
C 443	13.8	0.4	17	1	US-09-848-754A-809	Sequence 809, App	C 516	13.8	0.4	17	1	US-10-287-949A-2644	Sequence 2644, Ap
C 444	13.8	0.4	17	1	US-09-848-754A-1209	Sequence 1209, Ap	C 517	13.8	0.4	17	1	US-10-287-949A-2780	Sequence 2780, Ap
C 445	13.8	0.4	17	1	US-09-848-754A-1724	Sequence 1724, Ap	C 518	13.8	0.4	17	1	US-10-287-949A-3600	Sequence 3600, Ap
C 446	13.8	0.4	17	1	US-09-848-754A-1927	Sequence 1927, Ap	C 519	13.8	0.4	17	1	US-10-287-949A-4631	Sequence 4631, Ap
C 447	13.8	0.4	17	1	US-09-848-754A-2332	Sequence 2332, Ap	C 520	13.8	0.4	17	1	US-10-287-949A-5574	Sequence 5574, Ap
C 448	13.8	0.4	17	1	US-09-848-754A-2624	Sequence 2624, Ap	C 521	13.8	0.4	17	1	US-10-287-949A-5575	Sequence 5575, Ap
C 449	13.8	0.4	17	1	US-09-848-754A-2740	Sequence 2740, Ap	C 522	13.8	0.4	17	1	US-10-287-949A-6139	Sequence 6139, Ap
C 450	13.8	0.4	17	1	US-09-848-754A-3114	Sequence 3114, Ap	C 523	13.8	0.4	17	1	US-10-287-949A-7992	Sequence 7992, Ap
C 451	13.8	0.4	17	1	US-09-930-423-875	Sequence 875, App	C 524	13.8	0.4	17	1	US-10-287-949A-8417	Sequence 8417, Ap
C 452	13.8	0.4	17	1	US-09-930-423-1685	Sequence 1685, Ap	C 525	13.8	0.4	17	1	US-10-287-949A-9161	Sequence 9161, Ap
C 453	13.8	0.4	17	1	US-09-780-164-707	Sequence 707, App	C 526	13.8	0.4	17	1	US-10-712-672-69	Sequence 69, Appl
C 454	13.8	0.4	17	1	US-09-827-395A-164	Sequence 164, App	C 527	13.8	0.4	17	1	US-10-712-672-82	Sequence 82, Appl
C 455	13.8	0.4	17	1	US-09-740-332-3867	Sequence 3867, Ap	C 528	13.8	0.4	17	1	US-10-712-672-684	Sequence 684, App
C 456	13.8	0.4	17	1	US-09-745-237A-875	Sequence 875, App	C 529	13.8	0.4	17	1	US-10-712-672-1032	Sequence 1032, Ap
C 457	13.8	0.4	17	1	US-09-817-879-3867	Sequence 1875, Ap	C 530	13.8	0.4	17	1	US-10-712-672-1106	Sequence 1106, Ap
C 458	13.8	0.4	17	1	US-10-085-395-4	Sequence 4, Appli	C 531	13.8	0.4	17	1	US-10-669-841-1240	Sequence 1240, Ap
C 459	13.8	0.4	17	1	US-10-060-756A-1913	Sequence 1913, Ap	C 532	13.8	0.4	17	1	US-10-669-841-1943	Sequence 1943, Ap
C 460	13.8	0.4	17	1	US-10-060-756A-1914	Sequence 1914, Ap	C 533	13.8	0.4	17	1	US-10-669-841-6460	Sequence 6460, Ap
C 461	13.8	0.4	17	1	US-10-060-756A-1916	Sequence 1916, Ap	C 534	13.8	0.4	17	1	US-10-723-361-1176	Sequence 1176, Ap
C 462	13.8	0.4	17	1	US-10-060-998-1325	Sequence 1325, Ap	C 535	13.8	0.4	17	1	US-10-723-361-1580	Sequence 1580, Ap
C 463	13.8	0.4	17	1	US-10-163-552-498	Sequence 498, App	C 536	13.8	0.4	17	1	US-10-723-361-2270	Sequence 2270, Ap
C 464	13.8	0.4	17	1	US-10-156-306-519	Sequence 519, App	C 537	13.8	0.4	17	1	US-10-723-361-2271	Sequence 2271, Ap
C 465	13.8	0.4	17	1	US-10-156-306-1646	Sequence 1646, Ap	C 538	13.8	0.4	17	1	US-10-723-361-6855	Sequence 6855, Ap
C 466	13.8	0.4	17	1	US-10-156-306-2342	Sequence 2342, Ap	C 539	13.8	0.4	17	1	US-10-723-361-6929	Sequence 6929, Ap
C 467	13.8	0.4	17	1	US-10-156-306-4374	Sequence 4374, Ap	C 540	13.8	0.4	17	1	US-10-723-361-6930	Sequence 6930, Ap
C 468	13.8	0.4	17	1	US-10-156-306-4780	Sequence 4780, Ap	C 541	13.8	0.4	17	1	US-10-723-361-8116	Sequence 8116, Ap
C 469	13.8	0.4	17	1	US-10-331-873-85	Sequence 85, Appl	C 542	13.8	0.4	17	1	US-10-723-361-8454	Sequence 8454, Ap
C 470	13.8	0.4	17	1	US-10-238-700-1172	Sequence 1172, Ap	C 543	13.8	0.4	17	1	US-10-723-361-8873	Sequence 8873, Ap
C 471	13.8	0.4	17	1			C 544	13.8	0.4	17	1		

545	17	1	US-10-723-361-10318	A	Sequence 10318,	13.8	0.4	17	1	US-09-906-618-229	Sequence 229, App
546	17	1	US-10-645-471A-22	Sequence 22,	13.8	0.4	17	1	US-09-907-728-229	Sequence 229, App	
547	17	1	US-10-735-592-55	Sequence 55,	13.8	0.4	17	1	US-09-904-805-229	Sequence 229, App	
548	17	1	US-10-681-074-535	Sequence 535,	13.8	0.4	17	1	US-09-904-805-229	Sequence 229, App	
549	17	1	US-10-681-074-536	Sequence 536,	13.8	0.4	17	1	US-09-906-722A-229	Sequence 229, App	
550	17	1	US-10-681-074-3162	Sequence 3162,	13.8	0.4	17	1	US-09-906-722A-229	Sequence 229, App	
551	17	1	US-10-681-074-3163	Sequence 3163,	13.8	0.4	17	1	US-09-908-576-229	Sequence 229, App	
552	17	1	US-09-822-485-28	Sequence 28,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
553	17	1	US-09-909-320-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
554	17	1	US-09-909-088B-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
555	17	1	US-09-905-291A-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
556	17	1	US-09-902-853-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
557	17	1	US-09-907-853-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
558	17	1	US-09-907-841-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
559	17	1	US-09-904-011-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
560	17	1	US-09-903-640-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
561	17	1	US-09-908-093-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
562	17	1	US-09-906-742-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
563	17	1	US-09-906-838-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
564	17	1	US-09-907-613-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
565	17	1	US-09-907-942-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
566	17	1	US-09-904-859-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
567	17	1	US-09-909-204-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
568	17	1	US-09-904-820-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
569	17	1	US-09-904-786-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
570	17	1	US-09-906-646-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
571	17	1	US-09-906-700-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
572	17	1	US-09-903-786-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
573	17	1	US-09-902-903-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
574	17	1	US-09-903-749A-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
575	17	1	US-09-904-119-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
576	17	1	US-09-904-956-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
577	17	1	US-09-902-736-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
578	17	1	US-09-907-794-229	Sequence 229,	13.8	0.4	17	1	US-10-340-097-37	Sequence 37, App	
579	17	1	US-09-903-943-229	Sequence 229,	13.8	0.4	17	1	US-1		


```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-10

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 83 TGGCTTGGTCTGGGCGCAAG 102
      |||||
Db 20 TGGCTTGGTCTGGGCGCAAG 1

RESULT 6
US-10-003-354-11/c
; Sequence 11, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-11

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 TGGGCGCAAGTCCACGAG 112
      |||||
Db 20 TGGGCGCAAGTCCACGAG 1

RESULT 7
US-10-003-354-12/c
; Sequence 12, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-12

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 215 CGAATGGTGTGGCCTTGAC 234
      |||||
```

Db 20 CGAATGGTGTGGCCTTGAC 1

RESULT 8

US-10-003-354-13/c
; Sequence 13, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-13

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 236 GGTCCAGGAGCGGCTCGAC 255
 |||||
Db 20 GGTCCAGGAGCGGCTCGAC 1

RESULT 9

US-10-003-354-14/c
; Sequence 14, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-14

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 254 ACGTGTCTGAGGAGGCCG 273
 |||||
Db 20 ACGTGTCTGAGGAGGCCG 1

RESULT 10

US-10-003-354-15/c
; Sequence 15, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-15

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 322 TTGGAAGATTCGATTCGA 341
|||||
DB 20 TTGGAAGATTCGATTCGA 1

RESULT 11

US-10-003-354-16/c
; Sequence 16, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-16

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 336 TTCCGAGAGGAGGAGACC 355
|||||
DB 20 TTCCGAGAGGAGGAGAAC 1

RESULT 12

US-10-003-354-17/c
; Sequence 17, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-17

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 458 GCGGTCCCTTCCTGACCTT 477
|||||
DB 20 GCGGTCCCTTCCTGACCTT 1

RESULT 13

US-10-003-354-18/c
; Sequence 18, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-18

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CATCTGGAATCAAGAGACCC 505
|||||
DB 20 CATCTGGAATCAAGAGACCC 1

RESULT 14

US-10-003-354-19/c
; Sequence 19, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-19

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 500 AGACCCATGGCATCTGAGGT 519
|||||
DB 20 AGACCCATGGCATCTGAGGT 1

RESULT 15

US-10-003-354-20/c
; Sequence 20, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

```
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-20
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 514 TCAGGTGCCTTATGCTCTG 533
Db 20 TCAGGTGCCTTATGCTCTG 1

RESULT 16
US-10-003-354-21/c
; Sequence 21, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-21
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 526 TGCCTCTGGCATGCCATCA 545
Db 20 TGCCTCTGGCATGCCATCA 1

RESULT 17
US-10-003-354-22/c
; Sequence 22, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-22
```

US-10-003-354-22

```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 540 CCATCAAGAAATAGGCCAT 559
Db 20 CCATCAAGAAATAGGCCAT 1
```

RESULT 18

```
US-10-003-354-23/c
; Sequence 23, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-23
```

```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGGCCATAGAGTGTGATT 572
Db 20 AGGCCATAGAGTGTGATT 1
```

RESULT 19

```
US-10-003-354-24/c
; Sequence 24, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-24
```

```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 633 TAGGCATTACCCACTGTG 652
Db 20 TAGGCATTACCCACTGTG 1
```

RESULT 20

US-10-003-354-25/c

; Sequence 25, Application US/10003354
; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 25

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-25

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 649 TGTGGGAGCCTGAGTACCA 668

DB 20 TGTGGGAGCCTGAGTACCA 1

RESULT 21

US-10-003-354-26/c

; Sequence 26, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 26

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-26

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 678 GTGATGCTCCTCATGCAAGAT 697

DB 20 GTGATGCTCCTCATGCAAGAT 1

RESULT 22

US-10-003-354-27/c

; Sequence 27, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 27

; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-27

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 TTCGTTTCAAGACCTATGCA 790

DB 20 TTCGTTTCAAGACCTATGCA 1

RESULT 23

US-10-003-354-28/c

; Sequence 28, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 28

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-28

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 780 AGACCTATGCACCTGTGGC 799

DB 20 AGACCTATGCACCTGTGGC 1

RESULT 24

US-10-003-354-29/c

; Sequence 29, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 29

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-29

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 807 ACTTCGGGAGCTATTGGT 826

DB 20 ACTTCGGGAGCTATTGGT 1


```
RESULT 25
US-10-003-354-30/c
; Sequence 30, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-30

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 868 GCTGATTGAACCTCTGTAGCT 887
Db 20 GCTGATTGAACCTCTGTAGCT 1

RESULT 26
US-10-003-354-31/c
; Sequence 31, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-31

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 868 GCTGATTGAACCTCTGTAGCT 887
Db 20 GCTGATTGAACCTCTGTAGCT 1

RESULT 27
US-10-003-354-32/c
; Sequence 32, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
```

```
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-32
```

```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 979 GCTGCTCCAGGATACATA 998
Db 20 GCTGCTCCAGGATACATA 1
```

```
RESULT 28
US-10-003-354-33/c
; Sequence 33, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-33
```

```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 997 CATGAACCTCAACCAGAAC 1016
Db 20 CATGAACCTCAACCAGAAC 1
```

```
RESULT 29
US-10-003-354-34/c
; Sequence 34, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-34
```

```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-37

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1205 AAAGACCTAGACTTCTTACA 1224
      |||||
Db      20 AAAGACCTAGACTTCTTACA 1

RESULT 33
US-10-003-354-38/c
; Sequence 38, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-38

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1213 AGACTTCTTACAAGACATCC 1232
      |||||
Db      20 AGACTTCTTACAAGACATCC 1

RESULT 34
US-10-003-354-39/c
; Sequence 39, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-39
```

```
QY      1002 ACCTCAACCAAGCCCTCGG 1021
      |||||
Db      20 ACCTCAACCAAGCCCTCGG 1

RESULT 30
US-10-003-354-35/c
; Sequence 35, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-35

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1043 GGACTGTACTGTGTCAGGC 1062
      |||||
Db      20 GGACTGTACTGTGTCAGGC 1

RESULT 31
US-10-003-354-36/c
; Sequence 36, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-36

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1178 GAGCGAGAGAGCCCTCTTCC 1197
      |||||
Db      20 GAGCGAGAGAGCCCTCTTCC 1

RESULT 32
US-10-003-354-37/c
; Sequence 37, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
```

```
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-42

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1218 TCTTACAGACATCCTGTAT 1237
Db 20 TCTTACAGACATCCTGTAT 1

RESULT 35
US-10-003-354-40/c
; Sequence 40, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-40

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1285 GCAGCGTGACTGTTGGTGC 1304
Db 20 GCAGCGTGACTGTTGGTGC 1

RESULT 36
US-10-003-354-41/c
; Sequence 41, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-41

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1321 AATGGATTACAGCTCTTGA 1340
Db 20 AATGGATTACAGCTCTTGA 1

RESULT 37
US-10-003-354-42/c
; Sequence 42, Application US/10003354
```

```
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-42

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 TATAGATCATGCACACGAG 1373
Db 20 TATAGATCATGCACACGAG 1

RESULT 38
US-10-003-354-43/c
; Sequence 43, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-43

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 TAAGCAGTGAACACAGTAC 1399
Db 20 TAAGCAGTGAACACAGTAC 1

RESULT 39
US-10-003-354-44/c
; Sequence 44, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-44

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1452 TGAATCCATCCAGGAGAG 1471
|||
DB 20 TGAATCCATCCAGGAGAG 1

RESULT 40
US-10-003-354-45/c
; Sequence 45, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-45

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1480 GGGTGGTACCATGGAGACTG 1499
|||
DB 20 GGGTGGTACCATGGAGACTG 1

RESULT 41
US-10-003-354-46/c
; Sequence 46, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-46

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1526 CGGAATAGTAAGGGAAG 1545
|||
DB 20 CGGAATAGTAAGGGAAG 1

RESULT 42
US-10-003-354-47/c
; Sequence 47, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-47

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1552 GCTTATATGGCATCATG 1571
|||
DB 20 GCTTATATGGCATCATG 1

RESULT 43
US-10-003-354-48/c
; Sequence 48, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-48

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1580 CAGCTTACAGTTGTGTTAA 1599
|||
DB 20 CAGCTTACAGTTGTGTTAA 1

RESULT 44
US-10-003-354-49/c
; Sequence 49, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 49

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-49

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1591 GTTTGTTAAGAGTTGGAC 1610

DB 20 GTTTGTTAAGAGTTGGAGC 1

RESULT 45

US-10-003-354-50/c

; Sequence 50, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 50

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-50

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1730 CCTTCTCCTTCCAAAAGTT 1749

DB 20 CCTTCTCCTTCCAAAAGTT 1

RESULT 46

US-10-003-354-51/c

; Sequence 51, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 51

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-51

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1755 CTGGCTCATCTTCTCTCGG 1774

DB 20 CTGGCTCATCTTCTCTCGG 1

RESULT 47

US-10-003-354-52/c

; Sequence 52, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 52

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-52

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1766 TTCTCTCGGCGAGCAGGCTC 1785

DB 20 TTCTCTCGGCGAGCAGGCTC 1

RESULT 48

US-10-003-354-53/c

; Sequence 53, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 53

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-53

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1786 CAGTGGCAACTCCTGCATTA 1805

DB 20 CAGTGGCAACTCCTGCATTA 1

RESULT 49

US-10-003-354-54/c

; Sequence 54, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-54

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1815 CATGGTCTCTGGGAACAC 1834
|||||
Db 20 CATGGTCTCTGGGAACAC 1

RESULT 50
US-10-003-354-55/c
; Sequence 55, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-55

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1872 GCGTTACCTTGGTCGTCCT 1891
|||||
Db 20 GCGTTACCTTGGTCGTCCT 1

RESULT 51
US-10-003-354-56/c
; Sequence 56, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-56

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1884 GTCGTCCTGATGTTTACCT 1903
|||||
Db 20 GTCGTCCTGATGTTTACCT 1

RESULT 52
US-10-003-354-57/c
; Sequence 57, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-57

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1914 CTTTGGAGGAATCACTGAG 1933
|||||
Db 20 CTTTGGAGGAATCACTGAG 1

RESULT 53
US-10-003-354-58/c
; Sequence 58, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-58

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1967 CTAGTTGGAGAGACTTTGCA 1986
|||||
Db 20 CTAGTTGGAGAGACTTTGCA 1

RESULT 54
US-10-003-354-59/c
; Sequence 59, Application US/10003354
; Publication No. US20030114400A1

```

; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-003-354-59

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1980 CTTTGCAATGCTAACTACA 1999
Db 20 CTTTGCAATGCTAACTACA 1

RESULT 55
US-10-003-354-60/c
; Sequence 60, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-003-354-60

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2001 GTACAACCTTGGAAAGCTT 2020
Db 20 GTACAACCTTGGAAAGCTT 1

RESULT 56
US-10-003-354-61/c
; Sequence 61, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-003-354-61

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2011 GGAAAAGCTTGAAGTTGCAG 2030
Db 20 GGAAAAGCTTGAAGTTGCAG 1

RESULT 57
US-10-003-354-62/c
; Sequence 62, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-003-354-62

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2026 TGCAGATCAGAGTTCACCC 2045
Db 20 TGCAGATCAGAGTTCACCC 1

RESULT 58
US-10-003-354-63/c
; Sequence 63, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-003-354-63

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2039 TTCACCCATTAAAGCCCAAG 2058
Db 20 TTCACCCATTAAAGCCCAAG 1

```

```
RESULT 59
US-10-003-354-64/c
; Sequence 64, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-64
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2050 AGCGCAAGCCTCGAAGAC 2069
| | | | | | | | | | | | | | | |
Db 20 AGCGCAAGCCTCGAAGAC 1

RESULT 60
US-10-003-354-65/c
; Sequence 65, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-65
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2063 AGAAGACCTGGAACAAGATT 2082
| | | | | | | | | | | | | | | |
Db 20 AGAAGACCTGGAACAAGATT 1

RESULT 61
US-10-003-354-66/c
; Sequence 66, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
```

```
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-66
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2092 CTGTGATCCCAAGATGTCAG 2111
| | | | | | | | | | | | | | | |
Db 20 CTGTGATCCCAAGATGTCAG 1

RESULT 62
US-10-003-354-67/c
; Sequence 67, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-67
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2209 AAGAACCTTCTCTCCTTCTCT 2228
| | | | | | | | | | | | | | | |
Db 20 AAGAACCTTCTCTCCTTCTCT 1

RESULT 63
US-10-003-354-68/c
; Sequence 68, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-68
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2220 CTCCTTCTCTTCTCTCATGA 2239
```


Db 20 CTCCTTCCTCTTCCTCATGA 1
|||||

RESULT 64

US-10-003-354-69/c

; Sequence 69, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 69

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-69

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2231 TCCTCATGAATGGCCTTAG 2250

Db 20 TCCTCATGAATGGCCTTAG 1

RESULT 65

US-10-003-354-70/c

; Sequence 70, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 70

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-70

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2365 TTCATGCTGGAATGGGATT 2384

Db 20 TTCATGCTGGAATGGGATT 1

RESULT 66

US-10-003-354-71/c

; Sequence 71, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 71

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-71

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2388 GGACTTGGCAGCTTCTTTC 2407

Db 20 GGACTTGGCAGCTTCTTTC 1

RESULT 67

US-10-003-354-72/c

; Sequence 72, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 72

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-72

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2424 GGACCCGGACTCTTAATTC 2443

Db 20 GGACCCGGACTCTTAATTC 1

RESULT 68

US-10-003-354-73/c

; Sequence 73, Application US/10003354

; Publication No. US20030114400A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0348

; CURRENT APPLICATION NUMBER: US/10/003,354

; CURRENT FILING DATE: 2001-12-06

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 73

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-003-354-73

Query Match 0.5%; Score 20; DB 1; Length 20;

```
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2435 CTTAATTCCTCAGGACAGA 2454
      |||||
Db 20 CTTAATTCCTCAGGACAGA 1

RESULT 69
US-10-003-354-74/c
; Sequence 74, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-74

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2448 GGACAGACTAGTGGCACAT 2467
      |||||
Db 20 GGACAGACTAGTGGCACAT 1

RESULT 70
US-10-003-354-75/c
; Sequence 75, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-75

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3119 CTTAAACTCATGGGAGACA 3138
      |||||
Db 20 CTTAAACTCATGGGAGACA 1

RESULT 71
US-10-003-354-76/c
; Sequence 76, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
```

```
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-76

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3124 ACTCATGGGGAGACAGACA 3143
      |||||
Db 20 ACTCATGGGGAGACAGACA 1

RESULT 72
US-10-003-354-77/c
; Sequence 77, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-77

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3160 GTCATTGCTGTGCCATATGT 3179
      |||||
Db 20 GTCATTGCTGTGCCATATGT 1

RESULT 73
US-10-003-354-78/c
; Sequence 78, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE,
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-78

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3192 TCTTCATGCAGGAAGTTGG 3211
      |||
Db 20 TCTTCATGCAGGAAGTTGG 1

RESULT 74
US-10-003-354-79/c
; Sequence 79, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-79

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3242 CGCTACAAGAGTTGCGTT 3261
      |||
Db 20 CGCTACAAGAGTTGCGTT 1

RESULT 75
US-10-003-354-80/c
; Sequence 80, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-80

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3301 GGCCTGATCTCAGGCAGA 3320
      |||
Db 20 GGCCTGATCTCAGGCAGA 1

RESULT 76
```

```

US-10-003-354-81/c
; Sequence 81, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-81

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3317 CAGATTGTTGAATTCCTGTT 3336
      |||
Db 20 CAGATTGTTGAATTCCTGTT 1

RESULT 77
US-10-003-354-82/c
; Sequence 82, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-82

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3355 ACCCTGCCTTGATAATATGT 3374
      |||
Db 20 ACCCTGCCTTGATAATATGT 1

RESULT 78
US-10-003-354-83/c
; Sequence 83, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 83
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-83

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3363 TTGATAATATGTTAGCCCAT 3382
      |||||
Db 20 TTGATAATATGTTAGCCCAT 1

RESULT 79
US-10-003-354-84/c
; Sequence 84, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-84

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3386 CCAATAACTGCTATATTA 3405
      |||||
Db 20 CCAATAACTGCTATATTA 1

RESULT 80
US-10-003-354-85/c
; Sequence 85, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-85

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3520 TTTATTAAGCACAGTTCT 3539
      |||||
```

```
Db 20 TTTATTAAGCACAGTTCT 1

RESULT 81
US-10-003-354-86/c
; Sequence 86, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-86

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3631 CTACTTTGTATTGTTTCAGAA 3650
      |||||
Db 20 CTACTTTGTATTGTTTCAGAA 1

RESULT 82
US-10-003-354-87/c
; Sequence 87, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-87

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3640 ATTGTTCAGAAATGGCAAT 3659
      |||||
Db 20 ATTGTTCAGAAATGGCAAT 1

RESULT 83
US-10-098-263B-109556/c
; Sequence 109556, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
; APPLICANT: Mittman, Michael
; TITLE OF INVENTION: Human Microarray
; FILE REFERENCE: 3118.1
; CURRENT APPLICATION NUMBER: US/10/098,263B
; CURRENT FILING DATE: 2003-01-08
```

; PRIOR APPLICATION NUMBER: 60/276,759
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 131066
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 109556
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-098-263B-109556

Query Match 0.5%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 17;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 415 CTCGGGGCGTCTTCGGTCG 437
|||||
DB 24 CTCGGCCAGTCGTCGTCG 2

RESULT 84
US-10-344-093A-33
; Sequence 33, Application US/10344093A
; Publication No. US20040076969A1
; GENERAL INFORMATION:
; APPLICANT: CAILLOUX, Fabrice
; APPLICANT: GOBRON, Stephane
; TITLE OF INVENTION: Method for detecting known mutations in tube
; FILE REFERENCE: D19019 - 344 339
; CURRENT APPLICATION NUMBER: US/10/344,093A
; CURRENT FILING DATE: 2003-10-21
; PRIOR APPLICATION NUMBER: PCT/FR 01/02 574
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: FR 00/104 25
; PRIOR FILING DATE: 2000-08-08
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Primer for the detection of the mutations associated
; OTHER INFORMATION: with mucoviscidosis.
US-10-344-093A-33

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2566 CTTTCTCTCTCTTTTCTTTT 2586
|||||
DB 1 CTTTCTCTCTTTTCTTTT 21

RESULT 85
US-10-085-198-533
; Sequence 533, Application US/10085198
; Publication No. US2004009907A1
; GENERAL INFORMATION:
; APPLICANT: Alcabrook et al.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-279
; CURRENT APPLICATION NUMBER: US/10/085,198
; CURRENT FILING DATE: 2002-02-25
; PRIOR APPLICATION NUMBER: 60/271,646
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: 60/276,401
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/311,981
; PRIOR FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/312,858
; PRIOR FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: 60/271,840

; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 60/277,324
; PRIOR FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 60/286,096
; PRIOR FILING DATE: 2001-04-21
; PRIOR APPLICATION NUMBER: 60/299,695
; PRIOR FILING DATE: 2001-06-20
; PRIOR APPLICATION NUMBER: 60/315,614
; PRIOR FILING DATE: 2001-08-29
; PRIOR APPLICATION NUMBER: 60/272,405
; PRIOR FILING DATE: 2001-02-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 653
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 533
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide primer
US-10-085-198-533

Query Match 0.5%; Score 17.4; DB 1; Length 22;
Best Local Similarity 94.7%; Pred. No. 51;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 140 GGGGAAGTATCCCTGTG 158
|||||
DB 1 GGGGAAGTATCCCTGTG 19

RESULT 86
US-10-072-012-1054
; Sequence 1054, Application US/10072012
; Publication No. US20040033493A1
; GENERAL INFORMATION:
; APPLICANT: Tchernev, Velizar
; APPLICANT: Spytek, Kimberly
; APPLICANT: Zethusen, Bryan
; APPLICANT: Patturajan, Meera
; APPLICANT: Shinkets, Richard
; APPLICANT: Li, Li
; APPLICANT: Gangolli, Esha
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Anderson, David W.
; APPLICANT: Rastelli, Luca
; APPLICANT: Miller, Charles E.
; APPLICANT: Gerlach, Valerie
; APPLICANT: Taupier Jr, Raymond J.
; APPLICANT: Gusev, Vladimir V.
; APPLICANT: Colman, Steven D.
; APPLICANT: Wolenc, Adam R.
; APPLICANT: Pena, Carol E. A
; APPLICANT: Furtak, Katarzyna
; APPLICANT: Grosse, William M.
; APPLICANT: Alsobrook II, John P.
; APPLICANT: Lepley, Denise M.
; APPLICANT: Rieger, Daniel K.
; APPLICANT: Burgess, Catherine E.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-258
; CURRENT APPLICATION NUMBER: US/10/072,012
; CURRENT FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: 60/265,102
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 60/265,514
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 60/265,517
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 60/265,412
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 60/265,395

; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 60/266,406
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 60/266,767
; PRIOR FILING DATE: 2001-02-05
; PRIOR APPLICATION NUMBER: 60/267,057
; PRIOR FILING DATE: 2001-02-07
; PRIOR APPLICATION NUMBER: 60/266,975
; PRIOR FILING DATE: 2001-02-07
; PRIOR APPLICATION NUMBER: 60/267,459
; PRIOR FILING DATE: 2001-02-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1391
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1054
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Ag3010 Forward

US-10-072-012-1054

Query Match 0.5%; Score 17.4; DB 1; Length 22;
Best Local Similarity 94.7%; Pred. No. 51;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 140 GGGGAAGTATCCCTGTG 158
DB 1 GGGGAAGTATCCCTGTG 19

RESULT 87

US-10-028-248A-208/c
; Sequence 208, Application US/10028248A
; Publication No. US20030235882A1

GENERAL INFORMATION:

; APPLICANT: Shimkets, Richard
; APPLICANT: Patturajan, Meera
; APPLICANT: Vernet, Corine
; APPLICANT: Casman, Stacie
; APPLICANT: Malyankar, Uriel
; APPLICANT: Shenoy, Suresh
; APPLICANT: Spytek, Kimberly
; APPLICANT: Gangolli, Esha
; APPLICANT: Miller, Charles
; APPLICANT: Boldog, Ferenc
; APPLICANT: Li, Li
; APPLICANT: Taupier Jr, Raymond J
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Smithson, Glenda
; APPLICANT: Zerhusen, Bryan
; APPLICANT: Liu, Xiaohong
; APPLICANT: Colman, Steven
; APPLICANT: Tchernev, Velizar
; APPLICANT: Si, Jingsheng
; APPLICANT: Edinger, Shlomit
; APPLICANT: Stone, David
; APPLICANT: Sciore, Paul
; APPLICANT: Millet, Isabelle
; APPLICANT: Rothenberg, Mark
; TITLE OF INVENTION: NO. US20030235882A1el Nucleic Acids and Polypeptides and Methods
; TITLE OF INVENTION: Thereof
; FILE REFERENCE: 21402-222
; CURRENT APPLICATION NUMBER: US/10/028,248A
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 60/256619
; PRIOR FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: 60/262959
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: 60/272408
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/285189
; PRIOR FILING DATE: 2001-04-20

; PRIOR APPLICATION NUMBER: 60/308039
; PRIOR FILING DATE: 2001-07-26
; PRIOR APPLICATION NUMBER: 60/311266
; PRIOR FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 211
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 208
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
; OTHER INFORMATION: sequence
US-10-028-248A-208

Query Match 0.5%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 57;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 490 TGGATCAAGAGACCCATGGCA 511
DB 22 TGGATCAAGAGACTCAGGTA 1

RESULT 88

US-10-107-782-208/c

; Sequence 208, Application US/10107782
; Publication No. US20040018970A1

GENERAL INFORMATION:

; APPLICANT: Boldog, Ferenc,
; APPLICANT: Casman, Stacie
; APPLICANT: Colman, Steve,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Gangolli, Esha,
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Li, Li,
; APPLICANT: Liu, Xiaohong,
; APPLICANT: Malyankar, Uriel,
; APPLICANT: Miller, Charles,
; APPLICANT: Millet, Isabelle,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Sciore, Paul,
; APPLICANT: Shenoy, Suresh,
; APPLICANT: Shimkets, Richard,
; APPLICANT: Si, Jingsheng,
; APPLICANT: Smithson, Glenda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Stone, David,
; APPLICANT: Taupier, Raymond, jr.,
; APPLICANT: Tchernev, Velizar,
; APPLICANT: Vernet, Corine,
; APPLICANT: Zerhusen, Brian
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE THEREOF
; FILE REFERENCE: 21402-222CIP
; CURRENT APPLICATION NUMBER: US/10/107,782
; CURRENT FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: 10/028,248
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 60/256,619
; PRIOR FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: 60/262,959
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: 60/272,408
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/285,189
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: 60/308,039
; PRIOR FILING DATE: 2001-07-26
; PRIOR APPLICATION NUMBER: 60/311,266
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 60/279,344
; PRIOR FILING DATE: 2001-03-28

```
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: CurSeqList version 0.1
; SEQ ID NO 208
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-107-782-208

Query Match          0.5%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 57;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 490 TCGAATCAAGAGACCCATGCCA 511
DB 22 TCGAATCAAGAGACTCAGGGTA 1

RESULT 89
US-10-003-354-4
; Sequence 4, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: EXPRESSION
; CURRENT APPLICATION NUMBER: US/10/003,354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-003-354-4

Query Match          0.5%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 GGGAGTGGCCCCACAGA 299
DB 1 GGGAGTGGCCCCACAGA 17

RESULT 90
US-09-851-871-6/c
; Sequence 6, Application US/09851871
; Publication No. US20030176374A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, Clarence Frank
; APPLICANT: Vickers, Timothy A.
; APPLICANT: Karras, James G.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; FILE REFERENCE: ISPH-0543
; CURRENT APPLICATION NUMBER: US/09/851,871
; CURRENT FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: PCT/US00/14471
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 09/326,186
; PRIOR FILING DATE: 1999-06-04
; PRIOR APPLICATION NUMBER: 08/777,266
; PRIOR FILING DATE: 1996-12-31
; NUMBER OF SEQ ID NOS: 284
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-851-871-6

Query Match          0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3669 AAGTGATATATGTTTAAAT 3688
DB 20 AAGTGATACATGTTTAAAT 1

RESULT 91
US-10-444-206-6/c
; Sequence 6, Application US/10444206
; Publication No. US20040023917A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, Clarence Frank
; APPLICANT: Vickers, Timothy A.
; APPLICANT: Karras, James G.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; FILE REFERENCE: Modulation of the Expression of B7 Protein
; CURRENT APPLICATION NUMBER: US/10/444,206
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: 09/851,871
; PRIOR FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: PCT/US00/14471
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 09/326,186
; PRIOR FILING DATE: 1999-06-04
; PRIOR APPLICATION NUMBER: 08/777,266
; PRIOR FILING DATE: 1996-12-31
; NUMBER OF SEQ ID NOS: 444
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-444-206-6

Query Match          0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3669 AAGTGATATATGTTTAAAT 3688
DB 20 AAGTGATACATGTTTAAAT 1

RESULT 92
US-10-418-182-128/c
; Sequence 128, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551.2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: 60/373,558
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 423
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```



```
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Mark P. Roach
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHODIESTERASE 4D EXPRESSION
; FILE REFERENCE: RTS-0351
; CURRENT APPLICATION NUMBER: US/10/146,860
; CURRENT FILING DATE: 2002-05-15
; NUMBER OF SEQ ID NOS: 100
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-146-860-72

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 77;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3635 TTTGTATTGTTTCAGAAAT 3652
Db      2 TTTGTATTGATCAGAAAT 19

RESULT 98
US-09-765-081-286
; Sequence 286, Application US/09765081
; Patent No. US20020037508A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2008-001
; CURRENT APPLICATION NUMBER: US/09/765,081
; CURRENT FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: US 60/176,861
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 461
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 286
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-765-081-286

Query Match      0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 81;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1723 CTTGAAGCCTTCTCTTCCA 1742
Db      1 CTTAAGCCTKCTCTGCCA 20

RESULT 99
US-10-346-514-4/c
; Sequence 4, Application US/10346514
; Publication No. US20030211522A1
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Michalowsky, Lesley
; APPLICANT: Miller, Glenn
; APPLICANT: Weber, William
; TITLE OF INVENTION: METHODS FOR FETAL DNA DETECTION AND
; FILE REFERENCE: G2 2086.00
; CURRENT APPLICATION NUMBER: US/10/346,514
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: 60/349,877
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 13
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-346-514-4

Query Match      0.4%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 993 ACTACATGAACCTCAACC 1010
Db      20 ACTACATCAACCTCAACC 3

RESULT 100
US-09-742-201-4/c
; Sequence 4, Application US/09742201
; Patent No. US20020123091A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kirchhofer, Daniel K.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: No. US20020123091A1 Inhibitor of Hepatocyte Growth Factor Activation
; FILE REFERENCE: P1861R1US
; CURRENT APPLICATION NUMBER: US/09/742,201
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: PCT/US00/03565
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US00/06884
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/253,665
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: reverse PCR primer
US-09-742-201-4

Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 90;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 612 CCTGAAAGGTGCCATCCAGT 632
Db      21 CATGGAAGGCGCCATCCAGT 1

RESULT 101
US-10-116-949-39/c
; Sequence 39, Application US/10116949
; Publication No. US20030044911A1
; GENERAL INFORMATION:
; APPLICANT: Lerman, Michael I.
; APPLICANT: Minna, John D.
; APPLICANT: Latif, Farida
; APPLICANT: Wei, Ming-Hui
; APPLICANT: Sekido, Yoshitaka
; APPLICANT: Gao, Boning
; APPLICANT: Duh, Fuh-Mei
; TITLE OF INVENTION: Calcium Channel Compositions and Methods of Use Thereof
; FILE REFERENCE: NIH-05043
; CURRENT APPLICATION NUMBER: US/10/116,949
; CURRENT FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/470,443
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-12-22
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/114,359
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-12-30
```

```
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-116-949-39

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 90;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2305 CGGATTTTCAACTGCCCAACC 2325
      ||| ||||| ||||| ||||| |||
Db 21 CGTATGTTCAACTGCCCATCC 1

RESULT 102
US-10-083-246A-79/c
; Sequence 79, Application US/10083246A
; Publication No. US20030152936A1
; GENERAL INFORMATION:
; APPLICANT: Athena Diagnostics
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENETIC ANALYSIS OF POLYCYSTIC KIDNEY DISEASE
; FILE REFERENCE: 1133/2002
; CURRENT APPLICATION NUMBER: US/10/083,246A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 168
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 79
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: Synthetic primer
US-10-083-246A-79

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 90;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 723 TTCCCAAGTGAAGGAGCAACC 743
      ||| ||||| ||||| ||||| |||
Db 21 TTCCCAAGTGAAGGAGCAAGCC 1

RESULT 103
US-10-210-951-88/c
; Sequence 88, Application US/10210951
; Publication No. US20030170228A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Marsters, Scot A.
; APPLICANT: Pan, James
; APPLICANT: Pitti, Robert M.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stone, Donna M.
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR
; FILE REFERENCE: P2931R1C1
; CURRENT APPLICATION NUMBER: US/10/210,951
; CURRENT FILING DATE: 2002-08-02
```

```
; PRIOR APPLICATION NUMBER: 60/014699
; PRIOR FILING DATE: 1996-04-01
; PRIOR APPLICATION NUMBER: 60/026943
; PRIOR FILING DATE: 1996-09-23
; PRIOR APPLICATION NUMBER: 60/059121
; PRIOR FILING DATE: 1997-07-17
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/062037
; PRIOR FILING DATE: 1997-10-10
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063046
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066772
; PRIOR FILING DATE: 1997-11-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 258
; SEQ ID NO 88
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe.
US-10-210-951-88

Query Match          0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 90;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 612 CCTTGAAGTGCCATCCAGT 632
      ||| ||||| ||||| ||||| |||
Db 21 CATGGAAGGCGCCATCCAGT 1

RESULT 104
US-10-211-884-88/c
; Sequence 88, Application US/10211884
; Publication No. US20030175900A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Marsters, Scot A.
; APPLICANT: Pan, James
; APPLICANT: Pitti, Robert M.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stone, Donna M.
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR
; FILE REFERENCE: P2931R1C1
; CURRENT APPLICATION NUMBER: US/10/211,884
; CURRENT FILING DATE: 2002-08-02
; PRIOR APPLICATION NUMBER: 60/014699
; PRIOR FILING DATE: 1996-04-01
; PRIOR APPLICATION NUMBER: 60/026943
; PRIOR FILING DATE: 1996-09-23
; PRIOR APPLICATION NUMBER: 60/059121
; PRIOR FILING DATE: 1997-07-17
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/062037
; PRIOR FILING DATE: 1997-10-10
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
```

```
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063046
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066772
; PRIOR FILING DATE: 1997-11-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 258
; SEQ ID NO 88
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe.
US-10-211-884-88

Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 90;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      612 CCTGGAAGTGCCATCCAGT 632
DB      21 CATGGAAGGCGCCATCCAGT 1

RESULT 105
US-10-211-858-88/c
; Sequence 88, Application US/10211858
; Publication No. US20030211096A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Marsters, Scot A.
; APPLICANT: Pan, James
; APPLICANT: Pitti, Robert M.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stone, Donna M.
; APPLICANT: Watanabe, Colin K.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR
; CURRENT APPLICATION NUMBER: US/10/211,858
; PRIOR FILING DATE: 2002-08-02
; PRIOR APPLICATION NUMBER: 60/014699
; PRIOR FILING DATE: 1996-04-01
; PRIOR APPLICATION NUMBER: 60/026943
; PRIOR FILING DATE: 1996-09-23
; PRIOR APPLICATION NUMBER: 60/059121
; PRIOR FILING DATE: 1997-07-17
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/062037
; PRIOR FILING DATE: 1997-10-10
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063046
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066772
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 258
; SEQ ID NO 88
; LENGTH: 21
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe.
US-10-211-858-88

Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 90;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      612 CCTGGAAGTGCCATCCAGT 632
DB      21 CATGGAAGGCGCCATCCAGT 1

RESULT 106
US-10-410-031-188
; Sequence 188, Application US/10410031
; Publication No. US20040010817A1
; GENERAL INFORMATION:
; APPLICANT: Shockey, Jay M.
; APPLICANT: Schnurr, Judy
; APPLICANT: Browne, John A.
; TITLE OF INVENTION: Plant Acyl-CoA Synthetases
; FILE REFERENCE: DOW-07654
; CURRENT APPLICATION NUMBER: US/10/410,031
; CURRENT FILING DATE: 2003-04-09
; NUMBER OF SEQ ID NOS: 191
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 188
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-410-031-188

Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 90;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2567 TTCTCTCTCTTTTTCCTTC 2587
DB      1 TTTTCTCTCTTTTTCCTTC 21

RESULT 107
US-10-444-795B-511
; Sequence 511, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125, 449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 511
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - mPTPIB1.4
US-10-444-795B-511

Query Match      0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 90;
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY      2096 GATCCCAAGATGTCAGCCCTT 2116
```



```
; Sequence 385, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 385
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-244-647-385

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2643 TCCAGAAGTGTGACAAGA 2661
Db 19 TCCGGAAGTGTGATAGA 1

RESULT 113
US-10-244-647-395/c
; Sequence 395, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 395
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-244-647-395

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2643 TCCAGAAGTGTGACAAGA 2661
Db 19 TCCGGAAGTGTGATAGA 1

RESULT 113
US-10-244-647-395/c
; Sequence 395, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 395
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-244-647-395

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2644 CCAGAAGTGTGACAAGAT 2662
Db 19 CCGGAAGTGTGATAGAT 1

RESULT 114
US-10-244-647-1031
; Sequence 1031, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1031
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1031

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 98;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2643 TCCAGAAGTGTGACAAGA 2661
Db 1 UCCGGAAGUGUGAUAAGA 19

RESULT 115
US-10-244-647-1041
; Sequence 1041, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1041
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1041

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 98;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2644 CCAGAAAGTGTGACAAAGAT 2662
Db 1 CCGGAAGUGUGAUAAGAU 19

* RESULT 116
US-09-824-322B-360/c
; Sequence 360, Application US/09824322B
; Publication No. US20030022848A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALFA
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/09/824,322B
; CURRENT FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 360
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-824-322B-360

Query Match          0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 486 CATCTGGAATCAAGAGACC 504
Db 20 CATCTGGAATCTGGAGACC 2

* RESULT 117
US-10-408-969-3/c
; Sequence 3, Application US/10408969
; Publication No. US20030170759A1
; GENERAL INFORMATION:
; APPLICANT: O'Brien, Timothy J.
; APPLICANT: Underwood, Lowell J.
; APPLICANT: Tanimoto, Hirotooshi
; APPLICANT: Shigemasa, Kazushi
; TITLE OF INVENTION: Uses of Antileukoprotease in Carcinoma
; FILE REFERENCE: D6247D
; CURRENT APPLICATION NUMBER: US/10/408,969
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: US 09/692,820
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
```

```
; OTHER INFORMATION: Forward oligonucleotide primer for PCR
; OTHER INFORMATION: amplification of antileukoprotease
US-10-408-969-3

Query Match          0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1904 CAGACTCCACCTTTGGAGG 1922
Db 19 CAGACTCCAGCTTTGAAGG 1

* RESULT 118
US-10-161-996-140/c
; Sequence 140, Application US/10161996
; Publication No. US20030224515A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-161-996-140

Query Match          0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1776 GAGCAGGCTCCAGTGGCAA 1794
Db 20 GGCAGGTTCCAGTGGCAA 2

* RESULT 119
US-10-161-996-260
; Sequence 260, Application US/10161996
; Publication No. US20030224515A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 260
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
US-10-161-996-260

Query Match          0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1776 GAGCAGGCTCCAGTGGCAA 1794
Db 1 GGCAGGTTCCAGTGGCAA 19
```

```
RESULT 120
US-10-174-465-12
; Sequence 12, Application US/10174465
; Publication No. US20030232772A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6
; FILE REFERENCE: PTS-0055
; CURRENT APPLICATION NUMBER: US/10/174,465
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-465-12

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245
Db 2 CCTTCAGCTGGTCCAGGTG 20

RESULT 121
US-10-174-465-48/c
; Sequence 48, Application US/10174465
; Publication No. US20030232772A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6
; FILE REFERENCE: PTS-0055
; CURRENT APPLICATION NUMBER: US/10/174,465
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-174-465-48

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245
Db 2 CCTTCAGCTGGTCCAGGTG 20

RESULT 122
US-10-174-465-12
; Sequence 12, Application US/10174465
; Publication No. US20030232772A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6
; FILE REFERENCE: PTS-0055
; CURRENT APPLICATION NUMBER: US/10/174,465
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-174-465-48

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245
Db 19 CCTTCAGCTGGTCCAGGTG 1

RESULT 123
US-10-348-431-12
; Sequence 12, Application US/10348431
; Publication No. US20030232778A1
; GENERAL INFORMATION:
; APPLICANT: Eric G. Marcusson
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING
; FILE REFERENCE: ISPH-0728
; CURRENT APPLICATION NUMBER: US/10/348,431
; CURRENT FILING DATE: 2003-01-17
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
; FEATURE:
US-10-348-431-12

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 966 AATTTCTGCAGAGCTGCT 984
Db 2 AAATCTGCAGAGCTGCT 20
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-348-431-12

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245
Db 2 CCTTCAGCTGGTCCAGGTG 20

RESULT 124
US-10-289-762-5256
; Sequence 5256, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5256
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-5256

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245
Db 19 CCTTCAGCTGGTCCAGGTG 1

RESULT 125
US-10-348-431-48/c
; Sequence 48, Application US/10348431
; Publication No. US20030232778A1
; GENERAL INFORMATION:
; APPLICANT: Eric G. Marcusson
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING
; FILE REFERENCE: ISPH-0728
; CURRENT APPLICATION NUMBER: US/10/348,431
; CURRENT FILING DATE: 2003-01-17
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-348-431-48

Query Match      0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGGAG 245
Db 19 CCTTCAGCTGGTCCAGGTG 1
```

RESULT 125
US-10-380-195A-6/c
; Sequence 6, Application US/10380195A
; Publication No. US20040072776A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Kiyama, Satoshi
; APPLICANT: Nelson, Colleen
; APPLICANT: Rennie, Paul
; TITLE OF INVENTION: Antisense Insulin-Like Growth Factor Binding Protein (IGFBP)-2
; FILE REFERENCE: UBC.P-023
; CURRENT APPLICATION NUMBER: US/10/380,195A
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: PCT/US01/28748
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: US 60/232,641
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IGFBP2 antisense
US-10-380-195A-6

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 231 GAGCTGTCAGGAGCCGG 249
||||| ||||| ||||| ||||| |||||
Db 20 GAGCTCGTCGGAGCCGG 2

RESULT 126
US-10-380-195A-50/c
; Sequence 50, Application US/10380195A
; Publication No. US20040072776A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Kiyama, Satoshi
; APPLICANT: Nelson, Colleen
; APPLICANT: Rennie, Paul
; TITLE OF INVENTION: Antisense Insulin-Like Growth Factor Binding Protein (IGFBP)-2
; FILE REFERENCE: UBC.P-023
; CURRENT APPLICATION NUMBER: US/10/380,195A
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: PCT/US01/28748
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: US 60/232,641
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IGFBP2 antisense
US-10-380-195A-50

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 231 GAGCTGTCAGGAGCCGG 249
||||| ||||| ||||| ||||| |||||
Db 20 GAGCTCGTCGGAGCCGG 2

RESULT 127
US-10-300-263-60/c
; Sequence 60, Application US/10300263
; Publication No. US20040096834A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
; FILE REFERENCE: RTS-0431
; CURRENT APPLICATION NUMBER: US/10/300,263
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-263-60

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 968 TTCTCGAGAAGCTGCTTC 986
||||| ||||| ||||| ||||| |||||
Db 20 TTCTCGAGATGCTGCTGC 2

RESULT 128
US-10-300-263-129
; Sequence 129, Application US/10300263
; Publication No. US20040096834A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
; FILE REFERENCE: RTS-0431
; CURRENT APPLICATION NUMBER: US/10/300,263
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 129
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-300-263-129

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 968 TTCTCGAGAAGCTGCTTC 986
||||| ||||| ||||| ||||| |||||
Db 1 TTCTCGAGATGCTGCTGC 19

RESULT 129
US-10-688-706-2238/c
; Sequence 2238, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GPAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2238
; LENGTH: 20


```

; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-2238

```

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17: Conservative 0; Mismatches 2; Indels

Qy 3130 GGGGAGACAGCAGATTCTT 3148
|||
20 GGTGAGACAGCAGATACCTT 2
db

```

RESULT 130
US-10-688-706-2484/c
; Sequence 2484, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broshchat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2484
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
; US-10-688-706-2484

```

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17: Conservative 0; Mismatches 2; Indels

Qy 3130 GGGGAGACAGCAGATTCTT 3148
|||
pb 19 GGTGAGACAGCAGATACCTT 1

```

RESULT 131
US-10-688-706-3048
; Sequence 3048, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broscat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3048
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-3048

```

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17: Conservative 0; Mismatches 2; Indels

Qy 2594 AAGGAAAAGCACACAGCA 2612
|||||
pb 1 AAGGAAAAGGCAACATCA 19

```

RESULT 132
US-10-688-706-3052
; Sequence 3052, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Brochat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3052
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-3052

```

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2594 AAGGAAAAGCACACAGCA 2612
||| ||| ||| ||| |||
nb 2 AAGGAAAAGCAAACATCA 20

```

RESULT 133
US-10-652-795-360/c
; Sequence 360, Application US/10652795
; Publication No. US20040142346A1
;
; GENERAL INFORMATION:
;
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
;
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEO
;
; FILE OF INVENTION: ALPHA) EXPRESSION
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/10/652,795
; CURRENT FILING DATE: 2003-08-29
;
; PRIOR APPLICATION NUMBER: US/09/824,322B
; PRIOR FILING DATE: 2001-04-02
;
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
;
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
;
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 360
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
;
; FEATURE:
;
; OTHER INFORMATION: Synthetic
ITS-10-652-795-360

```

Query Match	0.4%	Score 15.8;	DB 1;	Length 20;
Best Local Similarity	89.5%	Pred. No. 1e+02;		
Mismatches	0.	Mismatches	2	Indels

QY 486 CATCTGGAATCAAGAGACC 504

Db 20 CATCTGGAATCTGGAGACC 2

RESULT 134

US-10-647-918-360/c
; Sequence 360, Application US/10647918
; Publication No. US20040152652A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALPHA
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/10/647,918
; CURRENT FILING DATE: 2003-08-26
; PRIOR APPLICATION NUMBER: US/09/824,322B
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 360
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-647-918-360

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 486 CATCTGGAATCAAGAGACC 504

Db 20 CATCTGGAATCTGGAGACC 2

RESULT 135

US-10-412-137-40/c
; Sequence 40, Application US/10412137
; Publication No. US20040203141A1
; GENERAL INFORMATION:
; APPLICANT: Dubcovsky, Jorge
; APPLICANT: Yan, Liuling
; TITLE OF INVENTION: USE OF THE AP1 GENE PROMOTER TO CONTROL
; FILE REFERENCE: THE VERNALIZATION RESPONSE AND FLOWERING TIME IN GRASSES
; CURRENT APPLICATION NUMBER: US/10/412,137
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-412-137-40

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1942 TATTCCTGACCCAGTTTC 1960

Db 20 TATTCGTGACACCAAGTTTC 2

RESULT 136

US-10-723-947-40/c
; Sequence 40, Application US/10723947
; Publication No. US20040205848A1
; GENERAL INFORMATION:
; APPLICANT: Dubcovsky, Jorge
; APPLICANT: Yan, Liuling
; APPLICANT: Loukoianov, Artem
; TITLE OF INVENTION: GENES RESPONSIBLE FOR VERNALIZATION
; FILE REFERENCE: REGULATION IN TEMPERATE GRASSES AND USES THEREOF
; CURRENT APPLICATION NUMBER: US/10/723,947
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 10/412,137
; PRIOR FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 159
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-723-947-40

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1942 TATTCCTGACCCAGTTTC 1960

Db 20 TATTCGTGACACCAAGTTTC 2

RESULT 137

US-09-205-658-321/c
; Sequence 321, Application US/09205658
; Patent No. US20010029617A1
; GENERAL INFORMATION:
; APPLICANT: Ruvkun, Gary
; APPLICANT: Ogg, Scott
; TITLE OF INVENTION: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR
; FILE REFERENCE: IMPAIRED GLUCOSE TOLERANCE CONDITIONS
; CURRENT APPLICATION NUMBER: US/09/205,658
; CURRENT FILING DATE: 1998-12-03
; EARLIER FILING DATE: 1997-05-15
; EARLIER APPLICATION NUMBER: 08/888,534
; EARLIER FILING DATE: 1997-07-07
; EARLIER APPLICATION NUMBER: US98/10080
; EARLIER FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 328
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 321
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Caenorhabditis elegans
US-09-205-658-321

Query Match 0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 CGAATTCGAGAGAGGAAG 351

Db 19 CGAATTCGAGAGAGGAAG 1

RESULT 138

US-09-963-693-321/c
; Sequence 321, Application US/09963693
; Publication No. US20030181364A1
; GENERAL INFORMATION:

```
; APPLICANT: Ruvkun, Gary
; APPLICANT: Ogg, Scott
; TITLE OF INVENTION: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR
; FILE REFERENCE: 00786/351004
; CURRENT APPLICATION NUMBER: US/09/963,693
; CURRENT FILING DATE: 2001-09-25
; PRIOR APPLICATION NUMBER: US/09/205,658
; PRIOR FILING DATE: 1998-12-03
; PRIOR APPLICATION NUMBER: 08/857,076
; PRIOR FILING DATE: 1997-05-15
; PRIOR APPLICATION NUMBER: 08/888,534
; PRIOR FILING DATE: 1997-07-07
; PRIOR APPLICATION NUMBER: US98/10080
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 328
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 321
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Caenorhabditis elegans
US-09-963-693-321

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 CGATTCCGAGAGAGGAAG 351
DB 19 CGAATTCGAGAGAGGAAG 1

RESULT 139
US-10-418-182-106
; Sequence 106, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551.2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: 60/373,558
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 423
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-418-182-106

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTTTT 2585
DB 3 TTTTCTCTCTCTCTCTCTCTTTT 21

RESULT 140
US-10-418-182-122/c
; Sequence 122, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551.2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16

; APPLICANT: Ruvkun, Gary
; APPLICANT: Ogg, Scott
; TITLE OF INVENTION: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR
; FILE REFERENCE: 00786/351004
; CURRENT APPLICATION NUMBER: US/09/963,693
; CURRENT FILING DATE: 2001-09-25
; PRIOR APPLICATION NUMBER: US/09/205,658
; PRIOR FILING DATE: 1998-12-03
; PRIOR APPLICATION NUMBER: 08/857,076
; PRIOR FILING DATE: 1997-05-15
; PRIOR APPLICATION NUMBER: 08/888,534
; PRIOR FILING DATE: 1997-07-07
; PRIOR APPLICATION NUMBER: US98/10080
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 328
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 321
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-418-182-122

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2568 TTCTCTCTCTCTCTCTCTTTT 2586
DB 20 TTTTCTCTCTCTCTCTCTTTT 2

RESULT 141
US-10-753-646-23
; Sequence 23, Application US/10753646
; Publication No. US20040138127A1
; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; APPLICANT: Davidson, Donald J.
; TITLE OF INVENTION: NOVEL ANTIANGIOGENIC PEPTIDES,
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING SAME AND METHODS FOR INHIBITING
; FILE REFERENCE: 5940.US.P3
; CURRENT APPLICATION NUMBER: US/10/753,646
; CURRENT FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: US/08/924,287A
; PRIOR FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: US 08/851,350
; PRIOR FILING DATE: 1997-05-05
; PRIOR APPLICATION NUMBER: US 08/832,087
; PRIOR FILING DATE: 1997-04-03
; PRIOR APPLICATION NUMBER: US 08/643,219
; PRIOR FILING DATE: 1996-05-03
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cassette Primer
US-10-753-646-23

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2995 GAGATTTTCTCTCTCTCTTC 3013
DB 2 GGGCTTTTCTCTCTCTCTTC 20

RESULT 142
US-10-753-646-33/c
; Sequence 33, Application US/10753646
; Publication No. US20040138127A1
; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; APPLICANT: Davidson, Donald J.
; TITLE OF INVENTION: NOVEL ANTIANGIOGENIC PEPTIDES,
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING SAME AND METHODS FOR INHIBITING
; FILE REFERENCE: 5940.US.P3
; CURRENT APPLICATION NUMBER: US/10/753,646
```

```
; CURRENT FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: US/08/924,287A
; PRIOR FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: US 08/851,350
; PRIOR FILING DATE: 1997-05-05
; PRIOR APPLICATION NUMBER: US 08/832,087
; PRIOR FILING DATE: 1997-04-03
; PRIOR APPLICATION NUMBER: US 08/643,219
; PRIOR FILING DATE: 1996-05-03
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-753-646-33

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2995 GAGATTTTTCCTTC 3013
Db 20 GGGCTTTTTCCTTC 2

RESULT 143
US-10-786-720-1376/c
; Sequence 1376, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1376
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-1376

Query Match      0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3633 ACTTGTATGTTTCAGAAA 3651
Db 20 ACTTGTCTCTTCAGAAA 2

RESULT 144
US-09-780-533A-2559
; Sequence 2559, Application US/09780533A
; Publication No. US2003006011A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MEH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
```

```
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2559

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 3640 ATTGTTTCAGAAATGCGCA 3656
Db 1 AUAUUCAGAAUUGGCA 17

RESULT 145
US-09-780-164-1042
; Sequence 1042, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1042
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-1042

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 337 TCCGAGAAGAGGAAGAA 353
Db 1 UCCAGAAGAGGAAGAA 17

RESULT 146
US-10-061-201-1266/c
; Sequence 1266, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIORITY APPLICATION NUMBER: PCT/US01/00670
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: US 09/864,761
; PRIORITY FILING DATE: 2001-05-23
; PRIORITY APPLICATION NUMBER: US 60/328,205
; PRIORITY FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1266
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1267
Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CATGGGCTGGGAGATCA 2861
Db 17 CATGGGCTGGGAGATCA 1

RESULT 147
US-10-061-201-1267/c
; Sequence 1267, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00666
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00667
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00664
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00669
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00665
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00668
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00663
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: PCT/US01/00670
; PRIORITY FILING DATE: 2001-01-30
; PRIORITY APPLICATION NUMBER: US 09/864,761
; PRIORITY FILING DATE: 2001-05-23
; PRIORITY APPLICATION NUMBER: US 60/328,205
; PRIORITY FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1267
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1267
Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCATGGGCTGGGAGATC 2860
Db 17 CCATGGGCTGGGAGATC 1

RESULT 148
US-10-349-143-6580/c
; Sequence 6580, Application US/10349143
; Publication No. US20030008732A1
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; APPLICANT: Jacqueline Wyatt
```

```
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIORITY APPLICATION NUMBER: US/09/422,978
; PRIORITY FILING DATE: 1999-10-20
; PRIORITY APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIORITY FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIORITY APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIORITY FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIORITY APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIORITY FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6580
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-12595 for SEQ 2646,
US-10-349-143-6580
Query Match      0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 468 CCTGTACCTCTGTCTCA 484
Db 18 CCTGTACCTCTGTCTTA 2

RESULT 149
US-10-308-264-591/c
; Sequence 591, Application US/10308264
; Publication No. US20040029133A1
; GENERAL INFORMATION:
; APPLICANT: Herrnstadt, Corinna
; TITLE OF INVENTION: MITOCHONDRIAL DNA POLYMORPHISM
; FILE REFERENCE: 660088.461
; CURRENT APPLICATION NUMBER: US/10/308,264
; CURRENT FILING DATE: 2002-11-25
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 591
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-308-264-591
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 ACAGGTTTGTAAAGAG 1603
Db 19 ACAGGTTTGTAAAGATG 3

RESULT 150
US-09-898-361-98
; Sequence 98, Application US/09898361
; Publication No. US20030008732A1
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; APPLICANT: Jacqueline Wyatt
```

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0158
; CURRENT APPLICATION NUMBER: US/09/898,361
; CURRENT FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-898-361-98

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 265 GGAGGCCCGGAGGGGC 281
Db 4 GGAGGCCCGGAGGAGGC 20

RESULT 151
US-09-888-361-98
; Sequence 98, Application US/09888361
; Publication No. US2003006494A1
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
; FILE REFERENCE: RTS-0158
; CURRENT APPLICATION NUMBER: US/09/888,361
; CURRENT FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-888-361-98

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 265 GGAGGCCCGGAGGGGC 281
Db 4 GGAGGCCCGGAGGAGGC 20

RESULT 152
US-10-181-846-157
; Sequence 157, Application US/10181846
; Publication No. US2003008297A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTSP-0363
; CURRENT APPLICATION NUMBER: US/10/181,846
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 157
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-157

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 CTCCTTCCTCTCTCTCA 2236
Db 4 CTCCTTCCTCTCTCTCA 20

RESULT 153
US-10-006-911-33/c
; Sequence 33, Application US/10006911
; Publication No. US2003012527A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COLLAPLIN RESPONSE MEDIATOR PROTEIN 2 EXP
; FILE REFERENCE: RTS-0200
; CURRENT APPLICATION NUMBER: US/10/006,911
; CURRENT FILING DATE: 2001-11-08
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-911-33

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3281 TCTTGTGAGGGGAAGAA 3297
Db 18 TCTTATCAGGGGAAGAA 2

RESULT 154
US-10-420-845-13/c
; Sequence 13, Application US/10420845
; Publication No. US20030180885A1
; GENERAL INFORMATION:
; APPLICANT: PILETZ, John E.
; APPLICANT: IVANOV, Tina R.
; TITLE OF INVENTION: DNA MOLECULES ENCODING IMIDALINE RECEPTIVE POLYPEPTIDES
; TITLE OF INVENTION: AND POLYPEPTIDES ENCODED THEREBY
; FILE REFERENCE: Corrected Sequence Listing
; CURRENT APPLICATION NUMBER: US/10/420,845
; CURRENT FILING DATE: 2003-04-23
; PRIOR APPLICATION NUMBER: US/08/922,635A
; PRIOR FILING DATE: 1997-09-03
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 08/650,766
; PRIOR FILING DATE: EARLIER FILING DATE: 1996-05-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/012,600
; PRIOR FILING DATE: EARLIER FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-420-845-13

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1756 TGGCTCATCTTTCTCTC 1772
```

Db 19 TGGCTCACCTTTCTCTC 3
|||||

RESULT 155
US-10-181-856-46
; Sequence 46, Application US/10181856
; Publication No. US20030212018A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEK2 EXPRESSION
; FILE REFERENCE: RTSP-0345
; CURRENT APPLICATION NUMBER: US/10/181,856
; CURRENT FILING DATE: 2002-07-18
; PRIOR APPLICATION NUMBER: PCT/US01/01361
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/488,744
; PRIOR FILING DATE: 2000-01-20
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-856-46

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1311 GCTTCAAGATAATGGAT 1327
|||||
Db 2 GCTTAAGATAATGGAT 18

RESULT 156
US-10-421-763-14/c
; Sequence 14, Application US/10421763
; Publication No. US20030224429A1
; GENERAL INFORMATION:
; APPLICANT: PILETZ, John E.
; APPLICANT: IVANOV, Tina R.
; TITLE OF INVENTION: DNA SEQUENCE ENCODING A HUMAN IMIDAZOLINE RECEPTOR AND
; FILE REFERENCE: Corrected Sequence Listing
; CURRENT APPLICATION NUMBER: US/10/421,763
; CURRENT FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US/08/650,766D
; PRIOR FILING DATE: 1996-05-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/012,600
; PRIOR FILING DATE: EARLIER FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-421-763-14

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1756 TGGCTCATCTTTCTCTC 1772
|||||
Db 19 TGGCTCACCTTTCTCTC 3

RESULT 157
US-10-364-748-60
; Sequence 60, Application US/10364748
; Publication No. US20030224968A1
; GENERAL INFORMATION:
; APPLICANT: Fink, John K.
; APPLICANT: Zhao, Xinpeng
; TITLE OF INVENTION: Atlastin
; FILE REFERENCE: UM-07745
; CURRENT APPLICATION NUMBER: US/10/364,748
; CURRENT FILING DATE: 2003-02-11
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-364-748-60

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2569 TCTTCTCTTTTTTTTT 2585
|||||
Db 2 TCTTTTCTTTTTTTTT 18

RESULT 158
US-10-349-143-6240/c
; Sequence 6240, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilyia
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6240
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-10304 for SEQ 2306,
US-10-349-143-6240

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1918 GGAGGAATCATGTAGG 1934
|||||
Db 18 GGAGGAATCATGTAGG 2

RESULT 159
US-10-458-939-23/c
; Sequence 23, Application US/10458939
; Publication No. US20040018535A1
; GENERAL INFORMATION:

```
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Fogel, Gary B.
; APPLICANT: Porto, V. William
; APPLICANT: Griffey, Richard H.
; APPLICANT: Ecker, David J.
; TITLE OF INVENTION: Detection of RNA Structural Elements
; FILE REFERENCE: IBIS0005-100/IBIS-0418US
; CURRENT APPLICATION NUMBER: US/10/458,939
; CURRENT FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: US 60/387,342
; PRIOR FILING DATE: 2002-06-10
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-458-939-23

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2178 GGGAGCTGCTCCTCCA 2194
Db 18 GTGGAGCTGCTCCTCCA 2

RESULT 160
US-10-406-686A-98
; Sequence 98, Application US/10406686A
; Publication No. US2004003586A1
; GENERAL INFORMATION:
; APPLICANT: CROOKE, HELEN RACHEL
; APPLICANT: SHEA, JACQUELINE ELIZABETH
; APPLICANT: FELDMAN, ROBERT GRAHAM
; APPLICANT: COUTEBROZE, SYLVAIN GABRIEL
; APPLICANT: LEGROS, FRANCOIS-XAVIER
; TITLE OF INVENTION: ATTENUATED GRAM NEGATIVE BACTERIA
; FILE REFERENCE: 454313-3171.1
; CURRENT APPLICATION NUMBER: US/10/406,686A
; CURRENT FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: 60/370,282
; PRIOR FILING DATE: 2002-04-05
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Pasteurella multocida
US-10-406-686A-98

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3266 ATCTGATCCTTCAACTC 3282
Db 1 ATCTGATCCTTCAACTC 17

RESULT 161
US-10-304-125-50/C
; Sequence 50, Application US/10304125
; Publication No. US20040102405A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION
```

```
; FILE REFERENCE: PTS-0056
; CURRENT APPLICATION NUMBER: US/10/304,125
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-304-125-50

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1588 CAGGTTTGTAAAGAGT 1604
Db 17 CAGGTATGTTAAGAGT 1

RESULT 162
US-10-304-125-117
; Sequence 117, Application US/10304125
; Publication No. US20040102405A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION
; FILE REFERENCE: PTS-0056
; CURRENT APPLICATION NUMBER: US/10/304,125
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION:
US-10-304-125-117

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1588 CAGGTTTGTAAAGAGT 1604
Db 4 CAGGTATGTTAAGAGT 20

RESULT 163
US-10-698-402-4
; Sequence 4, Application US/10698402
; Publication No. US20040142431A1
; GENERAL INFORMATION:
; APPLICANT: GENODYSEE
; TITLE OF INVENTION: New polynucleotides and polypeptides of the IFN alpha 5 gene
; FILE REFERENCE: BIF 022984 EXTENSIONS
; CURRENT APPLICATION NUMBER: US/10/698,402
; CURRENT FILING DATE: 2003-11-03
; PRIOR APPLICATION NUMBER: FR 0105919
; PRIOR FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-698-402-4

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
```


Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2637 CAGAACTCAGAGTGT 2653
|||||
DB 3 CAGAACTCAGAGTGT 19

RESULT 164

US-10-731-739-467/c
; Sequence 467, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of llq13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/10/731,739
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US/09/544,398B
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US/09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US/60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US/60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 467
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-731-739-467

Query Match 0.4%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 1.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2997 GATTTTGTCTTC 3013
|||||
DB 18 GATTTTGTCTTC 2

RESULT 165

US-09-726-096A-1
; Sequence 1, Application US/09726096A
; Publication No. US20010016652A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Maier, Martin A.
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Back
; FILE REFERENCE: IS184528
; CURRENT APPLICATION NUMBER: US/09/726,096A
; CURRENT FILING DATE: 2000-11-29
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-methoxyethoxy (MOE)
US-09-726-096A-1

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
|||||
DB 1 TTTTCTCTCTCTTTTTTTT 20

RESULT 166

US-09-916-369A-1
; Sequence 1, Application US/09916369A
; Publication No. US20020058802A1
; GENERAL INFORMATION:
; APPLICANT: Dellinger, Douglas J
; APPLICANT: Perbost, Michael GM
; APPLICANT: Caruthers, Marvin H
; APPLICANT: Betley, Jason R
; TITLE OF INVENTION: Synthesis of Polynucleotides Using Combined Oxidation/Deprotection
; FILE REFERENCE: 10003869-1
; CURRENT APPLICATION NUMBER: US/09/916,369A
; CURRENT FILING DATE: 2001-07-21
; PRIOR APPLICATION NUMBER: US/09/627,249
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic sequence
US-09-916-369A-1

Query Match 0.4%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
|||||
DB 1 TTTTCTCTCTCTTTTTTTT 20

RESULT 167

US-09-973-788A-55/c
; Sequence 55, Application US/09973788A
; Patent No. US2002012574A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storchoff, James J.
; APPLICANT: Elghariani, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-110
; CURRENT APPLICATION NUMBER: US/09/973,788A
; CURRENT FILING DATE: 2002-03-05
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55


```

CORRESPONDENCE ADDRESS:
ADDRESSER: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/263,959
FILING DATE: 05-MAR-1999
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McMaisters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 920010.426C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 894:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-263-959-894

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2569 TCTTCTCTTTTCTTTTCT 2588
Db 20 TTTCTTTTCTTTCTTTCT 1

RESULT 173
US-09-760-500A-55/c
Sequence 55, Application US/09760500A
Patent No. US20020155442A1
GENERAL INFORMATION:
APPLICANT: Mirkin, Chad A.
APPLICANT: Letsinger, Robert L.
APPLICANT: Mucic, Robert C.
APPLICANT: Storhoff, James J.
APPLICANT: Elghanian, Robert
APPLICANT: Tatton, Thomas A.
TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
TITLE OF INVENTION: AND USES THEREFOR
FILE REFERENCE: 00-715-A
CURRENT APPLICATION NUMBER: US/09/760,500A
CURRENT FILING DATE: 2002-03-05
PRIOR APPLICATION NUMBER: 09/603,830
PRIOR FILING DATE: 2000-06-26
PRIOR APPLICATION NUMBER: 09/344,667
PRIOR FILING DATE: 1999-06-25
PRIOR APPLICATION NUMBER: 09/240,755
PRIOR FILING DATE: 1999-01-29
PRIOR APPLICATION NUMBER: PCT/US97/12783
PRIOR FILING DATE: 1997-07-21
PRIOR APPLICATION NUMBER: 60/031,809
PRIOR FILING DATE: 1996-07-29
PRIOR APPLICATION NUMBER: 60/200,161
PRIOR FILING DATE: 2000-04-26
NUMBER OF SEQ ID NOS: 64
SOFTWARE: Microsoft Word 2000
SEQ ID NO 55
LENGTH: 20
TYPE: DNA

```



```
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-976-378A-55

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 177
US-09-976-577-55/c
; Sequence 55, Application US/09976577
; Patent No. US20020155462A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghamian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-120
; CURRENT APPLICATION NUMBER: US/09/976,577
; CURRENT FILING DATE: 2002-03-05
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-976-577-55

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 178
US-09-771-554-5
; Sequence 5, Application US/09771554
; Patent No. US20020155496A1
; GENERAL INFORMATION:
; APPLICANT: CHARLES, Marie Helene
; APPLICANT: FIGA, Nadia
; APPLICANT: BATTAIL-POIROT, Nicole
; APPLICANT: VERON, Laurent
; APPLICANT: DELAIR, Thierry
; APPLICANT: MANDRAND, Bernard
; TITLE OF INVENTION: SATURATED AND UNSATURATED ABIETANE DERIVATIVES, DERIVED CONJUGATE
```

```
; TITLE OF INVENTION: USES IN A DIAGNOSTIC COMPOSITION, A REAGENT AND A DEVICE
; FILE REFERENCE: 108473
; CURRENT APPLICATION NUMBER: US/09/771,554
; CURRENT FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: PCT/FR99/01846
; PRIOR FILING DATE: 1999-07-27
; PRIOR APPLICATION NUMBER: FR 98/10084
; PRIOR FILING DATE: 1998-07-31
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-09-771-554-5

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 179
US-09-975-498-55/c
; Sequence 55, Application US/09975498
; Publication No. US20020160381A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghamian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-114
; CURRENT APPLICATION NUMBER: US/09/975,498
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-975-498-55

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1
```

```
RESULT 180
US-09-966-312-55/c
; Sequence 55, Application US/09966312
; Patent No. US20020164605A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-15
; CURRENT APPLICATION NUMBER: US/09/966,312
; CURRENT FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-966-312-55

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTT 2586
DB 20 TTTT 1

RESULT 181
US-09-927-777A-55/c
; Sequence 55, Application US/09927777A
; Patent No. US20020172953A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; APPLICANT: Garimella, Viswanadham
; APPLICANT: Li, Zhi
; APPLICANT: Park, So-Jung
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-653-A
; CURRENT APPLICATION NUMBER: US/09/927,777A
; CURRENT FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/820,279
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 2001-01-12
```

```
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/192,699
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; PRIOR APPLICATION NUMBER: 60/213,906
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 60/224,631
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/254,392
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/255,235
; PRIOR FILING DATE: 2000-12-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-927-777A-55

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTT 2586
DB 20 TTTT 1

RESULT 182
US-09-927-777A-70/c
; Sequence 70, Application US/09927777A
; Patent No. US20020172953A1
; GENERAL INFORMATION:
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; APPLICANT: Garimella, Viswanadham
; APPLICANT: Li, Zhi
; APPLICANT: Park, So-Jung
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-653-A
; CURRENT APPLICATION NUMBER: US/09/927,777A
; CURRENT FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/820,279
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
```

```

; OTHER INFORMATION: Description of Artificial Sequence:random
US-09-966-491A-55
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0

Qy 2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 184
US-09-976-971A-55/c
; Sequence 55, Application US/09976971A
; Publication No. US20020182613A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-118
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US/09/976,971A
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
US-09-976-971A-55
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0

Qy 2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 185
US-09-880-505-83/c
; Sequence 83, Application US/09880505
; Publication No. US20030007976A1
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Tan, Paul L.J.
; APPLICANT: Prestidge, Ross
; TITLE OF INVENTION: Methods and Compounds for the Treatment
; FILE REFERENCE: 11000.1007c2
; CURRENT APPLICATION NUMBER: US/09/880,505

```

```
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US 09/324,542
; PRIOR FILING DATE: 1999-06-02
; PRIOR APPLICATION NUMBER: US 08/997,080
; PRIOR FILING DATE: 1997-12-23
; NUMBER OF SEQ ID NOS: 194
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Made in a lab
US-09-880-505-83
```

```
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 2567 TTCTCTCTCTCTCTCTCTCTTT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 20 TTTTCTCTCTCTCTCTCTCTTTT 1
```

RESULT 186

```
US-09-820-279B-55/c
; Sequence 55, Application US/09820279B
; Publication No. US2003002169A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Stornhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Tatton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-1085-A
; CURRENT APPLICATION NUMBER: US/09/820,279B
; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-820-279B-55
```

```
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 2567 TTCTCTCTCTCTCTCTCTCTTT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 20 TTTTCTCTCTCTCTCTCTCTTTT 1
```

RESULT 187

```
US-09-888-326-2/c
; Sequence 2, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc_Feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: phosphodiester backbone
US-09-888-326-2
```

```
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 2567 TTCTCTCTCTCTCTCTCTTTT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 20 TTTTCTCTCTCTCTCTCTTTT 1
```

RESULT 188

```
US-09-888-326-838
; Sequence 838, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 838
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc_Feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-838
```

```
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 2567 TTCTCTCTCTCTCTCTCTTTT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTCTCTCTCTCTCTCTTTT 20
```

RESULT 189

```
US-09-888-326-839
```


; Sequence 839, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; TITLE OF INVENTION: Cell Lysis and Treating Cancer
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 839
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: phosphodiester backbone
US-09-888-326-839

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
DB 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 190
US-09-981-344-55/c
; Sequence 55, Application US/09981344
; Publication No. US20030044805A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-i22
; CURRENT APPLICATION NUMBER: US/09/981,344
; PRIOR FILING DATE: 2002-03-05
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-981-344-55

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
DB 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 191
US-09-957-318A-55/c
; Sequence 55, Application US/09957318A
; Publication No. US20030049630A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-i2
; CURRENT APPLICATION NUMBER: US/09/957,318A
; CURRENT FILING DATE: 2002-03-05
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-957-318A-55

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
DB 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 192
US-09-974-500A-55/c
; Sequence 55, Application US/09974500A
; Publication No. US20030049631A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-i7
; CURRENT APPLICATION NUMBER: US/09/974,500A
; CURRENT FILING DATE: 2002-04-01


```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 20

RESULT 199
US-09-906-158-85
; Sequence 85, Application US/09906158
; Publication No. US20030078217A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 3 EXPRE
; FILE REFERENCE: RTS-0257
; CURRENT APPLICATION NUMBER: US/09/906.158
; CURRENT FILING DATE: 2001-07-14
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-906-158-85

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 972 TGCAGAGCTGCTCCAGGA 991
Db 1 TGTAGCACCTGCTCCAGGA 20

RESULT 200
US-09-954-556-49
; Sequence 49, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRE
; FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954.556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-49

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2738 GCTCCTCTTTAACTCTCC 2757
Db 1 GCTCCTGCTTAACTCTCTTC 20

RESULT 201
US-09-776-479-226
; Sequence 226, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-226

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 20

RESULT 203
US-09-776-479-556
; Sequence 556, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
```

```
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-226

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 20

RESULT 202
US-09-776-479-226
; Sequence 226, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-226

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 20

RESULT 203
US-09-776-479-556
; Sequence 556, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
```

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3461 AGGAAAGAAATCTTGCTATT 3480
||||| ||| ||||| |||||
Db 1 AGGAAGGAACCTTGGATATT 20

RESULT 208

US-09-953-047-25/c
; Sequence 25, Application US/09953047
; Publication No. US20030087854A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 EXPRESSION
; FILE REFERENCE: RTS-0157
; CURRENT APPLICATION NUMBER: US/09/953,047
; CURRENT FILING DATE: 2001-03-10
; NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-047-25

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2189 CCTCCATCTCTCTGCTGAAG 2208
||||| ||| ||||| |||||
Db 20 CCTCCATCTCTGGCTGAAG 1

RESULT 209

US-09-976-601A-55/c
; Sequence 55, Application US/09976601A
; Publication No. US20030124528A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-i16
; CURRENT APPLICATION NUMBER: US/09/976,601A
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence

US-09-976-601A-55

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTTTT 2586
||||| ||| ||||| |||||
Db 20 TTCTCTCTCTCTCTCTCTTTT 1

RESULT 210

US-09-975-059A-55/c
; Sequence 55, Application US/09975059A
; Publication No. US20030143538A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-i15
; CURRENT APPLICATION NUMBER: US/09/975,059A
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTTTT 2586
||||| ||| ||||| |||||
Db 20 TTCTCTCTCTCTCTCTCTTTT 1

RESULT 211

US-09-976-968A-55/c
; Sequence 55, Application US/09976968A
; Publication No. US20030148282A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-i17


```
RESULT 215
US-10-208-357-26/c
; Sequence 26, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:
; APPLICANT: Kurz, Markus
; APPLICANT: Lohse, Peter
; APPLICANT: Wagner, Richard
; TITLE OF INVENTION: Peptide Acceptor Ligation Methods
; FILE REFERENCE: 50036/031002
; CURRENT APPLICATION NUMBER: US/10/208,357
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US/09/619,103
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/145,834
; PRIOR FILING DATE: 1999-07-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: designed sequence for nucleic acid purification
US-10-208-357-26
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTTCTCTCTTTTTTTTTT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 216
US-10-081-885A-1/c
; Sequence 1, Application US/10081885A
; Publication No. US20020192710A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Stephen
; TITLE OF INVENTION: Diagnostics, Assay Methods and Amelioration of Muscular
; FILE REFERENCE: 94-00
; CURRENT APPLICATION NUMBER: US/10/081,885A
; CURRENT FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/270645
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: US 60/286890
; PRIOR FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide useful as a primer
US-10-081-885A-1
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1864 GGAGCCAGCGGTTCACCTTG 1883
Db 20 GGACCCAGCGGTGCAGCTTG 1

RESULT 217
US-10-051-643-83/c
; Sequence 83, Application US/10051643
```

```
; Publication No. US20020197265A1
; GENERAL INFORMATION:
; APPLICANT: Tan, Paul L. J.
; TITLE OF INVENTION: Methods and Compounds for the Treatment
; TITLE OF INVENTION: of Immunologically-Mediated Diseases of the Respiratory
; TITLE OF INVENTION: System using Mycobacterium Vaccae
; FILE REFERENCE: 11000.1008c2
; CURRENT APPLICATION NUMBER: US/10/051,643
; CURRENT FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: US09/156,181
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: US 08/996,624
; PRIOR FILING DATE: 1997-12-23
; NUMBER OF SEQ ID NOS: 208
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Made in a lab
US-10-051-643-83
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTTCTCTCTTTTTTTTTT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 218
US-10-176-055-11/c
; Sequence 11, Application US/10176055
; Publication No. US20030013109A1
; GENERAL INFORMATION:
; APPLICANT: Evident Technologies
; TITLE OF INVENTION: Hairpin Sensors Using Quenchable Fluorescing Agents
; FILE REFERENCE: 11739/26
; CURRENT APPLICATION NUMBER: US/10/176,055
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: 60/299,460
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Target sequence
; OTHER INFORMATION: Target sequence that is desired to be detected and
; OTHER INFORMATION: that has a nucleotide sequence that is
; OTHER INFORMATION: complementary to the sequence of complementary
; OTHER INFORMATION: probe of hairpin loop assembly
US-10-176-055-11
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTTCTCTCTTTTTTTTTT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 219
US-10-117-267-1
; Sequence 1, Application US/10117267
; Publication No. US20030045698A1
```


; APPLICANT: Saigone Corporation
 ; TITLE OF INVENTION: Nucleic Acid Amplification Using an RNA Polymerase and
 ; TITLE OF INVENTION: DNA/RNA Mixed Polymer Intermediate Products
 ; FILE REFERENCE: 018048-001710US
 ; CURRENT APPLICATION NUMBER: US/10/077,383

```

; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: US 60/296,812
; PRIOR FILING DATE: 2001-06-07
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:(A)-12-20
; OTHER INFORMATION: homopolymer spacer sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)..(20)
; OTHER INFORMATION: a at positions 13-20 may be present or absent
US-10-077-383-5

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTTCTTTTTTTTTT 2586
      ||| ||| ||| ||| ||| ||| |||
Db 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 224
US-10-077-383-6
; Sequence 6, Application US/10077383
; Publication No. US2003005044A1
; GENERAL INFORMATION:
; APPLICANT: Haydock, Paul V.
; APPLICANT: U'Ren, Jack
; APPLICANT: Saigene Corporation
; TITLE OF INVENTION: Nucleic Acid Amplification Using an RNA Polymerase and
; FILE OF INVENTION: DNA/RNA Mixed Polymer Intermediate Products
; FILE REFERENCE: 018048-001710US
; CURRENT APPLICATION NUMBER: US/10/077.383
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: US 60/296,812
; PRIOR FILING DATE: 2001-06-07
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:(T)-12-20
; OTHER INFORMATION: homopolymer spacer sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)..(20)
; OTHER INFORMATION: t at positions 13-20 may be present or absent
US-10-077-383-6

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTTCTTTTTTTTTT 2586
      ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTTTTTTTTTTTTTTTTT 20

RESULT 225
US-10-017-995-226
; Sequence 226, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids

```



```
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; PRIOR APPLICATION NUMBER: 60/213,906
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 60/224,631
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/254,392
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/254,418
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: 60/255,235
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: 60/255,236
; PRIOR FILING DATE: 2000-04-01
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-10-008-978-55
```

```
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 2567 TTCTCTCTCTTTTTTTTTT 2586
||| ||| ||| ||| ||| ||| |||
Db 20 TTTT'TTTTTTTTTTTTTT 1
```

```
RESULT 232
US-10-008-978-70/c
; Sequence 70, Application US/10008978
; Publication No. US20030087242A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; APPLICANT: Garimella, Viswanadham
; APPLICANT: Li, Zhi
; APPLICANT: Park, So-Jung
; APPLICANT: Lu, Gang
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-1272-C
; CURRENT APPLICATION NUMBER: US/10/008,978
; CURRENT FILING DATE: 2002-05-20
```

```
; PRIOR APPLICATION NUMBER: 09/927,777
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/820,279
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/192,699
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; PRIOR APPLICATION NUMBER: 60/213,906
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 60/224,631
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/254,392
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/254,418
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/255,235
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: 60/255,236
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: 60/282,640
; PRIOR FILING DATE: 2000-04-01
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-10-008-978-70
```

```
Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 2567 TTCTCTCTCTTTTTTTTTT 2586
||| ||| ||| ||| ||| ||| |||
Db 20 TTTT'TTTTTTTTTTTTTT 1
```

```
RESULT 233
US-10-188-404-66
; Sequence 66, Application US/10188404
; Publication No. US20030105286A1
; GENERAL INFORMATION:
; APPLICANT: Egholm, Michael
; APPLICANT: Neilsen, Peter
; APPLICANT: Buchardt, Ole
; APPLICANT: Dueholm, Kim L.
; APPLICANT: Christensen, Leif
; APPLICANT: Coull, James M.
; APPLICANT: Kiehl, John
; APPLICANT: Griffith, Michael
; TITLE OF INVENTION: Linked Peptide Nucleic Acids
; FILE REFERENCE: ISIS5042
; CURRENT APPLICATION NUMBER: US/10/188,404
; CURRENT FILING DATE: 2002-07-01
```



```

;
; US-10-371-066-16
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
;
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2567 TTTCTCTCTCTTTTTTTTTT 2586
Db      1 TTTTTTTTTTTTTTTTTTTT 20

RESULT 239
US-10-340-097-53/c
; Sequence 53, Application US/10340097
; Publication No. US20030162276A1
; GENERAL INFORMATION:
; APPLICANT: Rattner, Amir
; APPLICANT: Sun, Hui
; APPLICANT: Lupski, James R.
; APPLICANT: Nathans, Jeremy
; APPLICANT: Anderson, Kent L.
; APPLICANT: Leppert, Mark
; APPLICANT: Dean, Michael
; APPLICANT: Singh, Nanda
; APPLICANT: Shroyer, No. US20030162276Alh F.
; APPLICANT: Smallwood, Philip M.
; APPLICANT: Allikmets, Rando
; APPLICANT: Lewis, Richard A.
; APPLICANT: Li, Yixin
; TITLE OF INVENTION: Nucleic Acid And Amino Acid Sequences For ATP-Binding Ca
; TITLE OF INVENTION: Transporter And Methods Of Screening For Agents That Mo
; TITLE OF INVENTION: Transporter
; FILE REFERENCE: BYLR0065
; CURRENT APPLICATION NUMBER: US/10/340,097
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: US/09/032,438A
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/039,388
; PRIOR FILING DATE: 1997-02-27
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-340-097-53

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1296 GTTTGGTGTGCAGAGCTTC 1315
Db      20 GCTTGTGCAGGAGCTTC 1

RESULT 240
US-10-336-215-53/c
; Sequence 53, Application US/10336215
; Publication No. US20030170852A1
; GENERAL INFORMATION:
; APPLICANT: Allikmets, Rando
; APPLICANT: Anderson, Kent L.
; APPLICANT: Dean, Michael
; APPLICANT: Leppert, Mark
; APPLICANT: Lewis, Richard A.
; APPLICANT: Li, Yixin
; APPLICANT: Lupski, James R.
; APPLICANT: Nathans, Jeremy
; APPLICANT: Rattner, Amir

```

APPLICANT: Shroyer, No. US20030170852Alh F.
APPLICANT: Singh, Nanda
APPLICANT: Smallwood, Philip
APPLICANT: Sun, Hui
TITLE OF INVENTION: Methods of Screening And Diagnostics Using ATP-Binding Cassette
FILE REFERENCE: APPI0089
CURRENT APPLICATION NUMBER: US/10/336,215
CURRENT FILING DATE: 2003-04-11
PRIOR APPLICATION NUMBER: 60/039,388
PRIOR FILING DATE: 1997-02-27
PRIOR APPLICATION NUMBER: 09/032,438
PRIOR FILING DATE: 1998-02-27
NUMBER OF SEQ ID NOS: 120
SOFTWARE: PatentIn version 3.2
SEQ ID NO 53
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide primer
US-10-336-215-53

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1296 GTTGGTGTGCGAGAGCTTC 1315
Db 20 GCTTGGTGTGCGAGAGCTTC 1

RESULT 241
US-10-336-219-53/c
Sequence 53, Application US/10336219
Publication No. US20030170853A1

GENERAL INFORMATION:
APPLICANT: Allikmets, Rando
APPLICANT: Anderson, Kent L.
APPLICANT: Dean, Michael
APPLICANT: Leppert, Mark
APPLICANT: Lewis, Richard A.
APPLICANT: Li, Yixin
APPLICANT: Luksi, James R.
APPLICANT: Nathans, Jeremy
APPLICANT: Rattner, Amir
APPLICANT: Shroyer, No. US20030170853Alh F.
APPLICANT: Singh, Nanda
APPLICANT: Smallwood, Philip
APPLICANT: Sun, Hui
TITLE OF INVENTION: Methods Of Gene Therapy Using Nucleic Acid Sequences For
FILE REFERENCE: BYLR0072
CURRENT APPLICATION NUMBER: US/10/336,219
CURRENT FILING DATE: 2003-01-03
PRIOR APPLICATION NUMBER: 60/039,388
PRIOR FILING DATE: 1997-02-27
PRIOR APPLICATION NUMBER: 09/032,438
PRIOR FILING DATE: 1998-02-27
NUMBER OF SEQ ID NOS: 120
SOFTWARE: PatentIn version 3.2
SEQ ID NO 53
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide primer
US-10-336-219-53

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1296 GTTGGTGTGCGAGAGCTTC 1315
Db 20 GCTTGGTGTGCGAGAGCTTC 1

RESULT 242

US-10-410-324-55/c
Sequence 55, Application US/10410324
Publication No. US20030180783A1
GENERAL INFORMATION:
APPLICANT: Mirkin, Chad A.
APPLICANT: Letsinger, Robert L.
APPLICANT: Mucic, Robert C.
APPLICANT: Storhoff, James J.
APPLICANT: Elghanian, Robert
APPLICANT: Taton, Thomas A.
TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
FILE REFERENCE: 00-713-126
CURRENT APPLICATION NUMBER: US/10/410,324
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: 09/961,949
PRIOR FILING DATE: 2001-09-20
PRIOR APPLICATION NUMBER: 09/603,830
PRIOR FILING DATE: 2000-06-26
PRIOR APPLICATION NUMBER: 09/344,667
PRIOR FILING DATE: 1999-06-25
PRIOR APPLICATION NUMBER: 09/240,755
PRIOR FILING DATE: 1999-01-29
PRIOR APPLICATION NUMBER: PCT/US97/12783
PRIOR FILING DATE: 1997-07-21
PRIOR APPLICATION NUMBER: 60/031,809
PRIOR FILING DATE: 1996-07-29
PRIOR APPLICATION NUMBER: 60/200,161
PRIOR FILING DATE: 2000-04-26
NUMBER OF SEQ ID NOS: 64
SOFTWARE: Microsoft Word 2000
SEQ ID NO 55
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: random
US-10-410-324-55

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 243

US-10-266-983-55/c
Sequence 55, Application US/10266983
Publication No. US20030207296A1
GENERAL INFORMATION:
APPLICANT: Park, So-Jung
APPLICANT: Taton, Thomas Andrew
APPLICANT: Mirkin, Chad A.
TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
FILE REFERENCE: 01-1565-A
CURRENT APPLICATION NUMBER: US/10/266,983
CURRENT FILING DATE: 2002-10-08
PRIOR APPLICATION NUMBER: 09/927,777
PRIOR FILING DATE: 2001-08-10
PRIOR APPLICATION NUMBER: 09/820,279
PRIOR FILING DATE: 2001-03-28
PRIOR APPLICATION NUMBER: 09/760,500

```
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/192,699
; PRIOR FILING DATE: 2000-03-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-10-266-983-55

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db      20 TTTTCTCTCTCTCTCTCTCTTTT 1

RESULT 244
US-10-266-983-70/c
; Sequence 70, Application US/10266983
; Publication No. US20030207296A1
; GENERAL INFORMATION:
; APPLICANT: Park, So-Jung
; APPLICANT: Mirkin, Chad A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 01-1565-A
; CURRENT APPLICATION NUMBER: US/10/266,983
; CURRENT FILING DATE: 2002-10-08
; PRIOR APPLICATION NUMBER: 09/927,777
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/820,279
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/192,699
; PRIOR FILING DATE: 2000-03-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-10-266-983-70

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db      20 TTTTCTCTCTCTCTCTCTCTTTT 1

RESULT 245
US-10-314-578-226
; Sequence 226, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Joerg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-226

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db      1 TTTTCTCTCTCTCTCTCTCTTTT 20

RESULT 246
US-10-314-578-556
; Sequence 556, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Joerg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
```



```
RESULT 255
US-10-388-263-638
; Sequence 638, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowsett, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeill, John
; APPLICANT: Freier, Susan M.
; APPLICANT: Sasmor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 638
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-638

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3461 AGGAAGAATCTTGCTATT 3480
||||| ||| ||| ||| |||
DB 1 AGGAAGGAATCTTGATATT 20

RESULT 256
US-10-173-208-18
; Sequence 18, Application US/10173208
; Publication No. US20030232435A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF AMYLOID BETA PROTEIN PRECURSOR EXPRESSION
; FILE REFERENCE: HTS-0023
; CURRENT APPLICATION NUMBER: US/10/173,208
; CURRENT FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-173-208-18

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2721 TTGCTCTGCCAGACGAGCT 2740
||||| ||| ||| ||| |||
DB 1 TTGCTCTTCTGAGCAGCT 20

RESULT 257
US-10-173-208-54/c
; Sequence 54, Application US/10173208
; Publication No. US20030232435A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF AMYLOID BETA PROTEIN PRECURSOR EXPRESSION
; FILE REFERENCE: HTS-0023
; CURRENT APPLICATION NUMBER: US/10/173,208
; CURRENT FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-173-208-54

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2721 TTGCTCTGCCAGACGAGCT 2740
||||| ||| ||| ||| |||
DB 20 TTGCTCTTCTGAGCAGCT 1

RESULT 258
US-10-174-559-74
; Sequence 74, Application US/10174559
; Publication No. US20030232773A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF DRAK1 EXPRESSION
; FILE REFERENCE: PTS-0006
; CURRENT APPLICATION NUMBER: US/10/174,559
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 112
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-559-74

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1215 ACTTCTTACAAGACATCCCT 1234
||||| ||| ||| ||| |||
DB 1 ACTTCTTCAAGACTTACCT 20

RESULT 259
US-10-373-406B-26
; Sequence 26, Application US/10373406B
; Publication No. US20040034866A1
; GENERAL INFORMATION:
; APPLICANT: Cahoon, Edgar B.
; APPLICANT: Coughlan, Sean J.
; APPLICANT: Cahoon, Rebecca E.
; APPLICANT: Butler, Karlene H.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ALTERING
; TITLE OF INVENTION: TOCOTRIENOL CONTENT
; FILE REFERENCE: 1522
; CURRENT APPLICATION NUMBER: US/10/373,406B
; CURRENT FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 68
; PRIOR FILING DATE: 2002-03-22
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-373-406B-26

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 886 CTCTGGAGCTAGTGGTCC 905
Db 1 CTCTAGAACTAGTGGATCC 20

RESULT 260
US-10-630-401-25/c
; Sequence 25, Application US/10630401
; Publication No. US20040048824A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 EXPRESSION
; FILE REFERENCE: RTS-0157
; CURRENT APPLICATION NUMBER: US/10/630,401
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/953,047
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-401-25

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2189 CCTCATCTCTTCTCTGAAG 2208
Db 20 CCTCATCTCTCTGGCTGAAG 1

RESULT 261
US-10-640-618-55/c
; Sequence 55, Application US/10640618
; Publication No. US2004007231A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; APPLICANT: Garimella, Viswanadham
; APPLICANT: Li, Zhi
; APPLICANT: So-Jung Park
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-1085-G
; CURRENT APPLICATION NUMBER: US/10/640,618
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: 09/820,279
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 60/192,699
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: 60/254,392
; PRIOR FILING DATE: 2001-12-08
; PRIOR APPLICATION NUMBER: 60/255,235
; PRIOR FILING DATE: 2000-12-11
```

```
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/213,906
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-10-640-618-55

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTTCTTCTCTCTTTTTTTTTT 2586
Db 20 TTTTCTTTTTTTTTTTTTTTT 1

RESULT 262
US-10-280-183A-429
; Sequence 429, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A.
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Chatterjee, Aurobindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shanru
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D.
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G.
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; TITLE OF INVENTION: CARBOHYDRATE COMPOUNDS AND OTHER SWEETENERS
; FILE REFERENCE: PC18306A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 429
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mouse
US-10-280-183A-429

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2068 ACCTGGAAACAGATTCTGCC 2087
Db 1 ACATGGACAGGATCTGCC 20
```

Query	Seq ID	Score	DB 1	DB 2	DB 3	DB 4	DB 5	DB 6	DB 7	DB 8	DB 9	DB 10	DB 11	DB 12	DB 13	DB 14	DB 15	DB 16	DB 17	DB 18	DB 19	DB 20	DB 21	DB 22	DB 23	DB 24	DB 25	DB 26	DB 27	DB 28	DB 29	DB 30	DB 31	DB 32	DB 33	DB 34	DB 35	DB 36	DB 37	DB 38	DB 39	DB 40	DB 41	DB 42	DB 43	DB 44	DB 45	DB 46	DB 47	DB 48	DB 49	DB 50	DB 51	DB 52	DB 53	DB 54	DB 55	DB 56	DB 57	DB 58	DB 59	DB 60	DB 61	DB 62	DB 63	DB 64	DB 65	DB 66	DB 67	DB 68	DB 69	DB 70	DB 71	DB 72	DB 73	DB 74	DB 75	DB 76	DB 77	DB 78	DB 79	DB 80	DB 81	DB 82	DB 83	DB 84	DB 85	DB 86	DB 87	DB 88	DB 89	DB 90	DB 91	DB 92	DB 93	DB 94	DB 95	DB 96	DB 97	DB 98	DB 99	DB 100	DB 101	DB 102	DB 103	DB 104	DB 105	DB 106	DB 107	DB 108	DB 109	DB 110	DB 111	DB 112	DB 113	DB 114	DB 115	DB 116	DB 117	DB 118	DB 119	DB 120	DB 121	DB 122	DB 123	DB 124	DB 125	DB 126	DB 127	DB 128	DB 129	DB 130	DB 131	DB 132	DB 133	DB 134	DB 135	DB 136	DB 137	DB 138	DB 139	DB 140	DB 141	DB 142	DB 143	DB 144	DB 145	DB 146	DB 147	DB 148	DB 149	DB 150	DB 151	DB 152	DB 153	DB 154	DB 155	DB 156	DB 157	DB 158	DB 159	DB 160	DB 161	DB 162	DB 163	DB 164	DB 165	DB 166	DB 167	DB 168	DB 169	DB 170	DB 171	DB 172	DB 173	DB 174	DB 175	DB 176	DB 177	DB 178	DB 179	DB 180	DB 181	DB 182	DB 183	DB 184	DB 185	DB 186	DB 187	DB 188	DB 189	DB 190	DB 191	DB 192	DB 193	DB 194	DB 195	DB 196	DB 197	DB 198	DB 199	DB 200	DB 201	DB 202	DB 203	DB 204	DB 205	DB 206	DB 207	DB 208	DB 209	DB 210	DB 211	DB 212	DB 213	DB 214	DB 215	DB 216	DB 217	DB 218	DB 219	DB 220	DB 221	DB 222	DB 223	DB 224	DB 225	DB 226	DB 227	DB 228	DB 229	DB 230	DB 231	DB 232	DB 233	DB 234	DB 235	DB 236	DB 237	DB 238	DB 239	DB 240	DB 241	DB 242	DB 243	DB 244	DB 245	DB 246	DB 247	DB 248	DB 249	DB 250	DB 251	DB 252	DB 253	DB 254	DB 255	DB 256	DB 257	DB 258	DB 259	DB 260	DB 261	DB 262	DB 263	DB 264	DB 265	DB 266	DB 267	DB 268	DB 269	DB 270	DB 271	DB 272	DB 273	DB 274	DB 275	DB 276	DB 277	DB 278	DB 279	DB 280	DB 281	DB 282	DB 283	DB 284	DB 285	DB 286	DB 287	DB 288	DB 289	DB 290	DB 291	DB 292	DB 293	DB 294	DB 295	DB 296	DB 297	DB 298	DB 299	DB 300	DB 301	DB 302	DB 303	DB 304	DB 305	DB 306	DB 307	DB 308	DB 309	DB 310	DB 311	DB 312	DB 313	DB 314	DB 315	DB 316	DB 317	DB 318	DB 319	DB 320	DB 321	DB 322	DB 323	DB 324	DB 325	DB 326	DB 327	DB 328	DB 329	DB 330	DB 331	DB 332	DB 333	DB 334	DB 335	DB 336	DB 337	DB 338	DB 339	DB 340	DB 341	DB 342	DB 343	DB 344	DB 345	DB 346	DB 347	DB 348	DB 349	DB 350	DB 351	DB 352	DB 353	DB 354	DB 355	DB 356	DB 357	DB 358	DB 359	DB 360	DB 361	DB 362	DB 363	DB 364	DB 365	DB 366	DB 367	DB 368	DB 369	DB 370	DB 371	DB 372	DB 373	DB 374	DB 375	DB 376	DB 377	DB 378	DB 379
-------	--------	-------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------

QY 2567 TTCTCTCTCTTTTTTTT 2586
|||||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 276

US-10-671-395-184
; Sequence 184, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-184

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
|||||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 277

US-10-671-395-185
; Sequence 185, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 185
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-185

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
|||||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 278

US-10-671-395-185
; Sequence 185, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE

US-10-671-395-186
; Sequence 186, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-186

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
|||||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 279

US-10-671-395-187
; Sequence 187, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 187
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-187

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTTTTTTTT 2586
|||||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 280

US-10-671-395-188
; Sequence 188, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE

RESULT 282
 US-10-671-395-190
 ; Sequence 190, Application US/10671395
 ; Publication No. US20040132063A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Pharmacia Corp.
 ; APPLICANT: Gierse, James K.
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
 ; TITLE OF INVENTION: EXPRESSION
 ; FILE REFERENCE: 1179/1/US
 ; CURRENT APPLICATION NUMBER: US/10/671,395
 ; CURRENT FILING DATE: 2003-09-25
 ; PRIOR APPLICATION NUMBER: 60/413,549
 ; PRIOR FILING DATE: 2002-09-25
 ; NUMBER OF SEQ ID NOS: 1809

US-10-671-395-192

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCT 2586

Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 285

US-10-671-395-193
; Sequence 193, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-193

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCT 2586

Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 286

US-10-671-395-194
; Sequence 194, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 194
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-194

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCT 2586

Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 287

US-10-671-395-195
; Sequence 195, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-195

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCT 2586

Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 288

US-10-671-395-196
; Sequence 196, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-196

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCT 2586

Db 1 TTTTCTCTCTCTCTCTCTCTCT 20

RESULT 289

US-10-671-395-197
; Sequence 197, Application US/10671395

; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-274

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 303

US-10-671-395-275
; Sequence 275, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 275
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-275

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 304

US-10-671-395-276
; Sequence 276, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 276
; LENGTH: 20
; TYPE: DNA

; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-276

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 305

US-10-671-395-277
; Sequence 277, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 277
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-277

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 306

US-10-671-395-311
; Sequence 311, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 311
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-311

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;

```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 307
US-10-671-395-338
; Sequence 338, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 338
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-338

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 308
US-10-671-395-376
; Sequence 376, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-376

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20
```

```
RESULT 309
US-10-671-395-403
; Sequence 403, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 403
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-403

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 310
US-10-671-395-427
; Sequence 427, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 427
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-427

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 311
US-10-671-395-444
; Sequence 444, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
```

[illegible]

QY 2940 GTTGTCTTTCTAAATGTCAA 2959
|||||
Db 1 GTTGTCTTTCTGGATGTCAA 20

RESULT 316
US-10-728-399-211
; Sequence 211, Application US/10728399
; Publication No. US20040132078A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Colca, Jerry
; TITLE OF INVENTION: ANTISENSE MODULATION OF MITONEET EXPRESSION
; FILE REFERENCE: 01455_1
; CURRENT APPLICATION NUMBER: US/10/728,399
; CURRENT FILING DATE: 2003-12-05
; NUMBER OF SEQ ID NOS: 627
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 211
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human mitoneet antisense
US-10-728-399-211

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2941 TTGTTTTCTAAATGTGAAG 2960
|||||
Db 1 TTGTCCTTTCTGGATGTGAAG 20

RESULT 317
US-10-661-088-12/c
; Sequence 12, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0206
; CURRENT APPLICATION NUMBER: US/10/661,088
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-088-12

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTTTTTTTT 2586
|||||
Db 20 TTTTCTCTCTCTTTTTTTT 1

RESULT 318
US-10-661-088-15
; Sequence 15, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0206
; CURRENT APPLICATION NUMBER: US/10/661,088
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-088-15

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTTTTTTTT 2586
|||||
Db 1 TTTTCTCTCTCTTTTTTTT 20

RESULT 319
US-10-661-097-12/c
; Sequence 12, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0204
; CURRENT APPLICATION NUMBER: US/10/661,097
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-097-12

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTTTTTTTT 2586
|||||
Db 20 TTTTCTCTCTCTTTTTTTT 1

RESULT 320
US-10-661-097-15
; Sequence 15, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0204
; CURRENT APPLICATION NUMBER: US/10/661,097
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-097-15

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTCTCTCTCTCTCTCTCTCTCT 20

RESULT 321
US-10-661-355-12/c
; Sequence 12, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
; FILE REFERENCE: 029849/0208
; CURRENT APPLICATION NUMBER: US/10/661,355
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-355-12

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 322
US-10-661-355-15
; Sequence 15, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
; FILE REFERENCE: 029849/0208
; CURRENT APPLICATION NUMBER: US/10/661,355
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-355-15

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTCTTT 2586
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TTTTCTCTCTCTCTCTCTCTCTTT 20

RESULT 323
US-10-661-099-12/c
; Sequence 12, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
; FILE REFERENCE: 029849/0203
; CURRENT APPLICATION NUMBER: US/10/661,099
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-099-12

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2567 TTCTCTCTCTCTCTCTCTTTT 2586
||| ||| ||| ||| ||| ||| ||| |||

; SEQ ID NO 121
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-188-777-121

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2602 AGCACACGACACA 2616
|||||
DB 2 AGCACACGACACA 16

RESULT 329
US-09-891-332A-84
; Sequence 84, Application US/09891332A
; Patent No. US20020168646A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Deb K.
; Solus, Joseph
; Yang, Shuwei

TITLE OF INVENTION: Polymerases for Analyzing or Typing Polymorphic
Nucleic Acid Fragments and Uses Thereof

NUMBER OF SEQUENCES: 93
CORRESPONDENCE ADDRESS:
ADDRESS: STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C
STREET: 1100 New York Ave., N.W., Suite 600
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005-3934

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/891,332A
FILING DATE: 27-Jun-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/019,160
FILING DATE: <Unknown>
APPLICATION NUMBER: US 60/037,393
FILING DATE: 07-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Esmond, Robert W.
REGISTRATION NUMBER: 32,893
REFERENCE/DOCKET NUMBER: 0942.4250002

TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-2600
TELEFAX: 202-371-2540

INFORMATION FOR SEQ ID NO: 84:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: both

MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 84:
US-09-891-332A-84

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1442 TCCACAGCCATGGATCC 1459
|||||
DB 1 TCCACAGCCATGTAACC 18

RESULT 330

US-10-244-647-388/c
; Sequence 388, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Ue
TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/060 (MBHB02-1000)
CURRENT APPLICATION NUMBER: US/10/244,647
CURRENT FILING DATE: 2003-04-14
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/393,924
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: PCT US02/09187
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/296,876
PRIOR FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 1524
SOFTWARE: PatentIn version 3.0
SEQ ID NO 388
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-244-647-388

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2645 CAGAAGTGTTCACAGAT 2662
|||||
DB 19 CGAAGTGTTCATAGAT 2

RESULT 331

US-10-244-647-559/c
; Sequence 559, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Ue
TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/060 (MBHB02-1000)
CURRENT APPLICATION NUMBER: US/10/244,647
CURRENT FILING DATE: 2003-04-14
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/393,924
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: PCT US02/09187
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/296,876
PRIOR FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 1524
SOFTWARE: PatentIn version 3.0
SEQ ID NO 559
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-244-647-559

```
; Query Match 0.4%; Score 14.8; DB 1; Length 19;
; Best Local Similarity 88.9%; Pred. No. 1.6e+02;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2643 TCCGAGAGTGTGTGACAAG 2660
DB 18 TCCGAGAGTGTGTGATAAG 1

RESULT 332
US-10-244-647-1034
; Sequence 1034, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1034
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1034

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2645 CAGAGTGTGTGACAAGT 2662
DB 1 CGGAGUGUGUAAGAU 18

RESULT 333
US-10-244-647-1205
; Sequence 1205, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
```

```
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1205
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1205

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2643 TCCGAGAGTGTGTGACAAG 2660
DB 2 UCCGAGAGUGUGUAAG 19

RESULT 334
US-10-294-228-19/c
; Sequence 19, Application US/10294228
; Publication No. US20040018176A1
; GENERAL INFORMATION:
; APPLICANT: Tolentino, Michael J.
; APPLICANT: Reich, Samuel Jotham
; TITLE OF INVENTION: Compositions and Methods for siRNA
; TITLE OF INVENTION: Inhibition of Angiogenesis
; FILE REFERENCE: 43826-1
; CURRENT APPLICATION NUMBER: US/10/294,228
; CURRENT FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: US 60/398,417
; PRIOR FILING DATE: 2002-07-24
; NUMBER OF SEQ ID NOS: 80
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Targeting Sequence
US-10-294-228-19

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3144 TTCTTGCTTGTGTGAGGT 3161
DB 18 TGCTGCTTGTGTGAGGT 1

RESULT 335
US-10-309-230-239/c
; Sequence 239, Application US/10309290
; Publication No. US20040023241A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook II, John P.
; APPLICANT: Anderson, David W.
; APPLICANT: Boldog, Ferenc L.
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Chillakuru, Rajeev A.
; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Gerlach, Valerie L.
; APPLICANT: Gorman, Linda
; APPLICANT: Gould-Rothberg, Bonnie E.
; APPLICANT: Guo, Xiaojia
; APPLICANT: Jeffers, Michael E.
; APPLICANT: Ji, Weizhen
; APPLICANT: Li, Li
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Miller, Charles E.
; APPLICANT: Murphey, Ryan
```

```
; APPLICANT: Patturajan, Meera
; APPLICANT: Peyman, John A.
; APPLICANT: Rastelli, Luca
; APPLICANT: Rieger, Daniel K.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Smithson, Glenda
; APPLICANT: Starling, Gary
; APPLICANT: Taupier, Raymond J.
; APPLICANT: Voss, Edward Z.
; APPLICANT: Zhong, Hainong
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-502A
; CURRENT APPLICATION NUMBER: US/10/309,290
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/336,600
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: 60/338,285
; PRIOR FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/341,346
; PRIOR FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/341,477
; PRIOR FILING DATE: 2001-12-17
; PRIOR APPLICATION NUMBER: 60/341,540
; PRIOR FILING DATE: 2001-12-17
; PRIOR APPLICATION NUMBER: 60/342,592
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: 60/344,297
; PRIOR FILING DATE: 2001-12-27
; PRIOR APPLICATION NUMBER: 60/344,903
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/373,288
; PRIOR FILING DATE: 2002-04-17
; PRIOR APPLICATION NUMBER: 60/380,981
; PRIOR FILING DATE: 2002-05-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 274
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 239
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-309-290-239

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 363 AAGAGAGCCAGCGCTCG 380
Db 19 AAGAGAGCCAGGATGCTG 2

RESULT 336
US-09-898-361-98/c
; Sequence 98, Application US/09898361
; Publication No. US2003008732A1
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; TITLE OF INVENTION: JACQUELINE WYATT
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
; FILE REFERENCE: RTS-0158
; CURRENT APPLICATION NUMBER: US/09/898,361
; CURRENT FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-309-290-239

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 363 AAGAGAGCCAGCGCTCG 380
Db 19 AAGAGAGCCAGGATGCTG 2

RESULT 336
US-09-898-361-98/c
; Sequence 98, Application US/09898361
; Publication No. US2003008732A1
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; TITLE OF INVENTION: JACQUELINE WYATT
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
; FILE REFERENCE: RTS-0158
; CURRENT APPLICATION NUMBER: US/09/898,361
; CURRENT FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-309-290-239
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-898-361-98
Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 410 GCCTCTCTCCGGCGCTCG 427
Db 20 GCCTCTCTCCGGCGCTCG 3

RESULT 337
US-09-888-361-98/c
; Sequence 98, Application US/09888361
; Publication No. US2003006494A1
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0158
; CURRENT APPLICATION NUMBER: US/09/888,361
; CURRENT FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-888-361-98

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 410 GCCTCTCTCCGGCGCTCG 427
Db 20 GCCTCTCTCCGGCGCTCG 3

RESULT 338
US-09-756-095-16
; Sequence 16, Application US/09756095
; Patent No. US20020115207A1
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Garcia-Blanco, Mariano A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
; TITLE OF INVENTION: SPLICOSOME MEDIATED RNA TRANS-SPLICING
; FILE REFERENCE: A31304-B-A 072874.0134
; CURRENT APPLICATION NUMBER: US/09/756,095
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 09/158,863
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 09/133,717
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 09/087,233
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 08/766,354
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: 60/008,317
; PRIOR FILING DATE: 1995-12-07
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapien
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-756-095-16

Query Match 0.4%; Score 14.4; DB 1; Length 17;
```

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2573 CTTCTTTTTTTTCT 2588
||||| |||||||
Db 1 CTTCTTTTTTTTCT 16

RESULT 339
US-09-941-492-16
; Sequence 16, Application US/09941492
; Publication No. US20030027250A1
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd
; APPLICANT: Garcia-Blanco, Mariano M.
; APPLICANT: Puttaraju, Madalah
; APPLICANT: Mansfield, Gary S.
; TITLE OF INVENTION: METHODS OF COMPOSITIONS FOR USE IN
; FILE REFERENCE: A31304-BAE (072874.0156)
; CURRENT APPLICATION NUMBER: US/09/941,492
; PRIOR FILING DATE: 2002-04-01
; PRIOR APPLICATION NUMBER: 09/838,858
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: 09/756,096
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 09/158,863
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 09/133,717
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 09/087,233
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 08/766,354
; PRIOR FILING DATE: 1996-12-13
; NUMBER OF SEQ ID NOS: 125
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-941-492-16

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2573 CTTCTTTTTTTTCT 2588
||||| |||||||
Db 1 CTTCTTTTTTTTCT 16

RESULT 340
US-09-730-289B-880/c
; Sequence 880, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCE: MBH00-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; PRIOR FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 880
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-880

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3490 TAATTTACTATTATG 3505
||||| |||||||
Db 16 TAATTTACTATTATG 1

RESULT 341
US-09-780-533A-1235
; Sequence 1235, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1235
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1235

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 3640 ATTGTTTCAAAATGCG 3655
|: : ||||| :|||
Db 2 AUUAUCAGAAAUUGC 17

RESULT 342
US-09-780-533A-2172/c
; Sequence 2172, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2172
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2172

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTT 2586
||||| |||||||
Db 17 TTCTTCTTTTTTTT 2

```
RESULT 343
US-09-877-478-523/c
; Sequence 523, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 523
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-523

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
Db 17 GAAGTGTTCATAGAT 2

RESULT 344
US-09-877-478-1239/c
; Sequence 1239, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 523
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-523

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
Db 17 GAAGTGTTCATAGAT 2
```

```
RESULT 345
US-09-756-096A-16
; Sequence 16, Application US/09756096A
; Publication No. US2003007754A1
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Garcia-Blanco, Mariano A.
; APPLICANT: Puttaraju, Madaiha
; APPLICANT: Mansfield, Gary S.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
; FILE REFERENCE: A31304-B-A-B 072874.0135
; CURRENT APPLICATION NUMBER: US/09/756,096A
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 09/158,863
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 09/133,717
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 09/087,233
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 08/766,354
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: 60/008,317
; PRIOR FILING DATE: 1995-12-15
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-756-096A-16

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2573 CTTCCTTTTTTTTCT 2588
Db 1 CTTCCTTTTTTTTCT 16

RESULT 346
US-09-838-858-16
; Sequence 16, Application US/09838858
; Publication No. US20030148937A1
; GENERAL INFORMATION:
; APPLICANT: Mansfield, Gary S.
; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Garcia-Blanco, Mariano A.
; APPLICANT: Walsh, Christopher E.
```



```
; APPLICANT: Chao, Hengjun
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
; FILE OF INVENTION: SPLICOSOME MEDIATED RNA TRANS-SPLICING
; FILE REFERENCE: A31304-BAD 072874.01
; CURRENT APPLICATION NUMBER: US/09/838,858
; CURRENT FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: 09/756,096
; PRIOR FILING DATE: 2001-02-08
; PRIOR APPLICATION NUMBER: 09/158,863
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 09/133,717
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 09/087,233
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 08/766,354
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: 60/008,317
; PRIOR FILING DATE: 1995-12-15
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-838-858-16
```

```
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2573 CTCTCTCTCTCTCTCTCT 2588
||||| |||||||
Db 1 CTCTCTCTCTCTCTCTCT 16
```

```
RESULT 347
US-10-156-306-517
; Sequence 517, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 517
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-517
```

```
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. No. 1.8e+02;
Matches 1; Conservative 14; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2571 TTCTCTCTCTCTCTCTCT 2586
::: |||:|||||:
Db 2 UUAUUCUUUUUUUUUUU 17
```

```
RESULT 348
US-10-156-306-518
; Sequence 518, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
```

```
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 518
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-518
```

```
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. No. 1.8e+02;
Matches 1; Conservative 14; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2571 TTCTCTCTCTCTCTCTCT 2586
::: |||:|||||:
Db 1 UUAUUCUUUUUUUUUUU 16
```

```
RESULT 349
US-10-156-306-520
; Sequence 520, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 520
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-520
```

```
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. No. 1.8e+02;
Matches 1; Conservative 14; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2571 TTCTCTCTCTCTCTCTCT 2586
::: |||:|||||:
Db 2 UUCUUUUUUUUUUUUUUU 17
```

```
RESULT 350
US-10-156-306-521
; Sequence 521, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 521
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-521
```

```
Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. No. 1.8e+02;
Matches 1; Conservative 14; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2571 TTCTTCTTTTCTTTT 2586
      :|::: :|::: :|:::
Db 1 UUCUUUUUUUUUUUU 16

RESULT 351
US-10-156-306-7025/c
; Sequence 7025, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7025
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7025

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 846 TGTATTCCTCTGCAG 861
      ||||| ||||| |||||
Db 17 TGTACTCCCTCTGCAG 2

RESULT 352
US-10-156-306-7026/c
; Sequence 7026, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7026
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7026

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 846 TGTATTCCTCTGCAG 861
      ||||| ||||| |||||
Db 16 TGTACTCCCTCTGCAG 1

RESULT 353
US-10-061-201-1265/c
; Sequence 1265, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1265
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1265

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2846 ATGGGCTGGGAGATCA 2861
      ||||| ||||| |||||
Db 17 ATGGGCTGGGTGATCA 2

RESULT 354
US-10-061-201-1268/c
; Sequence 1268, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1268
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

US-10-061-201-1268

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCATGGGCTGGGAGAT 2859
DB 16 CCATGGGCTGGGTGAT 1

RESULT 355

US-10-061-201-1937/c
; Sequence 1937, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1937
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1937

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GCTGAGGGGAGGGG 392
DB 17 GCTGAGGGGAGGAGG 2

RESULT 356

US-10-061-201-1938/c
; Sequence 1938, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1938
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1938

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GCTGAGGGGAGGGG 392
DB 16 GCTGAGGGGAGGAGG 1

RESULT 357

US-10-230-006-1207
; Sequence 1207, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1207
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1207

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 1.8e+02;
Matches 7; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 3467 GAATTCCTGCTATTTT 3482
DB 1 GAAUUCUGGCUAUUUU 16

RESULT 358

US-10-342-902-523/c
; Sequence 523, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave

; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MEHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 523
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-523

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTGACAAAGAT 2662
DB 17 GAAGTGTGACAAAGAT 2

RESULT 359
US-10-342-902-1239/c
; Sequence 1239, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MEHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1239
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1239

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2647 GAAGTGTGACAAAGAT 2662
DB 16 GAAGTGTGACAAAGAT 1
RESULT 360
US-10-138-674-5149
; Sequence 5149, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5149
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5149

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2590 AAAAAAGCAAAAGCA 2605
DB 1 AAAAAAGCAAAAGCA 16

RESULT 361
US-10-138-674-6286/c
; Sequence 6286, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6286
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6286

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2139 TTCTACTTGGTCATCA 2154
DB 17 TTCTACTTGGTCATCA 2

RESULT 362
US-10-138-674-6287/c

```
; Sequence 6287, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6287
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6287

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2139 TTCTACTTGGTCATCA 2154
DB 16 TTCTTCTTGGTCATCA 1

RESULT 363
US-10-287-949A-5149
; Sequence 5149, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5149
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5149

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2590 AAAAAAGGAAAAAGCA 2505
DB 1 AAAAAAGCAAAAGCA 16

RESULT 364
US-10-287-949A-6286/c
; Sequence 6286, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6286
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6286

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2139 TTCTACTTGGTCATCA 2154
DB 17 TTCTTCTTGGTCATCA 2

RESULT 365
US-10-287-949A-6287/c
; Sequence 6287, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6287
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6287

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2139 TTCTACTTGGTCATCA 2154
DB 16 TTCTTCTTGGTCATCA 1

RESULT 366
US-10-712-672-68/c
; Sequence 68, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowirza, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 68
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-68

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2252 GCCTCAGAGAGTTGAG 2267
      |||||
Db 17 GCCTCAGAGAGTTGAG 2

RESULT 367
US-10-712-672-685/c
; Sequence 685, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 685
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-685

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2252 GCCTCAGAGAGTTGAG 2267
      |||||
Db 16 GCCTCAGAGAGTTGAG 1

RESULT 368
US-10-669-841-523/c
; Sequence 523, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
```

```
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 523
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-523

Query Match          0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTGACAGAT 2662
      |||||
Db 17 GAAGTGTGATAGAT 2

RESULT 369
US-10-669-841-1239/c
; Sequence 1239, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
```

; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1239
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1239

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
Db 16 GAAGTGTTCAGTAAAT 1

RESULT 370
US-09-969-373-2495
; Sequence 2495, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2495
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-2495

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 CTATGTGTCAGCGAC 925
Db 2 CTATGATCCAGCGAC 17

RESULT 371
US-10-091-281-201
; Sequence 201, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 201
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative XBBF/RFX1.02 motif

US-10-091-281-201

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1827 GGGAAACAAGGCACA 1842
Db 2 GGGAAACAAGGAACA 17

RESULT 372
US-10-349-143-11340/c
; Sequence 11340, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Iliya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11340
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-4332 for SEQ 3475, in complemer
US-10-349-143-11340

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1072 GAACATTCGATTGTG 1087
Db 16 GAACATTCGATTGTG 1

RESULT 373
US-10-224-005-154
; Sequence 154, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fosnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADC
; FILE REFERENCE: 900/041 (MBHB01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 154
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:

```
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-224-005-154

Query Match          0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 278 GGGGGGGGAGTGGCC 293
    ||| |||||:||||
Db 1 GGGAGGGGAGGUGGCC 16

RESULT 374
US-10-224-005-315/c
; Sequence 315, Application US/10224005
; Publication No. US2003014732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fornaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD)
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/041 (MBHB01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 315
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-224-005-315

Query Match          0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 278 GGGGGGGGAGTGGCC 293
    ||| |||||:||||
Db 19 GGGAGGGGAGTGGCC 4

RESULT 375
US-10-400-382-87/c
; Sequence 87, Application US/10400382
; Publication No. US20030190659A1
; GENERAL INFORMATION:
; APPLICANT: LaCasse, Eric
; APPLICANT: McManus, Daniel
; APPLICANT: Durkin, Jonathan P.
; TITLE OF INVENTION: Antisense IAP Nucleobase Oligomers and
; TITLE OF INVENTION: Uses Thereof
; FILE REFERENCE: 07891/025004
; CURRENT APPLICATION NUMBER: US/10/400,382
; CURRENT FILING DATE: 2003-03-27
; PRIOR APPLICATION NUMBER: US 60/367,853
; PRIOR FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 460
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 87
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: based on Homo sapiens.
; OTHER INFORMATION: Each nucleobase may be part of a ribonucleotide,
; OTHER INFORMATION: deoxyribonucleotide, or nucleotide analog
; FEATURE:
; NAME/KEY: misc_feature
```

```
; LOCATION: 4, 13, 17
; OTHER INFORMATION: n = T or U
US-10-400-382-87

Query Match          0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTCTG 2589
    ||| |||||:||||
Db 19 TTNTCCNTTTTCTG 1

RESULT 376
US-10-244-647-392/c
; Sequence 392, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) U
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 392
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-244-647-392

Query Match          0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTGACAGAT 2662
    |||||:|||||
Db 19 GAAGTGTGATAGAT 4

RESULT 377
US-10-244-647-394/c
; Sequence 394, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) U
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
```


;
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 394
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense 1
US-10-244-647-394

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
|||||:|||||
Db 18 GAAGTGTTCATAGAT 3

RESULT 378
US-10-244-647-1038
; Sequence 1038, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; PRIOR FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1038
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1038

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
|||||:|||||
Db 1 GAAGUGUGAUAAGAU 16

RESULT 379
US-10-244-647-1040
; Sequence 1040, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; PRIOR FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1038
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1038

;
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1040

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 68.8%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2647 GAAGTGTTCACAGAT 2662
|||||:|||||
Db 2 GAAGUGUGAUAAGAU 17

RESULT 380
US-10-187-975-190
; Sequence 190, Application US/10187975
; Publication No. US20030224982A1
; GENERAL INFORMATION:
; APPLICANT: Li, Li
; APPLICANT: Shenoy, Suresh
; APPLICANT: Patturajan, Meeta
; APPLICANT: Ellerman, Karen
; APPLICANT: Gorman, Linda
; APPLICANT: Zhong, Mei
; APPLICANT: Catterton, Elina
; APPLICANT: Spyttek, Kimberly
; APPLICANT: Miller, Charles
; APPLICANT: Edinger, Shlomit
; APPLICANT: Hjalit, Tord
; APPLICANT: Gerlach, Valerie
; APPLICANT: Shimkets, Richard
; APPLICANT: Taupier, Raymond J. Jr.
; APPLICANT: Anderson, David
; APPLICANT: Guo, Xiaojia
; APPLICANT: Baumgartner, Jason
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Peyman, John
; APPLICANT: Smithson, Glennnda
; APPLICANT: Casman, Stacie
; APPLICANT: Voss, Edward
; APPLICANT: Boldog, Ferenc
; APPLICANT: Pena, Carol
; APPLICANT: Chapoval, Andrei
; APPLICANT: Rastelli, Luca
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Vernte, Corine
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING
; FILE REFERENCE: 21402-397A
; CURRENT APPLICATION NUMBER: US/10/187,975
; CURRENT FILING DATE: 2002-07-02
; PRIOR APPLICATION NUMBER: 60/303,046
; PRIOR FILING DATE: 2001-07-05
; PRIOR APPLICATION NUMBER: 60/303,828
; PRIOR FILING DATE: 2001-07-09

```

; PRIOR APPLICATION NUMBER: 60/304,502
; PRIOR FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 60/305,011
; PRIOR FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 60/305,262
; PRIOR FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 60/305,673
; PRIOR FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: 60/306,085
; PRIOR FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 60/307,536
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/308,228
; PRIOR FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/308,877
; PRIOR FILING DATE: 2001-07-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 288
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 190
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-187-975-190

```

```

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 1437 TGTATTCACAGCCAT 1452
Db 4 TGAATTCACAGCCAT 19

```

```

RESULT 381
US-10-309-290-212
; Sequence 212, Application US/10309290
; Publication No. US20040023241A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook II, John P.
; APPLICANT: Anderson, David W.
; APPLICANT: Boldog, Ferenc L.
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Chillakuru, Rajeev A.
; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Gerlach, Valerie L.
; APPLICANT: Gorman, Linda
; APPLICANT: Gould-Rothberg, Bonnie E.
; APPLICANT: Guo, Xiaojia
; APPLICANT: Jeffers, Michael E.
; APPLICANT: Ji, Weizhen
; APPLICANT: Li, Li
; APPLICANT: Malvankar, Uriel M.
; APPLICANT: Miller, Charles E.
; APPLICANT: Murphey, Ryan
; APPLICANT: Patturajan, Meera
; APPLICANT: Peyman, John A.
; APPLICANT: Rastelli, Luca
; APPLICANT: Rieger, Daniel K.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Smithson, Glenda
; APPLICANT: Starling, Gary
; APPLICANT: Taupier, Raymond J.
; APPLICANT: Voss, Edward Z.
; APPLICANT: Zhong, Haihong
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-502A
; CURRENT APPLICATION NUMBER: US/10/309,290
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/336,600

```

```

; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: 60/338,285
; PRIOR FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/341,346
; PRIOR FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/341,477
; PRIOR FILING DATE: 2001-12-17
; PRIOR APPLICATION NUMBER: 60/341,540
; PRIOR FILING DATE: 2001-12-17
; PRIOR APPLICATION NUMBER: 60/342,592
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: 60/344,297
; PRIOR FILING DATE: 2001-12-27
; PRIOR APPLICATION NUMBER: 60/344,903
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/373,288
; PRIOR FILING DATE: 2002-04-17
; PRIOR APPLICATION NUMBER: 60/380,981
; PRIOR FILING DATE: 2002-05-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 274
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 212
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-309-290-212

```

```

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 221 GTGTGGCCTTGAGCTG 236
Db 2 GTGTGGCCTTGAGCAG 17

```

```

RESULT 382
US-10-236-392-357/c
; Sequence 357, Application US/10236392
; Publication No. US20040067490A1
; GENERAL INFORMATION:
; APPLICANT: Anderson, David W.
; APPLICANT: Boldog, Ferenc L.
; APPLICANT: Burgess, Catherine, E.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Catterton, Elina
; APPLICANT: Chapoval, Andrei
; APPLICANT: Crabtree, Julie
; APPLICANT: Edinger, Shlomit, R.
; APPLICANT: Ellerman, Karen
; APPLICANT: Gerlach, Valerie
; APPLICANT: Gorman, Linda
; APPLICANT: Grosse, William M.
; APPLICANT: Gusev, Vladamir
; APPLICANT: Kekuda, Ramesh
; APPLICANT: LaRocheille, William J.
; APPLICANT: Li, Li
; APPLICANT: MacDougall, John R.
; APPLICANT: Malvankar, Uriel M.
; APPLICANT: Miller, Charles E.
; APPLICANT: Millet, Isabelle
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Patturajan, Meera
; APPLICANT: Pena, Carol A.
; APPLICANT: Peyman, John A.
; APPLICANT: Rastelli, Luca
; APPLICANT: Reiger, Daniel K.
; APPLICANT: Rothenberg, Mark E.
; APPLICANT: Shenoy, Suresh
; APPLICANT: Shimkets, Richard A.

```

```
; APPLICANT: Smithson, Glenna
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-442A
; CURRENT APPLICATION NUMBER: US/10/236,392
; PRIOR FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US09/540,763
; PRIOR FILING DATE: 2000-03-30
; PRIOR APPLICATION NUMBER: US60/390,155
; PRIOR FILING DATE: 2002-06-19
; PRIOR APPLICATION NUMBER: US09/635,949
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US60/318,765
; PRIOR FILING DATE: 2001-09-12
; PRIOR APPLICATION NUMBER: US60/357,303
; PRIOR FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: US60/367,753
; PRIOR FILING DATE: 2002-03-25
; PRIOR APPLICATION NUMBER: US60/369,479
; PRIOR FILING DATE: 2002-04-02
; PRIOR APPLICATION NUMBER: US09/659,634
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: US60/318,120
; PRIOR FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: US60/318,130
; PRIOR FILING DATE: 2001-09-07
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 794
; SOFTWARE: Custom
; SEQ ID NO 357
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-236-392-357

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2457 AGCTGGCACCATTATCC 2472
DB 17 AGCTGGCACCATTATCC 2

RESULT 383
US-10-327-598-823
; Sequence 823, Application US/10327598
; Publication No. US20040181039A1
; GENERAL INFORMATION:
; APPLICANT: Krah, Eugene
; APPLICANT: Guo, Honliang
; APPLICANT: Aiyappa, Ashok
; APPLICANT: Lawton, Robert
; TITLE OF INVENTION: Canine Immunoglobulin Variable Domains, Caninized Antibodies, and
; FILE REFERENCE: 01-799-A
; CURRENT APPLICATION NUMBER: US/10/327,598
; PRIOR FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/344,874
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 1139
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 823
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION:
US-10-327-598-823

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
```

```
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 233 GCTGGTCCAGAGCGC 248
DB 4 GCTGGTCAAGAGCGC 19

RESULT 384
US-10-280-183A-429/c
; Sequence 429, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Chatterjee, Aurobindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shanru
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G.
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; FILE REFERENCE: PC18306A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 429
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mouse
US-10-280-183A-429

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.3e+02; 3; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2874 GGCAGAAATCCTGTTCACTG 2892
DB 20 GCCAGAAATCCTGTTCCATG 2

RESULT 385
US-09-866-108-950/c
; Sequence 950, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 950
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-950
```

```
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 3428 CTGCCTGCTTTGC 3441
|||||
Db 17 CTGCCTGCTTTGC 4
```

RESULT 386

```
US-09-866-108-951/c
; Sequence 951, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 951
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-951
```

```
Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 3428 CTGCCTGCTTTGC 3441
|||||
Db 16 CTGCCTGCTTTGC 3
```

RESULT 387

```
US-09-866-108-952/c
; Sequence 952, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
```

; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-952

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCTGTCTTTGC 3441
| | | | | | | | | | | | | | | | | |
Db 15 CTGCTGTCTTTGC 2

RESULT 388
US-09-866-108-953/c
; Sequence 953, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 953
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-953

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3428 CTGCTGTCTTTGC 3441
| | | | | | | | | | | | | | | | | |
Db 14 CTGCTGTCTTTGC 1

RESULT 389
US-09-818-875-3366/c
; Sequence 3366, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3366

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 CTTCCCGATGAAG 734
| | | | | | | | | | | | | | | | | |
Db 14 CTTCCCGATGAAG 1

RESULT 390
US-09-818-875-3367
; Sequence 3367, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3367
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3367

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 CTTTCCCGAGTGAAG 734
|||||
Db 4 CTTTCCCGAGTGAAG 17

RESULT 391

US-09-780-533A-2560
; Sequence 2560, Application US/09780533A
; Publication No. US2003006611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2560
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2560

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 3645 TCAGAAATGGCAAA 3658
:|||||
Db 1 UCAGAAAUAGGCAAA 14

RESULT 392

US-10-209-787-3366/c
; Sequence 3366, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 60/181,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3366

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 CTTTCCCGAGTGAAG 734
|||||
Db 14 CTTTCCCGAGTGAAG 1

RESULT 393

US-10-209-787-3367
; Sequence 3367, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 60/181,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3367
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3367

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 CTTTCCCGAGTGAAG 734
|||||
Db 4 CTTTCCCGAGTGAAG 17

RESULT 394

US-10-261-185-3366/c
; Sequence 3366, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30

; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3366

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 721 CTTTCCCAAGTGAAG 734
| | | | | | | | | | | | | | | | | |
Db 14 CTTTCCCAAGTGAAG 1

RESULT 395
US-10-261-185-3367
; Sequence 3367, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3367
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3367

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 721 CTTTCCCAAGTGAAG 734
| | | | | | | | | | | | | | | | | |
Db 4 CTTTCCCAAGTGAAG 17

RESULT 396
US-10-138-674-6605/c
; Sequence 6605, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6605

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1818 CGGTCTCTGGGAA 1831
| | | | | | | | | | | | | | | | | |
Db 17 CGGTCTCTGGGAA 4

RESULT 397
US-10-138-674-6606/c
; Sequence 6606, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6606
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6606

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1818 CGGTCTCTGGGAA 1831
| | | | | | | | | | | | | | | | | |
Db 16 CGGTCTCTGGGAA 3

RESULT 398
US-10-287-949A-6605/c
; Sequence 6605, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6605

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;

```
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CGGTCTCTGGGAA 1831
    |||||
Db 17 CGGTCTCTGGGAA 4

RESULT 399
US-10-287-949A-6606/c
; Sequence 6606, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6606
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6606

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CGGTCTCTGGGAA 1831
    |||||
Db 16 CGGTCTCTGGGAA 3

RESULT 400
US-10-723-361-950/c
; Sequence 950, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 951
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-951

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCCTGTCTTTGC 3441
    |||||
Db 16 CTGCCTGTCTTTGC 3

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCCTGTCTTTGC 3441
    |||||
Db 16 CTGCCTGTCTTTGC 3
```



```
RESULT 402
US-10-723-361-952/c
; Sequence 952, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-952

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCTGTCTTTGC 3441
DB 14 CTGCTGTCTTTGC 1
|||||

RESULT 403
US-10-723-361-953/c
; Sequence 953, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-952

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCTGTCTTTGC 3441
DB 15 CTGCTGTCTTTGC 2
|||||

RESULT 404
US-10-681-074-3366/c
; Sequence 3366, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: Napro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 3366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3366

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 CTTTCCAGTGAAG 734
DB 14 CTTTCCAGTGAAG 1
|||||

RESULT 405
US-10-681-074-3367
; Sequence 3367, Application US/10681074
; Publication No. US20040175722A1
```

```
US-10-723-361-952/c
; Sequence 952, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
```


; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1176

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 20 GAAGGACGAGGAGGAGGG 36
Db 1 GAAGGACAAAGGAGGG 17
||||| |||||

RESULT 409
US-09-866-108-1580/c
; Sequence 1580, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1580
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1580

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2981 ATCATTCTCCAGGAGG 2997
Db 17 ATCCTTCTCCAGGAGCAG 1
||||| |||||

RESULT 410
US-09-866-108-2270
; Sequence 2270, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860

Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 414 CCTCCGGCGCTGCT 430
DB 1 CCTCCGGCGCTTCCGCT 17

RESULT 412
US-09-866-108-6855
; Sequence 6855, Application US/09866108
; Patent No. US20020049800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6855
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6855

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 TCCTCCGGCGCTGCTC 429
DB 1 TCCTCCGGCGCTTCCGC 17

RESULT 411
US-09-866-108-2271
; Sequence 2271, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2271
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2271

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
; Sequence 6856, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 6856
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6856
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1174 GAAAGAGCGAGAGAGC 1190
Db 1 GAAGCAGCGAGAGAGC 17
```

```
RESULT 414
US-09-866-108-6929/c
; Sequence 6929, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
```

```
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 6929
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6929
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 3318 AGATTGTGAATTCCTG 3334
Db 17 AGCTTCTGAATTCCTG 1
```

```
RESULT 415
US-09-866-108-6930/c
; Sequence 6930, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6930
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6930
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3317 CAGATTCTTGAATTCCT 3333
Db 17 CAGCTTCTTGAATTCCT 1
```

```
RESULT 416
US-09-866-108-8116
; Sequence 8116, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8116
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8116
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 CTGCCAGAGCAGCTCC 2742
Db 1 CTGCCAGAGCGGCTTC 17
```

```
RESULT 417
US-09-866-108-8454
; Sequence 8454, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
```

;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Acomica Sequence Listing Engine
;; SEQ ID NO 8454
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-8454

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1357 AGATCATGCACACGAG 1373
Db 1 AGAGCATGCACACGAG 17
|||||

RESULT 418
US-09-866-108-8873/c
; Sequence 8873, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8873
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108-8873

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2182 AGTGTCTCTCCATCTT 2198
Db 17 AGCTCTCTCCCATCTT 1
|||||

RESULT 419
US-09-866-108-10318
; Sequence 10318, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10318
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10318

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1764 CTTTCTCTCGGGATCA 1780
Db 1 CTTTCTCTCGGGATCA 17
|||||

```
RESULT 420
US-09-827-998-196
; Sequence 196, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 196
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-196

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2916 TTTTGCATTTTGAATA 2932
Db 1 TTTTGCATTTTGAATA 17

RESULT 421
US-09-827-998-483/c
; Sequence 483, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 483
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-483

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTTTTTC 2587
Db 17 TTCCTCTTTTTC 1

RESULT 422
US-09-827-998-775/c
; Sequence 775, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
```

```
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 775
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-775

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 TGAGTACCAACACGAG 676
Db 17 TGGGTACCACACGAG 1

RESULT 423
US-09-827-998-776/c
; Sequence 776, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 776
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-776

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 659 CTGAGTACCAACACGAG 675
Db 17 CTGGGTACCACACGAG 1

RESULT 424
US-09-817-014-131
; Sequence 131, Application US/09817014
; Patent No. US20020106646A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammateo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De Longueville, Françoise
; TITLE OF INVENTION: IDENTIFICATION OF BIOLOGICAL
; TITLE OF INVENTION: (MICRO)ORGANISMS BY DETECTION OF THEIR HOMOLOGOUS NUCLEOTIDE
; TITLE OF INVENTION: SEQUENCES ON ARRAYS
; FILE REFERENCE: VANM213.001AUS
; CURRENT APPLICATION NUMBER: US/09/817,014
```


; CURRENT FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 131
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: consensus primer for Consensus subtype 1C
; OTHER INFORMATION: antisense
US-09-817-014-131

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2392 TTGGCAGCTTCTTTCC 2408
|||||
Db 1 TTGGAAGCTTCTTTTC 17

RESULT 425
US-09-817-014-136
; Sequence 136, Application US/09817014
; Patent No. US20020106646A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammateo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De Longueville, Francoise
; TITLE OF INVENTION: IDENTIFICATION OF BIOLOGICAL
; TITLE OF INVENTION: (MICRO)ORGANISMS BY DETECTION OF THEIR HOMOLOGOUS NUCLEOTIDE
; FILE REFERENCE: VANM213.001AUS
; CURRENT APPLICATION NUMBER: US/09/817,014
; CURRENT FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 136
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: consensus primer for Consensus subtype 2C
; OTHER INFORMATION: antisense
US-09-817-014-136

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2392 TTGGCAGCTTCTTTCC 2408
|||||
Db 1 TTGGAAGCTTCTTTTC 17

RESULT 426
US-09-864-785-551/c
; Sequence 551, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 551
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-551

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1171 CCAGAAAGCGGAGAGA 1187
|||||
Db 17 CCAAAAAGAGAGAGAGA 1

RESULT 427
US-09-825-805-720
; Sequence 720, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 720
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-720

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 365 GAGAGCCAGCGGCTGA 381
|||||
Db 1 GAGAGCCAGCCUCUGA 17

```
RESULT 428
US-09-818-875-535/c
; Sequence 535, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-535

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTGTGTTTCTA 2951
    |||||
DB 17 TTCTAGTTGTTTGCTA 1

RESULT 429
US-09-818-875-536
; Sequence 536, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-536

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTGTGTTTCTA 2951
    |||||
DB 17 TTCTAGTTGTTTGCTA 1

RESULT 430
US-09-818-875-3162/c
; Sequence 3162, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3162
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3162

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCAGCTTCTCTTC 2576
    |||||
DB 17 TCTAGCTTCTCTTC 1

RESULT 431
US-09-818-875-3163
; Sequence 3163, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3163
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3163

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTGTGTTTCTA 2951
    |||||
DB 17 TTCTAGTTGTTTGCTA 1
```

```
|||||
Db 1 TTCTAGTTGTTTGCTA 17

RESULT 430
US-09-818-875-3162/c
; Sequence 3162, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3162
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3162

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCAGCTTCTCTTC 2576
    |||||
DB 17 TCTAGCTTCTCTTC 1

RESULT 431
US-09-818-875-3163
; Sequence 3163, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3163
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3163

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTGTGTTTCTA 2951
    |||||
DB 17 TTCTAGTTGTTTGCTA 1
```

```
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCAGCTTCTTCTTC 2576
Db ||||| ||||| |||||
1 TCTCAGCTTCTTCTTC 17

RESULT 432
US-09-780-533A-237/c
; Sequence 237, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 237
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-237

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTTCTTCTTCTTCTT 2585
Db ||||| ||||| |||||
1 TTTTCTTCTTCTTCTT 1

RESULT 433
US-09-780-533A-1771
; Sequence 1771, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1771
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1771

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 3431 CCTGTCTTGTGCTCCAT 3447
Db ||||| ||||| |||||
1 CCUGUCUGACUGCCAU 17

RESULT 434
US-09-780-533A-2321
; Sequence 2321, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2321
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2321

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 3432 CTGTCTTGTGCTCCATG 3448
Db ||||| ||||| |||||
1 CUGUCUGACUGCCAU 17

RESULT 435
US-09-780-533A-2461/c
; Sequence 2461, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2461
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2461

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2568 TTCTTCTTCTTCTTCTT 2584
Db ||||| ||||| |||||
1 TTCTTCTTCTTCTTCTT 1

RESULT 436
US-09-780-533A-2462/c
; Sequence 2462, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
```

; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2462
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2462

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2215 CTTCTCTCTTCCTTCTT 2231
Db 17 CTTCTCTCTTCATCTT 1

RESULT 437
US-09-927-046-299/c
; Sequence 299, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 299
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-299

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2230 TTCCTCATGAATGGGCC 2246
Db 17 TTCCTCATGAATGGGCC 1

RESULT 438
US-09-927-046-1429
; Sequence 1429, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride

; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1429
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1429

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2964 TACCAATGAATTTTAG 2980
Db 1 UACUAAUGUAUUUAG 17

RESULT 439
US-09-927-046-2074
; Sequence 2074, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-2074

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2086 CCATCTCTGTGATCCCA 2102
Db 1 CCUCUCUGGGAUCCCA 17

RESULT 440
US-09-877-478-1240/c
; Sequence 1240, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20

;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 08/433,993
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 08/434,504
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6586
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 1240
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-09-877-478-1240

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2643 TCCAGAGTGTGACAA 2659
DB 17 TCCGGAAGTGTGATAA 1

RESULT 441
US-09-877-478-2087/c
;; Sequence 2087, Application US/09877478
;; Publication No. US20030068301A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Draper, Kenneth
;; APPLICANT: Blatt, Larry
;; APPLICANT: McSwiggen, Jim
;; APPLICANT: Morrissey, Dave
;; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;; FILE REFERENCE: MBH00-845-H (400/029)
;; CURRENT APPLICATION NUMBER: US/09/877,478
;; CURRENT FILING DATE: 2001-12-31
;; PRIOR APPLICATION NUMBER: US 07/882,712
;; PRIOR FILING DATE: 1992-05-14
;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 08/433,993
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 08/434,504
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6586
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2087
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-09-877-478-2087

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2645 CACAAGTGTGACAAGA 2661
DB 17 TCCGGAAGTGTGATAA 1

Db 17 CGGAAGTGTGATAAGA 1

RESULT 442
US-09-877-478-2088/c
;; Sequence 2088, Application US/09877478
;; Publication No. US20030068301A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Draper, Kenneth
;; APPLICANT: Blatt, Larry
;; APPLICANT: McSwiggen, Jim
;; APPLICANT: Morrissey, Dave
;; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;; FILE REFERENCE: MBH00-845-H (400/029)
;; CURRENT APPLICATION NUMBER: US/09/877,478
;; CURRENT FILING DATE: 2001-12-31
;; PRIOR APPLICATION NUMBER: US 07/882,712
;; PRIOR FILING DATE: 1992-05-14
;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 08/433,993
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 08/434,504
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6586
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2088
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-09-877-478-2088

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2643 TCCAGAGTGTGACAA 2659
DB 17 TCCGGAAGTGTGATAA 1

RESULT 443
US-09-848-754A-809
;; Sequence 809, Application US/09848754A
;; Publication No. US20030073207A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
;; FILE REFERENCE: MBH00-958-I (400/018)
;; CURRENT APPLICATION NUMBER: US/09/848,754A
;; CURRENT FILING DATE: 2001-05-03
;; NUMBER OF SEQ ID NOS: 9645
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 809
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-848-754A-809

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1586 TACAGGTTTGTAAAGAA 1602
:|||| :|:|:|
Db 1 UACAGCAUGUUAAGAA 17

RESULT 444

US-09-848-754A-1209/c
; Sequence 1209, Application US/09848754A
; Publication No. US20030073207A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1209

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-848-754A-1209

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1822 CTCGGGGGACACAAAG 1838
|||:|:|:|
Db 17 CTCGGGGGACACAAAG 1

RESULT 445

US-09-848-754A-1724
; Sequence 1724, Application US/09848754A
; Publication No. US20030073207A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1724

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-848-754A-1724

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 718 CTTCTTCCCGATGAAG 734
|:|:|:|
Db 1 CUUCUUCUCCCAAGGAAG 17

RESULT 446

US-09-848-754A-1927/c
; Sequence 1927, Application US/09848754A
; Publication No. US20030073207A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1927
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1927

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2755 TCCTCTCTTGATGAATT 2771
|||||:|:|
Db 17 TCCTCTCTTGATGAATT 1

RESULT 447

US-09-848-754A-2332/c
; Sequence 2332, Application US/09848754A
; Publication No. US20030073207A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2332

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-848-754A-2332

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1824 CTGGGGACACAAAGGCA 1840
|:|:|:|
Db 17 CGGGGGAGCACAAAGGCA 1

RESULT 448

US-09-848-754A-2624
; Sequence 2624, Application US/09848754A
; Publication No. US20030073207A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2624

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-848-754A-2624

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1829 GAACACAAAGCCAAAGT 1845
|||:|:|:|
Db 1 GAGCACAAAGCCAAAGU 17

RESULT 449

```
US-09-848-754A-2740/c
; Sequence 2740, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2740
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2740

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3107 ACCTAATATTTCTTAA 3123
| | | | | | | | | | | | | | |
Db 17 ATCAATACTTCTTAA 1

RESULT 450
US-09-848-754A-3114
; Sequence 3114, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3114
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3114

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1834 CAAGGCACAGTGACAA 1850
| | | | | | | | | | | | | | |
Db 1 CAAGGCACAGUAACAA 17

RESULT 451
US-09-930-423-875/c
; Sequence 875, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens

US-09-930-423-875
Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1457 TCCATCCAGGAGAGGC 1473
| | | | | | | | | | | | | | |
Db 17 TCCATCAAGGCAGAGGC 1

RESULT 452
US-09-930-423-1685
; Sequence 1685, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1685
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1685

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.3e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2260 GAGTTGAGGACCGCAGC 2276
| | | | | | | | | | | | | | |
Db 1 GAGUUCAGGACCGCAGC 17

RESULT 453
US-09-780-164-707
; Sequence 707, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 707
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-707

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 2.3e+02;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 3435 TCTTTGCTGCCATGTTT 3451
| | | | | | | | | | | | | | |
Db 1 UCUUUGCUGCCAUUUCU 17

RESULT 454
US-09-827-395A-164
```

```
; Sequence 164, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 164
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-164

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 103 GTCCAGCAGCCAGCTT 119
|: ||||| ||||| :
Db 1 GUGCCAGCUGCCAGCUU 17

RESULT 455
US-09-740-332-3867/c
; Sequence 3867, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3867

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2843 GCCATGGCGCTGGGAGAT 2859
||||| |||||
Db 17 GCCATGGACCGGAGAT 1

RESULT 456
US-09-745-237A-875/c
; Sequence 875, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
```

```
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-875

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1457 TCCATCCAGGAGGAGGC 1473
||||| ||||| |||||
Db 17 TCCATCAGGCAGAGGC 1

RESULT 457
US-09-745-237A-1685
; Sequence 1685, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1685
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1685

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.3e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2260 GAGTTGAGGACCGCAGC 2276
||||: ||||| |||||
Db 1 GAGUUCAGGACGCGACG 17

RESULT 458
US-09-817-879-3867/c
; Sequence 3867, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; TITLE OF INVENTION: Hepatitis C Virus Infection
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3867

Query Match      0.4%; Score 13.8; DB 1; Length 17;
```



```
; ORGANISM: Homo sapiens
US-10-060-756A-1913

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2843 GCCATGGGCTGGAGAT 2859
DB 17 GCCATGGACCGGAGAT 1

RESULT 459
US-10-085-395-4/c
; Sequence 4, Application US/10085395
; Publication No. US2003008306A1
; GENERAL INFORMATION:
; APPLICANT: Turnbull, Kenneth
; APPLICANT: Selvasekaran, Janardhanam
; TITLE OF INVENTION: CIRCULAR POLYNUCLEOTIDE TEMPLATES AND METHOD FOR
; TITLE OF INVENTION: OLIGONUCLEOTIDES
; FILE REFERENCE: ARK007/98215B
; CURRENT APPLICATION NUMBER: US/10/085,395
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/080,198
; PRIOR FILING DATE: 1998-03-31
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: WordPerfect 8.0 (saved in ASCII format)
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; NAME/KEY: Misc structure
; OTHER INFORMATION: Oligonucleotide
US-10-085-395-4

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTTTTTC 2587
DB 17 TTCCTCTTTTTC 1

RESULT 460
US-10-060-756A-1913/c
; Sequence 1913, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1913
; LENGTH: 17
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-060-756A-1914

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 586 AACATATAAAGACAA 602
DB 17 AACATATAAAGACTA 1

RESULT 462
US-10-060-756A-1916/c
; Sequence 1916, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1916
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1916

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 584 ACAACATATAAAGAC 600
| | | | | | | | | | | | | | | | | | | | | |
Db 17 AAAACATATATAAAGAC 1

RESULT 463

US-10-060-998-1325
; Sequence 1325, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu. Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1325
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1325

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3225 ATATCCCTCTCCCTCC 3241
| | | | | | | | | | | | | | | | | | | | | |
Db 1 ATATCCCTCTCCCTCC 17

RESULT 464

US-10-163-552-498
; Sequence 498, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 498

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-498

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 365 GAGAGCCAGCCGCTGA 381
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GAGAGCCAGCCGCTGA 17

RESULT 465

US-10-156-306-519
; Sequence 519, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 519
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-519

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 2.3e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

Qy 2569 TCCTCTCTCTTTT 2585
:
Db 1 UAUUCUUUUUUUUUU 17

RESULT 466

US-10-156-306-1646
; Sequence 1646, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1646
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1646

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 2.3e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

Qy 2566 CTTTCTCTCTTTT 2582
| :
Db 1 CUUUUUUUUUUUUUUU 17

RESULT 467

```
US-10-156-306-2342/c
; Sequence 2342, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2342
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2342

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3000 TTTTTCCTCTCTCA 3016
Db 17 TATTTTCTGCTCTCA 1

RESULT 468
US-10-156-306-4374/c
; Sequence 4374, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4374
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4374

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1299 TGGTCTGCAGAGCTTC 1315
Db 17 TGATCTGGAGAGCTTC 1

RESULT 469
US-10-156-306-4780/c
; Sequence 4780, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4780
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4780
```

```
US-10-156-306-4780
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4780

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 GGTGCTGCAGAGCTTCA 1316
Db 17 GATGCTGGAGAGCTTCA 1

RESULT 470
US-10-331-873-85
; Sequence 85, Application US/10331873
; Publication No. US20030129641A1
; GENERAL INFORMATION:
; APPLICANT: YANO, Hideo
; APPLICANT: NISHIDA, Michio
; APPLICANT: SUZUKI, Osamu
; TITLE OF INVENTION: METHOD FOR DETERMINING BIOSPECIES CONTAINED IN
; TITLE OF INVENTION: TEST SPECIMEN AND KIT USED FOR THE SAME
; FILE REFERENCE: OP1414
; CURRENT APPLICATION NUMBER: US/10/331,873
; CURRENT FILING DATE: 2002-12-27
; PRIOR APPLICATION NUMBER: JP 2001-396943
; PRIOR FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 85
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer: amplify cytochrome b gene
US-10-331-873-85

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3545 GGGTGGGAGGAATATT 3561
Db 1 GGGTGAAGGAATTTT 17

RESULT 471
US-10-238-700-1172
; Sequence 1172, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1172
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-1172

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 2.3e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 3684 TTAATGTAATAACTTT 3700
Db 1 UUAAGAAUUAACUUU 17

RESULT 472
US-10-333-461-24
; Sequence 24, Application US/10333461
; Publication No. US20030165952A1
; GENERAL INFORMATION:
; APPLICANT: Global Genomics AB
; APPLICANT: Linnarsson, Sten
; APPLICANT: Ernfors, Patrik
; APPLICANT: Bauren, Goran
; TITLE OF INVENTION: Methods for analysis and identification of transcribed
; FILE REFERENCE: smwfp5941752
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: GB 0018016.6
; PRIOR FILING DATE: 2000-07-21
; PRIOR APPLICATION NUMBER: US 60/219,925
; PRIOR FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-333-461-24

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTCTTTTTC 2587
Db 1 TTTTTCCTTTTTC 17

RESULT 473
US-10-061-201-1263/c
; Sequence 1263, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1264

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2847 TGGGCTGGGAGATCATA 2863
Db 17 TGGGCTGGGAGATCACA 17

RESULT 475
US-10-061-201-1868/c
; Sequence 1868, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
```

```
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1263

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2848 GGGCTGGGAGATCATA 2864
Db 17 GGGCTGGGAGATCAG 17

RESULT 474
US-10-061-201-1264/c
; Sequence 1264, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1264
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1264

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2847 TGGGCTGGGAGATCATA 2863
Db 17 TGGGCTGGGAGATCACA 17

RESULT 475
US-10-061-201-1868/c
; Sequence 1868, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
```

```
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1868
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1868

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3569 GGGCTGGGTCTTAGGGA 3585
DB 17 GGGCTGGGTCTTAGGGA 1

RESULT 476
US-10-061-201-1939/c
; Sequence 1939, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1939
; LENGTH: 17

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1939

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 375 CCGCTGAGGGGAGGGG 391
DB 17 CCGCTGAGGGGAGGAG 1

RESULT 477
US-10-352-253A-24
; Sequence 24, Application US/103525253A
; Publication No. US20030175908A1
; GENERAL INFORMATION:
; APPLICANT: Linnarsson, Sten
; APPLICANT: Ernfors, Patrik
; APPLICANT: Bauren, Goran
; APPLICANT: Metsis, Ales
; APPLICANT: Pihlak, Arno
; APPLICANT: Montelius, Andreas
; TITLE OF INVENTION: Methods And Means For Manipulating Nucleic Acid
; FILE REFERENCE: 620-234
; CURRENT APPLICATION NUMBER: US/10/352,253A
; CURRENT FILING DATE: 2003-01-28
; PRIOR APPLICATION NUMBER: US 60/352,215
; PRIOR FILING DATE: 2002-01-29
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-352-253A-24

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCITTTTTTTTC 2587
DB 1 TTTTITTTTTTTTTTC 17

RESULT 478
US-10-056-229-132
; Sequence 132, Application US/10056229
; Publication No. US20030198943A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammattéo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De Longueville, Francoise
; TITLE OF INVENTION: IDENTIFICATION OF A LARGE NUMBER OF
; TITLE OF INVENTION: BIOLOGICAL (MICRO)ORGANISMS GROUPS AT DIFFERENT
; TITLE OF INVENTION: LEVELS BY THEIR DETECTION ON A SAME ARRAY
; FILE REFERENCE: VANM213.001CP1
; CURRENT APPLICATION NUMBER: US/10/056,229
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 09/817,014
```

```
; PRIOR FILING DATE: 2001-03-23
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 132
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: consensus primer for Consensus subtype 1C
; OTHER INFORMATION: antisense
US-10-056-229-132

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2392 TTGGCAGCTTCTTTTC 2408
||||| |||||||
Db 1 TTGGAAGCTTCTTTTC 17

RESULT 479
US-10-056-229-137
; Sequence 137, Application US/10056229
; Publication No. US20030198943A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammattéo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De Longueville, Françoise
; TITLE OF INVENTION: IDENTIFICATION OF A LARGE NUMBER OF
; TITLE OF INVENTION: BIOLOGICAL (MICRO)ORGANISMS GROUPS AT DIFFERENT
; TITLE OF INVENTION: LEVELS BY THEIR DETECTION ON A SAME ARRAY
; FILE REFERENCE: VANM213.001CP1
; CURRENT APPLICATION NUMBER: US/10/056,229
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 09/817,014
; PRIOR FILING DATE: 2001-03-23
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 137
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: consensus primer for Consensus subtype 2C
; OTHER INFORMATION: antisense
US-10-056-229-137

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2392 TTGGCAGCTTCTTTTC 2408
||||| |||||||
Db 1 TTGGAAGCTTCTTTTC 17

RESULT 480
US-10-430-882-164
; Sequence 164, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
```

```
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MEH800-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 164
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-164

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 103 GTCCGAGCAGCCAGCTT 119
|: ||||| |||||:
Db 1 GUGCCAGCUGCCAGCUU 17

RESULT 481
US-10-352-255A-24
; Sequence 24, Application US/10352255A
; Publication No. US20030215839A1
; GENERAL INFORMATION:
; APPLICANT: LONNERBERG, Peter
; APPLICANT: OLDIN, Mats
; APPLICANT: LINNARSSON, Sten
; APPLICANT: ERNFORS, Patrik
; TITLE OF INVENTION: Methods and Means for Identification of Gene Features
; FILE REFERENCE: 620-235
; CURRENT APPLICATION NUMBER: US/10/352,255A
; CURRENT FILING DATE: 2003-01-28
; PRIOR APPLICATION NUMBER: US 60/352,245
; PRIOR FILING DATE: 2002-01-29
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-352-255A-24

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTC 2587
||||| |||||||
Db 1 TTTTTC 17

RESULT 482
US-10-209-787-535/C
; Sequence 535, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
```

APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 535
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-535

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTTGTTTCTTA 2951
DB 17 TTCTAGTTGTTTGCTA 1

RESULT 483
US-10-209-787-536
Sequence 536, Application US/10209787
Publication No. US20030217377A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 536
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-536

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTTGTTTCTTA 2951
DB 1 TTCTAGTTGTTTGCTA 17

RESULT 484
US-10-209-787-3162/c
Sequence 3162, Application US/10209787
Publication No. US20030217377A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 3162
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-3162

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCAGCTTCTTCTTC 2576
DB 17 TCTCAGCTTCTTCTTC 1

RESULT 485
US-10-209-787-3163
Sequence 3163, Application US/10209787
Publication No. US20030217377A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 3163
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-3163

```
Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCAGCTTTCTTCTTC 2576
Db 1 TCTCAGCCTTCTTCTTC 17

RESULT 486
US-10-261-185-535/c
; Sequence 535, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: NaPro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-535

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTTGTTTCTTA 2951
Db 17 TTCTAGTTGTTTCTTA 1

RESULT 487
US-10-261-185-536
; Sequence 536, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: NaPro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
```

```
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-536

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2935 TTCTGGTTGTTTCTTA 2951
Db 1 TTCTAGTTGTTTCTTA 17

RESULT 488
US-10-261-185-3162/c
; Sequence 3162, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: NaPro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3162
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3162

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2560 TCCAGCTTTCTTCTTC 2576
Db 17 TCTCAGCCTTCTTCTTC 1

RESULT 489
US-10-261-185-3163
; Sequence 3163, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: NaPro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
```


RESULT 491
US-10-342-902-1240/c
; Sequence 1240, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sinna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McGswaggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent
; FILE REFERENCE: 400/075 (WEH000-845-1
; CURRENT APPLICATION NUMBER: US/10/342
; CURRENT FILING DATE: 2003-01-15

QY . 2645 CAGAAAGTGTGACAAGA 2661

```
Db      17  CGGAAGTGTGATAAGA 1
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 493
US-10-342-902-2088/c
; Sequence 2088, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2088
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2088

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2643  TCCGAGAGTGTGACAA 2659
Db      17  TCCGAGAGTGTGATAA 1
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 494
US-10-675-685-196
; Sequence 196, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 196
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-196

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db      17  TGGGTACCAACACAG 676
QY      660  TGGGTACCAACACAG 676
Db      17  TGGGTACCAACACAG 1
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 497
US-10-675-685-776/c
; Sequence 775, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 775
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-775

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db      17  TGGGTACCAACACAG 676
QY      660  TGGGTACCAACACAG 676
Db      17  TGGGTACCAACACAG 1
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 495
US-10-675-685-483/c
; Sequence 483, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 483
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-483

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2571  TTCTTCTTTTTC 2587
Db      17  TTCTTCTTTTTC 1
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 496
US-10-675-685-775/c
; Sequence 775, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 775
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-775

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db      17  TGGGTACCAACACAG 676
QY      660  TGGGTACCAACACAG 676
Db      17  TGGGTACCAACACAG 1
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 497
US-10-675-685-776/c
; Sequence 775, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 775
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-775

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db      17  TGGGTACCAACACAG 676
QY      660  TGGGTACCAACACAG 676
Db      17  TGGGTACCAACACAG 1
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

; Sequence 776, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 776
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-776

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 659 CTGACTACACACACAGA 675
DB 17 CTGGGTACACACACAGA 1

RESULT 498

US-10-138-674-1070
; Sequence 1070, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1070
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1070

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 2.3e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTTCTCTTTTTTTTTT 2585
DB 1 UCUCUUUUUUUUUUUUU 17

RESULT 499

US-10-138-674-1071
; Sequence 1071, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

US-10-138-674-1071
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1071
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1071

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 2.3e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTCTCTTTTTTTTTT 2586
DB 1 CUACUUUUUUUUUUUUU 17

RESULT 500

US-10-138-674-1074
; Sequence 1074, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1074

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 2.3e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTCTCTTTTTTTTTT 2586
DB 1 CUUUUUUUUUUUUUUUU 17

RESULT 501

US-10-138-674-1075
; Sequence 1075, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1075
; LENGTH: 17
; TYPE: RNA

```
; ORGANISM: Homo sapiens
US-10-138-674-1075

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 2.3e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTCTTTTCTT 2587
      : : : : : : : : : :
Db 1 UUUUUUUUUUUUUUUC 17

RESULT 502
US-10-138-674-2644/c
; Sequence 2644, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2644
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2644

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 TTCTGCAGAGCTGCTT 985
      ||||| ||||| |||||
Db 17 TTCTTCAGAGCTTCTT 1

RESULT 503
US-10-138-674-2780/c
; Sequence 2780, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2780
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2780

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 AAAAATGCATCAAAAT 1133
      ||||||| | |||||

; ORGANISM: Homo sapiens
US-10-138-674-1075

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 2.3e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTCTTTTCTTTTCTT 2587
      : : : : : : : : : :
Db 1 UUUUUUUUUUUUUUUC 17

RESULT 504
US-10-138-674-3600/c
; Sequence 3600, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3600
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3600

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2590 AAAAAGGAAAGACAC 2606
      ||||| ||||| |||||
Db 17 AAAAACAAGACAC 1

RESULT 505
US-10-138-674-4631/c
; Sequence 4631, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4631
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4631

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2931 TATATTCTGTTCTTTT 2947
      ||||| ||||| |||||
Db 17 TATTGTGTTGTTT 1

RESULT 506
US-10-138-674-5574
; Sequence 5574, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5574
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5574

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1733 TCTCTTCCAAAAGTTT 1749
DB 1 UCUCUCCAUAAUUU 17

RESULT 507
US-10-138-674-5575
; Sequence 5575, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5575
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5575

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1734 CTCCTTCCAAAAGTTT 1750
DB 1 CUCCUCCAUAAUUU 17

RESULT 508
US-10-138-674-6139
; Sequence 6139, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
```

```
; . NUMBER OF SEQ ID NOS: 20822
; . SOFTWARE: PatentIn version 3.0
; . SEQ ID NO 6139
; . LENGTH: 17
; . TYPE: RNA
; . ORGANISM: Homo sapiens
US-10-138-674-6139

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 585 CAACATATAAAAGACA 601
DB 1 CAGCAUACAAAAGACA 17

RESULT 509
US-10-138-674-7992/c
; Sequence 7992, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7992

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2391 CTTGCAGCTTCTTTC 2407
DB 17 CTTCTCAGCTTCTTTC 1

RESULT 510
US-10-138-674-8417/c
; Sequence 8417, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8417
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8417

Query Match 0.4%; Score 13.8; DB 1; Length 17;
```

```
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 AGGGGCGGGAGGTGG 291
DB 17 AGGAGGCGGGAGGTGG 1

RESULT 511
US-10-287-949A-1071
; Sequence 1071, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-9161/c
; Sequence 9161, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-9161

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3121 TARACTCATGGGAGAC 3137
DB 17 TARACCCATGGTGAGAC 1

RESULT 512
US-10-287-949A-1070
; Sequence 1070, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1070
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1070

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTCTCTCTTTT 2585
DB 1 UCUCUUUUUUUUUUU 17

RESULT 513
```

```
US-10-287-949A-1071
; Sequence 1071, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1071
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1071

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 2.3e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTCTCTTTT 2586
DB 1 CUACUUUUUUUUUUU 17

RESULT 514
US-10-287-949A-1074
; Sequence 1074, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1074

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 2.3e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTCTCTTTT 2586
DB 1 CUUUUUUUUUUUUUU 17

RESULT 515
US-10-287-949A-1075
; Sequence 1075, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
```

```
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1075

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 2.3e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTC 2587
Db 1 UUUUUUUUUUUUUUC 17

RESULT 516
US-10-287-949A-2644/c
; Sequence 2644, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2644
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2644

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 TTCTGCAGAGCTGCTT 985
Db 17 TTCTTCAGAGCTTCTT 1

RESULT 517
US-10-287-949A-2780/c
; Sequence 2780, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2780
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2780

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 AAAAATGCATATCAAAAT 1133
Db 17 AAAAATGAAAATCAAAAT 1

RESULT 518
US-10-287-949A-3600/c
; Sequence 3600, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3600
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3600

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2590 AAAAAGGAAAAGCAC 2606
Db 17 AAAAACAACAAAAGCAC 1

RESULT 519
US-10-287-949A-4631/c
; Sequence 4631, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4631
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4631

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2931 TATATTCTGTTGTTT 2947
```

Db 17 TATTTCGTGGTGTGTTT 1

RESULT 520

US-10-287-949A-5574
; Sequence 5574, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5574
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5574

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1733 TCTCCTTCCAAAAGTTT 1749
Db 1 UCUCUCCAUAAAUUU 17

RESULT 521

US-10-287-949A-5575
; Sequence 5575, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5575
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5575

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1734 CTCCTTCCAAAAGTTT 1750
Db 1 CUUCUCCAUAAAUUU 17

RESULT 522

US-10-287-949A-6139
; Sequence 6139, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6139
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6139

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 585 CAACATATAAAAAGACA 601
Db 1 CAGCAUACAAAAAGACA 17

RESULT 523

US-10-287-949A-7992/c
; Sequence 7992, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7992

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2391 CTTCGAGCTTCTTCTTC 2407
Db 17 CTTCGAGCTTCTTCTTC 1

RESULT 524

US-10-287-949A-8417/c
; Sequence 8417, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A


```
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8417
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8417

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 AGGGGGCGGGGAGGTGG 291
Db 17 AGGAGCGCGGAGGTGG 1

RESULT 525
US-10-287-949A-9161/c
; Sequence 9161, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9161

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3121 TAAACTCATGGCGAGAC 3137
Db 17 TAAACCCATGGTGAGAC 1

RESULT 526
US-10-712-672-69/c
; Sequence 69, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR FILING DATE: 2000-04-14
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 69
; LENGTH: 17
; TYPE: RNA

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-69

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2250 GTGCTCAGAGAGTTGA 2266
Db 17 GGGCTCAGAGAGCTGA 1

RESULT 527
US-10-712-672-82
; Sequence 82, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 82
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-82

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 3034 CTCCTGTTGTGGAGCT 3050
Db 1 CCCCGUUUCUGAGCU 17

RESULT 528
US-10-712-672-684/c
; Sequence 684, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 684
; LENGTH: 17
; TYPE: RNA
```

```

; ORGANISM: Homo sapiens
US-10-712-672-684

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2253 CCTCAGAGAGCTTGAGGA 2269
    |||||
Db 17 CCTCAGAGAGCTTGAGTA 1

RESULT 529
US-10-712-672-1032
; Sequence 1032, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1032
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1032

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1683 TCCAGCGCTTCATGTC 1699
    |||||
Db 1 UCCUACGCUCAUGGC 17

RESULT 530
US-10-712-672-1106
; Sequence 1106, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1106
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

```

```

US-10-712-672-1106

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2296 TGGGTGGTACGGATTTT 2312
    :|||:|||||:
Db 1 UGGUGGCGACGCUUUU 17

RESULT 531
US-10-669-841-1240/c
; Sequence 1240, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/04205 (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1240
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1240

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2643 TCCGAGAGTGTTCACAA 2659
    |||||
Db 17 TCCGAGAGTGTTCATAA 1

RESULT 532
US-10-669-841-1943/c
; Sequence 1943, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1943
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1943

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2645 CAGAGTGTTCACAGA 2661
DB 17 CGGAGTGTGTATAAGA 1

RESULT 533
US-10-669-841-6460/c
; Sequence 6460, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26

```

```

; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6460
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6460

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2843 GCCATGGCTGGGAGAT 2859
DB 17 GCCATGGACCGGAGAT 1

RESULT 534
US-10-723-361-1176
; Sequence 1176, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669

```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1176
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 20 GAAGGACGGAGAGGGG 36
||||| |||||
DB 1 GAAGGACAAAGAGGGG 17
```

```
RESULT 535
US-10-723-361-1580/c
; Sequence 1580, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1580
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1580
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2981 ATCATTTCTCCAGAGGAG 2997
```

```
DB 17 ATCCITTCAGAGCAG 1
||||| ||||| ||||| ||
```

```
RESULT 536
US-10-723-361-2270
; Sequence 2270, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2270
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2270
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 413 TCCTCCGGCGCTGCTC 429
||||| ||||| |||||
DB 1 TCCTCCGGCGCTTCGGC 17
```

```
RESULT 537
US-10-723-361-2271
; Sequence 2271, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
```

```
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2271
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2271
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 414 CCTCCGGGCGTCTGCT 430
DB 1 CCTCCGGGCGTCTGCT 17

RESULT 538
US-10-723-361-6855
; Sequence 6855, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6855
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6855
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1173 AGAAGCAGCGAGAGAAG 1189
DB 1 AGAAGCAGCGAGAGAAG 17
```

```
RESULT 539
US-10-723-361-6856
; Sequence 6856, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6856
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6856
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1174 GAAAGCAGCGAGAGAAGC 1190
DB 1 GAAAGCAGCGAGAGAAGC 17
```

RESULT 540
US-10-723-361-6929/c
; Sequence 6929, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6929
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6929

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3318 AGATTGTTGAATTCCTG 3334
Db 17 AGCTTCTTGAATTCCTG 1

RESULT 541
US-10-723-361-6930/c
; Sequence 6930, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6930
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6930

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3317 CAGATTGTTGAATTCCT 3333
Db 17 CAGCTTCTTGAATTCCT 1

RESULT 542
US-10-723-361-8116
; Sequence 8116, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8116
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8116

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2726 CTGCCAGAGCAGCTCC 2742
Db 1 CTGCCAGAGCGGCTTC 17

RESULT 543

US-10-723-361-8454
; Sequence 8454, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8454
; LENGTH: 17
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-723-361-8454

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1357 AGATCATGCACACGAG 1373
Db 1 AGAGCATGCACACGAG 17

RESULT 544

US-10-723-361-8873/c

; Sequence 8873, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8873
; LENGTH: 17
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-723-361-8873

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2182 AGCTGCTCTCCATCTT 2198
Db 17 AGCTGCTCTCCATCTT 1

RESULT 545

US-10-723-361-10318
; Sequence 10318, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10318
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10318

```


GENERAL INFORMATION:
 APPLICANT: KNIEC, ERIC B.
 APPLICANT: VAN BRABANT, ANJA
 TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
 TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
 FILE REFERENCE: NaPro-18 US
 CURRENT APPLICATION NUMBER: US/10/681,074
 CURRENT FILING DATE: 2003-10-07
 PRIOR APPLICATION NUMBER: US 60/453,360
 PRIOR FILING DATE: 2003-03-07
 PRIOR APPLICATION NUMBER: US 60/416,983
 PRIOR FILING DATE: 2002-10-07
 NUMBER OF SEQ ID NOS: 4375
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO 3163
 LENGTH: 17
 TYPE: DNA
 ORGANISM: Homo sapiens

```

; AFFILIATION: WOOD, WILLIAM J.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;   ACIDS Encoding the Same
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14

```

```
; CURRENT APPLICATION NUMBER: US/09/909,320
; CURRENT FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-909-320-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 554
US-09-909-088B-229/c
; Sequence 229, Application US/09909088B
; Patent No. US20020146709A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Flvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
```

```
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/909,088B
; CURRENT FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-909-088B-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 555
US-09-905-291A-229/c
; Sequence 229, Application US/09905291A
```

Patent No. US20020160374A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,291A
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: oligonucleotide probe
US-09-905-291A-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCG 166
|||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 556

US-09-902-853-229/c
; Sequence 229, Application US/09902853
; Publication No. US20020192659A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,853
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02

```

; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-853-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGGACGACG 1

RESULT 557
US-09-907-824-229/c
; Sequence 229, Application US/09907824
; Publication No. US20020197671A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,824
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08

```

```

; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-824-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGGACGACG 1

RESULT 558
US-09-907-841-229/c
; Sequence 229, Application US/09907841
; Publication No. US20020198366A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

```

;; TITLE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/907,841
;; CURRENT FILING DATE: 2001-11-20
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;; OTHER INFORMATION: oligonucleotide probe
US-09-907-841-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
| | | | | | | | | | | | | | | | | |
Db 17 TCCCTGTGACAGCAG 1

RESULT 559
US-09-904-011-229/c
; Sequence 229, Application US/09904011
; Publication No. US20030003530A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey

;; APPLICANT: Wood, William, I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/904,011
;; CURRENT FILING DATE: 2001-07-11
;; PRIOR APPLICATION NUMBER: 09/665,350
;; PRIOR FILING DATE: 2000-09-18
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic oligonucleotide Probe
US-09-904-011-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
| | | | | | | | | | | | | | | | | |
Db 17 TCCCTGTGACAGCAG 1

RESULT 560
US-09-903-640-229/c
; Sequence 229, Application US/09903640
; Publication No. US20030017463A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman

```
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,640
; PRIOR FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-640-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 561
US-09-908-093-229/c
; Sequence 229, Application US/09908093
; Publication No. US20030017498A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

```
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/908,093
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-908-093-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 562
US-09-906-742-229/c
; Sequence 229, Application US/09906742
; Publication No. US20030023054A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
```

```

; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,742
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-742-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
DB 17 TCCCTGTGGACGACG 1

RESULT 563
US-09-906-838-229/c
; Sequence 229, Application US/09906838
; Publication No. US20030027143A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,838
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
```

; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-838-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 564

US-09-907-613-229/c
; Sequence 229, Application US/09907613
; Publication No. US20030027145A1
; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,613
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-613-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 565

US-09-907-942-229/c
; Sequence 229, Application US/09907942
; Publication No. US20030027146A1
; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,942
; CURRENT FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26

;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-907-942-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAGCGG 166
DB 17 TCCCTGTGGAGCAG 1

RESULT 566
US-09-904-859-229/c
; Sequence 229, Application US/09904859
; Publication No. US20030036060A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann

;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William, I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/904,859
;; CURRENT FILING DATE: 2001-07-12
;; PRIOR APPLICATION NUMBER: 09/665,350
;; PRIOR FILING DATE: 2000-09-18
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-859-229
Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 150 TCCCTGTGGAGCGG 166
DB 17 TCCCTGTGGAGCAG 1
RESULT 567
US-09-909-204-229/c
; Sequence 229, Application US/09909204
; Publication No. US20030036061A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.

APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/909,204
CURRENT FILING DATE: 2001-07-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-909-204-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
Db 17 TCCCTGTGACAGCAG 1
RESULT 568
US-09-904-820-229/c
Sequence 229, Application US/09904820
Publication No. US20030036094A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/904,820
CURRENT FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999

;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-820-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 150 TCCCTGTGGAAAGCGG 166
DB 17 TCCCTGTGGACAGCAG 1

RESULT 569
US-09-904-786-229/c

;; Sequence 229, Application US/09904786
;; Publication No. US20030039969A1
;; GENERAL INFORMATION:
;; APPLICANT: Genentech, Inc.
;; APPLICANT: Ashkenazi, Avi
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gerber, Hanspeter
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, A.
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth, J.
;; APPLICANT: Kljavin, Ivar J.
;; APPLICANT: Mather, Jennie P.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William, I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/904,786
;; CURRENT FILING DATE: 2001-07-12
;; PRIOR APPLICATION NUMBER: 09/665,350
;; PRIOR FILING DATE: 2000-09-18
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-786-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 150 TCCCTGTGGAAAGCGG 166
DB 17 TCCCTGTGGACAGCAG 1

Db 17 TCCCTGTGGACAGCAG 1

RESULT 570

US-09-906-646-229/c
;; Sequence 229, Application US/09906646
;; Publication No. US20030039971A1
;; GENERAL INFORMATION:
;; APPLICANT: Genentech, Inc.
;; APPLICANT: Ashkenazi, Avi
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerber, Hanspeter
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, A.
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth, J.
;; APPLICANT: Kljavin, Ivar J.
;; APPLICANT: Mather, Jennie P.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William, I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/906,646
;; CURRENT FILING DATE: 2002-01-22
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-906-646-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 571

US-09-906-700-229/c
; Sequence 229, Application US/09906700
; Publication No. US2003003972A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,700
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-906-700-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 572

US-09-903-786-229/c
; Sequence 229, Application US/09903786
; Publication No. US20030044793A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,786
; PRIOR APPLICATION NUMBER: 2001-07-11
; PRIOR FILING DATE: 09/665,350
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048

;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-786-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
| | | | | | | | | | | | | | | | | |
Db 17 TCCCTGTGGACAGCAG 1

RESULT 573
US-09-902-903-229/c
; Sequence 229, Application US/09902903
; Publication No. US20030044839A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James

;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William, I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/902,903
;; CURRENT FILING DATE: 2001-07-10
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;; OTHER INFORMATION: oligonucleotide probe
US-09-902-903-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
| | | | | | | | | | | | | | | | | |
Db 17 TCCCTGTGGACAGCAG 1

RESULT 574
US-09-903-749A-229/c
; Sequence 229, Application US/09903749A
; Publication No. US20030045693A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kijavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/903,749A
PRIOR FILING DATE: 2001-07-11
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-903-749A-229
Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGCGAAGCGG 166
Db 17 TCCCTGTGCGACAGCAG 1
RESULT 575
US-09-904-119-229/c
Sequence 229, Application US/09904119
Publication No. US20030049621A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kijavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/904,119
PRIOR FILING DATE: 2001-07-11
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-119-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
|||||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 576

US-09-904-956-229/c
; Sequence 229, Application US/09904956
; Publication No. US20030049622A1

GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide probe
US-09-904-956-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
|||||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 577

US-09-902-736-229/c
; Sequence 229, Application US/09902736
; Publication No. US20030049676A1

GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/902,736
; PRIOR FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: 09/665,350

```
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-736-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 578
US-09-794-229/c
; Sequence 229, Application US/09907794
; Publication No. US20030049677A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
```

```
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,794
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-794-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 579
US-09-903-943-229/c
; Sequence 229, Application US/09903943
; Publication No. US20030054349A1
```



```
;
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
; US-903-943-229
;
; Query Match      0.4%; Score 13.8; DB 1; Length 18;
; Best Local Similarity 88.2%; Pred. No. 2.5e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 150 TCCCTGTGTGAAAGCGG 166
;      |||||
; Db 17 TCCCTGTGCACAG 1
;
; RESULT 580
; US-904-462-229/c
; Sequence 229, Application US/09904462
; Publication No US20030054351A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,943
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```

; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-462-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 581
US-09-907-925-229/c
; Sequence 229, Application US/09907925
; Publication No. US20030054352A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,925
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28

```

```

; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-925-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 582
US-09-902-692-229/c
; Sequence 229, Application US/09902692
; Publication No. US20030054400A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey

```

APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/902,692
PRIOR FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-902-692-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
Db 17 TCCCTGTGGACAGCAG 1

RESULT 583

US-09-903-520-229/c
Sequence 229, Application US/09903520
Publication No. US20030054401A1
GENERAL INFORMATION:

APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/903,520
CURRENT FILING DATE: 2001-07-11
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-520-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
Db 17 TCCCTGTGGACAGCAG 1

RESULT 584

US-09-905-056-229/c

; Sequence 229, Application US/09905056

; Publication No. US20030054441A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kijavlin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/905,056

; PRIOR FILING DATE: 2002-01-22

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30

; PRIOR APPLICATION NUMBER: PCT/US99/28564

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/30095

; PRIOR FILING DATE: 1999-12-16

; PRIOR APPLICATION NUMBER: PCT/US99/30911

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US00/00219

; PRIOR FILING DATE: 2000-01-05

; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 229

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide probe

US-09-905-056-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAGCGG 166

| | | | | | | | | | | | | | | |

Db 17 TCCCTGTGGACAG 1

RESULT 585

US-09-909-064-229/c

; Sequence 229, Application US/09909064

; Publication No. US20030059772A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kijavlin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/909,064

; PRIOR FILING DATE: 2001-07-18

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-909-064-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 586

US-09-904-553-229/c
; Sequence 229, Application US/09904553
; Publication No. US20030059828A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,553
; CURRENT FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-553-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 587

US-09-905-381-229/c
; Sequence 229, Application US/09905381
; Publication No. US20030059829A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann

APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/905,381
PRIOR FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-381-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGGAAGCGG 166
DB 17 TCCCTGTGGACAGCAG 1

RESULT 588

US-09-485-229/c
Sequence 229, Application US/09904485
Publication No. US20030064367A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.

APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/904,485
PRIOR FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-485-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
QY 150 TCCCTGTGGAAGCGG 166
DB 17 TCCCTGTGGACAGCAG 1

RESULT 589
US-09-905-348-229/c
; Sequence 229, Application US/09905348
; Publication No. US2003064923A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,348
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15

US-09-905-348-229
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-905-348-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
DB 17 TCCCTGTGGACAGCAG 1

RESULT 590
US-09-905-088-229/c
; Sequence 229, Application US/09905088
; Publication No. US20030073077A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,088
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
```

```
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-088-229
```

```
Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1
```

```
RESULT 591
US-09-907-575-229/c
; Sequence 229, Application US/09907575
; Publication No. US20030073079A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US/09/907,575
; PRIOR APPLICATION NUMBER: PCT/US00/04414
```

```
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-575-229
```

```
Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1
```

```
RESULT 592
US-09-905-075-229/c
; Sequence 229, Application US/09905075
; Publication No. US20030077583A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
```


APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/905,075
CURRENT FILING DATE: 2001-07-13
Prior application data removed. Check file wrapper or PALM.
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-905-075-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
Db 17 TCCCTGTGACAGCAG 1

RESULT 593

US-09-902-759-229/c
Sequence 229, Application US/09902759
Publication No. US20030077654A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/902,759
CURRENT FILING DATE: 2001-07-10
Prior application data removed. Check file wrapper or PALM.
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-902-759-229

Prior Application Number: US 60/145,698
Prior Filing Date: 1999-07-26
Prior Application Number: US 60/146,222
Prior Filing Date: 1999-07-28
Prior Application Number: PCT/US99/20594
Prior Filing Date: 1999-09-08
Prior Application Number: PCT/US99/20944
Prior Filing Date: 1999-09-13
Prior Application Number: PCT/US99/21090
Prior Filing Date: 1999-09-15
Prior Application Number: PCT/US99/21547
Prior Filing Date: 1999-09-15
Prior Application Number: PCT/US99/23089
Prior Filing Date: 1999-10-05
Prior Application Number: PCT/US99/28214
Prior Filing Date: 1999-11-29
Prior Application Number: PCT/US99/28313
Prior Filing Date: 1999-11-30
Prior Application Number: PCT/US99/28564
Prior Filing Date: 1999-12-02
Prior Application Number: PCT/US99/28565
Prior Filing Date: 1999-12-02
Prior Application Number: PCT/US99/30095
Prior Filing Date: 1999-12-16
Prior Application Number: PCT/US99/30911
Prior Filing Date: 1999-12-20
Prior Application Number: PCT/US99/30999
Prior Filing Date: 1999-12-20
Prior Application Number: PCT/US00/00219
Prior Filing Date: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-902-759-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
Db 17 TCCCTGTGACAGCAG 1

RESULT 594

US-09-902-634-229/c
Sequence 229, Application US/09902634
Publication No. US20030082540A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James

```
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,634
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-634-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAGCGG 166
Db 17 TCCCTGTGGAGCGG 1

RESULT 595
US-09-902-713-229/c
; Sequence 229, Application US/09902713
; Publication No. US20030082541A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
```

```
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,713
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-713-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 150 TCCCCTGTGGAAAGCGG 166
Db 17 TCCCCTGTGGACAGCAG 1

RESULT 596
US-09-907-979-229/c
; Sequence 229, Application US/09907979
; Publication No. US20030082542A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,979
; PRIOR FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/146,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
```

```
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-979-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCCTGTGGAAAGCGG 166
Db 17 TCCCCTGTGGACAGCAG 1

RESULT 597
US-09-994-311-7
; Sequence 7, Application US/09994311
; Publication No. US20030082556A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/09/994,311
; CURRENT FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-7

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTC 2587
Db 1 TTTTTCCTTTTTC 17

RESULT 598
US-09-902-615-229/c
; Sequence 229, Application US/09902615
; Publication No. US20030092002A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
```

```
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,615
; CURRENT FILING DATE: 2001-12-14
; Prior application data removed. Check file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-902-615-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 599
US-09-903-925-229/c
; Sequence 229, Application US/09903925
; Publication No. US20030096233A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,925
; CURRENT FILING DATE: 2001-07-11
```

```
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-925-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 600
US-09-906-760A-229/c
; Sequence 229, Application US/09906760A
; Publication No. US20030096340A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
```

APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kijavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/906,760A
CURRENT FILING DATE: 2001-07-16
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-906-760A-229
Query Match 0.48; Score 13.8; DB 1; Length 18;
Best Local Similarity 89.28; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 150 TCCCTGTGGAAACGG 166
Db 17 TCCCTGTGGACACAG 1
RESULT 601
US-09-903-823-229/c
Sequence 229 Application US/09903823
Publication No. US20030104381A1

```
Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 602
US-09-907-652-229/c
; Sequence 229, Application US/09907652
; Publication No. US2003010469A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,652
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-08-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 603
US-09-902-572A-229/c
; Sequence 229, Application US/09902572A
; Publication No. US2003010893A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,572A
; PRIOR FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
```

```
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR APPLICATION data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-902-572A-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 604
US-09-902-979-229/c
; Sequence 229, Application US/09902979
; Publication No. US20030113718A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Ivar J.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,979
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
```

```
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-979-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
      |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 605
US-09-905-125-229/c
; Sequence 229, Application US/09905125
; Publication No. US20030113719A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Acids Encoding the Same
```

FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/905,125
CURRENT FILING DATE: 2001-07-12
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-125-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 606

US-09-906-815A-229/c
Sequence 229, Application US/09906815A
Publication No. US20030113838A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Macher, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/906,815A
CURRENT FILING DATE: 2001-07-16
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-906-815A-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 607


```
US-09-905-449-229/c
; Sequence 229, Application US/09905449
; Publication No. US2003012952A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,449
; CURRENT FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-806-229/c
; Sequence 229, Application US/09903806
; Publication No. US20030130489A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,806
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-806-229
; Query Match 0.4%; Score 13.8; DB 1; Length 18;
; Best Local Similarity 88.2%; Pred. No. 2.5e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 150 TCCCTGTGGAAGCGG 166
Db 17 TCCCTGTGACAGCAG 1
RESULT 608
US-09-903-806-229/c
; Sequence 229, Application US/09903806
; Publication No. US20030130489A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,449
; CURRENT FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-992-229/c
; Sequence 229, Application US/09904992
; Publication No. US20030135025A1
; Query Match 0.4%; Score 13.8; DB 1; Length 18;
; Best Local Similarity 88.2%; Pred. No. 2.5e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 150 TCCCTGTGGAAGCGG 166
Db 17 TCCCTGTGACAGCAG 1
RESULT 609
US-09-904-992-229/c
; Sequence 229, Application US/09904992
; Publication No. US20030135025A1
```

GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,992
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe

US-09-904-992-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||||
DB 17 TCCCTGTGGACAGCAG 1

RESULT 610

US-09-904-938-229/c
; Sequence 229, Application US/09904838
; Publication No. US20030148370A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,838
; PRIOR FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095

;
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-838-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCCTGTGACAGCAG 1

RESULT 611

US-09-906-777-229/c
; Sequence 229, Application US/09906777
; Publication No. US20030148371A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,777
; PRIOR FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08

;
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-777-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCCTGTGACAGCAG 1

RESULT 612

US-09-903-603A-229/c
; Sequence 229, Application US/09903603A
; Publication No. US20030148419A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: GNE.1618P2C12
; CURRENT APPLICATION NUMBER: US/09/903,603A
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-903-603A-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
||| ||||| |||
Db 17 TCCCTGTGACAGCAG 1

RESULT 613

US-09-904-532-229/c
; Sequence 229, Application US/09904532
; Publication No. US2003015292A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,532
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-532-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
||| ||||| |||
Db 17 TCCCTGTGACAGCAG 1

```
RESULT 614
US-09-904-766-229/c
; Sequence 229, Application US/09904766
; Publication No. US20030152999A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,766
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; * OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; * OTHER INFORMATION: oligonucleotide probe
US-09-904-766-229
Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
Db 17 TCCCTGTGGACAGCAG 1

RESULT 615
US-09-904-920A-229/c
; Sequence 229, Application US/09904920A
; Publication No. US20030166051A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,920A
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
```

; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-904-920A-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
||| ||||| ||||| |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 616

US-09-904-877A-229/c
; Sequence 229, Application US/09904877A
; Publication No. US20030186358A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904, 877A
; CURRENT FILING DATE: 2002-08-08
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143, 048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145, 698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146, 222
; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-877A-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
||| ||||| ||||| |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 617

US-09-903-562-229/c
; Sequence 229, Application US/09903562
; Publication No. US20030187238A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903, 562
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143, 048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145, 698
; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-562-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
|||||
DB 17 TCCCTGTGACAGCAG 1

RESULT 618
US-09-906-618-229/c
; Sequence 229, Application US/09906618
; Publication No. US20030190610A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,618
; PRIOR FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-618-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
|||||
DB 17 TCCCTGTGACAGCAG 1

RESULT 619
US-09-907-728-229/c
; Sequence 229, Application US/09907728
; Publication No. US20030190611A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen

APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerbitsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/907,728
PRIOR FILING DATE: 2001-07-17
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-728-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166

Db 17 TCCCTGTGGACAGCAG 1
RESULT 620
US-09-904-805-229/c
Sequence 229, Application US/09904805
Publication No. US20030211568A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Deanoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerbitsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/904,805
CURRENT FILING DATE: 2001-07-12
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20


```

; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-805-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 621
US-09-904-938A-229/c
; Sequence 229, Application US/09904938A
; Publication No. US20030211569A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,938A
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-938A-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 622
US-09-906-722A-229/c
; Sequence 229, Application US/09906722A
; Publication No. US20030215904A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: GNE.1618p2C61
; CURRENT APPLICATION NUMBER: US/09/906,722A
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
```

```
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-722A-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
    |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 623
US-09-908-576-229/c
; Sequence 229, Application US/09908576
; Publication No. US2004000553A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Mather, Jennie P.
```

```
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/908,576
; CURRENT FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: US/09/665,350B
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-908-576-229

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
    |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 624
US-10-181-603-24/c
; Sequence 24, Application US/10181603
; Publication No. US20030049662A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RTSP-0342
; CURRENT APPLICATION NUMBER: US/10/181,603
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01165
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/487,444
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 24
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-603-24

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1537 AGGGGAAGGCTCTGC 1553
      ||||| ||||| |||||
Db 18 AGGGGAATGCGCTTTTC 2

RESULT 625
US-10-340-097-37/c
; Sequence 37, Application US/10340097
; Publication No. US20030162276A1
; GENERAL INFORMATION:
; APPLICANT: Rattner, Amir
; APPLICANT: Sun, Hui
; APPLICANT: Lupski, James R.
; APPLICANT: Nathans, Jeremy
; APPLICANT: Anderson, Kent L.
; APPLICANT: Leppert, Mark
; APPLICANT: Dean, Michael
; APPLICANT: Singh, Nanda
; APPLICANT: Shroyer, No. US20030162276A1h F.
; APPLICANT: Smallwood, Philip M.
; APPLICANT: Allikmets, Rando
; APPLICANT: Lewis, Richard A.
; APPLICANT: Li, Yixin
; TITLE OF INVENTION: Nucleic Acid And Amino Acid Sequences For ATP-Binding Cassette
; TITLE OF INVENTION: Transporter And Methods Of Screening For Agents That Modify ATP-
; TITLE OF INVENTION: Transporter
; FILE REFERENCE: BYLR0065
; CURRENT APPLICATION NUMBER: US/10/340,097
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: US/09/032,438A
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/039,388
; PRIOR FILING DATE: 1997-02-27
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 37
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-340-097-37

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 205 CCATGCCAGCGCAATGG 221
      ||||| ||||| |||||
Db 18 CCATGCACGCGCAATGG 2

RESULT 626
US-10-333-461-18
; Sequence 18, Application US/10333461
; Publication No. US20030165952A1
; GENERAL INFORMATION:
; APPLICANT: Global Genomics AB
; APPLICANT: Linarsson, Sten
; APPLICANT: Ernfor, Patrik
; APPLICANT: Bauren, Goran
; TITLE OF INVENTION: Methods for analysis and identification of transcribed
; TITLE OF INVENTION: genes, and fingerprinting
; FILE REFERENCE: smwfp5941752
; CURRENT APPLICATION NUMBER: US/10/333,461
; CURRENT FILING DATE: 2003-01-21
```

```
; PRIOR APPLICATION NUMBER: GB 0018016.6
; PRIOR FILING DATE: 2000-07-21
; PRIOR APPLICATION NUMBER: US 60/219,925
; PRIOR FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-333-461-18

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTC 2587
      ||||| ||||| |||||
Db 1 TTTTTCCTTTTTC 17

RESULT 627
US-10-374-207-28
; Sequence 28, Application US/10374207
; Publication No. US20030170822A1
; GENERAL INFORMATION:
; APPLICANT: Itoh, No. US20030170822A1uyuki
; TITLE OF INVENTION: Fibroblast Growth Factor-Like Molecules and Uses Thereof
; FILE REFERENCE: 08035.0001-02000
; CURRENT APPLICATION NUMBER: US/10/374,207
; CURRENT FILING DATE: 2003-02-25
; PRIOR APPLICATION NUMBER: US 09/822,485
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/540,118
; PRIOR FILING DATE: 2000-03-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:PCR primer
US-10-374-207-28

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2058 GCCTCAGAAGACTTGA 2074
      ||||| ||||| |||||
Db 1 GCCTCAGAGACCAAGGA 17

RESULT 628
US-10-336-215-37/c
; Sequence 37, Application US/10336215
; Publication No. US20030170852A1
; GENERAL INFORMATION:
; APPLICANT: Allikmets, Rando
; APPLICANT: Anderson, Kent L.
; APPLICANT: Dean, Michael
; APPLICANT: Leppert, Mark
; APPLICANT: Lewis, Richard A.
; APPLICANT: Li, Yixin
; APPLICANT: Lupski, James R.
; APPLICANT: Nathans, Jeremy
; APPLICANT: Rattner, Amir
; APPLICANT: Shroyer, No. US20030170852A1h F.
; APPLICANT: Singh, Nanda
```

```
; APPLICANT: Smallwood, Philip
; APPLICANT: Sun, Hui
; TITLE OF INVENTION: Methods Of Screening And Diagnostics Using ATP-Binding Cassette
; FILE OF INVENTION: Transporter
; FILE REFERENCE: APT10089
; CURRENT APPLICATION NUMBER: US/10/336,215
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/039,388
; PRIOR FILING DATE: 1997-02-27
; PRIOR APPLICATION NUMBER: 09/032,438
; PRIOR FILING DATE: 1998-02-27
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-336-215-37

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 205 CCATGCCACGCGAATGG 221
      ||||| ||||| ||||| |||||
Db 18 CCATGACACGCGAATGG 2

RESULT 629
US-10-336-219-37/c
; Sequence 37, Application US/10336219
; Publication No. US20030170853A1
; GENERAL INFORMATION:
; APPLICANT: Allikmets, Rando
; APPLICANT: Anderson, Kent L.
; APPLICANT: Dean, Michael
; APPLICANT: Leppert, Mark
; APPLICANT: Lewis, Richard A.
; APPLICANT: Li, Yixin
; APPLICANT: Lupski, James R.
; APPLICANT: Nathans, Jeremy
; APPLICANT: Rattner, Amir
; APPLICANT: Shroyer, No. US20030170853A1h F.
; APPLICANT: Singh, Nanda
; APPLICANT: Smallwood, Philip
; APPLICANT: Sun, Hui
; TITLE OF INVENTION: Methods Of Gene Therapy Using Nucleic Acid Sequences For
; FILE OF INVENTION: ATP-Binding Cassette Transporter
; FILE REFERENCE: BYLR0072
; CURRENT APPLICATION NUMBER: US/10/336,219
; CURRENT FILING DATE: 2003-01-03
; PRIOR APPLICATION NUMBER: 60/039,388
; PRIOR FILING DATE: 1997-02-27
; PRIOR APPLICATION NUMBER: 09/032,438
; PRIOR FILING DATE: 1998-02-27
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-336-219-37

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 205 CCATGCCACGCGAATGG 221
      ||||| ||||| ||||| |||||
```

```
Db 18 CCATGACACGCGAATGG 2

RESULT 630
US-10-352-253A-18
; Sequence 18, Application US/10352253A
; Publication No. US20030175908A1
; GENERAL INFORMATION:
; APPLICANT: Linnarsson, Sten
; APPLICANT: Ernfors, Patrik
; APPLICANT: Bauren, Goran
; APPLICANT: Metsis, Ats
; APPLICANT: Pihlak, Arno
; APPLICANT: Montelius, Andreas
; TITLE OF INVENTION: Methods And Means For Manipulating Nucleic Acid
; FILE REFERENCE: 620-234
; CURRENT APPLICATION NUMBER: US/10/352,253A
; CURRENT FILING DATE: 2003-01-28
; PRIOR APPLICATION NUMBER: US 60/352,215
; PRIOR FILING DATE: 2002-01-29
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-352-253A-18

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTCTTTTTTTTTC 2587
      ||||| ||||| ||||| |||||
Db 1 TTTTCTTTTTTTTTC 17

RESULT 631
US-10-299-976-229/c
; Sequence 229, Application US/10299976
; Publication No. US20030180312A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P1618P2C85
```

; CURRENT APPLICATION NUMBER: US/10/299,976
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-299-976-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||
DB 17 TCCCTGTGGACAGCAG 1

RESULT 632
US-10-299-937-229/c
; Sequence 229, Application US/102999937
; Publication No. US20030185846A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P1618P2C86
; CURRENT APPLICATION NUMBER: US/10/299,937
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-299-937-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||
DB 17 TCCCTGTGGACAGCAG 1

RESULT 633
US-10-298-993-229/c
; Sequence 229, Application US/102989993
; Publication No. US20030211576A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey

APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P618P2C84
; CURRENT APPLICATION NUMBER: US/10/298,993
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-298-993-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
|||||||
DB 17 TCCCTGTGGACAGC 1

RESULT 634
US-10-352-255A-18
; Sequence 18, Application US/10352255A
; Publication No. US20030215839A1
; GENERAL INFORMATION:
; APPLICANT: LONNERBERG, Peter
; APPLICANT: OLDIN, Mats
; APPLICANT: LINNARSSON, Sten
; APPLICANT: ERNFORS, Patrik
; TITLE OF INVENTION: Methods and Means for Identification of Gene Features
; FILE REFERENCE: 620-235
; CURRENT APPLICATION NUMBER: US/10/352,255A
; CURRENT FILING DATE: 2003-01-28
; PRIOR APPLICATION NUMBER: US 60/352,245
; PRIOR FILING DATE: 2002-01-29
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-352-255A-18

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2571 TTCTTCTTTTTC 2587
|||||||
DB 1 TTTTTC 17

RESULT 635
US-10-448-923-229/c
; Sequence 229, Application US/10448923
; Publication No. US20030225253A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deanoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: KJjavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/448,923
; CURRENT FILING DATE: 2003-05-29
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-448-923-229

		Query Match Best Local Similarity 0.4%; Score 13.8; DB 1; Length 18; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	150	TCCCTGTGGAAGCGG 166 	
Db	17	TCCCTGTGACAGCAG 1 	
		RESULT 636 US-10-108-260A-5386 ; Sequence 5386, Application US/10108260A ; Publication No. US20040005560A1 ; GENERAL INFORMATION: ; APPLICANT: HELIX RESEARCH INSTITUTE ; TITLE OF INVENTION: No. US20040005560A1el full length cDNA ; FILE REFERENCE: H1-A0106 ; CURRENT APPLICATION NUMBER: US/10/108,260A ; CURRENT FILING DATE: 2002-03-27 ; NUMBER OF SEQ ID NOS: 5458 ; SOFTWARE: PatentIn Ver. 2.1 ; SEQ ID NO 5386 ; LENGTH: 18 ; TYPE: DNA ; ORGANISM: Artificial Sequence ; FEATURE: ; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized P US-10-108-260A-5386	
		Query Match Best Local Similarity 0.4%; Score 13.8; DB 1; Length 18; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	2562	CCAGCTTCTTCTTCTT 2578 	
Db	1	CCAGCTTCTTCTCAT 17 	
		RESULT 637 US-10-108-260A-5447/C ; Sequence 5447, Application US/10108260A ; Publication No. US20040005560A1 ; GENERAL INFORMATION: ; APPLICANT: HELIX RESEARCH INSTITUTE ; TITLE OF INVENTION: No. US20040005560A1el full length cDNA ; FILE REFERENCE: H1-A0106 ; CURRENT APPLICATION NUMBER: US/10/108,260A ; CURRENT FILING DATE: 2002-03-27 ; NUMBER OF SEQ ID NOS: 5458 ; SOFTWARE: PatentIn Ver. 2.1 ; SEQ ID NO 5447 ; LENGTH: 18 ; TYPE: DNA ; ORGANISM: Artificial Sequence ; FEATURE: ; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized P US-10-108-260A-5447	
		Query Match Best Local Similarity 0.4%; Score 13.8; DB 1; Length 18; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	1240	TCCTTTTGGATGCTG 1256 	
Db	18	TCCTTGGATGATGCTG 2 	
		RESULT 638 US-10-349-143-7122 ; Sequence 7122, Application US/10349143 ; Publication No. US20040005584A1 ; GENERAL INFORMATION: ; APPLICANT: Cohen, Daniel ; APPLICANT: Blumenfeld, Marta ; APPLICANT: Chumakov, Ilya ; TITLE OF INVENTION: Biallelic markers for use in constructing a high density... ; FILE REFERENCE: GENSET.020CPI ; CURRENT APPLICATION NUMBER: US/10/349,143 ; CURRENT FILING DATE: 2003-01-21 ; PRIOR APPLICATION NUMBER: US/09/422,978 ; PRIOR FILING DATE: 1999-10-20 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850 ; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732 ; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614 ; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21 ; NUMBER OF SEQ ID NOS: 11796 ; SEQ ID NO 7122 ; LENGTH: 18 ; TYPE: DNA ; ORGANISM: Homo Sapiens ; FEATURE: ; NAME/KEY: primer_bind ; LOCATION: 1..18 ; OTHER INFORMATION: upstream amplification primer 99-9839 for SEQ 3707, US-10-349-143-7641 ; Query Match Best Local Similarity 0.4%; Score 13.8; DB 1; Length 18; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	2033	TCAGAGTTCACCCATTA 2049 	
Db	1	TCAGAGTTCACCCATTA 17 	

```
RESULT 640
US-10-349-143-9605/c
; Sequence 9605, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; PRIOR FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9605
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6077 for SEQ 1740, in compleme
US-10-349-143-9605

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3581 AGCGAAAGGAATGGGGA 3597
||| ||||| ||||| |||||
Db 17 AGAGAGAGGAATGGGGA 1

RESULT 641
US-10-449-656-229/c
; Sequence 229, Application US/10449656
; Publication No. US2004000565A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

```
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/449,656
; CURRENT FILING DATE: 2003-05-29
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-449-656-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAAGCGG 166
||| ||||| ||||| |||||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 642
US-10-448-713-229/c
; Sequence 229, Application US/10448713
; Publication No. US20040006211A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
```


APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/10/448,713
CURRENT FILING DATE: 2003-05-29
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-448-713-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 643
US-10-425-447-229/c
Sequence 229, Application US/10425447
Publication No. US2004002331A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Mathew, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.

APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/10/425,447
CURRENT FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-425-447-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAGCGG 166
|||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 644
US-10-138-674-3979
Sequence 3979, Application US/10138674
Publication No. US2004007565A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEH00-876-N (400/049)
CURRENT APPLICATION NUMBER: US/10/138,674
CURRENT FILING DATE: 2002-05-03
NUMBER OF SEQ ID NOS: 20822
SOFTWARE: PatentIn version 3.0
SEQ-ID-NO 3979
LENGTH: 18
TYPE: RNA
ORGANISM: Mus musculus
US-10-138-674-3979

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;

```
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2488 CTCCTGACTCTCGAA 2504
   ||| ||| ||| |||
Db 2 CUCUCAGACCCUGGAA 18

RESULT 645
US-10-287-949A-3979
; Sequence 3979, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3979
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3979

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2488 CTCCTGACTCTCGAA 2504
   ||| ||| ||| |||
Db 2 CUCUCAGACCCUGGAA 18

RESULT 646
US-10-672-794-13/c
; Sequence 13, Application US/10672794
; Publication No. US20040126794A1
; GENERAL INFORMATION:
; APPLICANT: Bugawan et al.
; TITLE OF INVENTION: Detection of Susceptibility to Autoimmune Diseases
; FILE REFERENCE: 1803-318-999
; CURRENT APPLICATION NUMBER: US/10/672,794
; CURRENT FILING DATE: 2003-09-25
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Artificial Sequence Type: Probe for HLA-C Allele
; FEATURE:
; OTHER INFORMATION: Sequence attaches to BSA at Position 1 on 5' end
US-10-672-794-13

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 366 AGAGCCAGCCCTCGAG 382
   |||| |||| ||||
Db 17 AGAGCGAGCGCGGTGAG 1

RESULT 647
US-10-215-371-229/c
; Sequence 229, Application US/10215371
```

```
; Publication No. US20040137561A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Chen, Jian
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth
; APPLICANT: Pennica, Diane
; APPLICANT: Wood, William I.
; APPLICANT: Yuan, Jean
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P1618P2C83
; CURRENT APPLICATION NUMBER: US/10/215,371
; CURRENT FILING DATE: 2002-08-08
; PRIOR APPLICATION NUMBER: US 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: PCT/US98/18824
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: US 60/099,803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: US 60/062,285
; PRIOR FILING DATE: 1997-10-17
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-10-215-371-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
   ||||| ||||| |||
Db 17 TCCCTGTGGACAGCAG 1

RESULT 648
US-10-731-739-128/c
; Sequence 128, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/10/731,739
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US/09/544,398B
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-731-739-128

Query Match 0.4%; Score 13.8; DB 1; Length 18;
```

```
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1453 GGAATCCATCCAGGGAG 1469
DB 18 GGAAGCCATCGAGGGAG 2

RESULT 649
US-10-731-739-282/c
; Sequence 282, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/10/731,739
; PRIOR FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US/09/544,398B
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 282
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-731-739-282

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2740 TCCTCTTTAAACTCCTC 2756
DB 17 TCCTCTTGAGCTCCTC 1

RESULT 650
US-10-771-187-229/c
; Sequence 229, Application US/10771187
; Publication No. US20040185531A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
```

```
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 39780-1618P2C78C1
; CURRENT APPLICATION NUMBER: US/10/771,187
; PRIOR FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: 09/909,064
; PRIOR FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: PCT/US98/19437
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: PCT/US98/19330
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/088,026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/066,770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/065,186
; PRIOR FILING DATE: 1997-11-12
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-771-187-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
DB 17 TCCCTGTGACACAG 1

RESULT 651
US-10-418-182-128
; Sequence 128, Application US/10418182
; Publication No. US2003028302A1
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551.2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: 60/373,558
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 423
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-418-182-128

Query Match 0.4%; Score 13.8; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 GAAGAGAGAACCGGA 358
DB 4 GAAGAGAGAGAGAGGA 20
```

```
RESULT 652
US-09-738-363-27
; Sequence 27, Application US/09738363
; Patent No. US20010010932A1
; GENERAL INFORMATION:
; APPLICANT: Schnepf, Harry E.
; Payne, Jewel M.
; Narva, Kenneth E.
; Focerrada, Luis
; TITLE OF INVENTION: Nematocidal Proteins
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jay M. Sanders
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/738,363
; FILING DATE: 15-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/076,137
; FILING DATE: 12-MAY-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Sanders, Jay
; REGISTRATION NUMBER: 39,355
; REFERENCE/DOCKET NUMBER: MA-200CCD3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 352-375-8100
; TELEFAX: 352-372-5800
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-09-738-363-27

Query Match          0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
||:|||||:|||||
DB 2 AAYTACAAGCWCACACC 17

RESULT 653
US-10-633-023-27
; Sequence 27, Application US/10633023
; Publication No. US20040018982A1
; GENERAL INFORMATION:
; APPLICANT: Schnepf, H. Ernest
; APPLICANT: Payne, Jewel
; APPLICANT: Narva, Kenneth
; APPLICANT: Focerrada, Luis
; TITLE OF INVENTION: Nematocidal Proteins
; FILE REFERENCE: MA-200CCD4
; CURRENT APPLICATION NUMBER: US/10/633,023
; CURRENT FILING DATE: 2003-07-31
; PRIOR APPLICATION NUMBER: US 09/738,363

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
||:|||||:|||||
DB 2 AAYTACAAGCWCACACC 17

RESULT 654
US-09-559-671A-74/c
; Sequence 74, Application US/09559671A
; Patent No. US20020051976A1
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020503US
; CURRENT APPLICATION NUMBER: US/09/559,671A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/198,431
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-559-671A-74

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

; PRIOR FILING DATE: 2000-12-15
; PRIOR APPLICATION NUMBER: US 09/076,137
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: US 08/316,301
; PRIOR FILING DATE: 1994-09-30
; PRIOR APPLICATION NUMBER: US 07/871,510
; PRIOR FILING DATE: 1992-04-23
; PRIOR APPLICATION NUMBER: US 07/830,050
; PRIOR FILING DATE: 1992-01-31
; PRIOR APPLICATION NUMBER: US 07/693,018
; PRIOR FILING DATE: 1991-05-03
; PRIOR APPLICATION NUMBER: US 07/675,772
; PRIOR FILING DATE: 1991-03-27
; PRIOR APPLICATION NUMBER: US 07/565,544
; PRIOR FILING DATE: 1990-08-10
; PRIOR APPLICATION NUMBER: US 07/557,246
; PRIOR FILING DATE: 1990-07-24
; PRIOR APPLICATION NUMBER: US 07/535,810
; PRIOR FILING DATE: 1990-06-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Forward oligonucleotide primer from 63B.
US-10-633-023-27

Query Match          0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
||:|||||:|||||
DB 2 AAYTACAAGCWCACACC 17
```

QY 2774 TTAAGGCTGAAGGAATGA 2791
| | | | : | | | | : | | |
DB 18 TTAARGAGKAAGGAWTGA 1

RESULT 655
US-09-954-692-74/c
; Sequence 74, Application US/09954692
; Publication No. US20030027156A1
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020500US
; CURRENT APPLICATION NUMBER: US/09/954,692
; CURRENT FILING DATE: 2001-09-12
; PRIOR APPLICATION NUMBER: US/08/769,062
; PRIOR FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-954-692-74

Query Match 0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
| | | | : | | | | : | | |
DB 18 TTAARGAGKAAGGAWTGA 1

Search completed: November 2, 2004, 09:58:08
Job time : 28 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 2, 2004, 09:53:17 : Search time 17 Seconds
(without alignments)
3.699 Million cell updates/sec

Title: US-10-003-354-3
Perfect score: 3713
Sequence: 1 attaacaggcgtgtagg.....aaacttaagtattatta 3713

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 484 seqs, 8468 residues

Total number of hits satisfying chosen parameters: 968

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 485 summaries

Database : fetch3rn1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	17.2	0.5	22	1 US-08-318-193-65	Sequence 65, Appl
C 2	16.8	0.5	20	1 US-08-531-556-51	Sequence 51, Appl
C 3	16.8	0.5	20	1 US-08-531-556-63	Sequence 63, Appl
C 4	16.8	0.5	20	1 US-08-472-416-51	Sequence 51, Appl
C 5	16.8	0.5	20	1 US-08-472-416-63	Sequence 63, Appl
C 6	16.8	0.5	20	1 US-08-777-266A-6	Sequence 6, Appl
C 7	16.8	0.5	20	1 US-09-326-186B-6	Sequence 6, Appl
C 8	16.4	0.4	18	1 US-08-890-980-64	Sequence 64, Appl
C 9	16.4	0.4	18	1 US-08-979-979-64	Sequence 64, Appl
C 10	16.4	0.4	18	1 US-09-032-894-64	Sequence 64, Appl
C 11	16.4	0.4	18	1 US-09-031-626-64	Sequence 64, Appl
C 12	16.4	0.4	19	1 US-08-656-906-3	Sequence 3, Appl
C 13	16.4	0.4	19	1 US-09-217-847-3	Sequence 3, Appl
C 14	16.2	0.4	21	1 US-08-896-410-18	Sequence 18, Appl
C 15	16.2	0.4	21	1 US-09-470-443-39	Sequence 39, Appl
C 16	16	0.4	21	1 US-09-657-472-683	Sequence 683, Appl
C 17	15.8	0.4	19	1 US-09-696-791-3363	Sequence 3363, Appl
C 18	15.8	0.4	20	1 US-09-488-671-25	Sequence 25, Appl
C 19	15.8	0.4	20	1 US-09-429-322-15	Sequence 15, Appl
C 20	15.8	0.4	20	1 US-09-313-933-360	Sequence 360, Appl
C 21	15.8	0.4	20	1 US-09-593-711A-62	Sequence 62, Appl
C 22	15.8	0.4	20	1 US-09-198-452A-5256	Sequence 5256, Appl
C 23	15.8	0.4	20	1 US-09-692-820A-3	Sequence 3, Appl
C 24	15.8	0.4	21	1 US-08-173-489C-118	Sequence 118, Appl
C 25	15.8	0.4	21	1 US-08-851-350-23	Sequence 23, Appl
C 26	15.8	0.4	21	1 US-08-851-350-33	Sequence 33, Appl
C 27	15.8	0.4	21	1 US-08-924-287A-23	Sequence 23, Appl
C 28	15.8	0.4	21	1 US-08-924-287A-33	Sequence 33, Appl
C 29	15.4	0.4	18	1 US-09-422-978-6580	Sequence 6580, Appl
C 30	15.4	0.4	19	1 US-08-222-177A-375	Sequence 375, Appl
C 31	15.4	0.4	20	1 US-08-650-766-14	Sequence 14, Appl
C 32	15.4	0.4	20	1 US-08-922-635-13	Sequence 13, Appl
C 33	15.4	0.4	20	1 US-09-428-584-19	Sequence 19, Appl

15.4	0.4	20	1	US-09-490-692-157	Sequence 157, Appl
15.4	0.4	20	1	US-09-593-711A-95	Sequence 95, Appl
15.4	0.4	20	1	US-09-488-744A-46	Sequence 46, Appl
15.4	0.4	20	1	US-09-780-175-38	Sequence 38, Appl
15.4	0.4	20	1	US-09-898-361-98	Sequence 98, Appl
15.4	0.4	20	1	US-09-422-978-6240	Sequence 6240, Appl
15.4	0.4	20	1	US-09-389-487-14	Sequence 14, Appl
15.4	0.4	20	1	US-09-544-398B-467	Sequence 467, Appl
15.4	0.4	20	1	US-08-107-411-5	Sequence 5, Appl
15.2	0.4	20	1	US-08-346-774-6	Sequence 6, Appl
15.2	0.4	20	1	US-08-146-504-16	Sequence 16, Appl
15.2	0.4	20	1	US-08-209-172-4	Sequence 4, Appl
15.2	0.4	20	1	US-08-379-593-5	Sequence 5, Appl
15.2	0.4	20	1	US-08-925-976-16	Sequence 16, Appl
15.2	0.4	20	1	US-08-997-080-83	Sequence 83, Appl
15.2	0.4	20	1	US-08-997-362-83	Sequence 83, Appl
15.2	0.4	20	1	US-09-018-422-4	Sequence 4, Appl
15.2	0.4	20	1	US-08-965-780-1	Sequence 1, Appl
15.2	0.4	20	1	US-08-873-970-83	Sequence 83, Appl
15.2	0.4	20	1	US-09-120-853-14	Sequence 14, Appl
15.2	0.4	20	1	US-09-428-584-20	Sequence 20, Appl
15.2	0.4	20	1	US-08-765-340-96	Sequence 96, Appl
15.2	0.4	20	1	US-09-095-855-83	Sequence 83, Appl
15.2	0.4	20	1	US-09-351-351-4	Sequence 4, Appl
15.2	0.4	20	1	US-09-407-675-1	Sequence 1, Appl
15.2	0.4	20	1	US-09-250-075-1	Sequence 1, Appl
15.2	0.4	20	1	US-09-183-931-4	Sequence 4, Appl
15.2	0.4	20	1	US-09-173-936B-14	Sequence 14, Appl
15.2	0.4	20	1	US-09-454-704A-13	Sequence 13, Appl
15.2	0.4	20	1	US-09-484-617-78	Sequence 78, Appl
15.2	0.4	20	1	US-09-324-542-83	Sequence 83, Appl
15.2	0.4	20	1	US-09-705-160-4	Sequence 4, Appl
15.2	0.4	20	1	US-09-205-426-63	Sequence 63, Appl
15.2	0.4	20	1	US-09-619-103-26	Sequence 26, Appl
15.2	0.4	20	1	US-09-726-096A-1	Sequence 1, Appl
15.2	0.4	20	1	US-09-844-521-33	Sequence 33, Appl
15.2	0.4	20	1	US-09-603-830-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-976-978A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-344-260A-10	Sequence 10, Appl
15.2	0.4	20	1	US-09-961-949A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-966-431A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-957-313A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-966-312-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-975-062A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-976-971A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-974-500A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-032-438C-53	Sequence 53, Appl
15.2	0.4	20	1	US-09-976-577-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-973-788A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-976-617A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-967-409A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-820-279D-70	Sequence 70, Appl
15.2	0.4	20	1	US-09-820-279D-70	Sequence 70, Appl
15.2	0.4	20	1	US-09-957-318A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-957-318A-55	Sequence 55, Appl
15.2	0.4	20	1	US-09-981-344-55	Sequence 55, Appl
15.2	0.4	20	1	PCT-US93-07603-6	Sequence 6, Appl
15.2	0.4	20	1	US-09-527-030G-114	Sequence 114, Appl
15.2	0.4	18	1	US-09-019-160-84	Sequence 84, Appl
14.8	0.4	18	1	US-09-588-995A-59	Sequence 59, Appl
14.8	0.4	19	1	US-09-559-306-1	Sequence 1, Appl
14.8	0.4	19	1	US-09-696-791-1218	Sequence 1218, Appl
14.8	0.4	19	1	US-09-696-791-2994	Sequence 2994, Appl
14.8	0.4	19	1	US-09-696-791-3364	Sequence 3364, Appl
14.8	0.4	19	1	US-09-696-791-3720	Sequence 3720, Appl
14.8	0.4	19	1	US-09-696-791-3721	Sequence 3721, Appl
14.8	0.4	20	1	US-09-898-361-98	Sequence 98, Appl
14.8	0.4	17	1	US-08-390-850-418	Sequence 418, Appl
14.4	0.4	17	1	US-08-435-634-418	Sequence 418, Appl
14.4	0.4	17	1	US-09-133-717-16	Sequence 16, Appl
14.4	0.4	17	1	US-09-158-863C-16	Sequence 16, Appl
14.4	0.4	17	1	US-09-371-772B-5149	Sequence 5149, Appl
14.4	0.4	17	1	US-09-371-772B-6286	Sequence 6286, Appl

c 107	14.4	0.4	17	1	US-09-371-772B-6287	Sequence 6287, Ap	c 180	13.8	0.4	18	1	US-09-902-775A-229	Sequence 229, App
c 108	14.4	0.4	18	1	US-09-161-244-73	Sequence 73, Appl	c 181	13.8	0.4	18	1	US-09-032-438C-37	Sequence 37, Appl
c 109	14.4	0.4	18	1	US-09-422-978-11340	Sequence 11340, A	c 182	13.8	0.4	18	1	US-09-906-700-229	Sequence 229, App
c 110	14.4	0.4	19	1	US-09-696-791-2458	Sequence 2458, Ap	c 183	13.8	0.4	18	1	US-09-903-603A-229	Sequence 229, App
c 111	14.4	0.4	19	1	US-09-696-791-2459	Sequence 2459, Ap	c 184	13.8	0.4	18	1	US-09-544-398B-128	Sequence 128, App
c 112	14.4	0.4	14	1	US-08-998-099-343	Sequence 343, App	c 185	13.8	0.4	18	1	US-09-544-398B-282	Sequence 282, App
c 113	14.4	0.4	17	1	US-09-371-772B-6605	Sequence 6605, Ap	c 186	13.8	0.4	18	1	US-09-696-791-4287	Sequence 4287, Ap
c 114	14.4	0.4	17	1	US-09-371-772B-6606	Sequence 6606, Ap	c 187	13.8	0.4	18	1	US-09-994-311-7	Sequence 7, Appl
c 115	14.4	0.4	17	1	US-09-866-108A-950	Sequence 950, App	c 188	13.8	0.4	18	1	US-09-142-108C-28	Sequence 28, Appl
c 116	14.4	0.4	17	1	US-09-866-108A-951	Sequence 951, App	c 189	13.8	0.4	18	1	PCT-US91-03680-73	Sequence 73, Appl
c 117	14.4	0.4	17	1	US-09-866-108A-952	Sequence 952, App	c 190	13.8	0.4	18	1	PCT-US95-07744A-36	Sequence 36, Appl
c 118	14.4	0.4	17	1	US-09-866-108A-953	Sequence 953, App	c 191	13.8	0.4	18	1	5175384-7	Patent No. 5175384
c 119	14.4	0.4	18	1	US-09-422-978-4657	Sequence 4657, Ap	c 192	13.6	0.4	17	1	US-07-876-280-19	Sequence 19, Appl
c 120	14.4	0.4	18	1	US-09-601-144-19	Sequence 19, Appl	c 193	13.6	0.4	17	1	US-08-049-783-17	Sequence 17, Appl
c 121	13.8	0.4	17	1	US-08-985-162-809	Sequence 809, App	c 194	13.6	0.4	17	1	US-08-158-232-24	Sequence 24, Appl
c 122	13.8	0.4	17	1	US-08-584-040-2546	Sequence 2546, Ap	c 195	13.6	0.4	17	1	US-08-304-626-24	Sequence 24, Appl
c 123	13.8	0.4	17	1	US-08-584-040-2547	Sequence 2547, Ap	c 196	13.6	0.4	17	1	US-08-316-301A-27	Sequence 27, Appl
c 124	13.8	0.4	17	1	US-08-584-040-2550	Sequence 2550, Ap	c 197	13.6	0.4	17	1	US-08-611-928-24	Sequence 24, Appl
c 125	13.8	0.4	17	1	US-08-584-040-2551	Sequence 2551, Ap	c 198	13.6	0.4	17	1	US-09-224-024-8	Sequence 8, Appl
c 126	13.8	0.4	17	1	US-08-584-040-5765	Sequence 5765, Ap	c 199	13.6	0.4	17	1	US-09-173-891-24	Sequence 24, Appl
c 127	13.8	0.4	17	1	US-08-584-040-5943	Sequence 5943, Ap	c 200	13.6	0.4	17	1	US-09-076-137-27	Sequence 27, Appl
c 128	13.8	0.4	17	1	US-08-584-040-7816	Sequence 7816, Ap	c 201	13.6	0.4	17	1	PCT-US92-03624-27	Sequence 27, Appl
c 129	13.8	0.4	17	1	US-09-474-432B-721	Sequence 721, App	c 202	13.6	0.4	17	1	PCT-US94-07902-8	Sequence 8, Appl
c 130	13.8	0.4	17	1	US-09-371-772B-1070	Sequence 1070, Ap	c 203	13.6	0.4	17	1	US-09-339-913B-74	Sequence 74, Appl
c 131	13.8	0.4	17	1	US-09-371-772B-1071	Sequence 1071, Ap	c 204	13.6	0.4	18	1	US-09-339-904A-74	Sequence 74, Appl
c 132	13.8	0.4	17	1	US-09-371-772B-1074	Sequence 1074, Ap	c 205	13.6	0.4	18	1	US-08-769-062B-74	Sequence 74, Appl
c 133	13.8	0.4	17	1	US-09-371-772B-1075	Sequence 1075, Ap	c 206	13.6	0.4	18	1	US-09-344-002B-74	Sequence 74, Appl
c 134	13.8	0.4	17	1	US-09-371-772B-2644	Sequence 2644, Ap	c 207	13.6	0.4	18	1	US-09-559-565C-74	Sequence 74, Appl
c 135	13.8	0.4	17	1	US-09-371-772B-2780	Sequence 2780, Ap	c 208	13.6	0.4	18	1	US-09-693-350-74	Sequence 74, Appl
c 136	13.8	0.4	17	1	US-09-371-772B-3600	Sequence 3600, Ap	c 209	13.6	0.4	18	1	US-09-693-389-74	Sequence 74, Appl
c 137	13.8	0.4	17	1	US-09-371-772B-4631	Sequence 4631, Ap	c 210	13.6	0.4	18	1	US-09-559-671A-74	Sequence 74, Appl
c 138	13.8	0.4	17	1	US-09-371-772B-5574	Sequence 5574, Ap	c 211	13.6	0.4	18	1	US-09-339-928A-74	Sequence 74, Appl
c 139	13.8	0.4	17	1	US-09-371-772B-5575	Sequence 5575, Ap	c 212	13.6	0.4	18	1	US-08-363-240A-69	Sequence 69, Appl
c 140	13.8	0.4	17	1	US-09-371-772B-6139	Sequence 6139, Ap	c 213	13.4	0.4	15	1	US-08-292-620A-292	Sequence 292, App
c 141	13.8	0.4	17	1	US-09-476-387-720	Sequence 720, App	c 214	13.4	0.4	15	1	US-08-667-338B-9	Sequence 9, Appl
c 142	13.8	0.4	17	1	US-09-401-063-809	Sequence 809, App	c 215	13.4	0.4	15	1	US-08-893-204C-1	Sequence 2, Appl
c 143	13.8	0.4	17	1	US-09-150-867-5	Sequence 5, Appl	c 216	13.4	0.4	15	1	US-08-832-021-25	Sequence 25, Appl
c 144	13.8	0.4	17	1	US-09-827-998-196	Sequence 196, App	c 217	13.4	0.4	15	1	US-08-832-021-59	Sequence 59, Appl
c 145	13.8	0.4	17	1	US-09-827-998-483	Sequence 483, App	c 218	13.4	0.4	15	1	US-09-071-845-292	Sequence 292, App
c 146	13.8	0.4	17	1	US-09-827-998-775	Sequence 775, App	c 219	13.4	0.4	15	1	US-09-486-453-1	Sequence 1, Appl
c 147	13.8	0.4	17	1	US-09-827-998-776	Sequence 776, App	c 220	13.4	0.4	15	1	US-08-741-881-72	Sequence 72, Appl
c 148	13.8	0.4	17	1	US-09-866-108A-1176	Sequence 1176, Ap	c 221	13.4	0.4	16	1	US-08-739-158-72	Sequence 72, Appl
c 149	13.8	0.4	17	1	US-09-866-108A-1580	Sequence 1580, Ap	c 222	13.4	0.4	16	1	US-08-739-167-72	Sequence 72, Appl
c 150	13.8	0.4	17	1	US-09-866-108A-2270	Sequence 2270, Ap	c 223	13.4	0.4	16	1	US-08-404-796-72	Sequence 72, Appl
c 151	13.8	0.4	17	1	US-09-866-108A-2271	Sequence 2271, Ap	c 224	13.4	0.4	16	1	US-08-931-869-72	Sequence 72, Appl
c 152	13.8	0.4	17	1	US-09-866-108A-6855	Sequence 6855, Ap	c 225	13.4	0.4	16	1	US-09-350-399-72	Sequence 16, Appl
c 153	13.8	0.4	17	1	US-09-866-108A-6856	Sequence 6856, Ap	c 226	13.4	0.4	16	1	US-08-911-894-15	Sequence 15, Appl
c 154	13.8	0.4	17	1	US-09-866-108A-6929	Sequence 6929, Ap	c 227	13.4	0.4	16	1	US-09-350-399-72	Sequence 72, Appl
c 155	13.8	0.4	17	1	US-09-866-108A-6930	Sequence 6930, Ap	c 228	13.4	0.4	16	1	US-08-373-124A-1435	Sequence 1435, Ap
c 156	13.8	0.4	17	1	US-09-866-108A-8116	Sequence 8116, Ap	c 229	13.4	0.4	16	1	US-08-373-124A-1437	Sequence 1437, Ap
c 157	13.8	0.4	17	1	US-09-866-108A-8454	Sequence 8454, Ap	c 230	13.4	0.4	16	1	US-08-435-628-1435	Sequence 1435, Ap
c 158	13.8	0.4	17	1	US-09-866-108A-8873	Sequence 8873, Ap	c 231	13.4	0.4	17	1	US-08-435-628-1437	Sequence 1437, Ap
c 159	13.8	0.4	17	1	US-09-866-108A-10318	Sequence 10318, A	c 232	13.4	0.4	17	1	US-08-173-489C-96	Sequence 96, Appl
c 160	13.8	0.4	18	1	US-08-261-822A-36	Sequence 36, Appl	c 233	13.4	0.4	17	1	US-08-985-162-341	Sequence 341, App
c 161	13.8	0.4	18	1	US-08-311-486C-1129	Sequence 1129, Ap	c 234	13.4	0.4	17	1	US-08-584-040-1931	Sequence 1931, App
c 162	13.8	0.4	18	1	US-08-811-028-26	Sequence 26, Appl	c 235	13.4	0.4	17	1	US-08-584-040-1932	Sequence 1932, App
c 163	13.8	0.4	18	1	US-09-161-244-45	Sequence 45, Appl	c 236	13.4	0.4	17	1	US-08-584-040-2544	Sequence 2544, Ap
c 164	13.8	0.4	18	1	US-09-289-377-11	Sequence 11, Appl	c 237	13.4	0.4	17	1	US-08-584-040-2545	Sequence 2545, Ap
c 165	13.8	0.4	18	1	US-09-289-466-21	Sequence 21, Appl	c 238	13.4	0.4	17	1	US-08-584-040-4333	Sequence 4333, Ap
c 166	13.8	0.4	18	1	US-09-213-719-37	Sequence 37, Appl	c 239	13.4	0.4	17	1	US-08-584-040-6072	Sequence 6072, Ap
c 167	13.8	0.4	18	1	US-09-213-719-44	Sequence 44, Appl	c 240	13.4	0.4	17	1	US-08-679-645-883	Sequence 883, App
c 168	13.8	0.4	18	1	US-09-487-444-24	Sequence 24, Appl	c 241	13.4	0.4	17	1	US-08-679-645-885	Sequence 885, App
c 169	13.8	0.4	18	1	US-09-630-706-27	Sequence 27, Appl	c 242	13.4	0.4	17	1	US-09-371-772B-476	Sequence 476, App
c 170	13.8	0.4	18	1	US-08-584-040-8321	Sequence 8321, Ap	c 243	13.4	0.4	17	1	US-09-371-772B-1068	Sequence 1068, Ap
c 171	13.8	0.4	18	1	US-09-270-140A-26	Sequence 26, Appl	c 244	13.4	0.4	17	1	US-09-371-772B-1069	Sequence 1069, Ap
c 172	13.8	0.4	18	1	US-09-637-751A-7	Sequence 7, Appl	c 245	13.4	0.4	17	1	US-09-371-772B-2100	Sequence 2100, Ap
c 173	13.8	0.4	18	1	US-09-422-978-7122	Sequence 7122, Ap	c 246	13.4	0.4	17	1	US-09-371-772B-2909	Sequence 2909, Ap
c 174	13.8	0.4	18	1	US-09-422-978-7641	Sequence 7641, Ap	c 247	13.4	0.4	17	1	US-09-371-772B-4766	Sequence 4766, Ap
c 175	13.8	0.4	18	1	US-09-422-978-9605	Sequence 9605, Ap	c 248	13.4	0.4	17	1		
c 176	13.8	0.4	18	1	US-09-371-772B-3979	Sequence 3979, Ap	c 249	13.4	0.4	17	1		
c 177	13.8	0.4	18	1	US-09-764-422A-4	Sequence 4, Appl	c 250	13.4	0.4	17	1		
c 178	13.8	0.4	18	1	US-09-907-794A-229	Sequence 229, App	c 251	13.4	0.4	17	1		
c 179	13.8	0.4	18	1	US-09-905-125A-229	Sequence 229, App	c 252	13.4	0.4	17	1		

C 253	13.4	0.4	17	1	US-09-371-772B-5493	Sequence 5493, Ap	12.8	0.3	17	1	US-08-373-124A-1136	Sequence 1136, Ap
C 254	13.4	0.4	17	1	US-09-371-772B-5494	Sequence 5494, Ap	12.8	0.3	17	1	US-08-373-124A-1813	Sequence 1813, Ap
C 255	13.4	0.4	17	1	US-09-371-772B-5860	Sequence 5860, Ap	12.8	0.3	17	1	US-08-373-124A-2169	Sequence 2169, Ap
C 256	13.4	0.4	17	1	US-09-401-063-341	Sequence 341, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 257	13.4	0.4	17	1	US-09-529-812A-3	Sequence 3, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 258	13.4	0.4	17	1	US-09-866-108A-2268	Sequence 2268, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 259	13.4	0.4	17	1	US-09-866-108A-2269	Sequence 2269, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 260	13.4	0.4	17	1	US-09-866-108A-8114	Sequence 8114, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 261	13.4	0.4	17	1	US-09-866-108A-8115	Sequence 8115, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 262	13.4	0.4	17	1	US-09-866-108A-9590	Sequence 9590, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 263	13.4	0.4	17	1	US-09-866-108A-9591	Sequence 9591, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 264	13.4	0.4	17	1	US-09-866-108A-9592	Sequence 9592, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 265	13	0.4	14	1	US-08-294-424-33	Sequence 33, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 266	13	0.4	15	1	US-08-319-492B-59	Sequence 59, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 267	13	0.4	15	1	US-08-319-492B-60	Sequence 60, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 268	13	0.4	15	1	US-08-292-620A-366	Sequence 366, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 269	13	0.4	15	1	US-08-292-620A-367	Sequence 367, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 270	13	0.4	15	1	US-08-292-620A-368	Sequence 368, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 271	13	0.4	15	1	US-09-071-845-366	Sequence 366, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 272	13	0.4	15	1	US-09-071-845-367	Sequence 367, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 273	13	0.4	15	1	US-09-071-845-368	Sequence 368, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 274	13	0.4	16	1	US-09-133-717-11	Sequence 11, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 275	13	0.4	16	1	US-09-158-863C-11	Sequence 11, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 276	13	0.4	16	1	US-09-527-030G-88	Sequence 88, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 277	13	0.4	16	1	5256545-2	Patent No. 5256545	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 278	13	0.4	16	1	5256545-34	Patent No. 5256545	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 279	13	0.4	17	1	US-08-998-099-82	Sequence 82, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 280	13	0.4	17	1	US-08-998-099-83	Sequence 83, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 281	13	0.4	17	1	US-09-371-772B-6604	Sequence 6604, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 282	13	0.4	17	1	US-09-866-108A-949	Sequence 949, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 283	13	0.4	17	1	US-09-866-108A-954	Sequence 954, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 284	13	0.4	17	1	US-09-404-912-362	Sequence 362, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 285	12.8	0.3	16	1	US-08-119-773-12	Sequence 12, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 286	12.8	0.3	16	1	US-08-236-311-25	Sequence 25, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 287	12.8	0.3	16	1	US-07-971-978-36	Sequence 36, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 288	12.8	0.3	16	1	US-07-971-978-42	Sequence 42, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 289	12.8	0.3	16	1	US-07-971-978-60	Sequence 60, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 290	12.8	0.3	16	1	US-08-320-559-6	Sequence 6, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 291	12.8	0.3	16	1	US-08-327-392-6	Sequence 6, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 292	12.8	0.3	16	1	US-08-753-147-192	Sequence 192, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 293	12.8	0.3	16	1	US-08-415-370-2	Sequence 2, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 294	12.8	0.3	16	1	US-08-687-551-15	Sequence 15, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 295	12.8	0.3	16	1	US-08-173-489C-29	Sequence 29, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 296	12.8	0.3	16	1	US-08-545-860D-6	Sequence 6, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 297	12.8	0.3	16	1	US-09-141-764-2	Sequence 2, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 298	12.8	0.3	16	1	US-08-851-843A-131	Sequence 131, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 299	12.8	0.3	16	1	US-08-457-918-25	Sequence 25, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 300	12.8	0.3	16	1	US-08-854-050-131	Sequence 131, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 301	12.8	0.3	16	1	US-09-430-323-131	Sequence 131, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 302	12.8	0.3	16	1	US-08-666-341A-65	Sequence 65, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 303	12.8	0.3	16	1	US-09-507-345A-2	Sequence 2, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 304	12.8	0.3	16	1	US-09-619-103-22	Sequence 22, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 305	12.8	0.3	16	1	US-09-739-928-2	Sequence 2, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 306	12.8	0.3	16	1	US-09-060-299-447	Sequence 447, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 307	12.8	0.3	16	1	US-09-402-923A-447	Sequence 447, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 308	12.8	0.3	16	1	US-09-371-772B-5893	Sequence 5893, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 309	12.8	0.3	16	1	US-09-371-772B-5974	Sequence 5974, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 310	12.8	0.3	16	1	US-09-371-772B-6017	Sequence 6017, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 311	12.8	0.3	16	1	US-09-371-772B-7077	Sequence 7077, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 312	12.8	0.3	16	1	US-09-479-005A-94	Sequence 94, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 313	12.8	0.3	16	1	US-09-479-005A-117	Sequence 117, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 314	12.8	0.3	16	1	US-09-479-005A-304	Sequence 304, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 315	12.8	0.3	16	1	US-10-157-408-25	Sequence 25, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 316	12.8	0.3	16	1	US-09-958-610A-1	Sequence 1, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 317	12.8	0.3	16	1	US-09-895-585-9	Sequence 9, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 318	12.8	0.3	16	1	US-09-477-392-59	Sequence 59, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 319	12.8	0.3	16	1	US-09-856-662-30	Sequence 30, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 320	12.8	0.3	16	1	US-09-152-059-70	Sequence 70, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 321	12.8	0.3	16	1	FCT-US94-04496-6	Sequence 6, Appl	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 322	12.8	0.3	17	1	US-08-390-850-488	Sequence 488, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 323	12.8	0.3	17	1	US-08-390-850-696	Sequence 696, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 324	12.8	0.3	17	1	US-08-373-124A-304	Sequence 304, App	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App
C 325	12.8	0.3	17	1	US-08-373-124A-1134	Sequence 1134, Ap	12.8	0.3	17	1	US-08-435-634-488	Sequence 488, App

399	12.8	0.3	17	1	US-09-371-772B-1287	Sequence 1287, Ap
c 400	12.8	0.3	17	1	US-09-371-772B-1519	Sequence 1519, Ap
c 401	12.8	0.3	17	1	US-09-371-772B-1601	Sequence 1601, Ap
c 402	12.8	0.3	17	1	US-09-371-772B-2149	Sequence 2149, Ap
c 403	12.8	0.3	17	1	US-09-371-772B-2150	Sequence 2150, Ap
c 404	12.8	0.3	17	1	US-09-371-772B-2285	Sequence 2285, Ap
c 405	12.8	0.3	17	1	US-09-371-772B-2645	Sequence 2645, Ap
c 406	12.8	0.3	17	1	US-09-371-772B-2779	Sequence 2779, Ap
c 407	12.8	0.3	17	1	US-09-371-772B-2781	Sequence 2781, Ap
c 408	12.8	0.3	17	1	US-09-371-772B-3262	Sequence 3262, Ap
c 409	12.8	0.3	17	1	US-09-371-772B-3299	Sequence 3299, Ap
c 410	12.8	0.3	17	1	US-09-371-772B-3368	Sequence 3368, Ap
c 411	12.8	0.3	17	1	US-09-371-772B-3465	Sequence 3465, Ap
c 412	12.8	0.3	17	1	US-09-371-772B-3599	Sequence 3599, Ap
c 413	12.8	0.3	17	1	US-09-371-772B-3601	Sequence 3601, Ap
c 414	12.8	0.3	17	1	US-09-371-772B-3933	Sequence 3933, Ap
c 415	12.8	0.3	17	1	US-09-371-772B-4222	Sequence 4222, Ap
c 416	12.8	0.3	17	1	US-09-371-772B-4223	Sequence 4223, Ap
c 417	12.8	0.3	17	1	US-09-371-772B-4632	Sequence 4632, Ap
c 418	12.8	0.3	17	1	US-09-371-772B-4936	Sequence 4936, Ap
c 419	12.8	0.3	17	1	US-09-371-772B-5092	Sequence 5092, Ap
c 420	12.8	0.3	17	1	US-09-371-772B-5093	Sequence 5093, Ap
c 421	12.8	0.3	17	1	US-09-371-772B-5370	Sequence 5370, Ap
c 422	12.8	0.3	17	1	US-09-371-772B-6336	Sequence 6336, Ap
c 423	12.8	0.3	17	1	US-09-371-772B-6337	Sequence 6337, Ap
c 424	12.8	0.3	17	1	US-09-371-772B-6358	Sequence 6358, Ap
c 425	12.8	0.3	17	1	US-09-371-772B-6600	Sequence 6600, Ap
c 426	12.8	0.3	17	1	US-09-401-063-213	Sequence 213, App
c 427	12.8	0.3	17	1	US-09-401-063-430	Sequence 430, App
c 428	12.8	0.3	17	1	US-09-827-998-195	Sequence 195, App
c 429	12.8	0.3	17	1	US-09-827-998-197	Sequence 197, App
c 430	12.8	0.3	17	1	US-09-827-998-482	Sequence 482, App
c 431	12.8	0.3	17	1	US-09-827-998-484	Sequence 484, App
c 432	12.8	0.3	17	1	US-09-827-998-772	Sequence 772, App
c 433	12.8	0.3	17	1	US-09-827-998-773	Sequence 773, App
c 434	12.8	0.3	17	1	US-09-827-998-774	Sequence 774, App
c 435	12.8	0.3	17	1	US-09-827-998-777	Sequence 777, App
c 436	12.8	0.3	17	1	US-09-529-812A-1	Sequence 1, Appli
c 437	12.8	0.3	17	1	US-09-866-108A-241	Sequence 241, App
c 438	12.8	0.3	17	1	US-09-866-108A-242	Sequence 242, App
c 439	12.8	0.3	17	1	US-09-866-108A-262	Sequence 262, App
c 440	12.8	0.3	17	1	US-09-866-108A-263	Sequence 263, App
c 441	12.8	0.3	17	1	US-09-866-108A-301	Sequence 301, App
c 442	12.8	0.3	17	1	US-09-866-108A-302	Sequence 302, App
c 443	12.8	0.3	17	1	US-09-866-108A-674	Sequence 674, App
c 444	12.8	0.3	17	1	US-09-866-108A-675	Sequence 675, App
c 445	12.8	0.3	17	1	US-09-866-108A-1175	Sequence 1175, Ap
c 446	12.8	0.3	17	1	US-09-866-108A-1177	Sequence 1177, Ap
c 447	12.8	0.3	17	1	US-09-866-108A-1579	Sequence 1579, Ap
c 448	12.8	0.3	17	1	US-09-866-108A-1581	Sequence 1581, Ap
c 449	12.8	0.3	17	1	US-09-866-108A-1875	Sequence 1875, Ap
c 450	12.8	0.3	17	1	US-09-866-108A-1876	Sequence 1876, Ap
c 451	12.8	0.3	17	1	US-09-866-108A-1881	Sequence 1881, Ap
c 452	12.8	0.3	17	1	US-09-866-108A-1882	Sequence 1882, Ap
c 453	12.8	0.3	17	1	US-09-866-108A-2066	Sequence 2066, Ap
c 454	12.8	0.3	17	1	US-09-866-108A-2067	Sequence 2067, Ap
c 455	12.8	0.3	17	1	US-09-866-108A-2272	Sequence 2272, Ap
c 456	12.8	0.3	17	1	US-09-866-108A-2423	Sequence 2423, Ap
c 457	12.8	0.3	17	1	US-09-866-108A-2424	Sequence 2424, Ap
c 458	12.8	0.3	17	1	US-09-866-108A-6014	Sequence 6014, Ap
c 459	12.8	0.3	17	1	US-09-866-108A-6015	Sequence 6015, Ap
c 460	12.8	0.3	17	1	US-09-866-108A-6397	Sequence 6397, Ap
c 461	12.8	0.3	17	1	US-09-866-108A-6398	Sequence 6398, Ap
c 462	12.8	0.3	17	1	US-09-866-108A-6854	Sequence 6854, Ap
c 463	12.8	0.3	17	1	US-09-866-108A-6857	Sequence 6857, Ap
c 464	12.8	0.3	17	1	US-09-866-108A-6928	Sequence 6928, Ap
c 465	12.8	0.3	17	1	US-09-866-108A-6931	Sequence 6931, Ap
c 466	12.8	0.3	17	1	US-09-866-108A-8117	Sequence 8117, Ap
c 467	12.8	0.3	17	1	US-09-866-108A-8453	Sequence 8453, Ap
c 468	12.8	0.3	17	1	US-09-866-108A-8455	Sequence 8455, Ap
c 469	12.8	0.3	17	1	US-09-866-108A-8872	Sequence 8872, Ap
c 470	12.8	0.3	17	1	US-09-866-108A-8874	Sequence 8874, Ap
c 471	12.8	0.3	17	1	US-09-866-108A-10317	Sequence 10317, A

ALIGNMENTS

RESULT 1

US-08-318-193-65/c
; Sequence 65, Application US/08318193
; Patent No. 5641663
; GENERAL INFORMATION:
; APPLICANT: GARVIN, Robert T.
; APPLICANT: MALEK, Lawrence T.
; TITLE OF INVENTION: AN EXPRESSION SYSTEM FOR THE SECRETION
; TITLE OF INVENTION: OF BIOACTIVE HUMAN GRANULOCYTE MACROPHAGE COLONY
; TITLE OF INVENTION: STIMULATING FACTOR (GM-CSF) AND OTHER HETEROLOGOUS
; TITLE OF INVENTION: PROTEINS FROM STREPTOMYCES
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 1800 Diagonal Road, Suite 500
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22313-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/318,193
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/935,314
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; APPLICATION NUMBER: US 07/224,568
; NAME: BENT, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 18740/116 CACO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)836-9300
; TELEFAX: (703)683-4109
; TELEX: 899149
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid;
; DESCRIPTION: Synthetic DNA oligonucleotide
; ANTI-SENSE: YES
US-08-318-193-65

Query Match 0.5%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 46;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 408 CGGCCTCTCGGCGCTGTC 429
DB 22 CGCGCGCTCCGGGCGTCGCG 1

RESULT 2

US-08-531-556-51/c
; Sequence 51, Application US/08531556
; Patent No. 5776682
; GENERAL INFORMATION:
; APPLICANT: Agoulnik, Alexander I
; APPLICANT: Kent First, Marijo
; APPLICANT: Muallem, Ariege
; TITLE OF INVENTION: MALE INFERTILITY Y-DELETION DETECTION
; NUMBER OF SEQUENCES: 124
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dewitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: WI
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/531,556
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 34506.034CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 608-831-2100
; TELEFAX: 608-831-2106
; INFORMATION FOR SEQ ID NO: 51:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-531-556-51

Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 50;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGGTTCCAGCGCTTCATGTG 1698
DB 20 CAGTTCAGTGTTCATGTG 1

RESULT 3

US-08-531-556-63/c
; Sequence 63, Application US/08531556
; Patent No. 5776682
; GENERAL INFORMATION:
; APPLICANT: Agoulnik, Alexander I
; APPLICANT: Kent First, Marijo
; APPLICANT: Muallem, Ariege
; TITLE OF INVENTION: MALE INFERTILITY Y-DELETION DETECTION
; NUMBER OF SEQUENCES: 124
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dewitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison

STATE: WI
COUNTRY: USA
ZIP: 53717-1914
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/531,556
FILING DATE:

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 34506.034CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-831-2100
TELEFAX: 608-831-2106
INFORMATION FOR SEQ ID NO: 63:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-531-556-63

Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 50;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGGTTCCAGCGCTTCATGTG 1698
DB 20 CAGTTCAGTGTTCATGTG 1

RESULT 4

US-08-472-416-51/c
; Sequence 51, Application US/08472416
; Patent No. 5783390
; GENERAL INFORMATION:
; APPLICANT: Agoulnik, A.
; APPLICANT: Kent, Marijo G.
; TITLE OF INVENTION: MALE INFERTILITY Y-DELETION DETECTION
; TITLE OF INVENTION: BATTERY
; NUMBER OF SEQUENCES: 94
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dewitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: WI
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,416
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 34506.034
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 608-831-2100
; TELEFAX: 608-831-2106
; INFORMATION FOR SEQ ID NO: 51:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-472-416-51
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 50;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGGTTCCAGCGCTTCATGTG 1698
Db 20 CAGTTCAGTGCCTTCATGTG 1

RESULT 5
US-08-472-416-63/c
; Sequence 63, Application US/08472416
; Patent No. 5783390
; GENERAL INFORMATION:
; APPLICANT: Agoulnik, A.
; APPLICANT: Kent, Marijo G.
; TITLE OF INVENTION: MALE INFERTILITY Y-DELETION DETECTION
; TITLE OF INVENTION: BATTERY
; NUMBER OF SEQUENCES: 94
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DeWitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: WI
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,416
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 34506.034
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 608-831-2100
; TELEFAX: 608-831-2106
; INFORMATION FOR SEQ ID NO: 63:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-472-416-63
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 50;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CGGTTCCAGCGCTTCATGTG 1698
Db 20 CAGTTCAGTGCCTTCATGTG 1

RESULT 6
US-08-777-266A-6/c
; Sequence 6, Application US/08777266A
; Patent No. 6077833
; GENERAL INFORMATION:
; APPLICANT: Clarence Frank Bennett
; APPLICANT: Timothy A. Vickers
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; TITLE OF INVENTION: Modulation of the Expression of B7 Protein
; NUMBER OF SEQUENCES: 125
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0201
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-777-266A-6
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 50;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3669 AAGTGATATATGTTTTTAAT 3688
Db 20 AAGTGATACATGTTTTTAAT 1

RESULT 7
US-09-326-186B-6/c
; Sequence 6, Application US/09326186B
; Patent No. 6319906
; GENERAL INFORMATION:
; APPLICANT: Bennett, Clarence Frank
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; TITLE OF INVENTION: Modulation of the Expression of B7 Protein
; FILE REFERENCE: ISPH-0376
; CURRENT APPLICATION NUMBER: US/09/326,186B
; CURRENT FILING DATE: 1999-06-04
; PRIOR APPLICATION NUMBER: 08/777,266
; PRIOR FILING DATE: 1996-12-31
; NUMBER OF SEQ ID NOS: 226
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-326-186B-6
Query Match 0.5%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 50;
```

```
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3669 AAGTCATATATGCTTTTAAAT 3688
DB 20 AAGTGATACATGTTTAAAT 1

RESULT 8
US-08-890-980-64
; Sequence 64, Application US/08890980
; Patent No. 5998141
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; TITLE OF INVENTION: SR-B1 NUCLEIC ACIDS AND USES THEREFOR
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 10-JUL-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: MIA-005.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
US-08-890-980-64

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
DB 1 TTGAGGCTGAAGGAATGA 18

RESULT 10
US-09-032-894-64
; Sequence 64, Application US/09032894
; Patent No. 6130041
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; TITLE OF INVENTION: SR-BI NUCLEIC ACIDS AND USES THEREFOR
; FILE REFERENCE: MIA-005.03
; CURRENT APPLICATION NUMBER: US/09/032,894
; CURRENT FILING DATE: 1998-02-27
; EARLIER APPLICATION NUMBER: 08/890,980
; EARLIER FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
US-09-032-894-64

Query Match 0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
DB 1 TTGAGGCTGAAGGAATGA 18

RESULT 11
US-09-031-626-64
; Sequence 64, Application US/09031626
; Patent No. 6228581
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; APPLICANT: Ordovas, Jose M.
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS AND KITS FOR BODY MASS AND
```

```
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS
; FILE REFERENCE: MIA-005.04
; CURRENT APPLICATION NUMBER: US/09/031,626
; CURRENT FILING DATE: 1998-02-27
; EARLIER APPLICATION NUMBER: 08/890,979
; EARLIER FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
US-09-031-626-64

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
Db 1 TTGAGGCTGAAGGAATGA 18

RESULT 12
US-08-656-906-3
; Sequence 3, Application US/08656906
; Patent No. 5972901
; GENERAL INFORMATION:
; APPLICANT: Ferkol Jr., Thomas W.
; APPLICANT: Davis, Pamela B.
; APPLICANT: Ziady, Assem-Galal
; TITLE OF INVENTION: Serpin Enzyme Complex Receptor -
; TITLE OF INVENTION: Mediated Gene Transfer
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/656,906
; FILING DATE: 03-JUN-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US 08/
; FILING DATE: 03-JUN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO WO 95/25809
; FILING DATE: 23-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/216,534
; FILING DATE: 23-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: CASE-02280
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
```

```
US-08-656-906-3

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2568 TTCTTCTCTCTCTCTCTTTT 2585
Db 2 TTCTTCTCTCTCTCTCTTTT 19

RESULT 13
US-09-217-847-3
; Sequence 3, Application US/09217847
; Patent No. 6200801
; GENERAL INFORMATION:
; APPLICANT: Ferkol Jr., Thomas W.
; APPLICANT: Davis, Pamela B.
; APPLICANT: Ziady, Assem-Galal
; TITLE OF INVENTION: Serpin Enzyme Complex Receptor -
; TITLE OF INVENTION: Mediated Gene Transfer
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/217,847
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: 08/656,906
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO WO 95/25809
; FILING DATE: 23-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/216,534
; FILING DATE: 23-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: CASE-02280
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-217-847-3

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2568 TTCTTCTCTCTCTCTTTT 2585
Db 2 TTCTTCTCTCTCTCTTTT 19

RESULT 14
```

US-08-896-410-18
; Sequence 18, Application US/08896410
; Patent No. 5834310
; GENERAL INFORMATION:
; APPLICANT: The Government of the United States of America,
; APPLICANT: as represented by the Secretary, Department of Health and Human
; APPLICANT: Services
; TITLE OF INVENTION: Mammalian Muscle NAD:Arginine
; TITLE OF INVENTION: ADP-ribosyltransferase
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th floor
; CITY: Newport
; STATE: California
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/896,410
; FILING DATE: 18-JUL-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/454,556
; FILING DATE: May 30, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Anita M. Kirkpatrick
; REGISTRATION NUMBER: 32,617
; REFERENCE/DOCKET NUMBER: NIH039.001DV1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-08-896-410-18

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 72;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 885 GCTCTGGAGCTAGTGGTCCC 905
DB 1 GCTCTAGAACTAGTGGATCCC 21

RESULT 15
US-09-470-443-39/c
; Sequence 39, Application US/09470443
; Patent No. 6441156
; GENERAL INFORMATION:
; APPLICANT: Lerman, Michael I.
; APPLICANT: Minna, John D.
; APPLICANT: Latif, Farida
; APPLICANT: Wei, Ming-Hui
; APPLICANT: Sekido, Yoshitaka
; APPLICANT: Gao, Boming
; APPLICANT: Duh, Fuh-Mei
; TITLE OF INVENTION: Calcium Channel Compositions and Methods of Use Thereof
; FILE REFERENCE: NIH-05043
; CURRENT APPLICATION NUMBER: US/09/470,443
; CURRENT FILING DATE: 1999-12-22
; EARLIER APPLICATION NUMBER: 60/114,359
; EARLIER FILING DATE: 1998-12-30
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: Patent In Ver. 2.0

; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE: Description of Artificial Sequence: Synthetic
US-09-470-443-39

Query Match 0.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 72;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2305 CGGATTTTCAACTGGCCCAAC 2325
DB 21 CGTATGTTCAACTGGCCCATCC 1

RESULT 16
US-09-657-472-683/c
; Sequence 683, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 683
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-683

Query Match 0.4%; Score 16; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 80;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2562 CCAGCTTTCTTCTTCTTT 2579
DB 21 CCAGCTTCTCTTCTTT 4

RESULT 17
US-09-696-791-3363
; Sequence 3363, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 3363
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens

; FEATURE:
; OTHER INFORMATION: Cyclin B1 ribozyme binding site
US-09-696-791-3363

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 77;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3441 CTGCCATGCTTTTACAG 3459
|||||
Db 1 CTGCCATGCTTTTATTCAG 19

RESULT 18
US-09-488-671-25
; Sequence 25, Application US/09488671A
; Patent No. 6187545
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF PEPCK-CYTOSOLIC EXPRESSION
; FILE REFERENCE: RTS-0123
; CURRENT APPLICATION NUMBER: US/09/488,671A
; CURRENT FILING DATE: 2000-01-21
; NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-488-671-25

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 959 GAGCGGAATTTCTGCAGA 977
|||||
Db 2 GAGGAGCATTTCTGCAGA 20

RESULT 19
US-09-429-322-15/c
; Sequence 15, Application US/09429322A
; Patent No. 6190869
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF PROTEIN KINASE C-THETA
; FILE REFERENCE: RTS-0100
; CURRENT APPLICATION NUMBER: US/09/429,322A
; CURRENT FILING DATE: 1999-10-26
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-429-322-15

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3272 TCCTTCACACTTTGTCAGG 3290
|||||
Db 19 TCCTGCCAGTCTTGTGAGG 1

RESULT 20
US-09-313-932-360/c
; Sequence 360, Application US/09313932A
; Patent No. 6228642
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TNF-
; FILE REFERENCE: ISPH-0356
; CURRENT APPLICATION NUMBER: US/09/313,932A
; CURRENT FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 501
; SEQ ID NO 360
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-313-932-360

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 486 CATCTGGAATCAAGACC 504
|||||
Db 20 CATCTGGAATCTGGAGACC 2

RESULT 21
US-09-593-711A-62
; Sequence 62, Application US/09593711A
; Patent No. 6271030
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTS-0118
; CURRENT APPLICATION NUMBER: US/09/593,711A
; CURRENT FILING DATE: 2000-06-14
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-62

Query Match 0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2182 AGCTGCTCTCCATCTTCT 2200
|||||
Db 1 AGCTGCTCCACCTTCTTCT 19

RESULT 22
US-09-198-452A-5256
; Sequence 5256, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; thereof and uses thereof, in particular for the diagnosis, prevention
; and treatment of infection
; FILE REFERENCE: 9710-003-999


```
;
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5256
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-5256

Query Match          0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 966 AATTTCGACGAGCTGCT 984
Db 2 AATCTCGAAGCTGCT 20

RESULT 23
US-09-692-820A-3/C
; Sequence 3, Application US/09692820A
; Patent No. 6602674
; GENERAL INFORMATION:
; APPLICANT: O'Brien, Timothy J.
; APPLICANT: Underwood, Lowell J.
; APPLICANT: Tanimoto, Hirocoshi
; APPLICANT: Shigemasa, Kazushi
; TITLE OF INVENTION: Uses of Antileukoprotease in Carcinoma
; FILE REFERENCE: D6247
; CURRENT APPLICATION NUMBER: US/09/692,820A
; CURRENT FILING DATE: 2000-01-18
; PRIOR APPLICATION NUMBER: US 60/159,972
; PRIOR FILING DATE: 1999-10-18
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Microsoft Word 98
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Forward oligonucleotide primer for PCR amplification of
; OTHER INFORMATION: antileukoprotease
US-09-692-820A-3

Query Match          0.4%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1904 CAGACTCCACCTTGAGG 1922
Db 19 CAGACTCCAGCTTTGAAG 1

RESULT 24
US-08-173-489C-118
; Sequence 118, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT

;
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 118:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 bases
; TYPE: nucleic acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from beta-globin
; DESCRIPTION: sequence region in Seq ID No. 5861244117
; HYPOTHETICAL: yes
; ANTI-SENSE: no
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 118 :FROM 1 TO 21
US-08-173-489C-118

Query Match          0.4%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 88;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTTCTCTCTTTTTC 2587
Db 3 TCTTCTCTTTTCTTTC 21

RESULT 25
US-08-851-350-23
; Sequence 23, Application US/08851350
; Patent No. 6057122
; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: NOVEL ANTIANGIOGENIC PEPTIDES,
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING SAME AND METHODS
; TITLE OF INVENTION: FOR INHIBITING ANGIOGENESIS
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851,350
; FILING DATE: 05-MAY-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Casuto, Dianne
; REGISTRATION NUMBER: 40,943
; REFERENCE/DOCKET NUMBER: 5940.US.P2
```



```
Qy 2995 GAGATTTTTTGGCTTC 3013
Db 20 GGGCTTTTTTGGCTTC 2

RESULT 29
US-09-422-978-6580/c
; Sequence 6580, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPL
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6580
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-12595 for SEQ 2646,
US-09-422-978-6580

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 88;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 468 CCTGTACCTTGTCTCA 484
Db 18 CCTGTACCTTGTCTCA 2

RESULT 30
US-08-222-177A-375
; Sequence 375, Application US/08222177A
; Patent No. 5592979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DeWitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
```

```
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865.601
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 375:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: mfd118p2
US-08-222-177A-375

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 94;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2057 AGCCTCAGAGACCTGG 2073
Db 2 AGCCTCAGAGACCTGG 18

RESULT 31
US-08-650-766-14/c
; Sequence 14, Application US/08650766D
; Patent No. 6015690
; GENERAL INFORMATION:
; APPLICANT: PILETZ, John E.
; APPLICANT: IVANOV, Tina R.
; TITLE OF INVENTION: DNA SEQUENCE ENCODING A HUMAN IMIDAZOLINE RECEPTOR AND
; TITLE OF INVENTION: METHOD FOR CLONING THE SAME
; FILE REFERENCE: Corrected Sequence Listing
; Patent No. 6015690
; CURRENT APPLICATION NUMBER: US/08/650,766D
; CURRENT FILING DATE: 1996-05-20
; EARLIER APPLICATION NUMBER: US 60/012,600
; EARLIER FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-650-766-14

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1756 TGGCTCATCTTTCTCTC 1772
Db 19 TGGCTCATCTTTCTCTC 3

RESULT 32
US-08-922-635-13/c
; Sequence 13, Application US/08922635A
; Patent No. 6033871
; GENERAL INFORMATION:
; APPLICANT: PILETZ, John E.
; APPLICANT: IVANOV, Tina R.
; TITLE OF INVENTION: DNA MOLECULES ENCODING IMIDALINE RECEPTIVE POLYPEPTIDES
; TITLE OF INVENTION: AND POLYPEPTIDES ENCODED THEREBY
; FILE REFERENCE: Corrected Sequence Listing
; Patent No. 6033871
; CURRENT APPLICATION NUMBER: US/08/922,635A
; CURRENT FILING DATE: 1997-09-03
; EARLIER APPLICATION NUMBER: 08/650,766
; EARLIER FILING DATE: 1996-05-20
```

;
; EARLIER APPLICATION NUMBER: 60/012,600
; EARLIER FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-922-635-13

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1756 TGGCTCATCTTCTCTC 1772
Db 19 TGGCTCACCTTCTCTC 3

RESULT 33

US-09-428-584-19
; Sequence 19, Application US/09428584
; Patent No. 6136604
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF METHIONINE AMINOPEPTIDASE 2 EXPRESSION
; FILE REFERENCE: RTS-0114
; CURRENT APPLICATION NUMBER: US/09/428,584
; CURRENT FILING DATE: 1999-10-27
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-428-584-19

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2568 TTCTTCTCTTTTCTT 2584
Db 3 TTCTTCTCTTTTCTT 19

RESULT 34

US-09-490-692-157
; Sequence 157, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTS-0120
; CURRENT APPLICATION NUMBER: US/09/490,692
; CURRENT FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 157
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-157

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 CTCCTTCTCTTCTCA 2236

Db 4 CTCCTTCTCTTCTTCA 20

RESULT 35

US-09-593-711A-95
; Sequence 95, Application US/09593711A
; Patent No. 6271030
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTS-0118
; CURRENT APPLICATION NUMBER: US/09/593,711A
; CURRENT FILING DATE: 2000-06-14
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-95

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1423 CCCCCAAAAGGCTCTGT 1439
Db 4 CCCCCAAAAGGCTTGT 20

RESULT 36

US-09-488-744A-46
; Sequence 46, Application US/09488744A
; Patent No. 6287860
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEK2 EXPRESSION
; FILE REFERENCE: RTS-0108
; CURRENT APPLICATION NUMBER: US/09/488,744A
; CURRENT FILING DATE: 2000-01-20
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-488-744A-46

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1311 GCTTCAAGATAATGGAT 1327
Db 2 GCTTAAAGATAATGGAT 18

RESULT 37

US-09-780-175-38/c
; Sequence 38, Application US/09780175
; Patent No. 6440738
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Susan M. Freier

```
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASEIN KINASE 2-BETA EXPRESSION
; FILE REFERENCE: RTS-0164
; CURRENT APPLICATION NUMBER: US/09/780,175
; CURRENT FILING DATE: 2001-02-08
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-780-175-38

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 CTCCTCCGGCGCTCGT 428
DB 20 CTCCTCCGGCGCTTCGT 4

RESULT 38
US-09-898-361-98
; Sequence 98, Application US/09898361
; Patent No. 6503152
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0158
; CURRENT APPLICATION NUMBER: US/09/898,361
; CURRENT FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-898-361-98

Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 265 GGAGCCCGGAGGGGC 281
DB 4 GGAGCCCGGAGGAGGC 20

RESULT 39
US-09-422-978-6240/c
; Sequence 6240, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6240
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-10304 for SEQ 2306,
US-09-422-978-6240
```

```
Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1918 GGAGGAATCAGTCAGG 1934
DB 18 GGAGGAATCAGAGG 2
```

```
RESULT 40
US-09-389-487-14/c
; Sequence 14, Application US/09389487
; Patent No. 6576742
; GENERAL INFORMATION:
; APPLICANT: PILETZ, John E.
; APPLICANT: IVANOV, Tina R.
; TITLE OF INVENTION: DNA SEQUENCE ENCODING A HUMAN IMIDAZOLINE RECEPTOR AND
; TITLE OF INVENTION: METHOD FOR CLONING THE SAME
; FILE REFERENCE: Corrected Sequence Listing
; Patent No. 6576742
; CURRENT APPLICATION NUMBER: US/09/389,487
; CURRENT FILING DATE: 1999-09-03
; EARLIER APPLICATION NUMBER: US 08/650,766
; EARLIER FILING DATE: 1996-05-20
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patent in ver. 2.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-389-487-14
```

```
Query Match          0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1756 TGGCTCATCTTCTCTC 1772
DB 19 TGGCTCACCTTTCTCTC 3
```

```
RESULT 41
US-09-544-398B-467/c
; Sequence 467, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 467
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-467

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2997 GATTTTTCCTTC 3013
Db 18 GATTTTTCCTTC 2

RESULT 42
US-08-107-411-5
; Sequence 5, Application US/08107411
; Patent No. 5340726
; GENERAL INFORMATION:
; APPLICANT: Waxman, Lloyd
; APPLICANT: Connolly, Thomas M.
; APPLICANT: Keller, Paul
; TITLE OF INVENTION: PROTEIN FOR INHIBITING
; TITLE OF INVENTION: COLLAGEN-STIMULATED PLATELET AGGREGATION
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O. Box 2000
; CITY: Rahway
; STATE: N.J.
; COUNTRY: USA
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/107,411
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/844,303
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Parr, Richard S.
; REGISTRATION NUMBER: 32,586
; REFERENCE/DOCKET NUMBER: 18415
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908) 594-4958
; TELEFAX: (908) 594-4720
; TELEX: ( ) 138825
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
US-08-107-411-5

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 885 GCTCTGGAGCTAGTGTTCC 904
Db 1 GCTCTAGAACTAGTGGATCC 20

RESULT 43
US-08-346-774-6
; Sequence 6, Application US/08346774
; Patent No. 5512444
```

```
; GENERAL INFORMATION:
; APPLICANT: Patard, Jean-Jacques; Brasseur, Francis;
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Method For Determining Bladder
; TITLE OF INVENTION: Tumors By Assaying For MAGE-1, 2, 3 OR 4
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/346,774
; FILING DATE: 30-NOVEMBER-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/204,727
; FILING DATE: 1-MARCH-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 551244man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5359.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-346-774-6

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 342 GAAGAGGAGAGACCGGATTG 361
Db 1 GAAGAGGAGAGACCGGCTTG 20

RESULT 44
US-08-146-504-16
; Sequence 16, Application US/08146504
; Patent No. 5605662
; GENERAL INFORMATION:
; APPLICANT: Heller, Michael J.; and Tu, Eugene
; TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
; TITLE OF INVENTION: MICROELECTRONIC SYSTEMS AND DEVICES FOR
; TITLE OF INVENTION: MOLECULAR BIOLOGICAL ANALYSIS AND
; TITLE OF INVENTION: DIAGNOSTICS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
```

```

US-08-209-172-4
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      342 GAAGAGGAAGAACCGGATTG 361
      |||||
Db      1 GAAGAGGAAGAACCGGTCIG 20

RESULT 46
US-08-379-593-5
; Sequence 5, Application US/08379593
; Patent No. 5849480
; GENERAL INFORMATION:
; APPLICANT: Cros, Philippe
; APPLICANT: Kurfurst, Robin
; APPLICANT: Battail, Nicole
; APPLICANT: Piga, Nadia
; TITLE OF INVENTION: HAPTEN ASSAY DEVICE AND USE THEREOF
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OLIFF & BERRIDGE
; STREET: 700 South Washington Street, Suite 300
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Floppy disk, 1.44M storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,593
; FILING DATE: 02-FEB-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Berridge, William P.
; REGISTRATION NUMBER: 30,024
; REFERENCE/DOCKET NUMBER: WPB 36056
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6400
; TELEFAX: 703-836-2787
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "SYNTHETIC DNA"
; FEATURE:
; OTHER INFORMATION: consists of nucleosides with an alpha anomer and carries
US-08-379-593-5

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2567 TTCTCTCTCTCTCTCTCTCTCTT 2586
      |||||
Db      1 TTTTCTCTCTCTCTCTCTCTCTT 20

RESULT 47
US-08-725-976-16
; Sequence 16, Application US/08725976
; Patent No. 5929208
; GENERAL INFORMATION:
; APPLICANT: Heller, Michael J. and Tu, Eugene
; TITLE OF INVENTION: METHOD FOR ELECTRONIC SYNTHESIS OF POLYMERS

```



```
;
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other
US-08-997-362-83

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db 20 TTTTCTCTCTCTCTCTCTCTTTT 1

RESULT 50
US-09-018-422-4
; Sequence 4, Application US/09018422A
; Patent No. 5985571
; GENERAL INFORMATION:
; APPLICANT: Van Baren, Nicolas
; APPLICANT: Brasseur, Francis
; APPLICANT: Boon-Falheur, Thierry
; TITLE OF INVENTION: Method For Determining Multiple Myeloma By
; TITLE OF INVENTION: Assaying For
; TITLE OF INVENTION: Expression of MAGE Genes
; FILE REFERENCE: LUD 5527-JEL
; CURRENT APPLICATION NUMBER: US/09/018,422A
; CURRENT FILING DATE: 1998-02-04
; NUMBER OF SEQ ID NOS: 12
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-09-018-422-4

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 342 GAAGAGGAAGAACCGGATTG 361
Db 1 GAAGAGGAAGAACCGGCTG 20

RESULT 51
US-08-965-780-1
; Sequence 1, Application US/08965780
; Patent No. 5986084
; GENERAL INFORMATION:
; APPLICANT: Pitsch, Stefan
; APPLICANT: Weiss, Patrick A.
; APPLICANT: Jenny, Luzi
; TITLE OF INVENTION: RIBONUCLEOSIDE-DERIVATIVE AND METHOD FOR
; TITLE OF INVENTION: PREPARING THE SAME
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KUBOVCIK & KUBOVCIK
; STREET: 900 17th Street, N.W., Suite 990
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/965,780

; FILING DATE: 07-NOV-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: CH 01931/97
; FILING DATE: 18-AUG-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubovcik, Ronald J.
; REGISTRATION NUMBER: 25,401
; REFERENCE/DOCKET NUMBER: FREI-002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-887-9023
; TELEFAX: 202-887-9093
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "oligoribonucleotide"
US-08-965-780-1

Query Match
Best Local Similarity 0.4%; Score 15.2; DB 1; Length 20;
Matches 0; Conservative 17; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTTTT 2586
Db 1 UUUUUUUUUUUUUUUUUUUU 20

RESULT 52
US-08-873-970-83/c
; Sequence 83, Application US/08873970
; Patent No. 6001361
; GENERAL INFORMATION:
; APPLICANT: Tan, Paul
; APPLICANT: Hiyama, Jun
; APPLICANT: Visser, Elizabeth
; APPLICANT: Skinner, Margot
; APPLICANT: Scott, Linda
; APPLICANT: Prestidge, Ross
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR
; TITLE OF INVENTION: TREATMENT AND DIAGNOSIS OF MYCOBACTERIAL INFECTIONS
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Ann W. Speckman
; STREET: 2601 Elliott Avenue, Suite 4185
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98121
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/873,970
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/705,347
; FILING DATE: 29-AUG-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Sleath, Janet
; REGISTRATION NUMBER: 37,007
; REFERENCE/DOCKET NUMBER: 11000.1002C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-269-0565
; TELEFAX: 206-269-0563
; TELEX:
; INFORMATION FOR SEQ ID NO: 83:
```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other
US-08-873-970-83

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTCT 2586
||| ||| ||| ||| ||| ||| ||| |||
DB 20 TTTTCTCTCTCTCTCTCTCTCTCT 1

RESULT 53

US-09-120-853-14/c
; Sequence 14, Application US/09120853
; Patent No. 6057437
; GENERAL INFORMATION:
; APPLICANT: Kamiya, Kinya
; APPLICANT: Matsuda, Yoko
; APPLICANT: Uchida, Kiyoshi
; TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID COMPOUND
; FILE REFERENCE: 07898/030001
; CURRENT APPLICATION NUMBER: US/09/120,853
; CURRENT FILING DATE: 1998-07-21
; EARLIER APPLICATION NUMBER: JP 213838/1997
; EARLIER FILING DATE: 1997-07-25
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Artificial
; OTHER INFORMATION: nucleic acid sequence
US-09-120-853-14

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2216 TTCTCTCTCTCTCTCTCTCTCT 2235
||| ||| ||| ||| ||| ||| ||| |||
DB 20 TTCTCTCTCTCTCTCTCTCTCTCC 1

RESULT 54

US-09-428-584-20
; Sequence 20, Application US/09428584
; Patent No. 6136604
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF METHIONINE AMINOPEPTIDASE 2 EXPRESSION
; FILE REFERENCE: RTS-0114
; CURRENT APPLICATION NUMBER: US/09/428,584
; CURRENT FILING DATE: 1999-10-27
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-428-584-20

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2567 TTCTCTCTCTCTCTCTCTCTTT 2586
||| ||| ||| ||| ||| ||| ||| |||
DB 1 TCTCTCTCTCTCTCTCTCTCTTTT 20

RESULT 55

US-08-765-340-96
; Sequence 96, Application US/08765340
; Patent No. 6150092
; GENERAL INFORMATION:
; APPLICANT: UCHIDA, K.,
; APPLICANT: UCHIDA, T.,
; APPLICANT: TANAKA, Y.,
; APPLICANT: MATSUDA, Y.,
; APPLICANT: KONDO, S.,
; TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
; TITLE OF INVENTION: COMPOUND
; NUMBER OF SEQUENCES: 185
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version
; SOFTWARE: #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/765,340
; FILING DATE: 23-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 145146/94
; FILING DATE: 27-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 311130/94
; FILING DATE: 21-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: SERUNIAN, LESLIE
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 1452-4005
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
US-08-765-340-96

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTTTT 2586
||| ||| ||| ||| ||| ||| ||| |||
DB 1 TTTTCTCTCTCTCTCTCTCTTTT 20

RESULT 56

US-09-095-855-83/c
; Sequence 83, Application US/09095855
; Patent No. 6160093
; GENERAL INFORMATION:

```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-09-351-351-4

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      342 GAAGAGGAAGAAGCCGGATTG 361
      |||||
Db       1 GAAGAGGAAGAAGCCGGTCTG 20

RESULT 58
US-09-407-675-1/c
; Sequence 1, Application US/09407675
; Patent No. 6169176
; GENERAL INFORMATION:
; APPLICANT: Bruice, Thomas C.
; TITLE OF INVENTION: DEOXYNUCLEIC ALKYL THIUREA COMPOUNDS AND USES THEREOF
; FILE REFERENCE: 30448.55US02
; CURRENT APPLICATION NUMBER: US/09/407,675
; CURRENT FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: 09/347,443
; PRIOR FILING DATE: 1999-07-02
; PRIOR APPLICATION NUMBER: 60/091,481
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/111,800
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Oligo 1
US-09-407-675-1

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2567 TTCTCTCTCTCTCTCTCTCTTT 2586
      |||||
Db       20 TTTTCTCTCTCTCTCTCTTT 1

RESULT 59
US-09-250-075-1
; Sequence 1, Application US/09250075
; Patent No. 6207819
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Maier, Martin A
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of
; FILE REFERENCE: ISIS3299
; CURRENT APPLICATION NUMBER: US/09/250,075
; CURRENT FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)

```


Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 586 AACATATATAAAGACAACTT 605
DB 20 AACATATGAATAACACTT 1

RESULT 64
US-09-324-542-83/c
; Sequence 83, Application US/09324542
; Patent No. 6328978
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Tan, Paul L.J.
; APPLICANT: Prestidge, Ross
; TITLE OF INVENTION: Methods and Compounds for the Treatment
; TITLE OF INVENTION: of Immunologically-Mediated Skin Disorders
; FILE REFERENCE: 11000.1007c1
; CURRENT APPLICATION NUMBER: US/09/324,542
; CURRENT FILING DATE: 1999-06-02
; EARLIER APPLICATION NUMBER: US 08/997,080
; EARLIER FILING DATE: 1997-12-23
; NUMBER OF SEQ ID NOS: 194
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Made in a lab
US-09-324-542-83

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTCTT 2586
DB 20 TTTTCTCTCTCTCTCTCTCTT 1

RESULT 65
US-09-705-160-4
; Sequence 4, Application US/09705160
; Patent No. 6387630
; GENERAL INFORMATION:
; APPLICANT: Van Baren, Nicolas
; APPLICANT: Brasseur, Francis
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: METHOD FOR DIAGNOSING LEUKEMIA BY DETERMINING
; TITLE OF INVENTION: TUMOR REJECTION ANTIGEN PRECURSORS
; FILE REFERENCE: LUD 5527.3-JEL/MAS
; CURRENT APPLICATION NUMBER: US/09/705,160
; CURRENT FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: US 09/183,931
; PRIOR FILING DATE: 1998 - 10 - 30
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE: PCR primer
; OTHER INFORMATION: Synthesized by oligonucleotide synthesis machine
US-09-705-160-4

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 342 GAAGAGGAGAACCGGATTG 361

DB 1 GAAGAGGAGAACCGGTTCTG 20

RESULT 66
US-09-205-426-83/c
; Sequence 83, Application US/09205426
; Patent No. 6406704
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Tan, Paul L. J.
; TITLE OF INVENTION: Compounds and Methods for Treatment and
; TITLE OF INVENTION: Diagnosis of Mycobacterial Infections
; FILE REFERENCE: 11000.1002c4
; CURRENT APPLICATION NUMBER: US/09/205,426
; CURRENT FILING DATE: 1998-12-04
; EARLIER APPLICATION NUMBER: 09/095,855
; EARLIER FILING DATE: 1998-06-11
; EARLIER APPLICATION NUMBER: 08/997,362
; EARLIER FILING DATE: 1997-12-23
; EARLIER APPLICATION NUMBER: 08/873,970
; EARLIER FILING DATE: 1997-06-12
; EARLIER APPLICATION NUMBER: 08/705,347
; EARLIER FILING DATE: 1996-08-29
; NUMBER OF SEQ ID NOS: 208
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Made in a lab
US-09-205-426-83

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTCTT 2586
DB 20 TTTTCTCTCTCTCTCTCTT 1

RESULT 67
US-09-619-103-26/c
; Sequence 26, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
; APPLICANT: Kurz, Markus
; APPLICANT: Lohse, Peter
; APPLICANT: Wagner, Richard
; TITLE OF INVENTION: Peptide Acceptor Ligation Methods
; FILE REFERENCE: 50036/031002
; CURRENT APPLICATION NUMBER: US/09/619,103
; CURRENT FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/145,834
; PRIOR FILING DATE: 1999-07-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-26

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCTCTCTCTCTCTT 2586
DB 20 TTTTCTCTCTCTCTCTT 1

Db 20 TTTTTCCTTTTTTTTTTTTTTT

RESULT 68
US-09-726-096A-1
; Sequence 1, Application US/09726096A
; Patent No. 6462184
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Maier, Martin A.
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Backbone Polymers
; FILE REFERENCE: ISIS4528
; CURRENT APPLICATION NUMBER: US/09/726,096A
; PRIOR FILING DATE: 2000-11-29
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; NAME/KEY: misc feature
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc.feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-methoxyethoxy (MOE)

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.le+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTCTCCTCTCTTTT 2586
 ||||| ||||||||
DB 1 TTTTTCCTTTTTTTTTTT 20

RESULT 69
US-09-844-521-33
; Sequence 33, Application US/09844521
; Patent No. 6492172
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Harris Busch
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF GU PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0163
; CURRENT APPLICATION NUMBER: US/09/844,521
; PRIORITY FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; NAME/KEY: Antisense oligonucleotide
; OTHER INFORMATION:

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.le+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2137 TCCTCACTGTGATCAA 2156
 ||||| ||||| |||||
DB 1 TCCTCCACTTGACGAAA 20

RESULT 70
US-09-603-830-55/c
; Sequence 55, Application US/09603830
; Patent No. 6506564
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 4149-1-1-1
; CURRENT APPLICATION NUMBER: US/09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR FILING DATE: 1997-07-21
; PRIOR FILING DATE: 1999-01-29
; PRIOR FILING DATE: 1999-04-26
; PRIOR FILING DATE: 2000-06-25
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20


```
US-09-976-971A-55/c
; Sequence 55, Application US/09976971A
; Patent No. 6682895
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-118
; CURRENT APPLICATION NUMBER: US/09/976,971A
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-976-971A-55
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2567 TTTCTTCTCTCTTTTTTTTTT 2586
      ||| ||| ||| ||| ||| ||| |||
Db 20 TTTTCTTTTTTTTTTTTTTTTTT 1

RESULT 80
US-09-032-438C-53/c
; Sequence 53, Application US/09032438C
; Patent No. 6713300
; GENERAL INFORMATION:
; APPLICANT: Ratner, Amir
; APPLICANT: Sun, Hui
; APPLICANT: Lupecki, James R.
; APPLICANT: Nathans, Jeremy
; APPLICANT: Anderson, Kent L.
; APPLICANT: Leppert, Mark
; APPLICANT: Dean, Michael
; APPLICANT: Singh, Nanda
; APPLICANT: Shroyer, No. 6713300h F.
; APPLICANT: Smallwood, Philip M.
; APPLICANT: Allikmets, Rando
; APPLICANT: Lewis, Richard A.
; APPLICANT: Li, Yixin
; TITLE OF INVENTION: Nucleic Acid And Amino Acid Sequences For ATP-Binding Cassette
; TITLE OF INVENTION: Transporter And Methods Of Screening For Agents That Modify
; FILE REFERENCE: BYLR-0065
; CURRENT APPLICATION NUMBER: US/09/032,438C
; CURRENT FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: US 60/039,388
; PRIOR FILING DATE: 1997-02-27
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-09-032-438C-53
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1296 GTTGTGCTGCAGAGCTTC 1315
      ||| ||| ||| ||| ||| ||| |||
Db 20 GCTTGTGCAGAGAGCTTC 1

RESULT 81
US-09-976-577-55/c
; Sequence 55, Application US/09976577
; Patent No. 6720147
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
```



```

; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-16
; CURRENT APPLICATION NUMBER: US/09/967,409A
; CURRENT FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-967-409A-55

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps

QY 2567 TTCTTCCTCTCTTTTTTTT 2586
DB 20 TTTTCTTTTTTTTTTTTTT 1

RESULT 85
US-09-820-279D-55/c
; Sequence 55, Application US/09820279D
; Patent No. 6750016
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; APPLICANT: Garimella, Viswanadham
; APPLICANT: Li, zhi
; APPLICANT: Park, So-Jung
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-1085-A
; CURRENT APPLICATION NUMBER: US/09/820,279D
; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13

```


RESULT 91
US-09-527-030G-114
; Sequence 114, Application US/09527030G
; Patent No. 6482598
; GENERAL INFORMATION:
; APPLICANT: VAN DOORN, Leen-Jan et al.
; TITLE OF INVENTION: Detection and identification of a

```

; INFORMATION FOR SEQ ID NO:
;
; SEQUENCE CHARACTERISTICS:
;     LENGTH: 18 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: both
;     TOPOLOGY: both
;     MOLECULE TYPE: cdna
; US-09-019-160-84

```

APPLICANT: VAN BOORN, Leen-Jan et al.

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1442 TCCACAGCCATGGAATCC 1459
|||||
DB 1 TCCACAGCCATGTAACC 18

RESULT 93
US-09-588-995A-59/c
; Sequence 59, Application US/09588995A
; Patent No. 6514597
; GENERAL INFORMATION:
; APPLICANT: PETERSEN, CAROLYN
; APPLICANT: BARNES, DEBRA A.
; APPLICANT: NELSON, RICHARD C.
; APPLICANT: GUT, JIRI
; TITLE OF INVENTION: METHODS FOR DETECTION OF CRYPTOSPORIDIUM SPECIES AND
; TITLE OF INVENTION: ISOLATES AND FOR DIAGNOSIS OF CRYPTOSPORIDIUM
; TITLE OF INVENTION: INFECTIONS
; FILE REFERENCE: 480.19-5
; CURRENT APPLICATION NUMBER: US/09/588.995A
; CURRENT FILING DATE: 2000-06-06
; PRIOR APPLICATION NUMBER: 08/827,171
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 08/928,361
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 08/700,651
; PRIOR FILING DATE: 1996-08-14
; PRIOR APPLICATION NUMBER: 08/415,751
; PRIOR FILING DATE: 1995-04-03
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 59
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-588-995A-59

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3257 TGGTTTCCATCTCATCC 3274
|||||
DB 18 TGGTTTGCATATGATCC 1

RESULT 94
US-09-559-306-1
; Sequence 1, Application US/09559306
; Patent No. 6642000
; GENERAL INFORMATION:
; APPLICANT: STRIZHKOV, BORIS
; APPLICANT: TILLIB, SERGEI
; APPLICANT: MIRZABEKOV, ANDREI
; APPLICANT: MIRZABEKOV, VIADIMIR
; TITLE OF INVENTION: PCR AMPLIFICATION ON MICROARRAYS OF GEL IMMOBILIZED
; TITLE OF INVENTION: OLIGONUCLEOTIDES
; FILE REFERENCE: 21416-90459
; CURRENT APPLICATION NUMBER: US/09/559.306
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/165,029
; PRIOR FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-559-306-1

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3361 CCTTGATAATATCTTACC 3378
|||||
DB 2 CCTTGATAATATCTTACC 19

RESULT 95
US-09-696-791-1218/c
; Sequence 1218, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1218
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk-we-hu ribozyme binding site
US-09-696-791-1218

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2984 ATTCTCCAGAGGAGATT 3001
|||||
DB 18 ATTCTCCAGAGCGGATT 1

RESULT 96
US-09-696-791-2994
; Sequence 2994, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2994
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin A1 ribozyme binding site
US-09-696-791-2994

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2559 CTCACGAGTTCTTCTTC 2576
|||||

Db 1 CTCCAGATTTCGTCTTC 18

RESULT 97

US-09-696-791-3364

; Sequence 3364, Application US/09696791

; Patent No. 6770633

; GENERAL INFORMATION:

; APPLICANT: Robbins, Joan M.

; APPLICANT: Tritz, Richard

; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE

; TITLE OF INVENTION: SKIN AND EYE DISEASES

; FILE REFERENCE: 480124.407

; CURRENT APPLICATION NUMBER: US/09/696,791

; CURRENT FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 4523

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3364

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; OTHER INFORMATION: Cyclin B1 ribozyme binding site

US-09-696-791-3364

Query Match 0.4%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3442 TGCCATGTTTTCACAG 3459

Db 1 TGCCATGTTTTCACAG 18

RESULT 98

US-09-696-791-3720

; Sequence 3720, Application US/09696791

; Patent No. 6770633

; GENERAL INFORMATION:

; APPLICANT: Robbins, Joan M.

; APPLICANT: Tritz, Richard

; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE

; TITLE OF INVENTION: SKIN AND EYE DISEASES

; FILE REFERENCE: 480124.407

; CURRENT APPLICATION NUMBER: US/09/696,791

; CURRENT FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 4523

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3720

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; OTHER INFORMATION: Cdc25 hs ribozyme binding site

US-09-696-791-3720

Query Match 0.4%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2194 ATCTCTCTCTGAAGAAG 2211

Db 2 AACTTCTCTCTGAAGAAG 19

RESULT 99

US-09-696-791-3721

; Sequence 3721, Application US/09696791

; Patent No. 6770633

; GENERAL INFORMATION:

; APPLICANT: Robbins, Joan M.

; APPLICANT: Tritz, Richard

; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE

; TITLE OF INVENTION: SKIN AND EYE DISEASES

; FILE REFERENCE: 480124.407

; CURRENT APPLICATION NUMBER: US/09/696,791

; CURRENT FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 4523

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3721

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; OTHER INFORMATION: Cdc25 hs ribozyme binding site

US-09-696-791-3721

Query Match 0.4%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2194 ATCTCTCTCTGAAGAAG 2211

Db 1 AACTTCTCTCTGAAGAAG 18

RESULT 100

US-09-898-361-98/c

; Sequence 98, Application US/09898361

; Patent No. 6503152

; GENERAL INFORMATION:

; APPLICANT: Susan Murray

; APPLICANT: Jacqueline Wyatt

; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR

; TITLE OF INVENTION: EXPRESSION

; FILE REFERENCE: RTS-0158

; CURRENT APPLICATION NUMBER: US/09/898,361

; CURRENT FILING DATE: 2001-06-21

; NUMBER OF SEQ ID NOS: 163

; SEQ ID NO 98

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-898-361-98

Query Match 0.4%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 1.4e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 410 GCCTCTCCGGCCGTCG 427

Db 20 GCCTCTCCGGCCGTCG 3

RESULT 101

US-08-390-850-418

; Sequence 418, Application US/08390850

; Patent No. 5612215

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151

; CORRESPONDENCE ADDRESS:

; ADDRESS: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

```
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 418:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-418

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2002 TACACCTTGGAAAAG 2017
Db 1 UACACCUUGAAAAAG 16

RESULT 102
US-08-390-850-418
; Sequence 418, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 418:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-418

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2002 TACACCTTGGAAAAG 2017
Db 1 UACACCUUGAAAAAG 16

RESULT 103
US-09-133-717-16
; Sequence 16, Application US/09133717
; Patent No. 6083702
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; TITLE OF INVENTION: METHODS AND COMPOSITION FOR USE IN SPLICESOME MEDIATED
; FILE REFERENCE: A31304-B
; CURRENT APPLICATION NUMBER: US/09/133,717
; CURRENT FILING DATE: 1998-08-13
; EARLIER APPLICATION NUMBER: 09/087,233
; EARLIER FILING DATE: 1998-05-28
; EARLIER APPLICATION NUMBER: 08/766,354
; EARLIER FILING DATE: 1996-12-13
; EARLIER APPLICATION NUMBER: 60/008,317
; EARLIER FILING DATE: 1995-12-07
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Human
US-09-133-717-16

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2573 CTTCTTTTCTTCTTCT 2588
Db 1 CTTCTGTTTTTCTTCT 16

RESULT 104
US-09-158-863C-16
; Sequence 16, Application US/09158863C
; Patent No. 6280978
; GENERAL INFORMATION:
```


; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Garcia-Blanco, Mariano A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
; TITLE OF INVENTION: SPLICEOSOME MEDIATED RNA TRANS-SPLICING
; FILE REFERENCE: 31304-B-A
; CURRENT APPLICATION NUMBER: US/09/158,863C
; CURRENT FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 09/133,717
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 09/087,233
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 08/766,354
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: 60/008,317
; PRIOR FILING DATE: 1995-12-07
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-158-863C-16

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2573 CTTCTTTTTTTTCT 2588
|||||
Db 1 CTTCTTTTTTTTCT 16

RESULT 105
US-09-371-772B-5149
; Sequence 5149, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5149
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5149

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2590 AAAAAAGGAAAGCA 2605
|||||
Db 1 AAAAAAGCAAGCA 16

RESULT 106
US-09-371-772B-6286/c
; Sequence 6286, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5149
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6286

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2139 TTCTACTTGGTCATCA 2154
|||||
Db 16 TTCTTCTTGGTCATCA 1

RESULT 106
US-09-161-244-73/c
; Sequence 73, Application US/09161244
; Patent No. 6004814
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6286
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6286

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2139 TTCTACTTGGTCATCA 2154
|||||
Db 17 TTCTTCTTGGTCATCA 2

RESULT 107
US-09-371-772B-6287/c
; Sequence 6287, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6287
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6287

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2139 TTCTACTTGGTCATCA 2154
|||||
Db 16 TTCTTCTTGGTCATCA 1

RESULT 106
US-09-161-244-73/c
; Sequence 73, Application US/09161244
; Patent No. 6004814
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank

; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD71 EXPRESSION
; FILE REFERENCE: RTS-0007
; CURRENT APPLICATION NUMBER: US/09/161.244
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 73
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-244-73

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 358 ATTGAAGAGAGCCAG 373
Db 18 ATTGAAGAGAGCCAG 3

RESULT 109
US-09-422-978-11340/c
; Sequence 11340, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11340
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-4332 for SEQ 3475, in complete
US-09-422-978-11340

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1072 GAACATTCGGATTCGTG 1087
Db 16 GAACATTCGATTCGTG 1

RESULT 110
US-09-696-791-2458
; Sequence 2458, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2458
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin F ribozyme binding site
US-09-696-791-2458

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 324 GGGAGATTCGATTC 339
Db 2 GGGAGATTCGAGTCC 17

RESULT 111
US-09-696-791-2459
; Sequence 2459, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2459
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin F ribozyme binding site
US-09-696-791-2459

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 324 GGGAGATTCGATTC 339
Db 1 GGGAGATTCGAGTCC 16

RESULT 112
US-08-998-099-343/c
; Sequence 343, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 343
; LENGTH: 14

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-343

Query Match          0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 273 GGAGGGGGCGGGGA 286
DB 14 GGAGGGGGCGGGGA 1

RESULT 113
US-09-371-772B-6605/c
; Sequence 6605, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6605

Query Match          0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CGGTCTCTCGGGAA 1831
DB 17 CGGTCTCTCGGGAA 4

RESULT 114
US-09-371-772B-6606/c
; Sequence 6606, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6606
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-09-371-772B-6606

Query Match          0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CGGTCTCTCGGGAA 1831
DB 16 CGGTCTCTCGGGAA 3

RESULT 115
US-09-866-108A-950/c
; Sequence 950, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 950
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-950

Query Match          0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCCTGTCTTTC 3441
DB 17 CTGCCTGTCTTTC 4

RESULT 116
US-09-866-108A-951/c
; Sequence 951, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 951
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-951

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCTGTCTTTCG 3441
Db 16 CTGCTGTCTTTCG 3

RESULT 117
US-09-866-108A-952/c
; Sequence 952, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 951
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-951
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-952

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCTGTCTTTCG 3441
Db 15 CTGCTGTCTTTCG 2

RESULT 118
US-09-866-108A-953/c
; Sequence 953, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 953
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-953

Query Match      0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3428 CTGCCTGCTTTGC 3441
DB 14 CTGCCTGCTTTGC 1

RESULT 119
US-09-422-978-4657/c
; Sequence 4657, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4657
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-16847 for SEQ 723,
US-09-422-978-4657

Query Match      0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 ACCTTCTCTCCTTC 2226
DB 17 ACCTTCTCTCCTTC 4

RESULT 120
US-09-601-144-19/c
; Sequence 19, Application US/09601144
; Patent No. 6566514
; GENERAL INFORMATION:
; APPLICANT: Wright, Jim A.
; APPLICANT: Young, Aiping H.
; APPLICANT: Lee, Yoon S.
; TITLE OF INVENTION: OLIGONUCLEOTIDE SEQUENCES COMPLEMENTARY TO THIOREDUXIN
; AND THIOREDUXIN REDUCTASE GENES AND METHODS OF USING
; TITLE OF INVENTION: SAME TO MODULATE CELL GROWTH
; FILE REFERENCE: 683-112US-A
; CURRENT APPLICATION NUMBER: US/09/601,144
; PRIOR APPLICATION NUMBER: 2000-10-18
; PRIOR FILING DATE: 2000-10-18
; PRIOR APPLICATION NUMBER: US 60/073,196
; PRIOR FILING DATE: 1998-01-30
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 19
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
```

```
US-09-601-144-19

Query Match      0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2011 GGAAGAGCTTTGAAG 2024
DB 16 GGAAGAGCTTTGAAG 3

RESULT 121
US-08-985-162-809
; Sequence 809, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Seghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 809:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-809

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1586 TACAGGTTTGTAAAG 1602
DB 1 UACAGCAUUGUUAAG 17

RESULT 122
US-08-584-040-2546
; Sequence 2546, Application US/08584040
```

```
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2546:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2546

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 1.8e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

QY 2569 TCTCTCTCTCTCTCTCTTTT 2585
Db 1 UCACUUUUUUUUUUUU 17

RESULT 123
US-08-584-040-2547
; Sequence 2547, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2547:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2547

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 1.8e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTCTCTCTCTCTCTCTTTT 2586
Db 1 CUACUUUUUUUUUUUU 17

RESULT 124
US-08-584-040-2550
; Sequence 2550, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
```


Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 TTCTGCAGAGCTGCTT 985
Db 17 TTCTCAGAGCTTCTT 1

RESULT 127

US-08-584-040-5943/c
; Sequence 5943, Application US/08584040

; Patent No. 6346398

; GENERAL INFORMATION:

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Stinchcomb, Dan T.

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: TREATMENT OF DISEASES OR

; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS

; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL

; NUMBER OF SEQUENCES: 8502

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/584,040

; FILING DATE: January 11, 1996

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/005,974

; FILING DATE: October 26, 1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 218/064

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 5943:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-584-040-5943

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 AAAAATGCATATCAAT 1133
Db 17 AAAAATGAATCAAT 1

RESULT 128

US-08-584-040-7816/c

; Sequence 7816, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7816:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7816

Query Match 0.4%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2590 AAAAAGGAAAGACAC 2606

Db 17 AAAAAGGAAAGACAC 1

RESULT 129

US-09-474-432B-721

; Sequence 721, Application US/09474432B

; Patent No. 6528640

; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.

; APPLICANT: Beigelman, Leo

; APPLICANT: Burgin, Alex

; APPLICANT: Beaudry, Amber

; APPLICANT: Karpeisky, Alex

; APPLICANT: Adamic, Jasenka

; APPLICANT: Sweedler, David

; APPLICANT: Zinnen, Shawn

; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot;

; FILE REFERENCE: MBHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 721
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-721

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 365 GAGAGCCAGCGCGTGA 381
DB 1 GAGAGCCAGCCCUUGA 17

RESULT 130
US-09-371-772B-1070
; Sequence 1070, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1070
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1070

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 1.8e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;
QY 2569 TCCTCTCTCTTTT 2585
DB 1 UCACUUUUUUUUUUU 17

RESULT 131
US-09-371-772B-1071
; Sequence 1071, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1071
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1071

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 1.8e+02;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;
QY 2570 CTTCTCTCTTTT 2586
DB 1 CUACUUUUUUUUUUU 17

RESULT 132
US-09-371-772B-1074
; Sequence 1074, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1074

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 1.8e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;
QY 2570 CTTCTCTCTTTT 2586
DB 1 CUUUUUUUUUUUUUU 17

RESULT 133
US-09-371-772B-1075
; Sequence 1075, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

```
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1075

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 5.9%; Pred. No. 1.8e+02;
Matches 1; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTCTCTTTTTC 2587
Db 1 UUUUUUUUUUUUUU 17

RESULT 134
US-09-371-772B-2644/c
; Sequence 2644, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2644
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2644

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 TTCGTCAGAGCTGCTT 985
Db 17 TTCTTCAGAGCTTCTT 1

RESULT 135
US-09-371-772B-2780/c
; Sequence 2780, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2780
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2780

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 AAAAATGCATATCAAAAT 1133
Db 17 AAAAATGAAATCAAAAT 1

RESULT 136
US-09-371-772B-3600/c
; Sequence 3600, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3600
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3600

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2590 AAAAAAGGAAAAAGCAC 2606
Db 17 AAAAAACAAAAAGCAC 1

RESULT 137
US-09-371-772B-4631/c
; Sequence 4631, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```

RESULT 139
US-09-371-772B-5575
; Sequence 5575, Application US/09371772B
; Patent No. 6566137
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, I
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent
; TITLE OF INVENTION: Levels of Vascula
; FILE REFERENCE: MBH00.876-J (237/198)

```

```

RESULT 141
US-09-476-387-720
; Sequence 720, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphat
; FILE REFERENCE: MBH00-831-C (249/073)

```

```
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 720
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-720

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 365 GAGAGCCAGCGCGTGA 381
Db 1 GAGAGCCAGCCUCUGA 17

RESULT 142
US-09-401-063-809
; Sequence 809, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
```

```
; INFORMATION FOR SEQ ID NO: 809:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-809

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1586 TACAGGTTTGTAAAGAA 1602
Db 1 UACAGCAUUGUUAAGAA 17

RESULT 143
US-09-150-867-5
; Sequence 5, Application US/09150867
; Patent No. 6645748
; GENERAL INFORMATION:
; APPLICANT: Wood, Kenneth W.
; APPLICANT: Sakowicz, Roman
; APPLICANT: Cleveland, Don W.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Plus End-Directed Microtubule Motor Required for
; TITLE OF INVENTION: Chromosome Segregation
; FILE REFERENCE: 18557C-000110US
; CURRENT APPLICATION NUMBER: US/09/150,867
; CURRENT FILING DATE: 1998-09-10
; EARLIER APPLICATION NUMBER: US 60/058,645
; EARLIER FILING DATE: 1997-09-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer
US-09-150-867-5

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1164 GGGCTTCCCAGAAAGAG 1180
Db 1 GGGCTGCCAGGAAGAG 17

RESULT 144
US-09-827-998-196
; Sequence 196, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDhMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 196
; LENGTH: 17
```

; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-827-998-196

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2916 TTTTGCAATTGAAATA 2932
|||||
Db 1 TTTTGCAATTTTAAATA 17

```

RESULT 145
US-09-827-998-483/c
; Sequence 483, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHWOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 483
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-483

```

Qy 2571 TTCCTCTTTTTC 2587
|||||
Db 17 TTCCTCTTTTTC 1

```

RESULT 146
US-09-827-998-775/c
; Sequence 775, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aescmica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 775
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-775

```

QY 660 TGAGTACCAAAACCAGAG 676
db 17 TGGGTACCACACCAGAG 1

```

RESULT 147
US-09-827-998-776/c
; Sequence 776, Application us/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL
; FILE REFERENCE: MDhMORT-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 776
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-776

```

Qy 659 CTGAGTACCAACCAGA 675
||| ||||| |||||
Db 17 CTGGGTACCAACCAGA 1

RESULT 148
US-09-866-108A-1176
; Sequence 1176, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A6MICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1176

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 20 GAAGGACGAGGAGGG 36
||||| |||||
Db 1 GAAGGACAAAGAGGG 17

RESULT 149
US-09-866-108A-1580/c
; Sequence 1580, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1580
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1580

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2981 ATCATTTCTCCAGAGGAG 2997
||| ||||| ||||| ||

Db 17 ATCCTTCTCCAGAGCAG 1
RESULT 150
US-09-866-108A-2270
; Sequence 2270, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2270
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2270

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 413 TCCTCCGGCGCTCGTC 429
||||| ||||| |||||
Db 1 TCCTCCGGCGCTTCGGC 17

RESULT 151
US-09-866-108A-2271
; Sequence 2271, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A

```
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2271
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2271

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      414  CCTCCGGGCGCTGCTCT 430
Db      1    CCTCCGGGCGCTGCGGCT 17

RESULT 152
US-09-866-108A-6855
; Sequence 6855, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2271
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2271

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      414  CCTCCGGGCGCTGCTCT 430
Db      1    CCTCCGGGCGCTGCGGCT 17

RESULT 152
US-09-866-108A-6855
; Sequence 6855, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6856
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6856

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1173  AGAAGAGCGGAGAGAG 1189
Db      1    AGAAGCGAGAGAGAG 17

RESULT 153
US-09-866-108A-6856
; Sequence 6856, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6856
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6856

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1173  AGAAGAGCGGAGAGAG 1189
Db      1    AGAAGCGAGAGAGAG 17
```

```
Db      1 GAAGCAGCGAGAGAGC 17
|||||
RESULT 154
US-09-866-108A-6929/c
; Sequence 6929, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6929
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6930

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3317 CAGATTGTTGAATTCCT 3333
|||||
Db      17 CAGCTTCTTGAATTCCT 1

RESULT 156
US-09-866-108A-8116
; Sequence 8116, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6929
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6929

Query Match      0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      3318 AGATTGTTGAATTCCTG 3334
|||||
Db      17 AGCTTCTTGAATTCCTG 1

RESULT 155
US-09-866-108A-6930/c
; Sequence 6930, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```


;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aemica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8116
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8116

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 CTGCCAGAGCGCTCC 2742
DB 1 CTGCCAGAGCGGCTTC 17

RESULT 157
US-09-866-108A-8454
;; Sequence 8454, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aemica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8454
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8454

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1357 AGATCATGCACACGAG 1373
DB 1 AGAGCATGCACAGCGAG 17
RESULT 158
US-09-866-108A-8873/c
;; Sequence 8873, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aemica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8873
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8873

Query Match 0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2182 AGCTGCTCTCCATCTT 2198
DB 17 AGCTCTCTCCCATCTT 1

RESULT 159
US-09-866-108A-10318
;; Sequence 10318, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

```
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6866188
; SEQ ID NO 10318
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10318

Query Match          0.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1764 CTTTCTCTCGCGGACCA 1780
DB 1 CTTTCTCTCGGGGATCA 17

RESULT 160
US-08-261-822A-36/c
; Sequence 36, Application US/08261822A
; Patent No. 5650553
; GENERAL INFORMATION:
; APPLICANT: Ecker, Joseph R. et al.
; TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
; TITLE OF INVENTION: and Pathogens
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5650553ris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/261.822A
; FILING DATE: 17-JUN-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Beardell, Lori Y.
; REGISTRATION NUMBER: 34,293
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
```

```
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-08-261-822A-36

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CTTTGAGCTGGTCCAGG 243
DB 18 CCAGGAGCTGGTCCAGG 2

RESULT 161
US-08-311-486C-1129/c
; Sequence 1129, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggan
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1129:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

two

```
; TOPOLOGY: linear
US-08-311-486C-1129

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 554 GCCCATAGAGTGTGA 570
Db 18 GCCCATAGAACTGATGA 2

RESULT 162
US-08-811-028-26/c
; Sequence 26, Application US/08811028C
; Patent No. 5891671
; GENERAL INFORMATION:
; APPLICANT: SUZUKI, Yuji
; APPLICANT: MAGOTA, Koji
; APPLICANT: MASUDA, Toyofumi
; TITLE OF INVENTION: METHOD FOR CLEAVING CHIMERIC ENZYME USING PROCESSING
; FILE OF INVENTION: ENZYME
; FILE REFERENCE: 001560-294
; CURRENT APPLICATION NUMBER: US/08/811,028C
; CURRENT FILING DATE: 1987-03-04
; EARLIER APPLICATION NUMBER: JP 8-70906
; EARLIER FILING DATE: 1996-03-04
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 26
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer S12
US-08-811-028-26

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2562 CCAGCTTCTCTCTCTT 2578
Db 17 CCAGGCTTCTCTCTT 1

RESULT 163
US-09-161-244-45
; Sequence 45, Application US/09161244
; Patent No. 6004814
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD71 EXPRESSION
; FILE REFERENCE: RTS-0007
; CURRENT APPLICATION NUMBER: US/09/161,244
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-244-45

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2014 AAAGCTTGAAGTGCAG 2030
Db 1 AAACCTTGAAGTGTCTG 17
```

```
; TOPOLOGY: linear
US-09-289-377-11
; Sequence 11, Application US/09289377
; Patent No. 6046321
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-I1 EXPRESSION
; FILE REFERENCE: RTS-0058
; CURRENT APPLICATION NUMBER: US/09/289,377
; CURRENT FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-289-377-11

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3631 CTACTTTGTATTGTCA 3647
Db 2 CTGCTTTGTATTGTTA 18

RESULT 165
US-09-289-466-21
; Sequence 21, Application US/09289466A
; Patent No. 6124272
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PDK-1 EXPRESSION
; FILE REFERENCE: RTS-0060
; CURRENT APPLICATION NUMBER: US/09/289,466A
; CURRENT FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-289-466-21

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2000 AGTACACCTTTGGAAAA 2016
Db 2 AGGACACCGTGGAAAA 18

RESULT 166
US-09-213-719-37/c
; Sequence 37, Application US/09213719B
; Patent No. 6150162
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION
; FILE REFERENCE: RTS-0006
; CURRENT APPLICATION NUMBER: US/09/213,719B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 37
; LENGTH: 18
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-719-37

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 726 CCAGTGAAGGAGCAAC 742
    ||||||| |||||
Db 17 CCAGTGAAGGAGCAGC 1

RESULT 167
US-09-213-719-44/c
; Sequence 44, Application US/09213719B
; Patent No. 6150162
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION
; FILE REFERENCE: RTS-0006
; CURRENT APPLICATION NUMBER: US/09/213,719B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 44
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-719-44

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1595 GTTAAGAAAGTTGGAGCA 1611
    ||||||| |||||
Db 18 GTCAAGAAAGTTGGAGCA 2

RESULT 168
US-09-487-444-24/c
; Sequence 24, Application US/09487444
; Patent No. 6159697
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RTS-0133
; CURRENT APPLICATION NUMBER: US/09/487,444
; CURRENT FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 24
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-444-24

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1537 AGGGGAAGGCTTCTGC 1553
    ||||||| |||||
Db 18 AGGGGAATGGCTTTTC 2
```

```
RESULT 169
US-09-630-706-27
; Sequence 27, Application US/09630706
; Patent No. 6277640
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF HER-3 EXPRESSION
; FILE REFERENCE: RTS-0053
; CURRENT APPLICATION NUMBER: US/09/630,706
; CURRENT FILING DATE: 2000-08-01
; NUMBER OF SEQ ID NOS: 94
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-630-706-27

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2266 AGGACCGCAGCATCCCC 2282
    ||||||| |||||
Db 1 AGGACCGCAGCATCGCC 17

RESULT 170
US-08-584-040-8321
; Sequence 8321, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; FILING DATE: January 11, 1996
; APPLICATION NUMBER: US/08/584,040
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
```



```
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-9839 for SEQ 3707,
US-09-422-978-7641

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2033 TCAGAGTTCACCCATT 2049
Db 1 TCAGAGTTCACCCATT 17

RESULT 175
US-09-422-978-9605/c
; Sequence 9605, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CPI
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/422,978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9605
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6077 for SEQ 1740, in compleme
US-09-422-978-9605

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3581 AGGGAAGGAATGGGA 3597
Db 17 AGAGAGGAATGGGA 1

RESULT 176
US-09-371-772B-3979
; Sequence 3979, Application US/0937172B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
```

```
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3979
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3979

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 1.9e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2488 CTCTCTGACTCTCTGGAA 2504
Db 2 CUUCAGACCCUGGAA 18

RESULT 177
US-09-764-422A-4
; Sequence 4, Application US/09764422A
; Patent No. 6569671
; GENERAL INFORMATION:
; APPLICANT: Okamoto, Tadashi
; APPLICANT: Yamamoto, No. 6569671luko
; APPLICANT: Suzuki, Tomohiro
; TITLE OF INVENTION: Pattern Exposure Method, Exposure Device,
; TITLE OF INVENTION: Formation of Nucleic Acid Array, And Formation
; TITLE OF INVENTION: of Peptide Array
; FILE REFERENCE: 03500.015257
; CURRENT APPLICATION NUMBER: US/09/764,422A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 1999-007554
; PRIOR FILING DATE: 1999-01-14
; NUMBER OF SEQ ID NOS: 5
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe Sequence
US-09-764-422A-4

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3441 CTGCCATGTTTTTACA 3457
Db 2 CTGGCATCTTTTTTACA 18

RESULT 178
US-09-907-794A-229/c
; Sequence 229, Application US/09907794A
; Patent No. 6635468
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavini, Ivar J.
```

```

; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,794A
; PRIOR FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-794A-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
    |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 179
US-09-905-125A-229/c
; Sequence 229, Application US/09905125A
; Patent No. 6664376
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,125A
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-905-125A-229

Query Match      0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAGCGG 166
    |||||
Db 17 TCCCTGTGACAGCAG 1

RESULT 179
US-09-905-125A-229/c
; Sequence 229, Application US/09905125A
; Patent No. 6664376
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,125A
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-905-125A-229
```

Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAACGG 166
| | | | | | | | | | | | | | | | | | | | | |
Db 17 TCCCTGTGGACACGAG 1

RESULT 180

US-09-902-775A-229/c
; Sequence 229, Application US/09902775A

; Patent No. 6686451

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas P.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/902.775A

; PRIOR FILING DATE: 2001-07-10

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-11-30

; PRIOR APPLICATION NUMBER: PCT/US99/28564

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30

; PRIOR APPLICATION NUMBER: PCT/US99/28564

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/30095

; PRIOR FILING DATE: 1999-12-16

; PRIOR APPLICATION NUMBER: PCT/US99/30911

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US00/00219

; PRIOR FILING DATE: 2000-01-05

; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 229.

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide probe

US-09-902-775A-229

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 150 TCCCTGTGGAAACGG 166

| | | | | | | | | | | | | | | | | | | | | |

Db 17 TCCCTGTGGACACGAG 1

RESULT 181

US-09-032-438C-37/c

; Sequence 37, Application US/09032438C

; Patent No. 6713300

; GENERAL INFORMATION:

; APPLICANT: Rattner, Amir

; APPLICANT: Sun, Hui

; APPLICANT: Lupski, James R.

; APPLICANT: Nathans, Jeremy

; APPLICANT: Anderson, Kent L.

; APPLICANT: Leppert, Mark

; APPLICANT: Dean, Michael

; APPLICANT: Singh, Nanda

; APPLICANT: Shroyer, No. 6713300h F.

; APPLICANT: Smallwood, Philip M.

; APPLICANT: Allikmets, Rando

; APPLICANT: Lewis, Richard A.

; APPLICANT: Li, Yixin

; TITLE OF INVENTION: Nucleic Acid And Amino Acid Sequences For ATP-Binding Cassette

; TITLE OF INVENTION: Transporter And Methods Of Screening For Agents That Modify

; TITLE OF INVENTION: ATP-Binding Cassette Transporter

; FILE REFERENCE: BYLR-0065

; CURRENT APPLICATION NUMBER: US/09/032.438C

; CURRENT FILING DATE: 1998-02-27

; PRIOR APPLICATION NUMBER: US 60/039,388

; PRIOR FILING DATE: 1997-02-27

; NUMBER OF SEQ ID NOS: 120

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 37

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Oligonucleotide primer

US-09-032-438C-37

Query Match 0.4%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 205 CCATGCCAGCGGATGG 221

| | | | | | | | | | | | | | | | | | | | | |

Db 18 CCATGACACGCGATGG 2

RESULT 182

US-09-906-700-229/c

; Sequence 229, Application US/09906700

; Patent No. 6725535

; GENERAL INFORMATION:


```

; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,700
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-700-229

```

```

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 150 TCCCTGTGGAAAGCGG 166
      |||||
Db 17 TCCCTGTGCACGAG 1

RESULT 183
US-09-903-603A-229/c
; Sequence 229, Application US/09903603A
; Patent No. 6767995
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: GNE.1618P2C12
; CURRENT APPLICATION NUMBER: US/09/903,603A
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16

```

```
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-903-603A-229
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 150 TCCCTGTGGGAAGCGG 166
Db 17 TCCCTGTGGACAGCAG 1
```

```
RESULT 184
US-09-544-398B-128/c
; Sequence 128, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-128
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1453 GGAATCCATCCAGGAG 1469
Db 18 GGAAGCCATCGAGGAG 2
```

```
RESULT 185
US-09-544-398B-282/c
; Sequence 282, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
```

```
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 282
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-282
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2740 TCCTCTTTAACTCCTC 2756
Db 17 TCCTCTTGAAGCTCCTC 1
```

```
RESULT 186
US-09-696-791-4287
; Sequence 4287, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4287
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-09-696-791-4287
```

```
Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2637 CAGAACTCCAGAAGTGT 2653
Db 2 CAGATCTCAGAAGTAT 18
```

```
RESULT 187
US-09-994-311-7
; Sequence 7, Application US/09994311
; Patent No. 6773886
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGI 100
; CURRENT APPLICATION NUMBER: US/09/994,311
; CURRENT FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-7

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTC 2587
DB 1 TTTTTCCTTTTTC 17

RESULT 188
US-09-142-108C-28
; Sequence 28, Application US/09142108C
; Patent No. 6774285
; GENERAL INFORMATION:
; APPLICANT: Brughiera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/09/142,108C
; CURRENT FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-09-142-108C-28

Query Match          0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTC 2587
DB 2 TTTTTCCTTTTTC 18

RESULT 189
PCT-US91-03680-73
; Sequence 73, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; BEST LOCAL SIMILARITY 88.2%; PRED. NO. 1.9E+02;
; MATCHES 15; CONSERVATIVE 0; MISMATCHES 2; INDELS 0; GAPS 0;

QY 2571 TTCTTCTTTTTC 2587
DB 2 TTTTTCCTTTTTC 18

RESULT 190
PCT-US95-07744A-36/c
; Sequence 36, Application PC/TUS9507744A
; GENERAL INFORMATION:
; APPLICANT: Trustees of The University of Pennsylvania
; TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
; TITLE OF INVENTION: and Pathogens
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & Norris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/07744A
; FILING DATE: 15-JUNE-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/261,822
; FILING DATE: June 17, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Beardell, Lori Y.
; REGISTRATION NUMBER: 34,293
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
```

; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
PCT-US95-07744A-36

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTTGAGCTGGTCCAGG 243
||| ||||| ||||| |||||
Db 18 CCAGGAGCTGGTCCAGG 2

RESULT 191

5175384-7
; Patent No. 5175384
; APPLICANT: KRIMPENFORT, PAULUS J.A.; BERNIS, ANTONIUS J.M.
; TITLE OF INVENTION: TRANSGENIC MICE DEPLETED IN MATURE
; T-CELLS AND METHODS FOR MAKING TRANSGENIC MICE
; NUMBER OF SEQUENCES: 14
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/280,218
; FILING DATE: 5-DEC-1998
; SEQ ID NO: 7:
; LENGTH: 18
5175384-7

Query Match 0.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 380 GAGGGGAGGGGGCTGC 396
||| ||||| ||||| |||||
Db 1 GAAGGGGAGGGAGGCTGC 17

RESULT 192

US-07-876-280-19
; Sequence 19, Application US/07876280
; Patent No. 5262158
; GENERAL INFORMATION:
; APPLICANT: Payne, Jewel M.
; APPLICANT: Cannon, Raymond J.C.
; APPLICANT: Bagley, Angela L.
; TITLE OF INVENTION: No. 5262158el Bacillus thuringiensis Isolates for
; TITLE OF INVENTION: Controlling Acarides
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David R. Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/876,280
; FILING DATE: 19920430
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Saliwanchik, David R.
; REGISTRATION NUMBER: 31,794

; REFERENCE/DOCKET NUMBER: M/S 104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 904-375-8100
; TELEFAX: 904-372-5800
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-07-876-280-19

Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
||| ||||| ||||| |||||
Db 2 AAYTACAGCWCACACC 17

RESULT 193

US-08-049-783-17
; Sequence 17, Application US/08049783
; Patent No. 5439881
; GENERAL INFORMATION:
; APPLICANT: Narva, Kenneth E
; APPLICANT: Schwab, George E
; APPLICANT: Payne, Jewel M
; TITLE OF INVENTION: Gene Encoding No. 5439881el Nematode-Active
; TITLE OF INVENTION: Toxins Cloned from Bacillus thuringiensis Isolates
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jeff Lloyd
; STREET: 2421 N.W. 41st Street
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/049,783
; FILING DATE: 19930419
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lloyd, Jeff
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 904-375-8100
; TELEFAX: 904-372-5800
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-08-049-783-17

Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
||| ||||| ||||| |||||
Db 2 AAYTACAGCWCACACC 17

RESULT 194

US-08-158-232-24
; Sequence 24, Application US/08158232
; Patent No. 5596071
; GENERAL INFORMATION:
; APPLICANT: Payne, Jewel
; APPLICANT: Kennedy, M. Keith
; APPLICANT: Randall, John Brooks
; APPLICANT: Meier, Henry
; APPLICANT: Uick, Heidi Jane
; APPLICANT: Foncecrada, Luis
; APPLICANT: Schwab, George E.
; APPLICANT: Fu, Jenny
; TITLE OF INVENTION: No. 5596071el Bacillus thuringiensis Toxins Active
; TITLE OF INVENTION: Against Hymenopteran Pests
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David R. Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/158,232
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/887,980
; FILING DATE: 22-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/797,645
; FILING DATE: 25-NOV-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/703,977
; FILING DATE: 22-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Saliwanchik, David R.
; REGISTRATION NUMBER: 31,794
; REFERENCE/DOCKET NUMBER: M/SCJ104.C1
; TELEPHONE: 904-375-8100
; TELEFAX: 904-372-5800
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-08-158-232-24
Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1993 ACTACAAGTACACC 2008
Db 2 AAYTACAGCWCACC 17
RESULT 195
US-08-304-626-24
; Sequence 24, Application US/08304626
; Patent No. 5616495
; GENERAL INFORMATION:
; APPLICANT: Payne, Jewel M.
; APPLICANT: Kennedy, M. Keith

; APPLICANT: Randall, John Brooks
; APPLICANT: Meier, Henry
; APPLICANT: Uick, Heidi Jane
; APPLICANT: Foncecrada, Luis
; APPLICANT: Schnepf, Harry E.
; APPLICANT: Schwab, George E.
; TITLE OF INVENTION: No. 5616495el Bacillus thuringiensis Isolates
; TITLE OF INVENTION: Active Against Hymenopteran Pests and Genes Encoding
; TITLE OF INVENTION: Hymenopteran-Active Toxins
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David R. Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/304,626
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/887,980
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Saliwanchik, David R.
; REGISTRATION NUMBER: 31,794
; REFERENCE/DOCKET NUMBER: M/SCJ 104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 904-375-8100
; TELEFAX: 904-372-5800
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-08-304-626-24
Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1993 AACTACAAGTACACC 2008
Db 2 AAYTACAGCWCACC 17
RESULT 196
US-08-316-301A-27
; Sequence 27, Application US/08316301A
; Patent No. 5753492
; GENERAL INFORMATION:
; APPLICANT: Schnepf, Harry E.
; APPLICANT: Schwab, George E.
; APPLICANT: Payne, Jewel M.
; APPLICANT: Narva, Kenneth E.
; APPLICANT: Foncecrada, Luis
; TITLE OF INVENTION: No. 5753492el Nematoe-Active Toxins and Genes
; TITLE OF INVENTION: Which Code Therefor
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Saliwanchik & Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA

ZIP: 32606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/316,301A
FILING DATE: 30-SEP-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/871,510
FILING DATE: 23-APR-1992
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/565,544
FILING DATE: 10-AUG-1990
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/693,018
FILING DATE: 03-MAY-1991
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/084,653
FILING DATE: 12-AUG-1987
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/830,050
FILING DATE: 31-JAN-1992
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Lloyd, Jeff
REGISTRATION NUMBER: 35,589
REFERENCE/DOCKET NUMBER: MA20CCDD1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 904-375-8100
TELEFAX: 904-372-5800
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-08-316-301A-27

Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1993 AACTACAAGTACAACC 2008
Db 2 AAYTACAGCWCACAC 17

RESULT 197

US-08-611-928-24
Sequence 24, Application US/08611928
Patent No. 5824792
GENERAL INFORMATION:
APPLICANT: Payne, Jewel
APPLICANT: Kennedy, M. Keith
APPLICANT: Randall, John Brooks
APPLICANT: Meier, Henry
APPLICANT: Uick, Heidi Jane
APPLICANT: Foncerrada, Luis
APPLICANT: Schnepf, H. Ernest
APPLICANT: Schwab, George E.
APPLICANT: Fu, Jenny
TITLE OF INVENTION: No. 5824792a1 Bacillus thuringiensis Toxins Active
TITLE OF INVENTION: Against Hymenopteran Pests
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:

ADDRESSEE: David R. Saliwanchik
STREET: 2421 N.W. 41st Street, Suite A-1
CITY: Gainesville
STATE: FL
COUNTRY: USA
ZIP: 32606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/611,928
FILING DATE: 06-MAR-1996
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/158,232
FILING DATE: 24-NOV-1993
APPLICATION NUMBER: US 07/887,980
FILING DATE: 22-MAY-1992
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/797,645
FILING DATE: 25-NOV-1991
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/703,977
FILING DATE: 22-MAY-1991
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Saliwanchik, David R.
REGISTRATION NUMBER: 31,794
REFERENCE/DOCKET NUMBER: M/SCJ104.C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 904-375-8100
TELEFAX: 904-372-5800
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-08-611-928-24

Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1993 AACTACAAGTACAACC 2008
Db 2 AAYTACAGCWCACAC 17

RESULT 198

US-09-224-024-8
Sequence 8, Application US/09224024
Patent No. 6056953
GENERAL INFORMATION:
APPLICANT: Leslie Hickie
APPLICANT: Jewel Payne
TITLE OF INVENTION: Materials and Methods for the Control of
TITLE OF INVENTION: Calliphoridae Pests
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: David R. Saliwanchik
STREET: 2421 N.W. 41st Street, Suite A-1
CITY: Gainesville
STATE: FL
COUNTRY: USA
ZIP: 32606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/224,024
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/856,226
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Saliwanchik, David R.
REGISTRATION NUMBER: 31,794
REFERENCE/DOCKET NUMBER: MA79
TELECOMMUNICATION INFORMATION:
TELEPHONE: 904-375-8100
TELEFAX: 904-372-5800
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-09-224-024-8

Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
DB 2 AAYTACAGCWCACACC 17

RESULT 199

US-09-173-891-24
Sequence 24, Application US/09173891
Patent No. 6077937
GENERAL INFORMATION:
APPLICANT: Payne, Jewel
APPLICANT: Kennedy, M. Keith
APPLICANT: Randall, John Brooks
APPLICANT: Meier, Henry
APPLICANT: Ulick, Heidi Jane
APPLICANT: Foncerrada, Luis
APPLICANT: Schnepf, H. Ernest
APPLICANT: Schwab, George E.
APPLICANT: Fu, Jenny
TITLE OF INVENTION: No. 6077937el Bacillus thuringiensis Toxins Active
TITLE OF INVENTION: Against Hymenopteran Pests
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: David R. Saliwanchik
STREET: 2421 N.W. 41st Street, Suite A-1
CITY: Gainesville
STATE: FL
COUNTRY: USA
ZIP: 32606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/173,891
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/159,232
FILING DATE:
APPLICATION NUMBER: US 07/887,980
FILING DATE: 22-MAY-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/797,645
FILING DATE: 25-NOV-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/703,977
FILING DATE: 22-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Saliwanchik, David R.
REGISTRATION NUMBER: 31,794
REFERENCE/DOCKET NUMBER: M/SCJ104.C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 904-375-8100
TELEFAX: 904-372-5800
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-09-173-891-24

Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
DB 2 AAYTACAGCWCACACC 17

RESULT 200

US-09-076-137-27
Sequence 27, Application US/09076137B
Patent No. 6166195
GENERAL INFORMATION:
APPLICANT: Schnepf, Harry E.
APPLICANT: Schwab, George E.
APPLICANT: Payne, Jewel M.
APPLICANT: Narva, Kenneth E.
APPLICANT: Foncerrada, Luis
TITLE OF INVENTION: No. 6166195el Nematode-Active Toxins and Genes Which Code
TITLE OF INVENTION: Therefor
FILE REFERENCE: MA-20CCCD2
CURRENT APPLICATION NUMBER: US/09/076,137B
CURRENT FILING DATE: 1998-05-12
EARLIER APPLICATION NUMBER: 08/316,301
EARLIER FILING DATE: 1994-09-30
NUMBER OF SEQ ID NOS: 42
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 27
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: forward primer
US-09-076-137-27

Query Match 0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
DB 2 AAYTACAGCWCACACC 17

RESULT 201

US-09-738-363-27
Sequence 27, Application US/09738363
Patent No. 6632792
GENERAL INFORMATION:
APPLICANT: Schnepf, Harry E.

```
;
; Schwab, George E.
; Payne, Jewel M.
; Narva, Kenneth E.
; Fonceerrada, Luis
;
; TITLE OF INVENTION: Nematocidal Proteins
;
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jay M. Sanders
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/738,363
; FILING DATE: 15-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/076,137
; FILING DATE: 12-MAY-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Sanders, Jay
; REGISTRATION NUMBER: 39,355
; REFERENCE/DOCKET NUMBER: MA-200CCD3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 352-375-8100
; TELEFAX: 352-372-5800
;
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-09-738-363-27
;
; Query Match 0.4%; Score 13.6; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 2e+02;
; Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
;
;
; Qy 1993 AACTACAAGTACACC 2008
; Db 2 AAYTACAGCWCACC 17
;
; RESULT 202
; PCT-US92-03624-27
; Sequence 27, Application PC/TUS9203624
; GENERAL INFORMATION:
; APPLICANT: Schnepf, Harry E.
; APPLICANT: Schwab, George E.
; APPLICANT: Payne, Jewel M.
; APPLICANT: Narva, Kenneth E.
; APPLICANT: Fonceerrada, Luis
; TITLE OF INVENTION: Novel Nematode-Active Toxins and Genes
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David R. Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

```
;
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/03624
; FILING DATE: 19920501
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Saliwanchik, David R.
; REGISTRATION NUMBER: 31,794
; REFERENCE/DOCKET NUMBER: MA20C2C1C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 904-375-8100
; TELEFAX: 904-372-5800
;
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; PCT-US92-03624-27
;
; Query Match 0.4%; Score 13.6; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 2e+02;
; Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
;
;
; Qy 1993 AACTACAAGTACACC 2008
; Db 2 AAYTACAGCWCACC 17
;
; RESULT 203
; PCT-US94-07902-8
; Sequence 8, Application PC/TUS9407902
; GENERAL INFORMATION:
; APPLICANT:
; APPLICANT: Street address: 4980 Carroll Canyon Road
; APPLICANT: City: San Diego
; APPLICANT: State/Province: California
; APPLICANT: Country: US
; APPLICANT: Postal code/zip: 92121
; APPLICANT: Phone number: (619) 453-8030
; APPLICANT: Telex number:
; TITLE OF INVENTION: Materials and Methods for the Control of
; TITLE OF INVENTION: Calliphoridae Pests
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David R. Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/07902
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Saliwanchik, David R.
; REGISTRATION NUMBER: 31,794
; REFERENCE/DOCKET NUMBER: MA79
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 904-375-8100
; TELEFAX: 904-372-5800
;
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: nucleic acid
```



```
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
PCT-US94-07902-8

Query Match      0.4%; Score 13.6; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1993 AACTACAAGTACAACC 2008
    ||:|||||:|||||
Db 2 AAYTACAAGCWCACCC 17

RESULT 204
US-09-339-913B-74/c
; Sequence 74, Application US/09339913B
; Patent No. 6303344
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020503US
; CURRENT APPLICATION NUMBER: US/09/339,913B
; CURRENT FILING DATE: 1999-06-24
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/198,431
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-339-913B-74

Query Match      0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
    |||||:|:|||||:|
Db 18 TTAARGAGKAAAGGAWTGA 1

RESULT 205
US-09-339-904A-74/c
; Sequence 74, Application US/09339904A
; Patent No. 6319713
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020504US
; CURRENT APPLICATION NUMBER: US/09/339,904A
; CURRENT FILING DATE: 1999-06-24
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/198,431
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30

; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-339-904A-74

Query Match      0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
    |||||:|:|||||:|
Db 18 TTAARGAGKAAAGGAWTGA 1

RESULT 206
US-08-769-062B-74/c
; Sequence 74, Application US/08769062B
; Patent No. 6335160
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020500US
; CURRENT APPLICATION NUMBER: US/08/769,062B
; CURRENT FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/198,431
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-08-769-062B-74

Query Match      0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
    |||||:|:|||||:|
Db 18 TTAARGAGKAAAGGAWTGA 1

RESULT 207
US-09-344-002B-74/c
; Sequence 74, Application US/09344002B
; Patent No. 6355484
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020502US
; CURRENT APPLICATION NUMBER: US/09/344,002B
; CURRENT FILING DATE: 1999-06-24
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/198,431
; PRIOR FILING DATE: 1995-10-30
```

```
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-344-002B-74

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2774 TTAAGGCTGAAGGAATGA 2791
Db 18 TTAARGAGKAAGGAWTGA 1

RESULT 208
US-09-559-565C-74/c
; Sequence 74, Application US/09559565C
; Patent No. 6455253
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020508US
; CURRENT APPLICATION NUMBER: US/09/559,565C
; CURRENT FILING DATE: 2000-04-27
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-559-565C-74

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2774 TTAAGGCTGAAGGAATGA 2791
Db 18 TTAARGAGKAAGGAWTGA 1

RESULT 209
US-09-693-350-74/c
; Sequence 74, Application US/09693350
; Patent No. 6579678
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020508US
; CURRENT APPLICATION NUMBER: US/09/693,350
; CURRENT FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
```

```
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-693-350-74

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2774 TTAAGGCTGAAGGAATGA 2791
Db 18 TTAARGAGKAAGGAWTGA 1

RESULT 210
US-09-693-389-74/c
; Sequence 74, Application US/09693389
; Patent No. 6586182
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020509US
; CURRENT APPLICATION NUMBER: US/09/693,389
; CURRENT FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-693-389-74

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2774 TTAAGGCTGAAGGAATGA 2791
Db 18 TTAARGAGKAAGGAWTGA 1

RESULT 211
US-09-559-671A-74/c
; Sequence 74, Application US/09559671A
; Patent No. 6613514
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020503US
; CURRENT APPLICATION NUMBER: US/09/559,671A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/198,431
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30
; NUMBER OF SEQ ID NOS: 101
```

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-559-671A-74

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
Db 18 TTAARGAGKAGGAWTGA 1

RESULT 212
US-09-339-926A-74/c
; Sequence 74, Application US/09339926A
; Patent No. 6653072
; GENERAL INFORMATION:
; APPLICANT: Patten, Phillip
; APPLICANT: Stemmer, Willem P.C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
; FILE REFERENCE: 02-020501US
; CURRENT APPLICATION NUMBER: US/09/339,926A
; CURRENT FILING DATE: 1999-06-24
; PRIOR APPLICATION NUMBER: 08/769,062
; PRIOR FILING DATE: 1996-12-18
; PRIOR APPLICATION NUMBER: 08/198,431
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/425,684
; PRIOR FILING DATE: 1995-04-18
; PRIOR APPLICATION NUMBER: 08/537,874
; PRIOR FILING DATE: 1995-10-30
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: degenerate
; OTHER INFORMATION: oligonucleotide used for alpha interferon
; OTHER INFORMATION: shuffling
US-09-339-926A-74

Query Match          0.4%; Score 13.6; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2774 TTAAGGCTGAAGGAATGA 2791
Db 18 TTAARGAGKAGGAWTGA 1

RESULT 213
US-08-363-240A-69
; Sequence 69, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Biegaler, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION OF VASCULAR DISEASES
```

```
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 69:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-69

Query Match          0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2182 AGCTGCTCTCCATC 2196
Db 1 AGCGUCGUCGCAUC 15

RESULT 214
US-08-292-620A-292/c
; Sequence 292, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
```



```
;; APPLICATION NUMBER: US/08/893,204C
;; FILING DATE: 7/15/97
;; CLASSIFICATION:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Rosenberg, Morton
;; REGISTRATION NUMBER: 26,049
;; REFERENCE/DOCKET NUMBER: MR2493-5
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (410) 465-6678
;; TELEFAX: (410) 461-3067
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
;; HYPOTHETICAL: yes
;; ANTI-SENSE: no
;; ORIGINAL SOURCE: synthetic
;; PUBLICATION INFORMATION:
;; AUTHORS: Katherine Meyer-Siegler
;; TITLE: Enhanced Expression of Macrophage Migration
;; TITLE: Inhibitory Factor in Prostatic Adenocarcinoma Metastases
;; JOURNAL: Urology
;; VOLUME: 48
;; ISSUE: 3
;; PAGES: 448-452
;; DATE: 1996
;; RELEVANT RESIDUES IN SEQ ID NO: 2: FROM 1 TO 15
US-08-893-204C-2

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2574 TTCCTTTTCTCT 2588
DB 1 TTTTCTTTTCTCT 15

RESULT 217
US-08-832-021-25
; Sequence 25, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 25
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-25

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2575 TCTTTTCTCTG 2589
DB 1 TTTTCTTTTCTG 15

RESULT 219
US-09-071-845-292/c
; Sequence 292, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
```

```
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 292:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-292

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 278 GGGCGGGGAGGTGGC 292
Db 15 GGGTGGGAGGTGGC 1

RESULT 220
US-09-179-665-9/c
; Sequence 9, Application US/09179665
; Patent No. 6132971
; GENERAL INFORMATION:
; APPLICANT: Thorpe, H. H.
; APPLICANT: Johnston, Dean H.
; APPLICANT: Napier, Mary E.
; APPLICANT: Loomis, Carson R.
; APPLICANT: Sistare, Mark F.
; APPLICANT: Kim, Jinheung
; TITLE OF INVENTION: Electrochemical Detection of Nucleic
; TITLE OF INVENTION: Acid Hybridization
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: PO Box 37428
; CITY: Raleigh
; STATE: NC
; COUNTRY: US
; ZIP: 27627
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/179,665
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/667,338
; FILING DATE: 20-JUN-1996
; APPLICATION NUMBER: US 60/016,625
; FILING DATE: 19-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/060,949
; FILING DATE: 27-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5470-107B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-854-1400
; TELEFAX: 919-854-1401

; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ANTI-SENSE: NO
; FEATURE:
; NAME/KEY: misc.binding
; LOCATION: complement (1..15)
; OTHER INFORMATION: /function= "G-T mismatch at base 8"
; OTHER INFORMATION: of bound moiety= "AAATATAGTATAAAA"
; OTHER INFORMATION: /bound_moiety= "AAATATAGTATAAAA"
; PUBLICATION INFORMATION:
; AUTHORS: Johnston, D. H.
; AUTHORS: Glasgow, K. C.
; AUTHORS: Thorp, H. H.
; TITLE: Electrochemical Measurement of the Solvent
; TITLE: Accessibility of Nucleobases Using Electron
; TITLE: Transfer between DNA and Metal Complexes
; JOURNAL: J. Am. Chem. Soc.
; VOLUME: 117
; ISSUE: 35
; PAGES: 8933-8938
; DATE: 1995
; US-09-179-665-9

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3656 AAATACAATATAAAA 3670
Db 15 AAATATAATATAAAA 1

RESULT 221
US-09-486-453-1
; Sequence 1, Application US/09486453
; Patent No. 6455071
; GENERAL INFORMATION:
; APPLICANT: Shchepinov, Mikhail Sergeevich
; APPLICANT: Southern, Edwin Mellor
; TITLE OF INVENTION: Branched Dendrimeric Structures
; FILE REFERENCE: GUE-38
; CURRENT APPLICATION NUMBER: US/09/486,453
; CURRENT FILING DATE: 2000-02-25
; PRIOR APPLICATION NUMBER: GB 9718129.1
; PRIOR FILING DATE: 1997-08-27
; NUMBER OF SEQ ID NOS: 1
; SEQ ID NO 1
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; US-09-486-453-1

Query Match 0.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2569 TCTTCTCTCTTTT 2583
Db 1 TCTTCTCTCTTTT 15

RESULT 222
US-08-741-881-72/c
; Sequence 72, Application US/08741881
; Patent No. 5789245
```

GENERAL INFORMATION:
APPLICANT: Dubensky Jr, Thomas W
APPLICANT: Polo, John M.
APPLICANT: Ibanez, Carlos E.
APPLICANT: Chang, Stephen M.W.
APPLICANT: Jolly, Douglas J.
APPLICANT: Driver, David A.
APPLICANT: Belli, Barbara A.
TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESS: SEED AND BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/741,881
FILING DATE: 30-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423C6 / 1146.007
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-741-881-72

Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
Db 16 AGCTCCTGTTTAAAC 2

RESULT 223
US-08-739-158-72/c
Sequence 72, Application US/08739158
Patent No. 5814482
GENERAL INFORMATION:
APPLICANT: Dubensky Jr, Thomas W
APPLICANT: Polo, John M.
APPLICANT: Jolly, Douglas J.
APPLICANT: Driver, David A.
TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESS: SEED AND BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/739,158
FILING DATE: 30-OCT-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423D3 / 1146.012
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-739-158-72

Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
Db 16 AGCTCCTGTTTAAAC 2

RESULT 224
US-08-739-167-72/c
Sequence 72, Application US/08739167
Patent No. 5843723
GENERAL INFORMATION:
APPLICANT: Dubensky Jr, Thomas W
APPLICANT: Polo, John M.
APPLICANT: Ibanez, Carlos E.
APPLICANT: Chang, Stephen M.W.
APPLICANT: Jolly, Douglas J.
APPLICANT: Driver, David A.
APPLICANT: Belli, Barbara A.
TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS AND ALPHAVIRUS
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESS: SEED AND BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/739,167
FILING DATE: 30-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423C7 / 1146.008
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-739-167-72

```
Query Match          0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
   ||||| |||||
Db 16 AGCTCCTGTTTAAAC 2

RESULT 225
US-08-404-796-72/c
; Sequence 72, Application US/08404796
; Patent No. 6015686
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; APPLICANT: Polo, John M.
; APPLICANT: Ibanez, Carlos E.
; APPLICANT: Chang, Stephen M.
; APPLICANT: Jolly, Douglas J.
; APPLICANT: Driver, David A.
; APPLICANT: Belli, Barbara A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/404,796
; FILING DATE: 15-MAR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/404,796
; FILING DATE: 15-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049.423C5 / 1146.006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 622-4900
; INFORMATION FOR SEQ ID NO: 72:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-404-796-72

Query Match          0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
   ||||| |||||
Db 16 AGCTCCTGTTTAAAC 2

RESULT 226
US-08-931-869-72/c
; Sequence 72, Application US/08931869
; Patent No. 6015694
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; APPLICANT: Polo, John M.
; APPLICANT: Ibanez, Carlos E.
; APPLICANT: Chang, Stephen M.
; APPLICANT: Jolly, Douglas J.
```

```
; APPLICANT: Driver, David A.
; APPLICANT: Belli, Barbara A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/931,869
; FILING DATE: 16-SEP-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/404,796
; FILING DATE: 15-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049.423C5 / 1146.006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 622-6031
; INFORMATION FOR SEQ ID NO: 72:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-931-869-72

Query Match          0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
   ||||| |||||
Db 16 AGCTCCTGTTTAAAC 2

RESULT 227
US-08-911-894-15
; Sequence 15, Application US/08911894
; Patent No. 6030830
; GENERAL INFORMATION:
; APPLICANT: Saxon, Andrew
; APPLICANT: Zhang, Ke
; APPLICANT: Fujieda, Shigeharu
; TITLE OF INVENTION: IMMUNOGLOBULIN TRANS-SPLICED TRANSCRIPTS
; TITLE OF INVENTION: AND USES THEREOF
; NUMBER OF SEQUENCES: 90
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Akin, Gump, Strauss, Hauer & Feld
; STREET: 816 Congress Avenue, Suite 1900
; CITY: Austin
; STATE: Texas
; COUNTRY: USA
; ZIP: 78701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/911,894
; FILING DATE: Concurrently Herewith
```


CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/023,579
FILING DATE: 19-AUG-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: 43496.0006
TELEPHONE: (512) 499-6200
TELEFAX: (512) 499-6290
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-911-894-15

Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2268 GACCGCAGCATCCCC 2282
Db 1 GACAGCAGCATCCCC 15

RESULT 228
US-08-911-894-16/c
Sequence 16, Application US/08911894
Patent No. 6030830
GENERAL INFORMATION:
APPLICANT: Saxon, Andrew
APPLICANT: Zhang, Ke
APPLICANT: Fujieda, Shigeharu
TITLE OF INVENTION: IMMUNOGLOBULIN TRANS-SPLICED TRANSCRIPTS
TITLE OF INVENTION: AND USES THEREOF
NUMBER OF SEQUENCES: 90
CORRESPONDENCE ADDRESS:
ADDRESSEE: Akin, Gump, Strauss, Hauer & Feld
STREET: 816 Congress Avenue, Suite 1900
CITY: Austin
STATE: Texas
COUNTRY: USA
ZIP: 78701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/911,894
FILING DATE: Concurrently Herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/023,579
FILING DATE: 19-AUG-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: 43496.0006
TELEPHONE: (512) 499-6200
TELEFAX: (512) 499-6290
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-911-894-16

Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2268 GACCGCAGCATCCCC 2282
Db 16 GACAGCAGCATCCCC 2

RESULT 229
US-09-350-399-72/c
Sequence 72, Application US/09350399
Patent No. 6342372
GENERAL INFORMATION:
APPLICANT: Dubensky Jr, Thomas W
Polo, John M.
Jolly, Douglas J.
Driver, David A.
TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/350,399
FILING DATE: 08-Jul-1999
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: McMaisters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423D1 / 1146.010
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 72:
US-09-350-399-72

Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
Db 16 AGCTCCTGTTTAAAC 2

RESULT 230
US-09-236-140A-72/c
Sequence 72, Application US/09236140A
Patent No. 6376236
GENERAL INFORMATION:
APPLICANT: Dubensky Jr, Thomas W
Polo, John M.
Ibanez, Carlos E.
Chang, Stephen M.W.
Jolly, Douglas J.

; Driver, David A.
; Belli, Barbara A.
; TITLE OF INVENTION: RECOMBINANT ALPHAVIRUS PARTICLES
; NUMBER OF SEQUENCES: 124
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OPPENHEIMER WOLFF & DONNELLY
; STREET: 840 NEWPORT CENTER DRIVE, SUITE 700
; CITY: NEWPORT BEACH
; STATE: CALIFORNIA
; COUNTRY: US
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/236,140A
; FILING DATE: 22-Jan-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Cullman, Louis C.
; REGISTRATION NUMBER: 39,645
; REFERENCE/DOCKET NUMBER: 20263.332 / 1146.020
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (949) 823 6000
; TELEFAX: (949) 823.6100
; INFORMATION FOR SEQ ID NO: 72:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 72:
US-09-236-140A-72

Query Match 0.4%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2737 AGCTCCTCTTTAAAC 2751
|||||
Db 16 AGCTCCTCTTTAAAC 2

RESULT 231
US-08-373-124A-1435
; Sequence 1435, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1435:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1435

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 634 AGGATTACCCACAC 648
|||||
Db 3 AGGCAUACCCACAC 17

RESULT 232
US-08-373-124A-1437
; Sequence 1437, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992

```
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1437:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1437

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 634 AGGCATTACCCAC 648
Db 2 AGCAUACCAAC 16

RESULT 233
US-08-435-628-1435
; Sequence 1435, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1437:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1437

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 634 AGGCATTACCCAC 648
Db 2 AGCAUACCAAC 16

RESULT 233
US-08-435-628-1435
; Sequence 1435, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
```

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1435:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-1435

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 634 AGGCATTACCCAC 648
Db 3 AGCAUACCAAC 17

RESULT 234
US-08-435-628-1437
; Sequence 1437, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1437:
; SEQUENCE CHARACTERISTICS:
```

```
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1437

Query Match          0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 634 AGGCATTACCCACAC 648
Db 2 AGGCAUACCAACAC 16
|||||:|||||

RESULT 235
US-08-173-489C-96/c
; Sequence 96, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER:
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: nucleic acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from superoxide
; DISCUSSION: dismutase sequence region in Seq ID No. 586124495
; HYPOTHETICAL: yes
; ANTI-SENSE: no
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 96 :FROM 1 TO 17
US-08-173-489C-96

Query Match          0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 276 GGGGGGGGGAGGTG 290
Db 15 GGGGGGGGGAGGGG 1
|||||:|||||

; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1437

Query Match          0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 634 AGGCATTACCCACAC 648
Db 2 AGGCAUACCAACAC 16
|||||:|||||

RESULT 236
US-08-985-162-341/c
; Sequence 341, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 341:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-341

Query Match          0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 256 GTGTCTGAGGGAGGC 270
Db 15 GTGCTGAGGGAGGC 1
|||||:|||||

RESULT 237
US-08-584-040-1931/c
; Sequence 1931, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
```

;; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;; NUMBER OF SEQUENCES: 8502
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1931:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-1931

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1968 TAGTTGGAGAGACTT 1982
Db 17 TAGTTGGAGAGATT 3

RESULT 238
US-08-584-040-1932/c
; Sequence 1932, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1932:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-1932

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1968 TAGTTGGAGAGACTT 1982
Db 15 TAGTTGGAGAGATT 1

RESULT 239
US-08-584-040-2544
; Sequence 2544, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2544:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2544

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 13.3%; Pred. No. 2.2e+02;
Matches 2; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

QY 2572 TCTTCTTTT TTTT 2586
Db 2 UCUCUUUUUUUU 16

RESULT 241
US-08-584-040-4333
; Sequence 4333, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4333:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4333

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 2.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2677 TTCCTCAGAGAGC 2691
Db 3 UUGCCUCAGAGAGC 17

; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2545:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
```

RESULT 242
US-08-584-040-6072
; Sequence 6072, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Scinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 6072:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-6072

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 3276 TCACCTCTTGTGTCAGG 3290
Db 3 UCCACUCCUGUCAGG 17

RESULT 243
US-08-679-645-883/c
; Sequence 883, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.

; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 883:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-883
Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3656 AAATACAATATAAAA 3670
Db 17 AAATACAATATAAAA 3
RESULT 244
US-08-679-645-884/c
; Sequence 884, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263

;
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; SUITE: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ;
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: Storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ;
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/679,645
 ; FILING DATE: July 12, 1996
 ; CLASSIFICATION: 800
 ;
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/001,135
 ; FILING DATE: July 13, 1995
 ; APPLICATION NUMBER: 08/300,726
 ; FILING DATE: September 2, 1994
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 219/247
 ;
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ;
 ; INFORMATION FOR SEQ ID NO: 884:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-679-645-884

```
Query Match      0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels
```

```

Qy      3656 AAATACAATAAAAA 3670
        ||||| |||||
Db      16 AAATACAATAAAAA 2

RESULT 245
US-08-679-645-885/c
; Sequence 885, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent B.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND
; TITLE OF INVENTION: MODULATION OF GE
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

```

```

, ZIP: 90071-2066
,
, COMPUTER READABLE FORM:
,
, MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
,
, MEDIUM TYPE: storage
,
, COMPUTER: IBM Compatible
,
, OPERATING SYSTEM: IBM P.C. DOS 5.0
,
, SOFTWARE: Word Perfect 5.1
,
, CURRENT APPLICATION DATA:
,
, APPLICATION NUMBER: US/08/679,645
,
, FILING DATE: July 12, 1996
,
, CLASSIFICATION: 800
,
, PRIOR APPLICATION DATA:
,
, APPLICATION NUMBER: 60/001,135
,
, FILING DATE: July 13, 1995
,
, APPLICATION NUMBER: 08/300,726
,
, FILING DATE: September 2, 1994
,
, ATTORNEY/AGENT INFORMATION:
,
, NAME: Warburg, Richard J.
,
, REGISTRATION NUMBER: 32,327
,
, REFERENCE/DOCKET NUMBER: 219/247
,
, TELECOMMUNICATION INFORMATION:
,
, TELEPHONE: (213) 489-1600
,
, TELEFAX: (213) 955-0440
,
, TELEX: 67-3510
,
, INFORMATION FOR SEQ ID NO: 885:
,
, SEQUENCE CHARACTERISTICS:
,
, LENGTH: 17 base pairs
,
, TYPE: nucleic acid
,
, STRANDEDNESS: single
,
, TOPOLOGY: linear
,
, US-08-679-645-885
,

```

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14: Conservative 0; Mismatches 1; Indels

Qy 3656 AAATACAATATAAAA 3670
Db 15 AAATACAATAATAAA 1

```

RESULT 246
US-09-371-772B-476/c
; Sequence 476, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavo, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; DETECTION OF LEVELS OF VASCULAR ENDO-
; THELIAL CELL GROWTH
; FILE REFERENCE: MEH800 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 476
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-476

```

Query Match 0.4%; Score 13.4; DB 1;
Best Local Similarity 93.3%; pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels

QY 1968 TAGTTGGAGAGACTT 1982

DB 17 TAGTGGAGAGATT 3

RESULT 247

```

US-09-371-772B-477/C
; Sequence 477, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; TITLE OF INVENTION: Levels of Vascular E
; FILE REFERENCE: MHH00,876-J (237/139)
; CURRENT APPLICATION NUMBER: US/09/371,772
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-477

```

Query Match	0.4%	Score 13.4;	DB 1;	Length 17;
Best Local Similarity	93.3%	Pred. No. 2.2e+02;		
Matches 14:	Conservative	0: Mismatches	1: Indels	0: Gaps

Qy 1968 TAGTTGGAGAGACTT 1982
db 15 TAGTTGGAGAGATT 1

RESIII.T 248

```

RESULT 248
US-09-371-772B-1068
; Sequence 1068, Application US/09371772B
; Patent No. 6566127
;
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
;
; TITLE OF INVENTION: Method and Reagent for
;
; TITLE OF INVENTION: Levels of Vascular Endothelial
;
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
;
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1068
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1068

```

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 13.3%; Pred. No. 2.2e+02;
Matches 2: Conservative 12; Mismatches 1; Indels 0; Gaps 0;

Qy 2572 TCTTCTTTTTTTTT 2586
 :|: |:::~::~:

Db 3 UCUACUJUUUUUUUU 17

RESULT 249

```

US-09-371-772B-1069
; Sequence 1069, Application US/09371772B
; Patent No. 6566127
;
; GENERAL INFORMATION:
;
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;
; APPLICANT: Pavco, Pam
;
; APPLICANT: McSwiggen, Jim
;
; APPLICANT: Stinchcomb, Dan
;
; APPLICANT: Escobedo, Jaime
;
; TITLE OF INVENTION: Method and Reagent for
;
; FILE REFERENCE: MHH00, 876-J (237/138)
;
; CURRENT APPLICATION NUMBER: US/09/371,772
;
; CURRENT FILING DATE: 1999-08-10
;
; PRIOR APPLICATION NUMBER: US 60/005,974
;
; PRIOR FILING DATE: 1995-10-26
;
; PRIOR APPLICATION NUMBER: US 08/584,040
;
; PRIOR FILING DATE: 1996-01-08
;
; NUMBER OF SEQ ID NOS: 14225
;
; SOFTWARE: PatentIn version 3.0
;
; SEQ ID NO 1069
;
; LENGTH: 17
;
; TYPE: RNA
;
; ORGANISM: Homo sapiens
;
US-09-371-772B-1069

```

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 13.3%; Pred. No. 2.2e+02;
Matches 2; Conservative 12; Mismatches 1; Indels

Qy 2572 TCTTCTTTT TTTT 2586
:|: |:|:|:|:|:|:|:
pb 2 UCUCUUUUUUUUU 16

RESIST. T 250

```

RESULT 250
US-09-371-772B-2100
; Sequence 2100, Application US/09371772B
; Patent No. 6566137
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2100
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2100

```

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 2.2e+02;
Matches 11: Conservative 3; Mismatches 1; Indels

Qy 2677 TTCCCTCAGAAGAGC 2691
db 3 UUGCCUCAGAAGAGC 17

RESULT 251
US-09-371-772B-2909
; Sequence 2909, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2909
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2909

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 3276 TCCACTCTTGTCCAGG 3290
:|||||:|:|||||
Db 3 UCCACUCCUGUCAGG 17

RESULT 252
US-09-371-772B-4766/c
; Sequence 4766, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4766
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4766

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1968 TAGTTGGAGAGACTT 1982
|||||||:|||||
Db 16 TAGTTGGAGAGATT 2

RESULT 253
US-09-371-772B-5493/c
; Sequence 5493, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5493
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5493

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3645 TCAGAAATGCGCAAT 3659
|||||:|||||
Db 17 TCATAAATGCGCAAT 3

RESULT 254
US-09-371-772B-5494/c
; Sequence 5494, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5494
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5494

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3645 TCAGAAATGCGCAAT 3659
|||||:|||||
Db 16 TCATAAATGCGCAAT 2

```

; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 341:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-09-401-063-341
;
; Query Match 0.4%; Score 13.4; DB 1; Length 17;
; Best Local Similarity 93.3%; Pred. No. 2.2e+02;
; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 256 GTGCTGTGAGGAGGC 270
; DB 15 GTGGCTGTGAGGAGGC 1
;
; RESULT 257
; US-09-529-812A-3/c
; Sequence 3, Application US/09529812A
; Patent No. 6682930
; GENERAL INFORMATION:
; APPLICANT: LU, CHANGDE
; TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN
; FILE REFERENCE: 017227/0160
; CURRENT APPLICATION NUMBER: US/09/529,812A
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/CN98/00248
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: CN 97106667.1
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Triplex
; OTHER INFORMATION: forming oligonucleotide
; OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
;
; US-09-529-812A-3
;
; Query Match 0.4%; Score 13.4; DB 1; Length 17;
; Best Local Similarity 93.3%; Pred. No. 2.2e+02;
; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 2220 CTCCTTCCTCTCTCT 2234
; DB 16 CTCCTTCCTCTCTCT 2
;
; RESULT 258
; US-09-866-108A-2268
; Sequence 2268, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

```

; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2268
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2268

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 413 TCCTCCGGCGCTCG 427
Db 3 TCCTCCGGCGCTTCG 17

RESULT 259
US-09-866-108A-2269
; Sequence 2269, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2269
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2269

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2269
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2269

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 413 TCCTCCGGCGCTCG 427
Db 2 TCCTCCGGCGCTTCG 16

RESULT 260
US-09-866-108A-8114
; Sequence 8114, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8114
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8114

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 2726 CTGCCAGAGCAGCT 2740
Db 3 CTGCCAGAGCGGCT 17

RESULT 261
US-09-866-108A-8115
; Sequence 8115, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9590

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2388 GGACTTGGCAGCTTT 2402
Db 17 GGACTGGCAGCTTT 3

RESULT 263
US-09-866-108A-9591/c
; Sequence 9591, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8115
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8115

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 CTGCCAGAGCAGCT 2740
Db 2 CTGCCAGAGCGGCT 16

RESULT 262
US-09-866-108A-9590/c
; Sequence 9590, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
```

;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 9591
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-9591

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2388 GGACTTGGCAGCTTT 2402
|||||
Db 16 GGACTGGCAGCTTT 2

RESULT 264
US-09-866-108A-9592/c
; Sequence 9592, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9592
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9592

Query Match 0.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2388 GGACTTGGCAGCTTT 2402
|||||
Db 15 GGACTGGCAGCTTT 1

RESULT 265
US-08-294-424-33/c
; Sequence 33, Application US/08294424
; Patent No. 5800984
; GENERAL INFORMATION:
; APPLICANT: Vary, Calvin
; TITLE OF INVENTION: NUCLEIC ACID SEQUENCE DETECTION BY
; TITLE OF INVENTION: TRIPLE HELIX FORMATION
; NUMBER OF SEQUENCES: 49
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/294,424
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/000,922
; FILING DATE: 16 JAN 1993
; APPLICATION NUMBER: US/07/629,601B
; FILING DATE: 17-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 00088-037001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 33 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-294-424-33

Query Match 0.4%; Score 13; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2223 CTTCTCTTCCTC 2235
|||||
Db 13 CTTCTCTTCCTC 1

RESULT 266
US-08-319-492B-59/c
; Sequence 59, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS

;; TITLE OF INVENTION: OF IL-5
;; NUMBER OF SEQUENCES: 751
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/319,492B
;; FILING DATE: October 7, 1994
;;
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/276
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 59:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-319-492B-59

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3520 TTTATTAAAGGACA 3532
Db 14 TTTATTAAAGGACA 2

RESULT 267
US-08-319-492B-60/c
; Sequence 60, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/319,492B
;; FILING DATE: October 7, 1994
;;
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/276
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 60:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-319-492B-60

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3520 TTTATTAAAGGACA 3532
Db 13 TTTATTAAAGGACA 1

RESULT 268
US-08-292-620A-366
; Sequence 366, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994

CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 366:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-366

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 30.8%; Pred. No. 2.2e+02;
Matches 4; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 68 TTTTTCAG 80
DB 3 UUUUUUUCAG 15

RESULT 269
US-08-292-620A-367
Sequence 367, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849

two

FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 367:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-367

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 30.8%; Pred. No. 2.2e+02;
Matches 4; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 68 TTTTTCAG 80
DB 2 UUUUUUUCAG 14

RESULT 270
US-08-292-620A-368
Sequence 368, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

two


```

; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 368:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-368

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 30.8%; Pred. No. 2.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 68 TTTTTCAG 80
Db 1 UUUUUUUCAG 13

RESULT 271
US-09-071-845-366
; Sequence 366, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 366:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-367

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 30.8%; Pred. No. 2.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 68 TTTTTCAG 80
Db 3 UUUUUUUCAG 15

RESULT 272
US-09-071-845-367
; Sequence 367, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 367:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-367

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 30.8%; Pred. No. 2.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```
Qy 68 TTTTTCAG 80
Db 2 UUUUUUUCAG 14

RESULT 273
US-09-071-845-368
; Sequence 368, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071.845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 368:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-368

Query Match 0.4%; Score 13; DB 1; Length 15;
Best Local Similarity 30.8%; Pred. No. 2.2e+02;
Matches 4; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 68 TTTTTCAG 80
Db 1 UUUUUUUCAG 13

RESULT 274
US-09-133-717-11
; Sequence 11, Application US/09133717
; Patent No. 6083702
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; TITLE OF INVENTION: METHODS AND COMPOSITION FOR USE IN SPLICOSOME MEDIATED
; FILE REFERENCE: A31304-B
; CURRENT APPLICATION NUMBER: US/09/133,717
; CURRENT FILING DATE: 1998-08-13
; EARLIER FILING DATE: 1998-05-28
; EARLIER APPLICATION NUMBER: 08/766,354
; EARLIER FILING DATE: 1996-12-13
; EARLIER APPLICATION NUMBER: 60/008,317
; EARLIER FILING DATE: 1995-12-07
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human
US-09-133-717-11

Query Match 0.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2572 TCTTCTTTTTTT 2584
Db 2 TCTTCTTTTTTT 14

RESULT 275
US-09-158-863C-11
; Sequence 11, Application US/09158863C
; Patent No. 6280978
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Garcia-Blanco, Mariano A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
; TITLE OF INVENTION: SPLICOSOME MEDIATED RNA TRANS-SPLICING
; FILE REFERENCE: 31304-B-A
; CURRENT APPLICATION NUMBER: US/09/158,863C
; CURRENT FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 09/133,717
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 09/087,233
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 08/766,354
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: 60/008,317
; PRIOR FILING DATE: 1995-12-07
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-158-863C-11

Query Match 0.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2572 TCTTCTTTTTTT 2584
Db 2 TCTTCTTTTTTT 14

RESULT 276
US-09-527-030G-88/c
; Sequence 88, Application US/09527030G
; Patent No. 6482588
```

GENERAL INFORMATION:
; APPLICANT: VAN DOORN, Leen-Jan et al.
; TITLE OF INVENTION: Detection and identification of Human Papillomavirus by PCR and c
; FILE REFERENCE: 3501-0101P
; CURRENT APPLICATION NUMBER: US/09/527,030G
; CURRENT FILING DATE: 2000-03-16
; NUMBER OF SEQ ID NOS: 497
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 88
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Type specific probe derived from the Human Papillomavirus (HPV)
US-09-527-030G-88

Query Match 0.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2114 CTTGCCCCAGCAA 2126
Db 16 CTTGCCCCAGCAA 4

RESULT 277
5256545-2
; Patent No. 5256545
; APPLICANT: BROWN, MICHAEL S.; GOLDSTEIN, JOSEPH L.; RUSSELL,
; DAVID W.; SUDHOF, THOMAS C.
; TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
; NUMBER OF SEQUENCES: 42
; CURRENT APPLICATION DATA:
; FILING DATE: 20-OCT-1989
; PRIOR APPLICATION NUMBER: US/07/425,852
; APPLICATION DATA:
; FILING DATE: 30-MAR-1987
; APPLICATION NUMBER: 33,330
; FILING DATE: 30-MAR-1987
; FILING DATE: 30-MAR-1987
; SEQ ID NO: 2
; LENGTH: 16
5256545-2

Query Match 0.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2748 AAACCTCTCTCT 2760
Db 1 AAACCTCTCTCT 13

RESULT 278
5256545-34/c
; Patent No. 5256545
; APPLICANT: BROWN, MICHAEL S.; GOLDSTEIN, JOSEPH L.; RUSSELL,
; DAVID W.; SUDHOF, THOMAS C.
; TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
; NUMBER OF SEQUENCES: 42
; CURRENT APPLICATION DATA:
; FILING DATE: 20-OCT-1989
; PRIOR APPLICATION NUMBER: US/07/425,852
; APPLICATION DATA:
; FILING DATE: 30-MAR-1987
; APPLICATION NUMBER: 33,330
; FILING DATE: 30-MAR-1987
; FILING DATE: 30-MAR-1987
; SEQ ID NO: 34
; LENGTH: 16
5256545-34

Query Match 0.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2748 AAACCTCTCTCT 2760
Db 16 AAACCTCTCTCT 4

RESULT 279
US-08-998-099-82
; Sequence 82, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT OF DISEASES
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 82
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-82

Query Match 0.4%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1164 GGGCTTCCAGAA 1176
Db 4 GGGCTTCCAGAA 16

RESULT 280
US-08-998-099-83
; Sequence 83, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT OF DISEASES
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 83
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-83

Query Match 0.4%; Score 13; DB 1; Length 17;

```
; Best Local Similarity 84.6%; Pred. No. 2.6e+02;
; Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1164 GGGCTTCCCGAA 1176
    ||||:|||||
Db 3 GGGCUUCCCGAA 15

RESULT 281
US-09-371-772B-6604/c
; Sequence 6604, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 6604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6604

Query Match 0.4%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1819 GGTCTCTGGGAA 1831
    |||||:|||||
Db 17 GGTCTCTGGGAA 5

RESULT 282
US-09-866-108A-949/c
; Sequence 949, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 954
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-954

Query Match 0.4%; Score 13; DB 1; Length 17;
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 949
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-949

Query Match 0.4%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3429 TGCCTGCTTTGC 3441
    |||||:|||||
Db 17 TGCCTGCTTTGC 5

RESULT 283
US-09-866-108A-954/c
; Sequence 954, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 954
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-954

Query Match 0.4%; Score 13; DB 1; Length 17;
```

Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0; Mismatches 0;
Matches 13; Conservative 0;
QY 3428 CTGCCTGCTTTG 3440
DB 13 CTGCCTGCTTTG 1

RESULT 284
US-09-404-912-362/c
; Sequence 362, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-362

Query Match 0.4%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0; Mismatches 0;
Matches 13; Conservative 0;
QY 257 TGTCTGAGGAGG 269
DB 16 TGTCTGAGGAGG 4

RESULT 285
US-08-119-773-12/c
; Sequence 12, Application US/08119773
; Patent No. 5460942
; GENERAL INFORMATION:
; APPLICANT: Chou, Janice Y.
; APPLICANT: Lei, Ke-Jian
; TITLE OF INVENTION: GLUCOSE-6-PHOSPHATASE: THE GENE AND
; TITLE OF INVENTION: PROTEIN AND RELATED MUTATIONS
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/119,773
; FILING DATE: 10-SEP-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Kenneth A.
; REGISTRATION NUMBER: 31,677

Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0; Mismatches 0;
Matches 13; Conservative 0;
QY 3428 CTGCCTGCTTTG 3440
DB 13 CTGCCTGCTTTG 1

REFERENCE/DOCKET NUMBER: 15280-175
TELEPHONE: (415) 543-9600
TELEFAX: (415) 543-5043
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-119-773-12

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02; Indels 0; Gaps 0; Mismatches 2;
Matches 14; Conservative 0;
QY 541 CATCAAGAAATAGGC 556
DB 16 CAGCAAGAAAGAGGC 1

RESULT 286
US-08-236-311-25/c
; Sequence 25, Application US/08236311
; Patent No. 5565335
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/236,311
; FILING DATE: 02-MAY-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Hasak, Janet E.
; REGISTRATION NUMBER: 28,616
; REFERENCE/DOCKET NUMBER: 444PIC2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1896
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-236-311-25


```
;
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/971,978
; FILING DATE: February 18, 1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/558,806
; FILING DATE: July 27, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucchi
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0333
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 60:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 1
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 2
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 3
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 4
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 5
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 6
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 7
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 8
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 9
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 10
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
```

```
;
; NAME/KEY: Modified-site
; LOCATION: 11
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 12
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 13
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 14
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 15
; OTHER INFORMATION: 5-iodo-2'-deoxyuridine
; OTHER INFORMATION: substitution
; US-07-971-978-60
;
; Query Match 0.3%; Score 12.8; DB 1; Length 16;
; Best Local Similarity 87.5%; Pred. No. 2.7e+02;
; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 2571 TTCTCTTTTTTTTT 2586
; || || || || || || || ||
; Db 1 TTTTTTTTTTTTTT 16
;
; RESULT 290
; US-08-320-559-6/c
; Sequence 6, Application US/08320559
; Patent No. 5633135
; GENERAL INFORMATION:
; APPLICANT: Croce, Carlo
; TITLE OF INVENTION: Diagnostics, Therapeutics and Methods for
; TITLE OF INVENTION: Detection and Treatment of Acute Leukemias
; TITLE OF INVENTION: Resulting from Chromosome Abnormalities in the
; TITLE OF INVENTION: All-1 Region
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5633135ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/320,559
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/062,443
; FILING DATE: 14 MAY 1993
; PRIOR APPLICATION DATA: US/07/971,094
; FILING DATE: 30-OCT-92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/886,830
; FILING DATE: 27-MAY-92
; PRIOR APPLICATION DATA:
```



```
; APPLICATION NUMBER: US/07/805,093
; FILING DATE: 11-DEC-91
; ATTORNEY/AGENT INFORMATION:
; NAME: Deluca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-0855
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: No
; US-08-320-559-6

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3008 CTCCTCTCATCTTTTC 3023
DB 16 CTCCTCTCACCTTTTC 1

RESULT 291
US-08-327-392-6/c
; Sequence 6, Application US/08327392
; Patent No. 5633136
; GENERAL INFORMATION:
; APPLICANT: Croce, Carlo
; APPLICANT: Canaan, Eli
; TITLE OF INVENTION: ALL-1 Polynucleotides and Monoclonal
; TITLE OF INVENTION: Antibodies for Leukemia Detection and
; TITLE OF INVENTION: Treatment
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5633136ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/327,392
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/971,094
; FILING DATE: 30-OCT-92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/888,830
; FILING DATE: 27-MAY-92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/805,093
; FILING DATE: 11-DEC-91
; ATTORNEY/AGENT INFORMATION:
; NAME: Deluca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
```

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: NO
; US-08-327-392-6

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3008 CTCCTCTCATCTTTTC 3023
DB 16 CTCCTCTCACCTTTTC 1

RESULT 292
US-08-753-147-192/c
; Sequence 192, Application US/08753147
; Patent No. 5770372
; GENERAL INFORMATION:
; APPLICANT: Concannon, Patrick
; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
; NUMBER OF SEQUENCES: 196
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson and Kindness
; STREET: 1420 5th Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/753,147
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sheiness, Diana K.
; REGISTRATION NUMBER: 35,356
; REFERENCE/DOCKET NUMBER: VMRC-1-9714
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 743-4387
; TELEFAX: (206) 224 0779
; INFORMATION FOR SEQ ID NO: 192:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-08-753-147-192

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 483 CAGCATCTGGATCAA 498
DB 16 CAGCATCTAGATCAA 1

RESULT 293
US-08-415-370-2
; Sequence 2, Application US/08415370
; Patent No. 5801155
; GENERAL INFORMATION:
```

```

1 FILING DATE:
2 CLASSIFICATION: 514
3 PRIOR APPLICATION DATA:
4 APPLICATION NUMBER: FR 94/01381
5 FILING DATE: 08-FEB-1994
6 PRIOR APPLICATION DATA:
7 APPLICATION NUMBER: WO PCT/FR95/00098
8 FILING DATE: 27-JAN-1995
9 ATTORNEY/AGENT INFORMATION:
10 NAME: Smith Ph.D., Julie K.
11 REGISTRATION NUMBER: 38,619
12 REFERENCE/DOCKET NUMBER: ST94007-US
13 TELECOMMUNICATION INFORMATION:
14 TELEPHONE: (610)454-3839
15 TELEFAX: (610)454-3808
16 INFORMATION FOR SEQ ID NO: 15:
17 SEQUENCE CHARACTERISTICS:
18 LENGTH: 16 base pairs
19 TYPE: nucleic acid
20 STRANDEDNESS: single
21 TOPOLOGY: linear
22 MOLECULE TYPE: other nucleic acid
23 DESCRIPTION: /desc = "oligonucleotide"
24
25 US-08-687-551-15
26
27 Query Match 0.33; Score 12.8; DB 1; Length 16;
28 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
29 Matches 14; Conservative 0; Mismatches 2; Indels
30
31 QY : 2571 TTCTTCTTTT TTTT 2586
32 : |||||
33 DB 1 TTTT TTTT TTTT 16
34
35 RESULT 295
36 US-08-173-489C-29
37 Sequence 29, Application US/08173489C
38 Patent No. 5861244
39 GENERAL INFORMATION:
40 APPLICANT: WANG, C.-G.
41 APPLICANT: HEPBURN, A. G.
42 TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
43 TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
44 NUMBER OF SEQUENCES: 365
45 CORRESPONDENCE ADDRESS:
46 ADDRESS: PROFILE DIAGNOSTIC SCIENCES, INC.,
47 STREET: 510 EAST 73RD STREET,
48 CITY: NEW YORK
49 STATE: NEW YORK
50 COUNTRY: USA
51 ZIP: 10021.
52 COMPUTER READABLE FORM:
53 MEDIUM TYPE: 3.5 inch, 1.44mb storage
54 COMPUTER: IBM PC/XT/AT
55 OPERATING SYSTEM: MS-DOS version 6.2
56 SOFTWARE: Wordperfect Version 5.1
57 CURRENT APPLICATION DATA:
58 APPLICATION NUMBER: US/08/173,489C
59 FILING DATE: 22 DEC 1993
60 CLASSIFICATION: 435
61 PRIOR APPLICATION DATA:
62 APPLICATION NUMBER: US 07/968,436
63 FILING DATE: 29 OCT 1992
64 ATTORNEY/AGENT INFORMATION:
65 NAME: Handelman, Joseph H.
66 REGISTRATION NUMBER: 26,179
67 REFERENCE/DOCKET NUMBER: U9518-6
68 TELECOMMUNICATION INFORMATION:
69 TELEPHONE: (attorney) (212) 708-1880
70 TELEFAX: (attorney) (212) 246-8959
71 INFORMATION FOR SEQ ID NO: 29:
72 SEQUENCE CHARACTERISTICS:
73 LENGTH: 16 base pairs

```

TYPE: Nucleic Acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
DESCRIPTION: dystrophin gene (Accession # M18533,
M17154, M18026) nucleotides 3800 to 3815
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
POSITION IN GENOME:
CHROMOSOME/SEGMENT: X-chromosome
MAP POSITION: Xp21.3-p21.1
PUBLICATION INFORMATION:
AUTHORS: Koenig, M, Hoffman, E P, Bertelson, C J,
Monaco, A P, Feener, C, Kunkel, L M.
TITLE: Complete cloning of the
Duchenne muscular dystrophy (DMD) cDNA and
preliminary genomic organization of the DMD
TITLE: Gene in normal and affected individuals
JOURNAL: Cell
VOLUME: 50
PAGES: 509-517
DATE: 1987
AUTHORS: Hoffman, E P, Monaco, A P, Feener, C C,
Kunkel, L M.
TITLE: Conservation of the Duchenne
TITLE: muscular dystrophy gene in mice and humans
JOURNAL: Science
VOLUME: 238
PAGES: 347-350
DATE: 1987
AUTHORS: Koenig, M, Monaco, A P, Kunkel, L M.
TITLE: The complete sequence of
TITLE: dystrophin predicts a rod-shaped cytoskeletal
TITLE: protein
JOURNAL: Cell
VOLUME: 53
PAGES: 219-228
DATE: 1988
RELEVANT RESIDUES IN SEQ ID NO: 29 :FROM 1 TO 16
US-08-173-489C-29

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2782 GAAGGATGAAGAG 2797
Db 1 GAAGAGTGAAGAG 16

RESULT 296
US-08-545-860D-6/c
Sequence 6, Application US/08545860D
Patent No. 6040140
GENERAL INFORMATION:
APPLICANT: Croce, Carlo
TITLE OF INVENTION: Diagnostics, Therapeutics and Methods
for Detection and Treatment of Acute Leukemias
TITLE OF INVENTION: Resulting from Chromosome Abnormalities in the All-1 Region
NUMBER OF SEQUENCES: 94
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz &
STREET: One Liberty Place, 46th floor
CITY: Philadelphia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/545,860D
FILING DATE: 07-MAR-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04496
FILING DATE: 22-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10930
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/327,392
FILING DATE: 19-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/320,559
FILING DATE: 11-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/062,443
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/971,094
FILING DATE: 30-OCT-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/888,839
FILING DATE: 27-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/805,093
FILING DATE: 11-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Deluca Esq., Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: TJJ-1262
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 16
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: NO
US-08-545-860D-6

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3008 CTCCTCTCATCTTTC 3023
Db 16 CTCCTCTCACCTTTC 1

RESULT 297
US-09-141-764-2
Sequence 2, Application US/09141764
Patent No. 6084102
GENERAL INFORMATION:
APPLICANT: Kutyavin, Igor V.
APPLICANT: Lukhtanov, Eugeny A.
APPLICANT: Gamper, Howard B.
APPLICANT: Meyer, Jr., Rich B.
TITLE OF INVENTION: COVALENTLY LINKED OLIGONUCLEOTIDE
TITLE OF INVENTION: MINOR
TITLE OF INVENTION: GROOVE BINDER CONJUGATES
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: KLEIN & SZEKERES
STREET: 4199 Campus Drive, Suite 700
CITY: Irvine

```
; STATE: CA
; COUNTRY: USA
; ZIP: 92715
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/141,764
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/415,370
; FILING DATE: 03-APR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Szekeres, Gabor L.
; REGISTRATION NUMBER: 28,675
; REFERENCE/DOCKET NUMBER: 491-09-PA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-854-5502
; TELEFAX: 714-854-4897
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-141-764-2

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
Db 1 TTTTCTTTTTTTTTT 16

RESULT 298
US-08-851-843A-131/c
; Sequence 131, Application US/08851843A
; Patent No. 6093809
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; APPLICANT: Lingner, Joachim
; APPLICANT: Nakamura, Toru
; APPLICANT: Chapman, Karen B.
; APPLICANT: Morin, Gregg B.
; APPLICANT: Harley, Calvin
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: No. 6093809el Telomerase
; NUMBER OF SEQUENCES: 225
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851,843A
; FILING DATE: 06-MAY-1997
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/846,017
; FILING DATE: 25-APR-1997
; CLASSIFICATION:
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/844,419
; FILING DATE: 18-APR-1997
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002930US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-851-843A-131

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
Db 16 TTTTCTTTTTTTTTT 1

RESULT 299
US-08-457-918-25/c
; Sequence 25, Application US/08457918
; Patent No. 6117655
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/457,918
; FILING DATE: 1-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/236311
; FILING DATE: 02-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
```

```
, NAME: Kubinec, Jeffrey S.
, REGISTRATION NUMBER: 36,575
, REFERENCE/DOCKET NUMBER: P0444P1C3
, TELECOMMUNICATION INFORMATION:
, TELEPHONE: 415/225-8228
, TELEFAX: 415/952-9881
, TELEX: 910/371-7168
, INFORMATION FOR SEQ ID NO: 25:
, SEQUENCE CHARACTERISTICS:
, LENGTH: 16 bases
, TYPE: nucleic acid
, STRANDEDNESS: single
, TOPOLOGY: linear
US-08-457-918-25

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3287 CAGGGGAGAGAGGGG 3302
Db 16 CAGGGCAAGAGGTGG 1

RESULT 300
US-08-854-050-131/c
; Sequence 131, Application US/08854050
; Patent No. 6261836
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; APPLICANT: Lingner, Joachim
; APPLICANT: Nakamura, Toru
; APPLICANT: Chapman, Karen B.
; APPLICANT: Morin, Gregg B.
; APPLICANT: Harley, Calvin
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: No. 6261836el Telomerase
; NUMBER OF SEQUENCES: 225
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/854,050
; FILING DATE: 09-MAY-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/851,843
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/846,017
; FILING DATE: 25-APR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/844,419
; FILING DATE: 18-APR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002930US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
```

```
, REFERENCE/DOCKET NUMBER: 015389-002930US
, TELECOMMUNICATION INFORMATION:
, TELEPHONE: (415) 576-0200
, TELEFAX: (415) 576-0300
, INFORMATION FOR SEQ ID NO: 131:
, SEQUENCE CHARACTERISTICS:
, LENGTH: 16 base pairs
, TYPE: nucleic acid
, STRANDEDNESS: single
, TOPOLOGY: linear
US-08-854-050-131

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTTCTTTTTTTTTT 2586
Db 16 TTTTTTTTTTTTTTTT 1

RESULT 301
US-09-430-323-131/c
; Sequence 131, Application US/09430323
; Patent No. 6309867
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; APPLICANT: Lingner, Joachim
; APPLICANT: Nakamura, Toru
; APPLICANT: Chapman, Karen B.
; APPLICANT: Morin, Gregg B.
; APPLICANT: Harley, Calvin
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: No. 6309867el Telomerase
; NUMBER OF SEQUENCES: 225
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/430,323
; FILING DATE: 29-Oct-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/854,050
; FILING DATE: 09-MAY-1997
; APPLICATION NUMBER: US 08/851,843
; FILING DATE: 06-MAY-1997
; APPLICATION NUMBER: US 08/846,017
; FILING DATE: 25-APR-1997
; APPLICATION NUMBER: US 08/844,419
; FILING DATE: 18-APR-1997
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002930US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
```

```
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-09-430-323-131
Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTTCTTTTTTTTTT 2586
Db 16 TTTTTTTTTTTTTTTT 1

RESULT 302
US-08-666-341A-65/c
; Sequence 65, Application US/08666341A
; Patent No. 6365345
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Antisense nucleic Acids for the
; TITLE OF INVENTION: prevention and treatment of disorders in which expression
; TITLE OF INVENTION: of c-erbB plays a role
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman and Stern, PLLC
; STREET: 400 Seventh street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disc
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/666,341A
; FILING DATE: 15-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93120710.4
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
US-08-666-341A-65

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 555 GCCATAGAGTGTTGA 570
Db 16 GCCATAGAGTGTTGA 1

RESULT 303
US-09-507-345A-2
; Sequence 2, Application US/09507345A
; Patent No. 6426408
; GENERAL INFORMATION:
; APPLICANT: Kutyavin, Igor V.
; Lukhtanov, Eugeny A.
; Gamber, Howard B.
; Meyer Jr., Rich B.
; TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
; Groove Binder Conjugates
; NUMBER OF SEQUENCES: 12

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/507,345A
; FILING DATE: 18-Feb-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/415,370
; FILING DATE: 03-APR-1995
; APPLICATION NUMBER: US 09/141,764
; FILING DATE: 27-AUG-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Kezer, William B.
; REGISTRATION NUMBER: 37,369
; REFERENCE/DOCKET NUMBER: 17682A-003500US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-507-345A-2

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTTCTTTTTTTTTT 2586
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 304
US-09-619-103-22/c
; Sequence 22, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
; APPLICANT: Kurz, Markus
; APPLICANT: Lohse, Peter
; APPLICANT: Wagner, Richard
; TITLE OF INVENTION: Peptide Acceptor Ligation Methods
; FILE REFERENCE: 50036/031002
; CURRENT APPLICATION NUMBER: US/09/619,103
; CURRENT FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/145,834
; PRIOR FILING DATE: 1999-07-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-22

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
```

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTTTT 2586
Db 16 TTTTCTTTTCTTTT 1

RESULT 305
US-09-739-928-2
; Sequence 2, Application US/09739928
; Patent No. 6486308
; GENERAL INFORMATION:
; APPLICANT: Kutyavin, Igor V.
; Lukhtanov, Eugeny A.
; Gamber, Howard B.
; Meyer Jr., Rich B.
; TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
; Groove Binder Conjugates
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/739,928
; FILING DATE: 11-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/415,370
; FILING DATE: 03-APR-1995
; APPLICATION NUMBER: US 09/141,764
; FILING DATE: 27-AUG-1998
; APPLICATION NUMBER: US 09/507,345
; FILING DATE: 18-FEB-2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Kezer, William B.
; REGISTRATION NUMBER: 37,369
; REFERENCE/DOCKET NUMBER: 17682A-003510US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-739-928-2

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 16

RESULT 306
US-09-060-299-447
; Sequence 447, Application US/09060299
; Patent No. 6545137
; GENERAL INFORMATION:
; APPLICANT: Kutyavin, Igor V.
; Lukhtanov, Eugeny A.
; Gamber, Howard B.
; Meyer Jr., Rich B.
; TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
; Groove Binder Conjugates
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/739,928
; FILING DATE: 11-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/415,370
; FILING DATE: 03-APR-1995
; APPLICATION NUMBER: US 09/141,764
; FILING DATE: 27-AUG-1998
; APPLICATION NUMBER: US 09/507,345
; FILING DATE: 18-FEB-2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Kezer, William B.
; REGISTRATION NUMBER: 37,369
; REFERENCE/DOCKET NUMBER: 17682A-003510US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-739-928-2

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTTTT 2586
Db 1 TTTTCTTTTCTTTT 16

RESULT 307
US-09-402-923A-447
; Sequence 447, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A.
; Hess, John W.
; Caskey, Charles T.
; Cox, Roger D.
; Gerhold, David
; Hammond, Holly
; Hey, Patricia
; Kawaguchi, Yoshihiko
; Merriman, Tony R.
; Metzker, Michael L.
; TITLE OF INVENTION: No. 6555654e1 LDL-Receptor
```

```
APPLICANT: Todd, John A.
APPLICANT: Hess, John W.
APPLICANT: Caskey, Charles T.
APPLICANT: Cox, Roger D.
APPLICANT: Gerhold, David
APPLICANT: Hammond, Holly
APPLICANT: Hey, Patricia
APPLICANT: Kawaguchi, Yoshihiko
APPLICANT: Merriman, Tony R.
APPLICANT: Metzker, Michael L.
TITLE OF INVENTION: No. 6545137e1 Receptor
NUMBER OF SEQUENCES: 455
CORRESPONDENCE ADDRESS:
ADDRESSEE: Nixon and Vanderhye
STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
CITY: Arlington
STATE: Virginia
COUNTRY: US
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/060,299
FILING DATE: 15-APR-1998
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/043,553
FILING DATE: 15-APR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/048,740
FILING DATE: 05-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: B.J.Sadoff
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 620-35
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)816-4091
TELEFAX: (703)816-4100
INFORMATION FOR SEQ ID NO: 447:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-09-060-299-447

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1720 TCCCTTGAGCCTTCT 1735
Db 1 TCCCTTGAGCCTTCT 16

RESULT 307
US-09-402-923A-447
; Sequence 447, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A.
; Hess, John W.
; Caskey, Charles T.
; Cox, Roger D.
; Gerhold, David
; Hammond, Holly
; Hey, Patricia
; Kawaguchi, Yoshihiko
; Merriman, Tony R.
; Metzker, Michael L.
; TITLE OF INVENTION: No. 6555654e1 LDL-Receptor
```

NUMBER OF SEQUENCES: 455
CORRESPONDENCE ADDRESS:
ADDRESSEE: Nixon and Vanderhye
STREET: 1100 No. 655654th Glebe Road, Eighth Floor
CITY: Arlington
STATE: Virginia
COUNTRY: US
ZIP: VA 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/402,923A
FILING DATE: 14-Feb-2001
PRIOR APPLICATION NUMBER: PCT/GB96/01102
FILING DATE: 15-APR-1998
APPLICATION NUMBER: US 60/043,553
FILING DATE: 15-APR-1997
APPLICATION NUMBER: US 60/048,740
FILING DATE: 05-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: B.J. Sadoff
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 620-81
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)816-4091
TELEFAX: (703)816-4100
INFORMATION FOR SEQ ID NO: 447:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 447:
US-09-402-923A-447

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1720 TCCCTTGAAGCCTTCT 1735
|||||
Db 1 TCCCTTGCAGCCATCT 16

RESULT 308
US-09-371-772B-5893/c
; Sequence 5893, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5893
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-371-772B-5893

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2148 GTCATCAAAAAGGAG 2163
|||||
Db 16 GTCATCAAAACATGGAG 1

RESULT 309
US-09-371-772B-5974/c
; Sequence 5974, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5974
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5974

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2391 CTTGGCAGCTTCTTT 2406
|||||
Db 16 CTTCTCAGCTTCTTT 1

RESULT 310
US-09-371-772B-6017
; Sequence 6017, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6017
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6017


```
Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 2.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1265 AACGCTCTCTGTAGA 1280
DB 1 AAGGCUCUCUGUAUGA 16

RESULT 311
US-09-371-772B-7077/c
; Sequence 7077, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7077
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-7077

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1542 AAAGGCTCTGCTTTA 1557
DB 16 AAAGGCATCTGCTTCA 1

RESULT 312
US-09-479-005A-94
; Sequence 94, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 94
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-94

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 37.5%; Pred. No. 2.7e+02;
Matches 6; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 902 TCCTATTCTATGTGT 917
DB 1 UCCCUAUUCUGUGUUU 16

RESULT 313
US-09-479-005A-117
; Sequence 117, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 117
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-117

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 43.8%; Pred. No. 2.7e+02;
Matches 7; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 2581 TTTTCTGAAAAAG 2596
DB 1 UUUUUCUUAUAAAAAG 16

RESULT 314
US-09-479-005A-304
; Sequence 304, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 304
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-304

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 2.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3684 TTAATGTAATAACTT 3699
DB 1 UUAAGGAUAUAACUU 16

RESULT 315
```

US-10-157-408-25/c
; Sequence 25, Application US/10157408
; Patent No. 6710169
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/157,408
; FILING DATE: 28-May-2002
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/457,918
; FILING DATE: 1-JUN-1995
; APPLICATION NUMBER: 08/236311
; FILING DATE: 02-MAY-1994
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0444P1C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-8228
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-10-157-408-25
Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 3287 CAGGGGAGAGAGGGG 3302
Db 16 CAGGGCAAGAGGTGG 1
RESULT 316
US-09-958-610A-1/c
; Sequence 1, Application US/09958610A
; Patent No. 6756492
; GENERAL INFORMATION:
; APPLICANT: Beier, Markus
; APPLICANT: Hehse, Jorg
; TITLE OF INVENTION: Nucleoside Derivatives with Photolabile Protective Groups
; FILE REFERENCE: 03528.0135.PC0500
; CURRENT APPLICATION NUMBER: US/09/958,610A

; CURRENT FILING DATE: 2002-02-21
; PRIOR APPLICATION NUMBER: PCT/DE00/011448
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: DE 100 03 631.7
; PRIOR FILING DATE: 2000-01-28
; PRIOR APPLICATION NUMBER: DE 199 15. 867.3
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-09-958-610A-1
Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2571 TTCTTCTTTTTTTTTT 2586
Db 16 TTTTTTTTTTTTTTTT 1
RESULT 317
US-09-895-585-9
; Sequence 9, Application US/09895585
; Patent No. 6759039
; GENERAL INFORMATION:
; APPLICANT: Tsang, Wen-Ghih
; APPLICANT: Zheng, Tianli
; APPLICANT: Huang, Chang Jiang
; APPLICANT: AmCyt, Inc.
; TITLE OF INVENTION: Culturing Pancreatic Stem Cells Having a Specified,
; FILE REFERENCE: 021164-000100US
; CURRENT APPLICATION NUMBER: US/09/895,585
; CURRENT FILING DATE: 2002-12-10
; PRIOR APPLICATION NUMBER: US 60/215,634
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 60/246,306
; PRIOR FILING DATE: 2000-11-06
; PRIOR APPLICATION NUMBER: US 60/291,787
; PRIOR FILING DATE: 2001-05-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligo-(dT)-16
US-09-895-585-9
Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2571 TTCTTCTTTTTTTTTT 2586
Db 1 TTTTTTTTTTTTTTTT 16
RESULT 318
US-09-477-392-59
; Sequence 59, Application US/09477392
; Patent No. 6780986
; GENERAL INFORMATION:
; APPLICANT: Heintz, Nicholas
; APPLICANT: Houchens, Christopher
; TITLE OF INVENTION: RIP60 Nucleic Acid and Polypeptide

```
; TITLE OF INVENTION: Sequences and Uses Thereof
; FILE REFERENCE: V0139/7038 (HCL/WAT)
; CURRENT APPLICATION NUMBER: US/09/477,392
; CURRENT FILING DATE: 2000-01-04
; EARLIER APPLICATION NUMBER: US 60/114,745
; EARLIER FILING DATE: 1999-01-04
; EARLIER APPLICATION NUMBER: US 60/114,743
; EARLIER FILING DATE: 1999-01-04
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 59
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-477-392-59

Query Match          0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3479 TTTTTCATTAAT 3494
      |||||
Db 1 TTTTTCATTAAT 16

RESULT 319
US-09-856-662-30/c
; Sequence 30, Application US/09856662
; Patent No. 6790616
; GENERAL INFORMATION:
; APPLICANT: MORIBE, Toyoki et al.
; TITLE OF INVENTION: Method for typing HLA class 1 genes
; FILE REFERENCE: 0032-0261P
; CURRENT APPLICATION NUMBER: US/09/856,662
; CURRENT FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: JP F1998-335151
; PRIOR FILING DATE: 1998-11-26
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 30
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:DNA probe A555T
US-09-856-662-30

Query Match          0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 619 ACGTGCCATCCAGTA 634
      |||||
Db 16 ACGTGCCATCCAGTA 1

RESULT 320
US-09-152-059-70
; Sequence 70, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
; APPLICANT: WENGEL, JESPER
; APPLICANT: NIELSEN, POUL
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
; FILE REFERENCE: 49165 (71994)
; CURRENT APPLICATION NUMBER: US/09/152,059
; CURRENT FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/058,541
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 60/068,293
; PRIOR FILING DATE: 1997-12-19

; TITLE OF INVENTION: Sequences and Uses Thereof
; FILE REFERENCE: V0139/7038 (HCL/WAT)
; CURRENT APPLICATION NUMBER: US/09/477,392
; CURRENT FILING DATE: 2000-01-04
; EARLIER APPLICATION NUMBER: US 60/114,745
; EARLIER FILING DATE: 1999-01-04
; EARLIER APPLICATION NUMBER: US 60/114,743
; EARLIER FILING DATE: 1999-01-04
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 59
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-477-392-59

Query Match          0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3479 TTTTTCATTAAT 3494
      |||||
Db 1 TTTTTCATTAAT 16

RESULT 321
PCT-US94-04496-6/c
; Sequence 6, Application PC/TUS9404496
; GENERAL INFORMATION:
; APPLICANT: Croce, Carlo
; APPLICANT: Canaani, Eli
; TITLE OF INVENTION: Diagnostics, Therapeutics and Methods
; TITLE OF INVENTION: for Detection and Treatment of Acute Leukemias
; TITLE OF INVENTION: Resulting from Chromosome Abnormalities in the All-1
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz &
; ADDRESSEE: Norris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04496
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLuca Esq., Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1242
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: No
PCT-US94-04496-6
```

Query Match 0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3008 CTCCTCTCATCTTTTC 3023
Db 16 CTCCTCTCACCTTTTC 1

RESULT 322
US-08-390-850-488/c
; Sequence 488, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 488:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-488

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3330 TCCTGTTCTATCCCTT 3345
Db 17 TCCTGTTGTATCCCTT 2

RESULT 323
US-08-390-850-696/c

; Sequence 696, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 696:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-696

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 191 ACGTGAGTTCCTCCCC 206
Db 16 ACATGAGTACTTCCCC 1

RESULT 324
US-08-373-124A-304/c
; Sequence 304, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/373,124A
;; FILING DATE: January 13, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/245,466
;; FILING DATE: May 18, 1994
;; APPLICATION NUMBER: 08/192,943
;; FILING DATE: February 7, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;;
;; INFORMATION FOR SEQ ID NO: 304:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
;; US-08-373-124A-304

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3320 ATTGTTGAATTCCTGT 3335
Db 16 ATTGTAGATTCCTAGT 1

RESULT 325
US-08-373-124A-1134/c
; Sequence 1134, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/373,124A
;; FILING DATE: January 13, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/245,466
;; FILING DATE: May 18, 1994
;; APPLICATION NUMBER: 08/192,943
;; FILING DATE: February 7, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;;
;; INFORMATION FOR SEQ ID NO: 1134:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
;; US-08-373-124A-1134

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2153 CAAAAAGGAGTGTA 2168
Db 17 CAAAAAGAGAGTGCAA 2

RESULT 326
US-08-373-124A-1136/c
; Sequence 1136, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1136:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-1136

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2153 CAAAAAGGAGCTGTAA 2168
Db 16 CAAAAAGAGTGCAG 1

RESULT 327
US-08-373-124A-1813/c
; Sequence 1813, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2169:
; SEQUENCE CHARACTERISTICS:

; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1813:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-1813

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2904 TAATTATTACTATTTT 2919
Db 16 TCATTATTATTATTT 1

RESULT 328
US-08-373-124A-2169/c
; Sequence 2169, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2169:
; SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2169

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2592 AAAAGGAAAAAGCACA 2607
Db 17 AAAAGGAAAAAGGTACA 2

RESULT 329

US-08-373-124A-2171/c
Sequence 2171, Application US/08373124A
Patent No. 5646042

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES

NUMBER OF SEQUENCES: 2627

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/373,124A

FILING DATE: January 13, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/245,466

FILING DATE: May 18, 1994

APPLICATION NUMBER: 08/192,943

FILING DATE: February 7, 1994

APPLICATION NUMBER: 07/987,132

FILING DATE: December 7, 1992

APPLICATION NUMBER: 07/936,422

FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 209/035

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 2171:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-373-124A-2171

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2592 AAAAGGAAAAAGCACA 2607
Db 16 AAAAGGAAAAAGGTACA 1

RESULT 330

US-08-435-634-488/c

Sequence 488, Application US/08435634

Patent No. 5731295

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James

APPLICANT: Gustofson, John

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/435,634

FILING DATE: 05-MAY-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/390,850

FILING DATE: February 17, 1995

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5731295ember 12, 1993

APPLICATION NUMBER: 07/989,848

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 488:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-435-634-488

Query Match

0.3%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 3330 TCCTGTTCTATCCCTT 3345

Db 17 TCCTGTTCTATCCCTT 2

RESULT 331

US-08-435-634-696/c

```
; Sequence 696, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 696:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-696

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 191 ACGTGAGTCTTCCCC 206
Db 16 ACATGAGTACTTCCCC 1

RESULT 332
US-08-795-788-3/c
; Sequence 3, Application US/08795788
; Patent No. 5795770
; GENERAL INFORMATION:
; APPLICANT: GABER, RICHARD F.
; TITLE OF INVENTION: GENETICALLY ENGINEERED EUKARYOTIC
; ORGANISM CAPABLE OF DETECTING THE EXPRESSION OF
; HETEROLOGOUS ION CHANNELS AND METHOD TO USE SAME
; NUMBER OF SEQUENCES: 22
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: TILTON, FALLON, LUNGUMUS & CHESTNUT
; STREET: 100 SOUTH WACKER DRIVE, SUITE 960, HARTFORD
; CITY: CHICAGO
; STATE: ILLINOIS
; COUNTRY: USA
; ZIP: 60606-4002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/795,788
; FILING DATE: 05-FEB-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/923,094
; FILING DATE: 31-JUL-1992
; APPLICATION NUMBER: US 07/874,846
; FILING DATE: 27-APR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: FENTRESS, SUSAN B.
; REGISTRATION NUMBER: 31,327
; REFERENCE/DOCKET NUMBER: NU-9211CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/456-8000
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-08-795-788-3

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3038 TGTTCGTGGAGCTAAG 3053
Db 16 TGTTCGTGGAGCTTAG 1

RESULT 333
US-08-367-069-17/c
; Sequence 17, Application US/08367069
; Patent No. 5811538
; GENERAL INFORMATION:
; APPLICANT: Timothy A. Riley
; APPLICANT: Mark A. Reynolds
; APPLICANT: Lloyd R. Snyder
; APPLICANT: Robert E. Klem
; TITLE OF INVENTION: IMPROVED PROCESS FOR THE
; PURIFICATION OF OLIGOMERS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
```



```

; APPLICATION NUMBER: US/08/367,069
; FILING DATE: December 30, 1994
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below: 1
; APPLICATION NUMBER: 08/176,851
; FILING DATE: 30 December 1993
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: BIGGS, SUZANNE L.
; REGISTRATION NUMBER: 30,158
; REFERENCE/DOCKET NUMBER: 210/209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-0440
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-367-069-17

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CCTTCTCTCTCTCAT 2237
DB 17 CCTTCTCTCTCTCTCT 2

RESULT 334
US-08-435-628-304/c
; Sequence 304, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327

```

```

; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 304:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-304

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3320 ATTGTTGAATTCCTGT 3335
DB 16 ATTGTAATTCACGT 1

RESULT 335
US-08-435-628-1134/c
; Sequence 1134, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327

```

; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-1134

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2153 CAAAAAAGGAGTGTA 2168
|||||
Db 17 CAAAAAAGAGTGCAA 2

RESULT 336
US-08-435-628-1136/c
; Sequence 1136, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1136:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-1136

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2153 CAAAAAAGGAGTGTA 2168
|||||
Db 16 CAAAAAAGAGTGCAA 1

RESULT 337
US-08-435-628-1813/c
; Sequence 1813, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1813:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-1813

; Sequence 1733, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1733:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1733

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3244 TCTACAGAGTTGTGG 3259
Db 16 TCAACAAGAGTTGGG 1

RESULT 341
US-08-292-620A-1983
; Sequence 1983, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1983:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1983

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 2.8e+02;
Matches 6; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 2762 TTGATGAATTCCTAA 2777
Db 2 UUGAUGUAUUUUA 17

RESULT 342
US-08-173-489C-37/c
; Sequence 37, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA

ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 37:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
DESCRIPTION: dystrophin gene (Accession # M18533,
DESCRIPTION: M17154, M18026) nucleotides 5967 to 5983
HYPOTHETICAL: No
ANTI-SENSE: No
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
POSITION IN GENOME:
CHROMOSOME/SEGMENT: X-chromosome
MAP POSITION: Xp21.3-p21.1
PUBLICATION INFORMATION:
AUTHORS: Koenig, M, Hoffman, E P, Bertelson, C J,
AUTHORS: Monaco, A P, Feener, C, Kunkel, L M.
TITLE: Complete cloning of the
TITLE: Duchenne muscular dystrophy (DMD) cDNA and
TITLE: preliminary genomic organization of the DMD
TITLE: gene in normal and affected individuals
JOURNAL: Cell
VOLUME: 50
PAGES: 509-517
DATE: 1987
AUTHORS: Hoffman, E P, Monaco, A P, Feener, C C,
AUTHORS: Kunkel, L M.
TITLE: Conservation of the Duchenne
TITLE: muscular dystrophy gene in mice and humans
JOURNAL: Science
VOLUME: 238
PAGES: 347-350
DATE: 1987
AUTHORS: Koenig, M, Monaco, A P, Kunkel, L M.
TITLE: The complete sequence of
TITLE: dystrophin predicts a rod-shaped cytoskeletal
TITLE: protein
JOURNAL: Cell
VOLUME: 53
PAGES: 219-228
DATE: 1988
RELEVANT RESIDUES IN SEQ ID NO: 37 :FROM 1 TO 17
US-08-173-489C-37

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2187 CTCCTCCATCTTCTTC 2202
Db 17 CTCCTCTTTCTTCTTC 2

RESULT 343
US-08-173-489C-48
; Sequence 48, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 48:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 bases
; TYPE: Nucleic Acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from dystrophin
; DESCRIPTION: sequence region in Seq ID No. 586124447
; HYPOTHETICAL: Yes
; ANTI-SENSE: No
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 48 :FROM 1 TO 17
; US-08-173-489C-48

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2573 CTCCTTTTCTTCTTCT 2588
Db 1 CTCCTTTTCTTCTTCT 16

RESULT 344
US-08-885-126-3/c
; Sequence 3, Application US/08885126A
; Patent No. 5955597
; GENERAL INFORMATION:
; APPLICANT: Arnold, Lyle J.
; APPLICANT: Riley, Timothy A.
; APPLICANT: Reynolds, Mark A.
; APPLICANT: Schwartz, David A.
; TITLE OF INVENTION: CHIRALLY ENRICHED SYNTHETIC PHOSPHATE
; TITLE OF INVENTION: OLIGOMERS

```
; FILE REFERENCE: GENTA.020FW2
; CURRENT APPLICATION NUMBER: US/08/885.126A
; CURRENT FILING DATE: 1997-06-30
; EARLIER APPLICATION NUMBER: 08/343.018
; EARLIER FILING DATE: 1994-11-21
; EARLIER APPLICATION NUMBER: 08/154.013
; EARLIER FILING DATE: 1993-11-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Chemically synthesized oligomer
US-08-885-126-3

Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CCTTCTCTTCTCAT 2237
Db 17 CCTTCTCTCTCTCT 2

RESULT 345
US-08-755-587-212
; Sequence 212, Application US/08/755587
; Patent No. 6045997
; GENERAL INFORMATION:
; APPLICANT: Futreal, Phillip A
; APPLICANT: Wooster, Richard F
; APPLICANT: Ashworth, Alan
; APPLICANT: Stratton, Michael R
; TITLE OF INVENTION: Materials and methods relating to the
; TITLE OF INVENTION: identification and sequencing of the BRCA2 cancer
; TITLE OF INVENTION: susceptibility gene and uses thereof.
; NUMBER OF SEQUENCES: 222
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bell Seltzer Park & Gibson
; STREET: 310 UCB Plaza, 3605 Glenwood Avenue, PO Drawer 31107
; CITY: Raleigh
; STATE: NC
; COUNTRY: USA
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/755.587
; FILING DATE: 25-NOV-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9523959.6
; FILING DATE: 23-NOV-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9525555.0
; FILING DATE: 14-DEC-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9617961.9
; FILING DATE: 28-AUG-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kenneth D Sibley
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5405-135
; INFORMATION FOR SEQ ID NO: 212:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-755-587-212
```

```
Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2609 AGCACACAATTTCAAG 2624
Db 1 AGCAAGCAATTTCAAG 16

RESULT 346
US-08-985-162-213/c
; Sequence 213, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 213:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-213

Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1822 CTCTGGGGAACACAAG 1837
Db 16 CTCGGGGGAGACACAAG 1

RESULT 347
US-08-985-162-430
; Sequence 430, Application US/08985162
; Patent No. 6057156
```


RESULT 351
US-09-071-845-1733/c


```

; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1983:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1983

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 2.8e+02;
Matches 6; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 2762 TTGATGAATTCCTAA 2777
Db 2 UUGAUGAUUUUAUA 17

RESULT 353
US-08-760-615-12/c
; Sequence 12, Application US/08760615
; Patent No. 6200959
; GENERAL INFORMATION:
; APPLICANT: Haynes, Joel R
; APPLICANT: Schmaljohn, Connie S
; APPLICANT: Fuller, Deborah L
; APPLICANT: Schmaljohn, Alan
; APPLICANT: Jahrling, Peter B
; TITLE OF INVENTION: GENETIC INDUCTION OF ANTI-VIRAL IMMUNE
; TITLE OF INVENTION: RESPONSE AND GENETIC VACCINE FOR FILOVIRUS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Quarles & Brady
; STREET: 1 South Pinckney Street

; APPLICANT: Kenneth G. Draper
; CITY: Madison
; STATE: WI
; COUNTRY: US
; ZIP: 53703
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/760,615
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Berson, Bennett J
; REGISTRATION NUMBER: 37094
; REFERENCE/DOCKET NUMBER: 110229.91241
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 608-251-5000
; TELEFAX: 608-251-9166
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
; US-08-760-615-12

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3675 TATATGTTTAAATGT 3690
Db 17 TATATGGTCTTCATGT 2

RESULT 354
US-09-250-075-5
; Sequence 5, Application US/09250075
; Patent No. 6207819
; GENERAL INFORMATION:
; APPLICANT: Mancharan, Muthiah
; APPLICANT: Maier, Martin A
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of
; TITLE OF INVENTION: Mixed Backbone Oligomeric Compounds
; FILE REFERENCE: ISIS3299
; CURRENT APPLICATION NUMBER: US/09/250,075
; CURRENT FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: 2'-methoxyethoxy (NOE); modified linkage
; OTHER INFORMATION: Description of Artificial Sequence: No. 6207819el
; OTHER INFORMATION: Sequence
; US-09-250-075-5

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
Db 1 TTTTCTTTTTTTTTTT 16
```

```
RESULT 355
US-09-021-701-103
; Sequence 103, Application US/09021701
; Patent No. 6251588
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; APPLICANT: Wolber, Paul K.
; APPLICANT: Delenstarr, Glenda C.
; APPLICANT: Webb, Peter G.
; APPLICANT: Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
; STREET: 3000 Hanover Street
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,701
; FILING DATE: 10-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-236-2386
; TELEFAX: 650-852-8063
; INFORMATION FOR SEQ ID NO: 103:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-09-021-701-103

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3065 ACATTCTGTCGTGTT 3080
Db 2 ACCATTCTGTCGTGTT 17

RESULT 356
US-09-021-701-104
; Sequence 104, Application US/09021701
; Patent No. 6251588
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; APPLICANT: Wolber, Paul K.
; APPLICANT: Delenstarr, Glenda C.
; APPLICANT: Webb, Peter G.
; APPLICANT: Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
; STREET: 3000 Hanover Street
```

```
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,701
; FILING DATE: 10-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-236-2386
; TELEFAX: 650-852-8063
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-09-021-701-104

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3065 ACATTCTGTCGTGTT 3080
Db 1 ACCATTCTGTCGTGTT 15

RESULT 357
US-08-854-050-132
; Sequence 132, Application US/08854050
; Patent No. 6261836
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; APPLICANT: Lingner, Joachim
; APPLICANT: Nakamura, Toru
; APPLICANT: Chapman, Karen B.
; APPLICANT: Morin, Gregg B.
; APPLICANT: Harley, Calvin
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: No. 6261836el Telomerase
; NUMBER OF SEQUENCES: 225
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/854,050
; FILING DATE: 09-MAY-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/851,843
; FILING DATE: 06-MAY-1997
```

```
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA: US 08/846,017
; FILING DATE: 25-APR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/844,419
; FILING DATE: 18-APR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-0029300S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 132:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-854-050-132

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTCTCTCTCT 2586
Db 1 TTTTCTCTCTCTCTCTCT 16

RESULT 358
US-09-490-774-5/c
; Sequence 5, Application US/09490774
; Patent No. 6262036
; GENERAL INFORMATION:
; APPLICANT: Arnold Jr., Lyle J
; APPLICANT: Reynolds, Mark A
; APPLICANT: Giachetti, Christina
; TITLE OF INVENTION: Chimeric Oligonucleoside Compounds
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth St.
; CITY: Los Angeles
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,774
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/960,111
; FILING DATE:
; APPLICATION NUMBER: US/08/238,177
; FILING DATE: 04-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Meier, Paul H.
; REGISTRATION NUMBER: 32,274
; REFERENCE/DOCKET NUMBER: 207/174
; TELECOMMUNICATION INFORMATION:
```

```
; TELEPHONE: 213/489-1600
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHEICAL: no
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: GAG oligomer
; IDENTIFICATION METHOD: synthesis experiment
; US-09-490-774-5

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CCTTCCTCTCTCTCAT 2237
Db 17 CCTTCCTCTCTCTCCT 2

RESULT 359
US-08-821-827C-30
; Sequence 30, Application US/08821827C
; Patent No. 6297425
; GENERAL INFORMATION:
; APPLICANT: Scelonge, Christopher J.
; APPLICANT: Bidney, Dennis L.
; TITLE OF INVENTION: GENE ENCODING OXALATE DECARBOXYLASE FROM
; FILE REFERENCE: 0561A
; CURRENT APPLICATION NUMBER: US/08/821.827C
; CURRENT FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
; NAME/KEY: misc.feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: n = A,T,C or G
; US-08-821-827C-30

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCCTCTCTCTCTCTT 2586
Db 2 TTTTCTCTCTCTCTT 17

RESULT 360
US-09-290-202B-30
; Sequence 30, Application US/09290202B
; Patent No. 6303846
; GENERAL INFORMATION:
; APPLICANT: Scelonge, Christopher J.
; APPLICANT: Bidney, Dennis L.
; TITLE OF INVENTION: GENE ENCODING OXALATE DECARBOXYLASE FROM
; FILE REFERENCE: 0561D
; CURRENT APPLICATION NUMBER: US/09/290,202B
; CURRENT FILING DATE: 1999-04-12
; PRIOR APPLICATION NUMBER: 08/821,827
```



```
Db      16 GTCATCAACATGGAG 1
|||||
RESULT 363
US-08-584-040-2185
; Sequence 2185, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2185:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2185

Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 18.8%; Pred. No. 2.8e+02;
Matches 3; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY      3474 TGCTATTTTTCCTCA 3489
Db      1 UGCUUUUUUUUUUGA 16
|||||
RESULT 365
US-08-584-040-2494
; Sequence 2494, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2185:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2186

Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 18.8%; Pred. No. 2.8e+02;
Matches 3; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY      3474 TGCTATTTTTCCTCA 3489
Db      2 UGCUUUUUUUUUUGA 17
|||||
RESULT 364
US-08-584-040-2186
; Sequence 2186, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
```

```
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2494:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2494

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.8e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1265 AACGCTCTCTGTAAGA 1280
Db 1 AAGGCUCUCUGAUGA 16

RESULT 366
US-08-584-040-2548
; Sequence 2548, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
```

```
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2548:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2548

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. No. 2.8e+02;
Matches 1; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

Qy 2571 TTCTCTCTTTTTTTT 2586
Db 1 UACUUUUUUUUUUU 16

RESULT 367
US-08-584-040-2549
; Sequence 2549, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
```

```

; INFORMATION FOR SEQ ID NO: 2549:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2549

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. NO. 2.8e+02;
Matches 1; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

QY 2570 CTTCTTTCTTTTTC 2585
DB 2 CUUUUUUUUUUUUUU 17

RESULT 368
US-08-584-040-2552
; Sequence 2552, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2552:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2552

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. NO. 2.8e+02;
Matches 1; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

QY 2572 TCTCTTTTTC 2587
DB 1 UUUUUUUUUUUUUC 16

RESULT 369
US-08-584-040-2763
; Sequence 2763, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2763:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2763

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. NO. 2.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1733 TCTCCTTCCAAAAGT 1748
DB 2 UCUCUCCUCCAAUAUU 17

RESULT 370
US-08-584-040-3752/c
; Sequence 3752, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
```

APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3752:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-3752

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1242 TTTTGGGATGCTGA 1257
Db 17 TCTTTGTATGCTGA 2

RESULT 371
US-08-584-040-3834/c
Sequence 3834, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700

CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3834:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-3834

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1523 GCCCGGATAGTAAAG 1538
Db 17 GCTGGGATAGTAAAG 2

RESULT 372
US-08-584-040-4382/c
Sequence 4382, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040


```
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4382:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-4382

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 GCAGGTGGCAAGAAC 1076
DB 17 GCTGGTGGAAAGAAC 2

RESULT 373
US-08-584-040-4383/c
; Sequence 4383, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4382:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-4383

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 GCAGGTGGCAAGAAC 1076
DB 17 GCTGGTGGAAAGAAC 2

RESULT 374
US-08-584-040-5385
; Sequence 5385, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5385:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5385

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4383:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-4383

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 GCAGGTGGCAAGAAC 1076
DB 16 GCTGGTGGAAAGAAC 1

RESULT 374
US-08-584-040-5385
; Sequence 5385, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5385:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5385

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      3201 AGGGAAGTTGGAATG 3216
      ||||| :|||:|||||
Db      1 AGGGUGGUUGGAAUG 16
      ||||| :|||:|||||

RESULT 375
US-08-584-040-5766/c
; Sequence 5766, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5766:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5766

Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      969 TTCTGCAGAGCTGCT 984
      ||||| :|||:|||||
Db      16 TTCTCAGAGCTTCT 1
      ||||| :|||:|||||

RESULT 376
US-08-584-040-5942/c
; Sequence 5942, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela

```

```

; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5942:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5942

Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1118 AAAATGCATATCAAT 1133
      ||||| :|||:|||||
Db      17 AAAATGAAATCAAT 2
      ||||| :|||:|||||

RESULT 377
US-08-584-040-5944/c
; Sequence 5944, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street

```

STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5944:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5944

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1117 AAAATGCATATCAAA 1132
Db 16 AAAAATGAAATCAAA 1

RESULT 378
US-08-584-040-7456
Sequence 7456, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5944:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7456:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7456

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.8e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 540 CCATCAAGAAATAGG 555
Db 1 CCUCAAUAAUAGG 16

RESULT 379
US-08-584-040-7493
Sequence 7493, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7456:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

```
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7493:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7493

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 2.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 469 CTGTACCTGTCTTCA 484
Db 1 CUGAACCUUGUCA 16

RESULT 380
US-08-584-040-7572
; Sequence 7572, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7572:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7572

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 469 CTGTACCTGTCTTCA 484
Db 1 CUGAACCUUGUCA 16

RESULT 381
US-08-584-040-7680/c
; Sequence 7680, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7680:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7680

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1299 TGTGCTGCAGACCTT 1314
Db 17 TGTGCTGTAGACCTT 2

RESULT 382
US-08-584-040-7815/c
; Sequence 7815, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
```

```

; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 7815:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7815

```

```

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2591 AAAAAAGGAAAAAGCAC 2606
DB 17 AAAAAACAAAAAGCAC 2

```

```

RESULT 383
US-08-584-040-7817/c
; Sequence 7817, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon

```

```

; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 7817:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7817

```

```

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2590 AAAAAAGGAAAAAGCA 2605
DB 16 AAAAAACAAAAAGCA 1

```

```

RESULT 384
US-08-584-040-8150/c
; Sequence 8150, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8150:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8150

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2532 TTTTGGGGGATAAGG 2547
||||| ||||| |||||
DB 17 TTTTGGGAAAGGG 2

RESULT 385
US-09-495-140-26
; Sequence 26, Application US/09495140
; Patent No. 6376182
; GENERAL INFORMATION:
; APPLICANT: CHAO, LEE
; APPLICANT: CHAO, JULIE
; APPLICANT: SONG, QING
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CORRELATING
; TITLE OF INVENTION: TISSUE KALLIKREIN GENE PROMOTER POLYMORPHISMS WITH TREATMENT
; TITLE OF INVENTION: OF ESSENTIAL HYPERTENSION
; FILE REFERENCE: 19113.0081
; CURRENT APPLICATION NUMBER: US/09/495,140
; CURRENT FILING DATE: 2000-01-31
; EARLIER APPLICATION NUMBER: 09/389,566
; EARLIER FILING DATE: 1999-09-03
; EARLIER APPLICATION NUMBER: 08/856,141
; EARLIER FILING DATE: 1997-05-14
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:/No. 6376182e =
; OTHER INFORMATION: synthetic construct
US-09-495-140-26

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 273 GGACGGGGCGGGGAGG 288
||||| ||||| |||||
DB 1 GGACGGGGGGGGGGG 16

RESULT 386
US-09-619-103-23/c
; Sequence 23, Application US/09619103

; Patent No. 6429300
; GENERAL INFORMATION:
; APPLICANT: Kurz, Markus
; APPLICANT: Lohse, Peter
; APPLICANT: Wagner, Richard
; TITLE OF INVENTION: Peptide Acceptor Ligation Methods
; FILE REFERENCE: 50036/031002
; CURRENT APPLICATION NUMBER: US/09/619,103
; CURRENT FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/145,834
; PRIOR FILING DATE: 1999-07-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-23

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
||||| ||||| |||||
DB 17 TTTTCTTTTTTTTTT 2

RESULT 387
US-09-726-096A-5
; Sequence 5, Application US/09726096A
; Patent No. 6462184
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Maier, Martin A.
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Backt
; TITLE OF INVENTION: Oligomeric Compounds
; FILE REFERENCE: IS184528
; CURRENT APPLICATION NUMBER: US/09/726,096A
; CURRENT FILING DATE: 2000-11-29
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: 2'-methoxyethoxy (MOE); phosphorothioate
; OTHER INFORMATION: internucleoside linkage
US-09-726-096A-5

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TTCTTCTTTTTTTTTT 2586
||||| ||||| |||||
DB 1 TTTTCTTTTTTTTTT 16

RESULT 388
US-09-475-947A-118
; Sequence 118, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.

```

US/09-371-772B-645/c
; Sequence 645, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; TITLE OF INVENTION: Levels of Vascular Endothelial
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B

```

; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 645
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-645

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2148 GTCATCAAAAAGGAG 2163
|||||
Db 16 GTCATCAACATGGAG 1

RESULT 393
US-09-371-772B-730
; Sequence 730, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 730
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-730

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 18.8%; Pred. No. 2.8e+02;
Matches 3; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY 3474 TGCTATTTTTCATCA 3489
|||||
Db 2 UGCUUUUUUUUGA 17

RESULT 394
US-09-371-772B-731
; Sequence 731, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 731
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-731

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 18.8%; Pred. No. 2.8e+02;
Matches 3; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY 3474 TGCTATTTTTCATCA 3489
|||||
Db 1 UGCUUUUUUUUGA 16

RESULT 395
US-09-371-772B-1018
; Sequence 1018, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1018
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1018

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.8e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1265 AACGCTCTCTGTAAGA 1280
|||||
Db 1 AAGGCUCUCUGAUGA 16

RESULT 396
US-09-371-772B-1072
; Sequence 1072, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1519
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1519

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1242 TTTTGTGGATGCTGA 1257
| | | | | | | | | | | | | | | | | | | | |
Db 17 TCTTTTGTATGCTGA 2

RESULT 401

US-09-371-772B-1601/c
; Sequence 1601, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1601
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1601

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1523 GCCCGGATAGTAAG 1538
| | | | | | | | | | | | | | | | | | | | |
Db 17 GCTGGGAATAGTAAG 2

RESULT 402

US-09-371-772B-2149/c
; Sequence 2149, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2149
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2149

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 GCAGGTGGCAAGAAC 1076
| | | | | | | | | | | | | | | | | | | | |
Db 17 GCTGGTGGAAAGACA 2

RESULT 403

US-09-371-772B-2150/c
; Sequence 2150, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2150
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2150

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 GCAGGTGGCAAGAAC 1076
| | | | | | | | | | | | | | | | | | | | |
Db 16 GCTGGTGGAAAGACA 1

RESULT 404

US-09-371-772B-2285
; Sequence 2285, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2285
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2285

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3201 AGGGAAGTTGGAATG 3216
||||| |:::|||||
Db 1 AGGGUGGUUGGAAUG 16

RESULT 405

US-09-371-772B-2645/c
; Sequence 2645, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth Factor Receptor
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2645
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2645

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 TTCTGCAGAGCTGCT 984
||||| |:::|||||
Db 16 TTCTCAGAGCTTCT 1

RESULT 406

US-09-371-772B-2779/c
; Sequence 2779, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth Factor Receptor
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 2779
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2779

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1118 AAAATGCATATCAAT 1133
||||| |:::|||||
Db 17 AAAATGAAATCAAT 2

RESULT 407

US-09-371-772B-2781/c
; Sequence 2781, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth Factor Receptor
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2781
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2781

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 AAAATGCATATCAAA 1132
||||| |:::|||||
Db 16 AAAATGAAATCAAA 1

RESULT 408

US-09-371-772B-3262
; Sequence 3262, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth Factor Receptor
; FILE REFERENCE: MBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3262

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3262

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.8e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 540 CCATCAGAAAATAGG 555
||:|||||:|||||
Db 1 CCUCAAUAAAAUAGG 16

RESULT 409

US-09-371-772B-3299
; Sequence 3299, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3299
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3299

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 2.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 469 CTGTACCTTGTCTCA 484
||:|||||:|||||
Db 1 CUGAACCUUGUCA 16

RESULT 410

US-09-371-772B-3368
; Sequence 3368, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3368
; LENGTH: 17

; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3368

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.8e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2449 GACAGACTAGCTGGCA 2464
|||||||:|||||
Db 1 GACAGACUACCUUCA 16

RESULT 411

US-09-371-772B-3465/c
; Sequence 3465, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3465
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3465

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1299 TGGTGCTGCAGAGCTT 1314
|||||||:|||||
Db 17 TGGTGCTGTAGACCTT 2

RESULT 412

US-09-371-772B-3599/c
; Sequence 3599, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3599
; LENGTH: 17
; TYPE: RNA

```

; ORGANISM: Mus sp.
US-09-371-772B-3599

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2591 AAAAAAGGAAAGCAC 2606
    ||||| ||||| |||||
DB 17 AAAAAACAAAAAGCAC 2

RESULT 413
US-09-371-772B-3601/c
; Sequence 3601, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3601
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3601

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2590 AAAAAAGGAAAGCA 2605
    ||||| ||||| |||||
DB 16 AAAAAACAAAAAGCA 1

RESULT 414
US-09-371-772B-3933/c
; Sequence 3933, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3933
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
```

US-09-371-772B-3933

```

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 2532 TTTTGGGGGATAAGGG 2547
    ||||| ||||| |||||
DB 17 TTTTGTGGGAAAGGG 2
```

RESULT 415

```

US-09-371-772B-4222
; Sequence 4222, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4222
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4222
```

```

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 2598 AAAAAGCACACAGCAC 2613
    ||||| ||||| |||||
DB 2 AAAAGGCACCCAGCAC 17
```

RESULT 416

```

US-09-371-772B-4223
; Sequence 4223, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4223
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4223
```

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2599 AAAAGCACACAGCACA 2614
||| ||||| ||||| |||||
DB 1 AAAGCACCCAGCACA 16

RESULT 417
US-09-371-772B-4632/c
; Sequence 4632, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4632

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2931 TATATCTGGTTGTTT 2946
||| ||||| ||||| |||||
DB 16 TATTTTGTTGTTT 1

RESULT 418
US-09-371-772B-4936
; Sequence 4936, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4936
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4936

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 605 TCATCAGCCTTGAAG 620
||| ||||| ||||| |||||
DB 1 UCAUGAGCCUGGAAG 16

RESULT 419
US-09-371-772B-5092/c
; Sequence 5092, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5092
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5092

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 CCCGAGGGGGCGGG 285
||| ||||| ||||| |||||
DB 17 CCCTGAGGTGGCGGG 2

RESULT 420
US-09-371-772B-5093/c
; Sequence 5093, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5093
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5093

Query Match 0.3%; Score 12.8; DB 1; Length 17;

```
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 269 GCCCGAGGGCGGG 284
   ||||| ||||| |||||
Db 16 GCCCTGAGGTGGCGG 1

RESULT 421
US-09-371-772B-5370
; Sequence 5370, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5370
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5370

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.8e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1265 AACGCTCTCTGTGAAGA 1280
   ||||| :||| :|||
Db 2 AAGGCUCUCUGUAUGA 17

RESULT 422
US-09-371-772B-6336/c
; Sequence 6336, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6336

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2372 TGGAAATGGGATTGCT 2387
   ||||| ||||| |||||
Db 17 TTGAAATGGGATTGCT 2

RESULT 423
US-09-371-772B-6337/c
; Sequence 6337, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6337
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6337

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2372 TGGAAATGGGATTGCT 2387
   ||||| ||||| |||||
Db 16 TTGAAATGGGATTGCT 1

RESULT 424
US-09-371-772B-6358/c
; Sequence 6358, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6358
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6358

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 213:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-401-063-213

```

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1822 CTCGGGGAACAAAG 1837
||| ||||| |||||
Db 16 CTCGGGGAGACAAG 1

```

RESULT 427
US-09-401-063-430
; Sequence 430, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
;
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

```



```
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 430:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;
US-09-401-063-430

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 2.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 718 CTTCCTTCCCACTGAA 733
Db 2 CUUCUUUCCCAAGGAA 17

;
;
RESULT 428
US-09-827-998-195
; Sequence 195, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 195
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-195

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2916 TTTTGCAATTTGAAAT 2931
Db 2 TTTTGCAATTTTAAAT 17

;
;
RESULT 429
US-09-827-998-197
; Sequence 197, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 197
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
US-09-827-998-197

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2917 TTTTGCAATTTGAAATA 2932
Db 1 TTTTGCAATTTTAAATA 16

;
;
RESULT 430
US-09-827-998-482/c
; Sequence 482, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 482
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-482

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2572 TCCTCTCTTTTTC 2587
Db 17 TCCTCTCTTTTTC 2

;
;
RESULT 431
US-09-827-998-484/c
; Sequence 484, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 484
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-484

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2571 TCCTCTCTTTTTC 2586
```

```
Db      16 TTCTTCTTTTTTT 1
||||| |||||||
RESULT 432
US-09-827-998-772/c
; Sequence 772, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US 60/207,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 772
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-772
Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      663 GTACCACACGAGCG 678
Db      17 GTACCACACGAGTG 2
||||| |||||||
RESULT 433
US-09-827-998-773/c
; Sequence 773, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 773
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-773
Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      663 GTACCACACGAGCG 678
Db      17 GTACCACACGAGTG 2
||||| |||||||
RESULT 434
US-09-827-998-774/c
; Sequence 774, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US 60/207,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 774
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-774
Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      661 GAGTACCAACACGAG 676
Db      17 GGTACACACGAG 2
||||| |||||||
RESULT 435
US-09-827-998-777/c
; Sequence 777, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 777
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-777
Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      659 CTGAGTACCAACGAG 674
Db      16 CTGGGTACCAACGAG 1
||||| |||||||
RESULT 436
US-09-529-812A-1/c
; Sequence 1, Application US/09529812A
; Patent No. 6682930
; GENERAL INFORMATION:
; APPLICANT: LU, CHANGDE
; TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN
; FILE REFERENCE: 017227/0160
; CURRENT APPLICATION NUMBER: US/09/529,812A
```

; CURRENT FILING DATE: 2000-07-24
 ; PRIOR APPLICATION NUMBER: PCT/CN98/00248
 ; PRIOR FILING DATE: 1998-10-19
 ; PRIOR APPLICATION NUMBER: CN 97106667.1
 ; PRIOR FILING DATE: 1997-10-21
 ; NUMBER OF SEQ ID NOS: 18
 ; SOFTWARE: Patent in Ver. 2.1
 ; SEQ ID NO 1
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Triplex
 ; OTHER INFORMATION: forming oligonucleotide
 ; OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
 ; US-09-529-812A-1

Query Match 0.3%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2189 CCTCATCTCTCTCT 2204
 DB 17 CCTCATCTCTCTCT 2

RESULT 437
 US-09-866-108A-241/c
 ; Sequence 241, Application US/09866108A
 ; Patent No. 6686188
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEOMICA-7
 ; CURRENT APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-25
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30

```
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 262
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-262

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 TCTCTGTGATCCCAAG 2104
|||||
Db 2 TCTCTGTGATCCCAAG 17

RESULT 440
US-09-866-108A-263
; Sequence 263, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 262
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-262
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-263

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 TCTCTGTGATCCCAAG 2104
|||||
Db 1 TCTCTGTGATCCCAAG 16

RESULT 441
US-09-866-108A-301/c
; Sequence 301, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 301
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-301
```

```
Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2345 TTTTTCAGACCCCC 2360
Db 17 TCTTTTCAGTCCCC 2

RESULT 442
US-09-866-108A-302/c
; Sequence 302, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 302
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-302

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2345 TTTTTCAGACCCCC 2360
Db 16 TCTTTTCAGTCCCC 1

RESULT 443
US-09-866-108A-674
; Sequence 674, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 302
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-674

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2345 TTTTTCAGACCCCC 2360
Db 16 TCTTTTCAGTCCCC 1

RESULT 444
US-09-866-108A-675
; Sequence 675, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 675
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-675

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1183 AGAGAAGCCTCTCC 1198
||||| ||| |||
Db 1 AGAGAAGACTCATCC 16

RESULT 445
US-09-866-108A-1175
;; Sequence 1175, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AECOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866.108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 1175
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-1175

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 20 GAAGGACGGAGAGGG 35
||||| ||| |||
Db 2 GAAGGACAAAGAGGG 17

RESULT 446
US-09-866-108A-1177
;; Sequence 1177, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AECOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866.108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 1177
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-1177

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 21 AAGGACGGAGAGGG 36
||||| ||| |||
Db 1 AAGGACAAAGAGGG 16

RESULT 447
US-09-866-108A-1579/c
;; Sequence 1579, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.

```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1579
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-1579

Query Match      0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred No. 2,8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps

QY      2982 TCATTCTCCAGAGGAG 2997
Db      17 TCATTCTCCAGAGCAG 2

RESULT 448
US-09-866-108A-1581/c
; Sequence 1581, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

```

US-09-866-108A-1875

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 228 CTTGAGCTGGTCCAGG 243
| | | | | | | | | | | | | | | | | | |
Db 2 CCTGAGCTGGACCAGG 17

RESULT 450

US-09-866-108A-1876
; Sequence 1876, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1881
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-1881

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 228 CTTGAGCTGGTCCAGG 243
| | | | | | | | | | | | | | | | | | |
Db 1 CCTGAGCTGGACCAGG 16

RESULT 451

US-09-866-108A-1881/c
; Sequence 1881, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1881
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-1881

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 227 CCTTGAGCTGGTCCAG 242
| | | | | | | | | | | | | | | | | | |
Db 17 CCTGAGCTGGTCCAG 2

RESULT 452

US-09-866-108A-1882/c
; Sequence 1882, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1882
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1882

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 227 CCTGAGCTGTCCAG 242
||| |||||
DB 16 CCTGACCTGTCCAG 1

RESULT 453
US-09-866-108A-2066/c
; Sequence 2066, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2066
; LENGTH: 17
; TYPE: DNA

; ORGANISM: Homo sapiens
US-09-866-108A-2066
Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1050 ACTGTGTGCAGCAGG 1065
||||| |||||
DB 17 AATGTGGCAGGCAGG 2

RESULT 454
US-09-866-108A-2067/c
; Sequence 2067, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2067
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2067

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1050 ACTGTGTGCAGCAGG 1065
||||| |||||
DB 16 AATGTGGCAGGCAGG 1

RESULT 455
US-09-866-108A-2272
; Sequence 2272, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2272
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2272

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 415 CTCGGGGCGTCTGCT 430
Db 1 CTCGGGGCGTCTGCGCT 16

RESULT 456
US-09-866-108A-2423
; Sequence 2423, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2272
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2272
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2423

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 136 GAAAGGGGAAAGTATC 151
Db 2 GGAAGGGGAAAGTAAAC 17

RESULT 457
US-09-866-108A-2424
; Sequence 2424, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2424
; LENGTH: 17
```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2424

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 136 GAAAGGGGAAAGTATC 151
| | | | | | | | | | | | | | | | |
Db 1 GGAAGGGGAAAGTAAAC 16

RESULT 458

US-09-866-108A-6014
; Sequence 6014, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6014
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6014

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1290 GTGACTGTTTGGTGCT 1305
| | | | | | | | | | | | | | | | |
Db 2 GTGACAGTGTGGTGCT 17

RESULT 459

US-09-866-108A-6015
; Sequence 6015, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6015
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6015

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1290 GTGACTGTTTGGTGCT 1305
| | | | | | | | | | | | | | | | |
Db 1 GTGACAGTGTGGTGCT 16

RESULT 460

US-09-866-108A-6397/C
; Sequence 6397, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6397
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6397
```

```
Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 85 GCTTGGTCTGGCGCA 100
      ||||| ||||| |||||
DB 17 GCTTGATCTGGGAGCA 2
```

```
RESULT 461
US-09-866-108A-6398/c
; Sequence 6398, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6398
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6398
```

```
Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 85 GCTTGGTCTGGCGCA 100
      ||||| ||||| |||||
DB 16 GCTTGATCTGGGAGCA 1
```

```
RESULT 462
US-09-866-108A-6854
; Sequence 6854, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6854
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6854
```

```
Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1173 AGAAGAGCGAGAGAA 1188
      ||||| ||||| |||||
DB 2 AGAAGAGCGAGAGAA 17
```

```
RESULT 463
US-09-866-108A-6857
; Sequence 6857, Application US/09866108A
; Patent No. 6686188
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6857
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6857

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1175 AAAGACGAGAGAGC 1190
DB 1 AAGCAGGAGAGAGC 16

RESULT 464
US-09-866-108A-6928/c
; Sequence 6928, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6928

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3319 GATTGTTGAATTCCTG 3334
DB 17 GCTTCTGAATTCCTG 2

RESULT 465
US-09-866-108A-6931/c
; Sequence 6931, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
```

```
; SEQ ID NO 6931
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6931

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3317 CAGATTGTTGAATTC 3332
Db 16 CAGCTTCTTGAATTC 1

RESULT 466
US-09-866-108A-8117
; Sequence 8117, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8453
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8453

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1357 AGATCATGCACACGA 1372
Db 2 AGAGCATGCACACGA 17

RESULT 468
US-09-866-108A-8455
; Sequence 8455, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```
; SEQ ID NO 6931
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6931

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3317 CAGATTGTTGAATTC 3332
Db 16 CAGCTTCTTGAATTC 1

RESULT 466
US-09-866-108A-8117
; Sequence 8117, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8117
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8117

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2727 TGCCAGAGCAGCTTC 2742
Db 1 TGCCAGAGCAGCTTC 16

RESULT 467
US-09-866-108A-8453
; Sequence 8453, Application US/09866108A
```

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8455
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8455

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1358 GATCATGCACACGAG 1373
Db      1 GAGCATGCACACGAG 16

RESULT 469
US-09-866-108A-8872/c
; Sequence 8872, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8455
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8455

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1358 GATCATGCACACGAG 1373
Db      1 GAGCATGCACACGAG 16

RESULT 469
US-09-866-108A-8872/c
; Sequence 8872, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
```

```
; Patent No. 6686188
; SEQ ID NO 8872
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8872

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2183 GCTGCTCTCTCCATCTT 2198
Db      17 GCTGCTCTCTCCATCTT 2

RESULT 470
US-09-866-108A-8874/c
; Sequence 8874, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8874
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8874

Query Match          0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2182 AGCTGCTCTCTCCATCT 2197
Db      16 AGCTGCTCTCTCCATCT 1

RESULT 471
US-09-866-108A-10317
```

```
; Sequence 10317, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10317
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10317
```

```
Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1764 CTTTCTCTCGCGGAGC 1779
|||||
Db 2 CTTTCTCTCGGGATC 17
```

```
RESULT 472
US-09-866-108A-10319
; Sequence 10319, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
```

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10319
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10319
```

```
Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1765 TTTCTCTCGCGGAGCA 1780
|||||
Db 1 TTTCTCTCGGGATCA 16
```

```
RESULT 473
US-09-866-108A-10592
; Sequence 10592, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```


; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10592
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10592

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1714 GAAGATTCCTTGAAG 1729
DB 2 GAAGTGCCTTGAAG 17

RESULT 474

US-09-866-108A-10593
; Sequence 10593, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10593
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10593

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1714 GAAGATTCCTTGAAG 1729
DB 1 GAAGTGCCTTGAAG 16

RESULT 475

US-09-866-108A-10597
; Sequence 10597, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10597
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10597

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1719 TTCCCTTGAAGCCTTC 1734

DB 2 TCCCTTGAAGACTTC 17

RESULT 476
US-09-866-108A-10598
; Sequence 10598, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10598
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10598

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1719 TTCCCTTGAAGCCTTC 1734

DB 2 TCCCTTGAAGACTTC 17

RESULT 476
US-09-866-108A-10598
; Sequence 10598, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

/	PRIOR CONCERN FILING DATE:	2001-09-27
/	PRIOR APPLICATION NUMBER:	US 60/207,456
/	PRIOR FILING DATE:	2000-05-26
/	PRIOR APPLICATION NUMBER:	GB 24263.6
/	PRIOR FILING DATE:	2000-10-04
/	PRIOR APPLICATION NUMBER:	US 60/236,359
/	PRIOR FILING DATE:	2000-09-27
/	PRIOR APPLICATION NUMBER:	PCT/US01/006666
/	PRIOR FILING DATE:	2001-01-30
/	PRIOR APPLICATION NUMBER:	PCT/US01/006657
/	PRIOR FILING DATE:	2001-01-30
/	PRIOR APPLICATION NUMBER:	PCT/US01/006654
/	PRIOR FILING DATE:	2001-01-30
/	PRIOR APPLICATION NUMBER:	PCT/US01/006659
/	PRIOR FILING DATE:	2001-01-30
/	PRIOR APPLICATION NUMBER:	PCT/US01/006655
/	PRIOR FILING DATE:	2001-01-30
/	PRIOR APPLICATION NUMBER:	PCT/US01/006658
/	PRIOR FILING DATE:	2001-01-30
/	PRIOR APPLICATION NUMBER:	PCT/US01/006653
/	PRIOR FILING DATE:	2001-01-30
/	Remaining Prior Application date removed	

Qy	1721	CCCTTGAAGCCTTCTC	1736
Db	1	CCCTTGAAGACTTCCC	16

```
RESULT 479
US-09-866-108A-10727/c
; Sequence 10727, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10727
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-10728

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2267 GGACCCGAGCATCCCC 2282
DB 17 GGAGCCCGAGCATCCCC 2

RESULT 480
US-09-866-108A-10728/c
; Sequence 10728, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10727
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-10729

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2267 GGACCCGAGCATCCCC 2282
DB 17 GGAGCCCGAGCATCCCC 2
```

```
RESULT 481
US-09-866-108A-10756/c
; Sequence 10756, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10728
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-10728

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2267 GGACCCGAGCATCCCC 2282
DB 16 GGAGCCCGAGCATCCCC 1

RESULT 482
US-09-866-108A-10756/c
; Sequence 10756, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10728
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-10728
```

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10756
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10756

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3633 ACTTTGATTGTTTCAG 3648
|||||
Db 17 ACTTTATTGTTTCAG 2

RESULT 482

US-09-866-108A-10757/c
; Sequence 10757, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Shaaron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10757
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10757

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3633 ACTTTGATTGTTTCAG 3648
|||||
Db 16 ACTTTATTGTTTCAG 1

RESULT 483

US-10-059-877-26
; Sequence 26, Application US/10059877
; Patent No. 6747140
; GENERAL INFORMATION:
; APPLICANT: CHAO, LEE
; APPLICANT: CHAO, JULIE
; APPLICANT: SONG, QING
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CORRELATING
; TITLE OF INVENTION: TISSUE KALLIKREIN GENE PROMOTER POLYMORPHISMS WITH ESSENTIAL
; TITLE OF INVENTION: HYPERTENSION
; FILE REFERENCE: 19113.0081U2
; CURRENT APPLICATION NUMBER: US/10/059,877
; CURRENT FILING DATE: 2002-01-29
; PRIOR APPLICATION NUMBER: 09/495,140
; PRIOR FILING DATE: 2000-01-31
; PRIOR APPLICATION NUMBER: 09/389,566
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: 08/856,141
; PRIOR FILING DATE: 1997-05-14
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:/No. 6747140e =
; OTHER INFORMATION: synthetic construct
US-10-059-877-26

Query Match 0.3%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 273 GGAGGGGGGGGGAGG 288
|||||
Db 1 GGAGGGGGGGGGGGG 16

RESULT 484

US-09-129-603-4
; Sequence 4, Application US/09129603A
; Patent No. 6790944
; GENERAL INFORMATION:
; APPLICANT: Ishiwata, Tetsuyoshi
; APPLICANT: Sakurada, Mikiko
; APPLICANT: Nishimura, Ayako
; APPLICANT: Nakagawa, Satoshi
; APPLICANT: Kuga, Tetsuro
; APPLICANT: Nishi, Tatsunari
; APPLICANT: No. 6790944ura, No. 6790944uo
; APPLICANT: Sawada, Shigemasa
; APPLICANT: Nagase, Takahiro
; APPLICANT: Takei, Masami
; TITLE OF INVENTION: No. 6790944el Protein
; FILE REFERENCE: 766.25
; CURRENT APPLICATION NUMBER: US/09/129,603A
; CURRENT FILING DATE: 1998-08-05
; EARLIER APPLICATION NUMBER: PCT/JF97/04469
; EARLIER FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: other nucleic acid from homo sapiens, synthesized
; OTHER INFORMATION: DNA
US-09-129-603-4

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2572 TCTTCTTTTTTTTC 2587
Db 2 TTTTTTTTTTTTC 17

RESULT 485
PCT-US93-03942-3/c
; Sequence 3, Application PC/TUS9303942
; GENERAL INFORMATION:
; APPLICANT: GABER, RICHARD F.
; TITLE OF INVENTION: GENETICALLY ENGINEERED EUKARYOTIC
; TITLE OF INVENTION: ORGANISM CAPABLE OF DETECTING THE EXPRESSION
; TITLE OF INVENTION: OF HETEROLOGOUS ION CHANNELS AND METHOD TO
; TITLE OF INVENTION: USE SAME
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: TILTON, FALLON, LUNGWUS & CHESTNUT
; STREET: 100 SOUTH WACKER DRIVE, SUITE 960, HARTFORD PLAZA
; CITY: CHICAGO
; STATE: ILLINOIS
; COUNTRY: USA
; ZIP: 60606-4002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/03942
; FILING DATE: 19930421
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/874,846
; FILING DATE: 27-APR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: FENTRESS, SUSAN B.
; REGISTRATION NUMBER: 31,327
; REFERENCE/DOCKET NUMBER: NU-9211CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/456-8000
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
PCT-US93-03942-3

Query Match 0.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3038 TGTTCGTGGAGCTAAG 3053
Db 16 TGTTCGTGGAGCTTAG 1

Search completed: November 2, 2004, 09:53:38
Job time : 20 secs

